FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Lippi, G
   Simundic, AM
   Plebani, M
AF Lippi, Giuseppe
   Simundic, Ana-Maria
   Plebani, Mario
TI Potential preanalytical and analytical vulnerabilities in the laboratory
   diagnosis of coronavirus disease 2019 (COVID-19)
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Article
DE coronavirus; COVID-19; diagnosis; reverse transcription polymerase chain
   reaction (RT-PCR)
ID TIME
AB A novel zoonotic coronavirus outbreak is spreading all over the world. This pandemic disease has now been defined as novel coronavirus disease 2019 (COVID-19), and is sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the current gold standard for the etiological diagnosis of SARS-CoV-2 infection is (real time) reverse transcription polymerase chain reaction (rRT-PCR) on respiratory tract specimens, the diagnostic accuracy of this technique shall be considered a foremost prerequisite. Overall, potential RT-PCR vulnerabilities include general preanalytical issues such as identification problems, inadequate procedures for collection, handling, transport and storage of the swabs, collection of inappropriate or inadequate material (for quality or volume), presence of interfering substances, manual errors, as well as specific aspects such as sample contamination and testing patients receiving antiretroviral therapy. Some analytical problems may also contribute to jeopardize the diagnostic accuracy, including testing outside the diagnostic window, active viral recombination, use of inadequately validated assays, insufficient harmonization, instrument malfunctioning, along with other specific technical issues. Some practical indications can hence be identified for minimizing the risk of diagnostic errors, encompassing the improvement of diagnostic accuracy by combining clinical evidence with results of chest computed tomography (CT) and RT-PCR, interpretation of RT-PCR results according to epidemiologic, clinical and radiological factors, recollection and testing of upper (or lower) respiratory specimens in patients with negative RT-PCR test results and high suspicion or probability of infection, dissemination of clear instructions for specimen (especially swab) collection, management and storage, together with refinement of molecular target(s) and thorough compliance with analytical procedures, including quality assurance.
C1 [Lippi, Giuseppe] Univ Verona, Dept Neurosci Biomed & Movement, Sect Clin Biochem, Piazzale LA Scuro, I-37134 Verona, Italy.
   [Simundic, Ana-Maria] Univ Hosp Sveti Duh, Dept Med Lab Diagnost, Zagreb, Croatia.
   [Plebani, Mario] Univ Hosp Padova, Dept Lab Med, Padua, Italy.
RP Lippi, G (corresponding author), Univ Verona, Dept Neurosci Biomed & Movement, Sect Clin Biochem, Piazzale LA Scuro, I-37134 Verona, Italy.
EM giuseppe.lippi@univr.it
OI Plebani, Mario/0000-0002-0270-1711
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   [Anonymous], 2020, INTERIM GUIDANCE
   Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Centers for Disease Control and Prevention, INT GUID COLL HANDL
   Centers for Disease Control and Prevention, CDC 2019 NOV COR 201
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Corman VM, 2020, EUROSURVEILLANCE, V25, P35, DOI 10.2807/1560-7917.ES.2020.25.21.2001035
   Espy MJ, 2006, CLIN MICROBIOL REV, V19, P165, DOI 10.1128/CMR.19.1.165-256.2006
   Food and Drug Administration, 2020, NEW YORK SARS COV 2
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Irving SA, 2012, CLIN MED RES, V10, P215, DOI 10.3121/cmr.2012.1084
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Kam KQ, 2020, CLIN INFECT DIS, V71, P847, DOI 10.1093/cid/ciaa201
   Kim S, 2020, INSUFFICIENT SENSITI, DOI [10.20944/preprints202002., DOI 10.20944/PREPRINTS202002]
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Lepej SZ, 2020, CLIN MICROBIOL INFEC, V26, P411, DOI 10.1016/j.cmi.2019.09.017
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1131, DOI 10.1515/cclm-2020-0198
   Lippi G, 2020, DIAGNOSIS, V7, P79, DOI 10.1515/dx-2020-0015
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P518, DOI 10.1515/cclm-2019-1089
   Lippi G, 2019, CLIN CHEM LAB MED, V57, P974, DOI 10.1515/cclm-2018-1334
   Lippi G, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.04.02
   Lippi G, 2018, CLIN CHEM LAB MED, V56, P1660, DOI 10.1515/cclm-2017-0277
   Lippi G, 2018, CLIN CHEM LAB MED, V56, P718, DOI 10.1515/cclm-2017-1104
   Lippi G, 2017, CLIN CHEM LAB MED, V55, P962, DOI 10.1515/cclm-2016-0810
   Lippi G, 2016, CLIN CHEM LAB MED, V54, P1, DOI 10.1515/cclm-2015-1135
   Matos TR, 2017, J INVEST DERMATOL, V137, pE131, DOI 10.1016/j.jid.2017.04.001
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sharfstein JM, 2020, JAMA-J AM MED ASSOC, V323, P1437, DOI 10.1001/jama.2020.3864
   Shen ZJ, 2020, CLIN INFECT DIS, V71, P713, DOI 10.1093/cid/ciaa203
   Sheridan C, 2020, NAT BIOTECHNOL, V38, P382, DOI 10.1038/d41587-020-00002-2
   Spackman E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164261
   Spencer S, 2013, J CLIN MICROBIOL, V51, P3880, DOI 10.1128/JCM.01873-13
   Sun PF, 2020, J MED VIROL, V92, P612, DOI 10.1002/jmv.25735
   Tong ZD, 2020, EMERG INFECT DIS, V26, P1052, DOI 10.3201/eid2605.200198
   van Zyl G, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2052
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, COLL PRES SHIPP SPEC
   World Health Organization (WHO), 48 WHO
   Xie X, 2020, RADIOLOGY, V2020, P200343, DOI DOI 10.1148/RADIOL.2020200343
   Yi HG, 2020, CLIN INFECT DIS, V71, P884, DOI 10.1093/cid/ciaa219
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 47
TC 107
Z9 109
U1 11
U2 23
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1434-6621
EI 1437-4331
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PD JUL
PY 2020
VL 58
IS 7
SI SI
BP 1070
EP 1076
DI 10.1515/cclm-2020-0285
PG 7
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA LY2UV
UT WOS:000540382600007
PM 32172228
OA Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Ronchi, S
   Vischioni, B
   Bonora, M
   Barcellini, A
   Locati, LD
   Castelnuovo, P
   Nicolai, P
   Piazza, C
   Ansarin, M
   Benazzo, M
   Orli, E
AF Ronchi, Sara
   Vischioni, Barbara
   Bonora, Maria
   Barcellini, Amelia
   Locati, Laura D.
   Castelnuovo, Paolo
   Nicolai, Piero
   Piazza, Cesare
   Ansarin, Mohssen
   Benazzo, Marco
   Orli, Ester
TI Managing locally advanced adenoid cystic carcinoma of the head and neck
   during the COVID-19 pandemic crisis: Is this the right time for particle
   therapy?
SO ORAL ONCOLOGY
LA English
DT Letter
ID CARBON ION RADIOTHERAPY; RADIATION-THERAPY; MULTICENTER; TUMORS
C1 [Ronchi, Sara; Vischioni, Barbara; Bonora, Maria; Barcellini, Amelia; Orli, Ester] Natl Ctr Oncol Hadrontherapy CNAO, Pavia, Italy.
   [Locati, Laura D.] Fdn IRCCS Ist Nazl Tumori, Head & Neck Canc Med Oncol Unit, Milan, Italy.
   [Castelnuovo, Paolo] Univ Insubria, Div Otorhinolaryngol, Dept Biotechnol & Life Sci, Varese, Italy.
   [Castelnuovo, Paolo] Univ Insubria, Head & Neck Surg & Forens Dissect Res Ctr HNS & F, Dept Biotechnol & Life Sci, Varese, Italy.
   [Nicolai, Piero] Univ Padua, Dept Neurosci, Sect Otorhinolaryngol Head & Neck Surg, Padua, Italy.
   [Piazza, Cesare] Fdn IRCCS Ist Nazl Tumori, Dept Otorhinolaryngol Maxillofacial & Thyroid Sur, Milan, Italy.
   [Piazza, Cesare] Univ Milan, Dept Oncol & Oncohaematol, Milan, Italy.
   [Ansarin, Mohssen] European Inst Oncol IRCCS, IEO, Div Otolaryngol & Head Neck Surg, Milan, Italy.
   [Benazzo, Marco] Univ Pavia, Dept Otorhinolaryngol, IRCCS Policlin San Matteo Fdn, Pavia, Italy.
RP Vischioni, B (corresponding author), Natl Ctr Oncol Hadrontherapy, Radiat Oncol Clin Dept, Str Campeggi 53, I-27100 Pavia, Italy.
EM barbara.vischioni@cnao.it
RI Locati, Laura D/B-8163-2017; Barcellini, Amelia/AAK-9012-2020
OI Locati, Laura D/0000-0003-3315-2580; Barcellini,
   Amelia/0000-0002-1595-104X; Vischioni, Barbara/0000-0003-4920-2239
CR Achard V, 2020, INT J RADIAT ONCOL, V107, P600, DOI 10.1016/j.ijrobp.2020.03.008
   Akbaba S, 2019, CANCERS, V11, DOI 10.3390/cancers11111705
   Atallah S, 2020, EUR J CANCER, V130, P241, DOI 10.1016/j.ejca.2020.01.023
   Bonora M, 2019, RADIOTHER ONCOL, V133, pS659, DOI 10.1016/S0167-8140(19)31609-3
   Day AT, 2020, ORAL ONCOL, V105, DOI 10.1016/j.oraloncology.2020.104684
   De Felice F, 2020, RADIOTHER ONCOL, V147, P84, DOI 10.1016/j.radonc.2020.03.020
   Givi B, 2020, JAMA OTOLARYNGOL, V146, P579, DOI 10.1001/jamaoto.2020.0780
   Guazzo E, 2020, J NEURO-ONCOL, V150, P419, DOI 10.1007/s11060-019-03366-x
   Jensen AD, 2016, RADIOTHER ONCOL, V118, P272, DOI 10.1016/j.radonc.2015.05.010
   Jensen AD, 2015, CANCER-AM CANCER SOC, V121, P3001, DOI 10.1002/cncr.29443
   Jensen AD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-546
   Koto M, 2018, INT J RADIAT ONCOL, V102, P353, DOI 10.1016/j.ijrobp.2018.05.074
   Koto M, 2016, HEAD NECK-J SCI SPEC, V38, pE2122, DOI 10.1002/hed.24397
   Lambertini M, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000759
   Mizoe J, 2012, RADIOTHER ONCOL, V103, P32, DOI 10.1016/j.radonc.2011.12.013
   Morimoto K, 2014, JPN J CLIN ONCOL, V44, P428, DOI 10.1093/jjco/hyu010
   Orlandi E, 2019, SALIVARY GLAND CANC, DOI [10.1007/978-3-030-02958-6_11., DOI 10.1007/978-3-030-02958-6_11]
   Orlandi E, 2019, EJSO-EUR J SURG ONC, V45, P40, DOI 10.1016/j.ejso.2018.02.007
   Orlandi E, 2016, ORAL ONCOL, V60, P146, DOI 10.1016/j.oraloncology.2016.06.019
   Rackwitz T, 2019, SEMIN ONCOL, V46, P226, DOI 10.1053/j.seminoncol.2019.07.005
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Schulz-Ertner D, 2005, CANCER-AM CANCER SOC, V104, P338, DOI 10.1002/cncr.21158
   Soreide K, 2020, BRIT J SURG, V107, P1250, DOI 10.1002/bjs.11670
   Sulaiman NS, 2018, INT J RADIAT ONCOL, V100, P639, DOI 10.1016/j.ijrobp.2017.11.010
   Thomson DJ, 2020, INT J RADIAT ONCOL, V107, P618, DOI 10.1016/j.ijrobp.2020.04.016
   Vischioni B, 2020, RADIOTHER ONCOL, V145, P172, DOI 10.1016/j.radonc.2020.01.004
NR 26
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD JUL
PY 2020
VL 106
AR 104803
DI 10.1016/j.oraloncology.2020.104803
PG 2
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA LW7IU
UT WOS:000539317900016
OA Green Published
DA 2021-01-01
ER

PT J
AU Seleiman, MF
   Selim, S
   Alhammad, BA
   Alharbi, BM
   Juliatti, FC
AF Seleiman, Mahmoud F.
   Selim, Shaimaa
   Alhammad, Bushra Ahmed
   Alharbi, Basmah M.
   Juliatti, Fernando Cezar
TI WILL NOVEL CORONAVIRUS (COVID-19) PANDEMIC IMPACT AGRICULTURE, FOOD
   SECURITY AND ANIMAL SECTORS?
SO BIOSCIENCE JOURNAL
LA English
DT Article
DE COVID-19; Agriculture; Food security; Integrated pest management (IPM);
   Integrated plant disease management (IPDM); Animal productivity; Economy
ID QUALITY
AB The whole world is in a great danger due to the novel coronavirus (COVID-19) pandemic. In December 2019, the outbreak of COVID-19 took place in Wuhan, China and then rapidly spread all over the world. The current study provides potential expectations for the adverse impact of ( COVID-19). The global infection affected globe on agricultural level such as agriculture, food supplies and animal production sectors. Till today, 29th April 2020, there is no vaccine available for treating novel coronavirus, consequently, the outbreak resulted in closing borders and reducing production following social distancing measures. This short communication illustrates the possible implications and expected outcomes of the outbreak of coronavirus (COVID-19) on agricultural, food security, integrated pest management (IPM), animal productivity; and it predicts, as well, the possible adverse impacts on the economy worldwide. Brazil has one of the most important tropical agriculture in the world, being a leader in soybean production in the world. This chain impacts others such as meat and eggs. The impact of COVID-19 will be positive, encouraging the country to consolidate its leadership in the world market, stimulating exports, the machinery, inputs and fertilizers market, as well as generating employment and income in the country.
C1 [Seleiman, Mahmoud F.] King Saud Univ, Coll Food & Agr Sci, Plant Prod Dept, Riyadh, Saudi Arabia.
   [Seleiman, Mahmoud F.] Menoufia Univ, Fac Agr, Dept Crop Sci, Shibin Al Kawm, Egypt.
   [Selim, Shaimaa] Univ Menoufia, Fac Vet Med, Dept Nutr & Clin Nutr, Shibin Al Kawm, Egypt.
   [Alhammad, Bushra Ahmed] Prince Sattam Bin Abdulaziz Univ, Coll Sci & Humanity Studies, Biol Dept, Al Kharj, Saudi Arabia.
   [Alharbi, Basmah M.] Univ Tabuk, Fac Sci, Dept Biol, Tabuk, Saudi Arabia.
   [Juliatti, Fernando Cezar] Univ Fed Uberlandia, Uberlandia, MG, Brazil.
   [Juliatti, Fernando Cezar] CNPq, Brasilia, DF, Brazil.
RP Seleiman, MF (corresponding author), King Saud Univ, Coll Food & Agr Sci, Plant Prod Dept, Riyadh, Saudi Arabia.; Seleiman, MF (corresponding author), Menoufia Univ, Fac Agr, Dept Crop Sci, Shibin Al Kawm, Egypt.; Juliatti, FC (corresponding author), Univ Fed Uberlandia, Uberlandia, MG, Brazil.; Juliatti, FC (corresponding author), CNPq, Brasilia, DF, Brazil.
EM mseleiman@ksu.edu.sa; juliatti@ufu.br
RI Seleiman, Mahmoud F./AAT-3116-2020; Journal, Bioscience/AAW-3187-2020
CR [Anonymous], 2020, ASS PRESS
   Basso B, 2020, NAT SUSTAIN, V3, P254, DOI 10.1038/s41893-020-0510-0
   Bermejo A., 2004, NEW EC, V11, P164, DOI DOI 10.1111/J.1468-0041.2004.00357.X
   BURGUI D., 2020, CORONAVIRUS ACTION H, DOI [10.1111/j.1468-0041.2004.00357.x, DOI 10.1111/J.1468-0041.2004.00357.X]
   Buxton DR, 1996, ANIM FEED SCI TECH, V59, P37, DOI 10.1016/0377-8401(95)00885-3
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cyranoski D, 2020, NATURE, V579, P18, DOI 10.1038/d41586-020-00548-w
   EURACITY, 2020, GERM REL COR BORD CO, DOI DOI 10.1038/D41586-020-00548-W
   FAO, 2020, COR DIS 2019 COVID 1
   FAO, 2020, NOV COR COVID 19
   FOREIGN AGRICULTURAL SERVICE (FAS), 2020, LIV POULTR WORLD MAR
   GALE F., 2019, REP EC RES SERV
   Goumenou M, 2020, MOL MED REP, V21, P2293, DOI 10.3892/mmr.2020.11037
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hanashima M., 2012, ANN GIS, V18, P57, DOI DOI 10.1080/19475683.2011.647078
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   INFO MIGRANTES, 2020, SPAIN HIR FOR WORK C
   INTERNATIONAL LABOUR ORGANIZATION, 2020, COVID 19 STIM EC LAB
   INTERNATIONAL POULTRY COUNCIL (IPC), 2020, COV 19 IMP GLOB POUL
   INTERNATIONAL POULTRY COUNCIL (IPC), 2020, COR COULD DISR POULT
   JULIATTI F.C., 2020, PROJECOES MANEJO FIT
   Kwon Soo-Jeong, 2019, Journal of Crop Science and Biotechnology, V22, P481, DOI 10.1007/s12892-019-0277-0
   MARLOW S., 2020, COVID 19 EFFECTS FER
   Meuwissen MPM, 2019, AGR SYST, V176, DOI 10.1016/j.agsy.2019.102656
   NFFO, 2020, IMP COR FISH
   POWER M., 2020, EMERALD OPEN RES, V2, P1, DOI [10.35241/emeraldopenres.13539.1, DOI 10.35241/EMERALDODENRES.13539.1.]
   SAKAI A., 2020, EOS CROP MONITORING
   SELEIMAN M.F., 2014, USITC PUBL, V22
   Seleiman MF, 2017, AGR FOOD SCI, V26, P47, DOI 10.23986/afsci.60068
   Seleiman MF, 2013, BIOMASS BIOENERG, V59, P477, DOI 10.1016/j.biombioe.2013.07.021
   SHAHIDI F., 2020, J FOOD BIOACTIVES, V9, DOI [10.31665/JFB.2020.9212, DOI 10.31665/JFB.2020.9212.]
   Siche R, 2020, SCI AGROPEC, V11, P3, DOI 10.17268/sci.agropecu.2020.01.00
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   WHO, 2020, COR DIS COVID 19 PAN
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   WORLD ORGANIZATION FOR ANIMAL HELATH, 2020, QUEST ANS 2019 COR D
   WORLD TRADE ORGANIZATION, 2020, COVID 19 WORLD TRAD
   Wu F, 2013, RISK ANAL, V33, P2168, DOI 10.1111/risa.12064
   WUHAN MUNICIPAL HEALTH COMMISSION, 2019, WUH MUN HLTH COMM BR, DOI [10.1111/risa.12064, DOI 10.1111/RISA.12064]
   Yan YX, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072323
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 41
TC 2
Z9 2
U1 25
U2 34
PU UNIV FEDERAL UBERLANDIA
PI UBERLANDIA
PA AV PARA, 1720 CAMPUS UMUARAMA, UBERLANDIA, 38400-902, BRAZIL
SN 1981-3163
J9 BIOSCI J
JI Biosci. J.
PD JUL-AUG
PY 2020
VL 36
IS 4
BP 1315
EP 1326
DI 10.14393/BJ-v36n4a2020-54560
PG 12
WC Agriculture, Multidisciplinary; Agronomy; Biology
SC Agriculture; Life Sciences & Biomedicine - Other Topics
GA LW3WN
UT WOS:000539076500025
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Rossi, D
AF Rossi, David
TI Metronomic oral vinorelbine and lung cancer therapy during the COVID 19
   pandemic: A single-center experience
SO LUNG CANCER
LA English
DT Article
DE Oral; Vinorelbine; Lung cancer
ID AGENTS
AB COVID 19 pandemic is a worldwide health emergency. Every single Hospital and Department was forced to radically modify clinical practice decreasing or stopping daily activities. Oncological patients had to carry on treatments in order to prevent disease progression and improve their quality of life. However, many health workers may be a potential source of infection if not tested with swabs but this diagnostic procedure was not suitable universally in Italy. Aiming to reduce hospitalization of our patients with advanced lung cancer, vinorelbine in its metronomic formulation is one of the best strategy. Here, we report the experience with oral vinorelbine in a few patients of our Oncology Department.
C1 [Rossi, David] Azienda Osped Osped Riuniti Marche Nord, Struttura Complessa Oncol Med, Pesaro, Italy.
RP Rossi, D (corresponding author), Azienda Osped Osped Riuniti Marche Nord, Struttura Complessa Oncol Med, Pesaro, Italy.
EM david.rossi@ospedalimarchenord.it
CR [Anonymous], 2020, ESMO OPEN
   Calabro L, 2020, LANCET RESP MED, V8, P542, DOI 10.1016/S2213-2600(20)30170-3
   LEHNE G, 1990, ACTA ONCOL, V29, P113, DOI 10.3109/02841869009126530
   Magee DE, 2020, ANN ONCOL, V31, P50, DOI 10.1016/j.annonc.2019.10.008
   Nishino M, 2016, CLIN CANCER RES, V22, P6051, DOI 10.1158/1078-0432.CCR-16-1320
   Pujol JL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220988
NR 6
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-5002
EI 1872-8332
J9 LUNG CANCER
JI Lung Cancer
PD JUL
PY 2020
VL 145
BP 83
EP 84
DI 10.1016/j.lungcan.2020.05.001
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA LW0EO
UT WOS:000538820200012
PM 32416433
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Capuano, A
   Scavone, C
   Racagni, G
   Scaglione, F
AF Capuano, Annalisa
   Scavone, Cristina
   Racagni, Giorgio
   Scaglione, Francesco
CA Italian Soc Pharmacology
TI NSAIDs in patients with viral infections, including Covid-19: Victims or
   perpetrators?
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE NSAIDs; COX; COX-2; Viral infections; COVID-19; Literature review
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; VIRUS-INFECTION; INHIBITION;
   IBUPROFEN; RISK; COMPLICATIONS; INDOMETHACIN; EXPRESSION;
   CYCLOOXYGENASE-2; INFLAMMATION
AB Taking anti-inflammatory drugs, including non-steroidal (NSAIDs), during Covid-19 infection, how much is risky? The French Minister of Health, who has raised an alarm on a possible risk deriving from the use of ibuprofen for the control of fever and other symptoms during the disease, opened the debate a few days ago.
   In this paper we examine available evidence from preclinical and clinical studies that had analysed the role of COX in the inflammatory process and the effects of NSAIDs in patients with infections. Most of the published studies that suggested not protective effects of NSAIDs were mainly performed in vitro or on animals. Therefore, their meaning in humans is to be considered with great caution. Based also on data suggesting protective effects of NSAIDs, we concluded that currently there is no evidence suggesting a correlation between NSAIDs and a worsening of infections. Further studies will be certainly needed to better define the role of NSAIDs and particularly COX2 inhibitors in patients with infections. In the meantime, we must wait for results of the revision started by the PRAC on May 2019 on the association ibuprofen/ketoprofen and worsening of infections. Since nowadays no scientific evidence establishes a correlation between NSAIDS and worsening of COVID-19, patients should be advice against any NSAIDs self-medication when COVID-19 like symptoms are present.
C1 [Capuano, Annalisa; Scavone, Cristina] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.
   [Capuano, Annalisa; Scavone, Cristina] Reg Ctr Pharmacogilance, Naples, Campania Region, Italy.
   [Racagni, Giorgio] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy.
   [Scaglione, Francesco] Univ Milan, Dept Oncol & Oncohematol, Milan, Italy.
   [Scaglione, Francesco] ASST GOM Niguarda Hosp, Clin Pharmacol Unit, Milan, Italy.
RP Capuano, A (corresponding author), Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.; Capuano, A (corresponding author), Reg Ctr Pharmacogilance, Naples, Campania Region, Italy.
EM annalisa.capuano@unicampania.it
FU Italian Society of Pharmacology (SIF)
FX We are grateful for the help and support of the Italian Society of
   Pharmacology (SIF) which includes the following members: Prof Liberato
   Berrino, Dr Marzia Del Re, Prof Renato Bernardini, Prof Cristiano
   Chiamulera, Prof Antonio D'Avolio, Prof Gianluca Trifiro, Prof Luca
   Pani, Prof Emilio Clementi, Prof Romano Danesi, Prof Giuseppe Cirino,
   Prof Alessandro Mugelli, Prof Giambattista Bonanno, Prof Nicoletta
   Brunello, Prof Annamaria De Luca, Prof Patrizia Hrelia, Prof Marco
   Pistis, Prof Carla Ghelardini, Prof Maurizio Taglialatela
CR Alfajaro MM, 2017, J VIROL, V91, DOI 10.1128/JVI.01656-16
   Amici C, 2006, ANTIVIR THER, V11, P1021
   Amici C, 2015, CELL MICROBIOL, V17, P1391, DOI 10.1111/cmi.12446
   [Anonymous], 2020, EMA GIVES ADVICE USE
   Aronoff DM, 2003, MEDICINE, V82, P225, DOI 10.1097/00005792-200307000-00001
   Avril M.F., 2000, MED MALADIES INFECT, V30, P239, DOI [10.1016/S0399-077X(00)89136-2, DOI 10.1016/S0399-077X(00)89136-2]
   Bancos S, 2009, CELL IMMUNOL, V258, P18, DOI 10.1016/j.cellimm.2009.03.007
   Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9
   BRUNBUISSON CJL, 1985, BRIT MED J, V290, P1786, DOI 10.1136/bmj.290.6484.1786
   Cappell MS, 2000, GASTROENTEROL CLIN N, V29, P97, DOI 10.1016/S0889-8553(05)70109-6
   Carey MA, 2005, J IMMUNOL, V175, P6878, DOI 10.4049/jimmunol.175.10.6878
   Chaiamnuay S, 2006, AM J HEALTH-SYST PH, V63, P1837, DOI 10.2146/ajhp050519
   Chen N, 2000, VIROLOGY, V276, P44, DOI 10.1006/viro.2000.0562
   Cianferoni A, 2001, BLOOD, V97, P1742, DOI 10.1182/blood.V97.6.1742
   Dauletbaev N, 2010, RESPIRATION, V79, P234, DOI 10.1159/000255342
   Day RO, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3195
   Fitzgerald DW, 2012, CANCER PREV RES, V5, P34, DOI 10.1158/1940-6207.CAPR-11-0496
   FitzGerald Garret A., 2020, MISGUIDED DRUG ADVIC
   Francois P, 2010, ACTA PAEDIATR, V99, P861, DOI 10.1111/j.1651-2227.2010.01734.x
   Fukunaga K, 2005, J IMMUNOL, V174, P5033, DOI 10.4049/jimmunol.174.8.5033
   Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644
   Gandhi J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00538
   Ghosh R, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/536962
   Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550
   Hama R, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2345
   Hung I.F., 2019, O0815 ECCMID
   Hussain M, 2012, PHARMACOL RES, V66, P7, DOI 10.1016/j.phrs.2012.02.003
   Inaoka M, 2006, EXP DERMATOL, V15, P981, DOI 10.1111/j.1600-0625.2006.00505.x
   IP M, 1990, BRIT J RHEUMATOL, V29, P363
   Jin Y, 2011, J GENE MED, V13, P243, DOI 10.1002/jgm.1558
   Julkunen I, 2000, VACCINE, V19, pS32, DOI 10.1016/S0264-410X(00)00275-9
   KAPLAN HB, 1984, BIOCHEM PHARMACOL, V33, P371, DOI 10.1016/0006-2952(84)90228-4
   Kirkby NS, 2013, BIOCHEM BIOPH RES CO, V438, P249, DOI 10.1016/j.bbrc.2013.07.006
   Langhendries JP, 2016, MED HYPOTHESES, V87, P90, DOI 10.1016/j.mehy.2015.11.012
   Le Bourgeois M, 2016, J PEDIATR-US, V175, P47, DOI 10.1016/j.jpeds.2016.05.025
   Lee SMY, 2008, J INFECT DIS, V198, P525, DOI 10.1086/590499
   Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759
   Li CX, 2014, RECENT PAT ANTI-CANC, V9
   Mikaeloff Y, 2008, BRIT J CLIN PHARMACO, V65, P203, DOI 10.1111/j.1365-2125.2007.02997.x
   Mocarski ES, 2002, P NATL ACAD SCI USA, V99, P3362, DOI 10.1073/pnas.072075899
   Nunez O, 2004, GUT, V53, P1665, DOI 10.1136/gut.2003.038364
   PERIANIN A, 1984, BIOCHEM PHARMACOL, V33, P2239, DOI 10.1016/0006-2952(84)90661-0
   Prower E., 2015, BMJ CASE REP, DOI [10. 1136/bcr-2014-205237 2015:bcr2014205237, DOI 10.1136/BCR-2014-2052372015:BCR2014205237]
   Rafaniello C, 2016, PHARMACOL RES, V104, P108, DOI 10.1016/j.phrs.2015.12.026
   Rocca J, 2016, BRIT J PHARMACOL, V173, P1728, DOI 10.1111/bph.13464
   Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479
   Souyri C, 2008, CLIN EXP DERMATOL, V33, P249, DOI 10.1111/j.1365-2230.2007.02652.x
   VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Voiriot G, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060786
   Wongrakpanich S, 2018, AGING DIS, V9, P143, DOI 10.14336/AD.2017.0306
NR 50
TC 9
Z9 9
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JUL
PY 2020
VL 157
AR 104849
DI 10.1016/j.phrs.2020.104849
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LV9OY
UT WOS:000538778100023
PM 32360482
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Galimberti, S
   Baldini, C
   Barate, C
   Ricci, F
   Balducci, S
   Grassi, S
   Ferro, F
   Buda, G
   Benedetti, E
   Fazzi, R
   Baglietto, L
   Lucenteforte, E
   Di Paolo, A
   Petrini, M
AF Galimberti, Sara
   Baldini, Chiara
   Barate, Claudia
   Ricci, Federica
   Balducci, Serena
   Grassi, Susanna
   Ferro, Francesco
   Buda, Gabriele
   Benedetti, Edoardo
   Fazzi, Rita
   Baglietto, Laura
   Lucenteforte, Ersilia
   Di Paolo, Antonello
   Petrini, Mario
TI The CoV-2 outbreak: how hematologists could help to fight Covid-19
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE COVID-19; Ruxolitinib; TKIs; Begelomab; Baricitinib; Tocilizumab; GVHD;
   MAS
ID CHRONIC MYELOID-LEUKEMIA; VERSUS-HOST-DISEASE; MACROPHAGE ACTIVATION
   SYNDROME; INFLAMMATION; DASATINIB; RUXOLITINIB; INTERFERON; NILOTINIB;
   IMATINIB; BACTERIAL
AB COVID-19 is a medical emergency, with 20 % of patients presenting with severe clinical manifestations. From the pathogenetic point of view, COVID-19 mimics two other well-known diseases characterized by cytokine storm and hyper-activation of the immune response, with consequent organ damage: acute graft-versus-host disease (aGVHD) and macrophage activation syndrome (MAS). Hematologists are confident with these situations requiring a prompt therapeutic approach for switching off the uncontrolled cytokine release; here, we discuss pros and cons of drugs that are already employed in hematology in the light of their possible application in COVID-19. The most promising drugs might be: Ruxolitinib, a JAK1/2 inhibitor, with a rapid and powerful anticytokine effect, tyrosine kinase inhibitors (TKIs), with their good anti-inflammatory properties, and perhaps the anti-Cd26 antibody Begelomab. We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed.
C1 [Galimberti, Sara; Baldini, Chiara; Ricci, Federica; Balducci, Serena; Grassi, Susanna; Ferro, Francesco; Buda, Gabriele; Baglietto, Laura; Lucenteforte, Ersilia; Di Paolo, Antonello; Petrini, Mario] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy.
   [Barate, Claudia; Benedetti, Edoardo; Fazzi, Rita] AOUP, Pisa, Italy.
RP Galimberti, S (corresponding author), Osped S Chiara, Hematol, Edificio 11, I-56126 Pisa, Italy.
EM sara.galimberti@med.unipi.it
RI Di Paolo, Antonello/K-1413-2018
OI Di Paolo, Antonello/0000-0002-2661-6183; Lucenteforte,
   Ersilia/0000-0001-5608-5902; Baglietto, Laura/0000-0002-8193-7529
FU University of Pisa
FX The experimental part of the work has been supported by University of
   Pisa with PRA 2018 grant (PI, Prof. Petrini). This article is dedicated
   to all patients and all physicians that every day have to fight COVID-19
   and to all people that died during the pandemic.
CR Al-Salama ZT, 2018, DRUGS, V78, P761, DOI 10.1007/s40265-018-0908-4
   Albeituni S, 2019, BLOOD, V134, P147, DOI 10.1182/blood.2019000761
   Alsuliman T, 2020, CURR RES TRANSL MED, V68, P71, DOI 10.1016/j.retram.2019.10.001
   Alves R, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-019-02194-x
   Aqrawi LA, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1961-4
   Aratani Y, 2018, ARCH BIOCHEM BIOPHYS, V640, P47, DOI 10.1016/j.abb.2018.01.004
   Bacigalupo A, 2020, BONE MARROW TRANSPL, V55, P1580, DOI 10.1038/s41409-020-0855-z
   Bahal D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194797
   Bao JP, 2020, AGING-US, V12, P5152, DOI 10.18632/aging.102937
   Bergeron A, 2007, AM J RESP CRIT CARE, V176, P814, DOI 10.1164/rccm.200705-715CR
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Biggioggero M, 2019, DRUG DES DEV THER, V13, P57, DOI 10.2147/DDDT.S150580
   Blauvelt A, 2020, PATIENT PREFER ADHER, V14, P517, DOI 10.2147/PPA.S233993
   Bocchia M, 2016, ONCOTARGET, V7, P72311, DOI 10.18632/oncotarget.11100
   Bottazzi B, 2016, J HEPATOL, V64, P1416, DOI 10.1016/j.jhep.2016.02.029
   Brennan FH, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.98254
   Busilacchi EM, 2020, BIOL BLOOD MARROW TR, V26, P823, DOI 10.1016/j.bbmt.2020.01.014
   Busilacchi EM, 2018, BIOL BLOOD MARROW TR, V24, P267, DOI 10.1016/j.bbmt.2017.10.039
   Cai W, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131355
   Cao L, 2019, DEV COMP IMMUNOL, V96, P135, DOI 10.1016/j.dci.2019.03.005
   Caocci G, 2014, LEUKEMIA, V28, P225, DOI 10.1038/leu.2013.235
   Caocci G, 2020, INT J CARDIOL, V301, P163, DOI 10.1016/j.ijcard.2019.10.036
   Caocci G, 2018, AM J HEMATOL, V93, pE159, DOI 10.1002/ajh.25102
   Caocci G, 2015, EXP HEMATOL, V43, P1015, DOI 10.1016/j.exphem.2015.08.004
   Cardenas A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11058-3
   Cattaneo A, 2017, NEUROBIOL AGING, V49, P60, DOI 10.1016/j.neurobiolaging.2016.08.019
   Cheng Y, 2020, NEURAL REGEN RES, V15, P676, DOI 10.4103/1673-5374.266924
   Cortes JE, 2018, J CLIN ONCOL, V36, P231, DOI 10.1200/JCO.2017.74.7162
   Cortes JE, 2016, J CLIN ONCOL, V34, P2333, DOI 10.1200/JCO.2015.64.8899
   COVID-19 National Emergency Response Center Epidemiology and Case Management Team Korea Centers for Disease Control and Prevention, 2020, Osong Public Health Res Perspect, V11, P8, DOI 10.24171/j.phrp.2020.11.1.03
   de Lavallade H, 2008, BRIT J HAEMATOL, V141, P745, DOI 10.1111/j.1365-2141.2008.07108.x
   Deretic V, 2018, AUTOPHAGY, V14, P243, DOI 10.1080/15548627.2017.1402992
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Duan YJ, 2020, FA YI XUE ZA ZHI, V36, DOI [10.12116/j.issn.1004-5619.2020.02.001, DOI 10.12116/J.ISSN.1004-5619.2020.02.001]
   Dumas PY, 2019, CANCER MED-US, V8, P4976, DOI 10.1002/cam4.2371
   Ernst M, 2002, J EXP MED, V196, P589, DOI 10.1084/jem.20020873
   Fava C, 2019, HAEMATOLOGICA, V104, P1589, DOI 10.3324/haematol.2018.205054
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Funel N, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/2851949
   Gale RP, 1998, BLOOD, V91, P1810
   Gao P, 2018, J INTERF CYTOK RES, V38, P290, DOI 10.1089/jir.2018.0034
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grom AA, 2016, NAT REV RHEUMATOL, V12, P259, DOI 10.1038/nrrheum.2015.179
   Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017
   Gu W, 2020, J CLIN IMMUNOL, V40, P147, DOI 10.1007/s10875-019-00702-8
   Gui T, 2017, BIOTECH HISTOCHEM, V92, P107, DOI 10.1080/10520295.2017.1278792
   Hasselbalch HC, 2019, SEMIN IMMUNOPATHOL, V41, P5, DOI 10.1007/s00281-018-0700-2
   Hay KA, 2018, BRIT J HAEMATOL, V183, P364, DOI 10.1111/bjh.15644
   Hochhaus A, 2016, LEUKEMIA, V30, P1044, DOI 10.1038/leu.2016.5
   Hruska P, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218323
   Hsu KL, 2012, NAT CHEM BIOL, V8, P999, DOI [10.1038/NCHEMBIO.1105, 10.1038/nchembio.1105]
   Hughes A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00469
   Hui EF, 2017, SCIENCE, V355, P1428, DOI 10.1126/science.aaf1292
   Li H, 2020, EXPERT REV HEMATOL, V13, P565, DOI 10.1080/17474086.2020.1738214
   Iacobellis G, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108125
   Isaac R, 2017, CELL DEATH DIFFER, V24, P132, DOI 10.1038/cdd.2016.108
   Isfort Susanne, 2018, Recent Results Cancer Res, V212, P87, DOI 10.1007/978-3-319-91439-8_4
   Iurlo A, 2018, ANN HEMATOL, V97, P95, DOI 10.1007/s00277-017-3144-1
   Jagasia M., 2020, BLOOD, DOI [10.1182/blood.2020004823pii:blood.2020004823., DOI 10.1182/BLOOD.2020004823PII:BLOOD.2020004823]
   Jain P, 2013, CURR TREAT OPTION ON, V14, P127, DOI 10.1007/s11864-013-0234-8
   Joshua DE, 1997, BLOOD REV, V11, P191, DOI 10.1016/S0268-960X(97)90019-9
   Kattner AS, 2020, ANN HEMATOL, V99, P847, DOI 10.1007/s00277-020-03968-w
   Kerep AZ, 2019, BONE MARROW TRANSPL, V54, P76, DOI 10.1038/s41409-018-0224-3
   Khalid Farhan, 2020, Hematol Oncol Stem Cell Ther, DOI 10.1016/j.hemonc.2020.02.003
   Kharfan-Dabaja MA, 2009, BIOL BLOOD MARROW TR, V15, P1005, DOI 10.1016/j.bbmt.2009.04.003
   King-Kallimanis BL, 2020, QUAL LIFE RES, V29, P1903, DOI 10.1007/s11136-020-02448-y
   Kitisin K, 2007, ONCOGENE, V26, P7103, DOI 10.1038/sj.onc.1210513
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   Kroller-Schon S, 2018, EUR HEART J, V39, P3528, DOI 10.1093/eurheartj/ehy333
   Krzesniak M, 2020, CELL SIGNAL, V69, DOI 10.1016/j.cellsig.2020.109552
   Kusuyama J, 2016, J LIPID RES, V57, P1806, DOI 10.1194/jlr.M067207
   Lara-Guzman OJ, 2018, REDOX BIOL, V15, P1, DOI 10.1016/j.redox.2017.11.017
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lee S.C., 2014, BMJ CASE REP, DOI [10.1136/bcr-2014-204950, DOI 10.1136/BCR-2014-204950]
   Lelubre C, 2017, J LEUKOCYTE BIOL, V101, P1419, DOI 10.1189/jlb.5A0516-240R
   Leonardi I, 2018, SCIENCE, V359, P232, DOI 10.1126/science.aao1503
   Li H, 2019, BRIT J PHARMACOL, V176, P2209, DOI 10.1111/bph.14667
   Li N, 2020, WORLD J GASTROENTERO, V26, P478, DOI 10.3748/wjg.v26.i5.478
   Lind-Holst Marie, 2019, BMJ Case Rep, V12, DOI 10.1136/bcr-2019-229708
   Liong S, 2017, AM J REPROD IMMUNOL, V78, DOI 10.1111/aji.12696
   Lonskaya I, 2015, NEUROSCIENCE, V304, P316, DOI 10.1016/j.neuroscience.2015.07.070
   Ma L, 2017, STROKE, V48, P3108, DOI 10.1161/STROKEAHA.117.017681
   MacDonald KPA, 2017, J CLIN INVEST, V127, P2452, DOI 10.1172/JCI90593
   Maiti A, 2020, CANCER-AM CANCER SOC, V126, P1502, DOI 10.1002/cncr.32627
   Mangan MS, 2017, IMMUNOL CELL BIOL, V95, P884, DOI 10.1038/icb.2017.59
   Markic J, 2013, EUR J PEDIATR, V172, P1363, DOI 10.1007/s00431-013-2047-y
   Marschallinger J, 2020, NAT NEUROSCI, V23, P194, DOI 10.1038/s41593-019-0566-1
   Matsuo K, 2018, J INVEST DERMATOL, V138, P1764, DOI 10.1016/j.jid.2018.02.027
   McManigle W, 2019, HUM IMMUNOL, V80, P393, DOI 10.1016/j.humimm.2019.03.003
   Merhi Z, 2015, REPROD SCI, V22, P1220, DOI 10.1177/1933719115572484
   Miklos D, 2017, BLOOD, V130, P2243, DOI 10.1182/blood-2017-07-793786
   Moradinejad MH, 2011, MINERVA PEDIATR, V63, P459
   Nagaishi T, 2006, IMMUNITY, V25, P769, DOI 10.1016/j.immuni.2006.08.026
   Nassereddine S, 2017, ANTICANCER RES, V37, P1547, DOI 10.21873/anticanres.11483
   Nicastri E, 2020, EUROSURVEILLANCE, V25, P12, DOI 10.2807/1560-7917.ES.2020.25.11.2000230
   Niture Suryakant, 2019, J Cell Immunol, V1, P29
   Olivieri A, 2009, BLOOD, V114, P709, DOI 10.1182/blood-2009-02-204156
   Ono Takashi, 2020, Am J Ophthalmol Case Rep, V18, P100660, DOI 10.1016/j.ajoc.2020.100660
   Ostendorf T, 2020, IMMUNITY, V52, P591, DOI 10.1016/j.immuni.2020.03.009
   Prokunina-Olsson L, 2020, J EXP MED, V217, DOI 10.1084/jem.20200653
   Quero L, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03087
   Raanani P, 2002, ACTA HAEMATOL-BASEL, V107, P133, DOI 10.1159/000057631
   Ratcliffe C, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00144
   Ribes S, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-1700-4
   Ribon M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01346
   Rosenberg HF, 2015, INT J MOL SCI, V16, P15442, DOI 10.3390/ijms160715442
   Sacha T, 2019, FUTURE ONCOL, V15, P953, DOI 10.2217/fon-2018-0468
   Sanchez-Ortega I, 2016, CROAT MED J, V57, P247, DOI 10.3325/cmj.2016.57.247
   Sarantopoulos S, 2019, BLOOD, V133, P1191, DOI 10.1182/blood-2018-04-785899
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Schulert GS, 2015, ANNU REV MED, V66, P145, DOI 10.1146/annurev-med-061813-012806
   Scott LJ, 2017, DRUGS, V77, P1029, DOI 10.1007/s40265-017-0752-y
   Shi FX, 2020, KOREAN J RADIOL, V21, P537, DOI 10.3348/kjr.2020.0181
   Shi Y, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6941368
   Silbereisen A, 2019, JDR CLIN TRANSL RES, V4, P352, DOI 10.1177/2380084419844937
   Slade JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160511
   Smyth L, 2019, BRIT J HAEMATOL, V184, P469, DOI 10.1111/bjh.15118
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Sung PS, 2020, ADV EXP MED BIOL, V1204, P57, DOI 10.1007/978-981-15-1580-4_3
   Sweet K, 2018, LEUKEMIA RES, V74, P89, DOI 10.1016/j.leukres.2018.10.002
   Thompson PA, 2017, BRIT J HAEMATOL, V177, P543, DOI 10.1111/bjh.14524
   Tiribelli M, 2019, ANN HEMATOL, V98, P2609, DOI 10.1007/s00277-019-03802-y
   Touzelet O, 2020, MOL CELL PROTEOMICS, V19, P793, DOI 10.1074/mcp.RA119.001546
   Treon SP, 2020, BLOOD, V135, P1912, DOI 10.1182/blood.2020006288
   Trzybulska D, 2014, CELL IMMUNOL, V292, P40, DOI 10.1016/j.cellimm.2014.08.009
   Tsou YA, 2017, BIOCHEM CELL BIOL, V95, P394, DOI 10.1139/bcb-2016-0047
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Varughese T, 2018, CLIN INFECT DIS, V67, P687, DOI 10.1093/cid/ciy175
   Verstovsek S, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0527-7
   Waller EK, 2019, BIOL BLOOD MARROW TR, V25, P2002, DOI 10.1016/j.bbmt.2019.06.023
   Wang C, 2018, J BIOL CHEM, V293, P14839, DOI 10.1074/jbc.RA118.002907
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   Wang ZQ, 2017, ONCOTARGET, V8, P12664, DOI 10.18632/oncotarget.8610
   Watek M, 2019, MED SCI MONITOR, V25, P1452, DOI 10.12659/MSM.911904
   Xu TH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00184
   Yalniz FF, 2018, BIOL BLOOD MARROW TR, V24, P1920, DOI 10.1016/j.bbmt.2018.03.008
   Yildiz Halil, 2020, QJM, DOI 10.1093/qjmed/hcaa011
   Yoon BH, 2019, AM J OBSTET GYNECOL, V221, DOI 10.1016/j.ajog.2019.03.018
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Yun Y, 2020, ALLERGOL INT, V69, P232, DOI 10.1016/j.alit.2019.11.002
   Zaja F, 2007, BONE MARROW TRANSPL, V40, P273, DOI 10.1038/sj.bmt.1705725
   Zeiser R, 2015, LEUKEMIA, V29, P2062, DOI 10.1038/leu.2015.212
   Zhang CW, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-019-0655-8
   Zhou Q, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000157corr1
NR 144
TC 8
Z9 8
U1 4
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JUL
PY 2020
VL 157
AR 104866
DI 10.1016/j.phrs.2020.104866
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LV9OY
UT WOS:000538778100036
PM 32387301
OA Green Published
DA 2021-01-01
ER

PT J
AU Habtemariam, S
   Nabavi, SF
   Ghavami, S
   Cismaru, CA
   Berindan-Neagoe, I
   Nabavi, SM
AF Habtemariam, Solomon
   Nabavi, Seyed Fazel
   Ghavami, Saeid
   Cismaru, Cosmin Andrei
   Berindan-Neagoe, Ioana
   Nabavi, Seyed Mohammad
TI Possible use of the mucolytic drug, bromhexine hydrochloride, as a
   prophylactic agent against SARS-CoV-2 infection based on its action on
   the Transmembrane Serine Protease 2
SO PHARMACOLOGICAL RESEARCH
LA English
DT Letter
C1 [Habtemariam, Solomon] Univ Greenwich, Pharmacognosy Res Labs & Herbal Anal Serv, Cent Ave, Chatham ME4 4TB, Kent, England.
   [Nabavi, Seyed Fazel; Nabavi, Seyed Mohammad] Baqiyatallah Univ Med Sci, Baqiyatallah Hosp, Tehran, Iran.
   [Ghavami, Saeid] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada.
   [Cismaru, Cosmin Andrei; Berindan-Neagoe, Ioana] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom Biomed & Translat Med, Cluj Napoca, Romania.
   [Cismaru, Cosmin Andrei] Iuliu Hatieganu Univ Med & Pharm Cluj Napoca, Dept Funct Sci Immunol & Allergol, Cluj Napoca, Romania.
   [Berindan-Neagoe, Ioana] Iuliu Hatieganu Univ Med & Pharm Cluj Napoca, Res Ctr Adv Med Medfuture, Cluj Napoca, Romania.
   [Berindan-Neagoe, Ioana] Oncol Inst Prof Dr Ion Chiricuta, Funct Genom & Expt Pathol, Cluj Napoca, Romania.
RP Nabavi, SM (corresponding author), Baqiyatallah Univ Med Sci, Baqiyatallah Hosp, Tehran, Iran.
EM Nabavi208@gmail.com
RI Cismaru, Cosmin Andrei/AAD-1810-2020; Nabavi, Seyed Fazel/A-2223-2010
OI Cismaru, Cosmin Andrei/0000-0001-5716-8101; Ghavami,
   Saeid/0000-0001-5948-508X; HABTEMARIAM, SOLOMON/0000-0001-6743-2244
CR Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Limburg H, 2019, J VIROL, V93, DOI 10.1128/JVI.00649-19
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Zmora P, 2018, J BIOL CHEM, V293, P13863, DOI 10.1074/jbc.RA118.001273
NR 7
TC 5
Z9 6
U1 1
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JUL
PY 2020
VL 157
AR 104853
DI 10.1016/j.phrs.2020.104853
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LV9OY
UT WOS:000538778100026
PM 32360584
OA Green Published
DA 2021-01-01
ER

PT J
AU Kelleni, MT
AF Kelleni, Mina T.
TI Nitazoxanide/azithromycin combination for COVID-19: A suggested new
   protocol for early management
SO PHARMACOLOGICAL RESEARCH
LA English
DT Letter
DE SARS CoV-2; COVID-19; Nitazoxanide; Azithromycin; Interferons
ID AZITHROMYCIN; NITAZOXANIDE; IVERMECTIN; RESPONSES
AB Azithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019. Further, BCG vaccination is being considered for clinical trials aiming to test its potential for lowering COVID-19 morbidity and mortality. This article illustrates some structural and functional relationships that may gather these drugs and the author, basing on a combined pathophysiological and pharmacological approach, recommends the FDA-approved antidiarrhea drug; nitazoxanide, which has been previously suggested but unfortunately widely ignored, to be tested in combination with azithromycin for their potential activity against SARS CoV-2, soonest. The author also recommends testing their combined administration as early during the clinical course of COVID-19 as possible. Further, basing on the same represented concept, the author suggests more trials for interferons to be tested against SARS CoV-2, especially in severe and critical COVID-19 cases.
C1 [Kelleni, Mina T.] Menia Univ, Coll Med, Pharmacol Dept, Al Minya, Egypt.
   [Kelleni, Mina T.] Jouf Univ, Coll Pharm, Pharmacol Dept, Sakakah, Saudi Arabia.
RP Kelleni, MT (corresponding author), Menia Univ, Coll Med, Pharmacol Dept, Al Minya, Egypt.
EM mina.kelleni@mu.edu.eg
RI Kelleni, Mina/L-5463-2018
OI Kelleni, Mina/0000-0001-6290-6025
CR Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Coscione S, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006825
   Gautret, 2020, HYDROXYCHLOROQUINE A, DOI [10.1016/j.ijantimicag.2020.105949., DOI 10.1016/J.IJANTIMICAG.2020.105949]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   Haffizulla J, 2014, LANCET INFECT DIS, V14, P609, DOI 10.1016/S1473-3099(14)70717-0
   Kandeel M, 2012, INDIAN J PHARM SCI, V74, P592, DOI 10.4103/0250-474X.110635
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Menzel M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28698
   Padmanabhan S., 2020, POTENTIAL DUAL THERA
   Ramos-Soriano Asuncion G, 2015, Case Rep Gastroenterol, V9, P36, DOI 10.1159/000375116
   Riddell LA, 2001, AIDS RES HUM RETROV, V17, P789, DOI 10.1089/088922201750251981
   Rosenthal P.J., 2017, BASIC CLIN PHARM E, V14e
   Rossignol JF, 2014, ANTIVIR RES, V110, P94, DOI 10.1016/j.antiviral.2014.07.014
   Rossingol JF, 2016, J INFECT PUBLIC HEAL, V9, P227, DOI 10.1016/j.jiph.2016.04.001
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Smit MR, 2018, LANCET INFECT DIS, V18, P615, DOI 10.1016/S1473-3099(18)30163-4
   SOBOSLAY PT, 1994, CLIN EXP IMMUNOL, V96, P238, DOI 10.1111/j.1365-2249.1994.tb06548.x
   SRLF S SFMU GFRUP SPILF, 2020, REC EXP RES CAR PAT
   Wardhana, 2011, Acta Med Indones, V43, P185
   Wetzel D.M., 2017, GOODMAN GILMANS PHAR, V13e
   Williams Eni, 2020, INTERFERON POTENTIAL
   Zhou Q, 2020, INTERFERON A2B TREAT, DOI [10.1101/2020.04.06.20042580, DOI 10.1101/2020.04.06.20042580]
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 24
TC 13
Z9 14
U1 4
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JUL
PY 2020
VL 157
AR 104874
DI 10.1016/j.phrs.2020.104874
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LV9OY
UT WOS:000538778100021
PM 32360581
OA Green Published
DA 2021-01-01
ER

PT J
AU Yang, RC
   Liu, H
   Bai, C
   Wang, YC
   Zhang, XH
   Guo, R
   Wu, SY
   Wang, JX
   Leung, E
   Chang, H
   Li, P
   Liu, TG
   Wang, Y
AF Yang, Ruocong
   Liu, Hao
   Bai, Chen
   Wang, Yingchao
   Zhang, Xiaohui
   Guo, Rui
   Wu, Siying
   Wang, Jianxun
   Leung, Elaine
   Chang, Hang
   Li, Peng
   Liu, Tiegang
   Wang, Yi
TI Chemical composition and pharmacological mechanism of Qingfei Paidu
   Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019
   (COVID-19): In silico and experimental study
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Qingfei Paidu Decoction; Ma Xing Shi Gan Decoction; Corona virus disease
   2019; Network pharmacology; Traditional Chinese medicine
ID NATURAL-PRODUCTS; LICORICE; THERAPY; TANG
AB The Coronavirus Disease 2019 (COVID-19) pandemic has become a huge threaten to global health, which raise urgent demand of developing efficient therapeutic strategy. The aim of the present study is to dissect the chemical composition and the pharmacological mechanism of Qingfei Paidu Decoction (QFPD), a clinically used Chinese medicine for treating COVID-19 patients in China. Through comprehensive analysis by liquid chromatography coupled with high resolution mass spectrometry (MS), a total of 129 compounds of QFPD were putatively identified. We also constructed molecular networking of mass spectrometry data to classify these compounds into 14 main clusters, in which exhibited specific patterns of flavonoids (45 %), glycosides (15 %), carboxylic acids (10 %), and saponins (5 %). The target network model of QFPD, established by predicting and collecting the targets of identified compounds, indicated a pivotal role of Ma Xing Shi Gan Decoction (MXSG) in the therapeutic efficacy of QFPD. Supportively, through transcriptomic analysis of gene expression after MXSG administration in rat model of LPS-induced pneumonia, the thrombin and Toll-like receptor (TLR) signaling pathway were suggested to be essential pathways for MXSG mediated anti-inflammatory effects. Besides, changes in content of major compounds in MXSG during decoction were found by the chemical analysis. We also validate that one major compound in MXSG, i.e. glycyrrhizic acid, inhibited TLR agonists induced IL-6 production in macrophage. In conclusion, the integration of in silico and experimental results indicated that the therapeutic effects of QFPD against COVID-19 may be attributed to the anti-inflammatory effects of MXSG, which supports the rationality of the compatibility of TCM.
C1 [Yang, Ruocong; Bai, Chen; Wu, Siying; Wang, Jianxun; Li, Peng; Liu, Tiegang] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Bei San Huan East Rd, Beijing 100029, Peoples R China.
   [Liu, Hao; Wang, Yingchao; Zhang, Xiaohui; Guo, Rui; Wang, Yi] Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou 310058, Peoples R China.
   [Leung, Elaine] Macau Univ Sci & Technol, Macau, Peoples R China.
   [Chang, Hang] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA.
RP Liu, TG (corresponding author), Beijing Univ Chinese Med, Sch Tradit Chinese Med, Bei San Huan East Rd, Beijing 100029, Peoples R China.; Wang, Y (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou 310058, Peoples R China.
EM liutg@bucm.edu.cn; zjuwangyi@zju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81822047]; Double First-Class Personnel
   Office-High Level Scientific Research Team Research Fund
   [1000061020100]; National Key R&D Program of China [2017YFC1700106];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2019-JYB-JS-007,
   2019-JYB-XS-004]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2019M650593]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81822047), Double First-Class Personnel Office-High Level
   Scientific Research Team Research Fund (1000061020100), National Key R&D
   Program of China (2017YFC1700106), Fundamental Research Funds for the
   Central Universities (2019-JYB-JS-007, 2019-JYB-XS-004), China
   Postdoctoral Science Foundation (2019M650593).
CR [Anonymous], LAUNCH GLOB MEG 4 MO
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Chen L, 2020, HEALTH COMMUN, DOI 10.1080/10410236.2020.1751384
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   DENNIS G, 2003, GENOME BIOL, V4
   Ding J., 2017, MAT MED RES, V28, P1167
   Du Xiuxia, 2020, Methods Mol Biol, V2104, P25, DOI 10.1007/978-1-0716-0239-3_3
   Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381
   Fei YX, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01361
   FLORDAL PA, 1992, THROMB RES, V68, P295, DOI 10.1016/0049-3848(92)90086-P
   Gao K, 2018, PHARMACOL RES, V130, P93, DOI 10.1016/j.phrs.2018.01.011
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Goodrich JK, 2016, CELL HOST MICROBE, V19, P731, DOI 10.1016/j.chom.2016.04.017
   Goodrich JK, 2014, CELL, V159, P789, DOI 10.1016/j.cell.2014.09.053
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hardy RS, 2018, ENDOCR REV, V39, P519, DOI 10.1210/er.2018-00097
   Hsieh CF, 2012, J ETHNOPHARMACOL, V143, P57, DOI 10.1016/j.jep.2012.05.061
   Jackson MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05184-7
   Jackson MA, 2016, PEERJ, V4, DOI 10.7717/peerj.2341
   Kao ST, 2001, IMMUNOPHARM IMMUNOT, V23, P445, DOI 10.1081/IPH-100107343
   Kao TC, 2010, J AGR FOOD CHEM, V58, P8623, DOI 10.1021/jf101841r
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Li P, 2019, PHARMACOL RES, V141, P104, DOI 10.1016/j.phrs.2018.12.016
   Li XJY, 2019, PHARMACOL RES, V144, P210, DOI 10.1016/j.phrs.2019.04.025
   Lu H, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104773
   Mehta P., 2020, LANCET
   N.H.C.o.t. PRC S.A.o.T.C. Medicine, CHINESE J VIRAL DIS, P1
   Nazari S, 2017, PHYTOTHER RES, V31, P1635, DOI 10.1002/ptr.5893
   Oray M, 2016, EXPERT OPIN DRUG SAF, V15, P457, DOI 10.1517/14740338.2016.1140743
   Pluskal T, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-395
   Raoqiong W., 2020, PHARM CLIN CHIN MAT, P1
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Shen L, 2020, J MED ECON, V23, P456, DOI 10.1080/13696998.2020.1717500
   Tian GH, 2019, PHARMACOL RES, V144, P158, DOI 10.1016/j.phrs.2019.04.012
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang C, 2011, ANN INTERN MED, V155, P217, DOI 10.7326/0003-4819-155-4-201108160-00005
   Wang MX, 2016, NAT BIOTECHNOL, V34, P828, DOI 10.1038/nbt.3597
   Wiseman F.Y. Nigel, 2002, INTRO ENGLISH TERMIN
   Wu Y, 2019, NUCLEIC ACIDS RES, V47, pD1110, DOI 10.1093/nar/gky1021
   Xu HY, 2019, NUCLEIC ACIDS RES, V47, pD976, DOI 10.1093/nar/gky987
   Xu K, 2020, ZHEJIANG DA XUE XUE, V49, P1, DOI DOI 10.3785/J.ISSN.1008-9292.2020.02.02.0E0
   Xu X, 2016, PHARMACOL RES, V103, P105, DOI 10.1016/j.phrs.2015.11.015
   Yang C.H., 2009, RESUSCITATION, P1873
   Yilan Z., 2011, MODERN PREV MED, V38, P2227
NR 46
TC 20
Z9 20
U1 33
U2 42
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JUL
PY 2020
VL 157
AR 104820
DI 10.1016/j.phrs.2020.104820
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LV9OY
UT WOS:000538778100010
PM 32360484
OA Green Published
DA 2021-01-01
ER

PT J
AU Cunningham, L
   Kimber, I
   Basketter, DA
   McFadden, JP
AF Cunningham, Louise
   Kimber, Ian
   Basketter, David Arthur
   McFadden, John Paul
TI Why judiciously timed anti-IL 6 therapy may be of benefit in severe
   COVID-19 infection
SO AUTOIMMUNITY REVIEWS
LA English
DT Letter
DE Interleukin-6; IL-6; Perforin; COVID-19; SARS-CoV-2; Natural killer
   cells; Macrophage activation syndrome; Cytokine storm
ID DYSFUNCTION
C1 [Cunningham, Louise; McFadden, John Paul] Guys & St Thomas Hosp, St Johns Inst Dermatol, London, England.
   [Kimber, Ian] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England.
   [Basketter, David Arthur] DABMEB Consultancy Ltd, Sharnbrook, Beds, England.
RP Cunningham, L (corresponding author), Guys & St Thomas Hosp, St Johns Inst Dermatol, London, England.
EM louise.cunningham@gstt.nhs.uk
OI Cunningham, Louise/0000-0002-2009-3588
CR Cifaldi L, 2015, ARTHRITIS RHEUMATOL, V67, P3037, DOI 10.1002/art.39295
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Schulert GS, 2019, ARTHRITIS RHEUMATOL, V71, P1943, DOI 10.1002/art.41073
   Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057
   Voskoboinik I, 2015, NAT REV IMMUNOL, V15, P388, DOI 10.1038/nri3839
   Vredevoe DL, 2004, AM J CARDIOL, V93, P1007, DOI 10.1016/j.amjcard.2003.12.054
NR 6
TC 4
Z9 4
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1568-9972
EI 1873-0183
J9 AUTOIMMUN REV
JI Autoimmun. Rev.
PD JUL
PY 2020
VL 19
IS 7
SI SI
AR 102563
DI 10.1016/j.autrev.2020.102563
PG 2
WC Immunology
SC Immunology
GA LV0MB
UT WOS:000538137300010
PM 32380318
OA Green Published
DA 2021-01-01
ER

PT J
AU McGonagle, D
   Sharif, K
   O'Regan, A
   Bridgewood, C
AF McGonagle, Dennis
   Sharif, Kassem
   O'Regan, Anthony
   Bridgewood, Charlie
TI Re: Patiently waiting for the results of anti-IL 6 therapy in severe
   COVID-19 infection
SO AUTOIMMUNITY REVIEWS
LA English
DT Letter
C1 [McGonagle, Dennis; Sharif, Kassem; Bridgewood, Charlie] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med LIRMM, Leeds, W Yorkshire, England.
   [McGonagle, Dennis] Leeds Teaching Hosp, Leeds Biomed Res Ctr BRC, Natl Inst Hlth Res NIHR, Leeds, W Yorkshire, England.
   [Sharif, Kassem] Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Tel Aviv, Israel.
   [O'Regan, Anthony] Natl Univ Ireland, Med, Galway, Ireland.
   [O'Regan, Anthony] Saolta Univ, Healthcare Grp, Galway, Ireland.
RP McGonagle, D (corresponding author), Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England.
EM d.g.mcgonagle@leeds.ac.uk
OI Bridgewood, Charlie/0000-0001-6797-4633
CR Caso F, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102524
   Chatterjee S, 2020, RHEUMATOLOGY, V59
   Cunninghama K.I. L, 2020, AUTOIMMUN REV
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   McGonagle D, 2006, PLOS MED, V3, P1242, DOI 10.1371/journal.pmed.0030297
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Velazquez-Salinas L, 2019, ROLE INTERLEUKIN 6 V, V10
   Yang ML, 2017, SCI REP-UK, V7, DOI 10.1038/srep43829
NR 8
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1568-9972
EI 1873-0183
J9 AUTOIMMUN REV
JI Autoimmun. Rev.
PD JUL
PY 2020
VL 19
IS 7
SI SI
AR 102560
DI 10.1016/j.autrev.2020.102560
PG 2
WC Immunology
SC Immunology
GA LV0MB
UT WOS:000538137300007
PM 32361193
OA Green Published
DA 2021-01-01
ER

PT J
AU Ramirez, I
   De la Viuda, E
   Baquedano, L
   Coronado, P
   Llaneza, P
   Mendoza, N
   Otero, B
   Sanchez, S
   Cancelo, MJ
   Paramo, JA
   Cano, A
AF Ramirez, Isabel
   De la Viuda, Esther
   Baquedano, Laura
   Coronado, Pluvio
   Llaneza, Placido
   Mendoza, Nicolas
   Otero, Borja
   Sanchez, Sonia
   Jesus Cancelo, Ma
   Antonio Paramo, Jose
   Cano, Antonio
TI Managing thromboembolic risk with menopausal hormone therapy and
   hormonal contraception in the COVID-19 pandemic: Recommendations from
   the Spanish Menopause Society, Sociedad Espanola de Ginecologia y
   Obstetricia and Sociedad Espanola de Trombosis y Hemostasia
SO MATURITAS
LA English
DT Article
DE COVID-19; Venous thromboembolism prophylaxis; Hormone menopause therapy
ID WOMEN
AB COVID-19 is associated with a systemic inflammatory response with activation of coagulation in symptomatic patients. The possibility of coagulopathies in peri- and postmenopausal women taking estrogen therapies makes it necessary to consider antithrombotic strategies, such as the use of low molecular weight heparins (LMWH) at specific prophylactic or treatment doses for each individual case, depending on the risk factors that each woman presents.
   For such reasons, a panel of experts from various Spanish scientific societies has met to develop usage recommendations for managing menopausal women taking menopausal hormone therapy (MHT) or combined hormonal contraception (CHC) during the COVID-19 pandemic.
C1 [Ramirez, Isabel; De la Viuda, Esther; Baquedano, Laura; Coronado, Pluvio; Llaneza, Placido; Mendoza, Nicolas; Otero, Borja; Sanchez, Sonia; Jesus Cancelo, Ma; Cano, Antonio] Spanish Menopause Soc, Assoc Espanola Estudio Menopausia AEEM, Madrid, Spain.
   [De la Viuda, Esther; Baquedano, Laura; Coronado, Pluvio; Llaneza, Placido; Mendoza, Nicolas; Otero, Borja; Sanchez, Sonia; Jesus Cancelo, Ma; Cano, Antonio] Soc Espanola Ginecol & Obstetricia SEGO, Madrid, Spain.
   [Antonio Paramo, Jose] Soc Espanola Trombosis & Hemostasia SETH, Madrid, Spain.
RP Mendoza, N (corresponding author), Maestro Montero 21, Granada 18004, Spain.
EM isaramirezp@telefonica.net; esterdelaviuda@gmail.com;
   lbaquedanome@hotmail.com; pcoronadom@gmail.com; pllanezac@hotmail.com;
   nicomendozaladron@gmail.com; borja.otero@gmail.com; ssanmen@gmail.com;
   mcanceloh@sego.es; japaramo@unay.es; Antonio.Cano@uv.es
CR [Anonymous], 2020, FSRH CEU CLIN ADVICE
   BASTOS M, 2014, COCHRANE DB SYST REV
   Dalen JE, 2020, AM J MED, V133, P9, DOI 10.1016/j.amjmed.2019.05.050
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Lekovic D, 2017, BLOOD REV, V31, P151, DOI 10.1016/j.blre.2016.12.001
   Lidegaard O, 2012, NEW ENGL J MED, V366, P2257, DOI 10.1056/NEJMoa1111840
   Mantha S, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4944
   Martinez F, 2012, EUR J CONTRACEP REPR, V17, P7, DOI 10.3109/13625187.2011.643836
   Mendoza N, 2014, MATURITAS, V78, P45, DOI 10.1016/j.maturitas.2014.02.017
   Mendoza N, 2013, MENOPAUSE, V20, P754, DOI [10.1097/gme.0b013e31827b18c5, 10.1097/GME.0b013e31827b18c5]
   Mohammed K, 2015, J CLIN ENDOCR METAB, V100, P4012, DOI 10.1210/jc.2015-2237
   Shekelle PG, 1999, WESTERN J MED, V170, P348
   Sweetland S, 2012, J THROMB HAEMOST, V10, P2277, DOI 10.1111/j.1538-7836.2012.04919.x
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   VINOGRADOVA Y, 2019, BMJ-BRIT MED J, V364, DOI DOI 10.1136/BMJ.K4810
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
NR 17
TC 5
Z9 7
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-5122
EI 1873-4111
J9 MATURITAS
JI Maturitas
PD JUL
PY 2020
VL 137
BP 57
EP 62
DI 10.1016/j.maturitas.2020.04.019
PG 6
WC Geriatrics & Gerontology; Obstetrics & Gynecology
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA LU4XJ
UT WOS:000537759900010
PM 32498938
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Shah, B
   Modi, P
   Sagar, SR
AF Shah, Bhumi
   Modi, Palmi
   Sagar, Sneha R.
TI In silico studies on therapeutic agents for COVID-19: Drug repurposing
   approach
SO LIFE SCIENCES
LA English
DT Article
DE Corona virus; COVID-19; SARS-CoV-2; MERS-CoV; Docking studies; Antiviral
   drugs
ID PHARMACOPHORE; DOCKING
AB Aims: The severe acute respiratory syndrome coronavirus 2, better known as COVID-19 has become the current health concern to the entire world. Initially appeared in Wuhan, China around December 2019, it had spread to almost 187 countries due to its high contagious nature. Precautionary measures remain the sole obliging tactic to cease the person to person transmissions till any effective method of treatment or vaccine is developed. Amidst the pandemic, research and development of new molecule is labour-intensive and tedious process. Drug repurposing is the concept of identifying therapeutically potent molecule from the library of pre-existing molecules.
   Materials and methods: In the present study, 61 molecules that are already being used in clinics or under clinical scrutiny as antiviral agents are surveyed via docking study. Docking study was performed using Maestro interface (Schrodinger Suite, LLC, NY).
   Key findings: Out of these 61 molecules, 37 molecules were found to interact with > 2 protein structures of COVID-19. The docking results indicate that amongst the reported molecules, HIV protease inhibitors and RNA-dependent RNA polymerase inhibitors showed promising features of binding to COVID-19 enzyme. Along with these, Methisazone an inhibitor of protein synthesis, CGP42112A an angiotensin AT2 receptor agonist and ABT450 an inhibitor of the non-structural protein 3-4A might become convenient treatment option as well against COVID-19.
   Significance: The drug repurposing approach provide an insight about the therapeutics that might be helpful in treating corona virus disease.
C1 [Shah, Bhumi; Modi, Palmi; Sagar, Sneha R.] LJ Inst Pharm, SG Highway, Ahmadabad 382210, Gujarat, India.
   [Shah, Bhumi] KB Inst Pharmaceut Educ & Res, Gandhinagar 382023, Gujarat, India.
RP Shah, B (corresponding author), LJ Inst Pharm, SG Highway, Ahmadabad 382210, Gujarat, India.
EM bhumi.shah_ljip@ljinstitutes.edu.in
FU L.J. Institute of Pharmacy
FX Authors like to thank L.J. Institute of Pharmacy for research support.
   One of the authors would like to thank K. B. Institute of Pharmaceutical
   Education and Research for registration as research scholar.
CR [Anonymous], TITLE ERROR
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bhuvaneshwari S, 2019, SAR QSAR ENVIRON RES, V30, P81, DOI 10.1080/1062936X.2019.1566172
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa008
   Bryan-Marrugo O. L, 2015, MED U, V17, P165, DOI DOI 10.1016/J.RMU.2015.05.003
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carlesso A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39939-z
   Choy K., 2020, ANTIVIR RES
   Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI DOI 10.1128/CMR.00102-15
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Fearon D., 2020, PANDDA ANAL GROUP DE, DOI [10.2210/pdb5r81/pdb, DOI 10.2210/PDB5R81/PDB]
   Fearon D., 2020, PANDDA ANAL GROUP DE, DOI DOI 10.2210/PDB5R80/PDB
   Fearon D., 2020, PANDDA ANAL GROUP DE, DOI DOI 10.2210/PDB5R7Z/PDB.
   Fearon D., 2020, PANDDA ANAL GROUP DE, DOI DOI 10.2210/PDB5R7Y/PDB
   Fearon D., 2020, PANDDA ANAL GROUP DE, DOI [10.2210/pdb5r82/pdb, DOI 10.2210/PDB5R82/PDB]
   Gentile I, 2014, CURR MED CHEM, V21, P3261, DOI 10.2174/0929867321666140706125950
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Huang HB, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00138
   Jasuja H, 2014, MOL DIVERS, V18, P253, DOI 10.1007/s11030-013-9497-z
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Modi P, 2019, BIOORG CHEM, V87, P240, DOI 10.1016/j.bioorg.2019.02.044
   MORRIS DJ, 1992, J ANTIMICROB CHEMOTH, V29, P97, DOI 10.1093/jac/29.2.97
   Organization WH, 2020, COR DIS COVID 2019 S
   Pradeep H, 2012, MOL DIVERS, V16, P553, DOI 10.1007/s11030-012-9387-9
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sinha S, 2019, INT J BIOL MACROMOL, V140, P454, DOI 10.1016/j.ijbiomac.2019.08.061
   Smith T., CLIN DRUG INFORM CLI
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Vijayakumar S, 2018, J PHARM ANAL, V8, P413, DOI 10.1016/j.jpha.2017.07.006
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Zhang L., 2020, BINDING MECH REMDESI, DOI [10. 20944/preprints202003.0267.v1., DOI 10.20944/PREPRINTS202003.0267.V1]
NR 32
TC 52
Z9 53
U1 16
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD JUL 1
PY 2020
VL 252
AR 117652
DI 10.1016/j.lfs.2020.117652
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA LS6JY
UT WOS:000536489100010
PM 32278693
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Carneiro, A
   Wroclawski, ML
   Nahar, B
   Soares, A
   Cardoso, AP
   Kim, NJ
   Carvalho, FT
AF Carneiro, Arie
   Wroclawski, Marcelo Langer
   Nahar, Bruno
   Soares, Andrey
   Cardoso, Ana Paula
   Kim, Nam Jin
   Carvalho, Fabricio Torres
TI Impact of the COVID-19 Pandemic on the Urologist's clinical practice in
   Brazil: a management guideline proposal for low- and middle-income
   countries during the crisis period
SO INTERNATIONAL BRAZ J UROL
LA English
DT Article
ID RADICAL PROSTATECTOMY; UROTHELIAL CANCER; SURVIVAL; CISPLATIN;
   CHEMOTHERAPY; CARCINOMA; THERAPY; PLUME; LASER; RISK
AB This letter to the Editor aims to provide suggestions and recommendations for the management of urological conditions in times of COVID-19 crisis in Brazil and other low-and middle-income countries.
   It is important to highlight that one of the main characteristics of this pandemic is the oversaturation of the health system capacity, mostly due to a high demand for personal protective equipment (PPE), Hospital/ICU beds, as well as ventilators. In places with limited resources and where the health care systems are already saturated, such consideration is even more worrisome.
   Therefore, most worldwide authorities are recommending to avoid, as much as possible, patient's elective visits to hospitals, as well as a judicious use of the operating room in order to mitigate the strain put on the health system. While efforts should be directed to the care of COVID-19 patients, other conditions (especially urgencies and oncological cases) must continue to be assisted.
   Thus, through a panel of experts, we have prepared a practical guide for urologists based on the recommendations from the main Urologic Associations, as well as data from the literature to support the suggested management. We will try to follow the standard guideline recommendations from the American Urological Association (AUA) and European Association of Urology (EAU), with the aim of pursuing the best outcomes possible. However, some recommendations were based on the consensus of the panel, taking into consideration the reality of developing countries and the unprecedented situation caused by the COVID-19 crisis.
C1 [Carneiro, Arie; Wroclawski, Marcelo Langer] Hosp Albert Einstein, Dept Urol, Albert Einstein 627-303, BR-05652900 Sao Paulo, SP, Brazil.
   [Carneiro, Arie] Grp Int Urol Avancada, Sao Paulo, SP, Brazil.
   [Wroclawski, Marcelo Langer] Beneficiencia Portuguesa Sao Paulo, Dept Urol, Sao Paulo, SP, Brazil.
   [Nahar, Bruno] Univ Miami, Miller Sch Med, Dept Urol, Coral Gables, FL 33124 USA.
   [Soares, Andrey; Cardoso, Ana Paula] Hosp Albert Einstein, Dept Oncol Med, Sao Paulo, SP, Brazil.
   [Soares, Andrey] Ctr Paulista Oncol Oncoclin, Dept Oncol Med, Sao Paulo, SP, Brazil.
   [Soares, Andrey] Grp Latinoamer Oncol Cooperat, Sao Paulo, SP, Brazil.
   [Kim, Nam Jin] Hosp Albert Einstein, Programa Cirurgia & Cirurgia Robot, Sao Paulo, SP, Brazil.
   [Carvalho, Fabricio Torres] Hosp Albert Einstein, Dept Doencas Infecciosas, Sao Paulo, SP, Brazil.
   [Carvalho, Fabricio Torres] AC Camargo Canc Ctr, Dept Med Intens, Sao Paulo, SP, Brazil.
   [Carvalho, Fabricio Torres] AC Camargo Canc Ctr, Unidade Terapia Intens, Sao Paulo, SP, Brazil.
RP Carneiro, A (corresponding author), Hosp Albert Einstein, Dept Urol, Albert Einstein 627-303, BR-05652900 Sao Paulo, SP, Brazil.
EM arie.carneiro@einstein.br
RI Nahar, Bruno/AAY-8599-2020; Wroclawski, Marcelo/ABD-9384-2020
OI CARNEIRO, ARIE/0000-0002-0152-0513
CR Babjuk M, 2019, EUR UROL, V76, P639, DOI 10.1016/j.eururo.2019.08.016
   Balar AV, 2017, LANCET ONCOL, V18, P1483, DOI 10.1016/S1470-2045(17)30616-2
   Bill-Axelson A, 2014, NEW ENGL J MED, V370, P932, DOI 10.1056/NEJMoa1311593
   Boeri L, 2019, EUR UROL ONCOL, V2, P390, DOI 10.1016/j.euo.2018.09.004
   Burki TK, 2020, LANCET ONCOL, pS1470
   Capizzi PJ, 1998, LASER SURG MED, V23, P172, DOI 10.1002/(SICI)1096-9101(1998)23:3<172::AID-LSM7>3.0.CO;2-M
   Chi KN, 2019, NEW ENGL J MED, V381, P13, DOI 10.1056/NEJMoa1903307
   Corbett CJ, 2019, UROLOGY, V132, P143, DOI 10.1016/j.urology.2019.05.038
   Crawford ED, 2006, J UROLOGY, V175, P533, DOI 10.1016/S0022-5347(05)00161-8
   De Santis M, 2012, J CLIN ONCOL, V30, P191, DOI 10.1200/JCO.2011.37.3571
   Ficarra V, 2020, MINERVA UROL NEFROL, V23
   Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174
   Foster HE, 2018, J UROLOGY, V200, P612, DOI 10.1016/j.juro.2018.05.048
   Giusti G, 2020, J ENDOUROL, V34, P660, DOI 10.1089/end.2020.0209
   GLOSTER HM, 1995, J AM ACAD DERMATOL, V32, P436, DOI 10.1016/0190-9622(95)90065-9
   Hamdy FC, 2016, NEW ENGL J MED, V375, P1415, DOI 10.1056/NEJMoa1606220
   Hensman C, 1998, SURG ENDOSC-ULTRAS, V12, P1017, DOI 10.1007/s004649900771
   Himelstein AL, 2017, JAMA-J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussain SA, 2004, BRIT J CANCER, V91, P844, DOI 10.1038/sj.bjc.6602112
   Laguna MP, 2019, TESTICULAR CANC EURO
   Lei Shaoqing, 2020, ECLINICALMEDICINE, V9, P41
   Ling Y, 2020, CHIN MED J, V28
   Ljungberg B, 2019, RENAL CELL CARCINOMA
   Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126
   Park JC, 2016, J UROLOGY, V195, P880, DOI 10.1016/j.juro.2015.11.024
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Puliatti S, 2020, BJU INT, V125, pE7, DOI 10.1111/bju.15071
   Rini BI, 2019, NEW ENGL J MED, V380, P2582, DOI 10.1056/NEJMc1905518
   Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Stensland KD, 2020, EUR UROL
   Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747
   Tan WS, 2018, J UROLOGY, V200, P973, DOI 10.1016/j.juro.2018.04.065
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Tosco L, 2017, PROSTATE CANCER P D, V20, P407, DOI 10.1038/pcan.2017.29
   Wilt TJ, 2017, NEW ENGL J MED, V377, P132, DOI 10.1056/NEJMoa1615869
   Witjes JA, 2019, MUSCLE INVASIVE META
   Wroclawski ML, 2019, J GLOB ONCOL, V5, DOI 10.1200/JGO.19.00112
   Zapala P, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1310-0
NR 40
TC 15
Z9 18
U1 3
U2 18
PU BRAZILIAN SOC UROL
PI RIO DE JANEIRO
PA RUA BAMBINA, 153, RIO DE JANEIRO, 2251-050, BRAZIL
SN 1677-5538
EI 1677-6119
J9 INT BRAZ J UROL
JI Int. Braz J Urol
PD JUL-AUG
PY 2020
VL 46
IS 4
BP 501
EP 510
DI 10.1590/S1677-5538.IBJU.2020.04.03
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA LJ3ZW
UT WOS:000530107500003
PM 32271512
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ahmed, SSSJ
   Paramasivam, P
   Raj, K
   Kumar, V
   Murugesan, R
   Ramakrishnan, V
AF Ahmed, Shiek S. S. J.
   Paramasivam, Prabu
   Raj, Kamal
   Kumar, Vishal
   Murugesan, Ram
   Ramakrishnan, V
TI Regulatory Cross Talk Between SARS-CoV-2 Receptor Binding and
   Replication Machinery in the Human Host
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE SARS-CoV-2; Covid-19; transcriptome; systems biology; host mechanism;
   miRNA targets
ID COVID-19
AB We dissect the mechanism of SARS-CoV-2 in human lung host from the initial phase of receptor binding to viral replication machinery. Two independent lung protein interactome were constructed to reveal the signaling process on receptor activation and host protein hijacking machinery in the pathogenesis of virus. Further, we test the functional role of the hubs derived from the interactome. Most hubs proteins were differentially regulated on SARS-CoV-2 infection. Also, the proteins in viral replication hubs were related with cardiovascular disease, diabetes and hypertension confirming the vulnerability and severity of infection in the risk individual. Additionally, the hub proteins were closely linked with other viral infection, including MERS and HCoVs which suggest similar infection pattern in SARS-CoV-2. We identified five hubs that interconnect both networks that show the preparation of optimal environment in the host for viral replication process upon receptor attachment. Interestingly, we propose that seven potential miRNAs, targeting the intermediate phase that connects receptor and viral replication process a better choice as a drug for SARS-CoV-2.
C1 [Ahmed, Shiek S. S. J.; Murugesan, Ram] Chettinad Acad Res & Educ, Fac Allied Hlth Sci, Drug Discovery & Multiom Lab, Kelambakkam, India.
   [Paramasivam, Prabu] Univ New Mexico, Sch Med, Dept Neurol, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
   [Paramasivam, Prabu; Raj, Kamal] Madras Diabet Res Fdn, Chennai, Tamil Nadu, India.
   [Kumar, Vishal] Ctr AIDS & Res Educ, YRG CARE, Dept Immunol, Chennai, Tamil Nadu, India.
   [Ramakrishnan, V] Chettinad Acad Res & Educ, Fac Allied Hlth Sci, Genet, Kelambakkam, India.
RP Ahmed, SSSJ (corresponding author), Chettinad Acad Res & Educ, Fac Allied Hlth Sci, Drug Discovery & Multiom Lab, Kelambakkam, India.
EM shiekssjahmed@gmail.com
OI Prabu, Paramasivam/0000-0002-8626-1601
FU Chettinad Academy of Research and Education (CARE)
FX All authors thank Chettinad Academy of Research and Education (CARE) for
   the support. This manuscript has been released as a pre-print at
   [https://www.biorxiv.org/content/10.1101/2020.04.20.050138v2] (Shiek et
   al., 2020).
CR Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P333, DOI 10.23812/Editorial-Conti-2
   European Centre for Disease Prevention and Control, 2020, NOV COR DIS COVID 19
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gupta P, 2017, CURR ALZHEIMER RES, V14, P1198, DOI 10.2174/1567205014666170829101016
   Hopman J, 2020, JAMA-J AM MED ASSOC, V323, P1549, DOI 10.1001/jama.2020.4169
   Hussain A, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108142
   Kong WH, 2020, NAT MICROBIOL, V5, P675, DOI 10.1038/s41564-020-0713-1
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Shiek S. S. J., 2020, BIORXIV, DOI [10.1101/2020.04.20.050138v2, DOI 10.1101/2020.04.20.050138V2]
   Wang ZW, 2018, CIRCULATION, V137, P2344, DOI 10.1161/CIRCULATIONAHA.117.032380
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 19
TC 2
Z9 2
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD JUN 30
PY 2020
VL 11
AR 802
DI 10.3389/fphys.2020.00802
PG 13
WC Physiology
SC Physiology
GA MQ8DM
UT WOS:000553123600001
PM 32695025
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chatterjee, S
   Maity, A
   Chowdhury, S
   Islam, MA
   Muttinini, RK
   Sen, D
AF Chatterjee, Shilpa
   Maity, Arindam
   Chowdhury, Suchana
   Islam, Md Ataul
   Muttinini, Ravi K.
   Sen, Debanjan
TI In silico analysis and identification of promising hits against 2019
   novel coronavirus 3C-like main protease enzyme
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; cobicistat; drug hits; icatibant; main protease enzyme;
   nafarelin
ID LIGAND DOCKING; INHIBITORS; DESIGN; TOOL
AB The recent outbreak of the 2019 novel coronavirus disease (COVID-19) has been proved as a global threat. No particular drug or vaccine has not yet been discovered which may act specifically against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and causes COVID-19. For this highly infectious virus, 3CL-like main protease (3CL(pro)) plays a key role in the virus life cycle and can be considered as a pivotal drug target. Structure-based virtual screening of DrugBank database resulted in 20 hits against 3CL(pro). Atomistic 100 ns molecular dynamics of five top hits and binding energy calculation analyses were performed for main protease-hit complexes. Among the top five hits, Nafarelin and Icatibant affirmed the binding energy (g_MMPBSA) of -712.94 kJ/mol and -851.74 kJ/mol, respectively. Based on binding energy and stability of protein-ligand complex; the present work reports these two drug-like hits against SARS-CoV-2 main protease. Communicated by Ramaswamy H. Sarma
C1 [Chatterjee, Shilpa] Chosun Univ, Dept Biomed Sci, Gwangju, South Korea.
   [Maity, Arindam] Adamas Univ, Sch Pharmaceut Technol, Kolkata, India.
   [Chowdhury, Suchana; Sen, Debanjan] BCDA Coll Pharmaceut Technol, Kolkata, India.
   [Islam, Md Ataul] Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Div Pharm & Optometry, Manchester, Lancs, England.
   [Islam, Md Ataul] Univ Kwazulu Natal, Sch Hlth Sci, Durban, South Africa.
   [Muttinini, Ravi K.] Immunocure Discovery Solut Pvt Ltd, IKP, Hyderabad, India.
RP Sen, D (corresponding author), BCDA Coll Pharm & Technol, Dept Pharmaceut Technol, 78 Jessore Rd, Kolkata 700127, India.
EM debanjansen48@gmail.com
RI Maity, Arindam/AAQ-4943-2020; Islam, Dr. Md Ataul/N-1637-2013
OI Maity, Arindam/0000-0002-9418-6963; Islam, Dr. Md
   Ataul/0000-0001-6286-6262
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   BACHELARD H, 2018, FRONT PHARMACOL, V9, DOI DOI https://doi.org/10.3389/fphar.2018.00273
   Bhowmick S, 2020, J MOL STRUCT, V1216, DOI 10.1016/j.molstruc.2020.128316
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Crutchley RD, 2016, HIV AIDS-RES PALLIAT, V8, P47, DOI 10.2147/HIV.S99063
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145
   Douguet D, 2005, J MED CHEM, V48, P2457, DOI 10.1021/jm0492296
   Douguet D, 2018, ACS MED CHEM LETT, V9, P204, DOI 10.1021/acsmedchemlett.7b00462
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Gallicchio E, 2010, J CHEM THEORY COMPUT, V6, P2961, DOI 10.1021/ct1002913
   Garner C, 1994, J Obstet Gynecol Neonatal Nurs, V23, P563, DOI 10.1111/j.1552-6909.1994.tb01922.x
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Huang SY, 2007, PROTEIN SCI, V16, P43, DOI 10.1110/ps.062501507
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Islam MA, 2020, J BIOMOL STRUCT DYN, V38, P1798, DOI 10.1080/07391102.2019.1617785
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Klein KO, 2020, J MED ECON, V23, P407, DOI 10.1080/13696998.2019.1697700
   Korb O, 2009, J CHEM INF MODEL, V49, P84, DOI 10.1021/ci800298z
   Kufareva Irina, 2012, Methods Mol Biol, V857, P231, DOI 10.1007/978-1-61779-588-6_10
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lobanov MY, 2008, MOL BIOL+, V42, P623, DOI 10.1134/S0026893308040195
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muller FO, 1997, BRIT J CLIN PHARMACO, V44, P335, DOI 10.1046/j.1365-2125.1997.t01-1-00592.x
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   RIEDL MA, 2018, ORPHANET J RARE DIS, V13, DOI DOI https://doi.org/10.1186/s13023-018-0922-3
   ROSA SGV, 2020, REV PANAM SALUD PUBL, V44, DOI DOI https://doi.org/10.26633/RPSP.2020.40
   Taha MO, 2011, J CHEM INF MODEL, V51, P647, DOI 10.1021/ci100368t
   TYRRELL DA, 1966, LANCET, V1, P76
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   Wang D, 2016, J VIROL, V90, P2090, DOI 10.1128/JVI.02514-15
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Zhu XY, 2017, J VIROL, V91, DOI [10.1128/JVI.00003-17, 10.1128/jvi.00003-17]
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 51
TC 1
Z9 1
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1787228
EA JUN 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA ML7HN
UT WOS:000549632400001
PM 32608329
OA Bronze
DA 2021-01-01
ER

PT J
AU Huang, XQ
   Pearce, R
   Zhang, Y
AF Huang, Xiaoqiang
   Pearce, Robin
   Zhang, Yang
TI Research Paper De novo design of protein peptides to block association
   of the SARS-CoV-2 spike protein with human ACE2
SO AGING-US
LA English
DT Article
DE SARS-CoV-2; COVID-19; ACE2; antiviral therapeutic; peptide
ID BINDING-AFFINITY CHANGE; CORONAVIRUS; COMBINATION; PREDICTION;
   EVOLUTION; PROFILES; OUTBREAK; ENTRY
AB The outbreak of COVID-19 has now become a global pandemic that has severely impacted lives and economic stability. There is, however, no effective antiviral drug that can be used to treat COVID-19 to date. Built on the fact that SARS-CoV-2 initiates its entry into human cells by the receptor binding domain (RBD) of its spike protein binding to the angiotensin-converting enzyme 2 (hACE2), we extended a recently developed approach, EvoDesign, to design multiple peptide sequences that can competitively bind to the SARS-CoV-2 RBD to inhibit the virus from entering human cells. The protocol starts with the construction of a hybrid peptidic scaffold by linking two fragments grafted from the interface of the hACE2 protein (a.a. 22-44 and 351-357) with a linker glycine, which is followed by the redesign and refinement simulations of the peptide sequence to optimize its binding affinity to the interface of the SARS-CoV-2 RBD. The binding experiment analyses showed that the designed peptides exhibited a significantly stronger binding potency to hACE2 than the wild-type hACE2 receptor (with -53.35 vs. -46.46 EvoEF2 energy unit scores for the top designed and wild-type peptides, respectively). This study demonstrates a new avenue to utilize computationally designed peptide motifs to treat the COVID-19 disease by blocking the critical spike-RBD and hACE2 interactions.
C1 [Huang, Xiaoqiang; Pearce, Robin; Zhang, Yang] Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
   [Zhang, Yang] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.
RP Zhang, Y (corresponding author), Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.; Zhang, Y (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.
EM zhng@umich.edu
FU National Institute of General Medical SciencesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [GM083107,
   GM136422]; National Institute of Allergy and Infectious DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [AI134678]; National Science FoundationNational Science
   Foundation (NSF) [IIS1901191, DBI2030790]
FX This work is supported in part by the National Institute of General
   Medical Sciences (GM083107, GM136422), the National Institute of Allergy
   and Infectious Diseases (AI134678), and the National Science Foundation
   (IIS1901191, DBI2030790).
CR Arnold FH, 1998, ACCOUNTS CHEM RES, V31, P125, DOI 10.1021/ar960017f
   Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8
   Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003
   Han DP, 2006, VIROLOGY, V350, P15, DOI 10.1016/j.virol.2006.01.029
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang Q, 2020, FAST ASSESSMENT HUMA, DOI [10.1101/2020.02.01.930537, DOI 10.1101/2020.02.01.930537, 10.1101/2020.02.01.93053750.]
   Huang XQ, 2020, BIOINFORMATICS, V36, P2429, DOI 10.1093/bioinformatics/btz926
   Huang XQ, 2020, BIOINFORMATICS, V36, P1135, DOI 10.1093/bioinformatics/btz740
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Kan SBJ, 2016, SCIENCE, V354, P1048, DOI 10.1126/science.aah6219
   Kaspar AA, 2013, DRUG DISCOV TODAY, V18, P807, DOI 10.1016/j.drudis.2013.05.011
   Khersonsky O, 2011, J MOL BIOL, V407, P391, DOI 10.1016/j.jmb.2011.01.041
   KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lin S., 2020, BIORXIV, DOI [10.1101/2020.01.31.929695, DOI 10.1101/2020.01.31.929695]
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404
   Mitra P, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003298
   Mukherjee S, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp318
   Naider F, 2009, CURR OPIN STRUC BIOL, V19, P473, DOI 10.1016/j.sbi.2009.07.003
   Ning D, 2020, GENOMIC PROTEIN STRU, DOI [20.913368., DOI 10.1101/2020.01.20.913368, 10.1101/2020.01.20.913368]
   Pearce R, 2019, J MOL BIOL, V431, P2467, DOI 10.1016/j.jmb.2019.02.028
   Procko Erik, 2020, bioRxiv, DOI 10.1101/2020.03.16.994236
   Romero PA, 2009, NAT REV MOL CELL BIO, V10, P866, DOI 10.1038/nrm2805
   Schneider JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06845-3
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606
   Shultis D, 2015, J STRUCT BIOL, V191, P197, DOI 10.1016/j.jsb.2015.06.009
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Towns J, 2014, COMPUT SCI ENG, V16, P62, DOI 10.1109/MCSE.2014.80
   Turner NJ, 2009, NAT CHEM BIOL, V5, P568, DOI 10.1038/nchembio.203
   Upadhyaya P, 2015, ANGEW CHEM INT EDIT, V54, P7602, DOI 10.1002/anie.201502763
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Ward TR, 2008, ANGEW CHEM INT EDIT, V47, P7802, DOI 10.1002/anie.200802865
   World Health Organization, 2020, COR DIS COVID 2019 S
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiong P, 2017, J MOL BIOL, V429, P426, DOI 10.1016/j.jmb.2016.11.022
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yan RX, 2013, SCI REP-UK, V3, DOI 10.1038/srep02619
   Zhang G., 2020, BIORXIV, DOI [10.1101/2020.03.19.999318, DOI 10.1101/2020.03.19.999318]
   Zhang Y, 2004, PROTEINS, V57, P702, DOI 10.1002/prot.20264
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 46
TC 7
Z9 7
U1 14
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JUN 30
PY 2020
VL 12
IS 12
BP 11263
EP 11276
PG 14
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA MK3SW
UT WOS:000548704100010
PM 32544884
OA Green Published
DA 2021-01-01
ER

PT J
AU Bousquet, G
   Falgarone, G
   Deutsch, D
   Derolez, S
   Lopez-Sublet, M
   Goudot, FX
   Amari, K
   Uzunhan, Y
   Bouchaud, O
   Pamoukdjian, F
AF Bousquet, Guilhem
   Falgarone, Geraldine
   Deutsch, David
   Derolez, Sophie
   Lopez-Sublet, Marilucy
   Goudot, Francois-Xavier
   Amari, Khadaoudj
   Uzunhan, Yurdagul
   Bouchaud, Olivier
   Pamoukdjian, Frederic
TI ADL-dependency, D-Dimers, LDH and absence of anticoagulation are
   independently associated with one-month mortality in older inpatients
   with Covid-19
SO AGING-US
LA English
DT Article
DE COVID-19; geriatric assessment; mortality; predictive biomarkers;
   anticoagulation
ID PROTEIN
AB Background: To assess factors associated with one-month mortality among older inpatients with Covid-19.
   Results: The mean age was 78 +/- 7.8 years, 55.5% were men, CT scan lung damage was observed in 76% of the patients (mild 23%, moderate 38%, extensive 22%, and severe 7%). The mortality rate was 26%. Dependency/Activities of Daily Living (ADL) score <= 5/6, D-Dimers, LDH, and no anticoagulation by reference for curative were independently associated with one-month mortality. A score derived from the multivariate model showed good calibration and very good discrimination (Harrell's C index [95%CI] = 0.83 [0.79-0.87]).
   Conclusion: ADL-dependency, high serum levels of D-Dimers and LDH and the absence of anticoagulation were independently associated with one-month mortality among older inpatients with Covid-19.
   Methods: 108 consecutive older inpatients aged 65 and over with Covid-19 confirmed by RT-PCR and/or typical CT chest scan were prospectively included in a French single-centre cohort study from March to April 2020. A systematic geriatric assessment was performed. Covariates were lymphocyte count, serum levels of albumin, C-Reactive Protein, D-Dimers and Lactate Dehydrogenase (LDH), anticoagulation level, and exposure to the hydroxychloroquine and azithromycin combined therapy. Cox uni- and multivariate proportional-hazard regressions were performed to identify predictors of one-month mortality.
C1 [Bousquet, Guilhem] Hop Avicenne, AP HP, Oncol Med, F-93000 Bobigny, France.
   [Bousquet, Guilhem; Falgarone, Geraldine; Pamoukdjian, Frederic] Univ Sorbonne Paris Nord, MASCOT, Cardiovasc Markers Stressed Condit, U942,INSERM, F-93000 Bobigny, France.
   [Falgarone, Geraldine] Hop Avicenne, AP HP, Unite Med Ambulatoire UMA, F-93000 Bobigny, France.
   [Deutsch, David; Derolez, Sophie] Univ Sorbonne Paris Nord, F-93430 Villetaneuse, France.
   [Deutsch, David] Hop Avicenne, AP HP, Gastroenterol & Oncol Digest, F-93000 Bobigny, France.
   [Derolez, Sophie] Hop Avicenne, AP HP, Rhumatol, F-93000 Bobigny, France.
   [Lopez-Sublet, Marilucy] Hop Avicenne, AP HP, Med Interne, ESH Hypertens Excellence Ctr, F-93000 Bobigny, France.
   [Goudot, Francois-Xavier] Hop Avicenne, AP HP, Cardiol, F-93000 Bobigny, France.
   [Amari, Khadaoudj; Pamoukdjian, Frederic] Hop Avicenne, AP HP, Serv Med Geriatr, F-93000 Bobigny, France.
   [Uzunhan, Yurdagul] Hop Avicenne, AP HP, Pneumol, F-93000 Bobigny, France.
   [Uzunhan, Yurdagul] Univ Sorbonne Paris Nord, Hypoxia & Lung U1272, INSERM, F-93000 Bobigny, France.
   [Bouchaud, Olivier] Hop Avicenne, AP HP, Infect Dis, F-93000 Bobigny, France.
   [Bouchaud, Olivier] Lab Educ & Prat Sante, EA 3412, F-93000 Bobigny, France.
RP Pamoukdjian, F (corresponding author), Hop Avicenne, AP HP, Serv Med Geriatr, F-93000 Bobigny, France.
EM frederic.pamoukdjian@aphp.fr
RI Bousquet, Guilhem/O-2920-2015; Lopez-Sublet, Marilucy/AAY-5552-2020
CR Angeli E, 2020, AGING-US, V12, P4230, DOI 10.18632/aging.102876
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Chen TL, 2020, J GERONTOL A-BIOL, V75, P1788, DOI 10.1093/gerona/glaa089
   Cheng MP, 2020, ANN INTERN MED, V172, P726, DOI 10.7326/M20-1301
   Clement JP, 1997, ENCEPHALE, V23, P91
   Collins GS, 2015, J CLIN EPIDEMIOL, V68, P112, DOI 10.1016/j.jclinepi.2014.11.010
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Ellis G, 2004, BRIT MED BULL, V71, P45, DOI 10.1093/bmb/ldh033
   Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Ji D, 2020, CLIN INFECT DIS, V71, P1393, DOI 10.1093/cid/ciaa414
   KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kojima G, 2017, DISABIL REHABIL, V39, P1897, DOI 10.1080/09638288.2016.1212282
   LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179
   Li KW, 2020, EUR RADIOL, V30, P4407, DOI 10.1007/s00330-020-06817-6
   Li XiaoChen, 2020, Journal of Allergy and Clinical Immunology, V146, P110, DOI 10.1016/j.jaci.2020.04.006
   Mehta HB, 2016, J CLIN EPIDEMIOL, V79, P22, DOI 10.1016/j.jclinepi.2016.03.031
   MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N
   Raynaud-Simon A, 2011, CLIN NUTR, V30, P312, DOI 10.1016/j.clnu.2010.12.003
   Sanchez O, 2019, REV MAL RESPIR, V36, P249, DOI 10.1016/j.rmr.2019.01.003
   Shahid Z, 2020, J AM GERIATR SOC, V68, P926, DOI 10.1111/jgs.16472
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 24
TC 2
Z9 2
U1 1
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JUN 30
PY 2020
VL 12
IS 12
BP 11306
EP 11313
PG 8
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA MK3SW
UT WOS:000548704100014
PM 32576712
OA Green Published
DA 2021-01-01
ER

PT J
AU Setia, G
   Tyler, J
   Kwan, A
   Faguet, J
   Sharma, S
   Singh, S
   Azarbal, B
   Tompkins, R
   Chinchilla, D
   Ghandehari, S
AF Setia, Gayatri
   Tyler, Jeffrey
   Kwan, Alan
   Faguet, Josh
   Sharma, Shilpa
   Singh, Siddharth
   Azarbal, Babak
   Tompkins, Rose
   Chinchilla, Dinora
   Ghandehari, Sara
TI High thrombus burden despite thrombolytic therapy in ST-elevation
   myocardial infarction in a patient with COVID-19
SO REVIEWS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE COVID-19; acute coronary syndrome; ST-elevation myocardial infarction;
   thrombolysis
AB Consideration of thrombolysis as first-line reperfusion therapy in patients with COVID-19 and STEMI is recommended by ACC/SCAI guidelines. We describe a patient with COVID-19, who presented with ST-elevation myocardial infarction and was treated with thrombolysis and anticoagulation. He was later found to have a significant persistent thrombus burden requiring thrombectomy and stent placement. Invasive hemodynamics on multiple high-dose pressers revealed a high cardiac output state with low systemic vascular resistance, consistent with distributive rather than cardiogenic shock. Our case illustrates that thrombolytic therapy alone may not be adequate in patients with STEMI and COVID-19, as well as the importance of early invasive hemodynamics in management of shock in patient with STEMI and COVID-19 infection.
C1 [Setia, Gayatri; Faguet, Josh] Cedars Sinai Med Ctr, Div Gen Internal Med, Los Angeles, CA 90048 USA.
   [Tyler, Jeffrey; Kwan, Alan; Sharma, Shilpa; Singh, Siddharth; Azarbal, Babak; Tompkins, Rose] Cedars Sinai Med Ctr, Dept Cardiol, Los Angeles, CA 90048 USA.
   [Chinchilla, Dinora; Ghandehari, Sara] Cedars Sinai Med Ctr, Div Pulm & Crit Care Med, Los Angeles, CA 90048 USA.
RP Azarbal, B (corresponding author), Cedars Sinai Med Ctr, Dept Cardiol, Los Angeles, CA 90048 USA.
EM Babak.Azarbal@cshs.org
FU United StatesUnited States Agency for International Development (USAID)
   Funding Source: Medline
CR Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419
   Tan CW, 2020, AM J HEMATOL, V95, pE156, DOI 10.1002/ajh.25822
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Welt FGP, 2020, J AM COLL CARDIOL, V75, P2372, DOI 10.1016/j.jacc.2020.03.021
   Xiong TY, 2020, EUR HEART J, V41, P1798, DOI 10.1093/eurheartj/ehaa231
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 7
TC 0
Z9 0
U1 1
U2 1
PU IMR PRESS
PI WAN CHAI
PA RM 19C, LOCKHART CTR, 301-307 LOCKHART RD, WAN CHAI, 00000, HONG KONG
SN 1530-6550
EI 2153-8174
J9 REV CARDIOVASC MED
JI Rev. Cardiovasc. Med.
PD JUN 30
PY 2020
VL 21
IS 2
BP 289
EP 295
DI 10.31083/j.rcm.2020.02.92
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MK5NW
UT WOS:000548835000013
PM 32706216
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Radon, K
   Saathoff, E
   Pritsch, M
   Noller, JMG
   Kroidl, I
   Olbrich, L
   Thiel, V
   Diefenbach, M
   Riess, F
   Forster, F
   Theis, F
   Wieser, A
   Hoelscher, M
AF Radon, Katja
   Saathoff, Elmar
   Pritsch, Michael
   Noller, Jessica Michelle Guggenbuehl
   Kroidl, Inge
   Olbrich, Laura
   Thiel, Verena
   Diefenbach, Max
   Riess, Friedrich
   Forster, Felix
   Theis, Fabian
   Wieser, Andreas
   Hoelscher, Michael
CA KoCo19 Collaboration Grp
TI Protocol of a population-based prospective COVID-19 cohort study Munich,
   Germany (KoCo19)
SO BMC PUBLIC HEALTH
LA English
DT Article
DE COVID-19; Pandemics; Coronavirus infections; epidemiology; Panel study;
   Enzyme-linked Immunosorbent assay; Models; economic; Stress;
   psychological; Socio-economic factors; Spatial analysis; Geographic
   information systems
AB BackgroundDue to the SARS-CoV-2 pandemic, public health interventions have been introduced globally in order to prevent the spread of the virus and avoid the overload of health care systems, especially for the most severely affected patients. Scientific studies to date have focused primarily on describing the clinical course of patients, identifying treatment options and developing vaccines. In Germany, as in many other regions, current tests for SARS-CoV2 are not conducted on a representative basis and in a longitudinal design. Furthermore, knowledge about the immune status of the population is lacking. Nonetheless, these data are needed to understand the dynamics of the pandemic and hence to appropriately design and evaluate interventions. For this purpose, we recently started a prospective population-based cohort in Munich, Germany, with the aim to develop a better understanding of the state and dynamics of the pandemic.MethodsIn 100 out of 755 randomly selected constituencies, 3000 Munich households are identified via random route and offered enrollment into the study. All household members are asked to complete a baseline questionnaire and subjects >= 14years of age are asked to provide a venous blood sample of <= 3ml for the determination of SARS-CoV-2 IgG/IgA status. The residual plasma and the blood pellet are preserved for later genetic and molecular biological investigations. For twelve months, each household member is asked to keep a diary of daily symptoms, whereabouts and contacts via WebApp. If symptoms suggestive for COVID-19 are reported, family members, including children <14years, are offered a pharyngeal swab taken at the Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, for molecular testing for SARS-CoV-2. In case of severe symptoms, participants will be transferred to a Munich hospital. For one year, the study teams re-visits the households for blood sampling every six weeks.DiscussionWith the planned study we will establish a reliable epidemiological tool to improve the understanding of the spread of SARS-CoV-2 and to better assess the effectiveness of public health measures as well as their socio-economic effects. This will support policy makers in managing the epidemic based on scientific evidence.
C1 [Radon, Katja; Forster, Felix] Ludwig Maximilians Univ LMU, Univ Hosp Munich, Inst & Outpatient Clin Occupat Social & Environm, Ziemssenstr 1, D-80336 Munich, Germany.
   [Radon, Katja; Hoelscher, Michael] LMU Univ Hosp, Ctr Int Hlth, Munich, Germany.
   [Saathoff, Elmar; Pritsch, Michael; Noller, Jessica Michelle Guggenbuehl; Kroidl, Inge; Olbrich, Laura; Thiel, Verena; Diefenbach, Max; Riess, Friedrich; Wieser, Andreas; Hoelscher, Michael] LMU Univ Hosp Munich, Div Infect Dis & Trop Med, Leopoldstr 5, Munich, Germany.
   [Saathoff, Elmar; Kroidl, Inge; Hoelscher, Michael] German Ctr Infect Res DZIF, Partner Site Munich, Munich, Germany.
   [Theis, Fabian] Helmholtz Zentrum Munchen, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.
   [Theis, Fabian] Tech Univ Munich, Dept Math, Munich, Germany.
   [Theis, Fabian] Tech Univ Munich, Dept Life Sci, Munich, Germany.
   [Wieser, Andreas] Ludwig Maximilians Univ Munchen, Max von Pettenkofer Inst, Fac Med, Munich, Germany.
RP Radon, K (corresponding author), Ludwig Maximilians Univ LMU, Univ Hosp Munich, Inst & Outpatient Clin Occupat Social & Environm, Ziemssenstr 1, D-80336 Munich, Germany.; Radon, K (corresponding author), LMU Univ Hosp, Ctr Int Hlth, Munich, Germany.
EM katja.radon@med.lmu.de
RI Fuchs, Christiane/C-4956-2013
OI Fuchs, Christiane/0000-0003-3565-8315; Diefenbach,
   Maximilian/0000-0002-5581-885X
FU Bavarian State Ministry of Science and Art; LMU Klinikum Munchen;
   Helmholtz Zentrum MunchenHelmholtz Association
FX This project is funded by the Bavarian State Ministry of Science and
   Art, the LMU Klinikum Munchen and Helmholtz Zentrum Munchen. The funding
   bodies do not play a role in the design of the study and collection,
   analysis, nor in interpretation of data or in writing the manuscript.
CR Abdalla H, 2020, NATURE, DOI 10.1038/s41586-020-2455-x
   an der Heiden M, 2020, MODELLIERUNG BEISPIE
   [Anonymous], 2020, COR MUNCH AKT ENTW
   Boccia S, 2020, JAMA INT MED
   Bong C-L, 2020, ANESTH ANALG
   BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954
   Chowell G, 2020, LANCET, V395, P1093, DOI 10.1016/S0140-6736(20)30743-1
   Ciotti M, 2020, CHEMOTHERAPY, V64, P215, DOI [10.1159/000507423, 10.1080/10408363.2020.1783198]
   Enserink M, 2020, SCIENCE, V367, P1414, DOI 10.1126/science.367.6485.1414-b
   Ferguson N, 2020, REPORT 9 IMPACT NON
   Grill E, 2020, STELLUNGNAHME DTSCH
   Gupta M, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13329
   Ioannidis JPA, 2020, EUR J CLIN INVEST, V50, DOI [10.1111/eci.13222, 10.1111/eci.13223]
   Jefferson T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006207.pub4
   Julia M, 2019, J PUBLIC HEALTH-UK, V41, pE141, DOI 10.1093/pubmed/fdy111
   Khafaie Morteza Abdullatif, 2020, Osong Public Health Res Perspect, V11, P74, DOI 10.24171/j.phrp.2020.11.2.03
   Kim S, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e143
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   Landeshauptstadt Munchen, 2020, STAT AMT INT ANW BES
   Lemeshow S, 1985, World Health Stat Q, V38, P65
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Livingston E., 2020, JAMA
   Mavragani A., 2020, TRACKING COVID 19 EU
   Meisinger C, 2016, GESUNDHEITSWESEN, V78, P84, DOI 10.1055/s-0041-110916
   Park M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040967
   Robert Koch-Institut, 2020, COVID 19 FALLZ DTSCH
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Rothman KJ, 2013, INT J EPIDEMIOL, V42, P1012, DOI 10.1093/ije/dys223
   Schipf S, 2020, BUNDESGESUNDHEITSBLA, V63, P254, DOI 10.1007/s00103-020-03093-z
   Schupp J, 2012, BUNDESGESUNDHEITSBLA, V55, P767, DOI 10.1007/s00103-012-1496-1
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Stadt Munchen, 2020, ENTW COR FALL MUNCH
   Venkatesh A, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1379
   Verity Robert, 2020, LANCET INFECT DIS
   Weinmann T, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-018-0652-1
   Weinmann T, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6171-5
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Young R, 2015, J MARRIAGE FAM, V77, P277, DOI 10.1111/jomf.12144
NR 39
TC 1
Z9 1
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD JUN 30
PY 2020
VL 20
IS 1
DI 10.1186/s12889-020-09164-9
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MH6KN
UT WOS:000546835600001
PM 32605549
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wollina, U
   Fioranelli, M
   Goldust, M
   Lotti, T
AF Wollina, Uwe
   Fioranelli, Massimo
   Goldust, Mohamad
   Lotti, Torello
TI Psoriatic arthritis andCOVID-19 pandemic: Consequences in medical
   treatment?
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE biologics; COVID-19; psoriatic arthritis; small molecules; systemic
   medical treatment
ID P40 MONOCLONAL-ANTIBODY; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS;
   LUNG-DISEASE; INTEGRATED ANALYSIS; ALPHA INHIBITOR; BIOLOGIC-NAIVE;
   METHOTREXATE; PHASE-3; FIBROSIS
AB The COVID-19 pandemic has a strong negative impact on human society worldwide. Patients with immune-mediated disease may be prone to an increased risk of infection and/or more severe course. We review the available data for patients with psoriatic arthritis (PSA) and systemic treatments. Current treatment options are summarized. Based upon the experience with COVID-19, the following problems are addressed: (a) Can systemic treatment reduce comorbidities of PsA that are also comorbidities for COVID-19? Does systemic medical treatment pose an increased risk of infection with SARS-CoV-2? Does systemic drug therapy have an impact on the risk of pulmonary fibrosis-a factor with strong negative impact on COVID-19 outcome? Small molecules, inhibitors of tumor necrosis factor alfa, interleukin, and JAK inhibitors are considered. The data are inhomogeneous for the multiple drugs used in PsA. Although the risk for severe upper airway tract infections during clinical controlled trials was mostly in the range of placebo, these data have been obtained before the COVID-19 pandemic and should be interpreted with caution. Some biologics demonstrated an antifibrotic activity in vitro and in animal disease models. None of the biologics is indicated during an active infection with fever. In nonsymptomatic PsA patients, systemic drug therapy can be continued.
C1 [Wollina, Uwe] Acad Teaching Hosp, Stadt Klinikum Dresden, Dept Dermatol & Allergol, Friedrichstr 41, D-01067 Dresden, Germany.
   [Fioranelli, Massimo] G Marconi Univ, Dept Nucl Phys Subnucl & Radiat, Rome, Italy.
   [Goldust, Mohamad] Univ Rome G Marconi, Dept Dermatol, Rome, Italy.
   [Goldust, Mohamad] Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany.
   [Goldust, Mohamad] Univ Hosp Basel, Dept Dermatol, Basel, Switzerland.
   [Lotti, Torello] Univ Studies Guglielmo Marconi, Dept Dermatol, Rome, Italy.
RP Wollina, U (corresponding author), Acad Teaching Hosp, Stadt Klinikum Dresden, Dept Dermatol & Allergol, Friedrichstr 41, D-01067 Dresden, Germany.
EM uwe.wollina@klinikum-dresden.de
OI Wollina, Uwe/0000-0001-5933-2913; Fioranelli,
   Massimo/0000-0002-1319-8779
CR Altintas N, 2016, INFLAMMATION, V39, P65, DOI 10.1007/s10753-015-0224-z
   Arora G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13357
   Atzeni F, 2016, ISR MED ASSOC J, V18, P154
   Burmester GR, 2020, DRUG SAFETY, V43, P379, DOI 10.1007/s40264-020-00904-9
   Coates LC, 2016, ARTHRITIS RHEUMATOL, V68, P1060, DOI 10.1002/art.39573
   Combe B, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-2099-0
   Conway R, 2014, ARTHRITIS RHEUMATOL, V66, P803, DOI [10.1002/art.38322, 10.1002/art.38732]
   D'Angelo S, 2009, J RHEUMATOL, V36, P368, DOI 10.3899/jrheum.080596
   Deodhar A, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1882-2
   Deodhar A, 2020, LANCET, V395, P1115, DOI 10.1016/S0140-6736(20)30265-8
   Fragoulis GE, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00238
   Ghosh S, 2019, DRUG SAFETY, V42, P751, DOI 10.1007/s40264-019-00797-3
   Gladman D, 2017, NEW ENGL J MED, V377, P1525, DOI 10.1056/NEJMoa1615977
   Gossec L, 2016, ANN RHEUM DIS, V75, P499, DOI 10.1136/annrheumdis-2015-208337
   Hein G, 1998, BRIT J RHEUMATOL, V37, P463
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Kavanaugh A, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1901-3
   Kavanaugh A, 2017, ARTHRITIS RHEUMATOL, V69, P2151, DOI 10.1002/art.40226
   Kavanaugh A, 2014, ANN RHEUM DIS, V73, P1000, DOI 10.1136/annrheumdis-2013-204741
   Kingsley GH, 2012, RHEUMATOLOGY, V51, P1368, DOI 10.1093/rheumatology/kes001
   Kurita D, 2019, AM J SURG PATHOL, V43, P869, DOI 10.1097/PAS.0000000000001271
   Mantravadi S, 2017, EXPERT REV CLIN PHAR, V10, P899, DOI 10.1080/17512433.2017.1329009
   Mease PJ, 2020, LANCET, V395, P1126, DOI 10.1016/S0140-6736(20)30263-4
   Mease PJ, 2015, NEW ENGL J MED, V373, P1329, DOI 10.1056/NEJMoa1412679
   Mi S, 2011, J IMMUNOL, V187, P3003, DOI 10.4049/jimmunol.1004081
   Mikhaylov Daniela, 2019, J Clin Aesthet Dermatol, V12, P46
   Miller IM, 2013, J AM ACAD DERMATOL, V69, P1014, DOI 10.1016/j.jaad.2013.06.053
   MOLL J M H, 1973, Seminars in Arthritis and Rheumatism, V3, P55, DOI 10.1016/0049-0172(73)90035-8
   O'Rielly DD, 2018, EXPERT REV CLIN IMMU, V14, P993, DOI 10.1080/1744666X.2018.1540931
   Perez-Chada LM, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108397
   Ritchlin C, 2014, ANN RHEUM DIS, V73, P990, DOI 10.1136/annrheumdis-2013-204655
   Ritchlin Christopher T, 2019, BMC Rheumatol, V3, P52, DOI 10.1186/s41927-019-0094-3
   Ritchlin CT, 2017, NEW ENGL J MED, V376, P957, DOI 10.1056/NEJMra1505557
   Roubille C, 2015, ANN RHEUM DIS, V74, P480, DOI 10.1136/annrheumdis-2014-206624
   Rudnicka L, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13361
   Rungapiromnan W, 2020, J EUR ACAD DERMATOL, V34, P769, DOI 10.1111/jdv.16018
   Saunte DM, 2017, BRIT J DERMATOL, V177, P47, DOI 10.1111/bjd.15015
   Sisson TH, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13753
   Solovic I, 2010, EUR RESPIR J, V36, P1185, DOI 10.1183/09031936.00028510
   Spagnolo P, 2018, ARTHRITIS RHEUMATOL, V70, P1544, DOI 10.1002/art.40574
   Taylor W, 2006, ARTHRITIS RHEUM, V54, P2665, DOI 10.1002/art.21972
   Torres T, 2018, AM J CLIN DERMATOL, V19, P23, DOI 10.1007/s40257-017-0302-0
   Wollina U, 2001, CLIN RHEUMATOL, V20, P406, DOI 10.1007/s100670170004
   Wollina U, 2010, DERMATOL THER, V23, P123, DOI 10.1111/j.1529-8019.2010.01306.x
   Wu C., 2020, JAMA INTERN MED, DOI [10.1001/jamainternmed.2020.0994, 10. 1001, DOI 10.1001/JAMAINTERNMED.2020.0994]
   Xu YH, 2020, J INFECTION, V80, P394, DOI 10.1016/j.jinf.2020.02.017
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhang J, 2019, AM J PHYSIOL-LUNG C, V316, pL487, DOI 10.1152/ajplung.00301.2018
NR 49
TC 6
Z9 6
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD SEP
PY 2020
VL 33
IS 5
SI SI
AR e13743
DI 10.1111/dth.13743
EA JUN 2020
PG 5
WC Dermatology
SC Dermatology
GA OB4SO
UT WOS:000544007700001
PM 32478971
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ross, SB
   Wilson, MG
   Papillon-Ferland, L
   Elsayed, S
   Wu, PTE
   Battu, K
   Porter, S
   Rashidi, B
   Tamblyn, R
   Pilote, L
   Downar, J
   Bonnici, A
   Huang, AL
   Lee, TC
   McDonald, EG
AF Ross, Sydney B.
   Wilson, Marnie Goodwin
   Papillon-Ferland, Louise
   Elsayed, Sarah
   Wu, Peter E.
   Battu, Kiran
   Porter, Sandra
   Rashidi, Babak
   Tamblyn, Robyn
   Pilote, Louise
   Downar, James
   Bonnici, Andre
   Huang, Allen
   Lee, Todd C.
   McDonald, Emily G.
TI COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug
   Interactions in Older Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE polypharmacy; potentially inappropriate medications; hydroxychloroquine;
   COVID-19; deprescribing
ID MEDICATIONS; CRITERIA; EVENTS
AB BACKGROUND/OBJECTIVES Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infection. However, polypharmacy predisposes patients to increased risk of drug-drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials. We aimed to quantify the degree of polypharmacy and burden of potentially inappropriate medications (PIMs) that older hospitalized adults are taking that would interact with hydroxychloroquine. METHODS We reanalyzed data from the cohort of patients 65 years and older enrolled in the MedSafer pilot study. We first identified patients taking medications with potentially harmful drug-drug interactions with hydroxychloroquine that might exclude them from participation in a typical 2019 coronavirus disease (COVID-19) therapeutic trial. Next, we identified medications that were flagged by MedSafer as potentially inappropriate and crafted guidance around medication management if contemplating the use of hydroxychloroquine. RESULTS The cohort contained a total of 1,001 unique patients with complete data on their home medications at admission. Of these 1,001 patients, 590 (58.9%) were receiving one or more home medications that could potentially interact with hydroxychloroquine, and of these, 255 (43.2%) were flagged as potentially inappropriate by the MedSafer tool. Common classes of PIMs observed were antipsychotics, cardiac medications, and antidiabetic agents. CONCLUSION The COVID-19 pandemic highlights the importance of medication optimization and deprescribing PIMs in older adults. By acting now to reduce polypharmacy and use of PIMs, we can better prepare this vulnerable population for inclusion in trials and, if substantiated, pharmacologic treatment or prevention of COVID-19.
C1 [Ross, Sydney B.; Lee, Todd C.; McDonald, Emily G.] McGill Univ, Div Expt Med, Fac Med, Montreal, PQ, Canada.
   [Ross, Sydney B.; Elsayed, Sarah; Tamblyn, Robyn; Pilote, Louise; McDonald, Emily G.] McGill Univ, Ctr Outcomes Res & Evaluat, Hlth Ctr, Montreal, PQ, Canada.
   [Wilson, Marnie Goodwin] Univ British Columbia, Div Gen Internal Med, Vancouver, BC, Canada.
   [Papillon-Ferland, Louise] Inst Univ Geriatr Montreal, Dept Pharm, Montreal, PQ, Canada.
   [Wu, Peter E.] Univ Hlth Network, Div Gen Internal Med, Toronto, ON, Canada.
   [Battu, Kiran; Porter, Sandra] Univ Hlth Network, Dept Pharm, Toronto, ON, Canada.
   [Rashidi, Babak] Ottawa Hosp, Div Gen Internal Med, Ottawa, ON, Canada.
   [Pilote, Louise; McDonald, Emily G.] McGill Univ, Div Gen Internal Med, Hlth Ctr, Montreal, PQ, Canada.
   [Downar, James] Ottawa Hosp, Div Palliat Med, Ottawa, ON, Canada.
   [Bonnici, Andre] McGill Univ, Dept Pharm, Hlth Ctr, Montreal, PQ, Canada.
   [Huang, Allen] Ottawa Hosp, Div Geriatr Med, Ottawa, ON, Canada.
   [Lee, Todd C.; McDonald, Emily G.] McGill Univ, Clin Practice Assessment Unit, Hlth Ctr, Montreal, PQ, Canada.
   [Lee, Todd C.] McGill Univ, Div Infect Dis, Dept Med, Montreal, PQ, Canada.
RP McDonald, EG (corresponding author), Ctr Outcomes Res & Evaluat, 3E03 5252 Blvd Maisonneuve, Montreal, PQ H4A 3S5, Canada.
EM emily.mcdonald@mcgill.ca
FU Centre for Aging and Brain Health Innovation; Canadian Frailty Network;
   Fonds de recherche du Quebec - SanteFonds de la Recherche en Sante du
   Quebec
FX Funding for this project was provided by the Centre for Aging and Brain
   Health Innovation, the Canadian Frailty Network, and the Fonds de
   recherche du Quebec - Sante.
CR American Hospital Formulary Service, PHARM THER CLASS SYS
   [Anonymous], 2020, PLAQ HYDR SULF TABL
   [Anonymous], 2019, MED OV AM OTH DRUG P
   [Anonymous], 2019, PROD MON INCL PAT ME
   Applegate WB, 2020, J AM GERIATR SOC, V68, P681, DOI 10.1111/jgs.16426
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Bright R, 2020, REQUEST EMERGENCY US
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen ZW, 2020, EFFICACY HYDROXYCHLO
   EK MC, 2020, OPEN FORUM INFECT DI, V7
   Ellenbogen MI, 2020, DRUG AGING, V37, P57, DOI 10.1007/s40266-019-00726-0
   Fan HW, 2015, RHEUMATOL THER, V2, P183, DOI 10.1007/s40744-015-0012-0
   Fick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767
   Gallagher P, 2011, EUR J CLIN PHARMACOL, V67, P1175, DOI 10.1007/s00228-011-1061-0
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Geleris J, 2020, N ENGL J MED
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Graves T, 1997, ARCH INTERN MED, V157, P2205, DOI 10.1001/archinte.157.19.2205
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hamilton H, 2011, ARCH INTERN MED, V171, P1013, DOI 10.1001/archinternmed.2011.215
   Hamilton Hilary J, 2009, BMC Geriatr, V9, P5, DOI 10.1186/1471-2318-9-5
   Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660
   Malone MLH, 2020, J GERIATR EMERG MED, V1
   Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2
   McDonald EG, 2019, J AM GERIATR SOC, V67, P1843, DOI 10.1111/jgs.16040
   O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Przybyla H., FAMILY NEW YORK WOMA
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Roden Dan M, 2019, CIRCULATION, DOI [10.1161/CIRCULATIONAHA.120.047521, DOI 10.1161/CIRCULATI0NAHA.120.047521]
   Rowland C., WASHINGTON POST
   Sanders JM, 2020, JAMA
   University of Maryland School of Pharmacy, 2020, OPT MED MAN COVID 19
   US Food & Drug Administration, 2020, FDA CAUT US HYDR CHL
   US Food Drug and Administration, FACT SHEET HLTH CAR
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Woosley R, 2020, QTDRUG LIST
   World Health Organization, NOV COR
   World Health Organization, PNEUM UNKN CAUS
   World Health Organization, ROLL UPD COR DIS COV
   WorldOmeter, COVID 19 COR PAND
NR 44
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD AUG
PY 2020
VL 68
IS 8
BP 1636
EP 1646
DI 10.1111/jgs.16623
EA JUN 2020
PG 11
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA MZ2CQ
UT WOS:000544014000001
PM 32441771
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mayol, J
   Artucio, C
   Batista, I
   Puentes, A
   Villegas, J
   Quizpe, R
   Rojas, V
   Mangione, J
   Belardi, J
AF Mayol, J.
   Artucio, C.
   Batista, I
   Puentes, A.
   Villegas, J.
   Quizpe, R.
   Rojas, V
   Mangione, J.
   Belardi, J.
CA STEMI Working Grp Stent-Save Life
   Latin Amer Soc Interventional Card
TI An international survey in Latin America on the practice of
   interventional cardiology during the COVID-19 pandemic, with a
   particular focus on myocardial infarction
SO NETHERLANDS HEART JOURNAL
LA English
DT Article
DE ST-elevation myocardial infarction; COVID-19; Telematic survey;
   Percutaneous coronary intervention
AB Introduction A reduction in the number of interventional cardiology procedures has emerged as a result of the COVID-19 pandemic. A survey was performed to quantify this decrease and the impact on the management of myocardial infarction in Latin America. Methods A telematic survey was conducted for all countries in Latin America. Diagnostic catheterisations, coronary and structural interventions, as well as the incidence and delay to reperfusion therapy of myocardial infarction (STEMI), were recorded. Two periods were compared: from 24 February to 8 March 2020 (pre-COVID-19) and another 2-week period that varied according to country (COVID-19). Results Responses were obtained from 79 centres in 20 countries. There was a significant decrease in the number of diagnostic procedures (-65.2%), coronary interventions (-59.4%), structural therapeutics (-86.1%) and STEMI care (-51.2%). A decrease was noted in the incidence of STEMI, but also a delay in the time to STEMI reperfusion. While there was a variation in activity in interventional cardiology between countries, patient behaviour was rather homogeneous. Conclusions A significant reduction in healthcare activity has been noted during the COVID-19 pandemic, including STEMI care, with the risk of increased mortality and/or morbidity following STEMI. Healthcare providers should encourage patients with suspected symptoms of STEMI to call for emergency care to ensure rapid diagnosis and timely reperfusion treatment.
C1 [Mayol, J.; Batista, I] Ctr Cardiol Amer, Uruguay Hemodinamia Litoral, Montevideo, Salto, Uruguay.
   [Artucio, C.] Inst Cardiol Intervencionista Casa Galicia, Montevideo, Uruguay.
   [Artucio, C.] Hosp Cent FEAA, Serv Hemodinamia & Cardiol Intervencionista, Montevideo, Uruguay.
   [Puentes, A.] Hosp San Juan Dios, Santiago, Chile.
   [Villegas, J.] Clin San Rafael, Bogota, Colombia.
   [Quizpe, R.] Hosp Santa Ines, Cuenca, Ecuador.
   [Quizpe, R.] Hosp Jose Carrasco Arteaga, Cuenca, Ecuador.
   [Rojas, V] Hosp Clin, Asuncion, Paraguay.
   [Mangione, J.] Hosp Beneficencia Portuguesa, Sao Pablo, Brazil.
   [Belardi, J.] ICBA, Buenos Aires, DF, Argentina.
RP Mayol, J (corresponding author), Ctr Cardiol Amer, Uruguay Hemodinamia Litoral, Montevideo, Salto, Uruguay.
EM mayol.jorge@gmail.com
OI Mayol, Jorge/0000-0002-7739-287X; Urna Herbas, Luis
   Alberto/0000-0002-3800-8820
CR Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011
   Ibanez B, 2018, EUR HEART J, V39, P119, DOI 10.1093/eurheartj/ehx393
   Rodriguez-Leor O, 2020, REC INTERV CARDIOL, V2, P82, DOI DOI 10.24875/RECIC.M20000120
   Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631
NR 4
TC 1
Z9 1
U1 0
U2 0
PU BOHN STAFLEU VAN LOGHUM BV
PI HOUTEN
PA POSTBUS 246, 3990 GA HOUTEN, NETHERLANDS
SN 1568-5888
EI 1876-6250
J9 NETH HEART J
JI Neth. Heart J.
PD JUL
PY 2020
VL 28
IS 7-8
BP 424
EP 430
DI 10.1007/s12471-020-01440-y
EA JUN 2020
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MP0XT
UT WOS:000544541800001
PM 32607704
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Bosmuller, H
   Traxler, S
   Bitzer, M
   Haberle, H
   Raiser, W
   Nann, D
   Frauenfeld, L
   Vogelsberg, A
   Klingel, K
   Fend, F
AF Boesmueller, Hans
   Traxler, Selina
   Bitzer, Michael
   Haeberle, Helene
   Raiser, Wolfgang
   Nann, Dominik
   Frauenfeld, Leonie
   Vogelsberg, Antonio
   Klingel, Karin
   Fend, Falko
TI The evolution of pulmonary pathology in fatal COVID-19 disease: an
   autopsy study with clinical correlation
SO VIRCHOWS ARCHIV
LA English
DT Article
DE COVID-19; Autopsy; Lung; Capillaritis; Microthrombosis
ID CORONAVIRUS
AB The pandemia of coronavirus disease 2019 (COVID-19) has caused more than 355,000 confirmed deaths worldwide. However, publications on postmortem findings are scarce. We present the pulmonary findings in four cases of fatal COVID-19 with a spectrum of lung pathology reflecting disease course and duration, invasive therapies, and laboratory features. Early disease is characterized by neutrophilic, exudative capillaritis with microthrombosis and high levels of IL-1beta and IL-6. Later stages are associated with diffuse alveolar damage and ongoing intravascular thrombosis in small to medium-sized pulmonary vessels, occasionally with areas of infarction equivalents, accompanied by laboratory features of disseminated intravascular coagulation. In late stages, organizing pneumonia with extensive intra-alveolar proliferation of fibroblasts and marked metaplasia of alveolar epithelium can be observed. Viral RNA is encountered in the lung, with virus particles in endothelial cells and pneumocytes. In many patients, multi-organ failure with severe liver damage sets in finally, possibly as consequence of an early-onset pro-inflammatory cytokine storm and/or thrombotic microangiopathy.
C1 [Boesmueller, Hans; Traxler, Selina; Nann, Dominik; Frauenfeld, Leonie; Vogelsberg, Antonio; Klingel, Karin; Fend, Falko] Univ Hosp Tubingen, Dept Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.
   [Boesmueller, Hans; Traxler, Selina; Nann, Dominik; Frauenfeld, Leonie; Vogelsberg, Antonio; Klingel, Karin; Fend, Falko] Eberhard Karls Univ Tubingen, Liebermeisterstr 8, D-72076 Tubingen, Germany.
   [Bitzer, Michael] Univ Hosp Tubingen, Dept Internal Med 1, Tubingen, Germany.
   [Haeberle, Helene] Univ Hosp Tubingen, Dept Anaesthesiol, Tubingen, Germany.
   [Raiser, Wolfgang] Off Gen Med, Tubingen, Germany.
RP Bosmuller, H (corresponding author), Univ Hosp Tubingen, Dept Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.; Bosmuller, H (corresponding author), Eberhard Karls Univ Tubingen, Liebermeisterstr 8, D-72076 Tubingen, Germany.
EM hans.boesmueller@med.uni-tuebingen.de
FU Projekt DEAL
FX Open Access funding provided by Projekt DEAL.
CR Ackermann M, 2020, N ENGL J MED
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Barton LM, 2020, AM J CLIN PATHOL OKL
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hanley B, 2020, J CLIN PATHOL, V73, P239, DOI 10.1136/jclinpath-2020-206522
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Martinod K, 2014, BLOOD, V123, P2768, DOI 10.1182/blood-2013-10-463646
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mendez-Sanchez N, 2020, J CLIN TRANSL HEPATO, V8, P109, DOI 10.14218/JCTH.2020.00024
   Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Shi S, 2020, JAMA CARDIOL CHINA
   Spiezia L, 2020, THROMB HAEMOST
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wichmann D, 2020, ANN INTERN MED
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziegler C. G, 2020, CELL
NR 23
TC 18
Z9 18
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0945-6317
EI 1432-2307
J9 VIRCHOWS ARCH
JI Virchows Arch.
PD SEP
PY 2020
VL 477
IS 3
BP 349
EP 357
DI 10.1007/s00428-020-02881-x
EA JUN 2020
PG 9
WC Pathology
SC Pathology
GA NI0JE
UT WOS:000544547500003
PM 32607684
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rosell-Diaz, AM
   Mateos-Mayo, A
   Nieto-Benito, LM
   Balaguer-Franch, I
   de la Torre-Ruiz, EH
   Lainez-Nuez, A
   Suarez-Fernandez, R
   Bergon-Sendin, M
AF Rosell-Diaz, A. M.
   Mateos-Mayo, A.
   Nieto-Benito, L. M.
   Balaguer-Franch, I.
   de la Torre-Ruiz, E. Hernandez
   Lainez-Nuez, A.
   Suarez-Fernandez, R.
   Bergon-Sendin, M.
TI Exanthema and eosinophilia in COVID-19 patients: has viral infection a
   role in drug induced exanthemas?
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Letter
C1 [Rosell-Diaz, A. M.; Mateos-Mayo, A.; Nieto-Benito, L. M.; Balaguer-Franch, I.; de la Torre-Ruiz, E. Hernandez; Suarez-Fernandez, R.; Bergon-Sendin, M.] Hosp Gen Univ Gregorio Maranon, Dermatol Dept, Madrid, Spain.
   [Lainez-Nuez, A.] Hosp Gen Univ Gregorio Maranon, Allergol Dept, Madrid, Spain.
RP Rosell-Diaz, AM (corresponding author), Hosp Gen Univ Gregorio Maranon, Dermatol Dept, Madrid, Spain.
EM aroselld@gmail.com
OI Nieto-Benito, Lula Maria/0000-0002-7609-2736
CR Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Randhawa A, 2018, SCOT MED J, V63, P91, DOI 10.1177/0036933018763277
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Shiohara T, 2007, CLIN REV ALLERG IMMU, V33, P124, DOI 10.1007/s12016-007-8010-9
   Shiohara Tetsuo, 2006, Allergol Int, V55, P1, DOI 10.2332/allergolint.55.1
NR 5
TC 5
Z9 5
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
EI 1468-3083
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
PD OCT
PY 2020
VL 34
IS 10
BP E561
EP E563
DI 10.1111/jdv.16709
EA JUN 2020
PG 4
WC Dermatology
SC Dermatology
GA OS5KU
UT WOS:000545075300001
PM 32495400
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Grant, RC
   Rotstein, C
   Liu, G
   Forbes, L
   Vu, K
   Lee, R
   Ng, P
   Krzyzanowska, M
   Warr, D
   Knox, J
AF Grant, Robert C.
   Rotstein, Coleman
   Liu, Geoffrey
   Forbes, Leta
   Vu, Kathy
   Lee, Roy
   Ng, Pamela
   Krzyzanowska, Monika
   Warr, David
   Knox, Jennifer
TI Reducing dexamethasone antiemetic prophylaxis during the COVID-19
   pandemic: recommendations from Ontario, Canada
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE COVID-19; Antiemetic; Supportive care; Chemotherapy; Glucocorticoids
ID CHEMOTHERAPY-INDUCED NAUSEA; COMBINATION; PREVENTION; RISK
AB Purpose People with cancer face an elevated risk of infection and severe sequelae from COVID-19. Dexamethasone is commonly used for antiemetic prophylaxis with systemic therapy for cancer. However, dexamethasone is associated with increased risk of viral and respiratory infections, and causes lymphopenia, which is associated with worse outcomes during COVID-19 infections. Our purpose was to minimize dexamethasone exposure during antiemetic prophylaxis for systemic therapy for solid tumors during the COVID-19 pandemic, while maintaining control of nausea and emesis. Methods We convened an expert panel to systematically review the literature and formulate consensus recommendations. Results No studies considered the impact of dexamethasone-based antiemetic regimens on the risk and severity of COVID-19 infection. Expert consensus recommended modifications to the 2019 Cancer Care Ontario Antiemetic Recommendations. Conclusion Clinicians should prescribe the minimally effective dose of dexamethasone for antiemetic prophylaxis. Single-day dexamethasone dosing is recommended over multi-day dosing for regimens with high emetogenic risk excluding high-dose cisplatin, preferably in combination with palonosetron, netupitant, and olanzapine. For regimens with low emetogenic risk, 5-HT(3)antagonists are recommended over dexamethasone.
C1 [Grant, Robert C.; Liu, Geoffrey; Lee, Roy; Ng, Pamela; Krzyzanowska, Monika; Warr, David; Knox, Jennifer] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
   [Grant, Robert C.] Ontario Inst Canc Res, Toronto, ON, Canada.
   [Rotstein, Coleman] Univ Toronto, Div Infect Dis, Toronto, ON, Canada.
   [Forbes, Leta; Vu, Kathy; Krzyzanowska, Monika] Canc Care Ontario, Toronto, ON, Canada.
RP Knox, J (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
EM Jennifer.Knox@uhn.ca
RI Krzyzanowska, Monika K./ABG-3505-2020
OI Krzyzanowska, Monika K./0000-0001-5533-7418
CR Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   American Society of Clinical Oncology, 2020, COVID 19 PROV PRACT
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   BC Cancer, 2020, COVID 19 INF HLTH PR
   Cancer Care Ontario, 2020, PAND PLANN CLIN GUID
   Cancer Care Ontaro, 2019, ANT REC CHEM IND NAU
   Celio L, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6454-y
   Celio L, 2011, SUPPORT CARE CANCER, V19, P1217, DOI 10.1007/s00520-010-0941-7
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dranitsaris George, 2013, J Support Oncol, V11, P14
   ESMO, 2020, COVID 19 SUPP ONC PR
   Fardet L, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002024
   Furukawa N, 2015, SUPPORT CARE CANCER, V23, P3317, DOI 10.1007/s00520-015-2760-3
   Gu YL, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017364
   Hesketh PJ, 2017, J CLIN ONCOL, V35, P3240, DOI 10.1200/JCO.2017.74.4789
   Ito Y, 2018, J CLIN ONCOL, V36, P1000, DOI 10.1200/JCO.2017.74.4375
   Komatsu Y, 2015, CANCER SCI, V106, P891, DOI 10.1111/cas.12675
   Lansbury L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub3
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   McCrea JB, 2003, CLIN PHARMACOL THER, V74, P17, DOI 10.1016/S0009-9236(03)00066-3
   Morrow GR, 1998, ONCOLOGY-NY, V12, P32
   National Institute for Health and Care Excellence, 2020, COVID 19 RAP GUID DE
   Navari RM, 2013, SUPPORT CARE CANCER, V21, P1655, DOI 10.1007/s00520-012-1710-6
   Olnes MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23002
   Penel N, 2020, ANN ONCOL, V31, P965, DOI 10.1016/j.annonc.2020.03.308
   POLLERA CF, 1989, CANCER, V64, P1117, DOI 10.1002/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R
   Poston JT, 2020, JAMA-J AM MED ASSOC, V323, P1839, DOI 10.1001/jama.2020.4914
   Roila F, 1998, J CLIN ONCOL, V16, P2937, DOI 10.1200/JCO.1998.16.9.2937
   Roila F, 2016, ANN ONCOL, V27, pv119, DOI 10.1093/annonc/mdw270
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   STUCK AE, 1989, REV INFECT DIS, V11, P954
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Wolfe F, 2006, ARTHRITIS RHEUM-US, V54, P628, DOI 10.1002/art.21568
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhao X., INCIDENCE CLIN CHARA, DOI [10.1101/2020.03.17.20037572, DOI 10.1101/2020.03.17.20037572]
NR 36
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD OCT
PY 2020
VL 28
IS 10
BP 5031
EP 5036
DI 10.1007/s00520-020-05588-6
EA JUN 2020
PG 6
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA NL2KY
UT WOS:000544136500001
PM 32601854
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Li, XZ
   Jin, F
   Zhang, JG
   Deng, YF
   Shu, W
   Qin, JM
   Ma, X
   Pang, Y
AF Li, Xue-Zheng
   Jin, Feng
   Zhang, Jian-Guo
   Deng, Yun-Feng
   Shu, Wei
   Qin, Jing-Min
   Ma, Xin
   Pang, Yu
TI Treatment of coronavirus disease 2019 in Shandong, China: a cost and
   affordability analysis
SO INFECTIOUS DISEASES OF POVERTY
LA English
DT Article
DE COVID-19; Cost; Treatment; Affordability; China
AB Background Coronavirus disease 2019 (COVID-19) is now a global public threat. Given the pandemic of COVID-19, the economic impact of COVID-19 is essential to add value to the policy-making process. We retrospectively conducted a cost and affordability analysis to determine the medical costs of COVID-19 patients in China, and also assess the factors affecting their costs. Methods This analysis was retrospectively conducted in Shandong Provincial Chest Hospital between 24 January and 16 March 2020. The total direct medical expenditures were analyzed by cost factors. We also assessed affordability by comparing the simulated out-of-pocket expenditure of COVID-19 cases relative to the per capita disposable income. Differences between groups were tested by studentttest and Mann-Whitney test when appropriate. A multiple logistic regression model was built to determine the risk factors associated with high cost. Results A total of 70 COVID-19 patients were included in the analysis. The overall mean cost was USD 6827 per treated episode. The highest mean cost was observed in drug acquisition, accounting for 45.1% of the overall cost. Total mean cost was significantly higher in patients with pre-existing diseases compared to those without pre-existing diseases. Pre-existing diseases and the advanced disease severity were strongly associated with higher cost. Around USD 0.49 billion were expected for clinical manage of COVID-19 in China. Among rural households, the proportions of health insurance coverage should be increased to 70% for severe cases, and 80% for critically ill cases to avoid catastrophic health expenditure. Conclusions Our data demonstrate that clinical management of COVID-19 patients incurs a great financial burden to national health insurance. The cost for drug acquisition is the major contributor to the medical cost, whereas the risk factors for higher cost are pre-existing diseases and severity of COVID-19. Improvement of insurance coverage will need to address the barriers of rural patients to avoid the occurrence of catastrophic health expenditure.
C1 [Li, Xue-Zheng; Ma, Xin] Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Jinan, Peoples R China.
   [Li, Xue-Zheng; Jin, Feng; Deng, Yun-Feng; Qin, Jing-Min; Ma, Xin] Shandong Univ, Shandong Prov Chest Hosp, Cheeloo Coll Med, Prov Key Lab Resp Infect Dis Shandong, Jinan, Peoples R China.
   [Li, Xue-Zheng; Jin, Feng; Deng, Yun-Feng; Qin, Jing-Min; Ma, Xin] Shandong Univ, Shandon Prov Chest Hosp, Cheeloo Coll Med, Katharine Hsu Int Res Ctr Human Infect Dis, 44 Wenhuaxi Rd, Jinan 250012, Peoples R China.
   [Zhang, Jian-Guo] Shandong Univ, Shandong Prov Chest Hosp, Cheeloo Coll Med, Dept Planning & Finance, Jinan, Peoples R China.
   [Shu, Wei; Pang, Yu] Capital Med Univ, Beijing TB & Thorac Tumor Inst, Beijing Key Lab Drug Resistant TB Res, Beijing Chest Hosp,Natl Clin Lab TB, 9 Beiguan St, Beijing 101149, Peoples R China.
RP Ma, X (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Jinan, Peoples R China.; Ma, X (corresponding author), Shandong Univ, Shandong Prov Chest Hosp, Cheeloo Coll Med, Prov Key Lab Resp Infect Dis Shandong, Jinan, Peoples R China.; Ma, X (corresponding author), Shandong Univ, Shandon Prov Chest Hosp, Cheeloo Coll Med, Katharine Hsu Int Res Ctr Human Infect Dis, 44 Wenhuaxi Rd, Jinan 250012, Peoples R China.; Pang, Y (corresponding author), Capital Med Univ, Beijing TB & Thorac Tumor Inst, Beijing Key Lab Drug Resistant TB Res, Beijing Chest Hosp,Natl Clin Lab TB, 9 Beiguan St, Beijing 101149, Peoples R China.
EM mx79@hotmail.com; pangyupound@163.com
FU Shandong Taishan Scholar Program [TS201712099]; National Key Research
   Program of China [2018ZX10103-001]; Beijing Hospitals Authority' Ascent
   Plan [DFL20191601]
FX The study was supported by the Shandong Taishan Scholar Program
   (TS201712099), the National Key Research Program of China
   (2018ZX10103-001), and the Beijing Hospitals Authority' Ascent Plan
   (DFL20191601). The funders had no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Chand K, 2020, ARAB J CHEM, V13, P8248, DOI [10.1142/S0192415X20500378, 10.1016/j.arabjc.2020.01.009]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Guo RN, 2011, PUBLIC HEALTH, V125, P389, DOI 10.1016/j.puhe.2011.03.004
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liew MF, 2020, CRIT CARE, V24, DOI [10.1186/s13054-020-2814-x, 10.1186/s13054-020-2828-4]
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Ma JD, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0361-5
   MacIsaac J, 2018, TRANSFUSION, V58, P2729, DOI 10.1111/trf.14841
   Miravitlles M, 2003, CHEST, V123, P784, DOI 10.1378/chest.123.3.784
   Ni L, 2020, FRONT MED-PRC, V14, P210, DOI 10.1007/s11684-020-0757-x
   Qin Y, 2015, CLIN INFECT DIS, V61, P563, DOI 10.1093/cid/civ345
   Qin YM, 2007, PLANT CELL, V19, P3692, DOI 10.1105/tpc.107.054437
   Rossi G, 2017, LUNG CANCER-TARGETS, V8, P45, DOI 10.2147/LCTT.S120172
   Su TT, 2006, B WORLD HEALTH ORGAN, V84, P21, DOI 10.2471/BLT.05.023739
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   World Health Organization, NOV COR COVID 19 SIT
   Wu C, 2020, INFORM PROCESS MANAG, V57, DOI 10.1016/j.ipm.2020.102216
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xie JF, 2020, INTENS CARE MED, V46, P837, DOI 10.1007/s00134-020-05979-7
   Xie Y, 2020, J INFECTION, V81, P340, DOI 10.1016/j.jinf.2020.03.044
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhu K, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0690-z
NR 26
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-5162
EI 2049-9957
J9 INFECT DIS POVERTY
JI Infect. Dis. Poverty
PD JUN 29
PY 2020
VL 9
IS 1
AR 78
DI 10.1186/s40249-020-00689-0
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA MK5KH
UT WOS:000548825400001
PM 32600426
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Basu, S
   Holbrook, LT
   Kudlaty, K
   Fasanmade, O
   Wu, JH
   Burke, A
   Langworthy, BW
   Farzal, Z
   Mamdani, M
   Bennett, WD
   Fine, JP
   Senior, BA
   Zanation, AM
   Ebert, CS
   Kimple, AJ
   Thorp, BD
   Frank-Ito, DO
   Garcia, GJM
   Kimbell, JS
AF Basu, Saikat
   Holbrook, Landon T.
   Kudlaty, Kathryn
   Fasanmade, Olulade
   Wu, Jihong
   Burke, Alyssa
   Langworthy, Benjamin W.
   Farzal, Zainab
   Mamdani, Mohammed
   Bennett, William D.
   Fine, Jason P.
   Senior, Brent A.
   Zanation, Adam M.
   Ebert, Charles S., Jr.
   Kimple, Adam J.
   Thorp, Brian D.
   Frank-Ito, Dennis O.
   Garcia, Guilherme J. M.
   Kimbell, Julia S.
TI Numerical evaluation of spray position for improved nasal drug delivery
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DROPLET-SIZE DISTRIBUTION; AIR-FLOW; CHRONIC RHINOSINUSITIS; DEPOSITION;
   FLUID; DYNAMICS; SIMULATIONS; ATOMIZATION; PATTERNS; 2P
AB Topical intra-nasal sprays are amongst the most commonly prescribed therapeutic options for sinonasal diseases in humans. However, inconsistency and ambiguity in instructions show a lack of definitive knowledge on best spray use techniques. In this study, we have identified a new usage strategy for nasal sprays available over-the-counter, that registers an average 8-fold improvement in topical delivery of drugs at diseased sites, when compared to prevalent spray techniques. The protocol involves re-orienting the spray axis to harness inertial motion of particulates and has been developed using computational fluid dynamics simulations of respiratory airflow and droplet transport in medical imaging-based digital models. Simulated dose in representative models is validated through in vitro spray measurements in 3D-printed anatomic replicas using the gamma scintigraphy technique. This work breaks new ground in proposing an alternative user-friendly strategy that can significantly enhance topical delivery inside human nose. While these findings can eventually translate into personalized spray usage instructions and hence merit a change in nasal standard-of-care, this study also demonstrates how relatively simple engineering analysis tools can revolutionize everyday healthcare. Finally, with respiratory mucosa as the initial coronavirus infection site, our findings are relevant to intra-nasal vaccines that are in-development, to mitigate the COVID-19 pandemic.
C1 [Basu, Saikat] South Dakota State Univ, Dept Mech Engn, Brookings, SD 57007 USA.
   [Holbrook, Landon T.; Wu, Jihong; Burke, Alyssa; Bennett, William D.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA.
   [Kudlaty, Kathryn; Fasanmade, Olulade; Farzal, Zainab; Mamdani, Mohammed; Senior, Brent A.; Zanation, Adam M.; Ebert, Charles S., Jr.; Kimple, Adam J.; Thorp, Brian D.; Kimbell, Julia S.] Univ N Carolina, Sch Med, Dept Otolaryngol Head & Neck Surg, Chapel Hill, NC 27599 USA.
   [Langworthy, Benjamin W.; Fine, Jason P.] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA.
   [Frank-Ito, Dennis O.] Duke Univ, Dept Head & Neck Surg & Commun Sci, Med Ctr, Durham, NC 27708 USA.
   [Garcia, Guilherme J. M.] Med Coll Wisconsin, Joint Dept Biomed Engn, Milwaukee, WI 53226 USA.
   [Garcia, Guilherme J. M.] Marquette Univ, Milwaukee, WI 53226 USA.
RP Basu, S (corresponding author), South Dakota State Univ, Dept Mech Engn, Brookings, SD 57007 USA.
EM Saikat.Basu@sdstate.edu
RI Garcia, Guilherme/J-9555-2013
OI Garcia, Guilherme/0000-0003-2995-9226
FU National Heart, Lung, and Blood Institute (NHLBI) of the National
   Institutes of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL122154]; National Center for Advancing
   Translational Sciences (NCATS) at NIH [KL2TR002490]; National Institute
   on Deafness and Other Communication Disorders (NIDCD) at NIH
   [T32DC005360]; SB's faculty start-up funds at the Department of
   Mechanical Engineering at South Dakota State University
FX The authors sincerely thank Dr. John S Rhee, MD, MPH (at the Department
   of Otolaryngology, Medical College of Wisconsin) for numerous fruitful
   discussions. Thanks are also due to Dr. Julie Suman (Next Breath, LLC)
   for the experimental measurement of nasal spray parameters. The authors
   additionally acknowledge: (a) Christopher Jadelis (at UNC Chapel Hill)
   for his assistance on the experimental setup; (b) several past/present
   UNC rhinology residents and fellows (Drs. Andrew Coniglio, Satyan
   Sreenath, Kibwei McKinney, Gita Madan, Parth Shah, and Stan McClurg) for
   their inputs; and (c) Dr. Ola Harrysson's group at NC State University
   (at the Edward P Fitts Department of Industrial and Systems
   Engineering), Matthew White (at NCSU), and Dr. Tim Horn (Director of
   Research, Center for Additive Manufacturing and Logistics at NCSU) for
   help on 3D printing. Finally, thanks are also due to Alison Turner and
   Carolyn Hamby (both at UNC School of Medicine) for their assistance in
   patient recruitment scheduling. The project was supported by: (a) the
   National Heart, Lung, and Blood Institute (NHLBI) of the National
   Institutes of Health (NIH), under award number R01HL122154 (PI: JSK);
   (b) the National Center for Advancing Translational Sciences (NCATS) at
   NIH, through award number KL2TR002490 (PI: AJK); (c) the National
   Institute on Deafness and Other Communication Disorders (NIDCD) at NIH,
   under award number T32DC005360 (ZF); and (d) SB's faculty start-up funds
   at the Department of Mechanical Engineering at South Dakota State
   University. Content of this study is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   NIH.
CR ANSYS, ANSYS FLUENT THEOR G
   Basu S, 2014, THESIS
   Basu S., 2019, B AM PHYS SOC
   Basu S., 2016, B AM PHYS SOC, V61
   Basu S., 2017, APS DIV FLUID DYN M
   Basu S, 2019, J AEROSOL MED PULM D, V32, pA19
   Basu S, 2018, INT J NUMER METH BIO, V34, DOI 10.1002/cnm.2946
   Basu S, 2017, FLUID DYN RES, V49, DOI 10.1088/1873-7005/aa9280
   Basu S, 2017, J FLUID MECH, V831, P72, DOI 10.1017/jfm.2017.563
   Basu S, 2017, J AEROSOL MED PULM D, V30, P14
   Basu S, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4932534
   Bennett W. D., 2012, A49 AIR POLLUTION RE, pA1742
   Benninger MS, 2004, OTOLARYNG HEAD NECK, V130, P5, DOI 10.1016/j.otohns.2003.10.007
   Benninger MS, 2003, OTOLARYNG HEAD NECK, V129, pS1, DOI 10.1016/S0194-5998(03)01397-4
   Borojeni AA, 2017, INT J NUMER METH BIO, V33, DOI 10.1002/cnm.2825
   Brandon BM, 2020, LARYNGOSCOPE, V130, pE817, DOI 10.1002/lary.28691
   Brandon BM, 2018, JAMA FACIAL PLAST SU, V20, P215, DOI 10.1001/jamafacial.2017.1994
   Burke A, 2019, J AEROSOL MED PULM D, V32, pA22
   Burrowes KS, 2017, WIRES SYST BIOL MED, V9, DOI 10.1002/wsbm.1392
   Calmet H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221330
   Cheng YS, 2001, J AEROSOL MED, V14, P267, DOI 10.1089/08942680152484199
   Dayal P, 2004, J PHARM SCI-US, V93, P1725, DOI 10.1002/jps.20090
   Doorly DJ, 2008, PHILOS T R SOC A, V366, P3225, DOI 10.1098/rsta.2008.0083
   Doughty DV, 2011, DRUG DEV IND PHARM, V37, P359, DOI 10.3109/03639045.2010.520321
   Ebert Jr C. S., 2018, B AM PHYS SOC, V63
   Farzal Z, 2019, INT FORUM ALLERGY RH
   Farzal Z, 2019, J AEROSOL MED PULM D, V32, pA38
   Finlay W. H., 2001, MECH INHALED PHARM A
   Frank DO, 2013, INT FORUM ALLERGY RH, V3, P834, DOI 10.1002/alr.21203
   Fung MC, 2013, J PHARM SCI-US, V102, P1024, DOI 10.1002/jps.23449
   Guo Y, 2005, PHARM RES, V22, P1871, DOI 10.1007/s11095-005-7391-9
   Han JN, 1997, EUR RESPIR J, V10, P161, DOI 10.1183/09031936.97.10010161
   Inthavong K, 2011, J AEROSOL SCI, V42, P100, DOI 10.1016/j.jaerosci.2010.11.008
   Inthavong K, 2015, J AEROSOL MED PULM D, V28, P59, DOI 10.1089/jamp.2013.1093
   Inthavong K, 2009, ENG APPL COMP FLUID, V3, P321, DOI 10.1080/19942060.2009.11015274
   Kelly JT, 2000, J APPL PHYSIOL, V89, P323
   Kim MH, 2019, PLOS ONE, V14
   Kimbell JS, 2018, RESP DRUG DELIVERY 2, V1, P181
   Kimbell JS, 2019, LASER SURG MED, V51, P150, DOI 10.1002/lsm.23005
   Kundoor V, 2011, PHARM RES-DORDR, V28, P1895, DOI 10.1007/s11095-011-0417-6
   Lee JS, 2006, J VIROL, V80, P4079, DOI 10.1128/JVI.80.8.4079-4087.2006
   Leong SC, 2010, RHINOLOGY, V48, P139, DOI 10.4193/Rhin09.133
   Liu XF, 2011, AAPS PHARMSCITECH, V12, P337, DOI 10.1208/s12249-011-9594-1
   Oberdick J., 2020, RETHINKING TRADITION
   Parikh A, 2001, RHINOLOGY, V39, P75
   Perkins EL, 2018, OTOLARYNG HEAD NECK, V158, P511, DOI 10.1177/0194599817742126
   Proctor D. F., 2017, NASAL TUMORS ANIMALS, VI, P1
   Rosenfeld RM, 2007, OTOLARYNG HEAD NECK, V137, pS1, DOI 10.1016/j.otohns.2007.06.726
   Rygg A, 2016, J AEROSOL MED PULM D, V29, P416, DOI 10.1089/jamp.2015.1252
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schroeter JD, 2016, J AEROSOL SCI, V95, P15, DOI 10.1016/j.jaerosci.2016.01.006
   Shanley KT, 2008, INHAL TOXICOL, V20, P1093, DOI 10.1080/08958370802130379 
   Sreenath S. B, 2018, 181100649 ARXIV
   Sridhar G. N., 2020, INTRANASAL VACCINE C
   Stremler MA, 2014, FLUID DYN RES, V46, DOI 10.1088/0169-5983/46/6/061410
   Stremler MA, 2011, J FLUID STRUCT, V27, P774, DOI 10.1016/j.jfluidstructs.2011.04.004
   Tracy L. F, 2019, INT FORUM ALLERGY RH
   Wilhelm FH, 2003, BEHAV MODIF, V27, P671, DOI 10.1177/0145445503256321
   Xi JX, 2008, INT J HEAT MASS TRAN, V51, P5562, DOI 10.1016/j.ijheatmasstransfer.2008.04.037
   Zhao K, 2014, INT FORUM ALLERGY RH, V4, P435, DOI 10.1002/alr.21319
   Zhao K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024618
   Zubair M, 2012, J MED BIOL ENG, V32, P77, DOI [10.5405/jmbe.873, 10.5405/jmbe.948]
NR 62
TC 1
Z9 1
U1 3
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 29
PY 2020
VL 10
IS 1
DI 10.1038/s41598-020-66716-0
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MJ8TO
UT WOS:000548360700004
PM 32601278
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Halford, B
AF Halford, Bethany
TI Doctors explore a popular heartburn drug for treating COVID-19
SO CHEMICAL & ENGINEERING NEWS
LA English
DT Article
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0009-2347
EI 1520-605X
J9 CHEM ENG NEWS
JI Chem. Eng. News
PD JUN 29
PY 2020
VL 98
IS 25
BP 25
EP 26
PG 2
WC Chemistry, Multidisciplinary; Engineering, Chemical
SC Chemistry; Engineering
GA MI7LP
UT WOS:000547584700035
DA 2021-01-01
ER

PT J
AU Gonzalez-Gerez, JJ
   Bernal-Utrera, C
   Anarte-Lazo, E
   Garcia-Vidal, JA
   Botella-Rico, JM
   Rodriguez-Blanco, C
AF Jose Gonzalez-Gerez, Juan
   Bernal-Utrera, Carlos
   Anarte-Lazo, Ernesto
   Antonio Garcia-Vidal, Jose
   Martin Botella-Rico, Jose
   Rodriguez-Blanco, Cleofas
TI Therapeutic pulmonary telerehabilitation protocol for patients affected
   by COVID-19, confined to their homes: study protocol for a randomized
   controlled trial
SO TRIALS
LA English
DT Article
DE Pandemics; Coronavirus infections; Physical therapy specialty;
   Telerehabilitation; Exercise therapy; Pulmonary ventilation; Randomized
   controlled trial; COVID-19
ID PHYSICAL-ACTIVITY; STAND TEST; EXERCISE; PROGRAM; STRENGTH; COPD
AB BackgroundIn December 2019, 27 cases of pneumonia, of unknown cause, were identified in the province of Hubei (China). The WHO declared the situation as a Public Health Emergency of International Concern, and it was finally declared a global pandemic on March 11, 2020. The Spanish Government obliges the entire population to remain confined to their homes, with the exception of essential basic services, to stop the spread of COVID-19. Home isolation implies a notable physical deconditioning. Telerehabilitation methods have reported positive experiences, and we propose to study in affected patients of COVID-19, due to the general house confinement of the entire Spanish population.MethodsPatients will be recruited in the regions of Andalusia, Murcia, and Valencia (Spain). Patients will remain confined to their homes, and there, they will carry out their assigned exercise program, which will be controlled telematically. Evaluators will attend to carry out all measurements at the beginning, during, and end of the study, telematically controlled. The patients will be randomly divided into three groups, two of them will perform a home exercise program (breathing exercises or non-specific exercises for muscle toning) and the third group will perform sedentary activities, using mental activation techniques, and will act as a sham group. We will evaluate respiratory variables and other variables of the physical state through physical tests, effort, and perceived fatigue. The data will be statistically analyzed, and the hypotheses will be tested between the groups, using the SPSS software, v.24, considering a 95% confidence interval.DiscussionWe will analyze the results, in terms of the level of fatigue and perceived exertion, physical health, and maintenance of respiratory activity of two types of exercise programs, toning and respiratory, applied in patients affected by COVID-19 during the period of home confinement. We intend to investigate a field not previously studied, such as the repercussion of carrying out a toning and respiratory exercise program in these patients, in historical circumstances that no one had previously observed in Spain, since the general population has never been forced to remain confined in their homes, due to a pandemic infection, by a coronavirus (COVID-19). Observing the effects that these two home exercise programs could produce in patients infected with COVID-19, we will try to better analyze and understand the mechanisms that are associated with the worsening of breathing in this type of patient.Trial registrationBrazilian Clinical Trial Registry RBR-6m69fc. Registered on March 31, 2020.
C1 [Jose Gonzalez-Gerez, Juan; Bernal-Utrera, Carlos; Rodriguez-Blanco, Cleofas] Fisiosur I D Res Inst, Almeria, Spain.
   [Jose Gonzalez-Gerez, Juan] Univ Almeria, Dept Nursing Physiotherapy & Med, Almeria, Spain.
   [Bernal-Utrera, Carlos] Univ Seville, Doctoral Program Hlth Sci, Seville, Spain.
   [Anarte-Lazo, Ernesto] Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Ctr Precis Rehabil Spinal Pain CPR Spine, Birmingham, W Midlands, England.
   [Antonio Garcia-Vidal, Jose] Univ Murcia, Physiotherapy Dept, Murcia, Spain.
   [Martin Botella-Rico, Jose] Univ Cardenal Herrera CEU, Physiotherapy Dept, Alicante, Spain.
   [Rodriguez-Blanco, Cleofas] Univ Seville, Physiotherapy Dept, Seville, Spain.
RP Bernal-Utrera, C (corresponding author), Fisiosur I D Res Inst, Almeria, Spain.; Bernal-Utrera, C (corresponding author), Univ Seville, Doctoral Program Hlth Sci, Seville, Spain.
EM cbernal495@gmail.com
RI Rodriguez-Blanco, Cleofas/AAT-5154-2020; Lazo, Ernesto
   Anarte/ABH-2942-2020
OI Rodriguez-Blanco, Cleofas/0000-0002-8674-9180; Lazo, Ernesto
   Anarte/0000-0002-9731-9039; Bernal Utrera, Carlos/0000-0002-6235-8353
CR Diago CAA, 2018, ARCH BRONCONEUMOL, V54, P74, DOI 10.1016/j.arbres.2017.08.001
   [Anonymous], 2020, HOME CARE PATIENTS C
   [Anonymous], 2020, RECOMENDACIONES FISI
   [Anonymous], 2020, CRITERIOS ATENCION C
   [Anonymous], 2020, REPWHO CHIN JOINT MI
   Beaumont M, 2015, CHRON RESP DIS, V12, P305, DOI 10.1177/1479972315594625
   Burkhalter N, 1996, Rev Lat Am Enfermagem, V4, P65, DOI 10.1590/S0104-11691996000300006
   Davies KAB, 2019, THER ADV ENDOCRINOL, V10, DOI 10.1177/2042018819888824
   de Roos P, 2018, PHYSIOTHERAPY, V104, P116, DOI 10.1016/j.physio.2016.08.005
   del Corral T, 2018, RESPIRATION, V95, P87, DOI 10.1159/000481264
   Devries MC, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12493
   Dimitrov S, 2017, BRAIN BEHAV IMMUN, V61, P60, DOI 10.1016/j.bbi.2016.12.017
   Eaton T, 2007, Chron Respir Dis, V4, P23, DOI 10.1177/1479972306074481
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Guan WJ, 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974, 10.1101/2020.02.06.20020974.]
   Head BA, 2009, TELEMED J E-HEALTH, V15, P44, DOI 10.1089/tmj.2008.0061
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hwang R, 2017, HEART LUNG, V46, P320, DOI 10.1016/j.hrtlng.2017.03.004
   Jones CJ, 1999, RES Q EXERCISE SPORT, V70, P113, DOI 10.1080/02701367.1999.10608028
   Kopper RJH, 2006, CHEST, V129, P886, DOI 10.1378/chest.129.4.886
   Laver KE, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010255.pub3
   LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Montero D, 2017, VASC MED, V22, P285, DOI 10.1177/1358863X17712103
   Nieman DC, 2019, J SPORT HEALTH SCI, V8, P201, DOI 10.1016/j.jshs.2018.09.009
   Noe E, 2015, EFFECTIVENESS USABIL
   Ozatevli S, 2007, RESP MED, V101, P286, DOI 10.1016/j.rmed.2006.05.007
   Piotrowicz E, 2019, AM HEART J, V217, P148, DOI 10.1016/j.ahj.2019.08.015
   Rodriguez-Pascual L, 2006, ARCH BRONCONEUMOL, V42, P144, DOI 10.1157/13085565
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Stavrou NAM, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00026
   Thompson DA, 2009, TELEMED J E-HEALTH, V15, P700, DOI 10.1089/tmj.2009.0021
   van Egmond MA, 2018, PHYSIOTHERAPY, V104, P277, DOI 10.1016/j.physio.2018.04.004
   Van Straaten MG, 2014, ARCH PHYS MED REHAB, V95, P1810, DOI 10.1016/j.apmr.2014.05.004
   Wakabayashi R, 2018, GERIATR GERONTOL INT, V18, P42, DOI 10.1111/ggi.13134
   Walhin JP, 2013, J PHYSIOL-LONDON, V591, P6231, DOI 10.1113/jphysiol.2013.262709
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, PNEUM UNKN CAUS CHIN
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yan CH, 2020, INT FORUM ALLERGY RH, V10, P806, DOI 10.1002/alr.22579
   Zanini A, 2015, INT J CHRONIC OBSTR, V10, P2423, DOI 10.2147/COPD.S91176
NR 41
TC 1
Z9 1
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 29
PY 2020
VL 21
IS 1
DI 10.1186/s13063-020-04494-w
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MG8BK
UT WOS:000546254800005
PM 32600378
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Stoll, F
   Blank, A
   Mikus, G
   Czock, D
   Foerster, KI
   Hermann, S
   Haussler, K
   Muhareb, A
   Hummler, S
   Weiss, J
   Burhenne, J
   Haefeli, WE
AF Stoll, Felicitas
   Blank, Antje
   Mikus, Gerd
   Czock, David
   Foerster, Kathrin I.
   Hermann, Simon
   Haeussler, Katja
   Muhareb, Amin
   Hummler, Simone
   Weiss, Johanna
   Burhenne, Juergen
   Haefeli, Walter E.
TI Impact of pantoprazole on absorption and disposition of
   hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A
   structured summary of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Trial protocol;
   Hydroxychloroquine; Pantoprazole; Absorption; Drug-drug interaction;
   Microdosing; Midazolam; Yohimbine
AB ObjectivesPrimary objective: Evaluation of the effect of the proton pump inhibitor (PPI) pantoprazole on the absorption of hydroxychloroquine (HCQ).Secondary objectives:center dot Evaluation of the relationship between HCQ concentrations in whole blood, plasma and intracellular concentrations in target cells - peripheral blood mononuclear cells (PBMCs).center dot Evaluation of HCQ as a potential perpetrator in drug-drug interactions at the level of cytochrome P450 (CYP) 3A4 and CYP2D6 (major drug metabolizing enzymes).Trial designSingle centre, open-label, parallel group, two-arm, phase I drug-drug interaction trial.ParticipantsHealthy volunteers (18-60 years old) are treated in the Clinical Pharmacological Trial Center of Heidelberg University Hospital, Germany.Intervention and comparator center dot Participants are randomized in a group to either receive a nine-day course of pantoprazole, or to a control group without pantoprazole. All participants receive a single dose of HCQ 400 mg.center dot Additionally, CYP3A4 and CYP2D6 phenotyping with microdosed probe drugs is performed using midazolam and yohimbine as enzyme activity markers, respectively.Main outcomesPrimary endpoint:Area under the curve (AUC)(0-72 h) and maximum concentration (C-max) of a single oral dose of 400 mg HCQ with and without pantoprazole (changes in these two values describe relevant aspects of exposure to HCQ with and without administration of pantoprazole).Secondary endpoints:center dot AUC(2-4 h), AUC(0-6 h) and C-max of midazolam and yohimbine.center dot Correlation of HCQ concentrations in whole blood with concentrations in plasma and peripheral blood mononuclear cells (PBMC).RandomisationParticipants are assigned to treatment groups by using a randomisation list (1:1, block size = 4) and consecutive enrolment.Blinding (masking)The trial is an open-label trial, participants and investigators are not blinded.Numbers to be randomised (sample size)A total number of 24 participants (12 per group) are planned to be randomised.Trial StatusProtocol version 2.1 dated 24/04/2020, first patient first visit. April 30th, 2020, recruitment ongoing, anticipated end of study June 30th, 2020.Trial registrationEudraCT Number: 2020-001470-30, registered on 31 March 2020 German Clinical trials register number / International Clinical Trials Registry Platform: DRKS00021573, registered on 27 April 2020Full protocolThe full trial protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full trial protocol. The trial protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
C1 [Stoll, Felicitas; Blank, Antje; Mikus, Gerd; Czock, David; Foerster, Kathrin I.; Hermann, Simon; Haeussler, Katja; Muhareb, Amin; Hummler, Simone; Weiss, Johanna; Burhenne, Juergen; Haefeli, Walter E.] Heidelberg Univ Hosp, Heidelberg, Baden Wurttembe, Germany.
RP Blank, A (corresponding author), Heidelberg Univ Hosp, Heidelberg, Baden Wurttembe, Germany.
EM antje.blank@med.uni-heidelberg.de
OI Blank, Antje/0000-0001-8743-5194
FU Department of Clinical Pharmacology and Pharmacoepidemiology of
   Heidelberg University Hospital, Germany; Ruprecht-Karls-University
   Heidelberg, Medical Faculty
FX The study is funded by the Department of Clinical Pharmacology and
   Pharmacoepidemiology of Heidelberg University Hospital, Germany. The
   legal sponsor of the trial is the Ruprecht-Karls-University Heidelberg,
   Medical Faculty, represented in law by Heidelberg University Hospital,
   Germany, and its commercial director Katrin Erk. The trial is
   investigator-initiated, therefore, the main investigator has obtained
   all rights and duties from the legal sponsor except contract management.
   The legal sponsor itself does not have a role in collection, management,
   analysis, and interpretation of data; writing of the report; and the
   decision to submit the report for publication.
NR 0
TC 1
Z9 1
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 29
PY 2020
VL 21
IS 1
AR 584
DI 10.1186/s13063-020-04476-y
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MG8BK
UT WOS:000546254800001
PM 32600363
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mestre-Gomez, B
   Lorente-Ramos, RM
   Rogado, J
   Franco-Moreno, A
   Obispo, B
   Salazar-Chiriboga, D
   Saez-Vaquero, T
   Torres-Macho, J
   Abad-Motos, A
   Cortina-Camarero, C
   Such-Diaz, A
   Ruiz-Velasco, E
   Churruca-Sarasqueta, J
   Munoz-Rivas, N
AF Mestre-Gomez, B.
   Lorente-Ramos, R. M.
   Rogado, J.
   Franco-Moreno, A.
   Obispo, B.
   Salazar-Chiriboga, D.
   Saez-Vaquero, T.
   Torres-Macho, J.
   Abad-Motos, A.
   Cortina-Camarero, C.
   Such-Diaz, A.
   Ruiz-Velasco, E.
   Churruca-Sarasqueta, J.
   Munoz-Rivas, N.
CA Infanta Leonor Thrombosis Res Grp
TI Incidence of pulmonary embolism in non-critically ill COVID-19 patients.
   Predicting factors for a challenging diagnosis
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article; Early Access
DE COVID-19; Pulmonary embolism; Hypercoagulable state; Antithrombotic
   therapy; Computed tomography pulmonary angiography
AB Recent studies suggest that thrombotic complications are a common phenomenon in the novel SARS-CoV-2 infection. The main objective of our study is to assess cumulative incidence of pulmonary embolism (PE) in non critically ill COVID-19 patients and to identify its predicting factors associated to the diagnosis of pulmonary embolism. We retrospectevely reviewed 452 electronic medical records of patients admitted to Internal Medicine Department of a secondary hospital in Madrid during Covid 19 pandemic outbreak. We included 91 patients who underwent a multidetector Computed Tomography pulmonary angiography(CTPA) during conventional hospitalization. The cumulative incidence of PE was assessed ant the clinical, analytical and radiological characteristics were compared between patients with and without PE. PE incidence was 6.4% (29/452 patients). Most patients with a confirmed diagnosed with PE recieved low molecular weight heparin (LMWH): 79.3% (23/29). D-dimer peak was significatly elevated in PE vs non PE patients (14,480 vs 7230 mcg/dL, p = 0.03). In multivariate analysis of patients who underwent a CTPA we found that plasma D-dimer peak was an independen predictor of PE with a best cut off point of > 5000 mu g/dl (OR 3.77; IC95% (1.18-12.16), p = 0.03). We found ninefold increased risk of PE patients not suffering from dyslipidemia (OR 9.06; IC95% (1.88-43.60). Predictive value of AUC for ROC is 75.5%. We found a high incidence of PE in non critically ill hospitalized COVID 19 patients despite standard thromboprophylaxis. An increase in D-dimer levels is an independent predictor for PE, with a best cut-off point of > 5000 mu g/ dl.
C1 [Mestre-Gomez, B.; Franco-Moreno, A.; Saez-Vaquero, T.; Torres-Macho, J.; Munoz-Rivas, N.] Infanta Leonor Univ Hosp, Internal Med Dept, Gran Via Este Ave 80, Madrid 28031, Spain.
   [Lorente-Ramos, R. M.; Salazar-Chiriboga, D.] Infanta Leonor Univ Hosp, Radiol Dept, Madrid, Spain.
   [Rogado, J.; Obispo, B.] Infanta Leonor Univ Hosp, Med Oncol Dept, Madrid, Spain.
   [Abad-Motos, A.] Infanta Leonor Univ Hosp, Anesthesiol Dept, Madrid, Spain.
   [Cortina-Camarero, C.] Infanta Leonor Univ Hosp, Cardiol Dept, Madrid, Spain.
   [Such-Diaz, A.] Infanta Leonor Univ Hosp, Dept Hosp Pharm, Madrid, Spain.
   [Ruiz-Velasco, E.] Infanta Leonor Univ Hosp, Nursing Dept, Madrid, Spain.
   [Churruca-Sarasqueta, J.] Infanta Leonor Univ Hosp, Hematoloy Dept, Madrid, Spain.
   [Torres-Macho, J.] Univ Complutense Madrid, Madrid, Spain.
RP Munoz-Rivas, N (corresponding author), Infanta Leonor Univ Hosp, Internal Med Dept, Gran Via Este Ave 80, Madrid 28031, Spain.
EM nmunozr@salud.madrid.org
OI Hernandez-Rivas, Jose-Angel/0000-0003-4550-757X; Abad-Motos,
   Ane/0000-0002-9644-2887; Sierra-Hidalgo, Fernando/0000-0003-4044-8304;
   Churruca Sarasqueta, Juan/0000-0003-1484-504X
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bompard F, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01365-2020
   Castiglione V, 2020, EUR HEART J-CARD PHA, V6, P258, DOI 10.1093/ehjcvp/pvaa042
   Chen J, 2020, FINDINGS ACUTE PULMO
   Ciceri F., 2020, CRIT CARE RESUSC
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Leonard-Lorant I, 2020, RADIOLOGY, V296, pE189, DOI 10.1148/radiol.2020201561
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 19
TC 5
Z9 5
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
DI 10.1007/s11239-020-02190-9
EA JUN 2020
PG 7
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA ME7YJ
UT WOS:000544870200001
PM 32613385
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Peck, RW
   Weiner, D
   Cook, J
   Powell, JR
AF Peck, Richard W.
   Weiner, Daniel
   Cook, Jack
   Robert Powell, J.
TI A Real-World Evidence Framework for Optimizing Dosing in All Patients
   with COVID-19
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
AB Potential treatments for coronavirus disease 2019 (COVID-19) are being investigated at unprecedented speed, and successful treatments will rapidly be used in tens or hundreds of thousands of patients. To ensure safe and effective use in all those patents it is essential also to develop, at unprecedented speed, a means to provide frequently updated, optimal dosing information for all patient subgroups. Success will require immediate collaboration between drug developers, academics, and regulators.
C1 [Peck, Richard W.] Roche Innovat Ctr, Clin Pharmacol Pharma Res & Early Dev, Basel, Switzerland.
   [Cook, Jack] Pfizer Inc, Clin Pharmacol, Groton, CT 06340 USA.
RP Peck, RW (corresponding author), Roche Innovat Ctr, Clin Pharmacol Pharma Res & Early Dev, Basel, Switzerland.
EM richard.peck@roche.com
FU Division Of Behavioral and Cognitive SciNational Science Foundation
   (NSF)NSF - Directorate for Social, Behavioral & Economic Sciences (SBE)
   [0904333] Funding Source: National Science Foundation
CR [Anonymous], 2020, LANCET, V395, P1168, DOI 10.1016/S0140-6736(20)30822-9
   CDC, 2020, GROUPS HIGH RISK SEV
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Goncalves Antonio, 2020, medRxiv, DOI 10.1101/2020.04.04.20047886
   Lee JI, 2010, CLIN PHARMACOKINET, V49, P295, DOI 10.2165/11319980-000000000-00000
   Powell JR, 2020, CLIN PHARMACOL THER, DOI 10.1002/cpt.1923
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Venkatakrishnan K, 2020, CLIN PHARMACOL THER, V108, P699, DOI 10.1002/cpt.1879
NR 8
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD NOV
PY 2020
VL 108
IS 5
BP 921
EP 923
DI 10.1002/cpt.1922
EA JUN 2020
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OA1YS
UT WOS:000543964800001
PM 32445484
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Zhai, P
   Ding, YB
   Li, YM
AF Zhai, Pan
   Ding, Yanbing
   Li, Yiming
TI The impact of COVID-19 on ischemic stroke
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Ischemic stroke; Hypoxemia; Case report
ID CORONAVIRUS; PNEUMONIA; SARS
AB Background The outbreak of a novel coronavirus since December 2019, became an emergency of major international concern. As of June 21, 2020, the SARS-CoV-2 pandemic has caused 8,769,844 confirmed infections with 463,745 fatal cases worldwide. The SARS-CoV-2 outbreak is a major challenge for clinicians. In our clinic, we found a rare case that a COVID-19 patient combined with ischemic stroke. Case presentation A 79-year-old man was admitted to the Hubei Provincial Hospital of Traditional Chinese Medicine due to right limb weakness for 1 day and slight cough for 1 week. At presentation, his oxygen saturation was 94.2% on room air and body temperature was 37.3 degrees C (99.0 degrees F) with some moist rales. Neurological examination showed right limb weakness, and the limb muscle strength was grade 4. The left leg and arms were unaffected. In addition, runs of speech were not fluent enough with tongue deviation. Laboratory studies showed lymphopenia and eosinophilic granulocytopenia. Chest CT revealed bilateral pulmonary parenchymal ground-glass and consolidative pulmonary opacities, with a peripheral lung distribution. Real-time polymerase chain reaction (RT-PCR) from throat swab sample was positive for SARS-CoV-2 nucleic acid. This patient was treated with antiviral drugs and anti-inflammatory drugs with supportive care until his discharge. Clopidogrel (75 mg) and atorvastatin (20 mg) were administered orally to treat acute ischemic stroke. After 12 days of treatment, he can walk normally and communicate with near fluent language. Conclusion We report an even more unusual case, a patient who was hospitalized for right limb weakness and was later diagnosed with COVID-19. Here, SARS-CoV-2 infection caused hypoxemia and excessive secretion of inflammatory cytokines, which contribute to the occurrence and development of ischemic stroke. Once COVID-19 patients show acute ischemic stroke, neurologists should cooperate with infectious disease doctors to help patients.
C1 [Zhai, Pan; Ding, Yanbing] Hubei Prov Hosp Tradit Chinese Med, Dept Neurol, Wuhan 430073, Hubei, Peoples R China.
   [Li, Yiming] Wuhan Univ, Zhongnan Hosp, Dept Crit Care Med, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
RP Li, YM (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Crit Care Med, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
EM lym-fly@whu.edu.cn
FU Professional Development Research Project of National Chinese Medicine
   Clinical Research Base of State Administration of Traditional Chinese
   Medicine [JDZX2015295]
FX This work was supported by Professional Development Research Project of
   National Chinese Medicine Clinical Research Base of State Administration
   of Traditional Chinese Medicine (No. JDZX2015295) to Yanbing Ding.
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Ham PB, 2017, PROG NEUROBIOL, V157, P92, DOI 10.1016/j.pneurobio.2016.06.006
   Hartmann P, 2015, CELL MOL LIFE SCI, V72, P3253, DOI 10.1007/s00018-015-1925-z
   Hess DC, 2020, TRANSL STROKE RES, V11, P322, DOI 10.1007/s12975-020-00818-9
   Hoffmann S, 2017, J CEREBR BLOOD F MET, V37, P3671, DOI 10.1177/0271678X16671964
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lee DTS, 2004, CLIN INFECT DIS, V39, P1247, DOI 10.1086/424016
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li SJ, 2017, PROG NEUROBIOL, V157, P79, DOI 10.1016/j.pneurobio.2017.01.001
   Regenhardt RW, 2018, JAMA NEUROL, V75, P1273, DOI 10.1001/jamaneurol.2018.1073
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 20
TC 9
Z9 9
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD JUN 29
PY 2020
VL 15
IS 1
AR 78
DI 10.1186/s13000-020-00994-0
PG 5
WC Pathology
SC Pathology
GA MG7NO
UT WOS:000546216100001
PM 32600350
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Aguila, EJT
   Cua, IHY
AF Aguila, Enrik John T.
   Cua, Ian Homer Y.
TI Repurposed GI Drugs in the Treatment of COVID-19
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Letter
ID CORONAVIRUS; RECEPTOR; VIRUS
C1 [Aguila, Enrik John T.; Cua, Ian Homer Y.] St Lukes Med Ctr Global City, Inst Digest & Liver Dis, Rizal Dr Cor 32nd St & 5th Ave, Taguig City 1634, Metro Manila, Philippines.
RP Aguila, EJT (corresponding author), St Lukes Med Ctr Global City, Inst Digest & Liver Dis, Rizal Dr Cor 32nd St & 5th Ave, Taguig City 1634, Metro Manila, Philippines.
EM enrikaguila@gmail.com
RI Aguila, Enrik John/AAU-7411-2020
OI Gandhi, Zainab/0000-0002-7214-4981; Aguila, Enrik
   John/0000-0003-3440-2406
CR Bojkova D., 2020, SARS COV 2 SARS COV, DOI [10.1101/2020.04.03.024257., DOI 10.1101/2020.04.03.024257, 10.1101/2020.04.03.024257]
   Bourinbaiar AS, 1996, LIFE SCI, V59, pPL365, DOI 10.1016/S0024-3205(96)00553-X
   Freedberg DE, 2020, GASTROENTEROLOGY, V159, P1129, DOI 10.1053/j.gastro.2020.05.053
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Kopel J, 2020, DIGEST DIS SCI, P1
   Kopel J, 2020, DIGEST DIS SCI, V65, P1932, DOI 10.1007/s10620-020-06362-8
   Perisetti A, 2020, CLIN GASTROENTEROL H, V18, P3054, DOI 10.1016/j.cgh.2020.06.008
   Sasaki T, 2005, EUR J PHARMACOL, V509, P201, DOI 10.1016/j.ejphar.2004.12.042
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
NR 10
TC 3
Z9 3
U1 4
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD AUG
PY 2020
VL 65
IS 8
BP 2452
EP 2453
DI 10.1007/s10620-020-06430-z
EA JUN 2020
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ML8PT
UT WOS:000544161500002
PM 32601778
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Joshi, T
   Sharma, P
   Joshi, T
   Pundir, H
   Mathpal, S
   Chandra, S
AF Joshi, Tanuja
   Sharma, Priyanka
   Joshi, Tushar
   Pundir, Hemlata
   Mathpal, Shalini
   Chandra, Subhash
TI Structure-based screening of novel lichen compounds against SARS
   Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19
SO MOLECULAR DIVERSITY
LA English
DT Article; Early Access
DE COVID-19; Lichen COMPOUNDS; Main protease; Molecular docking; Molecular
   dynamics simulation
ID HIGH-THROUGHPUT; DISCOVERY; DESIGN
AB The outbreak of SARS-CoV-2 and deaths caused by it all over the world have imposed great concern on the scientific community to develop potential drugs to combat Coronavirus disease-19 (COVID-19). In this regard, lichen metabolites may offer a vast reservoir for the discovery of antiviral drug candidates. Therefore, to find novel compounds against COVID-19, we created a library of 412 lichen compounds and subjected to virtual screening against the SARS-CoV-2 Main protease (Mpro). All the ligands were virtually screened, and 27 compounds were found to have high affinity with Mpro. These compounds were assessed for drug-likeness analysis where two compounds were found to fit well for redocking studies. Molecular docking, drug-likeness, X-Score, and toxicity analysis resulting in two lichen compounds, Calycin and Rhizocarpic acid with Mpro-inhibiting activity. These compounds were finally subjected to molecular dynamics simulation to compare the dynamics behavior and stability of the Mpro after ligand binding. The binding energy was calculated by MM-PBSA method to determine the intermolecular protein-ligand interactions. Our results showed that two compounds; Calycin and Rhizocarpic acid had the binding free energy of - 42.42 kJ mol/1 and - 57.85 kJ mol/1 respectively as compared to reference X77 (- 91.78 kJ mol/1). We concluded that Calycin and Rhizocarpic acid show considerable structural and pharmacological properties and they can be used as hit compounds to develop potential antiviral agents against SARS-CoV-2. These lichen compounds may be a suitable candidate for further experimental analysis.
C1 [Joshi, Tanuja; Chandra, Subhash] Kumaun Univ, Dept Bot, SSJ Campus, Almora 263601, Uttarakhand, India.
   [Sharma, Priyanka; Pundir, Hemlata] Kumaun Univ, Dept Bot, DSB Campus, Naini Tal 263001, Uttarakhand, India.
   [Joshi, Tushar; Mathpal, Shalini] Kumaun Univ, Dept Biotechnol, Dept Bhimtal, Bhimtal 263136, Uttarakhand, India.
RP Chandra, S (corresponding author), Kumaun Univ, Dept Bot, SSJ Campus, Almora 263601, Uttarakhand, India.
EM joshitanuja222@gmail.com; priyancisharma@gmail.com;
   tjoshi6869@gmail.com; hemapundir29@gmail.com;
   shalinimathpal.121@gmail.com; scjnu@yahoo.co.in
RI Joshi, Tushar/AAJ-9626-2020; Chandra, Subhash/AAN-6789-2020
OI Chandra, Subhash/0000-0002-8978-5427
CR Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   De Clercq E, 2002, NAT REV DRUG DISCOV, V1, P13, DOI 10.1038/nrd703
   Esimone CO, 2009, CHEMOTHERAPY, V55, P119, DOI 10.1159/000194974
   Fazio AT, 2007, Z NATURFORSCH C, V62, P543
   Gohlke H, 2000, J MOL BIOL, V295, P337, DOI 10.1006/jmbi.1999.3371
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hoelder S, 2012, MOL ONCOL, V6, P155, DOI 10.1016/j.molonc.2012.02.004
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huneck S., 1928, IDENTIFICATION LICHE, P29
   Ingolfsdottir K, 2002, PHYTOCHEMISTRY, V61, P729, DOI 10.1016/S0031-9422(02)00383-7
   Joshi N, 2020, MAHABODHI TEMPLE AT BODHGAYA: CONSTRUCTING SACRED PLACENESS, DECONSTRUCTING THE GREAT CASE OF 1895, P1
   Joshi T, 2020, J BIOMOL STRUCT DYN, V38, P3544, DOI 10.1080/07391102.2019.1664328
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lipinski CA, 2000, J PHARMACOL TOX MET, V44, P235, DOI 10.1016/S1056-8719(00)00107-6
   Mabkhot YN, 2016, MOLECULES, V21
   Mishra CB, 2018, EUR J MED CHEM, V151, P520, DOI 10.1016/j.ejmech.2018.04.007
   Molnar K, 2010, Z NATURFORSCH C, V65, P157
   Peterson B, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11010033
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Verma P, 2018, J BIOMOL STRUCT DYN, V36, P1182, DOI 10.1080/07391102.2017.1317025
   Wang RX, 2002, J COMPUT AID MOL DES, V16, P11, DOI 10.1023/A:1016357811882
NR 23
TC 2
Z9 2
U1 4
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1381-1991
EI 1573-501X
J9 MOL DIVERS
JI Mol. Divers.
DI 10.1007/s11030-020-10118-x
EA JUN 2020
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Applied; Chemistry,
   Medicinal; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA MD7HG
UT WOS:000544141200001
PM 32602074
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Xia, SY
   Wu, M
   Chen, S
   Zhang, T
   Ye, LN
   Liu, J
   Li, H
AF Xia, Siyu
   Wu, Ming
   Chen, Si
   Zhang, Tao
   Ye, Lina
   Liu, Jun
   Li, Hui
TI Long Term Culture of Human Kidney Proximal Tubule Epithelial Cells
   Maintains Lineage Functions and Serves as anEx vivoModel for Coronavirus
   Associated Kidney Injury
SO VIROLOGICA SINICA
LA English
DT Article
DE Conditionally reprogrammed cells (CRCs); Organoids; Kidney proximal
   tubule epithelial cells (KPTECs); SARS-CoVs; Angiotensin-converting
   enzyme 2 (ACE2)
ID SARS CORONAVIRUS; CANCER-CELLS; IMMORTALIZATION; COVID-19; TROPISM;
   GROWTH; MODEL; ENTRY; H5N1
AB The mechanism of how SARS-CoV-2 causes severe multi-organ failure is largely unknown. Acute kidney injury (AKI) is one of the frequent organ damage in severe COVID-19 patients. Previous studies have shown that human renal tubule cells could be the potential host cells targeted by SARS-CoV-2. Traditional cancer cell lines or immortalized cell lines are genetically and phenotypically different from host cells. Animal models are widely used, but often fail to reflect a physiological and pathogenic status because of species tropisms. There is an unmet need for normal human epithelial cells for disease modeling. In this study, we successfully established long term cultures of normal human kidney proximal tubule epithelial cells (KPTECs) in 2D and 3D culture systems using conditional reprogramming (CR) and organoids techniques. These cells had the ability to differentiate and repair DNA damage, and showed no transforming property. Importantly, the CR KPTECs maintained lineage function with expression of specific transporters (SLC34A3 and cubilin). They also expressed angiotensin-converting enzyme 2 (ACE2), a receptor for SARS-CoV and SARS-CoV-2. In contrast, cancer cell line did not express endogenous SLC34A3, cubilin and ACE2. Very interestingly, ACE2 expression was around twofold higher in 3D organoids culture compared to that in 2D CR culture condition. Pseudovirion assays demonstrated that SARS-CoV spike (S) protein was able to enter CR cells with luciferase reporter. This integrated 2D CR and 3D organoid cultures provide a physiologicalex vivomodel to study kidney functions, innate immune response of kidney cells to viruses, and a novel platform for drug discovery and safety evaluation.
C1 [Xia, Siyu; Wu, Ming; Chen, Si; Zhang, Tao; Liu, Jun; Li, Hui] Wuhan Univ, Sch Basic Med Sci, Inst Med Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.
   [Ye, Lina; Li, Hui] Wuhan Univ, Shenzhen Inst, Shenzhen 518057, Peoples R China.
RP Li, H (corresponding author), Wuhan Univ, Sch Basic Med Sci, Inst Med Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.
EM somhli@whu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81571396, 81771528]; Science, Technology and
   Innovation Commission of Shenzhen Municipality [JCYJ20170411090932146,
   JCYJ20170818110544730]
FX This work was supported by the National Natural Science Foundation of
   China (81571396 and 81771528); Science, Technology and Innovation
   Commission of Shenzhen Municipality (JCYJ20170411090932146,
   JCYJ20170818110544730).
CR Alkhilaiwi F, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100181
   Alkhilaiwi F, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0918-x
   Borodovsky A, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0745-1
   Brewington JJ, 2018, JOVE-J VIS EXP, V134, P57492, DOI DOI 10.3791/57492
   Chafekar A, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020093
   Chai J, 2020, CURR PHARM DESIGN, V26, P2657, DOI 10.2174/1381612826666200316155252
   Chan RWY, 2013, VIRUS RES, V178, P133, DOI 10.1016/j.virusres.2013.03.003
   Feng WQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123520
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo Y, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-39
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin Liting, 2018, Oncotarget, V9, P11503, DOI 10.18632/oncotarget.23817
   Kaye M, 2006, EMERG INFECT DIS, V12, P128, DOI 10.3201/eid1201.050496
   Kong SL, 2009, VIRUS RES, V145, P260, DOI 10.1016/j.virusres.2009.07.014
   Kowolik CM, 2004, ONCOGENE, V23, P5950, DOI 10.1038/sj.onc.1207801
   Krawczyk E, 2020, LAB INVEST, V100, P38, DOI 10.1038/s41374-019-0297-7
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Li Z, 2020, CAUTION KIDNEY DYSFU, DOI [10.1101/2020.02.08.20021212:2020.2002.2008.20021212, DOI 10.1101/2020.02.08.20021212:2020.2002.2008.20021212]
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Liu XF, 2017, NAT PROTOC, V12, P439, DOI 10.1038/nprot.2016.174
   Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Moorefield EC, 2018, BMC CELL BIOL, V19, DOI 10.1186/s12860-018-0165-0
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Nicolas N, 2019, ADV EXP MED BIOL, V1164, P101, DOI 10.1007/978-3-030-22254-3_8
   Orosz DE, 2004, IN VITRO CELL DEV-AN, V40, P22
   Palechor-Ceron N, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111327
   Pan XW, 2020, INTENS CARE MED, V46, P1114, DOI 10.1007/s00134-020-06026-1
   Peters-Hall JR, 2020, FASEB J, V34, P386, DOI 10.1096/fj.201902376R
   Peters-Hall JR, 2018, AM J PHYSIOL-LUNG C, V315, pL313, DOI 10.1152/ajplung.00355.2017
   Phillips Aled O, 2003, Curr Diab Rep, V3, P491, DOI 10.1007/s11892-003-0013-1
   Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6
   Saenz FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097666
   Sayej WN, 2018, PEDIATR RES, V84, P306, DOI 10.1038/s41390-018-0033-9
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Smith PL, 2006, METHOD ENZYMOL, V419, P194, DOI 10.1016/S0076-6879(06)19009-6
   Smits SL, 2011, J VIROL, V85, P4234, DOI 10.1128/JVI.02395-10
   Stewart BJ, 2019, SCIENCE, V365, P1461, DOI 10.1126/science.aat5031
   Suprynowicz FA, 2012, P NATL ACAD SCI USA, V109, P20035, DOI 10.1073/pnas.1213241109
   Wan ACA, 2019, TRENDS PHARMACOL SCI, V40, P161, DOI 10.1016/j.tips.2019.01.003
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang L, 2018, BIOCHEM BIOPH RES CO, V499, P735, DOI 10.1016/j.bbrc.2018.03.168
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Wang YN, 2020, AM J CANCER RES, V10, P249
   Wang ZL, 2019, MOL MED REP, V19, P4623, DOI 10.3892/mmr.2019.10160
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wieser M, 2008, AM J PHYSIOL-RENAL, V295, pF1365, DOI 10.1152/ajprenal.90405.2008
   Wolf S, 2017, PEDIAT ALLERG IMM-UK, V28, P810, DOI 10.1111/pai.12810
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 2020, COR DIS 2019 COVID 1
   World Health Organization (WHO), 2020, COR DIS 2019 CIVID 1
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xie CB, 2020, INT J INFECT DIS, V93, P264, DOI 10.1016/j.ijid.2020.02.050
   Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang S, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.66
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Ye GM, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.001
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Yuan H, 2017, SCI REP-UK, V7, DOI 10.1038/srep45617
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
   Zhang ZB, 2018, BIOCHEM BIOPH RES CO, V503, P2132, DOI 10.1016/j.bbrc.2018.08.001
   Zhou CY, 2020, LANCET INFECT DIS, V20, P510, DOI 10.1016/S1473-3099(20)30156-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu YQ, 2017, ONCOTARGET, V8, P15267, DOI 10.18632/oncotarget.14840
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 76
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1674-0769
EI 1995-820X
J9 VIROL SIN
JI Virol. Sin.
PD JUN
PY 2020
VL 35
IS 3
SI SI
BP 311
EP 320
DI 10.1007/s12250-020-00253-y
EA JUN 2020
PG 10
WC Virology
SC Virology
GA MF9LC
UT WOS:000544158200001
PM 32602046
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Irie, K
   Nakagawa, A
   Fujita, H
   Tamura, R
   Eto, M
   Ikesue, H
   Muroi, N
   Tomii, K
   Hashida, T
AF Irie, Kei
   Nakagawa, Atsushi
   Fujita, Hirotoshi
   Tamura, Ryo
   Eto, Masaaki
   Ikesue, Hiroaki
   Muroi, Nobuyuki
   Tomii, Keisuke
   Hashida, Tohru
TI Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
ID ALDEHYDE OXIDASE; INTENSIVE-CARE; PHARMACODYNAMICS; METABOLISM
AB Since December 2019, a novel coronavirus (severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID-19). The antiretroviral drug favipiravir (FPV) has been experimentally used for COVID-19 treatment since March 2020 in Japan. However, the pharmacokinetics of FPV in critically ill patients is unknown. We measured the serum concentration of FPV using high-performance liquid chromatography in patients with severe COVID-19 who were admitted to the intensive care unit and placed on mechanical ventilation. The patients were administered 1,600 mg of FPV twice daily on day 1, followed by 600 mg twice daily from day 2 to day 5 (or more if needed). Suspensions of FPV tablets were administered through a nasogastric tube. Seven patients were enrolled in this study. Forty-nine blood samples were obtained from the eligible patients to evaluate FPV concentration. The FPV trough (after 8-12 hours) concentrations of most samples were lower than the lower limit of quantification (1 mu g/mL) and half-maximal effective concentration (9.7 mu g/mL) against SARS-CoV-2 previously testedin vitro. FPV trough concentration in critically ill patients was much lower than that of healthy subjects in a previous clinical trial, which is a cause for great concern. Further study is required to determine the optimal strategy for treatment of patients with severe COVID-19.
C1 [Irie, Kei; Fujita, Hirotoshi; Tamura, Ryo; Ikesue, Hiroaki; Muroi, Nobuyuki; Hashida, Tohru] Kobe City Med Ctr Gen Hosp, Kobe City Hosp Org, Dept Pharm, Kobe, Hyogo, Japan.
   [Irie, Kei] Kobe Gakuin Univ, Fac Pharmaceut Sci, Dept Pharmaceut, Kobe, Hyogo, Japan.
   [Nakagawa, Atsushi; Tomii, Keisuke] Kobe City Med Ctr Gen Hosp, Kobe City Hosp Org, Dept Resp Med, Kobe, Hyogo, Japan.
   [Eto, Masaaki] Kobe City Med Ctr Gen Hosp, Kobe City Hosp Org, Dept Clin Lab, Kobe, Hyogo, Japan.
RP Irie, K (corresponding author), Kobe City Med Ctr Gen Hosp, Kobe City Hosp Org, Dept Pharm, Kobe, Hyogo, Japan.; Irie, K (corresponding author), Kobe Gakuin Univ, Fac Pharmaceut Sci, Dept Pharmaceut, Kobe, Hyogo, Japan.
EM kei_irie@pharm.kobegakuin.ac.jp
OI Ikesue, Hiroaki/0000-0002-8499-131X
CR Akabane T, 2011, XENOBIOTICA, V41, P372, DOI 10.3109/00498254.2010.549970
   [Anonymous], 2014, REPORT DELIBERATION
   [Anonymous], 2017, PACK INS AV TABL 200
   Couffignal C, 2014, BRIT J CLIN PHARMACO, V78, P1022, DOI 10.1111/bcp.12435
   deGatta MMF, 1996, J CLIN PHARM THER, V21, P417
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Domalaon K, 2017, ELECTROPHORESIS, V38, P1224, DOI 10.1002/elps.201600306
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Favie LMA, 2018, ANTIVIR THER, V23, P457, DOI 10.3851/IMP3210
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Jensen KG, 2017, DRUG METAB DISPOS, V45, P68, DOI 10.1124/dmd.116.072793
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Manevski N, 2019, J MED CHEM, V62, P10955, DOI 10.1021/acs.jmedchem.9b00875
   Pea F, 2003, CLIN PHARMACOKINET, V42, P589, DOI 10.2165/00003088-200342060-00008
   Pujal M, 2006, PHARM WORLD SCI, V28, P215, DOI 10.1007/s11096-006-9037-3
   Ray J, 2011, THER DRUG MONIT, V33, P387, DOI 10.1097/FTD.0b013e31821fb197
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Roberts JA, 2006, CLIN PHARMACOKINET, V45, P755, DOI 10.2165/00003088-200645080-00001
   Spinelli A, 2020, BRIT J SURG, V107, P785, DOI 10.1002/bjs.11627
   Nguyen THT, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005389
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
   World Health Organization, CLIN MAN SEV AC RESP
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 24
TC 8
Z9 8
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
PD SEP
PY 2020
VL 13
IS 5
BP 880
EP 885
DI 10.1111/cts.12827
EA JUN 2020
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NM3MV
UT WOS:000543899800001
PM 32475019
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Uysal, BB
   Ikitimur, H
   Yavuzer, S
   Ikitimur, B
   Uysal, H
   Islamoglu, MS
   Ozcan, E
   Aktepe, E
   Yavuzer, H
   Cengiz, M
AF Borku Uysal, Betul
   Ikitimur, Hande
   Yavuzer, Serap
   Ikitimur, Baris
   Uysal, Harun
   Islamoglu, Mehmet Sami
   Ozcan, Erkan
   Aktepe, Emre
   Yavuzer, Hakan
   Cengiz, Mahir
TI Tocilizumab challenge: A series of cytokine storm therapy experiences in
   hospitalized COVID-19 pneumonia patients
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE COVID-19; pneumonia; SARS-Cov-2; tocilizumab
AB To recognize the period of exaggerated cytokine response in patients with coronavirus disease 2019 (COVID-19) pneumonia, and to describe the clinical outcomes of using tocilizumab as a treatment option. The data of 12 adult COVID-19 pneumonia patients who were followed in the inpatient clinics of Biruni University Medical Faculty Hospital (Istanbul, Turkey) were retrospectively analyzed. Diagnostic tests, laboratory examinations, clinical findings, and computed tomography of the thorax imaging results were evaluated. A dramatic laboratory and clinical improvement was observed in 83% (10 out of 12) of patients after tocilizumab. In 17% (2 out of 12) of our patients, short-term ventilator support was required in the intensive care unit. The longest hospital stay was 18 days. However, in the end, all of our patients were discharged home with good health. Although arterial oxygen saturations (87.58 +/- 3.12%) dropped in room air in the pre-tocilizumab period, post-tocilizumab they normalized in all patients (94.42 +/- 1%). None of them had fever after tocilizumab treatment and the levels of C-reactive protein (13.08 +/- 12.89) were almost within normal limits. Eosinophil values were quite low at the time of diagnosis (10 +/- 17.06), but increased significantly post-tocilizumab (155.33 +/- 192.69). There is currently no proven treatment for COVID-19 induced by novel coronavirus SARS-CoV-2. Based on our experience with twelve adult COVID-19 pneumonia patients,we can say that tocilizumab, an IL-6 inhibitor, is more beneficial in preventing the damage caused by excessive cytokine response in the body if administered at the right time and provides clinical and radiological recovery.
C1 [Borku Uysal, Betul; Yavuzer, Serap; Islamoglu, Mehmet Sami; Ozcan, Erkan; Cengiz, Mahir] Biruni Univ, Dept Internal Med, Fac Med, Eski Londra Asfalti,10,Besyol, TR-34295 Istanbul, Turkey.
   [Ikitimur, Hande] Biruni Univ, Dept Pulm Dis, Fac Med, Istanbul, Turkey.
   [Ikitimur, Baris] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Cardiol, Istanbul, Turkey.
   [Uysal, Harun] Bezmialem Vakif Univ, Dept Anesthesiol & Reanimat, Fac Med, Istanbul, Turkey.
   [Aktepe, Emre] Biruni Univ, Dept Infect Dis, Fac Med, Istanbul, Turkey.
   [Yavuzer, Hakan] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Div Geriatr, Dept Internal Med, Istanbul, Turkey.
RP Uysal, BB (corresponding author), Biruni Univ, Dept Internal Med, Fac Med, Eski Londra Asfalti,10,Besyol, TR-34295 Istanbul, Turkey.
EM betulborku@yahoo.com
CR Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Antwi-Amoabeng D, 2020, J MED VIROL, V92, P2516, DOI 10.1002/jmv.26038
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Deftereos SG, 2020, HELLENIC J CARDIOL
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Gorbalenya A. E., 2020, SEVERE ACUTE RESP SY
   Grein J, 2020, N ENGL J MED
   Keshtkar-Jahromi M, 2020, AM J TROP MED HYG, V102, P932, DOI 10.4269/ajtmh.20-0230
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mazzitelli M, 2020, J MED VIROL
   Morrison AR, 2020, J MED VIROL, V92, P1791, DOI 10.1002/jmv.25907
   Ohe M, 2020, BIOSCI TRENDS, V14, P159, DOI 10.5582/bst.2020.03058
   Sanders JM, 2020, JAMA
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Turkish Ministry of Health, 2020, COVID 19 AD PAT MAN
   Turkish Ministry of Health, 2020, COVID 19 SARS COV2 I
   WHO, 2020, MOD TRANSM VIR CAUS
   WHO, 2020, REP WHO CHIN JOINT M
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wuhan Municipal Health Commision, 2020, REP CLUST PNEUM UNKN
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 24
TC 9
Z9 11
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2648
EP 2656
DI 10.1002/jmv.26111
EA JUN 2020
PG 9
WC Virology
SC Virology
GA NU0EN
UT WOS:000543916500001
PM 32484930
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zuo, Y
   Liu, YL
   Zhong, Q
   Zhang, K
   Xu, YH
   Wang, ZX
AF Zuo, Yan
   Liu, Yunlei
   Zhong, Qi
   Zhang, Ke
   Xu, Yuanhong
   Wang, Zhongxin
TI Lopinavir/ritonavir and interferon combination therapy may help shorten
   the duration of viral shedding in patients with COVID-19: A
   retrospective study in two designated hospitals in Anhui, China
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE associated factors; COVID-19; outcomes; treatment; viral shedding
ID CORONAVIRUS; VIRUS; PNEUMONIA
AB Prolonged viral shedding may pose a threat to the control of coronavirus disease-2019 (COVID-19), and data on the duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) shedding are still limited, with the associated factors being unknown. All adult patients with laboratory-confirmed COVID-19 were included in this retrospective cross-sectional study in two designated hospitals during 21 January 2020 to 16 March 2020 in Anhui, China. In all patients, data on the duration of SARS-CoV-2 RNA shedding were analyzed by reviewing all RNA detection results during hospitalization. In addition, demographic, clinical, treatment, laboratory, and outcome data were also collected from electronic medical records. Factors associated with prolonged viral shedding were analyzed with the Cox proportional hazards model. Among 181 patients, the mean age was 44.3 +/- 13.2 years, and 55.2% were male. The median duration of viral shedding from illness onset was 18.0 days (interquartile range [IQR], 15.0-24.0). Prolonged viral shedding was associated with longer hospital stays (P < .001) and higher medical costs (P < .001). The severity of COVID-19 had nothing to do with prolonged shedding. Moreover, the median time from onset to antiviral treatment initiation was 5.0 days (IQR, 3.0-7.0). Delayed antiviral treatment (hazard ratio [HR], 0.976; 95% confidence interval [CI], 0.962-0.990]) and lopinavir/ritonavir + interferon-alpha (IFN-alpha) combination therapy as the initial antiviral treatment (HR 1.649; 95% CI, 1.162-2.339) were independent factors associated with prolonged SARS-CoV-2 RNA shedding. SARS-CoV-2 showed prolonged viral shedding, causing increased hospital stays and medical costs. Early initiation of lopinavir/ritonavir + IFN-alpha combination therapy may help shorten the duration of SARS-CoV-2 shedding.
C1 [Zuo, Yan; Zhang, Ke; Xu, Yuanhong; Wang, Zhongxin] Anhui Med Univ, Affiliated Hosp 1, Dept Clin Lab, 218 Jixi Rd, Hefei, Anhui, Peoples R China.
   [Liu, Yunlei] Second Peoples Hosp Fuyang, Dept Clin Lab, Fuyang, Anhui, Peoples R China.
   [Zhong, Qi] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hefei, Anhui, Peoples R China.
RP Wang, ZX (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Clin Lab, 218 Jixi Rd, Hefei, Anhui, Peoples R China.
EM aywzhx87@163.com
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao YH, 2020, J MED VIROL, V92, P1449, DOI [10.1002/jmv.25822, 10.1080/10962247.2020.1815895]
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan PKS, 2012, J INFECT DIS, V206, P1359, DOI 10.1093/infdis/jis509
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng PKC, 2004, LANCET, V363, P1699, DOI 10.1016/S0140-6736(04)16255-7
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Fielding JE, 2014, INFLUENZA OTHER RESP, V8, P142, DOI 10.1111/irv.12216
   Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Lee N, 2009, J INFECT DIS, V200, P492, DOI 10.1086/600383
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu SB, 2020, J MED VIROL, DOI 10.1002/jmv.25776
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   National Health Commission of the People's Republic of China, 2020, CHIN MAN GUID COVID
   Ogimi C, 2017, J INFECT DIS, V216, P203, DOI 10.1093/infdis/jix264
   Oh MD, 2016, NEW ENGL J MED, V375, P1303, DOI 10.1056/NEJMc1511695
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2018, J INFECT DIS, V217, P1708, DOI 10.1093/infdis/jiy115
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yuan J, 2020, INFLAMM RES, V69, P599, DOI 10.1007/s00011-020-01342-0
   Zheng SF, 2018, CLIN INFECT DIS, V66, P1054, DOI 10.1093/cid/cix930
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 27
TC 6
Z9 6
U1 2
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2666
EP 2674
DI 10.1002/jmv.26127
EA JUN 2020
PG 9
WC Virology
SC Virology
GA NU0EN
UT WOS:000543916900001
PM 32492211
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Toombs, JM
   van den Abbeele, K
   Democratis, J
   Merricks, R
   Mandal, AKJ
   Missouris, CG
AF Toombs, Jessica M.
   van den Abbeele, Koenraad
   Democratis, Jane
   Merricks, Rhona
   Mandal, Amit K. J.
   Missouris, Constantinos G.
TI COVID-19 in three people living with HIV in the United Kingdom
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter; Early Access
DE antiretroviral therapy; COVID-19; HIV; morbidity; mortality; PLWH
C1 [Toombs, Jessica M.; van den Abbeele, Koenraad; Democratis, Jane; Merricks, Rhona; Mandal, Amit K. J.; Missouris, Constantinos G.] Wexham Pk Hosp, Dept Med, Frimley Hlth NHS Fdn Trust, Slough, Berks, England.
   [Toombs, Jessica M.; van den Abbeele, Koenraad; Democratis, Jane; Merricks, Rhona; Mandal, Amit K. J.; Missouris, Constantinos G.] Wexham Pk Hosp, Dept Microbiol, Frimley Hlth NHS Fdn Trust, Slough, Berks, England.
   [Toombs, Jessica M.; van den Abbeele, Koenraad; Democratis, Jane; Merricks, Rhona; Mandal, Amit K. J.; Missouris, Constantinos G.] Wexham Pk Hosp, Dept Infect Dis, Frimley Hlth NHS Fdn Trust, Slough, Berks, England.
   [Missouris, Constantinos G.] Univ Cyprus, Dept Cardiol, Med Sch, Nicosia, Cyprus.
RP Mandal, AKJ (corresponding author), Frimley Hlth NHS Fdn Trust, Wexham Pk Hosp, Slough, Berks, England.
EM amit.mandal@nhs.net
CR British HIV. Association, 2020, BHIVA GUID MAN AD HI
   Harter G, 2020, INFECTION, V48, P681, DOI 10.1007/s15010-020-01438-z
   Jockusch S, 2020, TRIPHOSPHATES 2 COMP, V22, P826
   Joob B, 2020, J MED VIROL, V92, P1415, DOI 10.1002/jmv.25782
   Karmen-Tuohy S, 2020, OUTCOMES HIV POSITIV, DOI DOI 10.1101/2020.05.07.20094797V1
   Nair V, 2020, AM J TRANSPLANT, V20, P1819, DOI 10.1111/ajt.15967
   Ridgway JP, 2020, AIDS PATIENT CARE ST, V34, P331, DOI 10.1089/apc.2020.0103
   Wu QJ, 2020, J MED VIROL, V92, P2325, DOI 10.1002/jmv.26006
NR 8
TC 6
Z9 6
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26178
EA JUN 2020
PG 3
WC Virology
SC Virology
GA MD4BI
UT WOS:000543913900001
PM 32542706
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ye, MX
   Fu, D
   Ren, Y
   Wang, FX
   Wang, D
   Zhang, F
   Xia, XY
   Lv, TF
AF Ye, Mingxiang
   Fu, Dian
   Ren, Yi
   Wang, Faxiang
   Wang, Dong
   Zhang, Fang
   Xia, Xinyi
   Lv, Tangfeng
TI Treatment with convalescent plasma for COVID-19 patients in Wuhan, China
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE convalescent plasma therapy; COVID-19; SARS-CoV-2
ID RESPIRATORY SYNDROME; CT FINDINGS; CORONAVIRUS; PNEUMONIA; HEALTH
AB The discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the outbreak of coronavirus disease 2019 (COVID-19) are causing public health emergencies. A handful pieces of literature have summarized its clinical and radiologic features, whereas therapies for COVID-19 are rather limited. To evaluate the efficacy of convalescent plasma therapy in COVID-19 patients, we did this timely descriptive study. Six laboratory-confirmed COVID-19 patients were enrolled and received the transfusion of ABO-compatible convalescent plasma. The efficacy of this intervention was determined by the alleviation of symptoms, changes in radiologic abnormalities and laboratory tests. No obvious adverse effect observed during the treatment. Transfusion of convalescent plasma led to a resolution of ground-glass opacities and consolidation in patients #1, #2, #3, #4, and #6. In patients #1 and #5 who presented with SARS-CoV-2 in throat swab, convalescent plasma therapy elicited an elimination of the virus. Serologic analysis indicated an immediate increase in anti-SARS-CoV-2 antibody titers in patients #2 and #3, but not in patient #1. This study indicates that convalescent plasma therapy is effective and specific for COVID-19. This intervention has a special significance for eliminating SARS-CoV-2 and is believed to be a promising state-of-the-art therapy during COVID-19 pandemic crisis.
C1 [Ye, Mingxiang; Wang, Dong; Zhang, Fang; Lv, Tangfeng] Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing 210002, Peoples R China.
   [Ye, Mingxiang; Fu, Dian; Ren, Yi; Wang, Faxiang; Wang, Dong; Zhang, Fang; Lv, Tangfeng] Wuhan Huoshenshan Hosp, Unit 4 1, Dept Infect Dis, Wuhan 420000, Peoples R China.
   [Fu, Dian] Nanjing Univ, Jinling Hosp, Dept Urol, Sch Med, Nanjing, Peoples R China.
   [Ren, Yi] Nanjing Univ, Jinling Hosp, Dept Emergency, Sch Med, Nanjing, Peoples R China.
   [Wang, Faxiang] 904 Hosp, Dept Emergency, Wuxi, Jiangsu, Peoples R China.
   [Xia, Xinyi] Nanjing Univ, Inst Lab Med, Jinling Hosp, Sch Med, Nanjing 210002, Peoples R China.
   [Xia, Xinyi] Wuhan Huoshenshan Hosp, Dept Lab Med, Wuhan 420000, Peoples R China.
RP Lv, TF (corresponding author), Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing 210002, Peoples R China.; Lv, TF (corresponding author), Wuhan Huoshenshan Hosp, Unit 4 1, Dept Infect Dis, Wuhan 420000, Peoples R China.; Xia, XY (corresponding author), Nanjing Univ, Inst Lab Med, Jinling Hosp, Sch Med, Nanjing 210002, Peoples R China.; Xia, XY (corresponding author), Wuhan Huoshenshan Hosp, Dept Lab Med, Wuhan 420000, Peoples R China.
EM xiaxynju@163.com; bairoushui@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81772500, 81802301]; Jiangsu Provincial Key
   Research and Development Program [BE2018713]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   81772500, 81802301; Jiangsu Provincial Key Research and Development
   Program, Grant/Award Number: BE2018713
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Gillespie TR, 2020, NATURE, V579, P497, DOI 10.1038/d41586-020-00859-y
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WH, 2020, AM J ROENTGENOL, V214, pW85, DOI 10.2214/AJR.20.23035
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   Jacobsen KH, 2020, LANCET, V395, P1013, DOI 10.1016/S0140-6736(20)30559-6
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Li MZ, 2020, ACAD RADIOL, V27, P603, DOI 10.1016/j.acra.2020.03.003
   Lian JS, 2020, CLIN INFECT DIS, V71, P740, DOI 10.1093/cid/ciaa242
   Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Matthay MA, 2020, LANCET RESP MED, V8, P433, DOI 10.1016/S2213-2600(20)30127-2
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Tuite AR, 2020, LANCET INFECT DIS, V20, P537, DOI 10.1016/S1473-3099(20)30227-9
   Wang YH, 2020, RADIOLOGY, V296, pE55, DOI 10.1148/radiol.2020200843
   Webster P, 2020, LANCET, V395, P936, DOI 10.1016/S0140-6736(20)30670-X
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yao X, 2020, CHINESE J PATHOL, V49, pE009
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Zhang JF, 2020, INT J INFECT DIS, V97, P212, DOI 10.1016/j.ijid.2020.03.007
   Zheng M, 2020, CELL MOL IMMUNOL, V17, P536, DOI 10.1038/s41423-020-0385-z
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 26
TC 92
Z9 96
U1 46
U2 49
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2020
VL 92
IS 10
BP 1890
EP 1901
DI 10.1002/jmv.25882
EA JUN 2020
PG 12
WC Virology
SC Virology
GA NK4OX
UT WOS:000543916100001
PM 32293713
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Chernyshov, PV
   Tomas-Aragones, L
   Augustin, M
   Svensson, A
   Bewley, A
   Poot, F
   Szepietowski, JC
   Marron, SE
   Manolache, L
   Pustisek, N
   Suru, A
   Salavastru, CM
   Blome, C
   Salek, MS
   Abeni, D
   Sampogna, F
   Dalgard, F
   Linder, D
   Evers, AWM
   Finlay, AY
AF Chernyshov, P. V.
   Tomas-Aragones, L.
   Augustin, M.
   Svensson, A.
   Bewley, A.
   Poot, F.
   Szepietowski, J. C.
   Marron, S. E.
   Manolache, L.
   Pustisek, N.
   Suru, A.
   Salavastru, C. M.
   Blome, C.
   Salek, M. S.
   Abeni, D.
   Sampogna, F.
   Dalgard, F.
   Linder, D.
   Evers, A. W. M.
   Finlay, A. Y.
TI Position statement of the European Academy of Dermatology and
   Venereology Task Force on Quality of Life and Patient Oriented Outcomes
   on quality of life issues in dermatologic patients during the COVID-19
   pandemic
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Article
ID FAMILY; IMPACT; MULTICENTER; SEVERITY; PAPER
AB The pandemic of COVID-19 is a global challenge for health care, and dermatologists are not standing apart from trying to meet this challenge. The European Academy of Dermatology and Venereology (EADV) has collected recommendations from its Task Forces (TFs) related to COVID-19. The Journal of the EADV has established a COVID-19 Special Forum giving free access to related articles. The psychosocial effects of the pandemic, an increase in contact dermatitis and several other skin diseases because of stress, disinfectants and protective equipment use, especially in healthcare workers, the temporary limited access to dermatologic care, the dilemma whether or not to pause immunosuppressive therapy, and, finally, the occurrence of skin lesions in patients infected by COVID-19 all contribute to significant quality of life (QoL) impairment. Here, we present detailed recommendations of the EADV TF on QoL and patient-oriented outcomes on how to improve QoL in dermatologic patients during the COVID-19 pandemic for several different groups of patients and for the general population.
C1 [Chernyshov, P. V.] Natl Med Univ, Dept Dermatol & Venereol, Kiev, Ukraine.
   [Tomas-Aragones, L.] Univ Zaragoza, Dept Psychol, Zaragoza, Spain.
   [Augustin, M.; Blome, C.] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, German Ctr Hlth Serv Res Dermatol, Hamburg, Germany.
   [Svensson, A.; Dalgard, F.] Skane Univ Hosp, Dept Dermatol & Venereol, Malmo, Sweden.
   [Bewley, A.] Whipps Cross Univ Hosp, London, England.
   [Bewley, A.] Queen Mary Univ, Sch Med, London, England.
   [Poot, F.] Univ Hosp Erasme, Dept Dermatol, Brussels, Belgium.
   [Szepietowski, J. C.] Wroclaw Med Univ, Dept Dermatol, Wroclaw, Poland.
   [Marron, S. E.] Univ Zaragoza, Hosp Miguel Servet, Dept Dermatol, Aragon Psychodermatol Res Grp GAI PD, Zaragoza, Spain.
   [Manolache, L.] Dali Med, Dermatol, Bucharest, Romania.
   [Pustisek, N.] Univ Zagreb, Sch Med, Childrens Hosp Zagreb, Zagreb, Croatia.
   [Suru, A.] Carol Davila Univ Med & Pharm, Dermatol Res Unit, Colentina Clin Hosp, Paediat Dermatol Discipline, Bucharest, Romania.
   [Salavastru, C. M.] Carol Davila Univ Med & Pharm, Colentina Clin Hosp, Dept Paediat Dermatol, Bucharest, Romania.
   [Salek, M. S.] Univ Hertfordshire, Sch Life & Med Sci, Hatfield, Herts, England.
   [Abeni, D.; Sampogna, F.] IDI IRCCS, Clin Epidemiol Unit, Rome, Italy.
   [Linder, D.] Ben Gurion Univ Negev, Dept Dermatol, Beer Sheva, Israel.
   [Evers, A. W. M.] Leiden Univ, Hlth Med & Neuropsychol Unit, Leiden, Netherlands.
   [Finlay, A. Y.] Cardiff Univ, Sch Med, Div Infect & Immun, Cardiff, Wales.
RP Chernyshov, PV (corresponding author), Natl Med Univ, Dept Dermatol & Venereol, Kiev, Ukraine.
EM chernyshovpavel@ukr.net
RI Chernyshov, Pavel/K-7900-2018; Suru, Alina/AAF-6935-2019
OI Chernyshov, Pavel/0000-0001-7275-4651; Tomas Aragones,
   Lucia/0000-0001-5891-628X; Szepietowski, Jacek/0000-0003-0766-6342;
   Suru, Alina/0000-0002-9747-9091
CR Agner T, 2008, CONTACT DERMATITIS, V59, P43, DOI 10.1111/j.1600-0536.2008.01362.x
   Atzori L, 2020, J EUR ACAD DERMATOL, V34, pE247, DOI 10.1111/jdv.16473
   Balato A, 2020, J EUR ACAD DERMATOL, V34, pE353, DOI 10.1111/jdv.16557
   Balestri R, 2020, J EUR ACAD DERMATOL, V34, pE357, DOI 10.1111/jdv.16571
   Basra MKA, 2007, BRIT J DERMATOL, V156, P929, DOI 10.1111/j.1365-2133.2007.07794.x
   Basra MKA, 2007, BRIT J DERMATOL, V156, P528, DOI 10.1111/j.1365-2133.2006.07617.x
   Benhadou F, 2020, J EUR ACAD DERMATOL, V34, pE363, DOI 10.1111/jdv.16590
   Chernyshov P, 2015, J EUR ACAD DERMATOL, V29, P2306, DOI 10.1111/jdv.13154
   Chernyshov PV, 2020, J EUR ACAD DERMATOL, V34, P1924, DOI 10.1111/jdv.16742
   Chernyshov PV, 2019, J EUR ACAD DERMATOL, V33, P1633, DOI 10.1111/jdv.15519
   Chernyshov PV, 2019, J EUR ACAD DERMATOL, V33, P816, DOI 10.1111/jdv.15487
   Chernyshov PV, 2018, J EUR ACAD DERMATOL, V32, P1410, DOI 10.1111/jdv.15048
   Chernyshov PV, 2018, J EUR ACAD DERMATOL, V32, pE181, DOI 10.1111/jdv.14693
   Chernyshov PV, 2018, J EUR ACAD DERMATOL, V32, P194, DOI 10.1111/jdv.14585
   Chernyshov PV, 2017, J EUR ACAD DERMATOL, V31, P576, DOI 10.1111/jdv.14058
   Chernyshov PV, 2019, DERMATOLOGY, V235, P167, DOI 10.1159/000496923
   Chernyshov Pavel V, 2018, J Clin Aesthet Dermatol, V11, P21
   Chernyshov PV, 2015, ACTA DERMATOVENER CR, V23, P247
   Ferrucci S, 2020, J EUR ACAD DERMATOL, V34, pE303, DOI 10.1111/jdv.16527
   Finlay AY, 2017, J EUR ACAD DERMATOL, V31, P424, DOI 10.1111/jdv.13985
   Casas CG, 2020, BRIT J DERMATOL, V183, P71, DOI 10.1111/bjd.19163
   Garcovich S, 2020, J EUR ACAD DERMATOL, V34, pE293, DOI 10.1111/jdv.16535
   Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158
   Gisondi P, 2020, J EUR ACAD DERMATOL, V34, P1196, DOI 10.1111/jdv.16515
   Kasperkiewicz M, 2020, J EUR ACAD DERMATOL, V34, pE302, DOI 10.1111/jdv.16525
   Lau MYZ, 2011, CONTACT DERMATITIS, V65, P138, DOI 10.1111/j.1600-0536.2011.01896.x
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Liu SL, 2020, NATURE, V577, P472, DOI 10.1038/d41586-020-00135-z
   Maniadakis N, 2018, ADV THER, V35, P1333, DOI 10.1007/s12325-018-0759-0
   Marasca C, 2020, J EUR ACAD DERMATOL, V34, pE249, DOI 10.1111/jdv.16476
   Nazzaro G, 2020, INT J DERMATOL, V59, pE238, DOI 10.1111/ijd.14926
   Pei S, 2020, J EUR ACAD DERMATOL, V34, pE354, DOI 10.1111/jdv.16570
   Piccolo V, 2020, J EUR ACAD DERMATOL, V34, pE291, DOI 10.1111/jdv.16526
   Prinsen CAC, 2013, J EUR ACAD DERMATOL, V27, P1195, DOI 10.1111/jdv.12090
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Sampogna F, 2017, J EUR ACAD DERMATOL, V31, P1429, DOI 10.1111/jdv.14288
   Stefaniak AA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13477
   Trettin B, 2020, BRIT J DERMATOL, V183, P516, DOI 10.1111/bjd.18876
   Wollenberg A, 2020, J EUR ACAD DERMATOL, V34, pE241, DOI 10.1111/jdv.16411
NR 39
TC 4
Z9 4
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
EI 1468-3083
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
PD AUG
PY 2020
VL 34
IS 8
BP 1666
EP 1671
DI 10.1111/jdv.16720
EA JUN 2020
PG 6
WC Dermatology
SC Dermatology
GA MZ2BW
UT WOS:000543798600001
PM 32498128
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lee, H
   Mantell, BS
   Richmond, ME
   Law, SP
   Zuckerman, WA
   Addonizio, LJ
   Lee, TM
   Lytrivi, ID
AF Lee, Hannah
   Mantell, Benjamin S.
   Richmond, Marc E.
   Law, Sabrina P.
   Zuckerman, Warren A.
   Addonizio, Linda J.
   Lee, Teresa M.
   Lytrivi, Irene D.
TI Varying presentations of COVID-19 in young heart transplant recipients:
   A case series
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE COVID-19; pediatrics; heart transplantation; immunosuppression
AB Background Immunosuppression is considered a risk factor for more severe clinical presentation of COVID-19. Limited data regarding clinical outcome exist in adults, whereas very little is known about the spectrum of the disease in pediatric heart transplant recipients. Methods We retrospectively reviewed the charts of young heart transplant patients from our tertiary care center during the coronavirus pandemic in New York City and identified patients infected with SARS-CoV-2. Results We present four cases with COVID-19 disease and elaborate on their presentation and clinical course. Conclusions Although far from conclusive and limited by the small sample size and selection bias, these cases demonstrate mild and self-limited disease despite immunosuppressive therapy and various comorbidities that are expected to increase the severity of the clinical picture based on extrapolation from the adult experience with this novel disease.
C1 [Lee, Hannah; Mantell, Benjamin S.; Richmond, Marc E.; Law, Sabrina P.; Zuckerman, Warren A.; Addonizio, Linda J.; Lee, Teresa M.; Lytrivi, Irene D.] Columbia Univ, Dept Pediat, Program Pediat Cardiomyopathy Heart Failure & Tra, Irving Med Ctr, New York, NY 10027 USA.
RP Lytrivi, ID (corresponding author), Columbia Univ, Dept Pediat, Program Pediat Cardiomyopathy Heart Failure & Tra, Irving Med Ctr, New York, NY 10027 USA.
EM Idl2108@cumc.columbia.edu
RI Mantell, Benjamin/ABE-2117-2020
OI Mantell, Benjamin/0000-0002-7700-6975; Richmond,
   Marc/0000-0001-5491-8085
CR Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Holzhauser L, 2020, AM J TRANSPLANT, V20, P2916, DOI 10.1111/ajt.15982
   Hsu JJ, 2020, AM J TRANSPLANT, V20, P1911, DOI 10.1111/ajt.15936
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kates OS, 2020, AM J TRANSPLANT, V20, P1885, DOI 10.1111/ajt.15944
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Mathies D, 2020, AM J TRANSPLANT, V20, P1925, DOI 10.1111/ajt.15932
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Ren ZL, 2020, J HEART LUNG TRANSPL, V39, P412, DOI 10.1016/j.healun.2020.03.008
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 12
TC 4
Z9 4
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2020
VL 24
IS 8
BP 1645
EP 1648
AR e13780
DI 10.1111/petr.13780
EA JUN 2020
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA PA5CQ
UT WOS:000543963400001
PM 32542914
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kandeel, M
   Abdelrahman, AHM
   Oh-Hashi, K
   Ibrahim, A
   Venugopala, KN
   Morsy, MA
   Ibrahim, MAA
AF Kandeel, Mahmoud
   Abdelrahman, Alaa H. M.
   Oh-Hashi, Kentaro
   Ibrahim, Abdelazim
   Venugopala, Katharigatta N.
   Morsy, Mohamed A.
   Ibrahim, Mahmoud A. A.
TI Repurposing of FDA-approved antivirals, antibiotics, anthelmintics,
   antioxidants, and cell protectives against SARS-CoV-2 papain-like
   protease
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; molecular dynamics; SARS-CoV-2; PLpro; protease
ID MOROXYDINE HYDROCHLORIDE; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE;
   INHIBITION; INTERFERON
AB SARS-CoV-2 or Coronavirus disease 19 (COVID-19) is a rapidly spreading, highly contagious, and sometimes fatal disease for which drug discovery and vaccine development are critical. SARS-CoV-2 papain-like protease (PLpro) was used to virtually screen 1697 clinical FDA-approved drugs. Among the top results expected to bind with SARS-CoV-2 PL(pro)strongly were three cell protectives and antioxidants (NAD+, quercitrin, and oxiglutatione), three antivirals (ritonavir, moroxydine, and zanamivir), two antimicrobials (doripenem and sulfaguanidine), two anticancer drugs, three benzimidazole anthelmintics, one antacid (famotidine), three anti-hypertensive ACE receptor blockers (candesartan, losartan, and valsartan) and other miscellaneous systemically or topically acting drugs. The binding patterns of these drugs were superior to the previously identified SARS CoV PL(pro)inhibitor, 6-mercaptopurine (6-MP), suggesting a potential for repurposing these drugs to treat COVID-19. The objective of drug repurposing is the rapid relocation of safe and approved drugs by bypassing the lengthy pharmacokinetic, toxicity, and preclinical phases. The ten drugs with the highest estimated docking scores with favorable pharmacokinetics were subjected to molecular dynamics (MD) simulations followed by molecular mechanics/generalized Born surface area (MM/GBSA) binding energy calculations. Phenformin, quercetin, and ritonavir all demonstrated prospective binding affinities for COVID-19 PL(pro)over 50 ns MD simulations, with binding energy values of -56.6, -40.9, and -37.6 kcal/mol, respectively. Energetic and structural analyses showed phenformin was more stable than quercetin and ritonavir. The list of the drugs provided herein constitutes a primer for clinical application in COVID-19 patients and guidance for further antiviral studies. Communicated by Ramaswamy H. Sarma
C1 [Kandeel, Mahmoud] King Faisal Univ, Coll Vet Med, Dept Biomed Sci, Al Hufuf 31982, Al Ahsa, Saudi Arabia.
   [Kandeel, Mahmoud] Kafrelshikh Univ, Fac Vet Med, Dept Pharmacol, Kafrelshikh, Egypt.
   [Abdelrahman, Alaa H. M.; Ibrahim, Mahmoud A. A.] Menia Univ, Fac Sci, Chem Dept, Computat Chem Lab, Al Minya, Egypt.
   [Oh-Hashi, Kentaro] Gifu Univ, Fac Engn, Dept Chem & Biomol Sci, Gifu, Japan.
   [Ibrahim, Abdelazim] King Faisal Univ, Coll Vet Med, Dept Pathol, Al Hufuf, Al Ahsa, Saudi Arabia.
   [Venugopala, Katharigatta N.; Morsy, Mohamed A.] King Faisal Univ, Coll Clin Pharm, Dept Pharmaceut Sci, Al Hasa, Saudi Arabia.
   [Venugopala, Katharigatta N.] Durban Univ Technol, Dept Biotechnol & Food Technol, ZA-4001 Durban, South Africa.
   [Morsy, Mohamed A.] Menia Univ, Fac Med, Dept Pharmacol, El Minia 61511, Egypt.
RP Kandeel, M (corresponding author), King Faisal Univ, Coll Vet Med, Dept Biomed Sci, Al Hufuf 31982, Al Ahsa, Saudi Arabia.
EM mkandeel@kfu.edu.sa
RI Ibrahim, Mahmoud/J-2936-2014; Abdelrahman, Alaa H. M./AAX-1803-2020;
   Venugopala, Katharigatta/M-4030-2016
OI Ibrahim, Mahmoud/0000-0003-4819-2040; Abdelrahman, Alaa H.
   M./0000-0003-3527-0126; Al-shabebi, Abdulkarem/0000-0003-0707-3088;
   Venugopala, Katharigatta/0000-0003-0680-1549
FU Deanship of Scientific Research at King Faisal University; Research
   Groups track [1811016]
FX The author acknowledge the Deanship of Scientific Research at King
   Faisal University for the financial support under Research Groups track
   (Grant No. 1811016).
CR Alfuwaires M, 2017, BIOL PHARM BULL, V40, P345, DOI 10.1248/bpb.b16-00870
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J VIROL, V88, P12511, DOI 10.1128/JVI.01294-14
   Bailey-Elkin BA, 2014, J BIOL CHEM, V289, P34667, DOI 10.1074/jbc.M114.609644
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Case D.A., 2016, AMBER 2016
   Croxtall JD, 2010, DRUGS, V70, P1885, DOI 10.2165/11204950-000000000-00000
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Mello CPP, 2018, EUR J PHARM SCI, V111, P443, DOI 10.1016/j.ejps.2017.10.027
   De Vivo M, 2016, J MED CHEM, V59, P4035, DOI 10.1021/acs.jmedchem.5b01684
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Frisch M. J., 2009, GAUSSIAN 09 VERSION
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Kandeel M, 2020, J MED VIROL, V92, P660, DOI 10.1002/jmv.25754
   Kandeel M, 2020, BIOMOL THER, V28, P311, DOI 10.4062/biomolther.2019.202
   Kandeel M, 2019, LETT DRUG DES DISCOV, V16, P584, DOI 10.2174/1570180815666180918161922
   Kandeel M, 2017, BIOL PHARM BULL, V40, P1086, DOI 10.1248/bpb.b17-00168
   Kerrigan John E, 2013, Methods Mol Biol, V993, P95, DOI 10.1007/978-1-62703-342-8_7
   Lei J, 2014, ANTIVIR RES, V109, P72, DOI 10.1016/j.antiviral.2014.06.011
   Lim J, 2020, J KOREAN MED SCI, V35
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Magri A, 2015, BIOORG MED CHEM LETT, V25, P5372, DOI 10.1016/j.bmcl.2015.09.029
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Massova I, 2000, PERSPECT DRUG DISCOV, V18, P113, DOI 10.1023/A:1008763014207
   Mielech AM, 2014, VIROLOGY, V450, P64, DOI 10.1016/j.virol.2013.11.040
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Shi JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144475
   Yang XX, 2014, J GEN VIROL, V95, P614, DOI 10.1099/vir.0.059014-0
   Yu XB, 2018, RES VET SCI, V117, P37, DOI 10.1016/j.rvsc.2017.11.007
   Yu XB, 2016, ANTIVIR RES, V131, P156, DOI 10.1016/j.antiviral.2016.05.008
   Zhao TF, 2017, J CARBOHYD CHEM, V36, P235, DOI 10.1080/07328303.2017.1390577
NR 35
TC 4
Z9 4
U1 10
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1784291
EA JUN 2020
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA ML5OS
UT WOS:000549515900001
PM 32597315
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yao, J
   Liu, YF
   Cheng, J
AF Yao, Jing
   Liu, Yanfang
   Cheng, Jing
TI Standardize the management procedures for breast cancer patients during
   the outbreak of COVID-19 in Wuhan, China
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE COVID-19; SARS-CoV-2; New coronavirus pneumonia; Breast cancer; Cancer
   therapy
AB Purpose The outbreak of the coronavirus disease 2019 (COVID-19) has led to interruption or delay in treatment of breast cancer patient. This commentary aims to standardize the management procedures and ensure complete or relatively complete treatment for breast cancer patients during the outbreak of COVID-19. Methods Provide detailed online diagnosis, online treatment recommendations, and face-to-face consultation suggestions. Results Breast cancer patients who are at high risk of COVID-19 are advised to consult online first. For patients who have undergone online consultation and need face-to-face consultation, try to go to the clinic alone and take necessary precautions. Medical staff should be provided with necessary training about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing and knowledge of standard precautions and personal protective equipment. Conclusions This commentary focused on breast cancer patients and provided suggestions to avoid the spread of COVID-19. Some of these suggestions are also suitable for cancer patients in other lesions. We hope our suggestions are useful to oncologists in other countries and help them to overcome this challenge.
C1 [Yao, Jing; Liu, Yanfang; Cheng, Jing] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Canc, Jiefang Rd 1277, Wuhan 430022, Peoples R China.
RP Cheng, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Canc, Jiefang Rd 1277, Wuhan 430022, Peoples R China.
EM Chenjin1118@hotmail.com
CR Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Oncology ASOC, 2020, COVID 19 PROV PRACT
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
NR 4
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD AUG
PY 2020
VL 183
IS 1
BP 213
EP 216
DI 10.1007/s10549-020-05743-x
EA JUN 2020
PG 4
WC Oncology
SC Oncology
GA MN9CU
UT WOS:000543688200001
PM 32594281
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Payne, L
   Flannery, H
   Gedara, CK
   Daniilidi, X
   Hitchcock, M
   Lambert, D
   Taylor, C
   Christie, D
AF Payne, Lara
   Flannery, Halina
   Kambakara Gedara, Chandrika
   Daniilidi, Xeni
   Hitchcock, Megan
   Lambert, Danielle
   Taylor, Charlotte
   Christie, Deborah
TI Business as usual? Psychological support at a distance
SO CLINICAL CHILD PSYCHOLOGY AND PSYCHIATRY
LA English
DT Article
DE E-therapies; remote therapies; telepsychology; telemental health;
   covid-19; psychological support; face-to-face therapies; paediatric
   psychology
ID COGNITIVE-BEHAVIORAL THERAPY; YOUNG-PEOPLE; COST-EFFECTIVENESS; WORKING
   ALLIANCE; DEPRESSION; HEALTH; INTERNET; INTERVENTIONS; TELEPHONE;
   PROGRAM
AB The impact of COVID-19 has challenged the long accepted 'norm' in delivery of psychological therapy. Public policies designed to reduce transmission have made it extremely difficult to meet with service-users safely in the traditional face-to-face context. E-therapies have existed in theory and practice since technological progress has made them possible. They can offer a host of advantages over face-to-face equivalents, including improved access, greater flexibility for service-users and professionals, and cost savings. However, despite the emerging evidence and anticipated positive value, implementation has been slower than anticipated. Concerns have been raised by service-users, clinicians, and public health organisations, identifying significant barriers to the wide spread use of e-therapies. In the current climate, many clinicians are offering e-therapies for the first time, without prior arrangement or training, as the only viable option to continue to support their clients. This paper offers a clinically relevant review of the e-therapies literature, including effectiveness and acceptability dilemmas and challenges that need to be addressed to support the safe use and growth of e-therapies in psychology services. Further research is needed to better understand what might be lost and what gained in comparison to face-to-face therapy, and for which client groups and settings it might be most effective.
C1 [Payne, Lara; Flannery, Halina; Kambakara Gedara, Chandrika; Daniilidi, Xeni; Hitchcock, Megan; Lambert, Danielle; Taylor, Charlotte; Christie, Deborah] Univ Coll London Hosp, Child & Adolescent Psychol Serv, London, England.
RP Payne, L (corresponding author), Univ Coll London Hosp, Child & Adolescent Psychol Serv, Paediat & Adolescent Div, 6th Floor Cent, London NW1 2PG, England.
EM lara.payne1@nhs.net
OI Flannery, Halina/0000-0003-2497-6991
CR Adamski Thomas, 2009, Caring, V28, P44
   Agar G., 2020, THEORY PRACTICE ONLI, P66
   Andersen MB, 2001, PROF PSYCHOL-RES PR, V32, P12, DOI 10.1037/0735-7028.32.1.12
   Andersson G, 2014, WORLD PSYCHIATRY, V13, P4, DOI 10.1002/wps.20083
   Andersson Gerhard, 2009, Cognitive Behaviour Therapy, V38, P196, DOI 10.1080/16506070903318960
   Andrews G, 2018, J ANXIETY DISORD, V55, P70, DOI 10.1016/j.janxdis.2018.01.001
   Banbury A, 2018, L J MED INTERNET RES, V2, P20
   Barak A, 2008, J TECHNOL HUMAN SERV, V26, P109, DOI 10.1080/15228830802094429
   Bashshur RL, 2000, ANNU REV PUBL HEALTH, V21, P613, DOI 10.1146/annurev.publhealth.21.1.613
   Baumeister H, 2014, INTERNET INTERV, V1, P205, DOI DOI 10.1016/J.INVENT.2014.08.003
   Bee PE, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-60
   Benavides-Vaello S, 2013, J BEHAV HEALTH SER R, V40, P111, DOI 10.1007/s11414-012-9299-6
   Benford P, 2009, J ASSIST TECHNOL, V3, P44, DOI 10.1108/17549450200900015
   Bower P, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f540
   Carlbring P, 2018, COGN BEHAV THERAPY, V47, P1, DOI 10.1080/16506073.2017.1401115
   Castro A, 2020, J AFFECT DISORDERS, V260, P514, DOI 10.1016/j.jad.2019.09.023
   Cavanagh K, 2013, J CONTEMP PSYCHOTHER, V43, P197, DOI 10.1007/s10879-013-9242-z
   Chadwick P, 2006, PERSON BASED COGNITI
   Chakrabarti S, 2015, WORLD J PSYCHIATR, V5, P286, DOI 10.5498/wjp.v5.i3.286
   Childwise, 2020, MON REP CHILDR MED U
   Christensen H, 2010, MED J AUSTRALIA, V192, pS53
   Clark D. M., 1995, SOCIAL PHOBIA DIAGNO, DOI DOI 10.1192/BJP.BP.114.146761
   Clark DM, 2009, BEHAV RES THER, V47, P910, DOI 10.1016/j.brat.2009.07.010
   Common Sense, 2019, COMM SENS CENS MED U
   Cook JE, 2002, CYBERPSYCHOL BEHAV, V5, P95, DOI 10.1089/109493102753770480
   Davies EB, 2014, J MED INTERNET RES, V16, P18, DOI 10.2196/jmir.3142
   Doze S, 1999, J TELEMED TELECARE, V5, P38, DOI 10.1258/1357633991932379
   Drum KB, 2014, PROF PSYCHOL-RES PR, V45, P309, DOI 10.1037/a0036127
   Egan G., 1990, SKILLED HELPER SYSTE
   Essau CA, 2012, BEHAV THER, V43, P450, DOI 10.1016/j.beth.2011.08.003
   Fisher E, 2019, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD011118.PUB3
   Greene CJ, 2010, J CONSULT CLIN PSYCH, V78, P746, DOI 10.1037/a0020158
   Haas LJ, 1996, PROF PSYCHOL-RES PR, V27, P154, DOI 10.1037/0735-7028.27.2.154
   Haig-Ferguson A, 2019, INTERNET INTERV, V15, P43, DOI 10.1016/j.invent.2018.12.003
   Haight B., 2005, WORKING OLDER ADULTS
   Haugh P. S., 2008, THERAPEUTIC RELATION
   Hawley KM, 2008, CHILD YOUTH CARE FOR, V37, P59, DOI 10.1007/s10566-008-9050-x
   Hilty DM, 2007, J RURAL HEALTH, V23, P163, DOI 10.1111/j.1748-0361.2007.00084.x
   Hilty DM, 2013, TELEMED E-HEALTH, V19, P444, DOI 10.1089/tmj.2013.0075
   Hoek W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043485
   Hollis C, 2017, J CHILD PSYCHOL PSYC, V58, P474, DOI 10.1111/jcpp.12663
   Khatri N, 2014, CLIN INTERV AGING, V9, P765, DOI 10.2147/CIA.S57832
   Kramer J, 2014, J MED INTERNET RES, V16, P40, DOI 10.2196/jmir.3261
   Lee P. L., 2018, J SYSTEMIC THERAPIES, V37, P1
   Lopez Amy, 2020, Mhealth, V6, P13, DOI 10.21037/mhealth.2019.11.04
   Lorentzen S, 2014, J PSYCHIATR MENT HLT, V21, P219, DOI 10.1111/jpm.12072
   Luik Annemarie I, 2017, Curr Sleep Med Rep, V3, P48, DOI 10.1007/s40675-017-0065-4
   Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438
   McGill BC, 2017, J ADOLESC YOUNG ADUL, V6, P568, DOI 10.1089/jayao.2017.0001
   McLaren P M, 1996, J Telemed Telecare, V2 Suppl 1, P59, DOI 10.1258/1357633961929303
   Melnyk BM, 2015, J CHILD ADOL PS NURS, V28, P147, DOI 10.1111/jcap.12119
   Miller MK, 2017, PROCEEDINGS OF THE 2017 ACM SIGCHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI'17), P5271, DOI 10.1145/3025453.3025548
   Mohr DC, 2008, CLIN PSYCHOL-SCI PR, V15, P243, DOI 10.1111/j.1468-2850.2008.00134.x
   Mohr DC, 2006, COGNITIVE THER RES, V30, P29, DOI 10.1007/s10608-006-9006-0
   Mohr DC, 2012, JAMA-J AM MED ASSOC, V307, P2278, DOI 10.1001/jama.2012.5588
   Morland LA, 2004, J TELEMED TELECARE, V10, P286, DOI 10.1258/1357633042026387
   Nardi B., 2016, INT J ADOLESCENT MED, V29
   National Health Service, 2019, NHS LONG TERM PLAN
   National Health Service, 2020, COVID 19 INF GOV ADV
   Olthuis J.V., 2016, COCHRANE DB SYST REV, V2016, P1
   Osenbach JE, 2013, DEPRESS ANXIETY, V30, P1058, DOI 10.1002/da.22165
   Paul Kari, 2020, GUARDIAN
   Pennant ME, 2015, BEHAV RES THER, V67, P1, DOI 10.1016/j.brat.2015.01.009
   Pennington M., 2019, THEORY PRACTICE ONLI, P79
   Portnoy S, 2016, CLIN CHILD PSYCHOL P, V21, P255, DOI 10.1177/1359104515586467
   Renn BN, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0077-1
   Richards D, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1639-5
   Richards P, 2015, BRIT J GUID COUNS, V43, P57, DOI 10.1080/03069885.2014.936824
   Shafran R, 2009, BEHAV RES THER, V47, P902, DOI 10.1016/j.brat.2009.07.003
   Shirk SR, 2003, J CONSULT CLIN PSYCH, V71, P452, DOI 10.1037/0022-006X.71.3.452
   Simpson J, 2001, J TELEMED TELECARE, V7, P155, DOI 10.1258/1357633011936318
   Simpson J, 2001, J TELEMED TELECARE, V7, P90, DOI 10.1258/1357633011936219
   Stallard P, 2008, EUR CHILD ADOLES PSY, V17, P283, DOI 10.1007/s00787-007-0665-5
   Stallard P, 2010, CHILD ADOL MENT H-UK, V15, P80, DOI 10.1111/j.1475-3588.2009.00540.x
   Stasiak K, 2014, BEHAV COGN PSYCHOTH, V42, P385, DOI 10.1017/S1352465812001087
   Stott R, 2013, BEHAV COGN PSYCHOTH, V41, P383, DOI 10.1017/S1352465813000404
   Sucala M, 2012, J MED INTERNET RES, V14, P175, DOI 10.2196/jmir.2084
   Tang WX, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012061
   Thew G. R., 2020, COGNITIVE BEHAV THER, V13, P1
   Thew Graham R, 2019, JMIR Form Res, V3, pe13446, DOI 10.2196/13446
   Turner J, 2018, J PSYCHIATR MENT HLT, V25, P285, DOI 10.1111/jpm.12440
   Turner J., 2015, THESIS
   Varker T, 2019, PSYCHOL SERV, V16, P621, DOI 10.1037/ser0000239
   Vos T, 2005, AUST NZ J PSYCHIAT, V39, P683, DOI 10.1111/j.1440-1614.2005.01652.x
   Weinberg H., 2020, THEORY PRACTICE ONLI, P174
   Weisz JR, 2006, PSYCHOL BULL, V132, P132, DOI 10.1037/0033-2909.132.1.132
   Wesson M, 2010, COGN BEH THER, V3, DOI 10.1017/S1754470X10000036
   Wild J, 2016, EUR J PSYCHOTRAUMATO, V7, DOI 10.3402/ejpt.v7.31019
   Wind TR, 2020, INTERNET INTERV, V20, DOI 10.1016/j.invent.2020.100317
   Ye XB, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-313
   Young LB, 2012, J TELEMED TELECARE, V18, P47, DOI 10.1258/jtt.2011.110608
NR 91
TC 0
Z9 0
U1 8
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1359-1045
EI 1461-7021
J9 CLIN CHILD PSYCHOL P
JI Clin. Child Psychol. Psychiatry
PD JUL
PY 2020
VL 25
IS 3
BP 672
EP 686
AR 1359104520937378
DI 10.1177/1359104520937378
EA JUN 2020
PG 15
WC Psychology, Clinical; Psychology, Developmental; Psychiatry; Psychology
SC Psychology; Psychiatry
GA MM1SM
UT WOS:000543758200001
PM 32594756
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Ferrara, F
   Granata, G
   Pelliccia, C
   La Porta, R
   Vitiello, A
AF Ferrara, Francesco
   Granata, Giovanni
   Pelliccia, Chiara
   La Porta, Raffaele
   Vitiello, Antonio
TI The added value of pirfenidone to fight inflammation and fibrotic state
   induced by SARS-CoV-2 Anti-inflammatory and anti-fibrotic therapy could
   solve the lung complications of the infection?
SO EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE Pirfenidone; Fibrotic; Inflammation; Cytokine; Interleukin; SARS-CoV-2
ID PNEUMONIA; WUHAN; CHINA
AB Aim SARS-CoV-2 infection has been divided by scientific opinion into three phases: the first as asymptomatic or slightly symptomatic and the second and the third with greater severity, characterized by a hyperinflammatory and fibrotic state, responsible for lung lesions, in some cases fatal. The development of antiviral drugs directed against SARS-CoV-2 and effective vaccines is progressing; meanwhile, the best pharmacological objective is related to the management of all the complications caused by this viral infection, mainly controlling the inflammatory and fibrotic state and preventing the infection from moving into the most serious phases. Subject and method Describe the scientific rationale related to the use of an antifibrotic therapy with pirfenidone, as monotherapy and/or in combination with anti-inflammatory drugs to manage and control complications of SARS-CoV-2 infection. Results Based on the scientific literature and epidemiological results and considering the pathophysiological, biological, and molecular characteristics of SARS-CoV-2, an antifibrotic drug such as pirfenidone as monotherapy or in combination with anti-inflammatory drugs can be (acting early, at the right doses and at the right time) therapeutically effective to avoid serious complications during viral infection. The same approach can also be effective as postinfection therapy in patients with residual pulmonary fibrotic damage. Management of inflammation and fibrotic status with a combination therapy of pirfenidone and IL-6 or IL-1 inhibitors could represent a pharmacological synergy with added value. Conclusion In this article, we consider the role of antifibrotic therapy with pirfenidone in patients with SARS-CoV-2 infection on going or in the stage of postinfection with pulmonary fibrotic consequences. The scientific rationale for its use is also described.
C1 [Ferrara, Francesco; Vitiello, Antonio] Usl Umbria 1, Perugia, Italy.
   [Granata, Giovanni] Asl Salerno, Salerno, Italy.
   [Pelliccia, Chiara] Usl Umbria 2, Terni, Italy.
   [La Porta, Raffaele] Asur Marche, Ancona, Italy.
RP Ferrara, F (corresponding author), Usl Umbria 1, Perugia, Italy.
EM francesco.ferrara@uslumbria1.it
RI Vitiello, Antonio/AAF-1421-2020; Ferrara, Francesco/AAU-7192-2020
OI Vitiello, Antonio/0000-0003-2623-166X; Ferrara,
   Francesco/0000-0001-9298-6783; La Porta, Raffaele/0000-0002-0569-369X
CR Asad M, 2020, IEEE J ELECTRON DEVI, V8, P457, DOI 10.1109/JEDS.2020.2988630
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   George PM, 2017, EXPERT REV CLIN PHAR, V10, P483, DOI 10.1080/17512433.2017.1295846
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   King CS, 2017, LANCET RESP MED, V5, P72, DOI 10.1016/S2213-2600(16)30222-3
   Laksmita OD, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229958
   Lancaster LH, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0057-2017
   Li YC, 2020, J MED VIROL, V92, P707, DOI 10.1002/jmv.25824
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Lota HK, 2013, EXPERT OPIN PHARMACO, V14, P79, DOI 10.1517/14656566.2013.758250
   Maher TM, 2020, LANCET RESP MED, V8, P147, DOI 10.1016/S2213-2600(19)30341-8
   Nathan SD, 2017, LANCET RESP MED, V5, P33, DOI 10.1016/S2213-2600(16)30326-5
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Veit T, 2019, AM J TRANSPLANT
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wells AU, 2020, LANCET RESP MED, V8, P453, DOI 10.1016/S2213-2600(20)30036-9
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Zhang T, 2020, CHINESE J TUBERCULOS
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 19
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0031-6970
EI 1432-1041
J9 EUR J CLIN PHARMACOL
JI Eur. J. Clin. Pharmacol.
PD NOV
PY 2020
VL 76
IS 11
BP 1615
EP 1618
DI 10.1007/s00228-020-02947-4
EA JUN 2020
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NZ9FZ
UT WOS:000543700900001
PM 32594204
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Asadi-Pooya, AA
   Attar, A
   Moghadami, M
   Karimzadeh, I
AF Asadi-Pooya, Ali A.
   Attar, Armin
   Moghadami, Mohsen
   Karimzadeh, Iman
TI Management of COVID-19 in people with epilepsy: drug considerations
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE Antiepileptic drug; COVID; Epilepsy; Interaction; Seizure
ID CONDUCTION
AB People with epilepsy (PWE) are neither more likely to be infected by the coronavirus nor are they more likely to have severe COVID-19 manifestations because they suffer from epilepsy. However, management of COVID-19 in PWE may be more complicated than that in other individuals. Drug-drug interactions could pose significant challenges and cardiac, hepatic, or renal problems, which may happen in patients with severe COVID-19, may require adjustment to antiepileptic drugs (AEDs). In this review, we first summarize the potential drug-drug interactions between AEDs and drugs currently used in the management of COVID-19. We then summarize other challenging issues that may happen in PWE, who have COVID-19 and are receiving treatment.
C1 [Asadi-Pooya, Ali A.] Shiraz Univ Med Sci, Epilepsy Res Ctr, Shiraz, Iran.
   [Asadi-Pooya, Ali A.] Thomas Jefferson Univ, Dept Neurol, Jefferson Comprehens Epilepsy Ctr, Philadelphia, PA 19107 USA.
   [Attar, Armin] Shiraz Univ Med Sci, Dept Cardiovasc Med, Shiraz, Iran.
   [Moghadami, Mohsen] Shiraz Univ Med Sci, Inst Hlth, Hlth Policy Res Ctr, Shiraz, Iran.
   [Karimzadeh, Iman] Shiraz Univ Med Sci, Dept Clin Pharm, Shiraz, Iran.
RP Asadi-Pooya, AA (corresponding author), Shiraz Univ Med Sci, Epilepsy Res Ctr, Shiraz, Iran.; Asadi-Pooya, AA (corresponding author), Thomas Jefferson Univ, Dept Neurol, Jefferson Comprehens Epilepsy Ctr, Philadelphia, PA 19107 USA.
EM aliasadipooya@yahoo.com; attar_armin@yahoo.com; mohsen168@gmail.com;
   karimzadehiman@yahoo.com
OI Asadi-Pooya, Ali/0000-0002-2598-7601; Karimzadeh,
   Iman/0000-0002-8956-4528
CR Asadi-Pooya AA, 2016, ANTIEPILEPTIC DRUGS
   Asadi-Pooya AA, 2020, SEIZURE-EUR J EPILEP, V79, P49, DOI 10.1016/j.seizure.2020.05.005
   Asadi-Pooya AA, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116832
   Brigo F, 2019, CNS DRUGS, V33, P771, DOI 10.1007/s40263-019-00652-0
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   DHATT MS, 1979, J CARDIOVASC PHARM, V1, P3, DOI 10.1097/00005344-197901000-00002
   Drew BJ, 2010, J AM COLL CARDIOL, V55, P934, DOI 10.1016/j.jacc.2010.01.001
   Farrokh S, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2066-1
   Huang CWW, 2018, J CLIN NEUROPHYSIOL, V35, P365, DOI 10.1097/WNP.0000000000000479
   Iroegbu JD, 2020, NEUROL SCI, V41, P1329, DOI 10.1007/s10072-020-04469-4
   KENNEBACK G, 1991, AM HEART J, V121, P1421, DOI 10.1016/0002-8703(91)90148-B
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Niazkar HR, 2020, NEUROL SCI, V41, P1667, DOI 10.1007/s10072-020-04486-3
   Patsalos PN, 2013, CLIN PHARMACOKINET, V52, P927, DOI 10.1007/s40262-013-0087-0
   Perucca E, 2006, BRIT J CLIN PHARMACO, V61, P246, DOI 10.1111/j.1365-2125.2005.02529.x
   Roden DM, 2020, J AM COLL CARDIOL, V75, P2623, DOI 10.1016/j.jacc.2020.04.016
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Nguyen T, 2016, AIDS REV, V18, P101
   Trinka E, 2017, SEIZURE-EUR J EPILEP, V44, P65, DOI 10.1016/j.seizure.2016.11.001
   van der Lee MJ, 2006, CLIN PHARMACOL THER, V80, P159, DOI 10.1016/j.clpt.2006.04.014
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhu JY, 2020, J MED VIROL, V92, P1902, DOI 10.1002/jmv.25884
NR 22
TC 5
Z9 5
U1 1
U2 1
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
PD AUG
PY 2020
VL 41
IS 8
BP 2005
EP 2011
DI 10.1007/s10072-020-04549-5
EA JUN 2020
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MN9HP
UT WOS:000543680500002
PM 32594268
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ricardo, JW
   Lipner, SR
AF Ricardo, Jose W.
   Lipner, Shari R.
TI Recommendations for treatment of nail psoriasis during theCOVID-19
   pandemic
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE biologics; COVID-19; immunosuppression; nail disorders; nail psoriasis;
   psoriasis; SARS-CoV-2
ID BIOLOGICS
AB The novel coronavirus disease 2019 (COVID-19) pandemic has resulted in a paradigm shift in disease management. Since immunosuppression may cause increased susceptibility to COVID-19, there is uncertainty as to whether systemically treated nail psoriasis patients are at increased infection risk. While specific data on nail psoriasis treatments and COVID-19 is lacking, we present clinical trial data on rates of upper respiratory infections, nasopharyngitis, viral infection, pneumonia and overall infections. Some systemic medications and biologics are associated with increased in infections risk compared to placebo in clinical trials. However, this data should be regarded cautiously since clinical trials on nail psoriasis, particularly controlled studies, are lacking. Our recommendations may be helpful in guiding physicians managing nail psoriasis patients during the COVID-19 pandemic.
C1 [Ricardo, Jose W.; Lipner, Shari R.] Weill Cornell Med, Dept Dermatol, 1305 York Ave, New York, NY 10021 USA.
RP Lipner, SR (corresponding author), Weill Cornell Med, Dept Dermatol, 1305 York Ave, New York, NY 10021 USA.
EM shl9032@med.cornell.edu
CR Di Lernia V, 2020, J AM ACAD DERMATOL, V82, pE217, DOI 10.1016/j.jaad.2020.04.004
   Herbein G, 2000, P SOC EXP BIOL MED, V223, P241, DOI 10.1046/j.1525-1373.2000.22335.x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Peterson D, 2020, J AM ACAD DERMATOL, V82, pE223, DOI 10.1016/j.jaad.2020.03.099
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Saunte DM, 2017, BRIT J DERMATOL, V177, P47, DOI 10.1111/bjd.15015
   Wan MT, 2020, J AM ACAD DERMATOL, V83, P677, DOI 10.1016/j.jaad.2020.05.035
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 9
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13757
DI 10.1111/dth.13757
EA JUN 2020
PG 3
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000543479100001
PM 32495952
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Brussow, H
AF Brussow, Harald
TI COVID-19: test, trace andisolate-newepidemiological data
SO ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID SEASONAL INFLUENZA; CARE; EPIDEMIC; DEATHS
AB In the absence of an efficient drug treatment or a vaccine, the control of the COVID-19 pandemic relies on classic infection control measures. Since these means are socially disruptive and come with substantial economic loss for societies, a better knowledge of the epidemiology of the new coronavirus epidemic is crucial to achieve control at a sustainable cost and within tolerable restrictions of civil rights.
C1 [Brussow, Harald] Katholieke Univ Leuven, Dept Biosyst, Lab Gene Technol, Leuven, Belgium.
RP Brussow, H (corresponding author), Katholieke Univ Leuven, Dept Biosyst, Lab Gene Technol, Leuven, Belgium.
EM haraldbruessow@yahoo.com
CR Anfinrud P, 2020, NEW ENGL J MED, V382, P2061, DOI 10.1056/NEJMc2007800
   [Anonymous], 2020, LANCET, V395, P1521, DOI 10.1016/S0140-6736(20)31140-5
   [Anonymous], 2020, ECONOMIST, P13
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Bahl Prateek, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa189
   Benezit F, 2020, LANCET INFECT DIS, V20, P1014, DOI 10.1016/S1473-3099(20)30297-8
   Bi QF, 2020, LANCET INFECT DIS, V20, P911, DOI 10.1016/S1473-3099(20)30287-5
   Bohmer MM, 2020, LANCET INFECT DIS, V20, P920, DOI 10.1016/S1473-3099(20)30314-5
   Bourouiba L., 2016, NEW ENGL J MED, V375, P8
   Burki T, 2020, LANCET, V395, P1602, DOI 10.1016/S0140-6736(20)31199-5
   Cheng Kar Keung, 2020, Lancet, DOI 10.1016/S0140-6736(20)30918-1
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6
   Dezecache G, 2020, CURR BIOL, V30, pR417, DOI 10.1016/j.cub.2020.04.010
   Drew DA, 2020, SCIENCE, V368, P1362, DOI 10.1126/science.abc0473
   Faust JS, 2020, JAMA INTERN MED, V180, P1045, DOI 10.1001/jamainternmed.2020.2306
   Fauver JR, 2020, CELL, V181, P990, DOI 10.1016/j.cell.2020.04.021
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Greenhalgh T, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1435
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Jordana J, 2020, LANCET, V395, P1611, DOI 10.1016/S0140-6736(20)31132-6
   Kansagra AP, 2020, NEW ENGL J MED, V383, P400, DOI 10.1056/NEJMc2014816
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Lai SJ, 2020, NATURE, V585, P410, DOI 10.1038/s41586-020-2293-x
   Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5
   Leon DA, 2020, LANCET, V395, pE81, DOI 10.1016/S0140-6736(20)30933-8
   Leung K, 2020, LANCET, V395, P1382, DOI 10.1016/S0140-6736(20)30746-7
   Lewis D, 2020, NATURE, V580, P175, DOI 10.1038/d41586-020-00974-w
   Li W, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa450., 10.1093/cid/ciaa450, DOI 10.1093/CID/CIAA450]
   Liao J, 2020, INNOVATION, V1, P100001, DOI [10.1016/j.xinn.2020.04.001, DOI 10.1016/J.XINN.2020.04.001]
   Little P, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1728
   Little P, 2015, LANCET, V386, P1631, DOI 10.1016/S0140-6736(15)60127-1
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Lu J, 2020, CELL, V181, P997, DOI 10.1016/j.cell.2020.04.023
   Lu X, 2020, NEW ENGL J MED, V23, P17, DOI DOI 10.1056/NEJMC200507354
   Maier BF, 2020, SCIENCE, V368, P742, DOI 10.1126/science.abb4557
   Mallapaty Smriti, 2020, Nature, DOI 10.1038/d41586-020-01095-0
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Newland K, 2020, SCIENCE, V368, P343, DOI 10.1126/science.abc3197
   Odone A, 2020, LANCET PUBLIC HEALTH, V5, pE310, DOI 10.1016/S2468-2667(20)30099-2
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Parmet WE, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2004211
   Parri N., 2020, NEW ENGL J MED, V382, P14
   Paterlini Marta, 2020, Nature, V580, P574, DOI 10.1038/d41586-020-01098-x
   Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012
   Schneider EC, 2020, NEW ENGL J MED, V383, P299, DOI 10.1056/NEJMp2014836
   Sood N, 2020, JAMA-J AM MED ASSOC, V323, P2425, DOI 10.1001/jama.2020.8279
   Tang JW, 2008, NEW ENGL J MED, V359, pE19, DOI 10.1056/NEJMicm072576
   Treibel TA, 2020, LANCET, V395, P1608, DOI 10.1016/S0140-6736(20)31100-4
   Tsang TK, 2020, LANCET PUBLIC HEALTH, V5, pE289, DOI 10.1016/S2468-2667(20)30089-X
   Wang X, 2020, LANCET GLOB HEALTH, V8, pE497, DOI 10.1016/S2214-109X(19)30545-5
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Yong SEF, 2020, LANCET INFECT DIS, V20, P809, DOI 10.1016/S1473-3099(20)30273-5
   Zhang JJ, 2020, SCIENCE, V368, P1481, DOI 10.1126/science.abb8001
   Zhang L., 2020, LANCET
NR 59
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-2912
EI 1462-2920
J9 ENVIRON MICROBIOL
JI Environ. Microbiol.
PD JUL
PY 2020
VL 22
IS 7
BP 2445
EP 2456
DI 10.1111/1462-2920.15118
EA JUN 2020
PG 12
WC Microbiology
SC Microbiology
GA MI7MZ
UT WOS:000543393900001
PM 32510748
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bahrami, M
   Kamalinejad, M
   Latifi, SA
   Seif, F
   Dadmehr, M
AF Bahrami, Mohsen
   Kamalinejad, Mohammad
   Latifi, Seied Amirhossein
   Seif, Farhad
   Dadmehr, Majid
TI Cytokine storm in COVID-19 and parthenolide: Preclinical evidence
SO PHYTOTHERAPY RESEARCH
LA English
DT Letter
DE coronavirus; COVID-19; feverfew; parthenolide; Tanacetum parthenium
AB A group of patients with pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported from China in December 2019. Although several antiviral drugs are widely tested, none of them has been approved as specific antiviral therapy for coronavirus disease 2019 (COVID-19). Accumulating evidence established a hyperinflammatory states or cytokine storm in COVID-19. Among these cytokines, IL-6 plays a key role in cytokine storm and can predict the adverse clinical outcomes and fatality in these patients. Based on the evidence of the significant role of IL-6 in cytokine storm, diabetes mellitus, and cardiovascular diseases as principal comorbidities, it seems that anti-cytokine therapy may be useful in patients with severe COVID-19 to reduce mortality. Recent studies demonstrated that herbal-derived natural products had immunosuppressive and anti-inflammatory properties and exhibited exceptional act on mediators of inflammation. Parthenolide is the principal sesquiterpene lactones and the main biologically active constituentTanacetum parthenium(commonly known as feverfew) which has could significantly reduce IL-1, IL-2, IL-6, IL-8, and TNF-alpha production pathways established in several human cell line models in vitro and in vivo studies. Therefore, parthenolide may be one of the herbal candidates for clinical evaluation.
C1 [Bahrami, Mohsen] Acad Ctr Educ Culture & Res, Tehran, Iran.
   [Kamalinejad, Mohammad] Shahid Beheshti Univ Med Sci, Sch Pharm, Tehran, Iran.
   [Latifi, Seied Amirhossein] Arak Univ Med Sci, Tradit & Complementary Med Res Ctr, Arak, Iran.
   [Seif, Farhad] Acad Ctr Educ Culture & Res, Dept Immunol & Allergy, Tehran, Iran.
   [Seif, Farhad] Iran Univ Med Sci, Neurosci Res Ctr, Tehran, Iran.
   [Dadmehr, Majid] Iran Univ Med Sci, Sch Persian Med, Tehran, Iran.
RP Dadmehr, M (corresponding author), Iran Univ Med Sci, Behesht St,Vahdat Islami St, Tehran, Iran.
EM majiddadmehr@yahoo.com
RI Dadmehr, Majid/AAH-6288-2019
OI Dadmehr, Majid/0000-0002-7032-8648; Kamalinejad,
   Mohammad/0000-0002-5946-4913; Seif, Farhad/0000-0003-1275-2157
CR Amirghofran Z, 2012, IRAN J ALLERGY ASTHM, V11, P111, DOI 011.02/ijaai.111119
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   George V. C., 2012, INT RES J PHARM, V3, P69
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Lopresti AL, 2020, PHYTOTHER RES, V34, P2493, DOI 10.1002/ptr.6701
   Magni P, 2012, PHYTOTHER RES, V26, P1405, DOI 10.1002/ptr.3732
   Pareek Anil, 2011, Pharmacogn Rev, V5, P103, DOI 10.4103/0973-7847.79105
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Wang MT, 2015, NAT PROD RES, V29, P1092, DOI 10.1080/14786419.2014.981541
   Williamson EM, 2020, BRIT J PHARMACOL, V177, P1227, DOI 10.1111/bph.14943
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 12
TC 3
Z9 3
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD OCT
PY 2020
VL 34
IS 10
BP 2429
EP 2430
DI 10.1002/ptr.6776
EA JUN 2020
PG 2
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OC4MU
UT WOS:000543523200001
PM 32472655
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Salama, M
   Ataman-Millhouse, L
   Braham, M
   Berjeb, K
   Khrouf, M
   Rodrigues, JK
   Reis, FM
   Cury-Silva, T
   Sanchez, F
   Romero, S
   Smitz, J
   Vasquez, L
   Vega, M
   Sobral, F
   Terrado, G
   Lombardi, MG
   Scarella, A
   Bourlon, MT
   Verduzco-Aguirre, H
   Sanchez, AM
   Adiga, SK
   Tholeti, P
   Udupa, KS
   Mahajan, N
   Patil, M
   Dalvi, R
   Venter, C
   Demetriou, G
   Geel, J
   Quintana, R
   Rodriguez, G
   Quintana, T
   Viale, L
   Fraguglia, M
   Coirini, M
   Remolina-Bonilla, YA
   Noguera, JAR
   Velasquez, JC
   Suarez, A
   Arango, GD
   Pineda, JID
   Aldecoa, MDC
   Javed, M
   Al Sufyan, H
   Daniels, N
   Oranye, BC
   Ogunmokun, AA
   Onwuzurigbo, KI
   Okereke, CJ
   Whesu, TC
   Woodruff, TK
AF Salama, M.
   Ataman-Millhouse, L.
   Braham, M.
   Berjeb, K.
   Khrouf, M.
   Rodrigues, J. K.
   Reis, F. M.
   Cury-Silva, T.
   Sanchez, F.
   Romero, S.
   Smitz, J.
   Vasquez, L.
   Vega, M.
   Sobral, F.
   Terrado, G.
   Lombardi, M. G.
   Scarella, A.
   Bourlon, M. T.
   Verduzco-Aguirre, H.
   Sanchez, A. M.
   Adiga, S. K.
   Tholeti, P.
   Udupa, K. S.
   Mahajan, N.
   Patil, M.
   Dalvi, R.
   Venter, C.
   Demetriou, G.
   Geel, J.
   Quintana, R.
   Rodriguez, G.
   Quintana, T.
   Viale, L.
   Fraguglia, M.
   Coirini, M.
   Remolina-Bonilla, Y. A.
   Noguera, J. A. R.
   Velasquez, J. C.
   Suarez, A.
   Arango, G. D.
   Pineda, J. I. D.
   Aldecoa, M. D. C.
   Javed, M.
   Al Sufyan, H.
   Daniels, N.
   Oranye, B. C.
   Ogunmokun, A. A.
   Onwuzurigbo, K. I.
   Okereke, C. J.
   Whesu, T. C.
   Woodruff, T. K.
TI Installing oncofertility programs for common cancers in limited resource
   settings (Repro-Can-OPEN Study): An extrapolation during the global
   crisis of Coronavirus (COVID-19) pandemic
SO JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
LA English
DT Article
DE oncofertility; cancer; limited resource settings; COVID-19; pandemic
ID FEMALE-PATIENTS; FERTILITY; PRESERVATION
AB Purpose The state of limited resource settings that Coronavirus (COVID-19) pandemic has created globally should be taken seriously into account especially in healthcare sector. In oncofertility, patients should receive their fertility preservation treatments urgently even in limited resource settings before initiation of anticancer therapy. Therefore, it is very crucial to learn more about oncofertility practice in limited resource settings such as in developing countries that suffer often from shortage of healthcare services provided to young patients with cancer. Methods As an extrapolation during the global crisis of COVID-19 pandemic, we surveyed oncofertility centers from 14 developing countries (Egypt, Tunisia, Brazil, Peru, Panama, Mexico, Colombia, Guatemala, Argentina, Chile, Nigeria, South Africa, Saudi Arabia, and India). Survey questionnaire included questions on the availability and degree of utilization of fertility preservation options in case of childhood cancer, breast cancer, and blood cancer. Results All surveyed centers responded to all questions. Responses and their calculated oncofertility scores showed different domestic standards for oncofertility practice in case of childhood cancer, breast cancer, and blood cancer in the developing countries under limited resource settings. Conclusions Medical practice in limited resource settings has become a critical topic especially after the global crisis of COVID-19 pandemic. Understanding the resources necessary to provide oncofertility treatments is important until the current COVID-19 pandemic resolves. Lessons learned will be valuable to future potential worldwide disruptions due to infectious diseases or other global crises.
C1 [Salama, M.; Ataman-Millhouse, L.; Woodruff, T. K.] Northwestern Univ, Feinberg Sch Med, Oncofertil Consortium, Chicago, IL 60611 USA.
   [Braham, M.; Berjeb, K.] Aziza Othmana Hosp Tunis, Tunis, Tunisia.
   [Khrouf, M.] FERTILLA, Clin Rose, Tunis, Tunisia.
   [Rodrigues, J. K.; Reis, F. M.; Cury-Silva, T.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Sanchez, F.; Romero, S.] Univ Peruana Cayetano Heredia, Lab Biol Reprod & Preservac Fertilidad, Lab Invest & Desarrollo, Lima, Peru.
   [Vasquez, L.] Hosp Edgardo Rebagliati Martins, Unidad Oncol Pediat, Lima, Peru.
   [Vega, M.] Sistema Nacl Investigadores, Panama Fertil, Panama City, Panama.
   [Sobral, F.; Terrado, G.; Lombardi, M. G.] Pregna Med Reprod, Buenos Aires, DF, Argentina.
   [Scarella, A.] Univ Valparaiso, Fac Med, Ctr Reprod Humana, Valparaiso, Chile.
   [Bourlon, M. T.; Verduzco-Aguirre, H.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
   [Sanchez, A. M.] Inst Nacl Perinatol Isidro Espinoza Los Reyes, Mexico City, DF, Mexico.
   [Adiga, S. K.; Tholeti, P.] Kasturba Med Coll & Hosp, Manipal Acad Higher Educ, Dept Clin Embryol, Fertil Preservat Ctr, Manipal, India.
   [Udupa, K. S.] Kasturba Med Coll & Hosp, Manipal Acad Higher Educ, Dept Med Oncol, Manipal, India.
   [Mahajan, N.] Mother & Child Hosp, New Delhi, India.
   [Patil, M.] Dr Patils Fertil & Endoscopy Clin, Bangalore, Karnataka, India.
   [Dalvi, R.] Hosp Inst Med Sci, Mumbai, Maharashtra, India.
   [Dalvi, R.] SRCC Childrens Hosp, Mumbai, Maharashtra, India.
   [Venter, C.] Vitalab Fertil Ctr, Johannesburg, South Africa.
   [Demetriou, G.] Univ Witwatersrand, Dept Med Oncol, Johannesburg, South Africa.
   [Geel, J.] Charlotte Maxeke Johannesburg Acad Hosp, Johannesburg, South Africa.
   [Quintana, R.; Rodriguez, G.; Quintana, T.; Viale, L.; Fraguglia, M.] Procrearte, Buenos Aires, DF, Argentina.
   [Coirini, M.] Hosp Ninos Victor J Vilela Rosario, Rosario, Santa Fe, Argentina.
   [Remolina-Bonilla, Y. A.; Noguera, J. A. R.; Velasquez, J. C.; Suarez, A.] Inst Nacl Cancerol, Bogota, Colombia.
   [Arango, G. D.] FERTIVIDA Fertil Ctr, Bogota, Colombia.
   [Pineda, J. I. D.; Aldecoa, M. D. C.] Inst Guatemalteco Seguridad Social IGSS, Guatemala City, Guatemala.
   [Javed, M.; Al Sufyan, H.] Thuriah Med Ctr, Riyadh, Saudi Arabia.
   [Daniels, N.; Oranye, B. C.; Ogunmokun, A. A.] Eko Hosp, Oncol & Fertil Ctr, Ekocorp Plc, Lagos, Nigeria.
   [Onwuzurigbo, K. I.; Okereke, C. J.; Whesu, T. C.] Kingswill Specialist Hosp, Lagos, Nigeria.
RP Salama, M; Woodruff, TK (corresponding author), Northwestern Univ, Feinberg Sch Med, Oncofertil Consortium, Chicago, IL 60611 USA.
EM eaims_gm@yahoo.com; lauren.ataman@northwestern.edu;
   braham.marouen@gmail.com; khadija.berjeb@yahoo.fr; moh.khrouf@gmail.com;
   jhenifer.kr.pesquisa@gmail.com; reis.ufmg@gmail.com;
   taynnaelcury@gmail.com; Flor.sanchez.r@upch.pe; Sergio.romero.l@upch.pe;
   Johan.smitz@upch.pe; lilianavasq@gmail.com; mgvega@outlook.com;
   fsobral@pregna.com.ar; gterrado@pregna.com.ar; mglombardi@intramed.net;
   anibal.scarella@uv.cl; maitebourlon@gmail.com;
   haydee_verduzco@hotmail.com; adrianmtz81@hotmail.com;
   satish.adiga@manipal.edu; prathima.t@manipal.edu;
   Udupa.karthik@manipal.edu; dr.nalinimahajan@gmail.com;
   drmadhuripatil59@gmail.com; rashmidalvi5@gmail.com; chrisv@vitalab.com;
   georgiademetriou@hotmail.com; Jennifer.geel@wits.ac.za;
   ramiroquintana@hotmail.com; gabriela.m.rodriguez@hotmail.com;
   Tquinta@hotmail.com; Viale.luz@gmail.com; landisofia@gmail.com;
   mdcoirini@yahoo.com.ar; yaremolinab@gmail.com;
   andrearussinoguera@gmail.com; jcvelasquez.2000@gmail.com;
   asuarez@cancer.gov.co; gdapalau@yahoo.es; jennifer.dom@gmail.com;
   mdcastroaldecoa@gmail.com; murid.javed@thuriah.com.sa;
   hamadsufyan@yahoo.com; nonsod@yahoo.com; ben.oranye@gmail.com;
   gbiteogunmokun@yahoo.com; kingeki@yahoo.com; okerekedubem@yahoo.com;
   toyin.whesu@gmail.com; tkw@northwestern.edu
RI Adiga, Satish Kumar/AAU-4386-2020
OI Adiga, Satish Kumar/0000-0002-2897-4697; Demetriou,
   Georgia/0000-0002-9029-0069; Salama, Mahmoud/0000-0002-0282-8018;
   Sanchez, Flor/0000-0003-1762-6184; Romero, Sergio/0000-0003-0621-8943;
   Braham, Marouen/0000-0002-8861-3471; Remolina Bonilla, Yuly
   Andrea/0000-0003-2388-5844; Tholeti, Prathima/0000-0003-2725-1451;
   Verduzco-Aguirre, Haydee Cristina/0000-0002-2300-7075
CR Ataman LM, 2020, JCO GLOB ONCOL, V6, P317, DOI 10.1200/JGO.2015.000307
   Bourlon MT, 2020, JCO GLOB ONCOL, V6, P314, DOI 10.1200/GO.19.00337
   Jeruss JS, 2009, NEW ENGL J MED, V360, P902, DOI 10.1056/NEJMra0801454
   Oktay K, 2018, J CLIN ONCOL, V36, P1994, DOI 10.1200/JCO.2018.78.1914
   Penzias A, 2019, FERTIL STERIL, V112, P1022, DOI 10.1016/j.fertnstert.2019.09.013
   Rashedi AS, 2020, JCO GLOB ONCOL, V6, P331, DOI 10.1200/JGO.2016.008144
   Salama M, 2019, ANN ONCOL, V30, P1760, DOI 10.1093/annonc/mdz284
   Salama M, 2019, ACTA OBSTET GYN SCAN, V98, P659, DOI 10.1111/aogs.13552
   Salama Mahmoud, 2018, J Glob Oncol, V4, P1, DOI 10.1200/JGO.17.00121
   Salama M, 2017, EXPERT REV HEMATOL, V10, P951, DOI 10.1080/17474086.2017.1371009
   Salama M, 2017, EXPERT REV ANTICANC, V17, P687, DOI 10.1080/14737140.2017.1335199
   Salama M, 2016, CRIT REV ONCOL HEMAT, V103, P10, DOI 10.1016/j.critrevonc.2016.04.002
   Salama M, 2015, CANCER METAST REV, V34, P807, DOI 10.1007/s10555-015-9600-2
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   von Wolff M, 2019, CLIN MED INSIGHTS-RE, V13, DOI 10.1177/1179558119845865
   Woodruff Teresa K., 2007, V138, P3
   Woodruff TK, 2015, REPRODUCTION, V150, pS1, DOI 10.1530/REP-15-0163
NR 17
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1058-0468
EI 1573-7330
J9 J ASSIST REPROD GEN
JI J. Assist. Reprod. Genet.
PD JUL
PY 2020
VL 37
IS 7
BP 1567
EP 1577
DI 10.1007/s10815-020-01821-7
EA JUN 2020
PG 11
WC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology
SC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology
GA MN9AL
UT WOS:000544206300001
PM 32594284
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhong, ZF
   Huang, J
   Yang, X
   Peng, JL
   Zhang, XY
   Hu, Y
   Fu, N
   Lin, HL
   Jiang, B
   Tian, YY
   Yao, HY
   Deng, LP
   Tang, XQ
   Zhou, JC
   Tang, J
   Xie, X
   Liu, Q
   Liu, J
   Dou, CY
   Dai, RJ
   Yan, B
   Yang, XF
AF Zhong, Zhe-Feng
   Huang, Jia
   Yang, Xia
   Peng, Jin-Ling
   Zhang, Xiao-Yan
   Hu, Yang
   Fu, Nian
   Lin, Hai-Lian
   Jiang, Bo
   Tian, Ya-Ying
   Yao, Hong-Yi
   Deng, Li-Pu
   Tang, Xiao-Qing
   Zhou, Jie-Can
   Tang, Jian
   Xie, Xia
   Liu, Qiong
   Liu, Jing
   Dou, Cheng-Yun
   Dai, Rong-Juan
   Yan, Bo
   Yang, Xue-Feng
TI Epidemiological and clinical characteristics of COVID-19 patients in
   Hengyang, Hunan Province, China
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE Novel coronavirus pneumonia; COVID-19; SARS-CoV-2; Epidemiology;
   Hengyang; Coronavirus disease 2019
AB BACKGROUND In December 2019, an ongoing outbreak of coronavirus disease 2019 (COVID-19) was first identified in Wuhan, China. The characteristics of COVID-19 patients treated in local hospitals in Wuhan are not fully representative of patients outside Wuhan. Therefore, it is highly essential to analyze the epidemiological and clinical characteristics of COVID-19 in areas outside Wuhan or Hubei Province. To date, a limited number of studies have concentrated on the epidemiological and clinical characteristics of COVID-19 patients with different genders, clinical classification, and with or without basic diseases. AIM To study the epidemiological and clinical characteristics of COVID-19 patients in Hengyang (China) and provide a reliable reference for the prevention and control of COVID-19. METHODS From January 16 to March 2, 2020, a total of 48 confirmed cases of COVID-19 were reported in Hengyang, and those cases were included in this study. The diagnostic criteria, clinical classification, and discharge standard related to COVID-19 were in line with the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) released by National Health Commission and National Administration of Traditional Chinese Medicine. The presence of SARS-CoV-2 in pharyngeal swab specimens was detected by quantitative reverse transcription polymerase chain reaction. All the data were imported into the excel worksheet and statistically analyzed by using SPSS 25.0 software. RESULTS A total of 48 cases of COVID-19 were collected, of which 1 was mild, 38 were moderate, and 9 were severe. It was unveiled that there were 31 (64.6%) male patients and 17 (35.4%) female patients, with a female-to-male ratio of 1.82:1. The range of age of patients with COVID-19 was dominantly 30-49 years old [25 (52.1%) of 48], followed by those aged over 60 years old [11 (22.9%)]. Besides, 29.2% (14 of 48) of patients had basic diseases, and 57.2% (8 of 14) of patients with basic diseases were aged over 60 years old. The occupations of 48 COVID-19 patients were mainly farmers working in agricultural production [15 (31.5%) of 48], rural migrant workers from Hengyang to Wuhan [15 (31.5%)], and service workers operating in the service sector [8 (16.7%)]. The mean latent period was 6.86 +/- 3.57 d, and the median was 7 [interquartile range (IQR): 4-9] d. The mean time from onset of symptoms to the first physician visit was 3.38 +/- 2.98 (95%CI: 2.58-9.18) d, with a median of 2 (IQR: 1-5) d, and the mean time from hospital admission to confirmed diagnosis was 2.29 +/- 2.11 (95%CI: 1.18-6.42) d, with a median of 2 (IQR: 1-3) d. The main symptoms were fever [43 (89.6%) of 48], cough and expectoration [41 (85.4%)], fatigue [22 (45.8%)], and chills [22 (45.8%)]. Other symptoms included poor appetite [13 (27.1%)], sore throat [9 (18.8%)], dyspnea [9 (18.8%)], diarrhea [7 (14.6%)], dizziness [5 (10.4%)], headache [5 (10.4%)], muscle pain [5 (10.4%)], nausea and vomiting [4 (8.3%)], hemoptysis [4 (8.3%)], and runny nose [1 (2.1%)]. The numbers of peripheral blood leukocytes, lymphocytes, and eosinophils were significantly reduced in the majority of the patients. The levels of C-reactive protein, fibrinogen, blood glucose, lactate dehydrogenase, D-dimer, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (gamma-GT), myoglobin (MB), and creatine kinase (CK) were increased in 64.6%, 44.7%, 43.2%, 37.0%, 29.5%, 22.9%,20.8%, 21.6%, 13.6%, and 12.8% of patients, respectively.
   The incidence of ALT elevation in male patients was remarkably higher than that in females (P< 0.
   01), while the incidences of AST, CK, and blood glucose elevations in severe patients were remarkably higher than those in moderate patients (P< 0.05, respectively). Except for the mild patients, chest computed tomography showed characteristic pulmonary lesions. All the patients received antiviral drugs, 38 (79.2%) accepted traditional Chinese medicine, and 2 (4.2%) received treatment of human umbilical-cord mesenchymal stem cells. On March 2, 2020, 48 patients with COVID-19 were all cured and discharged. CONCLUSION Based on our results, patients with COVID-19 often have multiple organ dysfunction or damage. The incidences of ALT elevation in males, and AST, CK, and blood glucose elevations in severe patients are remarkably higher.
C1 [Zhong, Zhe-Feng; Jiang, Bo; Tian, Ya-Ying] Univ South China, Affiliated Nanhua Hosp, Hengyang Med Coll, Dept Infect Dis, Hengyang 421002, Hunan, Peoples R China.
   [Huang, Jia; Hu, Yang; Fu, Nian; Lin, Hai-Lian; Yang, Xue-Feng] Univ South China, Affiliated Nanhua Hosp, Hengyang Med Coll, Dept Gastroenterol, 336 Dongfeng Rd, Hengyang 421002, Hunan, Peoples R China.
   [Yang, Xia; Peng, Jin-Ling; Zhang, Xiao-Yan] Univ South China, Affiliated Nanhua Hosp, Hengyang Med Coll, Dept Gen Practice, Hengyang 421002, Hunan, Peoples R China.
   [Yao, Hong-Yi; Deng, Li-Pu] Univ South China, Affiliated Nanhua Hosp, Hengyang Med Coll, Dept Intens Med, Hengyang 421002, Hunan, Peoples R China.
   [Tang, Xiao-Qing] Univ South China, Affiliated Hosp 1, Hengyang Med Coll, Inst Clin Med, Hengyang 421001, Hunan, Peoples R China.
   [Zhou, Jie-Can; Tang, Jian; Xie, Xia; Liu, Qiong; Liu, Jing; Dou, Cheng-Yun; Dai, Rong-Juan] Univ South China, Affiliated Hosp 1, Hengyang Med Coll, Dept Infect Dis, Hengyang 421001, Hunan, Peoples R China.
   [Yan, Bo] Univ South China, Affiliated Hosp 1, Hengyang Med Coll, Dept Cardiol, Hengyang 421001, Hunan, Peoples R China.
RP Yang, XF (corresponding author), Univ South China, Affiliated Nanhua Hosp, Hengyang Med Coll, Dept Gastroenterol, 336 Dongfeng Rd, Hengyang 421002, Hunan, Peoples R China.
EM yxf9988@126.com
FU Novel Coronavirus Pneumonia Emergency Project of University of South
   China [2020-15, 2020-25]; Hengyang Science and Technology Plan
   Project-Basic Research Project of Prevention and Treatment of the Novel
   Coronavirus Pneumonia [202010031577]; Scientific Research Project of
   Hunan Provincial Health and Family Planning Commission [A2017015];
   Natural Science Foundation of Hunan Province, ChinaNatural Science
   Foundation of Hunan Province [2016JJ5010]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81373465]
FX Supported by the Novel Coronavirus Pneumonia Emergency Project of
   University of South China, No. 2020-15 and No. 2020-25; the Hengyang
   Science and Technology Plan Project-Basic Research Project of Prevention
   and Treatment of the Novel Coronavirus Pneumonia, No. 202010031577; the
   Scientific Research Project of Hunan Provincial Health and Family
   Planning Commission, No. A2017015; the Natural Science Foundation of
   Hunan Province, China, No. 2016JJ5010; and the National Natural Science
   Foundation of China, No. 81373465.
CR [Anonymous], 2020, CHINESE MED J-PEKING, V133, P1087, DOI 10.1097/CM9.0000000000000819
   Cao J, 2020, CLIN INFECT DIS
   Chau TN, 2004, HEPATOLOGY, V39, P302, DOI 10.1002/hep.20111
   Gostic K, 2020, ELIFE, V9, DOI 10.7554/eLife.55570
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lee EYP, 2020, LANCET INFECT DIS, V20, P384, DOI 10.1016/S1473-3099(20)30134-1
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Sanders JM, 2020, JAMA
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wong SC, 2020, J HOSP INFECT
   Yeo C, 2020, LANCET GASTROENTEROL, V5, P335, DOI 10.1016/S2468-1253(20)30048-0
   Young BE, 2020, JAMA
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 3
Z9 3
U1 5
U2 5
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD JUN 26
PY 2020
VL 8
IS 12
BP 2554
EP 2565
DI 10.12998/wjcc.v8.i12.2554
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA MV9WF
UT WOS:000556698200014
PM 32607332
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kale, SD
   Mehrkens, BN
   Stegman, MM
   Kastelberg, B
   Carnes, H
   McNeill, RJ
   Rizzo, A
   Karyala, SV
   Coutermarsh-Ott, S
   Fretz, JA
   Sun, Y
   Koff, JL
   Rajagopalan, G
AF Kale, Shiv D.
   Mehrkens, Brittney N.
   Stegman, Molly M.
   Kastelberg, Bridget
   Carnes, Henry
   McNeill, Rachel J.
   Rizzo, Amy
   Karyala, Saikumar V.
   Coutermarsh-Ott, Sheryl
   Fretz, Jackie A.
   Sun, Ying
   Koff, Jonathan L.
   Rajagopalan, Govindarajan
TI "Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine
   Release Syndrome, and Its Modulation by Interferon-gamma, IL-17A, and a
   Janus Kinase Inhibitor
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE cytokine release syndrome; superantigens; HLA class II transgenic mice;
   multiple organ dysfucntion; JAK inhibitor
ID MULTIPLE ORGAN DYSFUNCTION; SYSTEMIC INFLAMMATORY RESPONSE;
   STAPHYLOCOCCAL-ENTEROTOXIN-B; TRANSGENIC MOUSE MODEL; RECEPTOR; SHOCK;
   CELLS; COLITIS; IL-22; GUT
AB Chimeric antigen receptor T cell (CART) therapy, administration of certain T cell-agonistic antibodies, immune check point inhibitors, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) and Toxic shock syndrome (TSS) caused by streptococcal as well as staphylococcal superantigens share one common complication, that is T cell-driven cytokine release syndrome (CRS) accompanied by multiple organ dysfunction (MOD). It is not understood whether the failure of a particular organ contributes more significantly to the severity of CRS. Also not known is whether a specific cytokine or signaling pathway plays a more pathogenic role in precipitating MOD compared to others. As a result, there is no specific treatment available to date for CRS, and it is managed only symptomatically to support the deteriorating organ functions and maintain the blood pressure. Therefore, we used the superantigen-induced CRS model in HLA-DR3 transgenic mice, that closely mimics human CRS, to delineate the immunopathogenesis of CRS as well as to validate a novel treatment for CRS. Using this model, we demonstrate that (i) CRS is characterized by a rapid rise in systemic levels of several Th1/Th2/Th17/Th22 type cytokines within a few hours, followed by a quick decline. (ii) Even though multiple organs are affected, small intestinal immunopathology is the major contributor to mortality in CRS. (iii) IFN-gamma deficiency significantly protected from lethal CRS by attenuating small bowel pathology, whereas IL-17A deficiency significantly increased mortality by augmenting small bowel pathology. (iv) RNA sequencing of small intestinal tissues indicated that IFN-gamma-STAT1-driven inflammatory pathways combined with enhanced expression of pro-apoptotic molecules as well as extracellular matrix degradation contributed to small bowel pathology in CRS. These pathways were further enhanced by IL-17A deficiency and significantly down-regulated in mice lacking IFN-gamma. (v) Ruxolitinib, a selective JAK-1/2 inhibitor, attenuated SAg-induced T cell activation, cytokine production, and small bowel pathology, thereby completely protecting from lethal CRS in both WT and IL-17A deficient HLA-DR3 mice. Overall, IFN-gamma-JAK-STAT-driven pathways contribute to lethal small intestinal immunopathology in T cell-driven CRS.
C1 [Kale, Shiv D.; Kastelberg, Bridget] Virginia Tech, Fralin Life Sci Inst, Blacksburg, VA USA.
   [Mehrkens, Brittney N.; Carnes, Henry; Rajagopalan, Govindarajan] Edward Via Coll Osteopath Med, Discipline Microbiol & Immunol, Blacksburg, VA 24060 USA.
   [Stegman, Molly M.] Virginia Tech, Coll Sci, Blacksburg, VA USA.
   [McNeill, Rachel J.] Virginia Tech, Virginia Maryland Coll Vet Med, Res & Grad Studies, Blacksburg, VA USA.
   [Rizzo, Amy] Virginia Tech, Off Univ Vet, Blacksburg, VA USA.
   [Karyala, Saikumar V.] Virginia Tech, Genom Sequencing Ctr, Blacksburg, VA USA.
   [Coutermarsh-Ott, Sheryl; Rajagopalan, Govindarajan] Virginia Tech, Virginia Maryland Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA.
   [Fretz, Jackie A.] Yale Sch Med, Dept Orthoped & Rehabil, Histol & Histomorphometry Lab, New Haven, CT USA.
   [Sun, Ying; Koff, Jonathan L.; Rajagopalan, Govindarajan] Yale Sch Med, Div Pulm Crit Care & Sleep Med, Dept Med, New Haven, CT 06510 USA.
RP Rajagopalan, G (corresponding author), Edward Via Coll Osteopath Med, Discipline Microbiol & Immunol, Blacksburg, VA 24060 USA.; Rajagopalan, G (corresponding author), Virginia Tech, Virginia Maryland Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA.; Rajagopalan, G (corresponding author), Yale Sch Med, Div Pulm Crit Care & Sleep Med, Dept Med, New Haven, CT 06510 USA.
EM govindarajan.rajagopalan@yale.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 AI68741]; Research Eureka
   Accelerator Program (REAP) by VCOM; Research Eureka Accelerator Program
   (REAP) by VT
FX This study was partly supported by NIH R01 AI68741 and Research Eureka
   Accelerator Program (REAP) supported by VCOM and VT to GR.
CR Afshar B, 2017, VIRULENCE, V8, P1390, DOI 10.1080/21505594.2017.1325070
   Anderson MR, 2001, CLIN IMMUNOL, V98, P85, DOI 10.1006/clim.2000.4960
   Armacki M, 2018, J CLIN INVEST, V128, P5056, DOI 10.1172/JCI97912
   Au-Yeung BB, 2014, P NATL ACAD SCI USA, V111, pE3679, DOI 10.1073/pnas.1413726111
   Beaurepaire C, 2009, J INTERF CYTOK RES, V29, P133, DOI 10.1089/jir.2008.0057
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Brosnahan AJ, 2016, METHODS MOL BIOL, V1396, P1, DOI 10.1007/978-1-4939-3344-0_1
   Brudno JN, 2016, BLOOD, V127, P3321, DOI 10.1182/blood-2016-04-703751
   Bruewer M, 2005, FASEB J, V19, P923, DOI 10.1096/fj.04-3260com
   Bueno Clara, 2007, Chem Immunol Allergy, V93, P161, DOI 10.1159/000100894
   Bugelski PJ, 2009, EXPERT REV CLIN IMMU, V5, P499, DOI 10.1586/ECI.09.31
   Cecconi M, 2018, LANCET, V392, P75, DOI 10.1016/S0140-6736(18)30696-2
   Chae WJ, 2010, P NATL ACAD SCI USA, V107, P5540, DOI 10.1073/pnas.0912675107
   Chau TA, 2009, NAT MED, V15, P641, DOI 10.1038/nm.1965
   Clark JA, 2007, SHOCK, V28, P384, DOI 10.1097/shk.0b013e31805569df
   Davies MR, 2015, NAT GENET, V47, P84, DOI 10.1038/ng.3147
   Dimitriou F, 2019, J IMMUNOTHER, V42, P29, DOI 10.1097/CJI.0000000000000236
   Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092
   Eriguchi Y, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121886
   Eyerich K, 2017, EUR J IMMUNOL, V47, P607, DOI 10.1002/eji.201646723
   Fan X, 2016, CELL, V164, P1198, DOI 10.1016/j.cell.2016.02.048
   Feng T, 2011, J IMMUNOL, V186, P6313, DOI 10.4049/jimmunol.1001454
   Fey PD, 2003, ANTIMICROB AGENTS CH, V47, P196, DOI 10.1128/AAC.47.1.196-203.2003
   Fragoulis GE, 2019, RHEUMATOLOGY, V58, P43, DOI 10.1093/rheumatology/key276
   Fry DE, 2012, AM SURGEON, V78, P1
   Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255
   Gerlach Herwig, 2016, F1000Res, V5, P2909, DOI 10.12688/f1000research.9092.1
   Green DS, 2017, J BIOL CHEM, V292, P13925, DOI 10.1074/jbc.R116.774745
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Honjo O, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0582-4
   Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668
   Imohl M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180757
   Johnson HM, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9564814
   Kaempfer R, 2017, RECEPTOR CLIN INVEST, V4, P1500, DOI [10.14800/rci.1500, DOI 10.14800/RCI.1500]
   Karau MJ, 2017, VIRULENCE, V8, P1148, DOI 10.1080/21505594.2016.1267894
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/nmeth.3317, 10.1038/NMETH.3317]
   Klingensmith NJ, 2016, CRIT CARE CLIN, V32, P203, DOI 10.1016/j.ccc.2015.11.004
   Latella G, 2020, DIGEST DIS SCI, V65, P1299, DOI 10.1007/s10620-020-06161-1
   Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729
   Lee JS, 2015, IMMUNITY, V43, P727, DOI 10.1016/j.immuni.2015.09.003
   Li HX, 2016, J CRIT CARE, V36, P24, DOI 10.1016/j.jcrc.2016.05.001
   Li J, 2018, MUCOSAL IMMUNOL, V11, P581, DOI 10.1038/mi.2017.97
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Majoros A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00029
   Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035
   McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021
   Mizoguchi A, 2018, J GASTROENTEROL, V53, P465, DOI 10.1007/s00535-017-1401-7
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Moran AE, 2011, J EXP MED, V208, P1279, DOI 10.1084/jem.20110308
   Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6
   Nava P, 2010, IMMUNITY, V32, P392, DOI 10.1016/j.immuni.2010.03.001
   O'Connor W, 2009, NAT IMMUNOL, V10, P603, DOI 10.1038/ni.1736
   Ogawa A, 2004, CLIN IMMUNOL, V110, P55, DOI 10.1016/j.clim.2003.09.013
   Ouyang WJ, 2019, IMMUNITY, V50, P871, DOI 10.1016/j.immuni.2019.03.020
   Padar M, 2019, J CRIT CARE, V52, P103, DOI 10.1016/j.jcrc.2019.04.001
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Piton G, 2013, CRIT CARE MED, V41, P2169, DOI 10.1097/CCM.0b013e31828c26b5
   Rajagopalan G, 2011, TISSUE ANTIGENS, V77, P589, DOI 10.1111/j.1399-0039.2010.01617.x
   Rajagopalan G, 2008, SHOCK, V30, P721, DOI 10.1097/SHK.0b013e31817048f7
   Rajagopalan G, 2009, PHYSIOL GENOMICS, V37, P279, DOI 10.1152/physiolgenomics.90385.2008
   Rossaint J, 2015, CRIT REV IMMUNOL, V35, P277, DOI 10.1615/CritRevImmunol.2015015461
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Schuhmann D, 2011, CLIN EXP IMMUNOL, V163, P65, DOI 10.1111/j.1365-2249.2010.04250.x
   Sertaridou E, 2015, ANN GASTROENTEROL, V28, P309
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Shohan M, 2020, IUBMB LIFE, V72, P1585, DOI 10.1002/iub.2295
   Silverstein R, 2004, J ENDOTOXIN RES, V10, P147, DOI 10.1179/096805104225004879
   Smith MK, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-1067-0
   Spinelli FR, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc5367
   Stephanou A, 2003, INT J EXP PATHOL, V84, P239, DOI 10.1111/j.0959-9673.2003.00363.x
   Stuebig T, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.2001.2001
   Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842
   Szabo PA, 2017, J IMMUNOL, V198, P2805, DOI 10.4049/jimmunol.1601366
   Tachibana M, 2020, INT IMMUNOL, V32, P187, DOI 10.1093/intimm/dxz076
   Tilahun AY, 2014, J IMMUNOL, V193, P2919, DOI 10.4049/jimmunol.1400980
   Tilahun AY, 2011, AM J PATHOL, V178, P2760, DOI 10.1016/j.ajpath.2011.02.033
   Tilahun AY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016764
   Tilahun ME, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027203
   Tsirigotis P, 2015, ANTIMICROB AGENTS CH, V59, P7367, DOI 10.1128/AAC.01533-15
   Vainchenker William, 2018, F1000Res, V7, P82, DOI 10.12688/f1000research.13167.1
   Wilson GJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002271
   Wu Guanming, 2014, F1000Res, V3, P146, DOI 10.12688/f1000research.4431.1
   Yajnanarayana SP, 2015, BRIT J HAEMATOL, V169, P824, DOI 10.1111/bjh.13373
   Yajnanarayana SP, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.2281.2281
   Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404
NR 86
TC 0
Z9 0
U1 7
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 26
PY 2020
VL 11
AR 1311
DI 10.3389/fimmu.2020.01311
PG 20
WC Immunology
SC Immunology
GA MO9PL
UT WOS:000551848000001
PM 32676080
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Azabou, E
   Bao, G
   Heming, N
   Bounab, R
   Moine, P
   Chevallier, S
   Chevret, S
   Resche-Rigon, M
   Siami, S
   Sharshar, T
   Lofaso, F
   Annane, D
AF Azabou, Eric
   Bao, Guillaume
   Heming, Nicholas
   Bounab, Rania
   Moine, Pierre
   Chevallier, Sylvain
   Chevret, Sylvie
   Resche-Rigon, Matthieu
   Siami, Shidaps
   Sharshar, Tarek
   Lofaso, Frederic
   Annane, Djillali
TI Randomized Controlled Study Evaluating Efficiency of Low Intensity
   Transcranial Direct Current Stimulation (tDCS) for Dyspnea Relief in
   Mechanically Ventilated COVID-19 Patients in ICU: The tDCS-DYSP-COVID
   Protocol
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; acute respiratory distress syndrome (ARDS); tDCS; dyspnea
   relief; brain; neuromodulation; mechanical ventilation; ICU
ID MOTOR CORTEX STIMULATION; AIR HUNGER; BRAIN; PAIN; EXCITABILITY;
   PERCEPTION; VALIDITY; RELIABILITY; ACTIVATION; SCORE
AB The severe respiratory distress syndrome linked to the new coronavirus disease (COVID-19) includes unbearable dyspneic suffering which contributes to the deterioration of the prognosis of patients in intensive care unit (ICU). Patients are put on mechanical ventilation to reduce respiratory suffering and preserve life. Despite this mechanical ventilation, most patients continue to suffer from dyspnea. Dyspnea is a major source of suffering in intensive care and one of the main factors that affect the prognosis of patients. The development of innovative methods for its management, especially non-drug management is more than necessary. In recent years, numerous studies have shown that transcranial direct current stimulation (tDCS) could modulate the perception of acute or chronic pain. In the other hand, it has been shown that the brain zones activated during pain and dyspnea are close and/or superimposed, suggesting that brain structures involved in the integration of aversive emotional component are shared by these two complex sensory experiences. Therefore, it can be hypothesized that stimulation by tDCS with regard to the areas which, in the case of pain have activated one or more of these brain structures, may also have an effect on dyspnea. In addition, our team recently demonstrated that the application of tDCS on the primary cortical motor area can modulate the excitability of the respiratory neurological pathways. Indeed, tDCS in anodal or cathodal modality reduced the excitability of the diaphragmatic cortico-spinal pathways in healthy subjects. We therefore hypothesized that tDCS could relieve dyspnea in COVID-19 patients under mechanical ventilation in ICU. This study was designed to evaluate effects of two modalities of tDCS (anodal and cathodal) vs. placebo, on the relief of dyspnea in COVID-19 patients requiring mechanical ventilation in ICU.
C1 [Azabou, Eric; Bao, Guillaume; Lofaso, Frederic] Univ Versailles St Quentin En Yvelines UVSQ, Paris Saclay Univ,Inserm UMR 1173, Raymond Poincare Hosp,Infect & Inflammat 2I, AP HP,Dept Physiol,Clin Neurophysiol & Neuromodul, Paris, France.
   [Azabou, Eric; Bao, Guillaume; Lofaso, Frederic] Univ Versailles St Quentin En Yvelines UVSQ, Paris Saclay Univ,Inserm UMR 1173, Raymond Poincare Hosp,Infect & Inflammat 2I, AP HP,Dept Physiol Crit Care Med,Clin Neurophysio, Paris, France.
   [Heming, Nicholas; Bounab, Rania; Moine, Pierre; Annane, Djillali] Univ Versailles St Quentin En Yvelines UVSQ, Paris Saclay Univ, Raymond Poincare Hosp,Infect & Inflammat 2I, AP HP,Gen Intens Care Unit,Inserm UMR 1173, Paris, France.
   [Chevallier, Sylvain] Univ Versailles St Quentin En Yvelines UVSQ, Paris Saclay Univ, Versailles Engn Syst Lab LISV, Velizy Villacoublay, France.
   [Chevret, Sylvie; Resche-Rigon, Matthieu] Hop St Louis, AP HP, Serv Biostat & Informat Med, Paris, France.
   [Chevret, Sylvie; Resche-Rigon, Matthieu] Inserm U1153 CRESS, Epidemiol & Clin Stat Tumor Resp & Resuscitat Ass, Paris, France.
   [Chevret, Sylvie; Resche-Rigon, Matthieu] Univ Paris 7 Diderot, Sorbonne Paris Cite, Paris, France.
   [Siami, Shidaps] CH Etampes Dourdan, Crit Care Med Unit, Etampes, France.
   [Sharshar, Tarek] Paris Descartes Univ, St Anne Hosp, Dept Neurointens Care Med, Paris, France.
   [Sharshar, Tarek] Inst Pasteur, Lab Human Histopathol & Anim Models, Paris, France.
RP Azabou, E (corresponding author), Univ Versailles St Quentin En Yvelines UVSQ, Paris Saclay Univ,Inserm UMR 1173, Raymond Poincare Hosp,Infect & Inflammat 2I, AP HP,Dept Physiol,Clin Neurophysiol & Neuromodul, Paris, France.; Azabou, E (corresponding author), Univ Versailles St Quentin En Yvelines UVSQ, Paris Saclay Univ,Inserm UMR 1173, Raymond Poincare Hosp,Infect & Inflammat 2I, AP HP,Dept Physiol Crit Care Med,Clin Neurophysio, Paris, France.
EM eric.azabou@aphp.fr
RI Chevallier, Sylvain/AAB-7621-2020
OI Chevallier, Sylvain/0000-0003-3027-8241
FU Clinical Research and Innovation Department of Assistance Publique -
   Hopitaux de Paris (APHP, DRCI); University of Versailles Saint Quentin
   en Yvelines (UVSQ); Paris Saclay University
FX The authors would like to thank our institutional sponsors Clinical
   Research and Innovation Department of Assistance Publique - Hopitaux de
   Paris (APHP, DRCI); the University of Versailles Saint Quentin en
   Yvelines (UVSQ) and the Paris Saclay University. We also thank the
   Methodology and Clinical Research Unit of the Saint Louis Hospital,
   Paris (URC Paris Saint Louis) for the methodological supports.
CR Ahmed T, 2020, CUREUS, V12, DOI 10.7759/cureus.7482
   Altschuler EL, 2020, MED HYPOTHESES, V141, DOI 10.1016/j.mehy.2020.109774
   Annane D, 2006, CRIT CARE MED, V34, P22, DOI 10.1097/01.CCM.0000194723.78632.62
   Antal A, 2008, PERCEPTION, V37, P367, DOI 10.1068/p5872
   Antal A, 2008, CLIN J PAIN, V24, P56, DOI 10.1097/AJP.0b013e318157233b
   Azabou E, 2013, RESP PHYSIOL NEUROBI, V189, P183, DOI 10.1016/j.resp.2013.07.024
   Bachmann CG, 2010, CLIN NEUROPHYSIOL, V121, P2083, DOI 10.1016/j.clinph.2010.05.005
   Banzett RB, 1996, RESP PHYSIOL, V103, P19, DOI 10.1016/0034-5687(95)00050-X
   Banzett RB, 2008, AM J RESP CRIT CARE, V177, P1384, DOI 10.1164/rccm.200711-1675OC
   Banzett RB, 2007, J NEUROPHYSIOL, V97, P959, DOI 10.1152/jn.00970.2006
   Banzett RB, 2015, EUR RESPIR J, V45, P1681, DOI 10.1183/09031936.00038914
   Banzett RB, 2014, EUR RESPIR J, V43, P1547, DOI 10.1183/09031936.00031114
   BARNES PJ, 1994, NEW ENGL J MED, V330, P1383, DOI 10.1056/NEJM199405123301910
   Binks AP, 2014, RESP PHYSIOL NEUROBI, V204, P78, DOI 10.1016/j.resp.2014.09.005
   Boggio PS, 2008, EUR J NEUROL, V15, P1124, DOI 10.1111/j.1468-1331.2008.02270.x
   Brunoni AR, 2011, INT J NEUROPSYCHOPH, V14, P1133, DOI 10.1017/S1461145710001690
   Cooke SF, 2006, BRAIN, V129, P1659, DOI 10.1093/brain/awl082
   Csifcsak G, 2009, PAIN MED, V10, P122, DOI 10.1111/j.1526-4637.2008.00508.x
   Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703
   Gandhi S, 2020, ACS CHEM NEUROSCI, V11, P1379, DOI 10.1021/acschemneuro.0c00217
   Geier MR, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109760
   Gracely RH, 2007, PULM PHARMACOL THER, V20, P433, DOI 10.1016/j.pupt.2006.12.005
   Hayward G, 2007, EUR J NEUROSCI, V25, P2224, DOI 10.1111/j.1460-9568.2007.05430.x
   Herigstad M, 2011, RESP MED, V105, P809, DOI 10.1016/j.rmed.2010.12.022
   Horowitz RI, 2020, RESPIR MED CASE REP, V30, DOI 10.1016/j.rmcr.2020.101063
   Iyer VN, 2009, MAYO CLIN PROC, V84, P694, DOI 10.1016/S0025-6196(11)60519-3
   Lansing RW, 2000, AM J RESP CRIT CARE, V162, P1690, DOI 10.1164/ajrccm.162.5.9907096
   Lansing RW, 2003, RESP PHYSIOL NEUROBI, V134, P77, DOI 10.1016/S1569-9048(02)00211-2
   Lefaucheur JP, 2008, BRAIN STIMUL, V1, P337, DOI 10.1016/j.brs.2008.07.003
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Mahler DA, 2015, CHEST, V147, P232, DOI 10.1378/chest.14-0800
   Meek PM, 2012, CHEST, V141, P1546, DOI 10.1378/chest.11-1087
   Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899
   Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x
   Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429
   Nitsche MA, 2009, NEUROTHERAPEUTICS, V6, P244, DOI 10.1016/j.nurt.2009.01.003
   Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004
   O'Connell NE, 2011, EUR J PHYS REHAB MED, V47, P309
   Parshall MB, 2012, AM J RESP CRIT CARE, V185, P435, DOI 10.1164/rccm.201111-2042ST
   Pascarella G, 2020, J INTERN MED, V288, P192, DOI 10.1111/joim.13091
   Peiffer C, 2001, AM J RESP CRIT CARE, V163, P951, DOI 10.1164/ajrccm.163.4.2005057
   Peiffer C, 2008, AM J RESP CRIT CARE, V177, P937, DOI 10.1164/rccm.200802-298ED
   Peiffer C, 2008, AM J RESP CRIT CARE, V177, P440, DOI 10.1164/rccm.200612-1774OC
   Peiffer C, 2011, AM J RESP CRIT CARE, V184, P867, DOI 10.1164/rccm.201108-1463ED
   Peiffer C, 2009, RESP PHYSIOL NEUROBI, V167, P61, DOI 10.1016/j.resp.2009.04.001
   Persichini R, 2015, ANESTHESIOLOGY, V123, P830, DOI 10.1097/ALN.0000000000000805
   Peyron R, 2007, NEUROIMAGE, V34, P310, DOI 10.1016/j.neuroimage.2006.08.037
   Raux M, 2007, ANESTHESIOLOGY, V107, P746, DOI 10.1097/01.anes.0000287005.58761.e8
   Raux M, 2007, J PHYSIOL-LONDON, V578, P569, DOI 10.1113/jphysiol.2006.120246
   Raux M, 2010, RESP PHYSIOL NEUROBI, V171, P67, DOI 10.1016/j.resp.2010.01.002
   Raux M, 2010, J APPL PHYSIOL, V108, P39, DOI 10.1152/japplphysiol.91454.2008
   Roche N, 2009, J PHYSIOL-LONDON, V587, P5653, DOI 10.1113/jphysiol.2009.177550
   Schmidt M, 2014, INTENS CARE MED, V40, P1, DOI 10.1007/s00134-013-3117-3
   Schmidt M, 2011, CRIT CARE MED, V39, P2059, DOI 10.1097/CCM.0b013e31821e8779
   Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138
   Tremoureux L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084534
   Tremoureux L, 2010, J APPL PHYSIOL, V108, P1127, DOI 10.1152/japplphysiol.91449.2008
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   von Leupoldt A, 2009, NEUROIMAGE, V48, P200, DOI 10.1016/j.neuroimage.2009.06.015
   Zangrillo A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02928-0
   Zheng X, 2011, NEUROIMAGE, V58, P26, DOI 10.1016/j.neuroimage.2011.06.018
NR 61
TC 2
Z9 2
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUN 26
PY 2020
VL 7
AR 372
DI 10.3389/fmed.2020.00372
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA MO8FC
UT WOS:000551753500001
PM 32671084
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rudd, CE
AF Rudd, Christopher E.
TI GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual
   Benefit of Inhibiting Viral Replication While Potentiating the Immune
   Response
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE T-Cells (or lymphocytes); COVID; CD8+; T lymphocyte subsets; viral (or
   virus); therapy
ID SYNTHASE KINASE 3; CELL-PROLIFERATION; NK CELLS; T-BET; PHOSPHORYLATION;
   PROTEIN; PD-1
AB The SARS-CoV2 (COVID-19) pandemic and uncertainties in developing a vaccine have created an urgent need for new therapeutic approaches. A key question is whether it is possible to make rational predictions of new therapies based on the presently available scientific and medical information. In this regard, I have noticed an omission in the present analysis in the literature related to the exploitation of glycogen synthase kinase 3 (GSK-3) as a therapeutic approach. This is based on two key observations, that GSK-3 inhibitors can simultaneously block SARs viral replication, while boosting CD8+ adaptive T-cell and innate natural killer (NK) responses. Firstly, it is already clear that GSK-3 phosphorylation of SARs CoV1 N protein on key serine residues is needed for viral replication such that small molecule inhibitors (SMIs) of GSK-3 can inhibit viral replication. In comparing protein sequences, I show here that the key sites in the N protein of SARs CoV1 N for replication are conserved in SARs CoV2. This strongly suggests that GSK-3 SMIs will also inhibit SARs Cov2 replication. Secondly, we and others have previously documented that GSK-3 SMIs markedly enhance CD8+ cytolytic T-cell (CTL) and NK cell anti-viral effector functions leading to a reduction in both acute and chronic viral infections in mice. My hypothesis is that the repurposing of low-cost inhibitors of GSK-3 such as lithium will limit SARS-CoV2 infections by both reducing viral replication and potentiating the immune response against the virus. To date, there has been no mention of this dual connection between GSK-3 and SARs CoV2 in the literature. To my knowledge, no other drugs exist with the potential to simultaneously target both viral replication and immune response against SARs CoV2.
C1 [Rudd, Christopher E.] Ctr Rech Maisonneuve Rosemont Hosp CR HMR, Montreal, PQ, Canada.
   [Rudd, Christopher E.] Univ Montreal, Dept Med, Montreal, PQ, Canada.
   [Rudd, Christopher E.] McGill Univ, Ctr Hlth, Dept Med, Div Endocrinol & Med Biochem, Montreal, PQ, Canada.
RP Rudd, CE (corresponding author), Ctr Rech Maisonneuve Rosemont Hosp CR HMR, Montreal, PQ, Canada.; Rudd, CE (corresponding author), Univ Montreal, Dept Med, Montreal, PQ, Canada.; Rudd, CE (corresponding author), McGill Univ, Ctr Hlth, Dept Med, Div Endocrinol & Med Biochem, Montreal, PQ, Canada.
EM christopher.e.rudd@umontreal.ca
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Cichocki F, 2017, CANCER RES, V77, P5664, DOI 10.1158/0008-5472.CAN-17-0799
   del Ser T, 2013, J ALZHEIMERS DIS, V33, P205, DOI 10.3233/JAD-2012-120805
   Eldar-Finkelman H, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00032
   Gong RJ, 2016, AM J PHYSIOL-RENAL, V311, pF1168, DOI 10.1152/ajprenal.00145.2016
   Guzman ML, 2007, BLOOD, V110, P4436, DOI 10.1182/blood-2007-05-088815
   Hill EV, 2015, EUR J IMMUNOL, V45, P1103, DOI 10.1002/eji.201444661
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Krueger J, 2017, IMMUNITY, V46, P529, DOI 10.1016/j.immuni.2017.04.003
   Lam VC, 2017, CURR OPIN IMMUNOL, V44, P43, DOI 10.1016/j.coi.2016.11.003
   Lazarevic V, 2011, NAT IMMUNOL, V12, P597, DOI 10.1038/ni.2059
   Lin L, 2007, INT J MASS SPECTROM, V268, P296, DOI 10.1016/j.ijms.2007.05.009
   Madhusoodanan J, 2020, P NATL ACAD SCI USA, V117, P10616, DOI 10.1073/pnas.2007346117
   Mizutani T, 2006, FEMS IMMUNOL MED MIC, V46, P236, DOI 10.1111/j.1574-695X.2005.00028.x
   Murru A, 2020, INT J BIPOLAR DISORD, V8, DOI 10.1186/s40345-020-00191-4
   Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99
   Patel P, 2017, CURR TOP DEV BIOL, V123, P277, DOI 10.1016/bs.ctdb.2016.11.011
   RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190
   Rudd CE, 2020, CELL REP, V30, P2075, DOI 10.1016/j.celrep.2020.01.076
   Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711
   Taylor A, 2018, CANCER RES, V78, P706, DOI 10.1158/0008-5472.CAN-17-0491
   Taylor A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01653
   Taylor A, 2016, IMMUNITY, V44, P274, DOI 10.1016/j.immuni.2016.01.018
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu CH, 2014, CELL HOST MICROBE, V16, P462, DOI 10.1016/j.chom.2014.09.009
   Wu CH, 2009, J BIOL CHEM, V284, P5229, DOI 10.1074/jbc.M805747200
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
NR 27
TC 1
Z9 1
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 26
PY 2020
VL 11
AR 1638
DI 10.3389/fimmu.2020.01638
PG 4
WC Immunology
SC Immunology
GA MO9NO
UT WOS:000551843100001
PM 32695123
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bonam, SR
   Muller, S
   Bayry, J
   Klionsky, DJ
AF Bonam, Srinivasa Reddy
   Muller, Sylviane
   Bayry, Jagadeesh
   Klionsky, Daniel J.
TI Autophagy as an emerging target for COVID-19: lessons from an old
   friend, chloroquine
SO AUTOPHAGY
LA English
DT Article
DE Autophagy; coronavirus; COVID-19; cytokine storm syndrome; SARS-CoV-2
ID HYDROXYCHLOROQUINE-INDUCED CARDIOMYOPATHY; TNF-ALPHA; CORONAVIRUS;
   RECEPTOR; INHIBITION; MECHANISM; HEART; DRUG; ACE2
AB During the last week of December 2019, Wuhan (China) was confronted with the first case of respiratory tract disease 2019 (coronavirus disease 2019, COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Due to the rapid outbreak of the transmission (similar to 3.64 million positive cases and high mortality as of 5 May 2020), the world is looking for immediate and better therapeutic options. Still, much information is not known, including origin of the disease, complete genomic characterization, mechanism of transmission dynamics, extent of spread, possible genetic predisposition, clinical and biological diagnosis, complete details of disease-induced pathogenicity, and possible therapeutic options. Although several known drugs are already under clinical evaluation with many in repositioning strategies, much attention has been paid to the aminoquinoline derivates, chloroquine (CQ) and hydroxychloroquine (HCQ). These molecules are known regulators of endosomes/lysosomes, which are subcellular organelles central to autophagy processes. By elevating the pH of acidic endosomes/lysosomes, CQ/HCQ inhibit the autophagic process. In this short perspective, we discuss the roles of CQ/HCQ in the treatment of COVID-19 patients and propose new ways of possible treatment for SARS-CoV-2 infection based on the molecules that selectivity target autophagy.
C1 [Bonam, Srinivasa Reddy; Bayry, Jagadeesh] Univ Paris, Inst Natl Sante & Rech Med, Equipe Immunopathol & Immunointervent Therapeut, Ctr Rech Cordeliers,Sorbonne Univ, Paris, France.
   [Muller, Sylviane] CNRS, Strasbourg, France.
   [Muller, Sylviane] Strasbourg Univ, Unit Biotechnol & Cell Signalling, Lab Excellence Med, Strasbourg, France.
   [Muller, Sylviane] Strasbourg Univ, Federat Hosp Univ OMICARE, Federat Med Translat Strasbourg FMTS, Strasbourg, France.
   [Muller, Sylviane] Univ Strasbourg, Chair Therapeut Immunol, Inst Adv Study USIAS, Strasbourg, France.
   [Klionsky, Daniel J.] Univ Michigan, Life Sci Inst, Ann Arbor, MI 48109 USA.
   [Klionsky, Daniel J.] Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.
RP Muller, S; Klionsky, DJ (corresponding author), Univ Michigan, Life Sci Inst, Ann Arbor, MI 48109 USA.; Muller, S; Klionsky, DJ (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.; Bonam, SR; Bayry, J (corresponding author), Ctr Rech Cordeliers, INSERM Unite 1138, 15 Rue Ecole Med, F-75006 Paris, France.
EM bsrpharmacy90@gmail.com; sylviane.muller@unistra.fr;
   jagadeesh.bayry@crc.jussieu.fr; klionsky@umich.edu
RI Bayry, Jagadeesh/A-6589-2011; BONAM, SRINIVASA REDDY/I-1342-2016
OI Bayry, Jagadeesh/0000-0003-0498-9808; BONAM, SRINIVASA
   REDDY/0000-0002-2888-2418; Klionsky, Daniel/0000-0002-7828-8118
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [GM131919]; European
   UnionEuropean Union (EU) [H2020-SC1-2019-874653-INDIGO]; Laboratoire
   d'Excellence en Recherche sur le Medicament et l'Innovation
   Therapeutique (FR) [ANR-10-LABX -0034]
FX This work was supported by the National Institutes of Health [GM131919];
   European Union Horizon H2020 programme [H2020-SC1-2019-874653-INDIGO];
   Laboratoire d'Excellence en Recherche sur le Medicament et l'Innovation
   Therapeutique (FR) [ANR-10-LABX -0034].
CR Abdin A, 2017, CLIN RES CARDIOL, V106, P234, DOI 10.1007/s00392-016-1064-z
   [Anonymous], NO CLIN BEN US HYDR
   [Anonymous], 2020, COVID 19 INCONCLUSIV
   [Anonymous], 2020, CHINESE CLIN TRIAL R
   [Anonymous], 2020, HYDROXYCHLOROQUINE B
   Martinez-Garcia EA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01497
   Bertram S, 2011, J VIROL, V85, P13363, DOI 10.1128/JVI.05300-11
   Bonam Srinivasa Reddy, 2020, Cell Rep Med, V1, P100016, DOI 10.1016/j.xcrm.2020.100016
   Bonam SR, 2019, NAT REV DRUG DISCOV, V18, P923, DOI 10.1038/s41573-019-0036-1
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Chatterjee P, 2020, INDIAN J MED RES, V151, P459, DOI 10.4103/ijmr.IJMR_2234_20
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758:2020.2003.2022.20040758, DOI 10.1101/2020.03.22.20040758:2020.2003.2022.20040758]
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Corley MJ, 2020, COMP IN VITRO TRANSC, DOI [10.1101/2020.04.13.039263:2020.2004.2013.039263, DOI 10.1101/2020.04.13.039263:2020.2004.2013.039263]
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Danilczyk U, 2006, CIRC RES, V98, P463, DOI 10.1161/01.RES.0000205761.22353.5f
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   FOX RI, 1993, SEMIN ARTHRITIS RHEU, V23, P82, DOI 10.1016/S0049-0172(10)80012-5
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gros F, 2014, BRIT J PHARMACOL, V171, P4337, DOI 10.1111/bph.12792
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   HU TY, 2020, NAT NANOTECHNOL 0323
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang MX, 2020, NATL SCI REV, V7, P1428, DOI 10.1093/nsr/nwaa113
   Hulme OJ, 2020, BAYESIAN REANALYSIS, DOI [10.1101/2020.03.31.20048777:2020.2003.2031.20048777, DOI 10.1101/2020.03.31.20048777:2020.2003.2031.20048777]
   Jang CH, 2006, RHEUMATOLOGY, V45, P703, DOI 10.1093/rheumatology/kei282
   King AMQ, 2012, 9 INT COMM TAX VIR, P806, DOI [10.1016/B978-0-12-384684-6.00068-9, DOI 10.1016/B978-0-12-384684-6.00068-9, 10.1016/B978-0-12-384684-6.00068-9.3.]
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kuznik A, 2011, J IMMUNOL, V186, P4794, DOI 10.4049/jimmunol.1000702
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Luk HKH, 2019, INFECT GENET EVOL, V71, P21, DOI 10.1016/j.meegid.2019.03.001
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Maisonnasse P, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-27223/v1(PREPRINT), DOI 10.21203/RS.3.RS-27223/V1(PREPRINT)]
   Masson JD, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8030047
   Matsuyama S, 2005, P NATL ACAD SCI USA, V102, P12543, DOI 10.1073/pnas.0503203102
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meng T, 2020, INSERT SEQUENCE SARS, DOI [10.1101/2020.02.08.926006:2020.2002.2008.926006, DOI 10.1101/2020.02.08.926006:2020.2002.2008.926006]
   Mohamed FE, 2015, LIVER INT, V35, P1063, DOI 10.1111/liv.12626
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Pellegrini P, 2014, AUTOPHAGY, V10, P562, DOI 10.4161/auto.27901
   Ramadan N, 2019, GERMS, V9, P35, DOI 10.18683/germs.2019.1155
   Renna M, 2011, J CLIN INVEST, V121, P3554, DOI 10.1172/JCI46095
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Savarino A, 2020, PHARMACOKINETIC BASE, DOI [10.1101/2020.04.23.20076471:2020.2004.2023.20076471, DOI 10.1101/2020.04.23.20076471:2020.2004.2023.20076471]
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shamshirian A, 2020, HYDROXYCHLOROQUINE V, DOI [10.1101/2020.04.14.20065276:2020.2004.2014.20065276, DOI 10.1101/2020.04.14.20065276:2020.2004.2014.20065276]
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Taccone FS, 2020, LANCET RESP MED, V8, P539, DOI 10.1016/S2213-2600(20)30172-7
   Tan YW, 2018, ANTIVIR RES, V149, P143, DOI 10.1016/j.antiviral.2017.11.017
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Tselios K, 2016, JCR-J CLIN RHEUMATOL, V22, P287, DOI 10.1097/RHU.0000000000000400
   Ujike M, 2015, VIRUSES-BASEL, V7, P1700, DOI 10.3390/v7041700
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Wang K, 2020, SARS COV 2 INVADES H, DOI [10.1101/2020.03.14.988345:2020.2003.2014.988345, DOI 10.1101/2020.03.14.988345:2020.2003.2014.988345]
   Wang M, 2020, CELL RES 0204, V30, P269, DOI [DOI 10.1038/S41422-020-0282-0, 10.1038/s41422-020-0282-0]
   Weber SM, 2000, J IMMUNOL, V165, P1534, DOI 10.4049/jimmunol.165.3.1534
   Wozniacka A, 2006, LUPUS, V15, P521, DOI 10.1191/0961203306lu2345oa
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yasuda H, 2008, AM J PHYSL RENAL PHY, V294, pF1050
   Yu B, 2020, SCI CHINA LIFE SCI, V63, P1515, DOI 10.1007/s11427-020-1732-2
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang LY, 2020, J PARKINSON DIS, V10, P523, DOI 10.3233/JPD-191768
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175
   1997, CLIN INFECT DIS O S1, V24
NR 89
TC 8
Z9 8
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD DEC 1
PY 2020
VL 16
IS 12
BP 2260
EP 2266
DI 10.1080/15548627.2020.1779467
EA JUN 2020
PG 7
WC Cell Biology
SC Cell Biology
GA PI0BT
UT WOS:000547370200001
PM 32522067
OA Bronze
DA 2021-01-01
ER

PT J
AU Liu, XK
   Yue, XP
   Liu, FR
   Wei, L
   Chu, YT
   Bao, HH
   Dong, YC
   Cheng, WJ
   Yang, LP
AF Liu, Xinkui
   Yue, Xinpei
   Liu, Furong
   Wei, Le
   Chu, Yuntian
   Bao, Honghong
   Dong, Yichao
   Cheng, Wenjie
   Yang, Linpeng
TI Analysis of clinical features and early warning signs in patients with
   severe COVID-19: A retrospective cohort study
SO PLOS ONE
LA English
DT Article
ID SARS; OUTBREAK
AB Coronavirus disease 2019 (COVID-19) was first identified in Wuhan, China, in December 2019. Although previous studies have described the clinical aspects of COVID-19, few studies have focused on the early detection of severe COVID-19. Therefore, this study aimed to identify the predictors of severe COVID-19 and to compare clinical features between patients with severe COVID-19 and those with less severe COVID-19. Patients admitted to designated hospital in the Henan Province of China who were either discharged or died prior to February 15, 2020 were enrolled retrospectively. Additionally, patients who underwent at least one of the following treatments were assigned to the severe group: continuous renal replacement therapy, high-flow oxygen absorption, noninvasive and invasive mechanical ventilation, or extracorporeal membrane oxygenation. The remaining patients were assigned to the non-severe group. Demographic information, initial symptoms, and first visit examination results were collected from the electronic medical records and compared between the groups. Multivariate logistic regression analysis was performed to determine the predictors of severe COVID-19. A receiver operating characteristic curve was used to identify a threshold for each predictor. Altogether,104 patients were enrolled in our study with 30 and 74 patients in the severe and non-severe groups, respectively. Multivariate logistic analysis indicated that patients aged >= 63 years (odds ratio = 41.0; 95% CI: 2.8, 592.4), with an absolute lymphocyte value of <= 1.02x10(9)/L (odds ratio = 6.1; 95% CI = 1.5, 25.2) and a C-reactive protein level of >= 65.08mg/L (odds ratio = 8.9; 95% CI = 1.0, 74.2) were at a higher risk of severe illness. Thus, our results could be helpful in the early detection of patients at risk for severe illness, enabling the implementation of effective interventions and likely lowering the morbidity of COVID-19 patients.
C1 [Liu, Xinkui; Yue, Xinpei; Liu, Furong; Wei, Le; Bao, Honghong; Dong, Yichao; Cheng, Wenjie; Yang, Linpeng] Zhenghzou Univ, Med Records Management Dept, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
   [Chu, Yuntian] Huazhong Univ Sci & Technol, Tongji Med Univ, Sch Hlth Care Management, Wuhan, Hubei, Peoples R China.
RP Liu, XK (corresponding author), Zhenghzou Univ, Med Records Management Dept, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
EM liuxk666@163.com
FU Medical Science and Technology Key Project of Henan Province
   [SB201901021]
FX This work was supported by the Medical Science and Technology Key
   Project of Henan Province SB201901021). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bi Q, 2020, EPIDEMIOLOGY TRANSMI, DOI [10.1101/2020.03.03.20028423, DOI 10.1101/2020.03.03.20028423V1]
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Chang HL, 2006, J FORMOS MED ASSOC, V105, P439, DOI 10.1016/S0929-6646(09)60183-2
   Gorbalenya AE, 2020, BIORXIV PREPRINT, DOI 10.1101/2020.02.07.937862v1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Health Commission of Henan Province, UPD EP SIT COVID 19
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang Tian-jun, 2003, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V17, P344
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Leong HN, 2006, ANN ACAD MED SINGAP, V35, P326
   Liu J, 2020, NEUTROPHIL TO LYMPHO, DOI [10.1101/2020.02.10.20021584, DOI 10.1101/2020.02.10.20021584]
   Lobo SMA, 2003, CHEST, V123, P2043, DOI 10.1378/chest.123.6.2043
   National Health Commission of the People' Republic of China, UPD EP SIT COVID 19
   Nikolich-Zugich J, 2020, GEROSCIENCE, V42, P505, DOI 10.1007/s11357-020-00186-0
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Shahid Z, 2020, J AM GERIATR SOC, V68, P926, DOI 10.1111/jgs.16472
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang Y, 2019, WETLANDS, V39, pS35, DOI 10.1007/s13157-019-01180-9
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Yin Chi-biao, 2003, Zhonghua Jiehe He Huxi Zazhi, V26, P343
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 27
TC 1
Z9 1
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 26
PY 2020
VL 15
IS 6
AR e0235459
DI 10.1371/journal.pone.0235459
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MG0YE
UT WOS:000545759800014
PM 32589691
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yin, WC
   Mao, CY
   Luan, XD
   Shen, DD
   Shen, QY
   Su, HX
   Wang, XX
   Zhou, FL
   Zhao, WF
   Gao, MQ
   Chang, SH
   Xie, YC
   Tian, GH
   Jiang, HW
   Tao, SC
   Shen, JS
   Jiang, Y
   Jiang, HL
   Xu, YC
   Zhang, SY
   Zhang, Y
   Xu, HE
AF Yin, Wanchao
   Mao, Chunyou
   Luan, Xiaodong
   Shen, Dan-Dan
   Shen, Qingya
   Su, Haixia
   Wang, Xiaoxi
   Zhou, Fulai
   Zhao, Wenfeng
   Gao, Minqi
   Chang, Shenghai
   Xie, Yuan-Chao
   Tian, Guanghui
   Jiang, He-Wei
   Tao, Sheng-Ce
   Shen, Jingshan
   Jiang, Yi
   Jiang, Hualiang
   Xu, Yechun
   Zhang, Shuyang
   Zhang, Yan
   Xu, H. Eric
TI Structural basis for inhibition of the RNA-dependent RNA polymerase from
   SARS-CoV-2 by remdesivir
SO SCIENCE
LA English
DT Article
ID CRYO-EM STRUCTURE; RESPIRATORY SYNDROME CORONAVIRUS; REPLICATION;
   PROTEIN; DISCOVERY; GS-5734; VIRUS; NSP12; EBOLA
AB The pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global crisis. Replication of SARS-CoV-2 requires the viral RNA-dependent RNA polymerase (RdRp) enzyme, a target of the antiviral drug remdesivir. Here we report the cryo-electron microscopy structure of the SARS-CoV-2 RdRp, both in the apo form at 2.8-angstrom resolution and in complex with a 50-base template-primer RNA and remdesivir at 2.5-angstrom resolution. The complex structure reveals that the partial double-stranded RNA template is inserted into the central channel of the RdRp, where remdesivir is covalently incorporated into the primer strand at the first replicated base pair, and terminates chain elongation. Our structures provide insights into the mechanism of viral RNA replication and a rational template for drug design to combat the viral infection.
C1 [Yin, Wanchao; Wang, Xiaoxi; Zhou, Fulai; Zhao, Wenfeng; Xie, Yuan-Chao; Tian, Guanghui; Shen, Jingshan; Jiang, Yi; Jiang, Hualiang; Xu, Yechun; Xu, H. Eric] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China.
   [Yin, Wanchao; Mao, Chunyou; Shen, Dan-Dan; Shen, Qingya; Zhang, Yan] Zhejiang Univ, Dept Biophys, Sir Run Run Shaw Hosp, Sch Med, Hangzhou 310058, Peoples R China.
   [Yin, Wanchao; Mao, Chunyou; Shen, Dan-Dan; Shen, Qingya; Zhang, Yan] Zhejiang Univ, Dept Pathol, Sir Run Run Shaw Hosp, Sch Med, Hangzhou 310058, Peoples R China.
   [Luan, Xiaodong; Zhang, Shuyang] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China.
   [Luan, Xiaodong; Zhang, Shuyang] Peking Union Med Coll, Dept Cardiol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
   [Luan, Xiaodong; Zhang, Shuyang] Chinese Acad Med Sci, Beijing 100730, Peoples R China.
   [Luan, Xiaodong; Zhang, Shuyang] Tsinghua Univ, Tsinghua Peking Ctr Life Sci, Beijing 100084, Peoples R China.
   [Su, Haixia; Shen, Jingshan; Jiang, Yi; Jiang, Hualiang; Xu, Yechun; Xu, H. Eric] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Gao, Minqi] WuxiBiortus Biosci Co Ltd, Jiangyin 214437, Peoples R China.
   [Chang, Shenghai] Zhejiang Univ, Ctr Cryoelectron Microscopy, Sch Med, Hangzhou 310058, Peoples R China.
   [Chang, Shenghai] Zhejiang Univ, Sir Run Run Shaw Hosp, Ctr Diagnost Electron Microscopy, Sch Med, Hangzhou 310058, Peoples R China.
   [Jiang, He-Wei; Tao, Sheng-Ce] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, Shanghai 200240, Peoples R China.
   [Zhang, Yan] Key Lab Immun & Inflammatory Dis Zhejiang Prov, Hangzhou 310058, Peoples R China.
RP Xu, YC; Xu, HE (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China.; Zhang, Y (corresponding author), Zhejiang Univ, Dept Biophys, Sir Run Run Shaw Hosp, Sch Med, Hangzhou 310058, Peoples R China.; Zhang, Y (corresponding author), Zhejiang Univ, Dept Pathol, Sir Run Run Shaw Hosp, Sch Med, Hangzhou 310058, Peoples R China.; Zhang, SY (corresponding author), Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China.; Zhang, SY (corresponding author), Peking Union Med Coll, Dept Cardiol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.; Zhang, SY (corresponding author), Chinese Acad Med Sci, Beijing 100730, Peoples R China.; Zhang, SY (corresponding author), Tsinghua Univ, Tsinghua Peking Ctr Life Sci, Beijing 100084, Peoples R China.; Xu, YC; Xu, HE (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Zhang, Y (corresponding author), Key Lab Immun & Inflammatory Dis Zhejiang Prov, Hangzhou 310058, Peoples R China.
EM ycxu@simm.ac.cn; shuyangzhang103@nrdrs.org; zhang_yan@zju.edu.cn;
   eric.xu@simm.ac.cn
OI yin, wanchao/0000-0002-6889-4907; Shen, Qingya/0000-0001-6602-7116;
   zhao, wenfeng/0000-0003-2517-4747; Luan, Xiaodong/0000-0002-1279-5432;
   Mao, Chunyou/0000-0001-5349-8592; Zhang, Yan/0000-0003-2189-0244
FU National Key R&D Programs of China [2018YFA0507002]; Shanghai Municipal
   Science and Technology Major Project [2019SHZDZX02, XDB08020303];
   Zhejiang University special scientific research fund for COVID-19
   prevention and control [E33]; National Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81922071];
   Science and Technology Commission of Shanghai MunicipalScience &
   Technology Commission of Shanghai Municipality (STCSM) [20431900100];
   Jack Ma Foundation [2020-CMKYGG-05]; CAMS Innovation Fund for "13th
   Five-Year" National Science and Technology Major Project for New Drugs
   [2019ZX09734001-002]; CAMS Innovation Fund for Medical Sciences
   [2020-I2M-CoV19-001]; Tsinghua University-Peking University Center for
   Life Sciences [045-160321001]; National Key Research and Development
   Program of China [2016YFA0500600]; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China (NSFC) [31970130,
   3167083]; National Key R&D Program of China [2016YFA0502301]; National
   Natural Science FoundationNational Natural Science Foundation of China
   (NSFC) [31770796]; National Science and Technology Major Project
   [2018ZX09711002]
FX This work was partially supported by the National Key R&D Programs of
   China 2018YFA0507002; Shanghai Municipal Science and Technology Major
   Project 2019SHZDZX02 and XDB08020303 to H.E.X.; Zhejiang University
   special scientific research fund for COVID-19 prevention and control E33
   and the National Science Foundation of China 81922071 to Y.Z.; Science
   and Technology Commission of Shanghai Municipal 20431900100 and Jack Ma
   Foundation 2020-CMKYGG-05 to H.J. and J.S.; CAMS Innovation Fund for
   "13th Five-Year" National Science and Technology Major Project for New
   Drugs 2019ZX09734001-002, CAMS Innovation Fund for Medical Sciences no.
   2020-I2M-CoV19-001, and Tsinghua University-Peking University Center for
   Life Sciences 045-160321001 to S.Z.; National Key Research and
   Development Program of China grant 2016YFA0500600 and National Natural
   Science Foundation of China 31970130 and 3167083 to S.-C.T.; National
   Key R&D Program of China 2016YFA0502301 to Y.X.; and National Natural
   Science Foundation 31770796 and National Science and Technology Major
   Project 2018ZX09711002 to Y.J.
CR Adams PD, 2011, METHODS, V55, P94, DOI 10.1016/j.ymeth.2011.07.005
   Ahn DG, 2012, ARCH VIROL, V157, P2095, DOI 10.1007/s00705-012-1404-x
   Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210
   Campagnola G, 2015, J VIROL, V89, P275, DOI 10.1128/JVI.01574-14
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gong P, 2010, P NATL ACAD SCI USA, V107, P22505, DOI 10.1073/pnas.1007626107
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Heymann JB, 2018, PROTEIN SCI, V27, P159, DOI 10.1002/pro.3293
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Johnson MA, 2010, J MOL BIOL, V402, P619, DOI 10.1016/j.jmb.2010.07.043
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lehmann KC, 2015, NUCLEIC ACIDS RES, V43, P8416, DOI 10.1093/nar/gkv838
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   McDonald SM, 2013, WIRES RNA, V4, P351, DOI 10.1002/wrna.1164
   Peti W, 2005, J VIROL, V79, P12905, DOI 10.1128/JVI.79.20.12905-12913.2005
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Soon FF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047857
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   te Velthuis AJW, 2014, CELL MOL LIFE SCI, V71, P4403, DOI 10.1007/s00018-014-1695-z
   van Hemert MJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000054
   Velthuis AJWT, 2010, NUCLEIC ACIDS RES, V38, P203, DOI 10.1093/nar/gkp904
   Venkataraman S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020076
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 46
TC 94
Z9 95
U1 49
U2 75
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JUN 26
PY 2020
VL 368
IS 6498
BP 1499
EP +
DI 10.1126/science.abc1560
PG 26
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MF3SA
UT WOS:000545264600046
PM 32358203
OA Green Published, Other Gold
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Allahyari, A
   Rahimi, H
   Khadem-Rezaiyan, M
   Mozaheb, Z
   Seddigh-Shamsi, M
   Bary, A
   Kamandi, M
   Azimi, SA
   HasanAbadi, SE
   Noferesti, A
   Shariatmaghani, SS
   Rafatpanah, H
   Khatami, S
   Imani, AJ
   Mortazi, H
   Nodeh, MM
AF Allahyari, Abolghasem
   Rahimi, Hossein
   Khadem-Rezaiyan, Majid
   Mozaheb, Zahra
   Seddigh-Shamsi, Mohsen
   Bary, Alireza
   Kamandi, Mostafa
   Azimi, Sajad Ataei
   HasanAbadi, Saeed Eslami
   Noferesti, Alireza
   Shariatmaghani, Somayeh Sadat
   Rafatpanah, Houshang
   Khatami, Shohreh
   Imani, Afshin Jabbar
   Mortazi, Hassan
   Nodeh, Mohammad Moeini
TI Effect of hydroxychloroquine on COVID-19 prevention in cancer patients
   undergoing treatment: a structured summary of a study protocol for a
   randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Protocol; Hydroxychloroquine;
   Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Breast cancer; Colon
   cancer; Prophylaxis
AB Objectives: In this study, we investigate the effect of hydroxychloroquine on the prevention of Novel Coronavirus Disease (COVID-19) in cancer patients being treated.
   Trial design: This is a multi-centre, two-arm, parallel-group, triple-blind, phase 2-3 randomised controlled trial.
   Participants: All patients over the age of 15 from 5 types of cancer are included in the study. Patients with acute lymphoid and myeloid leukemias in the first line treated with curative intent, patients with high-grade non-Hodgkin's lymphoma treated with leukemia protocols and patients with non-metastatic breast and colon cancer in the first line of treatment will enter the study. The exclusion criteria will include known sensitivity to Hydroxychloroquine, weight below 35 kilograms, history of retinopathy, history of any cardiac disease, acute respiratory tract infection in the last 2 months, having COVID-19 in the first two weeks of entering the trial, having Diabetes Mellitus, having an immuno-suppressive disease other than cancer, having chronic pulmonary disease and taking immuno-suppressant drug other than chemotherapeutic agents for current cancer. This study is performed in five academic centres affiliated to Mashhad University of Medical Sciences, Mashhad, Iran.
   Intervention and comparator: Patients are randomly assigned to two groups; one being given hydroxychloroquine and the other is given placebo. During two months of treatment, the two groups are treated with either hydroxychloroquine (Amin (R) Pharmaceutical Company, Isfahan, Iran) or placebo (identical in terms of shape, colour, smell) as a single 200 mg tablet every other day. Patients will be monitored for COVID-19 symptoms during the follow-up period. If signs or symptoms occur (fever, cough, shortness of breath), they will be examined and investigated with a high-resolution computed tomography (CT) scan of the lungs, COVID-19 specific IgM, IgG antibody assay and a nucleic acid amplification test (NAT) for the SARS-CoV-2 virus.
   Main outcomes: The primary end point of this study is to investigate the incidence of COVID-19 in patients being treated for their cancer over a 2-month period. Randomisation Randomisation will be performed using randomly permuted blocks. By using an online website () the randomization sequence will be produced by quadruple blocks. The allocation ratio in intervention and control groups is 1:1.
   Blinding (masking): Participants and caregivers do not know whether the patient is in the intervention or the control group. The outcome assessor and the data analyst are also blinded to group assignment.
   Numbers to be randomised (sample size): The calculated total sample size is 60 patients, with 30 patients in each group.
   Trial Status : The trial began on April 14, 2020 and recruitment is ongoing. Recruitment is anticipated to be completed by June 14, 2020 There has been no change in study protocol since approval, protocol version 1 was approved April 12, 2020.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Allahyari, Abolghasem; Rahimi, Hossein; Mozaheb, Zahra; Bary, Alireza; Kamandi, Mostafa; Azimi, Sajad Ataei; Noferesti, Alireza; Shariatmaghani, Somayeh Sadat; Imani, Afshin Jabbar; Mortazi, Hassan; Nodeh, Mohammad Moeini] Mashhad Univ Med Sci, Div Hematol & Oncol, Dept Internal Med, Fac Med, Mashhad, Razavi Khorasan, Iran.
   [Khadem-Rezaiyan, Majid] Mashhad Univ Med Sci, Clin Res Dev Unit, Community Med, Fac Med, Mashhad, Razavi Khorasan, Iran.
   [Seddigh-Shamsi, Mohsen] Mashhad Univ Med Sci, Dept Internal Med, Fac Med, Mashhad, Razavi Khorasan, Iran.
   [HasanAbadi, Saeed Eslami] Mashhad Univ Med Sci, Pharm Sch, Med Informat, Mashhad, Razavi Khorasan, Iran.
   [Rafatpanah, Houshang] Mashhad Univ Med Sci, Immunol Dept, Fac Med, Immunol, Mashhad, Razavi Khorasan, Iran.
   [Khatami, Shohreh] Mashhad Univ Med Sci, Dept Internal Med, Internal Med, Fac Med, Mashhad, Razavi Khorasan, Iran.
   [Nodeh, Mohammad Moeini] Ghaem Hosp, Hematol & Oncol Sect, Internal Med Dept, Ahmadabad Ave,Shariati Sq, Mashhad, Razavi Khorasan, Iran.
RP Nodeh, MM (corresponding author), Mashhad Univ Med Sci, Div Hematol & Oncol, Dept Internal Med, Fac Med, Mashhad, Razavi Khorasan, Iran.; Nodeh, MM (corresponding author), Ghaem Hosp, Hematol & Oncol Sect, Internal Med Dept, Ahmadabad Ave,Shariati Sq, Mashhad, Razavi Khorasan, Iran.
EM moeininm@mums.ac.ir
RI Nodeh, Mohammad Moeini/ABC-2015-2020
OI Nodeh, Mohammad Moeini/0000-0002-3713-7671
FU Mashhad University of Medical Sciences [990046]
FX All the financial resources required for this project have been provided
   by the Vice-Chancellor for Research of Mashhad University of Medical
   Sciences (code:990046). The funding body has no role in the design of
   this study, collection, analysis, and interpretation of data and in
   writing the manuscript.
NR 0
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 26
PY 2020
VL 21
IS 1
AR 575
DI 10.1186/s13063-020-04485-x
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MG0DX
UT WOS:000545707100007
PM 32586363
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Marietta, M
   Vandelli, P
   Mighali, P
   Vicini, R
   Coluccio, V
   D'Amico, R
AF Marietta, Marco
   Vandelli, Paola
   Mighali, Pasquale
   Vicini, Roberto
   Coluccio, Valeria
   D'Amico, Roberto
CA COVID-19 HD Study Grp
TI Randomised controlled trial comparing efficacy and safety of high versus
   low Low-Molecular Weight Heparin dosages in hospitalized patients with
   severe COVID-19 pneumonia and coagulopathy not requiring invasive
   mechanical ventilation (COVID-19 HD): a structured summary of a study
   protocol
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Protocol; Low-molecular weight
   heparin; Enoxaparin; Pneumonia; Coagulopathy
AB Objectives To assess whether high doses of Low Molecular Weight Heparin (LMWH) (i.e. Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (i.e., Enoxaparin 4000 IU once day), in hospitalized patients with COVID19 not requiring Invasive Mechanical Ventilation [IMV], are: more effective in preventing clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first: Death Acute Myocardial Infarction [AMI] Objectively confirmed, symptomatic arterial or venous thromboembolism [TE] Need of either: Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) or IMV in patients who at randomisation were receiving standard oxygen therapy IMV in patients who at randomisation were receiving non-invasive mechanical ventilation Similar in terms of major bleeding risk Trial design Multicentre, randomised controlled, superiority, open label, parallel group, two arms (1:1 ratio), in-hospital study. Participants Inpatients will be recruited from 7 Italian Academic and non-Academic Internal Medicine Units, 2 Infectious Disease Units and 1 Respiratory Disease Unit. Inclusion Criteria (all required)
   Age > 18 and < 80 years Positive SARS-CoV-2 diagnostic (on pharyngeal swab of deep airways material) Severe pneumonia defined by the presence of at least one of the following criteria: Respiratory Rate >= 25 breaths /min Arterial oxygen saturation <= 93% at rest on ambient air PaO2/FiO2 <= 300 mmHg Coagulopathy, defined by the presence of at least one of the following criteria: D-dimer >4 times the upper level of normal reference range Sepsis-Induced Coagulopathy (SIC) score >4 No need of IMV Exclusion Criteria
   Age 80 years IMV Thrombocytopenia (platelet count < 80.000 mm3) Coagulopathy: INR >1.5, aPTT ratio > 1.4 Impaired renal function (eGFR calculated by CKD-EPI Creatinine equation < 30 ml/min) Known hypersensitivity to enoxaparin History of heparin induced thrombocytopenia Presence of an active bleeding or a pathology susceptible of bleeding in presence of anticoagulation (e.g. recent haemorrhagic stroke, peptic ulcer, malignant cancer at high risk of haemorrhage, recent neurosurgery or ophthalmic surgery, vascular aneurysms, arteriovenous malformations) Concomitant anticoagulant treatment for other indications (e.g. atrial fibrillation, venous thromboembolism, prosthetic heart valves) Concomitant double antiplatelet therapy Administration of therapeutic doses of LMWH, fondaparinux, or unfractionated heparin (UFH) for more than 72 hours before randomization; prophylactic doses are allowed Pregnancy or breastfeeding or positive pregnancy test Presence of other severe diseases impairing life expectancy (e.g. patients are not expected to survive 28 days given their pre-existing medical condition) Lack or withdrawal of informed consent Intervention and comparator Control Group (Low-Dose LMWH):patients in this group will be administered Enoxaparin (Inhixa (R)) at standard prophylactic dose (i.e., 4000 UI subcutaneously once day). Intervention Group (High-Dose LMWH):patients in this group will be administered Enoxaparin (Inhixa (R)) at dose of 70 IU/kg every 12 hours, as reported in the following table.
   This dose is commonly used in Italy when a bridging strategy is required for the management of surgery or invasive procedures in patients taking anti-vitamin K oral anticoagulantsBody Weight (kg)Enoxaparin dose every 12 hours (IU)200050-69400070-89600090-1108000>11010000 The treatment with Enoxaparin will be initiated soon after randomization (maximum allowed starting time 12h after randomization). The treatment will be administered every 12 hours in the intervention group and every 24 hours in the control group. Treatments will be administered in the two arms until hospital discharge or the primary outcomes detailed below occur. Main outcomes Primary Efficacy Endpoint: Clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first: Death Acute Myocardial Infarction [AMI] Objectively confirmed, symptomatic arterial or venous thromboembolism [TE] Need of either: Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) or IMV in patients who at randomisation were in standard oxygen therapy by delivery interfaces Need for IMV, in patients who at randomisation were in Cpap or NIV Time to the occurrence of each of these events will be recorded. Clinical worsening will be analysed as a binary outcome as well as a time-to-event one. Secondary Efficacy Endpoints: Any of the following events occurring within the hospital stay Death Acute Myocardial Infarction [AMI] Objectively confirmed, symptomatic arterial or venous thromboembolism [TE] Need of either: Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) or IMV in patients who at randomisation were in standard oxygen therapy by delivery interfaces Need for IMV in patients who at randomisation were in Cpap or NIV Improvement of laboratory parameters of disease severity, including: o D-dimer level o Plasma fibrinogen levels o Mean Platelet Volume o Lymphocyte/Neutrophil ratio o IL-6 plasma levels Mortality at 30 days Information about patients' status will be sought in those who are discharged before 30 days on Day 30 from randomisation. Time to the occurrence of each of these events will be recorded. Each of these events will be analysed as a binary outcome and as a time-to-event one. Primary safety endpoint: Major bleeding, defined as an acute clinically overt bleeding associated with one or more of the following: Decrease in haemoglobin of 2 g/dl or more; Transfusion of 2 or more units of packed red blood cells; Bleeding that occurs in at least one of the following critical sites [intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal]; Bleeding that is fatal (defined as a bleeding event that was the primary cause of death or contributed directly to death); Bleeding that necessitates surgical intervention Time to the occurrence of each of these events will be recorded. Each of these events will be analysed as a binary outcome and as a time-to-event one.
   Secondary safety endpoint: Clinically Relevant non-major bleeding, defined as an acute clinically overt bleeding that does not meet the criteria for major and consists of: Any bleeding compromising hemodynamic Spontaneous hematoma larger than 25 cm2, or 100 cm2 if there was a traumatic cause Intramuscular hematoma documented by ultrasonography Epistaxis or gingival bleeding requiring tamponade or other medical intervention Bleeding from venipuncture for >5 minutes Haematuria that was macroscopic and was spontaneous or lasted for more than 24 hours after invasive procedures Haemoptysis, hematemesis or spontaneous rectal bleeding requiring endoscopy or other medical intervention Any other bleeding requiring temporary cessation of a study drug. Time to the occurrence of each of these events will be recorded. Each of these events will be analysed as a binary outcome and as a time-to-event one. Randomisation Randomisation (with a 1:1 randomisation ratio) will be centrally performed by using a secure, web-based system, which will be developed by the Methodological and Statistical Unit at the Azienda Ospedaliero-Universitaria of Modena. Randomisation stratified by 4 factors: 1) Gender (M/F); 2) Age (<75/>= 75 years); 3) BMI (<30/>= 30); 4) Comorbidities (0-1/>2) with random variable block sizes will be generated by STATA software. The web-based system will guarantee the allocation concealment. Blinding (masking) The study is conceived as open-label: patients and all health-care personnel involved in the study will be aware of the assigned group. Numbers to be randomised (sample size) The target sample size is based on the hypothesis that LMWH administered at high doses versus low doses will significantly reduce the risk of clinical worsening. The overall sample size in this study is expected to be 300 with 150 in the Low-Dose LMWH control group and 150 in the High-Dose LMWH intervention group, recruited over 10-11 months. Assuming an alpha of 5% (two tailed) and a percentage of patients who experience clinical worsening in the control group being between 25% and 30%, the study will have 80% power to detect at least 50% relative reduction in the risk of death between low and high doses of heparin. Trial Status Protocol version 1.2 of 11/05/2020. Recruitment start (expected): 08/06/2020 Recruitment finish (expected): 30/04/2021 Trial registration EudraCT 2020-001972-13, registered on April 17th, 2020 Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Marietta, Marco; Coluccio, Valeria] Azienda Osped Univ Modena, Osped Policlin, Dipartimento Oncol & Ematol, Modena, Italy.
   [Vandelli, Paola; Mighali, Pasquale; Vicini, Roberto; D'Amico, Roberto] Azienda Osped Univ Modena, Osped Policlin, Serv Formaz Ric & Innovaz, Modena, Italy.
   [D'Amico, Roberto] Univ Modena & Reggio Emilia, Cattedra Stat Med, Dipartimento Sci Med & Chirurg Maternoinfantili &, Modena, Italy.
RP Marietta, M (corresponding author), Azienda Osped Univ Modena, Osped Policlin, Dipartimento Oncol & Ematol, Modena, Italy.
EM marco.marietta@unimore.it
RI Clini, Enrico/ABE-6642-2020; Pietrangelo, Antonello/K-1517-2016
OI Clini, Enrico/0000-0002-1515-5094; Pietrangelo,
   Antonello/0000-0002-7411-935X
FU Azienda Ospedaliero-Universitaria di Modena, Italy
FX Funded by Azienda Ospedaliero-Universitaria di Modena, Italy. The
   funding body had no role in the design of the study and collection,
   analysis, and interpretation of data and in writing the manuscript.
NR 0
TC 8
Z9 8
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 26
PY 2020
VL 21
IS 1
AR 574
DI 10.1186/s13063-020-04475-z
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MG0DX
UT WOS:000545707100010
PM 32586394
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pantos, C
   Kostopanagiotou, G
   Armaganidis, A
   Trikas, A
   Tseti, I
   Mourouzis, I
AF Pantos, Constantinos
   Kostopanagiotou, Georgia
   Armaganidis, Apostolos
   Trikas, Athanasios
   Tseti, Ioulia
   Mourouzis, Iordanis
TI Triiodothyronine for the treatment of critically ill patients with
   COVID-19 infection: A structured summary of a study protocol for a
   randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; thyroid hormone;
   triiodothyronine; hypoxia; multi-organ dysfunction; viral infection
AB Objectives: Tissue hypoxia is the main cause of multi-organ dysfunction in sepsis. However, effective pharmacological treatments to combat sepsis-induced tissue hypoxia are not available. Emerging experimental and clinical evidence reveals an evolutionary conserved action of thyroid hormone (TH) to adapt injured tissue to hypoxic conditions via its action on p38 MAPK, Akt signaling pathways. In addition, TH has favorable effects on the immune system and viral load in infected tissue. Non-Thyroid Illness Syndrome is common in sepsis, acute myocardial infarction and trauma and is associated with increased mortality. Thus, TH may be a novel treatment in the setting of critical illness due to viral infection in which hypoxia prevails. The present study aims to address the efficacy and safety of acute administration of triiodothyronine (T3) in critically ill COVID-19 infected patients requiring mechanical respiratory support or Extra Corporeal Membrane Oxygenation (ECMO).
   Trial design: This study is a phase II, parallel, 2-arm (1:1 ratio), multi-centre, prospective, randomized, double-blind, placebo controlled trial.
   Participants: Male and female patients aged over 18 years old who are diagnosed with pulmonary infection due to COVID-19, admitted to Intensive Care Unit and requiring mechanical ventilation or ECMO will be enrolled in this trial. Patients will be excluded in cases of pregnancy, severe systemic disease with life expectancy less than 6 months, participation in another trial of an investigational drug or device, corticosteroid and/or sympathomimetic use before initiation of treatment. All data will be collected in electronic CRF files. Participants will start to be recruited from the ICU center of "ATTIKO" University Hospital in Greece. We aim to include two more clinical sites in the trial one from Greece and one from Germany
   Intervention and comparator: Intervention: T3 Solution for injection 10 mu g/ml. The dose administered will be 0.8g/kg i.v. bolus and will be followed by an infusion of 0.113g. kg-1.h-1 i.v. for 48 hours (therapeutic dose). After the first 48h, a maintenance dose will be administered corresponding to 50% of the therapeutic dose (0.057g. kg-1.h-1 i.v.). Drug administration will stop after successful weaning or end of follow up (maximum 30 days). Comparator: Placebo with composition and dosage identical apart from the active substance.
   Main outcomes: The primary outcome assessed in the present study will be the percentage of patients successfully weaned after 30 days of follow-up. Successful weaning is defined as no requirement for ventilatory support after extubation (mechanical support) or support from ECMO for 48 hours.
   Randomisation: An allocation sequence to one of the groups will be prepared by the Sponsor of the study. A 1:1 treatment allocation will be adopted. An electronic CRF will be used incorporating IWRS in order to assure proper randomization and unblinding in emergency cases. The representative of the sponsor will get a copy of randomization codes. The information of the randomization codes will then be locked in the database until the time at which an interim analysis or final analysis is performed.
   Blinding (masking): Participants, caregivers, and all investigators assessing the outcomes will be blinded to group assignment.
   Numbers to be randomised (sample size): The sample size of 60 patients (that indicates 30 subjects for each group) will have 84% power to detect the estimated difference between the two study groups. The criterion for significance (alpha) has been set at 0.05 and the test is 2-tailed.
   Trial Status: Protocol number T3inj-02/ThySupport, version 03, May 11, 2020. The trial is not recruiting yet. The trial will start recruitment June 18(th)2020. Estimated recruitment will finish June 18(th), 2021.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Pantos, Constantinos; Kostopanagiotou, Georgia; Trikas, Athanasios; Tseti, Ioulia; Mourouzis, Iordanis] Natl & Kapodistrian Univ Athens, Sch Med, Dept Pharmacol, 75 Mikras Asias Ave, Athens 11527, Greece.
   [Kostopanagiotou, Georgia] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Sch Med, Dept Anesthesiol 2, Athens, Greece.
   [Armaganidis, Apostolos] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Sch Med, Dept Crit Care 2, Athens, Greece.
RP Pantos, C (corresponding author), Natl & Kapodistrian Univ Athens, Sch Med, Dept Pharmacol, 75 Mikras Asias Ave, Athens 11527, Greece.
EM cpantos@med.uoa.gr
OI Pantos, Constantinos/0000-0003-2449-0991
FU Uni-Pharma S.A. (Greece); Data Monitoring Committee
FX The Thy-Support trial will be entirely financially supported by
   Uni-Pharma S.A. (Greece) including materials used in this study.
   Uni-Pharma S.A. will have full oversight of the design of the study and
   collection, analysis, and interpretation of data and in writing the
   manuscript. The sponsor will also fund the CRO (PHARMASSIST) which will
   undertake collection, analysis, and interpretation of data in
   collaboration with a Data Monitoring Committee.
NR 0
TC 1
Z9 1
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 26
PY 2020
VL 21
IS 1
AR 573
DI 10.1186/s13063-020-04474-0
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MG0DX
UT WOS:000545707100008
PM 32586399
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Stockmann, H
   Keller, T
   Buttner, S
   Jorres, A
   Kindgen-Milles, D
   Kunz, JV
   Leebmann, J
   Spies, C
   Trager, K
   Treskatsch, S
   Uhrig, A
   Willam, C
   Enghard, P
   Slowinski, T
AF Stockmann, Helena
   Keller, Theresa
   Buettner, Stefan
   Joerres, Achim
   Kindgen-Milles, Detlef
   Kunz, Julius Valentin
   Leebmann, Josef
   Spies, Claudia
   Traeger, Karl
   Treskatsch, Sascha
   Uhrig, Alexander
   Willam, Carsten
   Enghard, Philipp
   Slowinski, Torsten
CA CytoResc Trial Investigators
TI CytoResc - "CytoSorb" Rescue for critically ill patients undergoing the
   COVID-19 Cytokine Storm: A structured summary of a study protocol for a
   randomized controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomized controlled trial; protocol; cytokine storm;
   vasoplegic shock; extracorporeal cytokine elimination
AB Objectives: Approximately 8 - 10 % of COVID-19 patients present with a serious clinical course and need for hospitalization, 8% of hospitalized patients need ICU-treatment. Currently, no causal therapy is available and treatment is purely supportive. The main reason for death in critically ill patients is acute respiratory failure. However, in a number of patients a severe hyperinflammatory response with excessively elevated proinflammatory cytokines causes vasoplegic shock resistant to vasopressor therapy. A new polystyrene-based hemoadsorber (CytoSorb (R), Cytosorbents Inc., New Jersey, USA) has been shown to adsorb effectively cytokines and other middle molecular weight toxins this way reducing their blood concentrations. This has been routinely used in clinical practice in the EU for other conditions where a cytokine storm occurs and an observational study has just been completed on COVID-19 patients. We hypothesized that the extracorporeal elimination of cytokines in critically ill COVID-19 patients with suspected hyperinflammation and shock may stabilize hemodynamics and improve outcome. The primary endpoint is time until resolution of vasoplegic shock, which is a well implemented, clinically relevant endpoint in critical care studies.
   Trial design: Phase IIb, multicenter, prospective, open-label, randomized, 1:1 parallel group pilot study comparing the additional use of "CytoSorb" to standard of care without "CytoSorb".
   Participants: Patients are recruited from the Intensive Care Units (ICUs) of 7 participating centers in Germany (approximately 10 ICUs). All patients aged 18- 80 with positive polymerase chain reaction (PCR) test for SARS-CoV-2, a C-reactive protein (CRP) >= 100 mg/l, a Procalcitonin (PCT) < 2 ng/l, and suspected cytokine storm defined via a vasoplegic shock (Norepinephrine > 0.2 mu g/min/kg to achieve a Mean Arterial Pressure >= 65mmHg). Patients are included irrespective of indication for renal replacement therapy. Suspected or proven bacterial cause for vasoplegic shock is a contraindication.
   Intervention and comparator: Within 24 hours after meeting the inclusion criteria patients will be randomized to receive either standard of care or standard of care and additional "CytoSorb" therapy via a shaldon catheter for 3-7 days. Filter exchange is done every 24 hours. If patients receive antibiotics, an additional dose of antibiotics is administered after each change of "CytoSorb" filter in order to prevent underdosing due to "CytoSorb" treatment. Main outcomes Primary outcome is time to resolution of vasoplegic shock (defined as no need for vasopressors for at least 8 hours in order to sustain a MAP >= 65mmHg) in days. Secondary outcomes are 7 day mortality after fulfilling the inclusion criteria, mortality until hospital discharge, Interleukin-6 (IL-6) measurement on day 1 and 3, need for mechanical ventilation, duration of mechanical ventilation, duration of ICU-stay, catecholamine dose on day 1/2/3 after start of "CytoSorb" and acute kidney injury.
   Randomization: An electronic randomization will be performed using the study software secuTrial (R) administered by the Clinical Study Center (CSC) of the Charite - Universitatsmedizin Berlin, Germany. Randomization is done in blocks by 4 stratified by including center.
   Blinding (masking): The trial will be non-blinded for the clinicians and patients. The statistician will receive a blinded data set, so that all analyses will be conducted blinded.
   Numbers to be randomized (sample size): As this is a pilot study with the goal to examine the feasibility of the study design as well as the intervention effect, no formal sample size calculation was conducted. A total number of approximately 80-100 patients is planned (40-50 patients per group). Safety assessment is done after the inclusion of each 10 patients per randomization group.
   Trial Status: lease see the study protocol version from April 24 2020. Recruitment of patients is still pending.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Stockmann, Helena; Joerres, Achim; Kunz, Julius Valentin; Enghard, Philipp; Slowinski, Torsten] Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany.
   [Keller, Theresa] Charite Univ Med Berlin, Inst Biometry & Clin Epidemiol, Berlin, Germany.
   [Buettner, Stefan] Clin Aschaffenburg Alzenau, Dept Nephrol, Aschaffenburg, Germany.
   [Joerres, Achim] Univ Witten Herdecke, Clin Nephrol Transplantat Med & Intens Care Med, Med Ctr, Cologne, Germany.
   [Kindgen-Milles, Detlef] Heinrich Heine Univ Duesseldorf, Univ Hosp Dusseldorf, Dept Anesthesiol, Dusseldorf, Germany.
   [Leebmann, Josef] Passau Gen Hosp, Interdisciplinary Apheresis Ctr, Passau, Germany.
   [Spies, Claudia] Charite Univ Med Berlin, Dept Anesthesiol & Intens Care Med, CVK, CCM, Berlin, Germany.
   [Traeger, Karl] Univ Hosp Ulm, Dept Cardiac Anesthesiol, Ulm, Germany.
   [Treskatsch, Sascha] Charite Univ Med Berlin CBF, Dept Anesthesiol & Intens Care Med, Berlin, Germany.
   [Uhrig, Alexander] Charite Univ Med Berlin, Dept Internal Med Infect Dis & Pulm Med, Berlin, Germany.
   [Willam, Carsten] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Internal Med Nephrol & Hypertens 4, Erlangen, Germany.
   [Willam, Carsten] Univ Hosp Erlangen, Erlangen, Germany.
RP Slowinski, T (corresponding author), Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany.
EM torsten.slowinski@charite.de
FU German Federal Ministry of Education and Research (BMBF)Federal Ministry
   of Education & Research (BMBF)
FX Funding by the German Federal Ministry of Education and Research (BMBF)
   was applied. A decision is still pending. The BMBF will and had no role
   in the design of the study, collection, analysis, and interpretation of
   data and in writing the manuscript.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 26
PY 2020
VL 21
IS 1
AR 577
DI 10.1186/s13063-020-04501-0
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MG0DX
UT WOS:000545707100004
PM 32586396
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tornero, C
   Vallejo, R
   Cedeno, D
   Orduna, J
   Pastor, E
   Belaouchi, M
   Escamilla, B
   Laredo, M
   Garzando, MD
AF Tornero, Carlos
   Vallejo, Ricardo
   Cedeno, David
   Orduna, Jorge
   Pastor, Ernesto
   Belaouchi, Moncef
   Escamilla, Benigno
   Laredo, Marisa
   del Mar Garzando, Maria
TI A prospective, randomized, controlled study assessing vagus nerve
   stimulation using the gammaCore (R)-Sapphire device for patients with
   moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured
   summary of a study protocol for a randomised controlled trial"
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Protocol; Vague neurostimulation;
   Mechanical ventilation
AB Objectives Primary Objective: The primary objective is to reduce initiation of mechanical ventilator dependency in patients with moderate to severe CoViD- 19. This will be measured as the difference between the control group and active group for subjects admitted to the hospital for CoViD-19. Secondary Objectives: center dot To evaluate cytokine trends / Prevent cytokine storms center dot To evaluate supplemental oxygen requirements center dot To decrease mortality of CoViD-19 patients center dot Delay onset of ventilation Trial design The study is a single centre, 2-arm, prospective, randomized (ratio 1:1), controlled trial with parallel groups design to compare the reduction of respiratory distress in a CoViD-19 population, using the intervention of the gammaCore (R)-Sapphire device plus standard of care (active) vs. standard of care alone (SoC) - the control group. The gammaCore (R) treatments will be used acutely and prophylactically. The active and control groups will be matched for disease and severity. Participants i. Inclusion Criteria The subjects have to meet all of the following criteria to be eligible to enter the trial: Patient older than 18 years Been tested positive or suspected/presumed positive for CoViD-19 Has a cough, shortness of breath or respiratory O(2)Saturation less than or equal to 92% without need for mechanical ventilation or acute respiratory failure Agree to use the gammaCore (R)-Sapphire device as intended and to follow all of the requirements of the study including recording required study data Patient is able to provide signed and witnessed Informed Consent ii. Exclusion Criteria Subjects meeting any of the following criteria cannot be included in this research study: Pregnant women On home/therapy oxygen (i.e. for patients with Chronic Obstructive Pulmonary Disease) at baseline prior to development of CoViD-19 Patient already enrolled in a clinical trial using immunotherapeutic regimen for CoViD-19 History of aneurysm, intracranial hemorrhage, brain tumors, or significant head trauma Known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (eg, bruits or history of transient ischemic attack or cerebrovascular accident), congestive heart failure, known severe coronary artery disease, or recent myocardial infarction Uncontrolled high blood pressure (>140/90) Current implantation of an electrical and/or neurostimulator device, including but not limited to a cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant Current implantation of metal cervical spine hardware or a metallic implant near the gammaCore stimulation site Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with the follow-up requirements, or provide self-assessments is compromised (e.g. homeless, developmentally disabled and prisoner) Participants will be recruited from Hospital Clinico Universitario de Valencia in Spain. Intervention and comparator Intervention: Prophylactic: Administer 2 doses (at 2 minutes each) of gammaCore (R)-Sapphire, one dose on each side of the neck scheduled three times a day (morning, mid-day and 1 hour before bed at night). Acute respiratory failure or shortness of breath: Administer 2 doses (at 2 minutes each) of gammaCore (R)-Sapphire, one on each side of the neck. If shortness of breath (SOB) persists 20 minutes after the start of the first treatment, a second dose will be administered.
   Max doses per day is 9 or 18 stimulations. Plus standard of care Control: Standard of care: oxygen therapy, antibiotics and ventilatory support if necessary depending on the clinic Main outcomes Primary Endpoint: Initiation of mechanical ventilation, from randomization until ICU admission or hospital discharge, whatever occurs first Secondary Endpoints: Safety; ascertainment of Adverse Effects/Serious Adverse Events, from randomisation to ICU admission or hospital discharge, whatever occurs first Cytokine Storm measured by: Tumor necrosis factor alpha, Interleukin 6, Interleukin 1 beta. Days 1,3,5,10,15 and/or at hospital discharge Mortality and/or need for Critical Care admission, from randomisation until ICU admission or hospital discharge, whatever occurs first, O2 saturation levels , from randomization until ICU admission or hospital discharge, whatever occurs first Need for supplemental oxygen, from randomisation until ICU admission or hospital discharge, whatever occurs first Randomisation The patients are classified according to their oxygen levels as mild, moderate and severe and randomized according to their classification to the intervention and control in a ratio of 1:1. The randomization will be stratified for gender and age. Blinding (masking) This is an open label study, it is not possible to blind the participants and healthcare providers to the intervention. Numbers to be randomised (sample size) The total number of patients to be included in the study is 90, with 45 in each study group Trial Status The protocol version is 8.0 from 07(th)April 2020. The recruitment began 20th April 2020 and is expected to be complete 31st July 2020. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Tornero, Carlos; Orduna, Jorge; Pastor, Ernesto; Belaouchi, Moncef; Escamilla, Benigno; Laredo, Marisa; del Mar Garzando, Maria] Hosp Clin Univ Valencia, Anaesthesia Crit Care & Pain Management Unit, Valencia, Spain.
   [Vallejo, Ricardo; Cedeno, David] Millennium Pain Ctr, Dept Basic Sci, Bloomington, IL USA.
   [Vallejo, Ricardo; Cedeno, David] Illinois Wesleyan Univ, Dept Psychol, Bloomington, IL 61701 USA.
RP Tornero, C (corresponding author), Hosp Clin Univ Valencia, Anaesthesia Crit Care & Pain Management Unit, Valencia, Spain.
EM carlostornero@gmail.com
FU Spanish Institute of Health Carlos IIIInstituto de Salud Carlos III
FX The study is a candidate for a restricted grant of the Spanish Institute
   of Health Carlos III.
NR 0
TC 1
Z9 1
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 26
PY 2020
VL 21
IS 1
AR 576
DI 10.1186/s13063-020-04486-w
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MG0DX
UT WOS:000545707100009
PM 32586395
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sorokin, AV
   Karathanasis, SK
   Yang, ZH
   Freeman, L
   Kotani, K
   Remaley, AT
AF Sorokin, Alexander, V
   Karathanasis, Sotirios K.
   Yang, Zhi-Hong
   Freeman, Lita
   Kotani, Kazuhiko
   Remaley, Alan T.
TI COVID-19-Associated dyslipidemia: Implications for mechanism of impaired
   resolution and novel therapeutic approaches
SO FASEB JOURNAL
LA English
DT Article
DE COVID-19; dyslipidemia; inflammation; lipoproteins; oxidation
ID HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; ANTIINFLAMMATORY
   PROPERTIES; AIRWAY INFLAMMATION; CHOLESTEROL EFFLUX; OXIDATIVE STRESS;
   HDL; DISEASE; INFECTION; COVID-19
AB The current coronavirus disease 2019 (COVID-19) pandemic presents a global challenge for managing acutely ill patients and complications from viral infection. Systemic inflammation accompanied by a "cytokine storm," hemostasis alterations and severe vasculitis have all been reported to occur with COVID-19, and emerging evidence suggests that dysregulation of lipid transport may contribute to some of these complications. Here, we aim to summarize the current understanding of the potential mechanisms related to COVID-19 dyslipidemia and propose possible adjunctive type therapeutic approaches that modulate lipids and lipoproteins. Specifically, we hypothesize that changes in the quantity and composition of high-density lipoprotein (HDL) that occurs with COVID-19 can significantly decrease the anti-inflammatory and anti-oxidative functions of HDL and could contribute to pulmonary inflammation. Furthermore, we propose that lipoproteins with oxidized phospholipids and fatty acids could lead to virus-associated organ damage via overactivation of innate immune scavenger receptors. Restoring lipoprotein function with ApoA-I raising agents or blocking relevant scavenger receptors with neutralizing antibodies could, therefore, be of value in the treatment of COVID-19. Finally, we discuss the role of omega-3 fatty acids transported by lipoproteins in generating specialized proresolving mediators and how together with anti-inflammatory drugs, they could decrease inflammation and thrombotic complications associated with COVID-19.
C1 [Sorokin, Alexander, V; Karathanasis, Sotirios K.; Yang, Zhi-Hong; Freeman, Lita; Remaley, Alan T.] NHLBI, Lipoprot Metab Lab, Translat Vasc Med Branch, NIH, 10 Ctr Dr MSC 1454,Bldg 10,Magnuson CC,Room 5D-03, Bethesda, MD 20892 USA.
   [Karathanasis, Sotirios K.] NeoProgen, Baltimore, MD USA.
   [Kotani, Kazuhiko] Jichi Med Univ, Dept Clin Lab Med, Div Community & Family Med, Shimotsuke, Tochigi, Japan.
RP Sorokin, AV; Remaley, AT (corresponding author), NHLBI, Lipoprot Metab Lab, Translat Vasc Med Branch, NIH, 10 Ctr Dr MSC 1454,Bldg 10,Magnuson CC,Room 5D-03, Bethesda, MD 20892 USA.
EM sorokinav2@nhlbi.nih.gov; alan.remaley@nih.gov
FU HHS \ NIH \ National Heart, Lung, and Blood Institute (NHLBI)
FX HHS vertical bar NIH vertical bar National Heart, Lung, and Blood
   Institute (NHLBI)
CR Acharjee S, 2013, J AM COLL CARDIOL, V62, P1826, DOI 10.1016/j.jacc.2013.07.051
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Babin PJ, 1997, P NATL ACAD SCI USA, V94, P8622, DOI 10.1073/pnas.94.16.8622
   Bacchetti T, 2013, BRIT J DERMATOL, V168, P984, DOI 10.1111/bjd.12144
   Balzan S, 2018, LIFE SCI, V198, P79, DOI 10.1016/j.lfs.2018.02.024
   Barlage S, 2001, J LIPID RES, V42, P281
   Bergt C, 2003, ARTERIOSCL THROM VAS, V23, P1488, DOI 10.1161/01.ATV.0000090570.99836.9C
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   BREWER HB, 1983, ANN INTERN MED, V98, P623, DOI 10.7326/0003-4819-98-5-623
   Cepkova Magda, 2006, J Intensive Care Med, V21, P119, DOI 10.1177/0885066606287045
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Dai CL, 2012, AM J RESP CELL MOL, V47, P186, DOI 10.1165/rcmb.2011-0322OC
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Das UN, 2020, ARCH MED RES, V51, P282, DOI 10.1016/j.arcmed.2020.03.004
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   El Kebir D, 2012, P NATL ACAD SCI USA, V109, P14983, DOI 10.1073/pnas.1206641109
   Farid AS, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-92
   FEINGOLD KR, 1993, J CLIN ENDOCR METAB, V76, P1423, DOI 10.1210/jc.76.6.1423
   Getz GS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113479
   Goeijenbier M, 2017, VACCINE, V35, P5095, DOI 10.1016/j.vaccine.2017.07.095
   Goldstein MR, 2020, QJM-INT J MED, V113, P509, DOI 10.1093/qjmed/hcaa103
   GORDON DJ, 1989, NEW ENGL J MED, V321, P1311
   Gordon EM, 2019, J ALLERGY CLIN IMMUN, V144, P426, DOI 10.1016/j.jaci.2019.02.027
   Han CY, 2006, ARTERIOSCL THROM VAS, V26, P1806, DOI 10.1161/01.ATV.0000227472.70734.ad
   Han CY, 2016, J CLIN INVEST, V126, P266, DOI 10.1172/JCI83475
   Hayashida K, 2005, CIRCULATION, V112, P812, DOI 10.1161/CIRCULATIONAHA.104.468397
   He YE, 2020, J CARDIOVASC TRANSL, V13, P204, DOI 10.1007/s12265-019-09908-y
   Homann J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143141
   Hu X, 2020, LOW SERUM CHOLESTERO, DOI [10.2139/ssrn.3544826, DOI 10.2139/SSRN.3544826]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Iwai M, 2009, HYPERTENS RES, V32, P533, DOI 10.1038/hr.2009.74
   Jin Y, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012219
   Jira W, 1998, CHEM PHYS LIPIDS, V91, P1, DOI 10.1016/S0009-3084(97)00095-9
   Kabouridis PS, 2008, FEBS LETT, V582, P3711, DOI 10.1016/j.febslet.2008.10.006
   Karathanasis SK, 2017, CLIN CHEM, V63, P196, DOI 10.1373/clinchem.2016.257725
   Kendall AC, 2019, FASEB J, V33, P13014, DOI 10.1096/fj.201901501R
   Khovidhunkit W, 2004, J LIPID RES, V45, P1169, DOI 10.1194/jlr.R300019-JLR200
   Khovidhunkit W, 2001, J LIPID RES, V42, P967
   Kingwell BA, 2014, NAT REV DRUG DISCOV, V13, P445, DOI 10.1038/nrd4279
   Kockx M, 2018, J MOL MED, V96, P361, DOI 10.1007/s00109-018-1632-y
   Koopal C, 2017, CURR OPIN ENDOCRINOL, V24, P133, DOI 10.1097/MED.0000000000000316
   Kulminski AM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206873
   Kypreos KE, 2007, BIOCHEM J, V403, P359, DOI 10.1042/BJ20061048
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Levy BD, 2007, J IMMUNOL, V178, P496, DOI 10.4049/jimmunol.178.1.496
   Li H, 2020, J INFECTION, V80, P646, DOI 10.1016/j.jinf.2020.03.035
   Libby P, 2018, J AM COLL CARDIOL, V72, P2071, DOI 10.1016/j.jacc.2018.08.1043
   Low-Kam C, 2018, J AM HEART ASSOC, V7, P1
   Lubrano V, 2008, LIPIDS, V43, P945, DOI 10.1007/s11745-008-3227-9
   Lucero D, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2019.158537
   Madsen CM, 2019, CLIN CHEM, V65, P644, DOI 10.1373/clinchem.2018.299636
   Marais AD, 2019, PATHOLOGY, V51, P165, DOI 10.1016/j.pathol.2018.11.002
   Martinez-Martinez AB, 2020, NEUROBIOL DIS, V138, DOI 10.1016/j.nbd.2020.104809
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meyrelles SS, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-211
   Mickleborough TD, 2009, CLIN NUTR, V28, P71, DOI 10.1016/j.clnu.2008.10.012
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Moraitis AG, 2015, J CLIN LIPIDOL, V9, P81, DOI 10.1016/j.jacl.2014.09.014
   Morita M, 2013, CELL, V153, P112, DOI 10.1016/j.cell.2013.02.027
   Morton AM, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98045
   Navab M, 2000, J LIPID RES, V41, P1481
   Ortiz-Munoz G, 2014, BLOOD, V124, P2625, DOI 10.1182/blood-2014-03-562876
   Ossoli A, 2019, ARTERIOSCL THROM VAS, V39, P915, DOI 10.1161/ATVBAHA.118.311987
   Pamir N, 2016, J LIPID RES, V57, P246, DOI 10.1194/jlr.M063701
   Panigrahy D, 2020, CANCER METAST REV, V39, P337, DOI 10.1007/s10555-020-09889-4
   Pencina MJ, 2009, CIRCULATION, V119, P3078, DOI 10.1161/CIRCULATIONAHA.108.816694
   Pham T, 2005, BIOCHEMISTRY-US, V44, P7577, DOI 10.1021/bi0472696
   Pothineni NVK, 2017, J AM COLL CARDIOL, V69, P2759, DOI 10.1016/j.jacc.2017.04.010
   Qin YG, 2020, CRYSTALS, V10, DOI 10.3390/cryst10040245
   Rader DJ, 2009, J LIPID RES, V50, pS189, DOI 10.1194/jlr.R800088-JLR200
   Raffai RL, 2003, J BIOL CHEM, V278, P11670, DOI 10.1074/jbc.M212873200
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Ryoo S, 2011, ATHEROSCLEROSIS, V214, P279, DOI 10.1016/j.atherosclerosis.2010.10.044
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479
   Skarpengland T, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.006479
   Sluimer JC, 2008, J PATHOL, V215, P273, DOI 10.1002/path.2357
   Soares MP, 2017, NAT REV IMMUNOL, V17, P83, DOI 10.1038/nri.2016.136
   Sorokin AV, 2016, J NUTR BIOCHEM, V35, P58, DOI 10.1016/j.jnutbio.2016.05.012
   Souza PR, 2020, CIRC RES, V126, P75, DOI 10.1161/CIRCRESAHA.119.315506
   Stancel N, 2016, CLIN CHEM, V62, P320, DOI 10.1373/clinchem.2015.243923
   Sun XJ, 2020, CYTOKINE GROWTH F R, V53, P38, DOI 10.1016/j.cytogfr.2020.04.002
   Suzuki M, 2010, CIRCULATION, V122, P1919, DOI 10.1161/CIRCULATIONAHA.110.961193
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Trinder M, 2020, ARTERIOSCL THROM VAS, V40, P267, DOI 10.1161/ATVBAHA.119.313381
   van der Stoep M, 2014, CARDIOVASC RES, V103, P362, DOI 10.1093/cvr/cvu137
   Van Lenten BJ, 2004, CIRCULATION, V110, P3252, DOI 10.1161/01.CIR.0000147232.75456.B3
   Van Lenten BJ, 2001, CIRCULATION, V103, P2283
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Walkey AJ, 2011, CRIT CARE MED, V39, P1322, DOI 10.1097/CCM.0b013e3182120829
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Yamashita CM, 2014, RESPIRATION, V87, P416, DOI 10.1159/000358438
   Yang ZH, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030749
   Zeng H, 2012, J VIROL, V86, P667, DOI 10.1128/JVI.06348-11
   Zhang P, 2009, J INNATE IMMUN, V1, P358, DOI 10.1159/000161070
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 103
TC 5
Z9 5
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2020
VL 34
IS 8
BP 9843
EP 9853
DI 10.1096/fj.202001451
EA JUN 2020
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA NE3EW
UT WOS:000544290200001
PM 32588493
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Yang, LL
   Yu, ZH
   Xu, Y
   Liu, WJ
   Liu, L
   Mao, HJ
AF Yang, Lili
   Yu, Zhenghe
   Xu, You
   Liu, Wenjuan
   Liu, Lu
   Mao, Hongjing
TI Mental status of patients with chronic insomnia in China during COVID-19
   epidemic
SO INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY
LA English
DT Article
DE The COVID-19; chronic insomnia; mental health
ID POSTTRAUMATIC STRESS; SLEEP QUALITY; ANXIETY; DEPRESSION; DISORDERS
AB Aim: To study the sleep and mental health of chronic insomnia patients in China during coronavirus disease in 2019 (COVID-19) epidemic. Methods: A total of 764 patients with chronic insomnia were included in this study. From 17 January 2020 to 24 January 2020, insomnia, anxiety and physical symptoms were evaluated online, and they were followed up for 4 and 8 weeks. Main outcomes and indicators were assessed using the Pittsburgh Sleep Quality Index (PSQI) and each factor score, the General Anxiety Disorder-7 (GAD-7) and the Patient Health Questionnaire-15 (PHQ-15), respectively. In addition, insomnia, anxiety and physical symptoms were assessed at baseline and at the end of fourth and eighth weeks. Wilcoxon signed rank test was used to compare the changes in patients' scale scores at different time points. Results: Among the 764 participants, there were 755 and 738 evaluators who completed the fourth and eighth weeks, respectively, and the questionnaire completion rates were 98.82% and 96.60%, respectively. Among them, there are 459 (60.0%) aged 41-60 years old, 546 (71.5%) women, 218 (28.5%) men and 313 (41%) college degrees. After 8 weeks of follow-up, the differences in sleep status, anxiety symptoms and physical symptoms were statistically significant. Among the factors of PSQI, there were differences in subjective sleep quality, sleep latency, sleep duration, sleep disturbance (disorder), sleep efficiency and daytime function. At 4 weeks of follow-up, there was a statistically significant difference in the use of hypnotic drugs; at 8 weeks of follow-up, there was no statistically significant difference in the use of hypnotic drugs. Conclusion: Under the influence of the COVID-19, the sleep status and anxiety of patients with chronic insomnia are affected by the epidemic.
C1 [Yang, Lili; Yu, Zhenghe; Xu, You; Liu, Wenjuan; Mao, Hongjing] Zhejiang Univ, Dept Psychosomat Med, Hangzhou Peoples Hosp 7, Sch Med,Mental Hlth Ctr, 305 Tianmushan Rd, Hangzhou 310013, Zhejiang, Peoples R China.
   [Liu, Lu] Zhejiang Univ, Dept Special Examinat, Hangzhou Peoples Hosp 7, Sch Med,Mental Hlth Ctr, Hangzhou, Peoples R China.
RP Mao, HJ (corresponding author), Zhejiang Univ, Dept Psychosomat Med, Hangzhou Peoples Hosp 7, Sch Med,Mental Hlth Ctr, 305 Tianmushan Rd, Hangzhou 310013, Zhejiang, Peoples R China.
EM 13777861972@163.com
FU Hangzhou Science and Technology Commission project named `application
   research of insomnia diagnosis and treatment technology based on big
   data' [20191203B119]; Zhejiang Nature Foundation's public welfare
   project named `insomnia assisted diagnosis system based on medical image
   and artificial intelligence analysis' [LDF20H090004]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: This work
   was supported by funding from the Hangzhou Science and Technology
   Commission project named `application research of insomnia diagnosis and
   treatment technology based on big data' (project number: 20191203B119)
   and the Zhejiang Nature Foundation's public welfare project named
   `insomnia assisted diagnosis system based on medical image and
   artificial intelligence analysis' (project number: LDF20H090004).
CR Alvaro PK, 2013, SLEEP, V36, P1059, DOI 10.5665/sleep.2810
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU
   ASHTON H, 1991, J SUBST ABUSE TREAT, V8, P19, DOI 10.1016/0740-5472(91)90023-4
   BUYSSE DJ, 1991, SLEEP, V14, P331
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen XF, 2019, MED SCI MONITOR, V25, P7889, DOI 10.12659/MSM.917552
   Dahlgren A, 2005, SCAND J WORK ENV HEA, V31, P277, DOI 10.5271/sjweh.883
   Disease Prevention and Control Bureau National Health Commission of the People's Republic of China, 2020, NEW TYP COR INF PNEU
   Dong L, 2020, EMERG INFECT DIS, V26, P1616, DOI 10.3201/eid2607.200407
   Hawryluck L, 2004, EMERG INFECT DIS, V10, P1206, DOI 10.3201/eid1007.030703
   He X, 2010, SHANGHAI ARCH PSYCHI, V22, P200, DOI DOI 10.3969/J.ISSN.1002-0829.2010.04.002
   Holbrook AM, 2000, CAN MED ASSOC J, V162, P225
   Hu L, 1996, CHINESE J PSYCHIAT, V29, P103, DOI DOI 10.1007/BF02951625
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jarrin DC, 2014, J SLEEP RES, V23, P681, DOI 10.1111/jsr.12172
   Johnson EO, 2006, J PSYCHIATR RES, V40, P700, DOI 10.1016/j.jpsychires.2006.07.008
   Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008
   Lange T, 2010, ANN NY ACAD SCI, V1193, P48, DOI 10.1111/j.1749-6632.2009.05300.x
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M408
   National Health Commission of the People's Republic of China, 2020, 2200 FEBR 22 LAT INF
   Ohayon MM, 2009, SLEEP MED, V10, P952, DOI 10.1016/j.sleep.2009.07.008
   Person B, 2004, EMERG INFECT DIS, V10, P358, DOI 10.3201/eid1002.030750
   Shultz JM, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0741-y
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Van Reeth O, 2000, SLEEP MED REV, V4, P201, DOI 10.1053/smrv.1999.0097
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang P., 2003, CHINA DISTANCE ED, V12, P48
   [王一牛 Wang Yiniu], 2003, [心理科学进展, ADVANCES IN PSYCHOLOGICAL SCIENCE], V11, P387
   Wright JH, 2020, PSYCHOTHER PSYCHOSOM, V89, P130, DOI 10.1159/000507376
   Wu KK, 2005, EMERG INFECT DIS, V11, P1297, DOI 10.3201/eid1108.041083
   Wu KK, 2005, J TRAUMA STRESS, V18, P39, DOI 10.1002/jts.20004
   [杨莉莉 Yang Lili], 2019, [中国公共卫生, China Journal of Public Health], V35, P348
   Zhao S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020388
   Zheng L., 2003, SARS STRATEGIES HAND
NR 34
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0020-7640
EI 1741-2854
J9 INT J SOC PSYCHIATR
JI Int. J. Soc. Psychiatr.
PD DEC
PY 2020
VL 66
IS 8
BP 821
EP 826
AR 0020764020937716
DI 10.1177/0020764020937716
EA JUN 2020
PG 6
WC Psychiatry
SC Psychiatry
GA NC6XB
UT WOS:000545367700001
PM 32586205
OA Bronze
DA 2021-01-01
ER

PT J
AU Svenson, K
AF Svenson, Kylie
TI Teleanalytic Therapy in the Era of Covid-19: Dissociation in the
   Countertransference
SO JOURNAL OF THE AMERICAN PSYCHOANALYTIC ASSOCIATION
LA English
DT Article
DE dissociation; countertransference; transference; trauma; frame;
   covid-19; teleanalysis
ID TELEPHONE ANALYSIS
AB While we and our patients have many transferences to the modality of video or telephone therapy, these meanings are ultimately not intrinsic to the medium itself. Rather, they are symbolic meanings we make of the modality. This paper discusses the symbolic meanings that we attribute to teletherapy and the ways we may use these attributed meanings to dissociate the trauma of Covid-19. It also explores the clinical opportunities in identifying these dissociated countertransferential experiences and embodying them in our own and our patients' experiences.
C1 [Svenson, Kylie] 1902 Webster St, San Francisco, CA 94115 USA.
RP Svenson, K (corresponding author), 1902 Webster St, San Francisco, CA 94115 USA.
EM kyliesvensontherapy@gmail.com
CR Ehrlich LT, 2019, J AM PSYCHOANAL ASS, V67, P249, DOI 10.1177/0003065119847170
   Isaacs Russell G., 2015, SCREEN RELATIONS LIM
   Maroda KJ, 2007, PSYCHOANAL PSYCHOL, V24, P173, DOI 10.1037/0736-9735.24.1.173
   Mirkin M, 2011, PSYCHOANAL QUART, V80, P643, DOI 10.1002/j.2167-4086.2011.tb00100.x
   O'Dea Frawley-, 2003, PSYCHOANALYTIC PERSP, V1, P67, DOI DOI 10.1080/1551806X.2003.10472886
   Zalusky S, 1998, J AM PSYCHOANAL ASS, V46, P1221, DOI 10.1177/00030651980460041601
NR 6
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0003-0651
EI 1941-2460
J9 J AM PSYCHOANAL ASS
JI J. Am. Psychoanal. Assoc.
PD JUN
PY 2020
VL 68
IS 3
BP 447
EP 454
AR 0003065120938772
DI 10.1177/0003065120938772
EA JUN 2020
PG 8
WC Psychiatry; Psychology, Psychoanalysis
SC Psychiatry; Psychology
GA MP6UC
UT WOS:000544014900001
PM 32589054
DA 2021-01-01
ER

PT J
AU Baig, MS
   Alagumuthu, M
   Rajpoot, S
   Saqib, U
AF Baig, Mirza S.
   Alagumuthu, Manikandan
   Rajpoot, Sajjan
   Saqib, Uzma
TI Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting
   its Entry into the Host Cells
SO DRUGS IN R&D
LA English
DT Article
ID OUTBREAK; CORONAVIRUS; ACE2; COVID-19; EXPLAINS; HOMOLOG; SARS
AB Background and objective Coronavirus disease (COVID-19) is an ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Due to the incessant spread of the disease with substantial morbidity and mortality rates, there is an urgent demand for effective therapeutics and vaccines to control and diminish this pandemic. A critical step in the crosstalk between the virus and the host cell is the binding of SARS-CoV-2 spike protein to the angiotensin-converting enzyme 2 (ACE2) receptor present on the surface of the host cells. Hence, inhibition of this interaction could be a promising strategy to combat the SARS-CoV-2 infection. Methods Docking and Molecular Dynamics (MD) simulation studies revealed that designed peptide maintains their secondary structure and provide a highly specific and stable binding (blocking) to SARS-CoV-2. Results We have designed a novel peptide that could inhibit SARS-CoV-2 spike protein interaction with ACE2, thereby blocking the cellular entry of the virus. Conclusion Our findings suggest that computationally developed inhibitory peptide may be developed as an anti-SARS-CoV-2 agent for the treatment of SARS-CoV-2 infection. We further plan to pursue the peptide in cell-based assays and eventually for clinical trials.
C1 [Baig, Mirza S.; Alagumuthu, Manikandan; Rajpoot, Sajjan] Indian Inst Technol Indore IITI, Discipline Biosci & Biomed Engn BSBE, Indore, Madhya Pradesh, India.
   [Saqib, Uzma] Indian Inst Technol Indore IITI, Discipline Chem, Indore, Madhya Pradesh, India.
RP Baig, MS (corresponding author), Indian Inst Technol Indore IITI, Discipline Biosci & Biomed Engn BSBE, Indore, Madhya Pradesh, India.
EM msb.iit@iiti.ac.in
FU Indian Institute of Technology Indore (IITI) India
FX This study is supported by the Indian Institute of Technology Indore
   (IITI) India.
CR Anderson RM, 2004, PHILOS T R SOC B, V359, P1091, DOI 10.1098/rstb.2004.1490
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Bohmer C, 2005, BIOCHEM J, V389, P745
   Camargo SMR, 2009, GASTROENTEROLOGY, V136, P872, DOI 10.1053/j.gastro.2008.10.055
   Cascella M, 2020, FEATURES EVALUATION
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chatterjee P, 2018, LANCET, V391, P2200, DOI 10.1016/S0140-6736(18)31252-2
   Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X
   Donoghue M, 2003, J MOL CELL CARDIOL, V35, P1043, DOI 10.1016/S0022-2828(03)00177-9
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussain M, 2020, J MED VIROL, V92, P1580, DOI 10.1002/jmv.25832
   Jando J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184845
   Jimenez-Garcia B, 2013, BIOINFORMATICS, V29, P1698, DOI 10.1093/bioinformatics/btt262
   Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Kowalczuk S, 2008, FASEB J, V22, P2880, DOI 10.1096/fj.08-107300
   Kulkarni DD, 2013, INDIAN J VIROL, V24, P398, DOI 10.1007/s13337-013-0171-y
   Lewnard JA, 2018, LANCET, V392, P189, DOI 10.1016/S0140-6736(18)31443-0
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Morrow JK, 2012, CURR PHARM DESIGN, V18, P1255
   Oboho IK, 2015, NEW ENGL J MED, V372, P846, DOI 10.1056/NEJMoa1408636
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Procko E, 2020, SEQUENCE HUMAN ACE2, DOI [10.1101/2020.03.16.994236v1, DOI 10.1101/2020.03.16.994236V1]
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   Systemes DB, 2019, DISC STUD MOD ENV RE
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   Uddin M, 2020, SARS COV 2 COVID 19
   Uhal BD, 2013, EUR RESPIR J, V42, P198, DOI 10.1183/09031936.00015612
   van Zundert GCP, 2014, METHODS MOL BIOL, V1137, P163, DOI 10.1007/978-1-4939-0366-5_12
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang H, 2001, J BIOL CHEM, V276, P17132, DOI 10.1074/jbc.M006723200
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhao Y., 2020, SINGLE CELL RNA EXPR, DOI [10.1101/2020.01.26.919985v2, DOI 10.1101/2020.01.26.919985V2]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Q, 2020, STRUCTURE DIMERIC FU, DOI DOI 10.1101/2020.02.17.951848V1.FULL
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zisman LS, 2003, CIRCULATION, V108, P1707, DOI 10.1161/01.CIR.0000094734.67990.99
NR 59
TC 4
Z9 5
U1 12
U2 12
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1174-5886
EI 1179-6901
J9 DRUGS R&D
JI Drugs R&D
PD SEP
PY 2020
VL 20
IS 3
BP 161
EP 169
DI 10.1007/s40268-020-00312-5
EA JUN 2020
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MZ0CT
UT WOS:000543617900001
PM 32592145
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pantanetti, P
   Cangelosi, G
   Ambrosio, G
AF Pantanetti, Paola
   Cangelosi, Giovanni
   Ambrosio, Giuseppe
TI Potential role of incretins in diabetes and COVID-19 infection: a
   hypothesis worth exploring
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Article
DE Diabetes; Dipeptidyl peptidase-4; COVID-19; Gliptins; Inflammation
AB Patients with diabetes mellitus have been reported to be at a high risk of complications from SARS-CoV2 virus infection (COVID-19). In type 2 diabetes, there is a change in immune system cells, which shift from an anti-inflammatory to a predominantly pro-inflammatory pattern. This altered immune profile may induce important clinical consequences, including increased susceptibility to lung infections; and enhanced local inflammatory response. Furthermore, dipeptidyl peptidase 4 (DPP4) enzyme is highly expressed in the lung, and that it may have additional actions besides its effects on glucose metabolism, which might exert profound pro-inflammatory effects. We briefly review the impact on the inflammatory system of DPP4 for its possible detrimental effect on COVID-19 syndrome, and of DPP4 inhibitors (gliptins), currently used as glucose lowering agents, which may have the potential to exert positive pleiotropic effect on inflammatory diseases, in addition to their effects on glucose metabolism. Thanks to these ancillary effects, gliptins could potentially be "repurposed" as salutary drugs against COVID-19 syndrome, even in non-diabetic subjects. Clinical studies should be designed to investigate this possibility.
C1 [Pantanetti, Paola; Cangelosi, Giovanni] UO Diabetol Asur Marche, Area Vasta 4,Via Dante Zeppilli 18, I-63900 Fermo, Italy.
   [Ambrosio, Giuseppe] Univ Perugia, Sch Med, Div Cardiol, Perugia, Italy.
RP Pantanetti, P (corresponding author), UO Diabetol Asur Marche, Area Vasta 4,Via Dante Zeppilli 18, I-63900 Fermo, Italy.
EM paola.pantanetti@sanita.marche.it
RI Ambrosio, Giuseppe/C-6596-2013
OI Ambrosio, Giuseppe/0000-0002-9677-980X
CR Cattadori G, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107835
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Farsalinos K, 2020, INTERN EMERG MED, V15, P845, DOI 10.1007/s11739-020-02355-7
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Istituto Superiore della Sanita (ISS), 2020, CHAR COV 19 PAT DYIN
   Kawasaki T, 2018, AM J PHYSIOL-LUNG C, V315, pL834, DOI 10.1152/ajplung.00031.2018
   Meshkani R, 2016, CLIN CHIM ACTA, V462, P77, DOI 10.1016/j.cca.2016.08.015
   Morra ME, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1977
   REINHOLD D, 1994, IMMUNOBIOLOGY, V192, P121, DOI 10.1016/S0171-2985(11)80412-2
   Sadikot RT, 2009, J BIOMED NANOTECHNOL, V5, P614, DOI 10.1166/jbn.2009.1078
   Seferovic PM, 2020, EUR J HEART FAIL, V22, P196, DOI 10.1002/ejhf.1673
   Shao SY, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107503
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Soare A, 2020, ARTHRITIS RHEUMATOL, V72, P137, DOI 10.1002/art.41058
   Telikani Z, 2020, KOOMESH, V22, P71
   Violi F, 2020, INTERN EMERG MED, V15, P755, DOI 10.1007/s11739-020-02348-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 20
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
PD AUG
PY 2020
VL 15
IS 5
SI SI
BP 779
EP 782
DI 10.1007/s11739-020-02389-x
EA JUN 2020
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MZ0DG
UT WOS:000543623400002
PM 32592113
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Jackson, T
   Hobson, K
   Clare, H
   Weegmann, D
   Moloughney, C
   McManus, S
AF Jackson, Timothy
   Hobson, Katie
   Clare, Hannah
   Weegmann, Daniel
   Moloughney, Catherine
   McManus, Sally
TI End-of-life care in COVID-19: An audit of pharmacological management in
   hospital inpatients
SO PALLIATIVE MEDICINE
LA English
DT Article
DE COVID-19; symptom control; end-of-life care
AB Background: Hospital clinicians have had to rapidly develop expertise in managing the clinical manifestations of COVID-19 including symptoms common at the end of life, such as breathlessness and agitation. There is limited evidence exploring whether end-of-life symptom control in this group requires new or adapted guidance. Aim: To review whether prescribing for symptom control in patients dying with COVID-19 adhered to existing local guidance or whether there was deviation which may represent a need for revised guidance or specialist support in particular patient groups. Design/setting: A retrospective review of the electronic patient record of 61 hospital inpatients referred to the specialist palliative care team with swab-confirmed COVID-19 who subsequently died over a 1-month period. Intubated patients were excluded. Results: In all, 83% (40/48) of patients were prescribed opioids at a starting dose consistent with existing local guidelines. In seven of eight patients where higher doses were prescribed, this was on specialist palliative care team advice. Mean total opioid dose required in the last 24 h of life was 14 mg morphine subcutaneous equivalent, and mean total midazolam dose was 9.5 mg. For three patients in whom non-invasive ventilation was in place higher doses were used. Conclusion: Prescription of end-of-life symptom control drugs for COVID-19 fell within the existing guidance when supported by specialist palliative care advice. While some patients may require increased doses, routine prescription of higher starting opioid and benzodiazepine doses beyond existing local guidance was not observed.
C1 [Jackson, Timothy; Hobson, Katie; Clare, Hannah; Weegmann, Daniel; Moloughney, Catherine; McManus, Sally] Salford Royal NHS Fdn Trust, Stott Lane, Salford M6 8HD, Lancs, England.
RP Jackson, T (corresponding author), Salford Royal NHS Fdn Trust, Stott Lane, Salford M6 8HD, Lancs, England.
EM tim.jackson@srft.nhs.uk
RI Jackson, Tim/ABE-6342-2020
FU Salford Royal NHS Foundation Trust, Salford, UK
FX Salford Royal NHS Foundation Trust, Salford, UK
CR Association for Palliative Medicine, 2020, COVID 19 PALL END LI
   Greater Manchester and Eastern Cheshire Strategic Clinical Networks, 2019, PALL CAR PAIN SYMPT
   Lovell N, 2020, J PAIN SYMPTOM MANAG, V20, P32325167
   Radbruch L, 2020, LANCET, V395, P1467, DOI 10.1016/S0140-6736(20)30964-8
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Royal College of General Practitioners and the Association for Palliative Medicine, 2020, COMM PALL END LIF BE
   Turner J, 2020, J PAIN SYMPTOM MANAG, V20, P32387139
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
NR 8
TC 1
Z9 1
U1 2
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-2163
EI 1477-030X
J9 PALLIATIVE MED
JI Palliat. Med.
PD OCT
PY 2020
VL 34
IS 9
BP 1235
EP 1240
AR 0269216320935361
DI 10.1177/0269216320935361
EA JUN 2020
PG 6
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Medicine, General & Internal
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; General & Internal Medicine
GA NO5KE
UT WOS:000545335400001
PM 32588748
OA Bronze
DA 2021-01-01
ER

PT J
AU Seirafianpour, F
   Mozafarpoor, S
   Fattahi, N
   Sadeghzadeh-Bazargan, A
   Hanifiha, M
   Goodarzi, A
AF Seirafianpour, Farnoosh
   Mozafarpoor, Samaneh
   Fattahi, Nima
   Sadeghzadeh-Bazargan, Afsaneh
   Hanifiha, Melika
   Goodarzi, Azadeh
TI Treatment ofCOVID-19 with pentoxifylline: Could it be a potential
   adjuvant therapy?
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE antifibrosis; anti-inflammatory; anti-oxidant; apoptosis-regulatory;
   ARDS (acute respiratory distress syndrome); bronchodilator; circulation;
   coronavirus; COVID-19; immunomodulatory; oxygenation; pentoxifylline;
   Pentoxil; perfusion; review; SARS (severe acute respiratory syndrome);
   treatment
ID ACUTE LUNG INJURY; TNF-ALPHA; METAANALYSIS; SEPSIS
AB The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine derivative and it inhibits the phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifylline against COVID-19 pathogenesis, in Medline, Scopus, Web of Sciences, and Google Scholar up to 20 March 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID-19, coronavirus, treatment, anti-inflammatory, immunomodulatory, antifibrosis, oxygenation, circulation, bronchodilator, ARDS, and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline on controlling COVID-19 and its consequences. The antiviral, anti-inflammatory, anti-oxidative, immune-modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation-oxygenation properties, low price and safety, make it a promising drug to be considered for COVID-19 treatment, especially as an adjuvant therapy in combination with other drugs.
C1 [Seirafianpour, Farnoosh] Iran Univ Med Sci, Sch Med, Student Res Comm, Tehran, Iran.
   [Mozafarpoor, Samaneh] Isfahan Univ Med Sci, Skin Dis & Leishmaniasis Res Ctr, Dept Dermatol, Esfahan, Iran.
   [Fattahi, Nima; Hanifiha, Melika] Univ Tehran Med Sci, Endocrinol & Metab Populat Sci Inst, Noncommunicable Dis Res Ctr, Tehran, Iran.
   [Sadeghzadeh-Bazargan, Afsaneh; Goodarzi, Azadeh] Iran Univ Med Sci IUMS, Rasoul Akram Hosp, Dept Dermatol, Tehran, Iran.
   [Hanifiha, Melika] Univ Tehran Med Sci, Children Med Ctr, Tehran, Iran.
RP Goodarzi, A (corresponding author), Iran Univ Med Sci IUMS, Rasoul Akram Hosp, Niayesh Aven,Sattarkhan St, Tehran, Iran.
EM goodarzi.a@iums.ac.ir
RI seirafianpour, farnoosh/AAT-3885-2020
OI goodarzi, azadeh/0000-0002-1249-4429
CR AMVROSIEVA TV, 1993, VOP VIRUSOL+, V38, P230
   Bermejo Martin Jesus Fco, 2003, Med Sci Monit, V9, pSR29
   Brie D, 2016, J HYPERTENS, V34, P2318, DOI 10.1097/HJH.0000000000001086
   Cascella M, 2020, FEATURES EVALUATION
   Champion S, 2014, CARDIOVASC THER, V32, P159, DOI 10.1111/1755-5922.12076
   Dong JQ, 2018, MOL MED REP, V17, P1141, DOI 10.3892/mmr.2017.7953
   Gudziol V, 2009, ARCH OTOLARYNGOL, V135, P291, DOI 10.1001/archoto.2008.524
   Mahajan RP, 2005, BJA EDUC, V5, P52, DOI 10.1093/bjaceaccp/mki013
   Marques LJ, 1999, AM J RESP CRIT CARE, V159, P508, DOI 10.1164/ajrccm.159.2.9804085
   McCarty M. F., 2016, OPEN HEART, V3, P1
   Michetti C, 2003, J SURG RES, V115, P92, DOI 10.1016/S0022-4804(03)00219-1
   Nina Stafford N, 2020, BMJ-BRIT MED J, V369
   Parker R, 2013, Aliment Pharmacol Ther, V37, P845, DOI 10.1111/apt.12279
   Shahabinezhad F., 2020, THERAPEUTIC APPROACH, DOI [10.20944/preprints202003.0206.v2, DOI 10.20944/PREPRINTS202003.0206.V2]
   Staubach KH, 1998, ARCH SURG-CHICAGO, V133, P94, DOI 10.1001/archsurg.133.1.94
   Tian J, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-019-0697-8
   VanFurth AM, 1997, IMMUNOLOGY, V91, P193, DOI 10.1046/j.1365-2567.1997.00252.x
   Wen WX, 2017, ADV THER, V34, P1245, DOI 10.1007/s12325-017-0547-2
   World Health Organization, 2020, 29 WHO
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang SK, 2015, EXP THER MED, V9, P384, DOI 10.3892/etm.2014.2132
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 23
TC 1
Z9 1
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13733
DI 10.1111/dth.13733
EA JUN 2020
PG 4
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000543161400001
PM 32473070
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hoek, RAS
   Manintveld, OC
   Betjes, MGH
   Hellemons, ME
   Seghers, L
   Van Kampen, JAA
   Caliskan, K
   de Wetering, J
   den Hoogen, M
   Metselaar, HJ
   Hesselink, DA
AF Hoek, Rogier A. S.
   Manintveld, Olivier C.
   Betjes, Michiel G. H.
   Hellemons, Merel E.
   Seghers, Leonard
   Van Kampen, Jeroen A. A.
   Caliskan, Kadir
   de Wetering, Jacquelinevan
   den Hoogen, Martijnvan
   Metselaar, Herold J.
   Hesselink, Dennis A.
CA Rotterdam Transplant Grp
TI COVID-19 in solid organ transplant recipients: a single-center
   experience
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE COVID-19; organ transplantation; SARS-CoV-2; solid organ transplantation
ID REPLICATION; FRAILTY
AB Solid organ transplant (SOT) recipients may be at risk for severe COVID-19. Data on the clinical course of COVID-19 in immunosuppressed patients are limited, and the effective treatment strategy for these patients is unknown. We describe our institutional experience with COVID-19 in SOT. Demographic, clinical, and treatment data were extracted from the electronic patient files. A total of 23 SOT transplant recipients suffering from COVID-19 were identified (n = 3 heart;n = 15 kidney;n = 1 kidney-after-heart;n = 3 lung, andn = 1 liver transplant recipient). The presenting symptoms were similar to nonimmunocompromised patients. Eighty-three percent (19/23) of the patients required hospitalization, but only two of these were transferred to the intensive care unit. Five patients died from COVID-19; all had high Clinical Frailty Scores. In four of these patients, mechanical ventilation was deemed futile. In 57% of patients, the immunosuppressive therapy was not changed and only three patients were treated with chloroquine. Most patients recovered without experimental antiviral therapy. Modification of the immunosuppressive regimen alone could be a therapeutic option for SOT recipients suffering from moderate to severe COVID-19. Pre-existent frailty is associated with death from COVID-19.
C1 [Hoek, Rogier A. S.; Hellemons, Merel E.; Seghers, Leonard] Erasmus MC, Dept Pulm Med, Univ Med Ctr, Rotterdam, Netherlands.
   [Manintveld, Olivier C.; Caliskan, Kadir] Erasmus MC, Dept Cardiol, Univ Med Ctr, Rotterdam, Netherlands.
   [Betjes, Michiel G. H.; de Wetering, Jacquelinevan; den Hoogen, Martijnvan; Hesselink, Dennis A.] Erasmus MC, Dept Nephrol & Transplantat, Univ Med Ctr, Rotterdam, Netherlands.
   [Van Kampen, Jeroen A. A.] Erasmus MC, Dept Virosci, Univ Med Ctr, Rotterdam, Netherlands.
   [Metselaar, Herold J.] Erasmus MC, Dept Gastroenterol & Hepatol, Univ Med Ctr, Rotterdam, Netherlands.
RP Hoek, RAS (corresponding author), Erasmus MC, Univ Med Ctr Rotterdam, Dept Pulm Med, Room Rg 428,POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM r.hoek@erasmusmc.nl
RI van den Hoogen, Martijn W.F./H-7614-2012
OI van den Hoogen, Martijn W.F./0000-0003-0790-2405; Hoek,
   R.A.S./0000-0003-2165-3222; van Kampen, Jeroen/0000-0002-7625-8230
CR Ahn C, 2020, TRANSPLANTATION, DOI [10.1097/TP0000000000003258, DOI 10.1097/TP0000000000003258]
   Aigner C, 2020, J HEART LUNG TRANSPL, V39, P610, DOI 10.1016/j.healun.2020.04.004
   Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Bin L, 2020, AM J TRANSPLANT, P1, DOI [10.1111/ajt15901, DOI 10.1111/AJT15901]
   Brummel NE, 2017, AM J RESP CRIT CARE, V196, P64, DOI 10.1164/rccm.201605-0939OC
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carbajo-Lozoya J, 2014, VIRUS RES, V184, P44, DOI 10.1016/j.virusres.2014.02.010
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   de Vries APJ, 2020, TRANSPL IMMUNOL, V61, DOI 10.1016/j.trim.2020.101304
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meyer M, 2009, AM J RESP CELL MOL, V41, P590, DOI 10.1165/rcmb.2008-0155OC
   Mo Y, 2016, J ANTIMICROB CHEMOTH, V71, P3340, DOI 10.1093/jac/dkw338
   Murphy BS, 2008, J ANTIMICROB CHEMOTH, V61, P554, DOI 10.1093/jac/dkn007
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Poston JT, 2020, JAMA-J AM MED ASSOC, V323, P1839, DOI 10.1001/jama.2020.4914
   Qin JJ, 2020, HEPATOLOGY, V72, P1491, DOI 10.1002/hep.31257
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Sunazuka T, 2003, J ANTIBIOT, V56, P721, DOI 10.7164/antibiotics.56.721
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 30
TC 16
Z9 16
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0934-0874
EI 1432-2277
J9 TRANSPL INT
JI Transpl. Int.
PD SEP
PY 2020
VL 33
IS 9
BP 1099
EP 1105
DI 10.1111/tri.13662
EA JUN 2020
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA NJ8OM
UT WOS:000543065100001
PM 32460390
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Bekes, V
   Aafjes-van Doorn, K
   Prout, TA
   Hoffman, L
AF Bekes, Vera
   Aafjes-van Doorn, Katie
   Prout, Tracy A.
   Hoffman, Leon
TI Stretching the Analytic Frame: Analytic Therapists' Experiences with
   Remote Therapy During COVID-19
SO JOURNAL OF THE AMERICAN PSYCHOANALYTIC ASSOCIATION
LA English
DT Article
ID ATTITUDES
AB Remote therapy has been used by analytic therapists for quite some time, though many have been reluctant to use it regularly, out of concern that it might distort analytic frame and relational dynamics. Now the Covid-19 pandemic has forced therapists to make a sudden, across-the-board transition to remote therapy. This study reports on survey responses from 190 analytic therapists on their transition to online therapy via videoconferencing during the pandemic and their previous experience with remote therapy (the majority had such experience). During the pandemic they prepared themselves and their patients for the transition in a variety of ways. The majority of those surveyed reported feeling as confident and as competent in their online sessions as in their earlier in-person work. Moreover, despite technical and relational challenges, they remained as strong, emotionally connected, and authentic in their online therapy sessions as they were in person. These experiences during the pandemic led to more positive views of online therapy than they held before, but a majority still considered online therapy less effective than in-person sessions.
C1 [Bekes, Vera; Aafjes-van Doorn, Katie; Prout, Tracy A.] Yeshiva Univ, Ferkauf Grad Sch Psychol, 1165 Morris Pk Ave, Bronx, NY 10461 USA.
   [Hoffman, Leon] New York Psychoanalyt Soc & Inst, New York, NY USA.
RP Bekes, V (corresponding author), Yeshiva Univ, Ferkauf Grad Sch Psychol, 1165 Morris Pk Ave, Bronx, NY 10461 USA.
EM vera.bekes@yu.edu
OI Bekes, Vera/0000-0003-3043-5155
CR Aafjes-van Doorn K, 2020, COUNSELLING PSYCHOL
   Agar G, 2019, THEORY PRACTICE ONLI, P66
   Argentieri S., 2003, INSIGHT, V12, P17
   Bekes V, 2020, J PSYCHOTHER INTEGR, V30, P238, DOI 10.1037/int0000214
   Brottman Mikita, 2012, Psychoanal Rev, V99, P19, DOI 10.1521/prev.2012.99.1.19
   Connolly SL, 2020, CLIN PSYCHOL-SCI PR, V27, DOI 10.1111/cpsp.12311
   Ehrlich LT, 2019, J AM PSYCHOANAL ASS, V67, P249, DOI 10.1177/0003065119847170
   Migone P, 2013, PSYCHOANAL PSYCHOL, V30, P281, DOI 10.1037/a0031507
   Perle JG, 2013, J CLIN PSYCHOL, V69, P100, DOI 10.1002/jclp.21912
   Roesler C, 2017, J ANAL PSYCHOL, V62, P372, DOI 10.1111/1468-5922.12317
   Saul LJ, 1951, PSYCHOANAL QUART, V20, P287, DOI 10.1080/21674086.1951.11925845
   Scharff J., 2010, INT J PSYCHOANAL, V91, P989
   Scharff J.S, 2018, PSYCHOANALYSIS ONLIN
   Trub L., 2017, PSYCHOANALYTIC PERSP, V14, P219
NR 14
TC 0
Z9 0
U1 3
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0003-0651
EI 1941-2460
J9 J AM PSYCHOANAL ASS
JI J. Am. Psychoanal. Assoc.
PD JUN
PY 2020
VL 68
IS 3
BP 437
EP 446
AR 0003065120939298
DI 10.1177/0003065120939298
EA JUN 2020
PG 10
WC Psychiatry; Psychology, Psychoanalysis
SC Psychiatry; Psychology
GA MP6UC
UT WOS:000544201100001
PM 32589042
DA 2021-01-01
ER

PT J
AU Lambert, PH
   Ambrosino, DM
   Andersen, SR
   Baric, RS
   Black, SB
   Chen, RT
   Dekker, CL
   Didierlaurent, AM
   Graham, BS
   Martin, SD
   Molrine, DC
   Perlman, S
   Picard-Fraser, PA
   Pollard, AJ
   Qin, C
   Subbarao, K
   Cramer, JP
AF Lambert, Paul-Henri
   Ambrosino, Donna M.
   Andersen, Svein R.
   Baric, Ralph S.
   Black, Steven B.
   Chen, Robert T.
   Dekker, Cornelia L.
   Didierlaurent, Arnaud M.
   Graham, Barney S.
   Martin, Samantha D.
   Molrine, Deborah C.
   Perlman, Stanley
   Picard-Fraser, Philip A.
   Pollard, Andrew J.
   Qin, Chuan
   Subbarao, Kanta
   Cramer, Jakob P.
TI Consensus summary report for CEPI/BC March 12-13, 2020 meeting:
   Assessment of risk of disease enhancement with COVID-19 vaccines
SO VACCINE
LA English
DT Article
DE SARS-CoV-2; COVID-19; Vaccine safety; MERS-CoV vaccine; SARS-CoV-1
   vaccine; SARS-CoV-2 vaccine; Animal models; Enhanced disease; Vaccine
   adjuvants
ID ACUTE RESPIRATORY SYNDROME; IMMUNIZED BALB/C MICE; VIRUS RSV CHALLENGE;
   SARS-COV; MERS-COV; NUCLEOCAPSID PROTEIN; PROTECTIVE IMMUNITY;
   INFECTION; ANTIBODY; SPIKE
AB A novel coronavirus (CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China and has since spread as a global pandemic. Safe and effective vaccines are thus urgently needed to reduce the significant morbidity and mortality of Coronavirus Disease 2019 (COVID-19) disease and ease the major economic impact. There has been an unprecedented rapid response by vaccine developers with now over one hundred vaccine candidates in development and at least six having reached clinical trials. However, a major challenge during rapid development is to avoid safety issues both by thoughtful vaccine design and by thorough evaluation in a timely manner. A syndrome of "disease enhancement" has been reported in the past for a few viral vaccines where those immunized suffered increased severity or death when they later encountered the virus or were found to have an increased frequency of infection. Animal models allowed scientists to determine the underlying mechanism for the former in the case of Respiratory syncytial virus (RSV) vaccine and have been utilized to design and screen new RSV vaccine candidates. Because some Middle East respiratory syndrome (MERS) and SARS-CoV-1 vaccines have shown evidence of disease enhancement in some animal models, this is a particular concern for SARS-CoV-2 vaccines. To address this challenge, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency vACcines (SPEAC) convened a scientific working meeting on March 12 and 13, 2020 of experts in the field of vaccine immunology and coronaviruses to consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for safety assessment of COVID-19 vaccine candidates in accelerated vaccine development.
C1 [Lambert, Paul-Henri; Didierlaurent, Arnaud M.] Univ Geneva, Ctr Vaccinol, Geneva, Switzerland.
   [Andersen, Svein R.] Coalit Epidem Preparedness Innovat, Oslo, Norway.
   [Baric, Ralph S.] Univ N Carolina, Gillings Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA.
   [Black, Steven B.; Chen, Robert T.; Dekker, Cornelia L.] Task Force Global Hlth, Brighton Collaborat, Decatur, GA 30030 USA.
   [Qin, Chuan] Chinese Acad Med Sci & Peking Union Med Coll, Inst Lab Anim Sci, Beijing, Peoples R China.
   [Graham, Barney S.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Perlman, Stanley] Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA USA.
   [Pollard, Andrew J.] Univ Oxford, Dept Paediat, Oxford, England.
   [Subbarao, Kanta] Peter Doherty Inst Infect & Immun, WHO Collaborating Ctr Reference & Res Influenza, Melbourne, Vic, Australia.
   [Cramer, Jakob P.] Coalit Epidem Preparedness Innovat, London, England.
RP Dekker, CL (corresponding author), Task Force Global Hlth, Brighton Collaborat, Decatur, GA 30030 USA.
EM cdekker@stanford.edu
RI qin, chuan/ABG-4508-2020
OI Chen, Robert/0000-0002-3094-8367
FU Coalition for Epidemic Preparedness Innovations (CEPI)
FX We acknowledge the financial support provided by the Coalition for
   Epidemic Preparedness Innovations (CEPI) for our work under a service
   order entitled Safety Platform for Emergency vACcines (SPEAC) Project
   with the Brighton Collaboration, a program of the Task Force for Global
   Health, Decatur, GA, USA. We thank the following persons for their
   assistance: (1) the similar to 90 attendees of the meeting from many
   countries globally who provided invaluable discussion to move the field
   forward; (2) Angel Honrado and Imanol Urkola of WeDO, Jim Mootrey and
   Chantal Veira, Lisa Chung, Matt Dudley, and Gabriella Corrigan of the
   SPEAC/TFGH team for their logistical support; (3) other SPEAC Executive
   Board (Barbara Law, Wan-Ting Huang, Marc Gurwith, Miriam Sturkenboom)
   for their oversight and planning.
CR Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   [Anonymous], 2020, COVID 19 DAT CTR
   Bao PL, 2020, NATURE, V583, P103, DOI 10.1038/s41586-020-2350-5
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Boudreau CM, 2020, J CLIN INVEST, V130, P662, DOI 10.1172/JCI129520
   Burny W, 2017, FRONT IMMUNOL, V8, P14, DOI 10.3389/fimmu.2017.00943
   Chu YK, 2008, VIROLOGY, V374, P151, DOI 10.1016/j.virol.2007.12.032
   Cockrell AS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.226
   CONNORS M, 1992, J VIROL, V66, P7444, DOI 10.1128/JVI.66.12.7444-7451.1992
   CONNORS M, 1994, J VIROL, V68, P5321, DOI 10.1128/JVI.68.8.5321-5325.1994
   Couch RB, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-425
   Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Douglas MG, 2018, VIROLOGY, V517, P98, DOI 10.1016/j.virol.2017.12.006
   Enjuanes L, 2008, VIRUS RES, V133, P45, DOI 10.1016/j.virusres.2007.01.021
   Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894
   Francica JR, 2017, BLOOD ADV, V1, P2329, DOI 10.1182/bloodadvances.2017011411
   Frieman M, 2012, J VIROL, V86, P884, DOI 10.1128/JVI.05957-11
   Galson JD, 2016, SCI REP-UK, V6, DOI 10.1038/srep37229
   Harandi AM, 2018, SEMIN IMMUNOL, V39, P30, DOI 10.1016/j.smim.2018.08.001
   Hashem AM, 2019, J INFECT DIS, V220, P1558, DOI 10.1093/infdis/jiz137
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Johnson RF, 2016, VIROLOGY, V490, P49, DOI 10.1016/j.virol.2016.01.004
   Johnson RF, 2015, VIROLOGY, V485, P422, DOI 10.1016/j.virol.2015.07.013
   Khurana S, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0076-2
   Khurana S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002336
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Kim TW, 2004, J VIROL, V78, P4638, DOI 10.1128/JVI.78.9.4638-4645.2004
   Leroux-Roels G, 2016, CLIN IMMUNOL, V169, P16, DOI 10.1016/j.clim.2016.05.007
   Li K, 2017, P NATL ACAD SCI USA, V114, pE3119, DOI 10.1073/pnas.1619109114
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lurie N, 2020, N ENGL J MED
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Moris P, 2011, J CLIN IMMUNOL, V31, P443, DOI 10.1007/s10875-010-9490-6
   O'Hagan DT, 2017, CURR OPIN IMMUNOL, V47, P93, DOI 10.1016/j.coi.2017.07.010
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781
   Qin E, 2006, VACCINE, V24, P1028, DOI 10.1016/j.vaccine.2005.06.038
   Ren JG, 2020, INFECT DIS-NOR, V52, P571, DOI 10.1080/23744235.2020.1766105
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   Roberts A, 2005, J VIROL, V79, P5833, DOI 10.1128/JVI.79.9.5833-5838.2005
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Roberts A, 2006, VACCINE, V24, P7056, DOI 10.1016/j.vaccine.2006.07.009
   Roberts A, 2010, VIRAL IMMUNOL, V23, P509, DOI 10.1089/vim.2010.0028
   Rockx B., 2020, SCIENCE
   Sheahan T, 2011, J VIROL, V85, P217, DOI 10.1128/JVI.01805-10
   Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Sun PF, 2003, J IMMUNOL, V171, P6961, DOI 10.4049/jimmunol.171.12.6961
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Yu P, 2020, ANIMAL MODEL EXP MED, V3, P93
   Zhao JX, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5393
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 60
TC 18
Z9 18
U1 12
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUN 26
PY 2020
VL 38
IS 31
BP 4783
EP 4791
DI 10.1016/j.vaccine.2020.05.064
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LY9EV
UT WOS:000540831900001
PM 32507409
OA Green Published
DA 2021-01-01
ER

PT J
AU Dopytalska, K
   Mikucka-Wituszynska, A
   Ciechanowicz, P
   Szczerba, M
   Szymanska, E
   Walecka, I
AF Dopytalska, Klaudia
   Mikucka-Wituszynska, Agata
   Ciechanowicz, Piotr
   Szczerba, Michal
   Szymanska, Elzbieta
   Walecka, Irena
TI Organization of biologic therapy during the COVID-19 pandemic based on
   example of Dermatology Clinic Centre of Postgraduate Medical Education
   in Warsaw
SO JOURNAL OF DERMATOLOGICAL TREATMENT
LA English
DT Article; Early Access
DE Biologic treatment; psoriasis; COVID-19; dermatology
AB The COVID-19 pandemic spread to almost all countries in the world within a few months, necessitating changes in medical care for patients with SARS-CoV-2 infections as well as patients with various chronic diseases. Ensuring the safety of medical staff and patients in hospitals specializing in infectious diseases is a major logistical challenge. Psoriasis patients treated with immunosuppressive medications, including those under biologic therapy, are a special group. Many scientific societies do not recommend discontinuing therapy in patients without symptoms or confirmation of SARS-CoV-2 infection despite the potentially higher risk of respiratory tract infections in this patient population. Based on our own experience, we present the organization of the biologic therapy within the unit of a Single Specialty Infectious Hospital.
C1 [Dopytalska, Klaudia; Mikucka-Wituszynska, Agata; Ciechanowicz, Piotr; Szymanska, Elzbieta; Walecka, Irena] Minist Interior, Cent Clin Hosp, Dept Dermatol, Ctr Postgrad Med Educ, Woloska 137, PL-02507 Warsaw, Poland.
   [Szczerba, Michal] Univ Technol Katowice, Fac Med, Katowice, Poland.
RP Dopytalska, K (corresponding author), Minist Interior, Cent Clin Hosp, Dept Dermatol, Ctr Postgrad Med Educ, Woloska 137, PL-02507 Warsaw, Poland.
EM klaudia.dopytalska@cskmswia.pl
CR American Academy of Dermatology Association, GUID US BIOL AG COVI
   [Anonymous], REC SYST THER PERS P
   Balla Mamtha, 2020, J Clin Med Res, V12, P215, DOI 10.14740/jocmr4142
   Estebanez A, 2020, J EUR ACAD DERMATOL, V34, pE250, DOI 10.1111/jdv.16474
   French Society of Dermatology/Societe Francaise de Dermatologie (SFD ), REC DEC PAT ATT MAL
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   International League of Dermatological Societies, 2020, GUID US SYST THER PA
   International Psoriasis Council, STAT COR COVID 19 OU
   Italian Society of Dermatology SiDeMaST, COR VAD PAZ AFF PSOR
   Komunikat Ministra, 2020, KOMUNIKAT MINISTRA Z
   Mungmunpuntipantip R, 2020, J EUR ACAD DERMATOL, V34, pE246, DOI 10.1111/jdv.16483
   Price KN, 2020, J AM ACAD DERMATOL, V82, pE173, DOI 10.1016/j.jaad.2020.03.046
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
NR 14
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-6634
EI 1471-1753
J9 J DERMATOL TREAT
JI J. Dermatol. Treat.
DI 10.1080/09546634.2020.1782822
EA JUN 2020
PG 5
WC Dermatology
SC Dermatology
GA ML5SQ
UT WOS:000549526100001
PM 32569493
OA Bronze
DA 2021-01-01
ER

PT J
AU Fisher, S
   Ziv, M
AF Fisher, S.
   Ziv, M.
TI COVID-19 effect on phototherapy treatment utilization in dermatology
SO JOURNAL OF DERMATOLOGICAL TREATMENT
LA English
DT Article; Early Access
DE COVID-19; phototherapy; UVB; UVA; PUVA
AB Background:At the end of 2019, an innovative coronavirus caused an outbreak of pneumonia cases in Wuhan, a city Hubei Province of China. Despite the direct effect on the routine of all life aspects, there are no clinical guidelines regarding phototherapy treatment during COVID-19 pandemic and as a result, phototherapies units continued to deliver this therapy for patients worldwide. Objective:We wish to explore the phototherapy utilization among dermatologic patients. Methods:We marked all patients that continue to arrive and being treated during COVID-19 pandemic. Results:From March more than 50% of patients stopped arriving to treatments due to the fear of COVID-19 infection. Conclusions:COVID-19 has a major implication on chronic dermatology treatments such as phototherapy.
C1 [Fisher, S.; Ziv, M.] Emek Med Ctr, Dermatol & Venerol Dept, Afula, Israel.
   [Fisher, S.] Tel Aviv Univ, Sackler Sch Med, Steyer Sch Hlth Profess, Dept Nursing, Tel Aviv, Israel.
RP Fisher, S (corresponding author), Emek Med Ctr, Dermatol & Venerol Dept, Afula, Israel.
EM shanifisher@mail.tau.ac.il
CR [Anonymous], PEOPL WHO AR HIGH RI
   Carpenter SM, 2018, PSYCHOL HEALTH, V33, P58, DOI 10.1080/08870446.2017.1314478
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Herzinger T, 2016, J DTSCH DERMATOL GES, V14, P853, DOI [10.1111/ddg.12912, 10.1111/ddg.12912_g]
   Krenitsky A, 2020, CURR DERMATOL REP, V9, P10, DOI 10.1007/s13671-020-00290-6
   Lim HW, 2015, J AM ACAD DERMATOL, V72, P1078, DOI 10.1016/j.jaad.2015.03.017
   Mishel M H, 1999, Annu Rev Nurs Res, V17, P269
   Rademaker M, 2020, AUSTRALAS J DERMATOL, V61, P158, DOI 10.1111/ajd.13295
   Trahern J, 2020, PEDIAT EMERG MED REP, V25, P5
   Wright LJ, 2009, CURR PAIN HEADACHE R, V13, P133, DOI 10.1007/s11916-009-0023-z
NR 10
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-6634
EI 1471-1753
J9 J DERMATOL TREAT
JI J. Dermatol. Treat.
DI 10.1080/09546634.2020.1781043
EA JUN 2020
PG 3
WC Dermatology
SC Dermatology
GA ML7BR
UT WOS:000549617200001
PM 32586156
OA Bronze
DA 2021-01-01
ER

PT J
AU Barr, IG
   Rynehart, C
   Whitney, P
   Druce, J
AF Barr, Ian G.
   Rynehart, Cleve
   Whitney, Paul
   Druce, Julian
TI SARS-CoV-2 does not replicate in embryonated hen's eggs or in MDCK cell
   lines
SO EUROSURVEILLANCE
LA English
DT Article
ID INFLUENZA; CORONAVIRUS
AB The advent of COVID-19, has posed a risk that human respiratory samples containing human influenza viruses may also contain SARS-CoV-2. This potential risk may lead to SARS-CoV-2 contaminating conventional influenza vaccine production platforms as respiratory samples are used to directly inoculate embryonated hen's eggs and continuous cell lines that are used to isolate and produce influenza vaccines. We investigated the ability of these substrates to propagate SARS-CoV-2 and found that neither could support SARS-CoV-2 replication.
C1 [Barr, Ian G.; Rynehart, Cleve; Whitney, Paul] Peter Doherty Inst Infect & Immun, WHO Collaborating Ctr Reference & Res Influenza, Melbourne, Vic, Australia.
   [Barr, Ian G.; Whitney, Paul] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.
   [Barr, Ian G.] Federat Univ, Fac Sci & Technol, Gippsland, Vic, Australia.
   [Druce, Julian] Peter Doherty Inst Infect & Immun, Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia.
RP Barr, IG (corresponding author), Peter Doherty Inst Infect & Immun, WHO Collaborating Ctr Reference & Res Influenza, Melbourne, Vic, Australia.; Barr, IG (corresponding author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.; Barr, IG (corresponding author), Federat Univ, Fac Sci & Technol, Gippsland, Vic, Australia.
EM Ian.Barr@influenzacentre.org
FU Australian Government Department of HealthAustralian
   GovernmentDepartment of Health & Ageing
FX The authors would like to thank Rajeev Rudraraju and Francesca Mordant
   for provision of SARS-CoV-2 virus stock and Vero cells. The Melbourne
   WHO Collaborating Centre for Reference and Research on Influenza is
   supported by the Australian Government Department of Health.
CR Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Gregersen JP, 2008, VACCINE, V26, P3332, DOI 10.1016/j.vaccine.2008.03.075
   Hegde NR, 2015, HUM VACC IMMUNOTHER, V11, P1223, DOI 10.1080/21645515.2015.1016666
   Kaye M, 2006, EMERG INFECT DIS, V12, P128, DOI 10.3201/eid1201.050496
   Kim D, 2020, JAMA-J AM MED ASSOC, V323, P2085, DOI 10.1001/jama.2020.6266
   Lee JM, 2018, P NATL ACAD SCI USA, V115, pEB276, DOI 10.1073/pnas.1806133115
   Matrosovich M, 2003, J VIROL, V77, P8418, DOI 10.1128/JVI.77.15.8418-8425.2003
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Price OH, 2020, COMMUN DIS INTELL, V44, DOI 10.33321/cdi.2020.44.16
   Swayne DE, 2004, EMERG INFECT DIS, V10, P914, DOI 10.3201/eid1005.030827
   Takada K, 2019, NAT MICROBIOL, V4, P1268, DOI 10.1038/s41564-019-0433-6
   Trombetta CM, 2019, EXPERT REV VACCINES, V18, P737, DOI 10.1080/14760584.2019.1639503
NR 12
TC 2
Z9 1
U1 0
U2 0
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD JUN 25
PY 2020
VL 25
IS 25
AR 2001122
DI 10.2807/1560-7917.ES.2020.25.25.2001122
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA MJ5TL
UT WOS:000548152400002
PM 32613937
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Top, KA
   Macartney, K
   Bettinger, JA
   Tan, B
   Blyth, CC
   Marshall, HS
   Vaudry, W
   Halperin, SA
   McIntyre, P
AF Top, Karina A.
   Macartney, Kristine
   Bettinger, Julie A.
   Tan, Ben
   Blyth, Christopher C.
   Marshall, Helen S.
   Vaudry, Wendy
   Halperin, Scott A.
   McIntyre, Peter
CA IMPACT Investigator
   PAEDS Investigator
TI Active surveillance of acute paediatric hospitalisations demonstrates
   the impact of vaccination programmes and informs vaccine policy in
   Canada and Australia
SO EUROSURVEILLANCE
LA English
DT Article
ID IMMUNIZATION MONITORING PROGRAM; ACELLULAR PERTUSSIS-VACCINE;
   INFLUENZA-A; PANDEMIC INFLUENZA; SEASONAL INFLUENZA; VARICELLA VACCINE;
   FEBRILE SEIZURES; ADVERSE EVENTS; H1N1 2009; CHILDREN
AB Sentinel surveillance of acute hospitalisations in response to infectious disease emergencies such as the 2009 influenza A(H1N1)pdm09 pandemic is well described, but recognition of its potential to supplement routine public health surveillance and provide scalability for emergency responses has been limited. We summarise the achievements of two national paediatric hospital surveillance networks relevant to vaccine programmes and emerging infectious diseases in Canada (Canadian Immunization Monitoring Program Active; IMPACT from 1991) and Australia (Paediatric Active Enhanced Disease Surveillance; PAEDS from 2007) and discuss opportunities and challenges in applying their model to other contexts. Both networks were established to enhance capacity to measure vaccine preventable disease burden, vaccine programme impact, and safety, with their scope occasionally being increased with emerging infectious diseases' surveillance. Their active surveillance has increased data accuracy and utility for syndromic conditions (e.g. encephalitis), pathogen-specific diseases (e.g. pertussis, rotavirus, influenza), and adverse events following immunisation (e.g. febrile seizure), enabled correlation of biological specimens with clinical context and supported responses to emerging infections (e.g. pandemic influenza, parechovirus, COVID-19). The demonstrated long-term value of continuous, rather than incident-related, operation of these networks in strengthening routine surveillance, bridging research gaps, and providing scalable public health response, supports their applicability to other countries.
C1 [Top, Karina A.; Halperin, Scott A.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada.
   [Top, Karina A.; Halperin, Scott A.] IWK Hlth Ctr, Canadian Ctr Vaccinol, Halifax, NS, Canada.
   [Macartney, Kristine; McIntyre, Peter] Natl Ctr Immunisat Res & Surveillance, Sydney, NSW, Australia.
   [Macartney, Kristine; McIntyre, Peter] Childrens Hosp Westmead, Sydney, NSW, Australia.
   [Macartney, Kristine; McIntyre, Peter] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.
   [Bettinger, Julie A.] Univ British Columbia, Vancouver, BC, Canada.
   [Bettinger, Julie A.] British Columbia Childrens Hosp, Vaccine Evaluat Ctr, Vancouver, BC, Canada.
   [Tan, Ben] Univ Saskatchewan, Royal Univ Hosp, Saskatoon, SK, Canada.
   [Blyth, Christopher C.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia.
   [Blyth, Christopher C.] Univ Western Australia, Sch Med, Perth, WA, Australia.
   [Blyth, Christopher C.] Perth Childrens Hosp, Perth, WA, Australia.
   [Marshall, Helen S.] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia.
   [Marshall, Helen S.] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia.
   [Marshall, Helen S.] VIRTU Womens & Childrens Hlth Network, Adelaide, SA, Australia.
   [Vaudry, Wendy] Univ Alberta, Stollery Childrens Hosp, Edmonton, AB, Canada.
RP Top, KA (corresponding author), Dalhousie Univ, Dept Pediat, Halifax, NS, Canada.; Top, KA (corresponding author), IWK Hlth Ctr, Canadian Ctr Vaccinol, Halifax, NS, Canada.; Macartney, K (corresponding author), Natl Ctr Immunisat Res & Surveillance, Sydney, NSW, Australia.; Macartney, K (corresponding author), Childrens Hosp Westmead, Sydney, NSW, Australia.; Macartney, K (corresponding author), Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.
EM karina.top@dal.ca; Kristine.macartney@health.nsw.gov.au
RI Blyth, Christopher/ABG-8231-2020
OI Blyth, Christopher/0000-0003-2017-0683; Top, Karina/0000-0002-9981-368X
FU Australian Government Department of HealthAustralian
   GovernmentDepartment of Health & Ageing; Australian Government
   Department of Health, via the Influenza Complications Alert Network
   (FluCAN); NHMRCNational Health and Medical Research Council of Australia
   [1113851]; NHMRCNational Health and Medical Research Council of
   Australia
FX The Canadian Immunization Monitoring Program Active (IMPACT) is a
   national surveillance initiative managed by the Canadian Paediatric
   Society and conducted by the IMPACT network of paediatric investigators
   on behalf of the Public Health Agency of Canada's Centre for
   Immunization and Respiratory Infectious Diseases. The Paediatric Active
   Enhanced Disease Surveillance (PAEDS) network is coordinated by the
   National Centre for Immunisation Research and Surveillance (NCIRS) and
   receives funding from the Australian Government Department of Health,
   and participating state and territory departments of health in Western
   Australia, South Australia, Victoria, New South Wales, Queensland and
   Northern Territory. Funding for work on influenza is received in part
   from the Australian Government Department of Health, via the Influenza
   Complications Alert Network (FluCAN) and from NHMRC Partnership Grant
   (#1113851). Funding from the NHMRC has also contributed to surveillance
   and studies of other PAEDS conditions.
CR Abu-Raya B, 2020, J PEDIAT INF DIS SOC, V9, P118, DOI 10.1093/jpids/piy128
   Ahmadipour N, 2018, Can Commun Dis Rep, V44, P206, DOI 10.14745/ccdr.v44i09a04
   [Anonymous], 2014, Wkly Epidemiol Rec, V89, P545
   Baum U, 2020, CLIN INFECT DIS, V71, pE255, DOI 10.1093/cid/ciaa050
   Beard FH, 2019, MED J AUSTRALIA, V210, P484, DOI 10.5694/mja2.50141
   Bettinger J, 2016, PAEDIAT CHILD HLTH, V21, P274
   Bettinger JA, 2007, PEDIATR INFECT DIS J, V26, P31, DOI 10.1097/01.inf.0000247055.81541.04
   Bettinger JA, 2013, VACCINE, V32, P124, DOI 10.1016/j.vaccine.2013.03.063
   Bettinger JA, 2010, VACCINE, V28, P3180, DOI 10.1016/j.vaccine.2010.02.044
   Bettinger JA, 2010, VACCINE, V28, P2130, DOI 10.1016/j.vaccine.2009.12.026
   Blyth CC, 2016, EUROSURVEILLANCE, V21, P25, DOI 10.2807/1560-7917.ES.2016.21.30.30301
   Blyth CC, 2019, CLIN INFECT DIS, V68, P940, DOI 10.1093/cid/ciy597
   Bravo-Alcantara P, 2018, VACCINE, V36, P363, DOI 10.1016/j.vaccine.2017.04.069
   Britton PN, 2016, EPIDEMIOL INFECT, V144, P2117, DOI 10.1017/S0950268816000340
   Britton PN, 2017, CLIN INFECT DIS, V65, P653, DOI [10.1093/clinid/cix412, 10.1093/cid/cix412]
   Britton PN, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2848
   Burton C, 2014, PEDIATR INFECT DIS J, V33, P710, DOI 10.1097/INF.0000000000000272
   Buttery JP, 2011, VACCINE, V29, P3061, DOI 10.1016/j.vaccine.2011.01.088
   Carlin JB, 2013, CLIN INFECT DIS, V57, P1427, DOI 10.1093/cid/cit520
   Cheng AC, 2017, COMMUN DIS INTELL, V41, pE337
   Cheng AC, 2017, CLIN INFECT DIS, V64, P1564, DOI 10.1093/cid/cix209
   Tran D, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4643
   Deeks SL, 2005, PEDIATR INFECT DIS J, V24, P538, DOI 10.1097/01.inf.0000164769.22033.2c
   Deng L, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-2120
   Dodd CN, 2013, VACCINE, V31, P4448, DOI 10.1016/j.vaccine.2013.06.032
   Gibney KB, 2017, LANCET INFECT DIS, V17, P86, DOI 10.1016/S1473-3099(16)30309-7
   Gostin LO, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002042
   Halperin SA, 1999, CLIN INFECT DIS, V28, P1238, DOI 10.1086/514792
   Hasan AZ, 2018, VACCINE, V36, P4939, DOI 10.1016/j.vaccine.2018.06.001
   Helmuth IG, 2017, PEDIATR INFECT DIS J, V36, P31, DOI 10.1097/INF.0000000000001347
   Hirve S, 2020, INFLUENZA OTHER RESP, V14, P647, DOI 10.1111/irv.12688
   Hviid A, 2019, ANN INTERN MED, V170, P513, DOI 10.7326/M18-2101
   Jadavji T, 2003, PEDIATR INFECT DIS J, V22, P119
   Khandaker G, 2014, INFLUENZA OTHER RESP, V8, P636, DOI 10.1111/irv.12286
   Khandaker G, 2012, NEUROLOGY, V79, P1474, DOI 10.1212/WNL.0b013e31826d5ea7
   Khandaker G, 2011, EMERG INFECT DIS, V17, P1960, DOI 10.3201/eid1710.101670
   Kissling E, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.7.30464
   Law B, 2000, PEDIATR INFECT DIS J, V19, P1053, DOI 10.1097/00006454-200011000-00005
   Le Saux N, 2003, PEDIATRICS, V112, pE348, DOI 10.1542/peds.112.5.e348
   Le Saux N, 2016, CAN IMM C 2016 OTT O
   Le Saux N, 2010, PEDIATR INFECT DIS J, V29, P879, DOI 10.1097/INF.0b013e3181e20c94
   Li-Kim-Moy J, 2017, EPIDEMIOL INFECT, V145, P1451, DOI 10.1017/S0950268816003381
   Macartney K, 2017, JAMA PEDIATR, V171, P992, DOI 10.1001/jamapediatrics.2017.1965
   Macartney KK, 2015, VACCINE, V33, P1412, DOI 10.1016/j.vaccine.2014.10.071
   Marshall HS, 2019, J INFECT DIS, V219, P391, DOI 10.1093/infdis/jiy518
   Marshall HS, 2013, PEDIATR INFECT DIS J, V32, P530, DOI 10.1097/INF.0b013e31827e92b7
   McConnell A, 2007, PEDIATR INFECT DIS J, V26, P1025, DOI 10.1097/INF.0b013e31812f4f5b
   McNair J, 2018, PEDIATR INFECT DIS J, V37, P726, DOI 10.1097/INF.0000000000001850
   McRae JE, 2019, COMMUN DIS INTELL, V43, DOI 10.33321/cdi.2019.43.5
   Merdrignac L, 2017, P ESPID 2017 C 2017
   Mursalova N, 2018, VACCINE, V36, P7790, DOI 10.1016/j.vaccine.2018.02.045
   Paediatric Active Enhanced Disease Surveillance (PAEDS), 2020, COVID 19 KAW DIS KD
   Paterson BJ, 2013, COMMUN DIS INTELL, V37, pE149
   Quinn HE, 2018, PUBL HLTH ASS AUSTR
   Quinn HE, 2019, J INFECTION, V78, P220, DOI 10.1016/j.jinf.2018.11.009
   Sadarangani M, 2014, CLIN INFECT DIS, V59, P1208, DOI 10.1093/cid/ciu597
   Sauve LJ, 2010, PEDIATR INFECT DIS J, V29, P559, DOI 10.1097/INF.0b013e3181d2bb45
   Scheifele D, 1998, Can Commun Dis Rep, V24, P69
   Scheifele D, 1998, CAN COMMUN DIS REP, V24, P73
   Scheifele David W, 2003, Semin Pediatr Infect Dis, V14, P213, DOI 10.1016/S1045-1870(03)00036-0
   Scheifele DW, 1996, CAN MED ASSOC J, V154, P1041
   Sullivan SG, 2015, SUMMARY INFLUENZA SU
   Tan B., 2016, CAN IMM C OTT ONT
   Tan B, 2018, CAN PAED SOC ANN M Q
   Tan B, 2012, PEDIATR INFECT DIS J, V31, P956, DOI 10.1097/INF.0b013e318260cc4d
   Tate JE, 2018, NEW ENGL J MED, V378, P1521, DOI [10.1056/NEJMoa1713909, 10.1056/nejmoa1713909]
   Thielemans E, 2020, PEDIATR INFECT DIS J, V39, P379, DOI 10.1097/INF.0000000000002596
   Thomson G, 2010, EUROSURVEILLANCE, V15, P15, DOI [10.2807/ese.15.49.19745-en, DOI 10.2807/ESE.15.49.19745-EN]
   Tran D, 2012, PEDIATRICS, V130, P397, DOI 10.1542/peds.2011-3216
   Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369
NR 70
TC 0
Z9 0
U1 2
U2 2
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD JUN 25
PY 2020
VL 25
IS 25
AR 1900562
DI 10.2807/1560-7917.ES.2020.25.25.1900562
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA MJ5TL
UT WOS:000548152400005
PM 32613939
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Torneri, A
   Libin, P
   Vanderlocht, J
   Vandamme, AM
   Neyts, J
   Hens, N
AF Torneri, Andrea
   Libin, Pieter
   Vanderlocht, Joris
   Vandamme, Anne-Mieke
   Neyts, Johan
   Hens, Niel
TI A prospect on the use of antiviral drugs to control local outbreaks of
   COVID-19
SO BMC MEDICINE
LA English
DT Article
ID THERAPEUTIC-EFFICACY; REMDESIVIR; DYNAMICS; VIRUS; CHINA
AB Background: Current outbreaks of COVID-19 are threatening the health care systems of several countries around the world. Control measures, based on isolation, contact tracing, and quarantine, can decrease and delay the burden of the ongoing epidemic. With respect to the ongoing COVID-19 epidemic, recent modeling work shows that these interventions may be inadequate to control local outbreaks, even when perfect isolation is assumed. The effect of infectiousness prior to symptom onset combined with asymptomatic infectees further complicates the use of contact tracing. We aim to study whether antivirals, which decrease the viral load and reduce infectiousness, could be integrated into control measures in order to augment the feasibility of controlling the epidemic.
   Methods: Using a simulation-based model of viral transmission, we tested the efficacy of different intervention measures to control local COVID-19 outbreaks. For individuals that were identified through contact tracing, we evaluate two procedures: monitoring individuals for symptoms onset and testing of individuals. Additionally, we investigate the implementation of an antiviral compound combined with the contact tracing process.
   Results: For an infectious disease in which asymptomatic and presymptomatic infections are plausible, an intervention measure based on contact tracing performs better when combined with testing instead of monitoring, provided that the test is able to detect infections during the incubation period. Antiviral drugs, in combination with contact tracing, quarantine, and isolation, result in a significant decrease of the final size and the peak incidence, and increase the probability that the outbreak will fade out.
   Conclusion: In all tested scenarios, the model highlights the benefits of control measures based on the testing of traced individuals. In addition, the administration of an antiviral drug, together with quarantine, isolation, and contact tracing, is shown to decrease the spread of the epidemic. This control measure could be an effective strategy to control local and re-emerging outbreaks of COVID-19.
C1 [Torneri, Andrea; Hens, Niel] Univ Antwerp, Ctr Hlth Econ Res & Modelling Infect Dis, Antwerp, Belgium.
   [Libin, Pieter; Vanderlocht, Joris; Hens, Niel] Hasselt Univ, Interuniv Inst Biostatist & Stat Bioinformat, Data Sci Inst, Hasselt, Belgium.
   [Libin, Pieter] Vrije Univ Brussel, Dept Comp Sci, Artificial Intelligence Lab, Brussels, Belgium.
   [Libin, Pieter; Vandamme, Anne-Mieke; Neyts, Johan] KU Leuven Univ Leuven, Rega Inst Med Res Clin & Epidemiol Virol, Dept Microbiol & Immunol, Leuven, Belgium.
   [Vandamme, Anne-Mieke] Univ Nova Lisboa, Inst Higiene & Med Trop, Ctr Global Hlth & Trop Med, Unidade Microbiol, Lisbon, Portugal.
RP Hens, N (corresponding author), Univ Antwerp, Ctr Hlth Econ Res & Modelling Infect Dis, Antwerp, Belgium.; Hens, N (corresponding author), Hasselt Univ, Interuniv Inst Biostatist & Stat Bioinformat, Data Sci Inst, Hasselt, Belgium.
EM niel.hens@uhasselt.be
RI NEYTS, Johan/U-8267-2017
OI NEYTS, Johan/0000-0002-0033-7514
FU EpiPose project from the European Union's SC1-PHE-CORONAVIRUS-2020
   programme [101003688]; European Union's Horizon 2020 research and
   innovation programme [682540, 101003627]; University of Antwerp; Flemish
   Government under the "Onderzoeksprogramma Artificiele Intelligentie (AI)
   Vlaanderen" programme; Stichting Antoine Faes
FX This work is funded by the EpiPose project from the European Union's
   SC1-PHE-CORONAVIRUS-2020 programme, project number 101003688, by the
   European Union's Horizon 2020 research and innovation programme (grant
   agreement 682540-TransMID), the European Union's Horizon 2020 research
   and innovation program under grant agreement no. 101003627 (SCORE
   project), and the Stichting Antoine Faes. A.T. acknowledges support from
   the special research fund of the University of Antwerp. P.L. was
   supported by funding from the Flemish Government under the
   "Onderzoeksprogramma Artificiele Intelligentie (AI) Vlaanderen"
   programme.
CR [Anonymous], 2020, NY TIMES
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P6971, DOI 10.1073/pnas.94.13.6971
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Flahault A, 2020, LANCET, V395, P947, DOI 10.1016/S0140-6736(20)30521-3
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Ganyani T, 2020, EUROSURVEILLANCE, V25, P12, DOI 10.2807/1560-7917.ES.2020.25.17.2000257
   Gompertz B., 1825, PHILOS T ROY SOC LON, V115, P513, DOI [10.1098/RSTL.1825.0026, DOI 10.1098/RSTL.1825.0026]
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Klinkenberg D, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000012
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Malthus TR, 1992, MALTHUS ESSAY PRINCI
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   Nishiura H, 2020, INT J INFECT DIS
   Norrie JD, 2020, LANCET, V395, P1525, DOI 10.1016/S0140-6736(20)31023-0
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Rhodes PH, 1996, J ROY STAT SOC B MET, V58, P751
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Svensson A, 2007, MATH BIOSCI, V208, P300, DOI 10.1016/j.mbs.2006.10.010
   Tian HY, 2020, SCIENCE, V368, P638, DOI 10.1126/science.abb6105
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Willem L, 2020, SOCRATES ONLINE TOOL, DOI [10.1101/2020.03.03.20030627, DOI 10.1101/2020.03.03.20030627]
   World Health Organization, COR DIS 2019 COVID 1
   Zhang J, 2020, LANCET, DOI [10.1016/S1473-3099(20)30230-9, DOI 10.1016/S1473-3099(20)30230-9]
   Zhou P, 2020, NATURE, DOI [10.1038/s41586-0202012-7, DOI 10.1038/S41586-0202012-7]
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 36
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD JUN 25
PY 2020
VL 18
IS 1
AR 191
DI 10.1186/s12916-020-01636-4
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA MF9UY
UT WOS:000545683800002
PM 32586336
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kim, J
   Zhang, J
   Cha, Y
   Kolitz, S
   Funt, J
   Chong, RE
   Barrett, S
   Kusko, R
   Zeskind, B
   Kaufman, H
AF Kim, Jason
   Zhang, Jenny
   Cha, Yoonjeong
   Kolitz, Sarah
   Funt, Jason
   Escalante Chong, Renan
   Barrett, Scott
   Kusko, Rebecca
   Zeskind, Ben
   Kaufman, Howard
TI Advanced bioinformatics rapidly identifies existing therapeutics for
   patients with coronavirus disease-2019 (COVID-19)
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Artificial intelligence; Bioinformatics; Computational Biology;
   Coronavirus; Drug therapy
ID GENE-EXPRESSION; VIRUS; INHIBITORS; PROTEIN; SPIKE; RECEPTOR; DRUG; ACE
AB Background The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by Coronavirus disease-2019 (COVID-19). Methods We applied two computational approaches to identify potential therapeutics. First, we sought to identify existing FDA approved drugs that could block coronaviruses from entering cells by binding to ACE2 or TMPRSS2 using a high-throughput AI-based binding affinity prediction platform. Second, we sought to identify FDA approved drugs that could attenuate the gene expression patterns induced by coronaviruses, using our Disease Cancelling Technology (DCT) platform. Results Top results for ACE2 binding iincluded several ACE inhibitors, a beta-lactam antibiotic, two antiviral agents (Fosamprenavir and Emricasan) and glutathione. The platform also assessed specificity for ACE2 over ACE1, important for avoiding counterregulatory effects. Further studies are needed to weigh the benefit of blocking virus entry against potential counterregulatory effects and possible protective effects of ACE2. However, the data herein suggest readily available drugs that warrant experimental evaluation to assess potential benefit. DCT was run on an animal model of SARS-CoV, and ranked compounds by their ability to induce gene expression signals that counteract disease-associated signals. Top hits included Vitamin E, ruxolitinib, and glutamine. Glutathione and its precursor glutamine were highly ranked by two independent methods, suggesting both warrant further investigation for potential benefit against SARS-CoV-2. Conclusions While these findings are not yet ready for clinical translation, this report highlights the potential use of two bioinformatics technologies to rapidly discover existing therapeutic agents that warrant further investigation for established and emerging disease processes.
C1 [Kim, Jason; Zhang, Jenny; Cha, Yoonjeong; Kolitz, Sarah; Funt, Jason; Escalante Chong, Renan; Barrett, Scott; Kusko, Rebecca; Zeskind, Ben; Kaufman, Howard] Immuneering Corp, 245 Main St, Cambridge, MA 02142 USA.
RP Kusko, R (corresponding author), Immuneering Corp, 245 Main St, Cambridge, MA 02142 USA.
EM bkusko@immuneering.com
FU Immuneering Corporation
FX Immuneering Corporation funded this work.
CR Bazzino O, 1998, NEW ENGL J MED, V338, P1498
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Boheemen S, 2012, MBIO, V3
   BRADBURNE AF, 1967, BMJ-BRIT MED J, V3, P767, DOI 10.1136/bmj.3.5568.767
   Braselmann S, 2006, J PHARMACOL EXP THER, V319, P998, DOI 10.1124/jpet.106.109058
   Causer AJ, 2020, REDOX BIOL, V32, DOI 10.1016/j.redox.2020.101436
   Ciofu O, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007020.pub4
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   De Groot-Besseling RRJ, 2004, INT J CANCER, V112, P329, DOI 10.1002/ijc.20400
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Gin A, 2007, EXPERT REV ANTI-INFE, V5, P365, DOI 10.1586/14787210.5.3.365
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harrison C, 2014, J CELL COMMUN SIGNAL, V8, P195, DOI 10.1007/s12079-014-0236-8
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   JEONG YS, 1994, J VIROL, V68, P2615, DOI 10.1128/JVI.68.4.2615-2623.1994
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kusko R, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0259-3
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lewis BE, 1997, SEMIN THROMB HEMOST, V23, P197, DOI 10.1055/s-2007-996091
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Liu DL, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0512-1
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Matsushita K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051407
   Mudaliar S, 2015, DIABETES CARE, V38, P2344, DOI 10.2337/dc15-0642
   PALAMARA AT, 1995, ANTIVIR RES, V27, P237, DOI 10.1016/0166-3542(95)00008-A
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Pockros PJ, 2007, HEPATOLOGY, V46, P324, DOI 10.1002/hep.21664
   Rico-Mesa JS, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01291-4
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Sommerstein R, 2020, RE PREVENTING COVID
   Sunaga Y, 2001, EUR J PHARMACOL, V431, P119, DOI 10.1016/S0014-2999(01)01412-1
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Ujike M, 2015, VIRUSES-BASEL, V7, P1700, DOI 10.3390/v7041700
   Ung M, 2018, SESSION PO TB04 03 M
   Ung M, 2018, SESSION PO MCB04 06
   Uusitupa M, 1999, CURR OPIN LIPIDOL, V10, P3, DOI 10.1097/00041433-199902000-00002
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Yang M, 2019, DRUGS, V79, P515, DOI 10.1007/s40265-019-01078-0
   Zhao L, 2012, CELL HOST MICROBE, V11, P607, DOI 10.1016/j.chom.2012.04.011
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zisman LS, 2005, EUR HEART J, V26, P322, DOI 10.1093/eurheartj/ehi043
NR 45
TC 7
Z9 7
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JUN 25
PY 2020
VL 18
IS 1
AR 257
DI 10.1186/s12967-020-02430-9
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MG0VZ
UT WOS:000545754100001
PM 32586380
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Grifoni, A
   Weiskopf, D
   Ramirez, SI
   Mateus, J
   Dan, JM
   Moderbacher, CR
   Rawlings, SA
   Sutherland, A
   Premkumar, L
   Jadi, RS
   Marrama, D
   de Silva, AM
   Frazier, A
   Carlin, AF
   Greenbaum, JA
   Peters, B
   Krammer, F
   Smith, DM
   Crotty, S
   Sette, A
AF Grifoni, Alba
   Weiskopf, Daniela
   Ramirez, Sydney, I
   Mateus, Jose
   Dan, Jennifer M.
   Moderbacher, Carolyn Rydyznski
   Rawlings, Stephen A.
   Sutherland, Aaron
   Premkumar, Lakshmanane
   Jadi, Ramesh S.
   Marrama, Daniel
   de Silva, Aravinda M.
   Frazier, April
   Carlin, Aaron F.
   Greenbaum, Jason A.
   Peters, Bjoern
   Krammer, Florian
   Smith, Davey M.
   Crotty, Shane
   Sette, Alessandro
TI Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with
   COVID-19 Disease and Unexposed Individuals
SO CELL
LA English
DT Article
ID FOLLICULAR HELPER-CELLS; ANTIBODY-RESPONSES; SARS-CORONAVIRUS;
   PROTECTION; INFLUENZA; VACCINES; INFECTION; IMMUNITY; MEMORY; SHARE
AB Understanding adaptive immunity to SARS-CoV-2 is important for vaccine development, interpreting coronavirus disease 2019 (COVID-19) pathogenesis, and calibration of pandemic control measures. Using HLA class I and II predicted peptide "megapools," circulating SARS-CoV-2-specific CD8(+) and CD4(+) T cells were identified in similar to 70% and 100% of COVID-19 convalescent patients, respectively. CD4(+) T cell responses to spike, the main target of most vaccine efforts, were robust and correlated with the magnitude of the antiSARS-CoV-2 IgG and IgA titers. The M, spike, and N proteins each accounted for 11%-27% of the total CD4(+) response, with additional responses commonly targeting nsp3, nsp4, ORF3a, and ORF8, among others. For CD8(+) T cells, spike and M were recognized, with at least eight SARS-CoV-2 ORFs targeted. Importantly, we detected SARS-CoV-2-reactive CD4(+) T cells in similar to 40%-60% of unexposed individuals, suggesting cross-reactive T cell recognition between circulating "common cold" coronaviruses and SARS-CoV-2.
C1 [Grifoni, Alba; Weiskopf, Daniela; Ramirez, Sydney, I; Mateus, Jose; Dan, Jennifer M.; Moderbacher, Carolyn Rydyznski; Sutherland, Aaron; Marrama, Daniel; Frazier, April; Greenbaum, Jason A.; Peters, Bjoern; Crotty, Shane; Sette, Alessandro] La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, La Jolla, CA 92037 USA.
   [Ramirez, Sydney, I; Dan, Jennifer M.; Rawlings, Stephen A.; Carlin, Aaron F.; Peters, Bjoern; Smith, Davey M.; Crotty, Shane; Sette, Alessandro] Univ Calif San Diego, Dept Med, Div Infect Dis & Global Publ Hlth, La Jolla, CA 92037 USA.
   [Premkumar, Lakshmanane; Jadi, Ramesh S.; de Silva, Aravinda M.] Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27599 USA.
   [Krammer, Florian] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
RP Crotty, S; Sette, A (corresponding author), La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, La Jolla, CA 92037 USA.; Crotty, S; Sette, A (corresponding author), Univ Calif San Diego, Dept Med, Div Infect Dis & Global Publ Hlth, La Jolla, CA 92037 USA.
EM shane@lji.org; alex@lji.org
RI Jadi, Ramesh/AAV-2059-2020; Krammer, Florian/H-3237-2019; desilva,
   Aravinda/ABE-6260-2020; Rawlings, Stephen/ABA-6797-2020
OI Jadi, Ramesh/0000-0002-5710-4893; Krammer, Florian/0000-0003-4121-776X;
   desilva, Aravinda/0000-0003-3317-5950; Rawlings,
   Stephen/0000-0003-3637-1447; Ramirez, Sydney/0000-0002-7166-5195
FU Departamento Administrativo de Ciencia, Tecnologia e Innovacion
   (COLCIENCIAS)Departamento Administrativo de Ciencia, Tecnologia e
   Innovacion Colciencias; Pontificia Universidad Javeriana; NIH
   NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI42742]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [75N9301900065, U19 AI118626]; Bill and
   Melinda Gates FoundationBill & Melinda Gates Foundation; LJI
   Institutional Funds; Johnathan and Mary Tu Foundation; NIAIDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [AI135078]; UCSD Infectious Diseases Division [T32
   AI007036, T32 AI007384]
FX We would like to thank Cheryl Kim, director of the LJI flow cytometry
   core facility for outstanding expertise. We thank Prof. Peter Kim,
   Abigail Powell, PhD, and colleagues (Stanford) for RBD protein
   synthesized from Prof. Florian Krammer (Mt. Sinai) constructs. J.M. was
   supported by PhD student fellowships from the Departamento
   Administrativo de Ciencia, Tecnologia e Innovacion (COLCIENCIAS), and
   Pontificia Universidad Javeriana. This work was funded by the NIH NIAID
   under awards AI42742 (Cooperative Centers for Human Immunology) (S.C.
   and A.S.), National Institutes of Health contract Nr. 75N9301900065
   (A.S. and D.W.), and U19 AI118626 (A.S. and B.P.). The BD FACSymphony
   purchase was partially funded by the Bill and Melinda Gates Foundation
   and LJI Institutional Funds (S.C. and A.S.). This work was additionally
   supported in part by the Johnathan and Mary Tu Foundation (D.M.S.), the
   NIAID under K08 award AI135078 (J.D.), and UCSD T32s AI007036 and
   AI007384 Infectious Diseases Division (S.I.R. and S.A.R.).
CR Alshukairi AN, 2018, MBIO, V9, DOI [10.1128/mbio.01985-18, 10.1128/mBio.01985-18]
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Andrews SF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0522
   Antunes RDS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169086
   Arlehamn CSL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005760
   Bancroft T, 2016, CELL IMMUNOL, V304, P35, DOI 10.1016/j.cellimm.2016.05.002
   Blanco-Melo D., 2020, BIORXIV, DOI [10.1101/2020.03.24.004655, DOI 10.1101/2020.03.24.004655]
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Pro SC, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/763461
   Choe PG, 2017, EMERG INFECT DIS, V23, P1079, DOI 10.3201/eid2307.170310
   Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011
   Dan JM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau3776
   Dan JM, 2016, J IMMUNOL, V197, P983, DOI 10.4049/jimmunol.1600318
   Dhanda SK, 2019, NUCLEIC ACIDS RES, V47, pW502, DOI 10.1093/nar/gkz452
   Dhanda SK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01369
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Gorse GJ, 2010, CLIN VACCINE IMMUNOL, V17, P1875, DOI 10.1128/CVI.00278-10
   Gostic KM, 2016, SCIENCE, V354, P722, DOI 10.1126/science.aag1322
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Greenbaum JA, 2009, P NATL ACAD SCI USA, V106, P20365, DOI 10.1073/pnas.0911580106
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Grifoni A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01309
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Guo X., 2020, LONG TERM PERSISTENC, DOI [10.1101/2020.02.12.20021386, DOI 10.1101/2020.02.12.20021386]
   Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453
   Havenar-Daughton C, 2016, J IMMUNOL, V197, P994, DOI 10.4049/jimmunol.1600320
   Herati RS, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag2152
   Hinz D, 2016, CLIN EXP ALLERGY, V46, P705, DOI 10.1111/cea.12692
   Huang A.T., 2020, SYSTEMATIC REV ANTIB
   Irigoyen N, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005473
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Kissler SM, 2020, SCIENCE, DOI DOI 10.1101/2020.03.04.20031112
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Morou A, 2019, NAT IMMUNOL, V20, P1059, DOI 10.1038/s41590-019-0418-x
   Moutaftsi M, 2010, FUTURE MICROBIOL, V5, P221, DOI 10.2217/FMB.09.110
   Okba NMA, 2019, EMERG INFECT DIS, V25, P1868, DOI [10.3201/eid2509.190051, 10.3201/eid2510.190051]
   OSULLIVAN D, 1991, J IMMUNOL, V147, P2663
   Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12
   Paul S, 2015, J IMMUNOL METHODS, V422, P28, DOI 10.1016/j.jim.2015.03.022
   Peeples L, 2020, P NATL ACAD SCI USA, V117, P8218, DOI 10.1073/pnas.2005456117
   Reiss S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186998
   Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008
   Sette A, 2008, IMMUNITY, V28, P847, DOI 10.1016/j.immuni.2008.04.018
   Severance EG, 2008, CLIN VACCINE IMMUNOL, V15, P1805, DOI 10.1128/CVI.00124-08
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   Sidney J, 2010, J IMMUNOL, V185, P4189, DOI 10.4049/jimmunol.1001006
   Sidney J, 2010, J IMMUNOL, V184, P2492, DOI 10.4049/jimmunol.0903655
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tian Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02125
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Weiskopf D, 2015, J INFECT DIS, V212, P1743, DOI 10.1093/infdis/jiv289
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
   Zhao JC, 2011, J CLIN INVEST, V121, P4921, DOI 10.1172/JCI59777
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhao JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000636
   Zhao JX, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5393
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 70
TC 316
Z9 311
U1 102
U2 103
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JUN 25
PY 2020
VL 181
IS 7
BP 1489
EP +
DI 10.1016/j.cell.2020.05.015
PG 28
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MD2SA
UT WOS:000543822100009
PM 32473127
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Kosior, DA
   Undas, A
   Kopec, G
   Hryniewiecki, T
   Torbicki, A
   Mularek-Kubzdela, T
   Windygas, J
   Pruszczyk, P
AF Kosior, Dariusz A.
   Undas, Anetta
   Kopec, Grzegorz
   Hryniewiecki, Tomasz
   Torbicki, Adam
   Mularek-Kubzdela, Tatiana
   Windygas, Jerzy
   Pruszczyk, Piotr
TI Guidance for anticoagulation management in venous thromboembolism during
   the coronavirus disease 2019 pandemic in Poland An expert opinion of the
   Section on Pulmonary Circulation of the Polish Cardiac Society
SO KARDIOLOGIA POLSKA
LA English
DT Article
DE anticoagulation; coagulation abnormalities; coronavirus disease 2019;
   prophylaxis; venous thromboembolism
AB The coronavirus disease 2019 (COVID-19) pandemic affects anticoagulation not only in those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) but also in most patients who require daily anticoagulant therapy and are facing substantial limitations in medical care these days. Concomitantvenous thromboembolism (VTE), a potential cause of unexplained deaths, has frequently been reported in patients with COVID-19, but its management is still challenging due to the complexity between antithrombotic therapy and hematological alterations. In the era of COVID-19 pandemic, it is highly recommended for patients who require chronic anticoagulation to continue therapy to prevent thromboembolic events. To avoid regular and frequent blood tests and unnecessary exposure to SARS-CoV-2 during contacts with medical personnel, direct oral anticoagulants should be strongly preferred whenever possible. Current evidence is insufficient to recommend routine pharmacological antithrombotic prophylaxis in all hospitalized patients with COVID-19. In patients with COVID-19 who are suspected of VTE or in whom the diagnosis is confirmed, parentera I therapy with low-molecular-weight heparin should be initiated in the absence of contraindications. If heparin-induced thrombocytopenia is suspected, nonheparin anticoagulants should be used such as bivalirudin or fondaparinux. In case of confirmed acute pulmonary embolism, treatment should be guided by risk stratification as defined in the current guidelines.
C1 [Kosior, Dariusz A.] Polish Acad Sci, Mossakowski Med Res Ctr, Warsaw, Poland.
   [Kosior, Dariusz A.] Minist Interior & Adm, Dept Cardiol & Hypertens, Electrophysiol Lab, Cent Clin Hosp, Ul Woloska 137, PL-02507 Warsaw, Poland.
   [Undas, Anetta] Jagiellonian Univ Med Coll, Inst Cardiol, Krakow, Poland.
   [Kopec, Grzegorz] Jagiellonian Univ Med Coll, Dept Cardiac & Vasc Dis, John Paul II Hosp, Krakow, Poland.
   [Hryniewiecki, Tomasz] Inst Cardiol, Dept Acquired Cardiac Defect, Warsaw, Poland.
   [Torbicki, Adam] ECZ Otwock, European Hlth Ctr, Dept Pulm Circulat & Thromboembol Dis & Cardiol, Ctr Postgrad Med Educ, Otwock, Poland.
   [Mularek-Kubzdela, Tatiana] Poznan Univ Med Sci, Dept Cardiol 1, Poznan, Poland.
   [Windygas, Jerzy] Inst Hematol & Transfus Med, Lab Hemostasis & Metab Dis, Dept Hemostasis Disorders & Internal Med, Warsaw, Poland.
   [Pruszczyk, Piotr] Med Univ Warsaw, Dept Internal Med & Cardiol, Warsaw, Poland.
RP Kosior, DA (corresponding author), Minist Interior & Adm, Dept Cardiol & Hypertens, Electrophysiol Lab, Cent Clin Hosp, Ul Woloska 137, PL-02507 Warsaw, Poland.
EM dariusz.kosior@cskmswia.pl
OI Kopec, Grzegorz/0000-0001-9921-2801
CR Ao X, 2020, J MOL MED, V98, P1055, DOI 10.1007/s00109-020-01934-7
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bikdeli B., 2020, J AM COLL CARDIOL
   Danzi GB, 2020, EUR HEART J
   Fan BE, 2020, AM J HEMATOL
   Han H, 2020, CLIN CHEM LAB MED
   Harzallah I, 2020, J THROMB HAEMOST, V18, P2064, DOI 10.1111/jth.14867
   Klok FA, 2020, THROMB RES
   Konstantinides SV, 2020, EUR HEART J, V41, P543, DOI 10.1093/eurheartj/ehz405
   Lippi G, 2020, CLIN CHEM LAB MED
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Middeldorp S, 2020, J THROMB HAEMOST
   National Health Service, 2020, CLIN GUID MAN ANT SE
   Olsen NJ, 2013, SEMIN ARTHRITIS RHEU, V43, P264, DOI 10.1016/j.semarthrit.2013.01.001
   Steffel J, 2018, KARDIOL POL, V76, P1283, DOI 10.5603/KP.2018.0180
   Valgimigli M, 2018, EUR HEART J, V39, P213, DOI 10.1093/eurheartj/ehx419
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Xie Y, 2020, RADIOL CARDIOTHORAC, V2, pe200067, DOI [10.1148/ryct.2020200067, DOI 10.1148/RYCT.2020200067]
   Zhai Z, 2020, THROMB HAEMOST
NR 20
TC 2
Z9 2
U1 2
U2 2
PU POLSKIE TOWARZYSTOWO KARDIOLOGICZNE
PI WARSZAWA
PA UL STAWKI 3 A LOK 1-2, WARSZAWA, POLAND
SN 0022-9032
EI 1897-4279
J9 KARDIOL POL
JI Kardiol. Pol.
PD JUN 25
PY 2020
VL 78
IS 6
BP 642
EP 646
DI 10.33963/KP.15425
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MD5KJ
UT WOS:000544009700034
PM 32515570
OA Bronze
DA 2021-01-01
ER

PT J
AU Mehra, MR
   Desai, SS
   Kuy, S
   Henry, TD
   Patel, AN
AF Mehra, Mandeep R.
   Desai, Sapan S.
   Kuy, SreyRam
   Henry, Timothy D.
   Patel, Amit N.
TI Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in
   Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Mehra, Mandeep R.] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA.
   [Desai, Sapan S.] Surgisphere, Chicago, IL USA.
   [Kuy, SreyRam] Baylor Coll Med, Houston, TX 77030 USA.
   [Henry, Timothy D.] Christ Hosp, Cincinnati, OH 45219 USA.
   [Patel, Amit N.] Univ Utah, Salt Lake City, UT USA.
RP Mehra, MR (corresponding author), Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA.
EM mmehra@bwh.harvard.edu
OI Mehra, Mandeep/0000-0001-8683-7044; Desai, Sapan/0000-0002-5402-0176
CR Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
NR 1
TC 48
Z9 48
U1 2
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 25
PY 2020
VL 382
IS 26
BP 2582
EP 2582
DI 10.1056/NEJMc2021225
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MF9CW
UT WOS:000545636400045
PM 32501665
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Freeman, CL
   Mikhael, J
AF Freeman, Ciara L.
   Mikhael, Joseph
TI COVID-19 and myeloma: what are the implications for now and in the
   future?
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE myeloma therapy; cost benefit; health services research; COVID-19;
   telemedicine
ID REFRACTORY MULTIPLE-MYELOMA; STEM-CELL TRANSPLANTATION; ZOLEDRONIC ACID;
   COST; INFECTIONS; BORTEZOMIB; SINGLE; BLOOD; CORONAVIRUS; VACCINATION
AB The pandemic has affected every aspect of myeloma care. Immediate focus is minimising risk of contracting coronavirus disease 2019 (COVID-19) and the sequelae of infection. However, what does the future hold for our patients? What lessons will be taken forward to tackle myeloma in the fiscally constrained future? If we embrace the challenges that will emerge in the post-pandemic environment, the treatment delivered to patients could be more cost-effective and better tailored than before. Healthcare delivery post-COVID-19 will not return to how it was, and now is the time to invest in novel strategies to deliver the best possible outcomes for patients.
C1 [Freeman, Ciara L.] BC Canc, Ctr Lymphoid Canc, Vancouver, BC, Canada.
   [Freeman, Ciara L.] BC Canc, Div Med Oncol, Vancouver, BC, Canada.
   [Freeman, Ciara L.] Univ British Columbia, Vancouver, BC, Canada.
   [Mikhael, Joseph] City Hope Canc Ctr, Translat Genom Res Inst, Appl Canc Res & Drug Discovery, Duarte, CA USA.
RP Freeman, CL (corresponding author), BC Canc, Ctr Lymphoid Canc, Vancouver, BC, Canada.; Freeman, CL (corresponding author), BC Canc, Div Med Oncol, Vancouver, BC, Canada.; Freeman, CL (corresponding author), Univ British Columbia, Vancouver, BC, Canada.
EM ciara.freeman@bccancer.bc.ca
CR Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   Alemu A, 2016, CL LYMPH MYELOM LEUK, V16, P495, DOI 10.1016/j.clml.2016.06.006
   [Anonymous], 2020, REC PAT SUSP CONF CO
   [Anonymous], 2020, INT GUID COVID 19 MA
   [Anonymous], 2020, AI FINDS POT COVID 1
   Ayittey FK, 2020, J MED VIROL, V92, P473, DOI 10.1002/jmv.25706
   Bach PB, 2015, NEW ENGL J MED, V373, P1797, DOI 10.1056/NEJMp1512750
   Bittner B, 2018, BIODRUGS, V32, P425, DOI 10.1007/s40259-018-0295-0
   Blimark C, 2015, HAEMATOLOGICA, V100, P107, DOI 10.3324/haematol.2014.107714
   Bringhen S, 2019, HAEMATOLOGICA, V104, P1640, DOI 10.3324/haematol.2018.208272
   Carpenter PA, 2016, BLOOD, V127, P2824, DOI 10.1182/blood-2015-12-550475
   Cetin AE, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01593-2
   Clemens PL, 2017, CLIN PHARMACOKINET, V56, P915, DOI 10.1007/s40262-016-0477-1
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Dimopoulos MA, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-0300-y
   ESMO, 2020, ESMO MAN TREATM AD R
   Facon T, 2020, LEUKEMIA, V34, P224, DOI 10.1038/s41375-019-0539-0
   Fang L, 2020, LANCET RESP MED, V8, pE32, DOI 10.1016/S2213-2600(20)30159-4
   Faria-e-Castro M, 2020, EC BLOG ST LOUIS FED
   Fontana L, 2019, INFECT DIS CLIN N AM, V33, P523, DOI 10.1016/j.idc.2019.02.004
   Gibbs S, 2019, CL LYMPH MYELOM LEUK, V19, pE315, DOI 10.1016/j.clml.2019.09.518
   Go RS, 2017, J CLIN ONCOL, V35, P598, DOI 10.1200/JCO.2016.68.3805
   Goldstein DA, 2017, ONCOTARGET, V8, P71548, DOI 10.18632/oncotarget.17742
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Hahn M, 2015, HAEMATOLOGICA, V100, pE285, DOI 10.3324/haematol.2014.116772
   Himelstein AL, 2017, JAMA-J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Howard DH, 2011, JAMA-J AM MED ASSOC, V305, P2347, DOI 10.1001/jama.2011.793
   Huntington SF, 2015, LANCET HAEMATOL, V2, pE408, DOI 10.1016/S2352-3026(15)00151-9
   Jack A, 2007, BRIT MED J, V335, P122, DOI 10.1136/bmj.39267.432153.94
   John Hopkins University of Medicine Coronavirus Resource Centre, COVID 19 DASHB CTR S
   Keesara S, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005835
   Kleinpell RM, 2019, CRIT CARE MED, V47, P1442, DOI 10.1097/CCM.0000000000003925
   Kumar SK, 2017, CL LYMPH MYELOM LEUK, V17, P243, DOI 10.1016/j.clml.2017.02.024
   Larocca A, 2015, BLOOD, V126, P2179, DOI 10.1182/blood-2015-05-612960
   Lassalle A, 2016, ANN ONCOL, V27, P314, DOI 10.1093/annonc/mdv563
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Ljungman P, 2001, BONE MARROW TRANSPL, V28, P479, DOI 10.1038/sj.bmt.1703139
   Majumder MM, 2017, ONCOTARGET, V8, P56338, DOI 10.18632/oncotarget.17630
   Malik NN, 2009, NAT REV CLIN ONCOL, V6, P550, DOI 10.1038/nrclinonc.2009.113
   Mateos MV, 2020, LANCET HAEMATOL, V7, pE370, DOI 10.1016/S2352-3026(20)30070-3
   Mitra AK, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.56
   Montesarchio V, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-74
   Moreau P, 2016, NEW ENGL J MED, V374, P1621, DOI 10.1056/NEJMoa1516282
   Morgan KP, 2018, J ONCOL PHARM PRACT, V24, P332, DOI 10.1177/1078155217703792
   Odejide OO, 2016, JAMA INTERN MED, V176, P263, DOI 10.1001/jamainternmed.2015.6599
   Palumbo A, 2012, CL LYMPH MYELOM LEUK, V12, P5, DOI 10.1016/j.clml.2011.11.001
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612
   Porta-Sales J, 2017, J PAIN SYMPTOM MANAG, V54, P692, DOI 10.1016/j.jpainsymman.2017.04.012
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470-2045(18)30072-X
   Rajkumar S Vincent, 2018, Am Soc Clin Oncol Educ Book, V38, P662, DOI 10.1200/EDBK_200867
   Ramsenthaler C, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2410-2
   Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012
   @Rfonsi1, 2020, NEW STAND BC BEF COV
   Rico F, 2015, AM J MED QUAL, V30, P374, DOI 10.1177/1062860614536767
   Rosko Ashley, 2017, Am Soc Clin Oncol Educ Book, V37, P575, DOI 10.14694/EDBK_175171
   SANMIGUEL J, 2015, CLIN LYMPHOMA MYE S3, V15, pE174
   Sarah Thomson JF, 2014, EC CRISIS HLTH SYSTE
   Shah DP, 2012, AM J BLOOD RES, V2, P203
   Silva A, 2017, CANCER RES, V77, P3336, DOI 10.1158/0008-5472.CAN-17-0502
   Sirintrapun S Joseph, 2018, Am Soc Clin Oncol Educ Book, V38, P540, DOI 10.1200/EDBK_200141
   Sivaraj D, 2017, BIOL BLOOD MARROW TR, V23, P262, DOI 10.1016/j.bbmt.2016.11.010
   Sterling S, 2020, POLITICO
   Sweiss K, 2018, J ONCOL PRACT, V14, P684, DOI 10.1200/JOP.18.00085
   Tan CRC, 2019, CLIN PHARMACOKINET, V58, P157, DOI 10.1007/s40262-018-0679-9
   Teh BW, 2015, BRIT J HAEMATOL, V171, P100, DOI 10.1111/bjh.13532
   Ubels J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05348-5
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   WHO, 2020, COR DIS COVID 19 TEC
   Wolfromm A, 2017, BLOOD, V130
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 72
TC 2
Z9 2
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD JUL
PY 2020
VL 190
IS 2
BP 173
EP 178
DI 10.1111/bjh.16815
EA JUN 2020
PG 6
WC Hematology
SC Hematology
GA ML5DQ
UT WOS:000543033300001
PM 32428242
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Diamond, R
   Waite, F
AF Diamond, Rowan
   Waite, Felicity
TI Physical activity in a pandemic: A new treatment target for
   psychological therapy
SO PSYCHOLOGY AND PSYCHOTHERAPY-THEORY RESEARCH AND PRACTICE
LA English
DT Article; Early Access
DE COVID-19; exercise; sedentary behaviour; psychological techniques
ID WOMEN
AB The COVID-19 pandemic and its management are placing significant new strains on people's well-being, particularly those with pre-existing mental health conditions. Physical activity has been shown to improve mental as well as physical health. Increasing activity levels should be prioritized as a treatment target, especially when the barriers to exercise are greater than ever. Promoting physical activity has not traditionally been the remit of psychologists. Yet psychological theory and therapeutic techniques can be readily applied to address physical inactivity. We present theoretical perspectives and therapy techniques relating to (1) beliefs about physical activity, (2) motivation to be physically active, and (3) the sense of reward achieved through being physically active. We outline strategies to initiate and maintain physical activity during the COVID-19 pandemic, thereby benefitting mental and physical health. COVID-19 is demanding rapid and substantial change across the whole health care system. Psychological therapists can respond creatively by addressing physical activity, a treatable clinical target which delivers both mental and physical health benefits. Practitioner points
   Physical activity is essential for our mental and physical health. Yet COVID-19 presents novel barriers to physical activity. Psychological theory and techniques to address beliefs, motivation, and reward can be applied to increase physical activity during COVID-19. Physical activity is an important clinical target to sustain and improve mental health, especially in the current pandemic.
C1 [Diamond, Rowan; Waite, Felicity] Univ Oxford, Dept Psychiat, Oxford, England.
   [Diamond, Rowan] Oxford Cognit Therapy Ctr, Oxford, England.
   [Diamond, Rowan; Waite, Felicity] Oxford Hlth NHS Fdn Trust, Oxford, England.
RP Diamond, R (corresponding author), Univ Oxford, Dept Psychiat, Warneford Hosp, Warneford Lane, Oxford OX3 7JX, England.
EM rowan.diamond@psych.ox.ac.uk
OI Waite, Felicity/0000-0002-2749-1386
FU NIHR Oxford Health Biomedical Research Centre [BRC-1215-20005]
FX This project was funded by the NIHR Oxford Health Biomedical Research
   Centre (BRC-1215-20005). The views expressed are those of the authors
   and not necessarily those of the NHS, the NIHR, or the Department of
   Health.
CR Allen N, 2011, DIABETES TECHNOL THE, V13, P1091, DOI 10.1089/dia.2011.0088
   Ashdown-Franks G, 2020, SPORTS MED, V50, P151, DOI 10.1007/s40279-019-01187-6
   Beck AT, 1967, DEPRESSION CLIN EXPT
   Beck J. S., 2011, COGNITIVE BEHAV THER
   Bryant F. B., 2011, INT J WELLBEING, V1
   De Jong P, 1998, INTERVIEWING SOLUTIO
   Diamond J, 2020, ROUTLEDGE FOCUS, P1
   Doran GT, 1981, MANAGE REV, V70, P35, DOI DOI 10.1177/004057368303900411
   Firth J, 2019, LANCET PSYCHIAT, V6, P675, DOI 10.1016/S2215-0366(19)30132-4
   Gollwitzer P. M., 1993, EUROPEAN REV SOCIAL, V4, P141, DOI [DOI 10.1080/14792779343000059, 10.1080/14792779343000059]
   Hearon BA, 2018, BEHAV MED, V44, P108, DOI 10.1080/08964289.2016.1276428
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Holmes EA, 2010, CLIN PSYCHOL REV, V30, P349, DOI 10.1016/j.cpr.2010.01.001
   Kennerley H., 2016, INTRO COGNITIVE BEHA
   Lakerveld J, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-47
   Libby LK, 2007, PSYCHOL SCI, V18, P199, DOI 10.1111/j.1467-9280.2007.01872.x
   McNally S., 2015, EXERCISE MIRACLE CUR
   Miller W, 1991, MOTIVATIONAL INTERVI
   Stadler G, 2009, AM J PREV MED, V36, P29, DOI 10.1016/j.amepre.2008.09.021
   Suinn RM, 1997, CLIN PSYCHOL-SCI PR, V4, P189, DOI 10.1111/j.1468-2850.1997.tb00109.x
   Swann C, 2020, HEALTH PSYCHOL REV, DOI 10.1080/17437199.2019.1706616
NR 21
TC 3
Z9 3
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1476-0835
EI 2044-8341
J9 PSYCHOL PSYCHOTHER-T
JI Psychol. Psychother.-Theory Res. Pract.
DI 10.1111/papt.12294
EA JUN 2020
PG 8
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA MC2QY
UT WOS:000543139400001
PM 32588499
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Paderno, A
   Fior, M
   Berretti, G
   Del Bon, F
   Schreiber, A
   Grammatica, A
   Mattavelli, D
   Deganello, A
AF Paderno, Alberto
   Fior, Milena
   Berretti, Giulia
   Del Bon, Francesca
   Schreiber, Alberto
   Grammatica, Alberto
   Mattavelli, Davide
   Deganello, Alberto
TI COVID-19 and Total Laryngectomy-A Report of Two Cases
SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY
LA English
DT Article
DE COVID-19; coronavirus; SARS-CoV-2; laryngectomy; management
AB Objective: To date, no cases have been reported on the effects of COVID-19 in laryngectomees. Case Presentation: We herein presented two clinical cases of laryngectomized patients affected by COVID-19, detailing their clinical course and complications. Discussion: In our experience, permanent tracheostomy did not significantly affect the choice of treatment. However, dedicated devices and repeated tracheal toilettes may be needed to deal with oxygen-therapy-related tracheal crusting. Conclusion: In conclusion, laryngectomees should be considered a vulnerable population that may be at risk for worse outcomes of COVID-19 due to anatomical changes in their airways. The role of the ENT specialist is to guide airway management and inform the support-staff regarding specific needs of these patients.
C1 [Paderno, Alberto; Fior, Milena; Berretti, Giulia; Del Bon, Francesca; Schreiber, Alberto; Grammatica, Alberto; Mattavelli, Davide; Deganello, Alberto] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, ASST Spedali Civili Brescia, Unit Otorhinolayngol Head & Neck Surg, Brescia, Italy.
RP Paderno, A (corresponding author), Univ Brescia, ASST Spedali Civili Brescia, Unit Otorhinolayngol Head & Neck Surg, Piazza Spedali Civili 1, I-25123 Brescia, Italy.
EM albpaderno@gmail.com
RI Mattavelli, Davide/AAC-1548-2019
OI Mattavelli, Davide/0000-0001-7023-6746; DEGANELLO,
   ALBERTO/0000-0003-1008-7333; Schreiber, Alberto/0000-0002-1580-3928
CR Darin J, 1982, Respir Care, V27, P41
   Harlid R, 1996, AM J RESP CRIT CARE, V154, P124, DOI 10.1164/ajrccm.154.1.8680667
   Kelsey MC, 2000, J HOSP INFECT, V46, P12, DOI 10.1053/jhin.2000.0775
   Retel VP, 2015, EUR ARCH OTO-RHINO-L, V272, P2381, DOI 10.1007/s00405-015-3618-5
   Riva G, 2017, ANN OTO RHINOL LARYN, V126, P124, DOI 10.1177/0003489416676500
   van den Boer C, 2014, EUR ARCH OTO-RHINO-L, V271, P3297, DOI 10.1007/s00405-014-2927-4
NR 6
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0003-4894
EI 1943-572X
J9 ANN OTO RHINOL LARYN
JI Ann. Otol. Rhinol. Laryngol.
PD JAN
PY 2021
VL 130
IS 1
BP 104
EP 107
AR 0003489420935500
DI 10.1177/0003489420935500
EA JUN 2020
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA PG7KF
UT WOS:000543425100001
PM 32583671
OA Green Published
DA 2021-01-01
ER

PT J
AU Ramamurthy, VS
   Srivastava, DK
AF Ramamurthy, V. S.
   Srivastava, D. K.
TI Communication and management of public risks (with specific reference to
   the COVID-19 global pandemic)
SO CURRENT SCIENCE
LA English
DT Article
DE Communication and management; global pandemic; public risks and
   perception
AB We are in the midst of a global pandemic, the COVID-19. With no vaccine against the infection or medicines to treat the infected, the world is struggling to cope up with the increasing infections and casualties. It is recognized by everyone that the only option available to reduce the spread of the infection is to bring in lifestyle changes. Active participation by everyone is mandatory for success of this strategy. It is emphasized that the scientific community can play a very effective role in conveying this message across the entire population.
C1 [Ramamurthy, V. S.; Srivastava, D. K.] Natl Inst Adv Studies, Bengaluru 560012, India.
RP Ramamurthy, VS (corresponding author), Natl Inst Adv Studies, Bengaluru 560012, India.
EM vsramamurthy@gmail.com; srivastava.dinesh.kumar@gmail.com
NR 0
TC 0
Z9 0
U1 1
U2 1
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0011-3891
J9 CURR SCI INDIA
JI Curr. Sci.
PD JUN 25
PY 2020
VL 118
IS 12
BP 1878
EP 1884
DI 10.18520/cs/v118/i12/1878-1884
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MB0HH
UT WOS:000542289800010
DA 2021-01-01
ER

PT J
AU Cure, E
   Cure, MC
   Kucuk, A
AF Cure, Erkan
   Cure, Medine Cumhur
   Kucuk, Adem
TI Comment on "Smooth or Risky Revisit of an Old Malaria Drug for
   COVID-19?"
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Letter
C1 [Cure, Erkan] Ota & Jinemed Hosp, Dept Internal Med, Muradiye Mahallesi Nuzhetiye Cad, TR-34357 Istanbul, Turkey.
   [Cure, Medine Cumhur] Dept Biochem, Istanbul, Turkey.
   [Kucuk, Adem] Necmettin Erbakan Univ, Meram Tip Fac, Dept Rheumatol, Konya, Turkey.
RP Cure, E (corresponding author), Ota & Jinemed Hosp, Dept Internal Med, Muradiye Mahallesi Nuzhetiye Cad, TR-34357 Istanbul, Turkey.
EM erkancure@yahoo.com; medinecure@yahoo.com; drademk@gmail.com
RI ; CURE, Erkan/W-4922-2017
OI Kucuk, Adem/0000-0001-8028-1671; CURE, Erkan/0000-0001-7807-135X
CR Bezprozvanny I, 2009, TRENDS MOL MED, V15, P89, DOI 10.1016/j.molmed.2009.01.001
   Cure MC, 2020, CLIN RHEUMATOL, V39, P2101, DOI 10.1007/s10067-020-05144-x
   Cure E, 2020, J ENDOCRINOL INVESTI
   Jaballah M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122230
   Milosavljevic N, 2014, CELL REP, V7, P689, DOI 10.1016/j.celrep.2014.03.054
   Pahan P, 2020, J NEUROIMMUNE PHARM, V15, P174, DOI 10.1007/s11481-020-09923-w
   Prasad H, 2015, J BIOL CHEM, V290, P5311, DOI 10.1074/jbc.M114.602219
   Roden DM, 2006, HANDB EXP PHARMACOL, V171, P73
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang LF, 2015, J INTERF CYTOK RES, V35, P143, DOI 10.1089/jir.2014.0038
NR 10
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1557-1890
EI 1557-1904
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD SEP
PY 2020
VL 15
IS 3
SI SI
BP 345
EP 346
DI 10.1007/s11481-020-09938-3
EA JUN 2020
PG 2
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA NM0OV
UT WOS:000543270300001
PM 32588188
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tashkandi, E
   Zeeneldin, A
   AlAbdulwahab, A
   Elemam, O
   Elsamany, S
   Jastaniah, W
   Abdullah, S
   Alfayez, M
   Jazieh, AR
   Al-Shamsi, HO
AF Tashkandi, Emad
   Zeeneldin, Ahmed
   AlAbdulwahab, Amal
   Elemam, Omima
   Elsamany, Shereef
   Jastaniah, Wasil
   Abdullah, Shaker
   Alfayez, Mohammad
   Jazieh, Abdul Rahman
   Al-Shamsi, Humaid O.
TI Virtual Management of Patients With Cancer During the COVID-19 Pandemic:
   Web-Based Questionnaire Study
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE teleoncology; telemedicine; eHealth; cancer; COVID-19; public health
ID ADJUVANT CHEMOTHERAPY; INITIATION; SURVIVAL; TIME
AB Background: During the coronavirus disease (COVID-19) pandemic, patients with cancer in rural settings and distant geographical areas will be affected the most by curfews. Virtual management (telemedicine) has been shown to reduce health costs and improve access to care.
   Objective: The aim of this survey is to understand oncologists' awareness of and views on virtual management, challenges, and preferences, as well as their priorities regarding the prescribing of anticancer treatments during the COVID-19 pandemic.
   Methods: We created a self-administrated electronic survey about the virtual management of patients with cancer during the COVID-19 pandemic. We evaluated its clinical sensibility and pilot tested the instrument. We surveyed practicing oncologists in Gulf and Arab countries using snowball sampling via emails and social media networks. Reminders were sent 1 and 2 weeks later using SurveyMonkey.
   Results: We received 222 responses from validated oncologists from April 2-22, 2020. An awareness of virtual clinics, virtual multidisciplinary teams, and virtual prescriptions was reported by 182 (82%), 175 (79%), and 166 (75%) respondents, respectively. Reported challenges associated with virtual management were the lack of physical exam (n=134, 60%), patients' awareness and access (n=131, 59%), the lack of physical attendance of patients (n=93, 42%), information technology (IT) support (n=82, 37%), and the safety of virtual management (n=78, 35%). Overall, 111 (50%) and 107 (48%) oncologists did not prefer the virtual prescription of chemotherapy and novel immunotherapy, respectively. However, 188 (85%), 165 (74%), and 127 (57%) oncologists preferred the virtual prescription of hormonal therapy, bone modifying agents, and targeted therapy, respectively. In total, 184 (83%), 183 (83%), and 176 (80%) oncologists preferred to continue neoadjuvant, adjuvant, and perioperative treatments, respectively. Overall, 118 (53%) respondents preferred to continue first-line palliative treatment, in contrast to 68 (30%) and 47 (21%) respondents indicating a preference to interrupt second- and third-line palliative treatment, respectively. For administration of virtual prescriptions, all respondents preferred the oral route and 118 (53%) preferred the subcutaneous route. In contrast, 193 (87%) did not prefer the intravenous route for virtual prescriptions. Overall, 102 (46%) oncologists responded that they would "definitely" prefer to manage patients with cancer virtually.
   Conclusions: Oncologists have a high level of awareness of virtual management. Although their survey responses indicated that second- and third-line palliative treatments should be interrupted, they stated that neoadjuvant, adjuvant, perioperative, and first-line palliative treatments should continue. Our results confirm that oncologists' views on the priority of anticancer treatments are consistent with the evolving literature during the COVID-19 pandemic. Challenges to virtual management should be addressed to improve the care of patients with cancer.
C1 [Tashkandi, Emad; Zeeneldin, Ahmed; Elemam, Omima; Elsamany, Shereef; Alfayez, Mohammad] King Abdullah Med City, Oncol Ctr, Dept Med Oncol, POB 715, Mecca 21955, Saudi Arabia.
   [Tashkandi, Emad; Jastaniah, Wasil; Alfayez, Mohammad] Umm AlQura Univ, Coll Med, Mecca, Saudi Arabia.
   [Zeeneldin, Ahmed; Elsamany, Shereef] Cairo Univ, Natl Canc Inst, Cairo, Egypt.
   [AlAbdulwahab, Amal] King Abdullah Med City, Oncol Ctr, Mecca, Saudi Arabia.
   [Elemam, Omima] Mansoura Univ, Oncol Ctr, Dept Med Oncol, Mansoura, Egypt.
   [Jastaniah, Wasil; Abdullah, Shaker] Minist Natl Guard Hlth Affairs, King Abdul Aziz Med City, Princess Noorah Oncol Ctr, Jeddah, Saudi Arabia.
   [Jazieh, Abdul Rahman] King Saudi Bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia.
   [Al-Shamsi, Humaid O.] Alzahra Hosp, Dept Oncol, Dubai, U Arab Emirates.
   [Al-Shamsi, Humaid O.] Emirates Oncol Soc, Dubai, U Arab Emirates.
   [Al-Shamsi, Humaid O.] Univ Sharjah, Dept Med, Sharjah, U Arab Emirates.
RP Tashkandi, E (corresponding author), King Abdullah Med City, Oncol Ctr, Dept Med Oncol, POB 715, Mecca 21955, Saudi Arabia.
EM Tashkandi.e@kamc.med.sa
OI Al-Shamsi, Humaid O./0000-0003-3819-0500; Jazieh, Abdul
   Rahman/0000-0001-5465-7698; Tashkandi, Emad/0000-0002-0260-8947
FU Roche Products, Saudi Arabia
FX The authors wish to thank Roche Products, Saudi Arabia, for supporting
   the publication fee. We also thank all the oncologists in the MENA
   (Middle East and North Africa) region who participated in this survey.
CR Aday L. A., 2006, DESIGNING CONDUCTING
   Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   Arguelles Mendez L., 2016, STUDIES FUZZINESS SO, P339, DOI [10.1371/journal.pone.0071238, DOI 10.1371/JOURNAL.PONE.0071238]
   Biagi JJ, 2011, JAMA-J AM MED ASSOC, V305, P2335, DOI 10.1001/jama.2011.749
   Collins D, 2003, QUAL LIFE RES, V12, P229, DOI 10.1023/A:1023254226592
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Hazin R, 2010, LANCET ONCOL, V11, P204, DOI 10.1016/S1470-2045(09)70288-8
   Hofheinz RD, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70116-X
   Khairat S, 2020, JMIR PUBLIC HLTH SUR, V6, P214, DOI 10.2196/18811
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   McLean S, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0071238
   Ohannessian R, 2020, JMIR PUBLIC HLTH SUR, V6, P121, DOI 10.2196/18810
   Passmore C, 2002, FAM MED, V34, P281
   Raphael MJ, 2016, BREAST CANCER RES TR, V160, P17, DOI 10.1007/s10549-016-3960-3
   Shankar Abhishek, 2020, Asian Pac J Cancer Prev, V21, P569, DOI 10.31557/APJCP.2020.21.3.569
   Sirintrapun S Joseph, 2018, Am Soc Clin Oncol Educ Book, V38, P540, DOI 10.1200/EDBK_200141
   WOODWARD CA, 1988, MED EDUC, V22, P345, DOI 10.1111/j.1365-2923.1988.tb00764.x
   World Health Organization, COR DIS 2019
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 1
Z9 1
U1 4
U2 4
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD JUN 24
PY 2020
VL 22
IS 6
AR e19691
DI 10.2196/19691
PG 11
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA NM9MX
UT WOS:000568415700001
PM 32501807
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bravi, F
   Flacco, ME
   Carradori, T
   Volta, CA
   Cosenza, G
   De Togni, A
   Martellucci, CA
   Parruti, G
   Mantovani, L
   Manzoli, L
AF Bravi, Francesca
   Flacco, Maria Elena
   Carradori, Tiziano
   Volta, Carlo Alberto
   Cosenza, Giuseppe
   De Togni, Aldo
   Acuti Martellucci, Cecilia
   Parruti, Giustino
   Mantovani, Lorenzo
   Manzoli, Lamberto
TI Predictors of severe or lethal COVID-19, including Angiotensin
   Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a
   sample of infected Italian citizens
SO PLOS ONE
LA English
DT Article
ID UP-REGULATION; ACE2; EXPRESSION
AB Aims This retrospective case-control study was aimed at identifying potential independent predictors of severe/lethal COVID-19, including the treatment with Angiotensin-Converting Enzyme inhibitors (ACEi) and/or Angiotensin II Receptor Blockers (ARBs). Methods and results All adults with SARS-CoV-2 infection in two Italian provinces were followed for a median of 24 days. ARBs and/or ACEi treatments, and hypertension, diabetes, cancer, COPD, renal and major cardiovascular diseases (CVD) were extracted from clinical charts and electronic health records, up to two years before infection. The sample consisted of 1603 subjects (mean age 58.0y; 47.3% males): 454 (28.3%) had severe symptoms, 192 (12.0%) very severe or lethal disease (154 deaths; mean age 79.3 years; 70.8% hypertensive, 42.2% with CVD). The youngest deceased person aged 44 years. Among hypertensive subjects (n = 543), the proportion of those treated with ARBs or ACEi were 88.4%, 78.7% and 80.6% among patients with mild, severe and very severe/lethal disease, respectively. At multivariate analysis, no association was observed between therapy and disease severity (Adjusted OR for very severe/lethal COVID-19: 0.87; 95% CI: 0.50-1.49). Significant predictors of severe disease were older age (with AORs largely increasing after 70 years of age), male gender (AOR: 1.76; 1.40-2.23), diabetes (AOR: 1.52; 1.05-2.18), CVD (AOR: 1.88; 1.32-2.70) and COPD (AOR: 1.88; 1.11-3.20). Only gender, age and diabetes also predicted very severe/lethal disease. Conclusion No association was found between COVID-19 severity and treatment with ARBs and/or ACEi, supporting the recommendation to continue medication for all patients unless otherwise advised by their physicians.
C1 [Bravi, Francesca; Carradori, Tiziano; Volta, Carlo Alberto; Manzoli, Lamberto] St Anna Univ Hosp Ferrara, Ferrara, Italy.
   [Flacco, Maria Elena; Manzoli, Lamberto] Univ Ferrara, Dept Med Sci, Ferrara, Italy.
   [Volta, Carlo Alberto] Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy.
   [Cosenza, Giuseppe; De Togni, Aldo] Local Hlth Author Ferrara, Ferrara, Italy.
   [Acuti Martellucci, Cecilia] Univ Marche Reg, Dept Biomed Sci & Publ Hlth, Ancona, Italy.
   [Parruti, Giustino] Local Hlth Author Pescara, Cerveteri, Italy.
   [Mantovani, Lorenzo] Univ Milano Bicocca, Ctr Publ Hlth Res, Milan, Italy.
   [Mantovani, Lorenzo] IRCCS Multimed, Sesto San Giovanni, Italy.
RP Manzoli, L (corresponding author), St Anna Univ Hosp Ferrara, Ferrara, Italy.; Manzoli, L (corresponding author), Univ Ferrara, Dept Med Sci, Ferrara, Italy.
EM lmanzoli@post.harvard.edu
RI Martellucci, Cecilia Acuti/AAW-5903-2020; Flacco, Maria
   Elena/E-3306-2017; Manzoli, Lamberto/K-1895-2018
OI Martellucci, Cecilia Acuti/0000-0002-4308-2144; Flacco, Maria
   Elena/0000-0003-1404-4314; Manzoli, Lamberto/0000-0002-8129-9344
CR American Hearth A, 2020, PAT TAK ACE I ARBS W
   Aronson JK, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1313
   Bavishi C, 2020, JAMA CARDIOL, V5, P745, DOI 10.1001/jamacardio.2020.1282
   Cascella M, 2020, FEATURES EVALUATION
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   European Medicines A, 2020, EMA ADV CONT US MED
   European Society of C, 2020, POS STAT ESC COUNC H
   Fang l, 2020, LANCET RESP MED, DOI [10.1016/PII, DOI 10.1016/PII]
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Furuhashi M, 2015, AM J HYPERTENS, V28, P15, DOI 10.1093/ajh/hpu086
   Gallagher PE, 2008, AM J PHYSIOL-CELL PH, V295, pC1169, DOI 10.1152/ajpcell.00145.2008
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou YC1, 2009, AM J PHYSIOL-LUNG C, V296, pL288
   Igase M, 2005, AM J PHYSIOL-HEART C, V289, pH1013, DOI 10.1152/ajpheart.00068.2005
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Italian Institute of Statistics (ISTAT), 2020, ASP DAIL LIF HLTH ST
   Jarcho JA, 2020, NEW ENGL J MED, V382, P2462, DOI 10.1056/NEJMe2012924
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuster GM, 2020, EUR HEART J, V41, P1857, DOI 10.1093/eurheartj/ehaa335
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Luque M, 1996, J HYPERTENS, V14, P799, DOI 10.1097/00004872-199606000-00017
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Sommerstein R, 2020, BMJ-BRIT MED J, V368, pm810, DOI [10.1136/bmj.m810, DOI 10.1136/BMJ.M810]
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   WHO, 2020, LAB TEST COR DIS COV
   Williamson E., 2020, OPENSAFELY FACTORS A, DOI [10.1101/2020.05.06.20092999, DOI 10.1101/2020.05.06.20092999]
   Worldometers, 2020, COVID 19 COR OUTBR
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zisman LS, 2003, CIRCULATION, V108, P1707, DOI 10.1161/01.CIR.0000094734.67990.99
NR 43
TC 7
Z9 7
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 24
PY 2020
VL 15
IS 6
AR e0235248
DI 10.1371/journal.pone.0235248
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MF9GS
UT WOS:000545646600010
PM 32579597
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fang, BJ
   Zhang, W
   Wu, XX
   Huang, TR
   Li, HC
   Zheng, Y
   Che, JH
   Sun, ST
   Jiang, C
   Zhou, S
   Feng, J
AF Fang, Bangjiang
   Zhang, Wen
   Wu, Xinxin
   Huang, Tingrong
   Li, Huacheng
   Zheng, You
   Che, Jinhua
   Sun, Shuting
   Jiang, Chao
   Zhou, Shuang
   Feng, Jun
TI Shenhuang granule in the treatment of severe coronavirus disease 2019
   (COVID-19): study protocol for an open-label randomized controlled
   clinical trial
SO TRIALS
LA English
DT Article
DE Severe COVID-19; Shenhuang granule; "Truncation and Reversion" strategy;
   Randomized controlled trial
ID TOXICITY; GINSENG
AB Background: Currently, coronavirus disease 2019 (COVID-19) is continuously and rapidly circulating, causing heavy damage on public health. No effective antiviral treatment has been proved thus far. Traditional Chinese medicine (TCM) has been widely applied in the treatment of a variety of infection diseases in China, hoping to produce clinical effects and reduce the use of antibiotics and glucocorticoid. The aim of this study is to evaluate the efficacy and safety of Shenhuang granule in treatment of severe COVID-19.
   Methods/design: This multicenter, open-label randomized controlled trial is conducted in 160 participants with severe COVID-19. The participants will be randomly (1:1) divided into treatment group or control group. All participants are given standard therapy at the same time. The experiment will receive Shenhuang granule treatment twice a day for 14 days. The clinical indicators of patients will be assessed at baseline and at 3, 5, 7, and 14 days after treatment initiation. The primary outcome is 14-day clinical outcome. Adverse events will be monitored throughout the trial.
   Discussion: This will be the first randomized controlled trial, which evaluate the effect of Shenhuang granule in patients with severe COVID-19 in China. The results of this trial may not only provide evidence-based recommendations to clinicians to treat severe COVID-19, but also enrich the theory and practice of TCM in treating infectious diseases.
C1 [Fang, Bangjiang; Zhang, Wen; Wu, Xinxin; Che, Jinhua] Shanghai Univ Tradit Chinese Med, LongHua Hosp, Dept Emergency, 725 Wanping South Rd, Shanghai 200032, Peoples R China.
   [Fang, Bangjiang; Sun, Shuting] Hubei Univ Chinese Med, Clin Med Coll TCM, 1 Tanhualin, Wuhan 430065, Hubei, Peoples R China.
   [Huang, Tingrong; Li, Huacheng; Zheng, You] Huangshi Hosp TCM, Infect Dis Hosp, 6 Plaza Rd, Huangshi 435000, Hubei, Peoples R China.
   [Jiang, Chao] Xian Med Univ, Dept Neurol 3, Affiliated Hosp 2, 167 Text City East St, Xian 710032, Shanxi, Peoples R China.
   [Zhou, Shuang] Shanghai Univ Tradit Chinese Med, 1200 Cai Lun Rd,Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China.
   [Feng, Jun] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Emergency Internal Med, 1095 Jie Fang Ave, Wuhan 430030, Hubei, Peoples R China.
RP Zhou, S (corresponding author), Shanghai Univ Tradit Chinese Med, 1200 Cai Lun Rd,Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China.; Feng, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Emergency Internal Med, 1095 Jie Fang Ave, Wuhan 430030, Hubei, Peoples R China.
EM zhoushuang8008@163.com; andyterry555@163.com
FU Emergency Committee of the World Federation of Chinese Medicine
   Societies; Shanghai Society of Traditional Chinese Medicine, Novel
   Coronavirus Pneumonia Emergency Tackling Key Project [SJZLJZ.N01];
   National Key Research and Development Program of China [2018YFC1705900]
FX The trial is funded by the Emergency Committee of the World Federation
   of Chinese Medicine Societies and Shanghai Society of Traditional
   Chinese Medicine, Novel Coronavirus Pneumonia Emergency Tackling Key
   Project (SJZLJZ.N01). The study also received funding from the National
   Key Research and Development Program of China (2018YFC1705900). The
   Emergency Committee of the World Federation of Chinese Medicine
   Societies, Shanghai Society of Traditional Chinese Medicine, and
   National Key Research and Development Program of China play no part in
   the study design; collection, management, analysis, and interpretation
   of data; writing of the report; and the decision to submit the report
   for publication.
CR [Anonymous], 2020, GUID DIAGN TREATM NO
   [Anonymous], 2000, CHINESE PHARMACOPEIA, P18
   Brunkhorst FM, 2012, JAMA-J AM MED ASSOC, V307, P2390, DOI 10.1001/jama.2012.5833
   Chan PC, 2011, AM J CHINESE MED, V39, P779, DOI 10.1142/S0192415X11009184
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   [段小花 Duan Xiaohua], 2019, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V30, P345
   Fang BJ, 2017, J EMERG TRADIT CHINE, V26, P1724, DOI [10.3969/j.issn.1004-745X.2017.10.010, DOI 10.3969/J.ISSN.1004-745X.2017.10.010]
   Gao J, 2002, ACAD J SHANGHAI U TR, V16, P43, DOI [10.16306/j.1008-861x.2002.03.014, DOI 10.16306/J.1008-861X.2002.03.014]
   Gong WX, 2016, J PRACT TRADIT CHIN, V30, P64, DOI [10.13729/j.issn.1671-7813.2016.09.24, DOI 10.13729/J.ISSN.1671-7813.2016.09.24]
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Huang C, 2020, LANCET
   Kim YR, 2018, MICROB CELL, V5, P472, DOI 10.15698/mic2018.11.654
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang XQ, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/4985926
   Lin GM, 2011, J ZHEJIANG UNIV-SC B, V12, P563, DOI 10.1631/jzus.B1100006
   Sun LH, 2017, JETCM, V26, P9
   WANG Y, 2018, VIRUSES-BASEL, V10, DOI DOI 10.3390/V10090471
   World Health Organization, 2020, 99 WHO
   Xi XT, 2018, JETCM, V27, P105, DOI [10.3969/j.issn.1004-745X.2018.1.032, DOI 10.3969/J.ISSN.1004-745X.2018.1.032]
   [夏文广 Xia Wenguang], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P375
   Yao XL, 2020, J SURG RES, V245, P441, DOI 10.1016/j.jss.2019.07.094
   Ye BG, 2014, FOOD CHEM TOXICOL, V66, P278, DOI 10.1016/j.fct.2014.01.051
   Zhang Q, 2017, J CANCER, V8, P3945, DOI 10.7150/jca.22162
   [张文 Zhang Wen], 2020, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V40, P102
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu L, 2014, SHANGHAI J TRADIT CH, V10, P57, DOI [10.3969/j.issn.1004-745X.2017.11.002, DOI 10.3969/J.ISSN.1004-745X.2017.11.002]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu PT, 2001, SHANGHAI J TRADIT CH, P39, DOI [10.16305/j.1007-1334.2001.04.020, DOI 10.16305/J.1007-1334.2001.04.020]
NR 28
TC 1
Z9 1
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 24
PY 2020
VL 21
IS 1
AR 568
DI 10.1186/s13063-020-04498-6
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MR9JH
UT WOS:000553904700002
PM 32580752
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, Y
   Zhang, Y
   Yu, Q
   Zhu, K
AF Wang, Ying
   Zhang, Yang
   Yu, Qian
   Zhu, Kun
TI Convalescent Plasma Coupled With Medications for the Treatment of a
   Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on
   the Newly Established Guidelines for COVID-19 Remedy
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE convalescent plasma; COVID-19 (severe); drugs analysis; therapeutic
   strategy; guideline
ID CORONAVIRUS PNEUMONIA; INFLUENZA; THERAPY; RISK; MULTICENTER; EFFICACY;
   SAFETY
AB Given the extreme importance of the current pandemic caused by COVID-19 and due to the fact that scientists agree that there is no identified treatment, this paper analyzes in detail the treatment of a severe COVID-19 patient with convalescent plasma and drugs based on current guidelines for COVID-19 diagnosis and treatment. This can provide a reference for other medical institutions on rational drug use and pharmaceutical care for severe COVID-19 patients.
C1 [Wang, Ying; Yu, Qian; Zhu, Kun] Jilin Univ, Third Hosp Jilin Univ, Dept Pharm, Changchun, Peoples R China.
   [Zhang, Yang] Changshu Inst Technol, Sch Biol & Food Engn, Changshu, Jiangsu, Peoples R China.
RP Zhu, K (corresponding author), Jilin Univ, Third Hosp Jilin Univ, Dept Pharm, Changchun, Peoples R China.
EM zhukun@jlu.edu.cn
CR Ahrens I, 2007, TRANSFUS MED HEMOTH, V34, P44, DOI 10.1159/000097664
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Beigel JH, 2017, LANCET RESP MED, V5, P500, DOI 10.1016/S2213-2600(17)30174-1
   [边原 Bian Yuan], 2020, [中国新药与临床杂志, Chinese Journal of New Drugs and Clinical Remedies], V39, P212
   Bulgakova VA, 2017, TERAPEVT ARKH, V89, P62, DOI 10.17116/terarkh201789162-71
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   CHEN M, 2020, HER MED, V39, P483, DOI DOI 10.3870/j.issn.1004-0781.2020.04.010
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Compilation of information on COVID-19 treatment regimens, COMP INF COVID 19 TR
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He Y., 2001, W CHIN PHARM, V16, P44, DOI [10.3969/j.issn.1006-0103.2001.01.019, DOI 10.3969/J.ISSN.1006-0103.2001.01.019]
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Jiang H, 2020, ZHONGHUA JIZHEN YIXU, V29, P182, DOI DOI 10.3760/cma.j.issn.1671-0282.2020.0001
   Katz LM, 2014, TRANSFUSION, V54, P3247, DOI 10.1111/trf.12913
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li D. Y., 2019, J KUNMING MED U, V40, P59
   Lin S., 2020, BIORXIV, DOI [10.1101/2020.01.31.929695, DOI 10.1101/2020.01.31.929695]
   Liu DH, 2020, PROCEEDINGS OF THE ASME INTERNATIONAL DESIGN ENGINEERING TECHNICAL CONFERENCES AND COMPUTERS AND INFORMATION IN ENGINEERING CONFERENCE, 2019, VOL 1
   Liu Y., 2020, HER MED, V39, P621, DOI [10.3870/j.issn.1004-0781.2020.05.008, DOI 10.3870/j.issn.1004-0781.2020.05.008]
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Luo M., 2020, HER MED, V39, P505, DOI [10.3870/j.issn.1004-0781.2020.04.014, DOI 10.3870/j.issn.1004-0781.2020.04.014]
   Ma Q., 2018, CTR S PHAR, V12, P1799, DOI [10.7539/j.issn.1672-2981.2018.12.033, DOI 10.7539/J.ISSN.1672-2981.2018.12.033]
   MacLennan S, 2006, BEST PRACT RES CL HA, V19, P169, DOI 10.1016/j.beha.2005.01.033
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Melanson SEF, 2006, TRANSFUSION, V46, P1402, DOI 10.1111/j.1537-2995.2006.00909.x
   Micromedex, 2020, CHLOR
   Mora-Rillo M, 2015, LANCET RESP MED, V3, P554, DOI 10.1016/S2213-2600(15)00180-0
   National Health Commission of the People's Republic of China, 2020, DIAGN TREATM COVID 1
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Schaefer C, 2006, THROMB HAEMOSTASIS, V95, P949, DOI 10.1160/TH06-02-0108
   Serebruany VL, 2006, AM J MED, V119, P113, DOI 10.1016/j.amjmed.2005.03.044
   Shen J., 2020, CHIN J PHARMACOVIGIL, V17, P249, DOI [10.19803/j.1672-8629.2020.04.12, DOI 10.19803/J.1672-8629.2020.04.12]
   Shen KL, 2018, ZHONGHUA SHIYONG ERK, V33, P1301, DOI DOI 10.3760/cma.j.issn.2095-428X.2018.17.006
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, CLIN MAN SEV ACT RES
   Zhang L. P., 2014, CHIN J LAB DIAGN, V18, P1561
NR 41
TC 1
Z9 1
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 24
PY 2020
VL 11
AR 966
DI 10.3389/fphar.2020.00966
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ML3VJ
UT WOS:000549397400001
PM 32670071
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Deftereos, SG
   Giannopoulos, G
   Vrachatis, DA
   Siasos, GD
   Giotaki, SG
   Gargalianos, P
   Metallidis, S
   Sianos, G
   Baltagiannis, S
   Panagopoulos, P
   Dolianitis, K
   Randou, E
   Syrigos, K
   Kotanidou, A
   Koulouris, NG
   Milionis, H
   Sipsas, N
   Gogos, C
   Tsoukalas, G
   Olympios, CD
   Tsagalou, E
   Migdalis, I
   Gerakari, S
   Angelidis, C
   Alexopoulos, D
   Davlouros, P
   Hahalis, G
   Kanonidis, I
   Katritsis, D
   Kolettis, T
   Manolis, AS
   Michalis, L
   Naka, KK
   Pyrgakis, VN
   Toutouzas, KP
   Triposkiadis, F
   Tsioufis, K
   Vavouranakis, E
   Martinez-Dolz, L
   Reimers, B
   Stefanini, GG
   Cleman, M
   Goudevenos, J
   Tsiodras, S
   Tousoulis, D
   Iliodromitis, E
   Mehran, R
   Dangas, G
   Stefanadis, C
AF Deftereos, Spyridon G.
   Giannopoulos, Georgios
   Vrachatis, Dimitrios A.
   Siasos, Gerasimos D.
   Giotaki, Sotiria G.
   Gargalianos, Panagiotis
   Metallidis, Simeon
   Sianos, George
   Baltagiannis, Stefanos
   Panagopoulos, Periklis
   Dolianitis, Konstantinos
   Randou, Efthalia
   Syrigos, Konstantinos
   Kotanidou, Anastasia
   Koulouris, Nikolaos G.
   Milionis, Haralampos
   Sipsas, Nikolaos
   Gogos, Charalampos
   Tsoukalas, George
   Olympios, Christoforos D.
   Tsagalou, Eleftheria
   Migdalis, Ilias
   Gerakari, Styliani
   Angelidis, Christos
   Alexopoulos, Dimitrios
   Davlouros, Pericles
   Hahalis, George
   Kanonidis, Ioannis
   Katritsis, Demosthenes
   Kolettis, Theofilos
   Manolis, Antonios S.
   Michalis, Lampros
   Naka, Katerina K.
   Pyrgakis, Vlasios N.
   Toutouzas, Konstantinos P.
   Triposkiadis, Filippos
   Tsioufis, Konstantinos
   Vavouranakis, Emmanouil
   Martinez-Dolz, Luis
   Reimers, Bernhard
   Stefanini, Giulio G.
   Cleman, Michael
   Goudevenos, John
   Tsiodras, Sotirios
   Tousoulis, Dimitrios
   Iliodromitis, Efstathios
   Mehran, Roxana
   Dangas, George
   Stefanadis, Christodoulos
CA GRECCO-19 Investigators
TI Effect of Colchicine vs Standard Care on Cardiac and Inflammatory
   Biomarkers and Clinical Outcomes in Patients Hospitalized With
   Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial
SO JAMA NETWORK OPEN
LA English
DT Article
ID NLRP3 INFLAMMASOME; MECHANISMS
AB IMPORTANCE Severe acute respiratory syndrome coronavirus 2 infection has evolved into a global pandemic. Low-dose colchicine combines anti-inflammatory action with a favorable safety profile.
   OBJECTIVE To evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019 (COVID-19).
   DESIGN, SETTING, AND PARTICIPANTS In this prospective, open-label, randomized clinical trial (the Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention), 105 patients hospitalized with COVID-19 were randomized in a 1:1 allocation from April 3 to April 27, 2020, to either standard medical treatment or colchicine with standard medical treatment. The study took place in 16 tertiary hospitals in Greece.
   INTERVENTION Colchicine administration (1.5-mg loading dose followed by 0.5 mg after 60 min and maintenance doses of 0.5 mg twice daily) with standard medical treatment for as long as 3 weeks.
   MAIN OUTCOMES AND MEASURES Primary end points were (1) maximum high-sensitivity cardiac troponin level; (2) time for C-reactive protein to reach more than 3 times the upper reference limit; and (3) time to deterioration by 2 points on a 7-grade clinical status scale, ranging from able to resume normal activities to death. Secondary end points were (1) the percentage of participants requiring mechanical ventilation, (2) all-cause mortality, and (3) number, type, severity, and seriousness of adverse events. The primary efficacy analysis was performed on an intention-to-treat basis.
   RESULTS A total of 105 patients were evaluated (61 [58.1%] men; median [interquartile range] age, 64 [54-76] years) with 50 (47.6%) randomized to the control group and 55 (52.4%) to the colchicine group. Median (interquartile range) peak high-sensitivity cardiac troponin values were 0.0112 (0.0043-0.0093) ng/mL in the control group and 0.008 (0.004-0.0135) ng/mL in the colchicine group (P = .34). Median (interquartile range) maximum C-reactive protein levels were 4.5 (1.4-8.9) mg/dL vs 3.1 (0.8-9.8) mg/dL (P = .73), respectively. The clinical primary end point rate was 14.0% in the control group (7 of 50 patients) and 1.8% in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95% CI, 0.01-0.96; P = .02). Mean (SD) event-free survival time was 18.6 (0.83) days the in the control group vs 20.7 (0.31) in the colchicine group (log rank P = .03). Adverse events were similar in the 2 groups, except for diarrhea, which was more frequent with colchicine group than the control group (25 patients [45.5%] vs 9 patients [18.0%]; P = .003).
   CONCLUSIONS AND RELEVANCE In this randomized clinical trial, participants who received colchicine had statistically significantly improved time to clinical deterioration. There were no significant differences in high-sensitivity cardiac troponin or C-reactive protein levels. These findings should be interpreted with caution.
C1 [Deftereos, Spyridon G.; Giotaki, Sotiria G.; Angelidis, Christos; Alexopoulos, Dimitrios; Iliodromitis, Efstathios] Natl & Kapodistrian Univ Athens, Attikon Hosp, Dept Cardiol 2, 1Rimini St, Athens, Greece.
   [Giannopoulos, Georgios; Pyrgakis, Vlasios N.] G Gennimatas Gen Hosp Athens, Dept Cardiol, Athens, Greece.
   [Vrachatis, Dimitrios A.; Reimers, Bernhard; Stefanini, Giulio G.] Humanitas Clin & Res Hosp IRCCS, Cardio Ctr, Rozzano Milan, Italy.
   [Siasos, Gerasimos D.; Manolis, Antonios S.; Toutouzas, Konstantinos P.; Tsioufis, Konstantinos; Tousoulis, Dimitrios; Stefanadis, Christodoulos] Natl & Kapodistrian Univ Athens, Hippokrat Hosp, Dept Cardiol 1, Athens, Greece.
   [Gargalianos, Panagiotis; Stefanadis, Christodoulos] Athens Med Ctr, Athens, Greece.
   [Metallidis, Simeon] Aristotle Univ Thessaloniki, AHEPA Hosp, Dept Internal Med 1, Thessaloniki, Greece.
   [Sianos, George] Aristotle Univ Thessaloniki, AHEPA Hosp, Dept Cardiol 1, Thessaloniki, Greece.
   [Baltagiannis, Stefanos] Gen Hosp Kastoria, Dept Internal Med, Kastoria, Greece.
   [Panagopoulos, Periklis] Democritus Univ Thrace, Gen Hosp Alexandroupoli, Dept Internal Med 2, Alexandroupolis, Greece.
   [Dolianitis, Konstantinos] Mpodosakio Gen Hosp Ptolemaida, Dept Internal Med, Ptolemaida, Greece.
   [Randou, Efthalia] Gen Hosp Kozani, Dept Internal Med, Kozani, Greece.
   [Syrigos, Konstantinos] Natl & Kapodistrian Univ Athens, Gen Hosp Sotiria, Dept Internal Med 3, Athens, Greece.
   [Kotanidou, Anastasia] Natl & Kapodistrian Univ Athens, Gen Hosp Evangelismos, Intens Care Unit 1, Athens, Greece.
   [Koulouris, Nikolaos G.] Natl & Kapodistrian Univ Athens, Gen Hosp Sotiria, Dept Pneumonol 1, Athens, Greece.
   [Milionis, Haralampos] Univ Ioannina, Ioannina Univ Hosp, Dept Internal Med 1, Ioannina, Greece.
   [Sipsas, Nikolaos] Laikon Gen Hosp, Infect Dis Unit, Athens, Greece.
   [Gogos, Charalampos] Univ Hosp Patras, Internal Med Dept, Patras, Greece.
   [Tsoukalas, George] Gen Hosp Sotiria, Dept Pneumonol 4, Athens, Greece.
   [Olympios, Christoforos D.] Gen Hosp Elefsina Thriasio, Dept Cardiol, Elefsina, Greece.
   [Tsagalou, Eleftheria] Alexandra Hosp, Therapeut Dept, Athens, Greece.
   [Migdalis, Ilias] NIMTS Hosp, Med Dept 2, Athens, Greece.
   [Gerakari, Styliani] Gen Hosp West Attica Agia Varvara, Dept Internal Med, Athens, Greece.
   [Davlouros, Pericles; Hahalis, George] Univ Patras, Dept Cardiol, Med Sch, Patras, Greece.
   [Kanonidis, Ioannis] Aristotle Univ Thessaloniki, AHEPA Hosp, Dept Cardiol 2, Thessaloniki, Greece.
   [Katritsis, Demosthenes] Hygeia Hosp, Dept Cardiol 3, Athens, Greece.
   [Kolettis, Theofilos; Michalis, Lampros; Naka, Katerina K.; Goudevenos, John] Univ Ioannina, Ioannina Univ Hosp, Dept Cardiol, Ioannina, Greece.
   [Triposkiadis, Filippos] Univ Gen Hosp Larissa, Dept Cardiol, Larisa, Greece.
   [Vavouranakis, Emmanouil] Natl & Kapodistrian Univ Athens, Gen Hosp Sotiria, Dept Cardiol 3, Athens, Greece.
   [Martinez-Dolz, Luis] Hosp Univ & Politecn La Fe, Valencia, Spain.
   [Cleman, Michael] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA.
   [Tsiodras, Sotirios] Natl & Kapodistrian Univ Athens, Attikon Hosp, Dept Internal Med 4, Athens, Greece.
   [Mehran, Roxana; Dangas, George] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
RP Deftereos, SG (corresponding author), Natl & Kapodistrian Univ Athens, Attikon Hosp, Dept Cardiol 2, 1Rimini St, Athens, Greece.
EM spdeftereos@gmail.com
RI Stefanadis, Christodoulos/ABH-2232-2020; Siasos,
   Gerasimos/AAD-7218-2019; Naka, Katerina K./O-1431-2019
OI Stefanadis, Christodoulos/0000-0001-5974-6454; Siasos,
   Gerasimos/0000-0001-7601-8870; Naka, Katerina K./0000-0002-9900-9659;
   Reimers, Bernhard/0000-0002-9890-5582; KOULOURIS,
   NIKOLAOS/0000-0002-1719-7220
FU ELPEN Pharmaceuticals, Acarpia Pharmaceuticals
FX The study was funded by ELPEN Pharmaceuticals, Acarpia Pharmaceuticals,
   and Karian Pharmaceuticals.
CR Angelidis C, 2018, CURR PHARM DESIGN, V24, P659, DOI 10.2174/1381612824666180123110042
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Castano-Rodriguez C, 2018, MBIO, V9, DOI 10.1128/mBio.02325-17
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Deftereos S, 2020, EUR HEART J-CARD PHA, V6, P255, DOI 10.1093/ehjcvp/pvaa033
   Deftereos S, 2015, CIRCULATION, V132, P1395, DOI 10.1161/CIRCULATIONAHA.115.017611
   Deftereos S, 2013, J AM COLL CARDIOL, V62, P1817, DOI 10.1016/j.jacc.2013.08.726
   Deftereos SG, 2020, HELL J CARDIOL, V61, P42, DOI 10.1016/j.hjc.2020.03.002
   Demirel A, 2008, EUR J PEDIATR, V167, P279, DOI 10.1007/s00431-007-0475-2
   Dolinay T, 2012, AM J RESP CRIT CARE, V185, P1225, DOI 10.1164/rccm.201201-0003OC
   Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011
   Grailer JJ, 2014, J IMMUNOL, V192, P5974, DOI 10.4049/jimmunol.1400368
   Gupta N, 2019, THROMB RES, V181, P77, DOI 10.1016/j.thromres.2019.07.013
   Jones HD, 2014, AM J RESP CELL MOL, V50, P270, DOI 10.1165/rcmb.2013-0087OC
   Kaksonen M, 2018, NAT REV MOL CELL BIO, V19, P313, DOI 10.1038/nrm.2017.132
   Leung YY, 2015, SEMIN ARTHRITIS RHEU, V45, P341, DOI 10.1016/j.semarthrit.2015.06.013
   Li DD, 2018, MOL MED REP, V18, P4399, DOI 10.3892/mmr.2018.9427
   Marques-Da-Silva C, 2011, BRIT J PHARMACOL, V163, P912, DOI 10.1111/j.1476-5381.2011.01254.x
   Misawa T, 2013, NAT IMMUNOL, V14, P454, DOI 10.1038/ni.2550
   National Public Health Organization, COR DIS COVID 19
   Schulz KF, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-18
   Shah B, 2020, CIRC-CARDIOVASC INTE, V13, DOI 10.1161/CIRCINTERVENTIONS.119.008717
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388
   US National Library of Medicine, COLCH COR SARS COV2
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   World Health Organisation, R D BLUEPR COVID 19
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 34
TC 39
Z9 40
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD JUN 24
PY 2020
VL 3
IS 6
AR e2013136
DI 10.1001/jamanetworkopen.2020.13136
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA MG3YU
UT WOS:000545970200005
PM 32579195
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Alshamrani, M
   AlHarbi, A
   Alkhudair, N
   AlNajjar, F
   Khan, M
   Ben Obaid, A
   Khardaly, A
   Bajnaid, E
   Samarkandi, H
   AlAzmi, A
   Alabdali, S
   AlNahedh, M
AF Alshamrani, Majed
   AlHarbi, Atika
   Alkhudair, Nora
   AlNajjar, Fouad
   Khan, Mansoor
   Ben Obaid, Abdulaziz
   Khardaly, Amr
   Bajnaid, Eshtyag
   Samarkandi, Hadeel
   AlAzmi, Aeshah
   Alabdali, Salman
   AlNahedh, Mohammed
TI Practical strategies to manage cancer patients during the COVID-19
   pandemic: Saudi Oncology Pharmacy Assembly Experts recommendations
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Article
DE Coronavirus; COVID-19; cancer; pandemic; SOPA
ID METASTATIC BREAST-CANCER; ZOLEDRONIC ACID; ORAL ETOPOSIDE; OPEN-LABEL;
   INTERMITTENT CHEMOTHERAPY; SUBCUTANEOUS TRASTUZUMAB; INTRAVENOUS
   TRASTUZUMAB; COLORECTAL-CANCER; MULTIPLE-MYELOMA; ADJUVANT THERAPY
AB Purpose During COVID-19 pandemic, cancer patients are considered one of the most vulnerable to infection since they tend to have advanced age, multiple comorbidities, and are often immunosuppressed by their cancer or therapy. Hence, the Saudi Oncology Pharmacy Assembly has issued recommendations to reduce the frequency of cancer patients' visits to oncology centers during the pandemic while maintaining the access to cancer therapy and minimize the risk of exposure to coronavirus disease. Materials and methods A qualitative methodological approach was conducted in April 2020 using a virtual panel discussion for collection of recommendations. Results A total of 12 expert oncology pharmacy practitioners shared their knowledge and experiences in managing oncology patients during the COVID-19 pandemic. The participants recognized many fundamental recommendations that were already applied in many cancer centers since the start of the COVID-19 outbreak. On that basis, the panelists developed eight practice-related recommendations for action, with a main focus on cancer treatment modification. Conclusions In conclusion, delivering cancer care during the COVID-19 pandemic carries significant challenges. This paper addressed suggestions to properly manage cancer patients during difficult times. Implementing changes in practice mandates a national collaborative effort from different sectors to guarantee the quality and continuity of care. The SOPA expert panel developed these recommendations, to ultimately contribute in maintaining access to cancer therapy while minimizing the risk of COVID-19 exposure.
C1 [Alshamrani, Majed; Alkhudair, Nora; AlNajjar, Fouad; Ben Obaid, Abdulaziz; Khardaly, Amr; AlNahedh, Mohammed] Saudi Oncol Pharm Assembly, Riyadh, Saudi Arabia.
   [Alshamrani, Majed; AlHarbi, Atika; Khan, Mansoor; Ben Obaid, Abdulaziz; Alabdali, Salman] Minist Natl Guard Hlth Affairs, Pharmaceut Care Serv, Jeddah, Saudi Arabia.
   [Alkhudair, Nora] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia.
   [AlNajjar, Fouad] King Fahad Med City, Comprehens Canc Ctr, Pharmaceut Care Serv Dept, Riyadh, Saudi Arabia.
   [Khardaly, Amr] Minist Hlth, Therapeut Support Serv, Drug Policy & Control Dept, Riyadh, Saudi Arabia.
   [Bajnaid, Eshtyag] King Abdullah Med City, Clin Pharm Dept, Mecca, Saudi Arabia.
   [Samarkandi, Hadeel; AlNahedh, Mohammed] King Faisal Specialist Hosp & Res Ctr, Dept Pharmaceut Care, Oncol Pharm Serv, Riyadh, Saudi Arabia.
   [Alabdali, Salman] King Fahad Hosp, Minist Hlth, Almadina, Saudi Arabia.
RP Alshamrani, M (corresponding author), Minist Natl Guard Hlth Affairs, Dept Pharmaceut Care Serv, Jeddah 21423, Saudi Arabia.
EM Shamranima01@ngha.med.sa
RI Alnajjar, Fouad/AAU-3961-2020
OI Alnajjar, Fouad/0000-0003-1817-1046; Alshamrani,
   Majed/0000-0001-8747-7271; AlHarbi, Atika/0000-0003-1057-7631;
   Alkhudair, Nora/0000-0002-5998-4345
CR Aapro M, 2012, CANCER TREAT REV, V38, P120, DOI 10.1016/j.ctrv.2011.05.005
   Aguado C, 2014, WORLD J GASTROENTERO, V20, P6092, DOI 10.3748/wjg.v20.i20.6092
   Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   American Society of Clinical Oncology (ASCO), 2020, COVID 19 PAT CAR INF
   Angiolillo A, 2019, BLOOD, V134, DOI 10.1182/blood-2019-123565
   [Anonymous], 2020, INT GUID COVID 19 MA
   Berry SR, 2015, ANN ONCOL, V26, P477, DOI 10.1093/annonc/mdu272
   Bittner B, 2018, BIODRUGS, V32, P425, DOI 10.1007/s40259-018-0295-0
   Bourmaud A, 2014, ANN ONCOL, V25, P500, DOI 10.1093/annonc/mdt553
   Cameron D, 2017, LANCET ONCOL, V18, P929, DOI [10.1016/S1470-2045(17)30404-7, 10.1016/s1470-2045(17)30404-7]
   Cancer Patient Management During the COVID-19, 2020, CANC PAT MAN COVID 1
   Cardoso F, 2016, CANC TREAT COMM, DOI [10.1016/s2213-0896(16)06001-1, DOI 10.1016/S2213-0896(16)06001-1]
   Chakraborty R, 2018, LEUKEMIA, V32, P712, DOI 10.1038/leu.2017.256
   Chavez-MacGregor M, 2016, JAMA ONCOL, V2, P322, DOI 10.1001/jamaoncol.2015.3856
   Chionh F, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008398.pub2
   Coronavirus disease COVID-19: EBMT recommendations (update march 23 2020), 2020, COR DIS COVID 19 EBM
   COVID-19: guidelines for pharmacists and the pharmacy workforce. FIP 2020 <ext-link ext-link-type = uri xmlns:xlink = http://www.w3.org/1999/xlink xlink:href = https://www.fip.org/files/content/priority-areas/coronavirus/COVID-19-Guidelines-for-pharmacists-and-the-pharmacy-workforce.pdf>https://www.fip.org/files/content/priority-areas/coronavirus/COVID-19-Guidelines-for-pharmacists-and-the-pharmacy-workforce.pdf</ext-link>, 2020, COVID 19 GUID PHARM
   De Cock E, 2016, CANCER MED-US, V5, P389, DOI 10.1002/cam4.573
   Dimopoulos MA, 2019, LANCET, V393, P253, DOI 10.1016/S0140-6736(18)33003-4
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   European Society for Medical Oncology (ESMO), 2020, BREAST CANC COVID 19
   Giannone G, 2018, BREAST, V38, P160, DOI 10.1016/j.breast.2018.01.006
   Given BA, 2017, ASIA-PAC J ONCOL NUR, V4, P275, DOI 10.4103/apjon.apjon_7_17
   Guo Y, 2016, CANCER INVEST, V34, P94, DOI 10.3109/07357907.2015.1104689
   Heo YA, 2019, DRUGS, V79, P767, DOI 10.1007/s40265-019-01120-1
   Himelstein AL, 2017, JAMA-J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Jackson GH, 2019, LANCET ONCOL, V20, P57, DOI 10.1016/S1470-2045(18)30687-9
   Jacobs JM, 2017, J ONCOL PRACT, V13, pE474, DOI 10.1200/JOP.2016.019729
   Jacquin JP, 2020, BREAST, V49, P1, DOI 10.1016/j.breast.2019.10.002
   Krikorian S, 2019, J ONCOL PHARM PRACT, V25, P1590, DOI 10.1177/1078155218800384
   Kroschinsky FP, 2006, BLOOD, V108, p668A, DOI 10.1182/blood.V108.11.2357.2357
   Lala M, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.3062
   Leveque D, 2014, ANTICANCER RES, V34, P1579
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Loree JM, 2018, CLIN COLORECTAL CANC, V17, P65, DOI 10.1016/j.clcc.2017.10.011
   Lugtenburg P, 2017, HAEMATOL ONCOL SS2, V35, P185, DOI DOI 10.1002/
   MARTIN M, 1994, J CLIN ONCOL, V12, P986, DOI 10.1200/JCO.1994.12.5.986
   MATEOS MV, 2019, J CLIN ONCOL S, V37
   Mauri D, 2010, CANCER TREAT REV, V36, P69, DOI 10.1016/j.ctrv.2009.10.006
   McCall C, 2017, J PEDIATR ONCOL NURS, V34, P122, DOI 10.1177/1043454216646533
   Mckeage K., 2017, DRUGS THER PERSPECT, V33, P321, DOI [10.1007/s40267-017-0413-y, DOI 10.1007/S40267-017-0413-Y]
   Murthy V, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2018-000434
   Noguchi S, 2016, BREAST CANCER-TOKYO, V23, P771, DOI 10.1007/s12282-015-0637-4
   Ogimi C, 2019, J PEDIAT INF DIS SOC, V8, P21, DOI 10.1093/jpids/pix093
   Patton J., 2008, J ONCOL PRACT, V4, P175
   Petrelli F, 2019, CANCERS, V11, DOI 10.3390/cancers11040550
   Pivot X, 2017, EUR J CANCER, V86, P82, DOI 10.1016/j.ejca.2017.08.019
   Pivot X, 2014, ANN ONCOL, V25, P1979, DOI 10.1093/annonc/mdu364
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470-2045(18)30072-X
   Rajkumar SV, 2020, AM J HEMATOL, V95, P548, DOI 10.1002/ajh.25791
   Renner A, 2019, J GLOB ONCOL, V5, DOI 10.1200/JGO.19.00142
   Rivera E, 2008, CANCER-AM CANCER SOC, V112, P1455, DOI 10.1002/cncr.23321
   Shah NP, 2019, J NATL COMPR CANC NE, V17, P611, DOI 10.6004/jnccn.2019.5013
   Sharma Jivesh J, 2012, J Oncol Pract, V8, P68, DOI 10.1200/JOP.2011.000436
   Shell Abigail, 2019, Fed Pract, V36, pS22
   Sirintrapun S Joseph, 2018, Am Soc Clin Oncol Educ Book, V38, P540, DOI 10.1200/EDBK_200141
   Stadtmauer EA, 2019, J CLIN ONCOL, V37, P589, DOI 10.1200/JCO.18.00685
   Steger GG, 2018, CLIN BREAST CANCER, V18, pE41, DOI 10.1016/j.clbc.2017.05.012
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Sykes Claire, 2018, P T, V43, P154
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Valabrega G, 2015, BREAST J, V21, P241, DOI 10.1111/tbj.12398
   Walko CM, 2005, CLIN THER, V27, P23, DOI 10.1016/j.clinthera.2005.01.005
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang X, 2014, ONCOL LETT, V7, P1997, DOI 10.3892/ol.2014.1982
   Weingart Saul N, 2008, J Natl Compr Canc Netw, V6 Suppl 3, pS1
   Weinkove R, 2020, MED J AUSTRALIA, V212, P481, DOI 10.5694/mja2.50607
   Wex J, 2013, CLINICOECONOMIC OUTC, V5, P257, DOI 10.2147/CEOR.S44855
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhao X, 2020, ANN ONCOL, V31, P302, DOI 10.1016/j.annonc.2019.10.015
   Zinner NR, 2004, UROLOGY, V64, P1177, DOI 10.1016/j.urology.2004.07.033
NR 72
TC 0
Z9 0
U1 3
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078-1552
EI 1477-092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD SEP
PY 2020
VL 26
IS 6
BP 1429
EP 1440
AR 1078155220935564
DI 10.1177/1078155220935564
EA JUN 2020
PG 12
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA ND8AA
UT WOS:000543422900001
PM 32580641
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vafea, MT
   Atalla, E
   Georgakas, J
   Shehadeh, F
   Mylona, EK
   Kalligeros, M
   Mylonakis, E
AF Vafea, Maria Tsikala
   Atalla, Eleftheria
   Georgakas, Joanna
   Shehadeh, Fadi
   Mylona, Evangelia K.
   Kalligeros, Markos
   Mylonakis, Eleftherios
TI Emerging Technologies for Use in the Study, Diagnosis, and Treatment of
   Patients with COVID-19
SO CELLULAR AND MOLECULAR BIOENGINEERING
LA English
DT Article
DE Artificial intelligence; Nanomedicine; Vaccines; Drug repurposing;
   Monoclonal antibodies; Mathematical modeling; Big Data; Internet of
   Things; Community screening; Telemedicine; Robots; 3D-printing
ID VACCINES; DESIGN
AB Introduction The COVID-19 pandemic has caused an unprecedented health and economic worldwide crisis. Innovative solutions are imperative given limited resources and immediate need for medical supplies, healthcare support and treatments. Aim The purpose of this review is to summarize emerging technologies being implemented in the study, diagnosis, and treatment of COVID-19. Results Key focus areas include the applications of artificial intelligence, the use of Big Data and Internet of Things, the importance of mathematical modeling for predictions, utilization of technology for community screening, the use of nanotechnology for treatment and vaccine development, the utility of telemedicine, the implementation of 3D-printing to manage new demands and the potential of robotics. Conclusion The review concludes by highlighting the need for collaboration in the scientific community with open sharing of knowledge, tools, and expertise.
C1 [Vafea, Maria Tsikala; Atalla, Eleftheria; Georgakas, Joanna; Shehadeh, Fadi; Mylona, Evangelia K.; Kalligeros, Markos; Mylonakis, Eleftherios] Brown Univ, Rhode Isl Hosp, Infect Dis Div, Warren Alpert Med Sch, 593 Eddy St,3rd Floor,Suite 328-330, Providence, RI 02903 USA.
RP Mylonakis, E (corresponding author), Brown Univ, Rhode Isl Hosp, Infect Dis Div, Warren Alpert Med Sch, 593 Eddy St,3rd Floor,Suite 328-330, Providence, RI 02903 USA.
EM emylonakis@lifespan.org
OI Mylonakis, Eleftherios/0000-0002-4624-0777; Mylona, Evangelia
   K/0000-0002-5365-5348
CR Adam D, 2020, NATURE, V580, P316, DOI 10.1038/d41586-020-01003-6
   Alex Z, 2020, POTENTIAL COVID 2019
   Anggraeni S, 2020, BIORXIV, V5, P8
   Baharudin H, CORONAVIRUS SINGAPOR
   Barton CM, 2020, SCIENCE, V368, P482, DOI 10.1126/science.abb8637
   Bekiros S, 2020, CHAOS SOLITON FRACT, V136, DOI 10.1016/j.chaos.2020.109828
   Bray H., ROBOT WILL SEE YOU N
   Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y
   Chauhan V, 2020, J EMERG TRAUMA SHOCK, V13, P20, DOI 10.4103/JETS.JETS_32_20
   Chen FM, 2020, J MICROBIOL IMMUNOL
   Ciliberto G, 2020, DRUG DISCOV TODAY
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Dormont F, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz5466
   Edward H., 2020, LOGISTICS AGGRESSIVE
   Fernando SID, 2020, BIONANOSCIENCE, V10, P696, DOI 10.1007/s12668-020-00758-6
   Gozes O, 2020, ARXIV200305037P
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Hong YR, 2020, JMIR PUBLIC HLTH SUR, V6, P168, DOI 10.2196/18961
   Hosny A, 2018, NAT REV CANCER, V18, P500, DOI 10.1038/s41568-018-0016-5
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Hu Z., 2020, ARXIV200207112P
   Ienca M, 2020, NAT MED, DOI 10.1038/s41591-020-0832-5
   Ishack S, 2020, AM J MED
   Jiang XG, 2020, CMC-COMPUT MATER CON, V63, P537, DOI 10.32604/cmc.2020.010691
   Kelly CJ, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1426-2
   Kim YC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0188-3
   Kimmig R, 2020, J GYNECOL ONCOL, V31, DOI 10.3802/jgo.2020.31.e59
   Koh D, SPHCC EMPLOYS IOT TE
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Mahapatra S, 2020, REPURPOSING THERAPEU
   Mahmood S, 2020, JMIR PUBLIC HLTH SUR, V6, P226, DOI 10.2196/18980
   Mann DM, 2020, J AM MED INFORM ASS
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mei XY, 2020, NAT MED, V26, P1224, DOI 10.1038/s41591-020-0931-3
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Mohammed M., 2020, INT J PSYCHOSOC REHA, V24, P2287
   Narin A, 2020, ARXIV200310849P
   Naude W, 2020, AI SOC, V35, P761, DOI 10.1007/s00146-020-00978-0
   O'Neill P. H., APPLE GOOGLES COVID
   Panovska-Griffiths J, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08671-z
   Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243
   Peirlinck M, 2020, BIOMECH MODEL MECHAN, V19, P2179, DOI 10.1007/s10237-020-01332-5
   Pimentel TAPF, 2009, CHEM BIOL DRUG DES, V73, P53, DOI 10.1111/j.1747-0285.2008.00746.x
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Randhawa GS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232391
   Rhodes T, 2020, CRIT PUBLIC HEALTH, V30, P253, DOI 10.1080/09581596.2020.1748310
   Robert-Guroff M, 2007, CURR OPIN BIOTECH, V18, P546, DOI 10.1016/j.copbio.2007.10.010
   Sanders JM, 2020, JAMA
   Shi F., 2020, ARXIV200402731P
   Singh RP, 2020, DIABETES METAB SYND, V14, P521, DOI 10.1016/j.dsx.2020.04.041
   Stephenson J., 2020, REPORT PROPOSES COVI
   Swennen GRJ, 2020, INT J ORAL MAX SURG, V49, P673, DOI 10.1016/j.ijom.2020.03.015
   Tang YJ, 2020, EMERG MICROBES INFEC, V9, P827, DOI 10.1080/22221751.2020.1760146
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tino Rance, 2020, 3D Print Med, V6, P11, DOI 10.1186/s41205-020-00064-7
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang CJ, 2020, JAMA, P2020
   Wang Y, 2020, EBIOMEDICINE
   Wesemann C, 2020, MATERIALS, V13, DOI 10.3390/ma13081997
   who.int, 2020, ROLL UPD COR DIS COV
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yan L, 2020, PREDICTION CRITICALI
   Yang GZ, 2020, SCI ROBOT, V5, DOI 10.1126/scirobotics.aba5894
   Yang T, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10040224
   Zheng C., 2020, DEEP LEARNING BASED
NR 65
TC 3
Z9 3
U1 5
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1865-5025
EI 1865-5033
J9 CELL MOL BIOENG
JI Cell. Mol. Bioeng.
PD AUG
PY 2020
VL 13
IS 4
SI SI
BP 249
EP 257
DI 10.1007/s12195-020-00629-w
EA JUN 2020
PG 9
WC Cell & Tissue Engineering; Biophysics; Cell Biology; Engineering,
   Biomedical
SC Cell Biology; Biophysics; Engineering
GA NK8WI
UT WOS:000543059400001
PM 32837582
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Menzies, R
   Aqel, J
   Abdi, I
   Joseph, T
   Seale, H
   Nathan, SA
AF Menzies, Robert
   Aqel, Jalil
   Abdi, Ikram
   Joseph, Telphia
   Seale, Holly
   Nathan, Sally Anne
TI Why is influenza vaccine uptake so low among Aboriginal adults?
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE Oceanic Ancestry Group; adult; immunisation programs; health knowledge;
   attitudes; practice
ID HEALTH-CARE; IMMUNIZATION; COVERAGE; AUSTRALIA
AB Objectives:Determine major barriers to, and facilitators of, influenza vaccination of Aboriginal adults, in order to improve coverage from the current level of 30%. Methods:i) A focus group with 13 Aboriginal Immunisation Healthcare Workers; and ii) a cross-sectional survey of Aboriginal people aged >= 18 years at the 2017 New South Wales Koori Knockout (29 September-2 October). Results:The focus group nominated poor identification of Aboriginality in general practice. Of 273 survey respondents, a substantial minority (30%) were unaware of their eligibility for free influenza vaccination. More than half (52%) believed the vaccine could cause influenza, 40% reported there were better ways than vaccination for avoiding infection and 30% said they would not have the vaccine if it was offered to them. Regarding health service access, few reported experiencing difficulty (17%), feeling uncomfortable (15%) or being discriminated against (8%), but 53% reported not receiving a reminder from a health professional. Conclusions:Misconceptions about influenza disease and vaccine among Aboriginal people and inadequate identification of Aboriginality in general practice appear to be the greatest barriers to vaccination, rather than health service access in general. Implications for public health:More active communication to and targeting of Aboriginal adults is required; this is even more urgent following the arrival of COVID-19.
C1 [Menzies, Robert; Aqel, Jalil; Abdi, Ikram; Joseph, Telphia; Seale, Holly; Nathan, Sally Anne] Univ NSW, Sch Publ Hlth & Community Med, Sydney, NSW, Australia.
   [Menzies, Robert] Univ NSW, Kirby Inst, Sydney, NSW, Australia.
RP Menzies, R (corresponding author), Sanofi, Bldg D 12,24 Talavera Rd, Macquarie Pk, NSW 2113, Australia.
EM r.menzies@unsw.edu.au
RI Seale, Holly/D-4200-2011
OI Seale, Holly/0000-0002-1877-5395
CR Abbas KM, 2018, PEERJ, V6, DOI 10.7717/peerj.5171
   Abbott P, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-598
   Andrew MK, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-36
   Australian Department of Health, 2017, AUSTR INFL SURV REP
   Australian Institute of Health and Welfare, 2011, HLTH WELF AUSTR AB T, P1
   Australian Institute of Health and Welfare, 2011, AD VACC SURV 2009 SU
   Australian Technical Advisory Group on Immunisation, 2017, AUSTR IMM HDB
   Braun V, 2013, SUCCESSFUL QUALITATI
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]
   Charan Jaykaran, 2013, Indian J Psychol Med, V35, P121, DOI 10.4103/0253-7176.116232
   Dyda A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1820-8
   Hendry AJ, 2018, MED J AUSTRALIA, V209, P24, DOI 10.5694/mja18.00063
   Lawrence G, 2004, AUST FAM PHYSICIAN, V33, P4
   Leask J, 2008, AUST NZ J PUBL HEAL, V32, P224, DOI 10.1111/j.1753-6405.2008.00220.x
   Marrone S, 2007, INT J CIRCUMPOL HEAL, V66, P188, DOI 10.3402/ijch.v66i3.18254
   Marshall Robert J, 2010, Med Health R I, V93, P271
   Naidu L, 2013, COMMUN DIS INTELL, V37, pS1
   National Foundation for Infectious Diseases, 2009, SURV AD DO NOT REC I
   Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017
   Pritchard EN, 2011, NEW ZEAL MED J, V124, P75
   Randolph W, 2004, ANNU REV PUBL HEALTH, V25, P419, DOI 10.1146/annurev.publhealth.25.101802.123046
   Smailbegovic MS, 2003, CHILD CARE HLTH DEV, V29, P303, DOI 10.1046/j.1365-2214.2003.00347.x
   SPSS, 2013, STAT WIND VERS 22 0
   Ward K, 2012, AUST NZ J PUBL HEAL, V36, P369, DOI 10.1111/j.1753-6405.2012.00897.x
   Webster F, 2019, AUST NZ J PUBL HEAL, DOI 10.1111/1753-6405.12944
   Zimmerman RK, 2003, AM J MED, V114, P31, DOI 10.1016/S0002-9343(02)01421-3
NR 26
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1326-0200
EI 1753-6405
J9 AUST NZ J PUBL HEAL
JI Aust. N. Z. Publ. Health
PD AUG
PY 2020
VL 44
IS 4
BP 279
EP 283
DI 10.1111/1753-6405.13004
EA JUN 2020
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MX9WK
UT WOS:000542557100001
PM 32583522
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Wlodawer, A
   Dauter, Z
   Shabalin, I
   Gilski, M
   Brzezinski, D
   Kowiel, M
   Minor, W
   Rupp, B
   Jaskolski, M
AF Wlodawer, Alexander
   Dauter, Zbigniew
   Shabalin, Ivan
   Gilski, Miroslaw
   Brzezinski, Dariusz
   Kowiel, Marcin
   Minor, Wladek
   Rupp, Bernhard
   Jaskolski, Mariusz
TI Ligand-centered assessment of SARS-CoV-2 drug target models in the
   Protein Data Bank
SO FEBS JOURNAL
LA English
DT Article
DE coronavirus; COVID-19; spike glycoprotein; structure-guided drug
   discovery; viral proteases
ID SARS; CRYSTALLOGRAPHY; REFINEMENT; REQUIRES; CORRECT; DESIGN
AB A bright spot in the SARS-CoV-2 (CoV-2) coronavirus pandemic has been the immediate mobilization of the biomedical community, working to develop treatments and vaccines for COVID-19. Rational drug design against emerging threats depends on well-established methodology, mainly utilizing X-ray crystallography, to provide accurate structure models of the macromolecular drug targets and of their complexes with candidates for drug development. In the current crisis, the structural biological community has responded by presenting structure models of CoV-2 proteins and depositing them in the Protein Data Bank (PDB), usually without time embargo and before publication. Since the structures from the first-line research are produced in an accelerated mode, there is an elevated chance of mistakes and errors, with the ultimate risk of hindering, rather than speeding up, drug development. In the present work, we have used model-validation metrics and examined the electron density maps for the deposited models of CoV-2 proteins and a sample of related proteins available in the PDB as of April 1, 2020. We present these results with the aim of helping the biomedical community establish a better-validated pool of data. The proteins are divided into groups according to their structure and function. In most cases, no major corrections were necessary. However, in several cases significant revisions in the functionally sensitive area of protein-inhibitor complexes or for bound ions justified correction, re-refinement, and eventually reversioning in the PDB. The re-refined coordinate files and a tool for facilitating model comparisons are available at . Database Validated models of CoV-2 proteins are available in a dedicated, publicly accessible web service
C1 [Wlodawer, Alexander] NCI, Prot Struct Sect, Macromol Crystallog Lab, Frederick, MD 21701 USA.
   [Dauter, Zbigniew] NCI, Synchrotron Radiat Res Sect, Macromol Crystallog Lab, Argonne Natl Lab, Argonne, IL USA.
   [Shabalin, Ivan; Brzezinski, Dariusz; Minor, Wladek] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA USA.
   [Gilski, Miroslaw; Jaskolski, Mariusz] Adam Mickiewicz Univ, Fac Chem, Dept Crystallog, Poznan, Poland.
   [Gilski, Miroslaw; Brzezinski, Dariusz; Kowiel, Marcin; Jaskolski, Mariusz] Polish Acad Sci, Ctr Biocrystallog Res, Inst Bioorgan Chem, Poznan, Poland.
   [Brzezinski, Dariusz] Poznan Univ Tech, Inst Comp Sci, Poznan, Poland.
   [Rupp, Bernhard] KK Hofkristallamt, San Diego, CA USA.
   [Rupp, Bernhard] Med Univ Innsbruck, Inst Genet Epidemiol, Innsbruck, Austria.
RP Jaskolski, M (corresponding author), Adam Mickiewicz Univ, Fac Chem, Dept Crystallog, Poznan, Poland.
EM mariuszj@amu.edu.pl
RI Brzezinski, Dariusz/F-7789-2014; Shabalin, Ivan/H-1902-2016
OI Brzezinski, Dariusz/0000-0001-9723-525X; Shabalin,
   Ivan/0000-0003-3955-9242; Gilski, Miroslaw/0000-0002-3941-9947; Rupp,
   Bernhard/0000-0002-3300-6965; Minor, Wladek/0000-0001-7075-7090;
   Jaskolski, Mariusz/0000-0003-1587-6489
FU Intramural Research Program of the NIH, National Cancer Institute,
   Center for Cancer ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); NIGMSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01-GM132595]; Polish National
   Agency for Academic Exchange [PPN/BEK/2018/1/00058/U/00001]; FWF
   (Austrian Science Foundation)Austrian Science Fund (FWF) [P 32821];
   National Science Center (NCN, Poland) [2020/01/0/NZ1/00134]
FX We thank C.X. Weichenberger, Eurac Bozen, Italy, for PDB data mining
   with Twilight. We also thank David R. Cooper and Marek Grabowski for
   their help during our research and manuscript preparation. We are
   indebted to the anonymous reviewer for the extremely thoughtful and
   helpful suggestions. This work was supported in part by the Intramural
   Research Program of the NIH, National Cancer Institute, Center for
   Cancer Research, by NIGMS grant R01-GM132595. DB acknowledges the
   support of the Polish National Agency for Academic Exchange under Grant
   No. PPN/BEK/2018/1/00058/U/00001. BR acknowledges partial funding
   through FWF (Austrian Science Foundation) grant P 32821. We acknowledge
   support of the National Science Center (NCN, Poland), grant No.
   2020/01/0/NZ1/00134.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baker EN, 2020, ACTA CRYSTALLOGR F, V76, P158, DOI 10.1107/S2053230X20004847
   Blanc E, 2004, ACTA CRYSTALLOGR D, V60, P2210, DOI 10.1107/S0907444904016427
   BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0
   Burley SK, 2020, NATURE, V580, P167, DOI 10.1038/d41586-020-00888-7
   Burley SK, 2018, PROTEIN SCI, V27, P316, DOI 10.1002/pro.3331
   Congreve M, 2003, DRUG DISCOV TODAY, V8, P876, DOI 10.1016/S1359-6446(03)02831-9
   Dauter Z, 2018, ACTA CRYSTALLOGR D, V74, P939, DOI 10.1107/S2059798318009828
   Dauter Z, 2014, IUCRJ, V1, P179, DOI 10.1107/S2052252514005442
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   DiMasi JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/j.jhealeco.2016.01.012
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Ghosh AK, 2016, J MED CHEM, V59, P5172, DOI 10.1021/acs.jmedchem.5b01697
   Grabowski M, 2016, ACTA CRYSTALLOGR D, V72, P1181, DOI 10.1107/S2059798316014716
   Hassan MI, 2016, CURR TOP MED CHEM, V16, P899, DOI 10.2174/1568026616999150918145640
   Helliwell JR, 2019, IUCRJ, V6, P341, DOI 10.1107/S2052252519005918
   Henry NFM, 1969, INT TABLES XRAY CRYS
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hoffer L, 2018, MOL INFORM, V37, DOI 10.1002/minf.201800059
   Jaskolski M, 2015, FEBS J, V282, P4059, DOI 10.1111/febs.13397
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kowiel M, 2014, ACTA CRYSTALLOGR D, V70, P3290, DOI 10.1107/S1399004714024572
   Lee JE, 2008, NATURE, V454, P177, DOI 10.1038/nature07082
   Li F, 2008, J VIROL, V82, P6984, DOI 10.1128/JVI.00442-08
   Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949
   Minor W, 2016, STRUCTURE, V24, P216, DOI 10.1016/j.str.2015.12.010
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270
   Parks CD, 2020, J COMPUT AID MOL DES, V34, P99, DOI 10.1007/s10822-020-00289-y
   Pearce NM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15123
   Pearce NM, 2017, ACTA CRYSTALLOGR D, V73, P256, DOI 10.1107/S2059798317003412
   Porebski PJ, 2020, PROTEIN SCI, V29, P120, DOI 10.1002/pro.3747
   Porebski PJ, 2018, PROTEIN SCI, V27, P86, DOI 10.1002/pro.3272
   Raczynska JE, 2018, DRUG RESIST UPDATE, V40, P1, DOI 10.1016/j.drup.2018.08.001
   Rupp B, 2016, FEBS J, V283, P4452, DOI 10.1111/febs.13765
   Shabalin I, 2015, ACTA CRYSTALLOGR D, V71, P1965, DOI 10.1107/S139900471500629X
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316
   Smith M, 2020, CHEMRXIV11871402
   Suttisintong K, 2019, CURR TOP MED CHEM, V19, P1599, DOI 10.2174/1568026619666190712204050
   Thomas SE, 2019, PHILOS T R SOC A, V377, DOI 10.1098/rsta.2018.0422
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Weichenberger CX, 2013, ACTA CRYSTALLOGR F, V69, P195, DOI 10.1107/S1744309112044387
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wlodawer A, 2015, INHIBITORS HIV PROTE, P738
   Wlodawer A, 2018, FEBS J, V285, P444, DOI 10.1111/febs.14320
   Wlodawer A, 2013, FEBS J, V280, P5705, DOI 10.1111/febs.12495
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang HW, 2016, J APPL CRYSTALLOGR, V49, P1081, DOI 10.1107/S1600576716004428
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zheng HP, 2014, NAT PROTOC, V9, P156, DOI 10.1038/nprot.2013.172
NR 58
TC 4
Z9 4
U1 2
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD SEP
PY 2020
VL 287
IS 17
BP 3703
EP 3718
DI 10.1111/febs.15366
EA JUN 2020
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NK6MS
UT WOS:000542570600001
PM 32418327
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zeng, QL
   Li, GM
   Ji, FP
   Ma, SH
   Zhang, GF
   Xu, JH
   Lin, WB
   Xu, GH
   Zhang, GQ
   Li, GT
   Cui, GL
   Liu, N
   Zeng, FJ
   Ai, ZG
   Xu, GF
   Liang, J
   Zhang, MM
   Li, C
   Zhang, ZH
   Wang, ZS
   Li, ZF
   Yu, ZJ
AF Zeng, Qing-Lei
   Li, Guang-Ming
   Ji, Fanpu
   Ma, Shu-Huan
   Zhang, Guo-Fan
   Xu, Jiang-Hai
   Lin, Wan-Bao
   Xu, Guang-Hua
   Zhang, Guo-Qiang
   Li, Guo-Tao
   Cui, Guang-Lin
   Liu, Na
   Zeng, Fan-Jun
   Ai, Zhi-Guo
   Xu, Guang-Feng
   Liang, Jie
   Zhang, Min-Min
   Li, Cheng
   Zhang, Zhi-Hao
   Wang, Ze-Shuai
   Li, Zongfang
   Yu, Zu-Jiang
TI Clinical course and treatment efficacy of COVID-19 near Hubei Province,
   China: A multicentre, retrospective study
SO TRANSBOUNDARY AND EMERGING DISEASES
LA English
DT Article
DE anti-viral efficacy; clinical course; Coronavirus disease 2019
   (COVID-19); epidemiology; Henan Province; Severe acute respiratory
   syndrome coronavirus 2 (SARS-CoV-2); Shaanxi Province
ID MERS-COV; CORONAVIRUS; WUHAN
AB Currently, COVID-19 has been reported in nearly all countries globally. To date, little is known about the viral shedding duration, clinical course and treatment efficacy of COVID-19 near Hubei Province, China. This multicentre, retrospective study was performed in 12 hospitals in Henan and Shaanxi Provinces from 20 January to 8 February 2020. Clinical outcomes were followed up until 26 March 2020. The viral shedding duration, full clinical course and treatment efficacy were analysed in different subgroups of patients. A total of 149 COVID-19 patients were enrolled. The median age was 42 years, and 61.1% (91) were males. Of them, 133 (89.3%) had fever, 131 of 144 (91%) had pneumonia, 27 (18.1%) required intensive care unit (ICU) management, 3 (2%) were pregnant, and 3 (2%) died. Two premature newborns were negative for SARS-CoV-2. In total, the median SARS-CoV-2 shedding period and clinical course were 12 (IQR: 9-17; mean: 13.4, 95% CI: 12.5, 14.2) and 20 (IQR: 16-24; mean: 21.2, 95% CI: 20.1, 22.3) days, respectively, and ICU patients had longer median viral shedding periods (21 [17-24] versus 11 [9-15]) and clinical courses (30 [22-33] vs. 19 [15.8-22]) than non-ICU patients (bothp < .0001). SARS-CoV-2 clearances occurred at least 2 days before fatality in 3 non-survivors. Current treatment with any anti-viral agent or combination did not present the benefit of shortening viral shedding period and clinical course (allp > .05) in real-life settings. In conclusion, the viral shedding duration and clinical course in Henan and Shaanxi Provinces were shorter than those in Hubei Province, and current anti-viral therapies were ineffective for shortening viral shedding duration and clinical course in real-world settings. These findings expand our knowledge of the SARS-CoV-2 infection and may be helpful for management of the epidemic outbreak of COVID-19 worldwide. Further studies concerning effective anti-viral agents and vaccines are urgently needed.
C1 [Zeng, Qing-Lei; Zhang, Zhi-Hao; Yu, Zu-Jiang] Zhengzhou Univ, Dept Infect Dis, Affiliated Hosp 1, 1 Eastern Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Li, Guang-Ming; Ma, Shu-Huan; Zhang, Min-Min; Li, Cheng] Sixth Peoples Hosp Zhengzhou City, Dept Infect Dis, Zhengzhou, Henan, Peoples R China.
   [Ji, Fanpu] Xi An Jiao Tong Univ, Dept Infect Dis, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China.
   [Ji, Fanpu; Li, Zongfang] Xi An Jiao Tong Univ, Key Lab Environm & Genes Related Dis, Minist Educ China, Xian, Shaanxi, Peoples R China.
   [Zhang, Guo-Fan] Nanyang Med Coll, Dept Infect Dis, Affiliated Hosp 1, Nanyang, Henan, Peoples R China.
   [Xu, Jiang-Hai] Fifth Peoples Hosp Anyang City, Dept Infect Dis, Anyang, Henan, Peoples R China.
   [Lin, Wan-Bao] Xinyang Cent Hosp, Dept Infect Dis, Xinyang, Henan, Peoples R China.
   [Xu, Guang-Hua; Liu, Na] Yanan Univ, Dept Infect Dis, Affiliated Hosp, Yanan, Shaanxi, Peoples R China.
   [Zhang, Guo-Qiang; Li, Guo-Tao] Luoyang Cent Hosp, Dept Infect Dis, Luoyang, Henan, Peoples R China.
   [Cui, Guang-Lin] Zhengzhou Univ, Dept Clin Lab, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
   [Zeng, Fan-Jun; Ai, Zhi-Guo] Shangcheng Peoples Hosp, Dept Infect Dis, Shangcheng, Henan, Peoples R China.
   [Xu, Guang-Feng] Xiayi Peoples Hosp, Dept Infect Dis, Xiayi, Henan, Peoples R China.
   [Liu, Na] Sheqi Peoples Hosp, Dept Infect Dis, Sheqi, Henan, Peoples R China.
   [Liang, Jie] Qixian Peoples Hosp, Dept Infect Dis, Qixian, Henan, Peoples R China.
   [Wang, Ze-Shuai] Zhengzhou Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
   [Li, Zongfang] Xi An Jiao Tong Univ, Natl & Local Joint Engn Res Ctr Biodiag & Biother, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China.
RP Zeng, QL; Yu, ZJ (corresponding author), Zhengzhou Univ, Dept Infect Dis, Affiliated Hosp 1, 1 Eastern Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
EM zengqinglei2009@163.com; johnyuen@zzu.edu.cn
RI Zeng, Qing-Lei/ABG-3295-2020; Zeng, Qing-Lei/ABD-6706-2020
OI Zeng, Qing-Lei/0000-0002-2094-4784
FU Foundation for Distinguished Young Talents of Zhengzhou University
   Medical School [2020ZQLMS]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81970517];
   Zhongyuan (Henan) Thousand Outstanding Talents Plan [ZYQR201912179]; Key
   Scientific Research Project of Henan Higher Education Institutions of
   China [20B320028]
FX Foundation for Distinguished Young Talents of Zhengzhou University
   Medical School, Grant/Award Number: 2020ZQLMS; The National Natural
   Science Foundation of China, Grant/Award Number: 81970517; Zhongyuan
   (Henan) Thousand Outstanding Talents Plan, Grant/Award Number:
   ZYQR201912179; The Key Scientific Research Project of Henan Higher
   Education Institutions of China, Grant/Award Number: 20B320028
CR Aquino-Jarquin G, 2019, NANOMED-NANOTECHNOL, V18, P428, DOI 10.1016/j.nano.2019.03.006
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   Decaro N, 2020, VET MICROBIOL, V244, DOI 10.1016/j.vetmic.2020.108693
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1039, DOI 10.1001/jama.2020.1490
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Groneberg DA, 2005, LANCET INFECT DIS, V5, P147, DOI 10.1016/S1473-3099(05)70022-0
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   ICTV, 2020, NAM 2019 COR
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang FS, 2020, LANCET, V395, P391, DOI 10.1016/S0140-6736(20)30300-7
   WHO, 2020, 22 WHO
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, 105 WHO
   World Health Organization, 2020, 55 WHO
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 33
TC 2
Z9 2
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1865-1674
EI 1865-1682
J9 TRANSBOUND EMERG DIS
JI Transbound. Emerg. Dis.
PD NOV
PY 2020
VL 67
IS 6
BP 2971
EP 2982
DI 10.1111/tbed.13674
EA JUN 2020
PG 12
WC Infectious Diseases; Veterinary Sciences
SC Infectious Diseases; Veterinary Sciences
GA PC2BO
UT WOS:000542593100001
PM 32531138
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Robilotti, EV
   Babady, NE
   Mead, PA
   Rolling, T
   Perez-Johnston, R
   Bernardes, M
   Bogler, Y
   Caldararo, M
   Figueroa, CJ
   Glickman, MS
   Joanow, A
   Kaltsas, A
   Lee, YJ
   Lucca, A
   Mariano, A
   Morjaria, S
   Nawar, T
   Papanicolaou, GA
   Predmore, J
   Redelman-Sidi, G
   Schmidt, E
   Seo, SK
   Sepkowitz, K
   Shah, MK
   Wolchok, JD
   Hohl, TM
   Taur, Y
   Kamboj, M
AF Robilotti, Elizabeth V.
   Babady, N. Esther
   Mead, Peter A.
   Rolling, Thierry
   Perez-Johnston, Rocio
   Bernardes, Marilia
   Bogler, Yael
   Caldararo, Mario
   Figueroa, Cesar J.
   Glickman, Michael S.
   Joanow, Alexa
   Kaltsas, Anna
   Lee, Yeon Joo
   Lucca, Anabella
   Mariano, Amanda
   Morjaria, Sejal
   Nawar, Tamara
   Papanicolaou, Genovefa A.
   Predmore, Jacqueline
   Redelman-Sidi, Gil
   Schmidt, Elizabeth
   Seo, Susan K.
   Sepkowitz, Kent
   Shah, Monika K.
   Wolchok, Jedd D.
   Hohl, Tobias M.
   Taur, Ying
   Kamboj, Mini
TI Determinants of COVID-19 disease severity in patients with cancer
SO NATURE MEDICINE
LA English
DT Article
AB As of 10 April 2020, New York State had 180,458 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 9,385 reported deaths. Patients with cancer comprised 8.4% of deceased individuals(1). Population-based studies from China and Italy suggested a higher coronavirus disease 2019 (COVID-19) death rate in patients with cancer(2,3), although there is a knowledge gap as to which aspects of cancer and its treatment confer risk of severe COVID-19(4). This information is critical to balance the competing safety considerations of reducing SARS-CoV-2 exposure and cancer treatment continuation. From 10 March to 7 April 2020, 423 cases of symptomatic COVID-19 were diagnosed at Memorial Sloan Kettering Cancer Center (from a total of 2,035 patients with cancer tested). Of these, 40% were hospitalized for COVID-19, 20% developed severe respiratory illness (including 9% who required mechanical ventilation) and 12% died within 30 d. Age older than 65 years and treatment with immune checkpoint inhibitors (ICIs) were predictors for hospitalization and severe disease, whereas receipt of chemotherapy and major surgery were not. Overall, COVID-19 in patients with cancer is marked by substantial rates of hospitalization and severe outcomes. The association observed between ICI and COVID-19 outcomes in our study will need further interrogation in tumor-specific cohorts.
   Analysis of a large, single-center cohort of patients with cancer who were infected with COVID-19 uncovers factors associated with disease severity and interactions with anti-cancer therapies
C1 [Robilotti, Elizabeth V.; Babady, N. Esther; Mead, Peter A.; Rolling, Thierry; Bernardes, Marilia; Bogler, Yael; Caldararo, Mario; Figueroa, Cesar J.; Glickman, Michael S.; Joanow, Alexa; Kaltsas, Anna; Lee, Yeon Joo; Lucca, Anabella; Mariano, Amanda; Morjaria, Sejal; Nawar, Tamara; Papanicolaou, Genovefa A.; Predmore, Jacqueline; Redelman-Sidi, Gil; Schmidt, Elizabeth; Seo, Susan K.; Sepkowitz, Kent; Shah, Monika K.; Hohl, Tobias M.; Taur, Ying; Kamboj, Mini] Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis, 1275 York Ave, New York, NY 10021 USA.
   [Robilotti, Elizabeth V.; Kamboj, Mini] Mem Sloan Kettering Canc Ctr, Infect Control, 1275 York Ave, New York, NY 10021 USA.
   [Robilotti, Elizabeth V.; Mead, Peter A.; Figueroa, Cesar J.; Glickman, Michael S.; Kaltsas, Anna; Lee, Yeon Joo; Morjaria, Sejal; Papanicolaou, Genovefa A.; Redelman-Sidi, Gil; Seo, Susan K.; Sepkowitz, Kent; Shah, Monika K.; Wolchok, Jedd D.; Hohl, Tobias M.; Taur, Ying; Kamboj, Mini] Cornell Univ, Dept Med, Joan & Sanford Weill Med Coll, New York, NY 10065 USA.
   [Babady, N. Esther] Mem Sloan Kettering Canc Ctr, Dept Lab Med, Clin Microbiol Serv, 1275 York Ave, New York, NY 10021 USA.
   [Perez-Johnston, Rocio] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA.
   [Lucca, Anabella] Mem Sloan Kettering Canc Ctr, Employee Hlth & Wellness Serv, 1275 York Ave, New York, NY 10021 USA.
   [Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Dept Med, Ludwig Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA.
   [Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Dept Med, Parker Inst Canc Immunotherapy, 1275 York Ave, New York, NY 10021 USA.
RP Kamboj, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis, 1275 York Ave, New York, NY 10021 USA.; Kamboj, M (corresponding author), Mem Sloan Kettering Canc Ctr, Infect Control, 1275 York Ave, New York, NY 10021 USA.; Kamboj, M (corresponding author), Cornell Univ, Dept Med, Joan & Sanford Weill Med Coll, New York, NY 10065 USA.
EM kambojm@mskcc.org
OI Rolling, Thierry/0000-0002-0277-5067
FU Memorial Sloan Kettering Cancer Center [P30 CA008748]; Burroughs
   Wellcome Fund Investigator in the Pathogenesis of Infectious Diseases
   Award; Ludwig Collaborative and Swim Across America Laboratory; Parker
   Institute for Cancer Immunotherapy; Memorial Sloan Kettering Cancer
   Center Department of Medicine and Weill Cornell Medicine
FX This study was supported by the Memorial Sloan Kettering Cancer Center
   core grant (P30 CA008748), the Burroughs Wellcome Fund Investigator in
   the Pathogenesis of Infectious Diseases Award (to T.M.H.), the Ludwig
   Collaborative and Swim Across America Laboratory (to J.D.W.), the Parker
   Institute for Cancer Immunotherapy (to J.D.W.), the Memorial Sloan
   Kettering Cancer Center Department of Medicine and Weill Cornell
   Medicine.
CR CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Centers for Disease Control and Prevention, 2020, REAL TIM RT PCR PAN
   Centers for Disease Control and Prevention C, 2020, 2019 NOV COR 2019 NC
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Del Castillo M, 2016, CLIN INFECT DIS, V63, P1490, DOI 10.1093/cid/ciw539
   Garassino M. C., 2020, 2020 VIRT M AM ASS C
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Guan WJ, 2020, NEW ENGL J MED, V382, P1861, DOI 10.1056/NEJMc2005203
   Hijano DR, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03097
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   Hosmer Jr DW, 1999, APPL SURVIVAL ANAL R
   Hwang SW, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-93
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   New York State Department of Health, 2020, COVID 19 TRACK
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Whisenant JG, 2020, CANCER CELL, V37, P742, DOI 10.1016/j.ccell.2020.05.008
   WHO, 2020, REP WHO CHIN JOINT M
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
NR 27
TC 49
Z9 48
U1 5
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD AUG
PY 2020
VL 26
IS 8
BP 1218
EP +
DI 10.1038/s41591-020-0979-0
EA JUN 2020
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA MX8ZF
UT WOS:000543164300001
PM 32581323
OA Bronze
DA 2021-01-01
ER

PT J
AU Panigada, M
   Bottino, N
   Tagliabue, P
   Grasselli, G
   Novembrino, C
   Chantarangkul, V
   Pesenti, A
   Peyvandi, F
   Tripodi, A
AF Panigada, Mauro
   Bottino, Nicola
   Tagliabue, Paola
   Grasselli, Giacomo
   Novembrino, Cristina
   Chantarangkul, Veena
   Pesenti, Antonio
   Peyvandi, Flora
   Tripodi, Armando
TI Hypercoagulability of COVID-19 patients in intensive care unit: A report
   of thromboelastography findings and other parameters of hemostasis
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE factor VIII; hypercoagulability; protein C; protein S; sepsis; von
   Willebrand factor
ID COAGULATION; THROMBOSIS
AB Background The severe inflammatory state secondary to COVID-19 leads to a severe derangement of hemostasis that has been recently described as a state of disseminated intravascular coagulation (DIC) and consumption coagulopathy, defined as decreased platelet count, increased fibrin(ogen) degradation products such as D-dimer, as well as low fibrinogen. Aims Whole blood from 24 patients admitted at the intensive care unit because of COVID-19 was collected and evaluated with thromboelastography by the TEG point-of-care device on a single occasion and six underwent repeated measurements on two consecutive days for a total of 30 observations. Plasma was evaluated for the other parameters of hemostasis. Results TEG parameters are consistent with a state of hypercoagulability as shown by decreased values, and increased values of K angle and MA. Platelet count was normal or increased, prothrombin time and activated partial thromboplastin time were near(normal). Fibrinogen was increased and D-dimer was dramatically increased. C-reactive protein was increased. Factor VIII and von Willebrand factor (n = 11) were increased. Antithrombin (n = 11) was marginally decreased and protein C (n = 11) was increased. Conclusion The results of this cohort of patients with COVID-19 are not consistent with acute DIC, rather they support hypercoagulability together with a severe inflammatory state. These findings may explain the events of venous thromboembolism observed in some of these patients and support antithrombotic prophylaxis/treatment. Clinical trials are urgently needed to establish the type of drug, dosage, and optimal duration of prophylaxis.
C1 [Panigada, Mauro; Bottino, Nicola; Tagliabue, Paola; Pesenti, Antonio] Fdn IRCCS Ca Granda, Dept Anesthesia & Crit Care, Osped Maggiore, Milan, Italy.
   [Grasselli, Giacomo; Pesenti, Antonio; Peyvandi, Flora] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.
   [Novembrino, Cristina; Chantarangkul, Veena; Peyvandi, Flora; Tripodi, Armando] Fdn IRCCS Ca Granda Osped Maggiore, Angelo Bianchi Bon Hemophilia & Thrombosis Ctr, Via Pace 9, I-20122 Milan, Italy.
   [Novembrino, Cristina; Chantarangkul, Veena; Peyvandi, Flora; Tripodi, Armando] Fdn Luigi Villa, Via Pace 9, I-20122 Milan, Italy.
RP Tripodi, A (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore, Angelo Bianchi Bon Hemophilia & Thrombosis Ctr, Via Pace 9, I-20122 Milan, Italy.; Tripodi, A (corresponding author), Fdn Luigi Villa, Via Pace 9, I-20122 Milan, Italy.
EM armando.tripodi@unimi.it
RI Panigada, Mauro/K-4650-2014; Pesenti, Antonio/H-7483-2012
OI Panigada, Mauro/0000-0003-4841-9794; Pesenti,
   Antonio/0000-0003-2593-729X
CR Ammollo CT, 2011, J THROMB HAEMOST, V9, P1795, DOI 10.1111/j.1538-7836.2011.04422.x
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bucciarelli P, 2012, THROMB RES, V129, P591, DOI 10.1016/j.thromres.2011.08.020
   Campello E, 2015, THROMB RES, V135, P548, DOI 10.1016/j.thromres.2015.01.003
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107
   Kapoor S, 2018, THROMB RES, V170, P87, DOI 10.1016/j.thromres.2018.08.005
   Kupcinskiene K, 2017, MED SCI MONITOR, V23, P1819, DOI 10.12659/MSM.900769
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Raeven P, 2018, THERANOSTICS, V8, P3348, DOI 10.7150/thno.23453
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   Thomas W, 2018, J THROMB HAEMOST, V16, P2336, DOI 10.1111/jth.14265
   Tripodi A, 2013, ANN HEMATOL, V92, P1633, DOI 10.1007/s00277-013-1834-x
   Vazquez-Garza E, 2017, J THROMB THROMBOLYS, V44, P377, DOI 10.1007/s11239-017-1528-7
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 224
Z9 231
U1 18
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JUL
PY 2020
VL 18
IS 7
BP 1738
EP 1742
DI 10.1111/jth.14850
EA JUN 2020
PG 5
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA MG6WK
UT WOS:000542581400001
PM 32302438
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Melis, D
   Mugheddu, C
   Sanna, S
   Atzori, L
   Rongioletti, F
AF Melis, Daniele
   Mugheddu, Cristina
   Sanna, Silvia
   Atzori, Laura
   Rongioletti, Franco
TI Clinical efficacy, speed of improvement and safety of apremilast for the
   treatment of adult Psoriasis during COVID-19 pandemic
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE apremilast; COVID-19; efficacy; psoriasis; safety
ID SEVERE PLAQUE PSORIASIS; REAL-WORLD; PHASE-III; MODERATE; EXPERIENCE;
   INHIBITOR
AB Time to improvement is a crucial characteristic for effective treatments of chronic inflammatory conditions, such as psoriasis. Apremilast is a recently approved drug, belonging to the small molecule phosphodiesterase 4 inhibitors, whose optimal safety and efficacy profile is somewhat affected by slow activity rate in clinical trials. Real world case series are suggesting a more consistent improvement, and with this additional personal investigation on 48 patients, we signal that 58% of patients achieved Psoriasis Area and Severity Index (PASI) 50, and 19% PASI 75 improvement in the first 8 weeks of treatment. Results at 16-week are remarkable, with overall 55% of patients achieving PASI 75, 21% PASI 90 and 14% PASI 100. Only 8 patients (18, 6%) had slightly improved, although satisfied with the regimen, and determined to continue. Noteworthy, our population was rather problematic in terms of comorbidities (86%), and resistance to other treatments, with only 28% naive to systemics, including biologics. Moreover, the observation period includes the Italian outbreak of COVID-19 epidemic, and further information on apremilast safety are provided, no one of the patients having stopped treatment. In such a critical period, the apremilast satisfactory speed of therapeutic response in a real-world setting has further strengthens patient's compliance to remain safely at home, which is the best strategy to limit contagion.
C1 [Melis, Daniele; Mugheddu, Cristina; Sanna, Silvia; Atzori, Laura; Rongioletti, Franco] Univ Cagliari, Dept Med Sci & Publ Hlth, Dermatol Clin, Cagliari, Italy.
RP Atzori, L (corresponding author), Clin Dermatol, Via Osped 54, I-09124 Cagliari, Italy.
EM atzoril@unica.it
CR Brownstone ND, 2020, DERMATOLOGY THER, DOI 10.1007/s13555-020-00377-9
   Ighani A, 2018, J AM ACAD DERMATOL, V78, P801, DOI 10.1016/j.jaad.2017.09.067
   Kutlu O, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13383
   Mayba JN, 2017, J CUTAN MED SURG, V21, P145, DOI 10.1177/1203475416676030
   Mugheddu C, 2020, J EUR ACAD DERMATOL, V34, pE376, DOI 10.1111/jdv.16625
   Papadavid E, 2018, J EUR ACAD DERMATOL, V32, P1173, DOI 10.1111/jdv.14832
   Papp K, 2015, J AM ACAD DERMATOL, V73, P37, DOI 10.1016/j.jaad.2015.03.049
   Paul C, 2015, BRIT J DERMATOL, V173, P1387, DOI 10.1111/bjd.14164
   Vujic I, 2018, J EUR ACAD DERMATOL, V32, P254, DOI 10.1111/jdv.14598
   Wong TH, 2017, CLIN EXP DERMATOL, V42, P675, DOI 10.1111/ced.13150
   Zerilli T, 2015, PHARMACOL THERAPEUT, V40, P459
NR 11
TC 3
Z9 3
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13722
DI 10.1111/dth.13722
EA JUN 2020
PG 4
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000542422700001
PM 32475036
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rosenberg, ES
   Dufort, EM
   Udo, T
   Wilberschied, LA
   Kumar, J
   Tesoriero, J
   Weinberg, P
   Kirkwood, J
   Muse, A
   DeHovitz, J
   Blog, DS
   Hutton, B
   Holtgrave, DR
   Zucker, HA
AF Rosenberg, Eli S.
   Dufort, Elizabeth M.
   Udo, Tomoko
   Wilberschied, Larissa A.
   Kumar, Jessica
   Tesoriero, James
   Weinberg, Patti
   Kirkwood, James
   Muse, Alison
   DeHovitz, Jack
   Blog, Debra S.
   Hutton, Brad
   Holtgrave, David R.
   Zucker, Howard A.
TI Association of Treatment With Hydroxychloroquine or Azithromycin With
   In-Hospital Mortality in Patients With COVID-19 in New York State
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
AB Key PointsQuestionAmong patients with coronavirus disease 2019 (COVID-19), is there an association between use of hydroxychloroquine, with or without azithromycin, and in-hospital mortality? FindingsIn a retrospective cohort study of 1438 patients hospitalized in metropolitan New York, compared with treatment with neither drug, the adjusted hazard ratio for in-hospital mortality for treatment with hydroxychloroquine alone was 1.08, for azithromycin alone was 0.56, and for combined hydroxychloroquine and azithromycin was 1.35. None of these hazard ratios were statistically significant. MeaningAmong patients hospitalized with COVID-19, treatment with hydroxychloroquine, azithromycin, or both was not associated with significantly lower in-hospital mortality.
   ImportanceHydroxychloroquine, with or without azithromycin, has been considered as a possible therapeutic agent for patients with coronavirus disease 2019 (COVID-19). However, there are limited data on efficacy and associated adverse events. ObjectiveTo describe the association between use of hydroxychloroquine, with or without azithromycin, and clinical outcomes among hospital inpatients diagnosed with COVID-19. Design, Setting, and ParticipantsRetrospective multicenter cohort study of patients from a random sample of all admitted patients with laboratory-confirmed COVID-19 in 25 hospitals, representing 88.2% of patients with COVID-19 in the New York metropolitan region. Eligible patients were admitted for at least 24 hours between March 15 and 28, 2020. Medications, preexisting conditions, clinical measures on admission, outcomes, and adverse events were abstracted from medical records. The date of final follow-up was April 24, 2020. ExposuresReceipt of both hydroxychloroquine and azithromycin, hydroxychloroquine alone, azithromycin alone, or neither. Main Outcomes and MeasuresPrimary outcome was in-hospital mortality. Secondary outcomes were cardiac arrest and abnormal electrocardiogram findings (arrhythmia or QT prolongation). ResultsAmong 1438 hospitalized patients with a diagnosis of COVID-19 (858 [59.7%] male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or both were more likely than those not receiving either drug to have diabetes, respiratory rate >22/min, abnormal chest imaging findings, O-2 saturation lower than 90%, and aspartate aminotransferase greater than 40 U/L. Overall in-hospital mortality was 20.3% (95% CI, 18.2%-22.4%). The probability of death for patients receiving hydroxychloroquine+azithromycin was 189/735 (25.7% [95% CI, 22.3%-28.9%]), hydroxychloroquine alone, 54/271 (19.9% [95% CI, 15.2%-24.7%]), azithromycin alone, 21/211 (10.0% [95% CI, 5.9%-14.0%]), and neither drug, 28/221 (12.7% [95% CI, 8.3%-17.1%]). In adjusted Cox proportional hazards models, compared with patients receiving neither drug, there were no significant differences in mortality for patients receiving hydroxychloroquine+azithromycin (HR, 1.35 [95% CI, 0.76-2.40]), hydroxychloroquine alone (HR, 1.08 [95% CI, 0.63-1.85]), or azithromycin alone (HR, 0.56 [95% CI, 0.26-1.21]). In logistic models, compared with patients receiving neither drug cardiac arrest was significantly more likely in patients receiving hydroxychloroquine+azithromycin (adjusted OR, 2.13 [95% CI, 1.12-4.05]), but not hydroxychloroquine alone (adjusted OR, 1.91 [95% CI, 0.96-3.81]) or azithromycin alone (adjusted OR, 0.64 [95% CI, 0.27-1.56]), . In adjusted logistic regression models, there were no significant differences in the relative likelihood of abnormal electrocardiogram findings. Conclusions and RelevanceAmong patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. However, the interpretation of these findings may be limited by the observational design.
   This study examines associations between use of hydroxychloroquine, azithromycin, or both and in-hospital mortality, ECG changes, and cardiac arrest among patients with COVID-19 hospitalized in the metropolitan New York area in March 2020.
C1 [Rosenberg, Eli S.; Udo, Tomoko; Holtgrave, David R.] SUNY Albany, Sch Publ Hlth, Rensselaer, NY USA.
   [Dufort, Elizabeth M.; Wilberschied, Larissa A.; Kumar, Jessica; Tesoriero, James; Kirkwood, James; Muse, Alison; Blog, Debra S.; Hutton, Brad; Zucker, Howard A.] New York State Dept Hlth, Albany, NY USA.
   [Weinberg, Patti; DeHovitz, Jack] IPRO, Lake Success, NY USA.
   [DeHovitz, Jack] SUNY Downstate Hlth Sci Univ, Brooklyn, NY USA.
RP Rosenberg, ES (corresponding author), SUNY Albany, Dept Epidemiol & Biostat, Sch Publ Hlth, One Univ Pl,Room 123, Albany, NY 12203 USA.
EM erosenberg2@albany.edu
OI DeHovitz, Jack/0000-0001-7307-0614; Holtgrave, David/0000-0002-4321-7395
CR Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   COVID-19 Treatment Guidelines Panel, COVID 19 TREATM GUID
   Davis CE, 1986, MODERN STAT METHODS, P140
   FDA, 2020, FACT SHEET HLTH CAR
   FDA Drug Safety Communication, 2020, FDA CAUT US HYDR CHL
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gorgels APM, 2003, EUR HEART J, V24, P1204, DOI 10.1016/S0195-668X(03)00191-X
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Hung YM, 2018, INT J CLIN PRACT, V72, DOI 10.1111/ijcp.13095
   LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Low LS, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001339
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   McGhie TK, 2018, CLIN EXP RHEUMATOL, V36, P545
   New York State Department of Health, 2020, COVID 19 TRACK
   Petrilli CM, 2020, FACTORS ASS HOSPITAL, DOI [10.1101/2020.04.08.20057794, DOI 10.1101/2020.04.08.20057794]
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rosenberg ES, 2020, CLIN INFECT DIS, V71, P1953, DOI 10.1093/cid/ciaa549
   The Center for Systems Science and Engineering at Johns Hopkins University, 2020, COVID 19 DASHB
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 31
TC 219
Z9 221
U1 3
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUN 23
PY 2020
VL 323
IS 24
BP 2493
EP 2502
DI 10.1001/jama.2020.8630
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OS4QL
UT WOS:000590149400021
PM 32392282
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Vaduganathan, M
   van Meijgaard, J
   Mehra, MR
   Joseph, J
   O'Donnell, CJ
   Warraich, HJ
AF Vaduganathan, Muthiah
   van Meijgaard, Jeroen
   Mehra, Mandeep R.
   Joseph, Jacob
   O'Donnell, Christopher J.
   Warraich, Haider J.
TI Prescription Fill Patterns for Commonly Used Drugs During the COVID-19
   Pandemic in the United States
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Vaduganathan, Muthiah; Mehra, Mandeep R.] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.
   [van Meijgaard, Jeroen] GoodRx, Santa Monica, CA USA.
   [Joseph, Jacob; O'Donnell, Christopher J.; Warraich, Haider J.] VA Boston Healthcare Syst, Dept Med, Boston, MA USA.
RP Warraich, HJ (corresponding author), VA Boston Healthcare Syst, 1400 VFW Pkwy,4B-132, Boston, MA 02132 USA.
EM hwarraich@partners.org
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR002541] Funding Source: Medline
CR Food and Drug Administration, 2020, CURR RES DRUG SHORT
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Liu M, 2020, JAMA INTERN MED, V180, P1116, DOI 10.1001/jamainternmed.2020.1764
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   van Meijgaard J, 2020, GOODRX RES DATA DESC
NR 5
TC 12
Z9 11
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUN 23
PY 2020
VL 323
IS 24
BP 2524
EP 2526
DI 10.1001/jama.2020.9184
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA OS4QL
UT WOS:000590149400028
PM 32463459
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lee, M
   Eun, Y
   Park, K
   Heo, J
   Son, H
AF Lee, Miyoung
   Eun, Youngduck
   Park, Kyounghee
   Heo, Jeonghun
   Son, Hyunjin
TI Follow-up investigation of asymptomatic COVID-19 cases at diagnosis in
   Busan, Korea
SO EPIDEMIOLOGY AND HEALTH
LA English
DT Article
DE COVID-19; SARS-CoV-2; Asymptomatic infection; Asymptomatic transmission
AB OBJECTIVES: The objective of the study was to conduct a follow-up investigation of 10 asymptomatic patients at diagnosis among the 98 confirmed coronavirus disease 2019 (COVID-19) cases reported in Busan between February 21, 2020 and March 13, 2020 to determine whether asymptomatic infection and transmission during asymptomatic period are possible.
   METHODS: The study analyzed 10 asymptomatic, confirmed COVID-19 cases to determine whether asymptomatic infection is possible. We conducted in-depth interviews with patients and guardians; interviews with primary physicians; review of medical records and drug utilization review (DUR) reports; and base station-based location tracking.
   RESULTS: Among the 98, confirmed COVID-19 cases reported in Busan, the study analyzed 10 (10.2%) asymptomatic patients at diagnosis. The results confirmed that two (2.0%) patients reported to be asymptomatic during the initial epidemiological investigation, but turned symptomatic before diagnosis as per the in-depth interview results. Four cases (4.0%) of early detection led to confirmed diagnosis during the incubation period and presentation of symptoms after diagnosis. In addition, the remaining four patients (4.0%), having no subjective symptoms nor specific findings on chest radiography and computed tomography, remained asymptomatic until the isolation order was lifted. With regard to whether transmission during the asymptomatic period is possible, it was found that one out of 23 household contacts of the confirmed patients was identified as an additional confirmed case after coming in close contact with an index patient during the presymptomatic period.
   CONCLUSIONS: Among the 98 confirmed cases, asymptomatic infection was confirmed in four cases (4.0%). In addition, there was one additional confirmed case in which the patient was a family member who came in close contact with an index patient during the incubation period, thereby confirming that transmission during the asymptomatic period is possible. The possibility of transmission during the asymptomatic period has been confirmed; therefore, it is necessary to review the measures for expanding contact tracing that is currently being applied starting one day prior to the onset of symptoms.
C1 [Lee, Miyoung; Eun, Youngduck; Park, Kyounghee; Son, Hyunjin] Pusan Natl Univ Hosp, Busan Ctr Infect Dis Control & Prevent, 1001 Jungang Daero, Busan 47545, South Korea.
   [Lee, Miyoung; Eun, Youngduck; Son, Hyunjin] Epidem Intelligence Officer Busan Metropolitan Ci, Busan, South Korea.
   [Park, Kyounghee] Epidem Invest Team Busan Metropolitan City, Busan, South Korea.
   [Heo, Jeonghun] Busan Med Ctr, Div Internal Med, Busan, South Korea.
RP Son, H (corresponding author), Pusan Natl Univ Hosp, Busan Ctr Infect Dis Control & Prevent, 1001 Jungang Daero, Busan 47545, South Korea.
EM hjson78@gmail.com
CR [Anonymous], 2020, GLOB SURV COVID 19 C
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Korea Centers for Disease Control and Prevention, UPD COVID 19 KOR 25
   Korea Centers for Disease Control and Prevention, COVID 19 GUID PUBL H, P25
   Korea Centers for Disease Control and Prevention, COVID 19 GUID PUBL H, P34
   Ministry of Health and Welfare, 2020, IMS M RESP NOV COR I
   National Health Commission of the People's Republic of China, INV MAN GUID CLOS CO
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   World Health Organization, 2020, 1 FEW 10 FEX CAS CON
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 10
TC 0
Z9 0
U1 1
U2 1
PU KOREAN SOC EPIDEMIOLOGY
PI SUWON
PA DEPT SOCIAL & PREVENTIVE MEDICINE, SUNGKYUNKWAN UNIV SCH MEDICINE,
   SUWON, 16419, SOUTH KOREA
SN 2092-7193
J9 EPIDEMIOL HEALTH
JI Epidemiol. Health
PD JUN 23
PY 2020
VL 42
AR e2020046
DI 10.4178/epih.e2020046
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OD0LD
UT WOS:000579545000001
PM 32580531
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sen Gupta, PS
   Biswal, S
   Singha, D
   Rana, MK
AF Sen Gupta, Parth Sarthi
   Biswal, Satyaranjan
   Singha, Dipankar
   Rana, Malay Kumar
TI Binding insight of clinically oriented drug famotidine with the
   identified potential target of SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Letter; Early Access
ID HIGH-THROUGHPUT; VIRUS
C1 [Sen Gupta, Parth Sarthi; Biswal, Satyaranjan; Singha, Dipankar; Rana, Malay Kumar] Indian Inst Sci Educ & Res IISER Berhampur, Dept Chem Sci, Ganjam 760010, Odisha, India.
RP Rana, MK (corresponding author), Indian Inst Sci Educ & Res IISER Berhampur, Dept Chem Sci, Ganjam 760010, Odisha, India.
EM mrana@iiserbpr.ac.in
OI Rana, Malay Kumar/0000-0002-1713-8220; Sen Gupta, Parth
   Sarthi/0000-0002-3083-3957
FU IISER Berhampur
FX The authors acknowledge IISER Berhampur for computational support.
   P.S.S.G also sincerely acknowledges IISER Berhampur for providing him
   the Institute Postdoc Fellowship to carry out this work.
CR Bourinbaiar AS, 1996, LIFE SCI, V59, pPL365, DOI 10.1016/S0024-3205(96)00553-X
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   CHANDRA A, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1775127
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Cucinotta D, 2020, ACTA BIOMED, V91, P157, DOI [10.23750/abm.v91i1.9397, DOI 10.23750/ABM.V91I1.9397]
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Freedberg D. E., 2020, FAMOTIDINE USE IS AS, DOI [10.1101/2020.05.01.20086694, DOI 10.1101/2020.05.01.20086694]
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hess U, 1997, J NONVERBAL BEHAV, V21, P241, DOI 10.1023/A:1024952730333
   Khan Y, 2016, ADV FUNCT MATER, V26, P8764, DOI 10.1002/adfm.201603763
   Kiemer L, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-72
   Kong R., 2020, ARXIV200300163V1QBIO
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   LOBOGALO N, 2020, J BIOMOL STRUCT 0513, DOI DOI https://doi.org/10.1080/07391102.2020.1764393
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Owodunni OP, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227339
   Petropoulos F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231236
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   QUIMQUE MTJ, 2020, J BIOMOL STRUCT 0613, DOI DOI https://doi.org/10.1080/07391102.2020.1776639
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Schenone M, 2013, NAT CHEM BIOL, V9, P232, DOI [10.1038/NCHEMBIO.1199, 10.1038/nchembio.1199]
   SEKIGUCHI T, 1987, SCAND J GASTROENTERO, V22, P51, DOI 10.3109/00365528709090141
   SENGUPTA PS, 2020, J BIOMOL STRUCT 0314, DOI DOI https://doi.org/10.1080/07391102.2020.1736158
   Shin D., 2020, INHIBITION PAPAIN PR, DOI [10.21203/ rs.3.rs-27134/v1, DOI 10.21203/RS.3.RS-27134/V1]
   Singh VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1748111
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768149
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 35
TC 2
Z9 2
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1784795
EA JUN 2020
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MK8ZC
UT WOS:000549068800001
PM 32579065
DA 2021-01-01
ER

PT J
AU Jiang, SP
   Wang, RR
   Li, L
   Hong, DS
   Ru, RP
   Rao, YF
   Miao, J
   Chen, N
   Wu, XH
   Ye, ZQ
   Hu, YZ
   Xie, MH
   Zuo, MJ
   Lu, XY
   Qiu, YQ
   Liang, TB
AF Jiang, Saiping
   Wang, Rongrong
   Li, Lu
   Hong, Dongsheng
   Ru, Renping
   Rao, Yuefeng
   Miao, Jing
   Chen, Na
   Wu, Xiuhua
   Ye, Ziqi
   Hu, Yunzhen
   Xie, Minghua
   Zuo, Minjuan
   Lu, Xiaoyang
   Qiu, Yunqing
   Liang, Tingbo
TI Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients:
   A Multicenter, Retrospective, Observational Study
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE Incidence; risk factors; liver injury; COVID-19; disease severity
ID PNEUMONIA; WUHAN; CHINA
AB Background:Liver injury commonly occurs in patients with COVID-19. There is limited data describing the course of liver injury occurrence in patients with different disease severity, and the causes and risk factors are unknown. We aim to investigate the incidence, characteristics, risk factors, and clinical outcomes of liver injury in patients with COVID-19. Methods:This retrospective observational study was conducted in three hospitals (Zhejiang, China). From January 19, 2020 to February 20, 2020, patients confirmed with COVID-19 (>= 18 years) and without liver injury were enrolled and divided into non-critically ill and critically ill groups. The incidence and characteristics of liver injury were compared between the two groups. Demographics, clinical characteristics, treatments, and treatment outcomes between patients with or without liver injury were compared within each group. The multivariable logistic regression model was used to explore the risk factors for liver injury. Results:The mean age of 131 enrolled patients was 51.2 years (standard deviation[SD]: 16.1 years), and 70 (53.4%) patients were male. A total of 76 patients developed liver injury (mild, 40.5%; moderate, 15.3%; severe, 2.3%) with a median occurrence time of 10.0 days. Critically ill patients had higher and earlier occurrence (81.5 vs. 51.9%, 12.0 vs. 5.0 days;p< 0.001), greater injury severity (p< 0.001), and slower recovery (50.0 vs. 61.1%) of liver function than non-critically ill patients. Multivariable regression showed that the number of concomitant medications (odds ratio [OR]: 1.12, 95% confidence interval [CI]: 1.05-1.21) and the combination treatment of lopinavir/ritonavir and arbidol (OR: 3.58, 95% CI: 1.44-9.52) were risk factors for liver injury in non-critically ill patients. The metabolism of arbidol can be significantly inhibited by lopinavir/ritonavirin vitro(p< 0.005), which may be the underlying cause of drug-related liver injury. Liver injury was related to increased length of hospital stay (mean difference [MD]: 3.2, 95% CI: 1.3-5.2) and viral shedding duration (MD: 3.0, 95% CI: 1.0-4.9). Conclusions:Critically ill patients with COVID-19 suffered earlier occurrence, greater injury severity, and slower recovery from liver injury than non-critically ill patients. Drug factors were related to liver injury in non-critically ill patients. Liver injury was related to prolonged hospital stay and viral shedding duration in patients with COVID-19.
C1 [Jiang, Saiping; Wang, Rongrong; Li, Lu; Hong, Dongsheng; Rao, Yuefeng; Miao, Jing; Chen, Na; Wu, Xiuhua; Ye, Ziqi; Hu, Yunzhen; Lu, Xiaoyang] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Pharm, Hangzhou, Peoples R China.
   [Ru, Renping] Xixi Hosp Hangzhou, Dept Pharm, Hangzhou, Peoples R China.
   [Xie, Minghua] First Peoples Hosp Yuhang Dist, Dept Pharm, Hangzhou, Peoples R China.
   [Zuo, Minjuan] Publ Serv Platform Evaluat Innovat Drug Property, Hangzhou, Peoples R China.
   [Qiu, Yunqing] Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, Coll Med,Affiliated Hosp 1,Zhejiang Prov Key Lab, Hangzhou, Peoples R China.
   [Liang, Tingbo] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China.
RP Lu, XY (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Pharm, Hangzhou, Peoples R China.; Qiu, YQ (corresponding author), Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, Coll Med,Affiliated Hosp 1,Zhejiang Prov Key Lab, Hangzhou, Peoples R China.; Liang, TB (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China.
EM luxiaoyang@zju.edu.cn; qiuyq@zju.edu.cn; liangtingbo@zju.edu.cn
CR Al-Aqil FA, 2018, BBA-MOL BASIS DIS, V1864, P2927, DOI 10.1016/j.bbadis.2018.06.003
   Andrade RJ, 2019, J HEPATOL, V70, P1222, DOI 10.1016/j.jhep.2019.02.014
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Bangash MN, 2020, LANCET GASTROENTEROL, V5, P529, DOI 10.1016/S2468-1253(20)30084-4
   CAI Q, 2020, ALLERGY 0417, DOI DOI 10.1101/2020.02.17.20024018
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Deng P, 2013, ANTIMICROB AGENTS CH, V57, P1743, DOI 10.1128/AAC.02282-12
   Fan ZY, 2020, CLIN GASTROENTEROL H, V18, P1561, DOI 10.1016/j.cgh.2020.04.002
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Leise MD, 2014, MAYO CLIN PROC, V89, P95, DOI 10.1016/j.mayocp.2013.09.016
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   National Health Commission and State Administration of Traditional Chinese Medicine, 2020, DIAGN TREATM PROT NO
   National Institute of Diabetes and Digestive and Kidney Diseases, 2020, LIVERTOX CLIN RES IN
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Meng-zhao, 2004, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V26, P289
   WHO, 2020, MAP PROD WHO HLTH EM
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
NR 27
TC 2
Z9 2
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUN 23
PY 2020
VL 7
AR 347
DI 10.3389/fmed.2020.00347
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA MK3UF
UT WOS:000548707800001
PM 32656222
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alamri, MA
   ul Qamar, MT
   Mirza, MU
   Bhadane, R
   Alqahtani, SM
   Muneer, I
   Froeyen, M
   Salo-Ahen, OMH
AF Alamri, Mubarak A.
   ul Qamar, Muhammad Tahir
   Mirza, Muhammad Usman
   Bhadane, Rajendra
   Alqahtani, Safar M.
   Muneer, Iqra
   Froeyen, Matheus
   Salo-Ahen, Outi M. H.
TI Pharmacoinformatics and molecular dynamics simulation studies reveal
   potential covalent and FDA-approved inhibitors of SARS-CoV-2 main
   protease 3CL(pro)
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; 3CL protease; covalent inhibitors; paritaprevir;
   simeprevir; molecular dynamics simulation
ID DRUG DISCOVERY; CORONAVIRUS; DOCKING; DESIGN; BINDING; IDENTIFICATION;
   PERFORMANCE; SOFTWARE; GENERATION; PREDICTION
AB The SARS-CoV-2 was confirmed to cause the global pandemic of coronavirus disease 2019 (COVID-19). The 3-chymotrypsin-like protease (3CLpro), an essential enzyme for viral replication, is a valid target to combat SARS-CoV and MERS-CoV. In this work, we present a structure-based study to identify potential covalent inhibitors containing a variety of chemical warheads. The targeted Asinex Focused Covalent (AFCL) library was screened based on different reaction types and potential covalent inhibitors were identified. In addition, we screened FDA-approved protease inhibitors to find candidates to be repurposed against SARS-CoV-2 3CLpro. A number of compounds with significant covalent docking scores were identified. These compounds were able to establish a covalent bond (C-S) with the reactive thiol group of Cys145 and to form favorable interactions with residues lining the substrate-binding site. Moreover, paritaprevir and simeprevir from FDA-approved protease inhibitors were identified as potential inhibitors of SARS-CoV-2 3CLpro. The mechanism and dynamic stability of binding between the identified compounds and SARS-CoV-2 3CLpro were characterized by molecular dynamics (MD) simulations. The identified compounds are potential inhibitors worthy of further development as COVID-19 drugs. Importantly, the identified FDA-approved anti-hepatitis-C virus (HCV) drugs paritaprevir and simeprevir could be ready for clinical trials to treat infected patients and help curb COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Alamri, Mubarak A.; Alqahtani, Safar M.] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Dept Pharmaceut Chem, Alkarj, Saudi Arabia.
   [ul Qamar, Muhammad Tahir] Guangxi Univ, Coll Life Sci & Technol, Nanning, Peoples R China.
   [Mirza, Muhammad Usman; Froeyen, Matheus] Univ Leuven, Rega Inst Med Res, Dept Pharmaceut & Pharmacol Sci, Med Chem, Leuven, Belgium.
   [Bhadane, Rajendra; Salo-Ahen, Outi M. H.] Abo Akad Univ, Struct Bioinformat Lab, Fac Sci & Engn, Turku, Finland.
   [Bhadane, Rajendra; Salo-Ahen, Outi M. H.] Abo Akad Univ, Fac Sci & Engn, Pharmaceut Sci Lab, Pharm, Turku, Finland.
   [Muneer, Iqra] Univ Sci & Technol China, Sch Life Sci, Hefei, Peoples R China.
RP ul Qamar, MT (corresponding author), Guangxi Univ, Coll Life Sci & Technol, Nanning, Peoples R China.; Salo-Ahen, OMH (corresponding author), Abo Akad Univ, Struct Bioinformat Lab, Fac Sci & Engn, Turku, Finland.
EM m.tahirulqamar@hotmail.com; outi.salo-ahen@abo.fi
RI Mirza, Muhammad Usman/I-5970-2019; Bhadane, Rajendra/ABI-1257-2020;
   Qamar, Muhammad Tahir ul/E-5803-2015
OI Mirza, Muhammad Usman/0000-0001-9120-2414; Bhadane,
   Rajendra/0000-0002-7330-4801; Qamar, Muhammad Tahir
   ul/0000-0003-4832-4250; /0000-0001-6559-0871
FU Postdoctoral Project from Guangxi University
FX This work was supported by the Postdoctoral Project from Guangxi
   University. Authors would like to thank Guangxi University, Prince
   Sattam Bin Abdulaziz University, University of Leuven and Abo Akademi
   University for providing the necessary tools to conduct this research.
   The Sigrid Jus~elius Foundation, Biocenter Finland Bioinformatics and
   Drug Discovery and Chemical Biology networks, CSC IT Center for Science,
   Joe, Pentti and Tor Borg Memorial Fund and Prof. Mark Johnson and Dr.
   Jukka Lehtonen are gratefully acknowledged for the excellent
   computational infrastructure at the Abo Akademi University.
CR Ahmed B, 2018, NAT PROD RES, V32, P1123, DOI 10.1080/14786419.2017.1320786
   Ahmed T., 2020, CORONAVIRUS DIS 2019, DOI [10.20944/preprints202002.0358.v3, DOI 10.20944/PREPRINTS202002.0358.V3]
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Berman HM, 2003, PROTEIN STRUCTURE: DETERMINATION, ANALYSIS, AND APPLICATIONS FOR DRUG DISCOVERY, P389
   Biovia D. S., 2017, DISCOVERY STUDIO MOD
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Case D., 2018, AMBER 2018
   Chang HP, 2007, BIOPHYS J, V92, P1374, DOI 10.1529/biophysj.106.091736
   Chen F, 2016, PHYS CHEM CHEM PHYS, V18, P22129, DOI 10.1039/c6cp03670h
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   De Cesco S, 2017, EUR J MED CHEM, V138, P96, DOI 10.1016/j.ejmech.2017.06.019
   Durdagi S, 2018, J MOL GRAPH MODEL, V85, P122, DOI 10.1016/j.jmgm.2018.07.010
   DURRANI FG, 2019, BIOMOLECULES, V9, DOI DOI https://doi.org/10.3390/biom9040133
   Durrant JD, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-71
   Ece A, 2020, J BIOMOL STRUCT DYN, V38, P565, DOI 10.1080/07391102.2019.1583606
   ER M, 2018, CHEM CENT J, V12, DOI DOI https://doi.org/10.1186/s13065-018-0485-3
   Farag A., 2020, IDENTIFICATION FDA A, DOI [10.26434/chemrxiv.12003930.v4, DOI 10.26434/CHEMRXIV.12003930.V4]
   Flanagan ME, 2014, J MED CHEM, V57, P10072, DOI 10.1021/jm501412a
   Genheden S, 2010, J PHYS CHEM B, V114, P8505, DOI 10.1021/jp101461s
   Go YM, 2015, FREE RADICAL BIO MED, V84, P227, DOI 10.1016/j.freeradbiomed.2015.03.022
   Gohlke H, 2004, J COMPUT CHEM, V25, P238, DOI 10.1022/jcc.10379
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7
   Haider Z, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-0310-9
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:6<490::AID-JCC1>3.3.CO;2-V
   Hillaker E, 2020, PHARMACOTHERAPY, V40, P592, DOI 10.1002/phar.2403
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Hou TJ, 2004, CURR PHARM DESIGN, V10, P1011, DOI 10.2174/1381612043452721
   Huey R, 2008, USING AUTODOCK 4 AUT, P54
   IKRAM N, 2019, BIOMOLECULES, V9, DOI DOI https://doi.org/10.3390/biom9040124
   Jabbar B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03000
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   JIN Z, 2020, NATURE 0409, DOI DOI https://doi.org/10.1101/2020.02.26.964882
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kankanamalage ACG, 2018, EUR J MED CHEM, V150, P334, DOI 10.1016/j.ejmech.2018.03.004
   Kolb HC, 2003, DRUG DISCOV TODAY, V8, P1128, DOI 10.1016/S1359-6446(03)02933-7
   Kumar V, 2017, ANTIVIR RES, V141, P101, DOI 10.1016/j.antiviral.2017.02.007
   Kwong AD, 2011, NAT BIOTECHNOL, V29, P993, DOI 10.1038/nbt.2020
   Lagoutte R, 2017, CURR OPIN CHEM BIOL, V39, P54, DOI 10.1016/j.cbpa.2017.05.008
   Lee TW, 2005, J MOL BIOL, V353, P1137, DOI 10.1016/j.jmb.2005.09.004
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   Liu K, 2017, J COMPUT AID MOL DES, V31, P201, DOI 10.1007/s10822-016-0005-2
   Mah R, 2014, BIOORG MED CHEM LETT, V24, P33, DOI 10.1016/j.bmcl.2013.10.003
   McConachie SM, 2016, EXPERT REV CLIN PHAR, V9, P287, DOI 10.1586/17512433.2016.1129272
   McInnes C, 2007, CURR OPIN CHEM BIOL, V11, P494, DOI 10.1016/j.cbpa.2007.08.033
   MIRZA MU, 2016, SCI REP UK, V6, DOI DOI https://doi.org/10.1038/srep37313
   Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008
   Mirza MU, 2019, J MED VIROL, V91, P2029, DOI 10.1002/jmv.25357
   Mirza MU, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111748
   Mukherjee H, 2018, CURR OPIN CHEM BIOL, V44, P30, DOI 10.1016/j.cbpa.2018.05.011
   Mumtaz A, 2017, NAT PROD RES, V31, P1228, DOI 10.1080/14786419.2016.1233409
   Muneer I, 2019, ANTI-CANCER DRUG, V30, P363, DOI 10.1097/CAD.0000000000000727
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   PARVEEN A, 2019, INT J MOL SCI, V20, DOI DOI https://doi.org/10.3390/ijms20215282
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Poole LB, 2015, FREE RADICAL BIO MED, V80, P148, DOI 10.1016/j.freeradbiomed.2014.11.013
   Qamar MTU, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38450-1
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Roos K, 2019, J CHEM THEORY COMPUT, V15, P1863, DOI 10.1021/acs.jctc.8b01026
   Rotella DP, 2013, EXPERT OPIN DRUG DIS, V8, P1439, DOI 10.1517/17460441.2013.843525
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Schultz TW, 2006, SAR QSAR ENVIRON RES, V17, P413, DOI 10.1080/10629360600884371
   Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822-010-9352-6
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Shirato K, 2013, J VIROL, V87, P12552, DOI 10.1128/JVI.01890-13
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Sirin S, 2014, J CHEM INF MODEL, V54, P2334, DOI 10.1021/ci5002185
   Srivastava HK, 2012, J CHEM INF MODEL, V52, P3088, DOI 10.1021/ci300385h
   Stoermer M., 2020, HOMOLOGY MODELS CORO, DOI [10.26434/chemrxiv.11637294.v3., DOI 10.26434/CHEMRXIV.11637294.V3]
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tan JJ, 2006, J MOL STRUC-THEOCHEM, V766, P77, DOI 10.1016/j.theochem.2006.02.022
   Tan JZ, 2005, J MOL BIOL, V354, P25, DOI 10.1016/j.jmb.2005.09.012
   Tang Bowen, 2020, bioRxiv, DOI 10.1101/2020.03.03.972133
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   ul Qamar M.T., 2020, DESIGNING NEXT GENER, DOI [10.1101/2020.02.28.970343, DOI 10.1101/2020.02.28.970343]
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   ul Qamar MT, 2017, PAK J PHARM SCI, V30, P2119
   ul Qamar MT, 2016, INT J PHARMACOL, V12, P621, DOI 10.3923/ijp.2016.621.632
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Warshaviak DT, 2014, J CHEM INF MODEL, V54, P1941, DOI 10.1021/ci500175r
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Xiaojie, 2006, Drug Discov Today Technol, V3, P247, DOI 10.1016/j.ddtec.2006.09.008
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Zhou P, 2017, BMC GENOMICS, V18
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu K, 2014, J CHEM INF MODEL, V54, P1932, DOI 10.1021/ci500118s
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu RF, 2020, SYSTEMATIC REV REGIS, DOI [10.1101/2020.03.01.20029611, DOI 10.1101/2020.03.01.20029611]
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 99
TC 3
Z9 3
U1 6
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1782768
EA JUN 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MK0WA
UT WOS:000548507000001
PM 32579061
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Nimgampalle, M
   Devanathan, V
   Saxena, A
AF Nimgampalle, Mallikarjuna
   Devanathan, Vasudharani
   Saxena, Ambrish
TI Screening of Chloroquine, Hydroxychloroquine and its derivatives for
   their binding affinity to multiple SARS-CoV-2 protein drug targets
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Hydroxychloroquine; molecular docking; Chloroquine
   derivatives
ID RESPIRATORY SYNDROME-CORONAVIRUS; RNA-BINDING; COVID-19; VIRUS
AB Recently Chloroquine and its derivative Hydroxychloroquine have garnered enormous interest amongst the clinicians and health authorities' world over as a potential treatment to contain COVID-19 pandemic. The present research aims at investigating the therapeutic potential of Chloroquine and its potent derivative Hydroxychloroquine against SARS-CoV-2 viral proteins. At the same time screening was performed for some chemically synthesized derivatives of Chloroquine and compared their binding efficacy with chemically synthesized Chloroquine derivatives throughin silicoapproaches. For the purpose of the study, some essential viral proteins and enzymes were selected that are implicated in SARS-CoV-2 replication and multiplication as putative drug targets. Chloroquine, Hydroxychloroquine, and some of their chemically synthesized derivatives, taken from earlier published studies were selected as drug molecules. We have conducted molecular docking and related studies between Chloroquine and its derivatives and SARS-CoV-2 viral proteins, and the findings show that both Chloroquine and Hydroxychloroquine can bind to specific structural and non-structural proteins implicated in the pathogenesis of SARS-CoV-2 infection with different efficiencies. Our current study also shows that some of the chemically synthesized Chloroquine derivatives can also potentially inhibit various SARS-CoV-2 viral proteins by binding to them and concomitantly effectively disrupting the active site of these proteins. These findings bring into light another possible mechanism of action of Chloroquine and Hydroxychloroquine and also pave the way for further drug repurposing and remodeling. Communicated by Ramaswamy H. Sarma
C1 [Nimgampalle, Mallikarjuna; Devanathan, Vasudharani] Indian Inst Sci Educ & Res IISER Tirupati, Dept Biol, Tirupati, Andhra Pradesh, India.
   [Saxena, Ambrish] Indian Inst Technol IIT Tirupati, Ctr Sponsored Res & Consultancy, Tirupati, Andhra Pradesh, India.
RP Saxena, A (corresponding author), Indian Inst Technol IIT Tirupati, Renigunta Rd, Tirupati 517506, Andhra Pradesh, India.
EM ambrish@iittp.ac.in
OI Devanathan, Vasudharani/0000-0002-2052-400X; Saxena,
   Ambrish/0000-0001-8620-7683
FU IISER Tirupati; IIT Tirupati
FX The authors would like to thank IISER Tirupati and IIT Tirupati for
   their support.
CR Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Bommu UD, 2019, INTERDISCIP SCI, V11, P153, DOI 10.1007/s12539-017-0244-5
   CEBM, 2020, GLOB COV 19 CAS FAT
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   De Lamballerie X, 2008, VECTOR-BORNE ZOONOT, V8, P837, DOI 10.1089/vbz.2008.0049
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Egloff MP, 2004, P NATL ACAD SCI USA, V101, P3792, DOI 10.1073/pnas.0307877101
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2016, J MED VIROL, V88, P2044, DOI 10.1002/jmv.24678
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Ganesan A, 2017, EXPERT OPIN DRUG DIS, V12, P407, DOI 10.1080/17460441.2017.1291628
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gomes A, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.00983-18, 10.1128/aac.00983-18]
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hu TT, 2017, PROTEIN SCI, V26, P1037, DOI 10.1002/pro.3150
   Huang CC, 2014, NUCLEIC ACIDS RES, V42, pW478, DOI 10.1093/nar/gku377
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Littler D., 2020, CRYSTAL STRUCTURE SA, P1
   Matrosovich M, 2015, TOP CURR CHEM, V367, P1, DOI 10.1007/128_2013_466
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nimgampalle M, 2020, J BIOMOL STRUCT DYN, V38, P4669, DOI 10.1080/07391102.2019.1686066
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Rabby MII, 2020, J PHARM PHARM SCI, V23, P58, DOI 10.18433/jpps31002
   Savarino A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0178-0
   Scholz M., 2020, MED HYPOTHESES, P109815
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Stobart CC, 2013, J VIROL, V87, P12611, DOI 10.1128/JVI.02050-13
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Tricou Vianney, 2010, PLoS Negl Trop Dis, V4, pe785, DOI 10.1371/journal.pntd.0000785
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wee Sui-Lee, 2020, NY TIMES
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yeo KJ, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4826-1
   Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427
NR 40
TC 2
Z9 2
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1782265
EA JUN 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MJ4OJ
UT WOS:000548071200001
PM 32579059
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lizbeth, RSG
   Jazmin, GM
   Jose, CB
   Marlet, MA
AF Lizbeth, Ramirez-Salinas Gema
   Jazmin, Garcia-Machorro
   Jose, Correa-Basurto
   Marlet, Martinez-Archundia
TI Immunoinformatics study to search epitopes of spike glycoprotein from
   SARS-CoV-2 as potential vaccine
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Epitope; vaccine; SARS-CoV-2; coronavirus; spike glycoprotein
ID MHC CLASS-I; MOLECULAR-DYNAMICS; IDENTIFICATION; PREDICTION; PEPTIDES;
   BINDING
AB The Coronavirus disease named COVID-19 is caused by the virus reported in 2019 first identified in China. The cases of this disease have increased and as of June 1(st), 2020 there are more than 216 countries affected. Pharmacological treatments have been proposed based on the resemblance of the HIV virus. With regard to prevention there is no vaccine, thus, we proposed to explore the spike protein due to its presence on the viral surface, and it also contains the putative viral entry receptor as well as the fusion peptide (important in the genome release). In this work we have employedIn Silicotechniques such as immunoinformatics tools which permit the identification of potential immunogenic regions on the viral surface (spike glycoprotein). From these analyses, we identified four epitopes E332-370, E627-651, E440-464 and E694-715 that accomplish essential features such as promiscuity, conservation grade, exposure and universality, and they also form stable complexes with MHCII molecule. We suggest that these epitopes could generate a specific immune response, and thus, they could be used for future applications such as the design of new epitope vaccines against the SARS-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Lizbeth, Ramirez-Salinas Gema; Jose, Correa-Basurto; Marlet, Martinez-Archundia] Inst Politecn Nacl, Escuela Super Med, Lab Diseno & Desarrollo Nuevos Farmacos & Innovac, Mexico City 11340, DF, Mexico.
   [Jazmin, Garcia-Machorro] Inst Politecn Nacl, Escuela Super Med, Lab Med Conservac, Mexico City, DF, Mexico.
RP Marlet, MA (corresponding author), Inst Politecn Nacl, Escuela Super Med, Lab Diseno & Desarrollo Nuevos Farmacos & Innovac, Mexico City 11340, DF, Mexico.
EM marletm8@gmail.com
FU CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [254600]
FX We thank to CONACYT Project 254600. GLRS, JGM, JCB, MMA, are members of
   the National System of Researchers, SNI.
CR Agudelo WA, 2010, MINI-REV MED CHEM, V10, P746, DOI 10.2174/138955710791572488
   Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Apostolopoulos V, 2008, ADV EXP MED BIOL, V640, P252, DOI 10.1007/978-0-387-09789-3_19
   Calis J. J. A., 2019, INT REV IMMUNOL, V38, P307, DOI [https://doi.org/10.1080/08830185.2019.1657426, DOI 10.1080/08830185.2019.1657426]
   CAO YN, 2020, CELL DISCOV, V6, DOI DOI https://doi.org/10.1038/s41421-020-0147-1
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Doytchinova IA, 2005, J IMMUNOL, V174, P7085, DOI 10.4049/jimmunol.174.11.7085
   Ebrahimi S, 2019, APPL BIOCHEM BIOTECH, V187, P90, DOI 10.1007/s12010-018-2804-5
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Glykos NM, 2006, J COMPUT CHEM, V27, P1765, DOI 10.1002/jcc.20482
   Gonzalez-Galarza FF, 2011, NUCLEIC ACIDS RES, V39, pD913, DOI 10.1093/nar/gkq1128
   Hinrichs J, 2010, HAEMATOL-HEMATOL J, V95, P1373, DOI 10.3324/haematol.2009.016089
   Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   Li R, 2020, J INFECTION, V80, P469, DOI 10.1016/j.jinf.2020.02.013
   Liang SD, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-302
   Liu H, 2016, BIOINFORMATICS, V32, P2216, DOI 10.1093/bioinformatics/btw215
   Liu J, 2010, J VIROL, V84, P11849, DOI 10.1128/JVI.01464-10
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Nishiura H, 2020, J CLIN MED, P9
   Eunju OJ, 2014, J VIROL, V88, P7764, DOI 10.1128/JVI.00748-14
   Ou XY, 2016, J VIROL, V90, P5586, DOI 10.1128/JVI.00015-16
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Rose PW, 2017, NUCLEIC ACIDS RES, V45, pD271, DOI 10.1093/nar/gkw1000
   Saraav I, 2016, INFECT GENET EVOL, V44, P182, DOI 10.1016/j.meegid.2016.07.004
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   Takenaka M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042370
   Vajda S, 2017, PROTEINS, V85, P435, DOI 10.1002/prot.25219
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang RC, 2020, J INFECTION, V80, P354, DOI 10.1016/j.jinf.2020.01.017
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yin CC, 2020, GENOMICS, V112, P3588, DOI 10.1016/j.ygeno.2020.04.016
NR 37
TC 2
Z9 2
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1780944
EA JUN 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MJ5IC
UT WOS:000548122900001
PM 32583729
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Chikhale, RV
   Sinha, SK
   Patil, RB
   Prasad, SK
   Shakya, A
   Gurav, N
   Prasad, R
   Dhaswadikar, SR
   Wanjari, M
   Gurav, SS
AF Chikhale, Rupesh, V
   Sinha, Saurabh K.
   Patil, Rajesh B.
   Prasad, Satyendra K.
   Shakya, Anshul
   Gurav, Nilambari
   Prasad, Rupali
   Dhaswadikar, Suhas R.
   Wanjari, Manish
   Gurav, Shailendra S.
TI In-silicoinvestigation of phytochemicals fromAsparagus racemosusas
   plausible antiviral agent in COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Asparagus racemosus; Shatavari; Molecular docking; nCov-2019; Antiviral;
   IndianAyurveda; Pandemic disease
ID RESPIRATORY SYNDROME CORONAVIRUS; ASPARAGUS-RACEMOSUS; SARS;
   ENDORIBONUCLEASE; DESIGN
AB COVID-19 has ravaged the world and is the greatest of pandemics in human history, in the absence of treatment or vaccine the mortality and morbidity rates are very high. The present investigation was undertaken to screen and identify the potent leads from the Indian Ayurvedic herb,Asparagus racemosus(Willd.) against SARS-CoV-2 using molecular docking and dynamics studies. The docking analysis was performed on the Glide module of Schrodinger suite on two different proteins from SARS-CoV-2 viz. NSP15 Endoribonuclease and spike receptor-binding domain. Asparoside-C, Asparoside-D and Asparoside -F were found to be most effective against both the proteins as confirmed through their docking score and affinity. Further, the 100 ns molecular dynamics study also confirmed the potential of these compounds from reasonably lower root mean square deviations and better stabilization of Asparoside-C and Asparoside-F in spike receptor-binding domain and NSP15 Endoribonuclease respectively. MM-GBSA based binding free energy calculations also suggest the most favourable binding affinities of Asparoside-C and Asparoside-F with binding energies of -62.61 and -55.19 Kcal/mol respectively with spike receptor-binding domain and NSP15 Endoribonuclease.
C1 [Chikhale, Rupesh, V] Univ East Anglia, Sch Pharm, Norwich, Norfolk, England.
   [Sinha, Saurabh K.] Mohanlal Shukhadia Univ, Dept Pharmaceut Sci, Udaipur, Rajasthan, India.
   [Patil, Rajesh B.] Smt Kashibai Navale Coll Pharm, Sinhgad Tech Educ Societys, Pune, Maharashtra, India.
   [Prasad, Satyendra K.; Prasad, Rupali; Dhaswadikar, Suhas R.] RTM Univ, Dept Pharmaceut Sci, Nagpur, Maharashtra, India.
   [Shakya, Anshul] Dibrugarh Univ, Fac Sci & Engn, Dept Pharmaceut Sci, Dibrugarh, Assam, India.
   [Gurav, Nilambari] Goa Univ, PESs Rajaram & Tarabai Bandekar Coll Pharm, Taleigao, Goa, India.
   [Wanjari, Manish] Reg Ayurveda Res Inst Drug Dev, Gwalior, India.
   [Gurav, Shailendra S.] Goa Univ, Goa Coll Pharm, Dept Pharmacognosy, Taleigao, Goa, India.
RP Gurav, SS (corresponding author), Goa Univ, Goa Coll Pharm, Dept Pharmacognosy & Phytochem, Taleigao 403001, Goa, India.
EM shailendra.gurav@nic.in
RI Gurav, Shailendra/AAO-4240-2020; Prasad, Satyendra/ABD-2399-2020
OI Gurav, Shailendra/0000-0001-5564-2121; SHAKYA,
   ANSHUL/0000-0002-8232-4476; Prasad, Satyendra/0000-0002-4762-9733;
   Chikhale, Rupesh/0000-0001-5622-3981; Patil, Rajesh/0000-0003-2986-9546
CR ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   Bhardwaj K, 2008, J BIOL CHEM, V283, P3655, DOI 10.1074/jbc.M708375200
   Boonsom T, 2012, FITOTERAPIA, V83, P947, DOI 10.1016/j.fitote.2012.04.014
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Cardenas-Conejo Y, 2020, J MED VIROL, V92, P688, DOI 10.1002/jmv.25758
   Chen CJ, 2008, J ETHNOPHARMACOL, V120, P108, DOI 10.1016/j.jep.2008.07.048
   Chikhale R, 2018, BIOORG CHEM, V77, P84, DOI 10.1016/j.bioorg.2018.01.008
   Chikhale RV, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1778539
   CHOUDHURY C, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1771424
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Deng XF, 2018, VIROLOGY, V517, P157, DOI 10.1016/j.virol.2017.12.024
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Gurav S., 2014, INDIAN HERBAL DRUG M, P15, DOI [10.1007/978-1-4614-9515-4_4, DOI 10.1007/978-1-4614-9515-4_4]
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hoever G, 2005, J MED CHEM, V48, P1256, DOI 10.1021/jm0493008
   Jayawardena R, 2020, DIABETES METAB SYND, V14, P367, DOI 10.1016/j.dsx.2020.04.015
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kerzare D, 2016, J BRAZIL CHEM SOC, V27, P1998, DOI 10.5935/0103-5053.20160090
   Lalert L, 2018, J ETHNOPHARMACOL, V225, P336, DOI 10.1016/j.jep.2018.07.014
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Mandal SC, 2000, PHYTOTHER RES, V14, P118, DOI 10.1002/(SICI)1099-1573(200003)14:2&lt;118::AID-PTR493&gt;3.0.CO;2-P
   MENGIST HM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI DOI https://doi.org/10.1038/s41392-020-0178-y
   Mittal L, 2020, J BIOMOL STRUCT DYN, V38, P1612, DOI 10.1080/07391102.2019.1614480
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   OU XY, 2020, NAT COMMUN, V11, DOI DOI https://doi.org/10.1038/s41467-020-15562-9
   Pant A. M., 2014, BMC INFECT DIS, V14, DOI [10.1186/1471-2334-14-S3-P18, DOI 10.1186/1471-2334-14-S3-P18]
   Patwardhan B, 2020, J AYURVEDA INTEGR ME, V11, P1, DOI 10.1016/j.jaim.2020.03.001
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Raza A, 2015, WORLD POULTRY SCI J, V71, P523, DOI 10.1017/S0043933915002147
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Shah MA, 2014, BANGL J PHARMACOL, V9, P1, DOI 10.3329/bjp.v9i1.16672
   Shashi Alok, 2013, Asian Pacific Journal of Tropical Disease, V3, P242
   Singh R, 2016, NAT PROD RES, V30, P1896, DOI 10.1080/14786419.2015.1092148
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779132
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Tillu G, 2020, J ALTERN COMPLEM MED, V26, P360, DOI 10.1089/acm.2020.0129
   Uma B, 2009, INDIAN J PHARM SCI, V71, P342, DOI 10.4103/0250-474X.56017
   Upadhyay S, 2020, PLANT SCI, V290, DOI 10.1016/j.plantsci.2019.110291
   VERMA S, 2020, N S ARCH PHARMA 0509, DOI DOI https://doi.org/10.1007/s00210-020-01872-8
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   Wen Chih-Chun, 2011, J Tradit Complement Med, V1, P41
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 49
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1784289
EA JUN 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MI3FL
UT WOS:000547296300001
PM 32579064
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Schmitt, CA
   Bergey, CM
   Jasinska, AJ
   Ramensky, V
   Burt, F
   Svardal, H
   Jorgensen, MJ
   Freimer, NB
   Grobler, JP
   Turner, TR
AF Schmitt, Christopher A.
   Bergey, Christina M.
   Jasinska, Anna J.
   Ramensky, Vasily
   Burt, Felicity
   Svardal, Hannes
   Jorgensen, Matthew J.
   Freimer, Nelson B.
   Grobler, J. Paul
   Turner, Trudy R.
TI ACE2andTMPRSS2variation in savanna monkeys (Chlorocebusspp.): Potential
   risk for zoonotic/anthroponotic transmission of SARS-CoV-2 and a
   potential model for functional studies
SO PLOS ONE
LA English
DT Article
ID CORONAVIRUS SPIKE PROTEIN; SARS-CORONAVIRUS; VERVET MONKEYS; COVID-19;
   REHABILITATION; CONSERVATION; ACTIVATION; HUMANS; GENOME; GREEN
AB The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, has devastated health infrastructure around the world. Both ACE2 (an entry receptor) and TMPRSS2 (used by the virus for spike protein priming) are key proteins to SARS-CoV-2 cell entry, enabling progression to COVID-19 in humans. Comparative genomic research into critical ACE2 binding sites, associated with the spike receptor binding domain, has suggested that African and Asian primates may also be susceptible to disease from SARS-CoV-2 infection. Savanna monkeys (Chlorocebusspp.) are a widespread non-human primate with well-established potential as a bi-directional zoonotic/anthroponotic agent due to high levels of human interaction throughout their range in sub-Saharan Africa and the Caribbean. To characterize potential functional variation in savanna monkeyACE2andTMPRSS2, we inspected recently published genomic data from 245 savanna monkeys, including 163 wild monkeys from Africa and the Caribbean and 82 captive monkeys from the Vervet Research Colony (VRC). We found several missense variants. One missense variant inACE2(X:14,077,550; Asp30Gly), common inCh.sabaeus, causes a change in amino acid residue that has been inferred to reduce binding efficiency of SARS-CoV-2, suggesting potentially reduced susceptibility. The remaining populations appear as susceptible as humans, based on these criteria for receptor usage. All missense variants observed in wildCh.sabaeuspopulations are also present in the VRC, along with two splice acceptor variants (at X:14,065,076) not observed in the wild sample that are potentially disruptive to ACE2 function. The presence of these variants in the VRC suggests a promising model for SARS-CoV-2 infection and vaccine and therapy development. In keeping with a One Health approach, characterizing actual susceptibility and potential for bi-directional zoonotic/anthroponotic transfer in savanna monkey populations may be an important consideration for controlling COVID-19 epidemics in communities with frequent human/non-human primate interactions that, in many cases, may have limited health infrastructure.
C1 [Schmitt, Christopher A.] Boston Univ, Dept Anthropol, Boston, MA 02215 USA.
   [Bergey, Christina M.] Rutgers State Univ, Dept Genet, New Brunswick, NJ USA.
   [Jasinska, Anna J.; Freimer, Nelson B.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Ctr Neurobehav Genet, Los Angeles, CA 90024 USA.
   [Jasinska, Anna J.] Polish Acad Sci, Inst Bioorgan Chem, Poznan, Poland.
   [Jasinska, Anna J.] Eye Primates, Los Angeles, CA USA.
   [Ramensky, Vasily] Minist Healthcare Russian Federat, Fed State Inst Natl Med Res Ctr Therapy & Prevent, Moscow, Russia.
   [Burt, Felicity] Natl Hlth Lab Serv, Div Med Virol, Bloemfontein, Free State, South Africa.
   [Burt, Felicity] Univ Free State, Div Virol, Fac Hlth Sci, Bloemfontein, Free State, South Africa.
   [Svardal, Hannes] Univ Antwerp, Dept Biol, Antwerp, Belgium.
   [Svardal, Hannes] Nat Biodivers Ctr, Leiden, Netherlands.
   [Jorgensen, Matthew J.] Wake Forest Sch Med, Dept Pathol, Comparat Med Sect, Winston Salem, NC 27101 USA.
   [Grobler, J. Paul; Turner, Trudy R.] Univ Free State, Dept Genet, Bloemfontein, Free State, South Africa.
   [Turner, Trudy R.] Univ Wisconsin, Dept Anthropol, Milwaukee, WI 53201 USA.
RP Schmitt, CA (corresponding author), Boston Univ, Dept Anthropol, Boston, MA 02215 USA.
EM caschmit@bu.edu
RI Burt, Felicity/ABA-9124-2020
OI Burt, Felicity/0000-0002-7238-7799; Bergey,
   Christina/0000-0001-8336-8078; Svardal, Hannes/0000-0001-7866-7313
FU Boston University; NSFNational Science Foundation (NSF) [SOC 74-24166,
   BNS 770-3322, BCS 0938969]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01RR0163009,
   R01RR016300, R01OD010980]; University of WisconsinMilwaukee; University
   of the Free State, South Africa; University of Limpopo, South Africa;
   Coriell Institute; Austrian Ministry of Science and Research; National
   Institute of Neurological Disorders and Stroke (NINDS) Informatics
   Center for Neurogenetics and Neurogenomics [P30 NS062691]
FX This work was supported by funding from Boston University, to C.A.S.,
   http://www.bu.edu.There was no additional external funding received for
   this study. Original data collection was supported by funding from NSF
   (SOC 74-24166, BNS 770-3322, BCS 0938969) to T.R.T., http://www.nsf.gov;
   NIH (R01RR0163009) to N.B.F., and to N.B.F. for the UCLA Systems Biology
   Sample Repository (R01RR016300 and R01OD010980), http://www.nih.gov; the
   University of WisconsinMilwaukee to T.R.T., http://www.uwm.edu; The
   University of the Free State, South Africa, to J.P.G.,
   http://www.ufs.ac.za; the University of Limpopo, South Africa, to
   J.P.G., http://www.ul.ac.za; Coriell Institute, to T.R.T.,
   http://www.coriell.org; the Austrian Ministry of Science and Research,
   to H.S, https://www.bmbwf.gv.at/.We acknowledge the support of the
   National Institute of Neurological Disorders and Stroke (NINDS)
   Informatics Center for Neurogenetics and Neurogenomics (P30 NS062691),
   to N.B.F., http://www.ninds.nih.gov/.The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.; For the generation of this data, the
   authors gratefully acknowledge assistance in the field by Jennifer Danzy
   Cramer, Oliver "Pess" Morton, Yoon Jung, Stephanie Groman, David
   Jentsch, Eugene Redmond and the St. Kitts Biomedical Research Foundation
   in St. Kitts; veterinarians Lizanne Meiring, Murray Stokoe and numerous
   field assistants in South Africa including especially Gabriel Coetzer,
   Magali Jacquier, Helene DeNys, JD Pampush, Elzet Answegen, Tegan
   Gaetano, Dewald DuPlessis, Micah Beller, David Beller and Pess Morton;
   the University of Limpopo and the University of the Free State; and
   Mamkumba Sanneh, Katie Camfield, Michel Dione, Martin Antonio and the
   Medical Research Council in the Gambia. Collections of these data were
   conducted under permits and permissions issued by the following:
   Ethiopian Wildlife Conservation Authority; Gambia Department of Parks
   and Wildlife Management; Ministry of Tourism and Wildlife, Kenya; in
   South Africa the Department of Economic Development and Environmental
   Affairs, Eastern Cape; Department of Tourism, Environmental and Economic
   Affairs, Free State Province; Ezemvelo KZN Wildlife; Department of
   Economic Development, Environment and Tourism, Limpopo; the Department
   of Agriculture, Conservation and Environment, Mpumalanga and the
   Department of Environment and Nature Conservation, Northern Cape, as
   well as the South African National Department of Environmental Affairs.
CR Afar DEH, 2001, CANCER RES, V61, P1686
   American Veterinary Medical Association, COVID 19 FAQS PET OW
   Anderson CJ, 2017, SOUTHEAST NAT, V16, P19, DOI 10.1656/058.016.0103
   [Anonymous], 2017, IEEE T POWER SYSTEMS, VPP, P1, DOI DOI 10.1109/IEEESTD.2017.7920364
   Bao L, 2020, REINFECTION COULD NO, DOI [10.1101/2020.03.13.990226, DOI 10.1101/2020.03.13.990226, 10.1101/2020.03.13.990226.]
   Benavides J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031290
   Blaszczyk MB, 2017, ANIM BEHAV, V123, P91, DOI 10.1016/j.anbehav.2016.10.017
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Centers for Disease Control and Prevention, YOU HAV AN
   Chao S., 2020, INFECT NOVEL CORONAV, DOI [10.21203/rs.2.25200/v1, DOI 10.21203/RS.2.25200/V1]
   Chen H, 2020, SUSCEPTIBILITY FERRE, p20200330015347, DOI [10.1101/2020.03.30.015347, DOI 10.1101/2020.03.30.015347]
   Clark NL, 2005, PLOS GENET, V1, P335, DOI 10.1371/journal.pgen.0010035
   Cunningham F, 2019, NUCLEIC ACIDS RES, V47, pD745, DOI 10.1093/nar/gky1113
   Curwen V, 2004, GENOME RES, V14, P942, DOI 10.1101/gr.1858004
   Denham WW, 1982, J BARBADOS MUSEUM HI, V36, P211
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dore KM, 2018, FOLIA PRIMATOL, V89, P63, DOI 10.1159/000479064
   Gaetano TJ, 2014, S AFR J WILDL RES, V44, P56, DOI 10.3957/056.044.0105
   Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6
   Gillespie TR, 2008, YEARB PHYS ANTHROPOL, V51, P53, DOI 10.1002/ajpa.20949
   Grobler P, 2006, ECOLOGICAL ENV ANTHR, V2, P12
   Groves CP, 2001, PRIMATE TAXONOMY
   Healy A, 2014, ANIM WELFARE, V23, P353, DOI 10.7120/09627286.23.3.353
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hopman J, 2020, JAMA-J AM MED ASSOC, V323, P1549, DOI 10.1001/jama.2020.4169
   Huang X, 2019, BIOINFORMATICS, DOI [10.1093/bioinformatics/btz926.36, DOI 10.1093/BIOINFORMATICS/BTZ926.36]
   Jasinska AJ, 2013, ILAR J, V54, P122, DOI 10.1093/ilar/ilt049
   Jia HP, 2006, ADV EXP MED BIOL, V581, P479
   Karczewski K.J., 2019, GENOMICS, DOI [10.1101/531210, DOI 10.1101/531210]
   Kelly T.R., 2020, ONE HLTH OUTLOOK, V2, P1, DOI [10.1186/s42522-019-0007-9, DOI 10.1186/S42522-019-0007-9]
   Leendertz SAJ, 2017, MAMMAL REV, V47, P98, DOI 10.1111/mam.12082
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li R, 2020, J INFECTION, V80, P469, DOI 10.1016/j.jinf.2020.02.013
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Melin Amanda D, 2020, bioRxiv, DOI 10.1101/2020.04.09.034967
   Mikula P, 2018, BEHAV PROCESS, V147, P21, DOI 10.1016/j.beproc.2017.12.011
   Nasiri M.J., 2020, COVID 19 CLIN CHARAC, DOI [DOI 10.1101/2020.03.24.20042903, 10.1101/2020.03.24.20042903]
   Ramensky V, 2019, BURDEN DELETERIOUS V, DOI [10.1101/784132, DOI 10.1101/784132]
   Saj TL, 2001, AFR J ECOL, V39, P195, DOI 10.1046/j.0141-6707.2000.00299.x
   Schmitt CA, 2020, ANTHROPOGENIC FOOD E, DOI [10.1101/2020.04.18.048314, DOI 10.1101/2020.04.18.048314]
   Senghore M, 2016, APPL ENVIRON MICROB, V82, P5910, DOI 10.1128/AEM.01496-16
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Simmons G, 2013, ANTIVIR RES, V100, P605, DOI 10.1016/j.antiviral.2013.09.028
   South African Government, REG GUID COR COV 19
   Svardal H, 2017, NAT GENET, V49, P1705, DOI 10.1038/ng.3980
   The WHO Alliance for Maternal and Newborn Health Improvement late pregnancy dating study group, 2020, LANCET GLOB HEALTH, V8, pe545
   Turner TR, 2019, SAVANNA MONKEYS GENU
   Turner TR, 2018, AM J PHYS ANTHROPOL, V166, P682, DOI 10.1002/ajpa.23459
   Warren WC, 2015, GENOME RES, V25, P1921, DOI 10.1101/gr.192922.115
   Wimberger K, 2010, ANIM WELFARE, V19, P481
   Wolfe ND, 2004, LANCET, V363, P932, DOI 10.1016/S0140-6736(04)15787-5
   Wu C., 2020, SILICO ANAL INTERMED, DOI [10.26434/chemrxiv.12057996.v1, DOI 10.26434/CHEMRXIV.12057996.V1]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yu Pin, 2020, Animal Model Exp Med, V3, P93, DOI 10.1002/ame2.12108
   Zhang H, 2020, INTENS CARE MED, V3, P1, DOI DOI 10.1016/S0140-6736(20)30627-9
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
NR 61
TC 0
Z9 0
U1 5
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 23
PY 2020
VL 15
IS 6
AR e0235106
DI 10.1371/journal.pone.0235106
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ME9KK
UT WOS:000544972400038
PM 32574196
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Weiss, C
   Carriere, M
   Fusco, L
   Capua, I
   Regla-Nava, JA
   Pasquali, M
   Scott, AA
   Vitale, F
   Unal, MA
   Mattevi, C
   Bedognetti, D
   Merkoci, A
   Tasciotti, E
   Yilmazer, A
   Gogotsi, Y
   Stellacci, F
   Delogu, LG
AF Weiss, Carsten
   Carriere, Marie
   Fusco, Laura
   Capua, Ilaria
   Regla-Nava, Jose Angel
   Pasquali, Matteo
   Scott, Ames A.
   Vitale, Flavia
   Unal, Mehmet Altay
   Mattevi, Cecilia
   Bedognetti, Davide
   Merkoci, Arben
   Tasciotti, Ennio
   Yilmazer, Acelya
   Gogotsi, Yury
   Stellacci, Francesco
   Delogu, Lucia Gemma
TI Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic
SO ACS NANO
LA English
DT Article
ID MXENES COMPOSITE NANOSHEETS; ACUTE RESPIRATORY SYNDROME; FIELD-EFFECT
   TRANSISTOR; GRAPHENE OXIDE; PHOTODYNAMIC INACTIVATION; VIRUS
   INACTIVATION; DRINKING-WATER; DRUG-DELIVERY; VIRAL VECTORS; CARBIDE
   MXENE
AB The COVID-19 outbreak has fueled a global demand for effective diagnosis and treatment as well as mitigation of the spread of infection, all through large-scale approaches such as specific alternative antiviral methods and classical disinfection protocols. Based on an abundance of engineered materials identifiable by their useful physicochemical properties through versatile chemical functionalization, nanotechnology offers a number of approaches to cope with this emergency. Here, through a multidisciplinary Perspective encompassing diverse fields such as virology, biology, medicine, engineering, chemistry, materials science, and computational science, we outline how nanotechnology-based strategies can support the fight against COVID-19, as well as infectious diseases in general, including future pandemics. Considering what we know so far about the life cycle of the virus, we envision key steps where nanotechnology could counter the disease. First, nanoparticles (NPs) can offer alternative methods to classical disinfection protocols used in healthcare settings, thanks to their intrinsic antipathogenic properties and/or their ability to inactivate viruses, bacteria, fungi, or yeasts either photothermally or via photocatalysis-induced reactive oxygen species (ROS) generation. Nanotechnology tools to inactivate SARS-CoV-2 in patients could also be explored. In this case, nanomaterials could be used to deliver drugs to the pulmonary system to inhibit interaction between angiotensin-converting enzyme 2 (ACE2) receptors and viral S protein. Moreover, the concept of "nanoimmunity by design" can help us to design materials for immune modulation, either stimulating or suppressing the immune response, which would find applications in the context of vaccine development for SARS-CoV-2 or in counteracting the cytokine storm, respectively. In addition to disease prevention and therapeutic potential, nanotechnology has important roles in diagnostics, with potential to support the development of simple, fast, and cost-effective nanotechnology-based assays to monitor the presence of SARS-CoV-2 and related biomarkers. In summary, nanotechnology is critical in counteracting COVID-19 and will be vital when preparing for future pandemics.
C1 [Weiss, Carsten] Karlsruhe Inst Technol, Inst Biol & Chem Syst, Biol Informat Proc, D-76344 Eggenstein Leopoldshafen, Germany.
   [Carriere, Marie] Univ Grenoble Alpes, CEA, CNRS, IRIG,SyMMES CIBEST, F-38000 Grenoble, France.
   [Delogu, Lucia Gemma] Univ Padua, Dept Biomed Sci, I-35122 Padua, Italy.
   [Fusco, Laura; Bedognetti, Davide] Sidra Med, Canc Res Dept, Doha, Qatar.
   [Fusco, Laura] Univ Trieste, Dept Chem & Pharmaceut Sci, I-34127 Trieste, Italy.
   [Capua, Ilaria] Univ Florida, One Hlth Ctr Excellence, Gainesville, FL 32611 USA.
   [Regla-Nava, Jose Angel] La Jolla Inst Allergy & Immunol, Div Inflammat Biol, La Jolla, CA 92037 USA.
   [Pasquali, Matteo] Rice Univ, Dept Chem, Dept Chem & Biomol Engn, Houston, TX 77251 USA.
   [Pasquali, Matteo] Rice Univ, Dept Mat Sci & Nanoengn, Houston, TX 77251 USA.
   [Scott, Ames A.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5T 1R4, Canada.
   [Vitale, Flavia] Univ Penn, Ctr Neuroengn & Therapeut, Dept Neurol Bioengn Phys Med & Rehabil, Philadelphia, PA 19104 USA.
   [Vitale, Flavia] Corporal Michael J Crescenz Vet Affairs Med Ctr, Ctr Neurotrauma Neurockgenerat & Restorat, Philadelphia, PA 19104 USA.
   [Unal, Mehmet Altay; Yilmazer, Acelya] Ankara Univ, Stem Cell Inst, TR-06100 Ankara, Turkey.
   [Mattevi, Cecilia] Imperial Coll London, Dept Mat, London SW7 2AZ, England.
   [Merkoci, Arben] CSIC, Catalan Inst Nanosci & Nanotechnol ICN2, Nanobioelect & Biosensors Grp, Bellaterra 08193, Spain.
   [Merkoci, Arben] BIST, Bellaterra 08193, Spain.
   [Merkoci, Arben] ICREA Inst Catalana Recerca & Estudis Avancats, ES-08010 Barcelona, Spain.
   [Tasciotti, Ennio] Houston Methodist Hosp, Orthoped & Sports Med, Houston, TX 77030 USA.
   [Tasciotti, Ennio] MD Anderson, Dept Plast Surg, Houston, TX 77230 USA.
   [Yilmazer, Acelya] Ankara Univ, Fac Engn, Dept Biomed Engn, TR-06100 Ankara, Turkey.
   [Gogotsi, Yury] Drexel Univ, AJ Drexel Nanomat Inst, Philadelphia, PA 19104 USA.
   [Gogotsi, Yury] Drexel Univ, Mat Sci & Engn Dept, Philadelphia, PA 19104 USA.
   [Stellacci, Francesco] Ecole Polytech Fed Lausanne EPFL, Inst Mat, CH-1015 Lausanne, Switzerland.
   [Stellacci, Francesco] Ecole Polytech Fed Lausanne EPFL, Interfac Bioengn Inst, CH-1015 Lausanne, Switzerland.
RP Weiss, C (corresponding author), Karlsruhe Inst Technol, Inst Biol & Chem Syst, Biol Informat Proc, D-76344 Eggenstein Leopoldshafen, Germany.; Carriere, M (corresponding author), Univ Grenoble Alpes, CEA, CNRS, IRIG,SyMMES CIBEST, F-38000 Grenoble, France.; Delogu, LG (corresponding author), Univ Padua, Dept Biomed Sci, I-35122 Padua, Italy.
EM carsten.weiss@kit.edu; marie.carriere@cea.fr; luciagemma.delogu@unipd.it
RI Weiss, Carsten/I-1811-2013; UNAL, Mehmet Altay/AAD-2194-2019; Vitale,
   Flavia/AAS-1918-2020; Pasquali, Matteo/A-2489-2008
OI Weiss, Carsten/0000-0002-5380-3208; UNAL, Mehmet
   Altay/0000-0001-8607-5043; Delogu, Lucia Gemma/0000-0002-2329-7260;
   Mattevi, Cecilia/0000-0003-0005-0633; Pasquali,
   Matteo/0000-0001-5951-395X
FU European Union's Horizon 2020 research and innovation programme under
   the Marie Sklodowska-Curie GrantEuropean Union (EU) [734381]; University
   of Padua (Italy) DOR-2020; Turkish Academy of Sciences (TUBA)Turkish
   Academy of Sciences; CERCA programme/Generalitat de Catalunya; Severo
   Ochoa Centres of Excellence programme; Spanish Research Agency (AEI)
   [SEV-2017-0706]; European Research Council (ERC) under the European
   Union's Horizon 2020 research and innovation programmeEuropean Research
   Council (ERC) [819069]; Royal Society University Research Fellowship by
   the UK Royal Society [UF160539]; U.S. National Science
   FoundationNational Science Foundation (NSF) [DMR-1740795];
   "Investissements d'Avenir" French Government program of the French
   National Research Agency through the A*MIDEX projectFrench National
   Research Agency (ANR) [ANR-11-LABX-0064, ANR-11-IDEX-0001-02]
FX L.G.D. acknowledges the European Union's Horizon 2020 research and
   innovation programme under the Marie Sklodowska-Curie Grant Agreement
   No. 734381 (CARBOimmap), and the University of Padua (Italy) DOR-2020.
   A.Y. is thankful to the Turkish Academy of Sciences (TUBA) for financial
   support under the young investigator programme. A.M. thanks funding by
   the CERCA programme/Generalitat de Catalunya and the Severo Ochoa
   Centres of Excellence programme and by the Spanish Research Agency (AEI,
   Grant No. SEV-2017-0706) given to ICN2. C.M. would like to acknowledge
   the award of funding from the European Research Council (ERC) under the
   European Union's Horizon 2020 research and innovation programme (Grant
   Agreement No. 819069) and the award of a Royal Society University
   Research Fellowship (UF160539) by the UK Royal Society. Y.G. was
   supported by the U.S. National Science Foundation under Grant No.
   DMR-1740795. M.C. acknowledges the Labex SERENADE funded by the
   "Investissements d'Avenir" French Government program of the French
   National Research Agency (Grant No. ANR-11-LABX-0064) through the
   A*MIDEX project (Grant No. ANR-11-IDEX-0001-02). The authors acknowledge
   Prof. Sujan Shersta (La Jolla Institute for Allergy and Immunology) for
   suggestions in writing this manuscript. We thank Biorender software that
   was used to create the figures. Any opinion, findings, and conclusion or
   recommendations expressed in this material are those of the authors and
   do not necessarily reflect the views of the National Science Foundation.
CR Adesina SK, 2015, MOL PHARMACEUT, V12, P4175, DOI 10.1021/acs.molpharmaceut.5b00335
   Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Al-Lawati H, 2018, EXPERT OPIN DRUG DEL, V15, P397, DOI 10.1080/17425247.2018.1420053
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   ANASORI B, 2017, NAT REV, V2, P2, DOI DOI 10.1038/NATREVMATS.2016.98
   Anasori B., 2019, 2D METAL CARBIDES NI
   Anderson W French, 1990, Hum Gene Ther, V1, P331, DOI 10.1089/hum.1990.1.3-331
   Nguyen AT, 2015, SMALL, V11, P1039, DOI 10.1002/smll.201402985
   [Anonymous], 2015, Nature, V525, P305, DOI 10.1038/525305a
   [Anonymous], 98 WHO J HOPK U
   Bansal M, 2020, DIABETES METAB SYND, V14, P247, DOI 10.1016/j.dsx.2020.03.013
   Bapna K, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4769222
   Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Behnajady MA, 2013, CHEM ENG J, V228, P1207, DOI 10.1016/j.cej.2013.04.110
   Bhatia S, 2016, J AM CHEM SOC, V138, P8654, DOI 10.1021/jacs.5b12950
   Bogdan J, 2015, NANOSCALE RES LETT, V10, DOI 10.1186/s11671-015-1023-z
   Borkow G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011295
   Bugatti A, 2007, ANTIMICROB AGENTS CH, V51, P2337, DOI 10.1128/AAC.01362-06
   Burny W, 2017, FRONT IMMUNOL, V8, P14, DOI 10.3389/fimmu.2017.00943
   Byrne JA, 2015, MOLECULES, V20, P5574, DOI 10.3390/molecules20045574
   Cagno V, 2018, NAT MATER, V17, P195, DOI [10.1038/NMAT5053, 10.1038/nmat5053]
   Capua I, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120725
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen A, 2020, STRESS RESILIENCE: MOLECULAR AND BEHAVIORAL ASPECTS, P1, DOI 10.1016/C2016-0-03233-3
   Chen C, 2018, J MATER CHEM A, V6, P4617, DOI 10.1039/c7ta11347a
   Cheng HW, 2018, BIOORGAN MED CHEM, V26, P2262, DOI 10.1016/j.bmc.2018.02.012
   Chin Alex W H, 2020, Lancet Microbe, V1, pe10, DOI 10.1016/S2666-5247(20)30003-3
   CHOPPIN PW, 1980, REV INFECT DIS, V2, P40
   Chou SS, 2013, ANGEW CHEM INT EDIT, V52, P4160, DOI 10.1002/anie.201209229
   Cojocaru FD, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020171
   Costa L, 2012, VIRUSES-BASEL, V4, P1034, DOI 10.3390/v4071034
   Czapar AE, 2016, ACS NANO, V10, P4119, DOI 10.1021/acsnano.5b07360
   Dai C, 2017, ACS NANO, V11, P12696, DOI 10.1021/acsnano.7b07241
   Dai C, 2017, CHEM MATER, V29, P8637, DOI 10.1021/acs.chemmater.7b02441
   Darnell MER, 2004, J VIROL METHODS, V121, P85, DOI 10.1016/j.jviromet.2004.06.006
   De Gusseme B, 2010, APPL ENVIRON MICROB, V76, P1082, DOI 10.1128/AEM.02433-09
   de la Escosura-Muniz A, 2012, ACS NANO, V6, P7556, DOI 10.1021/nn301368z
   Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001
   Demkow U., 2016, CLIN APPL NEXT GENER, P217
   Dey P, 2018, ACS NANO, V12, P6429, DOI 10.1021/acsnano.8b01616
   Deysher G, 2020, ACS NANO, V14, P204, DOI 10.1021/acsnano.9b07708
   Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632
   Dolgin E, 2015, NATURE, V522, P26, DOI 10.1038/522026a
   Du T, 2018, ACS APPL MATER INTER, V10, P4369, DOI 10.1021/acsami.7b13811
   Dudley J., 2019, DRUG REPOSITIONING A
   Dunnill CW, 2011, DALTON T, V40, P1635, DOI 10.1039/c0dt00494d
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Fadeel B, 2018, ACS NANO, V12, P10582, DOI 10.1021/acsnano.8b04758
   Fasting C, 2012, ANGEW CHEM INT EDIT, V51, P10472, DOI 10.1002/anie.201201114
   Feng Z, 2020, NOVEL SEVERE ACUTE R, DOI [10.1101/2020.03.27.20045427, DOI 10.1101/2020.03.27.20045427]
   FRIEDMANN T, 1992, NAT GENET, V2, P93, DOI 10.1038/ng1092-93
   Fuchs AK, 2016, BIOMATERIALS, V85, P78, DOI 10.1016/j.biomaterials.2016.01.064
   Fusco L, 2020, THERANOSTICS, V10, P5435, DOI 10.7150/thno.40068
   Fusco L, 2020, CARBON, V160, P390, DOI 10.1016/j.carbon.2020.01.003
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Garcon N, 2011, BIODRUGS, V25, P217, DOI 10.2165/11591760-000000000-00000
   Gazzi A, 2020, J PHYS-MATER, V3, DOI 10.1088/2515-7639/ab9317
   Gazzi A, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00295
   Gholami MF, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201606477
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Govorov AO, 2007, NANO TODAY, V2, P30, DOI 10.1016/S1748-0132(07)70017-8
   Grass G, 2011, APPL ENVIRON MICROB, V77, P1541, DOI 10.1128/AEM.02766-10
   Han J, 2005, BIOMED ENVIRON SCI, V18, P176
   Han W, 2004, PROG BIOCHEM BIOPHYS, V31, P982
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Hantanasirisakul K, 2018, ADV MATER, V30, DOI 10.1002/adma.201804779
   Hinds W.C., 1999, AEROSOL TECHNOLOGY P
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   HogenEsch H, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0089-x
   Hojs N, 2020, CLIN J AM SOC NEPHRO, V15, P152, DOI 10.2215/CJN.01970219
   Hu Z, 2014, ANGEW CHEM INT EDIT, V53, P12794, DOI 10.1002/anie.201407898
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang JL, 2016, ANAL CHIM ACTA, V913, P121, DOI 10.1016/j.aca.2016.01.050
   Huang K, 2018, CHEM SOC REV, V47, P5109, DOI 10.1039/c7cs00838d
   Jackman JA, 2016, SMALL, V12, P1133, DOI 10.1002/smll.201500854
   Jang H, 2013, ANGEW CHEM INT EDIT, V52, P2340, DOI 10.1002/anie.201209222
   Jang H, 2010, ANGEW CHEM INT EDIT, V49, P5703, DOI 10.1002/anie.201001332
   Jimenez-Guardeno JM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005215
   Jing XN, 2018, BIOCONJUGATE CHEM, V29, P559, DOI 10.1021/acs.bioconjchem.8b00053
   Joe YH, 2016, J HAZARD MATER, V301, P547, DOI 10.1016/j.jhazmat.2015.09.017
   Jones ST, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax9318
   Jung JH, 2010, ANGEW CHEM INT EDIT, V49, P5708, DOI 10.1002/anie.201001428
   Kaiser JP, 2013, SCI TOTAL ENVIRON, V442, P282, DOI 10.1016/j.scitotenv.2012.10.009
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Keijzer C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026684
   Kerry RG, 2019, NANOMED-NANOTECHNOL, V18, P196, DOI 10.1016/j.nano.2019.03.004
   Kharkwal GB, 2011, LASER SURG MED, V43, P755, DOI 10.1002/lsm.21080
   Khater M, 2019, ANAL CHEM, V91, P4790, DOI 10.1021/acs.analchem.9b00340
   Kim HE, 2019, ENVIRON SCI TECHNOL, V53, P2679, DOI 10.1021/acs.est.8b06077
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Klucker MF, 2012, J PHARM SCI-US, V101, P4490, DOI 10.1002/jps.23311
   Knudsen NPH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19570
   Konda A, 2020, ACS NANO, V14, P6339, DOI 10.1021/acsnano.0c03252
   Kostarelos K, 2020, NAT NANOTECHNOL, V15, P343, DOI 10.1038/s41565-020-0687-4
   Kotov NA, 2010, SCIENCE, V330, P188, DOI 10.1126/science.1190094
   Kozlova EA, 2010, ENVIRON SCI TECHNOL, V44, P5121, DOI 10.1021/es100156p
   Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300
   Kunjiappan S, 2019, ANTI-CANCER AGENT ME, V19, P1966, DOI 10.2174/1871520619666190702145609
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lee BY, 2010, J NANOPART RES, V12, P2511, DOI 10.1007/s11051-009-9820-x
   Leung KH, 2015, CHEM SCI, V6, P2166, DOI 10.1039/c4sc03319a
   Li B, 2019, WIRES NANOMED NANOBI, V11, DOI 10.1002/wnan.1530
   Libalova H, 2018, CHEMOSPHERE, V196, P482, DOI 10.1016/j.chemosphere.2017.12.182
   Liga MV, 2013, ENVIRON SCI TECHNOL, V47, P6463, DOI 10.1021/es400196p
   Liga MV, 2011, WATER RES, V45, P535, DOI 10.1016/j.watres.2010.09.012
   Lim ME, 2012, BIOMATERIALS, V33, P1912, DOI 10.1016/j.biomaterials.2011.11.033
   Lin H, 2017, J AM CHEM SOC, V139, P16235, DOI 10.1021/jacs.7b07818
   Liu T, 2014, ADV MATER, V26, P3433, DOI 10.1002/adma.201305256
   Loeb S, 2018, ENVIRON SCI TECHNOL, V52, P205, DOI 10.1021/acs.est.7b04442
   Lovato A, 2020, ENT-EAR NOSE THROAT, DOI 10.1177/014556132092076220
   Low JX, 2018, J CATAL, V361, P255, DOI 10.1016/j.jcat.2018.03.009
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Lu JY, 2020, EMERG INFECT DIS, V26, P1628, DOI [10.3201/eid2607.200764, 10.3201/eid2611.203774]
   Lu L, 2008, ANTIVIR THER, V13, P253
   Lukashev AN, 2016, BIOCHEMISTRY-MOSCOW+, V81, P700, DOI 10.1134/S0006297916070063
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Lunnoo T, 2019, J PHYS CHEM C, V123, P3801, DOI 10.1021/acs.jpcc.8b07616
   Ma J, 2015, ACS NANO, V9, P10498, DOI 10.1021/acsnano.5b04751
   Maeda K, 2007, J PHYS CHEM C, V111, P7851, DOI 10.1021/jp070911w
   Mahler B, 2014, J AM CHEM SOC, V136, P14121, DOI 10.1021/ja506261t
   Maltez-da Costa M, 2012, NANO LETT, V12, P4164, DOI 10.1021/nl301726g
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Marks RM, 2001, J MED CHEM, V44, P2178, DOI 10.1021/jm000412i
   McKee AS, 2017, CURR OPIN IMMUNOL, V47, P44, DOI 10.1016/j.coi.2017.06.005
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meng FY, 2018, ACS NANO, V12, P10518, DOI 10.1021/acsnano.8b06494
   Molinaro R, 2016, NAT MATER, V15, P1037, DOI 10.1038/NMAT4644
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Mullard A, 2020, LANCET, V395, P1245, DOI 10.1016/S0140-6736(20)30894-1
   MURRAY JP, 1979, APPL ENVIRON MICROB, V37, P480, DOI 10.1128/AEM.37.3.480-486.1979
   Mycroft-West C., 2020, BIORXIV, P1, DOI [10.1101/2020.02.29.971093, DOI 10.1101/2020.02.29.971093]
   Naguib M, 2012, ACS NANO, V6, P1322, DOI 10.1021/nn204153h
   Naguib M, 2011, RSC ADV, V1, P1493, DOI 10.1039/c1ra00390a
   Naguib M, 2011, ADV MATER, V23, P4248, DOI 10.1002/adma.201102306
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Nasrallah GK, 2018, ENVIRON SCI-NANO, V5, P1002, DOI 10.1039/c7en01239j
   Nazari M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12377-5
   Nochi T, 2010, NAT MATER, V9, P572, DOI [10.1038/nmat2784, 10.1038/NMAT2784]
   Orecchioni M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01015-3
   Orecchioni M, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-138
   Orlowski P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104113
   Pandey RP, 2018, J MATER CHEM A, V6, P3522, DOI 10.1039/c7ta10888e
   Papp I, 2011, CHEMBIOCHEM, V12, P887, DOI 10.1002/cbic.201000776
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Park S, 2018, SCI TOTAL ENVIRON, V625, P477, DOI 10.1016/j.scitotenv.2017.12.318
   Parodi A, 2017, BIOMATERIALS, V147, P155, DOI 10.1016/j.biomaterials.2017.09.020
   Parolo C, 2013, CHEM SOC REV, V42, P450, DOI 10.1039/c2cs35255a
   Pentecost A, 2019, REGEN BIOMATER, V6, P163, DOI 10.1093/rb/rbz012
   Pescatori M, 2013, BIOMATERIALS, V34, P4395, DOI 10.1016/j.biomaterials.2013.02.052
   Presser V, 2012, ADV HEALTHC MATER, V1, P796, DOI 10.1002/adhm.201200044
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Qiu GG, 2020, ACS NANO, V14, P5268, DOI 10.1021/acsnano.0c02439
   Quesada-Gonzalez D, 2018, CHEM SOC REV, V47, P4697, DOI 10.1039/c7cs00837f
   Quesada-Gonzalez D, 2015, BIOSENS BIOELECTRON, V73, P47, DOI 10.1016/j.bios.2015.05.050
   Rabb H, 2020, J CLIN INVEST, V130, P2749, DOI 10.1172/JCI138871
   Rao GY, 2016, FRONT ENV SCI ENG, V10, DOI 10.1007/s11783-016-0854-x
   Rasool K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01714-3
   Rasool K, 2016, ACS NANO, V10, P3674, DOI 10.1021/acsnano.6b00181
   Regla-Nava JA, 2015, J VIROL, V89, P3870, DOI 10.1128/JVI.03566-14
   Riva Laura, 2020, bioRxiv, DOI 10.1101/2020.04.16.044016
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   Roy A, 2017, INNOVATIVE APPROACHES IN DRUG DISCOVERY: ETHNOPHARMACOLOGY, SYSTEMS BIOLOGY, AND HOLISTIC TARGETING, P65, DOI 10.1016/B978-0-12-801814-9.00003-9
   Rusnati M, 2009, PHARMACOL THERAPEUT, V123, P310, DOI 10.1016/j.pharmthera.2009.05.001
   Sametband M, 2014, ACS APPL MATER INTER, V6, P1228, DOI 10.1021/am405040z
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sarrazin S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004952
   Seah I, 2020, OCUL IMMUNOL INFLAMM, V28, P391, DOI 10.1080/09273948.2020.1738501
   Senanayake S. L., 2020, FUTURE DRUG DISCOVER, V2, pFDD40, DOI [10.4155/fdd-2020-0010, DOI 10.4155/FDD-2020-0010]
   Seo G, 2020, ACS NANO, V14, P5135, DOI 10.1021/acsnano.0c02823
   Seredych M., 2018, ACS APPL BIOMATER, V1, P436
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shetty Y, 2019, INT J PHARMACEUT, V558, P29, DOI 10.1016/j.ijpharm.2018.12.068
   Shi M, 2017, NANOSCALE, V9, P4739, DOI 10.1039/c6nr09102d
   Sim W, 2018, ANTIBIOTICS-BASEL, V7, DOI 10.3390/antibiotics7040093
   Singh L, 2017, THER ADV INFECT DIS, V4, P105, DOI 10.1177/2049936117713593
   Singh R, 2017, SCI REP-UK, V7, DOI 10.1038/srep42771
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Sohal IS, 2018, PART FIBRE TOXICOL, V15, DOI 10.1186/s12989-018-0265-1
   Sokolikova MS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08594-3
   Song ZY, 2015, SMALL, V11, P1171, DOI 10.1002/smll.201401706
   Stanford MG, 2019, ACS NANO, V13, P11912, DOI 10.1021/acsnano.9b05983
   Stencel-Baerenwald JE, 2014, NAT REV MICROBIOL, V12, P739, DOI 10.1038/nrmicro3346
   Sun BB, 2016, J MATER CHEM B, V4, P5496, DOI [10.1039/c6tb01131d, 10.1039/C6TB01131D]
   Sun D, 2015, CHEM MATER, V27, P3167, DOI 10.1021/acs.chemmater.5b01129
   Tang SC, 2016, ACS MACRO LETT, V5, P413, DOI 10.1021/acsmacrolett.5b00917
   Tu YS, 2013, NAT NANOTECHNOL, V8, P594, DOI [10.1038/nnano.2013.125, 10.1038/NNANO.2013.125]
   Tu ZX, 2018, ADV MATER, V30, DOI 10.1002/adma.201706709
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   United States Renal Data System, 2018, 2018 USRDS ANN DATA
   Urbankowski P, 2016, NANOSCALE, V8, P11385, DOI 10.1039/c6nr02253g
   van Dongen MJP, 2019, SCIENCE, V363, P1056, DOI 10.1126/science.aar6221
   van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Nguyen VH, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10040602
   Vincent M, 2017, GENE THER, V24, P123, DOI 10.1038/gt.2016.79
   Vonnemann J, 2014, NANOSCALE, V6, P2353, DOI 10.1039/c3nr04449a
   Wainwright M, 2003, INT J ANTIMICROB AG, V21, P510, DOI 10.1016/S0924-8579(03)00035-9
   Walther W, 2000, DRUGS, V60, P249, DOI 10.2165/00003495-200060020-00002
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Warnes SL, 2015, MBIO, V6, DOI 10.1128/mBio.01697-15
   Watkins K, 2018, CURR EMERG HOSP ME R, V6, P86, DOI 10.1007/s40138-018-0162-9
   Wiehe A, 2019, PHOTOCH PHOTOBIO SCI, V18, P2565, DOI 10.1039/c9pp00211a
   Wijeratne PA, 2019, INTERFACE FOCUS, V9, DOI 10.1098/rsfs.2018.0063
   Wong XY, 2020, ACS NANO, V14, P2585, DOI 10.1021/acsnano.9b08133
   Wong ZM, 2018, ACS APPL MATER INTER, V10, P39879, DOI 10.1021/acsami.8b14325
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Xie ZZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109419
   Xu BZ, 2016, ADV MATER, V28, P3333, DOI 10.1002/adma.201504657
   Yadavalli T, 2017, NANOMED-NANOTECHNOL, V13, P219, DOI 10.1016/j.nano.2016.08.016
   Yang Y., 2020, EXUBERANT ELEVATION, DOI [10.1101/2020.03.02.20029975, DOI 10.1101/2020.03.02.20029975]
   Ye SY, 2015, ACS APPL MATER INTER, V7, P21571, DOI 10.1021/acsami.5b06876
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Yoo JW, 2011, NAT REV DRUG DISCOV, V10, P521, DOI 10.1038/nrd3499
   Yu MY, 2016, J CONTROL RELEASE, V240, P24, DOI 10.1016/j.jconrel.2015.10.012
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu MT, 2014, HUM VACC IMMUNOTHER, V10, P2761, DOI 10.4161/hv.29589
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Ziem B, 2017, NANOSCALE, V9, P3774, DOI 10.1039/c7nr00611j
   Ziem B, 2016, ADV HEALTHC MATER, V5, P2922, DOI 10.1002/adhm.201600812
   Zodrow K, 2009, WATER RES, V43, P715, DOI 10.1016/j.watres.2008.11.014
NR 228
TC 29
Z9 29
U1 51
U2 57
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD JUN 23
PY 2020
VL 14
IS 6
BP 6383
EP 6406
DI 10.1021/acsnano.0c03697
PG 24
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA MD1OH
UT WOS:000543744100004
PM 32519842
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Mitchell, JP
   Berlinski, A
   Canisius, S
   Cipolla, D
   Dolovich, MB
   Gonda, I
   Hochhaus, G
   Kadrichu, N
   Lyapustina, S
   Mansour, HM
   Darquenne, C
   Clark, AR
   Newhouse, M
   Ehrmann, S
   Humphries, R
   Boushey, H
AF Mitchell, Jolyon P.
   Berlinski, Ariel
   Canisius, Sebastian
   Cipolla, David
   Dolovich, Myrna B.
   Gonda, Igor
   Hochhaus, Guenther
   Kadrichu, Nani
   Lyapustina, Svetlana
   Mansour, Heidi M.
   Darquenne, Chantal
   Clark, Andy R.
   Newhouse, Michael
   Ehrmann, Stephan
   Humphries, Robert
   Boushey, Homer
TI Urgent Appeal from International Society for Aerosols in Medicine (ISAM)
   During COVID-19: Clinical Decision Makers and Governmental Agencies
   Should Consider the Inhaled Route of Administration: A Statement from
   the ISAM Regulatory and Standardization Issues Networking Group
SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY
LA English
DT Letter
ID RECEIVING MECHANICAL VENTILATION; THERAPY; RIBAVIRIN; PULMONARY
C1 [Mitchell, Jolyon P.] Jolyon Mitchell Inhaler Consultancy Serv Inc, 1154 St Anthony Rd, London, ON N6H 2R1, Canada.
   [Berlinski, Ariel] Univ Arkansas Med Sci, Coll Med, Dept Pediat, Pulmonol Div, Little Rock, AR 72205 USA.
   [Canisius, Sebastian] ACLiRA Consulting GmbH, Ebsdorfergrund, Germany.
   [Cipolla, David] Insmed Inc, Bridgewater, NJ USA.
   [Dolovich, Myrna B.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Gonda, Igor] Respidex LLC, Dennis, MA USA.
   [Hochhaus, Guenther] Univ Florida, Coll Pharm, Gainesville, FL USA.
   [Kadrichu, Nani] Inspired Pulm Solut LLC, San Carlos, CA USA.
   [Lyapustina, Svetlana] Faegre Drinker Biddle & Reath LLP, Washington, DC USA.
   [Mansour, Heidi M.] Coll Med, Coll Pharm, Tucson, AZ USA.
   [Mansour, Heidi M.] Univ Arizona, Tucson, AZ USA.
   [Darquenne, Chantal] UCSD, Dept Med, La Jolla, CA USA.
   [Clark, Andy R.] Aerogen Pharma Corp, San Mateo, CA USA.
   [Newhouse, Michael] McMaster Univ, Fac Hlth Sci, St Josephs Hosp, Hamilton, ON, Canada.
   [Newhouse, Michael] McMaster Univ, Firestone Inst Resp Hlth, Hamilton, ON, Canada.
   [Ehrmann, Stephan] Ctr Hosp Reg, Tours, France.
   [Ehrmann, Stephan] Univ Tours, Med Intens Reanimat, Tours, France.
   [Humphries, Robert] VisionRealisation, Shepshed, Leics, England.
   [Boushey, Homer] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
RP Mitchell, JP (corresponding author), Jolyon Mitchell Inhaler Consultancy Serv Inc, 1154 St Anthony Rd, London, ON N6H 2R1, Canada.
EM mitchelljolyon@gmail.com
CR Ari A, 2020, RESP MED, V167, DOI 10.1016/j.rmed.2020.105987
   Ari A, 2012, J AEROSOL MED PULM D, V25, P319, DOI 10.1089/jamp.2011.0936
   Cipolla D, 2018, ADV DRUG DELIVER REV, V133, P1, DOI 10.1016/j.addr.2018.09.008
   Dolovich MB, 2005, CHEST, V127, P335, DOI 10.1378/chest.127.1.335
   Fernandez de Castro J, 1990, B MED HOSP INFANT M, V47, P449
   Fink JB, 2020, J AEROSOL MED UNPUB
   Hassoun M, 2019, MOL PHARMACEUT, V16, P1245, DOI 10.1021/acs.molpharmaceut.8b01200
   Hayden FG, 2000, NEW ENGL J MED, V343, P1282, DOI 10.1056/NEJM200011023431801
   Landray M, 2020, DESIGNING HIGH QUALI
   Laube BL, 2011, EUR RESPIR J, V37, P1308, DOI 10.1183/09031936.00166410
   Li J, 2020, ISAM WEBINAR 2020
   Li L, 2012, J HEART LUNG TRANSPL, V31, P839, DOI 10.1016/j.healun.2012.04.002
   SMITH DW, 1991, NEW ENGL J MED, V325, P24, DOI 10.1056/NEJM199107043250105
   Sun DX, 2020, AAPS J, V22, DOI 10.1208/s12248-020-00459-8
   Tavernier E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158604
   US Department of Health and Human Services, 1995, HIV AIDS NEWS FDA GR
   US Food and Drug Administration, 2020, GUID IND INV COVID 1
NR 17
TC 3
Z9 3
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1941-2711
EI 1941-2703
J9 J AEROSOL MED PULM D
JI J. Aerosol Med. Pulm. Drug Deliv.
PD AUG 1
PY 2020
VL 33
IS 4
BP 235
EP 238
DI 10.1089/jamp.2020.1622
EA JUN 2020
PG 4
WC Respiratory System
SC Respiratory System
GA MR1AC
UT WOS:000544393700001
PM 32589076
OA Bronze
DA 2021-01-01
ER

PT J
AU Zhou, S
   Zhou, ZY
   Ding, K
   Yuan, YX
   Loftin, C
   Zheng, F
   Zhan, CG
AF Zhou, Shuo
   Zhou, Ziyuan
   Ding, Kai
   Yuan, Yaxia
   Loftin, Charles
   Zheng, Fang
   Zhan, Chang-Guo
TI DREAM-in-CDM Approach and Identification of a New Generation of
   Anti-inflammatory Drugs Targeting mPGES-1
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PROSTAGLANDIN-E SYNTHASE-1; E-2 SYNTHASE-1; BIOLOGICAL EVALUATION;
   ACID-DERIVATIVES; MICE LACKING; INHIBITORS; 5-LIPOXYGENASE; DISCOVERY;
   PAIN; OPTIMIZATION
AB Microsomal prostaglandin E2 synthase-1 (mPGES-1) is known as an ideal target for next generation of anti-inflammatory drugs without the side effects of currently available anti-inflammatory drugs. However, there has been no clinically promising mPGES-1 inhibitor identified through traditional drug discovery and development route. Here we report a new approach, called DREAM-in-CDM (Drug Repurposing Effort Applying Integrated Modeling-in vitro/vivo-Clinical Data Mining), to identify an FDA-approved drug suitable for use as an effective analgesic targeting mPGES-1. The DREAM-in-CDM approach consists of three steps: computational screening of FDA-approved drugs; in vitro and/or in vivo assays; and clinical data mining. By using the DREAM-in-CDM approach, lapatinib has been identified as a promising mPGES-1 inhibitor which may have significant anti-inflammatory effects to relieve various forms of pain and possibly treat various inflammation conditions involved in other inflammation-related diseases such as the lung inflammation caused by the newly identified COVID-19. We anticipate that the DREAM-in-CDM approach will be used to repurpose FDA-approved drugs for various new therapeutic indications associated with new targets.
C1 [Zhou, Shuo; Zhou, Ziyuan; Ding, Kai; Yuan, Yaxia; Zheng, Fang; Zhan, Chang-Guo] Univ Kentucky, Coll Pharm, Mol Modeling & Biopharmaceut Ctr, 789 South Limestone St, Lexington, KY 40536 USA.
   [Zhou, Shuo; Zhou, Ziyuan; Ding, Kai; Yuan, Yaxia; Loftin, Charles; Zheng, Fang; Zhan, Chang-Guo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone St, Lexington, KY 40536 USA.
RP Zheng, F; Zhan, CG (corresponding author), Univ Kentucky, Coll Pharm, Mol Modeling & Biopharmaceut Ctr, 789 South Limestone St, Lexington, KY 40536 USA.; Zheng, F; Zhan, CG (corresponding author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone St, Lexington, KY 40536 USA.
EM fzhen2@uky.edu; zhan@uky.edu
FU Molecular Modeling and Biopharmaceutical Center at the University of
   Kentucky College of Pharmacy; National Science Foundation (NSF)National
   Science Foundation (NSF) [CHE-1111761]
FX This work was supported in part by the funding of the Molecular Modeling
   and Biopharmaceutical Center at the University of Kentucky College of
   Pharmacy and the National Science Foundation (NSF grant CHE-1111761).
   The authors also acknowledge the Computer Center at the University of
   Kentucky for supercomputing time on a Dell Supercomputer Cluster
   consisting of 388 nodes or 4,816 processors.
CR ANDERSEN HC, 1983, J COMPUT PHYS, V52, P24, DOI 10.1016/0021-9991(83)90014-1
   Bence AK, 2005, INVEST NEW DRUG, V23, P39, DOI 10.1023/B:DRUG.0000047104.45929.ea
   Boulet L, 2004, J BIOL CHEM, V279, P23229, DOI 10.1074/jbc.M400443200
   Bruno A, 2010, BIOCHEM PHARMACOL, V79, P974, DOI 10.1016/j.bcp.2009.11.011
   Case D., 2012, AMBER 12
   Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540
   Chien AJ, 2014, J CLIN ONCOL, V32, P1472, DOI 10.1200/JCO.2013.52.1161
   Chini MG, 2012, EUR J MED CHEM, V54, P311, DOI 10.1016/j.ejmech.2012.05.014
   Cote B, 2007, BIOORG MED CHEM LETT, V17, P6816, DOI 10.1016/j.bmcl.2007.10.033
   Degliesposti G, 2011, J BIOMOL SCREEN, V16, P129, DOI 10.1177/1087057110388276
   Ding K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23482-4
   Ding K, 2018, BIOORG MED CHEM LETT, V28, P858, DOI 10.1016/j.bmcl.2018.02.011
   Dong L, 2016, J BIOL CHEM, V291, P25641, DOI 10.1074/jbc.M116.757310
   EDWARDS JCW, 1981, J PATHOL, V134, P147, DOI 10.1002/path.1711340205
   Engblom D, 2003, NAT NEUROSCI, V6, P1137, DOI 10.1038/nn1137
   Fahmi H, 2004, CURR OPIN RHEUMATOL, V16, P623, DOI 10.1097/01.bor.0000129664.81052.8e
   Giroux A, 2009, BIOORG MED CHEM LETT, V19, P5837, DOI 10.1016/j.bmcl.2009.08.085
   Hamza A, 2011, BIOORGAN MED CHEM, V19, P6077, DOI 10.1016/j.bmc.2011.08.040
   Hamza A, 2010, J PHYS CHEM B, V114, P5605, DOI 10.1021/jp100668y
   Hanaka H, 2009, P NATL ACAD SCI USA, V106, P18757, DOI 10.1073/pnas.0910218106
   Hanke T, 2013, J MED CHEM, V56, P9031, DOI 10.1021/jm401557w
   Hieke M, 2011, J MED CHEM, V54, P4490, DOI 10.1021/jm200092b
   Huang XQ, 2006, BIOORGAN MED CHEM, V14, P3553, DOI 10.1016/j.bmc.2006.01.010
   Hudachek SF, 2013, J PHARMACOKINET PHAR, V40, P157, DOI 10.1007/s10928-012-9295-8
   Jin Y, 2016, CLIN PHARMACOL THER, V99, P274, DOI 10.1002/cpt.260
   Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200
   Koeberle A, 2015, BIOCHEM PHARMACOL, V98, P1, DOI 10.1016/j.bcp.2015.06.022
   Koeberle A, 2009, BIOORGAN MED CHEM, V17, P7924, DOI 10.1016/j.bmc.2009.10.025
   Kudo I, 2005, J BIOCHEM MOL BIOL, V38, P633
   Lee K, 2013, BIOORG MED CHEM LETT, V23, P75, DOI 10.1016/j.bmcl.2012.11.019
   Liedtke AJ, 2009, J MED CHEM, V52, P4968, DOI 10.1021/jm900481c
   Mathieu M., 2017, ENZO COMPOUNDS KNOWL
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Radmark O, 2010, J INTERN MED, V268, P5, DOI 10.1111/j.1365-2796.2010.02246.x
   Rastelli G, 2009, CHEM BIOL DRUG DES, V73, P283, DOI 10.1111/j.1747-0285.2009.00780.x
   Riendeau D, 2005, BIOORG MED CHEM LETT, V15, P3352, DOI 10.1016/j.bmcl.2005.05.027
   Schiffler MA, 2016, J MED CHEM, V59, P194, DOI 10.1021/acs.jmedchem.5b01249
   Serhan CN, 2003, P NATL ACAD SCI USA, V100, P8609, DOI 10.1073/pnas.1733589100
   Shang EC, 2014, BIOORG MED CHEM LETT, V24, P2764, DOI 10.1016/j.bmcl.2014.04.006
   Shiro T, 2013, BIOORGAN MED CHEM, V21, P2868, DOI 10.1016/j.bmc.2013.03.069
   Shiro T, 2013, BIOORGAN MED CHEM, V21, P2068, DOI 10.1016/j.bmc.2013.01.018
   Shiro T, 2012, BIOORG MED CHEM LETT, V22, P285, DOI 10.1016/j.bmcl.2011.11.015
   Terracciano S, 2015, ACS MED CHEM LETT, V6, P187, DOI 10.1021/ml500433j
   Trebino CE, 2005, J BIOL CHEM, V280, P16579, DOI 10.1074/jbc.M412075200
   Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Walker DP, 2013, BIOORG MED CHEM LETT, V23, P1120, DOI 10.1016/j.bmcl.2012.11.107
   Wang J, 2010, BIOORG MED CHEM LETT, V20, P1604, DOI 10.1016/j.bmcl.2010.01.060
   Wiegard A, 2012, EUR J MED CHEM, V48, P153, DOI 10.1016/j.ejmech.2011.12.009
   Wu TYH, 2010, BIOORG MED CHEM LETT, V20, P6978, DOI 10.1016/j.bmcl.2010.09.129
   Xu DG, 2008, J PHARMACOL EXP THER, V326, P754, DOI 10.1124/jpet.108.138776
   Zhou S, 2019, J CHEM INF MODEL, V59, P3839, DOI 10.1021/acs.jcim.9b00289
   Zhou ZY, 2017, BIOORG MED CHEM LETT, V27, P3739, DOI 10.1016/j.bmcl.2017.06.075
NR 55
TC 1
Z9 1
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 23
PY 2020
VL 10
IS 1
DI 10.1038/s41598-020-67283-0
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MD5FD
UT WOS:000543994900024
PM 32576928
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Grinspan, ZM
   Mytinger, JR
   Baumer, FM
   Ciliberto, MA
   Cohen, BH
   Dlugos, DJ
   Harini, C
   Hussain, SA
   Joshi, SM
   Keator, CG
   Knupp, KG
   McGoldrick, PE
   Nickels, KC
   Park, JT
   Pasupuleti, A
   Patel, AD
   Shahid, AM
   Shellhaas, RA
   Shrey, DW
   Singh, RK
   Wolf, SM
   Yozawitz, EG
   Yuskaitis, CJ
   Waugh, JL
   Pearl, PL
AF Grinspan, Zachary M.
   Mytinger, John R.
   Baumer, Fiona M.
   Ciliberto, Michael A.
   Cohen, Bruce H.
   Dlugos, Dennis J.
   Harini, Chellamani
   Hussain, Shaun A.
   Joshi, Sucheta M.
   Keator, Cynthia G.
   Knupp, Kelly G.
   McGoldrick, Patricia E.
   Nickels, Katherine C.
   Park, Jun T.
   Pasupuleti, Archana
   Patel, Anup D.
   Shahid, Asim M.
   Shellhaas, Renee A.
   Shrey, Daniel W.
   Singh, Rani K.
   Wolf, Steven M.
   Yozawitz, Elissa G.
   Yuskaitis, Christopher J.
   Waugh, Jeff L.
   Pearl, Phillip L.
CA Child Neurology Soc
   Practice Comm Executive Board
   Pediat Epilepsy Res Comm
   Infantile Spasms Special Interest
   Steering Comm
TI Management of Infantile Spasms During the COVID-19 Pandemic
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE infantile spasms; West syndrome; antiseizure drugs;
   electroencephalography; EEG
ID CARDIAC RHABDOMYOMA; TREATMENT RESPONSE; EPILEPSY SYNDROMES;
   MEDICAL-TREATMENT; AMERICAN-ACADEMY; WEST-SYNDROME; NEUROLOGY; CHILDREN;
   TOPIRAMATE; MULTICENTER
AB Circumstances of the COVID-19 pandemic have mandated a change to standard management of infantile spasms. On April 6, 2020, the Child Neurology Society issued an online statement of immediate recommendations to streamline diagnosis and treatment of infantile spasms with utilization of telemedicine, outpatient studies, and selection of first-line oral therapies as initial treatment. The rationale for the recommendations and specific guidance including follow-up assessment are provided in this manuscript. These recommendations are indicated as enduring if intended to outlast the pandemic, and limited if intended only for the pandemic health care crisis but may be applicable to future disruptions of health care delivery.
C1 [Grinspan, Zachary M.] Weill Cornell Med, New York, NY USA.
   [Mytinger, John R.; Patel, Anup D.] Nationwide Childrens Hosp, Columbus, OH USA.
   [Baumer, Fiona M.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
   [Ciliberto, Michael A.] Univ Iowa Hosp, Iowa City, IA USA.
   [Cohen, Bruce H.] Childrens Hosp, Med Ctr Akron, Akron, OH 44308 USA.
   [Dlugos, Dennis J.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [Harini, Chellamani; Yuskaitis, Christopher J.; Pearl, Phillip L.] Boston Childrens Hosp, Dept Neurol, 300 Longwood Ave, Boston, MA 02115 USA.
   [Hussain, Shaun A.] Univ Calif Los Angeles, Mattel Childrens Hosp, Los Angeles, CA USA.
   [Joshi, Sucheta M.; Shellhaas, Renee A.] Univ Michigan Pediat Neurol, Ann Arbor, MI USA.
   [Keator, Cynthia G.] Cook Childrens Med Ctr, Ft Worth, TX USA.
   [Knupp, Kelly G.] Childrens Hosp Colorado, Aurora, CO USA.
   [McGoldrick, Patricia E.; Wolf, Steven M.] Boston Childrens Hlth Phys, Hartsdale, NY USA.
   [Nickels, Katherine C.] Mayo Clin, Rochester, MN USA.
   [Park, Jun T.; Shahid, Asim M.] Univ Hosp Rainbow Babies & Childrens Hosp, Cleveland, OH USA.
   [Pasupuleti, Archana] Childrens Natl Hosp, Washington, DC USA.
   [Shrey, Daniel W.] Childrens Hosp Orange Cty, Orange, CA 92668 USA.
   [Singh, Rani K.] Levine Childrens Hosp Atrium Hlth Syst, Charlotte, NC USA.
   [Yozawitz, Elissa G.] Montefiore Med Syst, Bronx, NY USA.
   [Waugh, Jeff L.] Univ Texas Southwestern Med Ctr Southwestern, Dallas, TX USA.
RP Pearl, PL (corresponding author), Boston Childrens Hosp, Dept Neurol, 300 Longwood Ave, Boston, MA 02115 USA.
EM phillip.pearl@childrens.harvard.edu
RI ; Park, Jun/C-1894-2018
OI Baumer, Fiona/0000-0002-9162-9458; Park, Jun/0000-0002-9325-0038
CR Abu Dhais F, 2020, DEV MED CHILD NEUROL, V62, P62, DOI 10.1111/dmcn.14331
   Angappan D, 2019, EUR J PAEDIATR NEURO, V23, P136, DOI 10.1016/j.ejpn.2018.09.006
   Ashwal S, 2019, PEDIATR NEUROL, V92, P6, DOI 10.1016/j.pediatrneurol.2018.11.001
   Bahl Prateek, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa189
   Bailliard F, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-2
   Berg AT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193599
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Caraballo RH, 2009, EPILEPSIA, V50, P1176, DOI 10.1111/j.1528-1167.2008.01994.x
   Child Neurology Society, MAN INF SPASMS COVID
   Chu-Shore CJ, 2010, EPILEPSIA, V51, P1236, DOI 10.1111/j.1528-1167.2009.02474.x
   Chugani HT, 2010, EPILEPSIA, V51, P94, DOI 10.1111/j.1528-1167.2009.02460.x
   Dall TM, 2013, NEUROLOGY, V81, P470, DOI 10.1212/WNL.0b013e318294b1cf
   Davis PE, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016-4040
   Dayal P, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.9364
   Demarest ST, 2017, EPILEPSIA, V58, P2098, DOI 10.1111/epi.13937
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dura-Trave T, 2008, J CHILD NEUROL, V23, P878, DOI 10.1177/0883073808314898
   Eliyan Y, 2019, PEDIATR NEUROL, V99, P16, DOI 10.1016/j.pediatrneurol.2019.06.012
   Fox JR, 2020, EPILEPTIC DISORD, V22, P33, DOI 10.1684/epd.2020.1133
   Gaily E, 2001, DEV MED CHILD NEUROL, V43, P658, DOI 10.1017/S0012162201001207
   Gaily E, 2016, EPILEPSIA, V57, P1594, DOI 10.1111/epi.13514
   Gano D, 2013, PEDIATR NEUROL, V49, P401, DOI 10.1016/j.pediatrneurol.2013.08.007
   Glauser TA, 1998, EPILEPSIA, V39, P1324, DOI 10.1111/j.1528-1157.1998.tb01331.x
   Go CY, 2012, NEUROLOGY, V78, P1974, DOI 10.1212/WNL.0b013e318259e2cf
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Hiraishi S, 2000, HEART, V84, P170, DOI 10.1136/heart.84.2.170
   Hishitani T, 1997, CAN J CARDIOL, V13, P72
   Hong AM, 2010, EPILEPSIA, V51, P1403, DOI 10.1111/j.1528-1167.2010.02586.x
   Hosain SA, 2006, J CHILD NEUROL, V21, P17, DOI 10.1177/08830738060210011001
   Hussain Shaun A, 2020, Epilepsia Open, V5, P121, DOI 10.1002/epi4.12381
   Hussain Shaun A, 2018, Epilepsia Open, V3, P143, DOI 10.1002/epi4.12264
   Hussain Shaun A, 2018, Continuum (Minneap Minn), V24, P171, DOI 10.1212/CON.0000000000000558
   Hussain SA, 2014, EPILEPSIA, V55, P103, DOI 10.1111/epi.12460
   Joshi C, 2014, PEDIATR NEUROL, V51, P189, DOI 10.1016/j.pediatrneurol.2014.05.011
   Kang PB, 2016, NEUROLOGY, V87, P1384, DOI 10.1212/WNL.0000000000003147
   Karvelas G, 2009, SEIZURE-EUR J EPILEP, V18, P197, DOI 10.1016/j.seizure.2008.09.006
   KELLAWAY P, 1979, ANN NEUROL, V6, P214, DOI 10.1002/ana.410060306
   Kivity S, 2004, EPILEPSIA, V45, P255, DOI 10.1111/j.0013-9580.2004.30503.x
   Knupp KG, 2016, ANN NEUROL, V79, P475, DOI 10.1002/ana.24594
   Lee YJ, 2015, BRAIN DEV-JPN, V37, P37, DOI 10.1016/j.braindev.2014.02.009
   Li SJ, 2020, DEV MED CHILD NEUROL, V62, P575, DOI 10.1111/dmcn.14452
   Lo MD, 2019, J CHILD NEUROL, V34, P22, DOI 10.1177/0883073818807516
   LUDVIGSSON P, 1994, EPILEPSIA, V35, P802
   Lux AL, 2004, LANCET, V364, P1773, DOI 10.1016/S0140-6736(04)17400-X
   Mackay MT, 2004, NEUROLOGY, V62, P1668, DOI 10.1212/01.WNL.0000127773.72699.C8
   Mahmoud AA, 2013, NEUROSCIENCES, V18, P143
   McDonough TL, 2017, J CHILD NEUROL, V32, P630, DOI 10.1177/0883073817698628
   Mytinger JR, 2020, PEDIATR NEUROL, V104, P23, DOI 10.1016/j.pediatrneurol.2019.11.016
   Mytinger JR, 2015, EPILEPTIC DISORD, V17, P52, DOI 10.1684/epd.2014.0723
   Mytinger JR, 2012, J CHILD NEUROL, V27, P1289, DOI 10.1177/0883073812455692
   Nadig PL, 2020, INDIAN J PEDIATR, V87, P6, DOI 10.1007/s12098-019-03105-0
   Northrup H, 2013, PEDIATR NEUROL, V49, P243, DOI 10.1016/j.pediatrneurol.2013.08.001
   O'Callaghan FJK, 2018, LANCET CHILD ADOLESC, V2, P715, DOI 10.1016/S2352-4642(18)30244-X
   O'Callaghan FJK, 2011, EPILEPSIA, V52, P1359, DOI 10.1111/j.1528-1167.2011.03127.x
   O'Callaghan FK, 2017, LANCET NEUROL, V16, P33, DOI 10.1016/S1474-4422(16)30294-0
   O'Sullivan BP, 2009, LANCET, V373, P1891, DOI 10.1016/S0140-6736(09)60327-5
   Patel AD, 2018, NEUROLOGY, V90, P67, DOI 10.1212/WNL.0000000000004806
   Pellock JM, 2010, EPILEPSIA, V51, P2175, DOI 10.1111/j.1528-1167.2010.02657.x
   Perry MS, 2016, EPILEPSY CURR, V16, P299
   Pew Research Center, MOB FACT SHEET
   Prezioso G, 2018, ACTA NEUROL SCAND, V137, P4, DOI 10.1111/ane.12830
   Rantala H, 1999, J PEDIATR-US, V135, P761, DOI 10.1016/S0022-3476(99)70098-3
   Rasmusson KA, 2005, EPILEPSIA, V46, P767, DOI 10.1111/j.1528-1167.2005.44804.x
   RIIKONEN R, 1980, ARCH DIS CHILD, V55, P664, DOI 10.1136/adc.55.9.664
   Riikonen R, 2020, PEDIATR NEUROL, V108, P54, DOI 10.1016/j.pediatrneurol.2020.01.015
   Rogers MAM, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0958-6
   SIDENVALL R, 1995, EPILEPSIA, V36, P572, DOI 10.1111/j.1528-1157.1995.tb02569.x
   STARC TJ, 1994, AM J CARDIOL, V73, P57, DOI 10.1016/0002-9149(94)90727-7
   Taussig D, 2015, EUR J PAEDIATR NEURO, V19, P597, DOI 10.1016/j.ejpn.2015.04.003
   Trevathan E, 1999, EPILEPSIA, V40, P748, DOI 10.1111/j.1528-1157.1999.tb00773.x
   Velasquez SE, 2016, PEDIATR NEUROL, V64, P32, DOI 10.1016/j.pediatrneurol.2016.08.001
   WATANABE K, 1993, EPILEPSIA, V34, P679, DOI 10.1111/j.1528-1157.1993.tb00446.x
   Watanabe K, 1998, BRAIN DEV-JPN, V20, P1, DOI 10.1016/S0387-7604(97)00085-5
   Weber A, 2015, PEDIATR NEUROL, V53, P130, DOI 10.1016/j.pediatrneurol.2015.05.003
   Wilmshurst JM, 2015, EPILEPSIA, V56, P1185, DOI 10.1111/epi.13057
   Wilson NM, 2020, ANAESTHESIA, V75, P1086, DOI 10.1111/anae.15093
   Wirrell EC, 2015, EPILEPSIA, V56, P617, DOI 10.1111/epi.12951
   Wirrell EC, 2011, EPILEPSY RES, V95, P110, DOI 10.1016/j.eplepsyres.2011.03.009
   Yi ZS, 2019, SEIZURE-EUR J EPILEP, V71, P174, DOI 10.1016/j.seizure.2019.07.016
NR 79
TC 3
Z9 3
U1 3
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD OCT
PY 2020
VL 35
IS 12
BP 828
EP 834
AR 0883073820933739
DI 10.1177/0883073820933739
EA JUN 2020
PG 7
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA NN1FJ
UT WOS:000543092000001
PM 32576057
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Zhang, HY
   Wang, LW
   Chen, YY
   Wu, QJ
   Chen, GL
   Shen, XK
   Wang, Q
   Yan, YQ
   Zhong, YH
   Wang, XH
   Chua, MLK
   Xie, CH
   Yu, Y
AF Zhang, Hongyan
   Wang, Linwei
   Chen, Yuanyuan
   Wu, Qiuji
   Chen, Gaili
   Shen, Xiaokun
   Wang, Qun
   Yan, Youqin
   Zhong, Yahua
   Wang, Xinqhuan
   Chua, Melvin L. K.
   Xie, Conghua
   Yu, Yi
TI Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107
   patients with cancer from Wuhan, China
SO CANCER
LA English
DT Article
DE anticancer treatment; cancer; case fatality rate; coronavirus disease
   2019 (COVID-19); systemic therapy
AB Background Patients with cancer have a higher risk of coronavirus disease 2019 (COVID-19) than noncancer patients. The authors conducted a multicenter retrospective study to investigate the clinical manifestations and outcomes of patients with cancer who are diagnosed with COVID-19. Methods The authors reviewed the medical records of hospitalized patients who were treated at 5 hospitals in Wuhan City, China, between January 5 and March 18, 2020. Clinical parameters relating to cancer history (type and treatment) and COVID-19 were collected. The primary outcome was overall survival (OS). Secondary analyses were the association between clinical factors and severe COVID-19 and OS. Results A total of 107 patients with cancer were diagnosed with COVID-19, with a median age of 66 years (range, 37-98 years). Lung (21 patients; 19.6%), gastrointestinal (20 patients; 18.7%), and genitourinary (20 patients; 18.7%) cancers were the most common cancer diagnoses. A total of 37 patients (34.6%) were receiving active anticancer treatment when diagnosed with COVID-19, whereas 70 patients (65.4%) were on follow-up. Overall, 52.3% of patients (56 patients) developed severe COVID-19; this rate was found to be higher among patients receiving anticancer treatment than those on follow-up (64.9% vs 45.7%), which corresponded to an inferior OS in the former subgroup of patients (hazard ratio, 3.365; 95% CI, 1.455-7.782 [P = .005]). The detrimental effect of anticancer treatment on OS was found to be independent of exposure to systemic therapy (case fatality rate of 33.3% [systemic therapy] vs 43.8% [nonsystemic therapy]). Conclusions The results of the current study demonstrated that >50.0% of infected patients with cancer are susceptible to severe COVID-19. This risk is aggravated by simultaneous anticancer treatment and portends for a worse survival, despite treatment for COVID-19.
C1 [Zhang, Hongyan; Wang, Linwei; Chen, Yuanyuan; Wu, Qiuji; Chen, Gaili; Zhong, Yahua; Chua, Melvin L. K.; Xie, Conghua] Wuhan Univ, Dept Radiat & Med Oncol, Zhongnan Hosp, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
   [Chua, Melvin L. K.] Natl Canc Ctr Singapore, Div Radiat Oncol, 11 Hosp Crescent, Singapore 169610, Singapore.
   [Wang, Xinqhuan] Wuhan Univ, Dept Urol, Zhongnan Hosp, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
   [Zhang, Hongyan; Wang, Linwei; Chen, Yuanyuan; Wu, Qiuji; Chen, Gaili; Zhong, Yahua; Chua, Melvin L. K.; Xie, Conghua] Hubei Canc Clin Study Ctr, Hubei Key Lab Tumor Biol Behav, Wuhan, Peoples R China.
   [Shen, Xiaokun] Convalife Shanghai Co Ltd, Shanghai, Peoples R China.
   [Wang, Qun] Fifth Hosp Wuhan, Dept Oncol, Wuhan, Peoples R China.
   [Yan, Youqin] Seventh Hosp Wuhan, Dept Infect, Wuhan, Peoples R China.
   [Yu, Yi] Han Kou Hosp Wuhan, Dept Oncol, Wuhan, Peoples R China.
   [Wang, Xinqhuan] Wuhan Univ, Ctr Evidence Based & Translat Med, Zhongnan Hosp, Wuhan, Peoples R China.
   [Chua, Melvin L. K.] Natl Canc Ctr Singapore, Div Med Sci, Singapore, Singapore.
   [Chua, Melvin L. K.] Duke NUS Med Sch, Oncol Acad Programme, Singapore, Singapore.
RP Zhong, YH; Xie, CH (corresponding author), Wuhan Univ, Dept Radiat & Med Oncol, Zhongnan Hosp, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.; Chua, MLK (corresponding author), Natl Canc Ctr Singapore, Div Radiat Oncol, 11 Hosp Crescent, Singapore 169610, Singapore.; Wang, XH (corresponding author), Wuhan Univ, Dept Urol, Zhongnan Hosp, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
EM doctorzyh73@163.com; wangxinghuan@whu.edu.cn; chxie_65@whu.edu.cn
RI Chua, Melvin LK/ABG-6045-2020
OI Chua, Melvin LK/0000-0002-1648-1473
FU Health Commission of Hubei Province Scientific Research Project
   [WJ2019H002]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [2042018kf1037, 2042019kf0329]; Medical Science Advancement Program
   (Basic Medical Sciences) of Wuhan University [TFJC2018005]; Zhongnan
   Hospital of Wuhan University Science, Technology and Innovation Seed
   Fund [znpy2017049, znpy2018070]; National Medical Research Council
   Clinician-scientist award [NMRC/CSA/0027/2018]; National Science and
   Technology Major Projects for Major New Drugs Innovation and Development
   [2019ZX09301010]; Pudong New Area Science and Technology Development
   Foundation [PKX2019-S08]
FX Conghua Xie is supported by the Health Commission of Hubei Province
   Scientific Research Project (WJ2019H002); the Health Commission of Hubei
   Province Medical Leading Talent Project; Fundamental Research Funds for
   the Central Universities (2042018kf1037 and 2042019kf0329); the Medical
   Science Advancement Program (Basic Medical Sciences) of Wuhan University
   (TFJC2018005); and the Zhongnan Hospital of Wuhan University Science,
   Technology and Innovation Seed Fund (znpy2017049 and znpy2018070).
   Melvin L. K. Chua has received grants and personal fees from Ferring
   Singapore; has acted as a paid member of the advisory board for Janssen,
   Astellas, Merck, and Illumina; has acted as a paid member of the
   advisory board and received hardware for research from Varian; has
   received nonfinancial support (provision of an artificial intelligence
   contouring work station for research) from PAVmed Inc; and has received
   nonfinancial support from MedLever Inc and Decipher Biosciences for work
   performed outside of the current study. Dr. Chua also is supported by
   the National Medical Research Council Clinician-scientist award
   (NMRC/CSA/0027/2018). Xiaokun Shen is the founder and Chief Executive
   Officer of Convalife (Shanghai) Company Ltd and has an equity interest.
   Xiaokun Shen was supported in part by the National Science and
   Technology Major Projects for Major New Drugs Innovation and Development
   (2019ZX09301010) and Pudong New Area Science and Technology Development
   Foundation (PKX2019-S08). The other authors made no disclosures.
CR Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Centers for Disease Control and Prevention, INF LAB COR COVID 19
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   Fakhry N, 2020, EUR ANN OTORHINOLARY, V137, P159, DOI 10.1016/j.anorl.2020.04.008
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kattan J, 2020, IMMUNOTHERAPY-UK, V12, P351, DOI 10.2217/imt-2020-0077
   Thomson DJ, 2020, INT J RADIAT ONCOL, V107, P618, DOI 10.1016/j.ijrobp.2020.04.016
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wong JEL, 2020, JAMA-J AM MED ASSOC, V323, P1243, DOI 10.1001/jama.2020.2467
   World Health Organization, COR DIS 2019 COVID 1
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yahalom J, 2020, BLOOD, V135, P1829, DOI 10.1182/blood.2020006028
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ELECTRON J DIFFER EQ
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 7
Z9 7
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD SEP 1
PY 2020
VL 126
IS 17
BP 4023
EP 4031
DI 10.1002/cncr.33042
EA JUN 2020
PG 9
WC Oncology
SC Oncology
GA MX1VA
UT WOS:000541933300001
PM 32573776
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Brussow, H
AF Brussow, Harald
TI COVID-19: From pathogenesis models to the first drug trials
SO MICROBIAL BIOTECHNOLOGY
LA English
DT Article
ID SARS-COV-2
AB The number of people infected with SARS-CoV-2, and sadly dying from COVID-19, has exploded, and so the amount of literature on the novel coronavirus and the disease it causes has increased proportionately. The case numbers in some countries are beyond the epidemic peak, but the uncertainty about a second wave keeps politicians and societies under pressure. Appropriate decision-making and winning support from the population depends on precise scientific information rather than leaving the field to scaremongers of all proveniences. This mini-review is an update of earlier reports (Brussow,Microb Biotechnol2020a;13:607; Brussow,Microb Biotechnol2020b; ).
C1 [Brussow, Harald] Katholieke Univ Leuven, Lab Gene Technol, Dept Biosyst, Leuven, Belgium.
RP Brussow, H (corresponding author), Katholieke Univ Leuven, Lab Gene Technol, Dept Biosyst, Leuven, Belgium.
EM haraldbruessow@yahoo.com
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Bauchner H, 2020, JAMA-J AM MED ASSOC, V323, P2262, DOI 10.1001/jama.2020.8115
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chen X, 2020, CHINA PERSPECT-SER, P1
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Cyranoski David, 2020, Nature, DOI 10.1038/d41586-020-01284-x
   Deng L., 2020, J INFECTION, DOI [10.1038/d41586-020-01284-x, DOI 10.1038/D41586-020-01284-X]
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Ledford Heidi, 2020, Nature, DOI 10.1038/d41586-020-01295-8
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li Yueping, 2020, Med (N Y), V1, P105, DOI 10.1016/j.medj.2020.04.001
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Mancia G., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2006923, DOI 10.1056/NEJM0A2006923]
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta P, 2020, LANCET RHEUMATOL, V2, pE358, DOI 10.1016/S2665-9913(20)30096-5
   Ong EZY, 2020, CELL HOST MICROBE, V27, P879, DOI 10.1016/j.chom.2020.03.021
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Sajuthi Satria P, 2020, bioRxiv, DOI 10.1101/2020.04.09.034454
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Xiao KP, 2020, NATURE, V583, P286, DOI 10.1038/s41586-020-2313-x
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 48
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-7915
J9 MICROB BIOTECHNOL
JI Microb. Biotechnol.
PD SEP
PY 2020
VL 13
IS 5
BP 1289
EP 1299
DI 10.1111/1751-7915.13611
EA JUN 2020
PG 11
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA NG4AL
UT WOS:000541956600001
PM 32573950
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhou, CZ
   Huang, Z
   Tan, WJ
   Li, XY
   Yin, W
   Xiao, Y
   Tao, ZW
   Geng, S
   Hu, Y
AF Zhou, Changzhi
   Huang, Zhe
   Tan, Weijun
   Li, Xueying
   Yin, Wen
   Xiao, Yang
   Tao, Zhaowu
   Geng, Shuang
   Hu, Yi
TI Predictive factors of severe coronavirus disease 2019 in previously
   healthy young adults: a single-center, retrospective study
SO RESPIRATORY RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; Predictive factors; Retrospective study
ID CORTICOSTEROID TREATMENT; VIRAL LOAD; SARS; PNEUMONIA; MERS; WUHAN;
   CHINA
AB Background Several previously healthy young adults have developed Coronavirus Disease 2019 (COVID-19), and a few of them progressed to the severe stage. However, the factors are not yet determined. Method We retrospectively analyzed 123 previously healthy young adults diagnosed with COVID-19 from January to March 2020 in a tertiary hospital in Wuhan. Patients were classified as having mild or severe COVID-19 based on their respiratory rate, SpO(2), and PaO2/FiO(2)levels. Patients' symptoms, computer tomography (CT) images, preadmission drugs received, and the serum biochemical examination on admission were compared between the mild and severe groups. Significant variables were enrolled into logistic regression model to predict the factors affecting disease severity. A receiver operating characteristic (ROC) curve was applied to validate the predictive value of predictors. Result Age; temperature; anorexia; and white blood cell count, neutrophil percentage, platelet count, lymphocyte count, C-reactive protein, aspartate transaminase, creatine kinase, albumin, and fibrinogen values were significantly different between patients with mild and severe COVID-19 (P < 0.05). Logistic regression analysis confirmed that lymphopenia (P = 0.010) indicated severe prognosis in previously healthy young adults with COVID-19, with the area under the curve (AUC) was 0.791(95% Confidence Interval (CI) 0.704-0.877)(P < 0.001). Conclusion For previously healthy young adults with COVID-19, lymphopenia on admission can predict severe prognosis.
C1 [Zhou, Changzhi; Tan, Weijun; Li, Xueying; Yin, Wen; Xiao, Yang; Tao, Zhaowu; Geng, Shuang; Hu, Yi] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Dept Resp & Crit Care Med, Tongji Med Coll, Shengli St 26, Wuhan 430014, Hubei, Peoples R China.
   [Huang, Zhe] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Cardiac Funct Dept, Tongji Med Coll, Shengli St 26, Wuhan 430014, Hubei, Peoples R China.
RP Geng, S; Hu, Y (corresponding author), Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Dept Resp & Crit Care Med, Tongji Med Coll, Shengli St 26, Wuhan 430014, Hubei, Peoples R China.
EM gengshuangsky@126.com; huyi_resp@sina.com
CR [Anonymous], 2020, NOVEL CORONAVIRUS 20
   [Anonymous], 2020, CORONAVIRUS DIS 2019
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bellelli V, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2608-1
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   He ZP, 2005, INT J INFECT DIS, V9, P323, DOI 10.1016/j.ijid.2004.07.014
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Ko JH, 2016, J INFECTION, V73, P468, DOI 10.1016/j.jinf.2016.08.005
   Lee HKK, 2003, EMERG INFECT DIS, V9, P1491, DOI 10.3201/eid0911.030401
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Lin L, 2020, Zhonghua Yi Xue Za Zhi, V100, P805, DOI 10.3760/cma.j.cn112137-20200205-00199
   Memish ZA, 2014, J INFECT DIS, V210, P1590, DOI 10.1093/infdis/jiu292
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Y., 2020, EARLY LOW DOSE SHORT, DOI [10.1101/2020.03.06.20032342., DOI 10.1101/2020.03.06.20032342, 10.1101/2020.03.06. 20032342.]
   World Health Organization, 2020, CLIN MAN SEV AC RESP
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang JJ, 2020, ALLERGY, V75, P1809, DOI 10.1111/all.14316
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 23
TC 1
Z9 1
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1465-993X
J9 RESP RES
JI Respir. Res.
PD JUN 22
PY 2020
VL 21
IS 1
AR 157
DI 10.1186/s12931-020-01412-1
PG 8
WC Respiratory System
SC Respiratory System
GA MH8DF
UT WOS:000546951900003
PM 32571410
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Selcuk, M
   Cinar, T
   Keskin, M
   Cicek, V
   Kilic, S
   Kenan, B
   Dogan, S
   Asal, S
   Gunay, N
   Yildirim, E
   Keskin, U
   Orhan, AL
AF Selcuk, Murat
   Cinar, Tufan
   Keskin, Muhammed
   Cicek, Vedat
   Kilic, Sahhan
   Kenan, Behruz
   Dogan, Selami
   Asal, Suha
   Gunay, Nuran
   Yildirim, Ersin
   Keskin, Umran
   Orhan, Ahmet Lutfullah
TI Is the use of ACE inb/ARBs associated with higher in-hospital mortality
   in Covid-19 pneumonia patients?
SO CLINICAL AND EXPERIMENTAL HYPERTENSION
LA English
DT Article
DE Covid-19; ACE inh; ARBs; mortality; SARSCoV-2
ID ANGIOTENSIN-CONVERTING ENZYME-2; RECEPTOR
AB Introduction The present research aimed to determine the relation between the use of angiotensin-converting enzyme inhibitors (ACE inh) and angiotensinogen receptor blockers (ARBs) and in-hospital mortality of hypertensive patients diagnosed with Covid-19 pneumonia. Material and method In this retrospective study, we included 113 consecutive hypertensive patients admitted due to Covid-19 infection. In all patients, Covid-19 infection was confirmed with using reverse-transcription polymerase chain reaction. All patients were on ACE inh/ARBs or other antihypertensive therapy unless no contraindication was present. The primary outcome of the study was the in-hospital all-cause mortality. Results In total, 113 hypertensive Covid-19 patients were included, of them 74 patients were using ACE inh/ARBs. During in-hospital follow up, 30.9% [n = 35 patients] of patients died. The frequency of admission to the ICU and endotracheal intubation were significantly higher in patients using ACE inh/ARBs. In a multivariable analysis, the use of ACE inh/ARBs was an independent predictor of in-hospital mortality (OR: 3.66; 95%CI: 1.11-18.18;p= .032). Kaplan-Meir curve analysis displayed that patients on ACE inh/ARBs therapy had higher incidence of in-hospital death than those who were not. Conclusion The present study has found that the use of ACE inh/ARBs therapy might be associated with an increased in-hospital mortality in patients who were diagnosed with Covid-19 pneumonia. It is likely that ACE inh/ARBs therapy might not be beneficial in the subgroup of hypertensive Covid-19 patients despite the fact that there might be the possibility of some unmeasured residual confounders to affect the results of the study.
C1 [Selcuk, Murat; Cinar, Tufan; Keskin, Muhammed; Cicek, Vedat; Kilic, Sahhan; Kenan, Behruz; Dogan, Selami; Asal, Suha; Orhan, Ahmet Lutfullah] Hlth Sci Univ, Dept Cardiol, Sultan Abdulhamid Han Training & Res Hosp, Istanbul, Turkey.
   [Gunay, Nuran; Yildirim, Ersin] Hlth Sci Univ, Dept Cardiol, Umraniye Training & Res Hosp, Istanbul, Turkey.
   [Keskin, Umran] Hlth Sci Univ, Dept Internal Med, Haydarpasa Numune Training & Res Hosp, Istanbul, Turkey.
RP Cinar, T (corresponding author), Hlth Sci Univ, Dept Cardiol, Sultan Abdulhamid Han Training & Res Hosp, Istanbul, Turkey.
EM drtufancinar@gmail.com
RI Cinar, Tufan/ABD-4630-2020
OI Cinar, Tufan/0000-0001-8188-5020; Asal, Suha/0000-0002-3709-2506
CR Dhaun N, 2019, NAT REV CARDIOL, V16, P491, DOI 10.1038/s41569-019-0176-3
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Flack JM, 2020, TRENDS CARDIOVAS MED, V30, P160, DOI 10.1016/j.tcm.2019.05.003
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Igase M, 2008, HYPERTENS RES, V31, P553, DOI 10.1291/hypres.31.553
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li JY, 2020, DIABETES OBES METAB, V22, P1935, DOI 10.1111/dom.14057
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li YW, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104833
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Matsuyama R, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3881-4
   Morra ME, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1977
   Rico-Mesa JS, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01291-4
   Rodriguez-Iturbe B, 2017, PHYSIOL REV, V97, P1127, DOI 10.1152/physrev.00031.2016
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
NR 18
TC 10
Z9 10
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1064-1963
EI 1525-6006
J9 CLIN EXP HYPERTENS
JI Clin. Exp. Hypertens.
PD NOV 16
PY 2020
VL 42
IS 8
BP 738
EP 742
DI 10.1080/10641963.2020.1783549
EA JUN 2020
PG 5
WC Pharmacology & Pharmacy; Peripheral Vascular Disease
SC Pharmacology & Pharmacy; Cardiovascular System & Cardiology
GA MN4ZK
UT WOS:000547721500001
PM 32569491
OA Bronze
DA 2021-01-01
ER

PT J
AU Wang, JM
AF Wang, Junmei
TI Fast Identification of Possible Drug Treatment of Coronavirus Disease-19
   (COVID-19) through Computational Drug Repurposing Study
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID BINDING FREE-ENERGIES; MM-PBSA; ATOMIC CHARGES; ACCURATE; DOCKING;
   PERFORMANCE; MM/PBSA; MM/GBSA; PREDICTION; ALGORITHM
AB The recent outbreak of novel coronavirus disease-19 (COVID-19) calls for and welcomes possible treatment strategies using drugs on the market. It is very efficient to apply computer-aided drug design techniques to quickly identify promising drug repurposing candidates, especially after the detailed 3D structures of key viral proteins are resolved. The virus causing COVID-19 is SARS-CoV-2. Taking advantage of a recently released crystal structure of SARS-CoV-2 main protease in complex with a covalently bonded inhibitor, N3 (Liu et al., 10.2210/pdb6LU7/pdb), I conducted virtual docking screening of approved drugs and drug candidates in clinical trials. For the top docking hits, I then performed molecular dynamics simulations followed by binding free energy calculations using an end point method called MM-PBSA-WSAS (molecular mechanics/Poisson-Boltzmann surface area/weighted solvent-accessible surface area; Wang, et al. Chem. Rev. 2019, 119, 9478; Wang, et al. Curr. Comput.-Aided Drug Des. 2006, 2, 287; Wang; Hou J. Chem. Inf. Model., 2012, 52, 1199). Several promising known drugs stand out as potential inhibitors of SARS-CoV-2 main protease, induding carfilzomib, eravacycline, vali-ubicin, lopinavir, and elbasvir. Carfilzomib, an approved anticancer drug acting as a proteasome inhibitor, has the best MMPBSA-WSAS binding free energy, -13.8 kcal/mol. The second-best repurposing drug candidate, eravacycline, is synthetic halogenated tetracydine class antibiotic. Streptomycin, another antibiotic and a charged molecule, also demonstrates some inhibitory effect, even though the predicted binding free energy of the charged form (-3.8 kcal/mol) is not nearly as low as that of the neutral form (-7.9 kcal/mol). One bioactive, PubChem 23727975, has a binding free energy of -12.9 kcal/mol. Detailed receptor-ligand interactions were analyzed and hot spots for the receptor-ligand binding were identified. I found that one hot spot residue, His41, is a conserved residue across many viruses including SARS-CoV, SARS-CoV-2, MERS-CoV, and hepatitis C virus (HCV). The findings of this study can facilitate rational drug design targeting the SARS-CoV-2 main protease.
C1 [Wang, Junmei] Univ Pittsburgh, Dept Pharmaceut Sci, Sch Pharm, Pittsburgh, PA 15261 USA.
   [Wang, Junmei] Univ Pittsburgh, Computat Chem Genom Screening Ctr, Sch Pharm, Pittsburgh, PA 15261 USA.
RP Wang, JM (corresponding author), Univ Pittsburgh, Dept Pharmaceut Sci, Sch Pharm, Pittsburgh, PA 15261 USA.; Wang, JM (corresponding author), Univ Pittsburgh, Computat Chem Genom Screening Ctr, Sch Pharm, Pittsburgh, PA 15261 USA.
EM juw79@pitt.edu
RI Wang, Junmei/C-8636-2014
OI Wang, Junmei/0000-0002-9607-8229
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01GM079383,
   R21GM097617, P30DA035778]; Center for Research Computing (CRC) at
   University of Pittsburgh
FX The author gratefully acknowledges the funding support from the National
   Institutes of Health (R01GM079383, R21GM097617, and P30DA035778). The
   author also thanks the Center for Research Computing (CRC) at University
   of Pittsburgh for providing the computing resources. The author is
   grateful to Dr. Xiang Liu at Nankai University who kindly provided the
   PDB file of 6LU7 to me prior its release at www.rcsb.org.
CR BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004
   Capparelli EV, 2005, AIDS, V19, P949, DOI 10.1097/01.aids.0000171409.38490.48
   Case D., 2018, AMBER 2018
   Chen F, 2018, RNA, V24, P1183, DOI 10.1261/rna.065896.118
   Chen F, 2016, PHYS CHEM CHEM PHYS, V18, P22129, DOI 10.1039/c6cp03670h
   Darden T, 1999, STRUCT FOLD DES, V7, pR55, DOI 10.1016/S0969-2126(99)80033-1
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Frisch M.J., 2016, GAUSSIAN 16 REV B 01
   Hawkins GD, 1996, J PHYS CHEM-US, V100, P19824, DOI 10.1021/jp961710n
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hou TJ, 2011, J COMPUT CHEM, V32, P866, DOI 10.1002/jcc.21666
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kankanamalage ACG, 2018, EUR J MED CHEM, V150, P334, DOI 10.1016/j.ejmech.2018.03.004
   Karami M, 2017, J THEOR BIOL, V420, P180, DOI 10.1016/j.jtbi.2017.03.010
   Kongsted J, 2009, J COMPUT AID MOL DES, V23, P63, DOI 10.1007/s10822-008-9238-z
   Kuhn B, 2005, J MED CHEM, V48, P4040, DOI 10.1021/jm049081q
   Larini L, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2464095
   Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068
   Lee TS, 2017, J CHEM THEORY COMPUT, V13, P3077, DOI 10.1021/acs.jctc.7b00102
   Liao SM, 2013, CHEM CENT J, V7, DOI 10.1186/1752-153X-7-44
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Mishra SK, 2018, J PHYS CHEM B, V122, P8113, DOI 10.1021/acs.jpcb.8b03655
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Page CS, 2006, J COMPUT CHEM, V27, P1990, DOI 10.1002/jcc.20534
   Pei JM, 2007, BIOINFORMATICS, V23, P802, DOI 10.1093/bioinformatics/btm017
   Romano KP, 2010, P NATL ACAD SCI USA, V107, P20986, DOI 10.1073/pnas.1006370107
   SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043
   Sun HY, 2018, PHYS CHEM CHEM PHYS, V20, P14450, DOI 10.1039/c7cp07623a
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P22035, DOI 10.1039/c4cp03179b
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P16719, DOI 10.1039/c4cp01388c
   Swanson JMJ, 2004, BIOPHYS J, V86, P67, DOI 10.1016/S0006-3495(04)74084-9
   Wang EC, 2019, PHYS CHEM CHEM PHYS, V21, P18958, DOI 10.1039/c9cp04096j
   Wang EC, 2019, CHEM REV, V119, P9478, DOI 10.1021/acs.chemrev.9b00055
   Wang JM, 2001, J AM CHEM SOC, V123, P5221, DOI 10.1021/ja003834q
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2005, J MED CHEM, V48, P2432, DOI 10.1021/jm049606e
   Wang JM, 2006, CURR COMPUT-AID DRUG, V2, P287, DOI 10.2174/157340906778226454
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wang JM, 2019, J CHEM INF MODEL, V59, P53, DOI 10.1021/acs.jcim.8b00537
   Wang JM, 2012, J CHEM INF MODEL, V52, P1199, DOI 10.1021/ci300064d
   Wang L, 2015, J AM CHEM SOC, V137, P2695, DOI 10.1021/ja512751q
   Webb B., 2016, CURR PROTOC PROTEIN, V86
   Weng GQ, 2019, PHYS CHEM CHEM PHYS, V21, P10135, DOI 10.1039/c9cp01674k
   Wray R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002473
   Xu L, 2013, J PHYS CHEM B, V117, P8408, DOI 10.1021/jp404160y
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 48
TC 57
Z9 58
U1 78
U2 84
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
EI 1549-960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD JUN 22
PY 2020
VL 60
IS 6
BP 3277
EP 3286
DI 10.1021/acs.jcim.0c00179
PG 10
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA MD1ED
UT WOS:000543717300055
PM 32315171
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Fidahic, M
   Nujic, D
   Runjic, R
   Civljak, M
   Markotic, F
   Makaric, ZL
   Puljak, L
AF Fidahic, Mahir
   Nujic, Danijela
   Runjic, Renata
   Civljak, Marta
   Markotic, Filipa
   Makaric, Zvjezdana Lovric
   Puljak, Livia
TI Research methodology and characteristics of journal articles with
   original data, preprint articles and registered clinical trial protocols
   about COVID-19
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; Coronavirus; Original research; Clinical trial;
   Protocol; Preprint
AB Background The research community reacted rapidly to the emergence of COVID-19. We aimed to assess characteristics of journal articles, preprint articles, and registered trial protocols about COVID-19 and its causal agent SARS-CoV-2. Methods We analyzed characteristics of journal articles with original data indexed by March 19, 2020, in World Health Organization (WHO) COVID-19 collection, articles published on preprint servers medRxiv and bioRxiv by April 3, 2010. Additionally, we assessed characteristics of clinical trials indexed in the WHO International Clinical Trials Registry Platform (WHO ICTRP) by April 7, 2020. Results Among the first 2118 articles on COVID-19 published in scholarly journals, 533 (25%) contained original data. The majority was published by authors from China (75%) and funded by Chinese sponsors (75%); a quarter was published in the Chinese language. Among 312 articles that self-reported study design, the most frequent were retrospective studies (N = 88; 28%) and case reports (N = 86; 28%), analyzing patients' characteristics (38%). Median Journal Impact Factor of journals where articles were published was 5.099. Among 1088 analyzed preprint articles, the majority came from authors affiliated in China (51%) and were funded by sources in China (46%). Less than half reported study design; the majority were modeling studies (62%), and analyzed transmission/risk/prevalence (43%). Of the 927 analyzed registered trials, the majority were interventional (58%). Half were already recruiting participants. The location for the conduct of the trial in the majority was China (N = 522; 63%). The median number of planned participants was 140 (range: 1 to 15,000,000). Registered intervention trials used highly heterogeneous primary outcomes and tested highly heterogeneous interventions; the most frequently studied interventions were hydroxychloroquine (N = 39; 7.2%) and chloroquine (N = 16; 3%). Conclusions Early articles on COVID-19 were predominantly retrospective case reports and modeling studies. The diversity of outcomes used in intervention trial protocols indicates the urgent need for defining a core outcome set for COVID-19 research. Chinese scholars had a head start in reporting about the new disease, but publishing articles in Chinese may limit their global reach. Mapping publications with original data can help finding gaps that will help us respond better to the new public health emergency.
C1 [Fidahic, Mahir] Univ Tuzla, Fac Med, Tuzla, Bosnia & Herceg.
   [Nujic, Danijela] Fac Med, Dept Publ Hlth, Osijek, Croatia.
   [Nujic, Danijela] Fac Dent Med & Hlth, Dept Publ Hlth Humanities & Social Sci Biomed, Osijek, Croatia.
   [Runjic, Renata] Univ Split, Sch Med, Split, Croatia.
   [Civljak, Marta; Puljak, Livia] Catholic Univ Croatia, Ctr Evidence Based Med & Hlth Care, Ilica 242, Zagreb 10000, Croatia.
   [Markotic, Filipa] Croatian Agcy Med Prod & Med Devices, Zagreb, Croatia.
   [Makaric, Zvjezdana Lovric] Croatian Natl Inst Publ Hlth, Dept Epidemiol, Zagreb, Croatia.
RP Puljak, L (corresponding author), Catholic Univ Croatia, Ctr Evidence Based Med & Hlth Care, Ilica 242, Zagreb 10000, Croatia.
EM livia.puljak@unicath.hr
RI Nujic, Danijela/AAN-3972-2020; Puljak, Livia/D-5080-2017
OI Nujic, Danijela/0000-0002-7741-2236; Puljak, Livia/0000-0002-8467-6061
CR Borges do Nascimento IJ, 2020, CORONAVIRUS DIS COVI, DOI 10.1101/2020.04.16.20068213.
   Chen TF, 2020, MATH MODEL SIMULATIN, DOI 10.1101/2020.01.19.911669
   Civljak R, 2020, CROAT MED J, V61, P1, DOI 10.3325/cmj.2020.61.1
   COMET, 2020, COR OUTC SET DEV RES
   Eisen MB, 2020, ELIFE, P9
   EPPI Centre, COVID 19 LIV SYST MA
   Jackson JL, 2019, ANN INTERN MED, V171, P677, DOI 10.7326/M19-0891
   Jin X, 2020, ENGINEERING BEIJING
   Read J. M., 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.23.20018549, DOI 10.1101/2020.01.23.20018549]
   Retraction Watch, ELS INV HYDR COVID 1
   Ruano J, 2020, J CLIN EPIDEMIOL, V124, P183, DOI 10.1016/j.jclinepi.2020.04.015
   Song F, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14080
   *WHO, DAT PUBL COR DIS COV
   WHO, NOV COR CHIN
   Wolkewitz M, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-00972-6
   World Health Organization, NAM COR DIS COVID 19
   World Health Organization (WHO), 2020, NOV COR CHIN
   Worldometer, COVID 19 COR OUTBR
   Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270
   Zarin DA, 2017, NEW ENGL J MED, V376, P383, DOI 10.1056/NEJMsr1601330
NR 20
TC 6
Z9 6
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD JUN 22
PY 2020
VL 20
IS 1
AR 161
DI 10.1186/s12874-020-01047-2
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA MC6NY
UT WOS:000543402400001
PM 32571302
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Seyahi, E
   Poyraz, BC
   Sut, N
   Akdogan, S
   Hamuryudan, V
AF Seyahi, Emire
   Poyraz, Burc Cagri
   Sut, Necdet
   Akdogan, Selma
   Hamuryudan, Vedat
TI The psychological state and changes in the routine of the patients with
   rheumatic diseases during the coronavirus disease (COVID-19) outbreak in
   Turkey: a web-based cross-sectional survey
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE COVID-19; Outbreak; Health workers; Mental health; Anxiety; Depression;
   Post-traumatic stress; Sleep disorders; Rheumatology; Rheumatic diseases
ID POSTTRAUMATIC-STRESS-DISORDER; SARS; DISTRESS; IMPACT
AB We hypothesized that patients with rheumatic diseases (RD) would have increased psychological distress during the COVID-19 outbreak; therefore, assessed their psychological symptoms and changes in their routine. A web-based questionnaire survey was conducted in a cross-sectional design in three groups of participants: (1.) patients with RD, (2.) hospital workers, and (3.) high-school teachers/academic staff. Psychiatric status was evaluated using Hospital Anxiety and Depression Scale and Impact of Event Scale-Revised scale. Overall response rate was 34.7%. We studied 771 patients with RD, 535 hospital workers, and 917 teachers/academic staff. Most of the patients with RD were unwilling to go to the hospital (86%), while 22% discontinued their medications. Biological DMARDS were the most frequent drugs whose doses were altered. Only 4% were willing to take hydroxychloroquine for protection. Moreover, the frequency of anxiety (20%), depression (43%), and post-traumatic stress (28%) among patients with RD were found to be comparable to that found among the teachers/academic staff (23%, 43% and 29%, respectively), whereas significantly less than that observed among the hospital workers (40%, 62%, and 46%, respectively) (p < 0.001). Female gender, use of social media, having a comorbid disease, or a psychiatric disorder were found to be independently associated with psychiatric symptoms in total study population. The majority of the patients were unwilling to attend outpatient visits and one-fifth skipped or stopped their immunosuppressive agents. Psychiatric symptoms in patient's and teacher's populations were of considerable clinical concern, despite being significantly lower than that observed among the hospital workers.
C1 [Seyahi, Emire; Hamuryudan, Vedat] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Cerrahpasa Med Fac, Dept Internal Med,Div Rheumatol, TR-81310 Istanbul, Turkey.
   [Poyraz, Burc Cagri] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Div Geriatr Psychiat, Dept Psychiat, Istanbul, Turkey.
   [Sut, Necdet] Trakya Univ, Dept Biostat & Med Informat, Fac Med, Edirne, Turkey.
   [Akdogan, Selma] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Internal Med, Istanbul, Turkey.
RP Seyahi, E (corresponding author), Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Cerrahpasa Med Fac, Dept Internal Med,Div Rheumatol, TR-81310 Istanbul, Turkey.
EM eseyahi@yahoo.com; bcpoyraz@yahoo.com; necdetsut@yahoo.com;
   drslma.akdogan@gmail.com; vhamuryudan@yahoo.com
OI POYRAZ, BURC CAGRI/0000-0002-9056-9991; Hamuryudan,
   Vedat/0000-0001-6625-1652
CR Aydemir O, 1997, TURK PSIKIYATR DERG, V8, P280
   Chew NWS, 2020, BRAIN BEHAV IMMUN, V88, P559, DOI 10.1016/j.bbi.2020.04.049
   Chung BPM, 2005, J CLIN NURS, V14, P510, DOI 10.1111/j.1365-2702.2004.01072.x
   Corapcioglu A, 2006, YENI S, V44, P14, DOI DOI 10.1037/T00072-000
   Creamer M, 2003, BEHAV RES THER, V41, P1489, DOI 10.1016/j.brat.2003.07.010
   Dutheil Frederic, 2020, Psychol Med, P1, DOI 10.1017/S0033291720001336
   Galea S, 2005, EPIDEMIOL REV, V27, P78, DOI 10.1093/epirev/mxi003
   Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249
   Gao JL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231924
   Garfin DR, 2020, HEALTH PSYCHOL, V39, P355, DOI 10.1037/hea0000875
   Graef ER, 2020, ANN RHEUM DIS, V79, P734, DOI 10.1136/annrheumdis-2020-217480
   Hawryluck L, 2004, EMERG INFECT DIS
   Huang Jing, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa385
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Khalid I, 2016, CLIN MED RES, V14, P7, DOI 10.3121/cmr.2016.1303
   Kim Y, 2018, AM J INFECT CONTROL, V46, P781, DOI 10.1016/j.ajic.2018.01.012
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Lancee WJ, 2008, PSYCHIAT SERV, V59, P91, DOI 10.1176/ps.2008.59.1.91
   Lee AM, 2007, CAN J PSYCHIAT, V52, P233, DOI 10.1177/070674370705200405
   Lei L, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.924609
   Liu CZ, 2019, Int J Nurs Sci, V6, P187, DOI 10.1016/j.ijnss.2019.03.007
   Mak IWC, 2009, GEN HOSP PSYCHIAT, V31, P318, DOI 10.1016/j.genhosppsych.2009.03.001
   Mazza C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093165
   Morina N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083916
   Ni MY, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/19009
   Peng EYC, 2010, J FORMOS MED ASSOC, V109, P524, DOI 10.1016/S0929-6646(10)60087-3
   Reynolds DL, 2008, EPIDEMIOL INFECT, V136, P997, DOI 10.1017/S0950268807009156
   Smarr KL, 2011, ARTHRIT CARE RES, V63, pS454, DOI 10.1002/acr.20556
   Sun NN, 2020, AM J INFECT CONTROL, V48, P592, DOI 10.1016/j.ajic.2020.03.018
   Tolin DF, 2006, PSYCHOL BULL, V132, P959, DOI 10.1037/0033-2909.132.6.959
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Xiao H, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923549
   Zhang WR, 2020, PSYCHOTHER PSYCHOSOM, V89, P242, DOI 10.1159/000507639
NR 33
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0172-8172
EI 1437-160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD AUG
PY 2020
VL 40
IS 8
BP 1229
EP 1238
DI 10.1007/s00296-020-04626-0
EA JUN 2020
PG 10
WC Rheumatology
SC Rheumatology
GA MC3FK
UT WOS:000542091900002
PM 32572609
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tuccori, M
   Convertino, I
   Ferraro, S
   Cappello, E
   Valdiserra, G
   Focosi, D
   Blandizzi, C
AF Tuccori, Marco
   Convertino, Irma
   Ferraro, Sara
   Cappello, Emiliano
   Valdiserra, Giulia
   Focosi, Daniele
   Blandizzi, Corrado
TI The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors:
   Implications for Pharmacovigilance
SO DRUG SAFETY
LA English
DT Article
ID INFLUENZA-A VIRUS; ANTIVIRAL ACTIVITY; IN-VITRO; CORONAVIRUS;
   FAVIPIRAVIR; INHIBITION; CHLOROQUINE; MEDICATION
AB The coronavirus disease 2019 (COVID-19) pandemic that hit the world in 2020 triggered a massive dissemination of information (an "infodemic") about the disease that was channeled through the print, broadcast, web, and social media. This infodemic also included sensational and distorted information about drugs that likely first influenced opinion leaders and people particularly active on social media and then other people, thus affecting choices by individual patients everywhere. In particular, information has spread about some drugs approved for other indications (chloroquine, hydroxychloroquine, nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, favipiravir, and umifenovir) that could have led to inappropriate and therefore hazardous use. In this article, we analyze the rationale behind the claims for use of these drugs in COVID-19, the communication about their effects on the disease, the consequences of this communication on people's behavior, and the responses of some influential regulatory authorities in an attempt to minimize the actual or potential risks arising from this behavior. Finally, we discuss the role of pharmacovigilance stakeholders in emergency management and possible strategies to deal with other similar crises in the future.
C1 [Tuccori, Marco; Blandizzi, Corrado] Univ Hosp Pisa, Unit Adverse Drug React Monitoring, Via Roma 55, I-56126 Pisa, Italy.
   [Tuccori, Marco; Convertino, Irma; Ferraro, Sara; Cappello, Emiliano; Valdiserra, Giulia; Blandizzi, Corrado] Univ Hosp Pisa, Dept Clin & Expt Med, Unit Pharmacol & Pharmacovigilance, Pisa, Italy.
   [Focosi, Daniele] Pisa Univ Hosp, North Western Tuscany Blood Bank, Pisa, Italy.
RP Tuccori, M (corresponding author), Univ Hosp Pisa, Unit Adverse Drug React Monitoring, Via Roma 55, I-56126 Pisa, Italy.; Tuccori, M (corresponding author), Univ Hosp Pisa, Dept Clin & Expt Med, Unit Pharmacol & Pharmacovigilance, Pisa, Italy.
EM marco.tuccori@gmail.com
RI Convertino, Irma/AAB-4070-2020
OI Convertino, Irma/0000-0002-7883-3657
CR Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, CORR SERA
   [Anonymous], 2020, COVID 19 MOTIVAZIONI
   [Anonymous], MESSAGG
   [Anonymous], 2020, Q A HYDROXYCHLOROQUI
   [Anonymous], 2020, GUIDANCE MANAGEMENT
   [Anonymous], 2020, FUJIFILM ANNOUNCES S
   [Anonymous], NY TIMES
   [Anonymous], 2020, POSITION EUROPEAN NE
   [Anonymous], 2020, DH BIO STATEMENT HUM
   [Anonymous], 2020, COVID 19 ATTENZIONE
   [Anonymous], WASHINGTON POST
   Aronson JK, 2009, QJM-INT J MED, V102, P513, DOI 10.1093/qjmed/hcp052
   Beaumont P, GUARD
   Boseley S, 2020, GUARD
   Caddy S, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1790
   Cai Q, 2020, ENGINEERING, P4
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Caster O, 2018, DRUG SAFETY, V41, P1355, DOI 10.1007/s40264-018-0699-2
   Chang A, 2020, MMWR-MORBID MORTAL W, V69, P496, DOI [10.15585/mmwr.mm6916e1, 10.15585/mmwr.mm6916e1externalicon]
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Cheng H, 2020, J MED VIROL
   Convertino I, 2018, EXPERT OPIN DRUG SAF, V17, P1081, DOI 10.1080/14740338.2018.1531847
   Corrado P, 2020, SECOLO ITALIA
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Cuppini L., CORR SERA
   D'Aria I, 2020, REPUBB
   David Puente, 2020, OPEN ONLINE
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1168
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Deng L, 2020, J INFECT
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Di Castelnuovo A, ACE INHIBITORS ANGIO
   Di Grazia S, 2020, FED ITAL MED CHIR OD
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Dunn W., NEWSTATESMAN
   European Medicines Agency, 2020, EMA GIV ADV US NONST, V31, P18
   European Medicines Agency, 2020, EMA ADV CONT US MED
   European Society of Cardiology, 2020, POS STAT ESC COUNC H
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Focosi D, 2020, PREPRINTS
   Food and Drug Administration, FDA ADV PAT US NONST
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Glasziou PP, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1847
   Gnegel G, 2020, AM J TROP MED HYG
   Goldhill DH, 2018, P NATL ACAD SCI USA, V115, P11613, DOI 10.1073/pnas.1811345115
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Hanna Kuchler, 2020, FINACIAL TIMES
   Haviernik J, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040184
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jin ZN, 2015, ANTIMICROB AGENTS CH, V59, P7504, DOI 10.1128/AAC.01391-15
   Jordan Paul C., 2018, Antiviral Chemistry & Chemotherapy, V26, p2040206618764483, DOI 10.1177/2040206618764483
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Kim SS, 2004, EVAL HEALTH PROF, V27, P237, DOI 10.1177/0163278704267037
   Kolata G., NY TIMES
   Kupferschmidt K, SCI 80
   Lian N., 2020, CLIN MICROBIOL INFEC
   Lippi G, 2020, J MED VIROL, V92, P1759, DOI 10.1002/jmv.25860
   Ludwig M, 2020, STOPPING ACE INHIBIT
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Mancia G, 2020, N ENGL J MED
   Mary Kekatos, DLY MAIL
   McCall R, NEWSWEEK
   McCurry J, 2020, GUARD
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehra MR, 2020, LANCET LONDON ENGLAN, V6736, P31290
   Mehra MR, 2020, LANCET LONDON ENGLAN, V6736, P31324, DOI DOI 10.1016/S0140
   Nagata T, 2015, DISASTER MED PUBLIC, V9, P79, DOI 10.1017/dmp.2014.151
   O'Riordan M., 2020, TCTMD
   Ormond L, 2017, GENOME BIOL EVOL, V9, P1913, DOI 10.1093/gbe/evx138
   Orso D, 2020, EUR J EMERG MED ENGL
   Park A., 2020, TIME
   Pierri F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58166-5
   Pilkington V, 2020, J VIRUS ERAD, V6, P45
   Pshenichnaya NY, 2019, TERAPEVT ARKH, V91, P56, DOI 10.26442/00403660.2019.03.000127
   Puente D, OPEN ONLINE
   Qiao WL, 2015, CARDIOLOGY, V131, P97, DOI 10.1159/000375362
   Reynolds HR, 2020, N ENGL J MED
   Rizzardini G, 2020, CLIN STUDY EVALUATE
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schraer R, BBC NEWS
   Shanping J., 2020, PROSPECTIVE COHORT S
   Shi L, 2007, ARCH VIROL, V152, P1447, DOI 10.1007/s00705-007-0974-5
   Siordia JA, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104357
   Societa Italiana dell'Ipertensione Arteriosa, 2020, FARM ANT RISCH COVID
   Societa Italiana di Farmacologia, 2020, DOC INF SOC IT FARM
   Sun M L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P219, DOI [10.3760/cma.j.issn.1001-0939.2020.0014, 10.3760/cma.j.issn.1001-0939.2020.03.016]
   The New York Times Coronavirus Map, NY TIMES
   Vagvolgyi R, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01617
   Valvo L, 2020, INDICAZIONI RELATIVE
   Willsher K., 2020, GUARDIAN
   Wong JC, GUARDIAN
   Zarocostas J, 2020, LANCET, V395, P676, DOI 10.1016/S0140-6736(20)30461-X
NR 96
TC 0
Z9 0
U1 4
U2 4
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD AUG
PY 2020
VL 43
IS 8
BP 699
EP 709
DI 10.1007/s40264-020-00965-w
EA JUN 2020
PG 11
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA MU1WY
UT WOS:000542054300001
PM 32572842
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Anzivino, R
   Sciancalepore, PI
   Petrone, P
   D'Elia, A
   Petrone, D
   Quaranta, N
AF Anzivino, Roberta
   Sciancalepore, Pasqua Irene
   Petrone, Paolo
   D'Elia, Alessandra
   Petrone, Domenico
   Quaranta, Nicola
TI Tinnitus revival during COVID-19 lockdown: how to deal with it?
SO EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
LA English
DT Letter; Early Access
DE Tinnitus; COVID-19; Smartphone applications; Cognitive behavioural
   therapy; Retraining therapy; Sound therapy
C1 [Anzivino, Roberta; Petrone, Paolo; D'Elia, Alessandra; Petrone, Domenico] Di Venere Hosp, Otolaryngol Unit, Via Osped Venere 1, I-70131 Bari, BA, Italy.
   [Sciancalepore, Pasqua Irene; Quaranta, Nicola] Univ Bari Aldo Moro, Dept BMS Neurosci & Sensory Organs, Otolaryngol Unit, Bari, Italy.
RP Anzivino, R (corresponding author), Di Venere Hosp, Otolaryngol Unit, Via Osped Venere 1, I-70131 Bari, BA, Italy.
EM roberta.anzivino@gmail.com
CR Kraus KS, 2012, HEARING RES, V288, P34, DOI 10.1016/j.heares.2012.02.009
   Monzani D, 2008, ACTA OTORHINOLARYNGO, V28, P126
   Nagaraj MK, 2020, EUR ARCH OTO-RHINO-L, V277, P649, DOI 10.1007/s00405-019-05743-8
   Norena AJ, 2013, HEARING RES, V295, P161, DOI 10.1016/j.heares.2012.09.010
   Zenner HP, 2017, EUR ARCH OTO-RHINO-L, V274, P2079, DOI 10.1007/s00405-016-4401-y
NR 5
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0937-4477
EI 1434-4726
J9 EUR ARCH OTO-RHINO-L
JI Eur. Arch. Oto-Rhino-Laryn.
DI 10.1007/s00405-020-06147-9
EA JUN 2020
PG 2
WC Otorhinolaryngology
SC Otorhinolaryngology
GA MA7HU
UT WOS:000542084400002
PM 32572563
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ghani, MU
   Kumar, M
   Ghani, U
   Sonia, F
   Abbas, SA
AF Ghani, Muhammad Usman
   Kumar, Mukesh
   Ghani, Usman
   Sonia, Fnu
   Abbas, Syed Ali
TI Intracranial hemorrhage complicating anticoagulant prophylactic therapy
   in three hospitalized COVID-19 patients
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Article
DE Intracranial hemorrhage; COVID-19; Anticoagulation
AB SARS-CoV2 has led to a global pandemic affecting almost 3 million people in almost over 3 months. Various clinical presentations have been reported so far and no definite therapy is established. Anticoagulation is recommended by several experts to address the potential prothrombotic complications from COVID-19, but its safety and regimen need further clinical trials and safety and efficacy profile. Here, we present three cases of intracranial hemorrhage in three critically ill patients with COVID-19 and discuss their course in relation to various regimens of anticoagulation used.
C1 [Ghani, Muhammad Usman; Kumar, Mukesh; Ghani, Usman; Sonia, Fnu; Abbas, Syed Ali] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Med, 600 East 233 St, Bronx, NY 10470 USA.
RP Ghani, MU (corresponding author), Albert Einstein Coll Med, Montefiore Med Ctr, Dept Med, 600 East 233 St, Bronx, NY 10470 USA.
EM usmanghani162@gmail.com
CR Al-Hameed FM, 2017, SAUDI MED J, V38, P196, DOI 10.15537/smj.2017.2.16255
   Algahtani H, 2016, CASE REP NEUROL MED, V2016, P1
   Desforges M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010014
   Helms J, 2020, INTENS CARE MED, V46, P1, DOI DOI 10.HTTPS://D0I.0RG/10.1007/S00134-020-06062-X
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Vu D, 2020, EMERG RADIOL, V13, P1
NR 8
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1355-0284
EI 1538-2443
J9 J NEUROVIROL
JI J. Neurovirol.
PD AUG
PY 2020
VL 26
IS 4
BP 602
EP 604
DI 10.1007/s13365-020-00869-6
EA JUN 2020
PG 3
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA NE2CC
UT WOS:000542106400002
PM 32572835
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tepasse, PR
   Hafezi, W
   Lutz, M
   Kuhn, J
   Wilms, C
   Wiewrodt, R
   Sackarnd, J
   Keller, M
   Schmidt, HH
   Vollenberg, R
AF Tepasse, Phil-Robin
   Hafezi, Wali
   Lutz, Mathias
   Kuehn, Joachim
   Wilms, Christian
   Wiewrodt, Rainer
   Sackarnd, Jan
   Keller, Martin
   Schmidt, Hartmut H.
   Vollenberg, Richard
TI Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with
   fatal outcome and a review of the literature
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; rituximab; viraemia; pneumonia
AB SARS-CoV-2 infection can cause severe pneumonia (COVID-19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS-CoV-2 viraemia with fatal outcome in patients after rituximab therapy.
C1 [Tepasse, Phil-Robin; Wilms, Christian; Schmidt, Hartmut H.; Vollenberg, Richard] Univ Hosp Muenster, Dept Gastroenterol & Hepatol, Sect Infect Dis, Munster, Germany.
   [Hafezi, Wali; Kuehn, Joachim] Univ Hosp Muenster, Inst Virol, Munster, Germany.
   [Lutz, Mathias; Wiewrodt, Rainer] Univ Hosp Muenster, Dept Hematol & Oncol, Munster, Germany.
   [Sackarnd, Jan] Univ Hosp Muenster, Dept Cardiol & Angiol, Munster, Germany.
   [Keller, Martin] Univ Hosp Muenster, Dept Anesthesiol Intens Care Med & Pain Therapy, Munster, Germany.
RP Tepasse, PR (corresponding author), Univ Hosp Muenster, Albert Schweitzer Campus 1, D-48149 Munster, Germany.
EM phil-robin.tepasse@ukmuenster.de
OI Lutz, Mathias/0000-0002-2572-5687
CR Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Fishman JA, 2020, AM J TRANSPLANT, V20, P1765, DOI 10.1111/ajt.15890
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Lutz M, 2017, CANCER RES TREAT, V49, P548, DOI 10.4143/crt.2016.110
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Minotti C, 2020, J INFECTION, V81, pE61, DOI 10.1016/j.jinf.2020.04.026
   Peiris JSM, 2010, CURR OPIN IMMUNOL, V22, P475, DOI 10.1016/j.coi.2010.06.003
   Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
NR 14
TC 6
Z9 6
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD JUL
PY 2020
VL 190
IS 2
BP 185
EP 188
DI 10.1111/bjh.16896
EA JUN 2020
PG 4
WC Hematology
SC Hematology
GA ML5DQ
UT WOS:000541513200001
PM 32557623
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Brunasso, AMG
   Massone, C
AF Brunasso, Alexandra Maria Giovanna
   Massone, Cesare
TI Teledermatologic monitoring for chronic cutaneous autoimmune diseases
   with smartworking during COVID-19 emergency in a tertiary center in
   Italy
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE atopic dermatitis; COVID-19; psoriasis; smartworking; teledermatology;
   telemonitoring
AB Because of the coronavirus disease 2019 (COVID-19) emergency, on March 9, 2020 Italy went in lock-down imposing the closure of non-urgent outpatient clinics devoted to care of chronic, severe, inflammatory skin diseases that require periodic follow-up. In this emergency situation, due to the lack of a teledermatology platform and in order not to leave our vulnerable high-need patients without proper follow-up, we started a teledermatologic service in smartworking using phone calls and emails. The total number of patients scheduled was 195; in 12 cases, we were not able to talk to the patients. Remote monitoring was performed in 183 patients (126 moderate to severe psoriasis, 10 severe acne, 11 severe atopic dermatitis, 11 hidradenitis suppurativa, 9 blistering autoimmune diseases, and 16 other autoimmune skin diseases). During remote-visits, several interventions were conducted: triage for COVID-19 suspected symptoms, email check of clinical pictures and of laboratory examinations, advices for topical and systemic therapy continuation or discontinuation/switch and reschedule of next appointment. Only five patients required personal office visit (2.7%), reducing consistently the number of face-to face visits. Our real-life experience shows that remote monitoring was effective in preventing unnecessary worsening of severe chronic skin diseases and poor outcomes due to withdrawal of current therapy.
C1 [Brunasso, Alexandra Maria Giovanna; Massone, Cesare] Galliera Hosp, Dept Dermatol, Genoa, Italy.
RP Massone, C (corresponding author), Galliera Hosp, Dermatol Unit, Via Volta 6, I-16128 Genoa, Italy.
EM cesare.massone@galliera.it
OI massone, cesare/0000-0002-0996-643X; Brunasso, Alexandra Maria
   Giovanna/0000-0001-9122-9975
CR Armstrong AW, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3062
   Armstrong AW, 2019, J INVEST DERMATOL, V139, P1037, DOI 10.1016/j.jid.2018.09.039
   Bashi N, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.6571
   Gisondi P, 2020, J EUR ACAD DERMATOL, V34, P1196, DOI 10.1111/jdv.16515
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Jakhar D, 2020, CLIN EXP DERMATOL, V45, P739, DOI 10.1111/ced.14227
   Koller S, 2011, ACTA DERM-VENEREOL, V91, P680, DOI 10.2340/00015555-1148
   Omboni S, 2020, TELEMED E-HEALTH, V26, P973, DOI 10.1089/tmj.2020.0106
   Perkins S, 2020, J AM ACAD DERMATOL, V83, pE43, DOI 10.1016/j.jaad.2020.04.048
   Villani A, 2020, J DERMATOL TREAT, V31, P325, DOI 10.1080/09546634.2020.1750557
NR 10
TC 7
Z9 7
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
DI 10.1111/dth.13695
EA JUN 2020
PG 5
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000541549000001
PM 32458588
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Karadag, AS
   Kayiran, MA
   Lotti, T
   Wollina, U
AF Karadag, Ayse Serap
   Aslan Kayiran, Melek
   Lotti, Torello
   Wollina, Uwe
TI Immunosuppressive and immunomodulator therapy for rare or uncommon skin
   disorders in pandemic days
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE COVID-19; immunomodulatory drugs; immunosuppressive drugs; rare skin
   diseases
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; INFLAMMATORY-BOWEL-DISEASE; INFECTIOUS
   COMPLICATIONS; BIOLOGICAL THERAPY; SERIOUS INFECTION; SEVERE PSORIASIS;
   DOUBLE-BLIND; COVID-19; ADALIMUMAB; EFFICACY
AB Immunosuppressive and immunomodulatory therapies are important in dermatology, but indications are influenced by SARS-CoV-2. We will focus on skin disorders such as autoimmune connective tissue disorders, neutrophilic dermatoses, and vasculitis. Immunomodulators such as colchicine and antimalarials can easily be preferred taking their beneficial effects on COVID-19 into consideration and also given their wide spectrum of action. Among the conventional therapies, methotrexate, azathioprine, and mycophenolate mofetil increase the risk of infection, and thus their use is recommended only when necessary and at low doses. On the other hand, use of cyclosporine is also not recommended as it increases the risk of hypertension, which is susceptible to COVID-19. Anti-TNF agents from among the biological therapies appear to be slightly risky in terms of susceptibility to infection. However, there are ongoing studies which suggest that some biological treatments may reduce cytokine storm impeding the COVID-19 progression as a result, in spite of their susceptibilities to COVID-19. Patients, who will be started on immunosuppressive therapy, should be tested for COVID-19 prior to the therapy, and in the event that COVID-19 is suspected, the therapy should be discontinued.
C1 [Karadag, Ayse Serap; Aslan Kayiran, Melek] Istanbul Medeniyet Univ, Goztepe Res & Training Hosp, Dept Dermatol, Fac Med, Istanbul, Turkey.
   [Lotti, Torello] Univ Rome G Marconi, Dept Dermatol & Venereol, Rome, Italy.
   [Wollina, Uwe] Stadt Klinikum Dresden, Acad Teaching Hosp, Dept Dermatol & Allergol, Dresden, Germany.
RP Wollina, U (corresponding author), Stadt Klinikum Dresden, Acad Teaching Hosp, Dept Dermatol & Allergol, Dresden, Germany.
EM uwollina@gmail.com
OI Wollina, Uwe/0000-0001-5933-2913
CR Adwan MH, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0626-z
   Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   Altschuler EL, 2020, MED HYPOTHESES, V141, DOI 10.1016/j.mehy.2020.109774
   Amin M, 2018, J DERMATOL TREAT, V29, P347, DOI 10.1080/09546634.2017.1395796
   Annane D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002243.pub3
   Anstey AV, 2004, BRIT J DERMATOL, V151, P1123, DOI 10.1111/j.1365-2133.2004.06323.x
   Ashchyan HJ, 2018, J AM ACAD DERMATOL, V79, P1009, DOI 10.1016/j.jaad.2017.11.063
   Aydn F, 2018, DERMATOZ, V9, P1
   Banaszczyk Katarzyna, 2019, Reumatologia (Warsaw), V57, P158, DOI 10.5114/reum.2019.86426
   Beck KM, 2019, EXPERT OPIN BIOL TH, V19, P287, DOI 10.1080/14712598.2019.1579794
   Berardi S, 2020, INFLAMM RES, V69, P453, DOI 10.1007/s00011-020-01337-x
   Berth-Jones J, 2019, BRIT J DERMATOL, V180, P1312, DOI 10.1111/bjd.17587
   Bowles L, 2020, NEW ENGL J MED, V383, P288, DOI 10.1056/NEJMc2013656
   Broen JCA, 2020, NAT REV RHEUMATOL, V16, P167, DOI 10.1038/s41584-020-0374-8
   Bulut C, 2020, TURK J MED SCI, V50, P563, DOI 10.3906/sag-2004-172
   Careta MF, 2015, AN BRAS DERMATOL, V90, P62, DOI 10.1590/abd1806-4841.20152890
   Cavallasca JA, 2015, REUMATOL CLIN, V11, P221, DOI 10.1016/j.reuma.2014.09.003
   Conway R, 2014, ARTHRITIS RHEUMATOL, V66, P803, DOI [10.1002/art.38322, 10.1002/art.38732]
   D'Alessandro S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8010085
   Dalakas MC, 2011, CURR TREAT OPTION NE, V13, P311, DOI 10.1007/s11940-011-0119-8
   Damiani G, 2016, BRIT J DERMATOL, V175, P797, DOI 10.1111/bjd.14546
   Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475
   Dasgeb B, 2018, BRIT J DERMATOL, V178, P350, DOI 10.1111/bjd.15896
   de Jonge ME, 2005, CLIN PHARMACOKINET, V44, P1135, DOI 10.2165/00003088-200544110-00003
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   Deftereos S, 2020, EUR HEART J-CARD PHA, V6, P255, DOI 10.1093/ehjcvp/pvaa033
   Deftereos SG, 2020, HELL J CARDIOL, V61, P42, DOI 10.1016/j.hjc.2020.03.002
   Denton CP, 2016, RHEUMATOLOGY, V55, P1906, DOI 10.1093/rheumatology/kew224
   Dinarello CA, 2011, J INTERN MED, V269, P16, DOI 10.1111/j.1365-2796.2010.02313.x
   Emre S, 2019, DERMATOL THER, V32, DOI 10.1111/dth.12854
   Filosa A, 2018, GIORN ITAL DERMAT V, V153, P265, DOI 10.23736/S0392-0488.18.05841-8
   Findlay AR, 2015, MUSCLE NERVE, V51, P638, DOI 10.1002/mus.24566
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Ghaoui N, 2020, INT J DERMATOL, V59, P787, DOI 10.1111/ijd.14761
   Ghosh S, 2019, DRUG SAFETY, V42, P751, DOI 10.1007/s40264-019-00797-3
   Gordon KB, 2016, NEW ENGL J MED, V375, P345, DOI 10.1056/NEJMoa1512711
   Gordon K, 2012, J AM ACAD DERMATOL, V66, P241, DOI 10.1016/j.jaad.2010.12.005
   Gordon KB, 2018, LANCET, V392, P650, DOI 10.1016/S0140-6736(18)31713-6
   Griffiths CEM, 2015, J EUR ACAD DERMATOL, V29, P468, DOI 10.1111/jdv.12585
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107
   Hughes M, 2019, BRIT J HOSP MED, V80, P530, DOI 10.12968/hmed.2019.80.9.530
   Ibrahim A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010015
   Indian Council of Medical Research, ADV US HYDR PROPH SA
   Jacob S, 2020, J NEUROL SCI, V412, DOI 10.1016/j.jns.2020.116803
   Jawhara S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072272
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Jung C, 2008, MED J AUSTRALIA, V188, P409, DOI 10.5694/j.1326-5377.2008.tb01686.x
   Jung JY, 2017, KOREAN J INTERN MED, V32, P429, DOI 10.3904/kjim.2016.234
   Kakuta Y, 2018, J GASTROENTEROL, V53, P172, DOI 10.1007/s00535-017-1416-0
   Kalb RE, 2015, JAMA DERMATOL, V151, P961, DOI 10.1001/jamadermatol.2015.0718
   Khan S, 2011, RHEUM DIS CLIN N AM, V37, P143, DOI 10.1016/j.rdc.2011.01.001
   Kim J, 2017, AUSTRALAS J DERMATOL, V58, P5, DOI 10.1111/ajd.12406
   Kim SH, 2017, J INFECT CHEMOTHER, V23, P769, DOI 10.1016/j.jiac.2017.04.004
   Kimball AB, 2020, BRIT J DERMATOL, V182, P180, DOI 10.1111/bjd.17918
   Kimball AB, 2016, NEW ENGL J MED, V375, P422, DOI 10.1056/NEJMoa1504370
   Kurschus FC, 2017, J DERMATOL SCI, V87, P221, DOI 10.1016/j.jdermsci.2017.06.010
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4
   Li X, 2020, INT J INFECT DIS, V94, P128, DOI 10.1016/j.ijid.2020.03.053
   Liu DR, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-30
   Madan V, 2007, DERMATOL THER, V20, P239, DOI 10.1111/j.1529-8019.2007.00137.x
   Manson SC, 2009, RESP MED, V103, P975, DOI 10.1016/j.rmed.2009.01.003
   Marie I, 2011, SEMIN ARTHRITIS RHEU, V41, P48, DOI 10.1016/j.semarthrit.2010.08.003
   Mathian A, 2020, ANN RHEUM DIS, V79, P837, DOI 10.1136/annrheumdis-2020-217566
   Mease PJ, 2020, LANCET, V395, P1126, DOI 10.1016/S0140-6736(20)30263-4
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Menter A, 2008, J AM ACAD DERMATOL, V58, P106, DOI 10.1016/j.jaad.2007.09.010
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Misra DP, 2020, RHEUMATOL INT, V40, P679, DOI 10.1007/s00296-020-04515-6
   Molinelli E, 2019, EXPERT OPIN DRUG MET, V15, P367, DOI 10.1080/17425255.2019.1600670
   Monteagudo Luke Adam, 2020, ACR Open Rheumatol, V2, P276, DOI 10.1002/acr2.11135
   Navarro-Trivino FJ, 2018, ACTAS DERMO-SIFILOGR, V109, P323, DOI 10.1016/j.ad.2017.11.009
   Nelson CA, 2018, J AM ACAD DERMATOL, V79, P987, DOI 10.1016/j.jaad.2017.11.064
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Ocampo-Piraquive V, 2018, EXPERT REV CLIN IMMU, V14, P1043, DOI 10.1080/1744666X.2018.1538789
   Panaccione R, 2014, GASTROENTEROLOGY, V146, P392, DOI 10.1053/j.gastro.2013.10.052
   Papp K, 2013, J EUR ACAD DERMATOL, V27, P634, DOI 10.1111/j.1468-3083.2012.04515.x
   Papp KA, 2017, NEW ENGL J MED, V376, P1551, DOI 10.1056/NEJMoa1607017
   Pastuszczak M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006376
   Rabby MII, 2020, J PHARM PHARM SCI, V23, P58, DOI 10.18433/jpps31002
   Rademaker M, 2020, AUSTRALAS J DERMATOL, V61, P158, DOI 10.1111/ajd.13295
   Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297
   Ramirez J, 2018, EXPERT OPIN DRUG SAF, V17, P727, DOI 10.1080/14740338.2018.1486819
   Razek AAKA, 2016, NEURORADIOL J, V29, P222, DOI 10.1177/1971400916639605
   Reich K, 2017, LANCET, V390, P276, DOI 10.1016/S0140-6736(17)31279-5
   Reynolds SD, 2020, PEDIATR DERMATOL, V37, P424, DOI 10.1111/pde.14202
   Rice JB, 2017, CLIN THER, V39, P2216, DOI 10.1016/j.clinthera.2017.09.011
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Ritter ML, 2009, TRANSPL INFECT DIS, V11, P290, DOI 10.1111/j.1399-3062.2009.00407.x
   Robinson KP, 2018, AUSTRALAS J DERMATOL, V59, P278, DOI 10.1111/ajd.12795
   Sbidian E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011535.pub3
   Seksik P, 2009, ALIMENT PHARM THER, V29, P1106, DOI 10.1111/j.1365-2036.2009.03973.x
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Sharma VK, 2013, CLIN EXP DERMATOL, V38, P659, DOI 10.1111/ced.12073
   Shavit E, 2018, INT J LOW EXTR WOUND, V17, P218, DOI 10.1177/1534734618804982
   Shreberk-Hassidim R., 2017, J AM ACAD DERMATOL, V76, pe19, DOI DOI 10.1016/j.jaad.2016.12.004
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Slobodnick A, 2015, AM J MED, V128, P461, DOI 10.1016/j.amjmed.2014.12.010
   Stochmal A, 2020, CLIN REV ALLERG IMMU, V58, P40, DOI 10.1007/s12016-018-8718-8
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Tzanetakou V, 2016, JAMA DERMATOL, V152, P52, DOI 10.1001/jamadermatol.2015.3903
   Verstockt B, 2017, EXPERT OPIN DRUG SAF, V16, P809, DOI 10.1080/14740338.2017.1338273
   Vrachatis DA, 2018, CURR PHARM DESIGN, V24, P647, DOI 10.2174/138161282406180510170818
   Wang C, 2020, AUSTRALAS J DERMATOL, V61, P210, DOI 10.1111/ajd.13313
   Wang MY, 2019, CLIN IMMUNOL, V208, DOI 10.1016/j.clim.2019.108259
   Welsch K, 2017, EUR J IMMUNOL, V47, P1096, DOI 10.1002/eji.201646680
   West J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153740
   Writing Group of the Johns Hopkins University and Johns Hopkins Hospital COVID-19 Treatment Guidance Working Group [Internet], JHMI CLIN GUID AV PH
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yazdany J, 2020, ANN INTERN MED, V172, P754, DOI 10.7326/M20-1334
   Yiu ZZN, 2018, J INVEST DERMATOL, V138, P534, DOI 10.1016/j.jid.2017.10.005
   Yun JSW, 2020, J DERMATOL TREAT, V31, P46, DOI 10.1080/09546634.2019.1572864
   Zabotti A, 2020, EXPERT OPIN DRUG SAF, V19, P69, DOI 10.1080/14740338.2020.1703946
   Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8
   Zhou S, 2018, THER CLIN RISK MANAG, V14, P167, DOI 10.2147/TCRM.S155488
NR 116
TC 3
Z9 3
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD SEP
PY 2020
VL 33
IS 5
SI SI
AR e13686
DI 10.1111/dth.13686
EA JUN 2020
PG 10
WC Dermatology
SC Dermatology
GA OB4SO
UT WOS:000541554700001
PM 32458530
OA Bronze
DA 2021-01-01
ER

PT J
AU Camporesi, A
   Diaz-Rubio, F
   Carroll, CL
   Gonzalez-Dambrauskas, S
AF Camporesi, Anna
   Diaz-Rubio, Franco
   Carroll, Christopher L.
   Gonzalez-Dambrauskas, Sebastian
TI Protecting children from iatrogenic harm duringCOVID19pandemic
SO JOURNAL OF PAEDIATRICS AND CHILD HEALTH
LA English
DT Article
DE coronavirus; Covid-19; paediatric intensive care; paediatrics; therapy
AB Critical care management of patients with COVID-19 has been influenced by a mixture of public, media and societal pressure, as well as clinical and anecdotal observations from many prominent researchers and key opinion leaders. These factors may have affected the principles of evidence-based medicine and encouraged the widespread use of non-tested pharmacological and aggressive respiratory support therapies, even in intensive care units (ICUs). The COVID-19 pandemic has predominantly affected adult populations, while children appear to be relatively spared of severe disease. Notwithstanding, paediatric intensive care (PICU) clinicians may already have been influenced by changes in practices of adult ICUs, and these changes may pose unintended consequences to the vulnerable population in the PICU. In this article, we analyse several potential iatrogenic causes of the detrimental effects of the current pandemic to children and highlight the risks underlying a sudden change of clinical practice.
C1 [Camporesi, Anna] Childrens Hosp Vittore Buzzi, Div Pediat Anesthesia & Intens Care Unit, Dept Pediat, Milan, Italy.
   [Diaz-Rubio, Franco] Univ Desarrollo, Inst Ciencias & Innovac Med, Santiago, Chile.
   [Diaz-Rubio, Franco] Hosp El Carmen de Maipu, Unidad Paciente Crit Pediat, Santiago, Chile.
   [Carroll, Christopher L.] Connecticut Childrens, Dept Pediat, Hartford, CT USA.
   [Gonzalez-Dambrauskas, Sebastian] Red Colaborat Pediat Latinoamer LARed Network, Montevideo, Uruguay.
   [Gonzalez-Dambrauskas, Sebastian] Cuidados Intens Pediat Especializados CIPe Casa d, Montevideo, Uruguay.
RP Gonzalez-Dambrauskas, S (corresponding author), Dr Jose de Aguirre y Lecube 4863,CP PO 11400, Montevideo, Uruguay.
EM sgdambrauskas@gmail.com
RI DIAZ, FRANCO/I-9545-2019
OI DIAZ, FRANCO/0000-0003-4763-074X; Camporesi, Anna/0000-0002-1160-1456
CR Auriemma CL, 2019, INTENS CARE MED, V45, P1806, DOI 10.1007/s00134-019-05771-2
   Ganu SS, 2012, INTENS CARE MED, V38, P1177, DOI 10.1007/s00134-012-2566-4
   Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Herrera-perez D, 2019, ELIFE, V8, DOI 10.7554/eLife.45183
   Isaacs D, 1999, BRIT MED J, V319, P1618, DOI 10.1136/bmj.319.7225.1618
   Singer BD, 2020, AM J RESP CELL MOL, V63, P132, DOI 10.1165/rcmb.2020-0151LE
NR 8
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1034-4810
EI 1440-1754
J9 J PAEDIATR CHILD H
JI J. Paediatr. Child Health
PD JUL
PY 2020
VL 56
IS 7
BP 1010
EP 1012
DI 10.1111/jpc.14989
EA JUN 2020
PG 3
WC Pediatrics
SC Pediatrics
GA MQ7SG
UT WOS:000541646500001
PM 32568444
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kuderer, NM
   Choueiri, TK
   Shah, DP
   Shyr, Y
   Rubinstein, SM
   Rivera, DR
   Shete, S
   Hsu, CY
   Desai, A
   Lopes, GD
   Grivas, P
   Painter, CA
   Peters, S
   Thompson, MA
   Bakouny, Z
   Batist, G
   Bekaii-Saab, T
   Bilen, MA
   Bouganim, N
   Larroya, MB
   Castellano, D
   Del Prete, SA
   Doroshow, DB
   Egan, PC
   Elkrief, A
   Farmakiotis, D
   Flora, D
   Galsky, MD
   Glover, MJ
   Griffiths, EA
   Gulati, AP
   Gupta, S
   Hafez, N
   Halfdanarson, TR
   Hawley, JE
   Hsu, E
   Kasi, A
   Khaki, AR
   Lemmon, CA
   Lewis, C
   Logan, B
   Masters, T
   McKay, RR
   Mesa, RA
   Morgans, AK
   Mulcahy, MF
   Panagiotou, OA
   Peddi, P
   Pennell, NA
   Reynolds, K
   Rosen, LR
   Rosovsky, R
   Salazar, M
   Schmidt, A
   Shah, SA
   Shaya, JA
   Steinharter, J
   Stockerl-Goldstein, KE
   Subbiah, S
   Vinh, DC
   Wehbe, FH
   Weissmann, LB
   Wu, JTY
   Wulff-Burchfield, E
   Xie, ZE
   Yeh, A
   Yu, PP
   Zhou, AY
   Zubiri, L
   Mishra, S
   Lyman, GH
   Rini, BI
   Warner, JL
AF Kuderer, Nicole M.
   Choueiri, Toni K.
   Shah, Dimpy P.
   Shyr, Yu
   Rubinstein, Samuel M.
   Rivera, Donna R.
   Shete, Sanjay
   Hsu, Chih-Yuan
   Desai, Aakash
   Lopes, Gilberto de Lima, Jr.
   Grivas, Petros
   Painter, Corrie A.
   Peters, Solange
   Thompson, Michael A.
   Bakouny, Ziad
   Batist, Gerald
   Bekaii-Saab, Tanios
   Bilen, Mehmet A.
   Bouganim, Nathaniel
   Larroya, Mateo Bover
   Castellano, Daniel
   Del Prete, Salvatore A.
   Doroshow, Deborah B.
   Egan, Pamela C.
   Elkrief, Arielle
   Farmakiotis, Dimitrios
   Flora, Daniel
   Galsky, Matthew D.
   Glover, Michael J.
   Griffiths, Elizabeth A.
   Gulati, Anthony P.
   Gupta, Shilpa
   Hafez, Navid
   Halfdanarson, Thorvardur R.
   Hawley, Jessica E.
   Hsu, Emily
   Kasi, Anup
   Khaki, Ali R.
   Lemmon, Christopher A.
   Lewis, Colleen
   Logan, Barbara
   Masters, Tyler
   McKay, Rana R.
   Mesa, Ruben A.
   Morgans, Alicia K.
   Mulcahy, Mary F.
   Panagiotou, Orestis A.
   Peddi, Prakash
   Pennell, Nathan A.
   Reynolds, Kerry
   Rosen, Lane R.
   Rosovsky, Rachel
   Salazar, Mary
   Schmidt, Andrew
   Shah, Sumit A.
   Shaya, Justin A.
   Steinharter, John
   Stockerl-Goldstein, Keith E.
   Subbiah, Suki
   Vinh, Donald C.
   Wehbe, Firas H.
   Weissmann, Lisa B.
   Wu, Julie Tsu-Yu
   Wulff-Burchfield, Elizabeth
   Xie, Zhuoer
   Yeh, Albert
   Yu, Peter P.
   Zhou, Alice Y.
   Zubiri, Leyre
   Mishra, Sanjay
   Lyman, Gary H.
   Rini, Brian, I
   Warner, Jeremy L.
CA COVID-19 Canc Consortium
TI Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort
   study
SO LANCET
LA English
DT Article
ID PROSTATE; TMPRSS2
AB Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.
   Methods In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.
   Findings Of 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57-76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1.84, 95% CI 1.53-2.21), male sex (1.63, 1.07-2.48), smoking status (former smoker vs never smoked: 1.60, 1.03-2.47), number of comorbidities (two vs none: 4.50, 1.33-15.28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3.89, 2.11-7.18), active cancer (progressing vs remission: 5.20, 2.77-9.77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2.93, 1.79-4.79; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0.24, 0.07-0.84) or the US-Midwest (0.50, 0.28-0.90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.
   Interpretation Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Kuderer, Nicole M.] Adv Canc Res Grp, Kirkland, WA USA.
   [Choueiri, Toni K.; Bakouny, Ziad; Schmidt, Andrew; Steinharter, John] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Shah, Dimpy P.; Mesa, Ruben A.; Salazar, Mary] UT Hlth San Antonio MD Anderson Canc Ctr, Mays Canc Ctr, San Antonio, TX USA.
   [Shyr, Yu; Rubinstein, Samuel M.; Hsu, Chih-Yuan; Mishra, Sanjay; Rini, Brian, I; Warner, Jeremy L.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.
   [Rivera, Donna R.] NCI, Div Canc Control & Populat Sci, Rockville, MD USA.
   [Shete, Sanjay] MD Anderson Canc Ctr, Houston, TX USA.
   [Desai, Aakash; Hsu, Emily] Univ Connecticut, Farmington, CT USA.
   [Lopes, Gilberto de Lima, Jr.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA.
   [Grivas, Petros; Khaki, Ali R.; Yeh, Albert; Lyman, Gary H.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Grivas, Petros; Khaki, Ali R.; Yeh, Albert; Lyman, Gary H.] Univ Washington, Seattle, WA 98195 USA.
   [Painter, Corrie A.] Count Me In, Cambridge, MA USA.
   [Peters, Solange] Lausanne Univ, Lausanne, Switzerland.
   [Thompson, Michael A.] Advocate Aurora Hlth, Milwaukee, WI USA.
   [Batist, Gerald; Elkrief, Arielle] McGill Univ, Segal Canc Ctr, Jewish Gen Hosp, Montreal, PQ, Canada.
   [Bekaii-Saab, Tanios] Mayo Clin, Ctr Canc, Phoenix, AZ USA.
   [Bilen, Mehmet A.; Lewis, Colleen] Emory Univ, Inst Canc, Atlanta, GA 30322 USA.
   [Bouganim, Nathaniel; Vinh, Donald C.] McGill Univ, Hlth Ctr, Montreal, PQ, Canada.
   [Larroya, Mateo Bover; Castellano, Daniel] Hosp Univ 12 Octubre, Madrid, Spain.
   [Del Prete, Salvatore A.; Gulati, Anthony P.] Stamford Hosp, Stamford, CT USA.
   [Doroshow, Deborah B.; Galsky, Matthew D.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
   [Egan, Pamela C.; Farmakiotis, Dimitrios] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Flora, Daniel; Logan, Barbara] St Elizabeth Healthcare, Edgewood, KY USA.
   [Glover, Michael J.; Shah, Sumit A.; Wu, Julie Tsu-Yu] Stanford Univ, Stanford, CA 94305 USA.
   [Griffiths, Elizabeth A.] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA.
   [Gupta, Shilpa; Lemmon, Christopher A.; Pennell, Nathan A.] Cleveland Clin, Cleveland, OH 44106 USA.
   [Hafez, Navid; Masters, Tyler] Smilow Canc Hosp Yale New Haven, New Haven, CT USA.
   [Halfdanarson, Thorvardur R.; Xie, Zhuoer] Mayo Clin, Ctr Canc, Rochester, MN USA.
   [Hawley, Jessica E.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
   [Hsu, Emily; Yu, Peter P.] Hartford Hlth Care, Hartford, CT USA.
   [Kasi, Anup; Wulff-Burchfield, Elizabeth] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
   [McKay, Rana R.; Shaya, Justin A.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
   [Morgans, Alicia K.; Mulcahy, Mary F.; Wehbe, Firas H.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
   [Panagiotou, Orestis A.] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA.
   [Peddi, Prakash; Rosen, Lane R.] Willis Knighton Canc Ctr, Shreveport, LA USA.
   [Reynolds, Kerry; Rosovsky, Rachel; Zubiri, Leyre] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Stockerl-Goldstein, Keith E.; Zhou, Alice Y.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA.
   [Subbiah, Suki] LSU Hlth, Stanley S Scott Canc Ctr, New Orleans, LA USA.
   [Weissmann, Lisa B.] Mt Auburn Hosp, Cambridge, MA USA.
RP Warner, JL (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.
EM jeremy.warner@vumc.org
RI Khaki, Ali Raza/AAO-2437-2020; peters, solange/ABF-2187-2020; choueiri,
   Toni/ABE-7070-2020; Barnholtz-Sloan, Jill/A-4817-2011; Bakouny,
   Ziad/A-1149-2018; Kasi, Anup/ABF-5253-2020; Schmidt, Andrew/F-8446-2016;
   Halfdanarson, Thorvardur/AAO-8706-2020; shah, chintan/W-4011-2019;
   Desai, Aakash/ABD-6423-2020; Markham, Merry Jennifer/T-9446-2018;
   Friese, Christopher/D-2097-2013
OI Khaki, Ali Raza/0000-0002-4655-4426; choueiri, Toni/0000-0002-9201-3217;
   Barnholtz-Sloan, Jill/0000-0001-6190-9304; Bakouny,
   Ziad/0000-0003-1906-5704; Schmidt, Andrew/0000-0003-4930-4155;
   Halfdanarson, Thorvardur/0000-0001-8460-1257; shah,
   chintan/0000-0002-2441-908X; Markham, Merry
   Jennifer/0000-0003-3567-3494; Xie, Zhuoer/0000-0003-1266-9804; Friese,
   Christopher/0000-0002-2281-2056; Mishra, Sanjay/0000-0002-7775-9600;
   Zimmer, Andrea/0000-0002-1460-0774; Nagaraj,
   Gayathri/0000-0002-7586-6920; Yeh, Albert/0000-0003-3455-7360; Stover,
   Daniel/0000-0001-9003-8165
FU American Cancer SocietyAmerican Cancer Society; Hope Foundation for
   Cancer Research [MRSG-16-152-01-CCE]; Fonds de Recherche du Quebec-Sante
   clinician-scientist scholar program; Jim and Carol O'Hare Fund; National
   Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30 CA013696, P30 CA016056, P30 CA016672, P30 CA023100,
   P30 CA054174, P30 CA060553, P30 CA068485, P30 CA196521, T32 CA009515,
   T32 CA203703, UG1 CA189974, U01 CA231840]; National Human Genome
   Research InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Human
   Genome Research Institute (NHGRI) [T32 HG008341]; Vanderbilt Institute
   for Clinical and Translational Research (NCATS/NIH) [UL1 TR000445]
FX This study was partly supported by grants from the American Cancer
   Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE; to
   DPS); the Fonds de Recherche du Quebec-Sante clinician-scientist scholar
   program to DCV; the Jim and Carol O'Hare Fund (to SMR); the National
   Cancer Institute (P30 CA013696 to JEH; P30 CA016056 to EAG; P30 CA016672
   to JAS; P30 CA023100 to RRM; P30 CA054174 to DPS, MS, and RAM; P30
   CA060553 to FHW; P30 CA068485 to C-YH, BIR, JLW, SM, and YS; P30
   CA196521 to DBD and MDG; T32 CA009515 to ARK; T32 CA203703 to JEH; UG1
   CA189974 to GHL; and U01 CA231840 to JLW); and the National Human Genome
   Research Institute (T32 HG008341 to SMR). REDCap is developed and
   supported by Vanderbilt Institute for Clinical and Translational
   Research grant support (UL1 TR000445 from NCATS/NIH). We thank Pankil K
   Shah for statistical input, Margaret Madeleine for regulatory input, and
   Steven A Pergam for virological input.
CR Afar DEH, 2001, CANCER RES, V61, P1686
   Alexander LEC, 2015, CHEST, V148, P1307, DOI 10.1378/chest.15-0409
   Bleicher RJ, 2016, JAMA ONCOL, V2, P330, DOI 10.1001/jamaoncol.2015.4508
   Blimark C, 2015, HAEMATOLOGICA, V100, P107, DOI 10.3324/haematol.2014.107714
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   CDC COVID-19 Response Team, 2020, MMWR Morb Mortal Wkly Rep, V69, P477, DOI 10.15585/mmwr.mm6915e6
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Desai Aakash, 2020, Nat Cancer, P1, DOI 10.1038/s43018-020-0065-z
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lin BY, 1999, CANCER RES, V59, P4180
   Macarulla T, 2019, J CLIN ONCOL, V37, P230, DOI 10.1200/JCO.18.00089
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Marron JM, 2020, J CLIN ONCOL, V38, P2201, DOI 10.1200/JCO.20.00960
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P1873, DOI 10.1056/NEJMp2005492
   Samson P, 2015, ANN THORAC SURG, V99, P1906, DOI 10.1016/j.athoracsur.2015.02.022
   Smith J. C., 2020, CIGARETTE SMOKE TRIG, DOI [10.1101/2020.03.28.013672, DOI 10.1101/2020.03.28.013672]
   Stopsack KH, 2020, CANCER DISCOV, V10, P779, DOI 10.1158/2159-8290.CD-20-0451
   Strzelak A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15051033
   US Food & Drug Administration, 2020, FDA CAUT US HYDR CHL
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization (WHO), WHO DIR GEN OP REM M
   Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x
   Zukin M, 2013, J CLIN ONCOL, V31, P2849, DOI 10.1200/JCO.2012.48.1911
NR 36
TC 160
Z9 159
U1 18
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUN 20
PY 2020
VL 395
IS 10241
BP 1907
EP 1918
DI 10.1016/S0140-6736(20)31187-9
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA MQ2MV
UT WOS:000552732200031
PM 32473681
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Lee, LYW
   Cazier, JB
   Starkey, T
   Turnbull, CD
   Kerr, R
   Middleton, G
AF Lee, Lennard Y. W.
   Cazier, Jean Baptiste
   Starkey, T.
   Turnbull, C. D.
   Kerr, Rachel
   Middleton, Gary
CA UK Coronavirus Canc Monitoring Pro
TI COVID-19 mortality in patients with cancer on chemotherapy or other
   anticancer treatments: a prospective cohort study
SO LANCET
LA English
DT Article
AB Background Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with cancer.
   Methods In this prospective observational study, all patients with active cancer and presenting to our network of cancer centres were eligible for enrolment into the UK Coronavirus Cancer Monitoring Project (UKCCMP). The UKCCMP is the first COVID-19 clinical registry that enables near real-time reports to frontline doctors about the effects of COVID-19 on patients with cancer. Eligible patients tested positive for severe acute respiratory syndrome coronavirus 2 on RT-PCR assay from a nose or throat swab. We excluded patients with a radiological or clinical diagnosis of COVID-19, without a positive RT-PCR test. The primary endpoint was all-cause mortality, or discharge from hospital, as assessed by the reporting sites during the patient hospital admission.
   Findings From March 18, to April 26, 2020, we analysed 800 patients with a diagnosis of cancer and symptomatic COVID-19. 412 (52%) patients had a mild COVID-19 disease course. 226 (28%) patients died and risk of death was significantly associated with advancing patient age (odds ratio 9.42 [95% CI 6.56-10.02]; p<0.0001), being male (1.67 [1.19-2.34]; p=0.003), and the presence of other comorbidities such as hypertension (1.95 [1.36-2.80]; p<0.001) and cardiovascular disease (2.32 [1.47-3.64]). 281 (35%) patients had received cytotoxic chemotherapy within 4 weeks before testing positive for COVID-19. After adjusting for age, gender, and comorbidities, chemotherapy in the past 4 weeks had no significant effect on mortality from COVID-19 disease, when compared with patients with cancer who had not received recent chemotherapy (1.18 [0.81-1.72]; p=0.380). We found no significant effect on mortality for patients with immunotherapy, hormonal therapy, targeted therapy, radiotherapy use within the past 4 weeks.
   Interpretation Mortality from COVID-19 in cancer patients appears to be principally driven by age, gender, and comorbidities. We are not able to identify evidence that cancer patients on cytotoxic chemotherapy or other anticancer treatment are at an increased risk of mortality from COVID-19 disease compared with those not on active treatment. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Lee, Lennard Y. W.; Starkey, T.] Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England.
   [Middleton, Gary] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England.
   [Cazier, Jean Baptiste] Univ Birmingham, Ctr Computat Biol, Birmingham, W Midlands, England.
   [Kerr, Rachel] Univ Oxford, Dept Oncol, Oxford, England.
   [Turnbull, C. D.] Univ Oxford, Nuffield Dept Med, Oxford, England.
RP Lee, LYW (corresponding author), Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England.
EM l.lee.2@bham.ac.uk
RI Gennatas, Spyridon/ABE-4559-2020; Lee, Alvin Jun Xing/A-1047-2017;
   Bisht, Vartika/ABE-4370-2020
OI Gennatas, Spyridon/0000-0002-5635-7696; Lee, Alvin Jun
   Xing/0000-0002-7427-9142; Bisht, Vartika/0000-0002-1880-0597; Lee,
   Rebecca/0000-0003-2540-2009; Varnai, Csilla/0000-0003-0048-9507;
   Starkey, Thomas/0000-0002-6692-9563; Naksukpaiboon,
   Piangfan/0000-0001-8755-7976; Cazier, Jean-Baptiste/0000-0001-7581-9051
FU University of Birmingham; University of Oxford; National Institute for
   Health Research Oxford Biomedical Research
FX The authors thank the oncologists, acute physicians, and health-care
   staff working tirelessly on the frontlines of the COVID-19 pandemic. We
   would like to thank David Adams for giving support and approval for this
   project. This project was funded by the University of Birmingham (data
   collection and grants to JPC, LYWL, UKCCMP, and GM) and the University
   of Oxford (RK grants). LYWL is supported by the National Institute for
   Health Research Oxford Biomedical Research. Expanded UKCCMP
   acknowledgments are given in the appendix.
CR [Anonymous], COMP ACC OR NAS SWAB
   Coronavirus Project Supporters, COR PROJ SUPP
   Dai M, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3558017, DOI 10.2139/SSRN.3558017]
   GOV.UK, COVID 19 TRACK COR C
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   ICNARC, OUR NAT AUD PROGR NA
   Khleif SN, 2016, SKEELS HDB CANC THER
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8
   Saini KS, 2020, LANCET HAEMATOL, V7, pE432, DOI 10.1016/S2352-3026(20)30123-X
   The Lancet Oncology, 2020, Lancet Oncol, V21, P467, DOI 10.1016/S1470-2045(20)30175-3
   Thompson SJ, 2019, ZENODO, DOI [10.5281/ zenodo.3250616., DOI 10.5281/ZENODO.3250616]
   UK Coronavirus Canc, 2020, LANCET ONCOL, V21, P622, DOI 10.1016/S1470-2045(20)30230-8
   UK Office for National Statistics, CHAR NTHOS DYING COV
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
NR 18
TC 109
Z9 108
U1 9
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUN 20
PY 2020
VL 395
IS 10241
BP 1919
EP 1926
DI 10.1016/S0140-6736(20)31173-9
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA MQ2MV
UT WOS:000552732200032
PM 32473682
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Ghosh, R
   Chakraborty, A
   Biswas, A
   Chowdhuri, S
AF Ghosh, Rajesh
   Chakraborty, Ayon
   Biswas, Ashis
   Chowdhuri, Snehasis
TI Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2)
   main protease (Mpro) inhibitors - anin silicodocking and molecular
   dynamics simulation study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS CoV-2 main protease; docking; molecular dynamics
   simulation; green tea polyphenols; catechins
ID MUTATIONS V32I; HIV-1 PROTEASE; (-)-EPIGALLOCATECHIN-3-GALLATE;
   IDENTIFICATION; MECHANISMS; RESISTANCE; PNEUMONIA
AB Coronavirus disease 2019 (COVID-19) is a viral respiratory disease which caused global health emergency and announced as pandemic disease by World Health Organization. Lack of specific drug molecules or treatment strategy against this disease makes it more devastating. Thus, there is an urgent need of effective drug molecules to fight against COVID-19. The main protease (Mpro) of SARS CoV-2, a key component of this viral replication, is considered as a prime target for anti-COVID-19 drug development. In order to find potent Mpro inhibitors, we have selected eight polyphenols from green tea, as these are already known to exert antiviral activity against many RNA viruses. We have elucidated the binding affinities and binding modes between these polyphenols including a well-known Mpro inhibitor N3 (having binding affinity -7.0 kcal/mol) and Mpro using molecular docking studies. All eight polyphenols exhibit good binding affinity toward Mpro (-7.1 to -9.0 kcal/mol). However, only three polyphenols (epigallocatechin gallate, epicatechingallate and gallocatechin-3-gallate) interact strongly with one or both catalytic residues (His41 and Cys145) of Mpro. Molecular dynamics simulations (100 ns) on these three Mpro-polyphenol systems further reveal that these complexes are highly stable, experience less conformational fluctuations and share similar degree of compactness. Estimation of total number of intermolecular H-bond and MM-GBSA analysis affirm the stability of these three Mpro-polyphenol complexes. Pharmacokinetic analysis additionally suggested that these polyphenols possess favorable drug-likeness characteristics. Altogether, our study shows that these three polyphenols can be used as potential inhibitors against SARS CoV-2 Mpro and are promising drug candidates for COVID-19 treatment. Communicated by Ramaswamy H. Sarma
C1 [Ghosh, Rajesh; Chakraborty, Ayon; Biswas, Ashis; Chowdhuri, Snehasis] Indian Inst Technol Bhubaneswar, Sch Basic Sci, Bhubaneswar 752050, Odisha, India.
RP Biswas, A; Chowdhuri, S (corresponding author), Indian Inst Technol Bhubaneswar, Sch Basic Sci, Bhubaneswar 752050, Odisha, India.
EM abiswas@iitbbs.ac.in; snehasis@iitbbs.ac.in
OI Chakraborty, Ayon/0000-0002-1155-7862
FU IIT Bhubaneswar
FX RG acknowledges IIT Bhubaneswar for providing fellowship.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   ADEOYE AO, 2020, J BIOMOL STRUCT 0514, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1765876
   AI ZY, 2019, MOLECULES, V24, DOI DOI https://doi.org/10.3390/molecules24061185
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   BABADAEI MMN, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1767210
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767211
   BASIT A, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768150
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Calland N, 2012, HEPATOLOGY, V55, P720, DOI 10.1002/hep.24803
   Carneiro BM, 2016, VIROLOGY, V496, P215, DOI 10.1016/j.virol.2016.06.012
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen JZ, 2016, RSC ADV, V6, P58573, DOI 10.1039/c6ra09201b
   Chen JZ, 2015, J CHEM INF MODEL, V55, P1903, DOI 10.1021/acs.jcim.5b00173
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Fassina G, 2002, AIDS, V16, P939, DOI 10.1097/00002030-200204120-00020
   Frisch M. J., GAUSSIAN 09 REVISION
   Grum-Tokars V, 2008, VIRUS RES, V133, P63, DOI 10.1016/j.virusres.2007.02.015
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Ide K, 2016, CURR MED CHEM, V23, P4773, DOI 10.2174/0929867324666161123091010
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Ismail NA, 2017, INTERDISCIP SCI, V9, P499, DOI 10.1007/s12539-016-0157-8
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Lyu SY, 2005, ARCH PHARM RES, V28, P1293, DOI 10.1007/BF02978215
   MAHAJAN P, 2020, NETW MODEL ANAL HLTH, V9, DOI DOI https://doi.org/10.1007/s13721-020-0222-4
   MAHANTA S, 2020, J BIOMOL STRUCT 0522, DOI DOI https://doi.org/10.1080/07391102.2020.1768902
   MAHASE E, 2020, BMJ BRIT MED J, V368
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MITTAL L, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768151
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805
   Morris Garrett M, 2008, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0814s24
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Osman EEA, 2020, ACS INFECT DIS, V6, P1548, DOI 10.1021/acsinfecdis.0c00224
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Purohit R, 2014, J BIOMOL STRUCT DYN, V32, P1033, DOI 10.1080/07391102.2013.803264
   Rajendran V, 2018, J CELL BIOCHEM, V119, P918, DOI 10.1002/jcb.26257
   Rajendran V, 2016, MOL BIOSYST, V12, P2276, DOI 10.1039/c6mb00182c
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   SHARMA J, 2020, J BIOMOL STRUCT 0206, DOI DOI https://doi.org/10.1080/07391102.2020.1720818
   SINGH R, 2020, J BIOMOL STRUCT 0117, DOI DOI https://doi.org/10.1080/07391102.2020.1711809
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Huynh T, 2020, J PHYS CHEM LETT, V11, P4413, DOI 10.1021/acs.jpclett.0c00994
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Venugopal PP, 2020, PROTEINS, V88, P327, DOI 10.1002/prot.25807
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   Weber C, 2015, ANTIVIR RES, V113, P1, DOI 10.1016/j.antiviral.2014.11.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu J, 2008, ANTIVIR RES, V78, P242, DOI 10.1016/j.antiviral.2007.11.011
   Yan L, 2003, FEBS LETT, V554, P257, DOI 10.1016/S0014-5793(03)01115-3
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 76
TC 18
Z9 18
U1 4
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1779818
EA JUN 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MJ4MW
UT WOS:000548067200001
PM 32568613
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kumar, D
   Kumari, K
   Vishvakarma, VK
   Jayaraj, A
   Kumar, D
   Ramappa, VK
   Patel, R
   Kumar, V
   Dass, SK
   Chandra, R
   Singh, P
AF Kumar, Durgesh
   Kumari, Kamlesh
   Vishvakarma, Vijay Kumar
   Jayaraj, Abhilash
   Kumar, Dhiraj
   Ramappa, Venkatesh Kumar
   Patel, Rajan
   Kumar, Vinod
   Dass, Sujata K.
   Chandra, Ramesh
   Singh, Prashant
TI Promising inhibitors of main protease of novel corona virus to prevent
   the spread of COVID-19 using docking and molecular dynamics simulation
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; ZINC database; inhibitors; docking; MD simulations; MM-GBSA
ID THEORETICAL-MODEL; BINDING; SYSTEM; GENOME
AB Coronavirus disease-2019 (COVID-19) is a global health emergency and the matter of serious concern, which has been declared a pandemic by WHO. Till date, no potential medicine/ drug is available to cure the infected persons from SARS-CoV-2. This deadly virus is named as novel 2019-nCoV coronavirus and caused coronavirus disease, that is, COVID-19. The first case of SARS-CoV-2 infection in human was confirmed in the Wuhan city of the China. COVID-19 is an infectious disease and spread from man to man as well as surface to man . In the present work,in silicoapproach was followed to find potential molecule to control this infection. Authors have screened more than one million molecules available in the ZINC database and taken the best two compounds based on binding energy score. These lead molecules were further studied through docking against the main protease of SARS-CoV-2. Then, molecular dynamics simulations of the main protease with and without screened compounds were performed at room temperature to determine the thermodynamic parameters to understand the inhibition. Further, molecular dynamics simulations at different temperatures were performed to understand the efficiency of the inhibition of the main protease in the presence of the screened compounds. Change in energy for the formation of the complexes between the main protease of novel coronavirus and ZINC20601870 as well ZINC00793735 at room temperature was determined on applying MM-GBSA calculations. Docking and molecular dynamics simulations showed their antiviral potential and may inhibit viral replication experimentally. Communicated by Ramaswamy H. Sarma
C1 [Kumar, Durgesh; Vishvakarma, Vijay Kumar] Univ Delhi, Atma Ram Sanatan Dharma Coll, Dept Chem, New Delhi, India.
   [Kumar, Durgesh; Vishvakarma, Vijay Kumar; Chandra, Ramesh] Univ Delhi, Dept Chem, Drug Discovery & Dev Lab, Delhi, India.
   [Kumari, Kamlesh] Univ Delhi, Deen Dayal Upadhyaya Coll, Dept Zool, New Delhi, India.
   [Jayaraj, Abhilash] Indian Inst Technol, SCFBio, New Delhi, India.
   [Kumar, Dhiraj] Jiwaji Univ, Dept Zool, Gwalior, Madhya Pradesh, India.
   [Ramappa, Venkatesh Kumar] Babasaheb Bhimrao Ambedkar Univ, Dept Zool, Lucknow, Uttar Pradesh, India.
   [Patel, Rajan] Jamia Millia Islamia, CIRBS, New Delhi, India.
   [Kumar, Vinod] Jawaharlal Nehru Univ, Special Ctr Nano Sci, New Delhi, India.
   [Dass, Sujata K.; Singh, Prashant] BLK Super Special Hosp, Dept Neurol, New Delhi, India.
RP Singh, P (corresponding author), Univ Delhi, Atma Ram Sanatan Dharma Coll, Dept Chem, New Delhi, India.; Chandra, R (corresponding author), Univ Delhi, Dept Chem, Drug Discovery & Dev Lab, Delhi, India.; Kumari, K (corresponding author), Univ Delhi, Deen Dayal Upadhyaya Coll, Dept Zool, New Delhi, India.
EM biotechnano@gmail.com; acbrdu@hotmail.com; psingh@arsd.du.ac.in
OI Kumar, Deepak/0000-0003-2800-4540
FU Council of Scientific and Industrial Research (CSIR)Council of
   Scientific & Industrial Research (CSIR) - India [08/593/0002/2015/EMR
   I]; University of Delhi under DST-PURSE grant, Government of India;
   Council of Scientific and Industrial Research (CSIR), Government of
   IndiaCouncil of Scientific & Industrial Research (CSIR) - India
   [02/265/16/EMR II]; SERB-DST, Government of India. [EEQ/2016/00489]
FX Durgesh Kumar (DK) thankfully acknowledges to Council of Scientific and
   Industrial Research (CSIR, Reference no. 08/593/0002/2015/EMR I) for the
   fellowship. Another author, Prof. Ramesh Chandra (RC) thankfully
   acknowledges the financial assistance provided by the University of
   Delhi under DST-PURSE grant, Council of Scientific and Industrial
   Research (CSIR, Reference no. 02/265/16/EMR II), SERB-DST (Reference no.
   EEQ/2016/00489), Government of India.
CR Agarwal Anup, 2020, Indian J Med Res, V151, P177, DOI 10.4103/ijmr.IJMR_518_20
   Agarwal G, 2019, BIOINFORMATION, V15, P439, DOI 10.6026/97320630015439
   AHMED SF, 2020, VIRUSES BASEL, V12, DOI DOI HTTPS://DOI.ORG/10.3390/V12030254
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Akhmadiev NS, 2019, ADV PHARM BULL, V9, P674, DOI 10.15171/apb.2019.079
   Al-Refaei MA, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03221
   ALANAZI M, 2018, MOLECULES, V23, DOI DOI https://doi.org/10.3390/molecules23123203
   Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2020.02.033, 10.1016/j.jiph.2019.02.033]
   Almazan F, 2004, J VIROL, V78, P12683, DOI 10.1128/JVI.78.22.12683-12688.2004
   BABADAEI MMN, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1767210
   Bai J, 2020, J ENVIRON SCI HEAL A, V55, P669, DOI 10.1080/10934529.2020.1729616
   Balaji B, 2012, J ENZYM INHIB MED CH, V27, P832, DOI 10.3109/14756366.2011.618990
   Balasubramanian PK, 2019, J BIOMOL STRUCT DYN, V37, P2165, DOI 10.1080/07391102.2018.1479309
   BASIT A, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768150
   Bea I, 2006, J ORG CHEM, V71, P2056, DOI 10.1021/jo052469o
   Berkhout B, 2015, VIRUS RES, V202, P41, DOI 10.1016/j.virusres.2014.11.031
   BEURA S, 2020, J BIOMOL STRUCT 0604, DOI DOI https://doi.org/10.1080/07391102.2020.1772111
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   BOLDOG P, 2020, J CLIN MED, V9, DOI DOI https://doi.org/10.3390/jcm9020571
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Borkotoky S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1774419
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   Burley SK, 2018, PROTEIN SCI, V27, P316, DOI 10.1002/pro.3331
   Cai X, 2018, FISH SHELLFISH IMMUN, V78, P100, DOI 10.1016/j.fsi.2018.04.025
   COBCALAN NN, 2019, MOLECULES, V24, DOI DOI https://doi.org/10.3390/molecules24183387
   Cummins PL, 2019, J PHYS CHEM B, V123, P2679, DOI 10.1021/acs.jpcb.8b12088
   Du J, 2011, J COMPUT CHEM, V32, P2800, DOI 10.1002/jcc.21859
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   ELFIKY AA, 2020, J BIOMOL STRUCT 0424, DOI DOI https://doi.org/10.1080/07391102.2020.1758789
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761881
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Genheden S, 2012, J CHEM INF MODEL, V52, P2079, DOI 10.1021/ci3001919
   Greenidge PA, 2014, J CHEM INF MODEL, V54, P2697, DOI 10.1021/ci5003735
   Greenidge PA, 2016, CHEM BIOL DRUG DES, V88, P317, DOI 10.1111/cbdd.12763
   Gupta A, 2007, PROTEIN PEPTIDE LETT, V14, P632
   Jagannadh B, 1996, J PHYS CHEM-US, V100, P14339, DOI 10.1021/jp960929z
   Ji T, 2020, CLIN INFECT DIS, V71, P1454, DOI 10.1093/cid/ciaa390
   Kirby ME, 2018, J PHYS CHEM A, V122, P8007, DOI 10.1021/acs.jpca.8b06863
   KUMAR D, 2019, J BIOMOL STRUCT 0810, DOI DOI https://doi.org/10.1080/07391102.2019.1650830
   Kumar D, 2019, CHEMISTRYSELECT, V4, P4892, DOI 10.1002/slct.201803360
   Kumari K, 2017, CURR MED CHEM, V24, P4579, DOI 10.2174/0929867324666170529100929
   Kumari M, 2014, SPECTROCHIM ACTA A, V124, P349, DOI 10.1016/j.saa.2014.01.012
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lipinski CA, 2012, ADV DRUG DELIVER REV, V64, P4, DOI 10.1016/j.addr.2012.09.019
   Lohidashan K, 2018, BANGL J PHARMACOL, V13, P23, DOI 10.3329/bjp.v13i1.33625
   MADHAVARAM M, 2019, J RECEPT SIG TR 1018, DOI DOI https://doi.org/10.1080/10799893.2019.1660895
   Mitra S, 2019, ENT-EAR NOSE THROAT, V98, P28, DOI 10.1177/0145561318823311
   Morris Kevin F, 2020, Biochem Biophys Rep, V21, P100721, DOI 10.1016/j.bbrep.2019.100721
   Mukherjee G, 2013, PHYS CHEM CHEM PHYS, V15, P9107, DOI 10.1039/c3cp44697b
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   NAZ S, 2020, J BIOMOL STRUCT 0123, DOI DOI https://doi.org/10.1080/07391102.2020.1715259
   Nazarian SM, 2015, J NEURO-OPHTHALMOL, V35, P201, DOI 10.1097/WNO.0000000000000261
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pola M, 2018, ENZYME MICROB TECH, V117, P32, DOI 10.1016/j.enzmictec.2018.06.005
   Purohit R, 2014, J BIOMOL STRUCT DYN, V32, P1033, DOI 10.1080/07391102.2013.803264
   Rajendran V, 2018, J CELL BIOCHEM, V119, P918, DOI 10.1002/jcb.26257
   Roe DR, 2018, J COMPUT CHEM, V39, P2110, DOI 10.1002/jcc.25382
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   SHARMA J, 2020, J BIOMOL STRUCT 0206, DOI DOI https://doi.org/10.1080/07391102.2020.1720818
   Singh P, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02795
   Singh P, 2010, SPECTROCHIM ACTA A, V75, P983, DOI 10.1016/j.saa.2009.12.019
   SINGH R, 2020, J BIOMOL STRUCT 0117, DOI DOI https://doi.org/10.1080/07391102.2020.1711809
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Song LF, 2019, J CHEM INF MODEL, V59, P3128, DOI 10.1021/acs.jcim.9b00105
   THOMASRUDDEL D, 2020, ANAESTHESIST 0324, DOI DOI https://doi.org/10.1007/s00101-020-00760-3
   Vishvakarma VK, 2015, SPECTROCHIM ACTA A, V143, P319, DOI 10.1016/j.saa.2015.01.068
   Vishvakarma VK, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02124
   Vishvakarma Vijay Kumar, 2013, Drug Metabolism and Drug Interactions, V28, P31, DOI 10.1515/dmdi-2012-0036
   Zhang Z, 2009, J GEN PHYSIOL, V133, P263, DOI 10.1085/jgp.200810079
NR 72
TC 18
Z9 19
U1 6
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1779131
EA JUN 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MJ4NE
UT WOS:000548068000001
PM 32567995
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Arun, KG
   Sharanya, CS
   Abhithaj, J
   Francis, D
   Sadasivan, C
AF Arun, K. G.
   Sharanya, C. S.
   Abhithaj, J.
   Francis, Dileep
   Sadasivan, C.
TI Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual
   screening, molecular docking and molecular dynamics with main protease
   as the target
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; main protease; drug repurposing; E-pharmacophore; molecular
   docking; molecular dynamics
ID VIRUS-REPLICATION; CORONAVIRUS; DOXORUBICIN; INHIBITION; MODEL
AB Since its first report in December 2019 from China, the COVID-19 pandemic caused by the beta-coronavirus SARS-CoV-2 has spread at an alarming pace infecting about 5.59 million, and claiming the lives of more than 0.35 million individuals across the globe. The lack of a clinically approved vaccine or drug remains the biggest bottleneck in combating the pandemic. Drug repurposing can expedite the process of drug development by identifying known drugs which are effective against SARS-CoV-2. The SARS-CoV-2 main protease is a promising drug target due to its indispensable role in viral multiplication inside the host. In the present study an E-pharmacophore hypothesis was generated using a crystal structure of the viral protease in complex with an imidazole carbaximide inhibitor. Drugs available in the superDRUG2 database were used to identify candidate drugs for repurposing. The hits obtained from the pharmacophore based screening were further screened using a structure based approach involving molecular docking at different precisions. The binding energies of the most promising compounds were estimated using MM-GBSA. The stability of the interactions between the selected drugs and the target were further explored using molecular dynamics simulation at 100 ns. The results showed that the drugs Binifibrate and Bamifylline bind strongly to the enzyme active site and hence they can be repurposed against SARS-CoV-2. However, U.S Food and Drug Administration have withdrawn Binifibrate from the market as it was having some adverse health effects on patients. Communicated by Ramaswamy H. Sarma
C1 [Arun, K. G.; Sharanya, C. S.; Abhithaj, J.; Sadasivan, C.] Kannur Univ, Dept Biotechnol & Microbiol, Kannur, Kerala, India.
   [Francis, Dileep] Kristu Jayanti Coll, Dept Life Sci, Bengaluru, Karnataka, India.
RP Sadasivan, C (corresponding author), Kannur Univ, Dept Biotechnol & Microbiol, Kannur, Kerala, India.
EM csadasivan@gmail.com
RI j, abhithaj/AAV-3312-2020; Chittalakkottu, Sadasivan/AAR-1786-2020
OI j, abhithaj/0000-0002-6732-4486; 
FU Indian Council for Medical Research (ICMR), New Delhi, IndiaIndian
   Council of Medical Research (ICMR); Council of Scientific Industrial
   Research (CSIR) New Delhi, IndiaCouncil of Scientific & Industrial
   Research (CSIR) - India
FX The authors would like to thank Dr. Vinod Devaraji, Senior scientist,
   Schrodinger Inc for the help with performing the MD studies. Arun KG and
   Abhithaj J acknowledge the Indian Council for Medical Research (ICMR),
   New Delhi, India for financial support. Sharanya C S acknowledge Council
   of Scientific Industrial Research (CSIR) New Delhi, India for research
   fellowship.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   ANDERSEN KG, 2020, NAT MED 0317, DOI DOI HTTPS://DOI.ORG/10.1038/S41591-020-0820-9
   [Anonymous], 2018, GLID VERS 7 8
   [Anonymous], 2018, SCHRD REL 2018 1 MA
   ARYA A, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1773929
   ASH RJ, 1987, ANTIVIR RES, V8, P71, DOI 10.1016/0166-3542(87)90078-7
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Baden LR, 2020, NEW ENGL J MED, V382, P1851, DOI 10.1056/NEJMe2005477
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Bowers Kevin J., 2006, P ACM IEEE C SUP SC0, P11
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   CHOUDHURY C, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1771424
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   de Oliveira OV, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772885
   Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822-006-9087-6
   EDELSTEIN CL, 2020, AUTOPHAGY INHIBITION, V98, P234, DOI DOI 10.1016/J.KINT.2020.05.001
   ELFIKY AA, 2020, J BIOMOL STRUCT 0424, DOI DOI https://doi.org/10.1080/07391102.2020.1758789
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   HENDAUS MA, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1767691
   Himmelmann A, 1996, AM J HYPERTENS, V9, P517, DOI 10.1016/0895-7061(95)00340-1
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   Jeyaseelan R, 1996, AIDS RES HUM RETROV, V12, P569, DOI 10.1089/aid.1996.12.569
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kaptein SJF, 2010, ANTIMICROB AGENTS CH, V54, P5269, DOI 10.1128/AAC.00686-10
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   KUMAR A, 2020, J BIOMOL STRUCT 0602, DOI DOI https://doi.org/10.1080/07391102.2020.1772112
   Lyne PD, 2006, J MED CHEM, V49, P4805, DOI 10.1021/jm060522a
   Mitja O, 2020, LANCET GLOB HEALTH, V8, pE639, DOI 10.1016/S2214-109X(20)30114-5
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Muthusamy K, 2013, INTERDISCIP SCI, V5, P119, DOI 10.1007/s12539-013-0157-x
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   PAPAS TS, 1977, ANN NY ACAD SCI, V284, P566, DOI 10.1111/j.1749-6632.1977.tb21988.x
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Peng J, 2014, MOL MED REP, V9, P2221, DOI 10.3892/mmr.2014.2076
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Proekt A., 2019, PHARM PHYSL ANESTHES, P2
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Shrivastava-Ranjan P, 2018, MBIO, V9, DOI [10.1128/mBio.00660-18, 10.1128/mbio.00660-18]
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Siramshetty VB, 2018, NUCLEIC ACIDS RES, V46, pD1137, DOI 10.1093/nar/gkx1088
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   US Food and Drug Administration, 2016, WITHDRAWAL APPROVAL, V81, P22612
   Yan, 2020, XINHUANET, P22
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
NR 60
TC 5
Z9 5
U1 2
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1779819
EA JUN 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MJ0IQ
UT WOS:000547780100001
PM 31971048
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Chikhale, RV
   Gurav, SS
   Patil, RB
   Sinha, SK
   Prasad, SK
   Shakya, A
   Shrivastava, SK
   Gurav, NS
   Prasad, RS
AF Chikhale, Rupesh, V
   Gurav, Shailendra S.
   Patil, Rajesh B.
   Sinha, Saurabh K.
   Prasad, Satyendra K.
   Shakya, Anshul
   Shrivastava, Sushant K.
   Gurav, Nilambari S.
   Prasad, Rupali S.
TI Sars-cov-2 host entry and replication inhibitors from Indian ginseng:
   anin-silicoapproach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Withania somnifera; pandemic infection; COVID-19; IndianAyurveda;
   IndianRasayana; antiviral; in-silico; molecular docking and dynamics;
   Ashwagandha
ID WITHANIA-SOMNIFERA; MOLECULAR-DYNAMICS; CORONAVIRUS; PROTEIN
AB COVID-19 has ravaged the world and is the greatest of pandemics in modern human history, in the absence of treatment or vaccine, the mortality and morbidity rates are very high. The present investigation identifies potential leads from the plant Withania somnifera (Indian ginseng), a well-known antiviral, immunomodulatory, anti-inflammatory and a potent antioxidant plant, using molecular docking and dynamics studies. Two different protein targets of SARS-CoV-2 namely NSP15 endoribonuclease and receptor binding domain of prefusion spike protein from SARS-CoV-2 were targeted. Molecular docking studies suggested Withanoside X and Quercetin glucoside from W. somnifera have favorable interactions at the binding site of selected proteins, that is, 6W01 and 6M0J. The top-ranked phytochemicals from docking studies, subjected to 100ns molecular dynamics (MD) suggested Withanoside X with the highest binding free energy (Delta G(bind) = -89.42kcal/mol) as the most promising inhibitor. During MD studies, the molecule optimizes its conformation for better fitting with the receptor active site justifying the high binding affinity. Based on proven therapeutic, that is, immunomodulatory, antioxidant and anti-inflammatory roles and plausible potential against n-CoV-2 proteins, Indian ginseng could be one of the alternatives as an antiviral agent in the treatment of COVID 19.
   [GRAPHICS]
   .
C1 [Chikhale, Rupesh, V] Univ East Anglia, Sch Pharm, Norwich Res Pk, Norwich, Norfolk, England.
   [Gurav, Shailendra S.] Goa Univ, Goa Coll Pharm, Dept Pharmacognosy, Panaji, Goa, India.
   [Patil, Rajesh B.] Smt Kashibai Navale Coll Pharm, Sinhgad Tech Educ Soc, Pune, Maharashtra, India.
   [Sinha, Saurabh K.] Mohanlal Shukhadia Univ, Dept Pharmaceut Sci, Udaipur, Rajasthan, India.
   [Prasad, Satyendra K.; Prasad, Rupali S.] RTM Univ, Dept Pharmaceut Sci, Nagpur, Maharashtra, India.
   [Shakya, Anshul] Dibrugarh Univ, Fac Sci & Engn, Dept Pharmaceut Sci, Dibrugarh, Assam, India.
   [Shrivastava, Sushant K.] Banaras Hindu Univ, Indian Inst Technol, Dept Pharmaceut Engn & Technol, Varanasi, Uttar Pradesh, India.
   [Gurav, Nilambari S.] Goa Univ, PESs Rajaram & Tarabai Bandekar Coll Pharm, Ponda, Goa, India.
RP Patil, RB (corresponding author), Smt Kashibai Navale Coll Pharm, Sinhgad Tech Educ Soc, Pune, Maharashtra, India.; Gurav, SS (corresponding author), Goa Univ, Goa Coll Pharm, Dept Pharmacognosy & Phytochem, Panaji 403001, Goa, India.
EM shailendra.gurav@nic.in; rajshama1@yahoo.com
RI shrivastava, Sushant Kumar/ABF-4064-2020; Gurav,
   Shailendra/AAO-4240-2020; Prasad, Satyendra/ABD-2399-2020
OI shrivastava, Sushant Kumar/0000-0002-5500-4004; Gurav,
   Shailendra/0000-0001-5564-2121; Chikhale, Rupesh/0000-0001-5622-3981;
   SHAKYA, ANSHUL/0000-0002-8232-4476; Prasad,
   Satyendra/0000-0002-4762-9733; Patil, Rajesh/0000-0003-2986-9546
CR ABRAHAM A, 1968, PHYTOCHEMISTRY, V7, P957, DOI 10.1016/S0031-9422(00)82182-2
   Akram M, 2018, PHYTOTHER RES, V32, P811, DOI 10.1002/ptr.6024
   ANDERSEN HC, 1983, J COMPUT PHYS, V52, P24, DOI 10.1016/0021-9991(83)90014-1
   Arya A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1773929
   Beura S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772111
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Cai Z, 2015, CELL BIOCHEM BIOPHYS, V72, P727, DOI 10.1007/s12013-015-0524-9
   CHOUDHURY C, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1771424
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Dar NJ, 2015, CELL MOL LIFE SCI, V72, P4445, DOI 10.1007/s00018-015-2012-1
   Deng XF, 2018, VIROLOGY, V517, P157, DOI 10.1016/j.virol.2017.12.024
   ELSAKKA M, 1990, Revista Medico-Chirurgicala Societatii di Medici si Naturalisti din Iasi, V94, P385
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Gupta G. L., 2007, Pharmacognosy Reviews, V1, P129
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Gurav NS, 2020, J AYURVEDA INTEGR ME, V11, P243, DOI 10.1016/j.jaim.2019.10.004
   Gurav S., 2014, INDIAN HERBAL DRUG M, P186, DOI DOI 10.1007/978-1-4614-9515-4
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   HATTORI M, 1995, PHYTOTHER RES, V9, P270, DOI 10.1002/ptr.2650090408
   Jayawardena R, 2020, DIABETES METAB SYND, V14, P367, DOI 10.1016/j.dsx.2020.04.015
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Kambizi L, 2007, S AFR J SCI, V103, P359
   Krison I., 1980, J CHEM RES SYNOPSES, V10, P338
   Kumar A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772112
   KUMAR V, 2020, J BIOMOL STRUCT 0530, DOI DOI https://doi.org/10.1080/07391102.2020.1772108
   Lee TS, 2018, J CHEM INF MODEL, V58, P2043, DOI 10.1021/acs.jcim.8b00462
   MAHANTA S, 2020, J BIOMOL STRUCT 0522, DOI DOI https://doi.org/10.1080/07391102.2020.1768902
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Matsuda H, 2001, BIOORGAN MED CHEM, V9, P1499, DOI 10.1016/S0968-0896(01)00024-4
   Mishra KP, 2013, J VIROL ANTIVIR RES, V2, P2, DOI [10.4172/2324-8955.1000109, DOI 10.4172/2324-8955.1000109]
   MITTAL L, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768151
   Mukhtar M, 2008, VIRUS RES, V131, P111, DOI 10.1016/j.virusres.2007.09.008
   Pant M, 2012, INDIAN J SCI TECHNOL, V5, P2750
   Patwardhan B, 2020, CURR SCI INDIA, V118, P1158
   Peramo A, 2016, MOL SIMULAT, V42, P1263, DOI 10.1080/08927022.2016.1183000
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Price DJ, 2004, J CHEM PHYS, V121, P10096, DOI 10.1063/1.1808117
   Rastelli G, 2010, J COMPUT CHEM, V31, P797, DOI 10.1002/jcc.21372
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   THEVARAJAN I, 2020, NAT MED 0316, DOI DOI https://doi.org/10.1038/s41591-020-0819-2
   Tillu G, 2020, J ALTERN COMPLEM MED, V26, P360, DOI 10.1089/acm.2020.0129
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang W, 2001, J AM CHEM SOC, V123, P3986, DOI 10.1021/ja003164o
   Whisenant J, 2020, ACS MED CHEM LETT, V11, P1076, DOI 10.1021/acsmedchemlett.0c00233
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
NR 49
TC 3
Z9 3
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1778539
EA JUN 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MI9AL
UT WOS:000547690900001
PM 32568012
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Naik, VR
   Munikumar, M
   Ramakrishna, U
   Srujana, M
   Goudar, G
   Naresh, P
   Kumar, BN
   Hemalatha, R
AF Naik, Vankudavath Raju
   Munikumar, Manne
   Ramakrishna, Ungarala
   Srujana, Medithi
   Goudar, Giridhar
   Naresh, Pittla
   Kumar, Boiroju Naveen
   Hemalatha, Rajkumar
TI Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease
   -in silicoapproach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE 2019-nCOV; COVID-19; Remdesivir; sequence analysis; phylogeny; molecular
   docking; dynamics simulations
ID CORONAVIRUS; SARS; SEQUENCE; DOCKING
AB 2019 - Novel Coronavirus (2019-nCOV), enclosed large genome positive-sense RNA virus characterized by crown-like spikes that protrude from their surface, and have a distinctive replication strategy. The 2019-nCOV belongs to the Coronaviridae family, principally consists of virulent pathogens showing zoonotic property, has emerged as a pandemic outbreak with high mortality and high morbidity rate around the globe and no therapeutic vaccine or drugs against 2019-nCoV are discovered till now. In this study,in silicomethods and algorithms were used for sequence, structure analysis and molecular docking on M(pro)of 2019-nCOV. The co-crystal structure of 2019-nCOV protease, 6LU7 have similar to 99% identity with SARS-CoV protease. The 6LU7 residues, Cys145 and His164 are playing a significant role in replication and are essential for the survival of 2019-nCOV. Alongside, 2019-nCOV M(pro)sequence is non-homologous to human host-pathogen. Complete genome sequence analysis, structural and molecular docking results revealed that Remdesivir is having a better binding affinity with -8.2 kcal/mol than the rest of protease inhibitors, and peptide. Remdesivir is strongly forming h-bonds with crucial M(pro)residues, Cys145, and His164. Further, MD simulation analysis also confirmed, that these residues are forming H-bond with Remdesivir during 100 ns simulations run and found stable (similar to 99%) by RMSD and RMSF. Thus, presentin silicostudy at molecular approaches suggest that, Remdesivir is a potent therapeutic inhibitor against 2019-nCoV. Communicated by Ramaswamy H. Sarma
C1 [Naik, Vankudavath Raju] ICMR Natl Inst Nutr, Extens & Training Div, Hyderabad 500007, Telangana, India.
   [Munikumar, Manne; Naresh, Pittla] ICMR Natl Inst Nutr, NIN TATA Ctr Excellence Publ Hlth Nutr, Hyderabad, India.
   [Ramakrishna, Ungarala] ICMR Natl Inst Nutr, Food Safety Div, Hyderabad, India.
   [Srujana, Medithi] Symbiosis Int Deemed Univ, Symbiosis Institue Hlth Sci, Pune, Maharashtra, India.
   [Goudar, Giridhar] Food Qual Anal & Biochem Div, Biochem Res & Testing Lab, Dharwad, Karnataka, India.
   [Kumar, Boiroju Naveen] ICMR Natl Inst Nutr, Biostat Div, Hyderabad, India.
   [Hemalatha, Rajkumar] ICMR Natl Inst Nutr, Div Clin Epidemiol, Hyderabad, India.
RP Naik, VR (corresponding author), ICMR Natl Inst Nutr, Extens & Training Div, Hyderabad 500007, Telangana, India.; Munikumar, M (corresponding author), ICMR Natl Inst Nutr, NIN TATA Ctr Excellence Publ Hlth Nutr, Bioinformat, Hyderabad 500007, Telangana, India.
EM naik.vivaswan@icmr.gov.in; mannemunikumar.bioinfo@gmail.com
RI Munikumar, Manne/AAH-7526-2020
OI Munikumar, Manne/0000-0003-1838-122X
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Azam SS, 2013, THEOR BIOL MED MODEL, V10, DOI 10.1186/1742-4682-10-63
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Chen JL, 2020, MICROBES INFECT, V22, P69, DOI 10.1016/j.micinf.2020.01.004
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hay AJ, 2001, PHILOS T R SOC B, V356, P1861, DOI 10.1098/rstb.2001.0999
   HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Khandare AL, 2018, FLUORIDE, V51, P137
   Killerby ME, 2018, J CLIN VIROL, V101, P52, DOI 10.1016/j.jcv.2018.01.019
   Kumar B, 2018, ARCH VIROL, V163, P831, DOI 10.1007/s00705-018-3708-y
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Lee TW, 2005, J MOL BIOL, V353, P1137, DOI 10.1016/j.jmb.2005.09.004
   Leimkuhler BJ, 2004, J CHEM PHYS, V121, P108, DOI 10.1063/1.1740753
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Munikumar Manne, 2019, Informatics in Medicine Unlocked, V15, P80, DOI 10.1016/j.imu.2019.100187
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pradhan D, 2014, J BIOMOL STRUCT DYN, V32, P171, DOI 10.1080/07391102.2012.758056
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Rathi S, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30313-3
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Sliwoski G, 2014, PHARMACOL REV, V66, P334, DOI 10.1124/pr.112.007336
   TCHESNOKOV EP, 2019, VIRUSES BASEL, V11, DOI DOI https://doi.org/10.3390/v11040326
   Umamaheswari A, 2011, INTERDISCIP SCI, V3, P64, DOI 10.1007/s12539-011-0064-y
   Vilar S, 2011, J MOL GRAPH MODEL, V29, P809, DOI 10.1016/j.jmgm.2011.01.005
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
   Yu F, 2020, MICROBES INFECT, V22, P74, DOI 10.1016/j.micinf.2020.01.003
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 45
TC 0
Z9 0
U1 2
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1781694
EA JUN 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MI9GF
UT WOS:000547705900001
PM 32568620
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yadav, R
   Imran, M
   Dhamija, P
   Suchal, K
   Handu, S
AF Yadav, Rohitash
   Imran, Mohammed
   Dhamija, Puneet
   Suchal, Kapil
   Handu, Shailendra
TI Virtual screening and dynamics of potential inhibitors targeting RNA
   binding domain of nucleocapsid phosphoprotein from SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; docking; molecular dynamics; nucleocapsid phosphoprotein;
   SARS-CoV-2
ID TERMINAL DOMAIN; PROTEIN; DOCKING; GLIDE
AB The emergence of the coronavirus disease-2019 pandemic has led to an outbreak in the world. The SARS-CoV-2 is seventh and latest in coronavirus family with unique exonucleases for repairing any mismatches in newly transcribed genetic material. Therefore, drugs with novel additional mechanisms are required to simultaneously target and eliminate the virus. Thus, a newly deciphered N protein is taken as a target that belongs to SARS-CoV-2. They play a vital role in RNA transcription, viral replication and new virion formation. This study used virtual screening, molecular modeling and docking of the 8987 ligands from Asinex and PubChem databases against this novel target protein. Three hotspot sites having DScore >= 1 (Site 1, Site 2 and Site 3) for ligand binding were selected. Subsequently, high throughput screening, standard precision and extra precision docking process and molecular dynamics concluded three best drugs from two libraries. Two antiviral moieties from Asinex databases (5817 and 6799) have docking scores of -10.29 and -10.156; along with their respective free binding energies (Delta Gbind) of -51.96 and -64.36 on Site 3. The third drug, Zidovudine, is from PubChem database with docking scores of -9.75 with its binding free energies (Delta Gbind) of -59.43 on Site 3. The RMSD and RMSF were calculated for all the three drugs through molecular dynamics simulation studies for 50 ns. Zidovudine shows a very stable interaction with fluctuation starting at 2.4 angstrom on 2 ns and remained stable at 3 angstrom from 13 to 50 ns. Thus, paving the way for further biological validation as a potential treatment. Communicated by Ramaswamy H. Sarma
C1 [Yadav, Rohitash; Dhamija, Puneet; Handu, Shailendra] All India Inst Med Sci, Dept Pharmacol, Rishikesh, India.
   [Imran, Mohammed] Shaqra Univ, Coll Med, Dept Pharmacol, Shaqra, Saudi Arabia.
   [Suchal, Kapil] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
RP Yadav, R (corresponding author), All India Inst Med Sci, Dept Pharmacol, Rishikesh, India.
EM rohitashyadav1@gmail.com
OI Yadav, Rohitash/0000-0003-0859-5603; Dhamija, Puneet/0000-0002-2890-4939
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   BASIT A, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768150
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Butina D, 2002, DRUG DISCOV TODAY, V7, pS83, DOI 10.1016/S1359-6446(02)02288-2
   Chang CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065045
   Chen S., 2020, BIORXIV, DOI [10.1101/2020.03.06.977876., DOI 10.1101/2020.03.06.977876]
   CHEN T, 2020, BMJ BRIT MED J, V368, DOI DOI https://doi.org/10.1136/bmj.m1091
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   de Oliveira OV, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772885
   Dinesh DC, 2020, STRUCTURAL BASIS RNA, DOI [10.1101/2020.04.02.022194, DOI 10.1101/2020.04.02.022194]
   Du LY, 2008, VACCINE, V26, P1644, DOI 10.1016/j.vaccine.2008.01.025
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Eurosurveillance Editorial Team, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.5.200131e
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Lin SY, 2014, J MED CHEM, V57, P2247, DOI 10.1021/jm500089r
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Lo YS, 2013, FEBS LETT, V587, P120, DOI 10.1016/j.febslet.2012.11.016
   MAHANTA S, 2020, J BIOMOL STRUCT 0522, DOI DOI https://doi.org/10.1080/07391102.2020.1768902
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   MITTAL L, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768151
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Sato T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199348
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Surjit M, 2006, J BIOL CHEM, V281, P10669, DOI 10.1074/jbc.M509233200
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 41
TC 5
Z9 5
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1778536
EA JUN 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MI9BM
UT WOS:000547693600001
PM 32568013
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Brest, P
   Benzaquen, J
   Klionsky, DJ
   Hofman, P
   Mograbi, B
AF Brest, Patrick
   Benzaquen, Jonathan
   Klionsky, Daniel J.
   Hofman, Paul
   Mograbi, Baharia
TI Open questions for harnessing autophagy-modulating drugs in the
   SARS-CoV-2 war: hope or hype?
SO AUTOPHAGY
LA English
DT Article
DE Anti-viral; COVID-19; hydroxychloroquine; immunology; infection;
   inflammation; lysophagy; microbiology; plaquenil; virophagy
AB At a time when the world faces an emotional breakdown, crushing our dreams, if not, taking our lives, we realize that together we must fight the war against the COVID-19 outbreak even if almost the majority of the scientific community finds itself confined at home. Every day, we, scientists, listen to the latest news with its promises and announcements. Across the world, a surge of clinical trials trying to cure or slow down the coronavirus pandemic has been launched to bring hope instead of fear and despair. One first proposed clinical trial has drawn worldwide hype to the benefit of chloroquine (CQ), in the treatment of patients infected by the recently emerged deadly coronavirus (SARS-CoV-2). We should consider this information in light of the long-standing anti-inflammatory and anti-viral properties of CQ-related drugs. Yet, none of the articles promoting the use of CQ in the current pandemic evoked a possible molecular or cellular mechanism of action that could account for any efficacy. Here, given the interaction of viruses with macroautophagy (hereafter referred to as autophagy), a CQ-sensitive anti-viral safeguard pathway, we would like to discuss the pros, but also the cons concerning the current therapeutic options targeting this process.
C1 [Brest, Patrick; Benzaquen, Jonathan; Mograbi, Baharia] Univ Cote Azur, IRCAN, CNRS, INSERM,Ctr Antoine Lacassagne,FHU OncoAge, Nice, France.
   [Benzaquen, Jonathan] Univ Cote Azur, CHU Nice, Dept Pulm Med & Oncol, Nice, France.
   [Klionsky, Daniel J.] Univ Michigan, Life Sci Inst, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.
   [Hofman, Paul; Mograbi, Baharia] Univ Cote Azur, CHU Nice, Lab Clin & Expt Pathol LPCE, Nice, France.
RP Brest, P (corresponding author), Univ Cote Azur, Inst Res Canc, Nice IRCAN, Ctr Antoine Lacassagne,CNRS UMR7284,INSERM U1081, F-06189 Nice, France.
EM brest@univ-cotedazur.fr; mograbi@univ-cotedazur.fr
RI Mograbi, Baharia/Q-7953-2019; brest, patrick/B-7311-2012; Hofman,
   Paul/P-7654-2018
OI brest, patrick/0000-0002-1252-4747; Klionsky,
   Daniel/0000-0002-7828-8118; Hofman, Paul/0000-0003-0431-9353; Benzaquen,
   Jonathan/0000-0002-1899-9612; Mograbi, Baharia/0000-0002-1025-3429
FU French Government (Agence Nationale de Recherche, ANR) through the
   "Investments for the Future" LABEX SIGNALIFEFrench National Research
   Agency (ANR) [ANR-11-LABX-0028-01, R19162DD]; CANC'AIR Genexposomic
   project, Canceropole PACA; DREAL PACA, ARS PACA, Region Sud, INSERM;
   INCA Plan Cancer; Children Medical Safety Research Institute (CMSRI)
   [R17033DJA]; NIGMSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [GM131919]
FX French Government (Agence Nationale de Recherche, ANR) through the
   "Investments for the Future" LABEX SIGNALIFE [ANR-11-LABX-0028-01] and
   [AD-ME project R19162DD]; CANC'AIR Genexposomic project, Canceropole
   PACA; DREAL PACA, ARS PACA, Region Sud, INSERM; INCA Plan Cancer;
   Children Medical Safety Research Institute (CMSRI, Vaccinophagy project
   R17033DJA); NIGMS GM131919.
CR Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Boelaert JR, 2001, J CLIN VIROL, V20
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Brest P, 2011, NAT GENET, V43, P242, DOI 10.1038/ng.762
   Cao B, 2020, NEW ENGL J MED, V382
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Dong E., 2020, LANCET INFECT DIS, V20
   Gao J., 2020, BIOSCI TRENDS, V14
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, N ENGL J MED
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Kimmelman J, 2017, NATURE, V542, P25, DOI 10.1038/542025a
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu R, 2020, LANCET, V395
   Ma Y, 2013, IMMUNITY, V39
   Mahevas M, 2020, BMJ, V2019
   Meeran K, 1993, BR MED J, V307
   Nicola AM, 2011, MBIO, V2, DOI 10.1128/mBio.00167-11
   Richards AL, 2013, J VIROL, V87, P9966, DOI 10.1128/JVI.00460-13
   Sakai T, 2015, CANCER RES, V75
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 23
TC 2
Z9 2
U1 2
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD DEC 1
PY 2020
VL 16
IS 12
BP 2267
EP 2270
DI 10.1080/15548627.2020.1779531
EA JUN 2020
PG 4
WC Cell Biology
SC Cell Biology
GA PI0BT
UT WOS:000546618100001
PM 32521191
DA 2021-01-01
ER

PT J
AU Chen, JY
   Qiao, K
   Liu, F
   Wu, B
   Xu, X
   Jiao, GQ
   Lu, RG
   Li, HX
   Zhao, J
   Huang, J
   Yang, Y
   Lu, XJ
   Li, JS
   Jiang, SY
   Wang, DP
   Hu, CX
   Wang, GL
   Huang, DX
   Jiao, GH
   Wei, D
   Ye, SG
   Huang, JA
   Zhou, L
   Zhang, XQ
   He, JX
AF Chen, Jing-Yu
   Qiao, Kun
   Liu, Feng
   Wu, Bo
   Xu, Xin
   Jiao, Guo-Qing
   Lu, Rong-Guo
   Li, Hui-Xing
   Zhao, Jin
   Huang, Jian
   Yang, Yi
   Lu, Xiao-Jie
   Li, Jia-Shu
   Jiang, Shu-Yun
   Wang, Da-Peng
   Hu, Chun-Xiao
   Wang, Gui-Long
   Huang, Dong-Xiao
   Jiao, Guo-Hui
   Wei, Dong
   Ye, Shu-Gao
   Huang, Jian-An
   Zhou, Li
   Zhang, Xiao-Qin
   He, Jian-Xing
TI Lung transplantation as therapeutic option in acute respiratory distress
   syndrome for coronavirus disease 2019-related pulmonary fibrosis
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE Coronavirus disease 2019; Lung transplantation; Acute respiratory
   distress syndrome; Pulmonary fibrosis; Sequential Organ Failure
   Assessment score
AB Background Critical patients with the coronavirus disease 2019 (COVID-19), even those whose nucleic acid test results had turned negative and those receiving maximal medical support, have been noted to progress to irreversible fatal respiratory failure. Lung transplantation (LT) as the sole therapy for end-stage pulmonary fibrosis related to acute respiratory distress syndrome has been considered as the ultimate rescue therapy for these patients. Methods From February 10 to March 10, 2020, three male patients were urgently assessed and listed for transplantation. After conducting a full ethical review and after obtaining assent from the family of the patients, we performed three LT procedures for COVID-19 patients with illness durations of more than one month and extremely high sequential organ failure assessment scores. Results Two of the three recipients survived post-LT and started participating in a rehabilitation program. Pearls of the LT team collaboration and perioperative logistics were summarized and continually improved. The pathological results of the explanted lungs were concordant with the critical clinical manifestation, and provided insight towards better understanding of the disease. Government health affair systems, virology detection tools, and modern communication technology all play key roles towards the survival of the patients and their rehabilitation. Conclusions LT can be performed in end-stage patients with respiratory failure due to COVID-19-related pulmonary fibrosis. If confirmed positive-turned-negative virology status without organ dysfunction that could contraindicate LT, LT provided the final option for these patients to avoid certain death, with proper protection of transplant surgeons and medical staffs. By ensuring instant seamless care for both patients and medical teams, the goal of reducing the mortality rate and salvaging the lives of patients with COVID-19 can be attained.
C1 [Chen, Jing-Yu; Liu, Feng; Wu, Bo; Lu, Rong-Guo; Li, Hui-Xing; Zhao, Jin; Huang, Jian; Jiao, Guo-Hui; Wei, Dong; Ye, Shu-Gao; Zhou, Li; Zhang, Xiao-Qin] Nanjing Med Univ, Wuxi Peoples Hosp, Wuxi Lung Transplant Ctr, Wuxi 214023, Jiangsu, Peoples R China.
   [Qiao, Kun] Shenzhen Third Peoples Hosp, Dept Thorac Surg, Shenzhen 518100, Guangdong, Peoples R China.
   [Xu, Xin; He, Jian-Xing] Guangzhou Med Univ, Dept Thorac Surg Oncol, State Key Lab & Natl Clin Res Ctr Resp Dis, Affiliated Hosp 1, Guangzhou 510120, Guangdong, Peoples R China.
   [Jiao, Guo-Qing] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Cardiothorac Surg, Wuxi 214023, Jiangsu, Peoples R China.
   [Yang, Yi] Southeast Univ, Zhongda Hosp, Sch Med, Dept Crit Care Med, Nanjing 210009, Jiangsu, Peoples R China.
   [Lu, Xiao-Jie] Wuxi Fifth Hosp, Wuxi 214000, Jiangsu, Peoples R China.
   [Li, Jia-Shu] First Peoples Hosp Lianyungang City, Dept Resp Med & Crit Care Med, Lianyungang 222061, Jiangsu, Peoples R China.
   [Jiang, Shu-Yun; Wang, Da-Peng] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Crit Care Med, Wuxi 214023, Jiangsu, Peoples R China.
   [Hu, Chun-Xiao; Wang, Gui-Long; Huang, Dong-Xiao] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Anesthesiol, Wuxi 214023, Jiangsu, Peoples R China.
   [Huang, Jian-An] Soochow Univ, Affiliated Hosp 1, Dept Resp Med, Suzhou 215006, Jiangsu, Peoples R China.
RP Chen, JY (corresponding author), Nanjing Med Univ, Wuxi Peoples Hosp, Wuxi Lung Transplant Ctr, Wuxi 214023, Jiangsu, Peoples R China.
EM chenjy@wuxiph.com
OI chen, jingyu/0000-0002-0563-9749
FU Foundation for Special Projects of COVID-19 Prevention and Control in
   Wuxi City [SZSM201812058]
FX This study was supported by grants from the Chen Jingyu team of "Sanming
   Project of Medicine" in Shenzhen (No. SZSM201812058), and the Foundation
   for Special Projects of COVID-19 Prevention and Control in Wuxi City.
CR [Anonymous], 2020, CHINESE MED J-PEKING, V133, P1087, DOI 10.1097/CM9.0000000000000819
   Chang Y, 2018, TRANSPLANTATION, V102, P829, DOI 10.1097/TP.0000000000002004
   Chen JY, 2018, ORGAN TRANSPLANTATIO, V9, P325, DOI [10.3969/j.issn.1674-7445.2018.05.001, DOI 10.3969/J.ISSN.1674-7445.2018.05.001]
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang JF, 2017, HEPATOL SURG NUTR, V6, P212, DOI 10.21037/hbsn.2017.07.08
   Luo W, 2020, CLIN PATHOLOGY CRITI, DOI DOI 10.1016/S1473-3099(20)30086-4
   Salam S, 2017, ASAIO J, V63, pE66, DOI 10.1097/MAT.0000000000000450
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Q, 2019, ANN THORAC SURG, V108, pE233, DOI 10.1016/j.athoracsur.2019.02.035
   Wu B, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2019.10.26
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 13
TC 26
Z9 27
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366-6999
EI 2542-5641
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD JUN 20
PY 2020
VL 133
IS 12
BP 1390
EP 1396
DI 10.1097/CM9.0000000000000839
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA ME5UF
UT WOS:000544720000002
PM 32251003
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Doriguetto, PVT
   Americano, JP
   Devito, KL
AF Doriguetto, Paulo Victor Teixeira
   Americano, Julia Pereira
   Devito, Karina Lopes
TI Challenges for the dental radiology clinic in times of the COVID-19
   pandemic
SO ORAL RADIOLOGY
LA English
DT Letter
DE COVID-19; Coronavirus; Dental radiology
AB This letter addresses the challenges for the dental radiology clinic in times of the COVID-19 pandemic. It highlights the use of teleradiography and mobile devices, as well as the proper care in disinfecting these equipments. As there are still no specific therapies for COVID-19, biosafety measures that promote containment and prevent the spread of the virus are crucial to stop the outbreak and control a possible new infectious peak.
C1 [Doriguetto, Paulo Victor Teixeira; Americano, Julia Pereira] Univ Fed Juiz de Fora, Sch Dent, Masters Program Dent, Juiz De Fora, MG, Brazil.
   [Devito, Karina Lopes] Univ Fed Juiz de Fora, Sch Dent, Dept Dent Clin, Campus Univ S-N, BR-36036900 Juiz De Fora, MG, Brazil.
RP Devito, KL (corresponding author), Univ Fed Juiz de Fora, Sch Dent, Dept Dent Clin, Campus Univ S-N, BR-36036900 Juiz De Fora, MG, Brazil.
EM karina.devito@ufjf.edu.br
RI Devito, Karina/P-6030-2014
OI Devito, Karina/0000-0001-5037-5466
CR Pontual MLA, 2020, DENTOMAXILLOFAC RAD, V49, DOI 10.1259/dmfr.20200178
   Ather A, 2020, J ENDODONT, V46, P584, DOI 10.1016/j.joen.2020.03.008
   Bhardwaj N, 2020, ENVIRON RES, V186, DOI 10.1016/j.envres.2020.109569
   Brady A, 2019, INSIGHTS IMAGING, V10, DOI 10.1186/s13244-019-0721-y
   Brady RRW, 2012, TELEMED E-HEALTH, V18, P289, DOI 10.1089/tmj.2011.0147
   Estai M, 2017, TELEMED E-HEALTH, V23, P435, DOI 10.1089/tmj.2016.0122
   Giacomini GO, 2019, CLIN ORAL INVEST, V23, P1993, DOI 10.1007/s00784-019-02848-6
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kotris Ivan, 2017, Med Glas (Zenica), V14, P85, DOI 10.17392/878-16
   Meng L, 2020, J DENT RES, V99, P481, DOI 10.1177/0022034520914246
   Neri E, 2018, INSIGHTS IMAGING, V9, P247, DOI 10.1007/s13244-017-0589-7
   Saki M, 2020, ACAD RADIOL, V27, P1047, DOI 10.1016/j.acra.2020.04.040
   Sarode SC, 2017, J ORAL PATHOL MED, V46, P327, DOI 10.1111/jop.12500
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Vasconcelos TV, 2016, INT ENDOD J, V49, P386, DOI 10.1111/iej.12466
NR 15
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0911-6028
EI 1613-9674
J9 ORAL RADIOL
JI Oral Radiol.
PD OCT
PY 2020
VL 36
IS 4
BP 404
EP 405
DI 10.1007/s11282-020-00456-9
EA JUN 2020
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA NN5NW
UT WOS:000542728400002
PM 32564186
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cascarina, SM
   Ross, ED
AF Cascarina, Sean M.
   Ross, Eric D.
TI A proposed role for the SARS-CoV-2 nucleocapsid protein in the formation
   and regulation of biomolecular condensates
SO FASEB JOURNAL
LA English
DT Article
DE enveloped viruses; liquid-liquid phase separation; low-complexity
   domain; stress granule; viral capsid
ID LIQUID-PHASE-SEPARATION; HOST GENE-EXPRESSION; SARS-CORONAVIRUS; STRESS
   GRANULES; VIRUS-REPLICATION; INNATE IMMUNITY; NSP1; INTERFERON;
   INHIBITOR; PATHWAY
AB To date, the recently discovered SARS-CoV-2 virus has afflicted >6.9 million people worldwide and disrupted the global economy. Development of effective vaccines or treatments for SARS-CoV-2 infection will be aided by a molecular-level understanding of SARS-CoV-2 proteins and their interactions with host cell proteins. The SARS-CoV-2 nucleocapsid (N) protein is highly homologous to the N protein of SARS-CoV, which is essential for viral RNA replication and packaging into new virions. Emerging models indicate that nucleocapsid proteins of other viruses can form biomolecular condensates to spatiotemporally regulate N protein localization and function. Our bioinformatic analyses, in combination with pre-existing experimental evidence, suggest that the SARS-CoV-2 N protein is capable of forming or regulating biomolecular condensates in vivo by interaction with RNA and key host cell proteins. We discuss multiple models, whereby the N protein of SARS-CoV-2 may harness this activity to regulate viral life cycle and host cell response to viral infection.
C1 [Cascarina, Sean M.; Ross, Eric D.] Colorado State Univ, Dept Biochem & Mol Biol, 1870 Campus Delivery, Ft Collins, CO 80523 USA.
RP Ross, ED (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, 1870 Campus Delivery, Ft Collins, CO 80523 USA.
EM Eric.Ross@colostate.edu
OI Cascarina, Sean/0000-0002-3054-2332
FU HHS \ NIH \ National Institute of General Medical Sciences (NIGMS)
   [R35GM130352]
FX HHS vertical bar NIH vertical bar National Institute of General Medical
   Sciences (NIGMS), Grant/Award Number: R35GM130352
CR Alberti S, 2019, ANNU REV GENET, V53, P171, DOI 10.1146/annurev-genet-112618-043527
   Alenquer M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09549-4
   Anderson P, 2008, TRENDS BIOCHEM SCI, V33, P141, DOI 10.1016/j.tibs.2007.12.003
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bolognesi B, 2016, CELL REP, V16, P222, DOI 10.1016/j.celrep.2016.05.076
   Brocard M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008250
   Burke JM, 2020, J BIOL CHEM, V295, P1426, DOI 10.1074/jbc.RA119.011638
   Cascarina SM, 2020, PLOS COMPUT BIOL, V16, DOI [10.1371/journal.pcbi.1007487, 10.1371/journal.pcbi.1007487.r001, 10.1371/journal.pcbi.1007487.r002, 10.1371/journal.pcbi.1007487.r003, 10.1371/journal.pcbi.1007487.r004]
   Cascarina SM, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006256
   Case LB, 2019, SCIENCE, V363, P1093, DOI 10.1126/science.aau6313
   Chan CP, 2006, J VIROL, V80, P9279, DOI 10.1128/JVI.00659-06
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chang CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061196
   Chen CY, 2007, J MOL BIOL, V368, P1075, DOI 10.1016/j.jmb.2007.02.069
   Cid-Samper F, 2018, CELL REP, V25, P3422, DOI 10.1016/j.celrep.2018.11.076
   Cui L, 2015, J VIROL, V89, P9029, DOI 10.1128/JVI.01331-15
   Dang YJ, 2006, J BIOL CHEM, V281, P32870, DOI 10.1074/jbc.M606149200
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   FIOL CJ, 1987, J BIOL CHEM, V262, P14042
   Fukuhara T, 2006, P NATL ACAD SCI USA, V103, P11329, DOI 10.1073/pnas.0604616103
   Gaete-Argel A, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00336
   Goldstein SA, 2017, J VIROL, V91, DOI 10.1128/JVI.02201-16
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Guillen-Boixet J, 2020, CELL, V181, P346, DOI 10.1016/j.cell.2020.03.049
   Guseva S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz7095
   Hackbart M, 2020, P NATL ACAD SCI USA, V117, P8094, DOI 10.1073/pnas.1921485117
   Hatcher JM, 2018, CELL CHEM BIOL, V25, P460, DOI 10.1016/j.chembiol.2018.01.013
   Heger-Stevic J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007488
   Heinrich BS, 2018, MBIO, V9, DOI 10.1128/mBio.02290-17
   Hernandez-Vega A, 2017, CELL REP, V20, P2304, DOI 10.1016/j.celrep.2017.08.042
   Hosmillo M, 2019, ELIFE, V8, DOI 10.7554/eLife.46681
   Hou SM, 2017, J VIROL, V91, DOI 10.1128/JVI.00474-17
   Hu Y, 2017, J VIROL, V91, DOI 10.1128/JVI.02143-16
   Huang C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002433
   Hur S, 2019, ANNU REV IMMUNOL, V37, P349, DOI 10.1146/annurev-immunol-042718-041356
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Karakama Y, 2010, ANTIMICROB AGENTS CH, V54, P3179, DOI 10.1128/AAC.00113-10
   Khaperskyy DA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004217
   Kim HJ, 2013, NATURE, V495, P467, DOI 10.1038/nature11922
   Kim SSY, 2019, J BIOL CHEM, V294, P6430, DOI 10.1074/jbc.RA118.005868
   Krahling V, 2009, J VIROL, V83, P2298, DOI 10.1128/JVI.01245-08
   Law LMJ, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007798
   Li D, 2020, APPL COMPOS MATER, V27, P1, DOI 10.1007/s10443-019-09791-5
   Liu GQ, 2019, J VIROL, V93, DOI 10.1128/JVI.02299-18
   Lokugamage KG, 2012, J VIROL, V86, P13598, DOI 10.1128/JVI.01958-12
   Luo HB, 2005, FEBS LETT, V579, P2623, DOI 10.1016/j.febslet.2005.03.080
   Manivannan P, 2020, J VIROL, V94, DOI 10.1128/JVI.00205-20
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   McSwiggen DT, 2019, ELIFE, V8, DOI 10.7554/eLife.47098
   Monette A, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.084
   Mu JF, 2020, SCI CHINA LIFE SCI, DOI 10.1007/s11427-020-1692-1
   Nakagawa K, 2018, J VIROL, V92, DOI 10.1128/JVI.00902-18
   Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07
   Neuman BW, 2006, J VIROL, V80, P7918, DOI 10.1128/JVI.00645-06
   Ng CS, 2013, J VIROL, V87, P9511, DOI 10.1128/JVI.03248-12
   Nikolic J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00102-9
   Oh SW, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005444
   Onomoto K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043031
   Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195
   Peng TY, 2008, FEBS J, V275, P4152, DOI 10.1111/j.1742-4658.2008.06564.x
   Piotrowska J, 2010, J VIROL, V84, P3654, DOI 10.1128/JVI.01320-09
   Prescott EL, 2014, J VIROL, V88, P12599, DOI 10.1128/JVI.02029-14
   Raaben M, 2007, CELL MICROBIOL, V9, P2218, DOI 10.1111/j.1462-5822.2007.00951.x
   Rabouw HH, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005982
   Reineke LC, 2015, MBIO, V6, DOI 10.1128/mBio.02486-14
   Reineke LC, 2015, J VIROL, V89, P2575, DOI 10.1128/JVI.02791-14
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Rozelle DK, 2014, MOL CELL BIOL, V34, P2003, DOI 10.1128/MCB.01630-13
   Sanders DW, 2020, CELL, V181, P306, DOI 10.1016/j.cell.2020.03.050
   Scholte FEM, 2015, J VIROL, V89, P4457, DOI 10.1128/JVI.03612-14
   Shattuck JE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11550-w
   Shi CS, 2014, J IMMUNOL, V193, P3080, DOI 10.4049/jimmunol.1303196
   Simpson-Holley M, 2011, J VIROL, V85, P1581, DOI 10.1128/JVI.02247-10
   Slaine PD, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120388
   Sola I, 2011, J VIROL, V85, P5136, DOI 10.1128/JVI.00195-11
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   Takamatsu Y, 2020, MBIO, V11, DOI 10.1128/mBio.02565-19
   Tauber D, 2020, CELL, V180, P411, DOI 10.1016/j.cell.2019.12.031
   Vernon RM, 2018, ELIFE, V7, DOI 10.7554/eLife.31486
   Wang J, 2018, CELL, V174, P688, DOI 10.1016/j.cell.2018.06.006
   Wathelet MG, 2007, J VIROL, V81, P11620, DOI 10.1128/JVI.00702-07
   Weirich KL, 2017, P NATL ACAD SCI USA, V114, P2131, DOI 10.1073/pnas.1616133114
   Wong HH, 2018, VIROLOGY, V515, P165, DOI 10.1016/j.virol.2017.12.028
   Wu CH, 2009, J BIOL CHEM, V284, P5229, DOI 10.1074/jbc.M805747200
   Yang PG, 2020, CELL, V181, P325, DOI 10.1016/j.cell.2020.03.046
   Yoo JS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004012
   Zhao L, 2012, CELL HOST MICROBE, V11, P607, DOI 10.1016/j.chom.2012.04.011
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 92
TC 7
Z9 7
U1 5
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2020
VL 34
IS 8
BP 9832
EP 9842
DI 10.1096/fj.202001351
EA JUN 2020
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA NE3EW
UT WOS:000541814300001
PM 32562316
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Devogelaere, J
   D'hooghe, MB
   Vanderhauwaert, F
   D'haeseleer, M
AF Devogelaere, Jens
   D'hooghe, Marie B.
   Vanderhauwaert, Famke
   D'haeseleer, Miguel
TI Coronavirus disease 2019: favorable outcome in an immunosuppressed
   patient with multiple sclerosis
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; Immunosuppression; Multiple Sclerosis; Rituximab
ID COVID-19
AB The rapid and global spread of severe acute respiratory syndrome coronavirus 2, a viral pathogen responsible for the development of the "coronavirus disease of 2019" (COVID-19), has developed into an unprecedented health crisis with considerable case fatality rate. Patients with comorbidities are considered to be at higher risk for severe disease with acute respiratory failure, intensive care unit admission, and/or death. Particular vigilance has been warranted regarding the continuation of immunosuppressive treatments since viral clearing may be hampered in such cases. In contrast, it has also been hypothesized that overactive immune responses may trigger a cytokine storm associated with clinical deterioration, which has generated an interest in certain immunosuppressant drugs as potential treatment for COVID-19. We would like to present the first case report of a patient who was formally diagnosed with COVID-19 while being under disease-modifying treatment with rituximab, an anti-CD20 B cell depleting agent, for multiple sclerosis. The clinical picture was mild for which we have tried to provide an immunopathological framework.
C1 [Devogelaere, Jens; D'hooghe, Marie B.; Vanderhauwaert, Famke; D'haeseleer, Miguel] Nationaal Multiple Sclerose Ctr, Dept Neurol, Vanheylenstr 16, B-1820 Melsbroek, Belgium.
   [Devogelaere, Jens; D'hooghe, Marie B.; D'haeseleer, Miguel] Vrije Univ Brussel, Dept Neurol, B-1090 Brussels, Belgium.
   [Devogelaere, Jens; D'hooghe, Marie B.; D'haeseleer, Miguel] Vrije Univ Brussel, Ctr Neurosci, B-1090 Brussels, Belgium.
RP Devogelaere, J (corresponding author), Nationaal Multiple Sclerose Ctr, Dept Neurol, Vanheylenstr 16, B-1820 Melsbroek, Belgium.; Devogelaere, J (corresponding author), Vrije Univ Brussel, Dept Neurol, B-1090 Brussels, Belgium.; Devogelaere, J (corresponding author), Vrije Univ Brussel, Ctr Neurosci, B-1090 Brussels, Belgium.
EM Jens.killian.devogelaere@vub.be; marie.dhooghe@mscenter.be;
   famke.vanderhauwaert@mscenter.be; miguel.haeseleer@mscenter.be
OI Devogelaere, Jens/0000-0002-9410-581X; D'hooghe,
   Marie/0000-0002-0917-4176
CR Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Ineichen BV, 2020, MULT SCLER J, V26, P137, DOI 10.1177/1352458519858604
   KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Maloir Q, 2018, Rev Med Liege, V73, P370
   Novi G, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102120
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
NR 9
TC 2
Z9 2
U1 2
U2 2
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
PD AUG
PY 2020
VL 41
IS 8
BP 1981
EP 1983
DI 10.1007/s10072-020-04522-2
EA JUN 2020
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MN9HP
UT WOS:000541387600003
PM 32564270
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Graboyes, E
   Cramer, J
   Balakrishnan, K
   Cognetti, DM
   Lopez-Cevallos, D
   de Almeida, JR
   Megwalu, UC
   Moore, CE
   Nathan, CA
   Spector, ME
   Lewis, CM
   Brenner, MJ
AF Graboyes, Evan
   Cramer, John
   Balakrishnan, Karthik
   Cognetti, David M.
   Lopez-Cevallos, Daniel
   de Almeida, John R.
   Megwalu, Uchechukwu C.
   Moore, Charles E.
   Nathan, Cherie-Ann
   Spector, Matthew E.
   Lewis, Carol M.
   Brenner, Michael J.
TI COVID-19 pandemic and health care disparities in head and neck cancer:
   Scanning the horizon
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
   NECK
LA English
DT Article
DE COVID-19; head and neck cancer; health care delivery; racial and ethnic
   disparities; social determinants of health
ID AFRICAN-AMERICAN; SURVIVAL; OUTCOMES; IMPACT; TIME; RACE
AB The COVID-19 pandemic has profoundly disrupted head and neck cancer (HNC) care delivery in ways that will likely persist long term. As we scan the horizon, this crisis has the potential to amplify preexisting racial/ethnic disparities for patients with HNC. Potential drivers of disparate HNC survival resulting from the pandemic include (a) differential access to telemedicine, timely diagnosis, and treatment; (b) implicit bias in initiatives to triage, prioritize, and schedule HNC-directed therapy; and (c) the marked changes in employment, health insurance, and dependent care. We present four strategies to mitigate these disparities: (a) collect detailed data on access to care by race/ethnicity, income, education, and community; (b) raise awareness of HNC disparities; (c) engage stakeholders in developing culturally appropriate solutions; and (d) ensure that surgical prioritization protocols minimize risk of racial/ethnic bias. Collectively, these measures address social determinants of health and the moral imperative to provide equitable, high-quality HNC care.
C1 [Graboyes, Evan] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
   [Cramer, John] Wayne State Univ, Dept Otolaryngol Head & Neck Surg, Detroit, MI USA.
   [Balakrishnan, Karthik; Megwalu, Uchechukwu C.] Stanford Univ, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA.
   [Cognetti, David M.] Thomas Jefferson Univ, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19107 USA.
   [Lopez-Cevallos, Daniel] Oregon State Univ, Sch Language Culture & Soc, Corvallis, OR 97331 USA.
   [de Almeida, John R.] Univ Toronto, Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON, Canada.
   [Moore, Charles E.] Emory Univ, Dept Otolaryngol Head & Neck Surg, Atlanta, GA 30322 USA.
   [Nathan, Cherie-Ann] Louisiana State Univ, Hlth Sci Ctr, Dept Otolaryngol Head & Neck Surg, Shreveport, LA 71105 USA.
   [Spector, Matthew E.; Brenner, Michael J.] Univ Michigan, Dept Otolaryngol Head & Neck Surg, 1500 East Med Ctr Dr,SPC 5312,1904 Taubman Ctr, Ann Arbor, MI 48109 USA.
   [Lewis, Carol M.] Univ Texas MD Anderson Canc Ctr, Head & Neck Surg, Houston, TX 77030 USA.
RP Brenner, MJ (corresponding author), Univ Michigan, Dept Otolaryngol Head & Neck Surg, 1500 East Med Ctr Dr,SPC 5312,1904 Taubman Ctr, Ann Arbor, MI 48109 USA.
EM mbren@med.umich.edu
OI Cognetti, David/0000-0001-7039-3055; Graboyes, Evan/0000-0003-3766-468X
FU Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF)
   [DDCF2015209]; National Cancer InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [K08CA237858]
FX Doris Duke Charitable Foundation, Grant/Award Number: DDCF2015209;
   National Cancer Institute, Grant/Award Number: K08CA237858
CR Abel EA, 2018, J MED INTERNET RES, V20, DOI 10.2196/11350
   Balakrishnan K, 2019, OTOLARYNG CLIN N AM, V52, P35, DOI 10.1016/j.otc.2018.08.016
   Cannon RB, 2018, JAMA OTOLARYNGOL, V144, P1052, DOI 10.1001/jamaoto.2018.1792
   Manchanda EC, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2011359
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Figueroa JF, 2020, JAMA-J AM MED ASSOC, V323, P1553, DOI 10.1001/jama.2020.2436
   Goodwin WJ, 2008, HEAD NECK-J SCI SPEC, V30, P358, DOI 10.1002/hed.20710
   Gourin CG, 2006, LARYNGOSCOPE, V116, P1093, DOI 10.1097/01.mlg.0000224939.61503.83
   Graboyes EM, 2019, JAMA OTOLARYNGOL, V145, P166, DOI 10.1001/jamaoto.2018.2716
   Graboyes EM, 2017, CANCER-AM CANCER SOC, V123, P4841, DOI 10.1002/cncr.30939
   Guttmann DM, 2018, HEAD NECK-J SCI SPEC, V40, P1147, DOI 10.1002/hed.25091
   Ho AS, 2018, CANCER-AM CANCER SOC, V124, P3154, DOI 10.1002/cncr.31533
   Jan T, 2020, WASHINGTON POST
   Kasle DA, 2020, OTOLARYNG HEAD NECK, V163, P138, DOI 10.1177/0194599820928987
   Khariwala SS, 2020, JAMA OTOLARYNGOL, V146, P605, DOI 10.1001/jamaoto.2020.1188
   Liao DZ, 2019, JAMA OTOLARYNGOL, V145, P1001, DOI 10.1001/jamaoto.2019.2414
   Mahal BA, 2014, ORAL ONCOL, V50, P1177, DOI 10.1016/j.oraloncology.2014.09.004
   Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)74234-3
   Megwalu UC, 2016, OTOLARYNG HEAD NECK, V155, P969, DOI 10.1177/0194599816664331
   Metzl JM, 2014, SOC SCI MED, V103, P126, DOI 10.1016/j.socscimed.2013.06.032
   Miller DP, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.4953
   Molina MA, 2008, CANCER, V113, P2797, DOI 10.1002/cncr.23889
   Naghavi AO, 2016, CANCER EPIDEMIOL, V45, P18, DOI 10.1016/j.canep.2016.09.005
   Naghavi AO, 2016, CANCER-AM CANCER SOC, V122, P3529, DOI 10.1002/cncr.30212
   Owen WF, 2020, JAMA-J AM MED ASSOC, V323, P1905, DOI 10.1001/jama.2020.6547
   Prachand VN, 2020, J AM COLL SURGEONS, V231, P281, DOI 10.1016/j.jamcollsurg.2020.04.011
   Prasad A, 2020, HEAD NECK-J SCI SPEC, V42, P1308, DOI 10.1002/hed.26174
   Pronovost PJ, 2010, HEALTH SERV RES, V45, P1508, DOI 10.1111/j.1475-6773.2010.01144.x
   Sineshaw HM, 2020, JAMA OTOLARYNGOL, V146, P247, DOI 10.1001/jamaoto.2019.4310
   Smedley BD, 2003, UNEQUAL TREATMENT CO
   Tartak J. C., 2020, US MUST AVOID BUILDI
   Wadhera RK, 2020, JAMA-J AM MED ASSOC, V323, P2192, DOI 10.1001/jama.2020.7197
   Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598
   Williams DR, 2020, JAMA-J AM MED ASSOC, V323, P2478, DOI 10.1001/jama.2020.8051
   World Health Organization, 2020, CLIN MAN COVID 19 IN
   Wu V, 2020, HEAD NECK-J SCI SPEC, V42, P1202, DOI 10.1002/hed.26205
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
NR 37
TC 2
Z9 2
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
EI 1097-0347
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD JUL
PY 2020
VL 42
IS 7
SI SI
BP 1555
EP 1559
DI 10.1002/hed.26345
EA JUN 2020
PG 5
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA MF8CB
UT WOS:000541238700001
PM 32562325
OA Green Published, Bronze, Green Accepted
DA 2021-01-01
ER

PT J
AU De Cauwer, H
AF De Cauwer, Harald
TI The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell
   types: implications for ACE-inhibitor- and angiotensin II receptor
   blocker-based cardiovascular therapies: comment
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Letter
C1 [De Cauwer, Harald] Dimpna Reg Hosp, Dept Neurol, JB Stessenstr 2, B-2440 Geel, Belgium.
   [De Cauwer, Harald] Univ Antwerp, Fac Med & Hlth Sci, Antwerp, Belgium.
RP De Cauwer, H (corresponding author), Dimpna Reg Hosp, Dept Neurol, JB Stessenstr 2, B-2440 Geel, Belgium.; De Cauwer, H (corresponding author), Univ Antwerp, Fac Med & Hlth Sci, Antwerp, Belgium.
EM harald.decauwer@ziekenhuisgeel.be
CR Albini A, 2020, INTERN EMERG MED, V15, P759, DOI 10.1007/s11739-020-02364-6
   De Cauwer H, 2020, ACTA NEUROL BELG, DOI 10.1007/s13760-020-01373-8
   Gardiner K, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-2-reviews0002
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Stopsack KH, 2020, CANCER DISCOV, V10, P779, DOI 10.1158/2159-8290.CD-20-0451
NR 5
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
PD NOV
PY 2020
VL 15
IS 8
SI SI
BP 1581
EP 1582
DI 10.1007/s11739-020-02406-z
EA JUN 2020
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA OM3BZ
UT WOS:000541390800001
PM 32564289
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Basiri, A
   Pazhouhnia, Z
   Beheshtizadeh, N
   Hoseinpour, M
   Saghazadeh, A
   Rezaei, N
AF Basiri, Arefeh
   Pazhouhnia, Zahra
   Beheshtizadeh, Nima
   Hoseinpour, Mahdieh
   Saghazadeh, Amene
   Rezaei, Nima
TI Regenerative Medicine in COVID-19 Treatment: Real Opportunities and
   Range of Promises
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article; Early Access
DE COVID-19; Coronavirus; Regenerative medicine; Cell therapy;
   Immunotherapy; Natural killer cells; Mesenchymal stem cells
ID MESENCHYMAL STEM-CELLS; TOLL-LIKE RECEPTORS; SARS-COV; THERAPY;
   IMMUNOTHERAPY; CORONAVIRUSES; EXOSOMES; SERUM
AB Novel coronavirus disease (COVID-19) has attracted much attention around the world due to its rapid transmission among humans and relatively high mortality rate. Studies are increasing to find the best therapeutic approach for the disease and its management. Regenerative medicine offers various cell-tissue therapeutics and related products, such as stem cell therapy, natural killer (NK) cell therapy, Chimeric antigen receptor (CAR) T cell therapy, exosomes, and tissue products. Interestingly, mesenchymal stem cells (MSCs) can reduce inflammatory symptoms and protect against cytokine storm, which critically contributes to the COVID-19 progression. Notably, having the potentials to exert cytotoxic effects on infected cells and induce interferon production probably make NK cells a candidate for COVID-19 cell therapy. Besides, exosomes are one of the crucial products of cells that can exert therapeutic effects through the induction of immune responses and neutralizing antibody titers. The paper aims to briefly consider current options for COVID-19 therapy to show that there is no specific cure for COVID-19, and then assess the real opportunities and range of promises regenerative medicine can provide for specific treatment of COVID-19.
C1 [Basiri, Arefeh] Isfahan Univ Med Sci, Sch Adv Technol Med, Dept Biomat & Tissue Engn, Esfahan, Iran.
   [Basiri, Arefeh; Pazhouhnia, Zahra; Beheshtizadeh, Nima; Hoseinpour, Mahdieh; Saghazadeh, Amene] Univ Sci Educ & Res Network USERN, Systemat Review & Metaanal Expert Grp SRMEG, Tehran, Iran.
   [Pazhouhnia, Zahra; Beheshtizadeh, Nima; Hoseinpour, Mahdieh] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Tehran, Iran.
   [Pazhouhnia, Zahra; Hoseinpour, Mahdieh] ACECR, Royan Inst Stem Cell Biol & Technol, Dept Stem Cells & Dev Biol, Cell Sci Res Ctr, Tehran, Iran.
   [Saghazadeh, Amene; Rezaei, Nima] Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Childrens Med Ctr, Tehran, Iran.
   [Rezaei, Nima] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran.
   [Rezaei, Nima] Univ Sci Educ & Res Network USERN, Network Immun Infect Malignancy & Autoimmun NIIMA, Tehran, Iran.
RP Rezaei, N (corresponding author), Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Childrens Med Ctr, Tehran, Iran.; Rezaei, N (corresponding author), Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran.; Rezaei, N (corresponding author), Univ Sci Educ & Res Network USERN, Network Immun Infect Malignancy & Autoimmun NIIMA, Tehran, Iran.
EM rezaei_nima@tums.ac.ir
RI Rezaei, Nima/B-4245-2008
OI Rezaei, Nima/0000-0002-3836-1827; Basiri, Arefeh/0000-0002-2086-5912
CR Aghaeepour N, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan2946
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Akbari A, 2020, LIFE SCI, V249, DOI 10.1016/j.lfs.2020.117447
   Bari E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040924
   Beigel JH, 2018, LANCET INFECT DIS, V18, P410, DOI 10.1016/S1473-3099(18)30002-1
   Ben-Mordechai T, 2015, J CARDIOVASC PHARM T, V20, P36, DOI 10.1177/1074248414534916
   Biancone L, 2012, NEPHROL DIAL TRANSPL, V27, P3037, DOI 10.1093/ndt/gfs168
   Boda B, 2018, ANTIVIR RES, V156, P72, DOI 10.1016/j.antiviral.2018.06.007
   Burrello J, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00083
   Cardenes N, 2019, BMJ OPEN RESPIR RES, V6, DOI 10.1136/bmjresp-2018-000308
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen J., 2020, ENGINEERING
   Chen TS, 2010, NUCLEIC ACIDS RES, V38, P215, DOI 10.1093/nar/gkp857
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Cruz FF, 2015, STEM CELL TRANSL MED, V4, P1302, DOI 10.5966/sctm.2014-0280
   de Mendonca L, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0669-0
   Dillman RO, 2011, CANCER BIOTHER RADIO, V26, P1, DOI 10.1089/cbr.2010.0902
   Ebert AD, 2010, NAT REV DRUG DISCOV, V9, P1, DOI 10.1038/nrd3000
   Fathi N, 2020, CELL BIOL INT, V44, P1792, DOI 10.1002/cbin.11403
   Fehniger TA, 2016, TRENDS IMMUNOL, V37, P877, DOI 10.1016/j.it.2016.09.005
   Fong KY, 2002, ANN ACAD MED SINGAP, V31, P702
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Ge F, 2007, VIROLOGY, V360, P150, DOI 10.1016/j.virol.2006.10.016
   Gebler A, 2012, TRENDS MOL MED, V18, P128, DOI 10.1016/j.molmed.2011.10.004
   Geiger S, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0044-2017
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Greening DW, 2015, SEMIN CELL DEV BIOL, V40, P72, DOI 10.1016/j.semcdb.2015.02.009
   Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Jahanshahlu L, 2020, ARCH MED RES
   Jamali S, 2020, AUSTRALAS PLANT DIS, V15, DOI 10.1007/s13314-020-00388-7
   Jiang XJ, 2020, J MED VIROL, V92, P1807, DOI 10.1002/jmv.25941
   Karim MY, 2009, RHEUMATOLOGY, V48, P332, DOI 10.1093/rheumatology/ken476
   Khatri M, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0774-8
   Kilianski A, 2014, ANTIVIR RES, V101, P105, DOI 10.1016/j.antiviral.2013.11.004
   Kode JA, 2009, CYTOTHERAPY, V11, P377, DOI 10.1080/14653240903080367
   Kuate S, 2007, VIROLOGY, V362, P26, DOI 10.1016/j.virol.2006.12.011
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lai Ruenn Chai, 2012, Int J Proteomics, V2012, P971907, DOI 10.1155/2012/971907
   Lai ST, 2005, EUR J CLIN MICROBIOL, V24, P583, DOI 10.1007/s10096-005-0004-z
   Lee JW, 2011, STEM CELLS, V29, P913, DOI 10.1002/stem.643
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li XB, 2006, J CELL MOL MED, V10, P364, DOI 10.1111/j.1582-4934.2006.tb00405.x
   Lukomska B, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9628536
   Matthay MA, 2010, CHEST, V138, P965, DOI 10.1378/chest.10-0518
   McGuire LW, 1918, AM J PUBLIC HEALTH, V8, P741, DOI 10.2105/AJPH.8.10.741
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   Mohamed K, 2020, INFECT CONT HOSP EP, V41, P1245, DOI 10.1017/ice.2020.162
   Mok MY, 2016, EXPERT OPIN BIOL TH, V16, P927, DOI 10.1517/14712598.2016.1171840
   Momtazmanesh S., 2020, AM J TROP MED HYG
   Moradian N, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02364-2
   Naran K, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03158
   Nasab M.G., 2020, ARCH MED RES
   O'Sullivan TE, 2015, IMMUNITY, V43, P634, DOI 10.1016/j.immuni.2015.09.013
   Pevsner-Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood-2006-06-028704
   Porotto M, 2019, MBIO, V10, DOI 10.1128/mBio.00723-19
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ribeiro A, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt336
   Saghazadeh A, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106560
   Saghazadeh A, 2020, EXPERT REV CLIN IMMU, V16, P465, DOI 10.1080/1744666X.2020.1750954
   Saghazadeh A, 2017, EXPERT OPIN THER TAR, V21, P415, DOI 10.1080/14728222.2017.1299128
   Saleki K., 2020, REV NEUROSCIENCES, P1
   Schuster Manfred, 2006, Biotechnology Journal, V1, P138, DOI 10.1002/biot.200500044
   Services T., 2014, INT GUID NAT HLTH AU, P1
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Shetty AK, 2020, AGING DIS, V11, P462, DOI 10.14336/AD.2020.0301
   Smyth MJ, 2002, NAT REV CANCER, V2, P850, DOI 10.1038/nrc928
   Soleymaninejadian E, 2012, AM J REPROD IMMUNOL, V67, P1, DOI 10.1111/j.1600-0897.2011.01069.x
   Squillaro T, 2016, CELL TRANSPLANT, V25, P829, DOI 10.3727/096368915X689622
   Sundarakrishnan A, 2018, ADV DRUG DELIVER REV, V129, P78, DOI 10.1016/j.addr.2017.12.013
   Tomchuck SL, 2008, STEM CELLS, V26, P99, DOI 10.1634/stemcells.2007-0563
   Uccelli A, 2007, TRENDS IMMUNOL, V28, P219, DOI 10.1016/j.it.2007.03.001
   Uccelli A, 2015, ANN NY ACAD SCI, V1351, P114, DOI 10.1111/nyas.12815
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687
   Wang YD, 2004, CLIN IMMUNOL, V113, P145, DOI 10.1016/j.clim.2004.07.003
   Wang YM, 2020, J INFECT DIS, V221, P1688, DOI 10.1093/infdis/jiz656
   Wilkinson DC, 2017, STEM CELL TRANSL MED, V6, P622, DOI 10.5966/sctm.2016-0192
   Wilkinson DC, 2018, CURR PROTOC STEM CEL, V46, pe56
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yoon SR, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.114
   Yu B, 2014, INT J MOL SCI, V15, P4142, DOI 10.3390/ijms15034142
   Zhang LY, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.108748
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 87
TC 4
Z9 4
U1 6
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
DI 10.1007/s12015-020-09994-5
EA JUN 2020
PG 13
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA LZ7JN
UT WOS:000541399100001
PM 32564256
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Monajemi, H
   Zain, SM
AF Monajemi, Hadieh
   Zain, Sharifuddin M.
TI Strong inhibition of M-Protease activity of Coronavirus by using PX-12
   inhibitor based on ab initio ONIOM calculations
SO JOURNAL OF CHEMICAL RESEARCH
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV2; density functional theory; ONIOM; QM; MM; in silico
   drug design
AB In this study, the interaction of seven potential inhibitors in complex with SARS-CoV-2's M protease (M-pro) is modelled and optimized using ONIOM (Own N-layered Integrated molecular Orbital and molecular Mechanics; QM/MM) approach. Density functional theory is used for the small system and Universal Force Field is used for the rest of the molecule with ONIOM (m062x/6-311++G (d,p):UFF) model chemistry. The seven inhibitors that are used in this study are N3, ebselen, disulfiram, tideglusib, carmofur, shikonin and PX-12. The calculated interaction energy between the inhibitor and M(pro)shows a strong inhibition of M(pro)activity with N3, ebselen as well as PX-12 inhibitors. The two former inhibitors are previously reported as strong inhibitors; however, the strong inhibition effect of PX-12 has not been previously reported. The results of this study can provide useful insight into designing an effective inhibitor drug for SARS-nCoV, suggesting a better inhibition from PX-12 than ebselen.
C1 [Monajemi, Hadieh; Zain, Sharifuddin M.] Univ Malaya, Dept Chem, Kuala Lumpur 50603, Malaysia.
   [Monajemi, Hadieh] Univ Malaya, Data Intens Comp Ctr, Res & Innovat Complex, Kuala Lumpur, Malaysia.
RP Monajemi, H (corresponding author), Univ Malaya, Dept Chem, Kuala Lumpur 50603, Malaysia.
EM h.monajemi@hotmail.com
CR Balakrishnan V, 2020, PREPRINTS
   Chung LW, 2015, CHEM REV, V115, P5678, DOI 10.1021/cr5004419
   Frisch MJ, GAUSSIAN 09 REVISION
   Hatada R, 2020, CHEMRXIV
   Hoffmann M, 2020, BIORXIV
   Jin Z, 2020, NATURE, V9, P1
   Khaerunnisa S, 2020, ARXIV, V13, P1
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Rut W., 2020, BIORXIV
   Shu C, 2020, MEDICINE, V1, P41
   St John SE, 2015, BIOORGAN MED CHEM, V23, P6036, DOI 10.1016/j.bmc.2015.06.039
   Strodel B, 2020, PREPRINT
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang SN, 2010, PROTEIN CELL, V1, P371, DOI 10.1007/s13238-010-0044-8
NR 16
TC 0
Z9 0
U1 3
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1747-5198
EI 2047-6507
J9 J CHEM RES
JI J. Chem. Res
AR 1747519820938025
DI 10.1177/1747519820938025
EA JUN 2020
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA MY1QX
UT WOS:000558194500001
OA Other Gold
DA 2021-01-01
ER

PT J
AU Guglielmetti, G
   Quaglia, M
   Sainaghi, PP
   Castello, LM
   Vaschetto, R
   Pirisi, M
   Della Corte, F
   Avanzi, GC
   Stratta, P
   Cantaluppi, V
AF Guglielmetti, Gabriele
   Quaglia, Marco
   Sainaghi, Pier Paolo
   Castello, Luigi Mario
   Vaschetto, Rosanna
   Pirisi, Mario
   Della Corte, Francesco
   Avanzi, Gian Carlo
   Stratta, Piero
   Cantaluppi, Vincenzo
TI "War to the knife" against thromboinflammation to protect endothelial
   function of COVID-19 patients
SO CRITICAL CARE
LA English
DT Article
DE COVID-19; Thrombosis; Thromboinflammation; Heparin; Plasma; Endothelial
   dysfunction; Complement; Extracellular vesicles; Anticoagulation
AB In this viewpoint, we summarize the relevance of thromboinflammation in COVID-19 and discuss potential mechanisms of endothelial injury as a key point for the development of lung and distant organ dysfunction, with a focus on direct viral infection and cytokine-mediated injury. Entanglement between inflammation and coagulation and resistance to heparin provide a rationale to consider other therapeutic approaches in order to preserve endothelial function and limit microthrombosis, especially in severe forms. These strategies include nebulized heparin, N-acetylcysteine, plasma exchange and/or fresh frozen plasma, plasma derivatives to increase the level of endogenous anticoagulants (tissue factor pathway inhibitor, activated protein C, thrombomodulin, antithrombin), dipyridamole, complement blockers, different types of stem cells, and extracellular vesicles. An integrated therapy including these drugs has the potential to improve outcomes in COVID-19.
C1 [Guglielmetti, Gabriele; Quaglia, Marco; Sainaghi, Pier Paolo; Castello, Luigi Mario; Vaschetto, Rosanna; Pirisi, Mario; Della Corte, Francesco; Avanzi, Gian Carlo; Stratta, Piero; Cantaluppi, Vincenzo] Univ Piemonte Orientale UPO, Dept Translat Med, Sch Med, Novara, Italy.
RP Guglielmetti, G (corresponding author), Univ Piemonte Orientale UPO, Dept Translat Med, Sch Med, Novara, Italy.
EM gabrigug88@gmail.com
RI Quaglia, Marco/ABH-7159-2020; Corte, Francesco Della/ABI-7646-2020;
   Pirisi, Mario/ABF-2102-2020; Vaschetto, Rosanna/ABC-4671-2020
OI Quaglia, Marco/0000-0001-9423-9255; Corte, Francesco
   Della/0000-0003-1736-2318; Vaschetto, Rosanna/0000-0003-4625-4367;
   Guglielmetti, Gabriele/0000-0003-2531-499X; CASTELLO, Luigi
   Mario/0000-0001-8248-1976
FU Italian Ministry of Education, University and Research (MIUR) program
   "Departments of ExcellenceMinistry of Education, Universities and
   Research (MIUR) [20182022]; AGING Project - Department of Translational
   Medicine, University of Piemonte Orientale (UPO)
FX This study was (partially) funded by the Italian Ministry of Education,
   University and Research (MIUR) program "Departments of Excellence
   20182022", AGING Project - Department of Translational Medicine,
   University of Piemonte Orientale (UPO).
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Camprubi-Rimblas M, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.08
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Coppo P, 2003, MEDICINE, V82, P27, DOI 10.1097/00005792-200301000-00003
   Diurno F, 2020, EUR REV MED PHARMACO, V24, P4040, DOI 10.26355/eurrev_202004_20875
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Hofstra JJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8040
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu X, 2020, THERAPEUTIC EFFECTS, DOI [10.1101/2020.02.27.20027557, DOI 10.1101/2020.02.27.20027557]
   Maron-Gutierrez T, 2014, CURR OPIN CRIT CARE, V20, P122, DOI 10.1097/MCC.0000000000000061
   McGinn KA, 2019, J PHARM PRACT, V32, P163, DOI 10.1177/0897190017747143
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Miyoshi S, 2014, DRUG DES DEV THER, V8, P1211, DOI 10.2147/DDDT.S68030
   Mousavi S, 2015, ADV PHARMACOL SCI, V2015, DOI 10.1155/2015/507151
   Risitano AM, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0320-7
   Saha M, 2017, J THROMB HAEMOST, V15, P1889, DOI 10.1111/jth.13764
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   van den Boogaard FE, 2017, J AEROSOL MED PULM D, V30, P91, DOI 10.1089/jamp.2016.1317
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wu X, 2018, EXP CELL RES, V370, P13, DOI 10.1016/j.yexcr.2018.06.003
   Xiong M, 2020, BRIT J HAEMATOL, V189, P1050, DOI 10.1111/bjh.16725
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Zhang QW, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000013087, 10.1097/md.0000000000013087]
NR 25
TC 1
Z9 2
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD JUN 19
PY 2020
VL 24
IS 1
DI 10.1186/s13054-020-03060-9
PG 4
WC Critical Care Medicine
SC General & Internal Medicine
GA MI5VZ
UT WOS:000547476500002
PM 32560665
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chat, VS
   Uppal, SK
   Kearns, DG
   Wu, JJ
AF Chat, Vipawee S.
   Uppal, Shelley K.
   Kearns, Donovan G.
   Wu, Jashin J.
TI Clinical management of psoriasis patients during the COVID-19 pandemic
SO JOURNAL OF DERMATOLOGICAL TREATMENT
LA English
DT Letter; Early Access
DE Psoriasis; biologics; biological products/therapeutic use; dermatologic
   agents/therapeutic use; COVID-19; coronavirus; pandemic; management;
   telemedicine
AB Psoriasis is a systemic immune-mediated inflammatory disease that requires consistent treatment and follow-up. Given that COVID-19 will persist in the coming years, dermatologists need to adjust their practices accordingly to care for their patients, particularly psoriasis patients managed with systemic therapies. We provide guidelines for optimizing care for psoriasis patients, including considerations for medication management, lifestyle adjustments, and utilization of telemedicine.
C1 [Chat, Vipawee S.] Augusta Univ, Med Coll Georgia, Augusta, GA USA.
   [Uppal, Shelley K.] Albany Med Coll, Albany, NY USA.
   [Kearns, Donovan G.] Loma Linda Univ, Loma Linda Sch Med, Loma Linda, CA 92350 USA.
   [Wu, Jashin J.] Dermatol Res & Educ Fdn, Irvine, CA 92604 USA.
RP Wu, JJ (corresponding author), Dermatol Res & Educ Fdn, Irvine, CA 92604 USA.
EM jashinwu@gmail.com
CR Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Price KN, 2020, J AM ACAD DERMATOL, V82, pE173, DOI 10.1016/j.jaad.2020.03.046
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Wang CY, 2020, BRAIN BEHAV IMMUN, V87, P40, DOI 10.1016/j.bbi.2020.04.028
NR 5
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-6634
EI 1471-1753
J9 J DERMATOL TREAT
JI J. Dermatol. Treat.
DI 10.1080/09546634.2020.1781045
EA JUN 2020
PG 2
WC Dermatology
SC Dermatology
GA MK8UF
UT WOS:000549056100001
PM 32568009
DA 2021-01-01
ER

PT J
AU Prasanth, DSNBK
   Murahari, M
   Chandramohan, V
   Panda, SP
   Atmakuri, LR
   Guntupalli, C
AF Prasanth, D. S. N. B. K.
   Murahari, Manikanta
   Chandramohan, Vivek
   Panda, Siva Prasad
   Atmakuri, Lakshmana Rao
   Guntupalli, Chakravarthi
TI In silicoidentification of potential inhibitors fromCinnamonagainst main
   protease and spike glycoprotein of SARS CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Cinnamon; SARS CoV-2; main protease; spike glycoprotein; autodock
ID CORONAVIRUS; PREDICTION; RECEPTOR; IMPACT
AB Cinnamonhas been utilized to remedy a lot of afflictions of humans. Literary works illustrate that it possesses numerous biological activities. Our research study is intended to recognize the phyto-derived antiviral substances fromCinnamonagainst COVID-19 main protease enzyme and to understand thein silicomolecular basis of its activity. In the present study, 48 isolates compounds fromCinnamonretrieved from the PubMed database, are subjected to docking analysis. Docking study was performed using Autodock vina and PyRx software. Afterwards, admetSAR, as well as DruLiTo servers, were used to investigate drug-likeness prophecy. Our study shows that the nine phytochemicals ofCinnamonare very likely against the main protease enzyme of COVID-19. Further MD simulations could identify Tenufolin (TEN) and Pavetannin C1 (PAV) as hit compounds. Utilizing contemporary strategies, these phyto-compounds from a natural origin might establish a reliable medication or support lead identification. Identified hit compounds can be further taken forin vitroandin vivostudies to examine their effectiveness versus COVID-19.
C1 [Prasanth, D. S. N. B. K.; Guntupalli, Chakravarthi] Koneru Lakshmaiah Educ Fdn, KL Coll Pharm, Pharmacognosy Res Div, Vaddeswaram, India.
   [Murahari, Manikanta] MS Ramaiah Univ Appl Sci, Fac Pharm, Dept Pharmaceut Chem, Bangalore, Karnataka, India.
   [Chandramohan, Vivek] Siddaganga Inst Technol, Dept Biotechnol, Tumakuru, India.
   [Panda, Siva Prasad] Koneru Lakshmaiah Educ Fdn, KL Coll Pharm, Pharmacol Res Div, Vaddeswaram, India.
   [Atmakuri, Lakshmana Rao] VV Inst Pharmaceut Sci, Dept Pharmaceut Anal, Gudlavalleru, India.
RP Prasanth, DSNBK (corresponding author), Koneru Lakshmaiah Educ Fdn, KL Coll Pharm, Dept Pharmacognosy, Guntur, Andhra Pradesh, India.
EM dsnbkprasanth@kluniversity.in
RI DSNBK, Prasanth/R-8562-2019; Murahari, Manikanta/AAF-6158-2019; panda,
   siva prasad/ABE-4709-2020
OI DSNBK, Prasanth/0000-0001-5028-1283; Murahari,
   Manikanta/0000-0002-5404-4426; panda, siva prasad/0000-0002-6980-6761;
   A, Dr. Lakshmana Rao/0000-0001-5601-037X; Chandramohan,
   Vivek/0000-0001-8129-6621
FU Karnataka Biotechnology and Information Technology Services (KBITS),
   Bangalore
FX Vivek thank Karnataka Biotechnology and Information Technology Services
   (KBITS), Bangalore for providing the grant to establish the
   computational facility under Biotech Policy-II, Biotechnology Finishing
   School and Biotechnology Skill Enhancement Programme (BiSEP) at the
   Department of Biotechnology, Siddaganga Institute of Technology,
   Tumakuru - 572103, Karnataka.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Agostino M, 2009, J CHEM INF MODEL, V49, P2749, DOI 10.1021/ci900388a
   Benigni R, 2011, CHEM REV, V111, P2507, DOI 10.1021/cr100222q
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chaudhuri S, 2018, ANTIVIR RES, V155, P76, DOI 10.1016/j.antiviral.2018.05.005
   Cheng F, 2012, ADMETSAR COMPREHENSI
   Corman VM, 2019, INTERNIST, V60, P1136, DOI 10.1007/s00108-019-00671-5
   Cosconati S, 2010, EXPERT OPIN DRUG DIS, V5, P597, DOI 10.1517/17460441.2010.484460
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Design L., 2014, PHARMACOPHORE LIGAND
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761881
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e
   Fehr AR, 2017, ANNU REV MED, V68, P387, DOI 10.1146/annurev-med-051215-031152
   GANGADHARAPPA BS, 2019, J BIOMOL STRUCT 0921, DOI DOI https://doi.org/10.1080/07391102.2019.1667265
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Goel RK, 2011, MED CHEM RES, V20, P1509, DOI 10.1007/s00044-010-9398-y
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Khurana N, 2011, EUR J PHARMACOL, V662, P22, DOI 10.1016/j.ejphar.2011.04.048
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lai KF, 2018, J THORAC DIS, V10, P6314, DOI 10.21037/jtd.2018.09.153
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liebler DC, 2005, NAT REV DRUG DISCOV, V4, P410, DOI 10.1038/nrd1720
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Martinez JP, 2015, NAT PROD REP, V32, P29, DOI 10.1039/c4np00085d
   Menachery VD, 2020, J VIROL, V94, DOI 10.1128/JVI.01774-19
   Mittal M, 2008, BIOORG MED CHEM LETT, V18, P5347, DOI 10.1016/j.bmcl.2008.09.064
   Mohankumar T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57417-9
   MOHANRAJ K, 2018, SCI REP UK, V8, DOI DOI https://doi.org/10.1038/s41598-018-22631-z
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Pangastuti A., 2016, JURNAL TEKNOLOGI, V78, P1, DOI [https://doi.org/10.11113/jt.v78.8328, DOI 10.11113/JT.V78.8328]
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822-010-9352-6
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   To KKW, 2013, J THORAC DIS, V5, pS103, DOI 10.3978/j.issn.2072-1439.2013.06.02
   Townsend EA, 2013, AM J RESP CELL MOL, V48, P157, DOI 10.1165/rcmb.2012-0231OC
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   WHO, 2003, SUMM PROB SARS CAS O
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yang HB, 2019, BIOINFORMATICS, V35, P1067, DOI 10.1093/bioinformatics/bty707
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 66
TC 8
Z9 8
U1 1
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1779129
EA JUN 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MJ0BJ
UT WOS:000547761000001
PM 32567989
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tazikeh-Lemeski, E
   Moradi, S
   Raoufi, R
   Shahlaei, M
   Janlou, MAM
   Zolghadri, S
AF Tazikeh-Lemeski, Elham
   Moradi, Sajad
   Raoufi, Rahim
   Shahlaei, Mohsen
   Janlou, Mehr Ali Mahmood
   Zolghadri, Samaneh
TI Targeting SARS-COV-2 non-structural protein 16: a virtual drug
   repurposing study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; Drug repurposing; Molecular docking; Molecular dynamics
   simulation
ID UCSF CHIMERA; DOCKING; EFFICIENT; SYSTEM
AB Non-Structural Protein 16 (nsp-16), a viral RNA methyltransferase (MTase), is one of the highly viable targets for drug discovery of coronaviruses including SARS-CoV-2. In this study, drug discovery of SARS-CoV-2 nsp-16 has been performed by a virtual drug repurposing approach. First, drug shape-based screening (among FDA approved drugs) with a known template of MTase inhibitor, sinefungin was done and best compounds with high similarity scores were selected. In addition to the selected compounds, 4 nucleoside analogs of anti-viral (Raltgravir, Maraviroc and Favipiravir) and anti-inflammatory (Prednisolone) drugs were selected for further investigations. Then, binding energies and interaction modes were found by molecular docking approaches and compouds with lower energy were selected for further investigation. After that, Molecular dynamics (MD) simulation was carried to test the potential selected compounds in a realistic environment. The results showed that Raltegravir and Maraviroc among other compounds can bind strongly to the active site of the protein compared to sinefungin, and can be potential candidates to inhibit NSP-16. Also, the MD simulation results suggested that the Maraviroc and Raltegravir are more effective drug candidates than Sinefungin for inhibiting the enzyme. It is concluded that Raltegravir and Maraviroc which may be used in the treatment of COVID-19 after Invitro and invivo studies and clinical trial for final confirmation of drug effectiveness. Communicated by Ramaswamy H. Sarma
C1 [Tazikeh-Lemeski, Elham] Islamic Azad Univ, Dept Chem, Gorgan Branch, Gorgan, Golestan, Iran.
   [Moradi, Sajad; Shahlaei, Mohsen] Kermanshah Univ Med Sci, Nano Drug Delivery Res Ctr, Hlth Technol Inst, Kermanshah, Iran.
   [Raoufi, Rahim] Jahrom Univ Med Sci, Sch Med, Jahrom, Iran.
   [Janlou, Mehr Ali Mahmood] Islamic Azad Univ, Dept Biol, Gorgan Branch, Gorgan, Golestan, Iran.
   [Zolghadri, Samaneh] Islamic Azad Univ, Dept Biol, Jahrom Branch, Jahrom, Iran.
RP Raoufi, R (corresponding author), Jahrom Univ Med Sci, Sch Med, Jahrom, Iran.; Zolghadri, S (corresponding author), Islamic Azad Univ, Dept Biol, Jahrom Branch, Jahrom, Iran.
EM Sarahim1531@gmail.com; szjahromi@yahoo.com
FU Jahrom University of Medical Sciences
FX We would like to appreciate all those who have helped us in this work.
   The financial support given by the Jahrom University of Medical Sciences
   is gratefully acknowledged.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   AOUADI W, 2017, J VIROL, V91, DOI DOI https://doi.org/10.1128/JVI.02217-16
   ARABI YM, 2020, TRIALS, V21, DOI DOI https://doi.org/10.1186/s13063-019-3846-x
   Bennardo F, 2020, ORAL ONCOL, V106, DOI 10.1016/j.oraloncology.2020.104659
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Binder K, 1997, REP PROG PHYS, V60, P487, DOI 10.1088/0034-4885/60/5/001
   Bitencourt-Ferreira G, 2019, METHODS MOL BIOL, V2053, P189, DOI 10.1007/978-1-4939-9752-7_12
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Cha Y, 2018, BRIT J PHARMACOL, V175, P168, DOI 10.1111/bph.13798
   Chen Y, 2016, VIROL SIN, V31, P3, DOI 10.1007/s12250-016-3726-4
   Chrebet G, 2005, J BIOMOL SCREEN, V10, P355, DOI 10.1177/1087057104273333
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Decroly E, 2008, J VIROL, V82, P8071, DOI 10.1128/JVI.00407-08
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   FERNER RE, 2020, BMJ BRIT MED J, V369, DOI DOI https://doi.org/10.1136/bmj.m1432
   Friedberg MW, 2017, JAMA INTERN MED, V177, P1058, DOI 10.1001/jamainternmed.2017.2142
   FROIMOWITZ M, 1993, BIOTECHNIQUES, V14, P1010
   Goodsell David S, 2009, Cold Spring Harb Protoc, V2009, DOI 10.1101/pdb.prot5200
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Grosdidier A, 2011, J COMPUT CHEM, V32, P2149, DOI 10.1002/jcc.21797
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Harshitha K, 2020, INDIAN J MICROBIOL, V60, P254, DOI 10.1007/s12088-020-00857-8
   Hassan M, 2019, BIOMED PHARMACOTHER, V109, P2513, DOI 10.1016/j.biopha.2018.11.115
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767691
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Huang CC, 2014, NUCLEIC ACIDS RES, V42, pW478, DOI 10.1093/nar/gku377
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Ke M, 2012, VIRUS RES, V167, P322, DOI 10.1016/j.virusres.2012.05.017
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li JW, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04430-y
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Liu S, 2020, BIOINFORMATICS, V36, P3295, DOI 10.1093/bioinformatics/btaa224
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Ma DL, 2013, CHEM SOC REV, V42, P2130, DOI 10.1039/c2cs35357a
   Malde AK, 2011, J CHEM THEORY COMPUT, V7, P4026, DOI 10.1021/ct200196m
   Memish ZA, 2020, LANCET, V395, P1063, DOI 10.1016/S0140-6736(19)33221-0
   Menachery VD, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00346-17
   Menachery VD, 2014, VIRUS RES, V194, P191, DOI 10.1016/j.virusres.2014.09.009
   Meng XY, 2011, CURR COMPUT-AID DRUG, V7, P146
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pence HE, 2010, J CHEM EDUC, V87, P1123, DOI 10.1021/ed100697w
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   ROSA SGV, 2020, REV PANAM SALUD PUBL, V44, DOI DOI https://doi.org/10.26633/RPSP.2020.40
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Sang P, 2020, RSC ADV, V10, P15775, DOI 10.1039/d0ra01899f
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   SCHMOLDT A, 1975, BIOCHEM PHARMACOL, V24, P1639, DOI 10.1016/0006-2952(75)90094-5
   Scuccimarri R, 2020, J RHEUMATOL, V47, P783, DOI 10.3899/jrheum.200369
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Sodhi M, 2020, PHARMACOTHERAPY, V40, P487, DOI 10.1002/phar.2395
   Sohraby Farzin, 2019, Methods Mol Biol, V1903, P23, DOI 10.1007/978-1-4939-8955-3_2
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   vanAalten DMF, 1996, BIOPHYS J, V70, P684, DOI 10.1016/S0006-3495(96)79608-X
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wang YL, 2009, NUCLEIC ACIDS RES, V37, pW623, DOI 10.1093/nar/gkp456
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zoete V, 2016, J CHEM INF MODEL, V56, P1399, DOI 10.1021/acs.jcim.6b00174
   Zust R, 2011, NAT IMMUNOL, V12, P137, DOI 10.1038/ni.1979
NR 75
TC 2
Z9 2
U1 7
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1779133
EA JUN 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MI2SE
UT WOS:000547261800001
PM 32573355
OA Green Published
DA 2021-01-01
ER

PT J
AU Dai, WH
   Zhang, B
   Jiang, XM
   Su, HX
   Li, JA
   Zhao, Y
   Xie, X
   Jin, ZM
   Peng, JJ
   Liu, FJ
   Li, CP
   Li, Y
   Bai, F
   Wang, HF
   Cheng, X
   Cen, XB
   Hu, SL
   Yang, XN
   Wang, J
   Liu, X
   Xiao, GF
   Jiang, HL
   Rao, ZH
   Zhang, LK
   Xu, YC
   Yang, HT
   Liu, H
AF Dai, Wenhao
   Zhang, Bing
   Jiang, Xia-Ming
   Su, Haixia
   Li, Jian
   Zhao, Yao
   Xie, Xiong
   Jin, Zhenming
   Peng, Jingjing
   Liu, Fengjiang
   Li, Chunpu
   Li, You
   Bai, Fang
   Wang, Haofeng
   Cheng, Xi
   Cen, Xiaobo
   Hu, Shulei
   Yang, Xiuna
   Wang, Jiang
   Liu, Xiang
   Xiao, Gengfu
   Jiang, Hualiang
   Rao, Zihe
   Zhang, Lei-Ke
   Xu, Yechun
   Yang, Haitao
   Liu, Hong
TI Structure-based design of antiviral drug candidates targeting the
   SARS-CoV-2 main protease
SO SCIENCE
LA English
DT Article
ID CORONAVIRUS; INHIBITORS; 3C
AB SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the etiological agent responsible for the global COVID-19 (coronavirus disease 2019) outbreak. The main protease of SARS-CoV-2, M-pro, is a key enzyme that plays a pivotal role in mediating viral replication and transcription. We designed and synthesized two lead compounds (11a and 11b) targeting M-pro. Both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity. The x-ray crystal structures of SARS-CoV-2 M-pro in complex with 11a or 11b, both determined at a resolution of 1.5 angstroms, showed that the aldehyde groups of 11a and 11b are covalently bound to cysteine 145 of M-pro. Both compounds showed good pharmacokinetic properties in vivo, and 11a also exhibited low toxicity, which suggests that these compounds are promising drug candidates.
C1 [Dai, Wenhao; Su, Haixia; Li, Jian; Xie, Xiong; Peng, Jingjing; Li, Chunpu; Cheng, Xi; Hu, Shulei; Wang, Jiang; Jiang, Hualiang; Xu, Yechun; Liu, Hong] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Dai, Wenhao; Liu, Hong] China Pharmaceut Univ, Sch Pharm, Nanjing 210009, Jiangsu, Peoples R China.
   [Zhang, Bing; Zhao, Yao; Jin, Zhenming; Liu, Fengjiang; Bai, Fang; Wang, Haofeng; Yang, Xiuna; Jiang, Hualiang; Rao, Zihe; Yang, Haitao] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China.
   [Zhang, Bing; Zhao, Yao; Jin, Zhenming; Liu, Fengjiang; Bai, Fang; Wang, Haofeng; Yang, Xiuna; Jiang, Hualiang; Rao, Zihe; Yang, Haitao] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.
   [Jiang, Xia-Ming; Xiao, Gengfu; Zhang, Lei-Ke] Chinese Acad Sci, Ctr Biosafety Mega Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.
   [Su, Haixia; Li, Jian; Xie, Xiong; Peng, Jingjing; Li, Chunpu; Wang, Jiang; Jiang, Hualiang; Xu, Yechun; Liu, Hong] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Liu, Hong] Nanjing Univ Chinese Med, Coll Pharm, Nanjing 210023, Peoples R China.
   [Li, You; Cen, Xiaobo] Sichuan Univ, Westchina Hosp, Natl Chengdu Ctr Safety Evaluat Drugs, Chengdu 610041, Sichuan, Peoples R China.
   [Liu, Xiang] Nankai Univ, State Key Lab Med Chem Biol, Frontiers Sci Ctr Cell Response, Coll Pharm,Coll Life Sci, Tianjin 300353, Peoples R China.
RP Xu, YC; Liu, H (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, State Key Lab Drug Res, Shanghai 201203, Peoples R China.; Liu, H (corresponding author), China Pharmaceut Univ, Sch Pharm, Nanjing 210009, Jiangsu, Peoples R China.; Yang, HT (corresponding author), ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China.; Yang, HT (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.; Zhang, LK (corresponding author), Chinese Acad Sci, Ctr Biosafety Mega Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.; Xu, YC; Liu, H (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Liu, H (corresponding author), Nanjing Univ Chinese Med, Coll Pharm, Nanjing 210023, Peoples R China.
EM zhangleike@wh.iov.cn; ycxu@simm.ac.cn; yanght@shanghaitech.edu.cn;
   hliu@simm.ac.cn
OI Zhang, Bing/0000-0001-8556-8049; Jin, Zhenming/0000-0001-6448-820X; Dai,
   Wenhao/0000-0001-8508-7130; Liu, Fengjiang/0000-0002-9400-308X; Yang,
   Xiuna/0000-0003-3443-9815; Zhao, Yao/0000-0002-2932-2164
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21632008, 21672231, 21877118, 31970165,
   91953000, 81620108027]; Strategic Priority Research Program of the
   Chinese Academy of SciencesChinese Academy of Sciences [XDA12040107,
   XDA12040201]; Chinese Academy of Engineering [2020-CMKYGG-05]; Science
   and Technology Commission of Shanghai MunicipalityScience & Technology
   Commission of Shanghai Municipality (STCSM) [20431900100, 20431900200];
   National Key RAMP;D Program of China [2017YFC0840300, 2020YFC0841400,
   2020YFA0707500, 2017YFB0202604]; Department of Science and Technology of
   Guangxi Zhuang Autonomous Region [2020AB40007]; Frontier Biotechnologies
   Inc.; Ma Yun Foundation [2020-CMKYGG-05]
FX Supported by National Natural Science Foundation of China grants
   21632008, 21672231, 21877118, 31970165, 91953000, and 81620108027;
   Strategic Priority Research Program of the Chinese Academy of Sciences
   grants XDA12040107 and XDA12040201; Chinese Academy of Engineering and
   Ma Yun Foundation grant 2020-CMKYGG-05; Science and Technology
   Commission of Shanghai Municipality grants 20431900100 and 20431900200;
   National Key R&D Program of China grants 2017YFC0840300, 2020YFC0841400,
   2020YFA0707500, and 2017YFB0202604; Department of Science and Technology
   of Guangxi Zhuang Autonomous Region grant 2020AB40007; and Frontier
   Biotechnologies Inc.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Cao B, 2020, NEW ENGL J MED, V382
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cohen J, 2020, SCIENCE, DOI [10.1126/science.abb0659, DOI 10.1126/SCIENCE.ABB0659]
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Gorbalenya A. E., 2020, BIORXIV 2020 02 07 9
   Gorbalenya A. E., 2020, SEVERE ACUTE RESP SY
   Hayden FG, 2003, ANTIMICROB AGENTS CH, V47, P3907, DOI 10.1128/AAC.47.12.3907-3916.2003
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Ramajayam R, 2011, BIOCHEM SOC T, V39, P1371, DOI 10.1042/BST0391371
   Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhai YY, 2015, J MED CHEM, V58, P9414, DOI 10.1021/acs.jmedchem.5b01013
   Zhang L, 2020, MED CHEM RES, V29, P575, DOI 10.1007/s00044-020-02509-4
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 32
TC 112
Z9 113
U1 102
U2 142
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JUN 19
PY 2020
VL 368
IS 6497
BP 1331
EP +
DI 10.1126/science.abb4489
PG 35
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MD5NG
UT WOS:000544017600040
PM 32321856
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Abdolahi, N
   Kaheh, E
   Golsha, R
   Khodabakhshi, B
   Norouzi, A
   Khandashpoor, M
   Besharat, S
   Tavassoli, S
   Livani, S
   Azimi, SA
   Gharib, MH
   Peivandi, B
   Fazel, A
   Shirzad-Aski, H
   Roshandel, G
AF Abdolahi, Nafiseh
   Kaheh, Effat
   Golsha, Roghieh
   Khodabakhshi, Behnaz
   Norouzi, Alireza
   Khandashpoor, Mahmoud
   Besharat, Sima
   Tavassoli, Samane
   Livani, Somayeh
   Azimi, Sadegh Ali
   Gharib, Mohammad Hadi
   Peivandi, Babak
   Fazel, Abdolreza
   Shirzad-Aski, Hesamaddin
   Roshandel, Gholamreza
TI Letter to the editor: efficacy of different methods of combination
   regimen administrations including dexamethasone, intravenous
   immunoglobulin, and interferon-beta to treat critically ill COVID-19
   patients: a structured summary of a study protocol for a randomized
   controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Protocol; Corticosteroids;
   Patients management; Inflammation
AB ObjectivesThere is little information about Coronavirus Disease 2019 (COVID-19) management for critically ill patients. Most of these patients develop acute respiratory distress syndrome (ARDS) due to excessive inflammatory response and the ensuing cytokine storm. Anti-inflammatory drugs including corticosteroids can be used to effectively reduce the effect of this cytokine storm and lung damage. However, corticosteroids can have side effects, so simultaneous administration of immunoglobulin (IV-IG) and interferon-beta can help manage treatment using corticosteroids. Therefore, we designed a trial to test our hypothesis that early administration of dexamethasone in combination with IV-IG and interferon-beta can reduce the effect of the cytokine storm in critically ill patients COVID-19.Trial designA phase two multi-center randomized controlled trial (RCT) with three parallel arms (1:1:1 ratio).ParticipantsThey will be hospitalized patients with severe COVID-19 who have positive RT-PCR test and have blood oxygen saturation levels (SpO(2)) less than 90% and respiratory rate higher than 24 per minute or have involvement of more than 50% of their lung when viewed using computed tomography (CT)-scan. The age range of patients will be 18-70 years old.Exclusion criteria: the need for intubation; allergy, intolerance, or contraindication to any study drug including dexamethasone, IV-IG, and interferon-beta; pregnancy or lactation; known HIV positive or active hepatitis B or C.The study will be conducted in several hospitals of the Golestan province, Iran.Intervention and comparatorThe study subjects will be randomly allocated to three treatment arms: two experimental groups (two arms: Intervention 1 and Intervention 2) and one Control Group, which will be matched for age and sex using frequency matching method. Each eligible patient in the control arm will receive the standard treatment for COVID-19 based on WHO guidelines and the Ministry of the Health and Medical Education (MOHME) of Iran. Each patient in the Intervention Group 1 will receive the standard treatment for COVID-19 and dexamethasone, at the first 24 hours' time of admission. The intervention begins with the administration of dexamethasone based on the SpO(2) levels. If the level of SpO(2) does not improve after 24 hours, IV-IG (400 mg/kg once daily for 5 days) and interferon-beta (7 doses every other day) will be prescribed along with dexamethasone administration. In Intervention Group 2, the administration of dexamethasone will be started within the first 24 hours' time of admission and will be continued for 48-72 hours and then the SpO(2) level will be checked. Then, if the level of SpO(2) has not improved after that time, IV-IG and interferon-beta will be prescribed as the same dosage as Group 1. If the percentages of the SpO(2) level are between 85 and 90/ 80 and 85/ 75 and 80/ less than 75, the dosages will be 4 mg every 12 hours/ 4 mg every 8 hours/ 8 mg every 12 hours/ 8 mg every 8 hours, respectively.According to the WHO recommendation, all participants will have the best available supportive care with full monitoring.Main outcomesPrimary: An increase in the SpO(2) level to reach more than 90% in each case, which will be assessed by the oximeter.Secondary: The duration of hospital stays; intubation status and the percentage of patients who are free of mechanical ventilation; the mortality rates during hospitalization and one month after the admission time.
   RandomisationParticipants will be allocated into either control or intervention groups with a 1:1:1 allocation ratio using a computer random number generator to generate a table of random numbers for simple randomization.Blinding (masking)The project's principal investigator (PI) is unblinded. However, the PI will not analyse the data and interpret the results. An unblinded researcher (a pharmacist) will cover the drug's bottles with aluminium foil and prepare them interventions and control drugs in a syringe with a code so that patients are blinded. This person will have no patients contact. The staff and nurses, caring for the patients, will be unblinded for each study group due to the nature of this study. The staff that take outcome measurements will be blinded. The laboratory technicians will also be blinded as well as the statistical team. These study statisticians will have access to coded data and will analyse the data labelled as group X, group Y, and group Z.Numbers to be randomised (sample size)The target sample size will be 105 critically ill COVID-19 patients, who will be allocated randomly to the three trial arms with 35 patients in each group.Trial statusRecruitment is ongoing. The study began on April 18 2020 and will be completed June 19 2020. This summary describes protocol version 1; April 2 2020.Trial registrationhttps://www.irct.ir/. Identifier: IRCT20120225009124N4 version 1; Registration date: April 2 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The full protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines.
C1 [Abdolahi, Nafiseh; Kaheh, Effat; Tavassoli, Samane; Gharib, Mohammad Hadi] Golestan Univ Med Sci, Golestan Rheumatol Res Ctr, Gorgan, Golestan, Iran.
   [Golsha, Roghieh; Khodabakhshi, Behnaz; Besharat, Sima; Azimi, Sadegh Ali; Shirzad-Aski, Hesamaddin] Golestan Univ Med Sci, Infect Dis Res Ctr, Gorgan, Golestan, Iran.
   [Khodabakhshi, Behnaz; Norouzi, Alireza; Besharat, Sima; Roshandel, Gholamreza] Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, Golestan, Iran.
   [Khandashpoor, Mahmoud; Livani, Somayeh; Peivandi, Babak] Golestan Univ Med Sci, Sayad Shirazi Hosp, Clin Res Dev Ctr CRDC, Gorgan, Golestan, Iran.
   [Fazel, Abdolreza] Golestan Univ Med Sci, Canc Res Ctr, Gorgan, Golestan, Iran.
   [Fazel, Abdolreza] Golestan Univ Med Sci, Azar Hosp 5, Clin Res Dev Unit CRDU, Gorgan, Golestan, Iran.
RP Besharat, S; Shirzad-Aski, H (corresponding author), Golestan Univ Med Sci, Infect Dis Res Ctr, Gorgan, Golestan, Iran.; Besharat, S; Roshandel, G (corresponding author), Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, Golestan, Iran.
EM s_besharat_gp@yahoo.com
RI Shirzad-Aski, hesamaddin/T-8622-2019; Peivandi, Babak/AAU-5061-2020
OI Shirzad-Aski, hesamaddin/0000-0002-0773-1610; Besharat,
   Sima/0000-0002-8755-2216
FU Golestan University of Medical Sciences, Iran [111542]
FX The Golestan University of Medical Sciences, Iran supported the present
   RCT (grant no. 111542). The funders had no role in the design of the
   trial, the intervention procedures, data collection, evaluation and
   analysis, and selection of a journal for submitting the final version of
   the present protocol.
NR 0
TC 4
Z9 3
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 19
PY 2020
VL 21
IS 1
AR 549
DI 10.1186/s13063-020-04499-5
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MD5GI
UT WOS:000543998100006
PM 32560745
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Desilles, JP
   Gregoire, C
   Le Cossec, C
   Lambert, J
   Mophawe, O
   Losser, MR
   Lambiotte, F
   Le Tacon, S
   Cantier, M
   Engrand, N
   Trouiller, P
   Pottecher, J
AF Desilles, J. P.
   Gregoire, C.
   Le Cossec, C.
   Lambert, J.
   Mophawe, O.
   Losser, M. R.
   Lambiotte, F.
   Le Tacon, S.
   Cantier, M.
   Engrand, N.
   Trouiller, P.
   Pottecher, J.
TI Efficacy and safety of aerosolized intra-tracheal dornase alfa
   administration in patients with SARS-CoV-2-induced acute respiratory
   distress syndrome (ARDS): a structured summary of a study protocol for a
   randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Lung damage; Neutrophil
   extracellular traps; ARDS; Dornase alfa
AB ObjectivesSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammation and severe alveolar injury by releasing neutrophil extracellular traps (NETs). The backbones of many DAMPs and NETs are made of extracellular, cell-free DNA decorated with highly toxic compounds such as elastase, myeloperoxidase and citrullinated histones. Dornase alfa is a FDA-approved recombinant human DNAse 1 for the treatment of cystic fibrosis, which cleaves extracellular DNA and may break up cell-free DNA, loosening sticky mucus in the distal airways and reducing NETs-induced toxicity on alveolar pneumocytes. The COVIDornase trial intends to define the impact of aerosolized intra-tracheal dornase alfa administration on the severity and progression of acute respiratory distress syndrome (ARDS) in COVID-19 patients. This drug might make lung mucus thinner and looser, promoting improved clearance of secretions and reduce extracellular double-stranded DNA-induced hyperinflammation in alveoli, preventing further damage to the lungs.Trial designCOVIDornase is a prospective, randomized, controlled, 2-arm (1:1 ratio), multicentric, open-label clinical trial.ParticipantsThe study will recruit mechanically ventilated patients hospitalized in the intensive care unit (ICU) in the recruiting centres (at the time of writing: The Rothschild foundation hospital in Paris, the Strasbourg university hospitals, and Metz-Thionville hospital) who have been diagnosed with COVID-19 and meet ARDS criteria.Inclusion criteria- Adult patient (age >= 18 years old);- Hospitalized in ICU;- With severe COVID-19 pneumonia and ARDS according to Berlin criteria (PaO2/FiO(2) < 300 and PEEP > 5 cmH(2)O);- Intubated for less than 8 days;- With an anticipated duration of mechanical ventilation > 48 hours;- Carrier of an arterial catheter;- For whom 4 PaO2/FiO(2) values over the preceding 24 hours are available;Non-inclusion criteria- Known hypersensitivity to dornase alfa or any of its excipients;- Pregnant or breastfeeding status;- Patient under legal protection.Intervention and comparatorIntervention 1, Study groupDornase alfa (Pulmozyme (R), Roche, Switzerland) will be administered by aerosol, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer (Aerogen Solo (R), Aerogen, Ireland). The remainder of the management will be performed in accordance with good clinical practice, including mechanical ventilation (protective ventilation, PEEP > 5 cmH(2)O, tracheal balloon pressure check every 4 hours or automatic device, 30 degrees head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure < 30 cmH(2)O), neuromuscular blockers if necessary, prone position if PaO2/FiO(2) < 150, early enteral nutrition, glycemic control and a sedation protocol based on the RASS score.Intervention 2, ComparatorPatients will receive usual care in accordance with good practice (as detailed above), without aerosols.Main outcomesThe primary outcome is the occurrence of at least one grade improvement between D-0 (inclusion) and D-7 in the ARDS scale severity (Berlin criteria). For instance from "severe" to "moderate" or from "moderate" to "mild".
   RandomisationAll consecutive patients meeting the inclusion criteria will be randomised 1:1 using an eCRF-based, computer-generated randomisation table, either to the dornase alfa arm or to the control arm. An interim analysis will be performed after inclusion of 20 patients. Inclusions may be stopped at the interim analysis per data safety and monitoring board (DSMB) advice, if statistical analyses conclude on the futility or efficacy of the intervention or by other DSMB decision.Blinding (masking)The participants and caregivers will not be blinded to study group assignment. Those assessing the outcomes will be blinded to study group assignment.Numbers to be randomised (sample size)Fifty patients will be randomized to each group, 100 patients in total.Trial StatusProtocol version number 2, April 29(th), 2020. Recruitment is ongoing. The trial started recruitment on the 21(st) April 2020. We estimate recruitment will finish August 21(st) 2020.Trial registrationThe trial was registered in ClinicalTrials.gov on 21 April 2020, updated on 8 May 2020. Trial registration number is NCT04355364.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated. This Letter serves as a summary of the key elements of the full protocol.
C1 [Desilles, J. P.] Rothschild Fdn Hosp, Intervent Neuroradiol Dept, Biol Resource Ctr, Paris, France.
   [Desilles, J. P.] Univ Paris, Lab Vasc Translat Sci, INSERM, U1148, Paris, France.
   [Desilles, J. P.] Harvard Med Sch, Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
   [Gregoire, C.; Cantier, M.; Engrand, N.; Trouiller, P.] Rothschild Fdn Hosp, Dept Intens Care, Paris, France.
   [Le Cossec, C.; Lambert, J.; Mophawe, O.] Rothschild Fdn Hosp, Clin Res Unit, Paris, France.
   [Losser, M. R.] CHRU Nancy, Pole Anesthesie Reanimat, F-54000 Nancy, France.
   [Lambiotte, F.] Ctr Hosp Valenciennes, Serv Reanimat Polyvalente, Ave Desandrouin, F-59322 Valenciennes, France.
   [Le Tacon, S.] CHR Metz Thionville Site Mercy, Serv Reanimat Polyvalente, 1 Allee Chateau, F-57350 Ars Laquenexy, France.
   [Pottecher, J.] Hop Univ Strasbourg, Serv Anesthesie Reanimat Chirurg, Hop Hautepierre, 1 Ave Moliere, F-67098 Strasbourg, France.
   [Pottecher, J.] Univ Strasbourg, Federat Med Translat Strasbourg FMTS, Fac Med, EA3072, Strasbourg, France.
RP Desilles, JP (corresponding author), Rothschild Fdn Hosp, Intervent Neuroradiol Dept, Biol Resource Ctr, Paris, France.; Desilles, JP (corresponding author), Univ Paris, Lab Vasc Translat Sci, INSERM, U1148, Paris, France.
EM jpdesilles@for.paris
OI Desilles, Jean-Philippe/0000-0001-8395-6312
NR 0
TC 2
Z9 2
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 19
PY 2020
VL 21
IS 1
AR 548
DI 10.1186/s13063-020-04488-8
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MD5GI
UT WOS:000543998100005
PM 32560746
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xu, TM
   Lin, B
   Chen, C
   Liu, LG
   Xue, Y
AF Xu, Tian-min
   Lin, Bin
   Chen, Cong
   Liu, Long-gen
   Xue, Yuan
TI Non-optimal effectiveness of convalescent plasma transfusion and
   hydroxychloroquine in treating COVID-19: a case report
SO VIROLOGY JOURNAL
LA English
DT Article
DE COVID-19; SARS-CoV-2; Convalescent plasma; Hydroxychloroquine; Cycle
   threshold
AB Background Convalescent plasma (CP) transfusion was reported to be effective in treating critically ill patients with COVID-19, and hydroxychloroquine could potently inhibit SARS-CoV-2 in vitro. Herein, we reported a case receiving combination therapy with CP transfusion and hydroxychloroquine for the first time. Case presentation Laboratory findings showed high lactic acid level (2.1 mmol/L) and C-reactive protein (CRP, 48.8 mg/L), and low white blood cell count (1.96 x 10(9)/L) in a 65-year-old Chinese man, who was diagnosed with severe COVID-19. CP was intravenously given twice, and hydroxychloroquine was orally administrated for a week (0.2 g, three times a day). The lactic acid and C-reactive protein levels remained high (2.1 mmol/L and 73.23 mg/L, respectively), while the arterial oxyhemoglobin saturation decreased to 86% with a low oxygenation index (OI, 76 mmHg) on day 4 after CP transfusion. His temperature returned to normal and the OI ascended above 300 on day 11. Moreover, the RNA test remained positive in throat swab, and computed tomography revealed severe pulmonary lesions on day 11 after admission. Conclusion These findings suggested that the effectiveness of combination therapy with CP and hydroxychloroquine may be non-optimal, and specific therapy needs to be explored.
C1 [Xu, Tian-min] Third Peoples Hosp Changzhou, Dept Infect Dis, Changzhou, Jiangsu, Peoples R China.
   [Lin, Bin] First Peoples Hosp Jintan, Dept Infect Dis, Changzhou, Jiangsu, Peoples R China.
   [Chen, Cong] Changzhou Ctr Dis Control & Prevent, Changzhou, Jiangsu, Peoples R China.
   [Liu, Long-gen; Xue, Yuan] Third Peoples Hosp Changzhou, Inst Hepatol, 300 Lanling North Rd, Changzhou 213000, Jiangsu, Peoples R China.
RP Xue, Y (corresponding author), Third Peoples Hosp Changzhou, Inst Hepatol, 300 Lanling North Rd, Changzhou 213000, Jiangsu, Peoples R China.
EM xueyuan80908@163.com
RI xue, yuan/ABB-7406-2020
FU Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation
   of Jiangsu Province [BK20180183]; Science and Technology Project of
   Jintan [KJ201925]
FX This work was supported by the Natural Science Foundation of Jiangsu
   Province (Grant No. BK20180183), and the Science and Technology Project
   of Jintan (Grant No. KJ201925).
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
NR 6
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD JUN 19
PY 2020
VL 17
IS 1
AR 80
DI 10.1186/s12985-020-01354-6
PG 3
WC Virology
SC Virology
GA MD5EP
UT WOS:000543993500001
PM 32560646
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vahedi, E
   Ghanei, M
   Ghazvini, A
   Azadi, H
   Izadi, M
   Panahi, Y
   Fathi, S
   Salesi, M
   Saadat, SH
   Ghazale, AH
   Rezapour, M
   Mozafari, A
   Zand, N
   Parsaei, MR
   Ranjkesh, MH
   Jafari, R
   Movaseghi, F
   Darabi, E
AF Vahedi, Ensieh
   Ghanei, Mostafa
   Ghazvini, Ali
   Azadi, Hossein
   Izadi, Morteza
   Panahi, Yunes
   Fathi, Saeid
   Salesi, Mahmood
   Saadat, Seyed Hassan
   Ghazale, Amir Hossein
   Rezapour, Mohammad
   Mozafari, Abolfazl
   Zand, Nahid
   Parsaei, Mohammadreza Raesi
   Ranjkesh, Mohammad Hossein
   Jafari, Ramezan
   Movaseghi, Fatemeh
   Darabi, Enayat
TI The clinical value of two combination regimens in the Management of
   Patients Suffering from Covid-19 pneumonia: a single centered,
   retrospective, observational study
SO DARU-JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Coronavirus disease 2019; Combination therapy; Length of stay in
   hospitals (ALOS)
ID RESPIRATORY SYNDROME; LYMPHOCYTE SUBSETS; CYTOKINE STORM; WUHAN; CHINA
AB Background There is no identified pharmacological therapy for COVID-19 patients, where potential therapeutic strategies are underway to determine effective therapy under such unprecedented pandemic. Therefore, combination therapies may have the potential of alleviating the patient's outcome. This study aimed at comparing the efficacy of two different combination regimens in improving outcomes of patients infected by novel coronavirus (COVID-19).
   Methods This is a single centered, retrospective, observational study of 60 laboratory-confirmed COVID-19 positive inpatients (>= 18 years old) at two wards of the Baqiyatallah Hospital, Tehran, Iran. Patient's data including clinical and laboratory parameters were recorded. According to the drug regimen, the patients were divided into two groups; group I who received regimen I consisting azithromycin, prednisolone, naproxen, and lopinavir/ritonavir and group II who received regimen II including meropenem, levofloxacin, vancomycin, hydroxychloroquine, and oseltamivir.
   Results The oxygen saturation (SpO2) and temperature were positively changed in patients receiving regimen I compared to regimen II (P = 0.013 andP = 0.012, respectively). The serum level of C-reactive protein (CRP) changed positively in group I (P < 0.001). Although there was a significant difference in platelets between both groups (75.44 vs 51.62, P < 0.001), their change did not clinically differ between two groups. The findings indicated a significant difference of the average length of stay in hospitals (ALOS) between two groups, where the patients under regimen I showed a shorter ALOS (6.97 vs 9.93,P = 0.001).
   Conclusion This study revealed the beneficial effect of the short-term use of low-dose prednisolone in combination with azithromycin, naproxen and lopinavir/ritonavir (regimen I), in decreasing ALOS compared to regimen II. Since there is still lack of evidence for safety of this regimen, further investigation in our ongoing follow-up to deal with COVID-19 pneumonia is underway.
   Graphical abstract
C1 [Vahedi, Ensieh; Ghanei, Mostafa; Ghazvini, Ali; Azadi, Hossein; Salesi, Mahmood] Baqiyatallah Univ Med Sci, Syst Biol & Poisoning Inst, Chem Injuries Res Ctr, Tehran, Iran.
   [Izadi, Morteza] Baqiyatallah Univ Med Sci, Hlth Res Ctr, Tehran, Iran.
   [Panahi, Yunes] Baqiyatallah Univ Med Sci, Pharmacotherapy Dept, Fac Pharm, Tehran, Iran.
   [Fathi, Saeid] Univ Tehran, Tehran, Iran.
   [Saadat, Seyed Hassan] Baqiatallah Univ Med Sci, Lifestyle Inst, Behav Sci Res Ctr, Tehran, Iran.
   [Ghazale, Amir Hossein; Rezapour, Mohammad; Parsaei, Mohammadreza Raesi; Ranjkesh, Mohammad Hossein] Baqiyatallah Univ Med Sci, Student Res Comm, Tehran, Iran.
   [Mozafari, Abolfazl; Movaseghi, Fatemeh] Islamic Azad Univ, Qom Branch, Dept Med Sci, Qom, Iran.
   [Zand, Nahid] Qom Univ Med Sci, Dept Internal Med, Qom, Iran.
   [Jafari, Ramezan] Baqiyatallah Univ Med Sci, Dept Radiol & Chem Injury, Res Ctr, Tehran, Iran.
   [Darabi, Enayat] Univ Tehran Med Sci, Sch Publ Hlth, Tehran, Iran.
RP Ghanei, M (corresponding author), Baqiyatallah Univ Med Sci, Syst Biol & Poisoning Inst, Chem Injuries Res Ctr, Tehran, Iran.
EM mghaneister@gmail.com
OI Ghazale, Amir Hosein/0000-0002-6104-0669; Jafari,
   Ramezan/0000-0003-1099-4259
FU Vice Presidency for Science and Technology; Iranian Deputy of Research
   and Technology, Ministry of Health and Medical Education
FX The authors would like to thank the Baqiyatallah University of Medical
   Science for the facilities offered during study. Authors appreciate Dr.
   Pooneh Salari's valuable help in review and direct editing of the
   article. We would also like to thank Vice Presidency for Science and
   Technology and Iranian Deputy of Research and Technology, Ministry of
   Health and Medical Education for their supports.
CR Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Baden LR, 2020, NEW ENGL J MED, V382, P1851, DOI 10.1056/NEJMe2005477
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Cheng PK, 2004, INFECT DIS CLIN PRAC, V12, P387, DOI [10.1097/01.idc.0000144912.27311.19, DOI 10.1097/01.IDC.0000144912.27311.19]
   Choudhary R, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100684
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Cui W, 2003, CLIN INFECT DIS, V37, P857, DOI 10.1086/378587
   Gabriels James, 2020, HeartRhythm Case Rep, V6, P241, DOI 10.1016/j.hrcr.2020.03.017
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iranian Ministry of health and Medical Education, 2020, DIAGN THER FLOWCH CO
   Kim KD, 2007, NAT MED, V13, P1248, DOI 10.1038/nm1633
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lejal N, 2013, ANTIMICROB AGENTS CH, V57, P2231, DOI 10.1128/AAC.02335-12
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Li H, 2020, LEUKEMIA, V34, P1503, DOI 10.1038/s41375-020-0848-3
   Li TS, 2004, J INFECT DIS, V189, P648, DOI 10.1086/381535
   Litao MKS, 2014, PEDIATR ANN, V43, P417, DOI 10.3928/00904481-20140924-10
   Ma J, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108408
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Micallef J, 2020, THERAPIE, V75, P355, DOI 10.1016/j.therap.2020.05.003
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shojaei A, 2020, DARU, V28, P789, DOI 10.1007/s40199-020-00351-y
   Stower Hannah, 2020, Nat Med, V26, P465, DOI 10.1038/s41591-020-0849-9
   Sun XJ, 2020, CYTOKINE GROWTH F R, V53, P38, DOI 10.1016/j.cytogfr.2020.04.002
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   WHO, 2020, CLIN MAN SEV AC RESP
   WHO, 2020, 70 WHO
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
   Zheng CC, 2020, INT J INFECT DIS, V94, P74, DOI 10.1016/j.ijid.2020.03.047
   Zhou Z-G, 2020, SHORT TERM MODERATE, DOI [10.20944/preprints202003.0065.v1, DOI 10.20944/PREPRINTS202003.0065.V1]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 45
TC 3
Z9 3
U1 4
U2 4
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
EI 2008-2231
J9 DARU
JI DARU
PD DEC
PY 2020
VL 28
IS 2
BP 507
EP 516
DI 10.1007/s40199-020-00353-w
EA JUN 2020
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ3QF
UT WOS:000541331800001
PM 32562159
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Poncette, AS
   Mosch, L
   Spies, C
   Schmieding, M
   Schiefenhovel, F
   Krampe, H
   Balzer, F
AF Poncette, Akira-Sebastian
   Mosch, Lina
   Spies, Claudia
   Schmieding, Malte
   Schiefenhoevel, Fridtjof
   Krampe, Henning
   Balzer, Felix
TI Improvements in Patient Monitoring in the Intensive Care Unit: Survey
   Study
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE digital health; patient monitoring; monitoring; intensive care medicine;
   intensive care unit; technological innovation; user-centered; usability;
   online survey; transdisciplinary; REDCap; email
AB Background: Due to demographic change and, more recently, coronavirus disease (COVID-19), the importance of modern intensive care units (ICU) is becoming apparent. One of the key components of an ICU is the continuous monitoring of patients' vital parameters. However, existing advances in informatics, signal processing, or engineering that could alleviate the burden on ICUs have not yet been applied. This could be due to the lack of user involvement in research and development.
   Objective: This study focused on the satisfaction of ICU staff with current patient monitoring and their suggestions for future improvements. We aimed to identify aspects of monitoring that interrupt patient care, display devices for remote monitoring, use cases for artificial intelligence (AI), and whether ICU staff members are willing to improve their digital literacy or contribute to the improvement of patient monitoring. We further aimed to identify differences in the responses of different professional groups.
   Methods: This survey study was performed with ICU staff from 4 ICUs of a German university hospital between November 2019 and January 2020. We developed a web-based 36-item survey questionnaire, by analyzing a preceding qualitative interview study with ICU staff, about the clinical requirements of future patient monitoring. Statistical analyses of questionnaire results included median values with their bootstrapped 95% confidence intervals, and chi-square tests to compare the distributions of item responses of the professional groups.
   Results: In total, 86 of the 270 ICU physicians and nurses completed the survey questionnaire The majority stated they felt confident using the patient monitoring equipment, but that high rates of false-positive alarms and the many sensor cables interrupted patient care. Regarding future improvements, respondents asked for wireless sensors, a reduction in the number of false-positive alarms, and hospital standard operating procedures for alarm management. Responses to the display devices proposed for remote patient monitoring were divided. Most respondents indicated it would be useful for earlier alerting or when they were responsible for multiple wards. AI for ICUs would be useful for early detection of complications and an increased risk of mortality; in addition, the AI could propose guidelines for therapy and diagnostics. Transparency, interoperability, usability, and staff training were essential to promote the use of AI. The majority wanted to learn more about new technologies for the ICU and required more time for learning. Physicians had fewer reservations than nurses about AI-based intelligent alarm management and using mobile phones for remote monitoring.
   Conclusions: This survey study of ICU staff revealed key improvements for patient monitoring in intensive care medicine. Hospital providers and medical device manufacturers should focus on reducing false alarms, implementing hospital alarm standard operating procedures, introducing wireless sensors, preparing for the use of AI, and enhancing the digital literacy of ICU staff. Our results may contribute to the user-centered transfer of digital technologies into practice to alleviate challenges in intensive care medicine.
C1 [Poncette, Akira-Sebastian; Mosch, Lina; Spies, Claudia; Schmieding, Malte; Schiefenhoevel, Fridtjof; Krampe, Henning; Balzer, Felix] Charite Univ Med Berlin, Dept Anesthesiol & Intens Care Med, Charitepl 1, Berlin, Germany.
   [Poncette, Akira-Sebastian; Mosch, Lina; Spies, Claudia; Schmieding, Malte; Schiefenhoevel, Fridtjof; Krampe, Henning; Balzer, Felix] Free Univ Berlin, Charitepl 1, Berlin, Germany.
   [Poncette, Akira-Sebastian; Mosch, Lina; Spies, Claudia; Schmieding, Malte; Schiefenhoevel, Fridtjof; Krampe, Henning; Balzer, Felix] Humboldt Univ, Charitepl 1, Berlin, Germany.
   [Poncette, Akira-Sebastian; Mosch, Lina; Spies, Claudia; Schmieding, Malte; Schiefenhoevel, Fridtjof; Krampe, Henning; Balzer, Felix] Berlin Inst Hlth, Charitepl 1, Berlin, Germany.
   [Poncette, Akira-Sebastian; Schmieding, Malte; Schiefenhoevel, Fridtjof; Balzer, Felix] Einstein Ctr Digital Future, Berlin, Germany.
RP Balzer, F (corresponding author), Charite Univ Med Berlin, Dept Anesthesiol & Intens Care Med, Charitepl 1, Berlin, Germany.; Balzer, F (corresponding author), Free Univ Berlin, Charitepl 1, Berlin, Germany.; Balzer, F (corresponding author), Humboldt Univ, Charitepl 1, Berlin, Germany.; Balzer, F (corresponding author), Berlin Inst Hlth, Charitepl 1, Berlin, Germany.
EM felix.balzer@charite.de
OI Spies, Claudia/0000-0002-1062-0495; Poncette,
   Akira-Sebastian/0000-0003-4627-7016; Mosch, Lina
   Katharina/0000-0003-3154-2745; Balzer, Felix/0000-0003-1575-2056
CR Bach Tita Alissa, 2018, BMJ Open Qual, V7, pe000202, DOI 10.1136/bmjoq-2017-000202
   Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372
   Chung HU, 2020, NAT MED, V26, P418, DOI 10.1038/s41591-020-0792-9
   Cohen AB, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0220-z
   De Georgia M, 2020, NEUROCRITICAL CARE I
   De Georgia Michael A, 2015, ScientificWorldJournal, V2015, P727694, DOI 10.1155/2015/727694
   Duhm J, 2016, JMIR MHEALTH UHEALTH, V4, P155, DOI 10.2196/mhealth.5464
   Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34
   Garot O, 2020, BMC MED INFORM DECIS, V20, DOI 10.1186/s12911-020-1032-4
   Glasin J, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800275
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Haukoos JS, 2005, ACAD EMERG MED, V12, P360, DOI 10.1197/j.aem.2004.11.018
   Huske-Kraus D, 2018, MEASURING ALARM SYST, V2018, P89, DOI [10.29007/5vpj, DOI 10.29007/5VPJ]
   Koehler F, 2018, LANCET, V392, P1047, DOI 10.1016/S0140-6736(18)31880-4
   Koenig M., 2019, TELEMEDICINE ICU
   Komorowski M, 2019, INTENS CARE MED, V45, P1298, DOI 10.1007/s00134-019-05662-6
   Lambert DH, 2016, ANESTH ANALG, V123, P257, DOI 10.1213/ANE.0000000000001376
   Mendez F, 2015, COLOMB MEDICA, V46, P128
   Michard F, 2019, INTENS CARE MED, V45, P671, DOI 10.1007/s00134-018-5384-5
   Mlodzinski Eric, 2020, Pulm Ther, V6, P67, DOI 10.1007/s41030-020-00110-z
   Ozcan E, 2019, ALARM ICU ENVISIONIN
   Paksuniemi M, 2005, P ANN INT IEEE EMBS, P5182, DOI 10.1109/IEMBS.2005.1615645
   Pater CM, 2020, BMJ QUAL SAF, V29, P717, DOI 10.1136/bmjqs-2019-010368
   Perez MV, 2019, NEW ENGL J MED, V381, P1909, DOI 10.1056/NEJMoa1901183
   Poncette AS, 2020, J MED INTERNET RES, V22, DOI 10.2196/17004
   Poncette AS, 2019, JMIR MED INF, V7, P45, DOI 10.2196/13064
   R Core Team, 2018, R FDN STAT COMP
   Romare C, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/16055
   Tscholl DW, 2020, J MED INTERNET RES, V22, DOI 10.2196/15070
   TSCHOLL DW, 2019, BMC ANESTHESIOL, V19, DOI DOI 10.21203/RS.2.238/V2
   Wallin MKEB, 2004, ANESTH ANALG, V98, P763
   Weenk M, 2019, RESUSCITATION, V136, P47, DOI 10.1016/j.resuscitation.2019.01.017
   Wessel D, 2019, MUC 19 P MENSCH COMP, DOI [10.1145/3340764.3340766, DOI 10.1145/3340764.3340766]
   Wilken M, 2019, STUDIES HLTH TECHNOL, V273, P281, DOI [10.29007/5vpj, DOI 10.29007/5VPJ]
NR 35
TC 2
Z9 2
U1 15
U2 15
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD JUN 19
PY 2020
VL 22
IS 6
AR e19091
DI 10.2196/19091
PG 11
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA LZ7FI
UT WOS:000541388100001
PM 32459655
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sastre-Garriga, J
   Tintore, M
   Montalban, X
AF Sastre-Garriga, Jaume
   Tintore, Mar
   Montalban, Xavier
TI Keeping standards of multiple sclerosis care through the COVID-19
   pandemic
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE Multiple sclerosis; disease-modifying therapies; epidemiology; service
   delivery; COVID-19
C1 [Sastre-Garriga, Jaume; Tintore, Mar; Montalban, Xavier] Univ Autonoma Barcelona, Dept Neurol Neuroimmunol, Multiple Sclerosis Ctr Catalonia Cemcat, Hosp Univ Vall dHebron, Edifici Cemcat,P Vall dHebron 119-129, Barcelona 08035, Spain.
RP Sastre-Garriga, J (corresponding author), Univ Autonoma Barcelona, Dept Neurol Neuroimmunol, Multiple Sclerosis Ctr Catalonia Cemcat, Hosp Univ Vall dHebron, Edifici Cemcat,P Vall dHebron 119-129, Barcelona 08035, Spain.
EM jsastre-garriga@cem-cat.org
RI Montalban, Xavier/J-5938-2016; Sastre Garriga, Jaume/E-8605-2018
OI Montalban, Xavier/0000-0002-0098-9918; Sastre Garriga,
   Jaume/0000-0002-1589-2254; Tintore, Mar/0000-0001-9999-5359
CR Brownlee W, 2020, NEUROLOGY, V10, DOI DOI 10.1212/WNL.0000000000009507.APR
   Carod-Artal FJ, 2020, REV NEUROLOGIA, V70, P311, DOI 10.33588/rn.7009.2020179
   Costa-Frossard L, 2020, REV NEUROLOGIA, V70, P329, DOI 10.33588/rn.7009.2020155
   Dominguez-Gil B, 2020, CIR ESPAN, V98, P412, DOI 10.1016/j.ciresp.2020.04.012
   Escalon MX, 2020, AM J PHYS MED REHAB, V99, P453, DOI 10.1097/PHM.0000000000001451
   Klein BC, 2020, NEUROLOGY, V94, P903, DOI 10.1212/WNL.0000000000009494
   Legido-Quigley H, 2020, LANCET PUBLIC HEALTH, V5, pE251, DOI 10.1016/S2468-2667(20)30060-8
   Mitja O, 2020, LANCET, V395, P1193, DOI 10.1016/S0140-6736(20)30753-4
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Waldman G, 2020, NEUROLOGY, V94, P886, DOI 10.1212/WNL.0000000000009519
NR 10
TC 3
Z9 3
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD SEP
PY 2020
VL 26
IS 10
BP 1153
EP 1156
AR 1352458520931785
DI 10.1177/1352458520931785
EA JUN 2020
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NP1QZ
UT WOS:000542430100001
PM 32552382
OA Bronze
DA 2021-01-01
ER

PT J
AU Schett, G
   Manger, B
   Simon, D
   Caporali, R
AF Schett, Georg
   Manger, Bernhard
   Simon, David
   Caporali, Roberto
TI COVID-19 revisiting inflammatory pathways of arthritis
SO NATURE REVIEWS RHEUMATOLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; UP-REGULATION; SARS; INTERLEUKIN-6;
   BARICITINIB; INFECTIONS; INHIBITION; CYTOKINES; SEVERITY; CELLS
AB Coronavirus disease 2019 (COVID-19) is an infectious disease, caused by severe acute respiratory syndrome coronavirus 2, which predominantly affects the lungs and, under certain circumstances, leads to an excessive or uncontrolled immune activation and cytokine response in alveolar structures. The pattern of pro-inflammatory cytokines induced in COVID-19 has similarities to those targeted in the treatment of rheumatoid arthritis. Several clinical studies are underway that test the effects of inhibiting IL-6, IL-1 beta or TNF or targeting cytokine signalling via Janus kinase inhibition in the treatment of COVID-19. Despite these similarities, COVID-19 and other zoonotic coronavirus-mediated diseases do not induce clinical arthritis, suggesting that a local inflammatory niche develops in alveolar structures and drives the disease process. COVID-19 constitutes a challenge for patients with inflammatory arthritis for several reasons, in particular, the safety of immune interventions during the pandemic. Preliminary data, however, do not suggest that patients with inflammatory arthritis are at increased risk of COVID-19.
   This Perspective article explores similarities in the inflammatory processes underlying coronavirus disease 2019 (COVID-19) and rheumatoid arthritis, including the role of pro-inflammatory cytokines and the potential of anti-cytokine therapies to treat COVID-19, as well as the effect of the COVID-19 pandemic on rheumatology.
C1 [Schett, Georg; Manger, Bernhard; Simon, David] Friedrich Alexander Univ FAU Erlangen Nuremberg, Dept Med 3, Erlangen, Germany.
   [Schett, Georg; Manger, Bernhard; Simon, David] Univ Klinikum Erlangen, Erlangen, Germany.
   [Schett, Georg; Manger, Bernhard; Simon, David] FAU Erlangen Nuremberg, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany.
   [Caporali, Roberto] Univ Milan, G Pini Hosp, Res Ctr Adult & Pediat Rheumat Dis, Dept Clin Sci & Community Hlth, Milan, Italy.
RP Schett, G (corresponding author), Friedrich Alexander Univ FAU Erlangen Nuremberg, Dept Med 3, Erlangen, Germany.; Schett, G (corresponding author), Univ Klinikum Erlangen, Erlangen, Germany.; Schett, G (corresponding author), FAU Erlangen Nuremberg, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany.
EM Georg.Schett@uk-erlangen.de
OI Schett, Georg/0000-0001-8740-9615; Simon, David/0000-0001-8310-7820
FU German Research CouncilGerman Research Foundation (DFG) [DFG:
   FOR2438/2886, SFB1181, TRR241]; German Ministry of Science and
   Education; European Union (ERC Synergy grant 4DnanoSCOPE); EU/EFPIA
   Innovative Medicines Initiative 2 (project RTCure)
FX The work of G.S. is supported by the German Research Council (DFG:
   FOR2438/2886; SFB1181; TRR241), the German Ministry of Science and
   Education (project MASCARA), the European Union (ERC Synergy grant
   4DnanoSCOPE) and EU/EFPIA Innovative Medicines Initiative 2 (project
   RTCure).
CR An P, 2020, PROTECTION 318 INFLA
   Angelidis I, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08831-9
   Bechman K, 2019, RHEUMATOLOGY, V58, P1755, DOI 10.1093/rheumatology/kez087
   Blumentals WA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-158
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen ZZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12598
   Christian MD, 2004, CLIN INFECT DIS, V38, P1420, DOI 10.1086/420743
   Codarri L, 2011, NAT IMMUNOL, V12, P560, DOI 10.1038/ni.2027
   European Medicines Agency, 2020, COVID 19 CHLOR HYDR
   Favalli EG, 2020, LANCET INFECT DIS, V20, P1012, DOI 10.1016/S1473-3099(20)30262-0
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Fleming SB, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030023
   Friedman N, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100515
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hollander JE, 2020, NEJM CATALYST, P8, DOI [10.1056/CAT.20.0093, DOI 10.1056/CAT.20.0093]
   Hon KLE, 2003, LANCET, V361, P1701, DOI 10.1016/S0140-6736(03)13364-8
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussell T, 2001, EUR J IMMUNOL, V31, P2566, DOI 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L
   Joo YB, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1977-9
   Josset L, 2013, MBIO, V4, DOI 10.1128/mBio.00165-13
   Katsura H, 2019, STEM CELL REP, V12, P657, DOI 10.1016/j.stemcr.2019.02.013
   Kelesidis Theodoros, 2014, BMC Infect Dis, V14, P321, DOI 10.1186/1471-2334-14-321
   Law HKW, 2005, BLOOD, V106, P2366, DOI 10.1182/blood-2004-10-4166
   Li S, 2006, AM J CHINESE MED, V34, P937, DOI 10.1142/S0192415X06004417
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Marks M, 2016, CLIN MED, V16, P129, DOI 10.7861/clinmedicine.16-2-129
   Marotto D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102539
   Memish ZA, 2020, LANCET, V395, P1063, DOI 10.1016/S0140-6736(19)33221-0
   Meroni PL, 2018, CLIN EXP RHEUMATOL, V36, P317
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Norsa L, 2020, GASTROENTEROLOGY, V159, P371, DOI [10.1053/j.gastro.2020.03.062, 10.1053/j.gastro.2020.03.06]
   Pedersen KB, 2015, ENDOCRINOLOGY, V156, P4411, DOI 10.1210/en.2015-1556
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Praveen D, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105967
   Qian ZH, 2013, AM J RESP CELL MOL, V48, P742, DOI 10.1165/rcmb.2012-0339OC
   Rauber S, 2017, NAT MED, V23, P938, DOI 10.1038/nm.4373
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Ryzhakov G, 2011, J IMMUNOL, V187, P5357, DOI 10.4049/jimmunol.1100917
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Spinelli FR, 2020, ANN RHEUM DIS, V79, P666, DOI [10.1136/annrheumdis-2020-217367, 10.1136/annrheumdis-2020-217557]
   Starr ME, 2015, J GERONTOL A-BIOL, V70, P1508, DOI 10.1093/gerona/glu197
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tobinick E, 2004, CURR MED RES OPIN, V20, P39, DOI 10.1185/030079903125002757
   US Department of Health & Human Services Centers for Disease Control and Prevention, 2020, COR COVID 19
   Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057
   Viner RM, 2020, LANCET, V395, P1741, DOI 10.1016/S0140-6736(20)31129-6
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yoshikawa T, 2009, J VIROL, V83, P3039, DOI 10.1128/JVI.01792-08
   Zhang X, 2007, VIROLOGY, V365, P324, DOI 10.1016/j.virol.2007.04.009
NR 61
TC 4
Z9 5
U1 6
U2 6
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1759-4790
EI 1759-4804
J9 NAT REV RHEUMATOL
JI Nat. Rev. Rheumatol.
PD AUG
PY 2020
VL 16
IS 8
BP 465
EP 470
DI 10.1038/s41584-020-0451-z
EA JUN 2020
PG 6
WC Rheumatology
SC Rheumatology
GA MO4OW
UT WOS:000541316500001
PM 32561873
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Prasad, A
   Muthamilarasan, M
   Prasad, M
AF Prasad, Ashish
   Muthamilarasan, Mehanathan
   Prasad, Manoj
TI Synergistic antiviral effects against SARS-CoV-2 by plant-based
   molecules
SO PLANT CELL REPORTS
LA English
DT Article
DE SARS-CoV-2; Plant-based drugs; Antiviral biomolecules; Plant-based
   vaccines; Traditional medicine; Synergistic effect
ID SPIKE PROTEIN; CHINESE MEDICINE; CORONAVIRUS; SARS; IDENTIFICATION;
   REPLICATION; PREVENTION; VIRUS
AB The exponential spread of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emphasizes the immediate need for effective antiviral drugs and vaccines that could control and prevent the spread of this pandemic. Several new and repurposed drugs are being tested for their effectiveness in the treatment regime, and the development of vaccines is underway. The availability of genome sequence information of the virus and the identification of potential targets to neutralize and eradicate the infection have enabled the search for novel as well as existing molecules to perform the desired function. However, the application of plants in the development of potential biomolecules, such as antibiotics and vaccines, is limited. Traditional medicines involving plant-based formulations have proven successful in boosting immunity and providing tolerance to virus infections. Still, in-depth studies are not available to explore the bioactive compounds of plant origin and their mechanism of action. Given this, the current opinion article conveys our thoughts and perspectives on the promising usage of plant-based biomolecules in circumventing SARS-CoV-2, and how these molecules can work synergistically with other potential drugs for treating SARS-CoV-2.
C1 [Prasad, Ashish; Prasad, Manoj] Natl Inst Plant Genome Res, Aruna Asaf Ali Marg, New Delhi 110067, India.
   [Muthamilarasan, Mehanathan] Univ Hyderabad, Sch Life Sci, Dept Plant Sci, Hyderabad 500046, Telangana, India.
RP Prasad, M (corresponding author), Natl Inst Plant Genome Res, Aruna Asaf Ali Marg, New Delhi 110067, India.
EM manoj_prasad@nipgr.ac.in
OI Prasad, Manoj/0000-0003-0691-0163
FU J.C. Bose National Fellowship Grant of Department of Science and
   Technology, Government of India [JCB/2018/000001]; Council for
   Scientific and Industrial ResearchCouncil of Scientific & Industrial
   Research (CSIR) - India
FX Authors' work in this area is supported by J.C. Bose National Fellowship
   Grant of Department of Science and Technology, Government of India (File
   no.: JCB/2018/000001). A.P. acknowledges the Council for Scientific and
   Industrial Research, Govt. of India for research fellowship. Authors are
   thankful to DBT-eLibrary Consortium (DeLCON) for providing access to
   e-resources.
CR Achan J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-144
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Baldi A, 2008, BIORESOURCE TECHNOL, V99, P4609, DOI 10.1016/j.biortech.2007.06.061
   Chang FR, 2012, NAT PROD COMMUN, V7, P1415
   Chen CJ, 2008, J ETHNOPHARMACOL, V120, P108, DOI 10.1016/j.jep.2008.07.048
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Z, 2004, PHYTOTHER RES, V18, P592, DOI 10.1002/ptr.1485
   Cheng PW, 2006, CLIN EXP PHARMACOL P, V33, P612, DOI 10.1111/j.1440-1681.2006.04415.x
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Gautret P, 2020, J ANTIMICROB AGENTS, DOI [10.1016/j.ijantimicag.2020.105949, DOI 10.1016/J.IJANTIMICAG.2020.105949]
   Gomez N, 2000, ARCH VIROL, V145, P1725, DOI 10.1007/s007050070087
   Gomez N, 1998, VIROLOGY, V249, P352, DOI 10.1006/viro.1998.9315
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Ho TY, 2007, ANTIVIR RES, V74, P92, DOI 10.1016/j.antiviral.2006.04.014
   Hsieh LE, 2010, ANTIVIR RES, V88, P25, DOI 10.1016/j.antiviral.2010.06.010
   Kayser O, 2018, PLANTA MED, V84, P834, DOI 10.1055/a-0631-3876
   Keyaerts E, 2007, ANTIVIR RES, V75, P179, DOI 10.1016/j.antiviral.2007.03.003
   Khosroushahi AY, 2006, CELL BIOL INT, V30, P262, DOI 10.1016/j.cellbi.2005.11.004
   Lau TF, 2005, AM J CHINESE MED, V33, P345, DOI 10.1142/S0192415X05002965
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li HY, 2006, EXP BIOL MED, V231, P1346, DOI 10.1177/153537020623100808
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Lin SC, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2253-8
   O'Connor SE, 2015, ANNU REV GENET, V49, P71, DOI 10.1146/annurev-genet-120213-092053
   Park HR, 2012, ARCH PHARM RES, V35, P77, DOI 10.1007/s12272-012-0108-9
   Pogrebnyak N, 2005, P NATL ACAD SCI USA, V102, P9062, DOI 10.1073/pnas.0503760102
   Rosales-Mendoza S, 2020, EXPERT OPIN BIOL TH, V20, P545, DOI 10.1080/14712598.2020.1752177
   Rothan HA, 2020, FDA APPROVED GOLD DR, DOI [10.1101/2020.04.14.041228, DOI 10.1101/2020.04.14.041228]
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Shoseyov O, 2014, BIOENGINEERED, V5, P49, DOI 10.4161/bioe.26002
   Sivaraman D, 2020, REVEALING ANTIVIRAL, DOI [10.20944/preprints202003.0450.v1, DOI 10.20944/PREPRINTS202003.0450.V1]
   Takeyama Natsumi, 2015, Ther Adv Vaccines, V3, P139, DOI 10.1177/2051013615613272
   Thileepan T, 2018, J RES TRADIT MED, V4, P21, DOI [10.5455/jrtm.2018/298118, DOI 10.5455/JRTM.2018/298118]
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Xing J, 2020, REVERSAL INFECTED HO, DOI [10.1101/2020.04.07.030734, DOI 10.1101/2020.04.07.030734]
   Yang CW, 2010, ANTIVIR RES, V88, P160, DOI 10.1016/j.antiviral.2010.08.009
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Yi L, 2004, J VIROL, V78, P11334, DOI 10.1128/JVI.78.20.11334-11339.2004
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Zhong NS, 2004, PHILOS T R SOC B, V359, P1115, DOI 10.1098/rstb.2004.1491
NR 43
TC 3
Z9 3
U1 2
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-7714
EI 1432-203X
J9 PLANT CELL REP
JI Plant Cell Reports
PD SEP
PY 2020
VL 39
IS 9
BP 1109
EP 1114
DI 10.1007/s00299-020-02560-w
EA JUN 2020
PG 6
WC Plant Sciences
SC Plant Sciences
GA MZ0YC
UT WOS:000541305900001
PM 32561979
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Sagkan, RI
   Akin-Bali, DF
AF Ilikci Sagkan, Rahsan
   Akin-Bali, Dilara Fatma
TI Structural variations and expression profiles of the SARS-CoV-2 host
   invasion genes in lung cancer
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE ACE2; CD147; Covid-19; FURIN; lung cancer; severe acute respiratory
   syndrome coronavirus 2; TMPRSS2
AB Recent days have seen growing evidence of cancer's susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and of the effect of genomic differences on the virus' entrance genes in lung cancer. Genetic confirmation of the hypotheses regarding gene expression and mutation pattern of target genes, including angiotensin-converting enzyme-2 (ACE2), transmembrane serine protease 2 (TMPRSS2), basigin (CD147/BSG) and paired basic amino acid cleaving enzyme (FURIN/PCSK3), as well as correlation analysis, was done in relation to lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) using in silico analysis. Not only were gene expression and mutation patterns detected, but also there were correlation and survival analysis between ACE2 and other target genes expression levels. The total genetic anomaly carrying rate of target genes, including ACE2, TMPRSS2, CD147/BSG, and FURIN/PCSK3, was determined as 8.1% and 21 mutations were detected, with 7 of these mutations having pathogenic features. p.H34N on the RBD binding residues for SARS-CoV-2 was determined in our LUAD patient group. According to gene expression analysis results, though the TMPRSS2 level was statistically significantly decreased in the LUSC patient group compared to healthy control, the ACE2 level was determined to be high in LUAD and LUSC groups. There were no meaningful differences in the expression of CD147 and FURIN genes. The challenge for today is building the assessment of genomic susceptibility to COVID-19 in lung cancer, requiring detailed experimental laboratory studies, in addition to in silico analyses, as a way of assessing the mechanism of novel virus invasion that can be used in the development of effective SARS-CoV-2 therapy.
C1 [Ilikci Sagkan, Rahsan] Usak Univ, Sch Med, Dept Med Biol, Usak, Turkey.
   [Akin-Bali, Dilara Fatma] Nigde Omer Halisdemir Univ, Fac Med, Dept Med Biol, Nigde, Turkey.
RP Sagkan, RI (corresponding author), Usak Univ, Sch Med, Dept Med Biol, Usak, Turkey.
EM rahsan.ilikci@usak.edu.tr
OI Ilikci Sagkan, Rahsan/0000-0003-3844-6158
CR Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76
   Barta JA, 2019, ANN GLOB HEALTH, V85, DOI 10.5334/aogh.2419
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Bromberg Y, 2007, NUCLEIC ACIDS RES, V35, P3823, DOI 10.1093/nar/gkm238
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen YW, 2010, AM J PATHOL, V176, P2986, DOI 10.2353/ajpath.2010.090665
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hussain M, 2020, J MED VIROL, V92, P1580, DOI 10.1002/jmv.25832
   Kong Q, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01209-2
   Kumar Swatantra, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00571-5
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li GP, 2020, J AUTOIMMUN, V112, DOI 10.1016/j.jaut.2020.102463
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Moujaess E, 2020, CRIT REV ONCOL HEMAT, V150, DOI 10.1016/j.critrevonc.2020.102972
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Yan TT, 2020, FASEB J, V34, P6017, DOI 10.1096/fj.202000782
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1156-5
   Zhao Y, 2020, SINGLE CELL RNA EXPR
NR 28
TC 1
Z9 1
U1 3
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2637
EP 2647
DI 10.1002/jmv.26107
EA JUN 2020
PG 11
WC Virology
SC Virology
GA NU0EN
UT WOS:000541087600001
PM 32492203
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Chen, WY
   Yao, M
   Fang, ZX
   Lv, XD
   Deng, M
   Wu, Z
AF Chen, Wenyu
   Yao, Ming
   Fang, Zhixian
   Lv, Xiaodong
   Deng, Min
   Wu, Zhen
TI A study on clinical effect of Arbidol combined with adjuvant therapy on
   COVID-19
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE adjuvant therapy; Arbidol; COVID-19
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS INFECTIONS; ANTIVIRAL ACTIVITY;
   VIRUS; MECHANISM
AB This study aims to explore the clinical effect of Arbidol (ARB) combined with adjuvant therapy on patients with coronavirus disease 2019 (COVID-19). The study included 62 patients with COVID-19 admitted to the First Hospital of Jiaxing from January to March 2020, and all patients were divided into the test group and the control group according to whether they received ARB during hospitalization. Various indexes in the two groups before and after treatment were observed and recorded, including fever, cough, hypodynamia, nasal obstruction, nasal discharge, diarrhea, C-reactive protein (CRP), procalcitonin (PCT), blood routine indexes, blood biochemical indexes, time to achieve negative virus nucleic acid, and so on. The fever and cough in the test group were relieved markedly faster than those in the control group (P < .05); there was no obvious difference between the two groups concerning the percentage of patients with abnormal CRP, PCT, blood routine indexes, aspartate aminotransferase, and alanine aminotransferase (P > .05); the time for two consecutive negative nucleic acid tests in the test group were shorter than that in the control group; the hospitalization period of the patients in the test group and control group were (16.5 +/- 7.14) days and (18.55 +/- 7.52) days, respectively. ARB combined with adjuvant therapy might be able to relieve the fever of COVID-19 sufferers faster and accelerate the cure time to some degree, hence it's recommended for further research clinically.
C1 [Chen, Wenyu; Fang, Zhixian; Lv, Xiaodong] Jiaxing Univ, Hosp Jiaxing 1, Dept Respirat, Affiliated Hosp, Jiaxing, Peoples R China.
   [Yao, Ming] Jiaxing Univ, Ctr Pain Med, Affiliated Hosp, Hosp Jiaxing 1, Jiaxing, Peoples R China.
   [Deng, Min] Jiaxing Univ, Dept Infect Dis, Affiliated Hosp, Hosp Jiaxing 1, 1882 South Zhonghuan Rd, Jiaxing 314000, Peoples R China.
   [Wu, Zhen] Tongde Hosp Zhejiang Prov, Dept Orthoped, 234 Gucui Rd, Hangzhou 310012, Zhejiang, Peoples R China.
RP Deng, M (corresponding author), Jiaxing Univ, Dept Infect Dis, Affiliated Hosp, Hosp Jiaxing 1, 1882 South Zhonghuan Rd, Jiaxing 314000, Peoples R China.; Wu, Z (corresponding author), Tongde Hosp Zhejiang Prov, Dept Orthoped, 234 Gucui Rd, Hangzhou 310012, Zhejiang, Peoples R China.
EM dengmigaa@163.com; wuzhen1897621@163.com
OI Deng, Min/0000-0001-6432-3202; Wu, Zhen/0000-0001-5639-289X
FU Jiaxing Fight Novel Coronavirus Pneumonia Emergency Technology Attack
   Special Project in 2020 [2020GZ30001]; Jiaxing Key Laboratory of
   Precision Treatment for Lung Cancer; Jiaxing Medical Key Discipline
   (infectious diseases) Project [2019-zc-02]; Key Discipline of Jiaxing
   Respiratory Medicine Construction Project [2019-zc-04]
FX Jiaxing Fight Novel Coronavirus Pneumonia Emergency Technology Attack
   Special Project in 2020, Grant/Award Number: 2020GZ30001; Jiaxing Key
   Laboratory of Precision Treatment for Lung Cancer; Jiaxing Medical Key
   Discipline (infectious diseases) Project, Grant/Award Number:
   no.2019-zc-02; Key Discipline of Jiaxing Respiratory Medicine
   Construction Project, Grant/Award Number: No.2019-zc-04
CR Bande F, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/424860
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658
   Boriskin YS, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-56
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Gerna G, 2007, J CLIN VIROL, V38, P244, DOI 10.1016/j.jcv.2006.12.008
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Leneva IA, 2009, ANTIVIR RES, V81, P132, DOI 10.1016/j.antiviral.2008.10.009
   Liu Q, 2013, ACTA PHARMACOL SIN, V34, P1075, DOI 10.1038/aps.2013.54
   Morra ME, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1977
   Pecheur EI, 2007, BIOCHEMISTRY-US, V46, P6050, DOI 10.1021/bi700181j
   Pecheur EI, 2016, J VIROL, V90, P3086, DOI 10.1128/JVI.02077-15
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shi L, 2007, ARCH VIROL, V152, P1447, DOI 10.1007/s00705-007-0974-5
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Sun PF, 2020, J MED VIROL, V92, P1721, DOI 10.1002/jmv.25804
   Vabret A, 2008, J PAEDIATR CHILD H, V44, P176, DOI 10.1111/j.1440-1754.2007.01246.x
   Villalain J, 2010, J PHYS CHEM B, V114, P8544, DOI 10.1021/jp102619w
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 21
TC 6
Z9 6
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2702
EP 2708
DI 10.1002/jmv.26142
EA JUN 2020
PG 7
WC Virology
SC Virology
GA NU0EN
UT WOS:000541077600001
PM 32510169
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Goldust, M
   Agarwal, K
   Kroumpouzos, G
   Jafferany, M
   Lotti, T
   Podder, I
AF Goldust, Mohamad
   Agarwal, Komal
   Kroumpouzos, George
   Jafferany, Mohammad
   Lotti, Torello
   Podder, Indrashis
TI Mental health status of dermatologists during the COVID-19 pandemic: A
   technology-based therapy
SO DERMATOLOGIC THERAPY
LA English
DT Letter
C1 [Goldust, Mohamad] Univ Rome G Marconi, Rome, Italy.
   [Goldust, Mohamad] Univ Hosp Basel, Dept Dermatol, Basel, Switzerland.
   [Agarwal, Komal] CNMC, Dept Dermatol, Kolkata, India.
   [Kroumpouzos, George] Brown Univ, Dept Dermatol, Alpert Med Sch, Providence, RI 02912 USA.
   [Kroumpouzos, George] Med Sch Jundiai, Dept Dermatol, Sao Paulo, Brazil.
   [Jafferany, Mohammad] Cent Michigan Univ, Coll Med, Saginaw, MI USA.
   [Lotti, Torello] Univ Studies Guglielmo Marconi, Rome, Italy.
   [Podder, Indrashis] Coll Med & Sagore Dutta Hosp, Dept Dermatol, Kolkata, India.
RP Podder, I (corresponding author), Coll Med & Sagore Dutta Hosp, Dept Dermatol, Kolkata, India.
EM ipodder88@gmail.com
RI Agarwal, Komal/AAU-8078-2020
OI Jafferany, Mohammad/0000-0001-6358-9068; PODDER,
   INDRASHIS/0000-0002-9589-083X
CR Arora G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13359
   Caldaria A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13395
   Gupta M, 2020, DERMAT THER
   Liu NQ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112921
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Rudnicka L, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13361
   Sharma A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13398
   Tao J, 2020, BRIT J DERMATOL, V182, P1477, DOI 10.1111/bjd.19011
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
NR 9
TC 5
Z9 5
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13723
DI 10.1111/dth.13723
EA JUN 2020
PG 2
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000541158100001
PM 32474959
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Nickel, RS
   Margulies, S
   Frazer, B
   Luban, NLC
   Webb, J
AF Nickel, Robert Sheppard
   Margulies, Stefanie
   Frazer, Brittany
   Luban, Naomi L. C.
   Webb, Jennifer
TI Combination dose-escalated hydroxyurea and transfusion: an approach to
   conserve blood during the COVID-19 pandemic
SO BLOOD
LA English
DT Letter
ID SICKLE-CELL-ANEMIA; ABNORMAL TRANSCRANIAL DOPPLER; FLOW VELOCITIES;
   CHILDREN; HYDROXYCARBAMIDE; PREVENTION; THERAPY; DISEASE; STROKE
C1 [Nickel, Robert Sheppard; Margulies, Stefanie; Frazer, Brittany; Luban, Naomi L. C.; Webb, Jennifer] Childrens Natl Hosp, Div Hematol, Washington, DC USA.
   [Nickel, Robert Sheppard; Luban, Naomi L. C.; Webb, Jennifer] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA.
RP Nickel, RS (corresponding author), Childrens Natl Hosp, 111 Michigan Ave NW, Washington, DC 20010 USA.
EM rnickel@childrensnational.org
OI Nickel, Robert/0000-0003-4277-7523
FU National Blood Foundation Scientific Research Grants Program; Clinical
   and Translational Science Institute at Children's National Hospital
FX This work was supported by the National Blood Foundation Scientific
   Research Grants Program and the Clinical and Translational Science
   Institute at Children's National Hospital (R.S.N.).
CR American Society of Hematology, COVID 19 SICKL CELL
   Bernaudin F, 2016, BLOOD, V127, P1814, DOI 10.1182/blood-2015-10-675231
   Brousse V, 2013, BRIT J HAEMATOL, V160, P259, DOI 10.1111/bjh.12104
   Chou ST, 2018, BLOOD, V132, P1198, DOI 10.1182/blood-2018-05-851360
   DeBaun MR, 2020, BLOOD ADV, V4, P1554, DOI 10.1182/bloodadvances.2019001142
   DeBaun MR, 2020, BLOOD, V135, P1997, DOI 10.1182/blood.2020005992
   Delicou S, 2016, HEMATOLOGY TRANSFUSI, V2, P6
   Fields ME, 2019, BLOOD, V133, P2436, DOI 10.1182/blood-2018-09-876318
   Ghafuri DL, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26401
   Hankins JS, 2015, AM J HEMATOL, V90, P1099, DOI 10.1002/ajh.24198
   Hulbert ML, 2011, BLOOD, V117, P772, DOI 10.1182/blood-2010-01-261123
   John CC, 2019, BLOOD, V134, DOI 10.1182/blood-2019-125128
   Lagunju I A, 2013, Niger Postgrad Med J, V20, P181
   Lagunju I, 2015, PEDIATR BLOOD CANCER, V62, P1587, DOI 10.1002/pbc.25529
   McGann PT, 2019, AM J HEMATOL, V94, P871, DOI 10.1002/ajh.25510
   Nottage KA, 2016, BRIT J HAEMATOL, V175, P331, DOI 10.1111/bjh.14235
   Partanen M, 2020, BRIT J HAEMATOL, V189, P1192, DOI 10.1111/bjh.16519
   POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6
   Ware RE, 2015, HEMATOL-AM SOC HEMAT, P436, DOI 10.1182/asheducation-2015.1.436
   Ware RE, 2016, LANCET, V387, P661, DOI 10.1016/S0140-6736(15)01041-7
   Ware RE, 2012, BLOOD, V119, P3925, DOI 10.1182/blood-2011-11-392340
NR 21
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD JUN 18
PY 2020
VL 135
IS 25
BP 2320
EP 2322
DI 10.1182/blood.2020006582
PG 3
WC Hematology
SC Hematology
GA NR3SV
UT WOS:000571484400017
PM 32403134
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Robbiani, DF
   Gaebler, C
   Muecksch, F
   Lorenzi, JCC
   Wang, ZJ
   Cho, A
   Agudelo, M
   Barnes, CO
   Gazumyan, A
   Finkin, S
   Hagglof, T
   Oliveira, TY
   Viant, C
   Hurley, A
   Hoffmann, HH
   Millard, KG
   Kost, RG
   Cipolla, M
   Gordon, K
   Bianchini, F
   Chen, ST
   Ramos, V
   Patel, R
   Dizon, J
   Shimeliovich, I
   Mendoza, P
   Hartweger, H
   Nogueira, L
   Pack, M
   Horowitz, J
   Schmidt, F
   Weisblum, Y
   Michailidis, E
   Ashbrook, AW
   Waltari, E
   Pak, JE
   Huey-Tubman, KE
   Koranda, N
   Hoffman, PR
   West, AP
   Rice, CM
   Hatziioannou, T
   Bjorkman, PJ
   Bieniasz, PD
   Caskey, M
   Nussenzweig, MC
AF Robbiani, Davide F.
   Gaebler, Christian
   Muecksch, Frauke
   Lorenzi, Julio C. C.
   Wang, Zijun
   Cho, Alice
   Agudelo, Marianna
   Barnes, Christopher O.
   Gazumyan, Anna
   Finkin, Shlomo
   Hagglof, Thomas
   Oliveira, Thiago Y.
   Viant, Charlotte
   Hurley, Arlene
   Hoffmann, Hans-Heinrich
   Millard, Katrina G.
   Kost, Rhonda G.
   Cipolla, Melissa
   Gordon, Kristie
   Bianchini, Filippo
   Chen, Spencer T.
   Ramos, Victor
   Patel, Roshni
   Dizon, Juan
   Shimeliovich, Irina
   Mendoza, Pilar
   Hartweger, Harald
   Nogueira, Lilian
   Pack, Maggi
   Horowitz, Jill
   Schmidt, Fabian
   Weisblum, Yiska
   Michailidis, Eleftherios
   Ashbrook, Alison W.
   Waltari, Eric
   Pak, John E.
   Huey-Tubman, Kathryn E.
   Koranda, Nicholas
   Hoffman, Pauline R.
   West, Anthony P., Jr.
   Rice, Charles M.
   Hatziioannou, Theodora
   Bjorkman, Pamela J.
   Bieniasz, Paul D.
   Caskey, Marina
   Nussenzweig, Michel C.
TI Convergent antibody responses to SARS-CoV-2 in convalescent individuals
SO NATURE
LA English
DT Article; Early Access
ID NEUTRALIZING ANTIBODIES; SARS CORONAVIRUS; B-CELLS; VIRUS; BROAD
AB During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2(1-5). Here we report on 149 COVID-19-convalescent individuals. Plasma samples collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres; titres were less than 50 in 33% of samples, below 1,000 in 79% of samples and only 1% of samples had titres above 5,000. Antibody sequencing revealed the expansion of clones of RBD-specific memory B cells that expressed closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutralized the virus with half-maximal inhibitory concentrations (IC(50)values) as low as 2 ng ml(-1). In conclusion, most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
   Although rare, antibodies against the receptor-binding domain of SARS-CoV-2 that showed potent antiviral activity were obtained from all tested convalescent individuals, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
C1 [Robbiani, Davide F.; Gaebler, Christian; Lorenzi, Julio C. C.; Wang, Zijun; Cho, Alice; Barnes, Christopher O.; Gazumyan, Anna; Finkin, Shlomo; Hagglof, Thomas; Oliveira, Thiago Y.; Viant, Charlotte; Millard, Katrina G.; Cipolla, Melissa; Gordon, Kristie; Bianchini, Filippo; Chen, Spencer T.; Ramos, Victor; Patel, Roshni; Dizon, Juan; Shimeliovich, Irina; Mendoza, Pilar; Hartweger, Harald; Nogueira, Lilian; Pack, Maggi; Horowitz, Jill; Caskey, Marina; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.
   [Muecksch, Frauke; Schmidt, Fabian; Weisblum, Yiska; Hatziioannou, Theodora; Bieniasz, Paul D.] Rockefeller Univ, Lab Retrovirol, 1230 York Ave, New York, NY 10021 USA.
   [Agudelo, Marianna; Huey-Tubman, Kathryn E.; Koranda, Nicholas; Hoffman, Pauline R.; West, Anthony P., Jr.; Bjorkman, Pamela J.] CALTECH, Div Biol & BioL Engn, Pasadena, CA 91125 USA.
   [Hurley, Arlene] Rockefeller Univ, Hosp Program Direct, 1230 York Ave, New York, NY 10021 USA.
   [Hoffmann, Hans-Heinrich; Michailidis, Eleftherios; Ashbrook, Alison W.; Rice, Charles M.] Rockefeller Univ, Lab Virol & Infect Dis, 1230 York Ave, New York, NY 10021 USA.
   [Kost, Rhonda G.] Rockefeller Univ, Ctr Clin TransLat Sci, 1230 York Ave, New York, NY 10021 USA.
   [Waltari, Eric; Pak, John E.] Chan Zuckerberg Biohub, San Francisco, CA USA.
   [Bieniasz, Paul D.; Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.
   [Robbiani, Davide F.] Univ Svizzera Italiana, Inst Res Biomed, Bellinzona, Switzerland.
RP Robbiani, DF; Caskey, M; Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.; Bieniasz, PD (corresponding author), Rockefeller Univ, Lab Retrovirol, 1230 York Ave, New York, NY 10021 USA.; Bjorkman, PJ (corresponding author), CALTECH, Div Biol & BioL Engn, Pasadena, CA 91125 USA.; Bieniasz, PD; Nussenzweig, MC (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.; Robbiani, DF (corresponding author), Univ Svizzera Italiana, Inst Res Biomed, Bellinzona, Switzerland.
EM drobbiani@irb.usi.ch; bjorkman@caltech.edu; pbieniasz@rockefeller.edu;
   mcaskey@rockefeller.edu; nussen@rockefeller.edu
RI Robbiani, Davide F./AAF-7662-2019; Oliveira, Thiago Yukio
   Kikuchi/ABF-5186-2020; Cetrulo Lorenzi, Julio Cesar/B-5264-2008
OI Robbiani, Davide F./0000-0001-7379-3484; Oliveira, Thiago Yukio
   Kikuchi/0000-0002-2654-0879; Cetrulo Lorenzi, Julio
   Cesar/0000-0003-2492-3961; Ashbrook, Alison/0000-0003-1114-1426;
   Cipolla, Melissa/0000-0001-8156-2512; Michailidis,
   Eleftherios/0000-0002-9907-4346; Wang, Zijun/0000-0002-2095-2151;
   Gaebler, Christian/0000-0001-7295-8128; Mendoza Daroca,
   Pilar/0000-0003-2957-1811
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P01-AI138398-S1, 2U19AI111825];
   Caltech Merkin Institute for Translational Research; George Mason
   University; European ATAC consortium [EC 101003650]; G. Harold and Leila
   Y. Mathers Charitable Foundation; Robert S. Wennett Post-Doctoral
   Fellowship; National Center for Advancing Translational Sciences
   (National Institutes of Health Clinical and Translational Science Award
   programme) [UL1 TR001866]; Shapiro-Silverberg Fund for the Advancement
   of Translational Research;  [P50 AI150464];  [R01-AI091707-10S1]; 
   [R37-AI64003];  [R01AI78788]
FX We thank all study participants who devoted time to our research; B.
   Coller and S. Schlesinger, the Rockefeller University Hospital Clinical
   Research Support Office and nursing staff; J. L. DeRisi for facilitating
   interactions with the Chan Zuckerberg Biohub; all members of the M.C.N.
   laboratory for discussions; A. Escolano, G. Breton and B. Reis; M.
   Jankovic for laboratory support; and J. Vielmetter and the Protein
   Expression Center in the Beckman Institute at Caltech. This work was
   supported by NIH grant P01-AI138398-S1 (M.C.N., C.M.R. and P.J.B.) and
   2U19AI111825 (M.C.N. and C.M.R.); the Caltech Merkin Institute for
   Translational Research and P50 AI150464 (P.J.B.), George Mason
   University Fast Grants (D.F.R. and P.J.B.) and the European ATAC
   consortium EC 101003650 (D.F.R.); R01-AI091707-10S1 to C.M.R.;
   R37-AI64003 to P.D.B.; R01AI78788 to T. Hatziioannou; The G. Harold and
   Leila Y. Mathers Charitable Foundation to C.M.R. Electron microscopy was
   performed in the Caltech Beckman Institute Resource Center for
   Transmission Electron Microscopy (directors: S. Chen and A. Malyutin).
   C.G. was supported by the Robert S. Wennett Post-Doctoral Fellowship, in
   part by the National Center for Advancing Translational Sciences
   (National Institutes of Health Clinical and Translational Science Award
   programme, grant UL1 TR001866) and by the Shapiro-Silverberg Fund for
   the Advancement of Translational Research. P.D.B. and M.C.N. are
   investigators of the Howard Hughes Medical Institute.
CR ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Barnes CO, 2020, CELL, V182, P828, DOI 10.1016/j.cell.2020.06.025
   Bournazos S, 2017, IMMUNOL REV, V275, P285, DOI 10.1111/imr.12482
   Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   DeWitt WS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160853
   Ehrhardt SA, 2019, NAT MED, V25, P1589, DOI 10.1038/s41591-019-0602-4
   Feinberg MB, 2017, SCIENCE, V358, P865, DOI 10.1126/science.aaq0215
   Goddard TD, 2007, J STRUCT BIOL, V157, P281, DOI 10.1016/j.jsb.2006.06.010
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gralinski LE, 2015, J PATHOL, V235, P185, DOI 10.1002/path.4454
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359
   GUY HR, 1985, BIOPHYS J, V47, P61, DOI 10.1016/S0006-3495(85)83877-7
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Kane M, 2016, CELL HOST MICROBE, V20, P392, DOI 10.1016/j.chom.2016.08.005
   Klein F, 2014, J EXP MED, V211, P2361, DOI 10.1084/jem.20141050
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   Murugan R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8029
   Pappas L, 2014, NATURE, V516, P418, DOI 10.1038/nature13764
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024
   Rubelt F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049774
   Salazar G, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0019-3
   Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227
   Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930
   Schmidt F, 2020, J EXP MED, V217, DOI 10.1084/jem.20201181
   Schoofs T, 2019, IMMUNITY, V50, P1513, DOI 10.1016/j.immuni.2019.04.014
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Tiller T, 2007, IMMUNITY, V26, P205, DOI 10.1016/j.immuni.2007.01.009
   Van Rompay KKA, 2020, P NATL ACAD SCI USA, V117, P7981, DOI 10.1073/pnas.2000414117
   von Boehmer L, 2016, NAT PROTOC, V11, P1908, DOI 10.1038/nprot.2016.102
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wang Q, 2020, CELL HOST MICROBE, V28, P335, DOI 10.1016/j.chom.2020.05.010
   Wang ZJ, 2020, J IMMUNOL METHODS, V478, DOI 10.1016/j.jim.2019.112734
   Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 47
TC 120
Z9 119
U1 16
U2 20
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
DI 10.1038/s41586-020-2456-9
EA JUN 2020
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MV3CI
UT WOS:000556238800001
PM 32555388
OA Bronze, Green Accepted
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Kar, P
   Sharma, NR
   Singh, B
   Sen, A
   Roy, A
AF Kar, Pallab
   Sharma, Neeta Raj
   Singh, Bhupender
   Sen, Arnab
   Roy, Ayan
TI Natural compounds from Clerodendrum spp. as possible therapeutic
   candidates against SARS-CoV-2: An in silico investigation
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; Clerodendrumspp; molecular docking; drug-likeness; MM-GBSA;
   taraxerol; molecular dynamics simulations
ID DRUG DISCOVERY; RNA-POLYMERASE; SMALL-MOLECULE; PROTEIN; DOCKING;
   COVID-19
AB The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has rattled global public health, with researchers struggling to find specific therapeutic solutions. In this context, the present study employed anin silicoapproach to assess the inhibitory potential of the phytochemicals obtained from GC-MS analysis of twelveClerodendrumspecies against the imperative spike protein, main protease enzyme M(pro)and RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2. An extensive molecular docking investigation of the phytocompounds at the active binding pockets of the viral proteins revealed promising inhibitory potential of the phytochemicals taraxerol, friedelin and stigmasterol. Decent physicochemical attributes of the compounds in accordance with Lipinski's rule of five and Veber's rule further established them as potential therapeutic candidates against SARS-CoV-2. Molecular mechanics-generalized Born surface area (MM-GBSA) binding free energy estimation revealed that taraxerol was the most promising candidate displaying the highest binding efficacy with all the concerned SARS-CoV-2 proteins included in the present analysis. Our observations were supported by robust molecular dynamics simulations of the complexes of the viral proteins with taraxerol for a timescale of 40 nanoseconds. It was striking to note that taraxerol exhibited better binding energy scores with the concerned viral proteins than the drugs that are specifically targeted against them. The present results promise to provide new avenues to further evaluate the potential of the phytocompound taraxerolin vitroandin vivotowards its successful deployment as a SARS-CoV-2 inhibitor and combat the catastrophic COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Kar, Pallab; Sen, Arnab] Univ North Bengal, Dept Bot, Bioinformat Facil, Siliguri, India.
   [Sharma, Neeta Raj; Singh, Bhupender; Roy, Ayan] Lovely Profess Univ, Dept Biotechnol, Phagwara 144411, Punjab, India.
RP Sen, A (corresponding author), Univ North Bengal, Dept Bot, Bioinformat Facil, Siliguri, India.; Roy, A (corresponding author), Lovely Profess Univ, Dept Biotechnol, Phagwara 144411, Punjab, India.
EM ayanroy.bio@gmail.com; senarnab_nbu@hotmail.com
RI Roy, Ayan/ABD-5737-2020
OI Roy, Ayan/0000-0002-1578-4712
FU University of North Bengal
FX PK acknowledges University of North Bengal for providing fellowship to
   execute this work. AR, NRS and BS acknowledge Lovely Professional
   University, India for providing the necessary infrastructure facility.
   AS and PK acknowledge University of North Bengal, India for the
   infrastructure support to the work. The authors thank Dr. Devashan
   Naidoo (Centre for Algal Biotechnology, Faculty of Natural Sciences,
   Mangosuthu University of Technology, South Africa) for critical reading
   of the manuscript and thorough language correction. We also thank the
   anonymous reviewers for their suggestions which helped to improve the
   manuscript.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abdelli I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763199
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Peele KA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1770127
   Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   Al-Snafi A. E., 2016, IOSR J PHARM, V6, P68
   Amarowicz R, 2009, EUR J LIPID SCI TECH, V111, P411, DOI 10.1002/ejlt.200900102
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Antunes DA, 2017, CANCER RES, V77, pE55, DOI 10.1158/0008-5472.CAN-17-0511
   Ayaz M, 2019, STEROIDS, V141, P30, DOI 10.1016/j.steroids.2018.11.005
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767210
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   Basit A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768150
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Blomme EAG, 2016, CHEM RES TOXICOL, V29, P473, DOI 10.1021/acs.chemrestox.5b00407
   Boldrin PK, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-216
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Borges CMP, 2013, J BRAZIL CHEM SOC, V24, P1950, DOI 10.5935/0103-5053.20130244
   Chathuranga K, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070604
   Ciliberto G, 2020, DRUG DISCOV TODAY, V25, P946, DOI 10.1016/j.drudis.2020.04.005
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Dobryniewski Jacek, 2007, Przegl Lek, V64, P91
   El Asnaoui K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767212
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761881
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giweli A, 2012, MOLECULES, V17, P4836, DOI 10.3390/molecules17054836
   Gleeson MP, 2011, CURR TOP MED CHEM, V11, P358
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Gyebi GA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764868
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767691
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kar P, 2016, SYMBIOSIS, V70, P159, DOI 10.1007/s13199-016-0415-x
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779131
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   Lagorce D, 2017, BIOINFORMATICS, V33, P3658, DOI 10.1093/bioinformatics/btx491
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Lobo-Galo N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764393
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mahanta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768902
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Naidoo D, 2020, J ETHNOPHARMACOL, V248, DOI 10.1016/j.jep.2019.112305
   Nejadi Babadaei M. M., 2020, J BIOMOLECULAR STRUC, P1, DOI [10.1080/07391102.2020.1767211, DOI 10.1080/07391102.2020.1767211]
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   O'Neill VJ, 2002, BRIT J CANCER, V87, P933, DOI 10.1038/sj.bjc.6600591
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Paniri A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767690
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Patel JJ, 2014, J ETHNOPHARMACOL, V154, P268, DOI 10.1016/j.jep.2014.03.071
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Pouliot M, 2016, J MED CHEM, V59, P497, DOI 10.1021/acs.jmedchem.5b00361
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Schyman P, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00889
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768149
   Subash-Babu P, 2017, EXP TOXICOL PATHOL, V69, P630, DOI 10.1016/j.etp.2017.05.011
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Surapaneni S, 2018, J CAR MUT, V9, P313, DOI DOI 10.4172/2157-2518.1000313
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Takasaki M, 1999, BIOL PHARM BULL, V22, P606, DOI 10.1248/bpb.22.606
   Tang JJ, 2011, CELL METAB, V13, P44, DOI 10.1016/j.cmet.2010.12.004
   Tort FL, 2020, VIRUS RES, V283, DOI 10.1016/j.virusres.2020.197976
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Velthuis AJWT, 2010, NUCLEIC ACIDS RES, V38, P203, DOI 10.1093/nar/gkp904
   Vijayakumar B, 2014, PHARMACOGN MAG, V10, P639, DOI 10.4103/0973-1296.139809
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yao XY, 2013, INT IMMUNOPHARMACOL, V15, P316, DOI 10.1016/j.intimp.2012.12.032
   Yin W., 2020, STRUCTURAL BASIS INH, DOI [DOI 10.1101/2020.04.08.032763, 10.1101/2020.04.08.032763]
   Yoshida Y, 2003, J NUTR SCI VITAMINOL, V49, P277, DOI 10.3177/jnsv.49.277
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 98
TC 2
Z9 2
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1780947
EA JUN 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MQ3AY
UT WOS:000552770100001
PM 32552595
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Amin, SA
   Ghosh, K
   Gayen, S
   Jha, T
AF Amin, Sk. Abdul
   Ghosh, Kalyan
   Gayen, Shovanlal
   Jha, Tarun
TI Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo
   based QSAR, virtual screening and molecular docking study of
   somein-housemolecules as papain-like protease (PLpro) inhibitors
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; SARS-CoV PLpro; Monte Carlo based optimization;
   QSAR based virtual screening; ADME; molecular docking
ID THIOPURINE ANALOGS; DESIGN; IDENTIFICATION; NANOPARTICLES
AB World Health Organization characterized novel coronavirus disease (COVID-19), caused by severe acute respiratory syndrome (SARS) coronavirus-2 (SARS-CoV-2) as world pandemic. This infection has been spreading alarmingly by causing huge social and economic disruption. In order to response quickly, the inhibitors already designed against different targets of previous human coronavirus infections will be a great starting point for anti-SARS-CoV-2 inhibitors. In this study, our approach integrates different ligand based drug design strategies of somein-housechemicals. The study design was composed of some major aspects: (a) classification QSAR based data mining of diverse SARS-CoV papain-like protease (PLpro) inhibitors, (b) QSAR based virtual screening (VS) to identifyin-housemolecules that could be effective against putative target SARS-CoV PLpro and (c) finally validation of hits through receptor-ligand interaction analysis. This approach could be used to aid in the process of COVID-19 drug discovery. It will introduce key concepts, set the stage for QSAR based screening of active molecules against putative SARS-CoV-2 PLpro enzyme. Moreover, the QSAR models reported here would be of further use to screen large database. This study will assume that the reader is approaching the field of QSAR and molecular docking based drug discovery against SARS-CoV-2 PLpro with little prior knowledge. Communicated by Ramaswamy H. Sarma
C1 [Amin, Sk. Abdul; Jha, Tarun] Jadavpur Univ, Dept Pharmaceut Technol, Nat Sci Lab, Div Med & Pharmaceut Chem, POB 17020, Kolkata 700032, India.
   [Ghosh, Kalyan; Gayen, Shovanlal] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Lab Drug Design & Discovery, Sagar, Madhya Pradesh, India.
RP Jha, T (corresponding author), Jadavpur Univ, Dept Pharmaceut Technol, Nat Sci Lab, Div Med & Pharmaceut Chem, POB 17020, Kolkata 700032, India.; Gayen, S (corresponding author), Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Lab Drug Design & Discovery, Sagar, Madhya Pradesh, India.
EM shovanlal.gayen@gmail.com; tjupharm@yahoo.com
RI Amin, Sk. Abdul/AAX-8137-2020
OI Amin, Sk. Abdul/0000-0003-4799-7322; GHOSH, KALYAN/0000-0002-7936-5103;
   Gayen, Shovanlal/0000-0002-3367-578X
FU Council of Scientific and Industrial Research (CSIR), New Delhi,
   IndiaCouncil of Scientific & Industrial Research (CSIR) - India
   [09/096(0967)/2019-EMR-I]; RUSA 2.0 of UGC, New Delhi, India
FX Financial assistance from the Council of Scientific and Industrial
   Research (CSIR), New Delhi, India in the form of a Senior Research
   Fellowship (SRF) [FILE NO.: 09/096(0967)/2019-EMR-I, Dated: 01-04-2019]
   to Sk. Abdul Amin is thankfully acknowledged. Tarun Jha is also thankful
   for the financial support from RUSA 2.0 of UGC, New Delhi, India to
   Jadavpur University, Kolkata, India. We are very much thankful to the
   Department of Pharmaceutical Technology, Jadavpur University, Kolkata,
   India and Department of Pharmaceutical Sciences, Dr. Harisingh Gour
   University, India for providing the research facilities.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Peele KA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1770127
   ADEOYE AO, 2020, J BIOMOL STRUCT 0514, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1765876
   Adhikari N, 2017, VIRAL PROTEASES AND THEIR INHIBITORS, P317, DOI 10.1016/B978-0-12-809712-0.00011-3
   Adhikari N, 2016, BIOORGAN MED CHEM, V24, P4291, DOI 10.1016/j.bmc.2016.07.023
   AHMAD S, 2020, J BIOMOL STRUCT 0611, DOI DOI https://doi.org/10.1080/07391102.2020.1775129
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   AMIN M, 2020, J BIOMOL STRUCT 0703, DOI DOI https://doi.org/10.1080/07391102.2020.1775703
   Amin SA, 2018, J MED CHEM, V61, P6468, DOI 10.1021/acs.jmedchem.7b00782
   [Anonymous], DS VIS 3 5
   ANWAR F, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1775123
   ARYA A, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1773929
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767211
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767210
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Bandyopadhyay D, 2019, J CHEM INF MODEL, V59, P4880, DOI 10.1021/acs.jcim.9b00243
   BANERJEE S, 2020, SAR QSAR ENVIRO 0317, DOI DOI https://doi.org/10.1080/1062936X.2020.1734080
   BASIT A, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768150
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   BORKOTOKY S, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1774419
   CHANDRA A, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1775127
   Cheng KW, 2015, ANTIVIR RES, V115, P9, DOI 10.1016/j.antiviral.2014.12.011
   Chou CY, 2008, BIOCHEM PHARMACOL, V75, P1601, DOI 10.1016/j.bcp.2008.01.005
   CHOUDHURY C, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1771424
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   DEOLIVEIRA OV, 2020, J BIOMOL STRUCT 0601, DOI DOI https://doi.org/10.1080/07391102.2020.1772885
   Dutta S, 2019, FUTURE MED CHEM, V11, P1679, DOI 10.4155/fmc-2018-0361
   ELASNAOUI K, 2020, J BIOMOL STRUCT 0521, DOI DOI https://doi.org/10.1080/07391102.2020.1767212
   ELFIKY AA, 2020, J BIOMOL STRUCT 0424, DOI DOI https://doi.org/10.1080/07391102.2020.1758789
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Frieman M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028479
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Ghosh AK, 2010, J MED CHEM, V53, P4968, DOI 10.1021/jm1004489
   Ghosh AK, 2009, J MED CHEM, V52, P5228, DOI 10.1021/jm900611t
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Hajjo R, 2012, J MED CHEM, V55, P5704, DOI 10.1021/jm2011657
   Halder AK, 2015, RSC ADV, V5, P72373, DOI 10.1039/c5ra12606a
   Halder AK, 2013, MOL DIVERS, V17, P123, DOI 10.1007/s11030-013-9422-5
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   HENDAUS MA, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1767691
   HENDAUS MA, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1772110
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Jain S, 2020, J BIOMOL STRUCT DYN, V38, P66, DOI 10.1080/07391102.2019.1566093
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   KHAN MT, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1769733
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   KUMAR D, 2020, J BIOMOL STRUCT 0503, DOI DOI https://doi.org/10.1080/07391102.2020.1752310
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   LOBOGALO N, 2020, J BIOMOL STRUCT 0513, DOI DOI https://doi.org/10.1080/07391102.2020.1764393
   MAHANTA S, 2020, J BIOMOL STRUCT 0522, DOI DOI https://doi.org/10.1080/07391102.2020.1768902
   MITTAL L, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768151
   Mukherjee A, 2017, EUR J MED CHEM, V141, P37, DOI 10.1016/j.ejmech.2017.09.052
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   PANIRI A, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1767690
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Park JY, 2012, BIOORGAN MED CHEM, V20, P5928, DOI 10.1016/j.bmc.2012.07.038
   Patil VM, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117775
   Pillaiyar T, 2020, DRUG DISCOVERY TODAY
   Polishchuk P, 2017, J CHEM INF MODEL, V57, P2618, DOI 10.1021/acs.jcim.7b00274
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   SK MF, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1768149
   Toropov AA, 2019, SAUDI J BIOL SCI, V26, P1101, DOI 10.1016/j.sjbs.2018.05.013
   Toropov AA, 2013, CHEMOSPHERE, V92, P31, DOI 10.1016/j.chemosphere.2013.03.012
   Toropova AP, 2015, SAR QSAR ENVIRON RES, V26, P29, DOI 10.1080/1062936X.2014.984327
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   van Hilten N, 2019, J CHEM INF MODEL, V59, P644, DOI 10.1021/acs.jcim.8b00737
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   Worachartcheewan A, 2014, CHEMOMETR INTELL LAB, V138, P120, DOI 10.1016/j.chemolab.2014.07.017
NR 79
TC 7
Z9 7
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1780946
EA JUN 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MO4II
UT WOS:000551491200001
PM 32568618
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Severa, M
   Farina, C
   Salvetti, M
   Coccia, EM
AF Severa, Martina
   Farina, Cinthia
   Salvetti, Marco
   Coccia, Eliana Marina
TI Three Decades of Interferon-beta in Multiple Sclerosis: Can We Repurpose
   This Information for the Management of SARS-CoV2 Infection?
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE type I IFN; antiviral-activity; multiple scleorsis (MS);
   immunoregulation; SARS-CoV-2
ID IFN-BETA; THERAPY; CELLS
C1 [Severa, Martina; Coccia, Eliana Marina] Ist Super Sanita, Dept Infect Dis, Rome, Italy.
   [Farina, Cinthia] IRCSS San Raffaele Sci Inst, Inst Expt Neurol INSpe, Div Neurosci, Milan, Italy.
   [Salvetti, Marco] Sapienza Univ, Ctr Expt Neurol Therapies, St Andrea Hosp, Dept Neurosci Mental Hlth & Sensory Organs, Rome, Italy.
   [Salvetti, Marco] Ist Neurol Mediterraneo INM Neuromed, Pozzilli, Italy.
RP Coccia, EM (corresponding author), Ist Super Sanita, Dept Infect Dis, Rome, Italy.
EM eliana.coccia@iss.it
RI Farina, Cinthia/AAX-6453-2020
OI Farina, Cinthia/0000-0002-4466-9676
FU FISM (Fondazione Italiana Sclerosi Multipla)Fondazione Italiana Sclerosi
   Multipla (FISM) [2013/R/9]; Italian Ministry of HealthMinistry of
   Health, Italy [GR-2016-02363749]; 5 per mill public funding
FX This work was funded by FISM (Fondazione Italiana Sclerosi Multipla,
   grant 2013/R/9 to EC and CF) and co-financed by the 5 per mill public
   funding and in part by the Italian Ministry of Health (grant
   GR-2016-02363749 to MSe).
CR Annibali V, 2015, CYTOKINE GROWTH F R, V26, P221, DOI 10.1016/j.cytogfr.2014.10.010
   Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   De Jager P, 2009, CLIN IMMUNOL, V131, pS101, DOI 10.1016/j.clim.2009.03.294
   Feng X, 2002, J NEUROIMMUNOL, V129, P205, DOI 10.1016/S0165-5728(02)00182-0
   Giacomini E, 2013, EUR J IMMUNOL, V43, P1963, DOI 10.1002/eji.201243212
   Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073
   Gough DJ, 2012, IMMUNITY, V36, P166, DOI 10.1016/j.immuni.2012.01.011
   Jakimovski D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010050
   Malhotra S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023634
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Nguyen LS, 2020, CIRCULATION, V142, P303, DOI 10.1161/CIRCULATIONAHA.120.048238
   Nile SH, 2020, CYTOKINE GROWTH F R, V53, P66, DOI 10.1016/j.cytogfr.2020.05.002
   Novi G, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.101430
   Rizzo F, 2016, IMMUNOL CELL BIOL, V94, P886, DOI 10.1038/icb.2016.55
   Romano S, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00695
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Salvi R, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110267
   Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251
   Severa M, 2019, J AUTOIMMUN, V101, P1, DOI 10.1016/j.jaut.2019.04.006
   Severa M, 2015, CYTOKINE GROWTH F R, V26, P229, DOI 10.1016/j.cytogfr.2014.11.005
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Srinivasan S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24987-8
   Srinivasan S, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000337
   Trouillet-Assant S, 2020, J ALLERGY CLIN IMMUN, V146, P206, DOI 10.1016/j.jaci.2020.04.029
   van Baarsen LGM, 2006, GENES IMMUN, V7, P522, DOI 10.1038/sj.gene.6364324
   Veroni C, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0353-1
NR 28
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 18
PY 2020
VL 11
AR 1459
DI 10.3389/fimmu.2020.01459
PG 4
WC Immunology
SC Immunology
GA MH8BA
UT WOS:000546946200001
PM 32655578
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nghochuzie, NN
   Olwal, CO
   Udoakang, AJ
   Amenga-Etego, LNK
   Amambua-Ngwa, A
AF Nghochuzie, Nora Nganyewo
   Olwal, Charles Ochieng'
   Udoakang, Aniefiok John
   Amenga-Etego, Lucas Naam-Kayagre
   Amambua-Ngwa, Alfred
TI Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in
   Africa: Is the Future of Malaria Bleak?
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE malaria; plasmodium; COVID-19; SARS-CoV-2; ACE2; coronaviruses
ID RESISTANCE
AB Malaria remains a major global health burden, killing hundreds of thousands annually, especially in sub-Saharan Africa. In 2019, a Phase IV Expanded Programme on Immunization (EPI)-linked malaria vaccine implementation was underway. However, in December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with many clinical, epidemiological, and biological parallels to malaria, was reported in Wuhan, China. COVID-19 is spreading rapidly, and, as of the 3rd of June, 2020, more than 382,507 persons had died from COVID-19. Children under 5 years who suffer high malaria-attributable mortalities are largely asymptomatic for COVID-19. Considering that the malaria burden is highest in low-income tropical countries with little capacity to fund malaria control and eradication programs, the fight against malaria in these regions is likely to be hampered. Access to healthcare has generally been limited, while malaria interventions, such as seasonal malaria chemotherapy and distribution of insecticide-treated bed nets, have been suspended due to lockdowns. Likewise, the repurposing of antimalarials for treatment of COVID-19 shared symptoms and the shift in focus from the production of malaria rapid diagnostic tests (RDTs) to COVID-19 RDTs is a cause for concern in malaria-endemic regions. Children are less affected by the COVID-19 pandemic compared to the elderly. However, due to the fears of contracting SARS-CoV-2, the elderly who are worst affected by COVID-19 may not take children for malaria medication, resulting in high malaria-related mortalities among children. COVID-19 has disproportionately affected developed countries, threatening their donation capacity. These are likely to thwart malaria control efforts in low-income regions. Here, we present perspectives on the collateral impact of COVID-19 on malaria, especially in Africa.
C1 [Nghochuzie, Nora Nganyewo; Olwal, Charles Ochieng'; Udoakang, Aniefiok John; Amenga-Etego, Lucas Naam-Kayagre] Univ Ghana, West African Ctr Cell Biol Infect Pathogens WACCB, Accra, Ghana.
   [Nghochuzie, Nora Nganyewo; Olwal, Charles Ochieng'; Udoakang, Aniefiok John; Amenga-Etego, Lucas Naam-Kayagre] Univ Ghana, Dept Biochem Cell & Mol Biol, Coll Basic & Appl Sci, Accra, Gambia.
   [Amambua-Ngwa, Alfred] Med Res Council Unit Gambia LSHTM, Banjul, Gambia.
   [Amambua-Ngwa, Alfred] Univ London, London Sch Hyg & Trop Med, London, England.
RP Amambua-Ngwa, A (corresponding author), Med Res Council Unit Gambia LSHTM, Banjul, Gambia.; Amambua-Ngwa, A (corresponding author), Univ London, London Sch Hyg & Trop Med, London, England.
EM angwa@mrc.gm
RI Amambua-Ngwa, Alfred/ABA-7305-2020
OI NGANYEWO, NORA NGHOCHUZIE/0000-0003-1510-8404; Olwal,
   Charles/0000-0003-1747-2963
FU Pan-African Malaria Genetic Epidemiology Network (PAMGEN) PhD
   fellowship; Wellcome Trust through the African Academy of Science
   H3Africa ProgramWellcome Trust [H3A/18/002]
FX NN was supported by the Pan-African Malaria Genetic Epidemiology Network
   (PAMGEN) PhD fellowship. PAMGEN is a team (leader: AA-N) of African
   scientists studying the genetic interactions between human populations
   and malaria parasites in different environmental settings across Africa
   with funding from the Wellcome Trust through the African Academy of
   Science H3Africa Program (H3A/18/002).
CR Ademolue TW, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1796-x
   [Anonymous], 2020, GUARDIAN
   Bwire GM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60549-7
   Chanda-Kapata P, 2020, INT J INFECT DIS, V94, P151, DOI 10.1016/j.ijid.2020.04.007
   Cheng H, 2020, J MED VIROL, V92, P726, DOI [10.1002/jmv.25785, 10.2112/JCR-SI112-001.1]
   Delanghe JR, 2020, CLIN CHIM ACTA, V505, P192, DOI 10.1016/j.cca.2020.03.031
   Dhangadamajhi G, 2010, INFECT GENET EVOL, V10, P337, DOI 10.1016/j.meegid.2010.01.009
   Dhochak N, 2020, INDIAN J PEDIATR, V87, P537, DOI 10.1007/s12098-020-03322-y
   Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859
   Finnan D., 2020, ARTEMISIA MADAGASCAR
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Funck-Brentano Christian, 2020, Lancet, DOI 10.1016/S0140-6736(20)31174-0
   Haakenstad A, 2019, LANCET INFECT DIS, V19, P703, DOI 10.1016/S1473-3099(19)30165-3
   Hattori N, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0267-2
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kindzeka M., 2020, COVID 19 FRIGHTENS M
   Malaria S, 2014, TROP MED INT HEALTH, V19, P7, DOI [10.1111/tmi.12313, 10.1111/tmi.12313_2]
   Mwanza S, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1637-3
   Noedl H, 2008, NEW ENGL J MED, V359, P2619, DOI 10.1056/NEJMc0805011
   Picot S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-89
   Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6
   Saab YB, 2007, GENET RES, V89, P259, DOI 10.1017/S0016672307009019
   Saraiva VB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017174
   Sibley CH, 2001, TRENDS PARASITOL, V17, P582, DOI 10.1016/S1471-4922(01)02085-2
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   Wassmer SC, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00121
   WHO, 2020, WHO Q A MAL VACC IMP
   WHO, 2012, WHO POS STAT EFF NON
   WHO, 2020, TAIL MAL INT COVID 1
   WHO, 2020, WHO URG COUNTR MOV Q
   World Health Organization, 2020, ADV US POINT OF CAR
   World Health Organization, 2018, WORLD MAL REP 2019
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 34
TC 4
Z9 4
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD JUN 18
PY 2020
VL 11
AR 1476
DI 10.3389/fmicb.2020.01476
PG 5
WC Microbiology
SC Microbiology
GA MH5YT
UT WOS:000546805000001
PM 32625198
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kumar, V
   Roy, K
AF Kumar, V.
   Roy, K.
TI Development of a simple, interpretable and easily transferable QSAR
   model for quick screening antiviral databases in search of novel 3C-like
   protease (3CLpro) enzyme inhibitors against SARS-CoV diseases
SO SAR AND QSAR IN ENVIRONMENTAL RESEARCH
LA English
DT Article
DE 2D-QSAR; MLR; 3CLpro enzyme; SARS-CoV-2; Covid-19; docking and virtual
   screening
ID CORONAVIRUSES
AB In the context of recently emerged pandemic of COVID-19, we have performed two-dimensional quantitative structure-activity relationship (2D-QSAR) modelling using SARS-CoV-3CLpro enzyme inhibitors for the development of a multiple linear regression (MLR) based model. We have used 2D descriptors with an aim to develop an easily interpretable, transferable and reproducible model which may be used for quick prediction of SAR-CoV-3CLpro inhibitory activity for query compounds in the screening process. Based on the insights obtained from the developed 2D-QSAR model, we have identified the structural features responsible for the enhancement of the inhibitory activity against 3CLpro enzyme. Moreover, we have performed the molecular docking analysis using the most and least active molecules from the dataset to understand the molecular interactions involved in binding, and the results were then correlated with the essential structural features obtained from the 2D-QSAR model. Additionally, we have performed in silico predictions of SARS-CoV 3CLpro enzyme inhibitory activity of a total of 50,437 compounds obtained from two anti-viral drug databases (CAS COVID-19 antiviral candidate compound database and another recently reported list of prioritized compounds from the ZINC15 database) using the developed model and provided prioritized compounds for experimental detection of their performance for SARS-CoV 3CLpro enzyme inhibition.
C1 [Kumar, V.; Roy, K.] Jadavpur Univ, Dept Pharmaceut Technol, Drug Theoret & Cheminformat Lab, Kolkata, India.
RP Roy, K (corresponding author), Jadavpur Univ, Dept Pharmaceut Technol, Drug Theoret & Cheminformat Lab, Kolkata, India.
EM kunal.roy@jadavpuruniversity.in
RI Roy, Kunal/B-1673-2009; Kumar, Vinay/AAY-9695-2020
OI Roy, Kunal/0000-0003-4486-8074; Kumar, Vinay/0000-0002-6809-7633
FU Indian Council of Medical ResearchIndian Council of Medical Research
   (ICMR) [5/3/8/27/ITR-F/2018-ITR]; Science and Engineering Research Board
   [MTR/2019/000008]
FX This work was supported by the Indian Council of Medical Research
   [5/3/8/27/ITR-F/2018-ITR]; Science and Engineering Research Board
   [MTR/2019/000008].
CR Alexey G.M., 1995, J MOL BIOL, V247, P40
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Chen S, 2005, ACTA PHARMACOL SIN, V26, P99, DOI 10.1111/j.1745-7254.2005.00010.x
   Deng X, 2014, J VIROL, V88, P11886, DOI 10.1128/JVI.01528-14
   Dharmendra K, 2020, EURASIAN J MED ONCOL, V4, P8, DOI [10.14744/ejmo.2020.51418, DOI 10.14744/EJMO.2020.51418]
   Dietz L, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00245-20
   Ekins S, 2007, BRIT J PHARMACOL, V152, P21, DOI 10.1038/sj.bjp.0707306
   Fedorenko E, 2011, P NATL ACAD SCI USA, V108, P16428, DOI 10.1073/pnas.1112937108
   Gilson M.K., 2015, NUCLEIC ACIDS RES, V19, P1045
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Jacobs J., 2013, PROBE REPORTS NIH MO
   Kamboj A, 2012, J PHARM RES, V5, P2676
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Khan K, 2019, SAR QSAR ENVIRON RES, DOI 10.1080/1062936X.2019.1648315
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Mauri A, 2006, MATCH-COMMUN MATH CO, V56, P237
   Minitab I.N., 2000, MINITAB STAT SOFTW, V13
   Ramajayam R, 2010, BIOORGAN MED CHEM, V18, P7849, DOI 10.1016/j.bmc.2010.09.050
   Rizvi SMD, 2013, EXCLI J, V12, P831
   Roy K, 2018, ACS OMEGA, V3, P11392, DOI 10.1021/acsomega.8b01647
   Roy K, 2015, CHEMOMETR INTELL LAB, V145, P22, DOI 10.1016/j.chemolab.2015.04.013
   Shah R, 2018, CHEM CENT J, V12, DOI 10.1186/s13065-018-0511-5
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Todeschini R., 2009, MOL DESCRIPTORS CHEM, V41
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Veerasamy R., 2011, INT J DRUG DES DIS, V2, P511, DOI DOI 10.1016/J.FEBSLET.2005.06.031
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yap CW, 2011, J COMPUT CHEM, V32, P1466, DOI 10.1002/jcc.21707
   Yu XL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099964
   Zhavoronkov A., 2020, INSILICO MED HONG A, V307
NR 32
TC 6
Z9 6
U1 5
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1062-936X
EI 1029-046X
J9 SAR QSAR ENVIRON RES
JI SAR QSAR Environ. Res.
PD JUL 2
PY 2020
VL 31
IS 7
BP 511
EP 526
DI 10.1080/1062936X.2020.1776388
EA JUN 2020
PG 16
WC Chemistry, Multidisciplinary; Computer Science, Interdisciplinary
   Applications; Environmental Sciences; Mathematical & Computational
   Biology; Toxicology
SC Chemistry; Computer Science; Environmental Sciences & Ecology;
   Mathematical & Computational Biology; Toxicology
GA MI9OP
UT WOS:000545784200001
PM 32543892
OA Bronze
DA 2021-01-01
ER

PT J
AU Mancia, G
   Rea, F
   Ludergnani, M
   Apolone, G
   Corrao, G
AF Mancia, Giuseppe
   Rea, Federico
   Ludergnani, Monica
   Apolone, Giovanni
   Corrao, Giovanni
TI Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID II RECEPTOR BLOCKERS; PNEUMONIA; CORONAVIRUS
AB This population-based case-control study from northern Italy shows that the use of ACE inhibitors and ARBs was more frequent among patients with Covid-19 because of a higher prevalence of cardiovascular disease. However, there was no evidence that ACE inhibitors and ARBs affected the risk of Covid-19.
   Background A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covid-19) has not been well studied. Methods We carried out a population-based case-control study in the Lombardy region of Italy.A total of 6272 case patients in whom infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was confirmed between February 21 and March 11, 2020, were matched to 30,759 beneficiaries of the Regional Health Service (controls) according to sex, age, and municipality of residence. Information about the use of selected drugs and patients' clinical profiles was obtained from regional databases of health care use. Odds ratios and 95% confidence intervals for associations between drugs and infection, with adjustment for confounders, were estimated by means of logistic regression. Results Among both case patients and controls, the mean (+/- SD) age was 68 +/- 13 years, and 37% were women. The use of ACE inhibitors and ARBs was more common among case patients than among controls, as was the use of other antihypertensive and non-antihypertensive drugs, and case patients had a worse clinical profile. Use of ARBs or ACE inhibitors did not show any association with Covid-19 among case patients overall (adjusted odds ratio, 0.95 [95% confidence interval {CI}, 0.86 to 1.05] for ARBs and 0.96 [95% CI, 0.87 to 1.07] for ACE inhibitors) or among patients who had a severe or fatal course of the disease (adjusted odds ratio, 0.83 [95% CI, 0.63 to 1.10] for ARBs and 0.91 [95% CI, 0.69 to 1.21] for ACE inhibitors), and no association between these variables was found according to sex. Conclusions In this large, population-based study, the use of ACE inhibitors and ARBs was more frequent among patients with Covid-19 than among controls because of their higher prevalence of cardiovascular disease. However, there was no evidence that ACE inhibitors or ARBs affected the risk of COVID-19.
C1 [Mancia, Giuseppe] Univ Milano Bicocca, Milan, Italy.
   [Rea, Federico; Corrao, Giovanni] Natl Ctr Healthcare Res & Pharmacoepidemiol, Milan, Italy.
   [Rea, Federico; Corrao, Giovanni] Univ Milano Bicocca, Unit Biostat Epidemiol & Publ Hlth, Dept Stat & Quantitat Methods, Milan, Italy.
   [Ludergnani, Monica] Univ Milano Bicocca, Azienda Reg Innovaz & Acquisti, Milan, Italy.
   [Apolone, Giovanni] Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
   [Mancia, Giuseppe] Policlin Monza, Monza, Italy.
RP Corrao, G (corresponding author), Univ Milano Bicocca, Dept Stat & Quantitat Methods, Via Bicocca Arcimboldi 8,Edificio U7, I-20126 Milan, Italy.
EM giovanni.corrao@unimib.it
RI ; Apolone, Giovanni/R-9799-2016
OI REA, FEDERICO/0000-0001-7988-5101; CORRAO, GIOVANNI/0000-0002-1034-8444;
   Apolone, Giovanni/0000-0001-5179-104X
CR [Anonymous], 2020, SCI NEWS
   [Anonymous], COR EM
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Corrao G, 2015, HYPERTENSION, V66, P742, DOI 10.1161/HYPERTENSIONAHA.115.05463
   Corrao G, 2015, HYPERTENSION, V65, P490, DOI 10.1161/HYPERTENSIONAHA.114.04858
   Danser AHJ, 2020, HYPERTENSION
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL
   Halliday BP, 2019, LANCET, V393, P61, DOI 10.1016/S0140-6736(18)32484-X
   Hirakawa Y, 2016, J HYPERTENS, V34, P781, DOI 10.1097/HJH.0000000000000841
   Kreutz R, 2020, CARDIOVASC RES
   Kuster GM, 2020, EUR HEART J
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu CL, 2012, J HYPERTENS, V30, P2223, DOI 10.1097/HJH.0b013e328357a87a
   Onder G, 2020, JAMA
   Patel AB, 2020, JAMA
   Paul M, 2006, PHYSIOL REV, V86, P747, DOI 10.1152/physrev.00036.2005
   Rea F, 2019, J CLIN EPIDEMIOL, V116, P62, DOI 10.1016/j.jclinepi.2019.08.009
   Rea F, 2018, EUR HEART J, V39, P3654, DOI 10.1093/eurheartj/ehy420
   Shi S, 2020, JAMA CARDIOL
   Soler MJ, 2008, CURR HYPERTENS REP, V10, P410, DOI 10.1007/s11906-008-0076-0
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vardeny O, 2018, CIRC-HEART FAIL, V11, DOI 10.1161/CIRCHEARTFAILURE.117.004745
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 30
TC 249
Z9 251
U1 36
U2 38
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 18
PY 2020
VL 382
IS 25
BP 2431
EP 2440
DI 10.1056/NEJMoa2006923
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA MF9FX
UT WOS:000545644400008
PM 32356627
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Reynolds, HR
   Adhikari, S
   Pulgarin, C
   Troxel, AB
   Iturrate, E
   Johnson, SB
   Hausvater, A
   Newman, JD
   Berger, JS
   Bangalore, S
   Katz, SD
   Fishman, GI
   Kunichoff, D
   Chen, Y
   Ogedegbe, G
   Hochman, JS
AF Reynolds, Harmony R.
   Adhikari, Samrachana
   Pulgarin, Claudia
   Troxel, Andrea B.
   Iturrate, Eduardo
   Johnson, Stephen B.
   Hausvater, Anais
   Newman, Jonathan D.
   Berger, Jeffrey S.
   Bangalore, Sripal
   Katz, Stuart D.
   Fishman, Glenn I.
   Kunichoff, Dennis
   Chen, Yu
   Ogedegbe, Gbenga
   Hochman, Judith S.
TI Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ACUTE LUNG INJURY; RECEPTOR; LOSARTAN
AB There is concern that patients taking renin-angiotensin-aldosterone system inhibitors have an increased risk of Covid-19, because angiotensin-converting enzyme 2 is a receptor for the virus. This study showed no increase in likelihood of a positive Covid-19 test or severe Covid-19 in patients taking any of five common classes of antihypertensive drugs.
   Background There is concern about the potential of an increased risk related to medications that act on the renin-angiotensin-aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), because the viral receptor is angiotensin-converting enzyme 2 (ACE2). Methods We assessed the relation between previous treatment with ACE inhibitors, angiotensin-receptor blockers, beta-blockers, calcium-channel blockers, or thiazide diuretics and the likelihood of a positive or negative result on Covid-19 testing as well as the likelihood of severe illness (defined as intensive care, mechanical ventilation, or death) among patients who tested positive. Using Bayesian methods, we compared outcomes in patients who had been treated with these medications and in untreated patients, overall and in those with hypertension, after propensity-score matching for receipt of each medication class. A difference of at least 10 percentage points was prespecified as a substantial difference. Results Among 12,594 patients who were tested for Covid-19, a total of 5894 (46.8%) were positive; 1002 of these patients (17.0%) had severe illness. A history of hypertension was present in 4357 patients (34.6%), among whom 2573 (59.1%) had a positive test; 634 of these patients (24.6%) had severe illness. There was no association between any single medication class and an increased likelihood of a positive test. None of the medications examined was associated with a substantial increase in the risk of severe illness among patients who tested positive. Conclusions We found no substantial increase in the likelihood of a positive test for Covid-19 or in the risk of severe Covid-19 among patients who tested positive in association with five common classes of antihypertensive medications.
C1 [Reynolds, Harmony R.; Adhikari, Samrachana; Pulgarin, Claudia; Troxel, Andrea B.; Iturrate, Eduardo; Johnson, Stephen B.; Hausvater, Anais; Newman, Jonathan D.; Berger, Jeffrey S.; Bangalore, Sripal; Katz, Stuart D.; Fishman, Glenn I.; Kunichoff, Dennis; Chen, Yu; Ogedegbe, Gbenga; Hochman, Judith S.] NYU, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
RP Reynolds, HR (corresponding author), NYU, Dept Med, Cardiovasc Clin Res Ctr, Grossman Sch Med,Leon H Charney Div Cardiol, 530 First Ave,SKI-9R, New York, NY 10016 USA.
EM harmony.reynolds@nyulangone.org
OI Reynolds, Harmony/0000-0003-0284-0655; Adhikari,
   Samrachana/0000-0001-9954-5999; Hochman, Judith/0000-0002-5889-5981;
   Troxel, Andrea/0000-0002-1393-3075; Newman,
   Jonathan/0000-0001-6855-7305; Stuart, Katz/0000-0003-2340-2021; Chen,
   Yu/0000-0002-1519-4894; Iturrate, Eduardo/0000-0001-6434-2518;
   Bangalore, Sripal/0000-0001-9485-0652; Johnson,
   Stephen/0000-0002-6079-8419
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR001445] Funding Source: Medline
CR [Anonymous], 2018, OBSTET GYNECOL, V13, pe49
   Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659
   Blumenfeld JD, 1999, AM J HYPERTENS, V12, P451, DOI 10.1016/S0895-7061(99)00005-9
   D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He XL, 2007, SHOCK, V28, P106, DOI 10.1097/SHK.0b013e3180310f3a
   HFSA/ACC/AHA, 2020, HFSA ACC AHA STAT AD
   Jin FG, 2016, CHEST, V149, p155A, DOI 10.1016/j.chest.2016.02.161
   Lezama-Martinez D, 2018, J CARDIOVASC PHARM, V72, P291, DOI 10.1097/FJC.0000000000000629
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu L, 2009, ARCH BIOCHEM BIOPHYS, V481, P131, DOI 10.1016/j.abb.2008.09.019
   Matsuishi Y, 2016, LIFE SCI, V166, P27, DOI 10.1016/j.lfs.2016.10.010
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Walters TE, 2017, EUROPACE, V19, P1280, DOI 10.1093/europace/euw246
   Wang BY, 2020, J HUM HYPERTENS, DOI 10.1038/s41371-020-0314-8
   Yao SL, 2008, J SURG RES, V145, P25, DOI 10.1016/j.jss.2007.03.075
   Zhang LY, 2016, PANCREATOLOGY, V16, P726, DOI 10.1016/j.pan.2016.05.395
NR 20
TC 251
Z9 254
U1 25
U2 29
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 18
PY 2020
VL 382
IS 25
BP 2441
EP 2448
DI 10.1056/NEJMoa2008975
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA MF9FX
UT WOS:000545644400009
PM 32356628
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Jacobsen, JC
   Tran, KM
   Jackson, VA
   Rubin, EB
AF Jacobsen, Juliet C.
   Tran, Kathy M.
   Jackson, Vicki A.
   Rubin, Emily B.
TI Case 19-2020: A 74-Year-Old Man with Acute Respiratory Failure and
   Unclear Goals of Care
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID HOSPITAL CARDIAC-ARREST; CODE STATUS DISCUSSIONS; SHARED
   DECISION-MAKING; END; RESUSCITATION; SURVIVAL; LIFE; RECOMMENDATIONS;
   COMMUNICATION; INFORMATION
AB A 74-year-old man with lymphoma was admitted to the hospital during the Covid-19 pandemic because of rapidly progressive respiratory failure. Several years earlier, when he had been critically ill, he had expressed a desire for "do not resuscitate" status. More recently, he had indicated that he would try all therapies that may be helpful. A consultation was requested.
C1 [Jacobsen, Juliet C.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   Harvard Med Sch, Dept Med, Boston, MA 02115 USA.
RP Jacobsen, JC (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
CR Alfandre David, 2016, J Clin Ethics, V27, P21
   Back AL, 2008, CANCER-AM CANCER SOC, V113, P1897, DOI 10.1002/cncr.23653
   Back AL, 2011, ONCOLOGIST, V16, P342, DOI 10.1634/theoncologist.2010-0274
   Baker M., 2020, NY TIMES
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Berkey FJ, 2018, AM FAM PHYSICIAN, V98, P99
   Blinderman CD, 2012, JAMA-J AM MED ASSOC, V307, P917, DOI 10.1001/jama.2012.236
   Curtis JR, 2008, J PALLIAT MED, V11, P610, DOI 10.1089/jpm.2007.0209
   Curtis JR, 2020, JAMA
   Cwrtis JR, 2007, CHEST, V132, P748, DOI 10.1378/chest.07-0745
   de Vreede-Swagemakers JJM, 1998, HEART, V79, P356, DOI 10.1136/hrt.79.4.356
   Einstein DJ, 2016, JAMA ONCOL, V2, P429, DOI 10.1001/jamaoncol.2015.6349
   Einstein DJ, 2015, J PALLIAT MED, V18, P535, DOI 10.1089/jpm.2014.0373
   Elwyn G, 2012, J GEN INTERN MED, V27, P1361, DOI 10.1007/s11606-012-2077-6
   Evans LR, 2009, AM J RESP CRIT CARE, V179, P48, DOI 10.1164/rccm.200806-969OC
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   GREENE HL, 1990, AM J CARDIOL, V65, pB4
   Herlitz J, 2002, HEART, V88, P579, DOI 10.1136/heart.88.6.579
   Hoffmann TC, 2014, JAMA-J AM MED ASSOC, V312, P1295, DOI 10.1001/jama.2014.10186
   Isenschmid C, 2019, RESUSCITATION, V136, P21, DOI 10.1016/j.resuscitation.2018.10.022
   Jackson VA, 2013, J PALLIAT MED, V16, P894, DOI 10.1089/jpm.2012.0547
   Jacobsen J, 2018, J PAIN SYMPTOM MANAG, V55, P1229, DOI 10.1016/j.jpainsymman.2017.12.488
   Jacobsen J, 2011, J PALLIAT MED, V14, P331, DOI 10.1089/jpm.2010.0383
   Klitzman R, 2020, NY TIMES
   Kutner JS, 1999, SOC SCI MED, V48, P1341, DOI 10.1016/S0277-9536(98)00453-5
   Laffey JG, 2016, INTENS CARE MED, V42, P1865, DOI 10.1007/s00134-016-4571-5
   Mahase Elisabeth, 2020, BMJ, V368, pm1282, DOI 10.1136/bmj.m1282
   MARWICK TH, 1991, RESUSCITATION, V22, P129, DOI 10.1016/0300-9572(91)90003-H
   Muscedere J, 2017, INTENS CARE MED, V43, P1105, DOI 10.1007/s00134-017-4867-0
   Portanova J, 2015, RESUSCITATION, V96, P148, DOI 10.1016/j.resuscitation.2015.08.002
   Prochaska MT, 2015, J PAIN SYMPTOM MANAG, V50, P693, DOI 10.1016/j.jpainsymman.2015.05.004
   Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010
   Rea TD, 2003, CIRCULATION, V107, P2780, DOI 10.1161/01.CIR.0000070950.17208.2A
   Rea Thomas D, 2004, Curr Opin Crit Care, V10, P218, DOI 10.1097/01.ccx.0000125494.84614.fb
   Schenker Y, 2013, J PALLIAT MED, V16, P243, DOI 10.1089/jpm.2012.0331
   Sepucha KR, 2016, HEALTH AFFAIR, V35, P630, DOI 10.1377/hlthaff.2015.1376
   Sharma RK, 2014, J GEN INTERN MED, V29, P750, DOI 10.1007/s11606-014-2791-3
   Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879
   Sudore RL, 2010, ANN INTERN MED, V153, P256, DOI 10.7326/0003-4819-153-4-201008170-00008
   White DB, 2010, CRIT CARE MED, V38, P743, DOI 10.1097/CCM.0b013e3181c58842
   Wong MKY, 2014, CIRCULATION, V130, P1883, DOI 10.1161/CIRCULATIONAHA.114.010633
   Wu Z, 2020, JAMA
NR 43
TC 1
Z9 1
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 18
PY 2020
VL 382
IS 25
BP 2450
EP 2457
DI 10.1056/NEJMcpc2002419
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA MF9FX
UT WOS:000545644400011
PM 32459917
OA Bronze
DA 2021-01-01
ER

PT J
AU Mehra, MR
   Desai, SS
   Kuy, S
   Henry, TD
   Patel, AN
AF Mehra, Mandeep R.
   Desai, Sapan S.
   Kuy, SreyRam
   Henry, Timothy D.
   Patel, Amit N.
TI Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; ACE2
AB BACKGROUND
   Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in this clinical context.
   METHODS
   Using an observational database from 169 hospitals in Asia, Europe, and North America, we evaluated the relationship of cardiovascular disease and drug therapy with in-hospital death among hospitalized patients with Covid-19 who were admitted between December 20, 2019, and March 15, 2020, and were recorded in the Surgical Outcomes Collaborative registry as having either died in the hospital or survived to discharge as of March 28, 2020.
   RESULTS
   Of the 8910 patients with Covid-19 for whom discharge status was available at the time of the analysis, a total of 515 died in the hospital (5.8%) and 8395 survived to discharge. The factors we found to be independently associated with an increased risk of in-hospital death were an age greater than 65 years (mortality of 10.0%, vs. 4.9% among those <= 65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41), coronary artery disease (10.2%, vs. 5.2% among those without disease; odds ratio, 2.70; 95% CI, 2.08 to 3.51), heart failure (15.3%, vs. 5.6% among those without heart failure; odds ratio, 2.48; 95% CI, 1.62 to 3.79), cardiac arrhythmia (11.5%, vs. 5.6% among those without arrhythmia; odds ratio, 1.95; 95% CI, 1.33 to 2.86), chronic obstructive pulmonary disease (14.2%, vs. 5.6% among those without disease; odds ratio, 2.96; 95% CI, 2.00 to 4.40), and current smoking (9.4%, vs. 5.6% among former smokers or nonsmokers; odds ratio, 1.79; 95% CI, 1.29 to 2.47). No increased risk of in-hospital death was found to be associated with the use of ACE inhibitors (2.1% vs. 6.1%; odds ratio, 0.33; 95% CI, 0.20 to 0.54) or the use of ARBs (6.8% vs. 5.7%; odds ratio, 1.23; 95% CI, 0.87 to 1.74).
   CONCLUSIONS
   Our study confirmed previous observations suggesting that underlying cardiovascular disease is associated with an increased risk of in-hospital death among patients hospitalized with Covid-19. Our results did not confirm previous concerns regarding a potential harmful association of ACE inhibitors or ARBs with in-hospital death in this clinical context.
C1 [Mehra, Mandeep R.] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA.
   [Mehra, Mandeep R.] Harvard Med Sch, Boston, MA 02115 USA.
   [Desai, Sapan S.] Surgisphere, Chicago, IL USA.
   [Kuy, SreyRam] Baylor Coll Med, Houston, TX 77030 USA.
   [Kuy, SreyRam] Dept Vet Affairs, Houston, TX USA.
   [Henry, Timothy D.] Christ Hosp, Cincinnati, OH 45219 USA.
   [Patel, Amit N.] Univ Utah, Dept Biomed Engn, Salt Lake City, UT USA.
   [Patel, Amit N.] HCA Res Inst, Nashville, TN USA.
RP Mehra, MR (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM mmehra@bwh.harvard.edu
OI Mehra, Mandeep/0000-0001-8683-7044; Desai, Sapan/0000-0002-5402-0176
FU William Harvey Distinguished Chair in Advanced Cardiovascular Medicine
   at Brigham and Women's Hospital; Surgisphere
FX Supported by the William Harvey Distinguished Chair in Advanced
   Cardiovascular Medicine at Brigham and Women's Hospital. The development
   and maintenance of the Surgical Outcomes Collaborative database was
   funded by Surgisphere.
CR American College of Cardiology, 2020, HFSA ACC AHA STAT AD
   Arentz M, 2020, JAMA
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   European Society of Cardiology, 2020, POS STAT ESC COUNC H
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Guo T, 2020, JAMA CARDIOL
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Mehra MR, JACC HEART FAIL
   Nguyen JL, 2016, JAMA CARDIOL, V1, P274, DOI 10.1001/jamacardio.2016.0433
   Nicin L, 2020, EUR HEART J
   Patel AB, 2020, JAMA
   Rice GI, 2004, BIOCHEM J, V383, P45, DOI 10.1042/BJ20040634
   Ruan Q, 2020, INTENSIVE CARE MED
   Shi S, 2020, JAMA CARDIOL
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang L, 2020, INFLAMMATION, V43, P1772, DOI 10.1007/s10753-020-01251-8
   WHO, 2020, CLIN MAN SEV AC RESP
NR 22
TC 297
Z9 308
U1 36
U2 39
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 18
PY 2020
VL 382
IS 25
AR e102
DI 10.1056/NEJMoa2007621
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA MF9FX
UT WOS:000545644400030
PM 32356626
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Meza, HT
   Gil, AL
   Saldana, AS
   Yus, CV
   Baron, BP
   Mur, DS
   Moreno, JM
AF Tejada Meza, H.
   Lambea Gil, A.
   Sancho Saldana, A.
   Villar Yus, C.
   Pardinas Baron, B.
   Sagarra Mur, D.
   Marta Moreno, J.
CA Grp Seguimiento & Mejora Programa
TI Ischaemic stroke in the time of coronavirus disease 2019
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE COVID-19; stroke
ID SYSTEMATIC ANALYSIS; RISK-FACTORS; BURDEN
AB Background and purpose Stroke assistance is facing changes and new challenges since COVID-19 became pandemic. A variation on the patient influx might be one of the greater concerns, due to fewer people coming to emergency departments or coming too late. However, no data quantifying this have been published until now. The aim was to analyse the impact of the COVID-19 epidemic outbreak on hospital stroke admissions and their characteristics in our region. Methods The data of every patient admitted to any hospital of our healthcare system with a diagnosis of ischaemic stroke between 30 December 2019 and 19 April 2020 were reviewed. Demographic and clinical data were recorded and compared between periods before and after the setting of the state of emergency secondary to the COVID-19 outbreak. Results In total, 354 patients with ischaemic stroke were admitted in our study period. There was a weekly average of 27.5 cases before the setting of the state of emergency against 12 afterwards (P < 0.001). This drop in stroke cases occurred progressively from week 11, persisting in time despite the decrease in confirmed cases of COVID-19. No differences in the proportion of intravenous thrombolysis (21.1% vs. 21.5%,P = 0.935) or endovascular therapy (12.4% vs. 15.2%,P = 0.510) were found, nor in other demographic or clinical characteristics except for median onset-to-door time (102 vs. 183 min,P = 0.015). Conclusions This observational study offers the perspective of a whole region in one of the countries more heavily stricken by the SARS-CoV-2 epidemic and shows that the decrease of stroke events, since the beginning of the COVID-19 outbreak, happened globally and without any specific patient distribution.
C1 [Tejada Meza, H.; Lambea Gil, A.; Sancho Saldana, A.; Villar Yus, C.; Pardinas Baron, B.; Sagarra Mur, D.; Marta Moreno, J.] Hosp Univ Miguel Servet, Dept Neurol, Stroke Unit, Zaragoza, Spain.
   [Tejada Meza, H.] Hosp Univ Miguel Servet, Dept Radiol, Intervent Neuroradiol Unit, Zaragoza, Spain.
RP Meza, HT (corresponding author), Hosp Univ Miguel Servet, Dept Neurol, Dept Radiol, Intervent Radiol,Stroke Unit, Zaragoza 50009, Spain.
EM htmeza@gmail.com
RI Meza, Herbert Tejada/AAW-1598-2020; Lambea-Gil, Alvaro/AAS-4568-2020
OI Meza, Herbert Tejada/0000-0002-6506-1037; Lambea-Gil,
   Alvaro/0000-0003-1785-9201
CR [Anonymous], 2020, SIT COVID 19 ESP
   Ceballos MA, 2020, EFECTOS CRISIS COVID
   Cucinotta D, 2020, ACTA BIOMED, V91, P157, DOI [10.23750/abm.v91i1.9397, DOI 10.23750/ABM.V91I1.9397]
   ESO Executive Committee, 2020, LIK INCR RISK DEATH, P4053
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Feigin VL, 2016, LANCET NEUROL, V15, P913, DOI 10.1016/S1474-4422(16)30073-4
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6
   Li Y, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3550025, DOI 10.2139/SSRN.3550025]
   Li YB, 2019, ENVIRON GEOCHEM HLTH, V41, P2113, DOI 10.1007/s10653-019-00265-y
   Liu KM, 2020, J NEUROL NEUROSUR PS, V91, P669, DOI 10.1136/jnnp-2020-323177
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9
   Mahase Elisabeth, 2020, BMJ, V368, pm1282, DOI 10.1136/bmj.m1282
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Markus HS, 2020, INT J STROKE, V15, P361, DOI 10.1177/1747493020923472
   Palm F, 2013, EUR J EPIDEMIOL, V28, P373, DOI 10.1007/s10654-013-9772-4
   Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211
   Sipila JOT, 2017, ANN MED, V49, P310, DOI 10.1080/07853890.2016.1254350
   Situacion epidemiologica del coronavirus COVID-19 en Aragon [Internet], 2020, SIT EP COR COVID 19
   Toyoda K, 2018, CIRC J, V82, P1443, DOI 10.1253/circj.CJ-17-1310
   Truelsen T, 2006, EUR J NEUROL, V13, P581, DOI 10.1111/j.1468-1331.2006.01138.x
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 22
TC 5
Z9 5
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD SEP
PY 2020
VL 27
IS 9
BP 1788
EP 1792
DI 10.1111/ene.14327
EA JUN 2020
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA ND8GE
UT WOS:000542155100001
PM 32415888
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mucke, HAM
AF Mucke, Hermann A. M.
TI COVID-19 and the Drug Repurposing Tsunami
SO ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
LA English
DT Article
C1 [Mucke, Hermann A. M.] HM Pharma Consultancy, Enenkelstr 28-32, A-1160 Vienna, Austria.
RP Mucke, HAM (corresponding author), HM Pharma Consultancy, Enenkelstr 28-32, A-1160 Vienna, Austria.
EM h.mucke@hmpharmacon.com
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Alexander SPH, 2020, BRIT J PHARMACOL, V177, P4942, DOI 10.1111/bph.15094
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen YF, 2020, J GLOB HEALTH, V10, DOI [10.7189/jogh.10.011004, 10.7189/jogh-10-011004]
   Derwand R, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109815
   Dolgin E, 2020, NAT BIOTECHNOL, V38, P510, DOI [10.1038/s41587-020-0520-5, 10.1038/s41587-020-0528-x]
   Giovanetti M, 2020, J MED VIROL, V92, P518, DOI 10.1002/jmv.25699
   Horbach SPJM., 2020, PANDEMIC PUBLISHING, DOI [10.1101/2020.04.18.045963, DOI 10.1101/2020.04.18.045963]
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Schuchat A, 2020, MMWR-MORBID MORTAL W, V69, P551, DOI 10.15585/mmwr.mm6918e2
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Stoecklin SB, 2020, EUROSURVEILLANCE, V25, P20, DOI 10.2807/1560-7917.ES.2020.25.6.2000094
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2020, PNEUM UNKN CAUS CHIN
   Yu B, 2020, SCI CHINA LIFE SCI, V63, P1515, DOI 10.1007/s11427-020-1732-2
NR 19
TC 1
Z9 1
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-658X
EI 1557-8127
J9 ASSAY DRUG DEV TECHN
JI ASSAY DRUG DEV. TECHNOL.
PD JUL 1
PY 2020
VL 18
IS 5
BP 211
EP 214
DI 10.1089/adt.2020.996
EA JUN 2020
PG 4
WC Biochemical Research Methods; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA MN2BE
UT WOS:000541911600001
PM 32551883
DA 2021-01-01
ER

PT J
AU Hughes, DA
AF Hughes, Dyfrig A.
TI Acute chloroquine poisoning: A comprehensive experimental toxicology
   assessment of the role of diazepam
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID CARDIAC CONTRACTILITY; ANTIMALARIAL-DRUG; IN-VIVO; RAT; TOXICITY;
   BLOCKADE; ANIMALS
AB Background and Purpose Resurgence in the use of chloroquine as a potential treatment for COVID-19 has seen recent cases of fatal toxicity due to unintentional overdoses. Protocols for the management of poisoning recommend diazepam, although there are uncertainties in its pharmacology and efficacy in this context. The aim was to assess the effects of diazepam in experimental models of chloroquine cardiotoxicity. Experimental Approach In vitro experiments involved cardiac tissues isolated from rats and incubated with chloroquine alone or in combination with diazepam. In vivo models of toxicity involved chloroquine administered intravenously to pentobarbitone-anaesthetised rats and rabbits. Randomised, controlled treatment studies in rats assessed diazepam, clonazepam and Ro5-4864 administered: (i) prior, (ii) during and (iii) after chloroquine and the effects of diazepam: (iv) at high dose, (v) in urethane-anaesthetised rats and (vi) co-administered with adrenaline. Key Results Chloroquine decreased the developed tension of left atria, prolonged the effective refractory period of atria, ventricular tissue and right papillary muscles, and caused dose-dependent impairment of haemodynamic and electrocardiographic parameters. Cardiac arrhythmias indicated impairment of atrioventricular conduction. Studies (i), (ii) and (v) showed no differences between treatments and control. Diazepam increased heart rate in study (iv) and as with clonazepam also prolonged the QTc interval in study (iii). Combined administration of diazepam and adrenaline in study (vi) improved cardiac contractility but caused hypokalaemia. Conclusion and Implications Neither diazepam nor other ligands for benzodiazepine binding sites protect against or attenuate chloroquine cardiotoxicity. However, diazepam may augment the effects of positive inotropes in reducing chloroquine cardiotoxicity.
C1 [Hughes, Dyfrig A.] Bangor Univ, Ctr Hlth Econ & Med Evaluat, Bangor, Gwynedd, Wales.
   [Hughes, Dyfrig A.] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.
RP Hughes, DA (corresponding author), Bangor Univ, Ctr Hlth Econ & Med Evaluat, Sch Hlth Sci, Ardudwy, Holyhead Rd, Bangor LL57 2PZ, Gwynedd, Wales.
EM d.a.hughes@bangor.ac.uk
RI Hughes, Dyfrig/H-5252-2012
OI Hughes, Dyfrig/0000-0001-8247-7459
FU Wellcome TrustWellcome Trust [038570/Z/93/Z]; Health and Care Research
   Wales [SRL-19-18]
FX Wellcome Trust, Grant/Award Number: 038570/Z/93/Z; Health and Care
   Research Wales, Grant/Award Number: SRL-19-18
CR Agence Regionale de Sante, 2020, PRESS REL COR SIT PO
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS142, DOI 10.1111/bph.14749
   Bazett HC, 1920, HEART-J STUD CIRC, V7, P353
   Binding L., 2020, SKY NEWS
   Bondurand P. A., 1980, AFR MED, V179, P239
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Buckley NA, 1996, HUM EXP TOXICOL, V15, P909, DOI 10.1177/096032719601501108
   BURNS KF, 1966, TOXICOL APPL PHARM, V8, P429, DOI 10.1016/0041-008X(66)90052-4
   Busari S, 2020, CNN NEWS
   CLEMESSY JL, 1995, LANCET, V346, P877, DOI 10.1016/S0140-6736(95)92711-5
   Clemessy JL, 1996, INTENS CARE MED, V22, P1400, DOI 10.1007/BF01709558
   Coker SJ, 2000, BRIT J PHARMACOL, V129, P323, DOI 10.1038/sj.bjp.0703060
   Collado MC, 1998, BRIT J PHARMACOL, V123, P1047
   CROUZETTE J, 1983, J TOXICOL-CLIN TOXIC, V20, P271, DOI 10.3109/15563658308990070
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   DEMAZIERE J, 1992, ANN FR ANESTH, V11, P164, DOI 10.1016/S0750-7658(05)80009-7
   Djelardje S., 1976, THESIS
   ESSIEN EE, 1986, J PHARM PHARMACOL, V38, P543, DOI 10.1111/j.2042-7158.1986.tb04635.x
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Food and Drug Administration, REQ EM US AUTH US CH
   Gnassounou J. P., 1988, REANIM SOINS INTENS, V4, P61
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   IKHINMWIN MK, 1981, EUR J PHARMACOL, V69, P507, DOI 10.1016/0014-2999(81)90458-1
   JAEGER A, 1987, MED TOXICOL ADV DRUG, V2, P242, DOI 10.1007/BF03259868
   Jones AM, 2017, CRIME DELINQUENCY, V63, P759, DOI 10.1177/0011128715596989
   Juan-Fita MJ, 2006, ANESTH ANALG, V102, P676, DOI 10.1213/01.ane.0000197780.42409.5b
   Juan-Fita MJ, 2003, PHARMACOL TOXICOL, V93, P23, DOI 10.1034/j.1600-0773.2003.930103.x
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x
   Kim KS, 2010, ARCH PHARM RES, V33, P769, DOI 10.1007/s12272-010-0517-6
   LATINI R, 1988, EUR J PHARMACOL, V156, P87, DOI 10.1016/0014-2999(88)90150-1
   LOOAREESUWAN S, 1986, BRIT J CLIN PHARMACO, V22, P31, DOI 10.1111/j.1365-2125.1986.tb02876.x
   MARTINEZ E, 1995, EUR J PHARMACOL, V282, P169, DOI 10.1016/0014-2999(95)00325-F
   McGrath JC, 2015, BRIT J PHARMACOL, V172, P2427, DOI 10.1111/bph.12956
   MEERAN K, 1993, BRIT MED J, V307, P49, DOI 10.1136/bmj.307.6895.49
   Megarbane B, 2010, CLIN TOXICOL, V48, P904, DOI 10.3109/15563650.2010.518969
   Michel D, 2002, PHARMACOLOGY, V65, P187, DOI 10.1159/000064342
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703
   PENEFSKY ZJ, 1994, COMP BIOCHEM PHYS A, V109, P1, DOI 10.1016/0300-9629(94)90307-7
   RAJAH A, 1990, ANAESTHESIA, V45, P955, DOI 10.1111/j.1365-2044.1990.tb14629.x
   REUTER N, 1971, N-S ARCH PHARMAKOL, V268, P323, DOI 10.1007/BF00997265
   Richter W, 2011, BASIC RES CARDIOL, V106, P249, DOI 10.1007/s00395-010-0138-8
   RIOU B, 1988, NEW ENGL J MED, V318, P1, DOI 10.1056/NEJM198801073180101
   RIOU B, 1989, INTENS CARE MED, V15, P390
   RIOU B, 1988, INTENS CARE MED, V14, P610
   Rodriguez-Menchaca AA, 2008, P NATL ACAD SCI USA, V105, P1364, DOI 10.1073/pnas.0708153105
   Salinas E. M., 1993, J CELL MOL CARDIOL, V25, pS77
   Sanchez-Capula JA, 2001, J PHARMACOL EXP THER, V297, P437
   SimpliCity, 2020, 4 YEAR OLD GIRL NEAR
   SOFOLA OA, 1980, CAN J PHYSIOL PHARM, V58, P836, DOI 10.1139/y80-129
   Surinkaew S, 2011, CAN J CARDIOL, V27, DOI 10.1016/j.cjca.2010.12.023
   TONA L, 1990, EUR J PHARMACOL, V178, P293, DOI 10.1016/0014-2999(90)90108-I
   WANG JKT, 1984, MOL PHARMACOL, V25, P349
   Weniger H., 1979, REV SIDE EFFECTS TOX
   WHO Evidence Review Group, 2016, CARD ANT
   Xuan Z., 2020, PAPER
   Yanturali S, 2004, RESUSCITATION, V63, P347, DOI 10.1016/j.resuscitation.2004.06.018
   Zeegers A, 1998, LIFE SCI, V63, P1439, DOI 10.1016/S0024-3205(98)00411-1
NR 57
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD NOV
PY 2020
VL 177
IS 21
BP 4975
EP 4989
DI 10.1111/bph.15101
EA JUN 2020
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OC7OD
UT WOS:000540816900001
PM 32415690
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Alterio, D
   Volpe, S
   Marvaso, G
   Turturici, I
   Ferrari, A
   Leonardi, MC
   Lazzari, R
   Fiore, MS
   Bufi, G
   Cattani, F
   Arrobbio, C
   Patti, F
   Casbarra, A
   Cavallo, I
   Mastrilli, F
   Orecchia, R
   Jereczek-Fossa, BA
AF Alterio, Daniela
   Volpe, Stefania
   Marvaso, Giulia
   Turturici, Irene
   Ferrari, Annamaria
   Leonardi, Maria Cristina
   Lazzari, Roberta
   Fiore, Massimo Sarra
   Bufi, Giammaria
   Cattani, Federica
   Arrobbio, Camilla
   Patti, Filippo
   Casbarra, Alessia
   Cavallo, Iacopo
   Mastrilli, Fabrizio
   Orecchia, Roberto
   Jereczek-Fossa, Barbara Alicja
TI Head and neck cancer radiotherapy amidCOVID-19 pandemic: Report from
   Milan, Italy
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
   NECK
LA English
DT Article
DE COVID-19; departmental procedures; head and neck cancer; health care
   protections; radiation oncology
AB Background Management of head and neck cancers (HNC) in radiation oncology in the coronavirus disease 2019 (COVID-19) era is challenging. Aim of our work is to report organization strategies at a radiation therapy (RT) department in the first European area experiencing the COVID-19 pandemic. Methods We focused on (a) dedicated procedures for HNC, (b) RT scheduling, and (c) health care professionals' protection applied during the COVID-19 breakdown (from March 1, 2020 to April 30, 2020). Results Applied procedures are reported and discussed. Forty-three patients were treated. Image-guided, intensity modulated RT was performed in all cases. Median overall treatment time was 50 (interquartile range: 47-54.25) days. RT was interrupted/delayed in seven patients (16%) for suspected COVID-19 infection. Two health professionals managing HNC patients were proven as COVID-19 positive. Conclusion Adequate and well-timed organization allowed for the optimization of HNC patients balancing at the best of our possibilities patients' care and personnel's safety.
C1 [Alterio, Daniela; Volpe, Stefania; Marvaso, Giulia; Turturici, Irene; Ferrari, Annamaria; Leonardi, Maria Cristina; Lazzari, Roberta; Fiore, Massimo Sarra; Bufi, Giammaria; Arrobbio, Camilla; Patti, Filippo; Casbarra, Alessia; Cavallo, Iacopo; Jereczek-Fossa, Barbara Alicja] IRCCS, European Inst Oncol, Div Radiat Oncol, Milan, Italy.
   [Volpe, Stefania; Marvaso, Giulia; Arrobbio, Camilla; Patti, Filippo; Casbarra, Alessia; Cavallo, Iacopo; Jereczek-Fossa, Barbara Alicja] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy.
   [Cattani, Federica] IRCCS, European Inst Oncol, Med Phys Unit, Milan, Italy.
   [Mastrilli, Fabrizio] IRCCS, European Inst Oncol, CMO, Med Adm, Milan, Italy.
   [Orecchia, Roberto] IRCCS, European Inst Oncol, IEO, Sci Direct, Milan, Italy.
RP Volpe, S (corresponding author), IRCCS, European Inst Oncol, Div Radiat Oncol, Milan, Italy.
EM stefania.volpe@ieo.it
RI Volpe, Stefania/AAY-3321-2020
OI Sarra Fiore, Massimo/0000-0002-3453-9907; Volpe,
   Stefania/0000-0003-0498-2964
FU Italian Ministry of HealthMinistry of Health, Italy
FX This study was partially supported by the Italian Ministry of Health
   with "Progetto di Eccellenza." Stefania Volpe MD is a PhD student within
   the European School of Molecular Medicine (SEMM).
CR Achard V, 2020, INT J RADIAT ONCOL, V107, P600, DOI 10.1016/j.ijrobp.2020.03.008
   Balakrishnan K, 2020, OTOLARYNG HEAD NECK, V162, P804, DOI 10.1177/0194599820919751
   Bhattacharjee A, 2020, HEAD NECK-J SCI SPEC, V42, P1173, DOI 10.1002/hed.26196
   Chow VLY, 2020, HEAD NECK-J SCI SPEC, V42, P1367, DOI 10.1002/hed.26234
   Ciardo D, 2015, PHYS MEDICA, V31, P1015, DOI 10.1016/j.ejmp.2015.08.004
   Fakhry N, 2020, EUR ANN OTORHINOLARY, V137, P159, DOI 10.1016/j.anorl.2020.04.008
   Fazel A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00398
   Graboyes EM, 2019, JAMA OTOLARYNGOL, V145, P166, DOI 10.1001/jamaoto.2018.2716
   Gupta T, 2012, RADIOTHER ONCOL, V104, P343, DOI 10.1016/j.radonc.2012.07.001
   Huang SH, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0484-y
   Jereczek-Fossa BA, 2020, CLIN ONCOL-UK, V32, pE160, DOI 10.1016/j.clon.2020.04.007
   Kerr P, 2015, J OTOLARYNGOL-HEAD N, V44, DOI 10.1186/s40463-015-0068-4
   Kowalski LP, 2020, HEAD NECK-J SCI SPEC, V42, P1259, DOI 10.1002/hed.26164
   Lai THT, 2020, GRAEF ARCH CLIN EXP, V258, P1049, DOI 10.1007/s00417-020-04641-8
   Levy DA, 2020, JAMA OTOLARYNGOL, V146, P455, DOI 10.1001/jamaoto.2020.0222
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Moon SH, 2016, STRAHLENTHER ONKOL, V192, P377, DOI 10.1007/s00066-016-0959-y
   Mortensen HR, 2013, ACTA ONCOL, V52, P270, DOI 10.3109/0284186X.2012.742205
   Qiao J, 2020, LANCET, V395, P760, DOI 10.1016/S0140-6736(20)30365-2
   Ran Li, 2020, Clin Infect Dis, V71, P2218, DOI 10.1093/cid/ciaa287
   Sharma A, 2020, HEAD NECK-J SCI SPEC, V42, P1147, DOI 10.1002/hed.26216
   Shuman AG, 2020, HEAD NECK-J SCI SPEC, V42, P1214, DOI 10.1002/hed.26193
   Stordeur S, 2020, ORAL ONCOL, V102, DOI 10.1016/j.oraloncology.2019.104561
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Thomson DJ, 2020, INT J RADIAT ONCOL, V107, P618, DOI 10.1016/j.ijrobp.2020.04.016
   Winquist E, 2017, J OTOLARYNGOL-HEAD N, V46, DOI 10.1186/s40463-017-0199-x
   World Health Organization, RAT US PERS PROT EQ
   Yan F, 2020, HEAD NECK-J SCI SPEC, V42, P1150, DOI 10.1002/hed.26209
NR 29
TC 2
Z9 2
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
EI 1097-0347
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD JUL
PY 2020
VL 42
IS 7
SI SI
BP 1482
EP 1490
DI 10.1002/hed.26319
EA JUN 2020
PG 9
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA MF8CB
UT WOS:000540878800001
PM 32557972
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Spiro, JE
   Sisovic, S
   Ockert, B
   Bocker, W
   Siebenburger, G
AF Spiro, Judith E.
   Sisovic, Snezana
   Ockert, Ben
   Boecker, Wolfgang
   Siebenbuerger, Georg
TI Secondary tension pneumothorax in a COVID-19 pneumonia patient: a case
   report
SO INFECTION
LA English
DT Article; Early Access
DE COVID-19; Pneumothorax; Pneumonia; Multidetector computed tomography;
   Viral infections
AB Purpose Especially in elderly and multimorbid patients, Coronavirus Disease 2019 (COVID-19) may result in severe pneumonia and secondary complications. Recent studies showed pneumothorax in rare cases, but tension pneumothorax has only been reported once. Case presentation A 47-year-old male was admitted to the emergency department with fever, dry cough and sore throat for the last 14 days as well as acute stenocardia and shortage of breath. Sputum testing (polymerase chain reaction, PCR) confirmed SARS-CoV-2 infection. Initial computed tomography (CT) showed bipulmonary groundglass opacities and consolidations with peripheral distribution. Hospitalization with supportive therapy (azithromycin) as well as non-invasive oxygenation led to a stabilization of the patient. After 5 days, sputum testing was negative and IgA/IgG antibody titres were positive for SARS-CoV-2. The patient was discharged after 7 days. On the 11th day, the patient realized pronounced dyspnoea after coughing and presented to the emergency department again. CT showed a right-sided tension pneumothorax, which was relieved by a chest drain (Buelau) via mini open thoracotomy. Negative pressure therapy resulted in regression of the pneumothorax and the patient was discharged after 9 days of treatment. Conclusion Treating physicians should be aware that COVID-19 patients might develop severe secondary pulmonary complications such as acute tension pneumothorax.
C1 [Spiro, Judith E.] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiol, Munich, Germany.
   [Sisovic, Snezana] Ludwig Maximilians Univ Munchen, Univ Hosp Munich, Dept Internal Med Endocrinol 4, Munich, Germany.
   [Ockert, Ben; Boecker, Wolfgang; Siebenbuerger, Georg] Ludwig Maximilians Univ Munchen, Dept Gen Trauma & Reconstruct Surg, Univ Hosp Munich, Nussbaumstr 20, D-80336 Munich, Germany.
RP Siebenburger, G (corresponding author), Ludwig Maximilians Univ Munchen, Dept Gen Trauma & Reconstruct Surg, Univ Hosp Munich, Nussbaumstr 20, D-80336 Munich, Germany.
EM georg.siebenbuerger@med.uni-muenchen.de
FU Projekt DEAL
FX Open Access funding provided by Projekt DEAL. We thank the patient for
   granting us permission to publish this information.
CR Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   Flower Luke, 2020, BMJ Case Rep, V13, DOI 10.1136/bcr-2020-235861
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   Rubin GD, 2020, RADIOLOGY, V296, P172, DOI 10.1148/radiol.2020201365
   SALEHI S, 2020, EUR RADIOL 0428, DOI DOI 10.2214/AJR.20.23034
   Salzberger B, 2020, INFECTION, V48, P151, DOI 10.1007/s15010-020-01409-4
   Sun RH, 2020, KOREAN J RADIOL, V21, P541, DOI 10.3348/kjr.2020.0180
   Woodside Kenneth J, 2003, J Intensive Care Med, V18, P9, DOI 10.1177/0885066602239120
   Wu J, 2020, INVEST RADIOL, V55, P257, DOI 10.1097/RLI.0000000000000670
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Ye GM, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.001
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 14
TC 7
Z9 7
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
DI 10.1007/s15010-020-01457-w
EA JUN 2020
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA LZ4PK
UT WOS:000541208000001
PM 32557347
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mucchielli, L
AF Mucchielli, Laurent
TI Behind the French controversy over the medical treatment of Covid-19:
   The role of the drug industry
SO JOURNAL OF SOCIOLOGY
LA English
DT Article; Early Access
DE Covid-19; drug industry; French public debate; influence peddling;
   scientific production; therapeutics
AB This article explores the stakes of the very intense controversy that has developed in France around the medical treatment of Covid-19 (which finds some parallels in the United States of America). It centres on the therapeutic proposal of a Marseilles doctor, who has become a very divisive 'star' in public debates over the efficacy of treatment. The author shows that competition between this doctor's proposal and the commercial hopes of a major pharmaceutical company plays an important role. This company has managed to create links of interest with many other major doctors, some of whom are at the heart of the decision-making process concerning the management of the health crisis. Finally, the author places this episode within the broader question of the hold the drug industry has on scientific production within the medical field. The interdependence between health authorities and the pharmaceutical industry is anything but healthy. The Covid-19 debate conforms to a well-worn pattern of behaviour: public backlash over the transgressions of wealthy corporate actors, government regulatory responses insisting on greater levels of transparency, corporate circumvention of said regulations, resulting in the continuation of fraud and corruption.
C1 [Mucchielli, Laurent] Aix Marseille Univ, Aix En Provence, France.
RP Mucchielli, L (corresponding author), Aix Marseille Univ, Natl Ctr Sci Res CNRS, Lab Mediterraneen Sociol, Aix En Provence, France.
EM mucchielli@mmsh.univ-aix.fr
CR Abecassis P., 2018, EC MEDICAMENT
   Angell M., 2009, NEW YORK REV BOOKS
   Begaud B., 2020, FRANCE MALADE MEDICA
   Campion E., 2020, MARIANNE
   Capras RD, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55070372
   Contandriopoulos Andre-Pierre, 2008, Sante Publique, V20, P191
   Demarti C., 2020, QUOTIDIEN MED
   Fanelli D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005738
   Form Indep, 2006, MINISTER SANTE LIVRE
   Frachon I., 2010, MEDIATOR 150MG COMBI
   Ghaled J.-C., 2020, MEDIAPART       0428
   Gouin S., 2017, BASTA           1005
   Hauray B., 2019, MOUVEMENTS, V98, P53, DOI DOI 10.3917/M0UV.098.0053]
   Hill A., 2020, J VIRUS ERADICATION, V6
   Horel S., 2018, LOBBYTOMIE COMMENT L
   Horton R, 2015, LANCET, V385, P1380, DOI 10.1016/S0140-6736(15)60696-1
   Lacasse JR, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000230
   Light DW, 2013, J LAW MED ETHICS, V41, P590, DOI 10.1111/jlme.12068
   Liu A, 2020, FAIR PRICE GILEADS C
   McHenry L, 2012, ETHICAL HUM PSYCHOL, V14, P156, DOI [10.1891/1559-4343.14.3.156, DOI 10.1891/1559-4343.14.3.156]
   Montalban M., 2011, SAVOIR AGIR, V16, P13
   Mucchielli L., 2020, CAHIERS MED UTOPIQUE, P91
   Mucchielli L., 2019, DEVIANCE SOC, V4
   Mucchielli L., 2018, SOCIOLOGIE DELINQUAN
   Observatoire Francais des Multinationales, 2018, PHARM PAP LOBB MEG
   Pesty F., 2015, CONFLITS INTERET HEP
   Petitjean O., 2018, OBSERVATOIRE MULTINA
   Pierru F., 2013, BUREAUCRATISATION NE, P203
   Ravelli Q, 2015, STRATEGIE BACTERIE E
   Verhaeghe E., 2020, COURRIER STRATE 0330
   Verhaeghe E., 2020, COURRIER STRATE 0328
   Viudez N., 2020, IND PHARM       0323
NR 32
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1440-7833
EI 1741-2978
J9 J SOCIOL
JI J. Sociol.
AR 1440783320936740
DI 10.1177/1440783320936740
EA JUN 2020
PG 9
WC Sociology
SC Sociology
GA MQ3QP
UT WOS:000552811600001
OA Bronze
DA 2021-01-01
ER

PT J
AU Juliao, M
AF Juliao, Miguel
TI Administration of end-of-life drugs by family caregivers during
   covid-19: opportunity for future home prescribing plans
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Letter
RI Miguel Juliao, MSc/G-3868-2014
OI Miguel Juliao, MSc/0000-0001-9283-5045
CR Bowers B, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1615
NR 1
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD JUN 17
PY 2020
VL 369
AR m2408
DI 10.1136/bmj.m2408
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MK1TJ
UT WOS:000548568900006
PM 32554622
OA Bronze
DA 2021-01-01
ER

PT J
AU Sinha, SK
   Prasad, SK
   Islam, MA
   Gurav, SS
   Patil, RB
   AlFaris, NA
   Aldayel, TS
   AlKehayez, NM
   Wabaidur, SM
   Shakya, A
AF Sinha, Saurabh K.
   Prasad, Satyendra K.
   Islam, Md Ataul
   Gurav, Shailendra S.
   Patil, Rajesh B.
   AlFaris, Nora Abdullah
   Aldayel, Tahany Saleh
   AlKehayez, Nora M.
   Wabaidur, Saikh Mohammad
   Shakya, Anshul
TI Identification of bioactive compounds fromGlycyrrhiza glabraas possible
   inhibitor of SARS-CoV-2 spike glycoprotein and non-structural
   protein-15: a pharmacoinformatics study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; glycyrrhizic acid; glyasperin; liquiritin; liquorice
ID RESPIRATORY SYNDROME CORONAVIRUS; GLYCYRRHIZIC ACID; LICORICE;
   COMPONENT; DOCKING; VIRUS
AB At present, the world is facing a pandemic named as COVID-19, caused by SARS-CoV-2. Traditional Chinese medicine has recommended the use of liquorice (Glycyrrhiza species) in the treatment of infections caused by SARS-CoV-2. Therefore, the present investigation was carried out to identify the active molecule from the liquorice against different protein targets of COVID-19 using anin-silicoapproach. The molecular docking simulation study of 20 compounds along with two standard antiviral drugs (Lopinavir and Rivabirin) was carried out with the help of Autodock vina software using two protein targets from COVID-19 i.e. spike glycoprotein (PDB ID: 6VSB) and Non-structural Protein-15 (Nsp15) endoribonuclease (PDB ID: 6W01). From the observed binding energy and the binding interactions, glyasperin A showed high affinity towards Nsp15 endoribonuclease with uridine specificity, while glycyrrhizic acid was found to be best suited for the binding pocket of spike glycoprotein and also prohibited the entry of the virus into the host cell. Further, the dynamic behavior of the best-docked molecules inside the spike glycoprotein and Nsp15 endoribonuclease were explored through all-atoms molecular dynamics (MD) simulation study. Several parameters from the MD simulation have substantiated the stability of protein-ligand stability. The binding free energy of both glyasperin A and glycyrrhizic acid was calculated from the entire MD simulation trajectory through the MM-PBSA approach and found to high binding affinity towards the respective protein receptor cavity. Thus, glyasperin A and glycyrrhizic acid could be considered as the best molecule from liquorice, which could find useful against COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Sinha, Saurabh K.] Mohanlal Shukhadia Univ, Dept Pharmaceut Sci, Udaipur, Rajasthan, India.
   [Prasad, Satyendra K.] Rashtrast Tukad Maharaj Nagpur Univ, Dept Pharmaceut Sci, Nagpur, Maharashtra, India.
   [Islam, Md Ataul] Univ Manchester, Fac Biol, Sch Hlth Sci, Div Pharm & Optometry, Manchester, Lancs, England.
   [Islam, Md Ataul] Univ Kwazulu Natal, Sch Hlth Sci, Durban, South Africa.
   [Gurav, Shailendra S.] Goa Univ, Goa Coll Pharm, Dept Pharmacognosy, Panaji, Goa, India.
   [Patil, Rajesh B.] Smt Kashibai Navale Coll Pharm, Sinhgad Tech Educ Soc, Pune, Maharashtra, India.
   [AlFaris, Nora Abdullah; Aldayel, Tahany Saleh; AlKehayez, Nora M.] Princess Nourah Bint Abdulrahman Univ, Dept Phys Sport Sci, Nutr & Food Sci, Riyadh, Saudi Arabia.
   [Wabaidur, Saikh Mohammad] King Saud Univ, Coll Sci, Dept Chem, Riyadh, Saudi Arabia.
   [Shakya, Anshul] Dibrugarh Univ, Fac Sci & Engn, Dept Pharmaceut Sci, Dibrugarh 786004, Assam, India.
RP Shakya, A (corresponding author), Dibrugarh Univ, Fac Sci & Engn, Dept Pharmaceut Sci, Dibrugarh 786004, Assam, India.
EM anshulshakya@dibru.ac.in
RI Gurav, Shailendra/AAO-4240-2020; Prasad, Satyendra/ABD-2399-2020;
   AlFaris, Nora Abdullah/L-3942-2013; Islam, Dr. Md Ataul/N-1637-2013
OI Gurav, Shailendra/0000-0001-5564-2121; AlFaris, Nora
   Abdullah/0000-0002-9135-5725; Islam, Dr. Md Ataul/0000-0001-6286-6262;
   Prasad, Satyendra/0000-0002-4762-9733; Patil,
   Rajesh/0000-0003-2986-9546; SHAKYA, ANSHUL/0000-0002-8232-4476
FU Deanship of Scientific Research at Princess Nourah bint Abdulrahman
   University, Riyadh, Saudi Arabia through the Fast-track Research Funding
   Program
FX This research was funded by the Deanship of Scientific Research at
   Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
   through the Fast-track Research Funding Program.
CR ADEOYE AO, 2020, J BIOMOL STRUCT 0514, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1765876
   Baig MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112456
   Baker D., 1998, United States Patent, Patent No. [5,843,990, 5843990]
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bhardwaj K, 2008, J BIOL CHEM, V283, P3655, DOI 10.1074/jbc.M708375200
   BHOWMICK S, 2019, J BIOMOL STRUCT 0912, DOI DOI https://doi.org/10.1080/07391102.2019.1664334
   Bode Ann M, 2015, Curr Pharmacol Rep, V1, P60, DOI 10.1007/s40495-014-0015-5
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cheng FX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05116-5
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Curreli F, 2005, J CLIN INVEST, V115, P642, DOI 10.1172/JCI200523334
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   De Clercq E, 2000, MED RES REV, V20, P323, DOI 10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Ghannad MS, 2014, JUNDISHAPUR J MICROB, V7, DOI 10.5812/jjm.11616
   Grienke U, 2014, J NAT PROD, V77, P563, DOI 10.1021/np400817j
   Grienke U, 2010, J MED CHEM, V53, P778, DOI 10.1021/jm901440f
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Islam MA, 2020, J BIOMOL STRUCT DYN, V38, P1798, DOI 10.1080/07391102.2019.1617785
   Islam MA, 2019, J BIOMOL STRUCT DYN, V37, P4104, DOI 10.1080/07391102.2018.1544509
   Jiang MY, 2020, J ETHNOPHARMACOL, V249, DOI 10.1016/j.jep.2019.112439
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Kang ST, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105950
   KIM A, 2018, FRONT PHARMACOL, V9, DOI DOI https://doi.org/10.3389/fphar.2018.01455
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Kim Y, 2020, PSYCHOTHER PSYCHOSOM, V89, P395, DOI 10.1159/000506647
   Lim J, 2020, J KOREAN MED SCI, V35
   Liu YN, 2019, J ETHNOPHARMACOL, V243, DOI 10.1016/j.jep.2019.112076
   Meng XY, 2011, CURR COMPUT-AID DRUG, V7, P146
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Okimoto N, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000528
   OU XY, 2020, NAT COMMUN, V11, DOI DOI https://doi.org/10.1038/s41467-020-15562-9
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   PARIDA P, 2020, J BIOMOL STRUCT 0206, DOI DOI https://doi.org/10.1080/07391102.2020.1720819
   Pillaiyar T, 2020, EUR J MED CHEM, V195, DOI 10.1016/j.ejmech.2020.112275
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Prajapati Shashikant M, 2015, Ayu, V36, P157, DOI 10.4103/0974-8520.175551
   Ricagno S, 2006, P NATL ACAD SCI USA, V103, P11892, DOI 10.1073/pnas.0601708103
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Serafin MB, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105969
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang JJ, 2013, J ETHNOPHARMACOL, V147, P114, DOI 10.1016/j.jep.2013.02.017
   World Health Organization (WHO), 2020, COR DIS COVID 2019
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang R, 2017, PHARM BIOL, V55, P5, DOI 10.1080/13880209.2016.1225775
   Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   ZHOU YD, 2020, CELL DISCOV, V6, DOI DOI https://doi.org/10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 60
TC 3
Z9 3
U1 7
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1779132
EA JUN 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MI7NB
UT WOS:000547588500001
PM 32552462
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Aouidate, A
   Ghaleb, A
   Chtita, S
   Aarjane, M
   Ousaa, A
   Maghat, H
   Sbai, A
   Choukrad, M
   Bouachrine, M
   Lakhlifi, T
AF Aouidate, Adnane
   Ghaleb, Adib
   Chtita, Samir
   Aarjane, Mohammed
   Ousaa, Abdellah
   Maghat, Hamid
   Sbai, Abdelouahid
   Choukrad, M'barek
   Bouachrine, Mohammed
   Lakhlifi, Tahar
TI Identification of a novel dual-target scaffold for 3CLpro and RdRp
   proteins of SARS-CoV-2 using 3D-similarity search, molecular docking,
   molecular dynamics and ADMET evaluation
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; 2019-Novel Coronavirus; molecular docking; molecular dynamics;
   polymerase; main protease
AB The new SARS-CoV-2 coronavirus is the causative agent of the COVID-19 pandemic outbreak that affected whole the world with more than 6 million confirmed cases and over 370,000 deaths. At present, there are no effective treatments or vaccine for this disease, which constitutes a serious global health crisis. As the pandemic still spreading around the globe, it is of interest to use computational methods to identify potential inhibitors for the virus. The crystallographic structures of 3CLpro (PDB: 6LU7) and RdRp (PDB 6ML7) were used in virtual screening of 50000 chemical compounds obtained from the CAS Antiviral COVID19 database using 3D-similarity search and standard molecular docking followed by ranking and selection of compounds based on their binding affinity, computational techniques for the sake of details on the binding interactions, absorption, distribution, metabolism, excretion, and toxicity prediction; we report three 4-(morpholin-4-yl)-1,3,5-triazin-2-amine derivatives; two compounds (2001083-68-5 and 2001083-69-6) with optimal binding features to the active site of the main protease and one compound (833463-19-7) with optimal binding features to the active site of the polymerase for further consideration to fight COVID-19. The structural stability and dynamics of lead compounds at the active site of 3CLpro and RdRp were examined using molecular dynamics (MD) simulation. Essential dynamics demonstrated that the three complexes remain stable during simulation of 20 ns, which may be suitable candidates for further experimental analysis. As the identified leads share the same scaffold, they may serve as promising leads in the development of dual 3CLpro and RdRp inhibitors against SARS-CoV-2. Communicated by Ramaswamy H. Sarma.
C1 [Aouidate, Adnane; Ousaa, Abdellah; Maghat, Hamid; Sbai, Abdelouahid; Choukrad, M'barek; Bouachrine, Mohammed; Lakhlifi, Tahar] Moulay Ismail Univ, Fac Sci, Mol Chem & Nat Subst Lab, BP 11201, Meknes, Morocco.
   [Ghaleb, Adib] Cadi Ayyad Univ, Polydisciplinary Fac, Lab Analyt & Mol Chem LCAM, Safi, Morocco.
   [Chtita, Samir] Hassan II Univ Casablanca, Fac Sci Ben MSik, Lab Phys Chem Mat, Casablanca, Morocco.
   [Aarjane, Mohammed] Univ Moulay Ismail, Fac Sci, LCBAE, Meknes, Morocco.
   [Bouachrine, Mohammed] Sultan Moulay Sliman Univ, Est Khenifra, Beni Mellal, Morocco.
RP Aouidate, A (corresponding author), Moulay Ismail Univ, Fac Sci, Mol Chem & Nat Subst Lab, BP 11201, Meknes, Morocco.
EM a.aouidate@edu.ac.umi.ma
RI Samir, CHTITA/AAY-5591-2020
OI Samir, CHTITA/0000-0003-2344-5101; Aouidate, Adnane/0000-0002-9123-5504;
   aarjane, mohammed/0000-0002-7501-8569; Bouachrine,
   Mohammed/0000-0002-8901-047X
CR AOUIDATE A, 2018, CHEM CENT J, V12, DOI DOI HTTPS://DOI.ORG/10.1186/S13065-018-0401-X
   Aouidate Adnane, 2018, In Silico Pharmacology, V6, P5, DOI 10.1007/s40203-018-0043-7
   Azam SS, 2013, THEOR BIOL MED MODEL, V10, DOI 10.1186/1742-4682-10-63
   Berthold M. R., 2007, STUDIES CLASSIFICATI
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Chang YC, 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2., 10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   CHOUDHURY C, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1771424
   Dahlin JL, 2015, J MED CHEM, V58, P2091, DOI 10.1021/jm5019093
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   Dassault Systemes BIOVIA, 2016, DISC STUD MOD ENV RE
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Dobi K, 2014, MOLECULES, V19, P7008, DOI 10.3390/molecules19067008
   Gao Y., 2020, PDB6M71 RCSB
   Kennedy T, 1997, DRUG DISCOV TODAY, V2, P436, DOI 10.1016/S1359-6446(97)01099-4
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Koes DR, 2013, J CHEM INF MODEL, V53, P1893, DOI 10.1021/ci300604z
   Kooistra AJ, 2018, CHEMMEDCHEM, V13, P614, DOI 10.1002/cmdc.201700754
   Landrum G. A., RDKIT OPEN SOURCE CH
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Macchiagodena M, 2020, CHEM PHYS LETT, V750, DOI 10.1016/j.cplett.2020.137489
   MITTAL L, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768151
   Pall S, 2015, LECT NOTES COMPUT SC, V8759, P3, DOI 10.1007/978-3-319-15976-8_1
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Sheridan RP, 2007, EXPERT OPIN DRUG DIS, V2, P423, DOI 10.1517/17460441.2.4.423
   Turner P. J., XMGRACE 5 1 25
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
NR 35
TC 3
Z9 3
U1 3
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1779130
EA JUN 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MG1WU
UT WOS:000545823800001
PM 32552534
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Pinto, VM
   Derchi, GE
   Bacigalupo, L
   Pontali, E
   Forni, GL
AF Pinto, Valeria M.
   Derchi, Giorgio E.
   Bacigalupo, Lorenzo
   Pontali, Emanuele
   Forni, Gian Luca
TI COVID-19 in a Patient with beta-Thalassemia Major and Severe Pulmonary
   Arterial Hypertension
SO HEMOGLOBIN
LA English
DT Article
DE Angiotensin II receptor blockers (ARBs); coronavirus disease-19
   (COVID-19); pulmonary arterial hypertension (PAH); Sildenafil;
   thalassemic syndromes
ID SILDENAFIL
AB We here report the successful recovery from coronavirus disease-19 (COVID-19) pneumonia in a patient with beta-thalassemia major (beta-TM) and severe pulmonary arterial hypertension (PAH), focusing on the patient's comorbidities, therapeutic course and drug interaction.
C1 [Pinto, Valeria M.; Forni, Gian Luca] Ente Osped Ospedali Galliera, Congenital Anemia Ctr, Via Volta 6, I-16128 Genoa, Italy.
   [Derchi, Giorgio E.] Ist Clin Ligure Alta Specialita ICLAS, Cardiol, Genoa, Italy.
   [Bacigalupo, Lorenzo] Ente Osped Osped Galliera, Radiol, Genoa, Italy.
   [Pontali, Emanuele] Ente Osped Osped Galliera, Infect Dis Unit, Genoa, Italy.
RP Pinto, VM (corresponding author), Ente Osped Ospedali Galliera, Congenital Anemia Ctr, Via Volta 6, I-16128 Genoa, Italy.
EM valeria.pinto@galliera.it
OI Pontali, Emanuele/0000-0002-1085-0442
CR Derchi G, 2014, HAEMATOLOGICA, V99, pE17, DOI 10.3324/haematol.2013.095810
   Derchi G, 2014, CIRCULATION, V129, P338, DOI 10.1161/CIRCULATIONAHA.113.002124
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Modell B, 2008, J CARDIOVASC MAGN R, V10, DOI 10.1186/1532-429X-10-42
   Muirhead GJ, 2000, BRIT J CLIN PHARMACO, V50, P99, DOI 10.1046/j.1365-2125.2000.00245.x
   Taher AT, 2018, LANCET, V391, P155, DOI 10.1016/S0140-6736(17)31822-6
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 8
TC 3
Z9 3
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0363-0269
EI 1532-432X
J9 HEMOGLOBIN
JI Hemoglobin
PD MAY 3
PY 2020
VL 44
IS 3
BP 218
EP 220
DI 10.1080/03630269.2020.1779082
EA JUN 2020
PG 3
WC Biochemistry & Molecular Biology; Hematology
SC Biochemistry & Molecular Biology; Hematology
GA MR6FY
UT WOS:000545767300001
PM 32552139
DA 2021-01-01
ER

PT J
AU Widmer, AF
   Richner, G
AF Widmer, Andreas F.
   Richner, Gilles
TI Proposal for a EN 149 acceptable reprocessing method for FFP2
   respirators in times of severe shortage
SO ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL
LA English
DT Article
DE Reprocessing; Respirators; FFP2; Sterilization; Infection control;
   Personal protection equipment
ID INFLUENZA
AB Introduction Transmission of SARS-CoV-2 to health care workers (HCW) poses a major burden in the current COVID-19 pandemic. Unprotected exposure to a COVID-19 patient is a key risk factor for HCWs. Transmission mainly occurs by droplet transmission, or by aerosol generating procedures. Respirators such as filtering face piece masks (FFP2), also called respirators, are required to prevent transmission during aerosol generating procedures, as part of the personal protective equipment (PPE) for HCWs. However, many HCW were infected due to lack of PPE, or failure to use them. Therefore, the worldwide shortage of respirators triggered the development of reprocessing used FFP2 respirators or N95 respirators as standard in the US. Our proposal with H(2)O(2)plasma sterilization for decontamination allows to reprocess FFP2, while they still meet the filtration efficiency required by EN 149. The protocol is simple, uses available resources in hospitals and can be rapidly implemented to decrease the shortage of respirators during this crisis. The goal of the study was the evaluate if respirators can be reprocessed and still fulfill the requirements for filtration efficiency outlined by EN 149. Methods Used FFP2 respirators - Model 3 M Aura (TM) 1862+ - were sterilized using a low temperature process hydrogen peroxide (H2O2), V-PRO (R) maX Low Temperature, a FDA (Food and Drug Administration) approved method to decontaminate FFP2 respirators. Decontaminated respirators were further checked for residual peroxide by a single-gas detector for H2O2. The total inward leakage of the protective respirators was quantitatively tested with 10 test persons in an atmosphere charged with paraffin aerosol according to the European Standard EN 149. The fit factor was calculated as the inverse of the total inward leakage. Results Ten new and ten decontaminated FFP2 respirators were tested for filtration efficiency. None of the respirators exceeded the maximum acceptable concentration of peroxide. More than 4000 respirators have been reprocessed so far, at cost of approximately 0.3 Euro/piece. Conclusions FFP2 respirators can be safely reprocessed once after decontamination with plasma peroxide sterilization, whereafter they still fulfill EN 149 requirements. This allows to almost double the current number of available FFP2 respirators.
C1 [Widmer, Andreas F.] Univ Basel Hosp, Div Infect Dis & Hosp Epidemiol, CH-4031 Basel, Switzerland.
   [Widmer, Andreas F.] Univ Basel, CH-4031 Basel, Switzerland.
   [Richner, Gilles] Fed Off Civil Protect FOCP, Spiez Lab, Spiez, Switzerland.
RP Widmer, AF (corresponding author), Univ Basel Hosp, Div Infect Dis & Hosp Epidemiol, CH-4031 Basel, Switzerland.; Widmer, AF (corresponding author), Univ Basel, CH-4031 Basel, Switzerland.
EM andreas.widmer@usb.ch
FU University of Basel and Labor Spiez
FX University of Basel and Labor Spiez, No external funding.
CR [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   Blachere FM, 2018, J VIROL METHODS, V260, P98, DOI 10.1016/j.jviromet.2018.05.009
   Coulliette AD, 2013, APPL ENVIRON MICROB, V79, P2148, DOI 10.1128/AEM.03850-12
   Jee Y, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020013
   Kimball A, 2020, MMWR-MORBID MORTAL W, V69, P377, DOI 10.15585/mmwr.mm6913e1
   Lai MYY, 2005, CLIN INFECT DIS, V41, pE67, DOI 10.1086/433186
   Liao L, 2020, ACS NANO, V14, P6348, DOI 10.1021/acsnano.0c03597
   MacIntyre CR, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006577
   Okpara-Hofmann J, 2005, J HOSP INFECT, V59, P280, DOI 10.1016/j.jhin.2004.10.002
   Radonovich LJ, 2019, JAMA-J AM MED ASSOC, V322, P824, DOI 10.1001/jama.2019.11645
   Viscusi DJ, 2009, ANN OCCUP HYG, V53, P815, DOI 10.1093/annhyg/mep070
   Viscusi DJ, 2009, AM J INFECT CONTROL, V37, P381, DOI 10.1016/j.ajic.2008.09.021
   Widmer A, 2011, MANUAL CLIN MICROBIO, P14373
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 14
TC 1
Z9 1
U1 11
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2047-2994
J9 ANTIMICROB RESIST IN
JI Antimicrob. Resist. Infect. Control
PD JUN 17
PY 2020
VL 9
IS 1
AR 88
DI 10.1186/s13756-020-00744-3
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases;
   Microbiology; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Infectious Diseases;
   Microbiology; Pharmacology & Pharmacy
GA ME8RW
UT WOS:000544921800001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Khan, A
   Ali, SS
   Khan, MT
   Saleem, S
   Ali, A
   Suleman, M
   Babar, Z
   Shafiq, A
   Khan, M
   Wei, DQ
AF Khan, Abbas
   Ali, Syed Shujait
   Khan, Muhammad Tahir
   Saleem, Shoaib
   Ali, Arif
   Suleman, Muhammad
   Babar, Zainib
   Shafiq, Athar
   Khan, Mazhar
   Wei, Dong-Qing
TI Combined drug repurposing and virtual screening strategies with
   molecular dynamics simulation identified potent inhibitors for
   SARS-CoV-2 main protease (3CLpro)
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-COV-2; 3CLpro; drug-repurposing; virtual screening; binding free
   energy
ID RESPIRATORY SYNDROME CORONAVIRUS; VIRUS
AB The current coronavirus (SARS-COV-2) pandemic and phenomenal spread to every nook and cranny of the world has raised major apprehensions about the modern public health care system. So far as a result of this epidemic, 4,434,653 confirmed cases and 302,169 deaths are reported. The growing infection rate and death toll demand the use of all possible approaches to design novel drugs and vaccines to curb this disease. In this study, we combined drugs repurposing and virtual drug screening strategies to target 3CLpro, which has an essential role in viral maturation and replication. A total of 31 FDA approved anti-HIV drugs, and Traditional Chinese medicines (TCM) database were screened to find potential inhibitors. As a result, Saquinavir, and five drugs (TCM5280805, TCM5280445, TCM5280343, TCM5280863, and TCM5458190) from the TCM database were found as promising hits. Furthermore, results from molecular dynamics simulation and total binding free energy revealed that Saquinavir and TCM5280805 target the catalytic dyad (His41 and Cys145) and possess stable dynamics behavior. Thus, we suggest that these compounds should be tested experimentally against the SARS-COV-2 as Saquinavir has been reported to inhibit HIV protease experimentally. Considering the intensity of coronavirus dissemination, the present research is in line with the idea of discovering the latest inhibitors against the coronavirus essential pathways to accelerate the drug development cycle. Communicated by Ramaswamy H. Sarma.
C1 [Khan, Abbas; Khan, Muhammad Tahir; Ali, Arif; Shafiq, Athar; Wei, Dong-Qing] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Dept Bioinformat & Biol Stat, State Key Lab Microbial Metab, Shanghai 200240, Peoples R China.
   [Ali, Syed Shujait; Suleman, Muhammad] Univ Swat, Ctr Biotechnol & Microbiol, Swat, Pakistan.
   [Saleem, Shoaib] Quaid I Azam Univ, Natl Ctr Bioinformat, Islamabad, Pakistan.
   [Babar, Zainib] Shanghai Jiao Tong Univ, Sch Agr & Biol, Ctr Viticulture & Enol, Shanghai, Peoples R China.
   [Khan, Mazhar] Univ Sci & Technol China USTC, CAS Key Lab Innate Immun & Chron Dis, Hefei Natl Lab Phys Sci Microscale,CAS Ctr Excell, Collaborat Innovat Ctr Genet & Dev,Sch Life Sci, Hefei, Peoples R China.
   [Wei, Dong-Qing] Shanghai Jiao Tong Univ, Minist Educ & Sch Life Sci & Biotechnol, Shanghai Islamabad Belgrade Joint Innovat Ctr Ant, State Key Lab Microbial Metab,Joint Lab Int Coope, Shanghai, Peoples R China.
   [Wei, Dong-Qing] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai, Peoples R China.
   [Wei, Dong-Qing] Peng Cheng Lab, Shenzhen, Peoples R China.
RP Wei, DQ (corresponding author), Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Dept Bioinformat & Biol Stat, State Key Lab Microbial Metab, Shanghai 200240, Peoples R China.
EM dqwei@sjtu.edu.cn
RI khan, Muhammad Tahir/ABC-6368-2020
OI khan, Muhammad Tahir/0000-0003-1158-2133; Khan,
   Ameer/0000-0001-8768-6209
FU Key Research Area Grant of the Ministry of Science and Technology of
   China [2016YFA0501703]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [61832019,
   61503244]; Natural Science Foundation of Henan Province [162300410060];
   Joint Research Funds for Medical and Engineering and Scientific Research
   at Shanghai Jiao Tong University [YG2017ZD14]
FX Dong-Qing Wei is supported by the grants from the Key Research Area
   Grant 2016YFA0501703 of the Ministry of Science and Technology of China,
   the National Natural Science Foundation of China (Contract no. 61832019,
   61503244), the Natural Science Foundation of Henan Province
   (162300410060) and Joint Research Funds for Medical and Engineering and
   Scientific Research at Shanghai Jiao Tong University (YG2017ZD14). The
   computations were partially performed at the Center for HighPerformance
   Computing, Shanghai Jiao Tong University.
CR Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chen F, 2016, PHYS CHEM CHEM PHYS, V18, P22129, DOI 10.1039/c6cp03670h
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Dai W., 2020, STRUCTURE BASED DESI, P1
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Hernandez JJ, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00273
   Hou H, 2020, PLACENTA, V92, P1, DOI 10.1016/j.placenta.2020.01.013
   Hou TJ, 2012, J PROTEOME RES, V11, P2982, DOI 10.1021/pr3000688
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Khan A, 2019, RSC ADV, V9, P10326, DOI 10.1039/c9ra01007f
   Khan A, 2018, J MOL GRAPH MODEL, V82, P37, DOI 10.1016/j.jmgm.2018.03.004
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kim AE, 1998, J PHARMACOL EXP THER, V286, P1439
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lerner M. G., 2006, APBS PLUGIN PYMOL
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Price DJ, 2004, J CHEM PHYS, V121, P10096, DOI 10.1063/1.1808117
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Release Schrodinger, 2017, MAESTR
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Rose PW, 2017, NUCLEIC ACIDS RES, V45, pD271, DOI 10.1093/nar/gkw1000
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Schrodinger LLC, 2011, SCHROD SOFTW SUIT, P670
   SLEIGH SH, 2010, PHARM MED, V24, P151
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P16719, DOI 10.1039/c4cp01388c
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang YQ, 2019, J BIOMOL STRUCT DYN, V37, P4051, DOI 10.1080/07391102.2018.1537896
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 41
TC 8
Z9 9
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1779128
EA JUN 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MF9WA
UT WOS:000545686600001
PM 32552361
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Yin, XX
   Zheng, XR
   Peng, W
   Wu, ML
   Mao, XY
AF Yin, Xi-Xi
   Zheng, Xiang-Rong
   Peng, Wang
   Wu, Mao-Lan
   Mao, Xiao-Yuan
TI Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain
   Inflammation during the COVID-19 Outbreak
SO ACS CHEMICAL NEUROSCIENCE
LA English
DT Article
DE COVID-19; SARS-CoV-2; brain inflammation; VEGF; therapeutic target;
   ACE2; Ang II
AB The coronavirus disease 19 (COVID-19) pandemic has brought a great threat to global public health. Currently, mounting evidence has shown the occurrence of neurological symptoms in patients with COVID-19. However, the detailed mechanism by which the SARS-CoV-2 attacks the brain is not well characterized. Recent investigations have revealed that a cytokine storm contributes to brain inflammation and subsequently triggers neurological manifestations during the COVID-19 outbreak. Targeting brain inflammation may provide significant clues to the treatment of neurologic complications caused by SARS-CoV-2. Vascular growth factor (VEGF), which is widely distributed in the brain, probably plays a crucial role in brain inflammation via facilitating the recruitment of inflammatory cells and regulating the level of angiopoietins II (Ang II). Also, Ang II is considered as the products of SARS-CoV-2-attacking target, angiotensin-converting enzyme 2 (ACE2). Further investigation of the therapeutic potential and the underlying mechanisms of VEGF-targeted drugs on the neurological signs of COVID-19 are warranted. In any case, VEGF is deemed a promising therapeutic target in suppressing inflammation during SARS-CoV-2 infection with neurological symptoms.
C1 [Yin, Xi-Xi; Zheng, Xiang-Rong; Peng, Wang; Wu, Mao-Lan] Cent South Univ, Xiangya Hosp, Dept Pediat, Changsha 410008, Hunan, Peoples R China.
   [Mao, Xiao-Yuan] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Peoples R China.
   [Mao, Xiao-Yuan] Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Peoples R China.
   [Mao, Xiao-Yuan] Minist Educ, Engn Res Ctr Appl Technol Pharmacogen, Changsha 410078, Peoples R China.
   [Mao, Xiao-Yuan] Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Peoples R China.
RP Zheng, XR (corresponding author), Cent South Univ, Xiangya Hosp, Dept Pediat, Changsha 410008, Hunan, Peoples R China.; Mao, XY (corresponding author), Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Peoples R China.; Mao, XY (corresponding author), Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Peoples R China.; Mao, XY (corresponding author), Minist Educ, Engn Res Ctr Appl Technol Pharmacogen, Changsha 410078, Peoples R China.; Mao, XY (corresponding author), Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Peoples R China.
EM xrzheng@csu.edu.cn; xiaoyuanm@csu.edu.cn
OI Mao, Xiao-Yuan/0000-0002-5149-1204
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [NSFC 81873851, 81671293, 81974502]
FX The authors apologize to all the investigators whose work cannot be
   cited in this paper due to space constraints. This project was kindly
   funded by National Natural Science Foundation of China (NSFC 81873851,
   81671293 and 81974502).
CR Butler N, 2006, VIROLOGY, V347, P410, DOI 10.1016/j.virol.2005.11.044
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Huang YH, 2020, BRAIN BEHAV IMMUN, V87, P149, DOI 10.1016/j.bbi.2020.05.012
   Jiang SY, 2016, CELL PHYSIOL BIOCHEM, V40, P1105, DOI 10.1159/000453165
   Mao XY, 2020, NEUROSCIENCE, V437, P130, DOI 10.1016/j.neuroscience.2020.04.044
   Wang YX, 2020, EUR REV MED PHARMACO, V24, P3360, DOI 10.26355/eurrev_202003_20704
NR 6
TC 4
Z9 4
U1 2
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7193
J9 ACS CHEM NEUROSCI
JI ACS Chem. Neurosci.
PD JUN 17
PY 2020
VL 11
IS 12
BP 1704
EP 1705
DI 10.1021/acschemneuro.0c00294
PG 2
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences
   & Neurology
GA MB9PV
UT WOS:000542930500005
PM 32485101
DA 2021-01-01
ER

PT J
AU Wozniak, RJ
   Nixon, DF
   Marston, JL
AF Wozniak, Robert J.
   Nixon, Douglas F.
   Marston, Jez L.
TI Involvement of Cisgender and Transgender Individuals in Studies on the
   Impact of Hormonal Therapy on COVID-19
SO AIDS PATIENT CARE AND STDS
LA English
DT Letter
C1 [Wozniak, Robert J.; Nixon, Douglas F.; Marston, Jez L.] Weill Cornell Med, Dept Med, Div Infect Dis, Belfer Res Bldg,413 E 69th St,Room 530, New York, NY 10065 USA.
RP Wozniak, RJ (corresponding author), Weill Cornell Med, Dept Med, Div Infect Dis, Belfer Res Bldg,413 E 69th St,Room 530, New York, NY 10065 USA.
EM rjw4001@med.cornell.edu
RI Nixon, Douglas/AAU-5734-2020
OI Nixon, Douglas/0000-0002-2801-1786
CR Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Conti P, 2020, J BIOL REGUL HOMEOST, V34, DOI [10.23812/Editorial-Conti-3, DOI 10.23812/EDITORIAL-C0NTI-3]
   Corley MJ, 2020, DNA METHYLATION ANAL, V2020030295, DOI 10.20944/preprints202003.0295.v1.
   Duarte RR., 2020, REPURPOSING FDA APPR, DOI [10.26434/chemrxiv.12148764.v1, DOI 10.26434/CHEMRXIV.12148764.V1]
   Ghandehari S, 2020, ESTROGEN PATCH COVID
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Open Letter about Coronavirus and the LGBTQ Communities. National LGBT Cancer Network, 2020, OP LETT COR LGBTQ CO
   Roberts H, 2008, BRIT MED J, V336, P1203, DOI 10.1136/bmj.39556.666944.80
   Shatzel JJ, 2017, AM J HEMATOL, V92, P204, DOI 10.1002/ajh.24593
   Suba Z, 2020, J PHARM PHARM SCI, V23, P75, DOI 10.18433/jpps31069
NR 11
TC 0
Z9 0
U1 3
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD SEP 1
PY 2020
VL 34
IS 9
BP 367
EP 368
DI 10.1089/apc.2020.0118
EA JUN 2020
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA NO2NR
UT WOS:000541777600001
PM 32551880
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Ahmed, SF
   Quadeer, AA
   McKay, MR
AF Ahmed, Syed Faraz
   Quadeer, Ahmed A.
   McKay, Matthew R.
TI COVIDep: a web-based platform for real-time reporting of vaccine target
   recommendations for SARS-CoV-2
SO NATURE PROTOCOLS
LA English
DT Letter
C1 [Ahmed, Syed Faraz; Quadeer, Ahmed A.; McKay, Matthew R.] Hong Kong Univ Sci & Technol, Dept Elect & Comp Engn, Hong Kong, Peoples R China.
   [McKay, Matthew R.] Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Hong Kong, Peoples R China.
RP Quadeer, AA; McKay, MR (corresponding author), Hong Kong Univ Sci & Technol, Dept Elect & Comp Engn, Hong Kong, Peoples R China.; McKay, MR (corresponding author), Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Hong Kong, Peoples R China.
EM eeaaquadeer@ust.hk; m.mckay@ust.hk
RI Quadeer, Ahmed Abdul/AAD-7471-2020; Ahmed, Syed Faraz/K-3879-2012
OI Quadeer, Ahmed Abdul/0000-0002-5295-9067; Ahmed, Syed
   Faraz/0000-0002-6086-0307
FU General Research Fund of the Hong Kong Research Grants Council (RGC)
   [16204519]; Hong Kong Ph.D. Fellowship Scheme (HKPFS)
FX COVIDep is made possible by the open sharing of genome sequence data of
   SARS-CoV-2 sequences by research groups from around the world through
   the GISAID platform, and the open sharing of immunological data of
   experimentally determined SARS-CoV epitopes through the ViPR database.
   We gratefully acknowledge the contributions of all the researchers,
   scientists and technical staff involved (a detailed acknowledgment is
   available at the Acknowledgments page of the COVIDep platform). We thank
   N. Law and K. Pang for their technical support, and R. Louie, D.
   Morales-Jimenez, S. Sohail, N. Kundu, A. Shah and U. Abdullah for
   comments and suggestions that helped to improve the web application and
   its interface. M.R.M. and A.A.Q. were supported by the General Research
   Fund of the Hong Kong Research Grants Council (RGC) (grant 16204519).
   S.F.A. was supported by the Hong Kong Ph.D. Fellowship Scheme (HKPFS).
CR Ahmed S. F., 2020, PREPRINT BIORXIV, DOI [10.1101/2020.05.23.111385, DOI 10.1101/2020.05.23.111385]
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Chour W., 2020, PREPRINT MEDRXIV, DOI [10.1101/2020.05.04.20085779, DOI 10.1101/2020.05.04.20085779]
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Shomuradova A. S., 2020, PREPRINT BIORXIV, DOI [10.1101/2020.05.20.20107813, DOI 10.1101/2020.05.20.20107813]
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yin D., 2020, PREPRINT BIORXIV, DOI [10.1101/2020.05.14.093054, DOI 10.1101/2020.05.14.093054]
NR 12
TC 3
Z9 3
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
EI 1750-2799
J9 NAT PROTOC
JI Nat. Protoc.
PD JUL
PY 2020
VL 15
IS 7
BP 2141
EP 2142
DI 10.1038/s41596-020-0358-9
EA JUN 2020
PG 2
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA ME6JH
UT WOS:000540980500002
PM 32555466
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gazzaruso, C
   Stella, NC
   Mariani, G
   Tamburlini, A
   Garini, P
   Freddi, E
   Ravetto, C
   Coppola, A
   Gallotti, P
AF Gazzaruso, Carmine
   Carlo Stella, Nicoletta
   Mariani, Giuseppe
   Tamburlini, Anna
   Garini, Pietro
   Freddi, Elena
   Ravetto, Carolina
   Coppola, Adriana
   Gallotti, Pietro
TI Impact of anti-rheumatic drugs and steroids on clinical course and
   prognosis of COVID-19
SO CLINICAL RHEUMATOLOGY
LA English
DT Letter
C1 [Gazzaruso, Carmine] Hosp Grp San Donato, Ist Clin Beato Matteo, Emergency Unit, Corso Pavia 84, I-27029 Vigevano, Italy.
   [Gazzaruso, Carmine] Hosp Grp San Donato, Ist Clin Beato Matteo, Endocrinol Unit, Corso Pavia 84, I-27029 Vigevano, Italy.
   [Gazzaruso, Carmine; Coppola, Adriana] Hosp Grp San Donato, Ist Clin Beato Matteo, Ctr Appl Clin Res Ce RCA, Corso Pavia 84, I-27029 Vigevano, Italy.
   [Carlo Stella, Nicoletta; Mariani, Giuseppe; Tamburlini, Anna; Garini, Pietro; Freddi, Elena; Ravetto, Carolina; Gallotti, Pietro] Hosp Grp San Donato, Ist Clin Beato Matteo, Internal Med Oncol & Rheumatol Unit, Vigevano, Italy.
RP Gazzaruso, C (corresponding author), Hosp Grp San Donato, Ist Clin Beato Matteo, Emergency Unit, Corso Pavia 84, I-27029 Vigevano, Italy.; Gazzaruso, C (corresponding author), Hosp Grp San Donato, Ist Clin Beato Matteo, Endocrinol Unit, Corso Pavia 84, I-27029 Vigevano, Italy.; Gazzaruso, C (corresponding author), Hosp Grp San Donato, Ist Clin Beato Matteo, Ctr Appl Clin Res Ce RCA, Corso Pavia 84, I-27029 Vigevano, Italy.
EM c.gazzaruso@gmail.com
RI Gazzaruso, Carmine/F-9072-2018
OI Gazzaruso, Carmine/0000-0001-9974-0735
CR Cheng CF, 2020, CLIN RHEUMATOL, V39, P2025, DOI 10.1007/s10067-020-05160-x
   Dai JH, 2020, CLIN RHEUMATOL, V39, P2031, DOI 10.1007/s10067-020-05172-7
   Di Gennaro F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082690
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Gazzaruso C, 2020, CLIN RHEUMATOL, V39, P2095, DOI 10.1007/s10067-020-05180-7
   Michelena X, 2020, SEMIN ARTHRITIS RHEU, V50, P564, DOI 10.1016/j.semarthrit.2020.05.001
   Moiseev Sergey, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217676, 10.1136/annrheumdis-2020-217570, 10.1136/annrheumdis-2020-219265]
   Quartuccio L, 2020, JOINT BONE SPINE, p[S1297, 30088], DOI 10.1016/j.jbspin.2020.05.00
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Ye C, 2020, ANN RHEUM DIS, V79, P1007, DOI 10.1136/annrheumdis-2020-217627
NR 10
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD AUG
PY 2020
VL 39
IS 8
BP 2475
EP 2477
DI 10.1007/s10067-020-05239-5
EA JUN 2020
PG 3
WC Rheumatology
SC Rheumatology
GA MF9QW
UT WOS:000540683800001
PM 32548723
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gupta, AK
   Jneid, H
   Addison, D
   Ardehali, H
   Boehme, AK
   Borgaonkar, S
   Boulestreau, R
   Clerkin, K
   Delarche, N
   DeVon, HA
   Grumbach, IM
   Gutierrez, J
   Jones, DA
   Kapil, V
   Maniero, C
   Mentias, A
   Miller, PS
   Ng, SM
   Parekh, JD
   Sanchez, RH
   Sawicki, KT
   te Riele, ASJM
   Remme, CA
   London, B
AF Gupta, Ajay K.
   Jneid, Hani
   Addison, Daniel
   Ardehali, Hossein
   Boehme, Amelia K.
   Borgaonkar, Sanket
   Boulestreau, Romain
   Clerkin, Kevin
   Delarche, Nicolas
   DeVon, Holli A.
   Grumbach, Isabella M.
   Gutierrez, Jose
   Jones, Daniel A.
   Kapil, Vikas
   Maniero, Carmela
   Mentias, Amgad
   Miller, Pamela S.
   Ng, Sher May
   Parekh, Jai D.
   Sanchez, Reynaldo H.
   Sawicki, Konrad Teodor
   te Riele, Anneline S. J. M.
   Remme, Carol Ann
   London, Barry
TI Current Perspectives on Coronavirus Disease 2019 and Cardiovascular
   Disease: A White Paper by the JAHA Editors
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE cardiovascular disease; cardiovascular risk factors; coronavirus disease
   2019; COVID-19; management; SARS-CoV-2; treatment
ID EXTRACORPOREAL MEMBRANE-OXYGENATION; ACUTE MYOCARDIAL-INFARCTION; ACUTE
   CORONARY SYNDROME; ASSOCIATION TASK-FORCE; C-REACTIVE PROTEIN;
   RESPIRATORY SYNDROME; INVASIVE STRATEGY; AMERICAN-COLLEGE; COVID-19;
   THERAPY
AB Coronavirus Disease 2019 (COVID-19) has infected more than 3.0 million people worldwide and killed more than 200,000 as of April 27, 2020. In this White Paper, we address the cardiovascular co-morbidities of COVID-19 infection; the diagnosis and treatment of standard cardiovascular conditions during the pandemic; and the diagnosis and treatment of the cardiovascular consequences of COVID-19 infection. In addition, we will also address various issues related to the safety of healthcare workers and the ethical issues related to patient care in this pandemic.
C1 [Gupta, Ajay K.; Jones, Daniel A.; Kapil, Vikas; Maniero, Carmela] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, Charterhouse Sq, London EC1M 6BQ, England.
   [Grumbach, Isabella M.; Parekh, Jai D.; London, Barry] Univ Iowa, Dept Med, Carver Coll Med, Div Cardiovasc Med, 200 Hawkins Dr, Iowa City, IA 52242 USA.
   [Gupta, Ajay K.; Kapil, Vikas; Maniero, Carmela] Baits Heart Ctr, Bads Blood Pressure Ctr Excellence, London, England.
   [Gupta, Ajay K.; Jones, Daniel A.; Ng, Sher May] Barts Hlth NHS Trust, Royal London & St Bartholomews Hosp, London, England.
   [Jneid, Hani; Borgaonkar, Sanket] Baylor Coll Med, Div Cardiol, Houston, TX 77030 USA.
   [Addison, Daniel; Sanchez, Reynaldo H.] Ohio State Univ, Dept Med, Columbus, OH 43210 USA.
   [Ardehali, Hossein; Sawicki, Konrad Teodor] Northwestern Univ, Feinberg Cardiovasc & Renal Res Inst, Chicago, IL 60611 USA.
   [Boehme, Amelia K.; Gutierrez, Jose] Columbia Univ, Dept Neurol, Vagelos Coll Phys & Surg, New York, NY USA.
   [Boehme, Amelia K.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
   [Clerkin, Kevin] Columbia Univ, Dept Med, Vagelos Coll Phys & Surg, Div Cardiol, New York, NY USA.
   [Boulestreau, Romain; Delarche, Nicolas] Pau Hosp, Dept Cardiol, Pau, France.
   [DeVon, Holli A.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
   [Mentias, Amgad] Univ Iowa, Dept Internal Med, Div Cardiol, Iowa City, IA 52242 USA.
   [Miller, Pamela S.] Univ Calif Hlth, Ctr Nursing Excellence, Los Angeles, CA USA.
   [te Riele, Anneline S. J. M.] Univ Med Ctr Utrecht, Dept Cardiol, Div Heart & Lungs, Utrecht, Netherlands.
   [Remme, Carol Ann] Univ Amsterdam, Locat Acad Med Ctr, Heart Ctr, Dept Clin & Expt Cardiol,Med Ctr, Amsterdam, Netherlands.
RP Gupta, AK (corresponding author), Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, Charterhouse Sq, London EC1M 6BQ, England.; London, B (corresponding author), Univ Iowa, Dept Med, Carver Coll Med, Div Cardiovasc Med, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM ajay.gupta@qmulac.uk; barry-london@uiowa.edu
RI Mentias, Amgad/L-6104-2017
OI Mentias, Amgad/0000-0001-6555-2517; Jones, Daniel/0000-0003-1441-0417;
   Gupta, Ajay/0000-0001-5807-8503; Grumbach, Isabella/0000-0002-2285-3157
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [K12
   CA133250] Funding Source: Medline; NHLBI NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01 HL108932] Funding
   Source: Medline
CR a R-M, 2020, J CLIN MED, V9
   Aird WC, 2007, CURR DRUG TARGETS, V8, P501, DOI 10.2174/138945007780362782
   Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64
   Alhogbani T, 2016, ANN SAUDI MED, V36, P78, DOI 10.5144/0256-4947.2016.78
   Alvi RM, 2019, J AM COLL CARDIOL, V74, P3099, DOI 10.1016/j.jacc.2019.10.038
   American Hospital Association, 2003, PAT CAR PARTN
   American Society of Echocardiography, 2020, ASE STAT PROT PAT EC
   Amsterdam EA, 2014, CIRCULATION, V130, P2354, DOI 10.1161/CIR.0000000000000133
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Barbaro RP, 2015, AM J RESP CRIT CARE, V191, P894, DOI 10.1164/rccm.201409-1634OC
   Bartlett RH, 2020, ASAIO J, V66, P472, DOI 10.1097/MAT.0000000000001173
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Biddison ELD, 2019, CHEST, V155, P848, DOI 10.1016/j.chest.2018.09.025
   Bonello L, 2016, JACC-CARDIOVASC INTE, V9, P2267, DOI 10.1016/j.jcin.2016.09.017
   Caforio ALP, 2013, EUR HEART J, V34, P2636, DOI 10.1093/eurheartj/eht210
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao J, 2020, CLIN INFECT DIS
   Center for Disease Control and Prevention (CDC), 2020, INT INF PREV CONTR R
   Chang David, 2020, HeartRhythm Case Rep, V6, P237, DOI 10.1016/j.hrcr.2020.03.012
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chu H, 2016, J INFECT DIS, V213, P904, DOI 10.1093/infdis/jiv380
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   COVID-19 Surveillance Group. Istituto Superiore della Sanita', 2020, CHAR COVID 19 PAT DY
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Diamantis E, 2017, CURR CARDIOL REV, V13, P209, DOI 10.2174/1573403X13666170426104611
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Fox KAA, 2010, J AM COLL CARDIOL, V55, P2435, DOI 10.1016/j.jacc.2010.03.007
   Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164
   Ghanbari V, 2019, INT EMERG NURS, V43, P126, DOI 10.1016/j.ienj.2018.10.004
   Goncalves PDA, 2005, EUR HEART J, V26, P865, DOI 10.1093/eurheartj/ehi187
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   He X W, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P456, DOI 10.3760/cma.j.cn112148-20200228-00137
   Henriksen M, ANTI IL6 TREATMENT S
   Henry BM, 2020, LANCET RESP MED, V8, pE24, DOI 10.1016/S2213-2600(20)30119-3
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu Hongde, 2020, Eur Heart J, DOI 10.1093/eurheartj/ehaa190
   Hua A, 2020, EUR HEART J, V41, P2130, DOI 10.1093/eurheartj/ehaa253
   Huang C, 2020, LANCET, V395, P496, DOI 10.1016/S0140-6736(20)30252-X
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Jneid H, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/HCQ.0000000000000032
   Jneid H, 2016, JACC-CARDIOVASC INTE, V9, P2277, DOI 10.1016/j.jcin.2016.10.011
   Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7
   Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Lakkireddy DR, 2020, CIRCULATION, V141, pE823, DOI 10.1161/CIRCULATIONAHA.120.047063
   Li SSL, 2003, CIRCULATION, V108, P1798, DOI 10.1161/01.CIR.0000094737.21775.32
   Li X, 2020, ASAIO J, V66, P475, DOI 10.1097/MAT.0000000000001172
   Lim W, 2006, ARCH INTERN MED, V166, P2446, DOI 10.1001/archinte.166.22.2446
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Luna JM, 2014, STROKE, V45, P979, DOI 10.1161/STROKEAHA.113.002289
   Luo W, 2020, CLIN PATHOLOGY CRITI, DOI DOI 10.1016/S1473-3099(20)30086-4
   M C W., 2020, BMJ-BRIT MED J, V368, pm544, DOI 10.1136/bmj.l6968
   Mackall CL, 2017, CANCER DISCOV, V7, P1371, DOI 10.1158/2159-8290.CD-17-1084
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Millar JE, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1570-4
   Miura TA, 2007, VIROLOGY, V369, P288, DOI 10.1016/j.virol.2007.07.030
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   O'Connor RE, 2010, CIRCULATION, V122, pS787, DOI 10.1161/CIRCULATIONAHA.110.971028
   O'Gara PT, 2013, J AM COLL CARDIOL, V61, pE78, DOI 10.1016/j.jacc.2012.11.019
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Papadimos TJ, 2018, CRIT CARE MED, V46, P1842, DOI 10.1097/CCM.0000000000003416
   Public Health England, 2020, COVID 19 PERS PROT E
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
   Rao P, 2018, CIRC-HEART FAIL, V11, DOI 10.1161/CIRCHEARTFAILURE.118.004905
   Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646
   RISKI H, 1980, LANCET, V2, P100
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P1873, DOI 10.1056/NEJMp2005492
   Rothenberg FG, 2017, J INVEST MED, V65, P747, DOI 10.1136/jim-2016-000374
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sakabe Masao, 2013, J Cardiol Cases, V8, P173, DOI 10.1016/j.jccase.2013.08.002
   Shah PB, 2020, JACC-CARDIOVASC INTE, V13, P1484, DOI 10.1016/j.jcin.2020.04.001
   Shamoo Adil E., 2009, RESPONSIBLE CONDUCT
   Shao IY, 2019, STROKE, V50, P1046, DOI 10.1161/STROKEAHA.118.023443
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   Szerlip M, 2020, CATHETER CARDIO INTE, V96, P586, DOI 10.1002/ccd.28887
   Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631
   Thygesen K, 2019, EUR HEART J, V40, P237, DOI [10.1093/eurheartj/ehy462, 10.1016/j.jacc.2018.08.1038]
   Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang BY, 2020, J HUM HYPERTENS, DOI 10.1038/s41371-020-0314-8
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HE, 2013, J CRIT CARE, V28, P549, DOI 10.1016/j.jcrc.2012.11.002
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   Wang ZW, 2018, CIRCULATION, V137, P2344, DOI 10.1161/CIRCULATIONAHA.117.032380
   Welt FGP, 2020, J AM COLL CARDIOL, V75, P2372, DOI 10.1016/j.jacc.2020.03.021
   White Douglas, 2020, U PITTSBURGH DEP CRI
   White DB, 2020, JAMA-J AM MED ASSOC, V323, P1773, DOI 10.1001/jama.2020.5046
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   Wijeysundera HC, 2007, J AM COLL CARDIOL, V49, P422, DOI 10.1016/j.jacc.2006.09.033
   World Health Organization, 2016, REP WHO CHIN JOINT M
   World Health Organization (WHO), 2020, RAT US PERS PROT EQ, P1
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu CI, 2020, HEART RHYTHM, V17, P1456, DOI 10.1016/j.hrthm.2020.03.024
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang G, 2020, ANGIOTENSIN 2 RECEPT
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yu CM, 2006, POSTGRAD MED J, V82, P140, DOI 10.1136/pgmj.2005.037515
   Yuan S, 2015, MBIO, V6, DOI 10.1128/mBio.01120-15
   Yuan ZY, 2004, AM J PHYSIOL-HEART C, V286, pH83, DOI 10.1152/ajpheart.00536.2003
   Zeng J, 2020, INTENS CARE MED, V46, P1111, DOI 10.1007/s00134-020-05993-9
   Zhang F, 2020, MYOCARDIAL INJURY IS, DOI [10.1101/2020.03.21.20040121, DOI 10.1101/2020.03.21.20040121]
   Zhang GM, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01338-8
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 120
TC 10
Z9 11
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JUN 16
PY 2020
VL 9
IS 12
AR e017013
DI 10.1161/JAHA.120.017013
PG 23
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MN6XP
UT WOS:000550987700006
PM 32347144
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ramireddy, A
   Chugh, H
   Reinier, K
   Ebinger, J
   Park, E
   Thompson, M
   Cingolani, E
   Cheng, S
   Marban, E
   Albert, CM
   Chugh, SS
AF Ramireddy, Archana
   Chugh, Harpriya
   Reinier, Kyndaron
   Ebinger, Joseph
   Park, Eunice
   Thompson, Michael
   Cingolani, Eugenio
   Cheng, Susan
   Marban, Eduardo
   Albert, Christine M.
   Chugh, Sumeet S.
TI Experience With Hydroxychloroquine and Azithromycin in the Coronavirus
   Disease 2019 Pandemic: Implications for QT Interval Monitoring
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE azithromycin; COVID-19; hydroxychloroquine; monitoring; QT interval
ID PROLONGATION; RISKS
AB BACKGROUND: Despite a lack of clinical evidence, hydroxychloroquine and azithromycin are being administered widely to patients with verified or suspected coronavirus disease 2019 (COVID-19). Both drugs may increase risk of lethal arrhythmias associated with QT interval prolongation.
   METHODS AND RESULTS: We analyzed a case series of COVID-19- positive/suspected patients admitted between February 1, 2020, and April 4, 2020, who were treated with azithromycin, hydroxychloroquine, or a combination of both drugs. We evaluated baseline and postmedication QT interval (corrected QT interval [QTc]; Bazett) using 12-lead ECGs. Critical QTc prolongation was defined as follows: (1) maximum QTc >= 500 ms (if QRS <120 ms) or QTc >= 550 ms (if QRS >= 120 ms) and (2) QTc increase of >= 60 ms. Tisdale score and Elixhauser comorbidity index were calculated. Of 490 COVID-19-positive/suspected patients, 314 (64%) received either/both drugs and 98 (73 COVID-19 positive and 25 suspected) met study criteria (age, 62 +/- 17 years; 61% men). Azithromycin was prescribed in 28%, hydroxychloroquine in 10%, and both in 62%. Baseline mean QTc was 448 +/- 29 ms and increased to 459 +/- 36 ms (P= 0.005) with medications. Significant prolongation was observed only in men (18 +/- 43 ms versus -0.2 +/- 28 ms in women; P= 0.02). A total of 12% of patients reached critical QTc prolongation. Changes in QTc were highest with the combination compared with either drug, with much greater prolongation with combination versus azithromycin (17 +/- 39 ms versus 0.5 +/- 40 ms; P= 0.07). No patients manifested torsades de pointes.
   CONCLUSIONS: Overall, 12% of patients manifested critical QTc prolongation, and the combination caused greater prolongation than either drug alone. The balance between uncertain benefit and potential risk when treating COVID-19 patients should be carefully assessed.
C1 [Ramireddy, Archana; Chugh, Harpriya; Reinier, Kyndaron; Ebinger, Joseph; Cingolani, Eugenio; Cheng, Susan; Marban, Eduardo; Albert, Christine M.; Chugh, Sumeet S.] Cedars Sinai Hlth Syst, Smidt Heart Inst, Los Angeles, CA USA.
   [Park, Eunice; Thompson, Michael] Cedars Sinai Hlth Syst, Enterprise Informat Syst Data Intelligence Team, Los Angeles, CA USA.
RP Chugh, SS (corresponding author), Cedars Sinai Med Ctr, Inst Heart, Adv Hlth Sci Pavil,Suite A3100, Los Angeles, CA 90048 USA.
EM sumeet.chugh@cshs.org
OI Albert, Christine/0000-0002-2081-1121
FU Cedars-Sinai Health System
FX Cedars-Sinai Health System. Dr Chugh holds the Pauline and Harold Price
   Chair in Cardiac Electrophysiology Research.
CR a R-M, 2020, J CLIN MED, V9
   Capel RA, 2015, HEART RHYTHM, V12, P2186, DOI 10.1016/j.hrthm.2015.05.027
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giudicessi J.R., 2020, MAYO CLIN P, DOI [10.1016/j.mayocp.2020.03.024, DOI 10.1016/J.MAY0CP.2020.03.024]
   Hancox JC, 2013, THER ADV INFECT DIS, V1, P155, DOI 10.1177/2049936113501816
   Kim MH, 2005, PACE, V28, P1221, DOI 10.1111/j.1540-8159.2005.50146.x
   Lakkireddy D. R., 2020, HEART RHYTHM
   McGhie TK, 2018, CLIN EXP RHEUMATOL, V36, P545
   Ohe M, 2020, BIOSCI TRENDS, V14, P159, DOI 10.5582/bst.2020.03058
   Park M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040967
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Tang C, 2012, INTERN MED J, V42, P968, DOI 10.1111/j.1445-5994.2012.02886.x
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   Traebert M, 2004, EUR J PHARMACOL, V484, P41, DOI 10.1016/j.ejphar.2003.11.003
   van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang MD, 2017, CARDIOVASC TOXICOL, V17, P434, DOI 10.1007/s12012-017-9401-7
NR 18
TC 20
Z9 21
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JUN 16
PY 2020
VL 9
IS 12
AR e017144
DI 10.1161/JAHA.120.017144
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MN6XP
UT WOS:000550987700021
PM 32463348
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Selvaraj, C
   Dinesh, DC
   Panwar, U
   Abhirami, R
   Boura, E
   Singh, SK
AF Selvaraj, Chandrabose
   Dinesh, Dhurvas Chandrasekaran
   Panwar, Umesh
   Abhirami, Rajaram
   Boura, Evzen
   Singh, Sanjeev Kumar
TI Structure-based virtual screening and molecular dynamics simulation of
   SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying
   antiviral inhibitors against COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; nsp14; N7-MTase; RNA capping; Methyltransferase; COVID-19;
   TCM; natural products; molecular dynamics; ensemble sampling
ID TRADITIONAL CHINESE MEDICINE; BACILLUS-ANTHRACIS; MD SIMULATION; HTLV-1
   PR; HIV-PR; PROTEIN; DOCKING; BINDING; VIRUS; RECOGNITION
AB The recent pandemic caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) calls the whole world into a medical emergency. For tackling Coronavirus Disease 2019 (COVID-19), researchers from around the world are swiftly working on designing and identifying inhibitors against all possible viral key protein targets. One of the attractive drug targets is guanine-N7 methyltransferase which plays the main role in capping the 50-ends of viral genomic RNA and sub genomic RNAs, to escape the host's innate immunity. We performed homology modeling and molecular dynamic (MD) simulation, in order to understand the molecular architecture of Guanosine-P3-Adenosine-5',5'-Triphosphate (G3A) binding with C-terminal N7-MTase domain of nsp14 from SARS-CoV-2. The residue Asn388 is highly conserved in present both in N7-MTase from SARS-CoV and SARS-CoV-2 and displays a unique function in G3A binding. For an in-depth understanding of these substrate specificities, we tried to screen and identify inhibitors from the Traditional Chinese Medicine (TCM) database. The combination of several computational approaches, including screening, MM/GBSA, MD simulations, and PCA calculations, provides the screened compounds that readily interact with the G3A binding site of homology modeled N7-MTase domain. Compounds from this screening will have strong potency towards inhibiting the substrate-binding and efficiently hinder the viral 5'-end RNA capping mechanism. We strongly believe the final compounds can become COVID-19 therapeutics, with huge international support.
   [GRAPHICS]
   The focus of this study is to screen for antiviral inhibitors blocking guanine-N7 methyltransferase (N7-MTase), one of the key drug targets involved in the first methylation step of the SARS-CoV-2 RNA capping mechanism. Compounds binding the substrate-binding site can interfere with enzyme catalysis and impede 5'-end cap formation, which is crucial to mimic host RNA and evade host cellular immune responses. Therefore, our study proposes the top hit compounds from the Traditional Chinese Medicine (TCM) database using a combination of several computational approaches.
C1 [Selvaraj, Chandrabose; Panwar, Umesh; Abhirami, Rajaram; Singh, Sanjeev Kumar] Alagappa Univ, Dept Bioinformat, Comp Aided Drug Design & Mol Modeling Lab, Sci Block, Karaikkudi 630004, Tamil Nadu, India.
   [Dinesh, Dhurvas Chandrasekaran; Boura, Evzen] AS CR, Vvi, Inst Organ Chem & Biochem, Sect Mol Biol & Biochem, Prague 6, Czech Republic.
RP Selvaraj, C; Singh, SK (corresponding author), Alagappa Univ, Dept Bioinformat, Comp Aided Drug Design & Mol Modeling Lab, Sci Block, Karaikkudi 630004, Tamil Nadu, India.
EM drbioselva@gmail.com; skysanjeev@gmail.com
RI Dinesh, Dhurvas Chandrasekaran/AAR-1948-2020; Panwar, Umesh/F-2573-2018;
   Selvaraj, Chandrabose/F-4168-2012
OI Dinesh, Dhurvas Chandrasekaran/0000-0001-9125-4775; Panwar,
   Umesh/0000-0001-7777-7174; Selvaraj, Chandrabose/0000-0002-8115-0486
FU Dept. of Edn, Govt. of India [F.24-51/2014-U]; European Regional
   Development FundEuropean Union (EU); OP RDE; Project: "Chemical biology
   for drugging undruggable targets (ChemBioDrug)"
   [CZ.02.1.01/0.0/0.0/16_019/0000729]; Czech Academy of SciencesCzech
   Academy of Sciences [L200551951]; Academy of Sciences of Czech
   RepublicCzech Academy of Sciences [RVO: 61388963]; Indian Council of
   Medical ResearchIndian Council of Medical Research (ICMR)
   [ISRM/11/(19)/2017]
FX CS and SKS thankfully acknowledge RUSA-Phase 2.0 Policy (TNmultiGen),
   Dept. of Edn, Govt. of India (Grant No: F.24-51/2014-U). DCD and EB
   acknowledge European Regional Development Fund; OP RDE; Project:
   "Chemical biology for drugging undruggable targets (ChemBioDrug)" (No.
   CZ.02.1.01/0.0/0.0/16_019/0000729), Czech Academy of Sciences
   Post-doctoral Fellowship (No. L200551951 Programu podpory perspektivnich
   lidskych zdroju -postdoktorandu) and the Academy of Sciences of Czech
   Republic (RVO: 61388963). UP thank to Indian Council of Medical Research
   (ISRM/11/(19)/2017, dated:09.08.2018) for providing ICMR-SRF (Senior
   Research Fellowship).
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   Aksoydan B, 2018, J MOL GRAPH MODEL, V79, P103, DOI 10.1016/j.jmgm.2017.10.011
   Alogheli H, 2017, J CHEM INF MODEL, V57, P190, DOI 10.1021/acs.jcim.6b00443
   ANDERSEN KG, 2020, NAT MED 0317, DOI DOI HTTPS://DOI.ORG/10.1038/S41591-020-0820-9
   Bandaru S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186666
   Bawono P, 2014, METHODS MOL BIOL, V1079, P245, DOI 10.1007/978-1-62703-646-7_16
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Chen Y, 2016, VIROL SIN, V31, P3, DOI 10.1007/s12250-016-3726-4
   Chen Y, 2009, P NATL ACAD SCI USA, V106, P3484, DOI 10.1073/pnas.0808790106
   Childers MC, 2018, J PHYS CHEM B, V122, P6673, DOI 10.1021/acs.jpcb.8b02144
   CHINNASAMY S, 2019, J BIOMOL STRUCT 1011, DOI DOI https://doi.org/10.1080/07391102.2019.1674695
   Chinnasamy S, 2020, INT J BIOL MACROMOL, V144, P53, DOI 10.1016/j.ijbiomac.2019.12.091
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   Decroly E, 2012, NAT REV MICROBIOL, V10, P51, DOI 10.1038/nrmicro2675
   DiMaio Daniel, 2020, Annu Rev Virol, V7, piii, DOI 10.1146/annurev-vi-07-042020-100001
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Fazil MHUT, 2012, J BIOMOL STRUCT DYN, V30, P574, DOI 10.1080/07391102.2012.687523
   Ferron F, 2012, ANTIVIR RES, V96, P21, DOI 10.1016/j.antiviral.2012.07.007
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Grover A, 2012, BBA-PROTEINS PROTEOM, V1824, P1476, DOI 10.1016/j.bbapap.2012.05.016
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hercik K, 2017, ARCH VIROL, V162, P2091, DOI 10.1007/s00705-017-3345-x
   Kawatkar S, 2009, J COMPUT AID MOL DES, V23, P527, DOI 10.1007/s10822-009-9281-4
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Koonin EV, 2010, P NATL ACAD SCI USA, V107, P3283, DOI 10.1073/pnas.0915061107
   Kumar A, 2018, ACS OMEGA, V3, P18132, DOI 10.1021/acsomega.8b01002
   KUMAR D, 2020, J BIOMOL STRUCT 0503, DOI DOI https://doi.org/10.1080/07391102.2020.1752310
   LAI MMC, 1981, J VIROL, V38, P661, DOI 10.1128/JVI.38.2.661-670.1981
   Lionta E, 2014, CURR TOP MED CHEM, V14, P1923, DOI 10.2174/1568026614666140929124445
   LOBOGALO N, 2020, J BIOMOL STRUCT 0513, DOI DOI https://doi.org/10.1080/07391102.2020.1764393
   Ma Y, 2016, FRONT MED-PRC, V10, P28, DOI 10.1007/s11684-016-0434-2
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Martinez L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119264
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nakagawa K, 2016, ADV VIRUS RES, V96, P165, DOI 10.1016/bs.aivir.2016.08.001
   NGUYEN TT, 2014, THESCIENTIFICWORLDJO, V2014
   Onufriev AV, 2013, Q REV BIOPHYS, V46, P181, DOI 10.1017/S0033583513000024
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Patidar Kavisha, 2016, Asian Pac J Cancer Prev, V17, P2291
   Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628
   RAKHSHANI H, 2019, J MOL MODEL, V25, DOI DOI https://doi.org/10.1007/s00894-019-4232-z
   Rapp C, 2011, J CHEM INF MODEL, V51, P2082, DOI 10.1021/ci200033n
   Rayalu DJ, 2012, BIOINFORMATION, V8, P81
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   SELVARAJ C, 2014, J MOL MODEL, V20, DOI DOI https://doi.org/10.1007/s00894-014-2364-8
   Selvaraj C, 2018, FOOD CHEM TOXICOL, V112, P495, DOI 10.1016/j.fct.2017.08.028
   Selvaraj C, 2015, MOL BIOSYST, V11, P178, DOI 10.1039/c4mb00486h
   Selvaraj C, 2014, J MOL RECOGNIT, V27, P696, DOI 10.1002/jmr.2395
   Selvaraj C, 2014, CELL COMMUN ADHES, V21, P257, DOI 10.3109/15419061.2014.927444
   Selvaraj C, 2014, J RECEPT SIG TRANSD, V34, P361, DOI 10.3109/10799893.2014.898659
   Selvaraj C, 2014, J RECEPT SIG TRANSD, V34, P221, DOI 10.3109/10799893.2013.876044
   Selvaraj C, 2014, J BIOMOL STRUCT DYN, V32, P1333, DOI 10.1080/07391102.2013.818577
   Shafreen RMB, 2013, J MOL RECOGNIT, V26, P276, DOI 10.1002/jmr.2270
   Sivakamavalli J, 2014, J MOL RECOGNIT, V27, P173, DOI 10.1002/jmr.2348
   Sliwoski G, 2014, PHARMACOL REV, V66, P334, DOI 10.1124/pr.112.007336
   Swegat W, 2003, BIOPHYS J, V84, P1493, DOI 10.1016/S0006-3495(03)74962-5
   Thielemann HC, 2019, J MOL MODEL, V25, DOI 10.1007/s00894-019-4011-x
   Tripathi SK, 2012, J MOL RECOGNIT, V25, P504, DOI 10.1002/jmr.2216
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047
   Verma P, 2018, J BIOMOL STRUCT DYN, V36, P1182, DOI 10.1080/07391102.2017.1317025
   Vijayalakshmi P, 2013, J BIOMOL STRUCT DYN, V31, P561, DOI 10.1080/07391102.2012.706080
   Wang JG, 2018, EXPERT REV MOL MED, V20, DOI 10.1017/erm.2018.3
   Wang P, 2019, J ETHNOPHARMACOL, V236, P277, DOI 10.1016/j.jep.2018.07.008
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Webb B, 2017, METHODS MOL BIOL, V1654, P39, DOI 10.1007/978-1-4939-7231-9_4
   Wohlert J, 2004, BIOPHYS J, V87, P2433, DOI 10.1529/biophysj.104.044222
   Zhou SF, 2009, CURR MED CHEM, V16, P3480, DOI 10.2174/092986709789057635
NR 75
TC 4
Z9 4
U1 8
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1778535
EA JUN 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MK8VC
UT WOS:000549058400001
PM 32567979
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hamza, M
   Ali, A
   Khan, S
   Ahmed, S
   Attique, Z
   Rehman, SU
   Khan, A
   Ali, H
   Rizwan, M
   Munir, A
   Khan, AM
   Siddique, F
   Mehmood, A
   Nouroz, F
   Khan, S
AF Hamza, Muhammad
   Ali, Ashaq
   Khan, Suliman
   Ahmed, Saeed
   Attique, Zarlish
   Ur Rehman, Saad
   Khan, Ayesha
   Ali, Hussain
   Rizwan, Muhammad
   Munir, Anum
   Khan, Arshad Mehmood
   Siddique, Faiza
   Mehmood, Azhar
   Nouroz, Faisal
   Khan, Sajid
TI nCOV-19 peptides mass fingerprinting identification, binding, and
   blocking of inhibitors flavonoids and anthraquinone ofMoringa
   oleiferaand hydroxychloroquine
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; peptide mass fingerprinting; hydroxychloroquine;
   flavonoids; anthraquinone; AutoDock Vina
ID ANTIVIRAL ACTIVITY; AUTODOCK VINA; WEB SERVER; PROTEIN; OPTIMIZATION;
   PREDICTION; DOCKING
AB An rare pandemic of viral pneumonia occurs in December 2019 in Wuhan, China, which is now recognized internationally as Corona Virus Disease 2019 (COVID-19), the etiological agent classified as Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2). According to the World Health Organization (WHO), it has so far expanded to more than 213 countries/territories worldwide. Our study aims to find the viral peptides of SARS-COV-2 by peptide mass fingerprinting (PMF) in order to predict its novel structure and find an inhibitor for each viral peptide. For this reason, we calculated the mass of amino acid sequences translated from the SARS-CoV2 whole genome and identify the peptides that may be a target for inhibition. Molecular peptide docking withMoringa oleifera,phytochemicals (aqueous and ethanolic) leaf extracts of flavonoids (3.56 +/- 0.03), (3.83 +/- 0.02), anthraquinone (11.68 +/- 0.04), (10.86 +/- 0.06) and hydroxychloroquine present therapy of COVID-19 in Pakistan for comparative study. Results indicate that 15 peptides of SARS-CoV2 have been identified from PMF, which is then used as a selective inhibitor. The maximum energy obtained from AutoDock Vina for hydroxychloroquine is -5.1 kcal/mol, kaempferol (flavonoid) is -6.2 kcal/mol, and for anthraquinone -6 kcal/mol. Visualization of docking complex, important effects are observed regarding the binding of peptides to drug compounds. In conclusion, it is proposed that these compounds are effective antiviral agents against COVID-19 and can be used in clinical trials. Communicated by Ramaswamy H. Sarma
C1 [Hamza, Muhammad; Khan, Suliman] Zhengzhou Univ, Dept Cerebrovasc Dis, Affiliated Hosp 2, Zhengzhou, Peoples R China.
   [Hamza, Muhammad; Attique, Zarlish; Ur Rehman, Saad; Ali, Hussain; Rizwan, Muhammad; Munir, Anum; Siddique, Faiza; Mehmood, Azhar; Khan, Sajid] Govt Postgrad Coll Mandian Abbottabad, Dept Bioinformat, Abbottabad, Kpk, Pakistan.
   [Ali, Ashaq] Chinese Acad Sci, Wuhan Inst Virol, Wuhan, Peoples R China.
   [Ali, Ashaq] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Ahmed, Saeed] Huazhong Agr Univ, Wuhan, Hubei, Peoples R China.
   [Khan, Ayesha] COMSATS Abbottabad, Dept Biotechnol, Abbottabad, Kpk, Pakistan.
   [Khan, Arshad Mehmood] Govt Postgrad Coll Mandian Abbottabad, Dept Chem, Abbottabad, Kpk, Pakistan.
   [Nouroz, Faisal] Hazara Univ Mansehra, Dept Bioinformat, Mansehra, Kpk, Pakistan.
RP Khan, S (corresponding author), Zhengzhou Univ, Dept Cerebrovasc Dis, Affiliated Hosp 2, Zhengzhou, Peoples R China.; Khan, S (corresponding author), Govt Postgrad Coll Mandian Abbottabad, Dept Bioinformat, Abbottabad, Kpk, Pakistan.
EM suliman.khan18@mails.ucas.ac.cn; mrsajidk@gmail.com
RI Ali, Ashaq/ABF-3123-2020
OI Ali, Ashaq/0000-0003-3224-2891; Khan, Suliman/0000-0003-4954-0748
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45
   Baker P. R., 2008, P 56 ASME AM SOC MAS, P1
   BARNARD DL, 1992, ANTIVIR RES, V17, P63, DOI 10.1016/0166-3542(92)90091-I
   Berg J.M., 2002, BIOCH
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang MW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011955
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   CULP WC, 2020, A A PRACT, V14, DOI DOI https://doi.org/10.1213/XAA.0000000000001218
   Damodaran Senthilkumar, 2007, Genomics Proteomics & Bioinformatics, V5, P152, DOI 10.1016/S1672-0229(08)60002-9
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Drwal MN, 2014, NUCLEIC ACIDS RES, V42, pW53, DOI 10.1093/nar/gku401
   ELFIKY AA, 2020, J BIOMOL STRUCT 0424, DOI DOI https://doi.org/10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Fahmi I., 2020, COVID19 CORONAVIRUS, V2019, P1
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Gundry R. L., 2010, OCTOBER, V77, P342, DOI [https://doi.org/10.1002/0471142727.mb1025s88.Preparation, DOI 10.1002/0471142727.MB1025S88.PREPARATI0N]
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Gusman DH, 2017, YALE J BIOL MED, V90, P15
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Hamza M, 2019, ADV PHARMACOL PHARM, V7, P63, DOI 10.13189/app.2019.070402
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Henzel WJ, 2003, J AM SOC MASS SPECTR, V14, P931, DOI 10.1016/S1044-0305(03)00214-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussein HA, 2015, NUCLEIC ACIDS RES, V43, pW436, DOI 10.1093/nar/gkv462
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Jaghoori MM, 2016, J COMPUT AID MOL DES, V30, P237, DOI 10.1007/s10822-016-9900-9
   Kasolo JN, 2010, J MED PLANTS RES, V4, P753
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   KINI SG, 2017, BMC PLANT BIOL, V17, DOI DOI https://doi.org/10.1186/s12870-017-1014-6
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   KUMAR D, 2020, J BIOMOL STRUCT 0503, DOI DOI https://doi.org/10.1080/07391102.2020.1752310
   Kumar S., 2020, DRUG VACCINE DESIGN, DOI [10.20944/preprints202002.0071.v1., DOI 10.20944/PREPRINTS202002.0071.V1]
   Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329
   Liebler D. C., 2002, INTRO PROTEOMICS TOO, DOI [10.1007/978-1-59259-130-5, DOI 10.1007/978-1-59259-130-5]
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lobo-Galo N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764393
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maier HJ, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7
   Masunov A, 2001, J CHEM INF COMP SCI, V41, P1093, DOI 10.1021/ci010400l
   Matthiesen R., MASS SPECTROMETRY DA, DOI [10.1007/978-1-62703-392-3, DOI 10.1007/978-1-62703-392-3]
   Moyo B, 2011, AFR J BIOTECHNOL, V10, P12925
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nweze N. O., 2014, IOSR J PHARM BIOL SC, V9, P99, DOI DOI 10.9790/3008-091699103
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   SCHINAZI RF, 1990, ANTIVIR RES, V13, P265, DOI 10.1016/0166-3542(90)90071-E
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822-010-9352-6
   Semple SJ, 2001, ANTIVIR RES, V49, P169, DOI 10.1016/S0166-3542(01)00125-5
   Shinwari S., 2020, PAK J BOT, V52, P725, DOI [https://doi.org/10.30848/PJB2020-2(19), DOI 10.30848/PJB2020-2(19)]
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsugita A, 2000, ELECTROPHORESIS, V21, P1853, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1853::AID-ELPS1853>3.3.CO;2-P
   ULQAMAR MT, 2019, J TRANSL MED, V17, DOI DOI https://doi.org/10.1186/s12967-019-2116-8
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wilkins MR, 1999, METH MOL B, V112, P531
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yang QY, 2006, J CHEM THEORY COMPUT, V2, P1152, DOI 10.1021/ct060009c
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   YUAN SG, 2017, WIRES COMPUT MOL SCI, V7, DOI DOI https://doi.org/10.1002/wcms.1298
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
NR 70
TC 1
Z9 1
U1 6
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1778534
EA JUN 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MH5BF
UT WOS:000546743700001
PM 32567487
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Roden, DM
   Harrington, RA
   Poppas, A
   Russo, AM
AF Roden, Dan M.
   Harrington, Robert A.
   Poppas, Athena
   Russo, Andrea M.
TI Considerations for Drug Interactions on QTc in Exploratory COVID-19
   Treatment
SO CIRCULATION
LA English
DT Article
DE arrhythmias; cardiac; COVID-19; drug effects; drug-related side effects
   and adverse reactions; severe acute respiratory syndrome coronavirus 2
ID INTERVAL PROLONGATION; AZITHROMYCIN; RISKS
C1 [Roden, Dan M.] Vanderbilt Univ, Sch Med, Div Cardiovasc Med & Clin Pharmacol, Nashville, TN 37232 USA.
   [Harrington, Robert A.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
   [Poppas, Athena] Brown Univ, Sch Med, Cardiol Div, Providence, RI 02912 USA.
   [Russo, Andrea M.] Cooper Univ Hosp, Electrophysiol & Arrhythmia Serv, Camden, NJ USA.
   [Russo, Andrea M.] Rowan Univ, Cooper Med Sch, Clin Cardiac Electrophysiol Fellowship Program, Camden, NJ USA.
RP Roden, DM (corresponding author), Vanderbilt Univ, Sch Med, 1285B Med Res Bldg 4,2215B Garland Ave, Nashville, TN 37232 USA.
EM dan.roden@vumc.org
FU Boehringer IngelheimBoehringer Ingelheim; Boston ScientificBoston
   Scientific; Medilynx
FX Dr Roden has nothing to disclose. Dr Harrington is the president of the
   American Heart Association (unpaid) and served on the Stanford
   Healthcare Board of Directors from 2016 to 2018 (unpaid). Dr Poppas is
   the president of the American College of Cardiology. Dr Russo is the
   president of the Heart Rhythm Society; receives research study support
   from Boehringer Ingelheim, Boston Scientific, and Medilynx (all funding
   to the hospital); and serves on the Research Steering Committee for
   Boston Scientific and the Apple Heart Study (no honoraria).
CR Aromolaran AS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208321
   Capel RA, 2015, HEART RHYTHM, V12, P2186, DOI 10.1016/j.hrthm.2015.05.027
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Choi Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1574806
   de Olano J, 2019, AM J EMERG MED, V37, DOI 10.1016/j.ajem.2019.158387
   Giudicessi J.R., 2020, MAYO CLIN P, DOI [10.1016/j.mayocp.2020.03.024, DOI 10.1016/J.MAY0CP.2020.03.024]
   Huang BH, 2007, PACE, V30, P1579, DOI 10.1111/j.1540-8159.2007.00912.x
   Kauthale RR, 2015, J APPL TOXICOL, V35, P799, DOI 10.1002/jat.3074
   Kezerashvili A, 2007, J INTERV CARD ELECTR, V18, P243, DOI 10.1007/s10840-007-9124-y
   Kim MH, 2005, PACE, V28, P1221, DOI 10.1111/j.1540-8159.2005.50146.x
   Morgan ND, 2013, JCR-J CLIN RHEUMATOL, V19, P286, DOI 10.1097/RHU.0b013e31829d5e50
   Mosholder AD, 2013, NEW ENGL J MED, V368, P1665, DOI 10.1056/NEJMp1302726
   O'Laughlin JP, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/4626279
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Sears SP, 2016, DRUGS REAL WORLD OUT, V3, P99, DOI [DOI 10.1007/s40801-016-0062-9, 10.1007/s40801-016-0062-9]
   Simpson TF, CARDIOLOGY MAGAZINE
   Yang ZJ, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.115.003560
   Zhang MD, 2017, CARDIOVASC TOXICOL, V17, P434, DOI 10.1007/s12012-017-9401-7
NR 18
TC 46
Z9 47
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD JUN 16
PY 2020
VL 141
IS 24
BP E906
EP E907
DI 10.1161/CIRCULATIONAHA.120.047521
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA MG3MO
UT WOS:000545938400001
PM 32267732
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Costa, AN
   de Sa, ERA
   Bezerra, RDS
   Souza, JL
   Lima, FDA
AF Costa, Allan N.
   de Sa, Ezio R. A.
   Bezerra, Roosevelt D. S.
   Souza, Janilson L.
   Lima, Francisco das C. A.
TI Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the
   SARS-Coronavirus main peptidase: an investigation by docking and
   molecular dynamics
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Covid-19; buriti oil; molecular docking; molecular dynamic
ID AUTOMATED DOCKING; SIMULATIONS; BINDING
AB Statistics show alarming numbers of infected and killed in the world, caused by the Covid-19 pandemic, which still doesn't have a specific treatment and effective in combating all efforts to seek treatments and medications against this disease. Natural products are of relevant interest in the search for new drugs. Thus, Buriti oil (Mauritia flexuosa L.) is a natural product extracted from the fruit of the palm and is quite common in the legal Amazon region, Brazil. In the present work, the anti-Covid-19 biological activity of some constituents of Buriti oil was investigated using in silico methods of Molecular Docking and Molecular Dynamics Simulations. The main results of Molecular Docking revealed favorable interaction energies in the formation of the 2GTB peptidase complex (main peptidase of SARS-CoV) with the 13-cis-beta-carotene ligands (Delta G(bind) = -10.23Kcal mol(-1)), 9-cis -beta-carotene (Delta G(bind) = - 9.82 KCal mol(-1)), and alpha-carotene (Delta G(bind) = -8.34 Kcal mol(-1)). Molecular Dynamics simulations demonstrated considerable interaction for these ligands with emphasis on a-carotene. Such theoretical results encourage and enable a direction for experimental studies in vitro and in vivo, essential in the development of new drugs with enzymatic inhibitory action for Covid-19.
C1 [Costa, Allan N.] Fed Inst Educ Sci & Technol, Para Conceicao Araguaia Campus, Conceicao Do Araguaia, Brazil.
   [de Sa, Ezio R. A.] Fed Inst Educ Sci & Technol, Piaui Picos Campus, Picos, Brazil.
   [Bezerra, Roosevelt D. S.] Fed Inst Educ Sci & Technol, Piaui Teresina Cent Campus, BR-64000040 Teresina, PI, Brazil.
   [Souza, Janilson L.] Fed Inst Educ Sci & Technol, Maranhao Bacabal Campus, Bacabal, Brazil.
   [Lima, Francisco das C. A.] State Univ, Piaui Torquato Neto Campus, Teresina, Brazil.
   [Lima, Francisco das C. A.] Univ Estadual Piaui, Res Grp Computat Quantum Chem & Pharmaceut Planni, Piaui GPQQ&PF UESPI, Teresina, Brazil.
RP Bezerra, RDS (corresponding author), Fed Inst Educ Sci & Technol, Piaui Teresina Cent Campus, BR-64000040 Teresina, PI, Brazil.
EM rooseveltdsb@ifpi.edu.br
OI Alves de Sa, Ezio Raul/0000-0002-6340-7380; Bezerra,
   Roosevelt/0000-0002-1820-076X
FU IFPA; IFPI; IFMA
FX The authors thank IFPA, IFPI, and IFMA for financial and/or structural
   support.
CR Abraham M. J., 2018, GROMACS USER MANUAL
   Albuquerque MLS, 2005, J BRAZIL CHEM SOC, V16, P1113
   Alonso H, 2006, MED RES REV, V26, P531, DOI 10.1002/med.20067
   [Anonymous], 2018, PYMOL MOL GRAPH SYST
   Arcanjo DDR, 2017, EUR J MED CHEM, V139, P401, DOI 10.1016/j.ejmech.2017.08.019
   Atanasov AG, 2015, BIOTECHNOL ADV, V33, P1582, DOI 10.1016/j.biotechadv.2015.08.001
   Barros E. M. L., 2015, CONSCIENTIAE SAUDE, V13, P503, DOI [https://doi.org/10.5585/conssaude.v13n4.5175, DOI 10.5585/CONSSAUDE.V13N4.5175]
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bouchentouf S., 2020, IDENTIFICATION COMPO, P1
   Carneiro BT, 2011, REV VERDE, V6, P105
   COVID-19 Clinical Res Coalition, 2020, LANCET, V395, P1322, DOI 10.1016/S0140-6736(20)30798-4
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Ferreira E. T., 2019, BRAZILIAN J HLTH REV, V2, P1511
   Goodsell D.S., 2005, PROTEIN PROTEIN INTE
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   Gordon JC, 2005, NUCLEIC ACIDS RES, V33, pW368, DOI 10.1093/nar/gki464
   Guedes I. A., 2014, BIOINFORMATICS BIOL, P189
   Huey R., 2012, USING AUTODOCK4 AUTO
   Kerrigan John E, 2013, Methods Mol Biol, V993, P95, DOI 10.1007/978-1-62703-342-8_7
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kovalski L. M., 2013, CIENCIA EDUCACAO BAU, V19, P911, DOI [https://doi.org/10.1590/S1516-73132013000400009, DOI 10.1590/S1516-73132013000400009]
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lee TW, 2007, J MOL BIOL, V366, P916, DOI 10.1016/j.jmb.2006.11.078
   Lemkul J., 2019, LIVING J COMPUT MOL, V1, P5068, DOI [10.33011/livecoms.1.1.5068, DOI 10.33011/LIVECOMS.1.1.5068]
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Meng XY, 2011, CURR COMPUT-AID DRUG, V7, P146
   Monego DL, 2017, FOOD CHEM, V217, P37, DOI 10.1016/j.foodchem.2016.08.073
   Morris Garrett M, 2008, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0814s24
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Namba A. M., 2008, ECLET QUIM, V33, P13, DOI [10.1590/S0100-46702008000400002., DOI 10.1590/S0100-46702008000400002]
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Piccirillo E, 2018, QUIM NOVA, V41, P662, DOI 10.21577/0100-4042.20170210
   Ramos RM, 2012, J MOL MODEL, V18, P4013, DOI 10.1007/s00894-012-1383-6
   Ravindranath PA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004586
   Rocha JA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198476
   Samant L. R., 2020, COMP DOCKING ANAL RA, P1
   Shard AG, 2020, MICRO NANO TECHNOL, P1, DOI 10.1016/B978-0-12-814182-3.00001-8
   Silva SM, 2009, J AM OIL CHEM SOC, V86, P611, DOI 10.1007/s11746-009-1400-9
   Tautermann CS, 2015, COMPUT STRUCT BIOTEC, V13, P111, DOI 10.1016/j.csbj.2014.12.002
   Totrov M, 2008, CURR OPIN STRUC BIOL, V18, P178, DOI 10.1016/j.sbi.2008.01.004
   van der Spoel D, 1998, J CHEM PHYS, V108, P10220, DOI 10.1063/1.476482
   Wong SH, 2020, J GASTROEN HEPATOL, V35, P744, DOI 10.1111/jgh.15047
   Xu Z., 2020, NELFINAVIR WAS PREDI, P1
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 45
TC 0
Z9 0
U1 9
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1778538
EA JUN 2020
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MH4XV
UT WOS:000546734800001
PM 32567501
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lakshmi, SA
   Shafreen, RMB
   Priya, A
   Shunmugiah, KP
AF Alagu Lakshmi, Selvaraj
   Shafreen, Raja Mohamed Beema
   Priya, Arumugam
   Shunmugiah, Karutha Pandian
TI Ethnomedicines of Indian origin for combating COVID-19 infection by
   hampering the viral replication: using structure-based drug discovery
   approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Ethnomedicine; drug discovery; molecular docking; MD simulation; Binding
   energy; SARS-CoV-2 inhibitors
ID IN-VITRO; ANTIVIRAL ACTIVITIES; HERBAL MEDICINE; BERBERINE; CORONAVIRUS;
   SARS; SYMPTOMS; BIOFILM; ACID
AB In the present study, we have explored the interaction of the active components from 10 different medicinal plants of Indian origin that are commonly used for treating cold and respiratory-related disorders, through molecular docking analysis. In the current scenario, COVID-19 patients experience severe respiratory syndromes, hence it is envisaged from our study that these traditional medicines are very likely to provide a favourable effect on COVID-19 infections. The active ingredients identified from these natural products are previously reported for antiviral activities against large group of viruses. Totally 47 bioactives identified from the medicinal plants were investigated against the structural targets of SARS-CoV-2 (Mpro and spike protein) and human ACE2 receptor. The top leads were identified based on interaction energies, number of hydrogen bond and other parameters that explain their potency to inhibit SARS-CoV-2. The bioactive ligands such as Cucurbitacin E, Orientin, Bis-andrographolide, Cucurbitacin B, Isocucurbitacin B, Vitexin, Berberine, Bryonolic acid, Piperine and Magnoflorine targeted the hotspot residues of SARS-CoV-2 main protease. In fact, this protease enzyme has an essential role in mediating the viral replication and therefore compounds targeting this key enzyme are expected to block the viral replication and transcription. The top scoring conformations identified through docking analysis were further demonstrated with molecular dynamics simulation. Besides, the stability of the conformation was studied in detail by investigating the binding free energy using MM-PBSA method. Overall, the study emphasized that the proposed hit Cucurbitacin E and orientin could serve as a promising scaffold for developing anti-COVID-19 drug. Communicated by Ramaswamy H. Sarma
C1 [Alagu Lakshmi, Selvaraj; Shafreen, Raja Mohamed Beema; Priya, Arumugam; Shunmugiah, Karutha Pandian] Alagappa Univ, Dept Biotechnol, Sci Campus, Karaikkudi, Tamil Nadu, India.
RP Shunmugiah, KP (corresponding author), Alagappa Univ, Dept Biotechnol, Sci Campus, Karaikkudi, Tamil Nadu, India.
EM pandiansk@gmail.com
RI Shunmugiah, Karutha Pandian/B-6765-2018; Lakshmi, Selvaraj
   Alagu/AAX-9552-2020
OI Shunmugiah, Karutha Pandian/0000-0003-2925-0575; LAKSHMI,
   ALAGU/0000-0002-1305-3190
FU DBT, GOIDepartment of Biotechnology (DBT) India [BT/BI/25/012/2012];
   DST-FISTDepartment of Science & Technology (India)
   [SR/FST/LSI-639/2015(C)]; UGC-SAPUniversity Grants Commission, India
   [F.5-1/2018/DRS-II(SAP-II)]; DST-PURSE [SR/PURSE Phase 2/38 (G)];
   UGCUniversity Grants Commission, India [F.19-225/2018(BSR)]; RUSA 2.0
   [F.24-51/2014-U]
FX The authors sincerely acknowledge the computational and bioinformatics
   analysis provided by the Bioinformatics Infrastructure Facility (funded
   by DBT, GOI; File No. BT/BI/25/012/2012,BIF). The authors also
   thankfully acknowledge DST-FIST (Grant No. SR/FST/LSI-639/2015(C)),
   UGC-SAP (Grant No. F.5-1/2018/DRS-II(SAP-II)) and DST-PURSE (Grant No.
   SR/PURSE Phase 2/38 (G)). SKP is thankful to UGC for Mid-Career Award
   [F.19-225/2018(BSR)]. RBS is thankful to RUSA 2.0 [F.24-51/2014-U,
   Policy (TN MultiGen), Dept. of Edn, GoI].
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   ADEOYE AO, 2020, J BIOMOL STRUCT 0514, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1765876
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   Alsayari A, 2012, PLANTA MED, V78, P1104
   Anbarasu K, 2011, ASIAN PAC J TROP MED, V4, P819, DOI 10.1016/S1995-7645(11)60201-0
   Arjun Ram, 2009, International Journal of Pharmaceuticals Analysis, V1, P20
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Borgio JF, 2020, ARCH MED SCI, V16, P508, DOI 10.5114/aoms.2020.94567
   Chao Wen-Wan, 2010, Chin Med, V5, P17, DOI 10.1186/1749-8546-5-17
   CHEN K, 2009, PLOS ONE, V4, DOI DOI https://doi.org/10.1371/journal.pone.0004473
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   CHU M, 2016, SCI REP UK, V6, DOI DOI https://doi.org/10.1038/srep24748
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   de Oliveira OV, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772885
   Derosa G, 2016, ADV EXP MED BIOL, V928, P173, DOI 10.1007/978-3-319-41334-1_8
   Dkhil Mohamed A., 2014, Journal of Pure and Applied Microbiology, V8, P155
   ELFIKY AA, 2020, J BIOMOL STRUCT 0424, DOI DOI https://doi.org/10.1080/07391102.2020.1758789
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   FAHMY NM, 2020, CHEM BIODIVERS, V17, DOI DOI https://doi.org/10.1002/cbdv.201900511
   Gatbonton-Schwager TN, 2012, J NAT PROD, V75, P591, DOI 10.1021/np200823p
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hassan STS, 2017, S AFR J BOT, V108, P90, DOI 10.1016/j.sajb.2016.10.001
   Hayashi K, 2007, BIOORG MED CHEM LETT, V17, P1562, DOI 10.1016/j.bmcl.2006.12.085
   He M, 2016, FITOTERAPIA, V115, P74, DOI 10.1016/j.fitote.2016.09.011
   Hsu CH, 2008, EVID-BASED COMPL ALT, V5, P355, DOI 10.1093/ecam/nem035
   Hung TC, 2019, PHYTOMEDICINE, V53, P62, DOI 10.1016/j.phymed.2018.09.025
   Insoo Jang, 2009, [The Journal of Korean Oriental Internal Medicine, 대한한방내과학회지], V30, P571
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Jain J, 2020, J AYURVEDA INTEGR ME, V11, P329, DOI 10.1016/j.jaim.2018.05.006
   Jiang ZY, 2013, BIOORG MED CHEM LETT, V23, P2123, DOI 10.1016/j.bmcl.2013.01.118
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kamalarajan P., 2019, EUROPEAN J MED PLANT, P1, DOI [https://doi.org/10.9734/ejmp/2019/v30i430187, DOI 10.9734/EJMP/2019/V30I430187]
   Kaushik Ujjwal, 2015, Pharmacogn Rev, V9, P12, DOI 10.4103/0973-7847.156314
   KAVINILAVAN R, 2017, J PHARMACOGNOSY PHYT, V6, P749
   KHALLOUKI F, 2018, BIOMEDICINES, V6, DOI DOI https://doi.org/10.3390/biomedicines6010021
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kim HY, 2008, J CLIN VIROL, V41, P122, DOI 10.1016/j.jcv.2007.10.011
   Knipping K, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-137
   KUMAR D, 2020, J BIOMOL STRUCT 0503, DOI DOI https://doi.org/10.1080/07391102.2020.1752310
   Lam K Y, 2016, ADV PHARM SCI, V2016
   Lau JTF, 2005, J ALTERN COMPLEM MED, V11, P49, DOI 10.1089/acm.2005.11.49
   Lau TF, 2005, AM J CHINESE MED, V33, P345, DOI 10.1142/S0192415X05002965
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Li YL, 2002, J ETHNOPHARMACOL, V79, P365, DOI 10.1016/S0378-8741(01)00410-X
   LOBOGALO N, 2020, J BIOMOL STRUCT 0513, DOI DOI https://doi.org/10.1080/07391102.2020.1764393
   Mattummal R, 2018, TRADIT MED RES, V3, P215, DOI 10.12032/TMR201813080
   Meng XY, 2011, CURR COMPUT-AID DRUG, V7, P146
   Mohamed SM, 2010, NAT PROD RES, V24, P1395, DOI 10.1080/14786410902906959
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nakkeeran C., 2016, Journal of Chemical and Pharmaceutical Research, V8, P634
   NEAG MA, 2018, FRONT PHARMACOL, V9, DOI DOI https://doi.org/10.3389/fphar.2018.00557
   NORGAN AP, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-12
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Patel MB, 2012, J FUNCT FOODS, V4, P79, DOI 10.1016/j.jff.2011.08.002
   Peng LC, 2015, INT J CLIN EXP PATHO, V8, P5217
   Ramanathan M., 2019, ASIAN J PHARM RES DE, V7, P41, DOI [https://doi.org/10.22270/ajprd.v7i1.468, DOI 10.22270/AJPRD.V7I1.468]
   Reddy VLN, 2005, NAT PROD RES, V19, P223, DOI 10.1080/14786410410001709197
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Shafreen RMB, 2014, J MOL RECOGNIT, V27, P106, DOI 10.1002/jmr.2339
   Sharma P, 2016, COMB CHEM HIGH T SCR, V19, P656, DOI 10.2174/1386207319666160709192801
   Shukla P., 2019, INT J PHARM LIFE SCI, V10, P6406
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Systemes D., 2015, BIOVIA DISCOVERY STU
   TAN JQ, 2019, BMC COMPLEM ALTERN M, V19, DOI DOI https://doi.org/10.1186/s12906-019-2558-9
   TANAKA S, 1991, PLANTA MED, V57, P527, DOI 10.1055/s-2006-960199
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Varghese FS, 2016, J VIROL, V90, P9743, DOI 10.1128/JVI.01382-16
   VEERAMACHANENI GK, 2020, J BIOMOL STRUCT 0603, DOI DOI https://doi.org/10.1080/07391102.2020.1773318
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   Wang H., 2017, VIROL J, V14, DOI DOI https://doi.org/10.1186/s12985-016-0674-4
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wen Chih-Chun, 2011, J Tradit Complement Med, V1, P41
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu Y, 2011, CHIN J INTEGR MED, V17, P444, DOI 10.1007/s11655-011-0640-3
   Xie YF, 2020, DRUG DES DEV THER, V14, P87, DOI 10.2147/DDDT.S230857
   Xu D, 2011, BIOPHYS J, V101, P2525, DOI 10.1016/j.bpj.2011.10.024
   YADAV M, 2018, SCI REP UK, V8, DOI DOI https://doi.org/10.1038/s41598-018-23419-x
   Yu HH, 2005, J MED FOOD, V8, P454, DOI 10.1089/jmf.2005.8.454
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   ZHANG MF, 1989, ACTA PHARM SINIC, V10, P174
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 90
TC 3
Z9 3
U1 10
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1778537
EA JUN 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MJ0GS
UT WOS:000547775000001
PM 32573351
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Singh, A
   Mishra, A
AF Singh, Amit
   Mishra, Abha
TI Leucoefdin a potential inhibitor against SARS CoV-2 M-pro
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Leucoefdin; SARS CoV-2; M-Pro; docking; simulation
ID ACCURATE DOCKING; BINDING; PROTEIN; GLIDE
AB Leucoefdin an important constituent of various fruits such as banana, raspberry, etc. was explored to target M(Pro)protease of SARS Co-V 2. Ligand was found to bind at active site of M(Pro)with large negative binding energies in molecular docking and simulation study. The docking results showed that Leucoefdin interacted with the M(Pro)by forming hydrogen bonds, at Leu 141, His163, His 164, and Glu 166. Other non-bonded interactions were seen at Met49, Pro52, Tyr54, Phe140, Leu141, Cys145 and Met165. Results of Leucoefdin was in coherence with the recently reported M(Pro)protease-inhibitor complex. It even displayed better binding energies (kcal/mol) in HTVS (-6.28), SP (-7.28), XP (-9.29) and MMGBSA (-44.71) as compared to the reference ligand [HTVS (-4.87), SP (-6.79), XP (-5.75) and MMGBSA (-47.76)]. Leucoefdin-M(Pro)complex on molecular dynamic simulation showed initial fluctuations in RMSD plot for a certain period and attained equilibrium which remained stable during entire simulation for 150 ns. RMSF of protein showed less secondary structure fluctuations and a greater number of H-bond formation with Leucoefdin during 150 ns simulation. Post simulation MMGBSA analysis showed binding energy of -45.98 Kcal/mol. These findings indicated the potential of Leucoefdin as lead compound in R&D for drug discovery and development against SARS CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Singh, Amit] Inst Med Sci, Dept Pharmacol, Varanasi, Uttar Pradesh, India.
   [Mishra, Abha] BHU, Indian Inst Technol, Sch Biochem Engn, Varanasi, Uttar Pradesh, India.
RP Mishra, A (corresponding author), BHU, Indian Inst Technol, Sch Biochem Engn, Varanasi, Uttar Pradesh, India.
EM abham.bce@itbhu.ac.in
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   [Anonymous], 2015, LIGPREP VERS 3 4
   [Anonymous], 2015, PRIM VERS 4 0
   [Anonymous], 2015, GLID VERS 6 7
   [Anonymous], 2015, MACROMODEL VERS 10 8
   DREWES SE, 1966, BIOCHEM J, V98, P493, DOI 10.1042/bj0980493
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   GANGULY AK, 1958, TETRAHEDRON, V3, P225, DOI 10.1016/0040-4020(58)80017-4
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Halgren T, 2007, CHEM BIOL DRUG DES, V69, P146, DOI 10.1111/j.1747-0285.2007.00483.x
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Mobley DL, 2009, STRUCTURE, V17, P489, DOI 10.1016/j.str.2009.02.010
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Shivakumar D, 2010, J CHEM THEORY COMPUT, V6, P1509, DOI 10.1021/ct900587b
   US Department of Agriculture, 2017, WHY IS IT IMP EAT VE
   Wang L, 2015, J AM CHEM SOC, V137, P2695, DOI 10.1021/ja512751q
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
NR 23
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1777903
EA JUN 2020
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MF7HE
UT WOS:000545508000001
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Vihinen, M
AF Vihinen, Mauno
TI Strategy for Disease Diagnosis, Progression Prediction, Risk Group
   Stratification and Treatment-Case of COVID-19
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; pathogenicity model; diagnosis; progression
   prediction; poikilosis
ID CORONARY-ARTERY-DISEASE; EXTENT; SCORE; THERAPY
AB A novel strategy is presented for reliable diagnosis and progression prediction of diseases with special attention to COVID-19 pandemic. A plan is presented for how the model can be implemented worldwide in healthcare and how novel treatments and targets can be detected. The idea is based on poikilosis, pervasive heterogeneity, and variation at all levels, systems, and mechanisms. Poikilosis in diseases can be taken into account in pathogenicity model, which is based on distribution of three independent condition measures-extent, modulation, and severity. Pathogenicity model is a population or cohort-based description of disease components. Evidence-based thresholds can be applied to the pathogenicity model and used for diagnosis as well as for early detection of patients in risk of developing the most severe forms of the disease. Analysis of patients with differential course of disease can help in detecting biomarkers of diagnostic and prognostic significance. A practical and feasible plan is presented how the concepts can be implemented in practice. Collaboration of many actors, including the World Health Organization and national health authorities, will be essential for success.
C1 [Vihinen, Mauno] Lund Univ, Dept Expt Med Sci, BMC B13, Lund, Sweden.
RP Vihinen, M (corresponding author), Lund Univ, Dept Expt Med Sci, BMC B13, Lund, Sweden.
EM mauno.vihinen@med.lu.se
CR [Anonymous], 2010, AJCC CANC STAGING MA
   BOGATY P, 1993, CIRCULATION, V87, P1938, DOI 10.1161/01.CIR.87.6.1938
   CALIFF RM, 1985, J AM COLL CARDIOL, V5, P1055, DOI 10.1016/S0735-1097(85)80005-X
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Daperno M, 2004, GASTROINTEST ENDOSC, V60, P505, DOI 10.1016/S0016-5107(04)01878-4
   DASH H, 1977, BRIT HEART J, V39, P733
   Dippel E, 1997, LANCET, V350, P32, DOI 10.1016/S0140-6736(05)66242-3
   Hamada T, 2013, J GASTROENTEROL, V48, P1384, DOI 10.1007/s00535-013-0765-6
   Istituto Superiore della Sanita, 2020, REP CAR PAZ DEC POS
   Lin F, 2008, ATHEROSCLEROSIS, V197, P700, DOI 10.1016/j.atherosclerosis.2007.07.002
   LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532-5415.1968.tb02103.x
   MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015
   Matthay KK, 2010, BRIT J CANCER, V102, P1319, DOI 10.1038/sj.bjc.6605621
   REINHOLDKELLER E, 1994, ARTHRITIS RHEUM, V37, P919, DOI 10.1002/art.1780370622
   Solal-Celigny P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434
   SULLIVAN DR, 1990, AM HEART J, V119, P1262, DOI 10.1016/S0002-8703(05)80173-5
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5
   Vihinen M, 2017, HUM MUTAT, V38, P129, DOI 10.1002/humu.23144
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Weinreb NJ, 2010, GENET MED, V12, P44, DOI 10.1097/GIM.0b013e3181c39194
   WHO-China Joint Mission, 2020, REP WHO CHIN JOINT M
NR 23
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUN 16
PY 2020
VL 7
AR 294
DI 10.3389/fmed.2020.00294
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA MG5TB
UT WOS:000546093200001
PM 32613004
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nasim, S
   Hashmi, SH
   Azim, D
   Kumar, S
   Nasim, J
AF Nasim, Sundus
   Hashmi, Shariq Haider
   Azim, Dua
   Kumar, Sohail
   Nasim, Jasia
TI Tocilizumab for COVID-19: a real 'miracle drug'?
SO INFECTIOUS DISEASES
LA English
DT Letter
C1 [Nasim, Sundus; Azim, Dua; Kumar, Sohail; Nasim, Jasia] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan.
   [Hashmi, Shariq Haider] NYU, Grossman Sch Med, New York, NY USA.
RP Nasim, S (corresponding author), Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan.
EM sundusnasim9@gmail.com
CR Alzghari SK, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104380
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Hou W, 2020, INFECT DIS-NOR, V52, P498, DOI 10.1080/23744235.2020.1759817
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Luo W., 2020, CLIN PATHOLOGY CRITI
   Morrison AR, 2020, J MED VIROL, V92, P1791, DOI 10.1002/jmv.25907
   Strangfeld A, 2017, ANN RHEUM DIS, V76, P504, DOI 10.1136/annrheumdis-2016-209773
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
NR 10
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2374-4235
EI 2374-4243
J9 INFECT DIS-NOR
JI Infect. Dis.
PD SEP 1
PY 2020
VL 52
IS 9
BP 681
EP 682
DI 10.1080/23744235.2020.1780307
EA JUN 2020
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA MI1GO
UT WOS:000545507200001
PM 32644027
DA 2021-01-01
ER

PT J
AU Paskins, Z
   Crawford-Manning, F
   Bullock, L
   Jinks, C
AF Paskins, Z.
   Crawford-Manning, F.
   Bullock, L.
   Jinks, C.
TI Identifying and managing osteoporosis before and after COVID-19: rise of
   the remote consultation?
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE COVID-19; FLS; Osteoporosis; Telemedicine
ID FOLLOW-UP; CARE; TELEPHONE; SATISFACTION; TELEMEDICINE; MANAGEMENT;
   IMPACT; TRIAL
AB The COVID-19 pandemic is influencing methods of healthcare delivery. In this short review, we discuss the evidence for remote healthcare delivery in the context of osteoporosis. Introduction The COVID-19 pandemic has undoubtedly had, and will continue to have, a significant impact on the lives of people living with, and at risk of, osteoporosis and those caring for them. With osteoporosis outpatient and Fracture Liaison Services on pause, healthcare organisations have already moved to delivering new and follow-up consultations remotely, where staffing permits, by telephone or video. Methods In this review, we consider different models of remote care delivery, the evidence for their use, and the possible implications of COVID-19 on osteoporosis services. Results Telemedicine is a global term used to describe any use of telecommunication systems to deliver healthcare from a distance and encompasses a range of different scenarios from remote clinical data transfer to remote clinician-patient interactions. Across a range of conditions and contexts, there remains unclear evidence on the acceptability of telemedicine and the effect on healthcare costs. Within the context of osteoporosis management, there is some limited evidence to suggest telemedicine approaches are acceptable to patients but unclear evidence on whether telemedicine approaches support informed drug adherence. Gaps in the evidence pertain to the acceptability and benefits of using telemedicine in populations with hearing, cognitive, or visual impairments and in those with limited health literacy. Conclusion There is an urgent need for further health service evaluation and research to address the impact of remote healthcare delivery during COVID-19 outbreak on patient care, and in the longer term, to identify acceptability and cost- and clinical-effectiveness of remote care delivery on outcomes of relevance to people living with osteoporosis.
C1 [Paskins, Z.; Crawford-Manning, F.] Keele Univ, Sch Primary Community & Social Care, Stoke On Trent, Staffs, England.
   [Paskins, Z.; Crawford-Manning, F.] Haywood Acad Rheumatol Ctr, Stoke On Trent, Staffs, England.
   [Bullock, L.; Jinks, C.] Keele Univ, Sch Primary Community & Social Care, Newcastle Under Lyme, England.
RP Paskins, Z (corresponding author), Keele Univ, Sch Primary Community & Social Care, Stoke On Trent, Staffs, England.; Paskins, Z (corresponding author), Haywood Acad Rheumatol Ctr, Stoke On Trent, Staffs, England.
EM z.paskins@keele.ac.uk
OI Bullock, Laurna/0000-0002-4193-1835; paskins, zoe/0000-0002-7783-2986
FU National Institute for Health Research (NIHR) Clinician Scientist
   Award/NIHR AcademyNational Institute for Health Research (NIHR)
   [CS-2018-18-ST2-010]; NIHR Clinical Research Network Clinical Research
   Scholar Programme; NIHR Applied Research Collaboration West Midlands
FX ZP is funded by the National Institute for Health Research (NIHR)
   Clinician Scientist Award (CS-2018-18-ST2-010)/NIHR Academy. FCM is part
   funded by the NIHR Clinical Research Network Clinical Research Scholar
   Programme. CJ is part funded by the NIHR Applied Research Collaboration
   West Midlands. The views expressed are those of the author(s) and not
   necessarily those of the National Health Service, the NIHR, or the
   Department of Health & Social Care.
CR Agha Z, 2009, TELEMED J E-HEALTH, V15, P830, DOI 10.1089/tmj.2009.0030
   Artinian NT, 2007, NURS RES, V56, P312, DOI 10.1097/01.NNR.0000289501.45284.6e
   ATA, 2020, TEL FAQS
   Beaver K, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3147
   Bowles KH, 2009, J TELEMED TELECARE, V15, P344, DOI 10.1258/jtt.2009.090118
   'Briefly Summarised' Cochrane Norway, 2020, MOB PHON HLTH WORK P
   Carey JR, 2007, NEUROREHAB NEURAL RE, V21, P216, DOI 10.1177/1545968306292381
   Eccleston C, 2020, PAIN, V161, P889, DOI 10.1097/j.pain.0000000000001885
   Elliott RA, 2008, PHARM WORLD SCI, V30, P17, DOI 10.1007/s11096-007-9134-y
   Finkelstein SM, 2011, J TELEMED TELECARE, V17, P288, DOI 10.1258/jtt.2011.100712
   Flodgren G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002098.pub2
   Foster A, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0773-3
   Giordano A, 2009, INT J CARDIOL, V131, P192, DOI 10.1016/j.ijcard.2007.10.027
   Greenhalgh T, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m998
   Hammersley V, 2019, BRIT J GEN PRACT, V69, pE595, DOI 10.3399/bjgp19X704573
   Jaglal SB, 2012, OSTEOPOROSIS INT, V23, P87, DOI 10.1007/s00198-011-1726-7
   Lateef F., 2011, ETHICS MED, V27, P17
   Morguet AJ, 2008, CARDIOLOGY, V111, P134, DOI 10.1159/000119701
   Murphy J F A, 2019, Ir Med J, V112, P863
   National Institute for Health and Care Excellence, 2020, COVID 19 RAP GUID RH
   NHS England, 2020, US PHON CONS 2020
   Palcu P, 2020, OSTEOPOROSIS INT, V31, P351, DOI 10.1007/s00198-019-05182-5
   Parker S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019192
   Pinto A, 2010, J NEUROL NEUROSUR PS, V81, P1238, DOI 10.1136/jnnp.2010.206680
   Rada G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000105
   Rahimi SA, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1332259
   Rush KL, 2018, INT J MED INFORM, V118, P44, DOI 10.1016/j.ijmedinf.2018.07.007
   Saltzman J, 2020, BOSTON GLOBE
   Salzsieder Eckhard, 2011, J Diabetes Sci Technol, V5, P13
   Schousboe JT, 2005, DIS MANAG HEALTH OUT, V13, P395, DOI 10.2165/00115677-200513060-00004
   Sicotte C, 2011, TELEMED E-HEALTH, V17, P95, DOI 10.1089/tmj.2010.0142
   Slater H, 2016, BEST PRACT RES CL RH, V30, P483, DOI 10.1016/j.berh.2016.08.006
   Smith AC, 2020, J TELEMED TELECARE, V26, P309, DOI 10.1177/1357633X20916567
   Solomon DH, 2012, ARCH INTERN MED, V172, P477, DOI 10.1001/archinternmed.2011.1977
   Terry M, 2009, TELEMED J E-HEALTH, V15, P928, DOI 10.1089/tmj.2009.9932
   van den Berg N, 2012, MATURITAS, V73, P94, DOI 10.1016/j.maturitas.2012.06.010
   2019, NEW FRONT COLL ED, P1
NR 37
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
EI 1433-2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD SEP
PY 2020
VL 31
IS 9
BP 1629
EP 1632
DI 10.1007/s00198-020-05465-2
EA JUN 2020
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MZ6PM
UT WOS:000544760100001
PM 32548787
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Peng, Q
   Peng, RC
   Yuan, B
   Zhao, JR
   Wang, M
   Wang, XX
   Wang, Q
   Sun, Y
   Fan, Z
   Qi, JX
   Gao, GF
   Shi, Y
AF Peng, Qi
   Peng, Ruchao
   Yuan, Bin
   Zhao, Jingru
   Wang, Min
   Wang, Xixi
   Wang, Qian
   Sun, Yan
   Fan, Zheng
   Qi, Jianxun
   Gao, George F.
   Shi, Yi
TI Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core
   Polymerase Complex from SARS-CoV-2
SO CELL REPORTS
LA English
DT Article
ID DEPENDENT RNA-POLYMERASE; CRYSTAL-STRUCTURE; CORONAVIRUS; SARS;
   INSIGHTS; REPLICATION; PROTEIN
AB The ongoing global pandemic of coronavirus disease 2019 (COVID-19) has caused a huge number of human deaths. Currently, there are no specific drugs or vaccines available for this virus (SARS-CoV-2). The viral polymerase is a promising antiviral target. Here, we describe the near-atomic-resolution structure of the SARSCoV-2 polymerase complex consisting of the nsp12 catalytic subunit and nsp7-nsp8 cofactors. This structure highly resembles the counterpart of SARS-CoV with conserved motifs for all viral RNA-dependent RNA polymerases and suggests a mechanism of activation by cofactors. Biochemical studies reveal reduced activity of the core polymerase complex and lower thermostability of individual subunits of SARS-CoV-2 compared with SARS-CoV. These findings provide important insights into RNA synthesis by coronavirus polymerase and indicate adaptation of SARS-CoV-2 toward humans with a relatively lower body temperature than the natural bat hosts.
C1 [Peng, Qi; Peng, Ruchao; Yuan, Bin; Zhao, Jingru; Wang, Min; Wang, Xixi; Wang, Qian; Fan, Zheng; Qi, Jianxun; Gao, George F.; Shi, Yi] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.
   [Yuan, Bin; Zhao, Jingru; Wang, Qian; Sun, Yan; Qi, Jianxun; Gao, George F.; Shi, Yi] Univ Chinese Acad Sci, Savaid Med Sch, Beijing 100049, Peoples R China.
   [Qi, Jianxun; Gao, George F.; Shi, Yi] Chinese Acad Sci, Ctr Influenza Res & Early Warning CASCIRE, CAS TWAS Ctr Excellence Emerging Infect Dis CEEID, Beijing 100101, Peoples R China.
   [Shi, Yi] Univ Chinese Acad Sci, Chongqing Gen Hosp, Chongqing Key Lab Neurodegenerat Dis, Chongqing 400013, Peoples R China.
   [Shi, Yi] Jilin Univ, Coll Basic Med, Changchun 130021, Jilin, Peoples R China.
RP Shi, Y (corresponding author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.; Shi, Y (corresponding author), Univ Chinese Acad Sci, Savaid Med Sch, Beijing 100049, Peoples R China.; Shi, Y (corresponding author), Chinese Acad Sci, Ctr Influenza Res & Early Warning CASCIRE, CAS TWAS Ctr Excellence Emerging Infect Dis CEEID, Beijing 100101, Peoples R China.; Shi, Y (corresponding author), Univ Chinese Acad Sci, Chongqing Gen Hosp, Chongqing Key Lab Neurodegenerat Dis, Chongqing 400013, Peoples R China.; Shi, Y (corresponding author), Jilin Univ, Coll Basic Med, Changchun 130021, Jilin, Peoples R China.
EM shiyi@im.ac.cn
FU Strategic Priority Research Program of the CAS [XDB29010000]; National
   Science and Technology Major Project [2018ZX09711003, 2018ZX10101004];
   National Key Research and Development Program of China [2020YFC0845900];
   National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [81802007, 82041016, 81871658,
   81802010]; Bill and Melinda Gates FoundationBill & Melinda Gates
   Foundation; Young Elite Scientist Sponsorship Program (YESS) of the
   China Association for Science and Technology (CAST) [2018QNRC001];
   Excellent Young Scientist Program from the NSFC [81622031]; Youth
   Innovation Promotion Association of CAS [2015078]
FX We thank all staff members at the Center of Biological Imaging (CBI),
   Institute of Biophysics (IBP), Chinese Academy of Sciences (CAS) for
   assistance with data collection. We are grateful to the Core Facility of
   the Institute of Microbiology, CAS for assistance with SPR experiments.
   This study was supported by the Strategic Priority Research Program of
   the CAS (XDB29010000), the National Science and Technology Major Project
   (2018ZX10101004), the National Key Research and Development Program of
   China (2020YFC0845900), the National Natural Science Foundation of China
   (NSFC) (82041016, 81871658, and 81802010), and a grant from the Bill and
   Melinda Gates Foundation. M.W. is supported by the National Science and
   Technology Major Project (2018ZX09711003) and National Natural Science
   Foundation of China (NSFC) (81802007). R.P. is supported by the Young
   Elite Scientist Sponsorship Program (YESS) of the China Association for
   Science and Technology (CAST) (2018QNRC001). Y.S. is also supported by
   the Excellent Young Scientist Program from the NSFC (81622031) and the
   Youth Innovation Promotion Association of CAS (2015078).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Adedeji AO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036521
   Ahn DG, 2012, ARCH VIROL, V157, P2095, DOI 10.1007/s00705-012-1404-x
   Aktepe TE, 2018, CELL MICROBIOL, V20, DOI 10.1111/cmi.12884
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Duan WQ, 2017, EMBO J, V36, P919, DOI 10.15252/embj.201696241
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gerlach P, 2015, CELL, V161, P1267, DOI 10.1016/j.cell.2015.05.006
   Godoy AS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14764
   Gong P, 2010, P NATL ACAD SCI USA, V107, P22505, DOI 10.1073/pnas.1007626107
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hengrung N, 2015, NATURE, V527, P114, DOI 10.1038/nature15525
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kucukelbir A, 2014, NAT METHODS, V11, P63, DOI [10.1038/NMETH.2727, 10.1038/nmeth.2727]
   Lehmann KC, 2015, NUCLEIC ACIDS RES, V43, P8416, DOI 10.1093/nar/gkv838
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   O'Shea TJ, 2014, EMERG INFECT DIS, V20, P741, DOI 10.3201/eid2005.130539
   Peng RC, 2020, NATURE, V579, P615, DOI 10.1038/s41586-020-2114-2
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pflug A, 2014, NATURE, V516, P355, DOI 10.1038/nature14008
   Reich S, 2014, NATURE, V516, P361, DOI 10.1038/nature14009
   Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sevajol M, 2014, VIRUS RES, V194, P90, DOI 10.1016/j.virusres.2014.10.008
   Shi FY, 2013, CURR MED CHEM, V20, P3923
   Shi Y., 2020, INNOVATION, V1
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Vicenzi E, 2004, EMERG INFECT DIS, V10, P413, DOI 10.3201/eid1003.030683
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhao BY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14762
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 45
TC 10
Z9 10
U1 7
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JUN 16
PY 2020
VL 31
IS 11
AR 107774
DI 10.1016/j.celrep.2020.107774
PG 14
WC Cell Biology
SC Cell Biology
GA MA5SV
UT WOS:000541973800017
PM 32531208
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ni, L
   Ye, F
   Cheng, ML
   Feng, Y
   Deng, YQ
   Zhao, H
   Wei, P
   Ge, JW
   Gou, MT
   Li, XL
   Sun, L
   Cao, TS
   Wang, PZ
   Zhou, C
   Zhang, RR
   Liang, P
   Guo, H
   Wang, XQ
   Qin, CF
   Chen, F
   Dong, C
AF Ni, Ling
   Ye, Fang
   Cheng, Meng-Li
   Feng, Yu
   Deng, Yong-Qiang
   Zhao, Hui
   Wei, Peng
   Ge, Jiwan
   Gou, Mengting
   Li, Xiaoli
   Sun, Lin
   Cao, Tianshu
   Wang, Pengzhi
   Zhou, Chao
   Zhang, Rongrong
   Liang, Peng
   Guo, Han
   Wang, Xinquan
   Qin, Cheng-Feng
   Chen, Fang
   Dong, Chen
TI Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in
   COVID-19 Convalescent Individuals
SO IMMUNITY
LA English
DT Article
ID RESPIRATORY SYNDROME; SARS-CORONAVIRUS; RESPONSES; OUTBREAK
AB The World Health Organization has declared SARS-CoV-2 virus outbreak a worldwide pandemic. However, there is very limited understanding on the immune responses, especially adaptive immune responses to SARS-CoV-2 infection. Here, we collected blood from COVID-19 patients who have recently become virus-free, and therefore were discharged, and detected SARS-CoV-2-specific humoral and cellular immunity in eight newly discharged patients. Follow-up analysis on another cohort of six patients 2 weeks post discharge also revealed high titers of immunoglobulin G (IgG) antibodies. In all 14 patients tested, 13 displayed serum-neutralizing activities in a pseudotype entry assay. Notably, there was a strong correlation between neutralization antibody titers and the numbers of virus-specific T cells. Our work provides a basis for further analysis of protective immunity to SARS-CoV-2, and understanding the pathogenesis of COVID-19, especially in the severe cases. It also has implications in developing an effective vaccine to SARS-CoV-2 infection.
C1 [Ni, Ling; Feng, Yu; Wei, Peng; Gou, Mengting; Li, Xiaoli; Sun, Lin; Wang, Pengzhi; Dong, Chen] Tsinghua Univ, Inst Immunol, Beijing 100084, Peoples R China.
   [Ni, Ling; Feng, Yu; Wei, Peng; Gou, Mengting; Li, Xiaoli; Sun, Lin; Wang, Pengzhi; Dong, Chen] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China.
   [Ni, Ling; Dong, Chen] Beijing Friendship Hosp, Ctr Human Dis Immunomonitoring, Beijing 100050, Peoples R China.
   [Ye, Fang] Tsinghua Univ, Dept Hematol, Chui Yang Liu Hosp, Beijing 100022, Peoples R China.
   [Cheng, Meng-Li; Deng, Yong-Qiang; Zhao, Hui; Cao, Tianshu; Zhou, Chao; Zhang, Rongrong; Qin, Cheng-Feng] Acad Mil Med Sci, Inst Microbiol & Epidemiol, Dept Virol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.
   [Ge, Jiwan; Wang, Xinquan] Tsinghua Univ, Sch Life Sci, Beijing 100022, Peoples R China.
   [Liang, Peng; Chen, Fang] Tsinghua Univ, Dept Cardiol, Chui Yang Liu Hosp, Beijing 100022, Peoples R China.
   [Guo, Han] Tsinghua Univ, Dept Orthoped, Chui Yang Liu Hosp, Beijing 100022, Peoples R China.
   [Dong, Chen] Beijing Key Lab Immunol Res Chron Dis, Beijing 100084, Peoples R China.
RP Dong, C (corresponding author), Tsinghua Univ, Inst Immunol, Beijing 100084, Peoples R China.; Dong, C (corresponding author), Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China.; Dong, C (corresponding author), Beijing Friendship Hosp, Ctr Human Dis Immunomonitoring, Beijing 100050, Peoples R China.; Qin, CF (corresponding author), Acad Mil Med Sci, Inst Microbiol & Epidemiol, Dept Virol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.; Chen, F (corresponding author), Tsinghua Univ, Dept Cardiol, Chui Yang Liu Hosp, Beijing 100022, Peoples R China.; Dong, C (corresponding author), Beijing Key Lab Immunol Res Chron Dis, Beijing 100084, Peoples R China.
EM qincf@bmi.ac.cn; anzhenchenfang@163.com; chendong@tsinghua.edu.cn
RI dong, chen/B-3181-2009; Qin, Cheng-Feng/I-6839-2019
OI dong, chen/0000-0002-0084-9130; Qin, Cheng-Feng/0000-0002-0632-2807;
   zhou, chao/0000-0001-8839-980X
FU National Key Research and Development Program of China [2016YFC0906200,
   2016YFC130390, 2020YFA0707800]; Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [31991173,
   31821003, 31991170]; Beijing Municipal Science and Technology
   [Z181100001318007, Z181100006318015, Z171100000417005]; Zhejiang
   University Foundation [2020XGZX014]; Tsinghua University
FX We thank Drs. Rong Mu and Zhinan Ying for sharing secondary detection
   antibodies. We also thank Weijin Huang and Jianhui Nie from the
   procuratorate for sharing the plasmids for pseudovirus package. This
   work was supported in part by grants from the National Key Research and
   Development Program of China (2016YFC0906200 to C.D., 2016YFC130390 to
   L.N., and 2020YFA0707800 to X.W.), Natural Science Foundation of China
   (31991173, 31821003, and 31991170 to C.D.), Beijing Municipal Science
   and Technology (Z181100001318007, Z181100006318015, and Z171100000417005
   to C.D.), Zhejiang University Foundation (2020XGZX014 to C.D.), and
   award from Tsinghua University (to C.D.).
CR Cameron MJ, 2008, VIRUS RES, V133, P13, DOI 10.1016/j.virusres.2007.02.014
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894
   Di Pierro F, 2020, MINERVA GASTROENTERO, V66, P172, DOI 10.23736/S1121-421X.20.02697-5
   Haveri A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.11.2000266
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ko JH, 2017, DIAGN MICR INFEC DIS, V89, P106, DOI 10.1016/j.diagmicrobio.2017.07.006
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Phelan A.L., 2020, JAMA
   Shi YL, 2004, J CLIN VIROL, V31, P66, DOI 10.1016/j.jcv.2004.05.006
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Thiel V, 2008, CYTOKINE GROWTH F R, V19, P121, DOI 10.1016/j.cytogfr.2008.01.001
   Vijay R, 2016, CURR OPIN VIROL, V16, P70, DOI 10.1016/j.coviro.2016.01.011
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang WL, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.114
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Woo PCY, 2004, J CLIN MICROBIOL, V42, P2306, DOI 10.1128/JCM.42.5.2306-2309.2004
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xie S, 2018, CANCER IMMUNOL IMMUN, V67, P1685, DOI 10.1007/s00262-018-2227-8
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 25
TC 133
Z9 130
U1 22
U2 25
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD JUN 16
PY 2020
VL 52
IS 6
BP 971
EP +
DI 10.1016/j.immuni.2020.04.023
PG 10
WC Immunology
SC Immunology
GA MA4MT
UT WOS:000541890000012
PM 32413330
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Wu, J
   Song, DY
   Li, ZW
   Guo, BJ
   Xiao, YI
   Liu, WJ
   Liang, LM
   Feng, CJ
   Gao, TT
   Chen, YX
   Li, Y
   Wang, Z
   Wen, JY
   Yang, SN
   Liu, PP
   Wang, L
   Wang, YK
   Peng, L
   Stacey, GN
   Hu, Z
   Feng, GH
   Li, W
   Huo, Y
   Jin, RH
   Shyh-Chang, N
   Zhou, Q
   Wang, L
   Hu, BY
   Dai, HP
   Hao, J
AF Wu, Jun
   Song, Dingyun
   Li, Zhongwen
   Guo, Baojie
   Xiao, Yani
   Liu, Wenjing
   Liang, Lingmin
   Feng, Chunjing
   Gao, Tingting
   Chen, Yanxia
   Li, Ying
   Wang, Zai
   Wen, Jianyan
   Yang, Shengnan
   Liu, Peipei
   Wang, Lei
   Wang, Yukai
   Peng, Liang
   Stacey, Glyn Nigel
   Hu, Zheng
   Feng, Guihai
   Li, Wei
   Huo, Yan
   Jin, Ronghua
   Shyh-Chang, Ng
   Zhou, Qi
   Wang, Liu
   Hu, Baoyang
   Dai, Huaping
   Hao, Jie
TI Immunity-and-matrix-regulatory cells derived from human embryonic stem
   cells safely and effectively treat mouse lung injury and fibrosis
SO CELL RESEARCH
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; MESENCHYMAL STEM; EXPRESSION; THERAPY;
   DIAGNOSIS; EFFICACY; ARDS
AB Lung injury and fibrosis represent the most significant outcomes of severe and acute lung disorders, including COVID-19. However, there are still no effective drugs to treat lung injury and fibrosis. In this study, we report the generation of clinical-grade human embryonic stem cells (hESCs)-derived immunity- and matrix-regulatory cells (IMRCs) produced under good manufacturing practice requirements, that can treat lung injury and fibrosis in vivo. We generate IMRCs by sequentially differentiating hESCs with serum-free reagents. IMRCs possess a unique gene expression profile distinct from that of umbilical cord mesenchymal stem cells (UCMSCs), such as higher expression levels of proliferative, immunomodulatory and anti-fibrotic genes. Moreover, intravenous delivery of IMRCs inhibits both pulmonary inflammation and fibrosis in mouse models of lung injury, and significantly improves the survival rate of the recipient mice in a dose-dependent manner, likely through paracrine regulatory mechanisms. IMRCs are superior to both primary UCMSCs and the FDA-approved drug pirfenidone, with an excellent efficacy and safety profile in mice and monkeys. In light of public health crises involving pneumonia, acute lung injury and acute respiratory distress syndrome, our findings suggest that IMRCs are ready for clinical trials on lung disorders.
C1 [Wu, Jun; Li, Zhongwen; Guo, Baojie; Liu, Wenjing; Liang, Lingmin; Feng, Chunjing; Gao, Tingting; Chen, Yanxia; Wang, Lei; Wang, Yukai; Feng, Guihai; Li, Wei; Shyh-Chang, Ng; Zhou, Qi; Wang, Liu; Hu, Baoyang; Hao, Jie] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.
   [Wu, Jun; Li, Zhongwen; Guo, Baojie; Liu, Wenjing; Liang, Lingmin; Gao, Tingting; Chen, Yanxia; Wang, Lei; Wang, Yukai; Feng, Guihai; Li, Wei; Shyh-Chang, Ng; Zhou, Qi; Wang, Liu; Hu, Baoyang; Hao, Jie] Chinese Acad Sci, Inst Stem Cell & Regenerat, Beijing 100101, Peoples R China.
   [Wu, Jun; Li, Zhongwen; Guo, Baojie; Liu, Wenjing; Liang, Lingmin; Gao, Tingting; Chen, Yanxia; Wang, Lei; Wang, Yukai; Stacey, Glyn Nigel; Zhou, Qi; Wang, Liu; Hu, Baoyang; Hao, Jie] Chinese Acad Sci, Natl Stem Cell Resource Ctr, Beijing 100101, Peoples R China.
   [Song, Dingyun; Yang, Shengnan; Liu, Peipei; Dai, Huaping] Chinese Acad Med Sci, Dept Pulm & Crit Care Med, China Japan Friendship Hosp, Ctr Resp Med, Beijing 100029, Peoples R China.
   [Song, Dingyun; Yang, Shengnan; Liu, Peipei; Dai, Huaping] Chinese Acad Med Sci, Inst Resp Med, Natl Clin Res Ctr Resp Dis, Beijing 100029, Peoples R China.
   [Song, Dingyun; Liu, Peipei; Dai, Huaping] Chinese Acad Med Sci & Peking Union Med Coll, Grad Sch, Peking Union Med Coll, Beijing 100730, Peoples R China.
   [Guo, Baojie; Liang, Lingmin; Shyh-Chang, Ng; Zhou, Qi; Wang, Liu; Hu, Baoyang] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Xiao, Yani; Huo, Yan] Natl Inst Food & Drug Control, Natl Ctr Safety Evaluat Drugs, Beijing 100176, Peoples R China.
   [Li, Ying] Jilin Univ, Hosp 1, Dept Gastroenterol, Changchun 130061, Jilin, Peoples R China.
   [Wang, Zai; Wen, Jianyan; Peng, Liang] China Japan Friendship Hosp, Inst Clin Med Sci, Ctr Resp Med, Beijing, Peoples R China.
   [Wang, Zai; Wen, Jianyan; Peng, Liang] Chinese Acad Med Sci, Inst Resp Med, Beijing 100029, Peoples R China.
   [Wen, Jianyan] China Japan Friendship Hosp, Dept Cardiol, Beijing 100029, Peoples R China.
   [Yang, Shengnan] Med Univ Ha Er Bin, Haerbin 150081, Heilongjiang, Peoples R China.
   [Stacey, Glyn Nigel] Int Stem Cell Banking Initiat, 2 High St, Barley SG8 8HZ, Herts, England.
   [Hu, Zheng] Jilin Univ, Hosp 1, Minist Educ, Key Lab Organ Regenerat & Transplantat, Changchun 130061, Jilin, Peoples R China.
   [Hu, Zheng] Natl Local Joint Engn Lab Anim Models Human Dis, Changchun 130061, Jilin, Peoples R China.
   [Jin, Ronghua] Capital Med Univ, Beijing Youan Hosp, Beijing 100069, Peoples R China.
RP Hu, BY; Hao, J (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.; Hu, BY; Hao, J (corresponding author), Chinese Acad Sci, Inst Stem Cell & Regenerat, Beijing 100101, Peoples R China.; Hu, BY; Hao, J (corresponding author), Chinese Acad Sci, Natl Stem Cell Resource Ctr, Beijing 100101, Peoples R China.; Dai, HP (corresponding author), Chinese Acad Med Sci, Dept Pulm & Crit Care Med, China Japan Friendship Hosp, Ctr Resp Med, Beijing 100029, Peoples R China.; Dai, HP (corresponding author), Chinese Acad Med Sci, Inst Resp Med, Natl Clin Res Ctr Resp Dis, Beijing 100029, Peoples R China.; Dai, HP (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Grad Sch, Peking Union Med Coll, Beijing 100730, Peoples R China.; Hu, BY (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
EM byhu@ioz.ac.cn; daihuaping@ccmu.edu.cn; haojie@ioz.ac.cn
OI wen, jianyan/0000-0001-5762-6504
FU Beijing Municipal Science & Technology CommissionBeijing Municipal
   Science & Technology Commission [Z181100003818005]; National Key
   Research and Development Program [2018YFA0108400, 2017YFA0104403,
   2017YFA0105001, 2016YFA0101502, 2020YFC0843900, 2020YFC0841900];
   Strategic Priority Research Program of the Chinese Academy of
   SciencesChinese Academy of Sciences [XDA16030701, XDA16030401,
   XDA16040502]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [31621004]; Key Research
   Projects of the Frontier Science of the Chinese Academy of Sciences
   [QYZDY-SSW-SMC002]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2019M660791]
FX This work was supported by Beijing Municipal Science & Technology
   Commission (Z181100003818005 to Q.Z.), National Key Research and
   Development Program (2018YFA0108400 and 2017YFA0104403 to J.H.,
   2017YFA0105001 and 2016YFA0101502 to Liu W., 2020YFC0843900 to Q.Z.,
   2020YFC0841900 to B.H.), the Strategic Priority Research Program of the
   Chinese Academy of Sciences (XDA16030701 to Liu W., XDA16030401 to W.L.,
   XDA16040502 to J.H.), the National Natural Science Foundation of China
   (31621004 to Q.Z. and W.L.), the Key Research Projects of the Frontier
   Science of the Chinese Academy of Sciences (QYZDY-SSW-SMC002 to Q.Z.),
   and China Postdoctoral Science Foundation (2019M660791 to Lei W.).
CR Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Benyon RC, 1996, GASTROENTEROLOGY, V110, P821, DOI 10.1053/gast.1996.v110.pm8608892
   Berninger MT, 2017, EUR RADIOL, V27, P1105, DOI 10.1007/s00330-016-4457-5
   Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8
   Dhainaut JF, 2003, CRIT CARE MED, V31, pS258, DOI 10.1097/01.CCM.0000057901.92381.75
   Du C, 2018, INT J MOL MED, V41, P3175, DOI 10.3892/ijmm.2018.3516
   Fan E, 2018, JAMA-J AM MED ASSOC, V319, P698, DOI 10.1001/jama.2017.21907
   Gu Q, 2017, STEM CELL REP, V9, P366, DOI 10.1016/j.stemcr.2017.04.017
   Hamacher J, 2002, AM J RESP CRIT CARE, V166, P651, DOI 10.1164/rccm.2109004
   Han XP, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1426-0
   Horibata S, 2015, JOVE-J VIS EXP, DOI 10.3791/52727
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hwang NS, 2008, P NATL ACAD SCI USA, V105, P20641, DOI 10.1073/pnas.0809680106
   Kanelidis AJ, 2017, CIRC RES, V120, P1139, DOI 10.1161/CIRCRESAHA.116.309819
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/nmeth.3317, 10.1038/NMETH.3317]
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   Lee EJ, 2010, TISSUE ENG PT A, V16, P705, DOI 10.1089/ten.tea.2008.0596
   Lian QZ, 2007, STEM CELLS, V25, P425, DOI 10.1634/stemcells.2006-0420
   Marshall R, 1998, THORAX, V53, P815, DOI 10.1136/thx.53.10.815
   MILANI S, 1994, AM J PATHOL, V144, P528
   Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104
   Overmyer KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117232
   Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536-019-0083-6
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prasad VK, 2011, BIOL BLOOD MARROW TR, V17, P534, DOI 10.1016/j.bbmt.2010.04.014
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Serrano-Mollar Anna, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6030064
   Sgalla G, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0730-2
   Shi YF, 2012, TRENDS IMMUNOL, V33, P136, DOI 10.1016/j.it.2011.11.004
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Vodyanik MA, 2010, CELL STEM CELL, V7, P718, DOI 10.1016/j.stem.2010.11.011
   Wagers S, 2002, J APPL PHYSIOL, V92, P1802, DOI 10.1152/japplphysiol.00883.2001
   Walter J, 2014, LANCET RESP MED, V2, P1016, DOI 10.1016/S2213-2600(14)70217-6
   Weiss DJ, 2013, AM J RESP CRIT CARE, V188, P123, DOI 10.1164/rccm.201302-0351ED
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Yang J, 2019, STEM CELLS, DOI [10.1002/stem.1051, 10.1002/STEM.1051]
   Yang JB, 2014, REGEN MED RES, V2, DOI 10.1186/2050-490X-2-7
   Yoon HY, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0907-8
   Zhou Huanping, 2017, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V29, P1039, DOI 10.3760/cma.j.issn.2095-4352.2017.11.017
   Zhu YG, 2013, RESPIROLOGY, V18, P744, DOI 10.1111/resp.12093
NR 45
TC 3
Z9 3
U1 6
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD SEP
PY 2020
VL 30
IS 9
BP 794
EP 809
DI 10.1038/s41422-020-0354-1
EA JUN 2020
PG 16
WC Cell Biology
SC Cell Biology
GA NI2US
UT WOS:000540666800001
PM 32546764
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Wehling, M
AF Wehling, Martin
TI Calling for an exponential escalation scheme in vaccine development for
   COVID-19
SO EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE COVID-19; Vaccination; Seamless trial design; Adaptive design;
   Exponential growth
AB Purpose COVID-19 as a pandemic calls for rapid development of vaccines. Methods Here a proposal of a seamless, adaptive, phase 1-3 trial for accelerated vaccine development is described. Results Starting at 10, the number of vaccinated volunteers would exponentially increase by tenfold at an interval of 2 weeks; close surveillance of antibody responses, safety and efficacy is necessary. After only 16 weeks, general vaccination would be feasible if supply meets the demand. Conclusion A COVID-19 vaccine would be rapidly available at a slightly increased risk for undetected late side effects or insufficient efficacy if compared with standard vaccine development schemes.
C1 [Wehling, Martin] Heidelberg Univ, Inst Clin Pharmacol Mannheim, Med Fac Mannheim, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
RP Wehling, M (corresponding author), Heidelberg Univ, Inst Clin Pharmacol Mannheim, Med Fac Mannheim, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM martin.wehling@medma.uni-heidelberg.de
CR Ahmed SS, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2354
   Callaway E, 2020, NATURE, V580, P17, DOI 10.1038/d41586-020-00927-3
   Wehling Martin, 2015, PRINCIPLES TRANSLATI
NR 3
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0031-6970
EI 1432-1041
J9 EUR J CLIN PHARMACOL
JI Eur. J. Clin. Pharmacol.
PD OCT
PY 2020
VL 76
IS 10
BP 1471
EP 1472
DI 10.1007/s00228-020-02933-w
EA JUN 2020
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NL5ZX
UT WOS:000540684000001
PM 32548679
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Takahashi, N
   Abe, R
   Hattori, N
   Matsumura, Y
   Oshima, T
   Taniguchi, T
   Igari, H
   Nakada, T
AF Takahashi, Nozomi
   Abe, Ryuzo
   Hattori, Noriyuki
   Matsumura, Yosuke
   Oshima, Taku
   Taniguchi, Toshibumi
   Igari, Hidetoshi
   Nakada, Taka-aki
TI Clinical course of a critically ill patient with severe acute
   respiratory syndrome coronavirus 2 (SARS-CoV-2)
SO JOURNAL OF ARTIFICIAL ORGANS
LA English
DT Article
DE SARS-CoV-2; COVID-19; VV-ECMO; Respiratory failure
ID EXTRACORPOREAL MEMBRANE-OXYGENATION; MORTALITY
AB Although several studies have reported on the clinical and epidemiological characteristics of the patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), clinical course of the most severe cases requiring treatment in ICU have been insufficiently reported. A 73-year-old man traveling on a cruise ship with history of hypertension and dyslipidemia developed high fever, dyspnea and cough after 7 days of steroid treatment for sudden sensorineural hearing loss, and tested positive for SARS-CoV-2 in sputa polymerase chain reaction (PCR) examination. His respiratory function deteriorated despite treatments with lopinavir/ritonavir, oseltamivir, azithromycin and meropenem at a regional hospital. He was intubated and transferred to the ICU in the tertiary university hospital on day 10 (ICU day 1). Interferon beta-1b subcutaneous injection was initiated immediately to enhance anti-viral therapy, and favipiravir on ICU day 10 upon availability. Progression of organ dysfunctions necessitated inhalation of nitrogen oxide for respiratory dysfunction, noradrenaline for cardiovascular dysfunction and continuous renal replacement therapy for renal dysfunction. His blood samples PCR also tested positive for SARS-CoV-2, indicating viremia, concomitantly with elevated IL-6 levels. VV-ECMO was initiated after sudden exacerbation of respiratory dysfunction on ICU day 7 to maintain oxygenation. The sustained excessive inflammatory cytokines in the present case might have led to the exacerbation of the disease, requiring vigorous organ support therapies to allow for survival and recovery from the rapid progression of multiple organ dysfunctions and severe respiratory failure.
C1 [Takahashi, Nozomi; Abe, Ryuzo; Hattori, Noriyuki; Matsumura, Yosuke; Oshima, Taku; Nakada, Taka-aki] Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608677, Japan.
   [Taniguchi, Toshibumi; Igari, Hidetoshi] Chiba Univ Hosp, Dept Infect Dis, Chiba, Japan.
RP Nakada, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608677, Japan.
EM taka.nakada@nifty.com
OI Nakada, Taka-aki/0000-0002-4480-556X
CR Barbaro RP, 2015, AM J RESP CRIT CARE, V191, P894, DOI 10.1164/rccm.201409-1634OC
   Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Noah MA, 2011, JAMA-J AM MED ASSOC, V306, P1659, DOI 10.1001/jama.2011.1471
   Ohshimo S, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0306-8
   Puja M, 2020, LANCET, V395, P1033, DOI DOI 10.1016/S0140-6736(20)30628-0
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   World Health Organization, 2020, COR DIS COVID 2019 S
NR 9
TC 1
Z9 1
U1 3
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 1434-7229
EI 1619-0904
J9 J ARTIF ORGANS
JI J. Artif. Organs
PD DEC
PY 2020
VL 23
IS 4
BP 397
EP 400
DI 10.1007/s10047-020-01183-y
EA JUN 2020
PG 4
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA OR4KV
UT WOS:000540937500001
PM 32556649
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Atzrodt, CL
   Maknojia, I
   McCarthy, RDP
   Oldfield, TM
   Po, J
   Ta, KTL
   Stepp, HE
   Clements, TP
AF Atzrodt, Cassandra L.
   Maknojia, Insha
   McCarthy, Robert D. P.
   Oldfield, Tiara M.
   Po, Jonathan
   Ta, Kenny T. L.
   Stepp, Hannah E.
   Clements, Thomas P.
TI A Guide to COVID-19: a global pandemic caused by the novel coronavirus
   SARS-CoV-2
SO FEBS JOURNAL
LA English
DT Article
DE ACE2; coronavirus; COVID-19; CRISPR; MERS; MERS-CoV; SARS; SARS-CoV;
   SARS-CoV-2; vaccine
ID SARS-COV; SEROLOGICAL ASSAYS; TRANSMISSION; PATHOGENESIS; 2019-NCOV;
   PROTEIN; SPIKE; PCR; EPIDEMIOLOGY; MECHANISMS
AB The emergence of the SARS-CoV-2 strain of the human coronavirus has thrown the world into the midst of a new pandemic. In the human body, the virus causes COVID-19, a disease characterized by shortness of breath, fever, and pneumonia, which can be fatal in vulnerable individuals. SARS-CoV-2 has characteristics of past human coronaviruses, with close genomic similarities to SARS-CoV, the virus that causes the disease SARS. Like these related coronaviruses, SARS-CoV-2 is transmitted through the inhalation of droplets and interaction with contaminated surfaces. Across the world, laboratories are developing candidate vaccines for the virus - with vaccine trials underway in the United States and the United Kingdom - and considering various drugs for possible treatments and prophylaxis. Here, we provide an overview of SARS-CoV-2 by analyzing its virology, epidemiology, and modes of transmission while examining the current progress of testing procedures and possible treatments through drugs and vaccines.
C1 [Atzrodt, Cassandra L.; Maknojia, Insha; McCarthy, Robert D. P.; Oldfield, Tiara M.; Po, Jonathan; Ta, Kenny T. L.; Stepp, Hannah E.; Clements, Thomas P.] Vanderbilt Univ, Dept Biol Sci, 1210 Biol Sci MRB,465 21st St South, Nashville, TN 37235 USA.
RP Clements, TP (corresponding author), Vanderbilt Univ, Dept Biol Sci, 1210 Biol Sci MRB,465 21st St South, Nashville, TN 37235 USA.
EM thomas.clements@vanderbilt.edu
CR Abbott TR, 2020, DEV CRISPR PROPHYLAC, P1, DOI [10.1101/2020.03.13.991307, DOI 10.1101/2020.03.13.991307]
   Ahmed AE, 2018, EPIDEMIOL INFECT, V146, P489, DOI [10.1017/s095026881700293x, 10.1017/S095026881700293X]
   Al-Muharraqi MA, 2020, BRIT J ORAL MAX SURG, V58, P503, DOI 10.1016/j.bjoms.2020.04.014
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Andreasen V, 2011, B MATH BIOL, V73, P2305, DOI 10.1007/s11538-010-9623-3
   [Anonymous], 2020, ROCH TAK ABB COC 19
   [Anonymous], SHERL BIOSC REC FDA
   [Anonymous], FDA EM US AUTH
   [Anonymous], VRI MULT TEST
   [Anonymous], ABB REALTIME SARS CO
   Askham P, 2020, ICELAND COVID 19 SCR
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Auwaerter PG, CORONAVIRUS COVID 19
   Bell DM, 2004, EMERG INFECT DIS, V10, P1900, DOI 10.3201/eid1011.040729
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Black JRM, 2020, LANCET, V395, P1418, DOI 10.1016/S0140-6736(20)30917-X
   Blocken B, 2020, AERODYNAMICALLY EQUI
   Bolles M, 2011, CURR OPIN VIROL, V1, P624, DOI 10.1016/j.coviro.2011.10.012
   Brave A, 2007, MOL PHARMACEUT, V4, P18, DOI 10.1021/mp060098+
   Breugelmans JG, 2004, EMERG INFECT DIS, V10, P1502, DOI 10.3201/eid1008.040093
   Bridge JA, 2017, CANCER CYTOPATHOL, V125, P11, DOI 10.1002/cncy.21762
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Burmistrz M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031122
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   CDC, 2020, COR DIS 2019 COVID 1
   CDC, 2020, COR HUM COR TYP
   CDC, CDC PEOPL WHO AR HIG
   CDC, 2020, INT LOC CONF COVID 1
   CDC, 2019, SARS BAS FACTSH
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Chen JS, 2018, SCIENCE, V360, P436, DOI 10.1126/science.aar6245
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004
   Delamater PL, 2019, EMERG INFECT DIS, V25, P1, DOI 10.3201/eid2501.171901
   Detmer A, 2006, MICROB CELL FACT, V5, DOI 10.1186/1475-2859-5-23
   Dietz K, 1993, Stat Methods Med Res, V2, P23, DOI 10.1177/096228029300200103
   Dietz L, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00245-20
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Freeman WM, 1999, BIOTECHNIQUES, V26, P112, DOI 10.2144/99261rv01
   Frieman M, 2008, MICROBIOL MOL BIOL R, V72, P672, DOI 10.1128/MMBR.00015-08
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gao J, 2013, J VIROL, V87, P13134, DOI 10.1128/JVI.02433-13
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, INTENS CARE MED, V46, P780, DOI 10.1007/s00134-020-05981-z
   Gaunt ER, 2010, J CLIN MICROBIOL, V48, P2940, DOI 10.1128/JCM.00636-10
   Gilead Sciences, GIL ANN RES PHAS 3 T
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hawryluck L, 2004, EMERG INFECT DIS, V10, P1206, DOI 10.3201/eid1007.030703
   He JH, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040428
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Infantino M, 2020, ISR MED ASSOC J, V22, P203
   Ito Kyoji, 2020, Glob Health Med, V2, P96, DOI 10.35772/ghm.2020.01034
   Jin HL, 2005, BIOCHEM BIOPH RES CO, V328, P979, DOI 10.1016/j.bbrc.2005.01.048
   Kahn Jeffrey S, 2005, Pediatr Infect Dis J, V24, pS223, DOI 10.1097/01.inf.0000188166.17324.60
   Kamisar B, NBC NEWS
   Kapadia SU, 2005, VIROLOGY, V340, P174, DOI 10.1016/j.virol.2005.06.016
   Kelso JK, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-117
   Killerby ME, 2020, EMERG INFECT DIS, V26, P191, DOI 10.3201/eid2602.190697
   Konrad R, 2020, EUROSURVEILLANCE, V25, P13, DOI 10.2807/1560-7917.ES.2020.25.9.2000173
   Kuba K, 2006, CURR OPIN PHARMACOL, V6, P271, DOI 10.1016/j.coph.2006.03.001
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Kuznia R, CNN
   Lanese N, 2020, 1 CORONAVIRUS VACCIN
   Lau ALD, 2008, AGING MENT HEALTH, V12, P746, DOI 10.1080/13607860802380607
   Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Loftus P, 2020, WALL STR J
   Lokugamage Kumari G, 2020, bioRxiv, DOI 10.1101/2020.03.07.982264
   Lorusso ML, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10082948
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Michelen M, PATIENTS COVID 19 WH
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Nowotny N, 2014, EUROSURVEILLANCE, V19, P11, DOI 10.2807/1560-7917.ES2014.19.16.20781
   O'Connell MR, 2019, J MOL BIOL, V431, P66, DOI 10.1016/j.jmb.2018.06.029
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421
   Poltronieri P, 2015, CURR GENOMICS, V16, P327, DOI 10.2174/1389202916666150707160613
   Qiu Y, 2020, MICROBES INFECT
   Raeisossadati MJ, 2016, BIOSENS BIOELECTRON, V86, P235, DOI 10.1016/j.bios.2016.06.061
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Romsos EL, 2015, FORENSIC SCI INT-GEN, V18, P90, DOI 10.1016/j.fsigen.2015.04.008
   Ronnblom L, 2019, LUPUS SCI MED, V6, DOI 10.1136/lupus-2018-000270
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Ryan M, 2003, CRIT CARE, V7, P221, DOI 10.1186/cc1879
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Shamshirian A., 2020, HYDROXYCHLOROQUINE V, DOI [10.1101/2020.04.14.20065276, DOI 10.1101/2020.04.14.20065276]
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Shirato K, 2018, VIROLOGY, V517, P9, DOI 10.1016/j.virol.2017.11.012
   SIDDELL SG, 1983, INTERVIROLOGY, V20, P181, DOI 10.1159/000149390
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Stricker RB, 2020, J MED VIROL, V92, P1394, DOI 10.1002/jmv.25945
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Subramanian S, 2020, SOME FDA APPROVED DR
   Suranagi UD, 2020, REV CURRENT EVIDENCE, DOI [10.1101/2020.04.16.20068205, DOI 10.1101/2020.04.16.20068205]
   Tahamtan A, 2020, EXPERT REV MOL DIAGN, V20, P453, DOI [10.1080/14737159.2020.1757437, 10.1080/07435800.2020.1713802]
   Tan L, 2018, NANO RES, V11, P5338, DOI 10.1007/s12274-018-2091-z
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Vabret A, 2005, EMERG INFECT DIS, V11, P1225, DOI 10.3201/eid1108.050110
   van den Driessche P, 2008, LECT NOTES MATH, V1945, P159
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X
   Verdecchia P, 2020, EUROPEAN J INTERNAL, V20, P30151
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Vidyasagar A, 2018, WHAT IS CRISPR
   Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wevers BA, 2009, CLIN LAB MED, V29, P715, DOI 10.1016/j.cll.2009.07.007
   Wong JEL, 2020, JAMA-J AM MED ASSOC, V323, P1243, DOI 10.1001/jama.2020.2467
   Wong SC-Y, 2020, J HOSP INFECT, V20, P30174
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia TY, 2020, KOREAN J RADIOL, V21, P545, DOI 10.3348/kjr.2020.0240
   Xu RH, 2004, EMERG INFECT DIS, V10, P1030, DOI 10.3201/eid1006.030852
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young PJ, 2019, INTENS CARE MED, V45, P1382, DOI 10.1007/s00134-019-05729-4
   Zhang F, PROTOCOL DETECTION C
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
NR 144
TC 5
Z9 5
U1 4
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD SEP
PY 2020
VL 287
IS 17
BP 3633
EP 3650
DI 10.1111/febs.15375
EA JUN 2020
PG 18
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NK6MS
UT WOS:000540351800001
PM 32446285
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Brabander, T
   Hofland, H
AF Brabander, Tessa
   Hofland, Hans
TI Radionuclide therapy in the time of COVID-19
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Letter
C1 [Brabander, Tessa] Erasmus MC, Dept Radiol & Nucl Med, Rotterdam, Netherlands.
   [Hofland, Hans] Erasmus MC, ENETS Ctr Excellence, Endocrinol Sect, Dept InternalMedicine, Rotterdam, Netherlands.
RP Brabander, T (corresponding author), Erasmus MC, Dept Radiol & Nucl Med, Rotterdam, Netherlands.
EM t.brabander@erasmusmc.nl
RI Hofland, Johannes/I-6379-2013
CR Assadi M, 2020, EUR J NUCL MED MOL I, V47, P1779, DOI 10.1007/s00259-020-04780-4
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Zulfiqar AA, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2010472
NR 3
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1619-7070
EI 1619-7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD AUG
PY 2020
VL 47
IS 9
BP 2066
EP 2067
DI 10.1007/s00259-020-04921-9
EA JUN 2020
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA MF9WH
UT WOS:000540686200001
PM 32548661
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Havranek, B
   Islam, SM
AF Havranek, Brandon
   Islam, Shahidul M.
TI Anin silicoapproach for identification of novel inhibitors as potential
   therapeutics targeting COVID-19 main protease
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; molecular docking; SARS-CoV-2; molecular dynamics (MD)
   simulations; protease inhibitors; virtual screening; Mpro protease
ID HEPATITIS-C-VIRUS; SARS-CORONAVIRUS; SPIKE PROTEIN; FORCE-FIELD; FACTOR
   XA; CLEAVAGE; COMPLEX; CHARMM; OPTIMIZATION; SIMULATIONS
AB Respiratory disease caused by a novel coronavirus, COVID-19, has been labeled a pandemic by the World Health Organization. Very little is known about the infection mechanism for this virus. More importantly, there are no drugs or vaccines that can cure or prevent a person from getting COVID-19. In this study, the binding affinity of 2692 protease inhibitor compounds that are known in the protein data bank, are calculated against the main protease of the novel coronavirus with docking and molecular dynamics (MD). Both the docking and MD methods predict the macrocyclic tissue factor-factor VIIa (PubChem ID: 118098670) inhibitor to bind strongly with the main protease with a binding affinity of -10.6 and -10.0 kcal/mol, respectively. The TF-FVIIa inhibitors are known to prevent the coagulation of blood and have antiviral activity as shown in the case of SARS coronavirus. Two more inhibitors, phenyltriazolinones (PubChem ID: 104161460) and allosteric HCV NS5B polymerase thumb pocket 2 (PubChem ID: 163632044) have shown antiviral activity and also have high affinity towards the main protease of COVID-19. Furthermore, these inhibitors interact with the catalytic dyad in the active site of the COVID-19 main protease that is especially important in viral replication. The calculated theoretical dissociation constants of the proposed COVID-19 inhibitors are found to be very similar to the experimental dissociation constant values of similar protease-inhibitor systems. Communicated by Ramaswamy H. Sarma
C1 [Havranek, Brandon; Islam, Shahidul M.] Univ Illinois, Dept Chem, Chicago, IL 60607 USA.
RP Islam, SM (corresponding author), Univ Illinois, Dept Chem, Chicago, IL 60607 USA.
EM mshahidi@uic.edu
RI Islam, Shahidul M./A-9417-2011
OI Islam, Shahidul M./0000-0001-5769-6844; Havranek,
   Brandon/0000-0003-4397-684X
FU Advanced Cyberinfrastructure for Education and Research (ACER) at The
   University of Illinois at Chicago
FX The authors acknowledge the Advanced Cyberinfrastructure for Education
   and Research (ACER) at The University of Illinois at Chicago that have
   contributed to the research results reported within this paper. We also
   thank Dr. Justin Lorieau and Dr. Akhteruzzaman Molla for their
   insightful discussion.
CR ADELMAN SA, 1976, J CHEM PHYS, V64, P2375, DOI 10.1063/1.432526
   Al-Horani RA, 2016, EXPERT OPIN THER PAT, V26, P323, DOI 10.1517/13543776.2016.1154045
   Ali A, 2013, ACS CHEM BIOL, V8, P1469, DOI 10.1021/cb400100g
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   [Anonymous], 2015, SOV SOF
   Arthur DE, 2019, J KING SAUD UNIV SCI, V31, P1151, DOI 10.1016/j.jksus.2019.01.011
   Axelsen PH, 1998, J COMPUT CHEM, V19, P1278, DOI 10.1002/(SICI)1096-987X(199808)19:11<1278::AID-JCC7>3.0.CO;2-H
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Brass V, 2008, P NATL ACAD SCI USA, V105, P14545, DOI 10.1073/pnas.0807298105
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Case D.A., 2018, AMBER
   Chen H., 2020, 1 CLIN STUDY USING H, DOI [https://doi.org/10.1101/2020.03.22.20034041, DOI 10.1101/2020.03.22.20034041]
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Coates L, 2002, J MOL BIOL, V318, P1405, DOI 10.1016/S0022-2836(02)00197-3
   Cronin NB, 2000, J MOL BIOL, V303, P745, DOI 10.1006/jmbi.2000.4181
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dos Santos Andre Luis Souza, 2010, World J Biol Chem, V1, P21, DOI 10.4331/wjbc.v1.i2.21
   DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993
   Du LY, 2007, BIOCHEM BIOPH RES CO, V359, P174, DOI 10.1016/j.bbrc.2007.05.092
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Gerardin P, 2002, AM J TROP MED HYG, V66, P686, DOI 10.4269/ajtmh.2002.66.686
   Hartman AM, 2015, INT J MOL SCI, V16, P19184, DOI 10.3390/ijms160819184
   HENDAUS MA, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1767691
   Hinrichsen H, 2004, GASTROENTEROLOGY, V127, P1347, DOI 10.1053/j.gastro.2004.08.002
   Hoffmann M, 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Hucke O, 2014, J MED CHEM, V57, P1932, DOI 10.1021/jm4004522
   Kendrick BJL, 2006, ANAESTHESIA, V61, P899, DOI 10.1111/j.1365-2044.2006.04752.x
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Khushboo B., 2020, STRUCTURAL SIMILARIT, DOI [https://doi.org/10.26434/chemrxiv.12153615.v1, DOI 10.26434/CHEMRXIV.12153615.V1]
   Ladhani S, 2002, BRIT J HAEMATOL, V119, P839, DOI 10.1046/j.1365-2141.2002.03904.x
   Ladziata V, 2016, BIOORG MED CHEM LETT, V26, P5051, DOI 10.1016/j.bmcl.2016.08.088
   Lazarus RA, 2004, CURR MED CHEM, V11, P2275, DOI 10.2174/0929867043364568
   Lee J, 2016, J CHEM THEORY COMPUT, V12, P405, DOI 10.1021/acs.jctc.5b00935
   Liu X., 2020, 6LU7, DOI [https://doi.org/10.1038/s41586.020-2223-y, DOI 10.1038/S41586.020-2223-Y]
   McGivern DR, 2015, J VIROL, V89, P5362, DOI 10.1128/JVI.03188-14
   Nguyen JT, 2008, ARCH PHARM, V341, P523, DOI 10.1002/ardp.200700267
   Quan ML, 2010, BIOORG MED CHEM LETT, V20, P1373, DOI 10.1016/j.bmcl.2010.01.011
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Routh J., 2020, NIH CLIN TRIAL REMDE
   Ruch TR, 2012, VIRUSES-BASEL, V4, P363, DOI 10.3390/v4030363
   Ruf W, 2004, TRENDS IMMUNOL, V25, P461, DOI 10.1016/j.it.2004.07.002
   Schiering N, 2011, P NATL ACAD SCI USA, V108, P21052, DOI 10.1073/pnas.1110534108
   Scholar E., 2007, XPHARM COMPREHENSIVE
   Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang RX, 2002, J COMPUT AID MOL DES, V16, P11, DOI 10.1023/A:1016357811882
   Willyard C, 2020, NATURE, V581, P250, DOI 10.1038/d41586-020-01403-8
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu LL, 2011, ANTIVIR RES, V92, P204, DOI 10.1016/j.antiviral.2011.08.001
   Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997
   Ziebuhr J, 1999, J VIROL, V73, P177, DOI 10.1128/JVI.73.1.177-185.1999
NR 70
TC 4
Z9 4
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1776158
EA JUN 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA ME3OS
UT WOS:000544569000001
PM 32787631
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Murugan, NA
   Pandian, CJ
   Jeyakanthan, J
AF Murugan, Natarajan Arul
   Pandian, Chitra Jeyaraj
   Jeyakanthan, Jeyaraman
TI Computational investigation onAndrographis paniculataphytochemicals to
   evaluate their potency against SARS-CoV-2 in comparison to known
   antiviral compounds in drug trials
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; Andrographis paniculata; andrographolide;
   neoandrographolide; RNA-directed RNA polymerase; spike protein; Covid-19
ID RESPIRATORY SYNDROME CORONAVIRUS; VIRUS ACTIVITY; ANDROGRAPHOLIDE;
   REPLICATION; INHIBITORS; PROTEIN; DERIVATIVES; PNEUMONIA; INFECTION;
   TYPE-1
AB The outbreak due to SARS-CoV-2 (or Covid-19) is spreading alarmingly and number of deaths due to infection is aggressively increasing every day. Due to the rapid human to human transmission of Covid-19, we are in need to find a potent drug at the earliest by ruling-out the traditional time-consuming approach of drug development. This is only possible if we use reliable computational approaches for screening compounds from chemical space or by drug repurposing or by finding the phytochemicals and nutraceuticals from plants as they can be immediately used without the need for carrying out drug-trials to test safety and efficacy. A number of plant products were routinely suggested as drugs in traditional Indian and Chinese medicine. Here using molecular docking approach, and combined molecular dynamics and MM-GBSA based free energy calculations approach, we study the potency of the four selected phytochemicals namely andrographolide (AGP1), 14-deoxy 11,12-didehydro andrographolide (AGP2), neoandrographolide (AGP3) and 14-deoxy andrographolide (AGP4) fromA. paniculataplant against the four key targets including three non-structural proteins (3 L main protease (3CLpro), Papain-like proteinase (PLpro) and RNA-directed RNA polymerase (RdRp)) and a structural protein (spike protein (S)) of the virus which are responsible for replication, transcription and host cell recognition. The therapeutic potential of the selected phytochemicals against Covid-19 were also evaluated in comparison with a few commercially available drugs. The binding free energy data suggest that AGP3 could be used as a cost-effective drug-analog for treating covid-19 infection in developing countries. Communicated by Ramaswamy H. Sarma
C1 [Murugan, Natarajan Arul] KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Theoret Chem & Biol, S-10691 Stockholm, Sweden.
   [Pandian, Chitra Jeyaraj] Dr Umayal Ramanathan Coll Women, Dept Biotechnol, Karaikkudi, Tamil Nadu, India.
   [Jeyakanthan, Jeyaraman] Alagappa Univ, Dept Bioinformat, Karaikkudi, Tamil Nadu, India.
RP Murugan, NA (corresponding author), KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Theoret Chem & Biol, S-10691 Stockholm, Sweden.; Jeyakanthan, J (corresponding author), Alagappa Univ, Dept Bioinformat, Karaikkudi, Tamil Nadu, India.
EM murugan@kth.se; jjkanthan@gmail.com
FU Swedish Infrastructure Committee (SNIC) [snic2020-5-2]
FX This work was supported by the grant from the Swedish Infrastructure
   Committee (SNIC) for the projects "In-silico Diagnostic Probes Design"
   (snic2020-5-2). JJ gratefully acknowledges the MHRD-RUSA 2.0 [F.
   24/51/2014-U, Policy (TNMulti-Gen), Dept. of Edn. Govt. of India] for
   the infrastructure facilities provided to the Department of
   Bioinformatics, Alagappa University.
CR Abhishek Niranjan, 2010, Indian Journal of Natural Products and Resources, V1, P125
   Berman H, 2007, NUCLEIC ACIDS RES, V35, pD301, DOI 10.1093/nar/gkl971
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311
   Calabrese C, 2000, PHYTOTHER RES, V14, P333, DOI 10.1002/1099-1573(200008)14:5&lt;333::AID-PTR584&gt;3.0.CO;2-D
   Case D., 2016, AMBER 16
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chandramohan V, 2015, ADV VIROL, V2015, DOI 10.1155/2015/972067
   Chang YS, 2003, PHYTOTHER RES, V17, P426, DOI 10.1002/ptr.1155
   Chen H, 2014, BIOORG MED CHEM LETT, V24, P2353, DOI 10.1016/j.bmcl.2014.03.060
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Ekalaksananan T, 2015, NUTR CANCER, V67, P687, DOI 10.1080/01635581.2015.1019630
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Frisch M. J., 2013, GAUSSIAN 09 REVISION
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gupta S, 2017, ARCH VIROL, V162, P611, DOI 10.1007/s00705-016-3166-3
   Keyaerts E, 2007, ANTIVIR RES, V75, P179, DOI 10.1016/j.antiviral.2007.03.003
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Kim YJ, 2010, ANTIVIR RES, V88, P227, DOI 10.1016/j.antiviral.2010.08.016
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lee JC, 2014, BRIT J PHARMACOL, V171, P237, DOI 10.1111/bph.12440
   Lin TP, 2008, BIOL PHARM BULL, V31, P2018, DOI 10.1248/bpb.31.2018
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Mansouri S, 2009, J BIOL CHEM, V284, P31453, DOI 10.1074/jbc.M109.046235
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Narayanan N, 2020, VITAMIN B12 MAY INHI, DOI [10.20944/preprints202003.0347.v1, DOI 10.20944/PREPRINTS202003.0347.V1]
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Peng Guang-yong, 2002, Zhongguo Zhongyao Zazhi, V27, P147
   Pholphana N, 2013, CHIN MED-UK, V8, DOI 10.1186/1749-8546-8-2
   Poongavanam V, 2018, REV COMPUT MOL SCI, V8, P1
   Prussia A, 2011, INT J MOL SCI, V12, P4027, DOI 10.3390/ijms12064027
   Rastelli G, 2010, J COMPUT CHEM, V31, P797, DOI 10.1002/jcc.21372
   Renu Parasher, 2011, Electronic Journal of Environmental, Agricultural and Food Chemistry, V10, P2479
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Schaftenaar G, 2017, J COMPUT AID MOL DES, V31, P789, DOI 10.1007/s10822-017-0042-5
   Seubsasana S, 2011, MED CHEM, V7, P237, DOI 1573-4064/11 $58.00+.00
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Thisoda P, 2006, EUR J PHARMACOL, V553, P39, DOI 10.1016/j.ejphar.2006.09.052
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wintachai P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14179
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yu B, 2014, CHIN J INTEGR MED, V20, P540, DOI 10.1007/s11655-014-1860-0
   Yuan L, 2016, BIOORG MED CHEM LETT, V26, P769, DOI 10.1016/j.bmcl.2015.12.100
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang X, 2014, CHIN J NAT MEDICINES, V12, P186, DOI 10.1016/S1875-5364(14)60031-5
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 62
TC 3
Z9 3
U1 18
U2 20
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1777901
EA JUN 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA ME3PX
UT WOS:000544572100001
PM 32543978
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jang, WM
   Jang, DH
   Lee, JY
AF Jang, Won Mo
   Jang, Deok Hyun
   Lee, Jin Yong
TI Social Distancing and Transmission-reducing Practices during the 2019
   Coronavirus Disease and 2015 Middle East Respiratory Syndrome
   Coronavirus Outbreaks in Korea
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE COVID-19; MERS; Social Distancing; Face Mask; Hand Washing
ID HONG-KONG; SARS
AB Background: The absence of effective antiviral medications and vaccines increased the focus on non-pharmaceutical preventive behaviors for mitigating against the coronavirus disease 2019 (COVID-19) pandemic. To examine the current status of non-pharmaceutical preventive behaviors practiced during the COVID-19 outbreak and factors affecting behavioral activities, we compared to the 2015 Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in Korea.
   Methods: This was a serial cross-sectional population-based study in Korea with four surveys conducted on June 2 and 25, 2015 (MERS-CoV surveys), and February 4, and April 2, 2020 (COVID-19 surveys). Of 25,711 participants selected using random digit dialing numbers, 4,011 participants (aged >= 18 years) were successfully interviewed, for the 2020 COVID-19 (n = 2,002) and 2015 MERS-CoV (n = 2,009) epidemics were included. Participants were selected poststratification by sex, age, and province. The total number of weighted cases in this survey equaled the total number of unweighted cases at the national level. We measured the levels of preventive behaviors (social distancing [avoiding physical contact with others]), and practicing transmissionreducing behaviors such as wearing face mask and handwashing.
   Results: Between the surveys, respondents who reported practicing social distancing increased from 41.9%-58.2% (MERS-CoV) to 83.4%-92.3% (COVID-19). The response rate for the four surveys ranged between 13.7% and 17.7%. Practicing transmission-reducing behaviors (wearing face masks and handwashing) at least once during COVID-19 (78.8%, 80.2%) also increased compared to that during MERS-CoV (15.5%, 60.3%). The higher affective risk perception groups were more likely to practice transmission-reducing measures (adjusted odds ratio, 3.24-4.81; 95 confidence interval, 1.76-6.96) during both COVID-19 and MERS-CoV.
   Conclusion: The study findings suggest markedly increased proportions of nonpharmaceutical behavioral practices evenly across all subgroups during the two different novel virus outbreaks in Korea. Strategic interventions are needed to attempt based on preventive behavior works.
C1 [Jang, Won Mo] Hlth Insurance Review & Assessment Serv, Hlth Review & Assessment Comm, Wonju, South Korea.
   [Jang, Deok Hyun] Gallup Korea, Res Analyt & Commun, Seoul, South Korea.
   [Lee, Jin Yong] Seoul Natl Univ, Dept Hlth Policy & Management, Coll Med, Seoul, South Korea.
   [Lee, Jin Yong] Seoul Natl Univ, Dept Publ Hlth & Community Med, Seoul Metropolitan Govt, Boramae Med Ctr, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.
RP Lee, JY (corresponding author), Seoul Natl Univ, Dept Publ Hlth & Community Med, Seoul Metropolitan Govt, Boramae Med Ctr, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.
EM jylee2000@gmail.com
OI Jang, Won Mo/0000-0003-3277-7706; Lee, Jin Yong/0000-0002-7752-2697
FU Gallup Korea, an affiliation of Gallup International
FX We would like to thank Gallup Korea, an affiliation of Gallup
   International, for supporting surveys and data collection for this
   manuscript.
CR Bicker L., CORONAVIRUS S KOREA
   Bults M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-2
   Chen H, 2020, SOCIAL DISTANCE SARS, DOI [10.1101/2020.03.11.20033688, DOI 10.1101/2020.03.11.20033688]
   Choe SH, MERS TARNISHES KOREA
   Choi JW, 2015, J KOREAN MED ASSOC, V58, P624, DOI 10.5124/jkma.2015.58.7.624
   Choi JK, 2012, EPIDEMIOL HEALTH, V34, DOI 10.4178/epih/e2012009
   Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m751
   Fisher M, S KOREA FLATTENED CU
   Fung ICH, 2006, TROP MED INT HEALTH, V11, P1749, DOI 10.1111/j.1365-3156.2006.01734.x
   Heo JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064230
   Jang WM, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-033026
   Jang WM, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16122161
   Jones JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008032
   Kim EY, 2016, AM J INFECT CONTROL, V44, P1414, DOI 10.1016/j.ajic.2016.03.014
   Kim Soo Jeong, 2014, Osong Public Health Res Perspect, V5, P9, DOI 10.1016/j.phrp.2013.12.001
   Korea Centers for Disease Control and Prevention, UPD COVID 19 KOR
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   Lau JTF, 2003, J EPIDEMIOL COMMUN H, V57, P864, DOI 10.1136/jech.57.11.864
   Lee KM, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16081432
   Lee SY, 2016, EPIDEMIOL HEALTH, V38, DOI 10.4178/epih.e2016051
   Machida M, 2020, INT J INFECT DIS, V94, P139, DOI 10.1016/j.ijid.2020.04.014
   Na BJ, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e192
   Noh JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e182
   Park EC, 2015, J KOREAN MED ASSOC, V58, P714, DOI 10.5124/jkma.2015.58.8.714
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Siegrist M, 2000, RISK ANAL, V20, P713, DOI 10.1111/0272-4332.205064
   Song Do Young, 2005, Annals of Clinical Microbiology, V8, P105
   Tracht SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009018
   Vinck P, 2019, LANCET INFECT DIS, V19, P529, DOI 10.1016/S1473-3099(19)30063-5
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, BAS PROT MEAS NEW CO
NR 32
TC 3
Z9 3
U1 3
U2 4
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD JUN 15
PY 2020
VL 35
IS 23
AR e220
DI 10.3346/jkms.2020.35.e220
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA MA2MI
UT WOS:000541750700007
PM 32537955
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Crisafulli, S
   Isgro, V
   La Corte, L
   Atzeni , F
   Trifiro, G
AF Crisafulli, Salvatore
   Isgro, Valentina
   La Corte, Laura
   Atzeni, Fabiola
   Trifiro, Gianluca
TI Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of
   COVID-19: Rationale, Clinical Evidence and Risks
SO BIODRUGS
LA English
DT Article
ID RECEPTOR T-CELLS; CYTOKINE RELEASE SYNDROME; RHEUMATOID-ARTHRITIS;
   CORONAVIRUS; SARS; TOCILIZUMAB; REMISSIONS; SARILUMAB; PNEUMONIA;
   OUTBREAK
AB The epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been spreading globally, raising increasing concerns. This public health emergency has triggered a race to find medications to improve the prognosis of this disease. There is currently great interest in drug repositioning to manage SARS-CoV-2 infection, that is, the evaluation of the potential benefits of a drug that has already been proven safe and effective in humans for other approved indications. As interleukin-6 (IL-6) acts as a key driver of the inflammation associated with coronavirus disease 2019 (COVID-19), IL-6 and IL-6 receptor (IL-6R) inhibition appear to be promising targets for the treatment of COVID-19 patients. It is important to critically analyze the available evidence concerning the use of the available anti-IL-6 (siltuximab) and anti-IL-6R (tocilizumab and sarilumab) agents in COVID-19 patients, in terms of both benefit and risk. In this review, the pathogenesis of the cytokine storm induced by COVID-19, the role of IL-6 in this cytokine storm, the rationale for the use of anti-IL-6 agents, and key information on potential benefits and safety monitoring of these biologicals in COVID-19 patients is discussed.
C1 [Crisafulli, Salvatore; Isgro, Valentina; Trifiro, Gianluca] Univ Messina, Policlin Univ G Martino, Dept Biomed & Dent Sci & Morphofunct Imaging, Via Consolare Valeria 1, I-98125 Messina, Italy.
   [La Corte, Laura; Atzeni, Fabiola] Univ Messina, Dept Expt & Internal Med, Rheumatol Unit, Messina, Italy.
RP Trifiro, G (corresponding author), Univ Messina, Policlin Univ G Martino, Dept Biomed & Dent Sci & Morphofunct Imaging, Via Consolare Valeria 1, I-98125 Messina, Italy.
EM trifirog@unime.it
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Alfonso-Cristancho R, 2017, CLIN RHEUMATOL, V36, P25, DOI 10.1007/s10067-016-3435-2
   Alvi RM, 2019, J AM COLL CARDIOL, V74, P3099, DOI 10.1016/j.jacc.2019.10.038
   Angus DC, 2020, JAMA-J AM MED ASSOC, V323, P1895, DOI 10.1001/jama.2020.4984
   Ascierto PA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000878
   Brooks DG, 2006, NAT MED, V12, P1301, DOI 10.1038/nm1492
   Brudno JN, 2016, BLOOD, V127, P3321, DOI 10.1182/blood-2016-04-703751
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   Conti P, 2020, J BIOL REGUL HOMEOST, P34
   Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226
   Dholaria BR, 2019, BIODRUGS, V33, P45, DOI 10.1007/s40259-018-0324-z
   Diao B., 2020, REDUCTION FUNCTIONAL, DOI [10.1101/2020.02.18.20024364, DOI 10.1101/2020.02.18.20024364]
   European Centre for Disease Prevention and Control, 2020, SIT UPD WORLDW 24 MA
   European Medicines Agency, SILT SUMM PROD CHAR
   European Medicines Agency, TOC SUMM PROD CHAR
   European Medicines Agency, SAR SUMM PROD CHAR
   Farag NS, 2020, INT J BIOCHEM CELL B, V122, DOI 10.1016/j.biocel.2020.105738
   Fitzgerald JC, 2017, CRIT CARE MED, V45, pE124, DOI 10.1097/CCM.0000000000002053
   Frey NV, 2014, BLOOD, V45, pe124
   Grange S, 2011, INT J CLIN PHARM TH, V49, P648, DOI 10.5414/CP201549
   Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haraoui B, 2017, CLIN EXP RHEUMATOL, V35, P899
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ichinohe T, 2010, NAT IMMUNOL, V11, P404, DOI 10.1038/ni.1861
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jatiani Shashidhar S, 2010, Genes Cancer, V1, P979, DOI 10.1177/1947601910397187
   Jones SA, 2005, J INTERF CYTOK RES, V25, P241, DOI 10.1089/jir.2005.25.241
   June RR, 2016, EXPERT OPIN BIOL TH, V16, P1303, DOI 10.1080/14712598.2016.1217988
   Kochenderfer JN, 2015, J CLIN ONCOL, V33, P540, DOI 10.1200/JCO.2014.56.2025
   Kourbeti IS, 2014, CLIN INFECT DIS, V58, P1649, DOI 10.1093/cid/ciu185
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Liao Y, 2011, VIROLOGY, V420, P106, DOI 10.1016/j.virol.2011.09.003
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222
   Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mescher MF, 2006, IMMUNOL REV, V211, P81, DOI 10.1111/j.0105-2896.2006.00382.x
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340
   Office of the Chinese Medicine Bureau, STAT HLTH OFF MED LE
   Ogata A, 2019, MOD RHEUMATOL, V29, P258, DOI [10.1080/14397595.2018.1533514, 10.1080/14397595.2018.1546357]
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Raimondo MG, 2017, DRUG DES DEV THER, V11, P1593, DOI 10.2147/DDDT.S100302
   Rome BN, 2020, NEW ENGL J MED, V382, P2282, DOI 10.1056/NEJMp2009457
   Schinnerling K, 2017, CLIN EXP IMMUNOL, V189, P12, DOI 10.1111/cei.12966
   Schoels MM, 2013, ANN RHEUM DIS, V72, P583, DOI 10.1136/annrheumdis-2012-202470
   Shovman O, 2015, IMMUNOL RES, V61, P164, DOI 10.1007/s12026-014-8590-4
   Tan YJ, 2005, ANTIVIR RES, V65, P69, DOI 10.1016/j.antiviral.2004.10.001
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Turtle CJ, 2017, J CLIN ONCOL, V35, P3010, DOI 10.1200/JCO.2017.72.8519
   van Rhee F, 2014, LANCET ONCOL, V15, P966, DOI 10.1016/S1470-2045(14)70319-5
   Wei WE, 2020, MMWR-MORBID MORTAL W, V69, P411, DOI 10.15585/mmwr.mm6914e1
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang ML, 2020, CONTEMP NURSE, V56, P90, DOI [10.1080/10376178.2020.1742178, 10.1080/02713683.2020.1857781]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y, 2020, BIORXIV, DOI [10.1101/2020.02.12.945576, DOI 10.1101/2020.02.12.945576]
   Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 62
TC 5
Z9 5
U1 3
U2 3
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-8804
EI 1179-190X
J9 BIODRUGS
JI Biodrugs
PD AUG
PY 2020
VL 34
IS 4
BP 415
EP 422
DI 10.1007/s40259-020-00430-1
EA JUN 2020
PG 8
WC Oncology; Immunology; Pharmacology & Pharmacy
SC Oncology; Immunology; Pharmacology & Pharmacy
GA MT1KI
UT WOS:000541102900001
PM 32557214
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ma, CL
   Sacco, MD
   Hurst, B
   Townsend, JA
   Hu, YM
   Szeto, T
   Zhang, XJ
   Tarbet, B
   Marty, MT
   Chen, Y
   Wang, J
AF Ma, Chunlong
   Sacco, Michael Dominic
   Hurst, Brett
   Townsend, Julia Alma
   Hu, Yanmei
   Szeto, Tommy
   Zhang, Xiujun
   Tarbet, Bart
   Marty, Michael Thomas
   Chen, Yu
   Wang, Jun
TI Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2
   viral replication by targeting the viral main protease
SO CELL RESEARCH
LA English
DT Article
ID DRUG DISCOVERY; 3CL PROTEASE; CORONAVIRUS; PROTEINASE; MODEL; EFFICACY;
   SPECTRUM; BINDING; DESIGN
AB A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started to circulate among humans around December 2019, and it is now widespread as a global pandemic. The disease caused by SARS-CoV-2 virus is called COVID-19, which is highly contagious and has an overall mortality rate of 6.35% as of May 26, 2020. There is no vaccine or antiviral available for SARS-CoV-2. In this study, we report our discovery of inhibitors targeting the SARS-CoV-2 main protease (M-pro). Using the FRET-based enzymatic assay, several inhibitors including boceprevir, GC-376, and calpain inhibitors II, and XII were identified to have potent activity with single-digit to submicromolar IC(50)values in the enzymatic assay. The mechanism of action of the hits was further characterized using enzyme kinetic studies, thermal shift binding assays, and native mass spectrometry. Significantly, four compounds (boceprevir, GC-376, calpain inhibitors II and XII) inhibit SARS-CoV-2 viral replication in cell culture with EC(50)values ranging from 0.49 to 3.37 mu M. Notably, boceprevir, calpain inhibitors II and XII represent novel chemotypes that are distinct from known substrate-based peptidomimetic M(pro)inhibitors. A complex crystal structure of SARS-CoV-2 M(pro)with GC-376, determined at 2.15 angstrom resolution with three protomers per asymmetric unit, revealed two unique binding configurations, shedding light on the molecular interactions and protein conformational flexibility underlying substrate and inhibitor binding by M-pro. Overall, the compounds identified herein provide promising starting points for the further development of SARS-CoV-2 therapeutics.
C1 [Ma, Chunlong; Hu, Yanmei; Szeto, Tommy; Wang, Jun] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
   [Sacco, Michael Dominic; Zhang, Xiujun; Chen, Yu] Univ S Florida, Dept Mol Med, Morsani Coll Med, Tampa, FL 33612 USA.
   [Hurst, Brett; Tarbet, Bart] Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA.
   [Hurst, Brett; Tarbet, Bart] Utah State Univ, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA.
   [Townsend, Julia Alma; Marty, Michael Thomas] Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA.
RP Wang, J (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.; Chen, Y (corresponding author), Univ S Florida, Dept Mol Med, Morsani Coll Med, Tampa, FL 33612 USA.
EM ychen1@usf.edu; junwang@pharmacy.arizona.edu
RI Hu, Yanmei/ABA-7872-2020; Wang, Jun/AAX-5087-2020; Marty, Michael
   T/C-5897-2013
OI Wang, Jun/0000-0002-4845-4621; Marty, Michael T/0000-0001-8115-1772; Ma,
   Chunlong/0000-0002-5766-8189; Hu, Yanmei/0000-0003-0525-7342
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [AI147325];
   Arizona Biomedical Research Centre Young Investigator grant
   [ADHS18-198859]; Respiratory Diseases Branch, National Institute of
   Allergy and Infectious Diseases, NIH, USA [N01-AI-30048]; National
   Institute of General Medical Sciences, NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R35 GM128624];
   .S. Department of Energy, Office of Biological and Environmental
   ResearchUnited States Department of Energy (DOE) [DE-AC02-06CH11357]
FX This research was partially supported by the National Institutes of
   Health (NIH) (Grant AI147325) and the Arizona Biomedical Research Centre
   Young Investigator grant (ADHS18-198859) to J.W., B.H. and B.T. thanks
   for the support from the Respiratory Diseases Branch, National Institute
   of Allergy and Infectious Diseases, NIH, USA (Contract N01-AI-30048).
   J.A.T. and M.T.M. were funded by the National Institute of General
   Medical Sciences, NIH (Grant R35 GM128624 to M.T.M.). We thank Michael
   Kemp for assistance with crystallization and X-ray diffraction data
   collection. We also thank the staff members of the Advanced Photon
   Source of Argonne National Laboratory, particularly those at the
   Structural Biology Center (SBC), with X-ray diffraction data collection.
   SBC-CAT is operated by UChicago Argonne, LLC, for the U.S. Department of
   Energy, Office of Biological and Environmental Research under contract
   DE-AC02-06CH11357.
CR Akdemir O, 2008, J CLIN NEUROSCI, V15, P1130, DOI 10.1016/j.jocn.2007.08.011
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Barnard Dale L., 2004, Antiviral Chemistry & Chemotherapy, V15, P15
   Bonuccelli G, 2003, AM J PATHOL, V163, P1663, DOI 10.1016/S0002-9440(10)63523-7
   Cady SD, 2011, J AM CHEM SOC, V133, P4274, DOI 10.1021/ja102581n
   Cai QX, 2013, J VIROL, V87, P7348, DOI 10.1128/JVI.03541-12
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chuck CP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013197
   Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020, NAT MICROBIOL, V5, P536
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Delli Pizzi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056501
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hayden FG, 2003, ANTIMICROB AGENTS CH, V47, P3907, DOI 10.1128/AAC.47.12.3907-3916.2003
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12
   Kuo CJ, 2008, BIOORGAN MED CHEM, V16, P7388, DOI 10.1016/j.bmc.2008.06.015
   Li CM, 2010, J BIOL CHEM, V285, P28134, DOI 10.1074/jbc.M109.095851
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li SZ, 2013, BIOCHEM BIOPH RES CO, V437, P325, DOI 10.1016/j.bbrc.2013.06.088
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma CL, 2016, MOL PHARMACOL, V90, P188, DOI 10.1124/mol.116.105346
   MAHASE E, 2020, BMJ-BRIT MED J, V368, P48071, DOI DOI 10.1136/BMJ.M641
   Mani SK, 2008, AM J PHYSIOL-HEART C, V295, pH314, DOI 10.1152/ajpheart.00085.2008
   Marty MT, 2015, ANAL CHEM, V87, P4370, DOI 10.1021/acs.analchem.5b00140
   Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949
   MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Musharrafieh R, 2019, J VIROL, V93, DOI 10.1128/JVI.02221-18
   Ono Y, 2016, NAT REV DRUG DISCOV, V15, P854, DOI 10.1038/nrd.2016.212
   Pedersen NC, 2018, J FELINE MED SURG, V20, P378, DOI 10.1177/1098612X17729626
   Peng S, 2011, MOL BIOL REP, V38, P905, DOI 10.1007/s11033-010-0183-2
   Schneider M, 2012, J VIROL, V86, P10112, DOI 10.1128/JVI.01001-12
   Shang LQ, 2015, ANTIMICROB AGENTS CH, V59, P1827, DOI 10.1128/AAC.04698-14
   Shie JJ, 2005, BIOORGAN MED CHEM, V13, P5240, DOI 10.1016/j.bmc.2005.05.065
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wingfield P. T., 2017, CURR PROTOC PROTEIN, V88, P6141
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 53
TC 25
Z9 26
U1 12
U2 13
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD AUG
PY 2020
VL 30
IS 8
BP 678
EP 692
DI 10.1038/s41422-020-0356-z
EA JUN 2020
PG 15
WC Cell Biology
SC Cell Biology
GA MU8ZE
UT WOS:000540389900001
PM 32541865
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wolf, J
   Bruno, S
   Eichberg, M
   Jannat, R
   Rudo, S
   VanRheenen, S
   Coller, BA
AF Wolf, Jayanthi
   Bruno, Samantha
   Eichberg, Michael
   Jannat, Risat
   Rudo, Sharon
   VanRheenen, Susan
   Coller, Beth-Ann
TI Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and
   other epidemic pathogens
SO NPJ VACCINES
LA English
DT Article
AB The world is experiencing an unprecedented global pandemic of coronavirus disease 2019 (COVID-19) caused by a novel coronavirus, Severe Acute Respiratory Syndrome-coronavirus-2 (SARS-CoV-2). Development of new vaccines and therapeutics are important to achieve long-term prevention and control of the virus. Experience gained in the development of vaccines for Ebola virus disease provide important lessons in the regulatory, clinical, and manufacturing process that can be applied to SARS-CoV-2 and other epidemic pathogens. This report outlines the main lessons learned by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD) during development of an Ebola Zaire vaccine (ERVEBO (R)) and looks ahead to critical lessons beyond vaccine development. It highlights focus areas for public-private partnership and regulatory harmonization that can be directly applied to current vaccine development efforts for SARS-CoV-2, while drawing attention to the need for parallel consideration of issues beyond development that are equally important to achieve global preparedness and response goals.
C1 [Wolf, Jayanthi; Bruno, Samantha; Eichberg, Michael; Jannat, Risat; Rudo, Sharon; VanRheenen, Susan; Coller, Beth-Ann] Merck & Co Inc, Kenilworth, NJ 07033 USA.
RP Wolf, J (corresponding author), Merck & Co Inc, Kenilworth, NJ 07033 USA.
EM Jayanthi_Wolf@merck.com
OI Wolf, Jayanthi/0000-0002-2837-8262
CR Feldmann H, 2018, ANNU REV MICROBIOL, V72, P423, DOI 10.1146/annurev-micro-090817-062414
   Folayan Morenike Oluwatoyin, 2015, Pan Afr Med J, V22 Suppl 1, P10, DOI 10.11694/pamj.supp.2015.22.1.6216
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Higgs ES, 2017, CURR TOP MICROBIOL, V411, P229, DOI 10.1007/82_2017_53
   International Federation of Pharmaceutical Manufacturers & Associations, 2020, COMPL JOURN VACC
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   WHO, 2020, EB VIR DIS DEM REP C
   World Health Organization, 2020, ROADM INTR ROLL OUT
   World Health Organization, 2020, EB SIT REP MARCH 30
NR 9
TC 5
Z9 5
U1 3
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2059-0105
J9 NPJ VACCINES
JI npj Vaccines
PD JUN 15
PY 2020
VL 5
IS 1
AR 51
DI 10.1038/s41541-020-0204-7
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LY4VO
UT WOS:000540527700001
PM 32566261
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Caniglia, JL
   Guda, MR
   Asuthkar, S
   Tsung, AJ
   Velpula, KK
AF Caniglia, John L.
   Guda, Maheedhara R.
   Asuthkar, Swapna
   Tsung, Andrew J.
   Velpula, Kiran K.
TI A potential role for Galectin-3 inhibitors in the treatment of COVID-19
SO PEERJ
LA English
DT Article
DE Galectin-3; Cytokines; COVID-19
ID CRYSTAL-STRUCTURE; CORONAVIRUS; CYTOKINE
AB The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), the causative agent of coronavirus disease 2019 (COVID-19), has been declared a global pandemic by the World Health Organization. With no standard of care for the treatment of COVID-19, there is an urgent need to identify therapies that may be effective in treatment. Recent evidence has implicated the development of cytokine release syndrome as the major cause of fatality in COVID-19 patients, with elevated levels of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) observed in patients. Galectin-3 (Gal-3) is an animal lectin that has been implicated in the disease process of a variety of inflammatory conditions. Inhibitors of the small molecule Gal-3 have been shown to reduce the levels of both IL-6 and TNF-alpha in vitro and have shown anti-inflammatory effects in vivo. Additionally, a key domain in the spike protein of beta-coronaviridae, a genus which includes SARS-CoV2, is nearly identical in morphology to human Gal-3. These spike proteins are critical for the virus' entry into host cells. Here we provide a systematic review of the available literature and an impetus for further research on the use of Gal-3 inhibitors in the treatment of COVID-19. Further, we propose a dual mechanism by which Gal-3 inhibition may be beneficial in the treatment of COVID-19, both suppressing the host inflammatory response and impeding viral attachment to host cells.
C1 [Caniglia, John L.; Guda, Maheedhara R.; Asuthkar, Swapna] Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol Neurosurg & Pediat, Peoria, IL USA.
   [Tsung, Andrew J.; Velpula, Kiran K.] Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA.
   [Tsung, Andrew J.; Velpula, Kiran K.] Univ Illinois, Coll Med Peoria, Dept Neurosurg, Peoria, IL 61605 USA.
   [Tsung, Andrew J.; Velpula, Kiran K.] Univ Illinois, Coll Med Peoria, Dept Pediat, Peoria, IL 61605 USA.
   [Tsung, Andrew J.] Illinois Neurol Inst, Peoria, IL USA.
RP Velpula, KK (corresponding author), Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA.; Velpula, KK (corresponding author), Univ Illinois, Coll Med Peoria, Dept Neurosurg, Peoria, IL 61605 USA.; Velpula, KK (corresponding author), Univ Illinois, Coll Med Peoria, Dept Pediat, Peoria, IL 61605 USA.
EM velpula@uic.edu
CR Barnard KN, 2019, MBIO, V10, DOI 10.1128/mBio.02490-19
   Blaas D, 2016, WIEN MED WOCHENSCHR, V166, P211, DOI 10.1007/s10354-016-0461-2
   Blanchard H, 2014, EXPERT OPIN THER PAT, V24, DOI 10.1517/13543776.2014.947961
   Chalasani N, 2020, GASTROENTEROLOGY, V158, P1334, DOI 10.1053/j.gastro.2019.11.296
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen SS, 2015, CELL IMMUNOL, V294, P44, DOI 10.1016/j.cellimm.2015.01.017
   Chen YJ, 2018, AM J PATHOL, V188, P1031, DOI 10.1016/j.ajpath.2017.12.014
   Elola MT, 2018, CELL IMMUNOL, V333, P34, DOI 10.1016/j.cellimm.2018.03.008
   Fantini J, 2020, INT J ANTIMICROB AG, V55
   Filer A, 2009, ARTHRITIS RHEUM, V60, P1604, DOI 10.1002/art.24574
   Kaur M, 2018, ISCIENCE, V9, P101, DOI 10.1016/j.isci.2018.10.013
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Law HKW, 2005, BLOOD, V106, P2366, DOI 10.1182/blood-2004-10-4166
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li WT, 2017, P NATL ACAD SCI USA, V114, pE8508, DOI 10.1073/pnas.1712592114
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Patel Kishan P, 2020, J Clin Virol, V128, P104386, DOI 10.1016/j.jcv.2020.104386
   Peng GQ, 2012, J BIOL CHEM, V287, P41931, DOI 10.1074/jbc.M112.418210
   Peng GQ, 2011, P NATL ACAD SCI USA, V108, P10696, DOI 10.1073/pnas.1104306108
   Perricone C, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102468
   Ren ZL, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20192368
   Saito S, 2019, J THORAC DIS, V11, pS1740, DOI 10.21037/jtd.2019.04.62
   Stegmayr J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38497-8
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Uchino Y, 2018, IMMUNOLOGY, V154, P490, DOI 10.1111/imm.12899
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang Wen-Hung, 2020, J Microbiol Immunol Infect, V53, P925, DOI 10.1016/j.jmii.2019.09.005
   Whittaker A, 2020, ACTA NEUROL SCAND, V194, DOI [10.1016/j.clineuro.2020.105921., DOI 10.1016/J.CLINEURO.2020.105921]
   Wu GS, 2016, J NEUROCHEM, V136, P550, DOI 10.1111/jnc.13418
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 34
TC 3
Z9 3
U1 1
U2 1
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD JUN 15
PY 2020
VL 8
AR e9392
DI 10.7717/peerj.9392
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LX9RN
UT WOS:000540162600006
PM 32587806
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Patel, P
   Sengupta, N
AF Patel, Parita
   Sengupta, Neil
TI PPIs and Beyond: A Framework for Managing Anticoagulation-Related
   Gastrointestinal Bleeding in the Era of COVID-19
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Gastrointestinal bleeding; Anticoagulation; Thrombosis; COVID-19
ID CRITICALLY-ILL PATIENTS; PROTON-PUMP INHIBITORS; DEEP VENOUS THROMBOSIS;
   ORAL ANTICOAGULANTS; RISK; PREVENTION; WARFARIN; ASSOCIATION;
   RECURRENCE; MANAGEMENT
AB Coronavirus disease of 2019 (COVID-19) can be associated with high morbidity and mortality; patients with severe clinical manifestations may develop significant coagulopathy as well as unexpected thromboembolic complications. In response, centers are increasingly treating selected patients with intermediate-dose prophylactic or even therapeutic dose anticoagulation in order to prevent potentially catastrophic thrombotic complications. With this changing practice, the authors suspect that inpatient gastrointestinal consult teams across the country will be frequently managing COVID-19 patients with gastrointestinal bleeding (GIB). In order to reduce potentially avoidable hospital readmissions for GIB while improving patient outcomes, it is imperative to appropriately risk-stratify patients prior to initiation of anticoagulation. In this review, we discuss how to appropriately identify high-risk patients for GIB and how to mitigate GIB risk with proton-pump inhibitor co-therapy, medication reconciliation, andHelicobacter pyloritesting and treating in this complex and morbid population.
C1 [Patel, Parita; Sengupta, Neil] Univ Chicago, Sect Gastroenterol Hepatol & Nutr, Med Ctr, 5841 S Maryland Ave,MC 4076, Chicago, IL 60637 USA.
RP Sengupta, N (corresponding author), Univ Chicago, Sect Gastroenterol Hepatol & Nutr, Med Ctr, 5841 S Maryland Ave,MC 4076, Chicago, IL 60637 USA.
EM nsengupta@medicine.bsd.uchicago.edu
CR Abraham NS, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1857
   Abraham NS, 2013, CURR OPIN GASTROEN, V29, P676, DOI 10.1097/MOG.0b013e328365d415
   Abraham NS, 2010, CIRCULATION, V122, P2619, DOI 10.1161/CIR.0b013e318202f701
   Aoki T, 2015, CLIN GASTROENTEROL H, V13, P488, DOI 10.1016/j.cgh.2014.06.023
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barnes GD, 2020, J THROMB THROMBOLYS, V50, P72, DOI 10.1007/s11239-020-02138-z
   Barrett CD, 2020, J THROMB HAEMOST, V18, P2060, DOI 10.1111/jth.14860
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   BRUNNER G, 1989, SCAND J GASTROENTERO, V24, P101, DOI 10.3109/00365528909091254
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheung KS, 2017, WORLD J GASTROENTERO, V23, P1954, DOI 10.3748/wjg.v23.i11.1954
   Chey WD, 2017, AM J GASTROENTEROL, V112, P212, DOI 10.1038/ajg.2016.563
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cook D, 2005, CRIT CARE MED, V33, P1565, DOI 10.1097/01.CCM.0000171207.95319.B2
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Flack KF, 2017, CLIN GASTROENTEROL H, V15, P682, DOI 10.1016/j.cgh.2016.10.011
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Hansen ML, 2010, ARCH INTERN MED, V170, P1433, DOI 10.1001/archinternmed.2010.271
   Helms J, 2020, INTENS CARE MED 0504, DOI [DOI 10.1007/S00134-020-06062-X, 10.1007/s00134-020-06062-x]
   Hopkins RJ, 1996, GASTROENTEROLOGY, V110, P1244, DOI 10.1053/gast.1996.v110.pm8613015
   Hylek EM, 2007, CIRCULATION, V115, P2689, DOI 10.1161/CIRCULATIONAHA.106.653048
   Kaplan D, 2015, CHEST, V148, P1224, DOI 10.1378/chest.15-0287
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lanas A, 2007, AM J GASTROENTEROL, V102, P507, DOI 10.1111/j.1572-0241.2006.01062.x
   Lanza FL, 2009, AM J GASTROENTEROL, V104, P728, DOI 10.1038/ajg.2009.115
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Marik PE, 1997, CHEST, V111, P661, DOI 10.1378/chest.111.3.661
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Moayyedi P, 2019, GASTROENTEROLOGY, V157, P403, DOI 10.1053/j.gastro.2019.04.041
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Peery AF, 2019, GASTROENTEROLOGY, V156, P254, DOI [10.1053/j.gastro.2018.08.063, 10.1053/j.gastro.2018.11.060]
   Ray WA, 2018, JAMA-J AM MED ASSOC, V320, P2221, DOI 10.1001/jama.2018.17242
   Ray WA, 2016, GASTROENTEROLOGY, V151, P1105, DOI 10.1053/j.gastro.2016.08.054
   Regula J, 2006, AM J GASTROENTEROL, V101, P1747, DOI 10.1111/j.1572-0241.2006.00686.x
   Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316
   Saltzman JR, 2011, GASTROINTEST ENDOSC, V74, P1215, DOI 10.1016/j.gie.2011.06.024
   Scheiman JM, 2006, AM J GASTROENTEROL, V101, P701, DOI 10.1111/j.1572-0241.2006.00499.x
   Schelleman H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021447
   Sengupta N, 2017, AM J MED, V130, DOI 10.1016/j.amjmed.2016.12.009
   Shireman TI, 2004, STROKE, V35, P2362, DOI 10.1161/01.STR.0000141933.75462.c2
   Shorr AF, 2009, THROMB HAEMOSTASIS, V101, P139, DOI 10.1160/TH08-07-0468
   Strate LL, 2003, ARCH INTERN MED, V163, P838, DOI 10.1001/archinte.163.7.838
   Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Vaduganathan M, 2016, EXPERT OPIN DRUG SAF, V15, P1451, DOI 10.1080/14740338.2016.1227790
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Zhang CL, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015833
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 51
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD AUG
PY 2020
VL 65
IS 8
BP 2181
EP 2186
DI 10.1007/s10620-020-06408-x
EA JUN 2020
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ML8PT
UT WOS:000540211400001
PM 32537704
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Viel, T
   Chinta, S
   Rane, A
   Chamoli, M
   Buck, H
   Andersen, J
AF Viel, Tania
   Chinta, Shankar
   Rane, Anand
   Chamoli, Manish
   Buck, Hudson
   Andersen, Julie
TI Microdose lithium reduces cellular senescence in human astrocytes - a
   potential pharmacotherapy for COVID-19?
SO AGING-US
LA English
DT Article
DE senolytics; lithium; COVID-19; cell senescence; chronic inflammation
ID NEUROPATHOLOGY
AB Cell senescence is a process that causes growth arrest and the release of a senescence associated secretory phenotype (SASP), characterized by secretion of chemokines, cytokines, cell growth factors and metalloproteases, leading to a tissue condition that may precipitate cancers and neurodegenerative processes. With the recent pandemic of coronavirus, senolytic drugs are being considered as possible therapeutic tools to reduce the virulence of SARS-CoV-2. In the last few years, our research group showed that lithium carbonate at microdose levels was able to stabilize memory and change neuropathological characteristics of Alzheimer's disease (AD). In the present work, we present evidence that low-dose lithium can reduce the SASP of human iPSCs-derived astrocytes following acute treatment, suggesting that microdose lithium could protect cells from senescence and development of aging-related conditions. With the present findings, a perspective of the potential use of low-dose lithium in old patients from the "high risk group" for COVID-19 (with hypertension, diabetes and chronic obstructive pulmonary disease) is presented.
C1 [Viel, Tania] Univ Sao Paulo, Sch Arts Sci & Humanities, Lab Neuropharmacol Aging, Sao Paulo, SP, Brazil.
   [Chinta, Shankar] Touro Univ Calif, Vallejo, CA 94592 USA.
   [Chinta, Shankar; Rane, Anand; Chamoli, Manish; Andersen, Julie] Buck Inst Res Aging, Novato, CA 94945 USA.
   [Buck, Hudson] Santa Casa Sao Paulo Sch Med Sci, Dept Physiol Sci, Sao Paulo, SP, Brazil.
RP Viel, T (corresponding author), Univ Sao Paulo, Sch Arts Sci & Humanities, Lab Neuropharmacol Aging, Sao Paulo, SP, Brazil.
EM taniaviel@usp.br
RI Chamoli, Manish/I-8665-2019
OI Chamoli, Manish/0000-0003-0339-7894
FU Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [FAPESP 2018/05288-6]; Larry L. Hillblom Foundation;
   Pittsburgh Foundation; FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2019/03486-8]
FX TAV received a researcher fellowship from Sao Paulo Research Foundation
   (FAPESP 2018/05288-6). MC is supported by the postdoctoral fellowship
   from Larry L. Hillblom Foundation. JKA is supported by the Pittsburgh
   Foundation. HSB is supported by FAPESP (2019/03486-8) and is a CNPq
   researcher (307252/2017-5).
CR Bhat R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045069
   Birch J, 2018, PHARMACOL THERAPEUT, V183, P34, DOI 10.1016/j.pharmthera.2017.10.005
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Burton DGA, 2018, BIOGERONTOLOGY, V19, P447, DOI 10.1007/s10522-018-9763-7
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653
   Castillo-Quan JI, 2016, CELL REP, V15, P638, DOI 10.1016/j.celrep.2016.03.041
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chinta SJ, 2018, CELL REP, V22, P930, DOI 10.1016/j.celrep.2017.12.092
   Chinta SJ, 2015, EXP GERONTOL, V68, P3, DOI 10.1016/j.exger.2014.09.018
   Forlenza OV, 2019, BRIT J PSYCHIAT, V215, P668, DOI 10.1192/bjp.2019.76
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960
   Guttuso T, 2019, J NEUROL SCI, V402, P121, DOI 10.1016/j.jns.2019.05.016
   Habib A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.279
   Herold T, 2020, LEVEL IL 6 PREDICTS, DOI [10.1101/2020.04.01.20047381, DOI 10.1101/2020.04.01.20047381]
   Kirkland JL, 2017, J AM GERIATR SOC, V65, P2297, DOI 10.1111/jgs.14969
   Limanaqi F, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00450
   Monti D, 2017, MECH AGEING DEV, V165, P129, DOI 10.1016/j.mad.2016.12.008
   Moors TE, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0154-3
   Nowak JK, 2020, F1000RESEARCH, V9, P19
   Nunes MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142267
   Nunes MA, 2013, CURR ALZHEIMER RES, V10, P104
   Relano-Gines A, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0209-4
   Sargiacomo C, 2020, AGING-US, V12, P6511, DOI 10.18632/aging.103001
   Sikora Ewa, 2018, Postepy Biochem, V64, P110, DOI 10.18388/pb.2018_120
   Vieta E, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.8
   Wilson EN, 2020, J ALZHEIMERS DIS, V73, P723, DOI 10.3233/JAD-190862
   Woods G, 2018, TOXICOL SCI, V166, P16, DOI 10.1093/toxsci/kfy181
   Zmijewski JW, 2004, AGING CELL, V3, P309, DOI 10.1111/j.1474-9728.2004.00117.x
NR 29
TC 1
Z9 1
U1 10
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JUN 15
PY 2020
VL 12
IS 11
BP 10035
EP 10040
DI 10.18632/aging.103449
PG 6
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA LY5PF
UT WOS:000540580800004
PM 32534451
OA Green Published
DA 2021-01-01
ER

PT J
AU Zhao, MM
   Wang, ML
   Zhang, JH
   Gu, J
   Zhang, PG
   Xu, Y
   Ye, J
   Wang, Z
   Ye, D
   Pan, W
   Shen, B
   He, H
   Liu, MX
   Liu, ML
   Luo, Z
   Li, D
   Liu, JF
   Wan, J
AF Zhao, Mengmeng
   Wang, Menglong
   Zhang, Jishou
   Gu, Jian
   Zhang, Pingan
   Xu, Yao
   Ye, Jing
   Wang, Zhen
   Ye, Di
   Pan, Wei
   Shen, Bo
   He, Hua
   Liu, Mingxiao
   Liu, Menglin
   Luo, Zhen
   Li, Dan
   Liu, Jianfang
   Wan, Jun
TI Comparison of clinical characteristics and outcomes of patients with
   coronavirus disease 2019 at different ages
SO AGING-US
LA English
DT Article
DE 2019 novel coronavirus; coronavirus disease 2019; COVID-19; age;
   clinical characteristics; prognosis
ID EAST RESPIRATORY SYNDROME; MORTALITY; PNEUMONIA; SEPSIS
AB Background: Information about the clinical characteristics and mortality of patients with coronavirus disease 2019 at different ages is limited.
   Results: The older group had more patients with dyspnea and fewer patients with fever and muscle pain. Older patients had more underlying diseases, secondary infection, myocardial injury, renal dysfunction, coagulation dysfunction, and immune dysfunction on admission. More older patients received immunoglobulin therapy and mechanical ventilation. The proportions of patients with multiple organ injuries, critically ill patients and death increased significantly with age. The older groups had higher cumulative death risk than the younger group. Hypertension, cerebrovascular disease, comorbidities, acute cardiac injury, shock and complications are independent predictors of death.
   Conclusions: The symptoms of the elderly patients were more atypical, with more comorbidities, secondary infection, organ injuries, immune dysfunction and a higher risk of critical illness. Older age was an important risk factor for mortality.
   Methods: 1000 patients diagnosed with coronavirus disease 2019 from January 1, 2020 to February 14, 2020 were enrolled. According to age, patients were divided into group 1 (<60 years old), group 2 (60-74 years old) and group 3 (>= 75 years old). The clinical symptoms, first laboratory results, CT findings, organ injuries, disease severity and mortality were analyzed.
C1 [Zhao, Mengmeng; Wang, Menglong; Zhang, Jishou; Xu, Yao; Ye, Jing; Wang, Zhen; Ye, Di; Pan, Wei; Luo, Zhen; Liu, Jianfang; Wan, Jun] Wuhan Univ, Dept Cardiol, Renmin Hosp, Wuhan, Hubei, Peoples R China.
   [Zhao, Mengmeng; Wang, Menglong; Zhang, Jishou; Xu, Yao; Ye, Jing; Wang, Zhen; Ye, Di; Pan, Wei; Liu, Jianfang; Wan, Jun] Wuhan Univ, Cardiovasc Res Inst, Wuhan, Hubei, Peoples R China.
   [Zhao, Mengmeng; Wang, Menglong; Zhang, Jishou; Xu, Yao; Ye, Jing; Wang, Zhen; Ye, Di; Pan, Wei; Luo, Zhen; Liu, Jianfang; Wan, Jun] Hubei Key Lab Cardiol, Wuhan, Hubei, Peoples R China.
   [Gu, Jian; Zhang, Pingan] Wuhan Univ, Dept Clin Lab, Renmin Hosp, Wuhan, Hubei, Peoples R China.
   [Shen, Bo; He, Hua] Wuhan Univ, Dept Med Affairs, Renmin Hosp, Wuhan, Hubei, Peoples R China.
   [Liu, Mingxiao] Wuhan Univ, Med Qual Management Off, Renmin Hosp, Wuhan, Hubei, Peoples R China.
   [Liu, Menglin] Wuhan Univ, Dept Emergency, Renmin Hosp, Wuhan, Hubei, Peoples R China.
   [Li, Dan] Wuhan Univ, Dept Pediat, Renmin Hosp, Wuhan, Hubei, Peoples R China.
RP Wan, J (corresponding author), Wuhan Univ, Dept Cardiol, Renmin Hosp, Wuhan, Hubei, Peoples R China.; Wan, J (corresponding author), Wuhan Univ, Cardiovasc Res Inst, Wuhan, Hubei, Peoples R China.; Wan, J (corresponding author), Hubei Key Lab Cardiol, Wuhan, Hubei, Peoples R China.
EM whuwanjun@163.com
CR Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Cao M, 2020, CLIN FEATURES PATIEN
   Chen G, 2019, CLIN IMMUNOLOGIC FEA
   China NHCotPsRo, 2020, DIAGN TREATM GUID PN
   Choi KW, 2003, ANN INTERN MED, V139, P715, DOI 10.7326/0003-4819-139-9-200311040-00005
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Garout MA, 2018, CENT EUR J PUBL HEAL, V26, P87, DOI 10.21101/cejph.a4764
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Hong KH, 2018, THORAX, V73, P286, DOI 10.1136/thoraxjnl-2016-209313
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim YJ, 2019, INFECT DIS-NOR, V51, P502, DOI 10.1080/23744235.2019.1592217
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   LIU YS, 2020, CHIN MED J, DOI DOI 10.1097/CM9.0000000000000824
   Matsuno AK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217744
   Nikolich-Zugich J, 2018, NAT IMMUNOL, V19, P10, DOI 10.1038/s41590-017-0006-x
   Odegaard JI, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007724
   Opal SM, 2005, CLIN INFECT DIS, V41, pS504, DOI 10.1086/432007
   Patrick David M, 2006, Can J Infect Dis Med Microbiol, V17, P330
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Sun PF, 2020, J MED VIROL, V92, P1721, DOI 10.1002/jmv.25804
   Vaseghi G, 2020, CLIN CHARACTERIZATIO
   Verity R., 2020, LANCET INFECT DIS
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization (WHO), 2020, 93 WHO
   Wu C, 2020, HEART INJURY SIGNS A
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Y., 2020, EPIDEMIOLOGICAL CLIN, DOI [10.1101/2020.02.10.20021675, DOI 10.1101/2020.02.10.20021675]
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang B, 2020, CLIN CHARACTERISTICS
   Zhang G, 2020, CLIN FEATURES OUTCOM
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 37
TC 9
Z9 9
U1 10
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JUN 15
PY 2020
VL 12
IS 11
BP 10070
EP 10086
DI 10.18632/aging.103298
PG 17
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA LY5PF
UT WOS:000540580800007
PM 32499448
OA Green Published
DA 2021-01-01
ER

PT J
AU Francis, MJ
AF Francis, Michael James
TI A Veterinary Vaccine Development Process Map to assist in the
   development of new vaccines
SO VACCINE
LA English
DT Article
DE Veterinary vaccine; Vaccine development; Quality; Safety; Efficacy;
   Registration
AB The UK Government recognised the importance of vaccines in the control of new emerging disease threats and in 2015 established the UK Vaccine Network to focus on specific areas of need. One of these was the understanding of what is involved in the development of a new vaccine and what are the potential bottlenecks to a rapid response in the face of an epidemic such as Ebola, MERS and more recently COVID-19. A Working Group was established to initially produce a Vaccine Development Process Map for a Human Vaccine. However, in view of the importance of animal wellbeing and the significant impact of diseases with Zoonotic potential, a similar Map has been created outlining the Veterinary Vaccine Development Process. This paper describes the production of that Map and covers the process from the generation of a Target Product Profile (TPP) through Discovery and Feasibility, and on to Product Development and Registration. Crown Copyright (C) 2020 Published by Elsevier Ltd. All rights reserved.
C1 [Francis, Michael James] BioVacc Consulting Ltd, Red House,10 Market Sq, Amersham HP7 0DQ, England.
RP Francis, MJ (corresponding author), BioVacc Consulting Ltd, Red House,10 Market Sq, Amersham HP7 0DQ, England.
EM mike.francis@biovacc.com
CR Drury G, 2019, VACCINE, V37, P2415, DOI 10.1016/j.vaccine.2019.01.050
   Francis M. J., 2009, Veterinary pharmacovigilance: adverse reactions to veterinary medicinal products, P347, DOI 10.1002/9781444322958.ch15
   Francis MJ, 2018, VET CLIN N AM-SMALL, V48, P231, DOI 10.1016/j.cvsm.2017.10.002
   Heldens JGM, 2008, VET J, V178, P7, DOI 10.1016/j.tvjl.2007.11.009
   Jorge S, 2017, BIOTECH RES INNOV, V1, P6, DOI [10.1016/j.biori.2017.10.001, DOI 10.1016/J.BIORI.2017.10.001]
   Knight-Jones TJD, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.2839
   Noad RJ, 2019, VACCINE, V37, P6241, DOI 10.1016/j.vaccine.2019.09.009
   Woodland R, 2011, PROCEDIA VACCINOL, V5, P151, DOI 10.1016/j.provac.2011.10.013
NR 8
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUN 15
PY 2020
VL 38
IS 29
BP 4512
EP 4515
DI 10.1016/j.vaccine.2020.05.007
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LU1ZR
UT WOS:000537560500002
PM 32418794
OA Green Published
DA 2021-01-01
ER

PT J
AU Kandeel, M
   Al-Nazawi, M
AF Kandeel, Mahmoud
   Al-Nazawi, Mohammed
TI Virtual screening and repurposing of FDA approved drugs against COVID-19
   main protease
SO LIFE SCIENCES
LA English
DT Article
DE COVID-19, 2019-nCoV; 2019-Novel Coronavirus; Wuhan Coronavirus; Main
   protease; Molecular modeling
ID ACCURATE DOCKING; SARS; CORONAVIRUS; EVOLUTION; INHIBITORS; DISCOVERY;
   RIBAVIRIN; GLIDE
AB Aims: In December 2019, the Coronavirus disease-2019 (COVID-19) virus has emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure (main protease) was targeted in a virtual screening study by of FDA approved drugs dataset. In addition, a knowledge gap in relations of COVID-19 with the previously known fatal Coronaviruses (CoVs) epidemics, SARS and MERS CoVs, was covered by investigation of sequence statistics and phylogenetics.
   Materials and methods: Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the COVID-19 main protease were investigated.
   Keyfindings: COVID-19 Mpro formed a phylogenetic group with SARS CoV that was distant from MERS CoV. The identity% was 96.061 and 51.61 for COVID-19/SARS and COVID-19/MERS CoV sequence comparisons, respectively. The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. Of special interest, ribavirin had been used in treating cases of SARS CoV.
   Significance: The present study provided a comprehensive targeting of the first resolved COVID + 19 structure of Mpro and found a suitable save drugs for repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment.
C1 [Kandeel, Mahmoud; Al-Nazawi, Mohammed] King Faisal Univ, Coll Vet Med, Dept Biomed Sci, Al Hufuf 31982, Al Ahsa, Saudi Arabia.
   [Kandeel, Mahmoud] Kafrelshikh Univ, Dept Pharmacol, Fac Vet Med, Kafrelshikh 33516, Egypt.
RP Kandeel, M (corresponding author), King Faisal Univ, Coll Vet Med, Dept Biomed Sci, Al Hufuf 31982, Al Ahsa, Saudi Arabia.
EM mkandeel@kfu.edu.sa
FU Deanship of Scientific Research, King Faisal University; Research Groups
   track [1811016]
FX The authors acknowledge the Deanship of Scientific Research, King Faisal
   University for the financial support under Research Groups track (Grant
   No. 1811016).
CR Altaher Y, 2016, J BIOMOL STRUCT DYN, V34, P115, DOI 10.1080/07391102.2015.1014423
   Altaher Y, 2015, INT J PHARMACOL, V11, P243, DOI 10.3923/ijp.2015.243.247
   Crotty S, 2000, NAT MED, V6, P1375
   Desenclos JC, 2004, EMERG INFECT DIS, V10, P195, DOI 10.3201/eid1002.030351
   ElHefnawi M, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S17-S5
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Kandeel M, 2009, PARASITOLOGY, V136, P11, DOI 10.1017/S0031182008005301
   Kandeel M, 2019, LETT DRUG DES DISCOV, V16, P584, DOI 10.2174/1570180815666180918161922
   Koren G, 2003, CAN MED ASSOC J, V168, P1289
   Li WH, 2006, J VIROL, V80, P4211, DOI 10.1128/JVI.80.9.4211-4219.2006
   Li YH, 2019, ENGINEERING, V5, P940, DOI 10.1016/j.eng.2018.11.035
   Liu B, 2005, J COMPUT CHEM, V26, P484, DOI 10.1002/jcc.20186
   McKeage K, 2010, DRUGS, V70, P1857, DOI 10.2165/11204330-000000000-00000
   Murgueitio Manuela S, 2012, Drug Discov Today Technol, V9, pe219, DOI 10.1016/j.ddtec.2012.07.009
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pillaiyar T., 2020, DRUG DISCOV TODAY
   Raj U, 2016, INTERDISCIP SCI, V8, P132, DOI 10.1007/s12539-015-0109-8
   Sheikh A, 2020, J VIROL METHODS, V277, DOI 10.1016/j.jviromet.2019.113806
   Sirois S, 2004, J CHEM INF COMP SCI, V44, P1111, DOI 10.1021/ci034270n
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou ZG, 2008, ACS CHEM BIOL, V3, P765, DOI 10.1021/cb800176t
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 28
TC 57
Z9 58
U1 29
U2 122
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD JUN 15
PY 2020
VL 251
AR 117627
DI 10.1016/j.lfs.2020.117627
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA LK2VI
UT WOS:000530719800008
PM 32251634
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Shanker, AKK
   Bhanu, D
   Alluri, A
   Gupta, S
AF Shanker, Arun K. K.
   Bhanu, Divya
   Alluri, Anjani
   Gupta, Samriddhi
TI Whole-genome sequence analysis and homology modelling of the main
   protease and non-structural protein 3 of SARS-CoV-2 reveal an
   aza-peptide and a lead inhibitor with possible antiviral properties
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Article
ID RESPIRATORY SYNDROME-CORONAVIRUS; PAPAIN-LIKE PROTEASE; RNA-POLYMERASE;
   SARS-COV; REPLICATION; INSIGHTS; COMPLEX; DESIGN; UNIQUE
AB Viruses belonging to the family Coronaviridae consist of virulent pathogens that have a zoonotic property. Severe acute respiratory syndrome coronaviruses (SARS-CoVs) and Middle East respiratory syndrome coronaviruses (MERS-CoVs) of this family have emerged before and SARS-CoV-2 has emerged now globally. The characterization of spike glycoproteins, polyproteins and other viral proteins from viruses is important for antiviral drug development. Homology modelling of these proteins with known templates offers the opportunity to discover ligand-binding sites and explore the possible antiviral properties of these protein-ligand complexes. In this study, we performed a complete bioinformatic analysis, sequence alignment, comparison of multiple sequences and modelling of the SARS-CoV-2 whole-genome sequences, the spike protein and the polyproteins for homology with known proteins. We also analysed binding sites in these models for possible binding with ligands that exhibit antiviral properties. Our results indicated that the sequence of the polyprotein isolate SARS-CoV-2_HKU-SZ-001_2020 showed 98.94 percent identity to SARS-coronavirus NSP12 bound to NSP7 and NSP8 co-factors. The results also indicated that a part of the viral genome (residues 3268-3573 in Frame 2 with 306 amino acids) of the SARS-CoV-2 isolate Wuhan-Hu-1 (GenBank Accession Number MN908947.3) when modelled with template 2a5i of the PDB database showed 96 percent identity to a 3C-like peptidase of SARS-CoVs, which has the ability to bind with an aza-peptide epoxide (APE) known for the irreversible inhibition of SARS-CoV main peptidase. A docking profile with 9 different conformations of the ligand with the protein model using Autodock Vina showed an affinity of -7.1 kcal mol(-1). This region was conserved in 831 genomes of SARS-CoV-2. The part of the genome (residues 1568-1882 in Frame 2 with 315 amino acids) when modelled with template ; 3e9s of the PDB database showed 82 percent identity to a papain-like protease/deubiquitinase, which when complexed with ligand GRL0617 acts as an inhibitor and can block SARS-CoV replication. A docking profile with 9 different conformations of the ligand with the protein model using Autodock Vina showed an affinity of -7.9 kcal mol(-1). This region was conserved in 831 genomes of SARS-CoV-2. It is possible that these ligands can be used as antivirals of SARS-CoV-2.
C1 [Shanker, Arun K. K.; Bhanu, Divya] ICAR Cent Res Inst Dryland Agr, Hyderabad 500059, India.
   [Bhanu, Divya] Osmania Univ, Ctr Plant Mol Biol, Hyderabad, India.
   [Alluri, Anjani] Acharya NG Ranga Agr Univ, Adv Post Grad Ctr, Guntur, Andhra Pradesh, India.
   [Gupta, Samriddhi] Univ Hyderabad, Sch Life Sci, Dept Biochem, Hyderabad, India.
RP Shanker, AKK (corresponding author), ICAR Cent Res Inst Dryland Agr, Hyderabad 500059, India.
EM arunshank@gmail.com
RI Shanker, Arun K./C-4779-2009
OI Shanker, Arun K./0000-0001-5635-878X
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Bae JE, 2018, BIOCHEM BIOPH RES CO, V497, P368, DOI 10.1016/j.bbrc.2018.02.086
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Benson DA, 2000, NUCLEIC ACIDS RES, V28, P15, DOI 10.1093/nar/28.1.15
   Biasini M, 2013, ACTA CRYSTALLOGR D, V69, P701, DOI 10.1107/S0907444913007051
   Chaudhuri R, 2011, J MOL BIOL, V414, P272, DOI 10.1016/j.jmb.2011.09.030
   Chen YF, 2015, J BIOL CHEM, V290, P25293, DOI 10.1074/jbc.M115.662130
   Daczkowski CM, 2017, J MOL BIOL, V429, P1661, DOI 10.1016/j.jmb.2017.04.011
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   de Wit E, 2013, P NATL ACAD SCI USA, V110, P16598, DOI 10.1073/pnas.1310744110
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Egloff MP, 2004, P NATL ACAD SCI USA, V101, P3792, DOI 10.1073/pnas.0307877101
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Hall T., 2011, GERF B BIOSCI, V2, P60, DOI DOI 10.1017/S0317167100012865
   King RW, 2014, NAT CHEM BIOL, V10, P870, DOI 10.1038/nchembio.1671
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Kumar T.A., 2013, WIDE SPECTRUM, V1, P15, DOI DOI 10.5281/ZENODO.50733
   Laskowski RA, 1997, TRENDS BIOCHEM SCI, V22, P488, DOI 10.1016/S0968-0004(97)01140-7
   Lee TW, 2005, J MOL BIOL, V353, P1137, DOI 10.1016/j.jmb.2005.09.004
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Luo CM, 2018, J VIROL, V92, DOI 10.1128/JVI.00116-18
   Mansour M, 2017, EGYPT J ARCHAEOL RES, V7, P1
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Mukherjee P, 2008, BIOORGAN MED CHEM, V16, P4138, DOI 10.1016/j.bmc.2008.01.011
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Schauer NJ, 2020, J MED CHEM, V63, P2731, DOI 10.1021/acs.jmedchem.9b01138
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Subissi L, 2014, ANTIVIR RES, V101, P122, DOI 10.1016/j.antiviral.2013.11.006
   Sulea T, 2005, J VIROL, V79, P4550, DOI 10.1128/JVI.79.7.4550-4551.2005
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Velthuis AJWT, 2012, NUCLEIC ACIDS RES, V40, P1737, DOI 10.1093/nar/gkr893
   Velthuis AJWT, 2010, NUCLEIC ACIDS RES, V38, P203, DOI 10.1093/nar/gkp904
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   World Health Organization, 2020, COR
   Yost SA, 2013, CURR OPIN VIROL, V3, P137, DOI 10.1016/j.coviro.2013.03.009
NR 43
TC 4
Z9 4
U1 2
U2 2
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144-0546
EI 1369-9261
J9 NEW J CHEM
JI New J. Chem.
PD JUN 14
PY 2020
VL 44
IS 22
BP 9202
EP 9212
DI 10.1039/d0nj00974a
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA LZ0NT
UT WOS:000540929200008
OA Bronze
DA 2021-01-01
ER

PT J
AU Rath, D
   Petersen-Uribe, A
   Avdiu, A
   Witzel, K
   Jaeger, P
   Zdanyte, M
   Heinzmann, D
   Tavlaki, E
   Muller, K
   Gawaz, MP
AF Rath, Dominik
   Petersen-Uribe, Alvaro
   Avdiu, Alban
   Witzel, Katja
   Jaeger, Philippa
   Zdanyte, Monika
   Heinzmann, David
   Tavlaki, Elli
   Mueller, Karin
   Gawaz, Meinrad Paul
TI Impaired cardiac function is associated with mortality in patients with
   acute COVID-19 infection
SO CLINICAL RESEARCH IN CARDIOLOGY
LA English
DT Article
DE COVID-19; Cardiac function; Prognosis; Cardiovascular disease; Heart
   failure
ID EUROPEAN ASSOCIATION; ECHOCARDIOGRAPHY RECOMMENDATIONS
AB Background COVID-19 infection may cause severe respiratory distress and is associated with increased morbidity and mortality. Impaired cardiac function and/or pre-existing cardiovascular disease may be associated with poor prognosis. In the present study, we report a comprehensive cardiovascular characterization in the first consecutive collective of patients that was admitted and treated at the University Hospital of Tubingen, Germany. Methods 123 consecutive patients with COVID-19 were included. Routine blood sampling, transthoracic echocardiography and electrocardiography were performed at hospital admission. Results We found that impaired left-ventricular and right-ventricular function as well as tricuspid regurgitation > grade 1 were significantly associated with higher mortality. Furthermore, elevated levels of myocardial distress markers (troponin-I and NT pro-BNP) were associated with poor prognosis in this patient collective. Conclusion Impaired cardiac function is associated with poor prognosis in COVID-19 positive patients. Consequently, treatment of these patients should include careful guideline-conform cardiovascular evaluation and treatment. Thus, formation of a competent Cardio-COVID-19 team may represent a major clinical measure to optimize therapy of cardiovascular patients during this pandemic.
C1 [Rath, Dominik; Petersen-Uribe, Alvaro; Avdiu, Alban; Witzel, Katja; Jaeger, Philippa; Zdanyte, Monika; Heinzmann, David; Tavlaki, Elli; Mueller, Karin; Gawaz, Meinrad Paul] Eberhard Karls Univ Tubingen, Univ Hosp Tubingen, Dept Cardiol & Angiol, Otfried Muller Str 10, D-72076 Tubingen, Germany.
RP Gawaz, MP (corresponding author), Eberhard Karls Univ Tubingen, Univ Hosp Tubingen, Dept Cardiol & Angiol, Otfried Muller Str 10, D-72076 Tubingen, Germany.
EM meinrad.gawaz@med.uni-tuebingen.de
FU German Research Foundation (DFG)German Research Foundation (DFG)
   [374031971-TRR 240]
FX This project was supported by the German Research Foundation
   (DFG)-Project number 374031971-TRR 240.
CR [Anonymous], 2001, J Postgrad Med, V47, P199
   [Anonymous], 1997, Cardiovasc Res, V35, P2
   [Anonymous], 2002, Med Etika Bioet, V9, P12
   Bajwa EK, 2007, CRIT CARE MED, V35, P2484, DOI 10.1097/01.CCM.0000281852.36573.22
   Barnett R, 2019, LANCET, V393, P396, DOI 10.1016/S0140-6736(19)30148-5
   Deng Q, 2020, INT J CARDIOL, V311, P116, DOI 10.1016/j.ijcard.2020.03.087
   European Society of Cardiology, 2020, ESC GUID DIAGN MAN C
   Ikonomidis I, 2019, CLIN RES CARDIOL, V108, P1093, DOI 10.1007/s00392-019-01443-9
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Kobayashi M, 2020, CLIN RES CARDIOL, V109, P1392, DOI 10.1007/s00392-020-01639-4
   Lakkireddy DR, 2020, HEART RHYTHM, V17, pE233, DOI 10.1016/j.hrthm.2020.03.028
   Lancellotti P, 2010, EUR J ECHOCARDIOGR, V11, P307, DOI 10.1093/ejechocard/jeq031
   Lancellotti P, 2010, EUR J ECHOCARDIOGR, V11, P223, DOI 10.1093/ejechocard/jeq030
   Lang RM, 2015, J AM SOC ECHOCARDIOG, V28, P1, DOI 10.1016/j.echo.2014.10.003
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li GR, 2020, CLIN RES CARDIOL, DOI 10.1007/s00392-020-01653-6
   Lippi G, 2020, PROG CARDIOVASC DIS, V63, P390, DOI 10.1016/j.pcad.2020.03.001
   MAHASE E, 2020, BMJ-BRIT MED J, V368, P48071, DOI DOI 10.1136/BMJ.M641
   Nishimura RA, 2014, J AM COLL CARDIOL, V63, P2438, DOI 10.1016/j.jacc.2014.02.537
   Oren O, 2020, CORONAVIRUS DIS 2019
   Parasuraman S, 2016, IJC HEART VASC, V12, P45, DOI 10.1016/j.ijcha.2016.05.011
   Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Solaimanzadeh I, 2020, CUREUS, V12, DOI 10.7759/cureus.7343
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 26
TC 10
Z9 10
U1 3
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1861-0684
EI 1861-0692
J9 CLIN RES CARDIOL
JI Clin. Res. Cardiol.
PD DEC
PY 2020
VL 109
IS 12
SI SI
BP 1491
EP 1499
DI 10.1007/s00392-020-01683-0
EA JUN 2020
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OX4ZR
UT WOS:000540204400001
PM 32537662
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Bakkar, S
   Al-Omar, K
   Aljarrah, Q
   Al-Dabbas, M
   Al-Dabbas, N
   Samara, S
   Miccoli, P
AF Bakkar, Sohail
   Al-Omar, Khaled
   Aljarrah, Qusai
   Al-Dabbas, Moh'd
   Al-Dabbas, Nesrin
   Samara, Samara
   Miccoli, Paolo
TI Impact of COVID-19 on thyroid cancer surgery and adjunct therapy
SO UPDATES IN SURGERY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Pandemic; Thyroid surgery
AB COVID-19 has profoundly modified the way healthcare is delivered. Jordan imposed lockdown and restrictive policies between March 17 and May 20, 2020. We aimed to assess the impact of such measures on thyroid cancer treatment plans. In the specified period, 12 patients were scheduled for surgery. Since papillary carcinoma was the preoperative diagnosis in all cases, radioactive iodine ablation (RIA) therapy was also planned 3-4 weeks following surgery after withdrawing thyroxine and achieving a thyroid stimulating hormone (TSH) level > 30 mU/L. Thyroxine withdrawal is the routine method applied for RIA in Jordan as it is less costly compared to the rapid method of exogenous stimulation using recombinant TSH. All surgical procedures were performed without delay since all patients were asymptomatic per flu-like illness and came from a region of low COVID-19 prevalence. These included total thyroidectomy (n = 11), bilateral therapeutic central compartment neck dissection (n = 7), lateral compartment neck dissection (n = 5). However, the RIA treatment plan was altered considerably according to the period in which they were operated. 6 out of the 7 patients operated in March changed to the stimulated method of RIA at a considerable additional extra cost. The seventh patient and the April patient opt to delay RIA until after lockdown. The remaining cases (operated in May) followed the usual withdrawal method as restrictions were due to an end. The restrictive measures applied during COVID-19 did not affect the safe and timely delivery of surgical care. However, it added a financial and psychological burden to the entire cancer management plan.
C1 [Bakkar, Sohail; Al-Omar, Khaled] Hashemite Univ, Fac Med, Dept Surg, Zarqa 13133, Jordan.
   [Aljarrah, Qusai] Jordan Univ Sci & Technol, Fac Med, Dept Surg, Irbid 22110, Jordan.
   [Al-Dabbas, Moh'd; Al-Dabbas, Nesrin; Samara, Samara] Farah Med Campus FMC, Amman 11183, Jordan.
   [Miccoli, Paolo] Univ Pisa, Dept Surg Med Pathol & Crit Care, I-56124 Pisa, Italy.
RP Bakkar, S (corresponding author), Hashemite Univ, Fac Med, Dept Surg, Zarqa 13133, Jordan.
EM sohail.bakkar@gmail.com
RI Bakkar, Sohail/I-9838-2019
OI Bakkar, Sohail/0000-0001-8479-5901
CR Al-Omar K, 2020, UPDATES SURG, V72, P291, DOI 10.1007/s13304-020-00822-6
   American College of Surgeons (ACS), 2020, COVID 19 UPD GUID TR
   Commins J, 2020, SURGEON GEN URGES PR, P2020
   Fayed L, 2020, INSURANCE COVERAGE T
   HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x
   Kowalska A, 2015, THYROID RES, V8, pA16, DOI [10.1186/1756-6614-8-S1-A16, DOI 10.1186/1756-6614-8-S1-A16]
   Miccoli P, 2017, UPDATES SURG, V69, P145, DOI 10.1007/s13304-017-0449-5
   Stahel PF, 2020, PATIENT SAF SURG, V14, DOI 10.1186/s13037-020-00235-9
   SUTHERLAND ARTHUR M., 1957, BULL NEW YORK ACAD MED, V33, P428
NR 9
TC 1
Z9 1
U1 6
U2 6
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 2038-131X
EI 2038-3312
J9 UPDATES SURG
JI Updates Surg.
PD SEP
PY 2020
VL 72
IS 3
BP 867
EP 869
DI 10.1007/s13304-020-00833-3
EA JUN 2020
PG 3
WC Surgery
SC Surgery
GA NN4SN
UT WOS:000540192500001
PM 32537687
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Cozzi, E
   Faccioli, E
   Marinello, S
   Loy, M
   Congedi, S
   Calabrese, F
   Romagnoli, M
   Cattelan, AM
   Rea, F
AF Cozzi, Emanuele
   Faccioli, Eleonora
   Marinello, Serena
   Loy, Monica
   Congedi, Sabrina
   Calabrese, Fiorella
   Romagnoli, Micaela
   Cattelan, Anna M.
   Rea, Federico
TI COVID-19 pneumonia in lung transplant recipients: Report of 2 cases
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical research; practice; immunosuppressant; immunosuppression;
   immune modulation; infection and infectious agents - viral; lung
   disease; infectious; lung transplantation; pulmonology
AB Coronavirus disease 2019 (COVID-19) has been declared pandemic since March 2020. In Europe, Italy was the first nation affected by this infection. We report anamnestic data, clinical features, and therapeutic management of 2 lung transplant recipients with confirmed COVID-19 pneumonia. Both patients were in good clinical condition before the infection and were receiving immunosuppression with calcineurin inhibitors (CNI), mycophenolate mofetil, and corticosteroids. Whereas mycophenolate mofetil was withdrawn in both cases, CNI were suspended only in the second patient. The first patient always maintained excellent oxygen saturation throughout hospitalization with no need for additional oxygen therapy. He was discharged with a satisfactory pulmonary function and a complete resolution of radiological and clinical findings. However, at discharge SARS-CoV-2 RNA could still be detected in the nasopharyngeal swab and in the stools. The second patient required mechanical ventilation, had a progressive deterioration of his clinical conditions, and had a fatal outcome. Further insight into SARS-CoV-2 infection is eagerly awaited to improve the outcome of transplant recipients affected by COVID-19 pneumonia.
C1 [Cozzi, Emanuele] Univ Padua, Dept Cardiothorac Vasc Sci & Publ Hlth, Padua, Italy.
   [Cozzi, Emanuele] Padova Univ Hosp, Transplant Immunol Unit, Padua, Italy.
   [Cozzi, Emanuele] Natl Transplant Ctr, Rome, Italy.
   [Faccioli, Eleonora; Loy, Monica; Rea, Federico] Padova Univ Hosp, Thorac Surg & Lung Transplant Ctr, Dept Cardiothorac Vasc Sci & Publ Hlth, Padua, Italy.
   [Marinello, Serena; Cattelan, Anna M.] Padova Univ Hosp, Div Infect & Trop Dis, Padua, Italy.
   [Congedi, Sabrina] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy.
   [Calabrese, Fiorella] Padova Univ Hosp, Dept Cardiothorac Vasc Sci & Publ Hlth, Pathol Anat Unit, Padua, Italy.
   [Romagnoli, Micaela] Osped Ca Foncello, Pulmonol Unit, AULSS2 Marca Trevigiana, Treviso, Italy.
RP Cozzi, E (corresponding author), Univ Padua, Dept Cardiothorac Vasc Sci & Publ Hlth, Padua, Italy.; Cozzi, E (corresponding author), Padova Univ Hosp, Transplant Immunol Unit, Padua, Italy.; Cozzi, E (corresponding author), Natl Transplant Ctr, Rome, Italy.
EM emanuele.cozzi@unipd.it
CR Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
   AlGhamdi M, 2015, AM J TRANSPLANT, V15, P1101, DOI 10.1111/ajt.13085
   [Anonymous], 2020, WHO CORONAVIRUS DIS
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Bussalino E, 2020, AM J TRANSPLANT, V20, P1922, DOI 10.1111/ajt.15920
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang JF, 2020, AM J TRANSPLANT, V20, P1907, DOI 10.1111/ajt.15909
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Italian Ministry of Health, 2020, ITALIAN MINISTRY HLT
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Liu B, 2020, AM J TRANSPLANT, V20, P1891, DOI 10.1111/ajt.15901
   Ning L, 2020, AM J TRANSPLANT, V20, P1864, DOI 10.1111/ajt.15897
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Qin JJ, 2020, HEPATOLOGY, V72, P1491, DOI 10.1002/hep.31257
   Seminari E, 2020, AM J TRANSPLANT, V20, P1882, DOI 10.1111/ajt.15902
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou B, 2020, J THROMB THROMBOLYS, V50, P229, DOI 10.1007/s11239-020-02084-w
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 20
TC 7
Z9 7
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD OCT
PY 2020
VL 20
IS 10
BP 2933
EP 2937
DI 10.1111/ajt.15993
EA JUN 2020
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA NU4CB
UT WOS:000539963500001
PM 32400074
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hwang, ES
   Balch, CM
   Balch, GC
   Feldman, SM
   Golshan, M
   Grobmyer, SR
   Libutti, SK
   Margenthaler, JA
   Sasidhar, M
   Turaga, KK
   Wong, SL
   McMasters, KM
   Tanabe, KK
AF Hwang, E. Shelley
   Balch, Charles M.
   Balch, Glen C.
   Feldman, Sheldon M.
   Golshan, Mehra
   Grobmyer, Stephen R.
   Libutti, Steven K.
   Margenthaler, Julie A.
   Sasidhar, Madhu
   Turaga, Kiran K.
   Wong, Sandra L.
   McMasters, Kelly M.
   Tanabe, Kenneth K.
TI Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients
   Effectively through Turbulence and Change
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
AB Background The COVID-19 pandemic has posed extraordinary demands from patients, providers, and health care systems. Despite this, surgical oncologists must maintain focus on providing high-quality, empathetic care for the almost 2 million patients nationally who will be diagnosed with operable cancer this year. The focus of hospitals is transitioning from initial COVID-19 preparedness activities to a more sustained approach to cancer care. Methods Editorial Board members provided observations of the implications of the pandemic on providing care to surgical oncology patients. Results Strategies are presented that have allowed institutions to successfully prepare for cancer care during COVID-19, as well as other strategies that will help hospitals and surgical oncologists manage anticipated challenges in the near term. Perspectives are provided on: (1) maintaining a safe environment for surgical oncology care; (2) redirecting the multidisciplinary model to guide surgical decisions; (3) harnessing telemedicine to accommodate requisite physical distancing; (4) understanding interactions between SARS CoV-2 and cancer therapy; (5) considering the ethical impact of professional guidelines for surgery prioritization; and (6) advocating for our patients who require oncologic surgery in the midst of the COVID-19 pandemic. Conclusions Until an effective vaccine becomes available for widespread use, it is imperative that surgical oncologists remain focused on providing optimal care for our cancer patients while managing the demands that the COVID-19 pandemic will continue to impose on all of us.
C1 [Hwang, E. Shelley] Duke Univ, Dept Surg, Durham, NC USA.
   [Hwang, E. Shelley] Duke Canc Inst, Durham, NC USA.
   [Balch, Charles M.] Univ Texas MD Anderson Canc Ctr, Div Surg Oncol, Houston, TX 77030 USA.
   [Balch, Glen C.] Emory Univ, Dept Surg, Atlanta, GA USA.
   [Feldman, Sheldon M.] Montefiore Einstein Ctr Canc Care, Dept Surg, Bronx, NY USA.
   [Golshan, Mehra] Brigham & Womens Hosp, Dept Surg, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
   [Grobmyer, Stephen R.; Sasidhar, Madhu] Cleveland Clin Abu Dhabi, Oncol Inst, Abu Dhabi, U Arab Emirates.
   [Grobmyer, Stephen R.; Sasidhar, Madhu] Cleveland Clin Abu Dhabi, Pulm & Crit Care Med Inst, Abu Dhabi, U Arab Emirates.
   [Libutti, Steven K.] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
   [Margenthaler, Julie A.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
   [Turaga, Kiran K.] Univ Chicago, Pritzker Sch Med, Dept Surg, Chicago, IL 60637 USA.
   [Wong, Sandra L.] Geisel Sch Med, Dept Surg, Hanover, NH USA.
   [McMasters, Kelly M.] Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA.
   [Tanabe, Kenneth K.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
RP Tanabe, KK (corresponding author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
EM ktanabe@partners.org
OI Balch, Glen/0000-0002-1575-9170
CR Akladios C, 2020, J GYNECOL OBSTET HUM, V49, DOI 10.1016/j.jogoh.2020.101729
   American Academy of Otolaryngology-Head and Neck Surgery, 2020, AAO HNS PO STAT OT C
   American College of Surgeons, COVID 19 GUID TRIAG
   American College of Surgeons, COVID 19 EL CAS TRIA
   American Society of Anesthesiologists, 2020, COVID 19 FAQS 2020
   Antonoff M, 2020, ANN THORAC SURG, V110, P692, DOI 10.1016/j.athoracsur.2020.03.005
   Asiri Abdulmajid, 2018, Acta Inform Med, V26, P201, DOI 10.5455/aim.2018.26.201-206
   Bartlett DL, 2020, ANN SURG ONCOL, V27, P1717, DOI 10.1245/s10434-020-08461-2
   Berlinger N, 2020, ETHICAL FRAMEWORK HL, P1
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Bleicher RJ, 2018, ANN SURG ONCOL, V25, P2829, DOI 10.1245/s10434-018-6615-2
   Carolan A, 1919, CANC LETT
   Center for Medicare and Medicaid Services, MED TEL HLTH CAR PRO
   Chen Z, 2008, RADIOTHER ONCOL, V87, P3, DOI 10.1016/j.radonc.2007.11.016
   Cook TM, 2020, ANAESTHESIA
   European Society for Medical Oncology, CANC PAT MAN COVID 1
   Federation of State Medical Boards, 2020, STAT MOD REQ TEL RES
   Grass F, 2020, EJSO-EUR J SURG ONC, V46, P455, DOI 10.1016/j.ejso.2019.11.513
   Hsu T., 2020, NY TIMES
   Kaltenmeier Christof, 2019, Ann Surg, DOI 10.1097/SLA.0000000000003745
   Kane CK, 2018, HEALTH AFFAIR, V37, P1923, DOI 10.1377/hlthaff.2018.05077
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Marron JM, 2020, J CLIN ONCOL, V38, P2201, DOI 10.1200/JCO.20.00960
   Mazzaferro V, 2020, ANN SURG
   National Institutes of Health NCI Surveillance Epidemiology and End Results Program, 2020, CANC STAT FACTS COMM
   Shankar Abhishek, 2020, Asian Pac J Cancer Prev, V21, P569, DOI 10.31557/APJCP.2020.21.3.569
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Sidaway P, 2020, NAT REV CLIN ONCOL, DOI 10.1038/s41571-020-0366-2
   Tate C, 2020, US TODAY
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Topf MC, 2020, HEAD NECK-J SCI SPEC, V42, P1159, DOI 10.1002/hed.26184
   U.S. Food and Drug Administration, 2020, FDA GUID COND CLIN T
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   University of New Mexico Health Science Center ECHO Institute, 2020, PROJ ECH 2020
   Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Yang S, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.66
   Yu J, 2020, JAMA ONCOL
   Yuen E, 2020, ORAL ONCOL, V105, DOI 10.1016/j.oraloncology.2020.104738
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 42
TC 1
Z9 1
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD AUG
PY 2020
VL 27
IS 8
BP 2600
EP 2613
DI 10.1245/s10434-020-08673-6
EA JUN 2020
PG 14
WC Oncology; Surgery
SC Oncology; Surgery
GA MF1WT
UT WOS:000539937800005
PM 32535870
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Arshad, U
   Pertinez, H
   Box, H
   Tatham, L
   Rajoli, RKR
   Curley, P
   Neary, M
   Sharp, J
   Liptrott, NJ
   Valentijn, A
   David, C
   Rannard, SP
   O'Neill, PM
   Aljayyoussi, G
   Pennington, SH
   Ward, SA
   Hill, A
   Back, DJ
   Khoo, SH
   Bray, PG
   Biagini, GA
   Owen, A
AF Arshad, Usman
   Pertinez, Henry
   Box, Helen
   Tatham, Lee
   Rajoli, Rajith K. R.
   Curley, Paul
   Neary, Megan
   Sharp, Joanne
   Liptrott, Neill J.
   Valentijn, Anthony
   David, Christopher
   Rannard, Steve P.
   O'Neill, Paul M.
   Aljayyoussi, Ghaith
   Pennington, Shaun H.
   Ward, Stephen A.
   Hill, Andrew
   Back, David J.
   Khoo, Saye H.
   Bray, Patrick G.
   Biagini, Giancarlo A.
   Owen, Andrew
TI Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based
   on Plasma and Target Site Concentrations Derived from their Established
   Human Pharmacokinetics
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID RESISTANT PLASMODIUM-FALCIPARUM; STEADY-STATE PHARMACOKINETICS; PROTEASE
   INHIBITOR NELFINAVIR; TISSUE DISTRIBUTION; DOUBLE-BLIND; HIV;
   NITAZOXANIDE; INDOMETHACIN; REPLICATION; CHLOROQUINE
AB There is a rapidly expanding literature on thein vitroantiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). However, this has not been accompanied by a comprehensive evaluation of the target plasma and lung concentrations of these drugs following approved dosing in humans. Accordingly, concentration 90% (EC90) values recalculated fromin vitroanti-SARS-CoV-2 activity data was expressed as a ratio to the achievable maximum plasma concentration (C-max) at an approved dose in humans (C-max/EC(90)ratio). Only 14 of the 56 analyzed drugs achieved a C-max/EC(90)ratio above 1. A more in-depth assessment demonstrated that only nitazoxanide, nelfinavir, tipranavir (ritonavir-boosted), and sulfadoxine achieved plasma concentrations above their reported anti-SARS-CoV-2 activity across their entire approved dosing interval. An unbound lung to plasma tissue partition coefficient (KpUlung) was also simulated to derive a lung C-max/half-maximal effective concentration (EC50) as a better indicator of potential human efficacy. Hydroxychloroquine, chloroquine, mefloquine, atazanavir (ritonavir-boosted), tipranavir (ritonavir-boosted), ivermectin, azithromycin, and lopinavir (ritonavir-boosted) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC50. Nitazoxanide and sulfadoxine also exceeded their reported EC(50)by 7.8-fold and 1.5-fold in lung, respectively. This analysis may be used to select potential candidates for further clinical testing, while deprioritizing compounds unlikely to attain target concentrations for antiviral activity. Future studies should focus on EC(90)values and discuss findings in the context of achievable exposures in humans, especially within target compartments, such as the lungs, in order to maximize the potential for success of proposed human clinical trials.
C1 [Arshad, Usman; Pertinez, Henry; Box, Helen; Tatham, Lee; Rajoli, Rajith K. R.; Curley, Paul; Neary, Megan; Sharp, Joanne; Liptrott, Neill J.; Valentijn, Anthony; David, Christopher; Hill, Andrew; Back, David J.; Khoo, Saye H.; Owen, Andrew] Univ Liverpool, Dept Mol & Clin Pharmacol, Mat Innovat Factory, Liverpool, Merseyside, England.
   [Rannard, Steve P.; O'Neill, Paul M.] Univ Liverpool, Dept Chem, Liverpool, Merseyside, England.
   [Aljayyoussi, Ghaith; Pennington, Shaun H.; Ward, Stephen A.; Biagini, Giancarlo A.] Univ Liverpool Liverpool Sch Trop Med, Dept Trop Dis Biol, Liverpool, Merseyside, England.
   [Bray, Patrick G.] Pat Bray Elect, Wigan, England.
RP Owen, A (corresponding author), Univ Liverpool, Dept Mol & Clin Pharmacol, Mat Innovat Factory, Liverpool, Merseyside, England.
EM aowen@liverpool.ac.uk
RI Ward, Steve/G-6003-2015
OI Ward, Steve/0000-0003-2331-3192; Pennington, Shaun/0000-0002-7160-6275;
   Arshad, Usman/0000-0003-1586-1885; Liptrott, Neill/0000-0002-5980-8966
FU EPSRCEngineering & Physical Sciences Research Council (EPSRC)
   [EP/R024804/1, EP/S012265/1]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01AI134091,
   R24AI118397]; European CommissionEuropean CommissionEuropean Commission
   Joint Research Centre [761104]; Medical Research CouncilMedical Research
   Council UK (MRC) [MR/S00467X/1]; MRC Skills Development Fellowship;
   Unitaid (project LONGEVITY)
FX The authors received no funding for the current work. A.O. acknowledges
   research funding from EPSRC (EP/R024804/1; EP/S012265/1), NIH
   (R01AI134091; R24AI118397), European Commission (761104), and Unitaid
   (project LONGEVITY). G.A.B. acknowledges support from the Medical
   Research Council (MR/S00467X/1). G.A. acknowledges funding from the MRC
   Skills Development Fellowship.
CR Amici C, 2015, CELL MICROBIOL, V17, P1391, DOI 10.1111/cmi.12446
   Anderson VR, 2007, DRUGS, V67, P1947, DOI 10.2165/00003495-200767130-00015
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bojkova D., 2020, SARS COV 2 SARS COV, DOI [10.1101/2020.04.03.024257., DOI 10.1101/2020.04.03.024257, 10.1101/2020.04.03.024257]
   Browning DJ, 2014, HYDROXYCHLOROQUINE C, P35, DOI DOI 10.1007/978-1-4939-0597-3_2
   Bukreyeva N, 2020, J BIORXIV, DOI [10.1101/2020.04.07.028589, DOI 10.1101/2020.04.07.028589]
   Burger DM, 2006, ANTIMICROB AGENTS CH, V50, P3336, DOI 10.1128/AAC.00461-06
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chan-Tack KM, 2008, AIDS PATIENT CARE ST, V22, P843, DOI 10.1089/apc.2008.0043
   Chandrasekaran A, 2010, XENOBIOTICA, V40, P578, DOI 10.3109/00498254.2010.492879
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Chen W, 2017, CELL SIGNAL, V41, P89, DOI 10.1016/j.cellsig.2017.04.001
   Chen X., 2020, DETECTABLE SERUM SAR, DOI [10.1101/2020.02.29.20029520, DOI 10.1101/2020.02.29.20029520]
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Clerici M, 2011, J IMMUNOL, V186
   Corbett AH, 2002, ANN PHARMACOTHER, V36, P1193
   Damle B, 2008, ANTIMICROB AGENTS CH, V52, P2673, DOI 10.1128/AAC.01596-07
   de Kock M, 2017, CPT-PHARMACOMET SYST, V6, P430, DOI 10.1002/psp4.12181
   Diao B.H., J MEDRXIV, DOI [10.1101/2020.03.04.20031120, DOI 10.1101/2020.03.04.20031120]
   Drachman N, 2017, MAGN RESON MED, V78, P1121, DOI 10.1002/mrm.26473
   Fintelman-Rodrigues N., 2020, BIORXIV, DOI [10.1101/2020.04.04.020925, DOI 10.1101/2020.04.04.020925]
   FITCH CD, 1974, ANTIMICROB AGENTS CH, V6, P757, DOI 10.1128/AAC.6.6.757
   Flexner C, 2005, NAT REV DRUG DISCOV, V4, P955, DOI 10.1038/nrd1907
   Fox LM, 2005, CLIN INFECT DIS, V40, P1173, DOI 10.1086/428839
   Garnock-Jones KP, 2011, DRUGS, V71, P1333, DOI 10.2165/11207390-000000000-00000
   Gassen NC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13659-4
   Ge Y, 2020, BIORXIV, DOI [10.1101/2020.03.11.986836, DOI 10.1101/2020.03.11.986836]
   GEARY TG, 1990, BIOCHEM PHARMACOL, V40, P685, DOI 10.1016/0006-2952(90)90302-2
   Gekonge B, 2015, AIDS RES HUM RETROV, V31, P237, DOI 10.1089/aid.2014.0015
   GINSBURG H, 1989, BIOCHEM PHARMACOL, V38, P2645, DOI 10.1016/0006-2952(89)90550-9
   Goel P., 2020, STATPEARLS
   Gonzalez D, 2013, CLIN MICROBIOL REV, V26, P274, DOI 10.1128/CMR.00092-12
   Grein J., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2007016, DOI 10.1056/NEJM0A2007016]
   Gu JY, 2020, GASTROENTEROLOGY, V158, P1518, DOI 10.1053/j.gastro.2020.02.054
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Gupta A, 2017, MOL PHARMACEUT, V14, P1204, DOI 10.1021/acs.molpharmaceut.6b01089
   Haffizulla J, 2014, LANCET INFECT DIS, V14, P609, DOI 10.1016/S1473-3099(14)70717-0
   Harrison TS, 2005, DRUGS, V65, P2309
   Hickson SE, 2018, VIROLOGY, V518, P398, DOI 10.1016/j.virol.2018.03.023
   Hirani VN, 2004, DRUG METAB DISPOS, V32, P1462, DOI 10.1124/dmd.104.001743
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   James J S, 1997, AIDS Treat News, P1
   Jeon S., 2020, IDENTIFICATION ANTIV, DOI [10.1101/ 2020.03.20.999730., DOI 10.1101/2020.03.20.999730, 10.1101/2020.03.20.999730.]
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jurgeit A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002976
   Justice AC, 2008, CLIN INFECT DIS, V47, P1226, DOI 10.1086/592302
   Kawai R, 1998, J PHARMACOL EXP THER, V287, P457
   King JR, 2006, CLIN PHARMACOKINET, V45, P665, DOI 10.2165/00003088-200645070-00003
   Krudsood S, 2010, ANTIMICROB AGENTS CH, V54, P3730, DOI 10.1128/AAC.01187-09
   Kruse G, 2005, ANTIVIR THER, V10, P349
   La Porte CJL, 2009, ANTIMICROB AGENTS CH, V53, P4840, DOI 10.1128/AAC.00462-09
   Li R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074670
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   LIEN EA, 1991, CANCER RES, V51, P4837
   Lin CK, 2016, ONCOTARGET, V7, P8993, DOI 10.18632/oncotarget.7113
   Liu P, 2013, ANTIMICROB AGENTS CH, V57, P1672, DOI 10.1128/AAC.02139-12
   Liu Y., LANCET INFECT DIS, DOI [10.1016/S473-3099(20)30232-2, DOI 10.1016/S473-3099(20)30232-2]
   Lovegrove F.E., 2008, TRAVEL TROPICAL MED, P76
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Lv ZT, 2015, HIV AIDS-RES PALLIAT, V7, P95, DOI 10.2147/HIV.S79956
   Markowitz M, 2007, JAIDS-J ACQ IMM DEF, V45, P401, DOI 10.1097/QAI.0b013e318074eff5
   MCCHESNEY EW, 1967, TOXICOL APPL PHARM, V10, P501, DOI 10.1016/0041-008X(67)90089-0
   McHutchison JG, 2005, ANTIVIR THER, V10, P635
   Miller DS, 2013, LAB ANIM-UK, V47, P74, DOI 10.1258/la.2012.011157
   MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451
   Miner K, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00051
   Moss L, 2015, XENOBIOTICA, V45, P60, DOI 10.3109/00498254.2014.942409
   Motoya T, 2006, HIV MED, V7, P122, DOI 10.1111/j.1468-1293.2006.00356.x
   Murdoch D, 2004, DRUGS, V64, P2249, DOI 10.2165/00003495-200464190-00011
   NABANGCHANG K, 1994, BRIT J CLIN PHARMACO, V38, P278, DOI 10.1111/j.1365-2125.1994.tb04354.x
   Nalamachu S, 2014, POSTGRAD MED, V126, P92, DOI 10.3810/pgm.2014.07.2787
   Orman JS, 2008, DRUGS, V68, P1435, DOI 10.2165/00003495-200868100-00006
   Pharmaceuticals and Medical Devices Agency, 2018, REP DEL RES XOSP TAB
   Pharmaceuticals and Medical Devices Agency (PMDA), 2014, REP DEL RES
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Porche D J, 1997, J Assoc Nurses AIDS Care, V8, P81, DOI 10.1016/S1055-3290(97)80061-1
   Price RN, 1997, T ROY SOC TROP MED H, V91, P574, DOI 10.1016/S0035-9203(97)90032-8
   Pugin J, 2008, AM J RESP CELL MOL, V38, P362, DOI 10.1165/rcmb.2007-0114OC
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   RAINSFORD KD, 1992, CLIN PHARMACOL THER, V51, P415, DOI 10.1038/clpt.1992.41
   Raja A, 2003, NAT REV DRUG DISCOV, V2, P857, DOI 10.1038/nrd1232
   Ritchie EC, 2013, J AM ACAD PSYCHIATRY, V41, P224
   Rivulgo V, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/392010
   Rodgers T, 2005, J PHARM SCI-US, V94, P1259, DOI 10.1002/jps.20322
   Rodgers T, 2007, PHARM RES-DORDR, V24, P918, DOI 10.1007/s11095-006-9210-3
   Rodgers T, 2006, J PHARM SCI-US, V95, P1238, DOI 10.1002/jps.20502
   Rossignol JF, 2009, J BIOL CHEM, V284, P29798, DOI 10.1074/jbc.M109.029470
   Rossignol JF, 2014, ANTIVIR RES, V110, P94, DOI 10.1016/j.antiviral.2014.07.014
   Rossingol JF, 2016, J INFECT PUBLIC HEAL, V9, P227, DOI 10.1016/j.jiph.2016.04.001
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shida Y, 2011, JPN J CLIN PHARM THE, V42, P11, DOI DOI 10.3999/jscpt.42.11
   Smith CA, 2019, AGING CELL, V18, DOI 10.1111/acel.12893
   Streeck Hendrik, 2007, Ther Clin Risk Manag, V3, P641
   Sun CB, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00155
   Tett SE, 2000, J RHEUMATOL, V27, P1656
   Tilmanis D, 2017, ANTIVIR RES, V147, P142, DOI 10.1016/j.antiviral.2017.10.002
   Touret F., 2020, IN VITRO SCREENING F, DOI [10.1101/2020.04.03.023846., DOI 10.1101/2020.04.03.023846]
   Trabattoni D, 2016, SCI REP-UK, V6, DOI 10.1038/srep27148
   Unis G, 2016, FASEB J, V30
   US Food and Drug Administration (FDA), 2020, ABB L CLIN PHARM BIO
   VANDERKOOI G, 1988, BIOCHEM PHARMACOL, V37, P3623, DOI 10.1016/0006-2952(88)90394-2
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2016, ANTIVIR RES, V135, P81, DOI 10.1016/j.antiviral.2016.10.003
   Weston S., 2020, BIORXIV, DOI [10.1101/2020.03.25.008482, DOI 10.1101/2020.03.25.008482]
   Wong SH, 2020, J GASTROEN HEPATOL, V35, P744, DOI 10.1111/jgh.15047
   World Health Organisation, 2020, COVID 19 TRIALS INT
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Xu T., 2020, BIORXIV, DOI DOI 10.1101/2020.04.01.017624
   Xu Z., CELLS, DOI [10.26434/chemrxiv.12039888, DOI 10.26434/CHEMRXIV.12039888]
   Yamamoto N., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.06.026476, 10.1101/ 2020.04.06.026476]
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   YEH KC, 1985, AM J MED, V79, P3, DOI 10.1016/0002-9343(85)90510-8
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang H, 2020, DIGESTIVE SYSTEM IS, DOI [10.1101/2020.01.30.927806, DOI 10.1101/2020.01.30.927806]
   Zhang KYE, 2001, ANTIMICROB AGENTS CH, V45, P1086, DOI 10.1128/AAC.45.4.1086-1093.2001
   Zhang RH, 2019, J CANCER, V10, P1004, DOI 10.7150/jca.26277
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhang XW, 2004, BIOORGAN MED CHEM, V12, P2517, DOI 10.1016/j.bmc.2004.03.035
   Zhang Y., 2020, SITE SPECIFIC N GLYC, DOI [10.1101/ 2020.03.28.013276, DOI 10.1101/2020.03.28.013276, 10.1101/2020.03.28.013276.]
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
NR 121
TC 11
Z9 11
U1 3
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD OCT
PY 2020
VL 108
IS 4
BP 775
EP 790
DI 10.1002/cpt.1909
EA JUN 2020
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NQ3JW
UT WOS:000539894800001
PM 32438446
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Zhu, FC
   Li, YH
   Guan, XH
   Hou, LH
   Wang, WJ
   Li, JX
   Wu, SP
   Wang, BS
   Wang, Z
   Wang, L
   Jia, SY
   Jiang, HDC
   Wang, L
   Jiang, T
   Hu, Y
   Gou, JB
   Xu, SB
   Xu, JJ
   Wang, XW
   Wang, W
   Chen, W
AF Zhu, Feng-Cai
   Li, Yu-Hua
   Guan, Xu-Hua
   Hou, Li-Hua
   Wang, Wen-Juan
   Li, Jing-Xin
   Wu, Shi-Po
   Wang, Bu-Sen
   Wang, Zhao
   Wang, Lei
   Jia, Si-Yue
   Jiang, Hu-Dachuan
   Wang, Ling
   Jiang, Tao
   Hu, Yi
   Gou, Jin-Bo
   Xu, Sha-Bei
   Xu, Jun-Jie
   Wang, Xue-Wen
   Wang, Wei
   Chen, Wei
TI Safety, tolerability, and immunogenicity of a recombinant adenovirus
   type-5 vectored COVID-19 vaccine: a dose-escalation, open-label,
   non-randomised, first-in-human trial
SO LANCET
LA English
DT Article
ID CLINICAL CHARACTERISTICS; HEALTHY-ADULTS; EBOLA VACCINE; CORONAVIRUS;
   PROTECTION; RESPONSES; DISEASE; REGIMEN; CHINA; WUHAN
AB Background A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain.
   Methods We did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. Healthy adults aged between 18 and 60 years were sequentially enrolled and allocated to one of three dose groups (5 x 10(10), 1 x 10(11), and 1.5 x 10(11) viral particles) to receive an intramuscular injection of vaccine. The primary outcome was adverse events in the 7 days post-vaccination. Safety was assessed over 28 days post-vaccination. Specific antibodies were measured with ELISA, and the neutralising antibody responses induced by vaccination were detected with SARS-CoV-2 virus neutralisation and pseudovirus neutralisation tests. T-cell responses were assessed by enzyme-linked immunospot and flow-cytometry assays. This study is registered with ClinicalTrials.gov, NCT04313127.
   Findings Between March 16 and March 27, 2020, we screened 195 individuals for eligibility. Of them, 108 participants (51% male, 49% female; mean age 36.3 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. All enrolled participants were included in the analysis. At least one adverse reaction within the first 7 days after the vaccination was reported in 30 (83%) par-ticipants in the low dose group, 30 (83%) participants in the middle dose group, and 27 (75%) participants in the high dose group. The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. No serious adverse event was noted within 28 days post-vaccination. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination.
   Interpretation The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Hou, Li-Hua; Wu, Shi-Po; Wang, Bu-Sen; Xu, Jun-Jie; Chen, Wei] Beijing Inst Biotechnol, Beijing 100071, Peoples R China.
   [Zhu, Feng-Cai; Wang, Wen-Juan; Li, Jing-Xin; Jia, Si-Yue; Jiang, Hu-Dachuan] Jiangsu Prov Ctr Dis Control & Prevent, NHC Key Lab Enter Pathogen Microbiol, Nanjing 210009, Peoples R China.
   [Li, Yu-Hua; Wang, Ling] China Natl Inst Food & Drug Control, Beijing, Peoples R China.
   [Guan, Xu-Hua; Wang, Zhao; Wang, Lei] Hubei Prov Ctr Dis Control & Prevent, Wuhan, Peoples R China.
   [Jiang, Tao; Hu, Yi] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.
   [Gou, Jin-Bo] CanSino Biol, Tianjin, Peoples R China.
   [Xu, Sha-Bei; Wang, Wei] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Res Ctr, Wuhan 430032, Peoples R China.
   [Wang, Xue-Wen] Shanghai Canming Med Technol, Shanghai, Peoples R China.
RP Chen, W (corresponding author), Beijing Inst Biotechnol, Beijing 100071, Peoples R China.; Zhu, FC (corresponding author), Jiangsu Prov Ctr Dis Control & Prevent, NHC Key Lab Enter Pathogen Microbiol, Nanjing 210009, Peoples R China.; Wang, W (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Res Ctr, Wuhan 430032, Peoples R China.
EM jszfc@vip.sina.com; wwang@vip.126.com; cw0226@foxmail.com
OI wang, busen/0000-0001-9041-1919
FU National Key R&D Program of China; National Science and Technology Major
   Project; CanSino Biologics
FX National Key R&D Program of China, National Science and Technology Major
   Project, and CanSino Biologics.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6
   De Santis O, 2016, LANCET INFECT DIS, V16, P311, DOI 10.1016/S1473-3099(15)00486-7
   Dolzhikova IV, 2017, HUM VACC IMMUNOTHER, V13, P613, DOI 10.1080/21645515.2016.1238535
   Duan JZ, 2005, BIOCHEM BIOPH RES CO, V333, P186, DOI 10.1016/j.bbrc.2005.05.089
   Ewer K, 2016, NEW ENGL J MED, V374, P1635, DOI 10.1056/NEJMoa1411627
   Gray GE, 2014, LANCET INFECT DIS, V14, P388, DOI 10.1016/S1473-3099(14)70020-9
   Grein J, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2007016NEJMoa2007016., DOI 10.1056/NEJMOA2007016NEJMOA2007016]
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lurie N, 2020, NEW ENGL J MED
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Shukarev G, 2017, HUM VACC IMMUNOTHER, V13, P266, DOI 10.1080/21645515.2017.1264755
   Sprangers MC, 2003, J CLIN MICROBIOL, V41, P5046, DOI 10.1128/JCM.41.11.5046-5052.2003
   Venkatraman N, 2019, J INFECT DIS, V219, P1187, DOI 10.1093/infdis/jiy639
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wang X, 2020, NEUTRALIZING ANTIBOD, DOI 2020.04.15.20065623
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   World Health Organization, 2020, COR DIS COVID 2019 S
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wu F, 2020, NEUTRALIZING ANTIBOD
   Ye GM, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.001
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhu F-C, 2020, PROTOCOL SINGLE CTR
   Zhu FC, 2015, LANCET, V385, P2272, DOI 10.1016/S0140-6736(15)60553-0
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 31
TC 162
Z9 165
U1 37
U2 49
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUN 13
PY 2020
VL 395
IS 10240
BP 1845
EP 1854
DI 10.1016/S0140-6736(20)31208-3
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA NH4GA
UT WOS:000564628700027
PM 32450106
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Quimque, MTJ
   Notarte, KIR
   Fernandez, RAT
   Mendoza, MAO
   Liman, RAD
   Lim, JAK
   Pilapil, LAE
   Ong, JKH
   Pastrana, AM
   Khan, A
   Wei, DQ
   Macabeo, APG
AF Quimque, Mark Tristan J.
   Notarte, Kin Israel R.
   Fernandez, Rey Arturo T.
   Mendoza, Mark Andrew O.
   Liman, Rhenz Alfred D.
   Lim, Justin Allen K.
   Pilapil, Luis Agustin E.
   Ong, Jehiel Karsten H.
   Pastrana, Adriel M.
   Khan, Abbas
   Wei, Dong-Qing
   Macabeo, Allan Patrick G.
TI Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors
   targeting viral attachment, replication, post-translational modification
   and host immunity evasion infection mechanisms
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV2; fungal natural products; antiviral; molecular
   docking; molecular dynamics; ADMET
ID ENDOPHYTIC FUNGUS; METABOLITES; DERIVATIVES; CYTOTOXICITY; PATHWAYS;
   SOFTWARE; DOCKING; GRP78
AB The novel coronavirus SARS-CoV2, the causative agent of the pandemic disease COVID-19, emerged in December 2019 forcing lockdown of communities in many countries. The absence of specific drugs and vaccines, the rapid transmission of the virus, and the increasing number of deaths worldwide necessitated the discovery of new substances for anti-COVID-19 drug development. With the aid of bioinformatics and computational modelling, ninety seven antiviral secondary metabolites from fungi were docked onto five SARS-CoV2 enzymes involved in viral attachment, replication, post-translational modification, and host immunity evasion infection mechanisms followed by molecular dynamics simulation andin silicoADMET prediction (absorption, distribution, metabolism, excretion and toxicity) of the hit compounds. Thus, three fumiquinazoline alkaloids scedapin C (15), quinadoline B (19) and norquinadoline A (20), the polyketide isochaetochromin D1 (8), and the terpenoid 11a-dehydroxyisoterreulactone A (11) exhibited high binding affinities on the target proteins, papain-like protease (PLpro), chymotrypsin-like protease (3CLpro), RNA-directed RNA polymerase (RdRp), non-structural protein 15 (nsp15), and the spike binding domain to GRP78. Molecular dynamics simulation was performed to optimize the interaction and investigate the stability of the top-scoring ligands in complex with the five target proteins. All tested complexes were found to have dynamic stability. Of the five top-scoring metabolites, quinadoline B (19) was predicted to confer favorable ADMET values, high gastrointestinal absorptive probability and poor blood-brain barrier crossing capacities. Communicated by Ramaswamy H. Sarma
C1 [Quimque, Mark Tristan J.; Mendoza, Mark Andrew O.; Lim, Justin Allen K.; Pilapil, Luis Agustin E.; Ong, Jehiel Karsten H.; Macabeo, Allan Patrick G.] Univ Santo Tomas, Res Ctr Nat & Appl Sci, Lab Organ React Discovery & Synth LORDS, Espana Blvd, Manila 1015, Philippines.
   [Quimque, Mark Tristan J.; Liman, Rhenz Alfred D.] Univ Santo Tomas, Grad Sch, Manila, Philippines.
   [Quimque, Mark Tristan J.] Mindanao State Univ, Iligan Inst Technol, Coll Sci & Math, Chem Dept, Iligan, Philippines.
   [Notarte, Kin Israel R.; Fernandez, Rey Arturo T.; Pastrana, Adriel M.] Univ Santo Tomas, Fac Med & Surg, Manila, Philippines.
   [Khan, Abbas; Wei, Dong-Qing] Shanghai Jiao Tong Univ, Dept Bioinformat & Biostat, State Key Lab Microbial Metab, Shanghai, Peoples R China.
   [Wei, Dong-Qing] Shanghai Jiao Tong Univ, Minist Educ, Joint Lab Int Cooperat Metab & Dev Sci,State Key, Shanghai Islamabad Belgrade Joint Innovat Ctr Ant, Shanghai, Peoples R China.
   [Wei, Dong-Qing] Peng Cheng Lab, Shenzhen, Peoples R China.
RP Macabeo, APG (corresponding author), Univ Santo Tomas, Res Ctr Nat & Appl Sci, Lab Organ React Discovery & Synth LORDS, Espana Blvd, Manila 1015, Philippines.
EM agmacabeo@ust.edu.ph
OI Notarte, Kin Israel/0000-0002-6055-0886
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abdelli I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763199
   Peele KA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1770127
   Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   Alcantara J., 2010, VIRUS ADAPTATION TRE, V2, DOI [https://doi.org/10.2147/VAAT.S12733, DOI 10.2147/VAAT.S12733]
   Andersen PI, 2020, INT J INFECT DIS, V93, P268, DOI 10.1016/j.ijid.2020.02.018
   Arya R., 2020, POTENTIAL INHIBITORS, DOI [10.26434/chemrxiv.11860011.v1, DOI 10.26434/CHEMRXIV.11860011.V1]
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767211
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767210
   Bashyal BP, 2014, BIOORGAN MED CHEM, V22, P6112, DOI 10.1016/j.bmc.2014.08.039
   Basit A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768150
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   El Asnaoui K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767212
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761881
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Escobedo-Gonzalez R, 2017, MOLECULES, V22, DOI 10.3390/molecules22071060
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gao HQ, 2013, BIOORG MED CHEM LETT, V23, P1776, DOI 10.1016/j.bmcl.2013.01.051
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Gyebi GA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764868
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   He F, 2013, J NAT PROD, V76, P1182, DOI 10.1021/np300897v
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767691
   Huang LH, 2017, ORG LETT, V19, P4888, DOI 10.1021/acs.orglett.7b02238
   Huang ZH, 2017, BIOORG MED CHEM LETT, V27, P787, DOI 10.1016/j.bmcl.2017.01.032
   Hyde KD, 2019, FUNGAL DIVERS, V97, P1, DOI 10.1007/s13225-019-00430-9
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Ibrahim IM, 2019, LIFE SCI, V226, P156, DOI 10.1016/j.lfs.2019.04.022
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Khan A, 2019, RSC ADV, V9, P10326, DOI 10.1039/c9ra01007f
   Khan A, 2018, J MOL GRAPH MODEL, V82, P37, DOI 10.1016/j.jmgm.2018.03.004
   Khan MS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1715838
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Kindler E, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006195
   Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549
   Kuephadungphan W, 2019, MYCOL PROG, V18, P135, DOI 10.1007/s11557-018-1431-4
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752310
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu L, 2010, CHEM COMMUN, V46, P460, DOI 10.1039/b918330b
   Lobo-Galo N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764393
   Macabeo APG, 2020, MOLECULES, V25, DOI 10.3390/molecules25040965
   Macabeo APG, 2020, PHYTOCHEM LETT, V35, P147, DOI 10.1016/j.phytol.2019.11.010
   Mahanta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768902
   Mapook A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10040569
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nong XH, 2014, MAR DRUGS, V12, P6113, DOI 10.3390/md12126113
   Notarte KI, 2017, MYCOSPHERE, V8, P111, DOI 10.5943/mycosphere/8/1/10
   Notarte KI, 2018, ACTA BOT CROAT, V77, P141, DOI 10.2478/botcro-2018-0016
   Notarte KIR, 2019, PHILIPP J SCI, V148, P503
   Pang X, 2017, J NAT PROD, V80, P2595, DOI 10.1021/acs.jnatprod.6b00878
   Paniri A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767690
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Peng JX, 2013, J NAT PROD, V76, P1133, DOI 10.1021/np400200k
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Phukhamsakda C, 2019, J NAT PROD, V82, P2878, DOI 10.1021/acs.jnatprod.9b00604
   Phukhamsakda C, 2018, MOLECULES, V23, DOI 10.3390/molecules23092190
   Quinones QJ, 2008, HISTOL HISTOPATHOL, V23, P1409, DOI 10.14670/HH-23.1409
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sandargo B, 2019, ORG LETT, V21, P3286, DOI 10.1021/acs.orglett.9b01017
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Singh SB, 1998, TETRAHEDRON LETT, V39, P2243, DOI 10.1016/S0040-4039(98)00269-X
   Singh SB, 2003, BIOORG MED CHEM LETT, V13, P713, DOI 10.1016/S0960-894X(02)01057-0
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768149
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P16719, DOI 10.1039/c4cp01388c
   Tan SY, 2019, NAT PROD RES, V33, P1467, DOI 10.1080/14786419.2017.1416376
   Toukmaji A, 2000, J CHEM PHYS, V113, P10913, DOI 10.1063/1.1324708
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   WANG JM, 2001, ABSTR PAP AM CHEM 1, V222
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wang YQ, 2019, J BIOMOL STRUCT DYN, V37, P4051, DOI 10.1080/07391102.2018.1537896
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang JY, 2013, BIOINFORMATICS, V29, P2588, DOI 10.1093/bioinformatics/btt447
   Zaiyou J, 2017, MEDICINE, V96, P1
   Zhao JL, 2017, J NAT PROD, V80, P1819, DOI 10.1021/acs.jnatprod.7b00014
   Zhu TH, 2014, J ANTIBIOT, V67, P315, DOI 10.1038/ja.2013.135
NR 98
TC 6
Z9 7
U1 6
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1776639
EA JUN 2020
PG 18
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA ME6QC
UT WOS:000544776900001
PM 32476574
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sy, CL
   Aviso, KB
   Cayamanda, CD
   Chiu, ASF
   Lucas, RIG
   Promentilla, MAB
   Razon, LF
   Tan, RR
   Tapia, JFD
   Torneo, AR
   Ubando, AT
   Yu, DEC
AF Sy, C. L.
   Aviso, K. B.
   Cayamanda, C. D.
   Chiu, A. S. F.
   Lucas, R. I. G.
   Promentilla, M. A. B.
   Razon, L. F.
   Tan, R. R.
   Tapia, J. F. D.
   Torneo, A. R.
   Ubando, A. T.
   Yu, D. E. C.
TI Process integration for emerging challenges: optimal allocation of
   antivirals under resource constraints
SO CLEAN TECHNOLOGIES AND ENVIRONMENTAL POLICY
LA English
DT Article
DE Pharmaceutical shortage; Resource allocation; COVID-19; Mathematical
   programming; Disease outbreak; Sustainable Development Goals
ID DISASTER
AB The global scientific community has intensified efforts to develop, test, and commercialize pharmaceutical products to deal with the COVID-19 pandemic. Trials for both antivirals and vaccines are in progress; candidates include existing repurposed drugs that were originally developed for other ailments. Once these are shown to be effective, their production will need to be ramped up rapidly to keep pace with the growing demand as the pandemic progresses. It is highly likely that the drugs will be in short supply in the interim, which leaves policymakers and medical personnel with the difficult task of determining how to allocate them. Under such conditions, mathematical models can provide valuable decision support. In particular, useful models can be derived from process integration techniques that deal with tight resource constraints. In this paper, a linear programming model is developed to determine the optimal allocation of COVID-19 drugs that minimizes patient fatalities, taking into account additional hospital capacity constraints. Two hypothetical case studies are solved to illustrate the computational capability of the model, which can generate an allocation plan with outcomes that are superior to simple ad hoc allocation.
   [GRAPHICS]
   .
C1 [Sy, C. L.; Aviso, K. B.; Chiu, A. S. F.; Promentilla, M. A. B.; Razon, L. F.; Tan, R. R.; Tapia, J. F. D.; Ubando, A. T.] De La Salle Univ, Ctr Engn & Sustainable Dev Res, Manila, Philippines.
   [Cayamanda, C. D.] AnimoLabs Fdn Inc, Manila, Philippines.
   [Lucas, R. I. G.] De La Salle Univ, Lasallian Inst Dev & Educ Res, Manila, Philippines.
   [Torneo, A. R.] De La Salle Univ, Jesse M Robredo Inst Governance, Manila, Philippines.
   [Yu, D. E. C.] De La Salle Univ, Ctr Nat Sci & Environm Res, Manila, Philippines.
RP Tan, RR (corresponding author), De La Salle Univ, Ctr Engn & Sustainable Dev Res, Manila, Philippines.
EM raymond.tan@dlsu.edu.ph
RI Aviso, Kathleen/ABA-4589-2020; Chiu, Shun Fung/ABA-4570-2020; Torneo,
   Ador/AAB-9432-2019
OI Aviso, Kathleen/0000-0002-9994-5172; Torneo, Ador/0000-0002-6748-6987
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Arora N, 2010, DECIS SUPPORT SYST, V50, P304, DOI 10.1016/j.dss.2010.08.032
   Aviso KB, 2018, RESOUR CONSERV RECY, V128, P250, DOI 10.1016/j.resconrec.2016.07.009
   Bandyopadhyay S, 2020, CLEAN TECHNOL ENVIR, V22, P545, DOI 10.1007/s10098-020-01843-w
   Celiz MD, 2009, ENVIRON TOXICOL CHEM, V28, P2473, DOI 10.1897/09-173.1
   Corlett RT, 2020, BIOL CONSERV, V246, DOI 10.1016/j.biocon.2020.108571
   Cunningham AA, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0167
   Department of Health, 2020, PHIL HLTH SYST GLANC
   ELHALWAGI MM, 2006, PR SYST ENG, V7, P1
   Ferguson N, 2020, IMPACT NONPHARMACEUT, DOI [10.25561/77482, DOI 10.25561/77482]
   Ferrari R, 2020, EUR HEART J, V41, P2050, DOI 10.1093/eurheartj/ehaa326
   Friedler F, 2019, CURR OPIN CHEM ENG, V26, P58, DOI 10.1016/j.coche.2019.08.007
   Klemes JJ, 2020, RENEW SUST ENERG REV, V127, DOI 10.1016/j.rser.2020.109883
   Klemes JJ, 2018, RENEW SUST ENERG REV, V98, P439, DOI 10.1016/j.rser.2018.09.030
   Klemes JJ, 2013, CURR OPIN CHEM ENG, V2, P461, DOI 10.1016/j.coche.2013.10.003
   Koyuncu M, 2010, J MED SYST, V34, P61, DOI 10.1007/s10916-008-9216-y
   Kupferschmidt K., 2020, SCIENCE, DOI [10.11 26/science.abb8497, DOI 10.1126/SCIENCE.ABB8497, 10.1126/science.abb8497]
   Liu M, 2020, J OPER RES SOC, V71, P748, DOI 10.1080/01605682.2019.1582589
   Majumdar A, 2020, CLEAN TECHNOL ENVIR, V22, P11, DOI 10.1007/s10098-019-01766-1
   Medlock J, 2009, SCIENCE, V325, P1705, DOI 10.1126/science.1175570
   Musazzi UM, 2020, INT J PHARMACEUT, V579, DOI 10.1016/j.ijpharm.2020.119171
   Okuyama Y, 2014, ECON SYST RES, V26, P1, DOI 10.1080/09535314.2013.871505
   Philippine Statistics Authority, 2020, NAT QUICKST 2020
   Philippine Statistics Authority, 2020, 2018 QUICKST NAT CAP
   Santos Joost, 2020, Environment Systems & Decisions, V40, DOI 10.1007/s10669-020-09774-z
   Sun L, 2014, COMPUT OPER RES, V51, P350, DOI 10.1016/j.cor.2013.12.001
   Tuite AR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010520
   WHO, 2020, WHO COVID 19 DASHB
   Yaesoubi R, 2016, STAT MED, V35, P5189, DOI 10.1002/sim.7047
   Yu DEC, 2020, RESOUR CONSERV RECY, V159, DOI 10.1016/j.resconrec.2020.104868
   Yu KDS, 2020, PROC INTEGR OPTIM, V4, P183, DOI 10.1007/s41660-020-00113-y
   Yuan JJ, 2020, ECOSYST HEALTH SUST, V6, DOI 10.1080/20964129.2020.1741325
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 34
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1618-954X
EI 1618-9558
J9 CLEAN TECHNOL ENVIR
JI Clean Technol. Environ. Policy
PD AUG
PY 2020
VL 22
IS 6
BP 1359
EP 1370
DI 10.1007/s10098-020-01876-1
EA JUN 2020
PG 12
WC Green & Sustainable Science & Technology; Engineering, Environmental;
   Environmental Sciences
SC Science & Technology - Other Topics; Engineering; Environmental Sciences
   & Ecology
GA ML6VQ
UT WOS:000542844000003
PM 32837502
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Matheson, BE
   Bohon, C
   Lock, J
AF Matheson, Brittany E.
   Bohon, Cara
   Lock, James
TI Family-based treatment via videoconference: Clinical recommendations for
   treatment providers duringCOVID-19 and beyond
SO INTERNATIONAL JOURNAL OF EATING DISORDERS
LA English
DT Article
DE adolescents; anorexia nervosa; bulimia nervosa; COVID-19; dissemination;
   eating disorders treatment; family-based treatment (FBT);
   implementation; TeleHealth; videoconferencing
ID COGNITIVE-BEHAVIORAL THERAPY; EARLY WEIGHT-GAIN; TELEMENTAL HEALTH;
   BULIMIA-NERVOSA; EATING-DISORDERS; CULTURAL COMPETENCE; PRACTICE
   GUIDELINES; EARLY RESPONSE; ANOREXIA; ADOLESCENTS
AB The necessity to employ distance-based methods to deliver on-going eating disorder care due to the novel coronavirus (COVID-19) pandemic represents a dramatic and urgent shift in treatment delivery. Yet, TeleHealth treatments for eating disorders in youth have not been adequately researched or rigorously tested. Based on clinical experience within our clinic and research programs, we aim to highlight the common challenges clinicians may encounter in providing family-based treatment (FBT) via TeleHealth for children and adolescents with anorexia nervosa and bulimia nervosa. We also discuss possible solutions and offer practical considerations for providers delivering FBT in this format. Additional research in TeleHealth treatment for eating disorders in youth may lead to improved access, efficiency, and effectiveness of FBT delivered via videoconferencing.
C1 [Matheson, Brittany E.; Bohon, Cara; Lock, James] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
RP Matheson, BE (corresponding author), Stanford Univ, Sch Med, 401 Quarry Rd, Stanford, CA 94305 USA.
EM bmatheson@stanford.edu
CR Aardoom JJ, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0673-6
   Academy for Eating Disorders' Medical Care Standards Committee, 2016, EATING DISORDERS A G, P23
   Agras WS, 2017, BEHAV RES THER, V88, P26, DOI 10.1016/j.brat.2016.09.004
   Agras WS, 2014, JAMA PSYCHIAT, V71, P1279, DOI 10.1001/jamapsychiatry.2014.1025
   American Psychological Association, 2017, MULT GUID EC APPR CO, DOI [10.1037/e501962018-001, DOI 10.1037/E501962018-001]
   Anderson KE, 2017, INT J EAT DISORDER, V50, P1235, DOI 10.1002/eat.22759
   [Anonymous], 2008, J AM ACAD CHILD PSY, V47, P1468, DOI 10.1097/CHI.0b013e31818b4e13
   Backhaus A, 2012, PSYCHOL SERV, V9, P111, DOI 10.1037/a0027924
   Bauer S, 2013, INT J EAT DISORDER, V46, P508, DOI 10.1002/eat.22109
   Berryhill MB, 2019, TELEMED E-HEALTH, V25, P435, DOI 10.1089/tmj.2018.0058
   Blythin SPM, 2020, PSYCHOL PSYCHOTHER-T, V93, P134, DOI 10.1111/papt.12198
   Brooks E, 2013, ELSEV INSIGHT, P63, DOI 10.1016/B978-0-12-416048-4.00005-1
   Buchman Samantha, 2019, Int J Eat Disord, V52, P777, DOI 10.1002/eat.23088
   Caldwell B. E., 2017, BEST PRACTICES ONLIN
   Clus D, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.7898
   Couturier J, 2020, J EAT DISORD, V8, DOI 10.1186/s40337-020-0277-8
   Crum KI, 2016, J CHILD ADOL PSYCHOP, V26, P229, DOI 10.1089/cap.2015.0012
   Darcy AM, 2017, CHILD ADOL PSYCH CL, V26, P33, DOI 10.1016/j.chc.2016.07.010
   de Carvalho MR, 2017, BEHAV SCI-BASEL, V7, DOI 10.3390/bs7030043
   Doyle PM, 2010, INT J EAT DISORDER, V43, P659, DOI 10.1002/eat.20764
   Ertelt TW, 2011, INT J EAT DISORDER, V44, P687, DOI 10.1002/eat.20874
   Fernandez-Aranda F, 2020, EUR EAT DISORD REV, V28, P239, DOI 10.1002/erv.2738
   Fisher MM, 2014, J ADOLESCENT HEALTH, V55, P49, DOI 10.1016/j.jadohealth.2013.11.013
   Forsberg S, 2015, INT J EAT DISORDER, V48, P91, DOI 10.1002/eat.22337
   Forsberg S, 2014, EUR EAT DISORD REV, V22, P53, DOI 10.1002/erv.2242
   Hay P, 2014, AUST NZ J PSYCHIAT, V48, P977, DOI 10.1177/0004867414555814
   Hilty DM, 2013, TELEMED E-HEALTH, V19, P444, DOI 10.1089/tmj.2013.0075
   Isserlin L, 2012, PSYCHOTHERAPY, V49, P46, DOI 10.1037/a0023905
   Jenkins-Guarnieri MA, 2015, TELEMED E-HEALTH, V21, P652, DOI 10.1089/tmj.2014.0165
   Juarascio AS, 2015, EUR EAT DISORD REV, V23, P1, DOI 10.1002/erv.2327
   Kazdin AE, 2017, INT J EAT DISORDER, V50, P170, DOI 10.1002/eat.22670
   Kramer GM, 2016, J CHILD ADOL PSYCHOP, V26, P198, DOI 10.1089/cap.2015.0018
   Langarizadeh Mostafa, 2017, Acta Inform Med, V25, P240, DOI 10.5455/aim.2017.25.240-246
   Le Grange D., 2009, TREATING BULIMIA ADO
   le Grange D, 2008, INT J EAT DISORDER, V41, P755, DOI 10.1002/eat.20566
   le Grange D, 2007, ARCH GEN PSYCHIAT, V64, P1049, DOI 10.1001/archpsyc.64.9.1049
   Le Grange D, 2015, J AM ACAD CHILD PSY, V54, P886, DOI 10.1016/j.jaac.2015.08.008
   Le Grange D, 2014, INT J EAT DISORDER, V47, P124, DOI 10.1002/eat.22221
   Lock J, 2020, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00968
   Lock J, 2019, INT J EAT DISORDER, V52, P481, DOI 10.1002/eat.22980
   Lock J, 2019, INT J EAT DISORDER, V52, P746, DOI 10.1002/eat.23077
   Lock J, 2019, INT J EAT DISORDER, V52, P439, DOI 10.1002/eat.22994
   Lock J, 2010, ARCH GEN PSYCHIAT, V67, P1025, DOI 10.1001/archgenpsychiatry.2010.128
   Lock James, 2015, TREATMENT MANUAL ANO
   Lopez A, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1055-7
   Madden S, 2015, INT J EAT DISORDER, V48, P919, DOI 10.1002/eat.22414
   Matheson BE, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00092
   Melioli T, 2016, INT J EAT DISORDER, V49, P19, DOI 10.1002/eat.22477
   Mitchell JE, 2008, BEHAV RES THER, V46, P581, DOI 10.1016/j.brat.2008.02.004
   Mitchison D, 2020, PSYCHOL MED, V50, P981, DOI 10.1017/S0033291719000898
   Myers K, 2017, TELEMED E-HEALTH, V23, P779, DOI 10.1089/tmj.2017.0177
   Nagl M, 2016, EUR CHILD ADOLES PSY, V25, P903, DOI 10.1007/s00787-015-0808-z
   National Institute for Health and Care Excellence, 2017, EAT DIS REC TREATM
   Pereira T, 2006, INT J EAT DISORDER, V39, P677, DOI 10.1002/eat.20303
   Ralston AL, 2019, CLIN PSYCHOL-SCI PR, V26, DOI 10.1111/cpsp.12277
   Richards P, 2018, CLIN PSYCHOL-UK, V22, P171, DOI 10.1111/cp.12102
   Ryu S, 2010, HEALTHC INFORM RES, V16, P65, DOI 10.4258/hir.2010.16.1.65
   Schlegl S, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.3554
   Shingleton RM, 2013, PSYCHOTHERAPY, V50, P576, DOI 10.1037/a0031815
   Shore JH, 2018, TELEMED E-HEALTH, V24, P827, DOI 10.1089/tmj.2018.0237
   Silen Y, 2020, INT J EAT DISORDER, V53, P520, DOI 10.1002/eat.23236
   Simpson SG, 2014, AUST J RURAL HEALTH, V22, P280, DOI 10.1111/ajr.12149
   Sproch LE, 2019, PSYCHIAT CLIN N AM, V42, P243, DOI 10.1016/j.psc.2019.01.008
   Sue S, 2006, J COMMUNITY PSYCHOL, V34, P237, DOI 10.1002/jcop.20095
   Sue S, 2009, ANNU REV PSYCHOL, V60, P525, DOI 10.1146/annurev.psych.60.110707.163651
   Swanson SA, 2011, ARCH GEN PSYCHIAT, V68, P714, DOI 10.1001/archgenpsychiatry.2011.22
   Sweeney GM, 2019, INTERNET INTERV, V15, P93, DOI 10.1016/j.invent.2016.12.001
   Touyz S, 2020, J EAT DISORD, V8, DOI 10.1186/s40337-020-00295-3
   Traviss-Turner GD, 2017, EUR EAT DISORD REV, V25, P148, DOI 10.1002/erv.2507
   Waller G, 2020, INT J EAT DISORDER, V53, P1132, DOI 10.1002/eat.23289
   Wrape ER, 2019, J MARITAL FAM THER, V45, P296, DOI 10.1111/jmft.12319
   Zaitsoff SL, 2008, INT J EAT DISORDER, V41, P390, DOI 10.1002/eat.20515
   Zerwas SC, 2017, PSYCHOTHER PSYCHOSOM, V86, P47, DOI 10.1159/000449025
NR 73
TC 6
Z9 7
U1 7
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0276-3478
EI 1098-108X
J9 INT J EAT DISORDER
JI Int. J. Eating Disord.
PD JUL
PY 2020
VL 53
IS 7
BP 1142
EP 1154
DI 10.1002/eat.23326
EA JUN 2020
PG 13
WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology
SC Psychology; Nutrition & Dietetics; Psychiatry
GA MF6TT
UT WOS:000539825900001
PM 32533799
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Doggrell, SA
AF Doggrell, Sheila A.
TI Does lopinavir measure up in the treatment of COVID-19?
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Article
DE Clinical trial; COVID-19; lopinavir; ritonavir; LOTUS China
ID LOPINAVIR/RITONAVIR
AB Introduction Lopinavir in combination with ritonavir is approved for the treatment of HIV and has recently been subject to a clinical trial in severe COVID-19. Areas covered This evaluation is of LOTUS China (the Lopinavir Trial for Suppression of SARS-Cov-2 in China), which was a randomized trial in hospitalized subjects with COVID-9 in a respiratory sample and pneumonia. As, in severe COVID-19, lopinavir/ritonavir had no beneficial effects but increased gastrointestinal adverse effects, this combination should not be used at this stage of COVID-19. Expert opinion In my opinion, the rationale for undertaking a trial of lopinavir/ritonavir in COVID-19 was poor. The analysis of a modified intention to treat group analysis in LOTUS China may have introduced bias. After LOTUS China, there is probably no future for lopinavir in the treatment of severe COVID-19, but some clinical trials for prevention or in various stages of COVID-19 have recently started or are ongoing. The major limitation of these trials is that as lopinavir does not inhibit COVID-19, it is unlikely to prevent infection, reduce viral load, or reduce the severity. However, these trials may be worthwhile in finally determining whether lopinavir has any role in preventing or treating COVID-19.
C1 [Doggrell, Sheila A.] Queensland Univ Technol, Fac Hlth, Brisbane, Qld 4002, Australia.
RP Doggrell, SA (corresponding author), Queensland Univ Technol, Fac Hlth, Brisbane, Qld 4002, Australia.
EM sheila.doggrell@qut.edu.au
CR Bauman JL, 2020, PHARMACOTHERAPY, V40, P387, DOI 10.1002/phar.2387
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   ClinicalTrials.gov, COMPR SARS COV 2 INF
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002
   Mccoy CE, 2017, WEST J EMERG MED, V18, P1075, DOI 10.5811/westjem.2017.8.35985
   World Health Organization, SOL CLIN TRIAL COVID
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
NR 9
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3784
EI 1744-7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD AUG 2
PY 2020
VL 29
IS 8
BP 793
EP 796
DI 10.1080/13543784.2020.1777277
EA JUN 2020
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NX2JO
UT WOS:000545158800001
PM 32475183
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wu, Y
   Wang, FR
   Shen, CG
   Peng, WY
   Li, DL
   Zhao, C
   Li, ZH
   Li, SH
   Bi, YH
   Yang, Y
   Gong, YH
   Xiao, HX
   Fan, Z
   Tan, SG
   Wu, GZ
   Tan, WJ
   Lu, XC
   Fan, CF
   Wang, QH
   Liu, YX
   Zhang, C
   Qi, JX
   Gao, GF
   Gao, F
   Liu, L
AF Wu, Yan
   Wang, Feiran
   Shen, Chenguang
   Peng, Weiyu
   Li, Delin
   Zhao, Cheng
   Li, Zhaohui
   Li, Shihua
   Bi, Yuhai
   Yang, Yang
   Gong, Yuhuan
   Xiao, Haixia
   Fan, Zheng
   Tan, Shuguang
   Wu, Guizhen
   Tan, Wenjie
   Lu, Xuancheng
   Fan, Changfa
   Wang, Qihui
   Liu, Yingxia
   Zhang, Chen
   Qi, Jianxun
   Gao, George Fu
   Gao, Feng
   Liu, Lei
TI A noncompeting pair of human neutralizing antibodies block COVID-19
   virus binding to its receptor ACE2
SO SCIENCE
LA English
DT Article
ID SPIKE PROTEIN; SARS-COV; CORONAVIRUS; OUTBREAK; TARGET
AB Neutralizing antibodies could potentially be used as antivirals against the coronavirus disease 2019 (COVID-19) pandemic. Here, we report isolation of four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities. The antibodies B38 and H4 block binding between the spike glycoprotein receptor binding domain (RBD) of the virus and the cellular receptor angiotensin-converting enzyme 2 (ACE2). A competition assay indicated different epitopes on the RBD for these two antibodies, making them a potentially promising virus-targeting monoclonal antibody pair for avoiding immune escape in future clinical applications. Moreover, a therapeutic study in a mouse model validated that these antibodies can reduce virus titers in infected lungs. The RBD-B38 complex structure revealed that most residues on the epitope overlap with the RBD-ACE2 binding interface, explaining the blocking effect and neutralizing capacity. Our results highlight the promise of antibody-based therapeutics and provide a structural basis for rational vaccine design.
C1 [Wu, Yan; Zhang, Chen] Capital Med Univ, Sch Basic Med Sci, Dept Pathogen Microbiol, Beijing, Peoples R China.
   [Wu, Yan] Chinese Acad Sci, Beijing Inst Life Sci, Res Network Immun & Hlth RNIH, Beijing, Peoples R China.
   [Wang, Feiran; Shen, Chenguang; Peng, Weiyu; Li, Delin; Zhao, Cheng; Li, Zhaohui; Li, Shihua; Bi, Yuhai; Gong, Yuhuan; Fan, Zheng; Tan, Shuguang; Wang, Qihui; Qi, Jianxun; Gao, George Fu] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.
   [Wang, Feiran] Univ Sci & Technol China, Sch Life Sci, Hefei, Anhui, Peoples R China.
   [Shen, Chenguang; Li, Delin; Yang, Yang; Liu, Yingxia; Liu, Lei] Shenzhen Third Peoples Hosp, Shenzhen Key Lab Pathogen & Immun, Shenzhen, Peoples R China.
   [Peng, Weiyu] China Agr Univ, Coll Vet Med, Beijing, Peoples R China.
   [Li, Delin; Xiao, Haixia; Gao, Feng] Chinese Acad Sci, Tianjin Inst Ind Biotechnol, Lab Prot Engn & Vaccines, Tianjin, Peoples R China.
   [Zhao, Cheng] Shanxi Acad Adv Res & Innovat, Taiyuan, Peoples R China.
   [Li, Zhaohui] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Bi, Yuhai; Gong, Yuhuan] Chinese Acad Sci CASCIRE, Ctr Influenza Res & Early Warning, Beijing, Peoples R China.
   [Wu, Guizhen; Tan, Wenjie] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, NHC Key Lab Biosafety, Beijing, Peoples R China.
   [Lu, Xuancheng] Chinese Ctr Dis Control & Prevent, Lab Anim Ctr, Beijing, Peoples R China.
   [Fan, Changfa] Natl Inst Food & Drug Control, Inst Lab Anim Resources, Div Anim Model Res, Beijing, Peoples R China.
RP Wu, Y (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Pathogen Microbiol, Beijing, Peoples R China.; Wu, Y (corresponding author), Chinese Acad Sci, Beijing Inst Life Sci, Res Network Immun & Hlth RNIH, Beijing, Peoples R China.; Gao, GF (corresponding author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.; Liu, L (corresponding author), Shenzhen Third Peoples Hosp, Shenzhen Key Lab Pathogen & Immun, Shenzhen, Peoples R China.; Gao, F (corresponding author), Chinese Acad Sci, Tianjin Inst Ind Biotechnol, Lab Prot Engn & Vaccines, Tianjin, Peoples R China.
EM wuy@biols.ac.cn; gaof@im.ac.cn; gaofeng@tib.cas.cn;
   liulei3322@aliyun.com
RI Xiao, Haixia/AAZ-3374-2020
OI Xiao, Haixia/0000-0003-0032-5430; wu, yan/0000-0003-2734-0673
FU Zhejiang University special scientific research fund for COVID-19
   prevention and control [2020XGZX019]; National Science and Technology
   Major Project [2018ZX10733403]; National Key R&D Program of China
   [2018YFC1200603]; National Key Plan for Scientific Research and
   Development of China [2016YFD0500304]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [31872745, 81902058, 32041010]; National Science and Technology Major
   Projects of Infectious Disease Funds [2017ZX10304402]
FX This work was supported by the Zhejiang University special scientific
   research fund for COVID-19 prevention and control (2020XGZX019), the
   National Science and Technology Major Project (2018ZX10733403), the
   National Key R&D Program of China (2018YFC1200603), the National Key
   Plan for Scientific Research and Development of China (2016YFD0500304),
   National Natural Science Foundation of China (31872745, 81902058, and
   32041010), and the National Science and Technology Major Projects of
   Infectious Disease Funds (2017ZX10304402).
CR Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Knipe D.M., 2013, FIELDS VIROLOGY
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang QH, 2019, NAT MICROBIOL, V4, P1231, DOI 10.1038/s41564-019-0411-z
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Y, 2017, P NATL ACAD SCI USA, V114, pE7564, DOI 10.1073/pnas.1705176114
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010060
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 22
TC 105
Z9 101
U1 33
U2 48
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JUN 12
PY 2020
VL 368
IS 6496
BP 1274
EP +
DI 10.1126/science.abc2241
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MD5SF
UT WOS:000544031400039
PM 32404477
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Westerhoff, HV
   Kolodkin, AN
AF Westerhoff, Hans, V
   Kolodkin, Alexey N.
TI Advice from a systems-biology model of the corona epidemics
SO NPJ SYSTEMS BIOLOGY AND APPLICATIONS
LA English
DT Article
AB Using standard systems biology methodologies a 14-compartment dynamic model was developed for the Corona virus epidemic. The model predicts that: (i) it will be impossible to limit lockdown intensity such that sufficient herd immunity develops for this epidemic to die down, (ii) the death toll from the SARS-CoV-2 virus decreases very strongly with increasing intensity of the lockdown, but (iii) the duration of the epidemic increases at first with that intensity and then decreases again, such that (iv) it may be best to begin with selecting a lockdown intensity beyond the intensity that leads to the maximum duration, (v) an intermittent lockdown strategy should also work and might be more acceptable socially and economically, (vi) an initially intensive but adaptive lockdown strategy should be most efficient, both in terms of its low number of casualties and shorter duration, (vii) such an adaptive lockdown strategy offers the advantage of being robust to unexpected imports of the virus, e.g. due to international travel, (viii) the eradication strategy may still be superior as it leads to even fewer deaths and a shorter period of economic downturn, but should have the adaptive strategy as backup in case of unexpected infection imports, (ix) earlier detection of infections is the most effective way in which the epidemic can be controlled, whilst waiting for vaccines.
C1 [Westerhoff, Hans, V] Infrastruct Syst Biol Europe Netherlands ISBENL, Amsterdam, Netherlands.
   [Westerhoff, Hans, V; Kolodkin, Alexey N.] Vrije Univ Amsterdam, Mol Cell Biol, Amsterdam, Netherlands.
   [Westerhoff, Hans, V] Univ Amsterdam, Swammerdam Inst Life Sci, Synthet Syst Biol & Nucl Org, Amsterdam, Netherlands.
   [Westerhoff, Hans, V] Manchester Ctr Integrat Syst Biol, Manchester, Lancs, England.
   [Kolodkin, Alexey N.] Luxembourg Ctr Syst Biol, Luxembourg, Luxembourg.
RP Westerhoff, HV (corresponding author), Infrastruct Syst Biol Europe Netherlands ISBENL, Amsterdam, Netherlands.; Westerhoff, HV (corresponding author), Vrije Univ Amsterdam, Mol Cell Biol, Amsterdam, Netherlands.; Westerhoff, HV (corresponding author), Univ Amsterdam, Swammerdam Inst Life Sci, Synthet Syst Biol & Nucl Org, Amsterdam, Netherlands.; Westerhoff, HV (corresponding author), Manchester Ctr Integrat Syst Biol, Manchester, Lancs, England.
EM H.V.Westerhoff@VU.NL
RI Westerhoff, Hans/I-5762-2012
OI Westerhoff, Hans/0000-0002-0443-6114; Kolodkin,
   Alexey/0000-0002-7466-5027
CR Ferguson N, 9 IMP COLL COVID 19
   Hoops S, 2006, BIOINFORMATICS, V22, P3067, DOI 10.1093/bioinformatics/btl485
   Kitano H, 2005, NAT BIOTECHNOL, V23, P961, DOI 10.1038/nbt1111
   Kolodkin A.N., 2020, FAIRDOMHUB INVESTIG, DOI [10.15490/FAIRDOMHUB.1.INVESTIGATION.372.1, DOI 10.15490/FAIRDOMHUB.1.INVESTIGATI0N.372.1]
   Snoep JL, 2002, MOL BIOL REP, V29, P259, DOI 10.1023/A:1020350518131
   Westerhoff H.V., 2020, ADVICE SYSTEMS BIOL
   Westerhoff H.V., 2020, FAIRDOMHUB, DOI [10.15490/FAIRDOMHUB.1.MODEL.693.1, DOI 10.15490/FAIRD0MHUB.1.M0DEL.693.1]
NR 7
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2056-7189
J9 NPJ SYST BIOL APPL
JI npj Syst. Biol. Appl.
PD JUN 12
PY 2020
VL 6
IS 1
AR 18
DI 10.1038/s41540-020-0138-8
PG 5
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA MC5NI
UT WOS:000543332900001
PM 32532983
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ye, W
   Yao, M
   Dong, YC
   Ye, CT
   Wang, D
   Liu, H
   Ma, HW
   Zhang, H
   Qi, LB
   Yang, YW
   Wang, Y
   Zhang, L
   Cheng, LF
   Lv, X
   Xu, ZK
   Lei, YF
   Zhang, FL
AF Ye, Wei
   Yao, Min
   Dong, Yangchao
   Ye, Chuantao
   Wang, Dan
   Liu, He
   Ma, Hongwei
   Zhang, Hui
   Qi, Libin
   Yang, Yuewu
   Wang, Yuan
   Zhang, Liang
   Cheng, Linfeng
   Lv, Xin
   Xu, Zhikai
   Lei, Yingfeng
   Zhang, Fanglin
TI Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA
   Synthesis Inhibition
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE Remdesivir (GS-5734); antivirals; EV71; vRNA; cRNA; enterovirus
ID EBOLA-VIRUS; GLYCOPROTEIN
AB Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy. Thus, a therapeutic agent for the enterovirus-related disease is urgently needed. Remdesivir (GS-5734) is a novel monophosphoramidate adenosine analog prodrug that exhibits potent antiviral activity against diverse RNA virus families, including positive-senseCoronaviridaeandFlaviviridaeand negative-senseFiloviridae,Paramyxoviridae, andPneumoviridae. Currently, remdesivir is under phase 3 clinical development for disease COVID-19 treatment. Here, we found that remdesivir impeded both EV71 viral RNA (vRNA) and complementary (cRNA) synthesis, indicating that EV71 replication is inhibited by the triphosphate (TP) form of remdesivir. Moreover, remdesivir showed potent antiviral activity against diverse enteroviruses. These data extend the remdesivir antiviral activity to enteroviruses and indicate that remdesivir is a promising antiviral treatment for EV71 and other enterovirus infections.
C1 [Ye, Wei; Yao, Min; Dong, Yangchao; Liu, He; Ma, Hongwei; Zhang, Hui; Wang, Yuan; Zhang, Liang; Cheng, Linfeng; Lv, Xin; Xu, Zhikai; Lei, Yingfeng; Zhang, Fanglin] Fourth Mil Med Univ, Sch Preclin Med, Dept Microbiol, Xian, Shaanxi, Peoples R China.
   [Ye, Chuantao] Fourth Mil Med Univ, Tangdu Hosp, Dept Infect Dis, Xian, Shaanxi, Peoples R China.
   [Wang, Dan] Xian Med Univ, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China.
   [Qi, Libin; Yang, Yuewu] Fourth Mil Med Univ, Sch Preclin Med, Xian, Shaanxi, Peoples R China.
RP Ye, W; Lei, YF; Zhang, FL (corresponding author), Fourth Mil Med Univ, Sch Preclin Med, Dept Microbiol, Xian, Shaanxi, Peoples R China.
EM virologyyw@fmmu.edu.cn; yflei@fmmu.edu.cn; flzhang@fmmu.edu.cn
FU National Key Research and Development Program of China [2016YFC1200400];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81871697, 31600131, 81702003]; Open Fund of
   the State Key Laboratory of Pathogenic Microbial Biosafety [SKLPBS1834];
   Key Research and Development Program of Shaanxi Province [2020SF-227,
   2018JSTS03]
FX The present study was supported in part by grants from the National Key
   Research and Development Program of China (No. 2016YFC1200400) and the
   National Natural Science Foundation of China (Nos. 81871697, 31600131,
   and 81702003), the Open Fund of the State Key Laboratory of Pathogenic
   Microbial Biosafety (No. SKLPBS1834), the Key Research and Development
   Program of Shaanxi Province (No. 2020SF-227), and by a university
   supporting grant (No. 2018JSTS03). The funders had no role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Bruenn JA, 2003, NUCLEIC ACIDS RES, V31, P1821, DOI 10.1093/nar/gkg277
   Chang HW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069858
   Chang JL, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0474-9
   Cho A, 2012, BIOORG MED CHEM LETT, V22, P4127, DOI 10.1016/j.bmcl.2012.04.065
   Deng JX, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-73
   Fujii K, 2013, P NATL ACAD SCI USA, V110, P14753, DOI 10.1073/pnas.1217563110
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Jacobs M, 2016, LANCET, V388, P498, DOI 10.1016/S0140-6736(16)30386-5
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Kawakami E, 2011, J VIROL METHODS, V173, P1, DOI 10.1016/j.jviromet.2010.12.014
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Lee Kyung Yeon, 2016, Korean J Pediatr, V59, P395
   Lee YR, 2014, J BIOMED SCI, V21, DOI 10.1186/s12929-014-0080-4
   Liu JN, 2012, ARCH VIROL, V157, P539, DOI 10.1007/s00705-011-1198-2
   Lo MK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9242
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Peersen OB, 2017, VIRUS RES, V234, P4, DOI 10.1016/j.virusres.2017.01.026
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shu B, 2016, P NATL ACAD SCI USA, V113, pE4005, DOI 10.1073/pnas.1602591113
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Wang KR, 2019, CELL REP, V27, P2075, DOI 10.1016/j.celrep.2019.04.061
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang W, 2011, MICROBES INFECT, V13, P862, DOI 10.1016/j.micinf.2011.04.004
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Ye CT, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00201
   Ye W, 2015, INFECT GENET EVOL, V29, P146, DOI 10.1016/j.meegid.2014.11.009
NR 30
TC 3
Z9 3
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD JUN 12
PY 2020
VL 11
AR 1105
DI 10.3389/fmicb.2020.01105
PG 9
WC Microbiology
SC Microbiology
GA MD3GL
UT WOS:000543859600001
PM 32595613
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ye, QS
   Wang, H
   Xia, X
   Zhou, CL
   Liu, ZM
   Xia, ZE
   Zhang, Z
   Zhao, Y
   Yehenala, J
   Wang, S
   Zhou, GQ
   Hu, K
   Wu, B
   Wu, CT
   Wang, SL
   He, Y
AF Ye, Qingsong
   Wang, Hua
   Xia, Xia
   Zhou, Chenliang
   Liu, Zhiming
   Xia, Zun-en
   Zhang, Zhan
   Zhao, Yang
   Yehenala, Jun
   Wang, Si
   Zhou, Gangqiao
   Hu, Ke
   Wu, Bin
   Wu, Chu-Tse
   Wang, Songling
   He, Yan
TI Safety and efficacy assessment of allogeneic human dental pulp stem
   cells to treat patients with severe COVID-19: structured summary of a
   study protocol for a randomized controlled trial (Phase I/II)
SO TRIALS
LA English
DT Letter
DE COVID-19; randomised controlled trial; protocol; human dental pulp stem
   cells; dental stem cell banking
AB Objectives: To assess the safety and therapeutic effects of allogeneic human dental pulp stem cells (DPSCs) in treating severe pneumonia caused by COVID-19.
   Trial design: This is a single centre, two arm ratio 1:1, triple blinded, randomized, placebo-controlled, parallel group, clinical trial.
   Participants: Twenty serious COVID-19 cases will be enrolled in the trial from April 6th to December 31st 2020. Inclusion Criteria: hospitalised patients at Renmin Hospital of Wuhan University satisfy all criteria as below:
   1) Adults aged 18-65 years;
   2) Voluntarily participate in this clinical trial and sign the "informed consent form" or have consent from a legal representative.
   3) Diagnosed with severe pneumonia of COVID-19: nucleic acid test SARS-CoV-2 positive; respiratory distress (respiratory rate > 30 times / min); hypoxia (resting oxygen saturation < 93% or arterial partial pressure of oxygen / oxygen concentration < 300 mmHg).
   4) COVID-19 featured lung lesions in chest X-ray image.
   Exclusion Criteria: Patients will be excluded from the study if they meet any of the following criteria.
   1. Patients have received other experimental treatment for COVID-19 within the last 30 days;
   2. Patients have severe liver condition (e.g., Child Pugh score >=C or AST> 5 times of the upper limit);
   3. Patients with severe renal insufficiency (estimated glomerular filtration rate <=30mL / min/1.73 m(2)) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis;
   4. Patients who are co-infected with HIV, hepatitis B, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses;
   5. Female patients who have no sexual protection in the last 30 days prior to the screening assessment;
   6. Pregnant or lactating women or women using estrogen contraception;
   7. Patients who are planning to become pregnant during the study period or within 6 months after the end of the study period; 8. Other conditions that the researchers consider not suitable for participating in this clinical trial. Intervention and comparator: There will be two study groups: experimental and control. Both will receive all necessary routine treatment for COVID-19.
   The experimental group will receive an intravenous injection of dental pulp stem cells suspension (3.0x10(7)human DPSCs in 30ml saline solution) on day 1, 4 and 7; The control group will receive an equal amount of saline (placebo) on the same days. Clinical and laboratory observations will be performed for analysis during a period of 28 days for each case since the commencement of the study. Main outcomes 1. Primary outcome The primary outcome is Time To Clinical Improvement (TTCI). By definition, TTCI is the time (days) it takes to downgrade two levels from the following six ordered grades [(grade 1) discharge to (grade 6) death] in the clinical state of admission to the start of study treatments (hDPSCs or placebo). Six grades of ordered variables:GradeDescriptionGrade 1:Discharged of patient;Grade 2:Hospitalized without oxygen supplement;Grade 3:Hospitalized, oxygen supplement is required, but NIV / HFNC is not required;Grade 4:Hospitalized in intensive care unit, and NIV / HFNC treatment is required;Grade 5:Hospitalized in intensive care unit, requiring ECMO and/or IMV;Grade 6:Death. Abbreviations: NIV, non-invasive mechanical ventilation; HFNC, high-flow nasal catheter; IMV, invasive mechanical ventilation. 2. Secondary outcomes 2.1 vital signs: heart rate, blood pressure (systolic blood pressure, diastolic blood pressure).
   During the screening period, hospitalization every day (additional time points of D1, D4, D7 30min before injection, 2h +/- 30min, 24h +/- 30min after the injection) and follow-up period D90 +/- 3 days. 2.2 Laboratory examinations: during the screening period, 30 minutes before D1, D4, D7 infusion, 2h +/- 30min, 24h +/- 30min after the end of infusion, D10, D14, D28 during hospitalization or discharge day and follow-up period D90 +/- 3 days. 2.3 Blood routine: white blood cells, neutrophils, lymphocytes, monocytes, eosinophils, basophils, neutrophils, lymphocytes, monocytes, eosinophils Acidic granulocyte count, basophil count, red blood cell, hemoglobin, hematocrit, average volume of red blood cells, average red blood cell Hb content, average red blood cell Hb concentration, RDW standard deviation, RDW coefficient of variation, platelet count, platelet specific platelet average Volume, platelet distribution width,% of large platelets; 2.4 Liver and kidney function tests: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, prealbumin, total protein, albumin, globulin, white / globule ratio , Total bilirubin, direct bilirubin, cholinesterase, urea, creatinine, total carbon dioxide, uric acid glucose, potassium, sodium, chlorine, calcium, corrected calcium, magnesium, phosphorus, calcium and phosphorus product, anion gap, penetration Pressure, total cholesterol, triacylglycerol, high density lipoprotein cholesterol, Low density lipoprotein cholesterol, lipoprotein a, creatine kinase, lactate dehydrogenase, estimated glomerular filtration rate. 2.5 Inflammation indicators: hypersensitive C-reactive protein, serum amyloid (SAA); 2.6 Infectious disease testing: Hepatitis B (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb), Hepatitis C (Anti-HCV), AIDS (HIVcombin), syphilis (Anti-TP), cytomegalovirus CMV-IgM, cytomegalovirus CMV-IgG; only during the screening period and follow-up period D90 +/- 3. 2.7 Immunological testing: Collect peripheral blood to detect the phenotype of T lymphocyte, B lymphocyte, natural killer cell, Macrophage and neutrophil by using flow cytometry. Collect peripheral blood to detect the gene profile of mononuclear cells by using single-cell analyses. Collect peripheral blood serum to detect various immunoglobulin changes: IgA, IgG, IgM, total IgE; Collect peripheral blood serum to explore the changes of cytokines, Th1 cytokines (IL-1 beta, IL-2, TNF-a, ITN-gamma), Th2 cytokines (IL-4, IL-6, IL -10). 2.8 Pregnancy test: blood beta-HCG, female subjects before menopause are examined during the screening period and follow-up period D90 +/- 3. 2.9 Urine routine: color, clarity, urine sugar, bilirubin, ketone bodies, specific gravity, pH, urobilinogen, nitrite, protein, occult blood, leukocyte enzymes, red blood cells, white blood cells, epithelial cells, non-squamous epithelial cells , Transparent cast, pathological cast, crystal, fungus; 2.10 Stool Routine: color, traits, white blood cells, red blood cells, fat globules, eggs of parasites, fungi, occult blood (chemical method), occult blood (immune method), transferrin (2h +/- 30min after the injection and not detected after discharge). Randomization Block randomization method will be applied by computer to allocate the participants into experimental and control groups. The random ratio is 1:1.
   Blinding (masking) Participants, outcomes assessors and investigators (including personnel in laboratory and imaging department who issue the sample report or image observations) will be blinded.
   Injections of cell suspension and saline will be coded in accordance with the patient's randomisation group. The blind strategy is kept by an investigator who does not deliver the medical care or assess primary outcome results. Numbers to be randomized (sample size) Twenty participants will be randomized to the experimental and control groups (10 per group). Trial Status Protocol version number, hDPSC-CoVID-2019-02-2020 Version 2.0, March 13, 2020. Patients screening commenced on 16(th)April and an estimated date of the recruitment of the final participants will be around end of July. . Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Ye, Qingsong; Zhou, Chenliang; Liu, Zhiming; Xia, Zun-en; Zhang, Zhan; Zhao, Yang; Yehenala, Jun; Wang, Si; Hu, Ke] Wuhan Univ, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China.
   [Wang, Hua; Zhou, Gangqiao; Wu, Chu-Tse] Beijing Inst Radiat Med, Beijing 100850, Peoples R China.
   [Xia, Xia] Beijing SH Biotechnol Co Ltd, Beijing 100070, Peoples R China.
   [Wu, Bin] Tianjin Fopcells Pharmaceut Technol Co Ltd, Tianjin 300074, Peoples R China.
   [Wang, Songling] Capital Med Univ, Sch Stomatol, Beijing 100006, Peoples R China.
   [He, Yan] Wuhan Univ Sci & Technol, Tianyou Hosp, Wuhan 430064, Hubei, Peoples R China.
   [He, Yan] Utooth Biol Technol Co Ltd, Hubei Branch, Wuhan 430060, Hubei, Peoples R China.
RP Wu, CT (corresponding author), Beijing Inst Radiat Med, Beijing 100850, Peoples R China.; Wang, SL (corresponding author), Capital Med Univ, Sch Stomatol, Beijing 100006, Peoples R China.; He, Y (corresponding author), Wuhan Univ Sci & Technol, Tianyou Hosp, Wuhan 430064, Hubei, Peoples R China.
EM 139100026365@163.com; slwang@ccmu.edu.cn; helen-1101@hotmail.com
RI Ye, Adam/AAR-9145-2020
OI Ye, Adam/0000-0002-2868-9247
FU Chu-Tse Wu Foundation for Science & Technology Development
FX The trial has been financially funded by the Chu-Tse Wu Foundation for
   Science & Technology Development, a non-profit organization. The design
   of the study, as well as the collection, analysis and interpretation of
   data will not be influenced by the funding body. The writing of the
   protocol and the decision to submit for publication are compiled
   independent from the funding body.
NR 0
TC 5
Z9 5
U1 14
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 12
PY 2020
VL 21
IS 1
AR 520
DI 10.1186/s13063-020-04380-5
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MA9ZU
UT WOS:000542269900003
PM 32532356
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jain, SL
AF Jain, S. Lochlann
TI The WetNet: What the Oral Polio Vaccine Hypothesis Exposes about
   Globalized Interspecies Fluid Bonds
SO MEDICAL ANTHROPOLOGY QUARTERLY
LA English
DT Article; Early Access
DE HIV origins; The WetNet; experimentality; Africa; zoonosis
ID ATTENUATED POLIOMYELITIS VIRUS; ORIGIN; HIV/AIDS; CONGO; SV40
AB The author analyzes the aftermath of Edward Hooper's suggestion that the trial of an oral polio vaccine (OPV) in the Belgian colonies of Africa engendered the pandemic form of the AIDS virus, HIV-1. In response to Hooper's book, The River(1999), the Royal Society in London held a conference to debate the origins of HIV. Examination of the quick dismissal of the OPV theory opens a space for legitimately challenging the widely held belief that the vaccine contamination question was convincingly resolved. This article interrogates the relationship between historiography and the making of scientific facts and history, suggesting that historians have been too credulous of scientists' testimony. The further result of the lack of a thorough analysis of the evidence backing the OPV hypothesis has resulted in a missed opportunity to readThe Riveras one of the few detailed accounts of the immense social, political, technological, and interspecies infrastructure constituted by Cold War vaccine production. This biomedical infrastructure dramatically changed the geographic and interspecies mobility of viruses in ways that may be impossible to reconstruct. Yet these potential transmission routes remain crucial to acknowledge. The COVID-19 pandemic draws attention to the critical importance of studying The WetNet, a concept coined by the author to name the conceptual and material infrastructures of inter- and intraspecies fluid bonding.
C1 [Jain, S. Lochlann] Stanford Univ, Stanford, CA 94305 USA.
   [Jain, S. Lochlann] Kings Coll London, Global Hlth & Social Med, London, England.
RP Jain, SL (corresponding author), Stanford Univ, Stanford, CA 94305 USA.; Jain, SL (corresponding author), Kings Coll London, Global Hlth & Social Med, London, England.
EM lochjain@gmail.com
OI Jain, Lochlann/0000-0001-6911-6659
FU Stanford's Institute for Research in the Social Sciences; Stanford
   Humanities Center
FX This article has benefitted enormously discussions with many colleagues.
   In particular, I offer my heartfelt thanks to the audience at the
   Conspiracy/Theory Conference at the University of Chicago, October 2018,
   and especially the organizers, Joseph Masco and Lisa Wedeen. Heather
   Love, Maria Delores McVarish, Gregg Mitman, and the Oxidate Working
   Group deliberated with me on how to write about alternative histories.
   Stanley Plotkin, Elizabeth Tilly, Vinh-Kim Nguyen, Edward Hooper, Robin
   Weiss, and Preston Marx agreed to interviews, going out of their way to
   enable them; Alexis Roworth proposed the name "The WetNet," which I
   appreciate for its onomatopoeic quality; Miriam Ticktin, Emily
   Yates-Doer, Juliet Tempest, Katrina Karkazis, and Richard McKay gave
   exceptionally helpful comments on earlier drafts of this essay. Rachael
   Healy provided timely and energetic research assistance. Vincanne Adams
   and two anonymous reviewers for MAQ immeasurably helped improve the
   manuscript, and Carole Bernard ably and patiently copy-edited it.
   Research for this article was partially supported with Seed funding from
   Stanford's Institute for Research in the Social Sciences and the
   Stanford Humanities Center. Responsibility for all factual, grammatic,
   typographical, and interpretive errors remains with the author. I
   dedicate this essay to my magnificent, longstanding, and most
   significant other, Jake Kosek, who is always ready with a meal, a gin
   and tonic, a deep question, a joke, and the assurance that each of his
   friends, but especially me, is his very best. Thank you, Jake.
CR Ahuja N., 2013, MACAQUE CONNECTION C, P71
   ALLEN JG, 1969, ARCH SURG-CHICAGO, V98, P558
   Altman L, 1999, NY TIMES
   Bookchin D., 2004, VIRUS VACCINE TRUE S
   Cimons M., 1999, LOS ANGELES TIMES
   Clarke AE, 2016, SITUATIONAL ANAL PRA
   Cohen E, 2011, SOC TEXT, V29, P15, DOI 10.1215/01642472-1210247
   Cohen J., 2000, ATLANTIC MONTHLY
   COURTOIS G, 1958, BRIT MED J, V2, P187, DOI 10.1136/bmj.2.5090.187
   Crewdson J., 2003, SCI FICTIONS SCI MYS
   Curtis T, 1992, ROLLING STONE   0319, P108
   Curtis T, 1992, ROLLING STONE   0319, P106
   Curtis T., 1992, ROLLING STONE, P54
   EDDY BE, 1959, AM J PUBLIC HEALTH N, V49, P1486, DOI 10.2105/AJPH.49.11.1486
   Gallagher Catherine, 2018, TELLING IT IT WASNT
   Gilbert MTP, 2007, P NATL ACAD SCI USA, V104, P18566, DOI 10.1073/pnas.0705329104
   Hess David J., 2016, UNDONE SCI SOCIAL MO
   Hilleman MR, 1998, DEV BIOL STAND, V94, P183
   Hooper E, 2000, SCIENCE, V287, P233
   Hooper E, 2001, PHILOS T ROY SOC B, V356, P803, DOI 10.1098/rstb.2001.0860
   Hooper E., 2000, AIDS ORIGINS
   HOOPER E, 2000, RIVER JOURNEY SOURCE
   Hooper E., 2001, COMMUNICATION   0928
   Hooper E., 2007, OSTERRIETH ITS SIGNI
   HULL RN, 1958, AM J HYG, V68, P31, DOI 10.1093/oxfordjournals.aje.a119947
   KALTER SS, 1971, BACTERIOL REV, V35, P310, DOI 10.1128/MMBR.35.3.310-364.1971
   Keck F., 2018, MED ANTHR THEORY, V5, P1, DOI [10.17157/mat.5.3.372, DOI 10.17157/MAT.5.3.372]
   KOPROWSKI H, 1960, JAMA-J AM MED ASSOC, V174, P972, DOI 10.1001/jama.1960.63030080001006
   Larkin B, 2013, ANNU REV ANTHROPOL, V42, P327, DOI 10.1146/annurev-anthro-092412-155522
   Lewis Jr. A. M., 1973, BIOHAZARDS BIOL RES
   Markel H., 2011, BOOK ONLINE REV NEW
   Martin B, 2001, PHILOS T ROY SOC B, V356, P939, DOI 10.1098/rstb.2001.0868
   Martin B, 2010, SCI CULT-UK, V19, P215, DOI 10.1080/09505430903186088
   Martin Brian, 2001, Politics Life Sci, V20, P119
   Martin Brian, 2000, SCI CULTURE, V9, P109
   McKay Richard A., 2017, PATIENT ZERO MAKING
   Nattrass N., 2012, AIDS CONSPIRACY SCI
   Nelson-Rees WA, 2001, PHILOS T ROY SOC B, V356, P849, DOI 10.1098/rstb.2001.0873
   Offit P, 2005, CUTTER INCIDENT AM 1
   Osterrieth PM, 2001, PHILOS T ROY SOC B, V356, P839, DOI 10.1098/rstb.2001.0872
   Pepin Jacques, 2011, THE ORIGINS OF AIDS
   Plotkin SA, 2001, PHILOS T ROY SOC B, V356, P815, DOI 10.1098/rstb.2001.0861
   Plotkin SA, 2001, CLIN INFECT DIS, V32, P1068, DOI 10.1086/319612
   PLOTKIN SA, 1961, B WORLD HEALTH ORGAN, V24, P785
   Royal Society The, 2001, PHILOS T BIOL SCI, V356
   SHAH K, 1976, AM J EPIDEMIOL, V103, P1
   Shapin Steven, 2011, LEVIATHAN AIR PUMP H
   Sharp PM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006841
   Trivers R., 2000, TIMES HIGHER S  0218
   van Reybrouk D., 2014, CONGO EPIC HIST PEOP
   Vaughan R., 2000, LISTEN MUSIC LIFE H
   Wadman M., 2017, VACCINE RACE SCI POL
   Walker PR, 2003, NATURE, V422, P679, DOI 10.1038/422679a
   Weiss RA, 2001, PHILOS T R SOC B, V356, P947, DOI 10.1098/rstb.2001.0870
   Weiss RA, 2001, NATURE, V410, P1035, DOI 10.1038/35074222
   Weiss RA, 1999, SCIENCE, V286, P1305, DOI 10.1126/science.286.5443.1305
   White Hayden, 1978, TROPICS DISCOURSE ES
   Winograd T., 1992, MINDS BRAINS COMPUTE, P152
   Worobey M, 2016, NATURE, V539, P98, DOI 10.1038/nature19827
NR 59
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0745-5194
EI 1548-1387
J9 MED ANTHROPOL Q
JI Med. Anthropol. Q.
DI 10.1111/maq.12587
EA JUN 2020
PG 21
WC Anthropology; Public, Environmental & Occupational Health; Social
   Sciences, Biomedical
SC Anthropology; Public, Environmental & Occupational Health; Biomedical
   Social Sciences
GA LZ4FV
UT WOS:000541183100001
PM 32529703
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Ahmed, S
   Anirvan, P
AF Ahmed, Sakir
   Anirvan, Prajna
TI Targeting the immunology of coronavirus disease-19: synchronization
   creates symphony
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Letter
DE COVID-19; Immune therapy; Anticoagulation; Strategy
ID POTENTIAL TREATMENT
C1 [Ahmed, Sakir] KIIT Univ, Dept Clin Immunol & Rheumatol, Kalinga Inst Med Sci KIMS, Bhubaneswar 751024, Odisha, India.
   [Anirvan, Prajna] Sriram Chandra Bhanj Med Coll & Hosp, Dept Gastroenterol, Cuttack 753007, India.
RP Ahmed, S (corresponding author), KIIT Univ, Dept Clin Immunol & Rheumatol, Kalinga Inst Med Sci KIMS, Bhubaneswar 751024, Odisha, India.
EM sakir005@gmail.com; prajnaanirvan@gmail.com
RI Ahmed, Sakir/J-1876-2019
OI Ahmed, Sakir/0000-0003-4631-311X; Anirvan, Prajna/0000-0003-4494-0865
CR Ahmed S, 2020, CLIN RHEUMATOL, V39, P2099, DOI 10.1007/s10067-020-05145-w
   [Anonymous], 2020, SOLIDARITY CLIN TRIA
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419
   Choe YJ, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e127
   Gasparyan AY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e176
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Kernan KF, 2020, LANCET RHEUMATOL, V2, pE310, DOI 10.1016/S2665-9913(20)30129-6
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Lee J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e157
   Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
   Maldini CR, 2018, NAT REV IMMUNOL, V18, P605, DOI 10.1038/s41577-018-0042-2
   Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9
   O'Brien TR, 2020, CLIN INFECT DIS, V71, P1410, DOI 10.1093/cid/ciaa453
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Sarma P, 2020, J MED VIROL, V92, P776, DOI 10.1002/jmv.25898
   Shalhoub S, 2020, LANCET, V395, P1670, DOI 10.1016/S0140-6736(20)31101-6
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang RX, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.28
NR 22
TC 1
Z9 1
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0172-8172
EI 1437-160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD AUG
PY 2020
VL 40
IS 8
BP 1343
EP 1345
DI 10.1007/s00296-020-04624-2
EA JUN 2020
PG 3
WC Rheumatology
SC Rheumatology
GA MC3FK
UT WOS:000539955200002
PM 32533292
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Xia, T
   Wang, YF
AF Xia, Tian
   Wang, Yanfeng
TI Coronavirus disease 2019 and transplantation: The combination of
   lopinavir/ritonavir and hydroxychloroquine is responsible for excessive
   tacrolimus trough level and unfavorable outcome
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Letter
DE antibiotic: antiviral; clinical research/practice; complication:
   infectious; drug interaction; infectious disease; kidney
   transplantation/nephrology; liver transplantation/hepatology
C1 [Xia, Tian; Wang, Yanfeng] Wuhan Univ, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
RP Wang, YF (corresponding author), Wuhan Univ, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
EM yanfengwang@whu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81570079]
FX This research was supported by the National Natural Science Foundation
   of China, Grant Nos. 81570079.
CR Bartiromo M, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13286
   Chorin E, 2020, QT INTERVAL PATIENTS, V2020, DOI [10.1101/2020.04.02.20047050, DOI 10.1101/2020.04.02.20047050]
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Jain AB, 2003, LIVER TRANSPLANT, V9, P954, DOI 10.1053/jlts.2003.50171
   Prytula A, 2019, PEDIATR NEPHROL, V34, P31, DOI 10.1007/s00467-018-3892-8
NR 5
TC 4
Z9 4
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD SEP
PY 2020
VL 20
IS 9
BP 2630
EP 2631
DI 10.1111/ajt.15992
EA JUN 2020
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA PF2NZ
UT WOS:000539658300001
PM 32400965
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Marinella, MA
AF Marinella, Mark A.
TI Indomethacin and resveratrol as potential treatment adjuncts for
   SARS-CoV-2/COVID-19
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article
ID ANTIVIRAL ACTIVITY; INHIBITION; INFECTION; DRUGS
AB The ongoing pandemic caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2, also known as COVID-19) has led to unprecedented challenges for the global healthcare system. This novel coronavirus disease phenotype ranges from asymptomatic carriage to fulminant cytokine storm with respiratory failure, polyorgan dysfunction and death. Severe disease is characterised by exuberant inflammation resulting from high circulating cytokines such as interleukin-6 and tumour necrosis factor. These inflammatory mediators are responsible for the detrimental effects on the immune, hematologic, respiratory, renal, gastrointestinal and other body systems. In addition to inhibition of viral replication, blunting this inflammatory response before overt cytokine storm is important to improve outcomes. Although there are upcoming promising agents such as remdesivir and convalescent plasma, inexpensive, safe and widely available adjunct treatments to ameliorate disease burden would be welcome. Two potential anti-inflammatory agents include indomethacin, which has been shown in experimental models to decrease canine coronavirus levels in dogs and exhibit antiviral activity against several other viruses and the polyphenol, resveratrol, a potent antioxidant that has shown antiviral activity against several viruses.
C1 [Marinella, Mark A.] Wright State Univ, Sch Med, Div Hematol Oncol, Dayton, OH USA.
RP Marinella, MA (corresponding author), 2300 Miami Valley Dr, Centerville, OH 45415 USA.
EM Mmarinella@daytonphysicians.com
CR Abba Y, 2015, ADV VIROL, V2015, DOI 10.1155/2015/184241
   Amici C, 2006, ANTIVIR THER, V11, P1021
   Bahrami H, 2005, AM J GASTROENTEROL, V100, P856, DOI 10.1111/j.1572-0241.2005.41144.x
   Baldassarre ME, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03814
   Brunton LL, 2008, GOODMAN GILMANS MANU, P446
   Campagna M, 2010, BIOCHEM SOC T, V38, P50, DOI 10.1042/BST0380050
   Chen N, 2000, VIROLOGY, V276, P44, DOI 10.1006/viro.2000.0562
   Chmiel JF, 2015, J CYST FIBROS, V14, P720, DOI 10.1016/j.jcf.2015.03.007
   Cui QK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192692
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1086
   Gallelli L, 2013, OSTEOARTHR CARTILAGE, V21, P1400, DOI 10.1016/j.joca.2013.06.026
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Gupta R, 2020, DIABETES METAB SYND, V14, P251, DOI 10.1016/j.dsx.2020.03.012
   Lin SC, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2253-8
   Marinella MA, 2017, SUMMARY SELECTED PHY, P120
   Marinella MA, 2010, VIBRIO VULNIFICUS SE, P341
   Paules CI, 2019, NEW ENGL J MED, V380, P2185, DOI 10.1056/NEJMp1905099
   Ray N, 2004, J VIROL, V78, P12964, DOI 10.1128/JVI.78.23.12964-12974.2004
   Ray N, 2004, J VIROL, V78, P3489, DOI 10.1128/JVI.78.7.3489-3501.2004
   Reynolds AE, 2006, REV MED VIROL, V16, P393, DOI 10.1002/rmv.519
   Rossen JWA, 2004, J VIROL, V78, P9721, DOI 10.1128/JVI.78.18.9721-9730.2004
   Schroer J, 2008, P NATL ACAD SCI USA, V105, P19468, DOI 10.1073/pnas.0810740105
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhao XH, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090457
   Zhao XH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09365-0
   Zhao XH, 2016, ANTIVIR RES, V130, P93, DOI 10.1016/j.antiviral.2016.03.014
NR 26
TC 12
Z9 13
U1 4
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
PD SEP
PY 2020
VL 74
IS 9
AR e13535
DI 10.1111/ijcp.13535
EA JUN 2020
PG 3
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA NK7OK
UT WOS:000539648600001
PM 32412158
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sun, LJ
   Shen, LJ
   Fan, JF
   Gu, FJ
   Hu, M
   An, YR
   Zhou, Q
   Fan, HH
   Bi, JF
AF Sun, Lijun
   Shen, Lijun
   Fan, Junfen
   Gu, Fengjun
   Hu, Mei
   An, Yiran
   Zhou, Qing
   Fan, Huahao
   Bi, Jingfeng
TI Clinical features of patients with coronavirus disease 2019 from a
   designated hospital in Beijing, China
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE clinical features; coronavirus disease 2019; designated Hospital in
   Beijing; SARS-CoV-2
ID RESPIRATORY SYNDROME; PNEUMONIA; REMDESIVIR; INFECTION; EFFICACY; WUHAN;
   SARS
AB Clinical and laboratory data on patients with coronavirus disease 2019 (COVID-19) in Beijing, China, remain extremely limited. In this study, we summarized the clinical characteristics of patients with COVID-19 from a designated hospital in Beijing. In total, 55 patients with laboratory-confirmed SARS-CoV-2 infection in Beijing 302 Hospital were enrolled in this study. Demographic data, symptoms, comorbidities, laboratory values, treatments, and clinical outcomes were all collected and retrospectively analyzed. A total of 15 (27.3%) patients had severe symptoms, the mean age was 44.0 years (interquartile range [IQR], 34.0-56.0), and the median incubation period was 7.5 days (IQR, 5.0-11.8). A total of 26 (47.3%) patients had exposure history in Wuhan of less than 2 weeks, whereas 20 (36.4%) patients were associated with familial clusters. Also, eighteen (32.7%) patients had underlying comorbidities including hypertension. The most common symptom of illness was fever (45; 81.8%); 51 (92.7%) patients had abnormal findings on chest computed tomography. Laboratory findings showed that neutrophil count, percentage of lymphocyte, percentage of eosinophil, eosinophil count, erythrocyte sedimentation rate, albumin, and serum ferritin are potential risk factors for patients with a poor prognosis. A total of 26 patients (47.3%) were still hospitalized, whereas 29 (52.7%) patients had been discharged. Compared with patients in Wuhan, China, the symptoms of patients in Beijing are relatively mild. Older age, more comorbidities, and more abnormal prominent laboratory markers were associated with a severe condition. On the basis of antiviral drugs, it is observed that antibiotics treatment, appropriate dosage of corticosteroid, and gamma globulin therapy significantly improve patients' outcomes. Early identification and timely medical treatment are important to reduce the severity of patients with COVID-19.
C1 [Sun, Lijun; Bi, Jingfeng] Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing Hosp 302, Res Ctr Clin & Translat Med, Beijing 100039, Peoples R China.
   [Shen, Lijun] Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing Hosp 302, Liver Cirrhosis Diag & Treatment Ctr 1, Beijing 100039, Peoples R China.
   [Fan, Junfen] Capital Med Univ, Xuanwu Hosp, Inst Cerebrovasc Dis Res, Beijing, Peoples R China.
   [Fan, Junfen] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China.
   [Gu, Fengjun] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing Hosp 302, Med Informat Ctr Dept, Beijing, Peoples R China.
   [Hu, Mei] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing Hosp 302, Beijing, Peoples R China.
   [An, Yiran; Zhou, Qing] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing Hosp 302, Med Ctr Clin Lab, Beijing, Peoples R China.
   [Fan, Huahao] Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing 100029, Peoples R China.
RP Bi, JF (corresponding author), Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing Hosp 302, Res Ctr Clin & Translat Med, Beijing 100039, Peoples R China.; Fan, HH (corresponding author), Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing 100029, Peoples R China.
EM fanhuahao@mail.buct.edu.cn; 123bjf@163.com
OI zhou, qing/0000-0002-0069-559X; An, YiRan/0000-0002-7633-2330
FU Fundamental Research Funds for Central UniversitiesFundamental Research
   Funds for the Central Universities [BUCTZY2012]; National Key Research
   and Development Plan of China [2018ZX09711003-004-003]; China
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2019M65072]
FX Fundamental Research Funds for Central Universities, Grant/Award Number:
   BUCTZY2012; National Key Research and Development Plan of China,
   Grant/Award Number: 2018ZX09711003-004-003; China Postdoctoral Science
   Foundation, Grant/Award Number: 2019M65072
CR Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   [Anonymous], 2020, Chin Med J (Engl), DOI 10.1097/CM9.0000000000000819
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lin L, 2020, ZHONGHUA YI XUE ZA Z, V100
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Nishiura H, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020488
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YR, 2020, J INFECT DIS, V221, P1770, DOI 10.1093/infdis/jiaa119
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu JG, 2020, J INFECTION, V81, pE102, DOI 10.1016/j.jinf.2020.04.027
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yu P, 2020, J INFECT DIS, V221, P1757, DOI 10.1093/infdis/jiaa077
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 34
TC 7
Z9 8
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2020
VL 92
IS 10
BP 2055
EP 2066
DI 10.1002/jmv.25966
EA JUN 2020
PG 12
WC Virology
SC Virology
GA NK4OX
UT WOS:000539776000001
PM 32369208
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ma, SQ
   Zhang, J
   Wang, YS
   Xia, J
   Liu, P
   Luo, H
   Wang, MY
AF Ma, Shu-Qing
   Zhang, Jing
   Wang, Yu-Shan
   Xia, Jun
   Liu, Peng
   Luo, Hong
   Wang, Ming-Yi
TI Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an
   asymptomatic COVID-19 patient
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter
C1 [Ma, Shu-Qing; Zhang, Jing; Liu, Peng; Wang, Ming-Yi] Shandong Univ, Weihai Municipal Hosp, Cheeloo Coll Med, Dept Cent Lab, Weihai 264200, Shandong, Peoples R China.
   [Zhang, Jing] Shandong Univ, Weihai Municipal Hosp, Cheeloo Coll Med, Dept Infect Dis, Weihai, Shandong, Peoples R China.
   [Wang, Yu-Shan; Luo, Hong] Dalian Med Univ, Sch Lab Med, Dalian 116044, Liaoning, Peoples R China.
   [Xia, Jun] Weihai Chest Hosp, Dept Infect Dis, Weihai, Shandong, Peoples R China.
RP Wang, MY (corresponding author), Shandong Univ, Weihai Municipal Hosp, Cheeloo Coll Med, Dept Cent Lab, Weihai 264200, Shandong, Peoples R China.; Luo, H (corresponding author), Dalian Med Univ, Sch Lab Med, Dalian 116044, Liaoning, Peoples R China.
EM dlmuluo@163.com; wangmingyi1973@outlook.com
FU Key Research and Development Program of Weihai (Weihai Key Laboratory of
   Medical Microbiology and Immunology) [2017GGH08]
FX The study was supported by grants from Key Research and Development
   Program of Weihai (Weihai Key Laboratory of Medical Microbiology and
   Immunology, 2017GGH08).
CR Han YY, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108413
   Isidori AM, 2020, LANCET DIABETES ENDO, V8, P472, DOI 10.1016/S2213-8587(20)30149-2
   Jiang S, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016239
   National Health Commission of the People's Republic of China, 2020, NEW COR PNEUM PREV C
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, CLIN MAN SEV AC RESP
   Wu JG, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101673
   Zhang CT, 2020, J MED VIROL, V92, P1441, DOI 10.1002/jmv.25788
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 9
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2396
EP 2397
DI 10.1002/jmv.26086
EA JUN 2020
PG 2
WC Virology
SC Virology
GA NU0EN
UT WOS:000539775600001
PM 32470160
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Chen, D
   Li, XK
   Song, QF
   Hu, CC
   Su, FF
   Dai, JY
   Ye, YH
   Huang, JP
   Zhang, XM
AF Chen, Dong
   Li, Xiaokun
   Song, Qifa
   Hu, Chenchan
   Su, Feifei
   Dai, Jianyi
   Ye, Yinghai
   Huang, Jianping
   Zhang, Xiaoming
TI Assessment of Hypokalemia and Clinical Characteristics in Patients With
   Coronavirus Disease 2019 in Wenzhou, China
SO JAMA NETWORK OPEN
LA English
DT Article
AB IMPORTANCE Severe acute respiratory syndrome coronavirus 2 has caused a global outbreak of coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 binds angiotensin-converting enzyme 2 of the rennin-angiotensin system, resulting in hypokalemia.
   OBJECTIVE To investigate the prevalence, causes, and clinical implications of hypokalemia, including its possible association with treatment outcomes, among patients with COVID-19.
   DESIGN, SETTING, AND PARTICIPANTS This cohort study was conducted at Wenzhou Central Hospital and Sixth People's Hospital of Wenzhou, Wenzhou, China, from January 11, 2020, to February 15, 2020. Participants included patients who received a diagnosis of COVID-19 according to the criteria issued by the Chinese Health Bureau and were admitted to the hospital. The patients were classified as having severe hypokalemia (plasma potassium <3 mmol/L), hypokalemia (plasma potassium 3-3.5 mmol/L), and normokalemia (plasma potassium >3.5 mmol/L). The clinical features, therapy, and outcomes were compared between the 3 groups. Data analysis was conducted in March 2020.
   INTERVENTIONS The patients were given general support and antiviral therapy. Their epidemiological and clinical features were collected.
   MAIN OUTCOMES AND MEASURES The prevalence of hypokalemia and response to treatment with potassium supplements were measured by analyzing plasma and urine potassium levels.
   RESULTS One hundred seventy-five patients (87 female patients [50%]; mean [SD] age, 45 [14] years) were classified as having severe hypokalemia (31 patients [18%]), hypokalemia (64 patients [37%]), and normokalemia (80 patients [46%]). Patients with severe hypokalemia had statistically significantly higher body temperature (mean [SD], 37.6 degrees C [0.9 degrees C]) than the patients with hypokalemia (mean [SD], 37.2 degrees C [0.7 degrees C]; difference, 0.4 degrees C; 95% CI, 0.2-0.6 degrees C; P = .02) and the patients with normokalemia (mean [SD], 37.1 degrees C [0.8 degrees C]; difference, 0.5 degrees C; 95% CI, 0.3-0.7 degrees C; P = .005). Patients with higher levels of hypokalemia also had higher creatine kinase levels (severe hypokalemia, mean [SD], 200 [257] U/L [median, 113 U/L; interquartile range {IQR}, 61-242 U/L]; hypokalemia, mean [SD], 97 [85] U/L; and normokalemia, mean [SD], 82 [57] U/L), higher creatine kinase-MB fraction (severe hypokalemia, mean [SD], 32 [39] U/L [median, 14 U/L; IQR, 11-36 U/L]; hypokalemia, mean [SD], 18 [15] U/L; and normokalemia, mean [SD], 15 [8] U/L), higher lactate dehydrogenase levels (mean [SD], severe hypokalemia, 256 [88] U/L; hypokalemia, 212 [59] U/L; and normokalemia, 199 [61] U/L), and higher C-reactive protein levels (severe hypokalemia, mean [SD], 29 [23] mg/L; hypokalemia, mean [SD], 18 [20] mg/L [median, 12, mg/L; IQR, 4-25 mg/L]; and normokalemia, mean [SD], 15 [18] mg/L [median, 6 U/L; IQR, 3-17 U/L]). Of 40 severely and critically ill patients, 34 (85%) had hypokalemia. Patients with severe hypokalemia were given potassium at a dose of 40 mEq per day, for a total mean (SD) of 453 (53) mEq potassium chloride, during the hospital stay. The patients responded well to potassium supplements as they recovered.
   CONCLUSIONS AND RELEVANCE The correction of hypokalemia is challenging because of continuous renal potassium loss resulting from the degradation of angiotensin-converting enzyme 2. The high prevalence of hypokalemia among patients with COVID-19 suggests the presence of disordered rennin-angiotensin system activity, which increases as a result of reduced counteractivity of angiotensin-converting enzyme 2, which is bound by severe acute respiratory syndrome coronavirus 2.
C1 [Song, Qifa] Ningbo Municipal Ctr Dis Control & Prevent, Dept Microbiol, Ningbo 315010, Zhejiang, Peoples R China.
   [Chen, Dong; Hu, Chenchan; Su, Feifei; Dai, Jianyi; Ye, Yinghai; Huang, Jianping] Wenzhou Med Univ, Dept Infect Dis, Ding Li Clin Coll, Wenzhou, Zhejiang, Peoples R China.
   [Chen, Dong; Hu, Chenchan; Su, Feifei; Dai, Jianyi; Ye, Yinghai; Huang, Jianping] Sixth Peoples Hosp Wenzhou, Dept Infect Dis, Wenzhou, Zhejiang, Peoples R China.
   [Li, Xiaokun] Wenzhou Med Univ, Virus Res Inst, Wenzhou, Zhejiang, Peoples R China.
   [Zhang, Xiaoming] Wenzhou Municipal Ctr Dis Control & Prevent, Dept Microbiol, Wenzhou, Zhejiang, Peoples R China.
RP Song, QF (corresponding author), Ningbo Municipal Ctr Dis Control & Prevent, Dept Microbiol, Ningbo 315010, Zhejiang, Peoples R China.
EM qifasong@126.com
FU Key Scientific and Technological Innovation Projects of Wenzhou
   [ZY202004]; Natural Science Foundation of Ningbo [2017A610273]
FX This work was supported by the Key Scientific and Technological
   Innovation Projects of Wenzhou (grant ZY202004 to Dr Chen) and Natural
   Science Foundation of Ningbo (grant 2017A610273 to Dr Song).
CR Bielecka-Dabrowa A, 2012, INT J CARDIOL, V158, P12, DOI 10.1016/j.ijcard.2011.06.121
   Coca SG, 2005, AM J KIDNEY DIS, V45, P233, DOI 10.1053/j.ajkd.2004.10.015
   Fisch C, 1966, Prog Cardiovasc Dis, V8, P387, DOI 10.1016/S0033-0620(66)80029-4
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Macdonald JE, 2004, J AM COLL CARDIOL, V43, P155, DOI 10.1016/j.jacc.2003.06.021
   Rocha R, 1999, HYPERTENSION, V33, P232, DOI 10.1161/01.HYP.33.1.232
   Santos RAS, 2008, EXP PHYSIOL, V93, P519, DOI 10.1113/expphysiol.2008.042002
   Unwin RJ, 2011, NAT REV NEPHROL, V7, P75, DOI 10.1038/nrneph.2010.175
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Weiner ID, 1997, J AM SOC NEPHROL, V8, P1179
   Weir MR, 2010, CLIN J AM SOC NEPHRO, V5, P531, DOI 10.2215/CJN.07821109
   World Health Organization, INT SURV REC HUM INF
   Wu P, 2020, EUROSURVEILLANCE, V25
   Zhao JY, 2020, CHINESE MED J-PEKING, V133, P1347, DOI 10.1097/CM9.0000000000000866
NR 16
TC 22
Z9 25
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD JUN 11
PY 2020
VL 3
IS 6
AR e2011122
DI 10.1001/jamanetworkopen.2020.11122
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA MW0YA
UT WOS:000556772300003
PM 32525548
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gonzalez-Rubio, J
   Navarro-Lopez, C
   Lopez-Najera, E
   Lopez-Najera, A
   Jimenez-Diaz, L
   Navarro-Lopez, JD
   Najera, A
AF Gonzalez-Rubio, Jesus
   Navarro-Lopez, Carmen
   Lopez-Najera, Elena
   Lopez-Najera, Ana
   Jimenez-Diaz, Lydia
   Navarro-Lopez, Juan D.
   Najera, Alberto
TI Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients:
   Trying to Calm the Storm
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE cholinergic anti-inflammatory pathway; nicotine; Cytokine Release
   Syndrom (CRS); SARS-CoV-2 (virus); COVID; 19; lung
AB SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this "cytokine storm" and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (alpha 7nAchR). Nicotine, an exogenous alpha 7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients.
C1 [Gonzalez-Rubio, Jesus; Najera, Alberto] Univ Castilla La Mancha, Sch Med, Ctr Biomed Res, Albacete, Spain.
   [Navarro-Lopez, Carmen] Hosp Gen La Mancha Ctr, Serv Salud Castilla La Mancha, Ciudad Real, Spain.
   [Lopez-Najera, Elena] Salud Castilla & Leon, Gerencia Atenc Primaria, Avila, Spain.
   [Lopez-Najera, Ana] Salud Castilla & Leon, Gerencia Emergencias Sanitarias, Avila, Spain.
   [Jimenez-Diaz, Lydia; Navarro-Lopez, Juan D.] Univ Castilla La Mancha, Sch Med, Ctr Biomed Res, Ciudad Real, Spain.
RP Najera, A (corresponding author), Univ Castilla La Mancha, Sch Med, Ctr Biomed Res, Albacete, Spain.; Jimenez-Diaz, L; Navarro-Lopez, JD (corresponding author), Univ Castilla La Mancha, Sch Med, Ctr Biomed Res, Ciudad Real, Spain.
EM lydia.jimenez@uclm.es; Juan.Navarro@uclm.es; alberto.najera@uclm.es
RI de Dios Navarro Lopez, Juan/Q-9318-2019; Gonzalez-Rubio,
   Jesus/ABA-3935-2020; NAJERA, ALBERTO/U-1160-2019
OI de Dios Navarro Lopez, Juan/0000-0002-1877-7833; Gonzalez-Rubio,
   Jesus/0000-0002-9914-2505; NAJERA, ALBERTO/0000-0002-9939-6003; Jimenez
   Diaz, Lydia/0000-0001-9121-0334
FU University of Castilla-La Mancha Research Programme [2020-GRIN-28705]
FX This work was supported by University of Castilla-La Mancha Research
   Programme 2020-GRIN-28705.
CR Alraddadi BM, 2016, EMERG INFECT DIS, V22, P49, DOI 10.3201/eid2201.151340
   Borovikova LV, 2000, NATURE, V405, P458
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Changeux JP, 2020, CR BIOL, V343, P33, DOI 10.5802/crbiol.8
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Colombi D, 2020, RADIOLOGY, V296, pE86, DOI 10.1148/radiol.2020201433
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Farsalinos Konstantinos, 2020, Toxicol Rep, V7, P658, DOI 10.1016/j.toxrep.2020.04.012
   Gomes JP, 2018, PHARMACOL RES, V128, P101, DOI 10.1016/j.phrs.2017.10.005
   Gonzalez-Rubio J, 2020, OPEN SCI FRAMEWORK, DOI [10.31219/osf.io/chd2k, DOI 10.31219/OSF.IO/CHD2K]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lawrence H, 2019, J INFECTION, V79, P401, DOI 10.1016/j.jinf.2019.08.014
   Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729
   Liu SW, 2017, J EPIDEMIOL COMMUN H, V71, P154, DOI 10.1136/jech-2016-207805
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Mabley J, 2011, INFLAMMATION, V34, P231, DOI 10.1007/s10753-010-9228-x
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Papke RL, 2020, NEUROPHARMACOLOGY, V168, DOI 10.1016/j.neuropharm.2020.108021
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sandborn WJ, 1997, ANN INTERN MED, V126, P364, DOI 10.7326/0003-4819-126-5-199703010-00004
   Stead LF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub4
   Thomsen MS, 2012, CURR DRUG TARGETS, V13, P707, DOI 10.2174/138945012800399035
   Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339
   Yamada M, 2018, CURR OPIN PHARMACOL, V40, P18, DOI 10.1016/j.coph.2017.12.003
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 32
TC 3
Z9 3
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 11
PY 2020
VL 11
AR 1359
DI 10.3389/fimmu.2020.01359
PG 4
WC Immunology
SC Immunology
GA MD3WU
UT WOS:000543902100001
PM 32595653
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Convertino, I
   Tuccori, M
   Ferraro, S
   Valdiserra, G
   Cappello, E
   Focosi, D
   Blandizzi, C
AF Convertino, Irma
   Tuccori, Marco
   Ferraro, Sara
   Valdiserra, Giulia
   Cappello, Emiliano
   Focosi, Daniele
   Blandizzi, Corrado
TI Exploring pharmacological approaches for managing cytokine storm
   associated with pneumonia and acute respiratory distress syndrome in
   COVID-19 patients
SO CRITICAL CARE
LA English
DT Article
DE Sars-CoV-2; COVID-19; Cytokines; Interleukin-6; Tumor necrosis factor;
   Janus kinases; Molecular targeted therapy
ID MANAGEMENT; MECHANISMS; GOLIMUMAB; SARILUMAB
AB Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality. Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure. Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising. Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied. In this article, we discuss the potential advantages of the most promising pharmacological approaches.
C1 [Convertino, Irma; Tuccori, Marco; Ferraro, Sara; Valdiserra, Giulia; Cappello, Emiliano; Blandizzi, Corrado] Univ Pisa, Dept Clin & Expt Med, Unit Pharmacol & Pharmacovigilance, Pisa, Italy.
   [Tuccori, Marco; Blandizzi, Corrado] Pisa Univ Hosp, Unit Adverse Drug React Monitoring, Pisa, Italy.
   [Focosi, Daniele] Pisa Univ Hosp, North Western Tuscany Blood Bank, Pisa, Italy.
RP Tuccori, M (corresponding author), Univ Pisa, Dept Clin & Expt Med, Unit Pharmacol & Pharmacovigilance, Pisa, Italy.; Tuccori, M (corresponding author), Pisa Univ Hosp, Unit Adverse Drug React Monitoring, Pisa, Italy.
EM m.tuccori@ao-pisa.toscana.it
RI Convertino, Irma/AAB-4070-2020
OI Convertino, Irma/0000-0002-7883-3657
CR [Anonymous], RESTR US XELJ EMA RE
   Arora T, 2009, CYTOKINE, V45, P124, DOI 10.1016/j.cyto.2008.11.008
   Bae SC, 2019, Z RHEUMATOL, V78, P559, DOI 10.1007/s00393-018-0531-5
   Chen GH, 2020, J MED VIROL, V92, P3743, DOI 10.1002/jmv.25670
   Chen X, 2020, CLIN INFECT DIS, DOI 10.1093/cid/ciaa449
   Cortegiani A, 2020, J CRIT CARE
   Deng X., 2020, REGULATION INTERFERO
   FDA, COR COVID 19 UPD FDA
   Fragoulis GE, 2019, RHEUMATOLOGY, V58, P43, DOI 10.1093/rheumatology/key276
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hu S, 2013, J BIOL CHEM, V288, P27059, DOI 10.1074/jbc.M113.491530
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kaymakcalan Z, 2009, CLIN IMMUNOL, V131, P308, DOI 10.1016/j.clim.2009.01.002
   Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Malemud CJ, 2010, INT J INFERERON CYTO, V2, P97
   Markham A, 2019, DRUGS, V79, P887, DOI 10.1007/s40265-019-01131-y
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   McInnes IB, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1964-1
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206
   Qin C, 2020, CLIN INFECT DIS
   Raimondo MG, 2017, DRUG DES DEV THER, V11, P1593, DOI 10.2147/DDDT.S100302
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Riegler LL, 2019, THER CLIN RISK MANAG, V15, P323, DOI 10.2147/TCRM.S150524
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Shealy D, 2010, MABS-AUSTIN, V2, P428, DOI 10.4161/mabs.12304
   Song KP, 2020, POLYMERS-BASEL, V12, DOI 10.3390/polym12010132
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tanaka Y, 2014, ANN RHEUM DIS, V73, P1595, DOI 10.1136/annrheumdis-2013-205002
   Tracey D, 2008, PHARMACOL THERAPEUT, V117, P244, DOI 10.1016/j.pharmthera.2007.10.001
   Ueda N, 2013, INFLAMM BOWEL DIS, V19, P1224, DOI 10.1097/MIB.0b013e318280b169
   Wang Z, 2020, CLIN INFECT DIS
   Xu ZH, 2011, BRIT J CLIN PHARMACO, V72, P270, DOI 10.1111/j.1365-2125.2011.03964.x
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 35
TC 5
Z9 5
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD JUN 11
PY 2020
VL 24
IS 1
AR 331
DI 10.1186/s13054-020-03020-3
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA MC6KH
UT WOS:000543392800005
PM 32527304
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Marzo, T
   Messori, L
AF Marzo, Tiziano
   Messori, Luigi
TI A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of
   Auranofin
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Letter
C1 [Marzo, Tiziano] Univ Pisa, Dept Pharm, Via Bonanno Pisano 6, I-56126 Pisa, Italy.
   [Messori, Luigi] Univ Florence, Dept Chem, Via Lastr 3, I-50019 Sesto Fiorentino, Italy.
RP Marzo, T (corresponding author), Univ Pisa, Dept Pharm, Via Bonanno Pisano 6, I-56126 Pisa, Italy.
OI MARZO, TIZIANO/0000-0002-2567-3637; messori, luigi/0000-0002-9490-8014
CR Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Kim NH, 2007, IMMUNOLOGY, V122, P607, DOI 10.1111/j.1365-2567.2007.02679.x
   Liu NN, 2014, ONCOTARGET, V5, P5453, DOI 10.18632/oncotarget.2113
   Roder C, 2015, DRUGS R&D, V15, P13, DOI 10.1007/s40268-015-0083-y
   Rothan HA, 2020, FDA APPROVED GOLD DR, DOI [10.1101/2020.04.14.041228, DOI 10.1101/2020.04.14.041228]
   Savarino A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0178-0
   Zhang XN, 2019, BIOCHIMIE, V162, P46, DOI 10.1016/j.biochi.2019.03.015
NR 7
TC 4
Z9 4
U1 3
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD JUN 11
PY 2020
VL 11
IS 6
BP 1067
EP 1068
DI 10.1021/acsmedchemlett.0c00190
PG 2
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA MA2LI
UT WOS:000541747800004
PM 32547693
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Domling, A
   Li Gao
AF Domling, Alexander
   Li Gao
TI Chemistry and Biology of SARS-CoV-2
SO CHEM
LA English
DT Article
ID CORONAVIRUS PAPAIN-LIKE; BROAD-SPECTRUM INHIBITORS; COV 3CL PROTEASE;
   SARS; POTENT; DISCOVERY; VIRUS; SERIES
AB SARS-CoV-2 (previously 2019-nCoV or Wuhan coronavirus) caused an unprecedented fast-spreading worldwide pandemic. Although currently with a rather low mortality rate, the virus spread rapidly over the world using the modern world's traffic highways. The coronavirus (CoV) family members were responsible for several deadly outbreaks and epidemics during the last decade. Not only governments but also the scientific community reacted promptly to the outbreak, and information is shared quickly. For example, the genetic fingerprint was shared, and the 3D structure of key proteins was rapidly solved, which can be used for the discovery of potential treatments. An overview is given on the current knowledge of the spread, disease course, and molecular biology of SARS-CoV-2. We discuss potential treatment developments in the context of recent outbreaks, drug repurposing, and development timelines.
C1 [Domling, Alexander; Li Gao] Univ Groningen, Dept Pharm, Drug Design Grp, A Deusinglaan 1, NL-9713 Groningen, Netherlands.
   [Domling, Alexander] FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece.
RP Domling, A (corresponding author), Univ Groningen, Dept Pharm, Drug Design Grp, A Deusinglaan 1, NL-9713 Groningen, Netherlands.; Domling, A (corresponding author), FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece.
EM a.s.s.domling@rug.nl
FU ITN "Accelerated Early stage drug dIScovery" (AEGIS) [675555]; National
   Institute of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [2R01GM097082-05];
   European Lead Factory (IMI) [115489]; Qatar National Research Foundation
   [NPRP6-065-3-012]; Cofunds Alert [665250]; Prominent [754425]; KWF
   Kankerbestrijding grantKWF Kankerbestrijding [10504]; CSC
FX Research in the Domling laboratory is sponsored through ITN "Accelerated
   Early stage drug dIScovery" (AEGIS, grant agreement 675555), the
   National Institute of Health (NIH) (2R01GM097082-05), the European Lead
   Factory (IMI) (grant agreement 115489), the Qatar National Research
   Foundation (NPRP6-065-3-012), Cofunds Alert (grant agreement 665250),
   Prominent (grant agreement 754425), and KWF Kankerbestrijding grant
   (grant agreement 10504). L.G. is grateful for a CSC stipendship. Both
   authors are grateful to Micky Tortorella (GBH) for helpful discussions.
CR Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Berry M, 2015, VIRUSES-BASEL, V7, P6642, DOI 10.3390/v7122963
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen LR, 2005, BIOORG MED CHEM LETT, V15, P3058, DOI 10.1016/j.bmcl.2005.04.027
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198
   Ghosh AK, 2010, J MED CHEM, V53, P4968, DOI 10.1021/jm1004489
   Giacchello Ilaria, 2020, Curr Med Chem, DOI 10.2174/0929867327666200114115632
   Grubaugh ND, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0690-4
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Jacobs J, 2013, J MED CHEM, V56, P534, DOI 10.1021/jm301580n
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Jo S, 2019, CHEM BIOL DRUG DES, V94, P2023, DOI 10.1111/cbdd.13604
   Jordan Paul C., 2018, Antiviral Chemistry & Chemotherapy, V26, p2040206618764483, DOI 10.1177/2040206618764483
   Kang S., 2020, BIORXIV, DOI [10.1101/2020.03.06. 977876v2, DOI 10.1101/2020.03.06.977876V2]
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   Lin S., 2020, BIORXIV, DOI [10.1101/2020.01.31.929695, DOI 10.1101/2020.01.31.929695]
   Liu P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11110979
   Liu X., 2020, BIORXIV
   Martin S., 2020, HOMOLOGY MODELS WUHA, DOI [10.26434/chemrxiv.11637294.v1., DOI 10.26434/CHEMRXIV.11637294.V1]
   Moreno A.J., 2020, GLIPTIN REPURPOSING, DOI [10.26434/chemrxiv, DOI 10.26434/CHEMRXIV]
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Ramajayam R, 2010, BIOORGAN MED CHEM, V18, P7849, DOI 10.1016/j.bmc.2010.09.050
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Shie JJ, 2005, J MED CHEM, V48, P4469, DOI 10.1021/jm050184y
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Westover JB, 2018, ANTIVIR RES, V156, P38, DOI 10.1016/j.antiviral.2018.05.013
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Yang S, 2006, J MED CHEM, V49, P4971, DOI 10.1021/jm0603926
   Yoon JS, 2019, J MED CHEM, V62, P6346, DOI 10.1021/acs.jmedchem.9b00781
   Zhang Y, 2020, CHINA DAILY
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 47
TC 7
Z9 7
U1 7
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2451-9294
J9 CHEM-US
JI Chem
PD JUN 11
PY 2020
VL 6
IS 6
BP 1283
EP 1295
DI 10.1016/j.chempr.2020.04.023
PG 13
WC Chemistry, Multidisciplinary
SC Chemistry
GA LZ0EU
UT WOS:000540905600018
PM 32529116
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zarghami, A
   Farjam, M
   Fakhraei, B
   Hashemzadeh, K
   Yazdanpanah, MH
AF Zarghami, Arman
   Farjam, Mojtaba
   Fakhraei, Bahareh
   Hashemzadeh, Kosar
   Yazdanpanah, Mohammad Hosein
TI A Report of the Telepsychiatric Evaluation of SARS-CoV-2 Patients
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article
DE telemedicine; telepsychiatry; COVID-19; psychotherapy; psychosomatic;
   psychiatric disorders
ID VALIDITY; OUTBREAK; PHQ-9
AB Objective: During the current coronavirus disease 2019 (COVID-19) pandemic, telemedicine has been brought to the forefront of attention. This report aimed to assess psychiatric comorbidities in COVID-19 patients by utilizing telepsychiatry. Methods: COVID-19 patients admitted in Fasa University Hospital and nonhospitalized outpatients of Fasa city were interviewed by a psychiatrist through video chat for a 1-month period (March-April, 2020). Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder Assessment (GAD-7), and Perceived Stress Scale-14 (PSS 14) questionnaires were administered for all patients. Each patient's mental status was recorded, and if any psychiatric problem was diagnosed, supportive psychotherapy, pharmacotherapy, and follow-up visits based on the patient's condition were started. Result: From a total of 82 COVID-19 patients who entered the study, 32 (39.03%) and 50 (60.97%) subjects were inpatients and outpatients, respectively. Moreover, 32 (39.03%) subjects were male and 50 (60.97%) were female. Insomnia seen in 24 (29.3%) patients and adjustment disorder in 13 (15.9%) patients were the most common psychiatric disorders among a total of 33 (40.2%) patients suffering from mental illness. Female and hospitalized patients presented significantly more frequent comorbidities than males and outpatients. Conclusions: Psychiatric disorders were significantly more common in patients with hospital admission than those without and more frequent in female versus male subjects. There were no significant differences between male and female subjects with and without admission according to the PHQ-9, GAD-7, and PSS-14 scores. It was concluded that telepsychiatry in the early stages of mental problems during a catastrophic event like the coronavirus pandemic, can be an efficient instrument for the screening of psychosomatic comorbidities, so that pharmacological treatment (considering possible drug interactions with COVID-19 medications) and psychotherapeutic intervention can be optimized by psychiatrists.
C1 [Zarghami, Arman; Fakhraei, Bahareh] Fasa Univ Med Sci, Shariati Hosp, Dept Psychiat, Fasa, Iran.
   [Zarghami, Arman; Farjam, Mojtaba; Fakhraei, Bahareh; Yazdanpanah, Mohammad Hosein] Fasa Univ Med Sci, Noncommunicable Dis Res Ctr, Fasa, Iran.
   [Hashemzadeh, Kosar] Islamic Azad Univ, Dept Psychol, Fasa Branch, Fasa, Iran.
   [Yazdanpanah, Mohammad Hosein] Fasa Univ Med Sci, Student Res Comm, Fasa, Iran.
RP Fakhraei, B (corresponding author), Fasa Univ Med Sci, Sch Med, Dept Psychiat, Ebne Sina Sq, Fasa 7461686131, Iran.
EM b.fakhraee@gmail.com
RI Farjam, Mojtaba/O-3475-2017
OI Farjam, Mojtaba/0000-0003-4826-2846; Yazdanpanah, Mohammad
   Hosein/0000-0003-3645-9430
CR Badrfam R, 2020, ASIAN J PSYCHIATR, V50, DOI 10.1016/j.ajp.2020.101935
   Bo Hai-Xin, 2020, Psychol Med, P1, DOI 10.1017/S0033291720000999
   CAMUS P, 1994, AIP CONF PROC, P105
   Dadfar M, 2018, TRENDS PSYCHIATR PSY, V40, P144, DOI 10.1590/2237-6089-2017-0116
   Douglas CJ, 2008, AM J PSYCHIAT, V165, P445, DOI 10.1176/appi.ajp.2007.07121907
   Druss BG, 2020, JAMA PSYCHIAT, V77, P891, DOI 10.1001/jamapsychiatry.2020.0894
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Li W, 2020, INT J BIOL SCI, V16, P1732, DOI 10.7150/ijbs.45120
   Livingston E, 2020, JAMA-J AM MED ASSOC, V323, P1912, DOI 10.1001/jama.2020.5317
   Maroufizadeh S, 2014, PAYESH, V13, P457
   Mirghaed MT, 2020, INT J PREVENTIVE MED, V11, DOI 10.4103/ijpvm.IJPVM_510_18
   Naeinian M. R., 2011, CLIN PSYCHOL PERSONA, V2, P41
   Shore JH., 2020, WHAT IS TELEPSYCHIAT
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   ZHANG K, 2020, BRIT J PSYCHIAT, DOI DOI 10.1080/00071668.2020.1724877
NR 16
TC 2
Z9 2
U1 3
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
EI 1556-3669
J9 TELEMED E-HEALTH
JI Telemed. e-Health
PD DEC 1
PY 2020
VL 26
IS 12
BP 1461
EP 1465
DI 10.1089/tmj.2020.0125
EA JUN 2020
PG 5
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA PB7DQ
UT WOS:000541739700001
PM 32525755
DA 2021-01-01
ER

PT J
AU Grein, J
   Ohmagari, N
   Shin, D
   Diaz, G
   Asperges, E
   Castagna, A
   Feldt, T
   Green, G
   Green, ML
   Lescure, FX
   Nicastri, E
   Oda, R
   Yo, K
   Quiros-Roldan, E
   Studemeister, A
   Redinski, J
   Ahmed, S
   Bernett, J
   Chelliah, D
   Chen, D
   Chihara, S
   Cohen, SH
   Cunningham, J
   Monforte, AD
   Ismail, S
   Kato, H
   Lapadula, G
   L'Her, E
   Maeno, T
   Majumder, S
   Massari, M
   Mora-Rillo, M
   Mutoh, Y
   Nguyen, D
   Verweij, E
   Zoufaly, A
   Osinusi, AO
   DeZure, A
   Zhao, Y
   Zhong, L
   Chokkalingam, A
   Elboudwarej, E
   Telep, L
   Timbs, L
   Henne, I
   Sellers, S
   Cao, H
   Tan, SK
   Winterbourne, L
   Desai, P
   Mera, R
   Gaggar, A
   Myers, RP
   Brainard, DM
   Childs, R
   Flanigan, T
AF Grein, J.
   Ohmagari, N.
   Shin, D.
   Diaz, G.
   Asperges, E.
   Castagna, A.
   Feldt, T.
   Green, G.
   Green, M. L.
   Lescure, F-X
   Nicastri, E.
   Oda, R.
   Yo, K.
   Quiros-Roldan, E.
   Studemeister, A.
   Redinski, J.
   Ahmed, S.
   Bernett, J.
   Chelliah, D.
   Chen, D.
   Chihara, S.
   Cohen, S. H.
   Cunningham, J.
   Monforte, A. DArminio
   Ismail, S.
   Kato, H.
   Lapadula, G.
   L'Her, E.
   Maeno, T.
   Majumder, S.
   Massari, M.
   Mora-Rillo, M.
   Mutoh, Y.
   Nguyen, D.
   Verweij, E.
   Zoufaly, A.
   Osinusi, A. O.
   DeZure, A.
   Zhao, Y.
   Zhong, L.
   Chokkalingam, A.
   Elboudwarej, E.
   Telep, L.
   Timbs, L.
   Henne, I
   Sellers, S.
   Cao, H.
   Tan, S. K.
   Winterbourne, L.
   Desai, P.
   Mera, R.
   Gaggar, A.
   Myers, R. P.
   Brainard, D. M.
   Childs, R.
   Flanigan, T.
TI Compassionate Use of Remdesivir for Patients with Severe Covid-19
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
AB A cohort of patients with severe Covid-19 received treatment with remdesivir under a compassionate-use protocol. Improvement in oxygen-support status was observed in 68% of patients, and overall mortality was 13% over a median follow-up of 18 days.
   Background Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. Methods We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. Results Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. Conclusions In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)
C1 [Grein, J.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Shin, D.; Chelliah, D.] El Camino Hosp, Mountain View, CA USA.
   [Green, G.] Sutter Santa Rosa Reg Hosp, Santa Rosa, CA USA.
   [Studemeister, A.; Redinski, J.] Reg Med Ctr, San Jose, CA USA.
   [Majumder, S.] Good Samaritan Hosp, San Jose, CA USA.
   [Bernett, J.] John Muir Hlth, Walnut Creek, CA USA.
   [Cohen, S. H.] UC Davis Hlth, Sacramento, CA USA.
   [Ismail, S.] NorthBay Med Ctr, Fairfield, CA USA.
   [Osinusi, A. O.; DeZure, A.; Zhao, Y.; Zhong, L.; Chokkalingam, A.; Elboudwarej, E.; Telep, L.; Timbs, L.; Henne, I; Sellers, S.; Cao, H.; Tan, S. K.; Winterbourne, L.; Desai, P.; Mera, R.; Gaggar, A.; Myers, R. P.; Brainard, D. M.] Gilead Sci, 333 Lakeside Dr, Foster City, CA 94404 USA.
   [Ohmagari, N.] Natl Ctr Global Hlth & Med, Tokyo, Japan.
   [Oda, R.] Tokyo Bay Urayasu Ichikawa Med Ctr, Urayasu, Japan.
   [Yo, K.] Hiratsuka City Hosp, Hiratsuka, Kanagawa, Japan.
   [Kato, H.] Yokohama City Univ Med, Yokohama, Kanagawa, Japan.
   [Maeno, T.] Gunma Univ Hosp, Gunma, Japan.
   [Mutoh, Y.] Tosei Gen Hosp, Seto, Japan.
   [Diaz, G.] Providence Reg Med Ctr Everett, Everett, WA USA.
   [Green, M. L.] Univ Washington, Med Ctr Northwest, Seattle, WA 98195 USA.
   [Chihara, S.] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
   [Asperges, E.] Fdn IRCCS Policlin San Mateo, Pavia, Italy.
   [Castagna, A.] Ist Sci San Raffaele, IRCCS, Milan, Italy.
   [Monforte, A. DArminio] Univ Milan, Dept Hlth Serv, Azienda Socio Sanit Terr Spedali ASST Santi Paolo, Milan, Italy.
   [Nicastri, E.] IRCCS L Spallanzani, Natl Inst Infect Dis, Rome, Italy.
   [Quiros-Roldan, E.] Univ Brescia, ASST Civili Brescia, Brescia, Italy.
   [Lapadula, G.] Univ Milano Bicocca, San Gerardo Hosp, ASST Monza, Monza, Italy.
   [Massari, M.] Azienda Unite Sanit Locali IRCCS, Reggio Emilia, Italy.
   [Feldt, T.] Univ Klinikum Dusseldorf, Dusseldorf, Germany.
   [Lescure, F-X] Univ Paris, Infect Antimicrobiens Modelisat Evolut IAME, INSERM, Paris, France.
   [Lescure, F-X] Hop Xavier Bichat, AP HP, Dept Infect Dis, Paris, France.
   [L'Her, E.] Ctr Hosp Reg & Univ Brest La Cavale Blanche, Brest, France.
   [Nguyen, D.] Univ Hosp Bordeaux, Div Infect Dis & Trop Med, Bordeaux, France.
   [Ahmed, S.] St Alexius Med Ctr, Hoffman Estates, IL USA.
   [Chen, D.] Mackenzie Hlth, Richmond Hill, ON, Canada.
   [Cunningham, J.] Columbia Univ, Irving Med Ctr, New York, NY USA.
   [Mora-Rillo, M.] Hosp Univ La Paz Carlos III, Inst Invest Hosp Univ La Paz, Madrid, Spain.
   [Verweij, E.] Bernhoven Hosp, Uden, Netherlands.
   [Zoufaly, A.] Kaiser Franz Josef Hosp, Vienna, Austria.
   [Childs, R.] US Publ Hlth Serv Commissioned Corps, Washington, DC USA.
   [Flanigan, T.] Miriam Hosp, Providence, RI 02906 USA.
RP Brainard, DM (corresponding author), Gilead Sci, 333 Lakeside Dr, Foster City, CA 94404 USA.
EM diana.brainard@gilead.com
OI Lescure, Xavier/0000-0002-2828-125X
FU Gilead SciencesGilead Sciences [N/A] Funding Source: Medline
CR Arentz M, 2020, JAMA
   Baden LR, 2020, NEW ENGL J MED, V382, P1851, DOI 10.1056/NEJMe2005477
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   European Medicines Agency, 2020, SUMM COMP US REMD GI
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Intensive Care National Audit and Research Centre, 2020, ICNARC REP COVID 19
   Kujawski SA, 2020, 1 12 PATIENTS CORONA, DOI 10.1101/2020.03.09.20032896
   Lescure F.X., 2020, LANCET INFECT DIS
   Mahase Elisabeth, 2020, BMJ, V368, pm1282, DOI 10.1136/bmj.m1282
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Onder G, 2020, JAMA
   Poston J.T, 2020, JAMA
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V101623
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen C, 2020, JAMA
   Spinelli A, 2020, BRIT J SURG, V107, pE191, DOI 10.1002/bjs.11648
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Wu Z, 2020, JAMA
   Zhang C, 2020, LANCET GASTROENTEROL
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 29
TC 581
Z9 596
U1 59
U2 88
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 11
PY 2020
VL 382
IS 24
BP 2327
EP 2336
DI 10.1056/NEJMoa2007016
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA LZ3TR
UT WOS:000541151500012
PM 32275812
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Yen, BLJ
   Yen, ML
   Wang, LT
   Liu, KJ
   Sytwu, HK
AF Yen, B. Linju
   Yen, Men-Luh
   Wang, Li-Tzu
   Liu, Ko-Jiunn
   Sytwu, Huey-Kang
TI Current status of mesenchymal stem cell therapy for immune/inflammatory
   lung disorders: Gleaning insights for possible use inCOVID-19
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE ARDS; asthma; bacterial pneumonia; clinical trial; COPD; COVID-19;
   cytokine storm; influenza; IPF; MSCs
ID INDUCED PULMONARY-FIBROSIS; STROMAL CELLS; IN-VITRO; AIRWAY
   INFLAMMATION; INDUCED EMPHYSEMA; GROWTH-FACTOR; INJURY; VIRUS; SURVIVAL;
   INHIBIT
AB The broad immunomodulatory properties of human mesenchymal stem cells (MSCs) has allowed for wide application in regenerative medicine as well as immune/inflammatory diseases, including unmatched allogeneic use. The novel coronavirus disease COVID-19 has unleashed a pandemic in record time accompanied by an alarming mortality rate mainly due to pulmonary injury and acute respiratory distress syndrome. Since there are no effective preventive or curative therapies currently, MSC therapy (MSCT) has emerged as a possible candidate despite the lack of preclinical data of MSCs for COVID-19. Interestingly, MSCT preclinical data specifically on immune/inflammatory disorders of the lungs were among the earliest to be reported in 2003, with the first clinical use of MSCT for graft-vs-host disease reported in 2004. Since these first reports, preclinical data showing beneficial effects of MSC immunomodulation have accumulated substantially, and as a consequence, over a third of MSCT clinical trials now target immune/inflammatory diseases. There is much preclinical evidence for MSCT in noninfectious-including chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis-as well as infectious bacterial immune/inflammatory lung disorders, with data generally demonstrating therapeutic effects; however, for infectious viral pulmonary conditions, the preclinical evidence is more scarce with some inconsistent outcomes. In this article, we review the mechanistic evidence for clinical use of MSCs in pulmonary immune/inflammatory disorders, and survey the ongoing clinical trials-including for COVID-19-of MSCT for these diseases, with some perspectives and comment on MSCT for COVID-19.
C1 [Yen, B. Linju] Natl Hlth Res Inst NHRI, Inst Cellular & Syst Med, Regenerat Med Res Grp, Zhunan, Taiwan.
   [Yen, Men-Luh; Wang, Li-Tzu] Natl Taiwan Univ NTU Hosp, Dept Obstet Gynecol, Taipei, Taiwan.
   [Yen, Men-Luh; Wang, Li-Tzu] NTU, Coll Med, 1,Sect 1,Jen Ai Rd, Taipei 10051, Taiwan.
   [Liu, Ko-Jiunn] NHRI, Natl Inst Canc Res, Tainan, Taiwan.
   [Sytwu, Huey-Kang] NHRI, Natl Inst Infect Dis & Vaccinol, Zhunan, Taiwan.
   [Sytwu, Huey-Kang] Natl Def Med Ctr, Dept & Grad Inst Microbiol & Immunol, Taipei, Taiwan.
RP Yen, ML (corresponding author), NTU, Coll Med, 1,Sect 1,Jen Ai Rd, Taipei 10051, Taiwan.; Yen, BLJ (corresponding author), 35 Keyan Rd, Zhunan 35053, Taiwan.; Yen, ML (corresponding author), NTUH, Dept Obstet Gynecol, 1,Sect 1,Jen Ai Rd, Taipei 10051, Taiwan.
EM blyen@nhri.edu.tw; mlyen@ntu.edu.tw
OI YEN, MEN-LUH/0000-0003-3800-3664
FU Central Government S & T grant, Taiwan [109-1901-01-19-07]; NHRINational
   Health Research Institutes - Taiwan [09A1-CSPP06]; Taiwan Ministry of
   Science Technology [MOST-107-2314-B002-104-MY3]
FX Central Government S & T grant, Taiwan, Grant/Award Number:
   109-1901-01-19-07; NHRI, Grant/Award Number: 09A1-CSPP06; Taiwan
   Ministry of Science & Technology, Grant/Award Number:
   MOST-107-2314-B002-104-MY3
CR Anjos-Afonso F, 2004, J CELL SCI, V117, P5655, DOI 10.1242/jcs.01488
   Asami T, 2018, CYTOTHERAPY, V20, P302, DOI 10.1016/j.jcyt.2018.01.003
   Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X
   Bonfield TL, 2010, AM J PHYSIOL-LUNG C, V299, pL760, DOI 10.1152/ajplung.00182.2009
   Broekman W, 2016, RESP RES, V17, DOI 10.1186/s12931-015-0316-1
   Cahill EF, 2016, STEM CELL TRANSL MED, V5, P1307, DOI 10.5966/sctm.2015-0337
   Calkoen FGJ, 2014, STEM CELL TRANSL MED, V3, P899, DOI 10.5966/sctm.2013-0191
   Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008
   Cassatella MA, 2011, STEM CELLS, V29, P1001, DOI 10.1002/stem.651
   Chambers DC, 2014, RESPIROLOGY, V19, P1013, DOI 10.1111/resp.12343
   Chan MCW, 2016, P NATL ACAD SCI USA, V113, P3621, DOI 10.1073/pnas.1601911113
   Chang YS, 2009, CELL TRANSPLANT, V18, P869, DOI 10.3727/096368909X471189
   Chen Jiajia, 2020, Engineering (Beijing), V6, P1153, DOI 10.1016/j.eng.2020.02.006
   Chen PM, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-49
   Chen SY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0846-9
   Danchuk S, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt68
   Darwish I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071761
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Du YM, 2018, EXP CELL RES, V363, P114, DOI 10.1016/j.yexcr.2017.12.021
   Engela AU, 2013, CLIN EXP IMMUNOL, V174, P449, DOI 10.1111/cei.12199
   Fang XH, 2010, J BIOL CHEM, V285, P26211, DOI 10.1074/jbc.M110.119917
   Gao PS, 2014, J IMMUNOL, V192, P4560, DOI 10.4049/jimmunol.1303461
   Gasteiger G, 2016, IMMUNOL REV, V271, P200, DOI 10.1111/imr.12399
   Glassberg MK, 2017, CHEST, V151, P971, DOI 10.1016/j.chest.2016.10.061
   Glenn JD, 2014, STEM CELLS, V32, P2744, DOI 10.1002/stem.1755
   Gotts JE, 2014, AM J PHYSIOL-LUNG C, V307, pL395, DOI 10.1152/ajplung.00110.2014
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan XJ, 2013, J CELL BIOCHEM, V114, P323, DOI 10.1002/jcb.24377
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Gupta N, 2012, THORAX, V67, P533, DOI 10.1136/thoraxjnl-2011-201176
   Hall SRR, 2013, STEM CELLS, V31, P397, DOI 10.1002/stem.1270
   Hao Q, 2019, J IMMUNOL, V203, P1961, DOI 10.4049/jimmunol.1801534
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Hof-Nahor I, 2012, J CELL SCI, V125, P4640, DOI 10.1242/jcs.108860
   Huh JW, 2011, AM J PHYSIOL-LUNG C, V301, pL255, DOI 10.1152/ajplung.00253.2010
   International Society of Cell & Gene Therapy (ISCT), ISCT REL STAT UNPR S
   International Society of Stem Cell Research (ISSCR), ISSCR STAT REG MARK
   Ionescu L, 2012, AM J PHYSIOL-LUNG C, V303, pL967, DOI 10.1152/ajplung.00144.2011
   Jackson MV, 2016, STEM CELLS, V34, P2210, DOI 10.1002/stem.2372
   Karlsson H, 2008, BLOOD, V112, P532, DOI 10.1182/blood-2007-10-119370
   Katsha AM, 2011, MOL THER, V19, P196, DOI 10.1038/mt.2010.192
   Kennelly H, 2016, SCI REP-UK, V6, DOI 10.1038/srep38207
   Khatri M, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0774-8
   Khatri M, 2013, CELL TRANSPLANT, V22, P461, DOI 10.3727/096368912X656063
   Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544
   Lan YW, 2017, STEM CELL TRANSL MED, V6, P1006, DOI 10.5966/sctm.2016-0054
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7
   Le Blanc K, 2003, SCAND J IMMUNOL, V57, P11, DOI 10.1046/j.1365-3083.2003.01176.x
   Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209
   Lederer DJ, 2018, NEW ENGL J MED, V378, P1811, DOI 10.1056/NEJMra1705751
   Lee JW, 2009, P NATL ACAD SCI USA, V106, P16357, DOI 10.1073/pnas.0907996106
   Lee SH, 2011, ALLERGY ASTHMA IMMUN, V3, P205, DOI 10.4168/aair.2011.3.3.205
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li F, 2017, MOL IMMUNOL, V90, P11, DOI 10.1016/j.molimm.2017.06.032
   Li Y, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0395-z
   Lloyd CM, 2017, IMMUNITY, V46, P549, DOI 10.1016/j.immuni.2017.04.005
   Loy H, 2019, J INFECT DIS, V219, P186, DOI 10.1093/infdis/jiy478
   Maggini J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009252
   Malcherek G, 2014, LEUKEMIA, V28, P2388, DOI 10.1038/leu.2014.273
   Mansouri N, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128060
   McIntyre LA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147170
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Moll G, 2014, STEM CELLS, V32, P2430, DOI 10.1002/stem.1729
   Monsel A, 2015, AM J RESP CRIT CARE, V192, P324, DOI 10.1164/rccm.201410-1765OC
   Moodley Y, 2009, AM J PATHOL, V175, P303, DOI 10.2353/ajpath.2009.080629
   Morrison TJ, 2017, AM J RESP CRIT CARE, V196, P1275, DOI 10.1164/rccm.201701-0170OC
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100
   Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536-019-0083-6
   Postma DS, 2015, NEW ENGL J MED, V373, P1241, DOI 10.1056/NEJMra1411863
   Raffaghello L, 2008, STEM CELLS, V26, P151, DOI 10.1634/stemcells.2007-0416
   Rasmusson I, 2003, TRANSPLANTATION, V76, P1208, DOI 10.1097/01.TP.0000082540.43730.80
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Rubio GA, 2018, J CELL PHYSIOL, V233, P5503, DOI 10.1002/jcp.26418
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Schweitzer KS, 2011, AM J RESP CRIT CARE, V183, P215, DOI 10.1164/rccm.201001-0126OC
   Shigemura N, 2006, AM J TRANSPLANT, V6, P2592, DOI 10.1111/j.1600-6143.2006.01522.x
   Simonson OE, 2015, STEM CELL TRANSL MED, V4, P1199, DOI 10.5966/sctm.2015-0021
   Sinclair K, 2013, RESPIROLOGY, V18, P397, DOI 10.1111/resp.12050
   Sun YQ, 2012, STEM CELLS, V30, P2692, DOI 10.1002/stem.1241
   Tang GN, 2016, STEM CELLS DEV, V25, P883, DOI 10.1089/scd.2015.0339
   Thanunchai M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081805
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Tropea KA, 2012, AM J PHYSIOL-LUNG C, V302, pL829, DOI 10.1152/ajplung.00347.2011
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Wang LT, 2018, STEM CELLS, V36, P903, DOI 10.1002/stem.2795
   Wang LX, 2016, BOUND VALUE PROBL, DOI 10.1186/s13661-016-0584-9
   Weiss DJ, 2013, CHEST, V143, P1590, DOI 10.1378/chest.12-2094
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Yao Y, 2018, STEM CELL REP, V11, P1120, DOI 10.1016/j.stemcr.2018.09.012
   Zhen GH, 2010, CYTOTHERAPY, V12, P605, DOI 10.3109/14653241003745888
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 97
TC 3
Z9 4
U1 6
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD OCT
PY 2020
VL 9
IS 10
BP 1163
EP 1173
DI 10.1002/sctm.20-0186
EA JUN 2020
PG 11
WC Cell & Tissue Engineering
SC Cell Biology
GA NT1CD
UT WOS:000540640500001
PM 32526079
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Scully, EP
   Haverfield, J
   Ursin, RL
   Tannenbaum, C
   Klein, SL
AF Scully, Eileen P.
   Haverfield, Jenna
   Ursin, Rebecca L.
   Tannenbaum, Cara
   Klein, Sabra L.
TI Considering how biological sex impacts immune responses and COVID-19
   outcomes
SO NATURE REVIEWS IMMUNOLOGY
LA English
DT Article; Early Access
ID RESPIRATORY SYNDROME CORONAVIRUS; PLASMACYTOID DENDRITIC CELLS;
   IFN-ALPHA PRODUCTION; T-CELLS; MEDIATED RESPONSE; INFLUENZA;
   SUSCEPTIBILITY; CHROMOSOME; GENDER; SARS
AB Why are males more susceptible to severe COVID-19 than females? In this Perspective, Sabra Klein and colleagues consider the sex differences in the immune system that may contribute to this sex bias.
   A male bias in mortality has emerged in the COVID-19 pandemic, which is consistent with the pathogenesis of other viral infections. Biological sex differences may manifest themselves in susceptibility to infection, early pathogenesis, innate viral control, adaptive immune responses or the balance of inflammation and tissue repair in the resolution of infection. We discuss available sex-disaggregated epidemiological data from the COVID-19 pandemic, introduce sex-differential features of immunity and highlight potential sex differences underlying COVID-19 severity. We propose that sex differences in immunopathogenesis will inform mechanisms of COVID-19, identify points for therapeutic intervention and improve vaccine design and increase vaccine efficacy.
C1 [Scully, Eileen P.] Johns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD USA.
   [Haverfield, Jenna; Tannenbaum, Cara] Canadian Inst Hlth Res, Inst Gender & Hlth, Montreal, PQ, Canada.
   [Ursin, Rebecca L.; Klein, Sabra L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.
   [Tannenbaum, Cara] Univ Montreal, Ctr Rech, Inst Univ Geriatr Montreal, Fac Med, Montreal, PQ, Canada.
   [Klein, Sabra L.] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
RP Klein, SL (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.; Klein, SL (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
EM sklein2@jhu.edu
OI Haverfield, Jenna/0000-0002-4893-7797; Ursin,
   Rebecca/0000-0002-3398-331X
CR Alghamdi IG, 2014, INT J GEN MED, V7, P417, DOI 10.2147/IJGM.S67061
   Alosaimi B, 2020, CYTOKINE, V126, DOI 10.1016/j.cyto.2019.154895
   Asselta R, 2020, ACE2 TMPRSS2 VARIANT, DOI [10.1101/2020.03.30.20047878, DOI 10.1101/2020.03.30.20047878]
   Baratchian Mehdi, 2020, bioRxiv, DOI 10.1101/2020.04.21.051201
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Bartz D, 2020, JAMA INTERN MED, V180, P574, DOI 10.1001/jamainternmed.2019.7194
   Berghofer B, 2006, J IMMUNOL, V177, P2088, DOI 10.4049/jimmunol.177.4.2088
   Berlin David A, 2020, N Engl J Med, V383, P2451, DOI 10.1056/NEJMcp2009575
   Bischof E, 2020, J CLIN INVEST, V130, P3350, DOI 10.1172/JCI139306
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bongen E, 2019, CELL REP, V29, P1961, DOI 10.1016/j.celrep.2019.10.019
   Bynoe MS, 2000, P NATL ACAD SCI USA, V97, P2703, DOI 10.1073/pnas.040577497
   Canadian Institutes of Health Research, 2020, WHY SEX GEND NEED BE
   Carrel L, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0355
   Case LK, 2013, GENOME RES, V23, P1474, DOI 10.1101/gr.156703.113
   Centers for Disease Control and Prevention, 2020, MULT INFL SYNDR CHIL
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dragin N, 2016, J CLIN INVEST, V126, P1525, DOI 10.1172/JCI81894
   Dudley JP, 2020, CLIN INFECT DIS, V71, P863, DOI 10.1093/cid/ciaa354
   Dumanski J. P., 2020, IMMUNE CELLS LACKING, DOI [10.1101/673459, DOI 10.1101/673459]
   Ellegren H, 2007, NAT REV GENET, V8, P689, DOI 10.1038/nrg2167
   Eshima N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019409
   Falagas ME, 2007, RESP MED, V101, P1845, DOI 10.1016/j.rmed.2007.04.011
   Fink AL, 2018, P NATL ACAD SCI USA, V115, P12477, DOI 10.1073/pnas.1805268115
   Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718
   Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111
   Ghosh S, 2017, J IMMUNOL, V198, P1782, DOI 10.4049/jimmunol.1601166
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Gibson WT, 2020, BIORXIV, DOI [10.1101/2020.04.05.026633, DOI 10.1101/2020.04.05.026633]
   Golden LC, 2019, P NATL ACAD SCI USA, V116, P26779, DOI 10.1073/pnas.1910072116
   Griesbeck M, 2015, J IMMUNOL, V195, P5327, DOI 10.4049/jimmunol.1501684
   Grimaldi CM, 2006, J IMMUNOL, V176, P2703, DOI 10.4049/jimmunol.176.5.2703
   Grimaldi CM, 2002, J CLIN INVEST, V109, P1625, DOI 10.1172/JCI200214873
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Hall OJ, 2017, MUCOSAL IMMUNOL, V10, P1097, DOI 10.1038/mi.2017.35
   Hall OJ, 2017, J VIROL, V91, DOI 10.1128/JVI.02160-16
   Hall OJ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005840
   Halter S, 2020, ANAESTH CRIT CARE PA, V39, P35, DOI 10.1016/j.accpm.2019.07.014
   Heffernan DS, 2011, J TRAUMA, V71, P878, DOI 10.1097/TA.0b013e31822c0d31
   Hewagama A, 2009, GENES IMMUN, V10, P509, DOI 10.1038/gene.2009.12
   Hill L, 2011, MOL MED, V17, P211, DOI 10.2119/molmed.2010.00172
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwasaki A, 2012, ANNU REV MICROBIOL, V66, P177, DOI 10.1146/annurev-micro-092611-150203
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Klein SL, 2015, P NATL ACAD SCI USA, V112, P5257, DOI 10.1073/pnas.1502843112
   Klein SL, PLOS PATHOG
   Koff WC, 2020, NEW ENGL J MED, V383, P804, DOI 10.1056/NEJMp2006761
   Krementsov DN, 2017, P NATL ACAD SCI USA, V114, P3491, DOI 10.1073/pnas.1620889114
   Laffont S, 2014, J IMMUNOL, V193, P5444, DOI 10.4049/jimmunol.1303400
   Leng SX, 2020, CELL IMMUNOL, V348, DOI 10.1016/j.cellimm.2019.104024
   Leong HN, 2006, ANN ACAD MED SINGAP, V35, P326
   Liu Jun, 2010, Biol Sex Differ, V1, P6, DOI 10.1186/2042-6410-1-6
   Liu T, 2015, AM J SURG, V210, P911, DOI 10.1016/j.amjsurg.2015.03.021
   Heredia-Genestar JM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16296-4
   Marina S, 2020, LANCET, DOI [10.2139/ssrn.3576790, DOI 10.2139/SSRN.3576790]
   Markle JG, 2014, TRENDS IMMUNOL, V35, P97, DOI 10.1016/j.it.2013.10.006
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meier A, 2009, NAT MED, V15, P955, DOI 10.1038/nm.2004
   Meng YF, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008520
   Ministry of Health and Welfare of South Korea, 2020, DOM OCC STAT
   Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485
   Nikolich-Zugich J, 2020, GEROSCIENCE, V42, P505, DOI 10.1007/s11357-020-00186-0
   NYC, 2020, COVID 19 DAT
   Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415
   Oh HLJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.26
   Page ST, 2006, AM J PHYSIOL-ENDOC M, V290, pE856, DOI 10.1152/ajpendo.00484.2005
   Pauklin S, 2009, J EXP MED, V206, P99, DOI 10.1084/jem.20080521
   Peckham H, 2020, SEX BIAS COVID 19 ME, DOI [10.21203/rs.3.rs-23651/v2, DOI 10.21203/RS.3.RS-23651/V2]
   Peretz J, 2016, AM J PHYSIOL-LUNG C, V310, pL415, DOI 10.1152/ajplung.00398.2015
   Piasecka B, 2018, P NATL ACAD SCI USA, V115, pE488, DOI 10.1073/pnas.1714765115
   Polanczyk MJ, 2004, J IMMUNOL, V173, P2227, DOI 10.4049/jimmunol.173.4.2227
   Potluri T, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0124-6
   Qu K, 2015, CELL SYST, V1, P51, DOI 10.1016/j.cels.2015.06.003
   Robinson DP, 2014, J VIROL, V88, P4711, DOI 10.1128/JVI.02081-13
   Robinson Dionne P, 2011, Biol Sex Differ, V2, P8, DOI 10.1186/2042-6410-2-8
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sakiani S, 2013, NAT REV ENDOCRINOL, V9, P56, DOI 10.1038/nrendo.2012.206
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Schmiedel BJ, 2018, CELL, V175, P1701, DOI 10.1016/j.cell.2018.10.022
   Schurz H, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-018-0185-z
   Seillet C, 2012, BLOOD, V119, P454, DOI 10.1182/blood-2011-08-371831
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Souyris M, 2019, SEMIN IMMUNOPATHOL, V41, P153, DOI 10.1007/s00281-018-0712-y
   Souyris M, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8855
   Stopsack KH, 2020, CANCER DISCOV, V10, P779, DOI 10.1158/2159-8290.CD-20-0451
   Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tai P, 2008, J CELL PHYSIOL, V214, P456, DOI 10.1002/jcp.21221
   Tannenbaum C, 2019, NATURE, V575, P137, DOI 10.1038/s41586-019-1657-6
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tukiainen T, 2017, NATURE, V550, P244, DOI 10.1038/nature24265
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   vom Steeg LG, 2019, SEMIN IMMUNOPATHOL, V41, P189, DOI 10.1007/s00281-018-0718-5
   vom Steeg LG, 2017, HORM BEHAV, V88, P45, DOI 10.1016/j.yhbeh.2016.10.016
   vom Steeg LG, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005374
   Wang JL, 2016, P NATL ACAD SCI USA, V113, pE2029, DOI 10.1073/pnas.1520113113
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wong KC, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3681-4
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yee Mon Kristel Joy, 2019, Immunohorizons, V3, P121, DOI 10.4049/immunohorizons.1800066
   Zhang Q, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012917
   Zhao RZ, 2020, NATURE, V577, P416, DOI 10.1038/s41586-019-1873-0
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zhu ML, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11350
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 116
TC 39
Z9 39
U1 10
U2 12
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1474-1733
EI 1474-1741
J9 NAT REV IMMUNOL
JI Nat. Rev. Immunol.
DI 10.1038/s41577-020-0348-8
EA JUN 2020
PG 6
WC Immunology
SC Immunology
GA LX4PO
UT WOS:000539814700001
PM 32528136
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Barquera, R
   Collen, E
   Di, D
   Buhler, S
   Teixeira, J
   Llamas, B
   Nunes, JM
   Sanchez-Mazas, A
AF Barquera, Rodrigo
   Collen, Evelyn
   Di, Da
   Buhler, Stephane
   Teixeira, Joao
   Llamas, Bastien
   Nunes, Jose M.
   Sanchez-Mazas, Alicia
TI Binding affinities of 438HLAproteins to complete proteomes of seven
   pandemic viruses and distributions of strongest and weakestHLApeptide
   binders in populations worldwide
SO HLA
LA English
DT Article; Early Access
DE coronavirus; COVID-19; HIV; HLA population genetics; Indigenous
   Americans; influenza; natural selection; peptide-binding predictions;
   SARS-CoV-2
ID HLA CLASS-I; BALANCING SELECTION; SOFT SWEEPS; DIVERSITY; MHC; ALLELES;
   FREQUENCIES; CHIMPANZEES; ADAPTATION; EXPRESSION
AB We report detailed peptide-binding affinities between 438 HLA Class I and Class II proteins and complete proteomes of seven pandemic human viruses, including coronaviruses, influenza viruses and HIV-1. We contrast these affinities with HLA allele frequencies across hundreds of human populations worldwide. Statistical modelling shows that peptide-binding affinities classified into four distinct categories depend on the HLA locus but that the type of virus is only a weak predictor, except in the case of HIV-1. Among the strong HLA binders (IC50 <= 50), we uncovered 16 alleles (the top ones beingA*02:02,B*15:03andDRB1*01:02) binding more than 1% of peptides derived from all viruses, 9 (top ones includingHLA-A*68:01,B*15:25,C*03:02andDRB1*07:01) binding all viruses except HIV-1, and 15 (top onesA*02:01andC*14:02) only binding coronaviruses. The frequencies of strongest and weakest HLA peptide binders differ significantly among populations from different geographic regions. In particular, Indigenous peoples of America show both higher frequencies of strongest and lower frequencies of weakest HLA binders. As many HLA proteins are found to be strong binders of peptides derived from distinct viral families, and are hence promiscuous (or generalist), we discuss this result in relation to possible signatures of natural selection on HLA promiscuous alleles due to past pathogenic infections. Our findings are highly relevant for both evolutionary genetics and the development of vaccine therapies. However they should not lead to forget that individual resistance and vulnerability to diseases go beyond the sole HLA allelic affinity and depend on multiple, complex and often unknown biological, environmental and other variables.
C1 [Barquera, Rodrigo] Max Planck Inst Sci Human Hist, Dept Archaeogenet, Jena, Germany.
   [Collen, Evelyn; Teixeira, Joao] Univ Adelaide, Dept Genet & Evolut, Australian Ctr Ancient DNA ACAD, Adelaide, SA, Australia.
   [Di, Da; Buhler, Stephane; Nunes, Jose M.; Sanchez-Mazas, Alicia] Univ Geneva, Dept Genet & Evolut, Anthropol Unit, Geneva, Switzerland.
   [Buhler, Stephane] Geneva Univ Hosp, Dept Diagnost, Transplantat Immunol Unit, Geneva, Switzerland.
   [Buhler, Stephane] Geneva Univ Hosp, Dept Diagnost, Natl Reference Lab Histocompatibil, Geneva, Switzerland.
   [Teixeira, Joao; Llamas, Bastien] Univ Adelaide, Ctr Excellence Australian Biodivers & Heritage, Sch Biol Sci, Adelaide, SA, Australia.
   [Llamas, Bastien] Univ Adelaide, Environm Inst, Adelaide, SA, Australia.
   [Nunes, Jose M.; Sanchez-Mazas, Alicia] Univ Geneva, Inst Genet & Genom Geneva IGE3, Geneva, Switzerland.
RP Nunes, JM; Sanchez-Mazas, A (corresponding author), Univ Geneva, Dept Genet & Evolut, Anthropol Unit, Geneva, Switzerland.
EM jose.deabreununes@unige.ch; alicia.sanchez-mazas@unige.ch
RI Teixeira, Joao C./AAE-4189-2020
OI Teixeira, Joao C./0000-0001-6417-4702; Barquera,
   Rodrigo/0000-0003-0518-4518; Buhler, Stephane/0000-0001-6675-5287
FU Australian Government Research Training Program Stipend (RTPS)Australian
   Government; Australian Research CouncilAustralian Research Council
   [IN180100017, FT170100448]; European Cooperation in Science and
   TechnologyEuropean Cooperation in Science and Technology (COST)
   [BM0803]; MaxPlanck-GesellschaftMax Planck Society; Schweizerischer
   Nationalfonds zur Forderung der Wissenschaftlichen ForschungAustrian
   Science Fund (FWF) [310030_188820, 31003A_144180]
FX Australian Government Research Training Program Stipend (RTPS);
   Australian Research Council Discovery Indigenous Project, Grant/Award
   Number: IN180100017; Australian Research Council Future Fellowship,
   Grant/Award Number: FT170100448; European Cooperation in Science and
   Technology, Grant/Award Number: BM0803; MaxPlanck-Gesellschaft;
   Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen
   Forschung, Grant/Award Numbers: 310030_188820, 31003A_144180
CR Abdulla F, 2019, MICROB PATHOGENESIS, V137, DOI 10.1016/j.micpath.2019.103791
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Alicia SM, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20248
   Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   [Anonymous], 2019, SUMM INFL RISK ASS T
   Apps R, 2013, SCIENCE, V340, P87, DOI 10.1126/science.1232685
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Buhler S, 2016, IMMUNOGENETICS, V68, P401, DOI 10.1007/s00251-016-0918-x
   Buhler S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014643
   Carey BS, 2019, INT J IMMUNOGENET, V46, P307, DOI 10.1111/iji.12443
   De Groot NG, 2008, MOL ECOL, V17, P2074, DOI 10.1111/j.1365-294X.2008.03716.x
   de Groot NG, 2017, IMMUNOGENETICS, V69, P499, DOI 10.1007/s00251-017-1006-6
   El-Awar N, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/3406230
   Francisco RD, 2015, IMMUNOGENETICS, V67, P651, DOI 10.1007/s00251-015-0875-9
   Gfeller D, 2018, J IMMUNOL, V201, P3705, DOI 10.4049/jimmunol.1800914
   Gfeller D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01716
   Goeury T, 2018, HLA, V91, P148, DOI 10.1111/tan.13197
   Goeury T, 2018, HLA, V91, P36, DOI 10.1111/tan.13180
   Goulder PJR, 1996, AIDS RES HUM RETROV, V12, P1691, DOI 10.1089/aid.1996.12.1691
   Goulder PJR, 2000, J VIROL, V74, P5291, DOI 10.1128/JVI.74.11.5291-5299.2000
   Hermisson J, 2005, GENETICS, V169, P2335, DOI 10.1534/genetics.104.036947
   Hilton HG, 2017, IMMUNOGENETICS, V69, P567, DOI 10.1007/s00251-017-1001-y
   Hollenbach JA, 2001, HUM IMMUNOL, V62, P378, DOI 10.1016/S0198-8859(01)00212-9
   Holmes EC, 2004, PHILOS T R SOC B, V359, P1059, DOI 10.1098/rstb.2004.1478
   Hyun-Jung Lee Chloe, 2020, F1000Res, V9, P145, DOI 10.12688/f1000research.22507.1
   Jain S, 2019, MED MICROBIOL IMMUN, V208, P227, DOI 10.1007/s00430-019-00584-y
   Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Kaufman J, 2018, TRENDS IMMUNOL, V39, P367, DOI 10.1016/j.it.2018.01.001
   Kaur G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15924
   Key FM, 2014, CURR OPIN GENET DEV, V29, P45, DOI 10.1016/j.gde.2014.08.001
   Khan S, 2020, J CLIN MICROBIOL, V58, DOI [10.1128/JCM.01297-20, 10.1128/JCM.00187-20]
   Klein J, 2000, NEW ENGL J MED, V343, P702, DOI 10.1056/NEJM200009073431006
   KLEIN J, 1993, ANNU REV IMMUNOL, V11, P269, DOI 10.1146/annurev.immunol.11.1.269
   Leffler EM, 2013, SCIENCE, V339, P1578, DOI 10.1126/science.1234070
   Lenz TL, 2016, MOL BIOL EVOL, V33, P2555, DOI 10.1093/molbev/msw127
   Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9
   Lindo J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13175
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Manczinger M, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000131
   Mehra NK, 2010, HLA COMPLEX BIOL MED
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   Muraro E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00197
   Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20
   Novembre J, 2012, PHILOS T R SOC B, V367, P878, DOI 10.1098/rstb.2011.0305
   Nunes JM, 2014, TISSUE ANTIGENS, V83, P307, DOI 10.1111/tan.12356
   Otting N, 2019, IMMUNOGENETICS, V71, P13, DOI 10.1007/s00251-018-1080-4
   Parham P, 2005, NAT REV IMMUNOL, V5, P201, DOI 10.1038/nri1570
   Parham P., IMMUNE SYSTEM
   Patterson KB, 2002, AM J MED SCI, V323, P216, DOI 10.1097/00000441-200204000-00009
   Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101
   Pierini F, 2018, MOL BIOL EVOL, V35, P2145, DOI 10.1093/molbev/msy116
   Pinheiro J.C., 2000, MIXED EFFECTS MODELS, DOI [10.1007/b98882, DOI 10.1007/B98882]
   Pritchard JK, 2010, CURR BIOL, V20, pR208, DOI 10.1016/j.cub.2009.11.055
   R Core Team, 2018, R LANG ENV STAT COMP
   Racle J, 2019, NAT BIOTECHNOL, V37, P1283, DOI 10.1038/s41587-019-0289-6
   Riccio ME, 2011, HUM BIOL, V83, P405, DOI 10.3378/027.083.0306
   Robinson J, 2020, NUCLEIC ACIDS RES, V48, pD948, DOI 10.1093/nar/gkz950
   Sanchez-Mazas A, 2012, INT J IMMUNOGENET, V39, P459, DOI 10.1111/j.1744-313X.2012.01113.x
   Sanchez-Mazas Alicia, 2020, Swiss Med Wkly, V150, pw20214, DOI 10.4414/smw.2020.20214
   Sanchez-Mazas A, 2017, MOL ECOL, V26, P6238, DOI 10.1111/mec.14366
   Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594
   Shiina T, 2009, J HUM GENET, V54, P15, DOI 10.1038/jhg.2008.5
   Solberg OD, 2008, HUM IMMUNOL, V69, P443, DOI 10.1016/j.humimm.2008.05.001
   Spurgin LG, 2010, P ROY SOC B-BIOL SCI, V277, P979, DOI 10.1098/rspb.2009.2084
   Sun H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134334
   Takeshita LYC, 2014, TRANSFUS MED HEMOTH, V41, P352, DOI 10.1159/000368056
   Teixeira JC, 2015, MOL BIOL EVOL, V32, P1186, DOI 10.1093/molbev/msv007
   Venables W. N., 1999, MODERN APPL STAT S P
   Vina MAF, 2012, PHILOS T R SOC B, V367, P820, DOI 10.1098/rstb.2011.0320
   Wang Mingjun, 2014, Methods Mol Biol, V1184, P309, DOI 10.1007/978-1-4939-1115-8_17
   Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568
   Zhao WL, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006457
NR 73
TC 4
Z9 4
U1 3
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2059-2302
EI 2059-2310
J9 HLA
JI HLA
DI 10.1111/tan.13956
EA JUN 2020
PG 22
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA LX1MO
UT WOS:000539603100001
PM 32475052
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Manganotti, P
   Pesavento, V
   Stella, AB
   Bonzi, L
   Campagnolo, E
   Bellavita, G
   Fabris, B
   Luzzati, R
AF Manganotti, Paolo
   Pesavento, Valentina
   Stella, Alex Buoite
   Bonzi, Lucia
   Campagnolo, Elena
   Bellavita, Giulia
   Fabris, Bruno
   Luzzati, Roberto
TI Miller Fisher syndrome diagnosis and treatment in a patient with
   SARS-CoV-2
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Article
DE COVID-19; Miller Fisher syndrome; Cranial polyneuritis; Immunoglobulins
ID GUILLAIN-BARRE
AB This case report describes the clinical characteristics of a 50-year-old woman that developed SARS-CoV-2 pneumonia and was admitted at the COVID-19 dedicated unit where she developed neurological symptoms 10 days after admission. After neurological examination, including a panel of blood cerebrospinal fluid biomarkers, a diagnosis of Miller Fisher syndrome (MFS) was hypothesized and intravenous immunoglobulin therapy (IVIG) was initiated. Fourteen days after the start of IVIG treatment, the patient has been discharged at home with the resolution of respiratory symptoms and only minor hyporeflexia at the lower limbs, without any side effect.
C1 [Manganotti, Paolo; Stella, Alex Buoite; Bellavita, Giulia] Univ Trieste, Cattinara Univ Hosp ASUGI, Clin Unit Neurol, Dept Med Surg & Hlth Sci, Str Fiume 447, I-34149 Trieste, Italy.
   [Pesavento, Valentina; Bonzi, Lucia] Cattinara Univ Hosp ASUGI, Rehabil Unit, Via Giuseppe Lorenzo Gatteri 25-1, I-34125 Trieste, Italy.
   [Campagnolo, Elena; Fabris, Bruno] Univ Trieste, Cattinara Univ Hosp ASUGI, Dept Med Surg & Hlth Sci, Endocrinol Unit, Str Fiume 447, I-34149 Trieste, Italy.
   [Luzzati, Roberto] Univ Trieste, Cattinara Univ Hosp ASUGI, Dept Med Surg & Hlth Sci, Infect Dis Dept, Str Fiume 447, I-34149 Trieste, Italy.
RP Manganotti, P (corresponding author), Univ Trieste, Cattinara Univ Hosp ASUGI, Clin Unit Neurol, Dept Med Surg & Hlth Sci, Str Fiume 447, I-34149 Trieste, Italy.
EM pmanganotti@units.it
RI Stella, Alex Buoite/F-1788-2016; Luzzati, Roberto/B-8380-2014
OI Stella, Alex Buoite/0000-0002-4871-7022; Luzzati,
   Roberto/0000-0001-5546-0715
CR Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   POLO A, 1992, J NEUROL NEUROSUR PS, V55, P398, DOI 10.1136/jnnp.55.5.398
   Pusch E, 2018, ALLERGO J, V27, P28, DOI [10.1007/s40629-018-0056-0, 10.1007/s15007-018-1580-4]
   Sellers SA, 2017, INFLUENZA OTHER RESP, V11, P372, DOI 10.1111/irv.12470
   Wakerley BR, 2014, NAT REV NEUROL, V10, P537, DOI 10.1038/nrneurol.2014.138
   Wattanasit P, 2020, CASE REP NEUROL, V12, P92, DOI 10.1159/000506191
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
NR 7
TC 6
Z9 7
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1355-0284
EI 1538-2443
J9 J NEUROVIROL
JI J. Neurovirol.
PD AUG
PY 2020
VL 26
IS 4
BP 605
EP 606
DI 10.1007/s13365-020-00858-9
EA JUN 2020
PG 2
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA NE2CC
UT WOS:000539879100001
PM 32529516
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Moring, JC
   Dondanville, KA
   Fina, BA
   Hassija, C
   Chard, K
   Monson, C
   LoSavio, ST
   Wells, SY
   Morland, LA
   Kaysen, D
   Galovski, TE
   Resick, PA
AF Moring, John C.
   Dondanville, Katherine A.
   Fina, Brooke A.
   Hassija, Christina
   Chard, Kathleen
   Monson, Candice
   LoSavio, Stefanie T.
   Wells, Stephanie Y.
   Morland, Leslie A.
   Kaysen, Debra
   Galovski, Tara E.
   Resick, Patricia A.
TI Cognitive Processing Therapy for Posttraumatic Stress Disorder via
   Telehealth: Practical Considerations During the COVID-19 Pandemic
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID PERSON DELIVERY; HEALTH; PTSD; VETERANS; TRIAL
AB The global outbreak of COVID-19 has required mental health providers to rapidly rethink and adapt how they provide care. Cognitive processing therapy (CPT) is a trauma-focused, evidence-based treatment for posttraumatic stress disorder that is effective when delivered in-person or via telehealth. Given current limitations on the provision of in-person mental health treatment during the COVID-19 pandemic, this article presents guidelines and treatment considerations when implementing CPT via telehealth. Based on lessons learned from prior studies and clinical delivery of CPT via telehealth, recommendations are made with regard to overall strategies for adapting CPT to a telehealth format, including how to conduct routine assessments and ensure treatment fidelity.
C1 [Moring, John C.; Dondanville, Katherine A.; Fina, Brooke A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat & Behav Sci, San Antonio, TX 78229 USA.
   [Hassija, Christina] Calif State Univ San Bernardino, Dept Psychol, San Bernardino, CA 92407 USA.
   [Chard, Kathleen] Cincinnati VA Med Ctr, Cincinnati, OH USA.
   [Chard, Kathleen] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA.
   [Monson, Candice] Ryerson Univ, Dept Psychol, Toronto, ON, Canada.
   [LoSavio, Stefanie T.; Wells, Stephanie Y.; Resick, Patricia A.] Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, Durham, NC USA.
   [LoSavio, Stefanie T.; Wells, Stephanie Y.] Durham VA Hlth Care Syst, Durham, NC USA.
   [Wells, Stephanie Y.] VA VISN 6 Midatlantic Mental Illness Res Educ Cli, Durham, NC USA.
   [Morland, Leslie A.] VA San Diego Care Syst, Dept Vet Affairs, La Jolla, CA USA.
   [Morland, Leslie A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
   [Kaysen, Debra] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
   [Galovski, Tara E.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA USA.
   [Galovski, Tara E.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
RP Moring, JC (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, 7550 IH-10 West,Suite 1325, San Antonio, TX 78229 USA.
EM MoringJ@uthscsa.edu
FU National Institute of Health (NIH) Clinical and Translational Science
   Awards Program through the National Center for Advancing Clinical
   Translational SciencesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [KL2 TR002646];
   Patient-Centered Outcomes Research InstitutePatient-Centered Outcomes
   Research Institute - PCORI [PCORI-PCS1406-19295]; Clinical Sciences
   Research & Development Service of Department of Veterans Affairs Office
   of Research and Development [1I01CX001757]
FX John C. Moring was supported by the National Institute of Health (NIH)
   Clinical and Translational Science Awards Program through the National
   Center for Advancing Clinical Translational Sciences (KL2 TR002646; PI:
   Tsevat). The study sponsor had no role in the writing of this report nor
   in the decision to submit the article for publication. The views
   expressed herein are solely those of the authors and do not reflect an
   endorsement by or the official policy or position of the NIH. Manuscript
   preparation for Debra Kaysen was supported by a grant from the
   Patient-Centered Outcomes Research Institute (PCORI-PCS1406-19295; PIs:
   Fortney, Unutzer). The statements in this article are solely the
   responsibility of the authors and do not necessarily represent the views
   of the Patient-Centered Outcomes Research Institute, its Board of
   Governors, or its Methodology Committee. Manuscript preparation for
   Stefanie LoSavio was supported by grant #1I01CX001757 from the Clinical
   Sciences Research & Development Service of Department of Veterans
   Affairs Office of Research and Development (PI: Eric Dedert). The views
   expressed in this article are those of the authors and do not
   necessarily reflect the position or policy of the VA or the United
   States government or any of the institutions with which the authors are
   affiliated.
CR American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   American Psychiatric Association, 2020, TEL COVID 19 UPD TEL
   Bovin MJ, 2016, PSYCHOL ASSESSMENT, V28, P1379, DOI 10.1037/pas0000254
   Britt TW, 2007, MIL MED, V172, P157, DOI 10.7205/MILMED.172.2.157
   Brown FW, 2017, AM J PSYCHIAT, V174, P1126, DOI 10.1176/appi.ajp.2017.17040418
   Bryan CJ, 2016, DEPRESS ANXIETY, V33, P549, DOI 10.1002/da.22456
   Centers for Disease Control and Prevention, 2020, COR COVID 19
   Chard KM, 2005, J CONSULT CLIN PSYCH, V73, P965, DOI 10.1037/0022-006X.73.5.965
   Chew NWS, 2020, BRAIN BEHAV IMMUN, V88, P559, DOI 10.1016/j.bbi.2020.04.049
   Cuijpers P, 2019, JAMA PSYCHIAT, V76, P700, DOI 10.1001/jamapsychiatry.2019.0268
   Fortney JC, 2020, CONTEMP CLIN TRIALS, V90, DOI 10.1016/j.cct.2019.105873
   Galovski TE, 2012, J CONSULT CLIN PSYCH, V80, P968, DOI 10.1037/a0030600
   Gros DF, 2018, J TELEMED TELECARE, V24, P51, DOI 10.1177/1357633X16671096
   Hassija C, 2011, TELEMED E-HEALTH, V17, P309, DOI 10.1089/tmj.2010.0147
   Hoge CW, 2014, PSYCHIAT SERV, V65, P997, DOI 10.1176/appi.ps.201300307
   Kazdin AE, 2011, PERSPECT PSYCHOL SCI, V6, P21, DOI 10.1177/1745691610393527
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Maieritsch KP, 2016, J TELEMED TELECARE, V22, P238, DOI 10.1177/1357633X15596109
   McGeary DD, 2012, PAIN PRACT, V12, P570, DOI 10.1111/j.1533-2500.2012.00534.x
   Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898
   Morland LA, 2015, DEPRESS ANXIETY, V32, P811, DOI 10.1002/da.22397
   Morland LA, 2014, J CLIN PSYCHIAT, V75, P470, DOI 10.4088/JCP.13m08842
   Peterson A. L., 2019, SAN ANT COMBAT PTSD
   Prins A., 2015, PRIMARY CARE PTSD SC
   Resick P.A., 2017, COGNITIVE PROCESSING
   Resick PA, 2008, J CONSULT CLIN PSYCH, V76, P243, DOI 10.1037/0022-006X.76.2.243
   Resick PA, 2017, JAMA PSYCHIAT, V74, P28, DOI 10.1001/jamapsychiatry.2016.2729
   Richardson LK, 2009, CLIN PSYCHOL-SCI PR, V16, P323, DOI 10.1111/j.1468-2850.2009.01170.x
   Rosner R, 2019, JAMA PSYCHIAT, V76, P484, DOI 10.1001/jamapsychiatry.2018.4349
   US Department of Health and Human Services, 2020, NOT ENF DISCR TEL RE
   Wang CY, 2020, BRAIN BEHAV IMMUN, V87, P40, DOI 10.1016/j.bbi.2020.04.028
   Weathers F, 2013, LIFE EVENTS CHECKLIS
   Weathers F. W., 2013, PTSD CHECKLIST DSM 5
NR 33
TC 3
Z9 3
U1 4
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD AUG
PY 2020
VL 33
IS 4
BP 371
EP 379
DI 10.1002/jts.22544
EA JUN 2020
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA NE4JK
UT WOS:000539581400001
PM 32400911
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mathies, D
   Rauschning, D
   Wagner, U
   Mueller, F
   Maibaum, M
   Binnemann, C
   Waldeck, S
   Thinnes, K
   Braun, M
   Schmidbauer, W
   Hagen, RM
   Bickel, C
AF Mathies, Daniel
   Rauschning, Dominic
   Wagner, Ulrike
   Mueller, Frank
   Maibaum, Maja
   Binnemann, Christin
   Waldeck, Stephan
   Thinnes, Katrin
   Braun, Michael
   Schmidbauer, Willi
   Hagen, Ralf M.
   Bickel, Christoph
TI A case of SARS-CoV-2 pneumonia with successful antiviral therapy in a
   77-year-old man with a heart transplant
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE antibiotic; antiviral; clinical research; practice; heart
   transplantation; cardiology; immunosuppressant - calcineurin inhibitor;
   tacrolimus; immunosuppression; immune modulation; infection and
   infectious agents - viral; infectious disease; lung disease; infectious;
   off-label drug use
ID OUTBREAK
AB The SARS-CoV-2 infection can be seen as a single disease, but it also affects patients with relevant comorbidities who may have an increased risk of a severe course of infection. In this report, we present a 77-year-old patient with a heart transplant receiving relevant immunosuppressive therapy who tested positive for SARS-CoV-2 after several days of dyspnea, dry cough, and light general symptoms. Computed tomography confirmed interstitial pneumonia. The patient received antiviral therapy with hydroxychloroquine and showed no further deterioration of the clinical state. After 12 days of hospitalization, the patient was released; he was SARS-CoV-2 negative and completely asymptomatic.
C1 [Mathies, Daniel; Rauschning, Dominic; Wagner, Ulrike; Mueller, Frank; Maibaum, Maja; Binnemann, Christin; Bickel, Christoph] Bundeswehr Cent Hosp Koblenz, Dept Internal Med, Koblenz, Germany.
   [Waldeck, Stephan] Bundeswehr Cent Hosp Koblenz, Dept Radiol, Koblenz, Germany.
   [Thinnes, Katrin; Braun, Michael; Schmidbauer, Willi] Bundeswehr Cent Hosp Koblenz, Dept Anaesthesiol, Koblenz, Germany.
   [Hagen, Ralf M.] Bundeswehr Cent Hosp Koblenz, Dept Microbiol, Koblenz, Germany.
RP Rauschning, D (corresponding author), Bundeswehr Cent Hosp Koblenz, Dept Internal Med, Koblenz, Germany.
EM dominicrauschning@bundeswehr.org
OI Rauschning, Dominic/0000-0001-9284-8778
CR AlGhamdi M, 2015, AM J TRANSPLANT, V15, P1101, DOI 10.1111/ajt.13085
   Aslam S, 2020, GUIDANCE CARDIOTHORA
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Konrad R, 2020, EUROSURVEILLANCE, V25, P13, DOI 10.2807/1560-7917.ES.2020.25.9.2000173
   Kumar D, 2003, AM J TRANSPLANT, V3, P977, DOI 10.1034/j.1600-6143.2003.00197.x
   Li F., 2020, J HEART LUNG TRANSPL
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   National Health Commission and State Administration of Traditional Chinese Medicine, 2020, CHINESE MED J, V133, P1087
   Pham PTT, 2004, TRANSPLANTATION, V77, P1215, DOI 10.1097/01.TP.0000118413.92211.B6
   The Liverpool Drug Interaction Group (based at the University of Liverpool UK) in collaboration with the University Hospital of Basel (Switzerland) and Radboud UMC (Netherlands), 2020, COVID 19 DRUG INT
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270
   Zhou D, 2020, J ANTIMICROB CHEMOTH
NR 20
TC 11
Z9 11
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2020
VL 20
IS 7
BP 1925
EP 1929
DI 10.1111/ajt.15932
EA JUN 2020
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MD1JV
UT WOS:000539406700001
PM 32319218
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Brody, RM
   Albergotti, WG
   Shimunov, D
   Nicolli, E
   Patel, UA
   Harris, BN
   Bur, AM
AF Brody, Robert M.
   Albergotti, William Greer
   Shimunov, David
   Nicolli, Elizabeth
   Patel, Urjeet A.
   Harris, Brianna N.
   Bur, Andres M.
TI Changes in head and neck oncologic practice during theCOVID-19 pandemic
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
   NECK
LA English
DT Article
DE coronavirus; COVID-19; head and neck cancer; SARS-CoV-2; treatment
   delays; wellness
AB Introduction The COVID-19 pandemic has raised controversies regarding safe and effective care of patients with head and neck cancer. It is unknown how much the pandemic has changed surgeon practice. Methods A questionnaire was distributed to head and neck surgeons assessing opinions related to treatment and concerns for the safety of patients, self, family, and staff. Results A total of 88 head and neck surgeons responded during the study period. Surgeons continued to recommend primary surgical treatment for oral cavity cancers. Respondents were more likely to consider nonsurgical therapy for patients with early glottic cancers and HPV-mediated oropharynx cancer. Surgeons were least likely to be concerned for their own health and safety and had the greatest concern for their resident trainees. Conclusions This study highlights differences in the willingness of head and neck surgeons to delay surgery or alter plans during times when hospital resources are scarce and risk is high.
C1 [Brody, Robert M.; Shimunov, David] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, 3400 Spruce St,5 Ravdin, Philadelphia, PA 19104 USA.
   [Albergotti, William Greer] Augusta Univ, Med Coll Georgia, Dept Otolaryngol Head & Neck Surg, Augusta, GA USA.
   [Nicolli, Elizabeth] Univ Miami, Dept Otolaryngol Head & Neck Surg, Miami, FL USA.
   [Patel, Urjeet A.] Northwestern Univ, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60611 USA.
   [Harris, Brianna N.] Scripps Mem, Dept Otolaryngol Head & Neck Surg, San Diego, CA USA.
   [Bur, Andres M.] Univ Kansas, Dept Otolaryngol Head & Neck Surg, Kansas City, KS USA.
RP Brody, RM (corresponding author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, 3400 Spruce St,5 Ravdin, Philadelphia, PA 19104 USA.
EM robert.brody2@pennmedicine.upenn.edu
OI Bur, Andres/0000-0001-6879-6453; Harris, Brianna/0000-0001-6229-9907
CR Academy of Otolaryngology-Head and Neck Surgery, NEW REC REG URG NON
   Balakrishnan K, 2020, OTOLARYNG HEAD NECK, V162, P804, DOI 10.1177/0194599820919751
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Givi B, 2020, JAMA OTOLARYNGOL, V146, P579, DOI 10.1001/jamaoto.2020.0780
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Lei Shaoqing, 2020, EClinicalMedicine, V21, P100331, DOI 10.1016/j.eclinm.2020.100331
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liao DZ, 2019, JAMA OTOLARYNGOL, V145, P1001, DOI 10.1001/jamaoto.2019.2414
   Schutte HW, 2020, OTOLARYNG HEAD NECK, V162, P446, DOI 10.1177/0194599820906387
   Shuman AG, 2020, HEAD NECK-J SCI SPEC, V42, P1214, DOI 10.1002/hed.26193
   Werner MT, 2020, OTOLARYNG HEAD NECK, V162, P816, DOI 10.1177/0194599820921413
NR 11
TC 7
Z9 7
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
EI 1097-0347
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD JUL
PY 2020
VL 42
IS 7
SI SI
BP 1448
EP 1453
DI 10.1002/hed.26233
EA JUN 2020
PG 6
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA MF8CB
UT WOS:000539282800001
PM 32357380
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kang, JE
   Rhie, SJ
AF Kang, Ji Eun
   Rhie, Sandy Jeong
TI Practice considerations on the use of investigational anti-COVID-19
   medications: Dosage, administration and monitoring
SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
LA English
DT Article
DE COVID-19; investigational medication; SARS-CoV-2; severe acute
   respiratory syndrome
ID RESPIRATORY SYNDROME; HYDROXYCHLOROQUINE; CHLOROQUINE
AB What is known and Objective Understanding investigational medications is important. Many older drugs are being investigated for repurposing against COVID-19. We comment on various drugs currently undergoing such trials to optimize their safe use. Comment We describe medications used during early COVID-19 outbreaks in South Korea, focusing on practice aspects including the method of drug administration, drug formulation, patient-monitoring for adverse reactions and drug interactions informed by our experience during the 2015 outbreak of Middle East respiratory syndrome (MERS). We comment on hydroxychloroquine, chloroquine, lopinavir/ritonavir with zinc supplement, remdesivir, tocilizumab, ciclesonide, niclosamide and high-dose intravenous immunoglobulin (IVIG). What is new and conclusion Effective therapies are urgently needed to manage COVID-19, and existing drugs such as antivirals and antimalarials are under investigation for repurposing to meet this need. This process requires up-to-date drug information to ensure optimum use, particularly safety and efficacy profiles of the medications, until convincing evidence is reported.
C1 [Kang, Ji Eun; Rhie, Sandy Jeong] Ewha Womans Univ, Coll Pharm, Seoul, South Korea.
   [Kang, Ji Eun] Natl Med Ctr, Dept Pharm, Seoul, South Korea.
   [Rhie, Sandy Jeong] Ewha Womans Univ, Grad Sch Pharmaceut Sci, Seoul, South Korea.
RP Rhie, SJ (corresponding author), Ewha Womans Univ, Coll Pharm, Seoul, South Korea.
EM sandy.rhie@ewha.ac.kr
OI , sandy/0000-0003-2554-3370
FU Ministry of Education [2017R1D1A1B03033389]; National Research
   Foundation of Korea MSIT [2020R1A2C1009224]
FX Ministry of Education, Grant/Award Number: 2017R1D1A1B03033389; National
   Research Foundation of Korea MSIT, Grant/Award Number: 2020R1A2C1009224
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   [Anonymous], 2020, COVID 19 INVESTIGATI, DOI DOI 10.1101/2020.03.09.20032896V1.FULL.PDF
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa102
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen ZW, 2020, EFFICACY HYDROXYCHLO
   Choi WS, 2016, INFECT CHEMOTHER, V48, P118, DOI 10.3947/ic.2016.48.2.118
   Chong YP, 2015, INFECT CHEMOTHER, V47, P212, DOI 10.3947/ic.2015.47.3.212
   ClinicalTrials.gov, EFF SAR AZ HYDR SAR
   ClinicalTrials.gov, OP PROSP RETR RAND C
   ClinicalTrials.gov, FAV COMB TOC TREATM
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grein J, 2020, N ENGL J MED
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Matsuyama S., 2020, INHALED CORTICOSTERO, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   MIROCHNICK M, 1994, PEDIATR INFECT DIS J, V13, P827, DOI 10.1097/00006454-199409000-00016
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Pesko LJ, 1993, AM DRUGGIST, V207, P57
   Roques P, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050268
   Srlf.org, REC EXP PORT PRIS CH
   te Velthuis AJ, 2010, PLOS PATHOG, V4
   The Korean Society of Infectious Disease, TREATM REC COVID 19
   U.S. Food and Drug Administration (FDA), 2020, CHLOR PHOSPH HLTH CA
   U.S. Food and Drug Administration (FDA), HYDR SULF HLTH CAR P
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, CLIN MAN SEV AC RESP
   World Health Organization, COR DIS 2019 COVID 1
   World Health Organization, INT CLIN TRIALS REG
   World Health Organization, WHO R D BLUEPR AD HO
   Wu CJ, 2004, ANTIMICROB AGENTS CH, V48, P2693, DOI 10.1128/AAC.48.7.2693-2696.2004
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Xu Xiaoling, EFFECTIVE TREATMENT
   Xue J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109180
   Yao X, 2020, CLIN INFECT DIS
   Zhao Q, 2020, MICRO NANO TECHNOL, P1, DOI 10.1016/C2017-0-02305-4
NR 40
TC 1
Z9 1
U1 4
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-4727
EI 1365-2710
J9 J CLIN PHARM THER
JI J. Clin. Pharm. Ther.
PD OCT
PY 2020
VL 45
IS 5
BP 1199
EP 1205
DI 10.1111/jcpt.13199
EA JUN 2020
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NK6ML
UT WOS:000539277500001
PM 32524645
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cilia, R
   Bonvegna, S
   Straccia, G
   Andreasi, NG
   Elia, AE
   Romito, LM
   Devigili, G
   Cereda, E
   Eleopra, R
AF Cilia, Roberto
   Bonvegna, Salvatore
   Straccia, Giulia
   Andreasi, Nico Golfre
   Elia, Antonio E.
   Romito, Luigi M.
   Devigili, Grazia
   Cereda, Emanuele
   Eleopra, Roberto
TI Effects ofCOVID-19 on Parkinson's Disease Clinical Features:
   ACommunity-Based Case-ControlStudy
SO MOVEMENT DISORDERS
LA English
DT Article
ID BASAL GANGLIA
AB The impact of coronavirus disease 2019 (COVID-19) on clinical features of Parkinson's disease (PD) has been poorly characterized so far. Of 141 PD patients resident in Lombardy, we found 12 COVID-19 cases (8.5%), whose mean age and disease duration (65.5 and 6.3 years, respectively) were similar to controls. Changes in clinical features in the period January 2020 to April 2020 were compared with those of 36 PD controls matched for sex, age, and disease duration using the clinical impression of severity index for PD, the Movement Disorders Society Unified PD Rating Scale Parts II and IV, and the nonmotor symptoms scale. Motor and nonmotor symptoms significantly worsened in the COVID-19 group, requiring therapy adjustment in one third of cases. Clinical deterioration was explained by both infection-related mechanisms and impaired pharmacokinetics of dopaminergic therapy. Urinary issues and fatigue were the most prominent nonmotor issues. Cognitive functions were marginally involved, whereas none experienced autonomic failure. (c) 2020 International Parkinson and Movement Disorder Society
C1 [Cilia, Roberto; Bonvegna, Salvatore; Straccia, Giulia; Andreasi, Nico Golfre; Elia, Antonio E.; Romito, Luigi M.; Devigili, Grazia; Eleopra, Roberto] Fdn IRCCS Ist Neurol Carlo Besta, Dept Clin Neurosci, Parkinson & Movement Disorders Unit, Milan, Italy.
   [Straccia, Giulia] Univ Campania, Dept Med Sci & Adv Surg, Naples, Italy.
   [Cereda, Emanuele] Fdn IRCCS Policlin San Matteo, Clin Nutr & Dietet Unit, Pavia, Italy.
RP Cilia, R (corresponding author), Fdn IRCCS Ist Neurol Carlo Besta, Parkinson & Movement Disorders Unit, Via Celoria 11, I-20133 Milan, Italy.
EM roberto.cilia@istituto-besta.it
RI Romito, Luigi/D-6356-2014; Devigili, Grazia/AAB-9904-2019; Cereda,
   Emanuele/AAA-2247-2019
OI Romito, Luigi/0000-0002-6772-1035; Cereda, Emanuele/0000-0002-0747-1951
CR Antonini A, 2020, MOVEMENT DISORD, V35, P905, DOI 10.1002/mds.28104
   Asadi-Pooya AA, 2020, NEUROL SCI, V41, P2143, DOI 10.1007/s10072-020-04315-7
   Bi QF, 2020, LANCET INFECT DIS, V20, P911, DOI 10.1016/S1473-3099(20)30287-5
   Bloem BR, 2020, JAMA NEUROL, V77, P927, DOI 10.1001/jamaneurol.2020.1452
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Brugger F, 2015, NPJ PARKINSON DIS, V1, DOI 10.1038/npjparkd.2015.14
   Cova I, 2017, PARKINSONISM RELAT D, V34, P38, DOI 10.1016/j.parkreldis.2016.10.020
   Dipartimento della Protezione Civile, COVID 19 IT MON SIT
   Felger JC, 2012, FRONT NEUROENDOCRIN, V33, P315, DOI 10.1016/j.yfrne.2012.09.003
   Gabbrielli F, 2020, RAPPORTI ISS COVID 1
   Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Green HF, 2019, J PARKINSON DIS, V9, P705, DOI 10.3233/JPD-191699
   Helmich RC, 2020, J PARKINSON DIS, V10, P351, DOI 10.3233/JPD-202038
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim GU, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.04.040
   Labandeira-Garcia JL, 2013, MOVEMENT DISORD, V28, P1337, DOI 10.1002/mds.25614
   Lechien JR, 2020, J INTERN MED, V288, P335, DOI 10.1111/joim.13089
   Lindqvist D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047387
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Martinez-Martin P, 2006, MOVEMENT DISORD, V21, P208, DOI 10.1002/mds.20697
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Papa SM, 2020, MOVEMENT DISORD, V35, P711, DOI 10.1002/mds.28067
   Postuma RB, 2015, MOVEMENT DISORD, V30, P1591, DOI 10.1002/mds.26424
   Stoessl AJ, 2020, MOVEMENT DISORD, DOI 10.1002/mds.28069
   Titova N, 2017, INT REV NEUROBIOL, V132, P33, DOI 10.1016/bs.irn.2017.02.016
   Umemura A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094944
   Vijayan S, 2020, MOVEMENT DISORD, V35, P379, DOI 10.1002/mds.27932
   World Health Organization, 2020, GLOB SURV COVID 19 C
NR 30
TC 14
Z9 14
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD AUG
PY 2020
VL 35
IS 8
BP 1287
EP 1292
DI 10.1002/mds.28170
EA JUN 2020
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA MX8YX
UT WOS:000539328000001
PM 32449528
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Budhai, A
   Wu, AA
   Hall, L
   Strauss, D
   Paradiso, S
   Alberigo, J
   Hillyer, CD
   Jett, B
   Tobian, AAR
   Bloch, EM
   Sachais, BS
   Shaz, BH
AF Budhai, Alexandra
   Wu, Annie A.
   Hall, Lucette
   Strauss, Donna
   Paradiso, Sarai
   Alberigo, Jill
   Hillyer, Christopher D.
   Jett, Betsy
   Tobian, Aaron A. R.
   Bloch, Evan M.
   Sachais, Bruce S.
   Shaz, Beth H.
TI How did we rapidly implement a convalescent plasma program?
SO TRANSFUSION
LA English
DT Article
AB Since the beginning of the COVID-19 pandemic, the use of convalescent plasma as a possible treatment has been explored. Here we describe our experience as the first U.S. organization creating a COVID-19 convalescent plasma program to support its use through the single-patient emergency investigational new drug, the National Expanded Access Program, and multiple randomized controlled trials. Within weeks, we were able to distribute more than 8000 products, scale up collections to more than 4000 units per week, meet hospital demand, and support randomized controlled trials to evaluate the efficacy of convalescent plasma treatment. This was through strategic planning; redeployment of staff; and active engagement of hospital, community, and public health partners. Our partners helped with donor recruitment, testing, patient advocacy, and patient availability. The program will continue to evolve as we learn more about optimizing the product. Remaining issues to be resolved are antibody titers, dose, and at what stage of disease to transfuse.
C1 [Budhai, Alexandra; Hall, Lucette; Strauss, Donna; Paradiso, Sarai; Alberigo, Jill; Hillyer, Christopher D.; Jett, Betsy; Sachais, Bruce S.; Shaz, Beth H.] New York Blood Ctr Enterprises, 310 E 67th St, New York, NY 10065 USA.
   [Wu, Annie A.; Tobian, Aaron A. R.; Bloch, Evan M.] Johns Hopkins Sch Med, Baltimore, MD USA.
RP Shaz, BH (corresponding author), New York Blood Ctr Enterprises, 310 E 67th St, New York, NY 10065 USA.
EM bshaz@nybc.org
OI Shaz, Beth/0000-0002-2270-4821; Wu, Annie/0000-0002-0730-298X
CR [Anonymous], 2020, REC INV COVID 19 CON
   [Anonymous], 2020, NY TIMES
   [Anonymous], 2020, NAT COVID 19 CONV PL
   Bloch E, 2020, J CLIN INVEST
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   U.S. Food and Drug Administration, 2020, INV COVID 19 CONV PL
   US Food and Drug Administration, 2020, COR COVID 19 UPD FDA
NR 10
TC 4
Z9 4
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD JUL
PY 2020
VL 60
IS 7
BP 1348
EP 1355
DI 10.1111/trf.15910
EA JUN 2020
PG 8
WC Hematology
SC Hematology
GA ML7EE
UT WOS:000539491400001
PM 32449169
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Trasino, SE
AF Trasino, Steven E.
TI A role for retinoids in the treatment of COVID-19?
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Letter
DE COVID-19; IFN-I; interferons; retinoids; RIG-I; SARS-CoV-2; vitamin A
ID RESPIRATORY SYNDROME CORONAVIRUS; INTERFERON BETA-1B; VITAMIN-A;
   IN-VITRO; ACID; EXPRESSION; INFECTION; CELL; COMBINATION; MODULATION
AB The 2020 global outbreak of the novel coronavirus (SARS-CoV-2 or COVID-19) is a serious threat to international health, and thus, there is an urgent need for discovery of novel therapies or use of repurposed drugs that can make a significant impact on slowing the spread of the virus. Type 1 interferons (IFN-I) are a family cytokines of the early innate immune response to viruses that are being tested against SARS-CoV-2. However, coronaviruses similar to SARS-CoV-2 can suppress host IFN-I antiviral responses. Retinoids are a family molecules related to vitamin A that possess robust immune-modulating properties, including the ability to increase and potentiate the actions of IFN-I. Therefore, adjuvants such as retinoids, capable of increasing IFN-I-mediated antiviral responses, should be tested in combinations of IFN-I and antiviral drugs in pre-clinical studies of SARS-CoV-2.
C1 [Trasino, Steven E.] CUNY Hunter Coll, Sch Urban Publ Hlth, 2180 Third Ave, New York, NY 10021 USA.
RP Trasino, SE (corresponding author), CUNY Hunter Coll, Sch Urban Publ Hlth, 2180 Third Ave, New York, NY 10021 USA.
EM st1647@hunter.cuny.edu
CR Al-Tawfiq JA, 2014, INT J INFECT DIS, V20, P42, DOI 10.1016/j.ijid.2013.12.003
   Angulo A, 1998, J VIROL, V72, P4589, DOI 10.1128/JVI.72.6.4589-4600.1998
   Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363
   Chen SY, 2014, BRIT J NUTR, V111, P1586, DOI 10.1017/S0007114513004133
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Gudas LJ, 2012, BBA-MOL CELL BIOL L, V1821, P213, DOI 10.1016/j.bbalip.2011.08.002
   Hu Y, 2017, J VIROL, V91, DOI 10.1128/JVI.02143-16
   Kast RE, 2008, CANCER BIOL THER, V7, P1515, DOI 10.4161/cbt.7.10.6573
   Lee H, 2016, SCI REP-UK, V6, DOI 10.1038/srep25835
   Li BC, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.00465-18
   Lindner DJ, 1997, CLIN CANCER RES, V3, P931
   LIPPMAN SM, 1993, EUR J CANCER, V29A, pS9, DOI 10.1016/0959-8049(93)90618-P
   Luo XM, 2006, EXP BIOL MED, V231, P619
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Matikainen S, 1996, BLOOD, V88, P114
   Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410
   Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998
   Qu ZX, 2001, ARCH NEUROL-CHICAGO, V58, P87, DOI 10.1001/archneur.58.1.87
   Qu ZX, 1998, ARCH NEUROL-CHICAGO, V55, P315, DOI 10.1001/archneur.55.3.315
   Raverdeau M, 2014, J IMMUNOL, V192, P2953, DOI 10.4049/jimmunol.1303245
   Ross AC, 1996, FASEB J, V10, P979
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Soye KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022323
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Takeuchi O, 2009, IMMUNOL REV, V227, P75, DOI 10.1111/j.1600-065X.2008.00737.x
   Trottier C, 2008, ANTIVIR RES, V80, P45, DOI 10.1016/j.antiviral.2008.04.003
   Yang Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep17554
   Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x
   Zhang Q, 2020, J MED VIROL, V92, P540, DOI [10.1002/jmv.25733, 10.1080/07391102.2020.1771421]
NR 31
TC 5
Z9 5
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-1870
EI 1440-1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD OCT
PY 2020
VL 47
IS 10
BP 1765
EP 1767
DI 10.1111/1440-1681.13354
EA JUN 2020
PG 3
WC Pharmacology & Pharmacy; Physiology
SC Pharmacology & Pharmacy; Physiology
GA NJ8XY
UT WOS:000539767100001
PM 32459003
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wali, A
   Rizzo, V
   Bille, A
   Routledge, T
   Chambers, AJ
AF Wali, A.
   Rizzo, V.
   Bille, A.
   Routledge, T.
   Chambers, A. J.
TI Pneumomediastinum following intubation in COVID-19 patients: a case
   series
SO ANAESTHESIA
LA English
DT Article
DE acute respiratory distress syndrome; COVID-19; pneumomediastinum;
   surgical emphysema; tracheal injury
ID ACUTE LUNG INJURY; CHEST; VENTILATION; BAROTRAUMA; ARDS
AB The number of patients requiring tracheal intubation rose dramatically in March and April 2020 with the COVID-19 outbreak. Our thoracic surgery department has seen an increased incidence of severe pneumomediastinum referred for surgical opinion in intubated patients with COVID-19 pneumonitis. Here we present a series of five patients with severe pneumomediastinum requiring decompression therapy over a 7-day period in the current COVID-19 outbreak. We hypothesise that the mechanism for this is the aggressive disease pathophysiology with an increased risk of alveolar damage and tracheobronchial injury, along with the use of larger-bore tracheal tubes and higher ventilation pressures. We present this case series in order to highlight the increased risk of this potentially life-threatening complication among the COVID-19 patient cohort and offer guidance for its management to critical care physicians.
C1 [Wali, A.; Rizzo, V.; Bille, A.; Routledge, T.; Chambers, A. J.] Guys Hosp, Dept Thorac Surg, London, England.
RP Chambers, AJ (corresponding author), Guys Hosp, Dept Thorac Surg, London, England.
EM achambers1@nhs.net
CR Bejvan SM, 1996, AM J ROENTGENOL, V166, P1041, DOI 10.2214/ajr.166.5.8615238
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Byun Chun Sung, 2013, Korean J Thorac Cardiovasc Surg, V46, P383, DOI 10.5090/kjtcs.2013.46.5.383
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Eisner MD, 2002, AM J RESP CRIT CARE, V165, P978, DOI 10.1164/ajrccm.165.7.2109059
   GAMMON RB, 1992, CHEST, V102, P568, DOI 10.1378/chest.102.2.568
   Guan CS, 2019, ACAD RADIOL, V2020, P609
   Jacobi A, 2020, CLIN IMAG, V64, P35, DOI 10.1016/j.clinimag.2020.04.001
   Koullias GJ, 2004, EUR J CARDIO-THORAC, V25, P852, DOI 10.1016/j.ejcts.2004.01.042
   Okada M, 2014, RESPIR INVESTIG, V52, P36, DOI 10.1016/j.resinv.2013.06.001
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Scholten EL, 2017, CHEST, V151, P215, DOI 10.1016/j.chest.2016.06.032
   Simon M, 2016, RESP CARE, V61, P316, DOI 10.4187/respcare.04308
   Sun RH, 2020, KOREAN J RADIOL, V21, P541, DOI 10.3348/kjr.2020.0180
   Wang J, 2020, KOREAN J RADIOL, V21, P627, DOI 10.3348/kjr.2020.0281
   Wintermark M, 2001, CHEST, V120, P543, DOI 10.1378/chest.120.2.543
   Zhou CY, 2020, LANCET INFECT DIS, V20, P510, DOI 10.1016/S1473-3099(20)30156-0
   Zylak CM, 2000, RADIOGRAPHICS, V20, P1043, DOI 10.1148/radiographics.20.4.g00jl131043
NR 18
TC 5
Z9 5
U1 2
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD AUG
PY 2020
VL 75
IS 8
BP 1076
EP 1081
DI 10.1111/anae.15113
EA JUN 2020
PG 6
WC Anesthesiology
SC Anesthesiology
GA NE3DE
UT WOS:000539335000001
PM 32375200
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Li, YY
   Li, HG
   Zhou, LQ
AF Li, Yuanyuan
   Li, Honggang
   Zhou, Liquan
TI EZH2-mediated H3K27me3 inhibits ACE2 expression
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Coronavirus; SARS-CoV-2; ACE2; EZH2; H3.3
ID POLYCOMB; EZH2; CORONAVIRUS; PROTEIN; METHYLATION; PNEUMONIA
AB The outbreak of corona virus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is spreading globally and quickly, leading to emerging health issues. SARS-CoV-2 enters into and infects host cells through its spike glycoprotein recognizing the cell receptor Angiotensin-converting enzyme II (ACE2). Here, we noticed that ACE2 was further enhanced by SARS-CoV-2 infection. Human germ cells and early embryos express high level of ACE2. Notably, RNA-seq result showed that reduction of H3K27me3, but not H3K4/9/36me3, led to upregulation of Ace2 expression in mouse germ cell line GC-2. In agreement with this result, we found in human embryonic stem cells that ACE2 expression was significantly increased in absence of EZH2, the major enzyme catalyzing H3K27me3. ChIP-seq analysis further confirmed decrease of H3K27me3 signal and increase of H3K27ac signal at ACE2 promoter upon EZH2 knockout. Therefore, we propose that EZH2-mediated H3K27me3 at ACE2 promoter region inhibits ACE2 expression in mammalian cells. This regulatory pattern may also exist in other human cells and tissues. Our discovery provides clues for pathogenesis and targeted drug therapy towards ACE2 expression for prevention and adjuvant therapy of COVID-19. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Li, Yuanyuan; Li, Honggang; Zhou, Liquan] Huazhong Univ Sci & Technol, Tongji Med Coll, Inst Reprod Hlth, 13 Hangkong St, Wuhan, Peoples R China.
RP Li, HG; Zhou, LQ (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Inst Reprod Hlth, 13 Hangkong St, Wuhan, Peoples R China.
EM lhgyx@hotmail.com; zhouliquan@hust.edu.cn
OI Zhou, Li-quan/0000-0002-9332-9408
FU National Key R&D Program of China [2018YFC1004001]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [NSFC 31771661]
FX This work was supported by National Key R&D Program of China
   [2018YFC1004001] and the National Natural Science Foundation of China
   [NSFC 31771661].
CR ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786
   Cai G., 2020, BULK SINGLE CELL TRA, P2020
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cardoso C, 2000, EUR J HUM GENET, V8, P174, DOI 10.1038/sj.ejhg.5200439
   Chai X., 2020, BIORXIV, P2020
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen Y, 2020, ASIANS OTHER RACES E, DOI [10.20944/preprints202002.0258.v1, DOI 10.20944/PREPRINTS202002.0258.V1]
   Chou RH, 2011, AM J TRANSL RES, V3, P243
   Collinson A, 2016, CELL REP, V17, P2700, DOI 10.1016/j.celrep.2016.11.032
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Danilczyk U, 2003, J MOL MED, V81, P227, DOI 10.1007/s00109-003-0419-x
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Jia X, 2020, 2 THINGS COVID 19 MI, DOI [10.20944/preprints202002.0315.v1, DOI 10.20944/PREPRINTS202002.0315.V1]
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lei C., 2020, BIORXIV, P2020
   Li Z., 2020, CAUTION KIDNEY DYSFU, P2020
   Lin Z., 2020, BIORXIV, P2020
   Pan MR, 2018, CELL MOL LIFE SCI, V75, P209, DOI 10.1007/s00018-017-2596-8
   Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang P., 2020, BIORXIV, P2020
   Wang Xiao-Fei, 2020, J Reprod Dev, V66, P223, DOI 10.1262/jrd.2019-139
   Wang ZH, 2020, SN APPL SCI, V2, DOI 10.1007/s42452-020-2072-1
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan LY, 2013, NAT STRUCT MOL BIOL, V20, P1131, DOI 10.1038/nsmb.2660
   Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x
   Zhang H., 2020, BIORXIV, P2020
   Zhou P., DISCOVERY NOVEL CORO, DOI [DOI 10.1101/2020.01.22.914952, 10.1101/2020.01.22.914952v2., DOI 10.1101/2020.01.22.914952V2]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep28400
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 33
TC 4
Z9 4
U1 4
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 11
PY 2020
VL 526
IS 4
BP 947
EP 952
DI 10.1016/j.bbrc.2020.04.010
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LN3CE
UT WOS:000532819100013
PM 32291076
OA Green Published
DA 2021-01-01
ER

PT J
AU Liu, M
   Cheng, SZ
   Xu, KW
   Yang, Y
   Zhu, QT
   Zhang, H
   Yang, DY
   Cheng, SY
   Xiao, H
   Wang, JW
   Yao, HR
   Cong, YT
   Zhou, YQ
   Peng, S
   Kuang, M
   Hou, FF
   Cheng, KK
   Xiao, HP
AF Liu, Min
   Cheng, Shou-Zhen
   Xu, Ke-Wei
   Yang, Yang
   Zhu, Qing-Tang
   Zhang, Hui
   Yang, Da-Ya
   Cheng, Shu-Yuan
   Xiao, Han
   Wang, Ji-Wen
   Yao, He-Rui
   Cong, Yu-Tian
   Zhou, Yu-Qi
   Peng, Sui
   Kuang, Ming
   Hou, Fan-Fan
   Cheng, K. K.
   Xiao, Hai-Peng
TI Use of personal protective equipment against coronavirus disease 2019 by
   healthcare professionals in Wuhan, China: cross sectional study
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID TRANSMISSION
AB OBJECTIVE
   To examine the protective effects of appropriate personal protective equipment for frontline healthcare professionals who provided care for patients with coronavirus disease 2019 (covid-19).
   DESIGN
   Cross sectional study.
   SETTING
   Four hospitals in Wuhan, China.
   PARTICIPANTS
   420 healthcare professionals (116 doctors and 304 nurses) who were deployed to Wuhan by two affiliated hospitals of Sun Yat-sen University and Nanfang Hospital of Southern Medical University for 6-8 weeks from 24 January to 7 April 2020. These study participants were provided with appropriate personal protective equipment to deliver healthcare to patients admitted to hospital with covid-19 and were involved in aerosol generating procedures. 77 healthcare professionals with no exposure history to covid-19 and 80 patients who had recovered from covid-19 were recruited to verify the accuracy of antibody testing.
   MAIN OUTCOME MEASURES
   Covid-19 related symptoms (fever, cough, and dyspnoea) and evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, defined as a positive test for virus specific nucleic acids in nasopharyngeal swabs, or a positive test for IgM or IgG antibodies in the serum samples.
   RESULTS
   The average age of study participants was 35.8 years and 68.1% (286/420) were women. These study participants worked 4-6 hour shifts for an average of 5.4 days a week; they worked an average of 16.2 hours each week in intensive care units. All 420 study participants had direct contact with patients with covid-19 and performed at least one aerosol generating procedure. During the deployment period in Wuhan, none of the study participants reported covid-19 related symptoms. When the participants returned home, they all tested negative for SARS-CoV-2 specific nucleic acids and IgM or IgG antibodies (95% confidence interval 0.0 to 0.7%).
   CONCLUSION
   Before a safe and effective vaccine becomes available, healthcare professionals remain susceptible to covid-19. Despite being at high risk of exposure, study participants were appropriately protected and did not contract infection or develop protective immunity against SARS-CoV-2. Healthcare systems must give priority to the procurement and distribution of personal protective equipment, and provide adequate training to healthcare professionals in its use.
C1 [Liu, Min; Cheng, Shou-Zhen; Zhu, Qing-Tang; Zhang, Hui; Yang, Da-Ya; Cheng, Shu-Yuan; Xiao, Han; Peng, Sui; Kuang, Ming; Xiao, Hai-Peng] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510080, Peoples R China.
   [Xu, Ke-Wei; Wang, Ji-Wen; Yao, He-Rui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China.
   [Yang, Yang; Cong, Yu-Tian; Zhou, Yu-Qi] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Peoples R China.
   [Hou, Fan-Fan] Southern Med Univ, Nan Fang Hosp, Guangzhou, Peoples R China.
   [Cheng, K. K.] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.
RP Xiao, HP (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510080, Peoples R China.
EM xiaohp@mail.sysu.edu.cn
RI Taha, Samy/N-4620-2019; YANG, Da-ya/AAW-9137-2020
OI Taha, Samy/0000-0003-0284-7806; YANG, Da-ya/0000-0002-2881-9195
FU First Affiliated Hospital of Sun Yat-sen University
FX This work was funded by grants from the First Affiliated Hospital of Sun
   Yat-sen University. The funder was not involved in the design and
   conduct of the study; collection, analysis, interpretation of data,
   writing of the report, or decision to submit the article for
   publication.
CR CDC COVID-19 Response Team, 2020, MMWR Morb Mortal Wkly Rep, V69, P477, DOI 10.15585/mmwr.mm6915e6
   China NHC, ANSW CALL 42000 HCPS
   Johns Hopkins University and Medicine, COR COVID 19 GLOB CA
   Legido-Quigley H, 2020, LANCET PUBLIC HEALTH, V5, pE251, DOI 10.1016/S2468-2667(20)30060-8
   Li YF, 2020, J MED VIROL, V92, P903, DOI 10.1002/jmv.25786
   LINDSAY J, 2020, J MED VIROL, DOI DOI 10.1002/JMV.25919
   LIU J, 2020, J MED VIROL, DOI DOI 10.1002/JMV.25855
   MacIntyre CR, 2011, INFLUENZA OTHER RESP, V5, P170, DOI 10.1111/j.1750-2659.2011.00198.x
   Ran Li, 2020, Clin Infect Dis, V71, P2218, DOI 10.1093/cid/ciaa287
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Saunders-Hastings P, 2017, EPIDEMICS-NETH, V20, P1, DOI 10.1016/j.epidem.2017.04.003
   Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang J, 2020, J HOSP INFECT, V105, P100, DOI 10.1016/j.jhin.2020.03.002
   WHO-China Joint Mission, REP WHO CHIN JOINT M
   World Health Organization, CLEAN HANDS PROT INF
   World Health Organization, MOD TRANSM VIR CAUS
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Zeng H, 2020, JAMA-J AM MED ASSOC, V323, P1848, DOI 10.1001/jama.2020.4861
   Zhang ZR, 2020, FRONT MED-PRC, V14, P229, DOI 10.1007/s11684-020-0765-x
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
NR 22
TC 21
Z9 21
U1 5
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD JUN 10
PY 2020
VL 369
AR m2195
DI 10.1136/bmj.m2195
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA MK1TC
UT WOS:000548568100004
PM 32522737
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Hachim, MY
   Al Heialy, S
   Hachim, IY
   Halwani, R
   Senok, AC
   Maghazachi, AA
   Hamid, Q
AF Hachim, Mahmood Yaseen
   Al Heialy, Saba
   Hachim, Ibrahim Yaseen
   Halwani, Rabih
   Senok, Abiola C.
   Maghazachi, Azzam A.
   Hamid, Qutayba
TI Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated
   Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; interferon-induced transmembrane proteins;
   valproic acid; antiviral immunity
ID INFLUENZA
AB Current guidelines for COVID-19 management recommend the utilization of various repurposed drugs. Despite ongoing research toward the development of a vaccine against SARS-CoV-2, such a vaccine will not be available in time to contribute to the containment of the ongoing pandemic. Therefore, there is an urgent need to develop a framework for the rapid identification of novel targets for diagnostic and therapeutic interventions. We analyzed publicly available transcriptomic datasets of SARS-CoV infected humans and mammals to identify consistent differentially expressed genes then validated in SARS-CoV-2 infected epithelial cells transcriptomic datasets. Comprehensive toxicogenomic analysis of the identified genes to identify possible interactions with clinically proven drugs was carried out. We identified IFITM3 as an early upregulated gene, and valproic acid was found to enhance its mRNA expression as well as induce its antiviral action. These findings indicate that analysis of publicly available transcriptomic and toxicogenomic data represents a rapid approach for the identification of novel targets and molecules that can modify the action of such targets during the early phases of emerging infections like COVID-19.
C1 [Hachim, Mahmood Yaseen; Hachim, Ibrahim Yaseen; Halwani, Rabih; Maghazachi, Azzam A.; Hamid, Qutayba] Univ Sharjah, Coll Med, Sharjah Inst Med Res, Sharjah, U Arab Emirates.
   [Hachim, Mahmood Yaseen; Al Heialy, Saba; Senok, Abiola C.] Mohammed Bin Rashid Univ Med & Hlth Sci, Coll Med, Dubai, U Arab Emirates.
   [Al Heialy, Saba; Hamid, Qutayba] McGill Univ, Res Inst, Meakins Christie Labs, Hlth Ctr, Montreal, PQ, Canada.
RP Hamid, Q (corresponding author), Univ Sharjah, Coll Med, Sharjah Inst Med Res, Sharjah, U Arab Emirates.; Hamid, Q (corresponding author), McGill Univ, Res Inst, Meakins Christie Labs, Hlth Ctr, Montreal, PQ, Canada.
EM qalheialy@sharjah.ac.ae
RI Hachim, Mahmood/V-9662-2019
OI HACHIM, MAHMOOD/0000-0002-7096-0731; Maghazachi,
   Azzam/0000-0002-3310-678X
CR Allen EK, 2017, NAT MED, V23, P975, DOI 10.1038/nm.4370
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Benfield CTO, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.201900542
   Blanco-Melo D., 2020, BIORXIV, DOI [10.1101/2020.03.24.004655, DOI 10.1101/2020.03.24.004655]
   Boucontet L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01084
   Cameron MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045842
   Campbell RA, 2019, BLOOD, V133, P2013, DOI 10.1182/blood-2018-09-873984
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chesarino NM, 2017, EMBO REP, V18, P1740, DOI 10.15252/embr.201744100
   Chiquete E, 2020, METHODS OPEN LABEL P, DOI [10.1101/2020.04.26.20079988, DOI 10.1101/2020.04.26.20079988]
   Dai Y-J, 2020, HLTH INDIVIDUALS CAN
   Davis AP, 2019, NUCLEIC ACIDS RES, V47, pD948, DOI 10.1093/nar/gky868
   Domingo E., 2020, VIRUS AS POPULATIONS
   Everitt AR, 2012, NATURE, V484, P519, DOI 10.1038/nature10921
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Jimenez-Guardeno JM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004320
   Kummer S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060548
   Li K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003124
   McMichael TM, 2017, J BIOL CHEM, V292, P21517, DOI 10.1074/jbc.M117.800482
   Mitchell HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069374
   Nelemans T, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100961
   Ng LFP, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m634
   Rockx B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018558
   Shi GL, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0377-y
   Sims AC, 2013, J VIROL, V87, P3885, DOI 10.1128/JVI.02520-12
   Sixto-Lopez Y, 2020, J COMPUT AID MOL DES, V34, P857, DOI 10.1007/s10822-020-00304-2
   Spence JS, 2019, NAT CHEM BIOL, V15, P259, DOI 10.1038/s41589-018-0213-2
   Suddala KC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007532
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Wakim LM, 2013, NAT IMMUNOL, V14, P238, DOI 10.1038/ni.2525
   Wellington D, 2019, BIOMED J, V42, P19, DOI 10.1016/j.bj.2019.01.004
   Wisskirchen K, 2014, TRENDS PHARMACOL SCI, V35, P470, DOI 10.1016/j.tips.2014.06.004
   Yoshikawa T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008729
   Zani A, 2018, CURR CLIN MICROBIOL, V5, P229, DOI 10.1007/s40588-018-0103-0
   Zareba-Koziol M, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00175
NR 38
TC 5
Z9 5
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 10
PY 2020
VL 11
AR 1372
DI 10.3389/fimmu.2020.01372
PG 9
WC Immunology
SC Immunology
GA MD2PI
UT WOS:000543815100001
PM 32595654
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sivapalan, P
   Ulrik, CS
   Bojesen, RD
   Lapperre, TS
   Eklof, JV
   Hakansson, KEJ
   Browatzki, A
   Tidemansen, C
   Wilcke, JT
   Janner, J
   Gottlieb, V
   Meteran, H
   Porsbjerg, C
   Madsen, BL
   Moberg, M
   Pedersen, L
   Benfield, TL
   Lundgren, JD
   Knop, FK
   Biering-Sorensen, T
   Ghanizada, M
   Sonne, TP
   Bodtger, UCS
   Jensen, SG
   Rasmussen, DB
   Brondum, E
   Tupper, OD
   Sorensen, SW
   Alstrup, G
   Laursen, CB
   Moller, UW
   Sverrild, A
   Jensen, JUS
AF Sivapalan, Pradeesh
   Ulrik, Charlotte Suppli
   Bojesen, Rasmus Dahlin
   Lapperre, Therese Sophie
   Eklof, Josefin Viktoria
   Hakansson, Kjell Erik Julius
   Browatzki, Andrea
   Tidemansen, Casper
   Wilcke, Jon Torgny
   Janner, Julie
   Gottlieb, Vibeke
   Meteran, Howraman
   Porsbjerg, Celeste
   Madsen, Birgitte Lindegaard
   Moberg, Mia
   Pedersen, Lars
   Benfield, Thomas Lars
   Lundgren, Jens Dilling
   Knop, Filip Krag
   Biering-Sorensen, Tor
   Ghanizada, Muzhda
   Sonne, Tine Peick
   Bodtger, Uffe Christian Steinholtz
   Jensen, Sidse Graff
   Rasmussen, Daniel Bech
   Brondum, Eva
   Tupper, Oliver Djurhuus
   Sorensen, Susanne Wiemann
   Alstrup, Gitte
   Laursen, Christian Borbjerg
   Moller, Ulla Weinrich
   Sverrild, Asger
   Jensen, Jens-Ulrik Staehr
TI Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in
   Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary
   of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; azithromycin;
   hydroxychloroquine; respiratory infections
AB Objectives: The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as "days alive and out of hospital" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death.
   Trial design: This is a multi-centre,randomised, Placebo-controlled, 2-arm ratio 1:1, parallel group double-blind study.
   Participants: 226 participants are recruited at the trial sites/hospitals, where the study will take place in Denmark: Aalborg, Bispebjerg, Gentofte, Herlev, Hillerod, Hvidovre, Odense and Slagelse hospitals.
   Inclusion criteria:
   Patient admitted to Danish emergency departments, respiratory medicine departments or internal medicine departments
   Age >= 18 years
   Hospitalized <= 48 hours
   Positive COVID-19 test / diagnosis during the hospitalization (confirmed).
   Men or non-fertile women. Fertile women* must not be pregnant, i.e. negative pregnancy test must be available at inclusion
   Informed consent signed by the patient
   *Defined as after menarche and until postmenopausal (no menstruation for 12 months)
   Exclusion criteria:
   At the time of recruitment, the patient uses >5 LO2/min (equivalent to 40% FiO2 if measured)
   Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinoline derivatives
   Neurogenic hearing loss
   Psoriasis
   Retinopathy
   Maculopathy
   Visual field changes
   Breastfeeding
   Severe liver diseases other than amoebiasis (INR> 1.5 spontaneously)
   Severe gastrointestinal, neurological and hematological disorders (investigator-assessed)
   eGFR <45 ml/min/1.73 m2
   Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval (QTc (f) of> 480/470 ms).
   Myasthenia gravis
   Treatment with digoxin*
   Glucose-6-phosphate dehydrogenase deficiency
   Porphyria
   Hypoglycaemia (Blood glucose at any time since hospitalization of <3.0 mmol/L)
   Severe mental illness which significantly impedes cooperation
   Severe linguistic problems that significantly hinder cooperation
   Treatment with ergot alkaloids *The patient must not be treated with digoxin for the duration of the intervention. For atrial fibrillation/flutter, select according to the Cardiovascular National Treatment Guide (NBV): Calcium antagonist, Beta blocker, direct current (DC) conversion or amiodarone. In case of urgent need for digoxin treatment (contraindication for the aforementioned equal alternatives), the test drug should be paused, and ECG should be taken daily.
   Intervention and comparator: Control group:
   The control group will receive the standard treatment + placebo for both types of intervention medication at all times. If part or all the intervention therapy being investigated becomes standard treatment during the study, this may also be offered to the control group.
   Intervention group:
   The patients in the intervention group will also receive standard care. Immediately after randomisation to the intervention group, the patient will begin treatment with:
   Azithromycin:
   Day 1-3: 500 mg x 1
   Day 4-15: 250 mg x 1
   If the patient is unable to take the medication orally by themselves, the medication will, if possible, be administered by either stomach-feeding tube, or alternatively, temporary be changed to clarithromycin 500 mg x 2 (this only in agreement with either study coordinator Pradeesh Sivapalan or principal investigator Jens-Ulrik St AE hr Jensen). This will also be done in the control group if necessary. The patient will switch back to azithromycin when possible.
   Hydroxychloroquine:
   Furthermore, the patient will be treated with hydroxychloroquine as follows:
   Day 1-15: 200 mg x 2
   Main outcomes: Number of days alive and discharged from hospital within 14 days (summarises both whether the patient is alive and discharged from hospital) ("Days alive and out of hospital")
   Randomisation: The sponsor (Chronic Obstructive Pulmonary Disease Trial Network, COP:TRIN) generates a randomisation sequence. Randomisation will be in blocks of unknown size and the final allocation will be via an encrypted website (REDCap). There will be stratification for age (>70 years vs. <=70 years), site of recruitment and whether the patient has any of the following chronic lung diseases: COPD, asthma, bronchiectasis, interstitial lung disease (Yes vs. No).
   Blinding (masking): Participants and study personnel will both be blinded, i.e. neither will know which group the participant is allocated to.
   Numbers to be randomised (sample size): This study requires 226 patients randomised 1:1 with 113 in each group.
   Trial Status: Protocol version 1.8, from April 16, 2020. Recruitment is ongoing (first patient recruited April 6, 2020; final patient expected to be recruited October 31, 2020).
C1 [Sivapalan, Pradeesh; Eklof, Josefin Viktoria; Wilcke, Jon Torgny; Gottlieb, Vibeke; Meteran, Howraman; Sonne, Tine Peick; Jensen, Sidse Graff; Jensen, Jens-Ulrik Staehr] Univ Copenhagen, Sect Resp Med, Dept Med, Herlev & Gentofte Hosp, Hellerup, Denmark.
   [Sivapalan, Pradeesh; Bodtger, Uffe Christian Steinholtz] Zealand Univ Hosp, Dept Internal Med, Roskilde, Denmark.
   [Ulrik, Charlotte Suppli; Hakansson, Kjell Erik Julius; Tidemansen, Casper; Janner, Julie; Moberg, Mia; Brondum, Eva; Tupper, Oliver Djurhuus; Sorensen, Susanne Wiemann] Amager & Hvidovre Hosp Univ Copenhagen, Dept Resp Med, Hvidovre, Denmark.
   [Bojesen, Rasmus Dahlin] Univ Southern Denmark, Dept Surg, Naestved Slagelse Ringsted Hosp, Slagelse, Denmark.
   [Lapperre, Therese Sophie; Porsbjerg, Celeste; Moberg, Mia; Ghanizada, Muzhda] Univ Copenhagen, Dept Resp Med, Bispebjerg & Frederiksberg Hosp, Copenhagen, Denmark.
   [Browatzki, Andrea; Madsen, Birgitte Lindegaard] Univ Copenhagen, Dept Resp & Infect Dis, Nordsjaellands Hosp, Hillerod, Denmark.
   [Benfield, Thomas Lars] Univ Copenhagen, Dept Infect Dis, Amager & Hvidovre Hosp, Hvidovre, Denmark.
   [Lundgren, Jens Dilling] Univ Copenhagen, Dept Infect Dis, Rigshosp, Copenhagen, Denmark.
   [Knop, Filip Krag] Univ Copenhagen, Dept Clin Metab Res, Herlev & Gentofte Hosp, Hellerup, Denmark.
   [Biering-Sorensen, Tor] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Cardiol, Hellerup, Denmark.
   [Bodtger, Uffe Christian Steinholtz; Rasmussen, Daniel Bech; Alstrup, Gitte] Univ Southern Denmark, Dept Resp Med, Naestved Slagelse Ringsted Hosp, Slagelse, Denmark.
   [Bodtger, Uffe Christian Steinholtz] Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark.
   [Laursen, Christian Borbjerg] Univ Southern Denmark, Dept Resp Med, Odense Univ Hosp, Odense, Denmark.
   [Jensen, Jens-Ulrik Staehr] Aalborg Univ, Dept Resp Med, Aalborg Univ Hosp, Aalborg, Denmark.
RP Jensen, JUS (corresponding author), Univ Copenhagen, Sect Resp Med, Dept Med, Herlev & Gentofte Hosp, Hellerup, Denmark.
EM jens.ulrik.jensen@regionh.dk
RI Hakansson, Kjell EJ/D-3997-2016; Lundgren, Jens/AAE-6876-2019; Knop,
   Filip K/B-5130-2018
OI Hakansson, Kjell EJ/0000-0001-5804-0740; Pedersen,
   Lars/0000-0002-5950-652X; Laursen, Christian B./0000-0001-6382-9906;
   Biering-Sorensen, Tor/0000-0003-4209-2778; Knop, Filip
   K/0000-0002-2495-5034; Tidemandsen, Casper/0000-0001-6032-6414; Bodtger,
   Uffe/0000-0002-1231-9209
FU Novo Nordisk FoundationNovo Nordisk Foundation [DKK 2,162,646.22,
   NNF20SA0062834]
FX The research project is (investigator) initiated by COP:TRIN. Fund
   support has been obtained from the Novo Nordisk Foundation of DKK
   2,162,646.22 (case no. NNF20SA0062834). The funders had no role in the
   design of the study and collection, analysis, and interpretation of data
   and in writing the manuscript.
NR 0
TC 3
Z9 3
U1 3
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 10
PY 2020
VL 21
IS 1
AR 513
DI 10.1186/s13063-020-04409-9
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MA9TA
UT WOS:000542251800001
PM 32522282
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Eygeris, Y
   Patel, S
   Jozic, A
   Sahay, G
AF Eygeris, Yulia
   Patel, Siddharth
   Jozic, Antony
   Sahay, Gaurav
TI Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery
SO NANO LETTERS
LA English
DT Article
DE mRNA delivery; lipid nanoparticles; cryo-TEM; gene therapy
ID IN-VITRO; MEMBRANE; CHOLESTEROL; MODEL; ERGOSTEROL; SIRNA
AB Lipid nanoparticle (LNP) packaged mRNA vaccines have been deployed against infectious diseases such as COVID-19, yet their structural features remain unclear. Cholesterol, a major constituent within LNPs, contributes to their morphology that influences gene delivery. Herein, we examine the structure of LNPs containing cholesterol derivatives using electron microscopy, differential scanning calorimetry, and membrane fluidity assays. LNPs formulated with C24 alkyl derivatives of cholesterol show a polymorphic shape and various degrees of multilamellarity and lipid partitioning, likely due to phase separation. The addition of methyl and ethyl groups to the C24 alkyl tail of the cholesterol backbone induces multilamellarity (>50% increase compared to cholesterol), while the addition of a double bond induces lipid partitioning (>90% increase compared to cholesterol). LNPs with multilamellar and faceted structures, as well as a lamellar lipid phase, showed higher gene transfection. Unraveling the structure of mRNA-LNPs can enable their rational design toward enhanced gene delivery.
C1 [Eygeris, Yulia; Patel, Siddharth; Jozic, Antony; Sahay, Gaurav] Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Portland, OR 97201 USA.
   [Sahay, Gaurav] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA.
RP Sahay, G (corresponding author), Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Portland, OR 97201 USA.; Sahay, G (corresponding author), Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA.
EM sahay@ohsu.edu
OI Sahay, Gaurav/0000-0003-1071-0500
FU National Heart Lung Blood InstituteUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [1R01HL146736-01]; Cystic Fibrosis
   Foundation [SAHAY18G0]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U24GM129547]; Office
   of Biological and Environmental Research [grid.436923.9]
FX The authors thank the National Heart Lung Blood Institute
   (1R01HL146736-01) (G.S.) and the Cystic Fibrosis Foundation SAHAY18G0
   (G.S.) for their financial support. A portion of this research was
   supported by NIH grant U24GM129547 and performed at the Pacific
   Northwest Cryo-EM Center (PNCC) at OHSU and accessed through EMSL
   (grid.436923.9), a DOE Office of Science User Facility sponsored by the
   Office of Biological and Environmental Research. We also would like to
   thank Merritt Barber and Prof. Willie E. Rochefort at the Rheology
   Laboratory at Oregon State University for providing training and access
   to the DSC.
CR Arteta MY, 2018, P NATL ACAD SCI USA, V115, pE3351, DOI 10.1073/pnas.1720542115
   Bernsdorff C, 2003, J PHYS CHEM B, V107, P10658, DOI 10.1021/jp034922a
   Brown MF, 2012, BIOCHEMISTRY-US, V51, P9782, DOI 10.1021/bi301332v
   Coats MT, 2020, BIOTECHNOL J, V15, DOI 10.1002/biot.201900198
   Cullis PR, 2017, MOL THER, V25, P1467, DOI 10.1016/j.ymthe.2017.03.013
   GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665
   Haque ME, 2001, BIOCHEMISTRY-US, V40, P4340, DOI 10.1021/bi002030k
   ILLINGER D, 1995, BBA-BIOMEMBRANES, V1239, P58, DOI 10.1016/0005-2736(95)00135-P
   Imam ZI, 2017, CELL MOL BIOENG, V10, P387, DOI 10.1007/s12195-017-0489-4
   Iwahashi M, 2001, J OLEO SCI, V50, P693
   Jovanovic AA, 2018, EUR J LIPID SCI TECH, V120, DOI 10.1002/ejlt.201800039
   Kim HJ, 2015, ACS NANO, V9, P10214, DOI 10.1021/acsnano.5b03902
   Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012
   Krivanek R, 2008, BIOPHYS J, V94, P3538, DOI 10.1529/biophysj.107.122549
   Kulkarni JA, 2019, NANOSCALE, V11, P21733, DOI 10.1039/c9nr09347h
   Kulkarni JA, 2018, ACS NANO, V12, P4787, DOI 10.1021/acsnano.8b01516
   Kulkarni JA, 2017, NANOMED-NANOTECHNOL, V13, P1377, DOI 10.1016/j.nano.2016.12.014
   Leung AKK, 2015, J PHYS CHEM B, V119, P8698, DOI 10.1021/acs.jpcb.5b02891
   Lopez S, 2014, BBA-BIOMEMBRANES, V1838, P1638, DOI 10.1016/j.bbamem.2014.01.007
   MCELHANEY RN, 1982, CHEM PHYS LIPIDS, V30, P229, DOI 10.1016/0009-3084(82)90053-6
   Miller JB, 2017, ANGEW CHEM INT EDIT, V56, P1059, DOI 10.1002/anie.201610209
   Moderna, MOD WORK POT VACC CO
   Patel S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14527-2
   Patel S, 2017, NANO LETT, V17, P5711, DOI 10.1021/acs.nanolett.7b02664
   Paunovska K, 2018, NANO LETT, V18, P2148, DOI 10.1021/acs.nanolett.8b00432
   Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810
   Rietwyk S, 2017, ACS NANO, V11, P7572, DOI 10.1021/acsnano.7b04734
   Rizk M, 2017, PHARMACOGEN PERS MED, V10, P267, DOI 10.2147/PGPM.S87945
   Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278
   SIMON SA, 1982, SCIENCE, V216, P65, DOI 10.1126/science.7063872
   Sun JS, 2015, ADV MATER, V27, P1402, DOI 10.1002/adma.201404788
   TENCHOV B, 1991, CHEM PHYS LIPIDS, V57, P165, DOI 10.1016/0009-3084(91)90074-L
   Valeur B., 2009, DIGITAL ENCY APPL PH, P477, DOI DOI 10.1002/3527600434.EAP684
   Viger-Gravel J, 2018, J PHYS CHEM B, V122, P2073, DOI 10.1021/acs.jpcb.7b10795
   Winter R, 2000, Z KRISTALLOGR, V215, P454, DOI 10.1524/zkri.2000.215.8.454
   Zhang JT, 2011, LANGMUIR, V27, P9473, DOI 10.1021/la201464k
   Zhang XF, 2017, ACS APPL MATER INTER, V9, P25481, DOI 10.1021/acsami.7b08163
NR 37
TC 3
Z9 3
U1 10
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
EI 1530-6992
J9 NANO LETT
JI Nano Lett.
PD JUN 10
PY 2020
VL 20
IS 6
BP 4543
EP 4549
DI 10.1021/acs.nanolett.0c01386
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA MA1PZ
UT WOS:000541691200062
PM 32375002
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Schneider, KN
   Correa-Martinez, CL
   Gosheger, G
   Rickert, C
   Schorn, D
   Mellmann, A
   Schwierzeck, V
   Kampmeier, S
AF Schneider, K. N.
   Correa-Martinez, C. L.
   Gosheger, G.
   Rickert, C.
   Schorn, D.
   Mellmann, A.
   Schwierzeck, V.
   Kampmeier, S.
TI Assessing the spreading potential of an undetected case of COVID-19 in
   orthopaedic surgery
SO ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; MDRO; Nosocomial; Infection; Orthopaedics
AB Background With the novel coronavirus-induced disease (COVID-19), there is the fear of nosocomial infections and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmissions to healthcare workers (HCW). We report the case of a 64-year-old male patient who underwent explantation of a shoulder prosthesis due to a periprosthetic infection. He was tested SARS-CoV-2 positive 7 days after admission to the orthopaedic department following strict infection control measures, routinely including screening all patients for multi-drug-resistant organism (MDRO) colonization upon admission. Aim of our study is to report on the spreading potential of SARS-CoV-2 in a healthcare setting if standard contact precautions and infection control measures have been established. Methods All HCW with exposure to the patient from day of admission until confirmed diagnosis of COVID-19 were identified and underwent oropharyngeal swab testing for SARS-CoV-2 by real-time RT-PCR. Results Sixty-six HCW were identified: nine orthopaedic surgeons, four anaesthesiologists, 25 orthopaedic nurses, five nurse anesthetists, eight scrub nurses, five nursing students, two medical assistants and seven service employees. Fourteen HCW (21%) showed clinical symptoms compatible with a SARS-CoV-2 infection: cough (n = 4), sore throat (n = 3), nasal congestion (n = 3), dyspnea (n = 2), fever (n = 1), headache and myalgia (n = 1). SARS-CoV-2 was not detected in any of the 66 HCW. Conclusion Hygienic measures and contact precautions, aimed at preventing the spread of MRDO, may have helped to prevent a SARS-CoV-2 transmission to HCW-despite high-risk exposure during intubation, surgical treatment and general care.
C1 [Schneider, K. N.; Gosheger, G.; Rickert, C.; Schorn, D.] Univ Hosp Munster, Dept Orthopaed & Tumor Orthopaed, Albert Schweitzer Campus 1, D-48149 Munster, Germany.
   [Correa-Martinez, C. L.; Mellmann, A.; Schwierzeck, V.; Kampmeier, S.] Univ Hosp Munster, Inst Hyg, Albert Schweitzer Campus 1, D-48149 Munster, Germany.
RP Schneider, KN (corresponding author), Univ Hosp Munster, Dept Orthopaed & Tumor Orthopaed, Albert Schweitzer Campus 1, D-48149 Munster, Germany.
EM kristian.schneider@ukmuenster.de
RI Taha, Samy/N-4620-2019; Schwierzeck, Vera/AAL-3028-2020
OI Taha, Samy/0000-0003-0284-7806; Schwierzeck, Vera/0000-0003-4254-3700
FU Projekt DEAL; medical faculty of the University of Munster/Germany; Open
   Access Publication Fund of the University of Munster/Germany
FX Open Access funding provided by Projekt DEAL. This work was supported by
   the medical faculty of the University of Munster/Germany (fellowship of
   CR). The authors acknowledge support from the Open Access Publication
   Fund of the University of Munster/Germany.
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Anfinrud P, 2020, NEW ENGL J MED, V382, P2061, DOI 10.1056/NEJMc2007800
   [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   [Anonymous], 2020, NACH 22 TOTEN WURZBU
   [Anonymous], 2020, LEITUNG BERGMANN KLI
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Robert Koch Institut, 2020, KONT BEI RESP ERKR D
   Rong XM, 2020, MATH BIOSCI ENG, V17, P2725, DOI 10.3934/mbe.2020149
   Schwartz J, 2020, CLIN INFECT DIS, V71, P858, DOI [10.1093/cid/ciaa255, 10.1080/10409238.2020.1841726]
   Spychalski P, 2020, LANCET INFECT DIS, V20, P774, DOI [10.1016/S1473-3099(20)30246-2, 10.1016/S1473-3099(20)30245-0]
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wong SCY, 2020, J HOSP INFECT, V105, P119, DOI 10.1016/j.jhin.2020.03.036
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Zhan MK, 2020, NEW ENGL J MED, V382, P2267, DOI 10.1056/NEJMc2005696
NR 18
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0936-8051
EI 1434-3916
J9 ARCH ORTHOP TRAUM SU
JI Arch. Orthop. Trauma Surg.
DI 10.1007/s00402-020-03516-1
EA JUN 2020
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA LZ6XS
UT WOS:000541364800003
PM 32524227
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Ong, EZY
   Chan, YFZ
   Leong, WY
   Lee, NMY
   Kalimuddin, S
   Mohideen, SMH
   Chan, KS
   Tan, AT
   Bertoletti, A
   Ooi, EE
   Low, JGH
AF Ong, Eugenia Ziying
   Chan, Yvonne Fu Zi
   Leong, Wan Ying
   Lee, Natalie Mei Ying
   Kalimuddin, Shirin
   Mohideen, Salahudeen Mohamed Haja
   Chan, Kian Sing
   Tan, Anthony Tanoto
   Bertoletti, Antonio
   Ooi, Eng Eong
   Low, Jenny Guek Hong
TI A Dynamic Immune Response Shapes COVID-19 Progression
SO CELL HOST & MICROBE
LA English
DT Article
AB The inflammatory response to SARS-coronavirus-2 (SARS-CoV-2) infection is thought to underpin COVID-19 pathogenesis. We conducted daily transcriptomic profiling of three COVID-19 cases and found that the early immune response in COVID-19 patients is highly dynamic. Patient throat swabs were tested daily for SARS-CoV-2, with the virus persisting for 3 to 4 weeks in all three patients. Cytokine analyses of whole blood revealed increased cytokine expression in the single most severe case. However, most inflammatory gene expression peaked after respiratory function nadir, except expression in the IL1 pathway. Parallel analyses of CD4 and CD8 expression suggested that the pro-inflammatory response may be intertwined with T cell activation that could exacerbate disease or prolong the infection. Collectively, these findings hint at the possibility that IL1 and related pro-inflammatory pathways may be prognostic and serve as therapeutic targets for COVID-19. This work may also guide future studies to illuminate COVID-19 pathogenesis and develop host-directed therapies.
C1 [Ong, Eugenia Ziying; Leong, Wan Ying; Ooi, Eng Eong; Low, Jenny Guek Hong] SingHlth Duke NUS Acad Med Ctr, Viral Res & Expt Med Ctr, Singapore 169856, Singapore.
   [Ong, Eugenia Ziying; Leong, Wan Ying; Kalimuddin, Shirin; Tan, Anthony Tanoto; Bertoletti, Antonio; Ooi, Eng Eong; Low, Jenny Guek Hong] Duke NUS Med Sch, Program Emerging Infect Dis, Singapore 169857, Singapore.
   [Chan, Yvonne Fu Zi; Lee, Natalie Mei Ying; Kalimuddin, Shirin; Ooi, Eng Eong; Low, Jenny Guek Hong] Singapore Gen Hosp, Dept Infect Dis, Singapore 169608, Singapore.
   [Mohideen, Salahudeen Mohamed Haja] Singapore Gen Hosp, Dept Diagnost Radiol, Singapore 169608, Singapore.
   [Chan, Kian Sing] Singapore Gen Hosp, Dept Mol Pathol, Singapore 169608, Singapore.
RP Ooi, EE; Low, JGH (corresponding author), SingHlth Duke NUS Acad Med Ctr, Viral Res & Expt Med Ctr, Singapore 169856, Singapore.; Ooi, EE; Low, JGH (corresponding author), Duke NUS Med Sch, Program Emerging Infect Dis, Singapore 169857, Singapore.; Ooi, EE; Low, JGH (corresponding author), Singapore Gen Hosp, Dept Infect Dis, Singapore 169608, Singapore.
EM engeong.ooi@duke-nus.edu.sg; jenny.low@singhealth.com.sg
FU Tanoto Foundation; National Medical Research Council of Singapore,
   through the Clinician Scientist Awards
FX We thank all doctors and nurses in the isolation facility in Singapore
   General Hospital. ViREMiCS was established through generous support from
   the Tanoto Foundation. EEO and JGL are funded by the National Medical
   Research Council of Singapore, through the Clinician Scientist Awards.
CR Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim KD, 2007, NAT MED, V13, P1248, DOI 10.1038/nm1633
   Ong EZ, 2019, ANTIVIR RES, V166, P35, DOI 10.1016/j.antiviral.2019.03.013
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 6
TC 38
Z9 38
U1 10
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD JUN 10
PY 2020
VL 27
IS 6
BP 879
EP +
DI 10.1016/j.chom.2020.03.021
PG 6
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA LY8ED
UT WOS:000540760600008
PM 32359396
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Yu , BL
   Li , X
   Chen, J
   Ouyang, MQ
   Zhang, H
   Zhao, XG
   Tang, L
   Luo, Q
   Xu, M
   Yang, LZ
   Huang, GX
   Liu, XL
   Tang, JJ
AF Yu, Bilian
   Li, Xin
   Chen, Jin
   Ouyang, Mingqi
   Zhang, Hong
   Zhao, Xinge
   Tang, Liang
   Luo, Qin
   Xu, Min
   Yang, Lizhen
   Huang, Guxiang
   Liu, Xianling
   Tang, Jianjun
TI Evaluation of variation in D-dimer levels among COVID-19 and bacterial
   pneumonia: a retrospective analysis
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article
DE D-dimer; COVID-19; Bacterial pneumonia; Retrospective analysis
ID ACUTE RESPIRATORY SYNDROME; CLINICAL CHARACTERISTICS; COAGULATION;
   SEVERITY; OUTCOMES; DISEASE
AB In the recent outbreak of novel coronavirus infection worldwide, the risk of thrombosis and bleeding should be concerned. We aimed to observe the dynamic changes of D-dimer levels during disease progression to evaluate their value for thrombosis. In this study, we report the clinical and laboratory results of 57 patients with confirmed COVID-19 pneumonia and 46 patients with confirmed community-acquired bacterial pneumonia (CAP). And their concentrations of D-dimer, infection-related biomarkers, and conventional coagulation were retrospectively analyzed. The Padua prediction score is used to identify patients at high risk for venous thromboembolism (VTE). The results found that, on admission, both in COVID-19 patients and CAP patients, D-dimer levels were significantly increased, and compared with CAP patients, D-dimer levels were higher in COVID-19 patients (P < 0.05). Besides, we found that in COVID-19 patients, D-dimer were related with markers of inflammation, especially with hsCRP (R = 0.426, P < 0.05). However, there was low correlation between VTE score and D-dimer levels (Spearman's R = 0.264, P > 0.05) weakened the role of D-dimer in the prediction of thrombosis. After treatments, D-dimer levels decreased which was synchronous with hsCRP levels in patients with good clinical prognosis, but there were still some patients with anomalous increasing D-dimer levels after therapy. In conclusion, elevated baseline D-dimer levels are associated with inflammation but not with VTE score in COVID-19 patients, suggesting that it is unreasonable to judge whether anticoagulation is needed only according to D-dimer levels. However, the abnormal changes of D-dimer and inflammatory factors suggest that anticoagulant therapy might be needed.
C1 [Yu, Bilian; Chen, Jin; Ouyang, Mingqi; Tang, Liang; Luo, Qin; Tang, Jianjun] Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha 410011, Hunan, Peoples R China.
   [Li, Xin] Cent South Univ, Xiangya Hosp 2, Dept Vasc Surg, Changsha 410011, Hunan, Peoples R China.
   [Zhang, Hong] Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Surg, Changsha 410011, Hunan, Peoples R China.
   [Zhao, Xinge] Cent South Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha 410011, Hunan, Peoples R China.
   [Xu, Min] Cent South Univ, Xiangya Hosp 2, Dept Intens Care Unit, Changsha 410011, Hunan, Peoples R China.
   [Yang, Lizhen] Cent South Univ, Xiangya Hosp 2, Dept Resp Intens Care Unit, Changsha 410011, Hunan, Peoples R China.
   [Huang, Guxiang] Cent South Univ, Xiangya Hosp 2, Dept Geratol, Changsha 410011, Hunan, Peoples R China.
   [Liu, Xianling] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha 410011, Hunan, Peoples R China.
   [Yu, Bilian; Li, Xin; Zhang, Hong; Zhao, Xinge; Tang, Liang; Xu, Min; Yang, Lizhen; Huang, Guxiang; Liu, Xianling; Tang, Jianjun] Cent South Univ, Anti 2019 NCov Pneumonia Med Support Grp Wuhan, Xiangya Hosp 2, Tongji Med Coll,Tongji Hosp, Wuhan, Hubei, Peoples R China.
RP Tang, JJ (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha 410011, Hunan, Peoples R China.; Liu, XL (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha 410011, Hunan, Peoples R China.; Liu, XL; Tang, JJ (corresponding author), Cent South Univ, Anti 2019 NCov Pneumonia Med Support Grp Wuhan, Xiangya Hosp 2, Tongji Med Coll,Tongji Hosp, Wuhan, Hubei, Peoples R China.
EM liuxianling@csu.edu.cn; tom200210@csu.edu.cn
CR Agapakis DI, 2010, RESPIROLOGY, V15, P796, DOI 10.1111/j.1440-1843.2010.01773.x
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chong PY, 2004, ARCH PATHOL LAB MED, V128, P195
   Gralinski LE, 2013, MBIO, V4, DOI 10.1128/mBio.00271-13
   Guan WJ, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMoa2002032]
   Gunther A, 2000, AM J RESP CRIT CARE, V161, P454
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DSC, 2003, RESPIROLOGY, V8, pS20, DOI 10.1046/j.1440-1843.2003.00520.x
   Lang Z, 2003, CHINESE MED J-PEKING, V07, P17
   Lin L, 2020, Zhonghua Yi Xue Za Zhi, V100, pE001, DOI 10.3760/cma.j.issn.0376-2491.2020.0001
   Mao L., 2020, NEUROLOGICAL MANIFES, DOI [10.1101/2020.02.22.20026500., 10.1101/2020.02.22.20026500, DOI 10.1101/2020.02.22.20026500]
   Pettila V, 2002, INTENS CARE MED, V28, P1220, DOI 10.1007/s00134-002-1416-1
   Salluh JIF, 2011, J CRIT CARE, V26, P496, DOI 10.1016/j.jcrc.2011.02.001
   Shorr AF, 2002, CHEST, V121, P1262, DOI 10.1378/chest.121.4.1262
   Snijders D, 2012, EUR J INTERN MED, V23, P436, DOI 10.1016/j.ejim.2011.10.019
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   van Belle A, 2006, JAMA-J AM MED ASSOC, V295, P172
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
NR 26
TC 17
Z9 17
U1 2
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD OCT
PY 2020
VL 50
IS 3
BP 548
EP 557
DI 10.1007/s11239-020-02171-y
EA JUN 2020
PG 10
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA NS7SM
UT WOS:000540626100002
PM 32524516
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yi, CH
   Yi, YX
   Li, JW
AF Yi, Changhua
   Yi, Yongxiang
   Li, Junwei
TI mRNA Vaccines: Possible Tools to Combat SARS-CoV-2
SO VIROLOGICA SINICA
LA English
DT Article
ID CORONAVIRUS; SPIKE
C1 [Yi, Changhua; Yi, Yongxiang] Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Infect Dis, Affiliated Hosp, Nanjing 210003, Peoples R China.
   [Yi, Changhua; Yi, Yongxiang] Publ Hlth & Therapy Ctr Nanjing, Nanjing 211113, Peoples R China.
   [Li, Junwei] Qingdao Agr Univ, Coll Vet Med, Qingdao 266109, Peoples R China.
RP Yi, YX (corresponding author), Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Infect Dis, Affiliated Hosp, Nanjing 210003, Peoples R China.; Yi, YX (corresponding author), Publ Hlth & Therapy Ctr Nanjing, Nanjing 211113, Peoples R China.; Li, JW (corresponding author), Qingdao Agr Univ, Coll Vet Med, Qingdao 266109, Peoples R China.
EM ian0126@126.com; junwli@yeah.net
FU Priority Academic Talent Team Cultivation Program of Shandong Colleges
   and Universities; Shandong National Science Foundation [ZR2017MC002];
   Talent Program of Qingdao Agricultural University
FX This study was supported by the Priority Academic Talent Team
   Cultivation Program of Shandong Colleges and Universities, the Shandong
   National Science Foundation (ZR2017MC002), and the Talent Program of
   Qingdao Agricultural University.
CR [Anonymous], 2020, XINHUA NET
   [Anonymous], 2020, CNBETA
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Demoulins T, 2016, NANOMED-NANOTECHNOL, V12, P711, DOI 10.1016/j.nano.2015.11.001
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020
   Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450
   Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243
   Smith J., 2020, CUREVAC BIDS DEV 1 M
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Winarski KL, 2019, P NATL ACAD SCI USA, V116, P15194, DOI 10.1073/pnas.1821317116
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 19
TC 2
Z9 2
U1 3
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1674-0769
EI 1995-820X
J9 VIROL SIN
JI Virol. Sin.
PD JUN
PY 2020
VL 35
IS 3
SI SI
BP 259
EP 262
DI 10.1007/s12250-020-00243-0
EA JUN 2020
PG 4
WC Virology
SC Virology
GA MF9LC
UT WOS:000539837400001
PM 32524253
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hoffman, L
AF Hoffman, Louis
TI Existential-Humanistic Therapy and Disaster Response: Lessons From the
   COVID-19 Pandemic
SO JOURNAL OF HUMANISTIC PSYCHOLOGY
LA English
DT Article; Early Access
DE disaster response; trauma; existential-humanistic therapy;
   existential-integrative therapy; COVID-19
AB The COVID-19 pandemic has dramatically affected the mental health field. The unique distress caused by the pandemic along with the need for many to transition their therapy practices to TeleHealth/Telepsychology modalities caught many therapists, including existential-humanistic therapists, unprepared to make the necessary adjustments to treat clients in a manner that is safe and effective. Existential-humanistic therapy often is neglected with trauma and disaster relief work, despite its relevancy and important contributions. All therapies must adjust in crisis situations, particularly when adjustments to how services are offered are disrupted; however, the impact of these changes varies by therapeutic orientation. As an approach that values genuineness, empathy, and presence, existential-humanistic therapy faces unique challenges when employed with disaster response. However, when these challenges are faced, existential-humanistic therapy has much to offer disaster response, including consideration of existential guilt, existential shattering, existential anxiety, and existential perspectives on self-care.
C1 [Hoffman, Louis] Rocky Mt Humanist Counseling & Psychol Assoc, 655 Southpointe Court,Suite 200, Colorado Springs, CO 80906 USA.
RP Hoffman, L (corresponding author), Rocky Mt Humanist Counseling & Psychol Assoc, 655 Southpointe Court,Suite 200, Colorado Springs, CO 80906 USA.
EM lhoffman@rmhcpa.org
RI Hoffman, Louis/M-9766-2015
OI Hoffman, Louis/0000-0002-4288-0072
CR Bush AD, 2015, SIMPLE SELF CARE THE
   Dias J., 2019, EXISTENTIAL PSYCHOL, V2, P167
   Flynn S, 2019, INTEGRATED CARE TRAU, pvii
   Frankl V., 1984, MANS SEARCH MEANING
   Friedman M. J., 2006, INTERVENTIONS FOLLOW
   Hoffman L., 2002, AM PSYCH SOC ANN C
   Hoffman L., 2018, ENCY PSYCHOL RELIG, DOI [10.1007/978-3-642-27771-9_200193-1, DOI 10.1007/978-3-642-27771-9_200193-1]
   Hoffman L., 2018, ENCY PSYCHOL RELIG, DOI [10.1007/978-3-642-27771-9_200194-1, DOI 10.1007/978-3-642-27771-9_200194-1]
   Hoffman L., 2019, HUMANISTIC APPROACHE, DOI [10.4324/9781351133357, DOI 10.4324/9781351133357]
   Hoffman L., 2019, EXISTENTIAL PSYCHOL, V1, P1
   Hoffman L, 2015, J CONTEMP PSYCHOTHER, V45, P11, DOI 10.1007/s10879-014-9277-9
   Hoxie E., 2013, THESIS
   Hsu A., 2019, EXISTENTIAL PSYCHOL, V1, P111
   Joint Task Force Dev Telepsycholog, 2013, AM PSYCHOL, V68, P791, DOI 10.1037/a0035001
   Krug O. T., 2019, WILEY WORLD HDB EXIS, P257, DOI DOI 10.1002/9781119167198.CH15
   Krug OT, 2009, J HUMANIST PSYCHOL, V49, P329, DOI 10.1177/0022167809334001
   May R., 1958, EXISTENCE NEW DIMENS, P37, DOI [10.1037/11321-002, DOI 10.1037/11321-002]
   May Rollo., 1977, MEANING ANXIETY
   Norcross J.C., 2018, LEAVING IT OFFICE GU
   O'Donohue J., 1998, ANAM CARA BOOK CELTI
   Olweean S. S., 2019, INTEGRATED CARE TRAU, P161
   Pardess E., 2019, INTEGRATED CARE TRAU, P189
   Perle JG, 2011, CLIN PSYCHOL REV, V31, P1247, DOI 10.1016/j.cpr.2011.08.003
   Ren ZJ, 2020, J HUMANIST PSYCHOL, V60, P59, DOI 10.1177/0022167816675704
   Ren ZJ, 2018, J RELIG HEALTH, V57, P2313, DOI 10.1007/s10943-018-0584-4
   Ruzek J. I., 2006, INTERVENTIONS FOLLOW
   Schneider K. J., 2017, EXISTENTIAL HUMANIST, DOI [10.1037/0000042-000, DOI 10.1037/0000042-000]
   Schneider KJ, 2016, J PSYCHOTHER INTEGR, V26, P49, DOI 10.1037/a0039632
   Schneider KJ, 2008, EXISTENTIAL-INTEGRATIVE PSYCHOTHERAPY: GUIDEPOSTS TO THE CORE OF PRACTICE, pVII
   Serlin I. A., 2019, INTEGRATED CARE TRAU, P1
   Shallcross SL, 2014, J COUNS PSYCHOL, V61, P352, DOI 10.1037/a0036583
   Sharp KMH, 2017, J AGGRESS MALTREAT T, V26, P736, DOI 10.1080/10926771.2017.1289999
   Stolorow R. D, 1992, CONTEXT BEING INTERS
   Sword R., 2019, INTEGRATED CARE TRAU, P109
   Thrash J. C., 2019, EXISTENTIAL PSYCHOL, V1, P97
   Tillich P, 1952, COURAGE BE
   Vallejos L. M., 2015, THESIS
   Van Deurzen E., 2005, DICT EXISTENTIAL PSY
   Watson J. C., 2010, PERSON CTRED EXPERIE, P132
   Wolfe BE, 2008, EXISTENTIAL-INTEGRATIVE PSYCHOTHERAPY: GUIDEPOSTS TO THE CORE OF PRACTICE, P204
   Wong P. T. P., 2012, MEANING THEORIES RES
   Y Xianyi, 1959, LU X SELECTED WORKS, V1, P90
   Yalom I. D., 1980, EXISTENTIAL PSYCHOTH
   Yalom I. D., 2008, STARING SUN OVERCOMI, DOI [10.1080/08873260802350006, DOI 10.1080/08873260802350006]
   Yang M., 2019, EXISTENTIAL PSYCHOL, V2, P57
   Young B. H., 2006, INTERVENTIONS FOLLOW
NR 46
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-1678
EI 1552-650X
J9 J HUMANIST PSYCHOL
JI J. Humanist. Psychol.
AR 0022167820931987
DI 10.1177/0022167820931987
EA JUN 2020
PG 22
WC Psychology, Multidisciplinary
SC Psychology
GA LX2GD
UT WOS:000539654900001
OA Other Gold
DA 2021-01-01
ER

PT J
AU Cook, G
   Ashcroft, AJ
   Pratt, G
   Popat, R
   Ramasamy, K
   Kaiser, M
   Jenner, M
   Henshaw, S
   Hall, R
   Sive, J
   Stern, S
   Streetly, M
   Bygrave, C
   Soutar, R
   Rabin, N
   Jackson, GH
AF Cook, Gordon
   John Ashcroft, A.
   Pratt, Guy
   Popat, Rakesh
   Ramasamy, Karthik
   Kaiser, Martin
   Jenner, Matthew
   Henshaw, Sarah
   Hall, Rachel
   Sive, Jonathan
   Stern, Simon
   Streetly, Matthew
   Bygrave, Ceri
   Soutar, Richard
   Rabin, Neil
   Jackson, Graham H.
CA United Kingdom Myeloma Forum
TI Real-world assessment of the clinical impact of symptomatic infection
   with severe acute respiratory syndrome coronavirus (COVID-19 disease) in
   patients with multiple myeloma receiving systemic anti-cancer therapy
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Letter
DE COVID-19; multiple myeloma; systemic antic-cancer therapy
C1 [Cook, Gordon] Univ Leeds, Leeds Inst Clin Trial Res, Leeds, W Yorkshire, England.
   [Cook, Gordon] Univ Leeds, Leeds Canc Ctr, Leeds, W Yorkshire, England.
   [John Ashcroft, A.] Mid Yorkshire NHS Trust, Pinderfields Hosp, Dept Haematol, Wakefield, England.
   [Pratt, Guy] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England.
   [Popat, Rakesh; Sive, Jonathan; Rabin, Neil] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England.
   [Ramasamy, Karthik] Oxford Univ Hosp NHS FT, NIHR BRC Blood Theme, Oxford, England.
   [Kaiser, Martin] Inst Canc Res, London, England.
   [Jenner, Matthew] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England.
   [Henshaw, Sarah] Nottingham City Hosp, Dept Haematol, Nottingham, England.
   [Hall, Rachel] Royal Bournemouth & Christchurch Hosp NHS Fdn Tru, Bournemouth, Dorset, England.
   [Stern, Simon] Epsom & St Helier Univ Hosp NHS Trust, Dept Haematol, Carshalton, Surrey, England.
   [Streetly, Matthew] Guys & St Thomass Trust, Dept Haematol, London, England.
   [Bygrave, Ceri] Univ Hosp Wales, Dept Haematol, Cardiff, Wales.
   [Soutar, Richard] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland.
   [Jackson, Graham H.] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England.
RP Cook, G (corresponding author), Univ Leeds, Leeds Inst Clin Trial Res, Leeds, W Yorkshire, England.; Cook, G (corresponding author), Univ Leeds, Leeds Canc Ctr, Leeds, W Yorkshire, England.
EM g.cook@leeds.ac.uk
OI Ramasamy, Karthik/0000-0003-3385-3707
CR Binder M, 2019, AM J HEMATOL, V94, P306, DOI 10.1002/ajh.25365
   Chari A, 2020, EXPERT REV HEMATOL, V13, P421, DOI 10.1080/17474086.2020.1729734
   Costa LJ, 2017, BLOOD ADV, V1, P282, DOI 10.1182/bloodadvances.2016002493
   Cowan AJ, 2018, JAMA ONCOL, V4, P1221, DOI 10.1001/jamaoncol.2018.2128
   Drayson MT, 2019, LANCET ONCOL, V20, P1760, DOI 10.1016/S1470-2045(19)30506-6
   Fernando RC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38314-8
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kinross P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.11.2000285
   Landgren O, 2019, JAMA ONCOL, V5, P1293, DOI 10.1001/jamaoncol.2019.1568
   Lavi N, 2018, SUPPORT CARE CANCER, V26, P2425, DOI 10.1007/s00520-018-4079-3
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Teh BW, 2015, SUPPORT CARE CANCER, V23, P1901, DOI 10.1007/s00520-014-2550-3
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
NR 14
TC 15
Z9 15
U1 3
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD JUL
PY 2020
VL 190
IS 2
BP E83
EP E86
DI 10.1111/bjh.16874
EA JUN 2020
PG 4
WC Hematology
SC Hematology
GA ML5DQ
UT WOS:000539086800001
PM 32438482
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Kruglikov, IL
   Scherer, PE
AF Kruglikov, Ilja L.
   Scherer, Philipp E.
TI The Role of Adipocytes and Adipocyte-Like Cells in the Severity of
   COVID-19 Infections
SO OBESITY
LA English
DT Article
ID LIPOFIBROBLAST; MYOFIBROBLASTS
AB Coronavirus disease-2019 (COVID-19), caused by the highly pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), demonstrates high morbidity and mortality caused by development of a severe acute respiratory syndrome connected with extensive pulmonary fibrosis. In this Perspective, we argue that adipocytes and adipocyte-like cells, such as pulmonary lipofibroblasts, may play an important role in the pathogenic response to SARS-CoV-2. Expression of angiotensin-converting enzyme 2 (the functional receptor for SARS-CoV) is upregulated in adipocytes of patients with obesity and diabetes, which turns adipose tissue into a potential target and viral reservoir. This may explain why obesity and diabetes are potential comorbidities for COVID-19 infections. Similar to the recently established adipocyte-myofibroblast transition, pulmonary lipofibroblasts located in the alveolar interstitium and closely related to classical adipocytes demonstrate the ability to transdifferentiate into myofibroblasts that play an integral part of pulmonary fibrosis. This may significantly increase the severity of the local response to SARS-CoV-2 in the lung. To reduce the severity and mortality associated with COVID-19, we propose to probe for the clinical response to thiazolidinediones, peroxisome proliferator activated receptor gamma agonists that are well-known antidiabetic drugs. Thiazolidinediones are able to stabilize lipofibroblasts in their "inactive" state, preventing the transition to myofibroblasts and thereby reducing the development of pulmonary fibrosis and stimulating its resolution.
C1 [Kruglikov, Ilja L.] Wellcomet GmbH, Sci Dept, Karlsruhe, Germany.
   [Scherer, Philipp E.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Touchstone Diabet Ctr, Dallas, TX 75390 USA.
RP Scherer, PE (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Touchstone Diabet Ctr, Dallas, TX 75390 USA.
EM philipp.scherer@utsouthwestern.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01-DK55758, R01-DK099110,
   RC2-DK118620, P01-DK088761, P01-AG051459]; Novo Nordisk Research
   FoundationNovo Nordisk Foundation
FX PES is supported by NIH grants R01-DK55758, R01-DK099110, RC2-DK118620,
   P01-DK088761, and P01-AG051459. PES is also supported by an unrestricted
   grant from the Novo Nordisk Research Foundation.
CR Ahlbrecht K, 2014, AM J PHYSIOL-LUNG C, V307, pL605, DOI 10.1152/ajplung.00230.2014
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   El Agha E, 2017, CELL STEM CELL, V20, P261, DOI 10.1016/j.stem.2016.10.004
   Habiel DM, 2017, CURR PATHOBIOL REP, V5, P101, DOI 10.1007/s40139-017-0134-x
   Kheirollahi V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10839-0
   Kokeny G, 2020, CURR OPIN NEPHROL HY, V29, P171, DOI 10.1097/MNH.0000000000000580
   Kruglikov IL, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0627-y
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Marangoni RG, 2017, SCI REP, V7, P1
   Marangoni RG, 2015, ARTHRITIS RHEUMATOL, V67, P1062, DOI 10.1002/art.38990
   Mendy A, 2019, RESPIROLOGY, V24, P646, DOI 10.1111/resp.13486
   Naik Payal K, 2010, Expert Rev Respir Med, V4, P759, DOI 10.1586/ers.10.73
   Nalysnyk L, 2012, EUR RESPIR REV, V21, P355, DOI 10.1183/09059180.00002512
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Rehan VK, 2014, ANTIOXID REDOX SIGN, V21, P1893, DOI 10.1089/ars.2013.5793
   Straub LG, 2019, NAT METAB, V1, P334, DOI 10.1038/s42255-019-0041-z
   Tse GMK, 2004, J CLIN PATHOL, V57, P260, DOI 10.1136/jcp.2003.013276
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Zhang ZZ, 2019, J CLIN INVEST, V129, P5327, DOI 10.1172/JCI130239
   Zhu Y, 2020, SINGLE CELL ANAL ACE, DOI [10.20944/preprints202002.0221.v1, DOI 10.20944/PREPRINTS202002.0221.V1]
   Zuo W, 2010, MOLECULAR BIOLOGY OF THE SARS-CORONAVIRUS, P247, DOI 10.1007/978-3-642-03683-5_15
NR 21
TC 45
Z9 47
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD JUL
PY 2020
VL 28
IS 7
BP 1187
EP 1190
DI 10.1002/oby.22856
EA JUN 2020
PG 4
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA MA1KS
UT WOS:000539100100001
PM 32339391
OA Green Accepted, Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Loganathan, T
   Ramachandran, S
   Shankaran, P
   Nagarajan, D
   Mohan, SS
AF Loganathan, Tamizhini
   Ramachandran, Srimathy
   Shankaran, Prakash
   Nagarajan, Devipriya
   Mohan, Suma S.
TI Host transcriptome-guided drug repurposing for COVID-19 treatmen a
   meta-analysis based approach
SO PEERJ
LA English
DT Article
DE COVID-19; SARS-CoV-2; Drug repurposing; Host transcriptome
ID ACTIVATED PROTEIN-KINASE; ANTIVIRAL ACTIVITY; INTERFERON; EXPRESSION;
   GENE; INFECTION; CORONAVIRUS; INHIBITOR; RESPONSES; CYTOKINE
AB Background: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a pandemic by the World Health Organization, and the identification of effective therapeutic strategy is a need of the hour to combat SARS-CoV-2 infection. In this scenario, the drug repurposing approach is widely used for the rapid identification of potential drugs against SARS-CoV-2, considering viral and host factors.
   Methods: We adopted a host transcriptome-based drug repurposing strategy utilizing the publicly available high throughput gene expression data on SARS-CoV-2 and other respiratory infection viruses. Based on the consistency in expression status of host factors in different cell types and previous evidence reported in the literature, pro-viral factors of SARS-CoV-2 identified and subject to drug repurposing analysis based on DrugBank and Connectivity Map (CMap) using the web tool, CLUE.
   Results: The upregulated pro-viral factors such as TYMP, PTGS2, C1S, CFB, IF144, XAF1, CXCL2, and CXCL3 were identified in early infection models of SARS-CoV-2. By further analysis of the drug-perturbed expression profiles in the connectivity map, 27 drugs that can reverse the expression of pro-viral factors were identified, and importantly, twelve of them reported to have anti-viral activity. The direct inhibition of the PTGS2 gene product can be considered as another therapeutic strategy for SARS-CoV-2 infection and could suggest six approved PTGS2 inhibitor drugs for the treatment of COVID-19. The computational study could propose candidate repurposable drugs against COVID-19, and further experimental studies are required for validation.
C1 [Loganathan, Tamizhini; Ramachandran, Srimathy; Shankaran, Prakash; Nagarajan, Devipriya; Mohan, Suma S.] SASTRA Deemed Be Univ, Sch Chem & Biotechnol, Thanjavur, India.
RP Nagarajan, D; Mohan, SS (corresponding author), SASTRA Deemed Be Univ, Sch Chem & Biotechnol, Thanjavur, India.
EM devipriya@scbt.sastra.edu; sumamohtm@scbt.sastra.edu
CR Abou Khaled KJ, 2008, NEUROL CLIN, V26, P385, DOI 10.1016/j.ncl.2008.03.017
   Arakelyan A, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11120677
   Asgari S, 2017, P NATL ACAD SCI USA, V114, P8342, DOI 10.1073/pnas.1704259114
   Asmal M, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-226
   Azuma A, 2011, PHARMACOLOGY, V87, P204, DOI 10.1159/000324532
   Bautista-Carbajal P, 2017, VIROLOGY, V501, P188, DOI 10.1016/j.virol.2016.12.004
   Bego MG, 2012, J VIROL, V86, P3513, DOI 10.1128/JVI.06971-11
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Boasso A, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/580968
   Bouallegue A, 2007, CURR VASC PHARMACOL, V5, P45, DOI 10.2174/157016107779317161
   Cascella M, 2020, FEATURES EVALUATION
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Christ-Crain Mirjam, 2008, Expert Rev Respir Med, V2, P565, DOI 10.1586/17476348.2.5.565
   Congote LF, 2006, BIOCHEM BIOPH RES CO, V343, P617, DOI 10.1016/j.bbrc.2006.02.190
   Coronavirus Disease, 2019, 84 WHO
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   DeDiego ML, 2019, MBIO, V10, DOI 10.1128/mBio.01839-19
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Dong BH, 2004, J VIROL, V78, P8983, DOI 10.1128/JVI.78.17.8983-8993.2004
   Fensterl V, 2011, J INTERF CYTOK RES, V31, P71, DOI 10.1089/jir.2010.0101
   FREIREGARABAL M, 1993, PHARMACOL BIOCHEM BE, V46, P167, DOI 10.1016/0091-3057(93)90336-R
   Gane EJ, 2014, ANTIMICROB AGENTS CH, V58, P1136, DOI 10.1128/AAC.01515-13
   Ge Y, 2020, BIORXIV, DOI [10.1101/2020.03.11.986836, DOI 10.1101/2020.03.11.986836]
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Griego SD, 2000, J IMMUNOL, V165, P5211, DOI 10.4049/jimmunol.165.9.5211
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Hsu YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079518
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim ET, 2013, J VIROL, V87, P12949, DOI 10.1128/JVI.02291-13
   Kirkby NS, 2013, BIOCHEM BIOPH RES CO, V438, P249, DOI 10.1016/j.bbrc.2013.07.006
   Kristiansen H, 2010, J VIROL, V84, P11898, DOI 10.1128/JVI.01003-10
   Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200
   Lee CH, 2004, J IMMUNOL, V172, P7841, DOI 10.4049/jimmunol.172.12.7841
   Leisching G, 2019, INT J INFECT DIS, V80, pS77, DOI 10.1016/j.ijid.2019.02.029
   Lempp FA, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9070172
   Liao Y, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01097
   Liu M, 2007, FASEB J, V21, P1586, DOI 10.1096/fj.06-6589com
   Long HT, 2009, J INFECT DIS, V199, P537, DOI 10.1086/596507
   Melchjorsen J, 2003, J LEUKOCYTE BIOL, V74, P331, DOI 10.1189/jlb.1102577
   Mimidis Konstantinos, 2005, Rom J Gastroenterol, V14, P27
   Nukuzuma S, 2009, MICROBIOL IMMUNOL, V53, P496, DOI 10.1111/j.1348-0421.2009.00156.x
   Patzina C, 2014, J BIOL CHEM, V289, P6020, DOI 10.1074/jbc.M113.543892
   Raaben M, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-55
   Risner K, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11121151
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Satoh M, 2006, J ENDOTOXIN RES, V12, P21, DOI 10.1179/096805106X89062
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shephard A, 2015, ANTIVIR RES, V123, P158, DOI 10.1016/j.antiviral.2015.09.012
   Showalter SD, 2016, AIDS RES HUM RETROV, V7, P65
   Spence JS, 2019, NAT CHEM BIOL, V15, P259, DOI 10.1038/s41589-018-0213-2
   Spiegel M, 2004, J CLIN VIROL, V30, P211, DOI 10.1016/j.jcv.2003.11.013
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Teijaro JR, 2016, CURR OPIN VIROL, V16, P31, DOI 10.1016/j.coviro.2016.01.001
   Tian J, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00886
   Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w
   Xu WT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0022900
   Zeng HX, 2014, MOL BIOL REP, V41, P7697, DOI 10.1007/s11033-014-3662-z
   Zhang Y, 2015, NAT IMMUNOL, V16, P1215, DOI 10.1038/ni.3279
   Zhou G, 2015, NATURE PROTOCOLS, V10, P823
   Zhou Y, 2020, CELL DISCOV, V14, P6, DOI DOI 10.1038/S41421-020-0153
NR 61
TC 1
Z9 1
U1 2
U2 2
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD JUN 10
PY 2020
VL 8
AR e9357
DI 10.7717/peerj.9357
PG 27
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LW5AW
UT WOS:000539160400011
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU French, JA
   Brodie, MJ
   Caraballo, R
   Devinsky, O
   Ding, D
   Jehi, L
   Jette, N
   Kanner, A
   Modi, AC
   Newton, CR
   Patel, AA
   Pennell, PB
   Perucca, E
   Sander, JW
   Scheffer, IE
   Singh, G
   Williams, E
   Wilmshurst, J
   Cross, JH
AF French, Jacqueline A.
   Brodie, Martin J.
   Caraballo, Roberto
   Devinsky, Orrin
   Ding, Ding
   Jehi, Lara
   Jette, Nathalie
   Kanner, Andres
   Modi, Avani C.
   Newton, Charles R.
   Patel, Archana A.
   Pennell, Page B.
   Perucca, Emilio
   Sander, Josemir W.
   Scheffer, Ingrid E.
   Singh, Gagandeep
   Williams, Emma
   Wilmshurst, Jo
   Cross, J. Helen
TI Keeping people with epilepsy safe during the COVID-19 pandemic
SO NEUROLOGY
LA English
DT Article
AB ObjectivesTo provide information on the effect of the coronavirus disease of 2019 (COVID-19) pandemic on people with epilepsy and provide consensus recommendations on how to provide the best possible care for people with epilepsy while avoiding visits to urgent care facilities and hospitalizations during the novel coronavirus pandemic.MethodsThe authors developed consensus statements in 2 sections. The first was "How should we/clinicians modify our clinical care pathway for people with epilepsy during the COVID-19 pandemic?" The second was "What general advice should we give to people with epilepsy during this crisis? The authors individually scored statements on a scale of -10 (strongly disagree) to +10 (strongly agree). Five of 11 recommendations for physicians and 3/5 recommendations for individuals/families were rated by all the authors as 7 or above (strongly agree) on the first round of rating. Subsequently, a teleconference was held where statements for which there was a lack of strong consensus were revised.ResultsAfter revision, all consensus recommendations received a score of 7 or above. The recommendations focus on administration of as much care as possible at home to keep people with epilepsy out of health care facilities, where they are likely to encounter COVID-19 (including strategies for rescue therapy), as well as minimization of risk of seizure exacerbation through adherence, and through ensuring a regular supply of medication. We also provide helpful links to additional helpful information for people with epilepsy and health providers.ConclusionThese recommendations may help health care professionals provide optimal care to people with epilepsy during the coronavirus pandemic.
C1 [French, Jacqueline A.] NYU, Dept Neurol, NYU Grossman Sch Med, New York, NY 10003 USA.
   [Brodie, Martin J.] Scottish Epilepsy Initiat, Int Bur Epilepsy, Epilepsy Unit, Glasgow, Lanark, Scotland.
   [Caraballo, Roberto] Hosp JP Garrahan, Neurol, Buenos Aires, DF, Argentina.
   [Devinsky, Orrin] NYU Grossman Sch Med, Dept Neurol, New York, NY USA.
   [Ding, Ding] Fudan Univ, Huashan Hosp, Inst Neurol, Shanghai, Peoples R China.
   [Jehi, Lara] Cleveland Clin, Epilepsy Ctr, Cleveland, OH 44106 USA.
   [Jette, Nathalie] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
   [Kanner, Andres] Univ Miami, Miller Sch Med, Dept Neurol, Div Epilepsy, Coral Gables, FL 33124 USA.
   [Modi, Avani C.] Univ Cincinnati, Sch Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45221 USA.
   [Newton, Charles R.] KEMRI Wellcome Programme, Kilifi, Kenya.
   [Newton, Charles R.] Univ Oxford, Dept Psychiat, Oxford, England.
   [Patel, Archana A.] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, Div Epilepsy & Clin Neurophysiol, Boston, MA 02115 USA.
   [Pennell, Page B.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Perucca, Emilio] Univ Pavia, Dept Internal Med & Therapeut, Pavia, Italy.
   [Perucca, Emilio] IRCCS Mondino Fdn, ERN EpiCARE, Pavia, Italy.
   [Sander, Josemir W.] UCL, Inst Neurol, Queen Sq, London, England.
   [Sander, Josemir W.] Stichting Epilepsie Instelligen Nederland SEIN, Heemstede, Netherlands.
   [Scheffer, Ingrid E.] Univ Melbourne, Austin Hosp, Florey Inst, Melbourne, Vic, Australia.
   [Scheffer, Ingrid E.] Univ Melbourne, Royal Childrens Hosp, Florey Inst, Melbourne, Vic, Australia.
   [Scheffer, Ingrid E.] Univ Melbourne, Austin Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Scheffer, Ingrid E.] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Singh, Gagandeep] Dayanand Med Coll, Ludhiana, Punjab, India.
   [Williams, Emma] Matthews Friends Ketogen Dietary Therapies, London, England.
   [Wilmshurst, Jo] Red Cross War Mem Childrens Hosp, Neurosci Inst, Dept Paediat Neurol, Cape Town, South Africa.
   [Cross, J. Helen] Great Ormond St Hosp Sick Children, UCL NIHR BRC Great Ormond St Inst Child Hlth, London, England.
   [Cross, J. Helen] Young Epilepsy, ERN EpiCARE, Lingfield, England.
RP French, JA (corresponding author), NYU, Dept Neurol, NYU Grossman Sch Med, New York, NY 10003 USA.
EM Jacqueline.french@nyulangone.org
RI French, Jacqueline A/G-6795-2013; Sander, Ley/C-1576-2008; Scheffer,
   Ingrid/G-1668-2013; Newton, Charles/B-7578-2014
OI French, Jacqueline A/0000-0003-2242-8027; Sander,
   Ley/0000-0001-6041-9661; Devinsky, Orrin/0000-0003-0044-4632; Cross,
   Helen/0000-0001-7345-4829; Scheffer, Ingrid/0000-0002-2311-2174; Newton,
   Charles/0000-0002-6999-5507; Patel, Archana A/0000-0002-1159-0128
CR Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Colson P, 2020, INT J ANTIMICROB AG, DOI [10.1016/j.ijantimicag.2020.105923.105923, DOI 10.1016/J.IJANTIMICAG.2020.105923.105923]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Malcangi G, 2000, RHEUMATOL INT, V20, P31, DOI 10.1007/s002960000066
   Nath A, 2020, NEUROLOGY, V94, P809, DOI 10.1212/WNL.0000000000009455
   Ojeda J., 2016, J NEUROL DISORD, V4, P311
   Olson K R, 1994, Am J Emerg Med, V12, P392, DOI 10.1016/0735-6757(94)90185-6
   Russo E, CLIN RELEVANT DRUG D
   Sodhi M, 2020, CHEST, V158, P55, DOI 10.1016/j.chest.2020.03.040
   Sorbello M, 2020, ANAESTHESIA, V75, P724, DOI 10.1111/anae.15049
   Sun XJ, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4242-7
NR 15
TC 29
Z9 29
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JUN 9
PY 2020
VL 94
IS 23
BP 1032
EP 1037
DI 10.1212/WNL.0000000000009632
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA MU1LN
UT WOS:000555432800010
PM 32327490
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Nilsson, M
   Crowe, B
   Anglin, G
   Ball, G
   Munsaka, M
   Shahin, S
   Wang, W
AF Nilsson, Mary
   Crowe, Brenda
   Anglin, Greg
   Ball, Greg
   Munsaka, Melvin
   Shahin, Seta
   Wang, Wei
TI Clinical Trial Drug Safety Assessment for Studies and Submissions
   Impacted by COVID-19
SO STATISTICS IN BIOPHARMACEUTICAL RESEARCH
LA English
DT Article
DE Clinical trial; Coronavirus; COVID-19; Harms; Safety analysis; Safety
   review
ID ADVERSE EVENTS; STATISTICAL ISSUES; MODELS
AB In this article, we provide guidance on how safety analyses and reporting of clinical trial safety data may need to be modified, given potential impact from the COVID-19 pandemic. Impact could include missed visits, alternative methods for assessments (such as virtual visits), alternative locations for assessments (such as local labs), and study drug interruptions. Starting from the safety analyses typically included in Clinical Study Reports for Phase 2-4 clinical trials and integrated submission documents, we assess what modifications might be needed. If the impact from COVID-19 affects treatment arms equally, analyses of adverse events from controlled data can, to a large extent, remain unchanged. However, interpretation of summaries from uncontrolled data (summaries that include open-label extension data) will require even more caution than usual. Special consideration will be needed for safety topics of interest, especially events expected to have a higher incidence due to a COVID-19 infection or due to quarantine or travel restrictions (e.g., depression). Analyses of laboratory measurements may need to be modified to account for the combination of measurements from local and central laboratories.
C1 [Nilsson, Mary; Crowe, Brenda] Eli Lilly & Co, Indianapolis, IN 46285 USA.
   [Anglin, Greg; Wang, Wei] Eli Lilly Canada Inc, Toronto, ON, Canada.
   [Ball, Greg] Merck & Co Inc, Rahway, NJ 07065 USA.
   [Munsaka, Melvin] AbbVie Inc, N Chicago, IL USA.
   [Shahin, Seta] Amgen Inc, Thousand Oaks, CA 91320 USA.
RP Nilsson, M (corresponding author), Lilly Corp Ctr, Indianapolis, IN 46285 USA.
EM nilsson_mary_e@lilly.com
CR Akacha M, 2020, STAT BIOPHARM RES, V12, P419, DOI 10.1080/19466315.2020.1788984
   Allignol A, 2016, PHARM STAT, V15, P297, DOI 10.1002/pst.1739
   Allison P. D., 2018, CAUSAL ANAL COMPETIN
   Association of Clinical Research Organizations, 2020, CONS SUPP CLIN TRIAL
   Bender R, 2016, PHARM STAT, V15, P292, DOI 10.1002/pst.1740
   CDISC, 2020, CDISC INT US GUID CO
   CIOMS Working Group VI, 2005, MAN SAF INF CLIN TRI
   CIOMS Working Groups III and V, 1999, GUID PREP COR CLIN S
   Collins SH, 2020, STAT BIOPHARM RES, V12, P412, DOI 10.1080/19466315.2020.1779123
   Crowe B, 2013, STAT BIOPHARM RES, V5, P180, DOI 10.1080/19466315.2013.791640
   Crowe BJ, 2009, CLIN TRIALS, V6, P430, DOI 10.1177/1740774509344101
   European Medicines Agency, 2020, GUID MAN CLIN TRIALS
   European Medicines Agency, 2020, POINTS CONS IMPL COR
   Foulkes MA, 2007, STAT IND TECHNOL, P323, DOI 10.1007/978-0-8176-4542-7_21
   Geskus R. B., 2016, DATA ANAL COMPETING
   Hemmings R, 2020, STAT BIOPHARM RES, V12, P414, DOI 10.1080/19466315.2020.1785931
   Hengelbrock J, 2016, PHARM STAT, V15, P315, DOI 10.1002/pst.1757
   Karvanen J, 2003, DRUG INF J, V37, P101, DOI 10.1177/009286150303700112
   Kunz CU, 2020, STAT BIOPHARM RES, V12, P461, DOI 10.1080/19466315.2020.1799857
   Ma HJ, 2015, THER INNOV REGUL SCI, V49, P957, DOI 10.1177/2168479015587363
   McDermott MM, 2020, JAMA-J AM MED ASSOC, V323, P2135, DOI 10.1001/jama.2020.4689
   MedDRA, 2020, MEDDRA VERS 23 0 UPD
   Meyer RD, 2020, STAT BIOPHARM RES, V12, P399, DOI 10.1080/19466315.2020.1779122
   Nautiyal N, 2015, INT J PHARM SCI RES, V6, P4159, DOI 10.13040/IJPSR.0975-8232.6(10).4159-67
   PHUSE, 2013, AN DISPL ASS MEAS CE
   PHUSE, 2019, SAF AN WORKSH SLID
   PHUSE, 2017, AN DISPL ASS ADV EV
   PHUSE, 2015, AN DISPL ASS OUTL SH
   Proctor T, 2016, PHARM STAT, V15, P306, DOI 10.1002/pst.1758
   Rosario LA, 2012, DRUG INF J, V46, P523, DOI 10.1177/0092861512456839
   Senior JR, 2014, DRUG SAFETY, V37, pS9, DOI 10.1007/s40264-014-0182-7
   Singh S, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-138
   Stegherr R., 2019, 19120063 ARXIV
   TransCelerate Biopharma Inc, 2020, CLIN STUD REP CONS S
   U.S. Food and Drug Administration, 2020, FDA GUID COND CLIN T
   Unkel S, 2019, PHARM STAT, V18, P166, DOI 10.1002/pst.1915
   US Food and Drug Administration (FDA), 2009, GUID IND DRUG IND LI
NR 37
TC 1
Z9 1
U1 1
U2 1
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA
SN 1946-6315
J9 STAT BIOPHARM RES
JI Stat. Biopharm. Res.
PD OCT 1
PY 2020
VL 12
IS 4
BP 498
EP 505
DI 10.1080/19466315.2020.1804444
EA JUN 2020
PG 8
WC Mathematical & Computational Biology; Statistics & Probability
SC Mathematical & Computational Biology; Mathematics
GA OK5GB
UT WOS:000567564200001
OA Bronze
DA 2021-01-01
ER

PT J
AU Williamson, BN
   Feldmann, F
   Schwarz, B
   Meade-White, K
   Porter, DP
   Schulz, J
   van Doremalen, N
   Leighton, I
   Yinda, CK
   Perez-Perez, L
   Okumura, A
   Lovaglio, J
   Hanley, PW
   Saturday, G
   Bosio, CM
   Anzick, S
   Barbian, K
   Cihlar, T
   Martens, C
   Scott, DP
   Munster, VJ
   de Wit, E
AF Williamson, Brandi N.
   Feldmann, Friederike
   Schwarz, Benjamin
   Meade-White, Kimberly
   Porter, Danielle P.
   Schulz, Jonathan
   van Doremalen, Neeltje
   Leighton, Ian
   Yinda, Claude Kwe
   Perez-Perez, Lizzette
   Okumura, Atsushi
   Lovaglio, Jamie
   Hanley, Patrick W.
   Saturday, Greg
   Bosio, Catharine M.
   Anzick, Sarah
   Barbian, Kent
   Cihlar, Tomas
   Martens, Craig
   Scott, Dana P.
   Munster, Vincent J.
   de Wit, Emmie
TI Clinical benefit of remdesivir in rhesus macaques infected with
   SARS-CoV-2
SO NATURE
LA English
DT Article; Early Access
ID GS-5734
AB The nucleotide analogue prodrug remdesivir reduces viral load and lung disease in a rhesus macaque model of SARS-CoV-2 infection.
   Effective therapies to treat coronavirus disease 2019 (COVID-19) are urgently needed. While many investigational, approved, and repurposed drugs have been suggested as potential treatments, preclinical data from animal models can guide the search for effective treatments by ruling out those that lack efficacy in vivo. Remdesivir (GS-5734) is a nucleotide analogue prodrug with broad antiviral activity(1,2)that is currently being investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration(3,4). In animal models, remdesivir was effective against infection with Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV)(2,5,6). In vitro, remdesivir inhibited replication of SARS-CoV-2(7,8). Here we investigate the efficacy of remdesivir in a rhesus macaque model of SARS-CoV-2 infection(9). Unlike vehicle-treated animals, macaques treated with remdesivir did not show signs of respiratory disease; they also showed reduced pulmonary infiltrates on radiographs and reduced virus titres in bronchoalveolar lavages twelve hours after the first dose. Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment. At necropsy, remdesivir-treated animals had lower lung viral loads and reduced lung damage. Thus, treatment with remdesivir initiated early during infection had a clinical benefit in rhesus macaques infected with SARS-CoV-2. Although the rhesus macaque model does not represent the severe disease observed in some patients with COVID-19, our data support the early initiation of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia.
C1 [Williamson, Brandi N.; Meade-White, Kimberly; Schulz, Jonathan; van Doremalen, Neeltje; Yinda, Claude Kwe; Perez-Perez, Lizzette; Okumura, Atsushi; Munster, Vincent J.; de Wit, Emmie] NIAID, Virol Lab, NIH, Hamilton, MT USA.
   [Feldmann, Friederike; Lovaglio, Jamie; Hanley, Patrick W.; Saturday, Greg; Scott, Dana P.] NIAID, Rocky Mt Vet Branch, NIH, Hamilton, MT USA.
   [Schwarz, Benjamin; Leighton, Ian; Bosio, Catharine M.] NIAID, Lab Bacteriol, NIH, Hamilton, MT USA.
   [Porter, Danielle P.; Cihlar, Tomas] Gilead Sci, Foster City, CA USA.
   [Anzick, Sarah; Barbian, Kent; Martens, Craig] NIAID, Res Technol Branch, NIH, Hamilton, MT USA.
RP de Wit, E (corresponding author), NIAID, Virol Lab, NIH, Hamilton, MT USA.
EM emmie.dewit@nih.gov
RI Munster, Vincent/I-7607-2018
OI Munster, Vincent/0000-0002-2288-3196
FU Intramural Research Program of NIAID, NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
FX We thank E. Bunyan for preparing remdesivir; D. Babusis for providing
   synthetic standards for molecular analysis; A. Mora for preparing
   figures; T. Thomas, R. Rosenke and D. Long for assistance with
   histology; M. Holbrook and T. Bushmaker for technical assistance; and
   RMVB staff for animal care. This study was supported by the Intramural
   Research Program of NIAID, NIH.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Briese T, 2015, MBIO, V6, DOI 10.1128/mBio.01491-15
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Martin M., 2011, EMBNET J, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   US Food and Drug Administration, 2020, COR COVID 19 UPD FDA
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
NR 18
TC 21
Z9 21
U1 13
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
DI 10.1038/s41586-020-2423-5
EA JUN 2020
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NI7FZ
UT WOS:000565516300001
PM 32516797
OA Green Accepted
DA 2021-01-01
ER

PT J
AU Gupta, S
   Singh, AK
   Kushwaha, PP
   Prajapati, KS
   Shuaib, M
   Senapati, S
   Kumar, S
AF Gupta, Sanjay
   Singh, Atul Kumar
   Kushwaha, Prem Prakash
   Prajapati, Kumari Sunita
   Shuaib, Mohd
   Senapati, Sabyasachi
   Kumar, Shashank
TI Identification of potential natural inhibitors of SARS-CoV2 main
   protease by molecular docking and simulation studies
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; Curcuma longa; main protease; inhibitor; MD simulation
ID DYNAMICS
AB Coronaviruses are contagious pathogens primarily responsible for respiratory and intestinal infections. Research efforts to develop antiviral agents against coronavirus demonstrated the main protease (Mpro) protein may represent effective drug target. X-ray crystallographic structure of the SARS-CoV2 Mpro protein demonstrated the significance of Glu166, Cys141, and His41 residues involved in protein dimerization and its catalytic function. We performedin silicoscreening of compounds fromCurcuma longaL. (Zingiberaceae family) against Mpro protein inhibition. Employing a combination of molecular docking, scoring functions, and molecular dynamics simulations, 267 compounds were screened by docking on Mpro crystallographic structure. Docking score and interaction profile analysis exhibited strong binding on the Mpro catalytic domain with compounds C1(1E,6E)-1,2,6,7-tetrahydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione) and C2(4Z,6E)-1,5-dihydroxy-1,7-bis(4-hydroxyphenyl)hepta-4,6-dien-3-one as lead agents. Compound C1and C2showed minimum binding score (-9.08 and -8.07 kcal/mole) against Mpro protein in comparison to shikonin and lopinavir (approximate to -5.4 kcal/mole) a standard Mpro inhibitor. Furthermore, principal component analysis, free energy landscape and protein-ligand energy calculation studies revealed that these two compounds strongly bind to the catalytic core of the Mpro protein with higher efficacy than lopinavir, a standard antiretroviral of the protease inhibitor class. Taken together, this structure based optimization has provided lead on two natural Mpro inhibitors for further testing and development as therapeutics against human coronavirus. Communicated by Ramaswamy H. Sarma
C1 [Gupta, Sanjay] Case Western Reserve Univ, Dept Urol, Cleveland, OH 44106 USA.
   [Gupta, Sanjay] Univ Hosp Cleveland Med Ctr, Inst Urol, Cleveland, OH USA.
   [Gupta, Sanjay] Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA.
   [Gupta, Sanjay] Case Comprehens Canc Ctr, Div Gen Med Sci, Cleveland, OH USA.
   [Gupta, Sanjay] Louis Stokes Cleveland Vet Affairs Med Ctr, Dept Urol, Cleveland, OH USA.
   [Singh, Atul Kumar; Kushwaha, Prem Prakash; Prajapati, Kumari Sunita; Shuaib, Mohd; Kumar, Shashank] Cent Univ Punjab, Sch Basic & Appl Sci, Dept Biochem, Bathinda 151001, India.
   [Senapati, Sabyasachi] Cent Univ Punjab, Sch Hlth Sci, Dept Human Genet & Mol Med, Bathinda, India.
RP Kumar, S (corresponding author), Cent Univ Punjab, Sch Basic & Appl Sci, Dept Biochem, Bathinda 151001, India.
EM shashankbiochemau@gmail.com
RI ; kumar, shashank/M-1603-2013
OI SINGH, ATUL/0000-0003-0081-6109; kumar, shashank/0000-0002-9622-0512
FU Department of DefenseUnited States Department of Defense
   [W81XWH-19-1-0720, W81XWH-18-1-0618]; VA Merit ReviewUS Department of
   Veterans Affairs [1I01BX002494]; University Grants Commission,
   IndiaUniversity Grants Commission, India; University Grants Commission,
   IndiaUniversity Grants Commission, India [F.30-372/2017 (BSR)];
   Department of Science and Technology, IndiaDepartment of Science &
   Technology (India) [EEQ/2016/000350]; Central University of Punjab,
   Bathinda, India [GP-25]; CSIR-IndiaCouncil of Scientific & Industrial
   Research (CSIR) - India; DBT-IndiaDepartment of Biotechnology (DBT)
   India; DST-IndiaDepartment of Science & Technology (India)
FX Efforts are supported by the Department of Defense Grants
   W81XWH-19-1-0720 and W81XWH-18-1-0618 and VA Merit Review 1I01BX002494
   to SG. PPK acknowledges financial support from University Grants
   Commission, India in the form of CSIR-UGC Senior Research fellowship. SK
   acknowledges University Grants Commission, India and Department of
   Science and Technology, India for providing financial support in the
   form of UGC-BSR Research Start-Up-Grant [No. F.30-372/2017 (BSR)] and
   DST-SERB Grant [EEQ/2016/000350] respectively. SK acknowledges Central
   University of Punjab, Bathinda, India for providing Research Seed Money
   Grant [GP-25]. AKS, KSP, and MS acknowledge CSIR-India, DBT-India and
   DST-India funding agencies respectively for providing financial
   assistance in the form of Junior Research Fellowship.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Bahar I, 1998, PHYS REV LETT, V80, P2733, DOI 10.1103/PhysRevLett.80.2733
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Chitrala KN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109185
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   David CC, 2014, METHODS MOL BIOL, V1084, P193, DOI 10.1007/978-1-62703-658-0_11
   DeLano W.L., 2002, PYMOL
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   JIN Z, 2020, NATURE 0409, DOI DOI https://doi.org/10.1101/2020.02.26.964882
   Kalirajan Rajagopal, 2019, Curr Drug Res Rev, V11, P118, DOI 10.2174/2589977511666190912154817
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lu ZY, 2011, DATABASE-OXFORD, DOI 10.1093/database/baq036
   MITTAL L, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768151
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Stobart CC, 2013, J VIROL, V87, P12611, DOI 10.1128/JVI.02050-13
   Stobart CC, 2012, J VIROL, V86, P4801, DOI 10.1128/JVI.06754-11
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   UMESH, 2020, J BIOMOL STRUCT 0512, DOI DOI https://doi.org/10.1080/07391102.2020.1763202
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xie XQS, 2010, EXPERT OPIN DRUG DIS, V5, P1205, DOI 10.1517/17460441.2010.524924
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 29
TC 7
Z9 7
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1776157
EA JUN 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MF1BX
UT WOS:000545086700001
PM 32476576
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kumar, V
   Dhanjal, JK
   Bhargava, P
   Kaul, A
   Wang, J
   Zhang, H
   Kaul, SC
   Wadhwa, R
   Sundar, D
AF Kumar, Vipul
   Dhanjal, Jaspreet Kaur
   Bhargava, Priyanshu
   Kaul, Ashish
   Wang, Jia
   Zhang, Huayue
   Kaul, Sunil C.
   Wadhwa, Renu
   Sundar, Durai
TI Withanone and Withaferin-A are predicted to interact with transmembrane
   protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; Ashwagandha; Withanone; Withaferin-A; honey bee; propolis;
   caffeic acid phenethyl ester; molecular docking; binding; transmembrane
   protease serine 2 (TMPRSS2); inhibition
ID INFLUENZA-VIRUS; CORONAVIRUS; ASHWAGANDHA; CLEAVAGE; PROSTATE; PROPOLIS;
   CAMOSTAT; PROVIDE; TRYPSIN; TARGET
AB Coronavirus disease 2019 (COVID-19) initiated in December 2019 in Wuhan, China and became pandemic causing high fatality and disrupted normal life calling world almost to a halt. Causative agent is a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV). While new line of drug/vaccine development has been initiated world-wide, in the current scenario of high infected numbers, severity of the disease and high morbidity, repurposing of the existing drugs is heavily explored. Here, we used a homology-based structural model of transmembrane protease serine 2 (TMPRSS2), a cell surface receptor, required for entry of virus to the target host cell. Using the strengths of molecular docking and molecular dynamics simulations, we examined the binding potential of Withaferin-A (Wi-A), Withanone (Wi-N) and caffeic acid phenethyl ester to TPMRSS2 in comparison to its known inhibitor, Camostat mesylate. We found that both Wi-A and Wi-N could bind and stably interact at the catalytic site of TMPRSS2. Wi-N showed stronger interactions with TMPRSS2 catalytic residues than Wi-A and was also able to induce changes in its allosteric site. Furthermore, we investigated the effect of Wi-N on TMPRSS2 expression in MCF7 cells and found remarkable downregulation of TMPRSS2 mRNA in treated cells predicting dual action of Wi-N to block SARS-CoV-2 entry into the host cells. Since the natural compounds are easily available/affordable, they may even offer a timely therapeutic/preventive value for the management of SARS-CoV-2 pandemic. We also report that Wi-A/Wi-N content varies in different parts of Ashwagandha and warrants careful attention for their use. Communicated by Ramaswamy H. Sarma
C1 [Kumar, Vipul; Sundar, Durai] Indian Inst Technol IIT Delhi, Dept Biochem Engn & Biotechnol, DAILAB, New Delhi 110016, India.
   [Dhanjal, Jaspreet Kaur; Bhargava, Priyanshu; Kaul, Ashish; Wang, Jia; Zhang, Huayue; Kaul, Sunil C.; Wadhwa, Renu] Natl Inst Adv Ind Sci & Technol, DBT AIST Int Ctr Translat & Environm Res DAICTR, AIST INDIA DAILAB, Tsukuba, Ibaraki 3058565, Japan.
RP Sundar, D (corresponding author), Indian Inst Technol IIT Delhi, Dept Biochem Engn & Biotechnol, DAILAB, New Delhi 110016, India.; Wadhwa, R (corresponding author), Natl Inst Adv Ind Sci & Technol, DBT AIST Int Ctr Translat & Environm Res DAICTR, AIST INDIA DAILAB, Tsukuba, Ibaraki 3058565, Japan.
EM renu-wadhwa@aist.go.jp; sundar@dbeb.iitd.ac.in
FU AIST (Japan); DBT (Government of India)Department of Biotechnology (DBT)
   India
FX This study was supported by the funds granted by AIST (Japan) and DBT
   (Government of India).
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   Afar DEH, 2001, CANCER RES, V61, P1686
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   AMOROS M, 1994, J NAT PROD, V57, P644, DOI 10.1021/np50107a013
   [Anonymous], 2020, WHO CORONAVIRUS DIS
   Azouz Nurit P, 2020, bioRxiv, DOI 10.1101/2020.05.04.077826
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767210
   Bahgat MM, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-27
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Bertram S, 2011, J VIROL, V85, P13363, DOI 10.1128/JVI.05300-11
   Bottcher E, 2009, VACCINE, V27, P6324, DOI 10.1016/j.vaccine.2009.03.029
   Bottcher-Friebertshauser E, 2013, PATHOG DIS, V69, P87, DOI 10.1111/2049-632X.12053
   Bottcher-Friebertshauser E, 2012, VACCINE, V30, P7374, DOI 10.1016/j.vaccine.2012.10.001
   Bottcher-Friebertshauser E, 2011, J VIROL, V85, P1554, DOI 10.1128/JVI.01294-10
   Bottcher-Friebertshauser E, 2010, J VIROL, V84, P5605, DOI 10.1128/JVI.00140-10
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Thuy BTP, 2020, ACS OMEGA, V5, P8312, DOI 10.1021/acsomega.0c00772
   Cai Z, 2015, CELL BIOCHEM BIOPHYS, V72, P727, DOI 10.1007/s12013-015-0524-9
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chang Y. C., 2020, P MILITARY COMMUNICA, P1, DOI [10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Foulds Charles E, 2010, Mol Endocrinol, V24, P1090, DOI 10.1210/me.2009-0427
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gao R, 2014, MOL CANCER THER, V13, P2930, DOI 10.1158/1535-7163.MCT-14-0324
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   HENDAUS MA, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1767691
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kaul SC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166945
   Kaur A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194314
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kim TS, 2006, MOL CELL BIOL, V26, P965, DOI 10.1128/MCB.26.3.965-975.2006
   Konar A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027265
   KUMAR D, 2020, J BIOMOL STRUCT 0503, DOI DOI https://doi.org/10.1080/07391102.2020.1752310
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   KWON MJ, 2019, J APICULT RES 1204, DOI DOI https://doi.org/10.1080/00218839.2019.1695715
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Laporte M, 2017, CURR OPIN VIROL, V24, P16, DOI 10.1016/j.coviro.2017.03.018
   Latheef Shyma K., 2017, VirusDisease, V28, P115, DOI 10.1007/s13337-016-0355-3
   Lee MG, 1996, ARCH VIROL, V141, P1979, DOI 10.1007/BF01718208
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li XG, 2020, J MED VIROL, V92, P448, DOI 10.1002/jmv.25693
   Li XG, 2020, J MED VIROL, V92, P501, DOI 10.1002/jmv.25701
   Limburg H, 2019, J VIROL, V93, DOI 10.1128/JVI.00649-19
   Lin BY, 1999, CANCER RES, V59, P4180
   LOBOGALO N, 2020, J BIOMOL STRUCT 0513, DOI DOI https://doi.org/10.1080/07391102.2020.1764393
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Munagala R, 2011, CARCINOGENESIS, V32, P1697, DOI 10.1093/carcin/bgr192
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nejadi Babadaei M. M., 2020, J BIOMOLECULAR STRUC, P1, DOI [10.1080/07391102.2020.1767211, DOI 10.1080/07391102.2020.1767211]
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Park Y., 2011, ATLAS GENETICS CYTOG, V14, P1163, DOI [https://doi.org/10.4267/2042/44922, DOI 10.4267/2042/44922]
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Schrodinger, 2020, SCHROD REL 2020 1 MA
   SERKEDJIEVA J, 1992, J NAT PROD, V55, P294, DOI 10.1021/np50081a003
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   SHEN LW, 2020, SCI REP UK, V10, DOI DOI https://doi.org/10.1038/s41598-020-64368-8
   Shirato K, 2017, J VIROL, V91, DOI [10.1128/JVI.01387-16, 10.1128/jvi.01387-16]
   Shirato K, 2013, J VIROL, V87, P12552, DOI 10.1128/JVI.01890-13
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Varshney A., 2020, VIROL J, DOI [10.21203/rs.3.rs-17806/v1, DOI 10.21203/RS.3.RS-17806/V1]
   Wadhwa R, 2016, NEUROCHEM INT, V95, P109, DOI 10.1016/j.neuint.2015.09.001
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Widodo N, 2008, CANCER LETT, V262, P37, DOI 10.1016/j.canlet.2007.11.037
   Widodo N, 2009, J GERONTOL A-BIOL, V64, P1031, DOI 10.1093/gerona/glp088
   Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066
   Yamaya M, 2015, PULM PHARMACOL THER, V33, P66, DOI 10.1016/j.pupt.2015.07.001
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 88
TC 22
Z9 23
U1 6
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1775704
EA JUN 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA ME2WE
UT WOS:000544520800001
PM 32469279
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Jacome, R
   Campillo-Balderas, JA
   de Leon, SP
   Becerra, A
   Lazcano, A
AF Jacome, Rodrigo
   Alberto Campillo-Balderas, Jose
   Ponce de Leon, Samuel
   Becerra, Arturo
   Lazcano, Antonio
TI Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
SO SCIENTIFIC REPORTS
LA English
DT Article
ID VIRUS
AB As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.
C1 [Jacome, Rodrigo; Alberto Campillo-Balderas, Jose; Becerra, Arturo; Lazcano, Antonio] Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City, DF, Mexico.
   [Ponce de Leon, Samuel] Univ Nacl Autonoma Mexico, Programa Univ Invest Salud, Mexico City, DF, Mexico.
   [Lazcano, Antonio] Colegio Nacl, Mexico City, DF, Mexico.
RP Lazcano, A (corresponding author), Colegio Nacl, Mexico City, DF, Mexico.
EM alar@ciencias.unam.mx
RI Becerra, Arturo/J-8364-2015
OI Becerra, Arturo/0000-0002-7076-0342
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210
   Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Donaldson EF, 2015, HEPATOLOGY, V61, P56, DOI 10.1002/hep.27375
   Dragoni F, 2020, ANTIVIR RES, V175, DOI 10.1016/j.antiviral.2020.104708
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gan CS, 2018, CHEM BIOL DRUG DES, V91, P448, DOI 10.1111/cbdd.13091
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Jacome R, 2019, INT J INFECT DIS, V87, P143, DOI 10.1016/j.ijid.2019.07.033
   Jacome R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139001
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Maxmen A, 2020, NATURE, V578, P347, DOI 10.1038/d41586-020-00444-3
   McQuaid T, 2015, J CLIN TRANSL HEPATO, V3, P27, DOI 10.14218/JCTH.2014.00041
   Meng EC, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-339
   Mesci P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19526-4
   Ogando NS, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01813
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   WHO, 2020, COR DIS COVID 19 SIT
   WHO, 2020, SOL CLON TRIAL COVID
NR 26
TC 7
Z9 7
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 9
PY 2020
VL 10
IS 1
AR 9294
DI 10.1038/s41598-020-66440-9
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MD4QF
UT WOS:000543956000032
PM 32518317
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Majdic, G
AF Majdic, Gregor
TI Could Sex/Gender Differences in ACE2 Expression in the Lungs Contribute
   to the Large Gender Disparity in the Morbidity and Mortality of Patients
   Infected With the SARS-CoV-2 Virus?
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Article
DE lung; ACE2; COVID 19; sex difference; androgens
ID ANGIOTENSIN; SEX
AB COVID-19 morbidity and mortality have significant gender disparities, with higher prevalence and mortality in men. SARS-CoV-2 enters the lungs through the ACE2 enzyme, a member of the renin-angiotensin system (RAS). Although there are no data for the lung, the expressions of RAS components in other tissues are modulated by sex hormones, androgens, and estrogens. However, there are no data on sex-specific differences in ACE2 expression. If there is a sex difference in the expression of ACE2 in the lung, this could theoretically explain the gender disparity in COVID-19 disease. More importantly, although modulation of ACE2 will certainly not provide a cure for the COVID-19 disease, modulation of ACE2 by sex hormone modulators, if they affect the expression of ACE2, could potentially be developed into a supportive therapy for COVID-19 patients.
C1 [Majdic, Gregor] Univ Ljubljana, Inst Preclin Sci, Fac Vet, Ljubljana, Slovenia.
   [Majdic, Gregor] Univ Maribor, Sch Med, Inst Physiol, Maribor, Slovenia.
RP Majdic, G (corresponding author), Univ Ljubljana, Inst Preclin Sci, Fac Vet, Ljubljana, Slovenia.; Majdic, G (corresponding author), Univ Maribor, Sch Med, Inst Physiol, Maribor, Slovenia.
EM gregor.majdic@vf.uni-lj.si
FU Javna agencija za razidskovalno dejavnost [P4-0053]
FX GMwas supported by grant from Javna agencija za razidskovalno dejavnost
   (P4-0053).
CR Cai G., 2020, BULK SINGLE CELL TRA, DOI [10.1101/2020.02.05.20020107, DOI 10.1101/2020.02.05.20020107]
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Gupte M, 2012, ARTERIOSCL THROM VAS, V32, P1392, DOI 10.1161/ATVBAHA.112.248559
   Jin JM, 2020, GENDER DIFFERENCES P
   Kuba K, 2006, CURR OPIN PHARMACOL, V6, P271, DOI 10.1016/j.coph.2006.03.001
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   McGuire BB, 2007, KIDNEY BLOOD PRESS R, V30, P67, DOI 10.1159/000099150
   Peckham H, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-23651/v1, DOI 10.21203/RS.3.RS-23651/V1]
   Rabi DM, 2008, CAN J CARDIOL, V24, P491, DOI 10.1016/S0828-282X(08)70624-X
   Reckelhoff JF, 2001, HYPERTENSION, V37, P1199, DOI 10.1161/01.HYP.37.5.1199
   Riccardo F., 2020, EPIDEMIA COVID 19 I
   Sardu C, 2009, J Prev Med Hyg, V50, P191
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Ventura-Clapier R, 2017, CARDIOVASC RES, V113, P711, DOI 10.1093/cvr/cvx066
   White MC, 2019, BIOL SEX DIFFER, V10, DOI 10.1186/s13293-019-0247-5
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
NR 19
TC 2
Z9 2
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD JUN 9
PY 2020
VL 10
AR 327
DI 10.3389/fcimb.2020.00327
PG 3
WC Immunology; Microbiology
SC Immunology; Microbiology
GA MD3HP
UT WOS:000543862600001
PM 32582576
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Smith, ML
   Gandolfi, S
   Coshall, PM
   Rahman, PKSM
AF Smith, Matthew L.
   Gandolfi, Stefano
   Coshall, Philippa M.
   Rahman, Pattanathu K. S. M.
TI Biosurfactants: A Covid-19 Perspective
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE biosurfactants; Covid-19; handwash; soap; cleaning products; drug
   delivery
ID POTENTIAL THERAPEUTIC APPLICATIONS; VIRUS; SOPHOROLIPIDS; SURFACTANTS;
   RESPONSES; DISEASE; CELL
AB The recent outbreak in severe acute respiratory syndrome - coronavirus-2 (SARS-CoV-2) has demonstrated the complete inability of nations across the world to cope with the pressures of a global pandemic, especially one in which the only current feasible treatments are those which deal with the symptoms alone and not the viral cause. As the death toll rises, scientists begin to fall toward new avenues of research, with novelty showing itself to be an incredible and so far, underrated resource. In this case, the use of biosurfactants in dealing with this pandemic justifies extensive study with their potential applications being in the prevention of viral spread; dealing with the symptoms that develop after the incubation period; directly targeting viral infected cells and preventing the spread of the virus throughout the host, all in addition to also acting as potential drug delivery systems and cleaning agents. This extensive avenue of biosurfactants owes to the simplicity in their amphiphilic structure which permits them to interact directly with the lipid membrane of the coronavirus, in a way which wouldn't be of significant threat to the host. Although it could possibly interact and affect the virus, it could also affect human internal organs/cells by interacting with lipid membrane, if (biosurfactant is) ingested, and it still needs further studies in human models. The structure of the coronavirus, in this case SARS-CoV-2, is detrimentally dependent on the integrity of its lipid membrane which encloses its vital proteins and RNA. Biosurfactants possess the innate ability to threaten this membrane, a result of their own hydrophobic domains across their amphiphilic structure. With biosurfactants additionally being both natural and sustainable, while also possessing a remarkably low cytotoxicity, it is of no doubt that they are going to be of increasing significance in dealing with the current pandemic.
C1 [Smith, Matthew L.; Gandolfi, Stefano; Coshall, Philippa M.; Rahman, Pattanathu K. S. M.] Univ Portsmouth, Inst Biol & Biomed Sci, Sch Biol Sci, Ctr Enzyme Innovat, Portsmouth, Hants, England.
   [Rahman, Pattanathu K. S. M.] Wilton Ctr, TeeGene Biotech, Redcar, England.
RP Rahman, PKSM (corresponding author), Univ Portsmouth, Inst Biol & Biomed Sci, Sch Biol Sci, Ctr Enzyme Innovat, Portsmouth, Hants, England.; Rahman, PKSM (corresponding author), Wilton Ctr, TeeGene Biotech, Redcar, England.
EM pat.rahman@port.ac.uk
RI Rahman, Pattanathu/ABE-9417-2020
OI Smith, Matthew/0000-0002-0928-7082
FU Research England through the Expanding Excellence in England (E3) scheme
FX Authors thank Research England for funding support through the Expanding
   Excellence in England (E3) scheme.
CR Abdel-Mawgoud AM, 2010, APPL MICROBIOL BIOT, V86, P1323, DOI 10.1007/s00253-010-2498-2
   [Anonymous], 2015, FUEL CELLS B, V2015, P3, DOI [10.1016/S1464-2859(15)30109-7, DOI 10.1016/S1464-2859(15)30109-7]
   [Anonymous], 2016, FUEL CELLS B, V2016, P3
   Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Backhaus S, 2017, J LIPID RES, V58, P1055, DOI 10.1194/jlr.M071506
   Borsanyiova M, 2016, FOLIA MICROBIOL, V61, P85, DOI 10.1007/s12223-015-0413-z
   Byeon SE, 2008, J MICROBIOL BIOTECHN, V18, P1984, DOI 10.4014/jmb.0800.189
   Cabinet Office GOV.UK, 2020, TECHN SPEC PERS PROT
   Cameotra S. S., 2010, BIOSURFACTANTS ADV E
   Campos JM, 2013, BIOTECHNOL PROGR, V29, P1097, DOI 10.1002/btpr.1796
   Centers for Disease Control Prevention (CDC), 2019, KEEP HANDS CLEAN
   Das UN, 2020, ARCH MED RES, V51, P282, DOI 10.1016/j.arcmed.2020.03.004
   DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0
   Fracchia L., 2014, BIOSURFACTANTS PRODU, P245, DOI DOI 10.1201/B17599-15
   Fracchia L., 2018, MICROBIAL BIOSURFACT, P258
   Fracchia L, 2015, AIMS BIOENG, V2, P144, DOI 10.3934/bioeng.2015.3.144
   Fu SL, 2008, J SURG RES, V148, P77, DOI 10.1016/j.jss.2008.03.005
   Garoff H, 1998, MICROBIOL MOL BIOL R, V62, P1171, DOI 10.1128/MMBR.62.4.1171-1190.1998
   Gross R. A., 2007, Patent, Patent No. [2007/130738Al., 2007130738]
   Gudina EJ, 2013, TRENDS PHARMACOL SCI, V34, P667, DOI 10.1016/j.tips.2013.10.002
   Hamamoto I, 2013, JPN J INFECT DIS, V66, P276, DOI 10.7883/yoken.66.276
   Hong H, 2020, PEDIATR NEONATOL, V61, P131, DOI 10.1016/j.pedneo.2020.03.001
   Khan T. N., 2017, GEN MED OPEN ACCESS, V5, P4, DOI [10.4172/2327-5146.1000294, DOI 10.4172/2327-5146.1000294]
   Kim K, 1998, BIOCHEM PHARMACOL, V55, P975, DOI 10.1016/S0006-2952(97)00613-8
   Kiran GS, 2016, CRIT REV BIOTECHNOL, V36, P399, DOI 10.3109/07388551.2014.979758
   Klosowska-Chomiczewska I., 2011, P POL SWED UKR SEM R, P1
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Loleit M, 1996, IMMUNOBIOLOGY, V195, P61, DOI 10.1016/S0171-2985(96)80006-4
   Luks AM, 2020, HIGH ALT MED BIOL, V21, P192, DOI 10.1089/ham.2020.0055
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0
   Nakanishi M, 2009, J DRUG DELIV SCI TEC, V19, P165, DOI 10.1016/S1773-2247(09)50031-7
   Nitschke M, 2018, CRIT REV FOOD SCI, V58, P631, DOI 10.1080/10408398.2016.1208635
   Omkar T., 2020, J CURR PHARM RES, V10, P3680, DOI [10.33786/JCPR.2020.v10i02.006, DOI 10.33786/JCPR.2020.V10I02.006]
   Paine R, 2002, AM J PHYSIOL-LUNG C, V283, pL180, DOI 10.1152/ajplung.00430.2001
   Randhawa KKS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00454
   Ribeiro BG, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00434
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sajid M, 2020, IMMUNOL LETT, V223, P71, DOI 10.1016/j.imlet.2020.04.003
   Sandeep L., 2017, J ANAL PHARM RES, V4, DOI [10.15406/japlr.2017.04.00105, DOI 10.15406/JAPLR.2017.04.00105]
   Shah V, 2005, ANTIMICROB AGENTS CH, V49, P4093, DOI 10.1128/AAC.49.10.4093-4100.2005
   Singh P, 2019, J APPL MICROBIOL, V126, P2, DOI 10.1111/jam.14057
   Sosnowski T. R., 2009, ENG CHEM APP, V48, P176
   Van Hamme JD, 2006, BIOTECHNOL ADV, V24, P604, DOI 10.1016/j.biotechadv.2006.08.001
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Ware L.B., 2000, NEW ENGL J MED, V342, P16, DOI [DOI 10.1056/NEJM200005043421806, 10.1056/NEJM200005043421806]
   WIESMULLER KH, 1989, VACCINE, V7, P29, DOI 10.1016/0264-410X(89)90007-8
   World Health Organization (WHO), 2014, INF PREV CONTR EP PA, P65
   Yu YX, 2008, CHINESE J CHEM ENG, V16, P517, DOI 10.1016/S1004-9541(08)60115-9
NR 48
TC 1
Z9 1
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD JUN 9
PY 2020
VL 11
AR 1341
DI 10.3389/fmicb.2020.01341
PG 8
WC Microbiology
SC Microbiology
GA MC8FA
UT WOS:000543514400001
PM 32582137
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kawchuk, G
   Hartvigsen, J
   Harsted, S
   Nim, CG
   Nyiro, L
AF Kawchuk, Greg
   Hartvigsen, Jan
   Harsted, Steen
   Nim, Casper Glissmann
   Nyiroe, Luana
TI Misinformation about spinal manipulation and boosting immunity: an
   analysis of Twitter activity during the COVID-19 crisis
SO CHIROPRACTIC & MANUAL THERAPIES
LA English
DT Article
DE Social media; Twitter; Spinal manipulation; Chiropractic;
   Misinformation; Immunity
ID SOCIAL-MEDIA; HEALTH
AB Background Social media has become an increasingly important tool in monitoring the onset and spread of infectious diseases globally as well monitoring the spread of information about those diseases. This includes the spread of misinformation, which has been documented within the context of the emerging COVID-19 crisis. Understanding the creation, spread and uptake of social media misinformation is of critical importance to public safety. In this descriptive study, we detail Twitter activity regarding spinal manipulative therapy (SMT) and claims it increases, or "boosts", immunity. Spinal manipulation is a common intervention used by many health professions, most commonly by chiropractors. There is no clinical evidence that SMT improves human immunity. Methods Social media searching software (Talkwalker Quick Search) was used to describe Twitter activity regarding SMT and improving or boosting immunity. Searches were performed for the 3 months and 12 months before March 31, 2020 using terms related to 1) SMT, 2) the professions that most often provide SMT and 3) immunity. From these searches, we determined the magnitude and time course of Twitter activity then coded this activity into content that promoted or refuted a SMT/immunity link. Content themes, high-influence users and user demographics were then stratified as either promoting or refuting this linkage. Results Twitter misinformation regarding a SMT/immunity link increased dramatically during the onset of the COVID crisis. Activity levels (number of tweets) and engagement scores (likes + retweets) were roughly equal between content promoting or refuting a SMT/immunity link, however, the potential reach (audience) of tweets refuting a SMT/immunity link was 3 times higher than those promoting a link. Users with the greatest influence on Twitter, as either promoters or refuters, were individuals, not institutions or organizations. The majority of tweets promoting a SMT/immunity link were generated in the USA while the majority of refuting tweets originated from Canada. Conclusion Twitter activity about SMT and immunity increased during the COVID-19 crisis. Results from this work have the potential to help policy makers and others understand the impact of SMT misinformation and devise strategies to mitigate its impact.
C1 [Kawchuk, Greg] Univ Alberta, Dept Phys Therapy, Edmonton, AB, Canada.
   [Hartvigsen, Jan; Harsted, Steen] Univ Southern Denmark, Dept Sports Sci & Clin Biomech, Odense, Denmark.
   [Hartvigsen, Jan] Nord Inst Chiropract & Clin Biomech, Odense, Denmark.
   [Nim, Casper Glissmann] Univ Hosp Southern Denmark, Med Res Unit, Spinecentre Southern Denmark, Middelfart, Denmark.
   [Nim, Casper Glissmann] Univ Southern Denmark, Dept Reg Hlth Res, Odense, Denmark.
   [Nyiroe, Luana] Univ Zurich, Balgrist Univ Hosp, Dept Chiropract Med, Zurich, Switzerland.
RP Kawchuk, G (corresponding author), Univ Alberta, Dept Phys Therapy, Edmonton, AB, Canada.
EM greg.kawchuk@ualberta.ca
RI ; Harsted, Steen/C-6153-2019
OI Hartvigsen, Jan/0000-0002-5876-7410; Harsted, Steen/0000-0002-1879-2224;
   Glissmann Nim, Casper/0000-0001-5845-2622; Nyiro,
   Luana/0000-0003-2504-9719
FU Canadian Chiropractic Research Foundation
FX Funds from the Canadian Chiropractic Research Foundation were used to
   purchase Talkwalker access.
CR [Anonymous], CAN CHIR PAT SAF COV
   [Anonymous], 2020, VET RAD KOMM ICA DOK
   [Anonymous], FALS MISL ADV COVID
   [Anonymous], TEXT AN
   [Anonymous], RCC RES B SPIN MAN I
   [Anonymous], JOINT STAT UK
   [Anonymous], LETS WORK TOG PROT S
   [Anonymous], 2020, COVID 19 FALS MISL A
   [Anonymous], 2020, URGENT COVID 19 STAT
   [Anonymous], 2020, EFF SPIN ADJ MAN IMM
   [Anonymous], 2020, SOC MED US PLATF
   Bastani Peivand, 2020, J Med Internet Res, DOI 10.2196/18932
   Boyd-Barrett O, 2019, RUSSIAGATE PROPAGAND
   Bukhari M, 2018, RHEUMATOLOGY, V57, P773, DOI 10.1093/rheumatology/kex091
   Durant W, 2019, PERSPECT PUBLIC HEAL, V139, P280, DOI 10.1177/1757913919878655
   Harris JK, 2014, J MED INTERNET RES, V16, P162, DOI [10.2196/jmir.3622, 10.2196/jmir.2972]
   Hurwitz EL, 2012, J ELECTROMYOGR KINES, V22, P648, DOI 10.1016/j.jelekin.2012.01.006
   Husnayain A, 2020, INT J INFECT DIS, V95, P221, DOI 10.1016/j.ijid.2020.03.021
   International Telecommunication Union (ITU), 2019, MEAS DIG DEV FACTS F
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Larson HJ, 2020, NATURE, V580, P306, DOI 10.1038/d41586-020-00920-w
   Lee H, 2016, J AM MED INFORM ASSN, V23, P644, DOI 10.1093/jamia/ocv168
   Lee SB, PREPRINT, DOI [10.2196/preprints.19534, DOI 10.2196/PREPRINTS.19534]
   Marcon Alessandro R, 2016, JMIR Public Health Surveill, V2, pe153, DOI 10.2196/publichealth.5739
   Mian A, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01556-3
   Rolls K, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5312
   Sinnenberg L, 2017, AM J PUBLIC HEALTH, V107, pE1, DOI 10.2105/AJPH.2016.303512
   Smith GD, 2020, J CLIN NURS, V29, P1425, DOI 10.1111/jocn.15231
   Statista, 2020, LEAD COUNTR BAS NUMB
   Steffens MS, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7659-3
   Swire-Thompson B, 2020, ANNU REV PUBL HEALTH, V41, P433, DOI 10.1146/annurev-publhealth-040119-094127
   Wohn DY, 2016, SOC MEDIA SOC, V2, DOI 10.1177/2056305115626750
   World Health Organization (WHO), WHO DIR GEN OP REM M
   Yiannakoulias N, 2019, VACCINE, V37, P2057, DOI 10.1016/j.vaccine.2019.03.001
   Yun GW, 2016, INT J MED INFORM, V91, P67, DOI 10.1016/j.ijmedinf.2016.04.009
NR 35
TC 3
Z9 3
U1 5
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2045-709X
J9 CHIROPR MAN THER
JI Chiropr. Man. Ther.
PD JUN 9
PY 2020
VL 28
IS 1
AR 34
DI 10.1186/s12998-020-00319-4
PG 13
WC Rehabilitation
SC Rehabilitation
GA LZ8SN
UT WOS:000541490600001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Neto, ETD
   Kakehasi, AM
   Pinheiro, MD
   Ferreira, GA
   Marques, CDL
   da Mota, LMH
   Paiva, ED
   Pileggi, GCS
   Sato, EI
   Reis, APMG
   Xavier, RM
   Provenza, JR
AF dos Reis Neto, Edgard Torres
   Kakehasi, Adriana Maria
   Pinheiro, Marcelo de Medeiros
   Ferreira, Gilda Aparecida
   Lopes Marques, Claudia Diniz
   Henrique da Mota, Licia Maria
   Paiva, Eduardo dos Santos
   Salviato Pileggi, Gecilmara Cristina
   Sato, Emilia Inoue
   Monteiro Gomides Reis, Ana Paula
   Xavier, Ricardo Machado
   Provenza, Jose Roberto
TI Revisiting hydroxychloroquine and chloroquine for patients with chronic
   immunity-mediated inflammatory rheumatic diseases
SO ADVANCES IN RHEUMATOLOGY
LA English
DT Article
DE Hydroxychloroquine; Chloroquine; Antimalarials; Chronic immune-mediated
   inflammatory rheumatic diseases
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; RISK-FACTORS; DOUBLE-BLIND; EULAR
   RECOMMENDATIONS; ANTIMALARIAL-DRUGS; REDUCED RISK; LONG-TERM;
   MANAGEMENT; THROMBOSIS; ARTHRITIS
AB Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.
C1 [dos Reis Neto, Edgard Torres; Pinheiro, Marcelo de Medeiros; Sato, Emilia Inoue] Univ Fed Sao Paulo, Escola Paulista Med, Disciplina Reumatol, Sao Paulo, Brazil.
   [Kakehasi, Adriana Maria; Ferreira, Gilda Aparecida] Univ Fed Minas Gerais, Hosp Clin, Serv Reumatol, Belo Horizonte, MG, Brazil.
   [Lopes Marques, Claudia Diniz] Univ Fed Pernambuco, Hosp Clin, Serv Reumatol, Recife, PE, Brazil.
   [Henrique da Mota, Licia Maria; Monteiro Gomides Reis, Ana Paula] Hosp Univ UnB EBSERH, Brasilia, DF, Brazil.
   [Paiva, Eduardo dos Santos] Univ Fed Parana, Hosp Clin, Setv Reumatol, Curitiba, Parana, Brazil.
   [Salviato Pileggi, Gecilmara Cristina] Hosp Amor, Inst Ensino & Pesquisa IEP, Barretos, Brazil.
   [Xavier, Ricardo Machado] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Serv Reumatol, Porto Alegre, RS, Brazil.
   [Provenza, Jose Roberto] Pontificia Univ Catolica Campinas, Campinas, SP, Brazil.
RP Kakehasi, AM (corresponding author), Univ Fed Minas Gerais, Hosp Clin, Serv Reumatol, Belo Horizonte, MG, Brazil.
EM amkakehasi@gmail.com
RI MARQUES, CLAUDIA/P-4008-2019; Xavier, Ricardo Machado/G-4426-2012;
   Kakehasi, Adriana Maria/Y-9797-2018
OI MARQUES, CLAUDIA/0000-0002-3333-2621; Xavier, Ricardo
   Machado/0000-0001-6570-4533; Reis, AlessanRSS/0000-0001-8486-7469;
   Kakehasi, Adriana Maria/0000-0001-9411-7493
CR Akhavan PS, 2013, J RHEUMATOL, V40, P831, DOI 10.3899/jrheum.120572
   Amador-Patarroyo MJ, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/251730
   Andreoli L, 2017, ANN RHEUM DIS, V76, P476, DOI 10.1136/annrheumdis-2016-209770
   Aouhab Z, 2019, ACR Open Rheumatol, V1, P593, DOI 10.1002/acr2.11084
   Arnaud L, 2012, DRUG AGING, V29, P181, DOI 10.2165/11598550-000000000-00000
   Avina-Zubieta JA, 2008, ARTHRIT RHEUM-ARTHR, V59, P1690, DOI 10.1002/art.24092
   Babary H, 2018, INT J RHEUM DIS, V21, P84, DOI 10.1111/1756-185X.13159
   Baguet JP, 1999, HEART, V81, P221, DOI 10.1136/hrt.81.2.221
   Bahloul E, 2017, LUPUS, V26, P1304, DOI 10.1177/0961203317700486
   Beegle SH, 2013, DRUG DES DEV THER, V7, P325, DOI 10.2147/DDDT.S31064
   Bezerra ELM, 2005, ARTHRITIS RHEUM-US, V52, P3073, DOI 10.1002/art.21358
   Cairoli E, 2012, LUPUS, V21, P1178, DOI 10.1177/0961203312450084
   Cavazzana I, 2009, LUPUS, V18, P735, DOI 10.1177/0961203308101714
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Costedoat-Chalumeau N, 2014, PRESSE MED, V43, pE167, DOI 10.1016/j.lpm.2014.03.007
   ESDAILE J, 1991, NEW ENGL J MED, V324, P150
   ESDAILE JM, 1995, AM J MED, V98, P156
   Fanouriakis A, 2020, ANN RHEUM DIS, V79, P713, DOI [10.1136/annrheumdis-2020-216924, 10.1136/annrheumdis-2020-217804]
   Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis-2019-215089
   FDA, 2020, FACT SHEET HLTH CAR
   Fessler BJ, 2005, ARTHRITIS RHEUM, V52, P1473, DOI 10.1002/art.21039
   Fiehn C, 2020, Z RHEUMATOL, DOI 10.1007/s00393-020-00785-4
   Guillotin V, 2018, JOINT BONE SPINE, V85, P663, DOI 10.1016/j.jbspin.2018.03.006
   HAAR D, 1993, SCAND J RHEUMATOL, V22, P113, DOI 10.3109/03009749309099254
   Hahn BH, 2012, ARTHRIT CARE RES, V64, P797, DOI 10.1002/acr.21664
   da Mota LMH, 2018, ADV RHEUMATOL, V58, DOI 10.1186/s42358-018-0005-0
   Ibanez D, 2005, J RHEUMATOL, V32, P824
   Izmirly PM, 2012, CIRCULATION, V126, P76, DOI 10.1161/CIRCULATIONAHA.111.089268
   Jallouli M, 2013, JAMA DERMATOL, V149, P935, DOI 10.1001/jamadermatol.2013.709
   Jorge A, 2018, NAT REV RHEUMATOL, V14, P693, DOI 10.1038/s41584-018-0111-8
   Jung HJ, 2010, ARTHRITIS RHEUM-US, V62, P863, DOI 10.1002/art.27289
   Kaiser R, 2009, ANN RHEUM DIS, V68, P238, DOI 10.1136/ard.2008.093013
   Kasitanon N, 2006, LUPUS, V15, P366, DOI 10.1191/0961203306lu2313oa
   Klumb EM, 2015, REV BRAS REUMATOL, V55, P1, DOI 10.1016/j.rbr.2014.09.008
   Levy RA, 2001, LUPUS, V10, P401, DOI 10.1191/096120301678646137
   Li EC, 2010, PHARMACOTHERAPY, V30, P684, DOI 10.1592/phco.30.7.684
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Mok MY, 2005, J RHEUMATOL, V32, P622
   Molad Y, 2002, LUPUS, V11, P356, DOI 10.1191/0961203302lu203ra
   Nord JE, 2004, SEMIN ARTHRITIS RHEU, V33, P336, DOI 10.1016/j.semarthrit.2003.09.012
   Penn SK, 2010, J RHEUMATOL, V37, P1136, DOI 10.3899/jrheum.090994
   Petri M, 1996, SCAND J RHEUMATOL, V25, P191, DOI 10.3109/03009749609069986
   PETRI M, 1994, AM J MED, V96, P254, DOI 10.1016/0002-9343(94)90151-1
   Petri M, 2005, PREDICTORS RENAL INS
   Petri M, 2020, ARTHRITIS RHEUMATOL, V72, P448, DOI 10.1002/art.41121
   Petri M, 2012, ARTHRITIS RHEUM-US, V64, P4021, DOI 10.1002/art.34672
   Pileggi GS, 2019, ADV RHEUMATOL, V59, DOI 10.1186/s42358-019-0056-x
   Pons-Estel GJ, 2009, ARTHRIT RHEUM-ARTHR, V61, P830, DOI 10.1002/art.24538
   Ponticelli C, 2017, EXPERT OPIN DRUG SAF, V16, P411, DOI 10.1080/14740338.2017.1269168
   Rahman P, 1999, J RHEUMATOL, V26, P325
   Ramos-Casals M, 2020, ANN RHEUM DIS, V79, P3, DOI 10.1136/annrheumdis-2019-216114
   Rand JH, 2008, BLOOD, V112, P1687, DOI 10.1182/blood-2008-03-144204
   Rempenault C, 2018, ANN RHEUM DIS, V77, P98, DOI 10.1136/annrheumdis-2017-211836
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Ruiz-Irastorza G, 2006, LUPUS, V15, P577, DOI 10.1177/0961203306071872
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Ruiz-Irastorza G, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2764
   RUZICKA T, 1992, BRIT J DERMATOL, V127, P513, DOI 10.1111/j.1365-2133.1992.tb14851.x
   Sachet JC, 2007, LUPUS, V16, P273, DOI 10.1177/09612033070160040901
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Sharma AN, 2020, J AM ACAD DERMATOL, V83, P563, DOI 10.1016/j.jaad.2020.04.024
   Shinjo SK, 2010, ARTHRITIS RHEUM-US, V62, P855, DOI 10.1002/art.27300
   Sidoroff A, 2007, BRIT J DERMATOL, V157, P989, DOI 10.1111/j.1365-2133.2007.08156.x
   Singh JA, 2016, ARTHRITIS RHEUMATOL, V68, P1, DOI 10.1002/art.39480
   Sontheimer RD, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.03.05
   Souza DCC, 2010, CLIN EXP RHEUMATOL, V28, P519
   Tektonidou MG, 2019, ANN RHEUM DIS, V78, P1296, DOI 10.1136/annrheumdis-2019-215213
   Tektonidou MG, 2009, ARTHRIT RHEUM-ARTHR, V61, P29, DOI 10.1002/art.24232
   Thome R, 2013, IMMUNOL LETT, V153, P50, DOI 10.1016/j.imlet.2013.07.004
   Tsakonas E, 1998, LUPUS, V7, P80
   Tsankov N, 2000, Am J Clin Dermatol, V1, P159, DOI 10.2165/00128071-200001030-00003
   Tselios K, 2019, J RHEUMATOL, V46, P391, DOI 10.3899/jrheum.180124
   Tunks RD, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.09.020
   UROWITZ MB, 1976, AM J MED, V60, P221, DOI 10.1016/0002-9343(76)90431-9
   Valim V, 2015, REV BRAS REUMATOL, V55, P446, DOI 10.1016/j.rbr.2015.07.004
   van Vollenhoven RF, 2014, ANN RHEUM DIS, V73, P958, DOI 10.1136/annrheumdis-2013-205139
   Vilar MJP, 2002, LUPUS, V11, P528, DOI 10.1191/0961203302lu244xx
   Wasko MCM, 2007, JAMA-J AM MED ASSOC, V298, P187, DOI 10.1001/jama.298.2.187
   Yogasundaram H, 2018, ESC HEART FAIL, V5, P372, DOI 10.1002/ehf2.12276
   Yusuf IH, 2017, EYE, V31, P828, DOI 10.1038/eye.2016.298
NR 80
TC 2
Z9 2
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2523-3106
J9 ADV RHEUMATOL
JI Adv. Rheumatol.
PD JUN 9
PY 2020
VL 60
IS 1
AR 32
DI 10.1186/s42358-020-00134-8
PG 11
WC Rheumatology
SC Rheumatology
GA LZ3QK
UT WOS:000541143000001
PM 32517786
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tang, J
AF Tang, J.
TI What can we learn about corticosteroid therapy as a treatment for
   COVID-19?
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Letter
C1 [Tang, J.] Wuhan Univ, Dept Endocrinol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
RP Tang, J (corresponding author), Wuhan Univ, Dept Endocrinol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
EM jtang518@hotmail.com
OI Tang, Jun/0000-0002-6908-1027
CR Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214
   Li Yu-ming, 2004, Zhonghua Yi Xue Za Zhi, V84, P1348
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577
   Zhao R, 2017, OSTEOPOROSIS INT, V28, P1027, DOI 10.1007/s00198-016-3824-z
NR 5
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
EI 1433-2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD AUG
PY 2020
VL 31
IS 8
BP 1595
EP 1595
DI 10.1007/s00198-020-05487-w
EA JUN 2020
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MJ6XM
UT WOS:000539680500002
PM 32519174
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ni, M
   Tian, FB
   Xiang, DD
   Yu, B
AF Ni, Ming
   Tian, Fang-Bing
   Xiang, Dan-Dan
   Yu, Bing
TI Characteristics of inflammatory factors and lymphocyte subsets in
   patients with severe COVID-19
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE COVID-19; lymphopenia; proinflammatory; severe pneumonia
ID ACUTE RESPIRATORY SYNDROME; CORTICOSTEROID TREATMENT; CYTOKINE STORM;
   T-CELLS; PROCALCITONIN; MORTALITY; SARS; PNEUMONIA; INFECTION; THERAPY
AB To investigate the inflammatory factors and lymphocyte subsets which play an important role in the course of severe coronavirus disease 2019 (COVID-19). A total of 27 patients with severe COVID-19 who were admitted to Tongji Hospital in Wuhan from 1 to 21 February 2020 were recruited to the study. The characteristics of interleukin-1 beta (IL-1 beta), IL-2 receptor (IL-2R), IL-6, IL-8, IL-10, tumor necrosis factor-alpha (TNF)-alpha, C-reactive protein (CRP), serum ferritin and procalcitonin (PCT), and lymphocyte subsets of these patients were retrospectively compared before and after treatment. Before treatment, there was no significant difference in most inflammatory factors (IL-1 beta, IL-2R, IL-6, IL-8, IL-10, CRP, and serum ferritin) between male and female patients. Levels of IL-2R, IL-6, TNF-alpha, and CRP decreased significantly after treatment, followed by IL-8, IL-10, and PCT. Serum ferritin was increased in all patients before treatment but did not decrease significantly after treatment. IL-1 beta was normal in most patients before treatment. Lymphopenia was common among these patients with severe COVID-19. Analysis of lymphocyte subsets showed that CD4+ and particularly CD8+ T lymphocytes increased significantly after treatment. However, B lymphocytes and natural killer cells showed no significant changes after treatment. A pro-inflammatory response and decreased level of T lymphocytes were associated with severe COVID-19.
C1 [Ni, Ming; Tian, Fang-Bing; Xiang, Dan-Dan] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Infect Dis, Tongji Med Coll, Wuhan, Peoples R China.
   [Yu, Bing] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Tongji Med Coll, Wuhan 430030, Peoples R China.
RP Yu, B (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Tongji Med Coll, Wuhan 430030, Peoples R China.
EM yubing@hust.edu.cn
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   BENDER BS, 1992, J EXP MED, V175, P1143, DOI 10.1084/jem.175.4.1143
   Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287
   Cameron MJ, 2008, VIRUS RES, V133, P13, DOI 10.1016/j.virusres.2007.02.014
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen J, 2007, ANNU REV IMMUNOL, V25, P443, DOI 10.1146/annurev.immunol.25.022106.141706
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   Conti P, 2020, J BIOL REGUL HOMEOST, P34
   Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771
   Covington EW, 2018, PHARMACOTHERAPY, V38, P569, DOI 10.1002/phar.2112
   Das D, 2015, CLIN MICROBIOL INFEC, V21, DOI 10.1016/j.cmi.2015.02.014
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Hotchkiss RS, 2006, J IMMUNOL, V176, P5471, DOI 10.4049/jimmunol.176.9.5471
   Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952
   Hotchkiss RS, 2005, J IMMUNOL, V174, P5110, DOI 10.4049/jimmunol.174.8.5110
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jensen IJ, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007405
   Jiang Y, 2005, AM J RESP CRIT CARE, V171, P850, DOI 10.1164/rccm.200407-857OC
   Kim BG, 2013, KOREAN J INTERN MED, V28, P322, DOI 10.3904/kjim.2013.28.3.322
   Kritas SK, 2020, J BIOL REG HOMEOS AG, V34, P9, DOI 10.23812/20-Editorial-Kritas
   Luo Y, 2019, AGING-US, V11, P12685, DOI 10.18632/aging.102595
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   National Health Commission of China, 2020, DIAGN TREATM PROGR N
   Ng DL, 2016, AM J PATHOL, V186, P652, DOI 10.1016/j.ajpath.2015.10.024
   Nussing S, 2018, FRONT MED-PRC, V12, P34, DOI 10.1007/s11684-017-0606-8
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Simsek O, 2018, ARCH MED SCI, V14, P288, DOI 10.5114/aoms.2016.57886
   Slaats J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005973
   Soundravally R, 2015, INFECTION, V43, P13, DOI 10.1007/s15010-014-0683-4
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   van de Weg CAM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003214
   Wang W, 2010, BBA-GEN SUBJECTS, V1800, P760, DOI 10.1016/j.bbagen.2010.03.011
   WANG XK, 1995, ATHEROSCLEROSIS, V115, P89, DOI 10.1016/0021-9150(94)05503-B
   Williams AE, 2014, AM J PHYSIOL-LUNG C, V306, pL217, DOI 10.1152/ajplung.00311.2013
   Wu JP, 2014, ARCH MED RES, V45, P251, DOI 10.1016/j.arcmed.2014.03.004
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yam LYC, 2007, J INFECTION, V54, P28, DOI 10.1016/j.jinf.2006.01.005
NR 48
TC 3
Z9 3
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2600
EP 2606
DI 10.1002/jmv.26070
EA JUN 2020
PG 7
WC Virology
SC Virology
GA NU0EN
UT WOS:000538929200001
PM 32470153
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU La Rosee, F
   Bremer, HC
   Gehrke, I
   Kehr, A
   Hochhaus, A
   Birndt, S
   Fellhauer, M
   Henkes, M
   Kumle, B
   Russo, SG
   La Rosee, P
AF La Rosee, F.
   Bremer, H. C.
   Gehrke, I
   Kehr, A.
   Hochhaus, A.
   Birndt, S.
   Fellhauer, M.
   Henkes, M.
   Kumle, B.
   Russo, S. G.
   La Rosee, P.
TI The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe
   systemic hyperinflammation
SO LEUKEMIA
LA English
DT Article
ID TRANSPLANTATION; THERAPY; PATIENT
AB A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation. Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux). Patients were treated with efficacy/toxicity guided step up dosing up to 14 days. Retrospective analysis of CIS reduction and clinical outcome was performed. Out of 105 patients treated between March 30th and April 15th(,)2020, 14 patients with a CIS >= 10 out of 16 points received Rux over a median of 9 days with a median cumulative dose of 135 mg. A total of 12/14 patients achieved significant reduction of CIS by >= 25% on day 7 with sustained clinical improvement in 11/14 patients without short term red flag warnings of Rux-induced toxicity. Rux treatment for COVID-19 in patients with hyperinflammation is shown to be safe with signals of efficacy in this pilot case series for CRS-intervention to prevent or overcome multiorgan failure. A multicenter phase-II clinical trial has been initiated (NCT04338958).
C1 [La Rosee, F.] Tech Univ Dresden, Med Fak Carl Gustav Carus, Dresden, Germany.
   [Bremer, H. C.] Schwarzwald Baar Klinikum, Lungenzentrum Donaueschingen, Villingen Schwenningen, Germany.
   [Gehrke, I; Kehr, A.] Schwarzwald Baar Klinikum, Klin Innere Med 4, Villingen Schwenningen, Germany.
   [Hochhaus, A.; Birndt, S.] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany.
   [Fellhauer, M.] Schwarzwald Baar Klinikum, Inst Klin Pharm, Apotheke, Villingen Schwenningen, Germany.
   [Henkes, M.; La Rosee, P.] Schwarzwald Baar Klinikum, Klin Innere Med Hamatol Onkol Immunol Infektiol &, Villingen Schwenningen, Germany.
   [Kumle, B.] Schwarzwald Baar Klinikum, Klin Akut & Notfallmed, Villingen Schwenningen, Germany.
   [Russo, S. G.] Klin Anasthesiol Intens Notfall & Schmerzmed, Villingen Schwenningen, Germany.
   [Russo, S. G.] Univ Gottingen, Med Fak, Gottingen, Germany.
   [Russo, S. G.] Univ Witten Herdecke, Fak Gesundheit, Witten, Germany.
   [La Rosee, P.] Friedrich Schiller Univ Jena, Univ Klinikum Jena, Med Fak, Jena, Germany.
RP La Rosee, P (corresponding author), Schwarzwald Baar Klinikum, Klin Innere Med Hamatol Onkol Immunol Infektiol &, Villingen Schwenningen, Germany.; La Rosee, P (corresponding author), Friedrich Schiller Univ Jena, Univ Klinikum Jena, Med Fak, Jena, Germany.
EM paul.larosee@sbk-vs.de
OI La Rosee, Felicitas/0000-0002-4310-3582; Birndt,
   Sebastian/0000-0001-5430-899X
FU Projekt DEAL
FX We gratefully acknowledge the support of the entire Covid-19 task force
   of the Schwarzwald-Baar-Klinikum, in particular nursing staff,
   respiratory specialists and many colleagues supporting the daily
   Covid-19 board. In particular thanks to Eike Walter, Albert Benzing,
   Werner Huber, Anja Ruckert, Patricia Mohm, Stefanie Bergander, Robby
   Winkler, Kerstin Heine and Vanessa Kardinal. Patients and families for
   their sympathy and support. Open access funding provided by Projekt
   DEAL.
CR Ahmed A, 2019, LANCET HAEMATOL, V6, pE630, DOI 10.1016/S2352-3026(19)30156-5
   Beauverd Y, 2014, INT J HEMATOL, V100, P498, DOI 10.1007/s12185-014-1628-5
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Caocci G, 2014, LEUKEMIA, V28, P225, DOI 10.1038/leu.2013.235
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010
   Ehl S, 2018, J ALLER CL IMM-PRACT, V6, P1508, DOI 10.1016/j.jaip.2018.05.031
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Harrison C, 2012, NEW ENGL J MED, V366, P787, DOI 10.1056/NEJMoa1110556
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jagasia M, 2020, BLOOD, V135, P1739, DOI 10.1182/blood.2020004823
   La Rosee P, 2019, BLOOD, V133, P2465, DOI 10.1182/blood.2018894618
   Lussana F, 2017, J AUTOIMMUN, V85, P58, DOI 10.1016/j.jaut.2017.06.010
   Malavolta M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040909
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Perner F, 2016, LEUKEMIA, V30, P991, DOI 10.1038/leu.2015.218
   RKI, 2020, HINW ERK DIAGN THER
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sant'Antonio E, 2019, BRIT J HAEMATOL, V187, P286, DOI 10.1111/bjh.16174
   Song YG, 2020, INFECT CHEMOTHER, V52, P110, DOI 10.3947/ic.2020.52.1.110
   Taccone FS, 2020, LANCET RESP MED, V8, P539, DOI 10.1016/S2213-2600(20)30172-7
   Wang JS, 2020, HAEMATOLOGICA, V105, pE210, DOI 10.3324/haematol.2019.222471
   Wang W, 2020, DEFINITION RISKS CYT, DOI [10.1101/2020.02.26.20026989, DOI 10.1101/2020.02.26.20026989]
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang Y, 2020, EXUBERANT ELEVATION
   Zeiser R, 2015, LEUKEMIA, V29, P2062, DOI 10.1038/leu.2015.212
   Zeiser R, 2020, NEW ENGL J MED, V382, P1800, DOI 10.1056/NEJMoa1917635
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang Y, 2020, CHINA CDC WEEKLY
   Zhao YM, 2020, BONE MARROW TRANSPL, V55, P824, DOI 10.1038/s41409-019-0577-2
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 40
TC 27
Z9 28
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD JUL
PY 2020
VL 34
IS 7
BP 1805
EP 1815
DI 10.1038/s41375-020-0891-0
EA JUN 2020
PG 11
WC Oncology; Hematology
SC Oncology; Hematology
GA NI4DK
UT WOS:000539192300003
PM 32518419
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Rokohl, AC
   Loreck, N
   Matos, PAW
   Mor, JM
   Zwingelberg, S
   Grajewski, RS
   Cursiefen, C
   Heindl, LM
AF Rokohl, Alexander C.
   Loreck, Niklas
   Matos, Philomena A. Wawer
   Mor, Joel M.
   Zwingelberg, Sarah
   Grajewski, Rafael S.
   Cursiefen, Claus
   Heindl, Ludwig M.
TI The role of ophthalmology in the COVID-19 pandemic
SO OPHTHALMOLOGE
LA German
DT Article; Early Access
DE SARS-CoV-2; Ophthalmology; Coronavirus; Corona-Virus-Disease-19;
   Conjunctivitis
ID DISEASE 2019 COVID-19
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 19 (COVID-19) has led to a worldwide pandemic. This pandemic presents a huge challenge for the healthcare system and also for ophthalmologists. Previous studies and case reports indicated that SARS-CoV-2 also infects the conjunctiva resulting in conjunctivitis. In addition, infectious virus particles in the tear fluid can be potential sources of infection; however, the detection of SARS-CoV-2 RNA in the tear fluid has rarely been successful. Although isolated conjunctival involvement is highly unlikely, at the current point in time of the COVID-19 pandemic, practically every patient examined by an ophthalmologist could be infected with SARS-CoV-2. Therefore, protective and hygiene measures should currently be consistently followed to minimize the risk of spreading the virus. Currently, there are no treatment recommendations for conjunctivitis associated with COVID-19. Tear substitutes might be helpful for symptom relief but there is no evidence for a topical antiviral therapy. In the future ophthalmologists could play a decisive role in the screening of maculopathies that might occur during COVID-19 treatment using chloroquine or hydroxychloroquine.
C1 [Rokohl, Alexander C.] Univ Cologne, Med Fak, Zentrum Augenheilkunde, Kerpener Str 62, D-50924 Cologne, Germany.
   [Rokohl, Alexander C.] Uniklin Koln, Kerpener Str 62, D-50924 Cologne, Germany.
RP Rokohl, AC (corresponding author), Univ Cologne, Med Fak, Zentrum Augenheilkunde, Kerpener Str 62, D-50924 Cologne, Germany.; Rokohl, AC (corresponding author), Uniklin Koln, Kerpener Str 62, D-50924 Cologne, Germany.
EM alexander.rokohl@uk-koeln.de
RI Cursiefen, Claus/ABE-5284-2020; Rokohl, Alexander/K-6191-2019
OI Rokohl, Alexander/0000-0002-0224-3597
CR BERNSTEIN HN, 1983, AM J MED, V75, P25, DOI 10.1016/0002-9343(83)91267-6
   Cheema M, 2020, CAN J OPHTHALMOL, V55, pE125, DOI 10.1016/j.jcjo.2020.03.003
   Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hagmann SHF, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101649
   Holz FG, 2020, OPHTHALMOLOGE, V117, P295, DOI 10.1007/s00347-020-01097-3
   Li JPO, 2020, BRIT J OPHTHALMOL, V104, P297, DOI 10.1136/bjophthalmol-2020-315994
   Liang L, 2020, ACTA OPHTHALMOL, V98, P223, DOI 10.1111/aos.14413
   Liu XP, 2020, INFLUENZA OTHER RESP, V14, P472, DOI 10.1111/irv.12740
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Luers JC, 2020, LARYNGO RHINO OTOL, V99, P287, DOI 10.1055/a-1095-2344
   Luers Jan C, 2020, Clin Infect Dis, V71, P2262, DOI 10.1093/cid/ciaa525
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Parrish RK, 2020, AM J OPHTHALMOL, V213, pA1, DOI 10.1016/j.ajo.2020.02.014
   Peng YZ, 2020, J MED VIROL, DOI 10.1002/jmv.25753
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Seah I, 2020, OCUL IMMUNOL INFLAMM, V28, P391, DOI 10.1080/09273948.2020.1738501
   Seah IYJ, 2020, OPHTHALMOLOGY, V127, P977, DOI 10.1016/j.ophtha.2020.03.026
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wu P, 2020, JAMA OPHTHALMOL, V138, P575, DOI 10.1001/jamaophthalmol.2020.1291
   Xia JH, 2020, J MED VIROL, V92, P589, DOI 10.1002/jmv.25725
   Yu AY, 2020, EYE VISION, V7, DOI 10.1186/s40662-020-00187-2
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang X, 2020, OCUL SURF, V18, P360, DOI 10.1016/j.jtos.2020.03.010
NR 26
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0941-293X
EI 1433-0423
J9 OPHTHALMOLOGE
JI Ophthalmologe
DI 10.1007/s00347-020-01148-9
EA JUN 2020
PG 6
WC Ophthalmology
SC Ophthalmology
GA LW5JO
UT WOS:000539183000002
PM 32519117
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Shah, MB
   Lynch, RJ
   El-Haddad, H
   Doby, B
   Brockmeier, D
   Goldberg, DS
AF Shah, Malay B.
   Lynch, Raymond J.
   El-Haddad, Hanine
   Doby, Brianna
   Brockmeier, Diane
   Goldberg, David S.
TI Utilization of deceased donors during a pandemic: argument against using
   SARS-CoV-2-positive donors
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE donors and donation; editorial; personal viewpoint; ethics and public
   policy; infection and infectious agents - viral; infectious disease;
   organ allocation; organ procurement; organ procurement and allocation;
   organ transplantation in general
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become an unprecedented pandemic that has impacted society, disrupted hospital functions, strained health care resources, and impacted the lives of transplant professionals. Despite this, organ failure and the need for transplant continues throughout the United States. Considering the perpetual scarcity of deceased donor organs, Kates et al present a viewpoint that advocates for the utilization of coronavirus disease 2019 (COVID-19)-positive donors in selected cases. We present a review of the current literature that details the potential negative consequences of COVID-19-positive donors. The factors we consider include (1) the risk of blood transmission of SARS-CoV-2, (2) involvement of donor organs, (3) lack of effective therapies, (4) exposure of health care and recovery teams, (5) disease transmission and propagation, and (6) hospital resource utilization. While we acknowledge that transplant fulfills the mission of saving lives, it is imperative to consider the consequences not only to our recipients but also to the community and to health care workers, particularly in the absence of effective preventative or curative therapies. For these reasons, we believe the evidence and risks show that COVID-19 infection should continue to remain a contraindication for donation, as has been the initial response of donation and transplant societies.
C1 [Shah, Malay B.] Univ Kentucky, Coll Med, Div Abdominal Transplant Surg, Dept Surg, Lexington, KY 40506 USA.
   [Lynch, Raymond J.] Emory Univ, Sch Med, Dept Surg, Div Transplantat, Atlanta, GA 30322 USA.
   [El-Haddad, Hanine] Univ Kentucky, Coll Med, Dept Med, Div Infect Dis, Lexington, KY USA.
   [Doby, Brianna] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Brockmeier, Diane] Mid Amer Transplant, St Louis, MO USA.
   [Goldberg, David S.] Univ Miami, Miller Sch Med, Dept Med, Div Hepatol, Miami, FL 33136 USA.
RP Shah, MB (corresponding author), Univ Kentucky, Coll Med, Div Abdominal Transplant Surg, Dept Surg, Lexington, KY 40506 USA.
EM malay.shah@uky.edu
OI Doby, Brianna/0000-0001-9863-3276
CR [Anonymous], NON EL MED SERV TREA
   Association of Organ Procurement Organizations, COVID 19 COR B
   Canadian Blood Services, 2020, CONS GUID ORG DON TR
   Centers for Disease Control and Prevention, STRESS COPING
   Centers for Disease Control and Prevention, STRAT OPT SUPPL PPE
   Chang L, 2020, EMERG INFECT DIS, V26, P1631, DOI 10.3201/eid2607.200839
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Kates OS, 2020, AM J TRANSPLANT, V20, P1787, DOI 10.1111/ajt.16000
   Krein SL, 2018, JAMA INTERN MED, V178, P1016, DOI 10.1001/jamainternmed.2018.1898
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Maisch B, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00048
   Nussbaumer-Streit B, 2020, COCHRANE DB SYST REV, V4, DOI [10.1002/1001/archinte.166.10.1092, DOI 10.1002/14651858.CD01357432267544]
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Transplant Infectious Disease Section The Transplantation Society, 2020, GUID COR DIS 2019 CO
   United Network for Organ Sharing, TRANSPL TRENDS
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   WHO, COVID 19 DASHB
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang F, 2020, AM J PHYSIOL-RENAL, V318, pF1136, DOI 10.1152/ajprenal.00085.2020
   Zhou J, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao4966
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 29
TC 11
Z9 11
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2020
VL 20
IS 7
BP 1795
EP 1799
DI 10.1111/ajt.15969
EA JUN 2020
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MD1JV
UT WOS:000538800300001
PM 32368850
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wang, Y
   Chen, L
AF Wang, Yan
   Chen, Lei
TI Lung tissue distribution of drugs as a key factor for COVID-19 treatment
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Letter
ID REMDESIVIR; LOPINAVIR; RATS; SARS
C1 [Wang, Yan] Chinese Acad Sci, Ctr Translat Med Res & Dev, Shenzhen Inst Adv Technol, Shenzhen 518055, Peoples R China.
   [Chen, Lei] Rutgers State Univ, Human Genet Inst New Jersey, Dept Genet, Piscataway, NJ 08854 USA.
RP Wang, Y (corresponding author), Chinese Acad Sci, Ctr Translat Med Res & Dev, Shenzhen Inst Adv Technol, Shenzhen 518055, Peoples R China.; Chen, L (corresponding author), Rutgers State Univ, Human Genet Inst New Jersey, Dept Genet, Piscataway, NJ 08854 USA.
EM yan.wang@siat.ac.cn; lchen@dls.rutgers.edu
RI WANG, Yan/AAG-4630-2020; Abdelnabi, Rana/D-9526-2018
OI WANG, Yan/0000-0003-0671-7312; Abdelnabi, Rana/0000-0001-9771-7312;
   Chen, Lei/0000-0001-7812-508X
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Contini A, 2020, VIRTUAL SCREENING FD, DOI [10.26434/chemrxiv.11847381, DOI 10.26434/CHEMRXIV.11847381]
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Kumar GN, 2004, PHARM RES-DORDR, V21, P1622, DOI 10.1023/B:PHAM.0000041457.64638.8d
   MCCHESNEY EW, 1967, TOXICOL APPL PHARM, V10, P501, DOI 10.1016/0041-008X(67)90089-0
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   Ono C, 2003, J PHARM PHARMACOL, V55, P1647, DOI 10.1211/0022357022340
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
NR 13
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD NOV
PY 2020
VL 177
IS 21
BP 4995
EP 4996
DI 10.1111/bph.15102
EA JUN 2020
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OC7OD
UT WOS:000538938600001
PM 32424836
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kang, HYJ
   Wang, YS
   Tong, ZH
   Liu, XF
AF Kang, Hanyujie
   Wang, Yishan
   Tong, Zhaohui
   Liu, Xuefeng
TI Retest positive for SARS-CoV-2 RNA of "recovered" patients with
   COVID-19: Persistence, sampling issues, or re-infection?
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE coronavirus < virus classification; disease control; immunity;
   immunization < epidemiology; persistent infection < infection; SARS
   coronavirus < virus classification
AB "Retest Positive" for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) from "recovered" coronavirus disease-19 (COVID-19) has been reported and raised several important questions for this novel coronavirus and COVID-19 disease. In this commentary, we discussed several questions: (a) Can SARS-CoV-2 re-infect the individuals who recovered from COVID-19? This question is also associated with other questions: whether or not SARS-CoV-2 infection induces protective reaction or neutralized antibody? Will SARS-CoV-2 vaccines work? (b) Why could some recovered patients with COVID-19 be re-tested positive for SARS-CoV-2 RNA? (c) Are some recovered pwith atients COVID-19 with re-testing positive for SARS-CoV-2 RNA infectious? and (d) How should the COVID-19 patients with retest positive for SARS-CoV-2 be managed?
C1 [Kang, Hanyujie; Wang, Yishan; Tong, Zhaohui] Capital Med Univ, Beijing Chao Yang Hosp, Beijing Inst Resp Med, Dept Resp & Crit Care Med, Beijing 100020, Peoples R China.
   [Liu, Xuefeng] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Pathol, Washington, DC 20057 USA.
   [Liu, Xuefeng] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA.
RP Tong, ZH (corresponding author), Capital Med Univ, Beijing Chao Yang Hosp, Beijing Inst Resp Med, Dept Resp & Crit Care Med, Beijing 100020, Peoples R China.; Liu, XF (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Pathol, Washington, DC 20057 USA.; Liu, XF (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA.
EM tongzhaohuicy@sina.com; xuefeng.liu@georgetown.edu
CR An J., 2020, CLIN CHARACTERISTICS
   Bao L., 2020, REINFECTION COULD NO
   Cao H, 2020, J MED VIROL, V92, P2159, DOI 10.1002/jmv.26017
   Chen DB, 2020, INT J INFECT DIS, V93, P297, DOI 10.1016/j.ijid.2020.03.003
   Fu W, 2020, J MED VIROL, V92, P2298, DOI 10.1002/jmv.25968
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Huang J, 2020, RECURRENCE SARS COV
   Kipkorir V, 2020, J MED VIROL, V92, P2328, DOI 10.1002/jmv.26007
   Lan L, 2020, JAMA
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Qu YM, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101619
   Peron JPS, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1912
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YS, 2020, J MED VIROL, V92, P538, DOI 10.1002/jmv.25721
   Woelfel R., 2020, CLIN PRESENTATION VI
   Wu F, 2020, NEUTRALIZING ANTIBOD
   Xia G NW, 2020, SEROLOGICAL TEST IS
   Zhao S, 2020, INFECT DIS-NOR, V52, P284, DOI 10.1080/23744235.2020.1717598
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 22
TC 13
Z9 13
U1 2
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2263
EP 2265
DI 10.1002/jmv.26114
EA JUN 2020
PG 3
WC Virology
SC Virology
GA NU0EN
UT WOS:000538930600001
PM 32492212
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Marin-Hernandez, D
   Schwartz, RE
   Nixon, DF
AF Marin-Hernandez, Daniela
   Schwartz, Robert E.
   Nixon, Douglas F.
TI Epidemiological evidence for association between higher influenza
   vaccine uptake in the elderly and lower COVID-19 deaths in Italy
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter; Early Access
C1 [Marin-Hernandez, Daniela; Schwartz, Robert E.; Nixon, Douglas F.] Weill Cornell Med, Dept Med, Belfer Res Bldg,Room 530,413 E 69th St, New York, NY 10065 USA.
RP Nixon, DF (corresponding author), Weill Cornell Med, Dept Med, Belfer Res Bldg,Room 530,413 E 69th St, New York, NY 10065 USA.
EM dnixon@med.cornell.edu
RI Nixon, Douglas/AAU-5734-2020
OI Nixon, Douglas/0000-0002-2801-1786; Marin-Hernandez,
   Daniela/0000-0003-1362-6881
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA234614] Funding Source: Medline; NIDDK NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [R01 DK121072] Funding Source: Medline
CR [Anonymous], 1999, VACCINAZIONE ANTINFL
   Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases, INFL FLU VACC AR MAD
   de Waure C, 2019, EUR J PUBLIC HEALTH, V29, P900, DOI 10.1093/eurpub/ckz041
   Gregersen JP, 2011, FUTURE MICROBIOL, V6, P143, DOI [10.2217/fmb.10.161, 10.2217/FMB.10.161]
   Pinky L, 2020, J MED VIROL, V92, P2623, DOI 10.1002/jmv.26098
   Rubino S, 2020, J INFECT DEV COUNTR, V14, P265, DOI 10.3855/jidc.12734
   Seqirus, 2019, 1 CELL BAS QUADR INF
   Statista, 2020, IT COR DEATHS REG ST
NR 8
TC 12
Z9 12
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26120
EA JUN 2020
PG 2
WC Virology
SC Virology
GA LW1UJ
UT WOS:000538930100001
PM 32497290
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Herst, CV
   Burkholz, S
   Sidney, J
   Sette, A
   Harris, PE
   Massey, S
   Brasel, T
   Cunha-Neto, E
   Rosa, DS
   Chao, WCH
   Carback, R
   Hodge, T
   Wang, L
   Ciotlos, S
   Lloyd, P
   Rubsamen, R
AF Herst, C., V
   Burkholz, S.
   Sidney, J.
   Sette, A.
   Harris, P. E.
   Massey, S.
   Brasel, T.
   Cunha-Neto, E.
   Rosa, D. S.
   Chao, W. C. H.
   Carback, R.
   Hodge, T.
   Wang, L.
   Ciotlos, S.
   Lloyd, P.
   Rubsamen, R.
TI An effective CTL peptide vaccine for Ebola Zaire Based on Survivors'
   CD8+targeting of a particular nucleocapsid protein epitope with
   potential implications for COVID-19 vaccine design
SO VACCINE
LA English
DT Article
DE Ebola Zaire vaccine; CTL Vaccine; Controller; YQVNNLEEI; COVID-19;
   SARS-CoV-2; Flow Focusing
ID T-CELL EPITOPES; SARS CORONAVIRUS; VIRUS INFECTION; LYMPHOCYTE
   RESPONSES; NEURAL-NETWORKS; PROTECTION; BINDING; IDENTIFICATION;
   MACAQUES; RECEPTOR
AB The 2013-2016 West Africa EBOV epidemic was the biggest EBOV outbreak to date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of those individuals had a CD8+ response to at least one EBOV protein. The dominant response (25/26 subjects) was specific to the EBOV nucleocapsid protein (NP). It has been suggested that epitopes on the EBOV NP could form an important part of an effective T-cell vaccine for Ebola Zaire. We show that a 9-amino-acid peptide NP44-52 (YQVNNLEEI) located in a conserved region of EBOV NP provides protection against morbidity and mortality after mouse adapted EBOV challenge. A single vaccination in a C57BL/6 mouse using an adjuvanted microsphere peptide vaccine formulation containing NP44-52 is enough to confer immunity in mice. Our work suggests that a peptide vaccine based on CD8+ T-cell immunity in EBOV survivors is conceptually sound and feasible. Nucleocapsid proteins within SARS-CoV-2 contain multiple Class I epitopes with predicted HLA restrictions consistent with broad population coverage. A similar approach to a CTL vaccine design may be possible for that virus. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Herst, C., V; Burkholz, S.; Carback, R.; Hodge, T.; Wang, L.; Ciotlos, S.; Lloyd, P.; Rubsamen, R.] Flow Pharma Inc, 3451 Vincent Rd, Pleasant Hill, CA 94523 USA.
   [Massey, S.; Brasel, T.] Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.
   [Cunha-Neto, E.] Univ Sao Paulo, Lab Clin Immunol & Allergy LIM60, Sch Med, Sao Paulo, Brazil.
   [Cunha-Neto, E.; Rosa, D. S.] Inst Invest Immunol Iii INCT, Sao Paulo, Brazil.
   [Cunha-Neto, E.] Univ Sao Paulo, Sch Med, Heart Inst Incor, Sao Paulo, Brazil.
   [Rosa, D. S.] Fed Univ Sao Paulo UNIFESP EPM, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil.
   [Harris, P. E.] Columbia Univ, Dept Med, Sch Med, Endocrinol Div, New York, NY USA.
   [Rubsamen, R.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
   [Sidney, J.; Sette, A.] La Jolla Inst Allergy & Immunol, 9420 Athena Circle, La Jolla, CA 92037 USA.
   [Chao, W. C. H.] Univ Macau, E12 Ave Univ, Taipa, Macao, Peoples R China.
RP Rubsamen, R (corresponding author), Flow Pharma Inc, 3451 Vincent Rd, Pleasant Hill, CA 94523 USA.
EM reidrubsamen@alum.mit.edu
RI Cunha-Neto, Edecio/B-4157-2009
OI Cunha-Neto, Edecio/0000-0002-3699-3345
FU Flow Pharma, Inc.
FX All animal handling was done in accordance with NIH and institutional
   animal care and use guidelines by Aragen Bio-sciences in Morgan Hill
   California and the University of Texas, Medical Branch, Galveston Texas
   working in conjunction with the Galveston National Laboratory. The
   research was funded by Flow Pharma, Inc.
CR Agnandji ST, 2016, NEW ENGL J MED, V374, P1647, DOI 10.1056/NEJMoa1502924
   Alves DA, 2010, VET PATHOL, V47, P831, DOI 10.1177/0300985810378597
   Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Basler CF, 2009, J INTERF CYTOK RES, V29, P511, DOI 10.1089/jir.2009.0076
   Bassani-Sternberg M, 2015, MOL CELL PROTEOMICS, V14, P658, DOI 10.1074/mcp.M114.042812
   Bellan SE, 2014, LANCET, V384, P1499, DOI 10.1016/S0140-6736(14)61839-0
   Billeskov R, 2017, J IMMUNOL, V198, P3494, DOI 10.4049/jimmunol.1600965
   Blicher T, 2005, ACTA CRYSTALLOGR D, V61, P1031, DOI 10.1107/S0907444905013090
   Borthwick N, 2014, MOL THER, V22, P464, DOI 10.1038/mt.2013.248
   Brister JR, 2015, NUCLEIC ACIDS RES, V43, pD571, DOI 10.1093/nar/gku1207
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Cheung Y K, 2008, Hong Kong Med J, V14 Suppl 4, P27
   Cheung YK, 2007, VACCINE, V25, P6070, DOI 10.1016/j.vaccine.2007.05.025
   Cunha-Neto E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00640
   Dong SS, 2015, PROTEIN CELL, V6, P351, DOI 10.1007/s13238-015-0163-3
   Ebihara H, 2011, J INFECT DIS, V204, pS991, DOI 10.1093/infdis/jir336
   Eichmann M, 2014, TISSUE ANTIGENS, V84, P378, DOI 10.1111/tan.12413
   Feldmann H, 2003, NAT REV IMMUNOL, V3, P677, DOI 10.1038/nri1154
   Frank SA, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-229
   Geisbert TW, 2003, AM J PATHOL, V163, P2347, DOI 10.1016/S0002-9440(10)63591-2
   Gilbert SC, 2012, IMMUNOLOGY, V135, P19, DOI 10.1111/j.1365-2567.2011.03517.x
   Gupta M, 2005, J IMMUNOL, V174, P4198, DOI 10.4049/jimmunol.174.7.4198
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Harndahl M, 2006, LARGE SCALE ANAL PEP
   Hensley LE, 2002, IMMUNOL LETT, V80, P169, DOI 10.1016/S0165-2478(01)00327-3
   Huber SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00171
   Jain S, 2019, MED MICROBIOL IMMUN, V208, P227, DOI 10.1007/s00430-019-00584-y
   Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258
   Julia Ponomarenko, 2015, EBOLA ANAL IMMUNITY, DOI [10.1109/aisw.2015.7469230., DOI 10.1109/AISW.2015.7469230]
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   KALIDI I, 1988, TISSUE ANTIGENS, V31, P98, DOI 10.1111/j.1399-0039.1988.tb02070.x
   Lai CY, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01571
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Leffel EK, 2004, BIOSECUR BIOTERROR, V2, P186, DOI 10.1089/15387130460759236
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Martin-Banderas L, 2005, SMALL, V1, P688, DOI 10.1002/smll.200500087
   McElroy AK, 2015, P NATL ACAD SCI USA, V112, P4719, DOI 10.1073/pnas.1502619112
   Mekibib B, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8050148
   Nfon Charles K Leung, 2013, PLOS ONE, DOI [10.1371/journal.pone.0061904., DOI /10.1371/JOURNAL.PONE.0061904]
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Oh HLJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.26
   Ohno S, 2009, VACCINE, V27, P3912, DOI 10.1016/j.vaccine.2009.04.001
   Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036
   Pereyra F, 2014, J VIROL, V88, P12937, DOI 10.1128/JVI.01004-14
   Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271
   Rasmussen M, 2014, LARGE SCALE ANAL PEP
   Rezza G, 2015, HUM VACC IMMUNOTHER, V11, P1258, DOI 10.1080/21645515.2015.1021528
   Rubsamen RM, 2014, VACCINE, V32, P4111, DOI 10.1016/j.vaccine.2014.05.071
   Sakabe S, 2018, P NATL ACAD SCI USA, V115, pE7578, DOI 10.1073/pnas.1806200115
   SETTE A, 1994, MOL IMMUNOL, V31, P813, DOI 10.1016/0161-5890(94)90019-1
   Sidney John, 2013, Curr Protoc Immunol, VChapter 18, DOI 10.1002/0471142735.im1803s100
   Sidney John, 2006, SARS IEDB ENTRIES
   Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991
   Sridhar S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00195
   Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350
   Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108
   Sylvester-Hvid C Nielsen, 2004, SCANDINAVIAN J IMMUN, V59, P632, DOI [10.1111/j.0001-2815.2004.00221.x., DOI 10.1111/J.0001-2815.2004.00221.X]
   Takamatsu Y, 2018, P NATL ACAD SCI USA, V115, P1075, DOI 10.1073/pnas.1712263115
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Trolle T, 2016, J IMMUNOL, V196, P1480, DOI 10.4049/jimmunol.1501721
   Tsao YP, 2006, BIOCHEM BIOPH RES CO, V344, P63, DOI 10.1016/j.bbrc.2006.03.152
   Vita R, 2014, NUCL ACIDS RES
   Vogel OA, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00135
   Wan W, 2017, NATURE, V551, P394, DOI 10.1038/nature24490
   Wang FM, 1998, P NATL ACAD SCI USA, V95, P5217, DOI 10.1073/pnas.95.9.5217
   Warfield KL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118881
   Warfield KL, 2003, P NATL ACAD SCI USA, V100, P15889, DOI 10.1073/pnas.2237038100
   Wauquier N, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000837
   Weber DJ, 2013, VACCINES, V6
   Wilson JA, 2001, J VIROL, V75, P2660, DOI 10.1128/JVI.75.6.2660-2664.2001
   Wu G, 2005, J MOL MODEL, V11, P8, DOI 10.1007/s00894-004-0210-0
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
   Zhang LQ, 2006, J MED VIROL, V78, P1, DOI 10.1002/jmv.20499
   Zhao LX, 2013, HUM VACC IMMUNOTHER, V9, P2566, DOI 10.4161/hv.26088
   Zhou MH, 2006, J IMMUNOL, V177, P2138, DOI 10.4049/jimmunol.177.4.2138
NR 77
TC 4
Z9 4
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUN 9
PY 2020
VL 38
IS 28
BP 4464
EP 4475
DI 10.1016/j.vaccine.2020.04.034
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LT8KO
UT WOS:000537316500015
PM 32418793
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Borkotoky, S
   Banerjee, M
AF Borkotoky, Subhomoi
   Banerjee, Manidipa
TI A computational prediction of SARS-CoV-2 structural protein inhibitors
   fromAzadirachta indica(Neem)
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; natural compound; docking; molecular dynamics simulation;
   MM-PBSA
ID CORONAVIRUS-E-PROTEIN; IN-VITRO; MEMBRANE; TOOL; EXPRESSION; DOMAIN;
   MODEL; PORE
AB The rapid global spread of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has created an unprecedented healthcare crisis. The treatment for the severe respiratory illness caused by this virus is primarily symptomatic at this point, although the usage of a broad antiviral drug Remdesivir has been allowed on emergency basis by the Food and Drug Administration (FDA). The ever-increasing death toll highlights an urgent need for development of specific antivirals. In this work, we have utilized docking and simulation methods to identify small molecule inhibitors of SARS-CoV-2 Membrane (M) and Envelope (E) proteins, which are essential for virus assembly and budding. A total of 70 compounds from an Indian medicinal plant source (Azadirachta indicaor Neem) were virtually screened against these two proteins and further analyzed with molecular dynamics simulations, which resulted in the identification of a few common compounds with strong binding to both structural proteins. The compounds bind to biologically critical regions of M and E, indicating their potential to inhibit the functionality of these components. We hope that our computational approach may result in the identification of effective inhibitors of SARS-CoV-2 assembly. Communicated by Ramaswamy H. Sarma
C1 [Borkotoky, Subhomoi; Banerjee, Manidipa] Indian Inst Technol Delhi, Kusuma Sch Biol Sci, New Delhi, India.
RP Banerjee, M (corresponding author), Indian Inst Technol Delhi, Kusuma Sch Biol Sci, New Delhi, India.
EM mbanerjee@bioschool.iitd.ac.in
OI Borkotoky, Subhomoi/0000-0001-6752-4296
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   Akram M, 2018, PHYTOTHER RES, V32, P811, DOI 10.1002/ptr.6024
   Alzohairy MA, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/7382506
   Arndt AL, 2010, J VIROL, V84, P11418, DOI 10.1128/JVI.01131-10
   Badam Lalita, 1999, Journal of Communicable Diseases, V31, P79
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Barrett J., 2020, FDA ISSUES EMERGENCY
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   Bhattacharya D, 2016, NUCLEIC ACIDS RES, V44, pW406, DOI 10.1093/nar/gkw336
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   HENDAUS MA, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1767691
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Jimenez-Guardeno JM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004320
   Kawata M, 2001, CHEM PHYS LETT, V340, P165, DOI 10.1016/S0009-2614(01)00393-1
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Kuo L, 2016, J VIROL, V90, P4357, DOI 10.1128/JVI.03212-15
   Martonak R, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.075503
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   MOHANRAJ K, 2018, SCI REP UK, V8, DOI DOI https://doi.org/10.1038/s41598-018-22631-z
   Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Patridge E, 2016, DRUG DISCOV TODAY, V21, P204, DOI 10.1016/j.drudis.2015.01.009
   Perrier A, 2019, J BIOL CHEM, V294, P14406, DOI 10.1074/jbc.RA119.008964
   Pervushin K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000511
   Rajkumari J, 2018, MICROB PATHOGENESIS, V118, P48, DOI 10.1016/j.micpath.2018.03.012
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Salmas RE, 2017, J BIOMOL STRUCT DYN, V35, P1899, DOI 10.1080/07391102.2016.1199328
   SARKAR L, 2020, FRONT CELL NEUROSCI, V14, DOI DOI https://doi.org/10.3389/fncel.2020.00116
   SCHOEMAN D, 2019, VIROL J, V16, DOI DOI https://doi.org/10.1186/s12985-019-1182-0
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Surya W, 2018, BBA-BIOMEMBRANES, V1860, P1309, DOI 10.1016/j.bbamem.2018.02.017
   Teoh KT, 2010, MOL BIOL CELL, V21, P3838, DOI 10.1091/mbc.E10-04-0338
   Thomford NE, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061578
   Tiwari V, 2010, PHYTOTHER RES, V24, P1132, DOI 10.1002/ptr.3085
   Torres J, 2007, PROTEIN SCI, V16, P2065, DOI 10.1110/ps.062730007
   Torres J, 2006, BIOPHYS J, V91, P938, DOI 10.1529/biophysj.105.080119
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Verdia-Baguena C, 2012, VIROLOGY, V432, P485, DOI 10.1016/j.virol.2012.07.005
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang Y, 2005, BIOCHEM J, V392, P135, DOI 10.1042/BJ20050698
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 55
TC 5
Z9 5
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1774419
EA JUN 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MF1BS
UT WOS:000545086200001
PM 32462988
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Chandra, A
   Gurjar, V
   Qamar, I
   Singh, N
AF Chandra, Anshuman
   Gurjar, Vaishali
   Qamar, Imteyaz
   Singh, Nagendra
TI Identification of potential inhibitors of SARS-COV-2 endoribonuclease
   (EndoU) from FDA approved drugs: a drug repurposing approach to find
   therapeutics for COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; endonuclease; drug repurposing; molecular dynamic
   simulation; binding affinity; IC50
ID CORONAVIRUS ENDORIBONUCLEASE; HIGH-THROUGHPUT; SOFTWARE NEWS; GROMACS;
   PROTEIN; ZINC; TOOL
AB SARS-CoV-2 is causative agent of COVID-19, which is responsible for severe social and economic disruption globally. Lack of vaccine or antiviral drug with clinical efficacy suggested that drug repurposing approach may provide a quick therapeutic solution to COVID-19. Nonstructural protein-15 (NSP15) encodes for an uridylate-specific endoribonuclease (EndoU) enzyme, essential for virus life cycle and an attractive target for drug development. We have performedin silicobased virtual screening of FDA approved compounds targeting EndoU in search of COVID-19 drugs from commercially available approved molecules. Two drugs Glisoxepide and Idarubicin used for treatment for diabetes and leukemia, respectively, were selected as stronger binder of EndoU. Both the drugs bound to the active site of the viral endonuclease by forming attractive intermolecular interactions with catalytically essential amino acid residues, His235, His250, and Lys290. Molecular dynamics simulation studies showed stable conformation dynamics upon drugs binding to endoU. The binding free energies for Glisoxepide and Idarubicin were calculated to be -141 +/- 11 and -136 +/- 16 kJ/mol, respectively. The IC(50)were predicted to be 9.2 mu M and 30 mu M for Glisoxepide and Idarubicin, respectively. Comparative structural analysis showed the stronger binding of EndoU to Glisoxepide and Idarubicin than to uridine monophosphate (UMP). Surface area calculations showed buried are of 361.8 angstrom(2)by Glisoxepide which is almost double of the area occupied by UMP suggesting stronger binding of the drug than the ribonucleotide. However, further studies on these drugs for evaluation of their clinical efficacy and dose formulations may be required, which may provide a quick therapeutic option to treat COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Chandra, Anshuman; Qamar, Imteyaz; Singh, Nagendra] Gautam Buddha Univ, Sch Biotechnol, Greater Noida 201312, Uttar Pradesh, India.
   [Gurjar, Vaishali] Savitri Bai Phule Balika Inter Coll, Greater Noida, Uttar Pradesh, India.
RP Singh, N (corresponding author), Gautam Buddha Univ, Sch Biotechnol, Greater Noida 201312, Uttar Pradesh, India.
EM nagendratomar@gmail.com
OI Singh, Nagendra/0000-0003-0419-0684
FU Indian Council of Medical Research (ICMR)Indian Council of Medical
   Research (ICMR); Ministry of Health and Family Welfare, Govt. of India
   [BIC/12(31)/2012]; Council of Scientific and Industrial Research (CSIR),
   Human Resource Development Group (HRDG), India [37(1668)-16-EMR-II]
FX We are thankful to the Indian Council of Medical Research (ICMR),
   Ministry of Health and Family Welfare, Govt. of India [BIC/12(31)/2012]
   and Council of Scientific and Industrial Research (CSIR), Human Resource
   Development Group (HRDG), India [37(1668)-16-EMR-II].
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   ADEOYE AO, 2020, J BIOMOL STRUCT 0514, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1765876
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   BABADAEI MMN, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1767210
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767211
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Basiri M.R., 2020, J PHARM PHARMACOL, V8, P89, DOI [10.17265/2328-2150/2020.03.004., DOI 10.17265/2328-2150/2020.03.004]
   Bhardwaj K, 2004, J VIROL, V78, P12218, DOI 10.1128/JVI.78.22.12218-12224.2004
   Bhardwaj K, 2008, J BIOL CHEM, V283, P3655, DOI 10.1074/jbc.M708375200
   Bhardwaj K, 2006, J MOL BIOL, V361, P243, DOI 10.1016/j.jmb.2006.06.021
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Cascella M, 2020, FEATURES EVALUATION
   Chetri PB, 2019, PARASITOL RES, V118, P861, DOI 10.1007/s00436-019-06225-w
   Corkery DP, 2015, NUCLEUS-PHILA, V6, P279, DOI 10.1080/19491034.2015.1062194
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Deng XF, 2018, VIROLOGY, V517, P157, DOI 10.1016/j.virol.2017.12.024
   ELASNAOUI K, 2020, J BIOMOL STRUCT 0521, DOI DOI https://doi.org/10.1080/07391102.2020.1767212
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Fu TT, 2018, ACS CHEM NEUROSCI, V9, P1492, DOI 10.1021/acschemneuro.8b00059
   FUKUSHIMA T, 1993, INT J HEMATOL, V57, P121
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Hongjian Li, 2012, 2012 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), P77, DOI 10.1109/CIBCB.2012.6217214
   HU XP, 2017, J MOL MODEL, V23, DOI DOI https://doi.org/10.1007/s00894-017-3329-5
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   KIM Y, 2020, PROTEIN SCI 0502, DOI DOI https://doi.org/10.1002/pro.3873
   Kim Y., 2020, RCSB PDB 6WLC CRYSTA
   Koes DR, 2013, J CHEM INF MODEL, V53, P1893, DOI 10.1021/ci300604z
   KUMAR D, 2020, J BIOMOL STRUCT 0503, DOI DOI https://doi.org/10.1080/07391102.2020.1752310
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Liu XR, 2019, MOL IMMUNOL, V114, P100, DOI 10.1016/j.molimm.2019.07.003
   LOBOGALO N, 2020, J BIOMOL STRUCT 0513, DOI DOI https://doi.org/10.1080/07391102.2020.1764393
   Mahanta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768902
   MITTAL L, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768151
   Moesgaard L, 2020, J CHEM INF MODEL, V60, P2268, DOI 10.1021/acs.jcim.0c00086
   MOHAMMAD T, 2020, MOLECULES, V25, DOI DOI https://doi.org/10.3390/molecules25040823
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Ricagno S, 2006, P NATL ACAD SCI USA, V103, P11892, DOI 10.1073/pnas.0601708103
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Seino S, 2012, DIABETOLOGIA, V55, P2096, DOI 10.1007/s00125-012-2562-9
   SHUKLA R, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758787
   Shukla R, 2020, J BIOMOL STRUCT DYN, V38, P248, DOI 10.1080/07391102.2019.1571947
   Shukla R, 2018, TUBERCULOSIS, V108, P143, DOI 10.1016/j.tube.2017.11.013
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768149
   Steffen C, 2010, J COMPUT CHEM, V31, P2967, DOI 10.1002/jcc.21576
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vijgen L, 2005, J VIROL, V79, P1595, DOI 10.1128/JVI.79.3.1595-1604.2005
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   Xue WW, 2018, ACS CHEM NEUROSCI, V9, P1128, DOI 10.1021/acschemneuro.7b00490
NR 65
TC 0
Z9 1
U1 3
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1775127
EA JUN 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MD0TP
UT WOS:000543689600001
PM 32462970
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Maya, EAL
   van der Graaf, A
   Lanting, P
   van der Geest, M
   Fu, JY
   Swertz, M
   Franke, L
   Wijmenga, C
   Deelen, P
   Zhernakova, A
   Sanna, S
AF Maya, Esteban A. Lopera
   van der Graaf, Adriaan
   Lanting, Pauline
   van der Geest, Marije
   Fu, Jingyuan
   Swertz, Morris
   Franke, Lude
   Wijmenga, Cisca
   Deelen, Patrick
   Zhernakova, Alexandra
   Sanna, Serena
CA Lifelines Cohort Study
TI Lack of Association Between Genetic Variants at ACE2 and TMPRSS2 Genes
   Involved in SARS-CoV-2 Infection and Human Quantitative Phenotypes
SO FRONTIERS IN GENETICS
LA English
DT Article
DE PheWAS; ACE2; TMPRSS2; NSAIDs (non-steroidal anti-inflammatory drugs);
   ARBs (angiotensin II receptor blockers); COVID-19; SARS-CoV-2
ID GENOME-WIDE ASSOCIATION; COMBINATION THERAPY; RECEPTOR BLOCKERS;
   FETAL-HEMOGLOBIN; BCL11A
AB Coronavirus disease 2019 (COVID-19) shows a wide variation in expression and severity of symptoms, from very mild or no symptoms, to flu-like symptoms, and in more severe cases, to pneumonia, acute respiratory distress syndrome, and even death. Large differences in outcome have also been observed between males and females. The causes for this variability are likely to be multifactorial, and to include genetics. The SARS-CoV-2 virus responsible for the infection depends on two human genes: the human receptor angiotensin converting enzyme 2 (ACE2) for cell invasion, and the serine proteaseTMPRSS2for S protein priming. Genetic variation in these two genes may thus modulate an individual's genetic predisposition to infection and virus clearance. While genetic data on COVID-19 patients is being gathered, we carried out a phenome-wide association scan (PheWAS) to investigate the role of these genes in other human phenotypes in the general population. We examined 178 quantitative phenotypes including cytokines and cardio-metabolic biomarkers, as well as usage of 58 medications in 36,339 volunteers from the Lifelines population cohort, in relation to 1,273 genetic variants located in or nearACE2andTMPRSS2. While none reached our threshold for significance, we observed several interesting suggestive associations. For example, single nucleotide polymorphisms (SNPs) near theTMPRSS2genes were associated with thrombocytes count (p= 1.8 x 10(-5)). SNPs within theACE2gene were associated with (1) the use of angiotensin II receptor blockers (ARBs) combination therapies (p= 5.7 x 10(-4)), an association that is significantly stronger in females (p(diff)= 0.01), and (2) with the use of non-steroid anti-inflammatory and antirheumatic products (p= 5.5 x 10(-4)). While these associations need to be confirmed in larger sample sizes, they suggest that these variants could play a role in diseases such as thrombocytopenia, hypertension, and chronic inflammation that are often observed in the more severe COVID-19 cases. Further investigation of these genetic variants in the context of COVID-19 is thus promising for better understanding of disease variability. Full results are available at https://covid19research.nl.
C1 [Maya, Esteban A. Lopera; van der Graaf, Adriaan; Lanting, Pauline; van der Geest, Marije; Fu, Jingyuan; Swertz, Morris; Franke, Lude; Wijmenga, Cisca; Deelen, Patrick; Zhernakova, Alexandra; Sanna, Serena] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.
   [Fu, Jingyuan] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands.
   [Deelen, Patrick] Univ Med Ctr Utrecht, Dept Genet, Utrecht, Netherlands.
   [Sanna, Serena] Consiglio Nazl Ric CNR, Inst Genet & Biomed Res IRGB, Monserrato, Italy.
RP Sanna, S (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.; Sanna, S (corresponding author), Consiglio Nazl Ric CNR, Inst Genet & Biomed Res IRGB, Monserrato, Italy.
EM serena.sanna@irgb.cnr.it
RI Fu, Jingyuan/E-8980-2012; Zhernakova, Alexandra/ABA-9372-2020; Fu,
   Jingyuan/ABE-6868-2020
OI Fu, Jingyuan/0000-0001-5578-1236; Lopera Maya, Esteban
   Alexander/0000-0001-5862-3938; Lanting, Pauline/0000-0002-7288-4445
FU Netherlands Organization for Scientific Research (NWO)Netherlands
   Organization for Scientific Research (NWO) [SPI 92-266]; Dutch Ministry
   of Health, Welfare and Sport; Dutch Ministry of Economic AffairsMinistry
   of Economic Affairs, Netherlands; University Medical Center Groningen
   (UMCG the Netherlands); University of Groningen; UMCG Genetics Lifelines
   Initiative (UGLI); NWO Gravitation Netherlands Organ-on-Chip Initiative
   [024.003.001]; Netherlands Heart Foundation CVON grant [2018-27];
   EOSC-Life - European Union [824087]; NWO-VIDINetherlands Organization
   for Scientific Research (NWO) [016.178.056, VIDI 917.164.455];
   ERCEuropean Research Council (ERC) [715772]; NWO Gravitation grant
   ExposomeNL [024.004.017]
FX This work was supported by the Netherlands Organization for Scientific
   Research (NWO): NWO Spinoza Prize SPI 92-266 (to CW). The Lifelines
   Biobank initiative has been made possible by funding from the Dutch
   Ministry of Health, Welfare and Sport; the Dutch Ministry of Economic
   Affairs; the University Medical Center Groningen (UMCG the Netherlands);
   the University of Groningen and the Northern Provinces of the
   Netherlands. The generation and management of GWAS genotype data for the
   Lifelines Cohort Study was supported by the UMCG Genetics Lifelines
   Initiative (UGLI). JF was supported by NWO Gravitation Netherlands
   Organ-on-Chip Initiative (024.003.001) and the Netherlands Heart
   Foundation CVON grant 2018-27. MS was supported by EOSC-Life, funded by
   European Union's Horizon 2020 programme under grant agreement 824087 and
   NWO-VIDI grant VIDI 917.164.455. AZ was supported by ERC Starting Grant
   715772, NWO-VIDI grant 016.178.056, the Netherlands Heart Foundation
   CVON grant 2018-27, and NWO Gravitation grant ExposomeNL (024.004.017).
CR Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6
   Flack JM, 2007, INT J CLIN PRACT, V61, P2093, DOI 10.1111/j.1742-1241.2007.01577.x
   Francioli LC, 2015, NAT GENET, V47, P822, DOI 10.1038/ng.3292
   Gill D, 2020, ACE INHIBITION CARDI, DOI [10.1101/2020.04.10.20059121, DOI 10.1101/2020.04.10.20059121]
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Lettre G, 2008, P NATL ACAD SCI USA, V105, P11869, DOI 10.1073/pnas.0804799105
   Little P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1185
   Lopera E, 2020, LACK ASS GENETIC VAR, DOI [10.1101/2020.04.22.20074963, DOI 10.1101/2020.04.22.20074963]
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mas S, 2011, PHARMACOGENET GENOM, V21, P531, DOI 10.1097/FPC.0b013e328348c6db
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Menzel S, 2007, NAT GENET, V39, P1197, DOI 10.1038/ng2108
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Ram CVS, 2004, AM J HYPERTENS, V17, P277, DOI 10.1016/j.amjhyper.2003.09.002
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Scholtens S, 2015, INT J EPIDEMIOL, V44, P1172, DOI 10.1093/ije/dyu229
   Sediq R, 2018, CLIN EPIDEMIOL, V10, P981, DOI 10.2147/CLEP.S163037
   Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2
   Tigchelaar EF, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006772
   Uda M, 2008, P NATL ACAD SCI USA, V105, P1620, DOI 10.1073/pnas.0711566105
   van der Velde KJ, 2019, BIOINFORMATICS, V35, P1076, DOI 10.1093/bioinformatics/bty742
   Weilang Q., 2019, POWER CALCULATION TE
   Winkler TW, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005378
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zheng XW, 2017, BIOINFORMATICS, V33, P2251, DOI 10.1093/bioinformatics/btx145
   Zhernakova A, 2016, SCIENCE, V352, P565, DOI 10.1126/science.aad3369
   Zhernakova DV, 2018, NAT GENET, V50, P1524, DOI 10.1038/s41588-018-0224-7
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou W, 2018, NAT GENET, V50, P1335, DOI 10.1038/s41588-018-0184-y
NR 36
TC 5
Z9 5
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD JUN 8
PY 2020
VL 11
AR 613
DI 10.3389/fgene.2020.00613
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA MC8JY
UT WOS:000543527200001
PM 32582302
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mina, MJ
   Metcalf, CJE
   McDermott, AB
   Douek, DC
   Farrar, J
   Grenfell, BT
AF Mina, Michael J.
   Metcalf, C. Jessica E.
   McDermott, Adrian B.
   Douek, Daniel C.
   Farrar, Jeremy
   Grenfell, Bryan T.
TI A Global Immunological Observatory to meet a time of pandemics
SO ELIFE
LA English
DT Article
AB SARS-CoV-2 presents an unprecedented international challenge, but it will not be the last such threat. Here, we argue that the world needs to be much better prepared to rapidly detect, define and defeat future pandemics. We propose that a Global Immunological Observatory and associated developments in systems immunology, therapeutics and vaccine design should be at the heart of this enterprise.
C1 [Mina, Michael J.] Harvard Sch Publ Hlth, Ctr Communicable Dis Dynam, Dept Epidemiol, Boston, MA 02115 USA.
   [Mina, Michael J.] Harvard Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Mina, Michael J.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
   [Metcalf, C. Jessica E.; Grenfell, Bryan T.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.
   [Metcalf, C. Jessica E.; Grenfell, Bryan T.] Princeton Univ, Woodrow Wilson Sch, Princeton, NJ 08544 USA.
   [McDermott, Adrian B.; Douek, Daniel C.] NIH, Vaccine Res Ctr, Bldg 10, Bethesda, MD 20892 USA.
   [Farrar, Jeremy] Wellcome Trust Res Labs, London, England.
   [Grenfell, Bryan T.] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
RP Mina, MJ (corresponding author), Harvard Sch Publ Hlth, Ctr Communicable Dis Dynam, Dept Epidemiol, Boston, MA 02115 USA.; Mina, MJ (corresponding author), Harvard Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.; Mina, MJ (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.; Metcalf, CJE (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.; Metcalf, CJE (corresponding author), Princeton Univ, Woodrow Wilson Sch, Princeton, NJ 08544 USA.
EM mmina@hsph.harvard.edu; cmetcalf@princeton.edu
RI McDermott, Adrian B/E-7306-2011
OI Grenfell, Bryan/0000-0003-3227-5909; Mina, Michael/0000-0002-0674-5762
FU NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [DP5 OD028145] Funding Source: Medline
CR Carroll D, 2018, SCIENCE, V359, P872, DOI 10.1126/science.aap7463
   Daszak Peter, 2020, Biosaf Health, V2, P6, DOI 10.1016/j.bsheal.2020.01.003
   Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727
   Khan Saahir, 2020, bioRxiv, DOI 10.1101/2020.03.24.006544
   Kula T, 2019, CELL, V178, P1016, DOI 10.1016/j.cell.2019.07.009
   Metcalf CJE, 2017, LANCET, V389, P252, DOI 10.1016/S0140-6736(17)30054-5
   Metcalf CJE, 2016, LANCET, V388, P728, DOI 10.1016/S0140-6736(16)30164-7
   Morris DH, 2018, TRENDS MICROBIOL, V26, P102, DOI 10.1016/j.tim.2017.09.004
   Xu GJ, 2015, SCIENCE, V348, DOI 10.1126/science.aaa0698
NR 9
TC 3
Z9 3
U1 0
U2 0
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD JUN 8
PY 2020
VL 9
AR e58989
DI 10.7554/eLife.58989
PG 5
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA MA1WG
UT WOS:000541707700001
PM 32510329
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chaccour, C
   Ruiz-Castillo, P
   Richardson, MA
   Moncunill, G
   Casellas, A
   Carmona-Torre, F
   Giraldez, M
   Mota, JS
   Yuste, JR
   Azanza, JR
   Fernandez, M
   Reina, G
   Dobano, C
   Brew, J
   Sadaba, B
   Hammann, F
   Rabinovich, R
AF Chaccour, Carlos
   Ruiz-Castillo, Paula
   Richardson, Mary-Ann
   Moncunill, Gemma
   Casellas, Aina
   Carmona-Torre, Francisco
   Giraldez, Miriam
   Schwartz Mota, Juana
   Ramon Yuste, Jose
   Ramon Azanza, Jose
   Fernandez, Miriam
   Reina, Gabriel
   Dobano, Carlota
   Brew, Joe
   Sadaba, Belen
   Hammann, Felix
   Rabinovich, Regina
TI The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the
   Potential of Ivermectin to Reduce COVID-19 Transmission in low risk,
   non-severe COVID-19 patients in the first 48 hours after symptoms onset:
   A structured summary of a study protocol for a randomized control pilot
   trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; SARS-CoV-2; PCR; early
   treatment; ivermectin; antiviral; immunomodulatory;
   transmission-blocking
AB ObjectivesThe primary objective is to determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of patients with detectable SARS-CoV-2 RNA by Polymerase Chain Reaction (PCR) test from nasopharyngeal swab at day 7 post-treatment.The secondary objectives are: To assess the efficacy of ivermectin to reduce the SARS-CoV-2 viral load in the nasopharyngeal swab at day 7 post treatment.To assess the efficacy of ivermectin to improve symptom progression in treated patients.To assess the proportion of seroconversions in treated patients at day 21.To assess the safety of ivermectin at the proposed dose.To determine the magnitude of immune response against SARS-CoV-2.To assess the early kinetics of immunity against SARS-CoV-2.Trial designSAINT is a single centre, double-blind, randomized, placebo-controlled, superiority trial with two parallel arms. Participants will be randomized to receive a single dose of 400 mu g/kg ivermectin or placebo, and the number of patients in the treatment and placebo groups will be the same (1:1 ratio).ParticipantsThe population for the study will be patients with a positive nasopharyngeal swab PCR test for SARS-CoV-2, with non-severe COVID-19 disease, and no risk factors for progression to severity. Vulnerable populations such as pregnant women, minors (i.e.; under 18 years old), and seniors (i.e.; over 60 years old) will be excluded.Inclusion criteriaPatients diagnosed with COVID-19 in the emergency room of the Clinica Universidad de Navarra (CUN) with a positive SARS-CoV-2 PCR.Residents of the Pamplona basin ("Cuenca de Pamplona").The patient must be between the ages of 18 and 60 years of age.Negative pregnancy test for women of child bearing age*.The patient or his/her representative, has given informed consent to participate in the study.The patient should, in the PI's opinion, be able to comply with all the requirements of the clinical trial (including home follow up during isolation).Exclusion criteriaKnown history of ivermectin allergy.Hypersensitivity to any component of ivermectin.COVID-19 pneumonia. Diagnosed by the attending physician.Identified in a chest X-ray.Fever or cough present for more than 48 hours.Positive IgG against SARS-CoV-2 by rapid diagnostic test.Age under 18 or over 60 years.The following co-morbidities (or any other disease that might interfere with the study in the eyes of the PI): Immunosuppression.Chronic Obstructive Pulmonary Disease.Diabetes.Hypertension.Obesity.Acute or chronic renal failure.History of coronary disease.History of cerebrovascular disease.Current neoplasm.Recent travel history to countries that are endemic for (Angola, Cameroon, Central African Republic, Chad, Democratic Republic of Congo, Ethiopia, Equatorial, Guinea, Gabon, Republic of Congo, Nigeria and Sudan).Loa loaCurrent use of CYP 3A4 or P-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. Use of critical CYP3A4 substrate drugs such as warfarin.*Women of child bearing age may participate if they use a safe contraceptive method for the entire period of the study and at least one month afterwards. A woman is considered to not have childbearing capacity if she is post-menopausal (minimum of 2 years without menstruation) or has undergone surgical sterilization (at least one month before the study).
   The trial is currently planned at a single center, Clinica Universidad de Navarra, in Navarra (Spain), and the immunology samples will be analyzed at the Barcelona Institute for Global Health (ISGlobal), in Barcelona (Spain). Participants will be recruited by the investigators at the emergency room and/or COVID-19 area of the CUN. They will remain in the trial for a period of 28 days at their homes since they will be patients with mild disease. In the interest of public health and to contain transmission of infection, follow-up visits will be conducted in the participant's home by a clinical trial team comprising nursing and medical members. Home visits will assess clinical and laboratory parameters of the patients.Intervention and comparatorIvermectin will be administered to the treatment group at a 400 mu g/Kg dose (included in the EU approved label of Stromectol and Scabioral). The control group will receive placebo. There is no current data on the efficacy of ivermectin against the virus in vivo, therefore the use of placebo in the control group is ethically justified.Main outcomesPrimaryProportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment.Secondary Mean viral load as determined by PCR cycle threshold (Ct) at baseline and on days 4, 7, 14, and 21.Proportion of patients with fever and cough at days 4, 7, 14, and 21 as well as proportion of patients progressing to severe disease or death during the trial.Proportion of patients with seroconversion at day 21.Proportion of drug-related adverse events during the trial.Median levels of IgG, IgM, IgA measured by Luminex, frequencies of innate and SARS-CoV-2-specific T cells assessed by flow cytometry, median levels of inflammatory and activation markers measured by Luminex and transcriptomics.Median kinetics of IgG, IgM, IgA levels during the trial, until day 28.RandomisationEligible patients will be allocated in a 1:1 ratio using a randomization list generated by the trial statistician using blocks of four to ensure balance between the groups. A study identification code with the format "SAINT-##" (##: from 01 to 24) will be generated using a sequence of random numbers so that the randomization number does not match the subject identifier. The sequence and code used will be kept in an encrypted file accessible only to the trial statistician. A physical copy will be kept in a locked cabinet at the CUN, accessible only to the person administering the drug who will not enrol or attend to patient care. A separate set of 24 envelopes for emergency unblinding will be kept in the study file.Blinding (masking)The clinical trial team and the patients will be blinded. The placebo will not be visibly identical, but it will be administered by staff not involved in the clinical care or participant follow up.Numbers to be randomised (sample size)The sample size is 24 patients: 12 participants will be randomised to the treatment group and 12 participants to the control group.Trial StatusCurrent protocol version: 1.0 dated 16 of April 2020.Recruitment is envisioned to begin by May 14th and end by June 14th.Trial registrationEudraCT number: 2020-001474-29, registered April 1(st).Clinicaltrials.gov: submitted, pending numberFull protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Chaccour, Carlos; Ruiz-Castillo, Paula; Richardson, Mary-Ann; Moncunill, Gemma; Casellas, Aina; Carmona-Torre, Francisco; Giraldez, Miriam; Schwartz Mota, Juana; Ramon Yuste, Jose; Ramon Azanza, Jose; Fernandez, Miriam; Reina, Gabriel; Dobano, Carlota; Brew, Joe; Sadaba, Belen; Hammann, Felix; Rabinovich, Regina] Inst Salud Global Barcelona, Barcelona, Spain.
RP Chaccour, C (corresponding author), Inst Salud Global Barcelona, Barcelona, Spain.
EM carlos.chaccour@isglobal.org
RI Casellas, Aina/Q-1247-2016; Carmona-Torre, Francisco/Q-4438-2016;
   Moncunill, Gemma/B-7989-2011; Chaccour, Carlos/I-4149-2018
OI Casellas, Aina/0000-0003-4939-8411; Carmona-Torre,
   Francisco/0000-0002-8281-9583; Moncunill, Gemma/0000-0001-5105-9836;
   Hammann, Felix/0000-0003-0658-9330; Chaccour, Carlos/0000-0001-9812-050X
FU Barcelona Institute for Global Health (ISGlobal); Clinica Universidad de
   Navarra (CUN)
FX This study is funded by the Barcelona Institute for Global Health
   (ISGlobal) and the Clinica Universidad de Navarra (CUN). The placebo was
   contributed in kind by Idifarma.; The sponsor is a center of a
   non-for-profit academic institution. Some of the authors of this
   protocol and those participating in data collection, analysis,
   interpretation and report are employees of the sponsor.
NR 0
TC 1
Z9 1
U1 13
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 8
PY 2020
VL 21
IS 1
AR 498
DI 10.1186/s13063-020-04421-z
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LZ3AA
UT WOS:000541098100007
PM 32513289
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Eckhardt, CM
   Cummings, MJ
   Rajagopalan, KN
   Borden, S
   Bitan, ZC
   Wolf, A
   Kantor, A
   Briese, T
   Meyer, BJ
   Jacobson, SD
   Scotto, D
   Mishra, N
   Philip, NM
   Stotler, BA
   Schwartz, J
   Shaz, B
   Spitalnik, SL
   Eisenberg, A
   Hod, EA
   Justman, J
   Cheung, K
   Lipkin, WI
   O'Donnell, MR
AF Eckhardt, Christina M.
   Cummings, Matthew J.
   Rajagopalan, Kartik N.
   Borden, Sarah
   Bitan, Zachary C.
   Wolf, Allison
   Kantor, Alex
   Briese, Thomas
   Meyer, Benjamin J.
   Jacobson, Samuel D.
   Scotto, Dawn
   Mishra, Nischay
   Philip, Neena M.
   Stotler, Brie A.
   Schwartz, Joseph
   Shaz, Beth
   Spitalnik, Steven L.
   Eisenberg, Andrew
   Hod, Eldad A.
   Justman, Jessica
   Cheung, Ken
   Lipkin, W. Ian
   O'Donnell, Max R.
TI Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent
   plasma in severely ill adults with COVID-19: A structured summary of a
   study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; SARS-CoV-2; Respiratory Failure; Randomized controlled trial;
   Protocol; Convalescent Plasma; Anti-SARS-CoV-2 plasma
AB ObjectivesThe aim of this study is to evaluate the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection.Trial DesignThis is a prospective, single-center, phase 2, randomized, controlled trial that is blinded to participants and clinical outcome assessor.ParticipantsEligible participants include adults (>= 18 years) with evidence of SARS-CoV-2 infection by PCR test of nasopharyngeal or oropharyngeal swab within 14 days of randomization, evidence of infiltrates on chest radiography, peripheral capillary oxygen saturation (SpO2) <= 94% on room air, and/or need for supplemental oxygen, non-invasive mechanical ventilation, or invasive mechanical ventilation, who are willing and able to provide written informed consent prior to performing study procedures or who have a legally authorized representative available to do so. Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 <24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for >= 5 days, severe multi-organ failure, history of allergic reactions to transfused blood products per NHSN/CDC criteria, known IgA deficiency, and pregnancy. Included participants will be hospitalized at the time of randomization and plasma infusion.*Use of remdesivir as treatment for COVID-19 is permitted.The study will be undertaken at Columbia University Irving Medical Center in New York, USA.Intervention and comparatorThe investigational treatment is anti-SARS-CoV-2 human convalescent plasma. To procure the investigational treatment, volunteers who recovered from COVID-19 will undergo testing to confirm the presence of anti-SARS-CoV-2 antibody to the spike trimer at a 1:400 dilution. Donors will also be screened for transfusion-transmitted infections (e.g. HIV, HBV, HCV, WNV, HTLV-I/II, T. cruzi, ZIKV). If donors have experienced COVID-19 symptoms within 28 days, they will be screened with a nasopharyngeal swab to confirm they are SARS-CoV-2 PCR-negative. Plasma will be collected using standard apheresis technology by the New York Blood Center. Study participants will be randomized in a 2:1 ratio to receive one unit (200 - 250 mL) of anti-SARS-CoV-2 plasma versus one unit (200 - 250 mL) of the earliest available control plasma. The control plasma cannot be tested for presence of anti-SARS-CoV-2 antibody prior to the transfusion, but will be tested for anti- SARS-CoV-2 antibody after the transfusion to allow for a retrospective per-protocol analysis.Main outcomesThe primary endpoint is time to clinical improvement. This is defined as time from randomization to either discharge from the hospital or improvement by one point on the following seven-point ordinal scale, whichever occurs first.1. Not hospitalized with resumption of normal activities2. Not hospitalized, but unable to resume normal activities3. Hospitalized, not requiring supplemental oxygen4. Hospitalized, requiring supplemental oxygen5. Hospitalized, requiring high-flow oxygen therapy or non-invasive mechanical ventilation6. Hospitalized, requiring ECMO, invasive mechanical ventilation, or both7. DeathThis scale, designed to assess clinical status over time, was based on that recommended by the World Health Organization for use in determining efficacy end-points in clinical trials in hospitalized patients with COVID-19.
   A recent clinical trial evaluating the efficacy and safety of lopinavir- ritonavir for patients hospitalized with severe COVID-19 used a similar ordinal scale, as have recent clinical trials of novel therapeutics for severe influenza, including a post-hoc analysis of a trial evaluating immune plasma.The primary safety endpoints are cumulative incidence of grade 3 and 4 adverse events and cumulative incidence of serious adverse events during the study period.RandomizationStudy participants will be randomized in a 2:1 ratio to receive anti-SARS-CoV-2 plasma versus control plasma using a web-based randomization platform. Treatment assignments will be generated using randomly permuted blocks of different sizes to minimize imbalance while also minimizing predictability.Blinding (masking)The study participants and the clinicians who will evaluate post-treatment outcomes will be blinded to group assignment. The blood bank and the clinical research team will not be blinded to group assignment.Numbers to be randomized (sample size)We plan to enroll 129 participants, with 86 in the anti-SARS-CoV-2 arm, and 43 in the control arm. Among the participants, we expect 70% or n = 72 will achieve clinical improvement. This will yield an 80% power for a one-sided Wald test at 0.15 level of significance under the proportional hazards model with a hazard ratio of 1.5.Trial StatusProtocol AAAS9924, Version 17APR2020, 4/17/2020Start of recruitment: April 20, 2020Recruitment is ongoing.Trial registrationClinicalTrials.gov: NCT04359810Date of trial registration: April 24, 2020Retrospectively registeredFull protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Eckhardt, Christina M.; Cummings, Matthew J.; Rajagopalan, Kartik N.; Borden, Sarah; Bitan, Zachary C.; Wolf, Allison; Kantor, Alex; Briese, Thomas; Meyer, Benjamin J.; Jacobson, Samuel D.; Scotto, Dawn; Mishra, Nischay; Philip, Neena M.; Stotler, Brie A.; Schwartz, Joseph; Shaz, Beth; Spitalnik, Steven L.; Eisenberg, Andrew; Hod, Eldad A.; Justman, Jessica; Cheung, Ken; Lipkin, W. Ian; O'Donnell, Max R.] Columbia Univ, Med Ctr, New York, NY 10027 USA.
RP Eckhardt, CM (corresponding author), Columbia Univ, Med Ctr, New York, NY 10027 USA.
EM cme2113@cumc.columbia.edu
RI Lipkin, W. Ian/ABE-6216-2020
OI Lipkin, W. Ian/0000-0002-8768-9386; Shaz, Beth/0000-0002-2270-4821;
   Eckhardt, Christina/0000-0002-3249-926X
FU Amazon
FX This trial is funded by an unrestricted gift from Amazon. The funder
   played no role in the design of the study, the collection, analysis, and
   interpretation of data, or in writing the manuscript.
NR 0
TC 4
Z9 4
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 8
PY 2020
VL 21
IS 1
AR 499
DI 10.1186/s13063-020-04422-y
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LZ3AA
UT WOS:000541098100008
PM 32513308
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Faqihi, F
   Alharthy, A
   Alodat, M
   Asad, D
   Aletreby, W
   Kutsogiannis, DJ
   Brindley, PG
   Karakitsos, D
AF Faqihi, Fahad
   Alharthy, Abdulrahman
   Alodat, Mohammed
   Asad, Daood
   Aletreby, Waleed
   Kutsogiannis, Demetrios J.
   Brindley, Peter G.
   Karakitsos, Dimitrios
TI A pilot study of therapeutic plasma exchange for serious SARS CoV-2
   disease (COVID-19): A structured summary of a randomized controlled
   trial study protocol
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomized controlled trial; Protocol; Therapeutic plasma
   exchange; Intensive care unit; Life-threatening COVID-19; Cytokine
   release syndrome; Acute respiratory distress syndrome; Multisystem organ
   failure
AB ObjectivesTo evaluate the safety of therapeutic plasma exchange (TPE) in adult patients with serious/life-threatening COVID-19 requiring intensive care unit (ICU) admission, and associated 28-day mortality. Serious and life threatening COVID-19 are defined as per published literature (please, refer to the full protocol, Additional file 1). The rationale is that TPE can remove interleukins-3, 6, 8, 10, interferon-gamma and tumor necrosis factor-alpha. Thus, it may reduce the cytokine release syndrome associated with fulminant COVID-19 disease.Trial designPilot, interventional, open-label, randomized controlled multicenter trial.ParticipantsInclusion criteria are: 1) age >= 18 years old; 2) intubation and intensive care unit (ICU) admission; 3) serious and/or life-threatening COVID-19 (please, refer to the full protocol, Additional file 1). SARS-CoV-2 infection is confirmed by Real-Time-Polymerase-Chain-Reaction (RT-PCR) assays using QuantiNova Probe RT-PCR kit (Qiagen) in a Light-Cycler 480 real-time PCR system (Roche, Basel, Switzerland).Exclusion criteria are: 1) previous allergic reaction to plasma exchange or its ingredients (i.e., sodium citrate), 2) two consecutive negative RT-PCR tests for SARS-CoV-2 at least 24 hours apart, 3) mild COVID-19 not requiring ICU admission and 4) terminally ill patients receiving palliative care. The primary site will be King Saud Medical City (KSMC), Riyadh, Kingdom of Saudi Arabia (KSA). Also, the study will run in ICUs (Ministry of Health Cluster 1; Riyadh) and other centers in KSA pending their institutional review board (IRB) approval.Interventions and comparatorThe intervention group will receive TPE, plus empiric treatment for COVID-19. TPE is administered using the Spectra Optia TM Apheresis System equipped with the Depuro D2000 Adsorption Cartridge (Terumo BCT Inc., USA). The first dose is 1.5 plasma volumes, followed by one plasma volume on alternate days or daily for five to seven total treatments. Spectra Optia TM Apheresis System operates with acid-citrate dextrose anticoagulant (ACDA) as per Kidney Disease Improving Global Outcomes (KDIGO) 2019 guidelines. Plasma is replaced with albumin 5% or fresh frozen plasma in patients with coagulopathy (prothrombin time >37 seconds; international normalized ratio >3; activated partial thromboplastin time >100 or fibrinogen level <100 mg/d). TPE sessions are performed daily over four hours and laboratory markers measured daily. The comparators are controls not receiving TPE but usual empiric treatment for COVID-19 as per institutional, national and international recommendations. Both groups will receive standard ICU supportive care.Main outcomesPrimary study end-point is 28-day mortality and safety of TPE in serious and/or life-threatening COVID-19. Safety will be evaluated by the documentation of any pertinent adverse and/or serious adverse effects related to TPE as per institutional, national and international (Food and Drug Administration) guidelines. Secondary outcomes are: i) improvement in Sequential Organ Function Assessment (SOFA) score ; ii) changes in inflammatory markers: serum C-reactive protein, lactate dehydrogenase, ferritin, d-dimers and interleukin-6; iii) days on mechanical ventilation and ICU length of stay.RandomizationEligible consented patients are randomized (1:1 allocation) after stratification by ICU center and two PaO2/FIO2 ratio categories (> 150 and <= 150). Randomization occurs in variable block sizes of four to eight patients. A web-based randomization service, randomize.
   net, is used to allocate patients to their respective strata prior to the intervention or control therapy.Blinding (masking)Given the visibility of TPE machinery, the intervention will be unblinded; hence, no enrollment concealment will be expedited. The lack of allocation concealment will be mitigated by several measures (please, refer to the full protocol, Additional file 1).Numbers to be randomized (sample size)This pilot randomized trial aims to recruit a convenience sample of patients with serious and/or life-threatening COVID-19. Therefore, at least 20 patients are to be randomized to each group per participating center. We are hoping to consent and randomize approximately 60 patients in each group over a 3 to 6 months period giving a total of 120 participants.Trial StatusThe protocol version 1 was approved 29/04/2020. Recruitment is ongoing, and began on 01/05/2020. We estimate completion by 29/10/2020.Trial registrationRegistered at ISRCTN on 18/05/2020 (ISRCTN21363594; doi.10.1186/ ISRCTN21363594).Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
C1 [Faqihi, Fahad; Alharthy, Abdulrahman; Alodat, Mohammed; Asad, Daood; Aletreby, Waleed; Karakitsos, Dimitrios] King Saud Med City, Crit Care Dept, Riyadh, Saudi Arabia.
   [Faqihi, Fahad] Al Imam Abdulrahman Al Feisal Hosp, Crit Care Dept, Riyadh, Saudi Arabia.
   [Kutsogiannis, Demetrios J.; Brindley, Peter G.] Univ Alberta, Fac Med & Dent, Dept Crit Care, Edmonton, AB, Canada.
   [Karakitsos, Dimitrios] South Carolina Univ, Sch Med, Dept Internal Med, Columbia, SC 29208 USA.
   [Karakitsos, Dimitrios] USC, Keck Sch Med, Crit Care Dept, Los Angeles, CA USA.
RP Karakitsos, D (corresponding author), King Saud Med City, Crit Care Dept, Riyadh, Saudi Arabia.; Karakitsos, D (corresponding author), South Carolina Univ, Sch Med, Dept Internal Med, Columbia, SC 29208 USA.
EM karakitsosdimitrios@gmail.com
OI Aletreby, Waleed/0000-0001-8387-1829
FU King Saud Medical City
FX King Saud Medical City will provide funding that will facilitate
   collection, analysis, and interpretation of data of this study.
NR 0
TC 6
Z9 6
U1 4
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 8
PY 2020
VL 21
IS 1
AR 506
DI 10.1186/s13063-020-04454-4
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LZ3AA
UT WOS:000541098100015
PM 32513290
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Calderon, JM
   Zeron, HM
   Padmanabhan, S
AF Meneses Calderon, Jose
   Mendieta Zeron, Hugo
   Padmanabhan, Srivatsan
TI Treatment with Hydroxychloroquine vs Hydroxychloroquine plus
   Nitazoxanide in COVID-19 patients with risk factors for poor prognosis:
   A structured summary of a study protocol for a randomised controlled
   trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; Dual therapy;
   hydroxychloroquine; nitazoxanide; SARS-CoV-2; treatment regimen
AB ObjectivesTo determine the efficacy of Hydroxychloroquine vs. Hydroxychloroquine + Nitazoxanide in reducing the need for invasive mechanical ventilatory support for patients with COVID-19. Hydroxychloroquine is currently being used in multiple trials with varying doses in an attempt to treat COVID-19. Nitazoxanide has powerful antiviral effects and proven efficacy against a range of viruses including SARS and MERS. Dual therapy by combining appropriate doses of these two medications with diverse activities against COVID-19 is expected to be better than monotherapy with hydroxychloroquine.Trial designThis is a single centre, randomized, controlled, single blinded, 2 arm (ratio 1:1) parallel group trial.Participants86 COVID-19 positive patients that are being treated at the Health Institute of the State of Mexico (ISEM) in Toluca, State of Mexico will be recruited from May 14 to December 31, 2020.Inclusion criteria: Age older than 18 years.Hospitalised COVID-19 PCR test positive patients.Within the first 72 hours after performing the PCR test.Presence of risk factors for complications (at least one): over 60 years, history of diabetes mellitus, hypertension, and morbid obesity.Exclusion criteria: Patients with corrected QT interval (QTc) greater than 500ms at hospital admission.Patients who have inherent contraindications to each drug.Patients who are unable to consent.Patients who have previously received chloroquine.Patients already intubated.Elimination criteria: Patients whose clinical follow-up is lost or who decide not to continue in the studyIntervention and comparatorThe two management alternatives will be:Control - Hydroxychloroquine 200 mg taken orally every 12 hours for 7 days.Dual therapy - Hydroxychloroquine 400 mg taken orally every 12 hours for two days and then 200 mg taken orally every 12 hours for four days + Nitazoxanide 500 mg orally every 6 hours taken with food, for seven days.Main outcomesPrimary: Mechanical ventilation requirement assessed at one week.Percentage of COVID-19 positive patients who require mechanical ventilation . All patients will be monitored till hospital discharge or death.RandomisationPatients will be randomly allocated using allocation papers and opaque sealed envelopes to either receive the placebo or the dual therapy intervention treatment in a 1:1 ratio until we have recruited the required number of patients for each group.Blinding (masking)Trial participants will be blinded.Numbers to be randomised (sample size)86 participants will be randomized to each group, with 43 in the control group and 43 in the dual therapy group.Trial StatusProtocol version: 2, recruitment will begin on May 14 until sample size is reached , with the analysis deadline of December 31st 2020.Trial registrationClinicalTrials.gov Identifier: NCT04341493.Date of trial registration: April 10, 2020Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol
C1 [Meneses Calderon, Jose] Lic Adolfo Lopez Mateos Gen Hosp, Intens Care Unit, Internal Med, Toluca, Mexico.
   [Meneses Calderon, Jose] Monica Pretelini Saenz Maternal Perinatal Hosp, Toluca, Mexico.
   [Mendieta Zeron, Hugo] Univ Santiago de Compostela, Autonomous Univ State Mexico UAEMex, Internal Med & Med Sci UNAM, Endocrinol, Santiago De Compostela, Spain.
   [Mendieta Zeron, Hugo] UAEMex, Fac Med, Toluca, Mexico.
   [Mendieta Zeron, Hugo] Monica Pretelini Saenz Maternal Perinatal Hosp, Res Dept, Toluca, Mexico.
   [Padmanabhan, Srivatsan] St Joseph Med Ctr, Internal Med, Tacoma, WA USA.
RP Zeron, HM (corresponding author), Univ Santiago de Compostela, Autonomous Univ State Mexico UAEMex, Internal Med & Med Sci UNAM, Endocrinol, Santiago De Compostela, Spain.; Zeron, HM (corresponding author), UAEMex, Fac Med, Toluca, Mexico.
EM hmendietaz@uaemex.mx
RI Mendieta Zeron, Hugo/F-4460-2012
OI Mendieta Zeron, Hugo/0000-0003-3492-8950
NR 0
TC 4
Z9 4
U1 6
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 8
PY 2020
VL 21
IS 1
AR 504
DI 10.1186/s13063-020-04448-2
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LZ3AA
UT WOS:000541098100013
PM 32513231
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, C
   Li, JW
   Wu, Z
   Wang, H
   Que, CL
   Zhao, H
   Wang, GQ
AF Zhang, Chi
   Li, Jiawen
   Wu, Zhao
   Wang, He
   Que, Chengli
   Zhao, Hong
   Wang, Guiqiang
TI Efficacy and safety of Anluohuaxian in the treatment of patients with
   severe Coronavirus disease 2019-a multicenter, open label, randomized
   controlled study: a structured summary of a study protocol for a
   randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Protocol; Pulmonary fibrosis;
   Anluohuaxian
AB ObjectivesPatients with severe COVID-19 often suffer from significant pulmonary fibrosis. Although the pathogenesis of pulmonary fibrosis has not been fully explained, the signal pathways and cytokines involved are very similar to hepatic fibrosis. This has been successfully treated with the Anluohuaxian Pill, a proprietary Chinese medicine composed of a variety of Chinese herbal medicines. The aim of this study is to evaluate the efficacy and safety of Anluohuaxian in the treatment of pulmonary fibrosis in patients with severe COVID-19.Trial designThis is a prospective, multicenter, open, randomized controlled trial. The distribution ratio was 2:1, 500 cases in the experimental group and 250 cases in the control group.ParticipantsMinimum Age: 18 YearsMaximum Age: 80 YearsSex: AllGender Based: NoAccepts Healthy Volunteers: NoInclusion Criteria: Confirmed COVID-19, and the nucleic acid test of respiratory specimens such as sputum or nasopharyngeal swabs is negative twice after the treatment (sampling interval is at least 24 hours);Negative nucleic acid test of respiratory specimens such as sputum or nasopharyngeal swabs during screening visits;High-resolution CT of the lung (HRCT) indicates pulmonary fibrosis (thickness of lobular septum, honeycomb-like changes, with or without bronchial / pleural distraction);Voluntarily participate in research and sign informed consent.Exclusion Criteria: Combined with severe heart, lung (diagnosed with interstitial lung disease, bronchial asthma, chronic obstructive pulmonary disease, etc.), liver and kidney disease or with endocrine, rheumatic, neurologic, malignant and other systemic diseases;Have been diagnosed with connective tissue disease;Pregnant or lactating women;History of mental disorders, substance abuse or dependence;Have used other anti-pulmonary fibrosis drugs in the past 14 days, such as nintedanib, pirfenidone, penicillamine, colchicine, tumor necrosis factor alpha blocker, imatinib, glucocorticoid hormones, morphomycodyl esters, azathioprine, cyclophosphamide, interferon-gamma, and traditional Chinese medicine;Researchers consider it inappropriate to participate in research;Participating in other clinical research.This mutli-centre RCT will be undertaken in 9 trial centres: The Second People's Hospital of Fuyang, Ezhou Central Hospital, Huoshenshan Hospital of Wuhan, Jinyintan Hospital of Wuhan, Tongji Hospital of Huazhong University of Science and Technology, West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan Pulmonary Hospital, Zhongnan Hospital of Wuhan University, Wenzhou Medical University Affiliated First Hospital.Intervention and comparatorThe research drug is Anluohuaxian Pill, which is provided by Senlong Pharmaceutical Co., Ltd. The basic therapeutic drugs for COVID-19 involved in the study include antiviral drugs. Brands can be selected according to the treatment routines of each research center to facilitate the improvement of treatment compliance.Main outcomesPrimary Outcome Measure: Changes in high-resolution computer tomography of the lungChanges in ground-glass shadows, interstitial or air nodules found on high-resolution computer tomography[Time Frame: 3 months] Change in 6-minute walking distance[Time Frame: 3 months]RandomisationIn this study, the central randomization system (IWRS, an interactive network response system based on network) is used to randomise the groups. The subjects who met the entry criteria were randomly divided into the experimental group and the control group according to the proportion of 2:1.
   In this study, the block randomized grouping method is used, and the block length is 6. The random grouping program is set up by statistical and computer professionals in the randomization process.Blinding (masking)This is an open label trial. Trial participants, investigators, care givers, outcome assessors, and date analysts are not blinded to group assignment.Numbers to be randomised (sample size)750 patients are expected to be enrolled and the cases are allocated according to the ratio of 2 (Anluohuaxian combined with regular treatment group):1 (regular treatment group).Trial StatusProtocol version number 3.0, 10th April 2020. The recruitment has not yet started.Actual Study Start Date: April 1, 2020Estimated Primary Completion Date: June 1, 2020Estimated Study Completion Date: December 1, 2020Trial registrationClinicalTrials.gov ID: NCT04334265. Registered on 3 April 2020Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Zhang, Chi; Li, Jiawen; Wu, Zhao; Zhao, Hong; Wang, Guiqiang] Peking Univ First Hosp, Dept Infect Dis, Ctr Liver Dis, 8 Xishiku St, Beijing, Peoples R China.
   [Wang, He] Peking Univ First Hosp, Dept Radiol, 8 Xishiku St, Beijing 100034, Peoples R China.
   [Que, Chengli] Peking Univ First Hosp, Dept Resp Dis, 8 Xishiku St, Beijing 100034, Peoples R China.
   [Zhao, Hong; Wang, Guiqiang] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Guiqiang] Peking Univ Int Hosp, Beijing, Peoples R China.
RP Zhao, H; Wang, GQ (corresponding author), Peking Univ First Hosp, Dept Infect Dis, Ctr Liver Dis, 8 Xishiku St, Beijing, Peoples R China.
EM zhaohong_pufh@bjmu.edu.cn; john131212@126.com
OI Zhao, Hong/0000-0002-8069-9901
FU China Mega-Project for Infectious Diseases [2017ZX10203202,
   2013ZX10002005]; China Mega-Project for Innovative Drugs
   [2016ZX09101065]
FX This study was supported by China Mega-Project for Infectious Diseases
   (grant numbers 2017ZX10203202, 2013ZX10002005), China Mega-Project for
   Innovative Drugs (grant numbers 2016ZX09101065). The research drug,
   Anluohuaxian Pill, is provided by Senlong Pharmaceutical Co., Ltd The
   study funders had no role in study design; collection, analysis, and
   interpretation of data and in writing the manuscript.
NR 0
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 8
PY 2020
VL 21
IS 1
AR 495
DI 10.1186/s13063-020-04399-8
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LZ3AA
UT WOS:000541098100004
PM 32513299
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hanney, SR
   Wooding, S
   Sussex, J
   Grant, J
AF Hanney, Stephen R.
   Wooding, Steven
   Sussex, Jon
   Grant, Jonathan
TI From COVID-19 research to vaccine application: why might it take 17
   months not 17 years and what are the wider lessons?
SO HEALTH RESEARCH POLICY AND SYSTEMS
LA English
DT Article
DE COVID-19; Coronavirus disease; SARS-CoV-2; Vaccine; Time-lags; Research
   translation; Matrix; Pandemic; Trials; Timescales; World Health
   Organization
ID HEALTH
AB It is often said that it takes 17 years to move medical research from bench to bedside. In a coronavirus disease (COVID-19) world, such time-lags feel intolerable. In these extraordinary circumstances could years be made into months? If so, could those lessons be used to accelerate medical research when the crisis eases? To measure time-lags in health and biomedical research as well as to identify ways of reducing them, we developed and published (in 2015) a matrix consisting of overlapping tracks (or stages/phases) in the translation from discovery research to developed products, policies and practice. The matrix aids analysis by highlighting the time and actions required to develop research (and its translation) both (1) along each track and (2) from one track to another, e.g. from the discovery track to the research-in-humans track. We noted four main approaches to reducing time-lags, namely increasing resources, working in parallel, starting or working at risk, and improving processes. Examining these approaches alongside the matrix helps interpret the enormous global effort to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of COVID-19. Rapid progress in the discovery/basic and human research tracks is being made through a combination of large-scale funding, work being conducted in parallel (between different teams globally and through working in overlapping tracks), working at greater (but proportionate) risk to safety than usual, and adopting various new processes. The overlapping work of some of the teams involves continuing animal research whilst entering vaccine candidates into Phase I trials alongside planning their Phase II trials. The additional funding available helps to reduce some of the usual financial risks in moving so quickly. Going forward through the increasingly large human trials for safety, dosage and efficacy, it will be vital to overlap work in parallel in the often challenging public policy and clinical tracks. Thus, regulatory and reimbursement bodies are beginning and preparing rapid action to pull vaccines proving to be safe and effective through to extraordinarily rapid application to the general population. Monitoring the development of a COVID-19 vaccine using the matrix (modified as necessary) could help identify which of the approaches speeding development and deployment could be usefully applied more widely in the future.
C1 [Hanney, Stephen R.] Brunel Univ London, Hlth Econ Res Grp, Kingston Lane, Uxbridge, Middx, England.
   [Wooding, Steven] Univ Cambridge, Res Strategy Off, Old Sch, Cambridge, England.
   [Sussex, Jon] RAND Europe, Westbrook Ctr, Milton Rd, Cambridge, England.
   [Grant, Jonathan] Kings Coll London, Policy Inst Kings, Virginia Woolf Bldg,22 Kingsway, London, England.
RP Hanney, SR (corresponding author), Brunel Univ London, Hlth Econ Res Grp, Kingston Lane, Uxbridge, Middx, England.
EM stephen.hanney@brunel.ac.uk
OI Hanney, Stephen/0000-0002-7415-5932
FU United Kingdom's Medical Research Council [MR/K014773/1]
FX This Commentary was not funded; the matrix and time-lags paper were
   developed through funding from the United Kingdom's Medical Research
   Council grant MR/K014773/1 `Time Lags in the Translation of Medical
   Research: Developing a Case Study Approach to Achieve a Better
   Understanding' from the MRC's Economic Impact call from the Methodology
   Research Programme. The funder played no role in the conduct of that
   project.
CR Adams CP, 2006, HEALTH AFFAIR, V25, P420, DOI 10.1377/hlthaff.25.2.420
   [Anonymous], 2020, MOD LONZ ANN WORLDW
   [Anonymous], 2018, LIV EV AUSTR HLTH CA
   Apuzzo M, 2020, NY TIMES
   Balas E A, 2000, Yearb Med Inform, P65
   Buxton M., 2008, MED RES WHATS IT WOR
   Cai J, 2020, IRAN J RADIOL, V17, DOI 10.5812/iranjradiol.96419
   Callaway E, 2020, NATURE, V581, P363, DOI 10.1038/d41586-020-01092-3
   Callaway Ewen, 2020, Nature, DOI 10.1038/d41586-020-01247-2
   Charman E, 2013, MRC INSIGHT BLO 1217
   Devlin H, 2020, GUARDIAN
   Glover M, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/s12961-017-0276-7
   Glover M, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-99
   Gouglas D, 2018, LANCET GLOB HEALTH, V6, pE1386, DOI 10.1016/S2214-109X(18)30346-2
   Grant J, 2003, RES EVALUAT, V12, P217, DOI 10.3152/147154403781776618
   Grant J, 2020, REDRAWING FRONTIER
   Greenhalgh T, 2004, MILBANK Q, V82, P581, DOI 10.1111/j.0887-378X.2004.00325.x
   Grimshaw JM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-50
   Hanney S, 2005, SOC SCI MED, V60, P937, DOI 10.1016/j.socscimed.2004.06.038
   Hanney Stephen R, 2003, Health Res Policy Syst, V1, P2, DOI 10.1186/1478-4505-1-2
   Hodgson J, 2020, NAT BIOTECHNOL, V38, P523, DOI 10.1038/d41587-020-00005-z
   ICMRA, 2020, GLOB REG WORKSH COVI
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Khamsi R, 2020, NATURE, V580, P578, DOI 10.1038/d41586-020-01063-8
   Kirkpatrick D. D., 2020, NY TIMES
   Lane R, 2020, LANCET, V395, P1247, DOI 10.1016/S0140-6736(20)30796-0
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Macleod MR, 2014, LANCET, V383, P101, DOI 10.1016/S0140-6736(13)62329-6
   MAHASE E, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1679
   Marshall N, OXFORD U PARTNERS AS
   Morris ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/jrsm.2011.110180
   Palmer M, 2020, FT HLTH
   Silverman R, 2020, FINANCING SCALING IN
   Sussex J, 2010, PUBLICLY FUNDED VACC
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Trochim W, 2011, CTS-CLIN TRANSL SCI, V4, P153, DOI 10.1111/j.1752-8062.2011.00291.x
   Wooding S, 2015, INSIGHT EARLY ADOPTI
   Wratschko K, 2009, EMPIRICAL SETTING PH
NR 38
TC 6
Z9 5
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478-4505
J9 HEALTH RES POLICY SY
JI Health Res. Policy Syst.
PD JUN 8
PY 2020
VL 18
IS 1
AR 61
DI 10.1186/s12961-020-00571-3
PG 10
WC Health Policy & Services
SC Health Care Sciences & Services
GA LY8SG
UT WOS:000540797900001
PM 32513202
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Michel, L
   Schadendorf, D
   Rassaf, T
AF Michel, Lars
   Schadendorf, Dirk
   Rassaf, Tienush
TI Oncocardiology: new challenges, new opportunities
SO HERZ
LA English
DT Article
DE Cancer; Cardiovascular disease; Cardiotoxicity; COVID-19; Imaging
ID MEK INHIBITION; COMBINED BRAF; GROWTH
AB Patients with cancer are at a higher risk of cardiovascular disease, which contributes to significant morbidity and mortality. The rapid progress in the field of oncological treatments has led to a steady increase in long-term cancer survivors. Care for cardiovascular complications is therefore becoming increasingly important. In addition, the establishment of new oncological therapies has resulted in the identification of previously unknown cardiovascular side effects. Oncocardiology aims to detect and treat cardiovascular diseases associated with cancer and cancer therapy. Continuous scientific, clinical, and structural developments are necessary as the basis for the best care of the growing number of affected patients. This review summarizes current developments in the field of oncocardiology with regard to advances in cancer therapy and challenges in clinical oncocardiology work. Cardiovascular side effects by targeted cancer therapies are characterized and recent advances in the field of cardiovascular diagnostics are outlined. Developments to better integrate oncocardiology into the medical care system and perspectives for modern, patient-oriented care are shown. In light of the coronavirus disease 2019 (COVID-19) pandemic, current challenges and opportunities are highlighted. The relevance of profitable further advances in oncocardiology including standardized guidelines and educational programs is delineated as a mandatory requirement for the successful development of oncocardiology.
C1 [Michel, Lars; Rassaf, Tienush] Univ Hosp Essen, Med Fac, West German Heart & Vasc Ctr, Dept Cardiol & Vasc Med, Hufelandstr 55, D-45147 Essen, Germany.
   [Schadendorf, Dirk] Univ Hosp Essen, Dept Dermatol, Essen, Germany.
   [Schadendorf, Dirk] German Canc Consortium DKTK, Partner Site Essen Dusseldorf, Essen, Germany.
RP Rassaf, T (corresponding author), Univ Hosp Essen, Med Fac, West German Heart & Vasc Ctr, Dept Cardiol & Vasc Med, Hufelandstr 55, D-45147 Essen, Germany.
EM Tienush.Rassaf@uk-essen.de
CR Alhogbani T, 2016, ANN SAUDI MED, V36, P78, DOI 10.5144/0256-4947.2016.78
   CardioSmart, 2020, COR YOUR HEART
   Chari A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-915
   Destatis, 2017, TOD DEUTSCHL
   Dickerson T, 2019, BLOOD, V134, P1919, DOI 10.1182/blood.2019000840
   Efentakis P, 2019, BLOOD, V133, P710, DOI 10.1182/blood-2018-06-858415
   FDA, 2020, FDA APPR IBR PLUS RI
   Ganatra Sarju, 2020, JACC CardioOncol, V2, P350, DOI 10.1016/j.jaccao.2020.03.001
   Ganatra Sarju, 2018, JACC Clin Electrophysiol, V4, P1491, DOI 10.1016/j.jacep.2018.06.004
   Jain T, 2017, BLOOD CANCER J, V7, DOI 10.1038/s41408-017-0026-7
   Kang Y, 2014, EUR J HEART FAIL, V16, P300, DOI 10.1002/ejhf.8
   Keramida K, 2020, HEART FAIL REV, DOI 10.1007/s10741-020-09938-8
   Kim Jahae, 2020, J Nucl Cardiol, V27, P2154, DOI 10.1007/s12350-019-01617-y
   Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037
   Lyon AR, 2018, LANCET ONCOL, V19, pE447, DOI 10.1016/S1470-2045(18)30457-1
   Mahjoob Mohammad P., 2020, Cardiovascular & Hematological Disorders - Drug Targets, V20, P74, DOI 10.2174/1871529X19666190912150942
   McGowan JV, 2017, CARDIOVASC DRUG THER, V31, P63, DOI 10.1007/s10557-016-6711-0
   Meijers WC, 2018, CIRCULATION, V138, P678, DOI 10.1161/CIRCULATIONAHA.117.030816
   Michel L, 2020, EUR J HEART FAIL, V22, P350, DOI 10.1002/ejhf.1631
   Michel L, 2019, IJC HEART VASC, V25, DOI 10.1016/j.ijcha.2019.100420
   Michel L, 2018, J THORAC DIS, V10, pS4282, DOI 10.21037/jtd.2018.08.15
   Michel L, 2019, EUR J MED RES, V24, DOI 10.1186/s40001-018-0359-0
   Mincu RI, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.8890
   Parikh Amar, 2020, JACC CardioOncol, V2, P356, DOI 10.1016/j.jaccao.2020.04.003
   Peng J, 2019, Cardiooncology, V5, P12, DOI 10.1186/s40959-019-0049-2
   Rassaf T, 2020, KARDIOLOGE, V14, P267, DOI 10.1007/s12181-020-00395-z
   Ribas A, 2019, NAT MED, V25, P936, DOI 10.1038/s41591-019-0476-5
   Robinson ES, 2010, SEMIN NEPHROL, V30, P591, DOI 10.1016/j.semnephrol.2010.09.007
   Shah C, 2018, LEUKEMIA LYMPHOMA, V59, P2557, DOI 10.1080/10428194.2018.1437269
   Shanafelt TD, 2019, NEW ENGL J MED, V381, P432, DOI 10.1056/NEJMoa1817073
   Thompson PA, 2016, BRIT J HAEMATOL, V175, P462, DOI 10.1111/bjh.14324
   Totzeck M, 2019, INT J CARDIOL, V280, P163, DOI 10.1016/j.ijcard.2019.01.038
   Totzeck M, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006278
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Verberne HJ, 2020, J NUCL CARDIOL, V27, P940, DOI 10.1007/s12350-018-01584-w
   Vrontikis A, 2016, ONCOLOGY-NY, V30, P970
   Waddell KJ, 2020, JACC CARDIOONCOL, V2, P84, DOI [10.1016/j.jaccao.2020.02.006, DOI 10.1016/J.JACCAO.2020.02.006]
   Waxman AJ, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.4519
   Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI 10.1093/eurheartj/ehw211
   Zhao R, 2020, JACC CARDIOONCOL, V2, P13, DOI [10.1016/j.jaccao.2020.01.007, DOI 10.1016/J.JACCAO.2020.01.007]
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 41
TC 0
Z9 0
U1 1
U2 1
PU URBAN & VOGEL
PI MUNICH
PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY
SN 0340-9937
EI 1615-6692
J9 HERZ
JI Herz
PD NOV
PY 2020
VL 45
IS 7
BP 619
EP 625
DI 10.1007/s00059-020-04951-x
EA JUN 2020
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OH2CM
UT WOS:000538950600003
PM 32514587
OA Green Published
DA 2021-01-01
ER

PT J
AU Chai, PR
   Ferro, EG
   Kirshenbaum, JM
   Hayes, BD
   Culbreth, SE
   Boyer, EW
   Erickson, TB
AF Chai, Peter R.
   Ferro, E. G.
   Kirshenbaum, J. M.
   Hayes, B. D.
   Culbreth, S. E.
   Boyer, E. W.
   Erickson, T. B.
TI Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam:
   an Increasing Concern in the COVID-19 Pandemic
SO JOURNAL OF MEDICAL TOXICOLOGY
LA English
DT Article
DE COVID-19; hydroxycholorquine; Chloroquine; Drug-Related Side Effects;
   Adverse Reactions
ID PROPYLENE-GLYCOL TOXICITY; CHLOROQUINE; PHARMACOKINETICS; ADSORPTION
AB Introduction Recent attention on the possible use of hydroxychloroquine and chloroquine to treat COVID-19 disease has potentially triggered a number of overdoses from hydroxychloroquine. Toxicity from hydroxychloroquine manifests with cardiac conduction abnormalities, seizure activity, and muscle weakness. Recognizing this toxidrome and unique management of this toxicity is important in the COVID-19 pandemic. Case Report A 27-year-old man with a history of rheumatoid arthritis presented to the emergency department 7 hours after an intentional overdose of hydroxychloroquine. Initial presentation demonstrated proximal muscle weakness. The patient was found to have a QRS complex of 134 ms and QTc of 710 ms. He was treated with early orotracheal intubation and intravenous diazepam boluses. Due to difficulties formulating continuous diazepam infusions, we opted to utilize an intermitted intravenous bolus strategy that achieved similar effects that a continuous infusion would. The patient recovered without residual side effects. Discussion Hydroxychloroquine toxicity is rare but projected to increase in frequency given its selection as a potential modality to treat COVID-19 disease. It is important for clinicians to recognize the unique effects of hydroxychloroquine poisoning and initiate appropriate emergency maneuvers to improve the outcomes in these patients.
C1 [Chai, Peter R.; Culbreth, S. E.; Boyer, E. W.; Erickson, T. B.] Brigham & Womens Hosp, Dept Emergency Med, Div Med Toxicol, 75 Francis St, Boston, MA 02115 USA.
   [Chai, Peter R.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.
   [Chai, Peter R.; Boyer, E. W.] Fenway Inst, Boston, MA 02215 USA.
   [Chai, Peter R.] MIT, Koch Inst Integrated Canc Res, Boston, MA 02115 USA.
   [Ferro, E. G.; Kirshenbaum, J. M.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.
   [Hayes, B. D.] Harvard Med Sch, Dept Emergency Med, Boston, MA 02115 USA.
   [Hayes, B. D.] Massachusetts Gen Hosp, Dept Pharm, Boston, MA 02114 USA.
   [Culbreth, S. E.] Brigham & Womens Hosp, Dept Pharm, 75 Francis St, Boston, MA 02115 USA.
   [Erickson, T. B.] Harvard Humanitarian Inst, Boston, MA USA.
RP Chai, PR (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, Div Med Toxicol, 75 Francis St, Boston, MA 02115 USA.; Chai, PR (corresponding author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.; Chai, PR (corresponding author), Fenway Inst, Boston, MA 02215 USA.; Chai, PR (corresponding author), MIT, Koch Inst Integrated Canc Res, Boston, MA 02115 USA.
EM pchai@bwh.harvard.edu
OI chai, peter/0000-0003-0955-4117
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [K23DA044874, R44DA051106,
   R01DA047236]; e-ink corporation; Hans and Mavis Psychosocial Foundation;
   Philips Biosensing; Gilead SciencesGilead Sciences
FX PRC funded by NIH K23DA044874, R44DA051106 investigator initiated
   research grants from e-ink corporation, Hans and Mavis Psychosocial
   Foundation, Philips Biosensing and Gilead Sciences; EWB funded by NIH
   R01DA047236.
CR [Anonymous], 2020, REQUEST EMERGENCY US
   Clemessy JL, 1996, INTENS CARE MED, V22, P1400, DOI 10.1007/BF01709558
   Edwards E., 2020, NBC NEWS
   FRIEDENBERG W, 1973, JAMA-J AM MED ASSOC, V224, P901
   GREENBLATT DJ, 1989, THER DRUG MONIT, V11, P652, DOI 10.1097/00007691-198911000-00007
   KOUDOGBO B, 1986, J TOXICOL CLIN EXPER, V6, P307
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   MACKICHAN J, 1979, NEW ENGL J MED, V301, P332
   Magagnoli J, 2020, OUTCOMES HYDROXYCHLO
   Marquardt K, 2001, AM J EMERG MED, V19, P420, DOI 10.1053/ajem.2001.25774
   McBeth Paul B, 2015, Case Rep Emerg Med, V2015, P692948, DOI 10.1155/2015/692948
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   MEERAN K, 1993, BRIT MED J, V307, P49, DOI 10.1136/bmj.307.6895.49
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   MESTRE M, 1984, LIFE SCI, V35, P953, DOI 10.1016/0024-3205(84)90661-1
   Onuki Y, 2015, J PHARM HEALTH CARE, V1, DOI 10.1186/s40780-014-0009-9
   RIOU B, 1988, NEW ENGL J MED, V318, P1, DOI 10.1056/NEJM198801073180101
   RIOU B, 1988, INTENS CARE MED, V14, P610
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   VANSTONE JC, 1976, J LAB CLIN MED, V88, P87
   Verbaanderd C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.781
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wilson KC, 2000, NEW ENGL J MED, V343, P815, DOI 10.1056/NEJM200009143431115
   Wilson KC, 2005, CHEST, V128, P1674, DOI 10.1378/chest.128.3.1674
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   YLIRUUSI JK, 1986, AM J HOSP PHARM, V43, P2789, DOI 10.1093/ajhp/43.11.2789
NR 29
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1556-9039
EI 1937-6995
J9 J MED TOXICOL
JI J. Med. Toxicol.
PD JUL
PY 2020
VL 16
IS 3
SI SI
BP 314
EP 320
DI 10.1007/s13181-020-00790-8
EA JUN 2020
PG 7
WC Toxicology
SC Toxicology
GA MC7JB
UT WOS:000538963700001
PM 32514696
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU de Vries, AAF
AF de Vries, A. A. F.
TI Renin-angiotensin system inhibition in COVID-19 patients
SO NETHERLANDS HEART JOURNAL
LA English
DT Article
DE Angiotensin-converting enzyme; Angiotensin-converting enzyme inhibitor;
   Angiotensin II type-1 receptor blocker; Coronavirus disease 2019;
   Renin-angiotensin system; Severe acute respiratory syndrome coronavirus
   2
ID CONVERTING ENZYME 2; SARS CORONAVIRUS; GUIDELINES; UPDATE; ACE2
AB Angiotensin-converting enzyme (ACE) inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) are among the most widely prescribed drugs for the treatment of arterial hypertension, heart failure and chronic kidney disease. A number of studies, mainly in animals and not involving the lungs, have indicated that these drugs can increase expression of angiotensin-converting enzyme 2 (ACE2). ACE2 is the cell entry receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) that is currently battering the globe. This has led to the hypothesis that use of ACEIs and ARBs may increase the risk of developing severe COVID-19. In this point of view paper, possible scenarios regarding the impact of ACEI/ARB pharmacotherapy on COVID-19 are discussed in relation to the currently available evidence. Although further research on the influence of blood-pressure-lowering drugs, including those not targeting the renin-angiotensin system, is warranted, there are presently no compelling clinical data showing that ACEIs and ARBs increase the likelihood of contracting COVID-19 or worsen the outcome of SARS-CoV-2 infections. Thus, unless contraindicated, use of ACEIs/ARBs in COVID-19 patients should be continued in line with the recent recommendations of medical societies.
C1 [de Vries, A. A. F.] Leiden Univ, Med Ctr, Dept Cardiol, Lab Expt Cardiol, Leiden, Netherlands.
RP de Vries, AAF (corresponding author), Leiden Univ, Med Ctr, Dept Cardiol, Lab Expt Cardiol, Leiden, Netherlands.
EM a.a.f.de_vries@lumc.nl
CR Arendse LB, 2019, PHARMACOL REV, V71, P539, DOI 10.1124/pr.118.017129
   Bean DM, TREATMENT ACE INHIBI, DOI [10.1101/2020.04.07.20056788v2, DOI 10.1101/2020.04.07.20056788V2]
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Forrester SJ, 2018, PHYSIOL REV, V98, P1627, DOI 10.1152/physrev.00038.2017
   Galandrin S, 2016, HYPERTENSION, V68, P1365, DOI 10.1161/HYPERTENSIONAHA.116.08118
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Henry Christopher, 2018, Proc (Bayl Univ Med Cent), V31, P419, DOI 10.1080/08998280.2018.1499293
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kreutz R, 2020, CARDIOVASC RES, V116, P1688, DOI 10.1093/cvr/cvaa097
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuba K, 2013, CIRC J, V77, P301, DOI 10.1253/circj.CJ-12-1544
   LI J, 2020, DIABETES OBES M 0518, DOI DOI 10.1001/jamacardio.2020.1624
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Muus C., 2020, INTEGRATED ANAL SING, DOI [10.1101/2020.04.19.049254v2, DOI 10.1101/2020.04.19.049254V2]
   Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Tan WSD, 2018, CURR OPIN PHARMACOL, V40, P9, DOI 10.1016/j.coph.2017.12.002
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang D, 2019, PULM PHARMACOL THER, V58, DOI 10.1016/j.pupt.2019.101833
   Wang YW, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012272
   Wevers BA, 2010, FUTURE VIROL, V5, P145, DOI 10.2217/FVL.10.4
   Yancy CW, 2017, CIRCULATION, V136, pE137, DOI 10.1161/CIR.0000000000000509
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 28
TC 8
Z9 8
U1 1
U2 1
PU BOHN STAFLEU VAN LOGHUM BV
PI HOUTEN
PA POSTBUS 246, 3990 GA HOUTEN, NETHERLANDS
SN 1568-5888
EI 1876-6250
J9 NETH HEART J
JI Neth. Heart J.
PD JUL
PY 2020
VL 28
IS 7-8
BP 396
EP 405
DI 10.1007/s12471-020-01439-5
EA JUN 2020
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MP0XT
UT WOS:000539135500002
PM 32514935
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Dowsett, M
   Ellis, MJ
   Dixon, JM
   Gluz, O
   Robertson, J
   Kates, R
   Suman, VJ
   Turnbull, AK
   Nitz, U
   Christgen, M
   Kreipe, H
   Kuemmel, S
   Bliss, JM
   Barry, P
   Johnston, SR
   Jacobs, SA
   Ma, CX
   Smith, IE
   Harbeck, N
AF Dowsett, Mitch
   Ellis, Matthew J.
   Dixon, J. Michael
   Gluz, Oleg
   Robertson, John
   Kates, Ronald
   Suman, Vera J.
   Turnbull, Arran K.
   Nitz, Ulrike
   Christgen, Matthias
   Kreipe, Hans
   Kuemmel, Sherko
   Bliss, Judith M.
   Barry, Peter
   Johnston, Stephen R.
   Jacobs, Samuel A.
   Ma, Cynthia X.
   Smith, Ian E.
   Harbeck, Nadia
TI Evidence-based guidelines for managing patients with primary ER+ HER2-
   breast cancer deferred from surgery due to the COVID-19 pandemic
SO NPJ BREAST CANCER
LA English
DT Article
ID NEOADJUVANT ANASTROZOLE; INTERNATIONAL KI67; ENDOCRINE THERAPY;
   TAMOXIFEN; WOMEN; LETROZOLE; TRIAL; INDEX
AB Many patients with ER+ HER2- primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We have collated data from multiple international trials of presurgical endocrine therapy in order to provide guidance on the identification of patients who may have insufficiently endocrine-sensitive tumors and should be prioritised for early surgery or neoadjuvant chemotherapy rather than NeoET during or in the aftermath of the COVID-19 pandemic for safety or when surgical activity needs to be prioritized. For postmenopausal patients, our data provide strong support for the use of ER and PgR status at diagnosis for triaging of patients into three groups in which (taking into account clinical factors): (i) NeoET is likely to be inappropriate (Allred ER <6 or ER 6 and PgR <6) (ii) a biopsy for Ki67 analysis (on-treatment Ki67) could be considered after 2-4 weeks of NeoET (a: ER 7 or 8 and PgR <6 or b: ER 6 or 7 and PgR >= 6) or (iii) NeoET is an acceptable course of action (ER 8 and PgR >= 6). Cut-offs for percentage of cells positive are also given. For group (ii), a high early on-treatment level of Ki67 (>10%) indicates a higher priority for early surgery. Too few data were available for premenopausal patients to provide a similar treatment algorithm. These guidelines should be helpful for managing patients with early ER+ HER2- breast cancer during and in the aftermath of the COVID-19 crisis.
C1 [Dowsett, Mitch] Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London, England.
   [Dowsett, Mitch] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England.
   [Ellis, Matthew J.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.
   [Ellis, Matthew J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA.
   [Ellis, Matthew J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Ellis, Matthew J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Dixon, J. Michael] Western Gen Hosp, Edinburgh Breast Unit, Edinburgh, Midlothian, Scotland.
   [Gluz, Oleg; Nitz, Ulrike] Bethesda Hosp, Breast Ctr Niederrhein, Monchengladbach, Germany.
   [Gluz, Oleg] Westdeutsch Studiengrp, Monchengladbach, Germany.
   [Gluz, Oleg] Uniklin Koln, Cologne, Germany.
   [Robertson, John] Univ Nottingham, Royal Derby Hosp, Uttoxeter Rd, Derby, England.
   [Kates, Ronald; Harbeck, Nadia] West German Study Grp, Monchengladbach, Germany.
   [Suman, Vera J.] Mayo Clin, Div Biomed Stat & Informat, Dept Hlth Sci Res, Rochester, MN USA.
   [Turnbull, Arran K.] Univ Edinburgh, CRUK Edinburgh Ctr, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland.
   [Christgen, Matthias; Kreipe, Hans] Med Sch Hannover, Inst Pathol, Hannover, Germany.
   [Kuemmel, Sherko] Kliniken Essen Mitte, Essen, Germany.
   [Bliss, Judith M.] Inst Canc Res, Clin Trials & Stat Unit, London, England.
   [Barry, Peter; Johnston, Stephen R.; Smith, Ian E.] Royal Marsden Hosp, Breast Unit, London, England.
   [Jacobs, Samuel A.] Natl Surg Adjuvant Breast & Bowel Project Fdn, Pittsburgh, PA USA.
   [Ma, Cynthia X.] Washington Univ, Dept Med, Div Oncol, Sch Med, St Louis, MO 63110 USA.
   [Harbeck, Nadia] LMU Univ Hosp, Breast Ctr, Dept Obstet & Gynecol, Munich, Germany.
   [Harbeck, Nadia] LMU Univ Hosp, CCCLMU, Munich, Germany.
RP Dowsett, M (corresponding author), Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London, England.; Dowsett, M (corresponding author), Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England.
EM mitchell.dowsett@icr.ac.uk
RI Ellis, Matthew/ABE-6263-2020
OI Ellis, Matthew/0000-0002-8467-8534; Bliss, Judith/0000-0001-7957-7424
FU POETIC; PALLET; WSG-ADAPT; Royal Marden/Institute of Cancer Research
   NIHR Biomedical Research Centre; CRUKCancer Research UK; BANSS Stiftung
   Biedenkopf; National Cancer InstituteUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01-CA095614, U24-CA114736, U10-CA076001,
   U01-CA114722]; Breast Cancer Research Foundation;
   AstraZenecaAstraZeneca; NovartisNovartis; PfizerPfizer
FX The authors consider themselves representatives of the POETIC, PALLET,
   WSG-ADAPT, Z-1031, and ALTERNATE trialists. We thank them for their
   participation and support. We are grateful to Eugene Shuster and Ricardo
   Ribas in the Breast Cancer Now Toby Robins Research Centre and Lucy
   Kilburn for analysis of the POETIC and PALLET data (ES and LK) and for
   help with manuscript preparation (RR) and to Fiona MacNeill for review
   of the manuscript. Funded in part by the Royal Marden/Institute of
   Cancer Research NIHR Biomedical Research Centre. CRUK funded POETIC and
   provided part funding for PALLET. We are grateful to the BANSS Stiftung
   Biedenkopf, whose support for a Biedenkopf meeting in January 2016
   initiated the collaboration between the POETIC and WSG-ADAPT teams. The
   work on Z1031B and ALTERNATE was supported by by Grants No.
   R01-CA095614, U24-CA114736, U10-CA076001, and U01-CA114722 from the
   National Cancer Institute; by the Breast Cancer Research Foundation;
   AstraZeneca, Novartis and Pfizer for drug supply.
CR Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8
   DeCensi A, 2011, ANN ONCOL, V22, P582, DOI 10.1093/annonc/mdq427
   Dietz JR, 2020, BREAST CANCER RES TR, V181, P487, DOI 10.1007/s10549-020-05644-z
   Dowsett M, 2005, J CLIN ONCOL, V23, P2477, DOI 10.1200/JCO.2005.07.559
   Dowsett M., 2020, METADATA SUPPORTING
   Dowsett M, 2007, JNCI-J NATL CANCER I, V99, P167, DOI 10.1093/jnci/djk020
   Dowsett Mitch, 2011, Journal of the National Cancer Institute Monographs, P120, DOI 10.1093/jncimonographs/lgr034
   Dowsett M, 2011, JNCI-J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393
   Ellis MJ, 2017, J CLIN ONCOL, V35, P1061, DOI 10.1200/JCO.2016.69.4406
   Ellis MJ, 2011, J CLIN ONCOL, V29, P2342, DOI 10.1200/JCO.2010.31.6950
   Gluz O, 2014, J CLIN ONCOL
   Hofmann D, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-261
   Johnston S, 2019, J CLIN ONCOL, V37, P178, DOI 10.1200/JCO.18.01624
   Leung SCY, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2016.14
   LIU Y, 2020, J CLIN ONCOL S, V38
   LOW SC, 1992, BRIT J SURG, V79, P1314, DOI 10.1002/bjs.1800791224
   Marti C, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1027
   Miller WR, 2003, EUR J CANCER, V39, P462, DOI 10.1016/S0959-8049(02)00600-7
   Polley MYC, 2013, JNCI-J NATL CANCER I, V105, P1897, DOI 10.1093/jnci/djt306
   Smith IE, 2007, J CLIN ONCOL, V25, P3816, DOI 10.1200/JCO.2006.09.6578
   Young OE, 2008, EUR J CANCER, V44, P391, DOI 10.1016/j.ejca.2007.11.007
NR 21
TC 1
Z9 1
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2374-4677
J9 NPJ BREAST CANCER
JI npj Breast Cancer
PD JUN 8
PY 2020
VL 6
IS 1
AR 21
DI 10.1038/s41523-020-0168-9
PG 10
WC Oncology
SC Oncology
GA LW4UD
UT WOS:000539138300001
PM 32550266
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Steinchen, N
   Muller-Ladner, U
   Lange, U
AF Steinchen, N.
   Mueller-Ladner, U.
   Lange, U.
TI Biological therapy after COVID-19 infection No reactivation of a
   COVID-19 infection with positive SARS-CoV-2 antibody status under
   biological therapy
SO ZEITSCHRIFT FUR RHEUMATOLOGIE
LA German
DT Article
DE Immunsuppression; Biological therapy; Rheumatoid arthritis; COVID-19
   infection; Positive antibody status SARS-CoV2
ID RHEUMATOID-ARTHRITIS; EULAR RECOMMENDATIONS
AB A case with rheumatoid arthritis and insufficient compensation under disease-modifying combined long-term therapy with methotrexate and leflunomide is reported. After recovery from a COVID-19 infection, a tumor necrosis factor (TNF) inhibitor therapy was initiated. Until now no reactivation of the COVID-19 infection with positive SARS-CoV-2 antibody status has occurred.
C1 [Steinchen, N.] Rheumatol Kassel, Kassel, Germany.
   [Mueller-Ladner, U.; Lange, U.] Univ Giessen, Campus Kerckhoff, Abt Rheumatol, Klin Immunol,Osteol,Phys Med, Benekestr 2-8, D-61231 Bad Nauheim, Germany.
RP Lange, U (corresponding author), Univ Giessen, Campus Kerckhoff, Abt Rheumatol, Klin Immunol,Osteol,Phys Med, Benekestr 2-8, D-61231 Bad Nauheim, Germany.
EM U.Lange@kerckhoff-klinik.de
CR [Anonymous], 2020, ENTZ MED SCHUTZ COVI
   Kruger K, 2018, INTERNIST, V59, P341, DOI 10.1007/s00108-018-0397-2
   Kruger K, 2012, Z RHEUMATOL, V71, P592, DOI 10.1007/s00393-012-1038-0
   Schulze-Koops H, 2020, Z RHEUMATOL, V79, P385, DOI 10.1007/s00393-020-00799-y
   Smolen JS, 2016, ANN RHEUM DIS, V75, P3, DOI 10.1136/annrheumdis-2015-207524
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis-2016-210715
NR 6
TC 0
Z9 0
U1 2
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-1855
EI 1435-1250
J9 Z RHEUMATOL
JI Z. Rheumatol.
PD AUG
PY 2020
VL 79
IS 6
SI SI
BP 574
EP 577
DI 10.1007/s00393-020-00824-0
EA JUN 2020
PG 4
WC Rheumatology
SC Rheumatology
GA MU9KN
UT WOS:000539134400001
PM 32514854
OA Green Published
DA 2021-01-01
ER

PT J
AU Amorin-Woods, D
   Fraenkel, P
   Mosconi, A
   Nisse, M
   Munoz, S
AF Amorin-Woods, Deisy
   Fraenkel, Peter
   Mosconi, Andrea
   Nisse, Martine
   Munoz, Susana
TI Family Therapy and COVID-19: International Reflections during the
   Pandemic from Systemic Therapists across the Globe
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF FAMILY THERAPY
LA English
DT Article
DE COVID-19; collective trauma; family therapy; intergenerational trauma;
   cross-cultural; language; cultural diversity
ID TRAUMA; LENS
AB The COVID-19 pandemic has convulsed human communities across the globe like no previous event in history. Family therapists, paradoxically, given the core of their work is with systems, are also experiencing upheaval in professional and personal lives, trying to work amidst a society in chaos. This paper offers a collection of reflections by systemic and family therapists from diverse cultures and contexts penned in the midst of the pandemic. The main intention in distilling these narratives is to preserve the 'cultural diversity' and 'ecological position' of the contributors, guided by phenomenology, cultural ecology, and systemic worldviews of 'experiencing.' The second intention is to 'unite' promoting solidarity in this isolating situation by bringing each story together, creating its own metaphor of a family: united, connected, stronger. As a cross-cultural family practitioner, with a strong mission for collaboration, the lead author acknowledges the importance of Context - the nation and location of the experience; Culture - the manner in which culture impacts on experience; Collaboration - enhancing partnership, enriching knowledge, and mapping the journey's direction; and Connectedness - combating isolation while enhancing unity. Since the key transmission of culture is through language, raw reflections were sought initially in the practitioners' own language, which were translated for an English-speaking readership. These narratives are honest and rich descriptions of the authors' lived experiences, diverse and distinctive. The contributors trust colleagues will find these reflections helpful, validating and acknowledging the challenges of this unique period in history.
C1 [Amorin-Woods, Deisy] Insight Counselling & Relationship Ctr, Perth, WA, Australia.
   [Amorin-Woods, Deisy] Edith Cowan Univ, Sch Social Work & Social Sci, Perth, WA, Australia.
   [Fraenkel, Peter] Ackerman Inst Family, Ctr Work & Family, New York, NY USA.
   [Mosconi, Andrea] Paduan Ctr Family Therapy, Padua, Italy.
   [Nisse, Martine] Ctr Buttes Chaumont, Paris, France.
   [Munoz, Susana] Serbal Ctr Desarrollos Sistem, Santiago, Chile.
RP Amorin-Woods, D (corresponding author), Insight Counselling & Relationship Ctr, Perth, WA, Australia.; Amorin-Woods, D (corresponding author), Edith Cowan Univ, Sch Social Work & Social Sci, Perth, WA, Australia.
EM deisy.insightcounselling@bigpond.com; fraenkelorama@gmail.com;
   mosconial@gmail.com; martine.nisse@lecentredesbutteschaumont.org;
   esusana@gmail.com
RI Fraenkel, Peter/AAF-8144-2020
CR Amorin-Woods D., 2019, AUSTR ASS FAMILY THE, V43, P16
   Amorin-Woods D., 2016, CONV RES APF PROC TE
   Amorin-Woods D., 2016, AAFT NAT C CAIRNS AU
   Amorin-Woods D, 2020, AUST NZ J FAM THER, V41, P42, DOI 10.1002/anzf.1402
   Andolfi M., 2012, CHILDREN MARGINS BAM
   APONTE HJ, 1992, J MARITAL FAM THER, V18, P269, DOI 10.1111/j.1752-0606.1992.tb00940.x
   Bateson G., 1979, ADV SYSTEMS THEORY C
   Bowlby J., 1993, APEGO
   CECCHIN G, 1987, FAM PROCESS, V26, P405, DOI 10.1111/j.1545-5300.1987.00405.x
   Ellis C., 2000, AUTOETHNOGRAPHY PERS
   Erickson M. H., 1979, HYPNOTHERAPY EXPLORA
   Fraenkel P, 2002, FAM PROCESS, V41, P20, DOI 10.1111/j.1545-5300.2002.40102000020.x
   Fraenkel P., 2001, PSYCHOTHERAPY NETWOR, V25, P20
   Fraenkel P., 2001, WHY DO FOOLS FALL LO, P61
   Fraenkel P., 2020, TAO LOVE LIFE LESSON
   Fraenkel P, 2019, FAM PROCESS, V58, P569, DOI 10.1111/famp.12474
   Gunnell D, 2020, LANCET PSYCHIAT, V7, P468, DOI 10.1016/S2215-0366(20)30171-1
   James K, 2012, AUST NZ J FAM THER, V33, P189, DOI 10.1017/aft.2012.25
   Kubler-Ross E., 2009, 5 STAGES GRIEF
   Lao Tzu, WAY LIFE UNPUB
   Lee Susan K, 2009, Qual Prim Care, V17, P63
   Lum W, 2002, CONTEMP FAM THER, V24, P181, DOI 10.1023/A:1014385908625
   MacLean J, 2009, BIOL REPROD, P166
   Minuchin S., 1974, FAMILIES FAMILY THER
   Munoz S., 2019, VINCULO PERCEPCION C
   Nisse M., 2020, GENOGRAMMES AUJOURDH
   Nisse M., 2004, QUAND FAMILLE MARCHE
   Prigogine I., 2001, FIN CERTITUDES TEMPS
   Rhodes P, 2018, AUST NZ J FAM THER, V39, P232, DOI 10.1002/anzf.1291
   Rueda C, 2015, HISPANIA-J DEV INTER, V98, P452
   Selvini Palazzoli M., 1975, PARADOSSO CONTROPARA
   Selvini Palazzoli M., 1980, TERAPIA FAMILIARE, V19, P3
   Sluzki C., 1993, RED SOCIAL FRONTERA
   von Foerster Heinz, 1981, OBSERVING SYSTEMS
NR 34
TC 1
Z9 1
U1 6
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0814-723X
EI 1467-8438
J9 AUST NZ J FAM THER
JI Aust. N. Z. J. Fam. Ther.
PD JUN
PY 2020
VL 41
IS 2
BP 114
EP 132
DI 10.1002/anzf.1416
EA JUN 2020
PG 19
WC Family Studies
SC Family Studies
GA MB8VU
UT WOS:000538681600001
PM 32836731
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Govindarajan, R
   Berry, JD
   Paganoni, S
   Pulley, MT
   Simmons, Z
AF Govindarajan, Raghav
   Berry, James D.
   Paganoni, Sabrina
   Pulley, Michael T.
   Simmons, Zachary
TI Optimizing telemedicine to facilitate amyotrophic lateral sclerosis
   clinical trials
SO MUSCLE & NERVE
LA English
DT Article; Early Access
DE ALS; clinical trials; COVID-19; eConsent; telemedicine; telepresenter;
   telescreening
ID PSEUDOBULBAR AFFECT; ALSFRS-R; SCALE; RELIABILITY; TELEHEALTH;
   ENROLLMENT; INVENTORY; VALIDITY
AB Amyotrophic lateral sclerosis (ALS) has the largest drug pipeline among neuromuscular diseases, with over 160 companies actively involved in ALS research. There is a growing need to recruit trial participants, but ALS patients often have limited mobility and most ALS trials are conducted in a small number of major centers. These factors effectively limit patient participation, particularly for those in rural areas. The current coronavirus disease 2019 (COVID-19) pandemic has necessitated the more widespread use of telemedicine technology for clinical care, and has prompted consideration of its increased use for clinical trials. In this opinion piece, we describe the current state of telemedicine for recruitment, consenting, and screening of participants for clinical trials. We also summarize the available data on remote administration of outcome measures. Current challenges include validation of outcome measures for remote assessment, as well as technological, regulatory, and licensure barriers.
C1 [Govindarajan, Raghav] Univ Missouri, Dept Neurol, Columbia, MO 65212 USA.
   [Berry, James D.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
   [Berry, James D.] Massachusetts Gen Hosp, Neurol Clin Trials Unit, Boston, MA 02114 USA.
   [Paganoni, Sabrina] Massachusetts Gen Hosp, Healey Ctr ALS, Boston, MA 02114 USA.
   [Paganoni, Sabrina] Harvard Med Sch, Spaulding Rehabil Hosp, Dept PM&R, Boston, MA 02115 USA.
   [Pulley, Michael T.] Univ Florida, Dept Neurol, Jacksonville, FL USA.
   [Simmons, Zachary] Penn State Hlth MS Hershey Med Ctr, Dept Neurol, Hershey, PA USA.
RP Govindarajan, R (corresponding author), Univ Missouri, Dept Neurol, Columbia, MO 65212 USA.
EM govindarajanr@health.missouri.edu
OI Simmons, Zachary/0000-0001-8574-5332
CR Abe K, 2017, LANCET NEUROL, V16, P505, DOI 10.1016/S1474-4422(17)30115-1
   Bakker LA, 2020, J NEUROL NEUROSUR PS, V91, P75, DOI 10.1136/jnnp-2019-321138
   Bedlack RS, 2008, AMYOTROPH LATERAL SC, V9, P257, DOI 10.1080/17482960802195913
   Bedlack RS, 2010, AMYOTROPH LATERAL SC, V11, P502, DOI 10.3109/17482968.2010.484494
   BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901
   Berry JD, 2019, ANN CLIN TRANSL NEUR, V6, P873, DOI 10.1002/acn3.770
   Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8
   Brooks BR, 2004, NEUROLOGY, V63, P1364
   Bunnell BE, 2020, TELEMED E-HEALTH, V26, P51, DOI 10.1089/tmj.2018.0221
   Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5
   Dunn A., 2019, BIOPHARMADIVE
   EveryCRSReport.com, 2001, EVERYCRSREPORT
   Felgoise SH, 2018, MUSCLE NERVE, V58, P646, DOI 10.1002/mus.26203
   Geronimo A, 2019, AMYOTROPH LAT SCL FR, V20, P348, DOI 10.1080/21678421.2019.1587633
   Geronimo A, 2017, AMYOTROPH LAT SCL FR, V18, P555, DOI 10.1080/21678421.2017.1338298
   Gibbons CJ, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-101
   Hirsch IB, 2017, CLIN THER, V39, P1064, DOI 10.1016/j.clinthera.2017.03.018
   Holland JC, 1998, PSYCHO-ONCOL, V7, P460, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<460::AID-PON328>3.0.CO;2-R
   Horton DK, 2018, AMYOTROPH LAT SCL FR, V19, P126, DOI 10.1080/21678421.2017.1406953
   Jackson NM, 2020, CORONAVIRUS OFFERS O
   Jenkinson C, 1999, AMYOTROPH LATERAL SC, V1, P33
   Kaufmann P, 2007, AMYOTROPH LATERAL SC, V8, P42, DOI 10.1080/17482960600888156
   Kruse CS, 2018, J TELEMED TELECARE, V24, P4, DOI 10.1177/1357633X16674087
   Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3
   McCormack MC, 2020, PULMONARY FUNCTION L
   Melao A, CENTAUR PHASE 2 TRIA
   Montes J, 2006, NEUROLOGY, V67, P1294, DOI 10.1212/01.wnl.0000238505.22066.fc
   Nims P., 2013, ROLE TELEPRESENTER
   PERKINSON MA, 1994, J GERONTOL, V49, pS264, DOI 10.1093/geronj/49.5.S264
   Plowman EK, 2016, NEUROGASTROENT MOTIL, V28, P85, DOI 10.1111/nmo.12700
   Pulley MT, 2019, MUSCLE NERVE, V59, P34, DOI 10.1002/mus.26170
   Rutkove SB, 2019, AMYOTROPH LAT SCL FR, V20, P61, DOI 10.1080/21678421.2018.1541095
   Saltzman J., 2019, SPEED DRUG DEV MASS
   Sharpe TJ, 2019, ADOPTING ECONSENT BE, V18
   Smith RA, 2004, MULT SCLER J, V10, P679, DOI 10.1191/1352458504ms1106oa
   Stephens HE, 2016, AMYOTROPH LAT SCL FR, V17, P55, DOI 10.3109/21678421.2015.1069851
   Van De Rijn M, 2018, AMYOTROPH LAT SCL FR, V19, P143, DOI 10.1080/21678421.2017.1392577
   van Eijk RPA, 2019, J NEUROL, V266, P2387, DOI 10.1007/s00415-019-09427-5
   Weinstein RS, 2018, MED CLIN N AM, V102, P533, DOI 10.1016/j.mcna.2018.01.002
   Whisman MA, 2000, J CLIN PSYCHOL, V56, P545, DOI 10.1002/(SICI)1097-4679(200004)56:4<545::AID-JCLP7>3.0.CO;2-U
NR 40
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
DI 10.1002/mus.26921
EA JUN 2020
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA LV7LV
UT WOS:000538619200001
PM 32415876
OA Bronze
DA 2021-01-01
ER

PT J
AU Shivarov, V
   Ivanova, M
AF Shivarov, Velizar
   Ivanova, Milena
TI Clonal haematopoiesis and COVID-19: A possible deadly liaison
SO INTERNATIONAL JOURNAL OF IMMUNOGENETICS
LA English
DT Article
DE ARDS; clonal haematopoiesis; COVID-19; inflammation; SARS-CoV-2
ID RISK
AB We provide evidence for a linear correlation between the frequency of clonal haematopoiesis and COVID-19 mortality rate. We discuss the mechanistic explanations for this association mediated by a pathological inflammatory response. Our hypothesis can be tested in COVID-19-infected patients and eventually lead to new approaches to risk stratification and therapy.
C1 [Shivarov, Velizar] Sofiamed Univ Hosp, Dept Clin Hematol, Block 2,10 Dimitar Mollov Str, Sofia 1750, Bulgaria.
   [Shivarov, Velizar] Sofiamed Univ Hosp, Lab Clin Immunol, Sofia, Bulgaria.
   [Shivarov, Velizar] Sofia Univ St Kliment Ohridski, Dept Genet, Fac Biol, Sofia, Bulgaria.
   [Ivanova, Milena] Med Univ Sofia, Univ Hosp Alexandrovska, Dept Clin Immunol, Sofia, Bulgaria.
RP Shivarov, V (corresponding author), Sofiamed Univ Hosp, Dept Clin Hematol, Block 2,10 Dimitar Mollov Str, Sofia 1750, Bulgaria.
EM vshivarov@abv.bg
OI Shivarov, Velizar/0000-0001-5362-7999
CR Arends C. M., 2019, HAEMATOLOGICA, V2019, P223305, DOI [10.3324/haematol.2019.223305, DOI 10.3324/HAEMAT0L.2019.223305]
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Cook EK, 2020, EXP HEMATOL, V83, P85, DOI 10.1016/j.exphem.2020.01.011
   Cook EK, 2019, BLOOD ADV, V3, P2482, DOI 10.1182/bloodadvances.2018024729
   Cull AH, 2017, EXP HEMATOL, V55, P56, DOI 10.1016/j.exphem.2017.08.001
   Dorsheimer L, 2019, JAMA CARDIOL, V4, P25, DOI 10.1001/jamacardio.2018.3965
   Feng XM, 2011, HAEMATOL-HEMATOL J, V96, P602, DOI 10.3324/haematol.2010.030536
   Franceschi C, 2018, NAT REV ENDOCRINOL, V14, P576, DOI 10.1038/s41574-018-0059-4
   Fuster JJ, 2017, SCIENCE, V355, P842, DOI 10.1126/science.aag1381
   Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haney SL, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006334
   Hermouet S, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/145293
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jaiswal S, 2017, NEW ENGL J MED, V377, P111, DOI 10.1056/NEJMoa1701719
   Jaiswal S, 2019, SCIENCE, V366, P586, DOI 10.1126/science.aan4673
   Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617
   Li X, 2016, NAT IMMUNOL, V17, P806, DOI 10.1038/ni.3464
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sano S, 2018, J AM COLL CARDIOL, V71, P875, DOI 10.1016/j.jacc.2017.12.037
   Savola P, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0107-2
   Wang Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135204
NR 24
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-3121
EI 1744-313X
J9 INT J IMMUNOGENET
JI Int. J. Immunogenet.
PD AUG
PY 2020
VL 47
IS 4
BP 329
EP 331
DI 10.1111/iji.12503
EA JUN 2020
PG 3
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA ML9IN
UT WOS:000538758200001
PM 32515168
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sernicola, A
   Carnicelli, G
   Di Fraia, M
   Chello, C
   Furlan, C
   Muharremi, R
   Paolino, G
   Grieco, T
AF Sernicola, A.
   Carnicelli, G.
   Di Fraia, M.
   Chello, C.
   Furlan, C.
   Muharremi, R.
   Paolino, G.
   Grieco, T.
TI 'Toxic erythema' and eosinophilia associated with tocilizumab therapy in
   a COVID-19 patient
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Letter
ID DRUG REACTION
C1 [Sernicola, A.; Carnicelli, G.; Di Fraia, M.; Chello, C.; Muharremi, R.; Paolino, G.; Grieco, T.] Sapienza Univ Rome, Dermatol Unit, Rome, Italy.
   [Furlan, C.] Sapienza Univ Rome, Infect Dis Unit, Rome, Italy.
RP Grieco, T (corresponding author), Sapienza Univ Rome, Dermatol Unit, Rome, Italy.
EM teresa.grieco@uniroma1.it
RI Sernicola, Alvise/ABI-4605-2020; carnicelli, giorgia/AAM-7643-2020
OI Sernicola, Alvise/0000-0002-1985-0326; Grieco,
   Teresa/0000-0001-7855-6621; Di Fraia, Marco/0000-0002-9679-8859;
   Paolino, Giovanni/0000-0002-3032-2217
CR Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim DH, 2014, ALLERGY ASTHMA IMMUN, V6, P216, DOI 10.4168/aair.2014.6.3.216
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Massolino RI, 2018, RHEUMATOL ADV PRACT, V2, DOI 10.1093/rap/rky029
   Morrisroe K, 2015, RHEUMATOLOGY, V54, P2113, DOI 10.1093/rheumatology/kev275
   Nakamura M, 2009, EUR J DERMATOL, V19, P273, DOI 10.1684/ejd.2009.0642
   Rajaee A, 2018, SURG INFECT, V19, P107, DOI 10.1089/sur.2017.264
   Rocchi V, 2014, RHEUMATOLOGY, V53, P1527, DOI 10.1093/rheumatology/keu181
   Yoshiki R, 2010, J EUR ACAD DERMATOL, V24, P495, DOI 10.1111/j.1468-3083.2009.03437.x
   Zuelgaray E, 2017, ANN INTERN MED, V167, P141, DOI 10.7326/L16-0592
NR 10
TC 3
Z9 3
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
EI 1468-3083
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
PD AUG
PY 2020
VL 34
IS 8
BP E368
EP E370
DI 10.1111/jdv.16620
EA JUN 2020
PG 3
WC Dermatology
SC Dermatology
GA MZ2BW
UT WOS:000538674300001
PM 32386438
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Conti, A
   Lasagni, C
   Bigi, L
   Pellacani, G
AF Conti, A.
   Lasagni, C.
   Bigi, L.
   Pellacani, G.
TI Evolution of COVID-19 infection in four psoriatic patients treated with
   biological drugs
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Letter
C1 [Conti, A.; Lasagni, C.; Bigi, L.; Pellacani, G.] Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci, Transplant Oncol & Regenerat Med Dermatol Unit, Modena, Italy.
RP Conti, A (corresponding author), Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci, Transplant Oncol & Regenerat Med Dermatol Unit, Modena, Italy.
EM a.conti.dermo@gmail.com
RI Pellacani, Giovanni/E-8573-2011; Conti, Andrea/K-8793-2013
OI Pellacani, Giovanni/0000-0002-7222-2951; Conti,
   Andrea/0000-0003-4848-3817
CR Chen C, 2020, ZHONGHUA SHAO SHANG, V36, pE005
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Messina F, 2020, J EUR ACAD DERMATOL, V34, pE254, DOI 10.1111/jdv.16468
   Shi XL, 2013, CRIT CARE, V17, DOI 10.1186/cc13171
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 6
TC 12
Z9 13
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
EI 1468-3083
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
PD AUG
PY 2020
VL 34
IS 8
BP E360
EP E361
DI 10.1111/jdv.16587
EA JUN 2020
PG 2
WC Dermatology
SC Dermatology
GA MZ2BW
UT WOS:000538741100001
PM 32379913
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Anbarasu, A
   Ramaiah, S
   Livingstone, P
AF Anbarasu, Anand
   Ramaiah, Sudha
   Livingstone, Paul
TI Vaccine repurposing approach for preventing COVID 19: can MMR vaccines
   reduce morbidity and mortality?
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE COVID-19; SARS-CoV-2; children; innate immunity; MMR Vaccine;
   prophylaxis
AB The coronavirus disease (COVID-19) is resulting in millions of infected individuals with several hundred thousands dead throughout the world. Amidst all the havoc, one interesting observation in the present COVID-19 pandemic is the negligible symptoms in the young; particularly children below 10 years of age. We assume the extensive pediatric vaccination with MMR vaccines followed globally could have resulted in innate immune responses, e.g., induction of interferons (IFNs) and activated natural killer (NK) cells, thereby offering natural immunity against SARS-CoV-2 in the young population. Possible cross-protective innate immunity offered by MMR vaccination prompted us to suggest repurposing MMR vaccination for immuno-prophylaxis against COVID-19.
C1 [Anbarasu, Anand; Ramaiah, Sudha] Vellore Inst Technol, Sch Biosci & Technol, Vellore, Tamil Nadu, India.
   [Livingstone, Paul] Cardiff Metropolitan Univ, Sch Sports & Hlth Sci, Cardiff, Wales.
RP Anbarasu, A (corresponding author), Vellore Inst Technol, Sch Biosci & Technol, Med & Biol Comp Lab, Vellore 632014, Tamil Nadu, India.
EM aanand@vit.ac.in
RI Anbarasu, Anand/K-4076-2017
OI Anbarasu, Anand/0000-0003-2216-7488; Livingstone,
   Paul/0000-0002-1694-305X
FU Indian council of Medical Research (Government of India)Indian Council
   of Medical Research (ICMR) [2019-0810]
FX AA and SR thank the Indian council of Medical Research (Government of
   India, agency) for the research grant IRIS ID: 2019-0810.
CR Cameron MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045842
   Kelvin AA, 2020, LANCET INFECT DIS, V20, P633, DOI 10.1016/S1473-3099(20)30236-X
   Moss William J., 2008, WHO IMMUNOLOGICAL BA
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   SCHAPIRO JM, 1990, J MED VIROL, V30, P196, DOI 10.1002/jmv.1890300310
   Sleijfer S, 2005, PHARM WORLD SCI, V27, P423, DOI 10.1007/s11096-005-1319-7
   WHO, 2020, 80 WHO
NR 7
TC 0
Z9 0
U1 4
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD SEP 1
PY 2020
VL 16
IS 9
BP 2217
EP 2218
DI 10.1080/21645515.2020.1773141
EA JUN 2020
PG 2
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA NU9MN
UT WOS:000542822000001
PM 32501133
OA Bronze
DA 2021-01-01
ER

PT J
AU Taxonera, C
   Sagastagoitia, I
   Alba, C
   Manas, N
   Olivares, D
   Rey, E
AF Taxonera, Carlos
   Sagastagoitia, Inigo
   Alba, Cristina
   Manas, Norberto
   Olivares, David
   Rey, Enrique
TI 2019 novel coronavirus disease (COVID-19) in patients with inflammatory
   bowel diseases
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
AB Background Data on patients with inflammatory bowel diseases (IBD) who have had 2019 novel coronavirus (SARS-CoV-2) disease (COVID-19) are needed.
   Aim To report the clinical characteristics, including gastrointestinal symptoms, of COVID-19 in IBD patients, and to assess the risk of COVID-19 in IBD.
   Methods This case series included consecutive IBD patients with laboratory-confirmed COVID-19. Age-adjusted cumulative incidences were compared with the general population in the Madrid region.
   Results Through April 8, 12 of 1918 IBD patients were diagnosed with COVID-19. The average age was 52 years, 75% of the patients were female and 58.3% had Crohn's disease. Seven patients (58%) were on maintenance treatment with immunomodulators/biologics, of these four with combined therapy (33%). Eight patients (66%) required hospitalisation (one intensive care unit admission, and two deaths), and four patients were isolated at home. Nine patients had diarrhoea ranging between 4 and 10 loose stools per day (mean 5.4, SD 1.6). In five patients (42%) diarrhoea was a presenting symptom. In two patients, diarrhoea was the only symptom at debut. Cumulative incidence of COVID-19 was 6.2 per 1000 IBD patients. IBD patients had a lower adjusted incidence ratio of COVID-19 (OR 0.74, 95% CI 0.70-0.77; P < 0.001), and a similar associated mortality ratio (OR 0.95, 95% CI: 0.84-1.06; P = 0.36), compared with the general population.
   Conclusions IBD patients do not have an increased risk of COVID-19 and associated mortality compared with the general population. In many IBD patients, diarrhoea was a presenting symptom, and sometimes, was the only symptom at onset of COVID-19.
C1 [Taxonera, Carlos; Alba, Cristina; Manas, Norberto; Olivares, David; Rey, Enrique] Hosp Clin San Carlos, Inflammatory Bowel Dis Unit, Dept Gastroenterol, C Prof Martin Lagos S-N, Madrid 28040, Spain.
   [Taxonera, Carlos; Sagastagoitia, Inigo; Alba, Cristina; Manas, Norberto; Olivares, David; Rey, Enrique] Inst Invest Hosp Clin San Carlos IdISSC, Madrid, Spain.
   [Sagastagoitia, Inigo] Hosp Clin San Carlos, Dept Internal Med, Madrid, Spain.
RP Taxonera, C (corresponding author), Hosp Clin San Carlos, Inflammatory Bowel Dis Unit, Dept Gastroenterol, C Prof Martin Lagos S-N, Madrid 28040, Spain.
EM carlos.taxonera@salud.madrid.org
RI Rey, Enrique/B-9492-2008
OI Rey, Enrique/0000-0002-5060-7105; sagastagoitia,
   inigo/0000-0003-0905-1974
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen YF, 2020, J MED VIROL, V92, P833, DOI 10.1002/jmv.25825
   Fang WF, 2011, CRIT CARE, V15, DOI 10.1186/cc9979
   Ford AC, 2013, AM J GASTROENTEROL, V108, P1268, DOI 10.1038/ajg.2013.138
   Garg M, 2020, GUT, V69, P841, DOI 10.1136/gutjnl-2019-318512
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2004, EMERG INFECT DIS, V10, P1550, DOI 10.3201/eid1009.040058
   IOIBD, 2020, IOIBD UPD COVID19 PA
   Jacobs J, 2020, INFLAMM BOWEL DIS, V26, pE64, DOI 10.1093/ibd/izaa093
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Luo SH, 2020, CLIN GASTROENTEROL H, V18, P1636, DOI 10.1016/j.cgh.2020.03.043
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Mazza S, 2020, GUT, V69, P1148, DOI 10.1136/gutjnl-2020-321183
   Ning LG, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3950628
   Norsa L, 2020, GASTROENTEROLOGY, DOI [10. 1053/j.gastro.2020.03.062, DOI 10.1053/J.GASTR0.2020.03.062]
   Rubin DT, 2020, GASTROENTEROLOGY, DOI [10.1053/j.gastro.2020.04.012, DOI 10.1053/J.GASTR0.2020.04.012]
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Song FX, 2020, RADIOLOGY, V295, P210, DOI 10.1148/radiol.2020200274
   Song Y, 2020, GUT, V69, P1143, DOI 10.1136/gutjnl-2020-320891
   Turner Dan, 2020, J Pediatr Gastroenterol Nutr, DOI 10.1097/MPG.0000000000002729
   Tursi A, 2020, GUT, V69, P1364, DOI 10.1136/gutjnl-2020-321240
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   WHO, 2020, CLIN MAN SEV AC RESP
   Wisniewski A, 2020, UNITED EUR GASTROENT, V8, P303, DOI 10.1177/2050640619889763
   World Health Organization, COR DIS COVID 19 OUT
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou J, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao4966
NR 33
TC 30
Z9 30
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD JUL
PY 2020
VL 52
IS 2
BP 276
EP 283
DI 10.1111/apt.15804
EA JUN 2020
PG 8
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA MC6HY
UT WOS:000538299400001
PM 32359205
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Piemonti, L
   Landoni, G
AF Piemonti, Lorenzo
   Landoni, Giovanni
TI COVID-19 and islet transplantation: Different twins
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical decision-making; clinical trial design; cytokines; cytokine
   receptors; editorial; personal viewpoint; immune regulation; infection
   and infectious agents - viral; infectious disease; islet transplantation
ID ANTIINFLAMMATORY STRATEGIES; NEUTROPHIL EMIGRATION; CYTOKINE STORM;
   EDEMA FLUID; INHIBITION; ACTIVATION; CHEMOKINES; CXCR1/2
AB For those who work in the field of islet transplantation, the microvascular coronavirus disease 2019 (COVID-19) lung vessels obstructive thrombo-inflammatory syndrome (recently referred to as MicroCLOTS) is familiar, as one cannot fail to recognize the presence of similarities with the instant blood mediated inflammatory reaction (IBMIR) occurring in the liver hours and days after islet infusion. Evidence in both MicroCLOTS and IBMIR suggests the involvement of the coagulation cascade and complement system activation and proinflammatory chemokines/cytokines release. Identification and targeting of pathway(s) playing a role as "master regulator(s)" in the post-islet transplant detrimental inflammatory events could be potentially useful to suggest innovative COVID-19 treatments and vice versa. Scientific organizations across the world are fighting the COVID-19 pandemic. Islet transplantation, and more generally the transplantation scientific community, could contribute by suggesting strategies for innovative approaches. At the same time, in the near future, clinical trials in COVID-19 patients will produce an enormous quantity of clinical and translational data on the control of inflammation and complement/microthrombosis activation. These data will represent a legacy to be transformed into innovation in the transplant field. It will be our contribution to change a dramatic event into advancement for the transplant field and ultimately for our patients.
C1 [Piemonti, Lorenzo] IRCCS Osped San Raffaele, Diabet Res Inst, Milan, Italy.
   [Piemonti, Lorenzo; Landoni, Giovanni] Univ Vita Salute San Raffaele, Milan, Italy.
   [Landoni, Giovanni] IRCCS San Raffaele Sci Inst, Dept Anesthesia & Intens Care, Milan, Italy.
RP Piemonti, L (corresponding author), IRCCS Osped San Raffaele, Diabet Res Inst, Milan, Italy.; Piemonti, L (corresponding author), Univ Vita Salute San Raffaele, Milan, Italy.
EM piemonti.lorenzo@hsr.it
RI Piemonti, Lorenzo/P-7605-2017
OI Piemonti, Lorenzo/0000-0002-2172-2198; LANDONI,
   Giovanni/0000-0002-8594-5980
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   Carsana L, 2020, PULMONARY POSTMORTEM, DOI [10.1101/2020.04.19.20054262, DOI 10.1101/2020.04.19.20054262]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Choi SE, 2004, TRANSPL IMMUNOL, V13, P43, DOI 10.1016/j.trim.2004.04.001
   Ciceri F., 2020, CRIT CARE RESUSC
   Citro A, 2018, TRANSPLANTATION, V102, P240, DOI 10.1097/TP.0000000000001925
   Citro A, 2013, CURR DIABETES REP, V13, P733, DOI 10.1007/s11892-013-0401-0
   Citro A, 2012, J CLIN INVEST, V122, P3647, DOI 10.1172/JCI63089
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Gao T, 2020, HIGHLY PATHOGENIC CO, DOI [10.1101/2020.03.29.20041962, DOI 10.1101/2020.03.29.20041962]
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Goulding J, 2011, J INFECT DIS, V204, P1086, DOI 10.1093/infdis/jir467
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussell T, 2001, EUR J IMMUNOL, V31, P2566, DOI 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L
   Keane MP, 2002, J IMMUNOL, V169, P6515, DOI 10.4049/jimmunol.169.11.6515
   Kim JM, 2019, ISLETS, V11, P119, DOI 10.1080/19382014.2019.1650580
   Krupa A, 2004, AM J PHYSIOL-LUNG C, V286, pL1105, DOI 10.1152/ajplung.00277.2003
   Maffi P, 2020, DIABETES CARE, V43, P710, DOI 10.2337/dc19-1480
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Miller EJ, 1996, CRIT CARE MED, V24, P1448, DOI 10.1097/00003246-199609000-00004
   Min BH, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12374
   Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Nilsson B, 2014, MOL IMMUNOL, V61, P185, DOI 10.1016/j.molimm.2014.06.009
   Nilsson B, 2011, CURR OPIN ORGAN TRAN, V16, P620, DOI 10.1097/MOT.0b013e32834c2393
   Puneet P, 2005, AM J PHYSIOL-LUNG C, V288, pL3, DOI 10.1152/ajplung.00405.2003
   Sciascia S, 2020, CLIN EXP RHEUMATOL
   Stillie R, 2009, J LEUKOCYTE BIOL, V86, P529, DOI 10.1189/jlb.0208125
   von Zur-Muhlen B, 2019, TRANSPLANTATION, V103, P630, DOI 10.1097/TP.0000000000002425
   WINN RK, 1993, EXP LUNG RES, V19, P221, DOI 10.3109/01902149309031721
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang Y., 2020, EXUBERANT ELEVATION, DOI [10.1101/2020.03.02.20029975, DOI 10.1101/2020.03.02.20029975]
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zarbock A, 2008, BRIT J PHARMACOL, V155, P357, DOI 10.1038/bjp.2008.270
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou GB, 2020, FRONT MED-PRC, V14, P117, DOI 10.1007/s11684-020-0773-x
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 41
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2020
VL 20
IS 11
BP 2983
EP 2988
DI 10.1111/ajt.16001
EA JUN 2020
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OH7XN
UT WOS:000538297400001
PM 32400017
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Schmith, VD
   Zhou, J
   Lohmer, LRL
AF Schmith, Virginia D.
   Zhou, Jie (Jessie)
   Lohmer, Lauren R. L.
TI The Approved Dose of Ivermectin Alone is not the Ideal Dose for the
   Treatment of COVID-19
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
AB Caly et al.(1) reported that ivermectin inhibited severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) in vitro for up to 48 hours using ivermectin at 5 mu M. The concentration resulting in 50% inhibition (IC50; 2 mu M) was > 35x higher than the maximum plasma concentration (C-max) after oral administration of the approved dose of ivermectin when given fasted. Simulations were conducted using an available population pharmacokinetic model to predict total (bound and unbound) and unbound plasma concentration-time profiles after a single and repeat fasted administration of the approved dose of ivermectin (200 mu g/kg), 60 mg, and 120 mg. Plasma total C-max was determined and then multiplied by the lung:plasma ratio reported in cattle to predict the lung C-max after administration of each single dose. Plasma ivermectin concentrations of total (bound and unbound) and unbound concentrations do not reach the IC50, even for a dose level 10x higher than the approved dose. Even with the high lung:plasma ratio, ivermectin is unlikely to reach the IC50 in the lungs after single oral administration of the approved dose (predicted lung: 0.0873 mu M) or at doses 10x higher that the approved dose administered orally (predicted lung: 0.820 mu M). In summary, the likelihood of a successful clinical trial using the approved dose of ivermectin is low. Combination therapy should be evaluated in vitro. Repurposing drugs for use in coronavirus disease 2019 (COVID-19) treatment is an ideal strategy but is only feasible when product safety has been established and experiments of repurposed drugs are conducted at clinically relevant concentrations.
C1 [Schmith, Virginia D.; Zhou, Jie (Jessie); Lohmer, Lauren R. L.] Nuventra Pharma Sci, Durham, NC 27713 USA.
RP Schmith, VD (corresponding author), Nuventra Pharma Sci, Durham, NC 27713 USA.
EM gschmith@nuventra.com
OI Lohmer, Lauren/0000-0001-9716-4711
CR [Anonymous], 34 ANN M ROYAL COLL
   [Anonymous], 2018, STROMECTOL IV TABL P
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Centers for Disease Control and Prevention, 2009, US GROWTH CHARTS
   Duthaler U, 2019, BRIT J CLIN PHARMACO, V85, P626, DOI 10.1111/bcp.13840
   Guzzo CA, 2002, J CLIN PHARMACOL, V42, P1122, DOI 10.1177/009127002401382731
   Ji L., 2016, CHINESE J COMPARAT M, V26, P70
   KLOTZ U, 1990, EUR J CLIN PHARMACOL, V39, P607, DOI 10.1007/BF00316107
   Lespine A, 2005, VET PARASITOL, V128, P251, DOI 10.1016/j.vetpar.2004.11.028
   Lifschitz A, 2000, VET PARASITOL, V87, P327, DOI 10.1016/S0304-4017(99)00175-2
   Patel A., 2020, SSRN ELECT J
   SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7
   Turner SA, 2005, AM J TROP MED HYG, V73, P911, DOI 10.4269/ajtmh.2005.73.911
NR 13
TC 14
Z9 14
U1 2
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD OCT
PY 2020
VL 108
IS 4
BP 762
EP 765
DI 10.1002/cpt.1889
EA JUN 2020
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NQ3JW
UT WOS:000538300300001
PM 32378737
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU He, YF
   Lian, SJ
   Dong, YC
AF He, Yan-Fei
   Lian, Shi-Jie
   Dong, Yu-Chao
TI Clinical characteristics, diagnosis, and treatment of COVID-19: A case
   report
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Clinical characteristics; Diagnosis and treatment;
   Young adults; Case report
ID SARS
AB BACKGROUND
   Since December 2019, many cases of pneumonia caused by novel coronavirus have been discovered in Wuhan, China, and such cases have spread nationwide quickly. At present, coronavirus disease 2019 (COVID-19) is a worldwide pandemic. What are the clinical features of this disease? What is the clinical diagnosis and how should such patients be treated? As a clinician, mastery of the clinical characteristics, basic diagnosis, and treatment methods of COVID-19 are required to provide help to patients.
   CASE SUMMARY
   A 42-year-old male patient with a cough lasting 6 d without obvious cause, as well as fever and fatigue for 1 d, was admitted to Hankou Hospital on January 22, 2020 and transferred to Huoshenshan Hospital on February 4. The main clinical symptoms were dry cough, fatigue, and fever. He was diagnosed with COVID-19. From the 4(th) d of admission, the patient's condition gradually worsened, with increased respiratory rate and body temperature. Peripheral blood lymphocytes decreased progressively. On the 8(th) d of admission, the patient's highest temperature was 40.7 degrees C, and oxygen saturation was 83% despite high-flow oxygen inhalation. Chest computed tomography results showed that the virus progressed rapidly. The number of lesions significantly increased with expanded scope and increased density. The distribution of lesions advanced from peripheral to central. In addition to nasal catheter oxygen inhalation and symptomatic support, antiviral drugs were used throughout the treatment. On January 22, oseltamivir phosphate capsules were given orally (75 mg, twice daily) for 6 d. On January 24, three tablets of lopinavir and ritonavir were added orally (twice daily). After 6 d, this was changed to 0.2 g (two tablets) arbidol, taken orally (three times daily) for 5 d. During the severe stage, methylprednisolone was given (40 mg) once every 12 h, immunoglobulin (20 g) was administered by intravenous drip infusion once daily, and thymosin (1.6 mg) was injected subcutaneously once daily combined with immunotherapy. On February 2, symptoms decreased, various indicators improved, and pulmonary inflammation was obviously reduced. Throat swabs on February 4 and 9 were negative for novel coronavirus nucleic acid. After 19 d in the hospital, the patient was successfully treated and discharged.
   CONCLUSION
   COVID-19 in young adults can be successfully treated with active treatment. We report a typical case of COVID-19, analyze its clinical characteristics, summarize its clinical diagnosis and treatment experience, and provide a reference for clinical colleagues.
C1 [He, Yan-Fei; Lian, Shi-Jie] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 6, Cadre Hlth Care Dept, 6 Fucheng Rd, Beijing 100048, Peoples R China.
   [Dong, Yu-Chao] Naval Med Univ, Changhai Hosp, Dept Resp & Crit Care Med, Shanghai 200433, Peoples R China.
RP He, YF (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Med Ctr 6, Cadre Hlth Care Dept, 6 Fucheng Rd, Beijing 100048, Peoples R China.
EM heyanfeilc@163.com
CR [Anonymous], GUID DIAGN TREATM NO
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chinese Radiology Society, 2020, ZHONGHUAFANGSHEXUEZA, P54
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
   Li Q, 2020, CHINA CDC WEEKLY, V2, P79, DOI DOI 10.46234/ccdcw2020.022
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   The General Office of National Health Commission, COVID 19 DIAGN TREAT
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu X, 2020, EUR J NUCL MED MOL I, V47, P1275, DOI 10.1007/s00259-020-04735-9
   Yang LR, 2011, SHONG YIYAO, V51, P90
NR 16
TC 1
Z9 1
U1 6
U2 8
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD JUN 6
PY 2020
VL 8
IS 11
DI 10.12998/wjcc.v8.i11.2325
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA LZ0HW
UT WOS:000540913700028
PM 32548163
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Cummings, MJ
   Baldwin, MR
   Abrams, D
   Jacobson, SD
   Meyer, BJ
   Balough, EM
   Aaron, JG
   Claassen, J
   Rabbani, LE
   Hastie, J
   Hochman, BR
   Salazar-Schicchi, J
   Yip, NH
   Brodie, D
   O'Donnell, MR
AF Cummings, Matthew J.
   Baldwin, Matthew R.
   Abrams, Darryl
   Jacobson, Samuel D.
   Meyer, Benjamin J.
   Balough, Elizabeth M.
   Aaron, Justin G.
   Claassen, Jan
   Rabbani, LeRoy E.
   Hastie, Jonathan
   Hochman, Beth R.
   Salazar-Schicchi, John
   Yip, Natalie H.
   Brodie, Daniel
   O'Donnell, Max R.
TI Epidemiology, clinical course, and outcomes of critically ill adults
   with COVID-19 in New York City: a prospective cohort study
SO LANCET
LA English
DT Article
AB Background Over 40 000 patients with COVID-19 have been hospitalised in New York City (NY, USA) as of April 28, 2020. Data on the epidemiology, clinical course, and outcomes of critically ill patients with COVID-19 in this setting are needed.
   Methods This prospective observational cohort study took place at two NewYork-Presbyterian hospitals affiliated with Columbia University Irving Medical Center in northern Manhattan. We prospectively identified adult patients (aged >= 18 years) admitted to both hospitals from March 2 to April 1, 2020, who were diagnosed with laboratory-confirmed COVID-19 and were critically ill with acute hypoxaemic respiratory failure, and collected clinical, biomarker, and treatment data. The primary outcome was the rate of in-hospital death. Secondary outcomes included frequency and duration of invasive mechanical ventilation, frequency of vasopressor use and renal replacement therapy, and time to in-hospital clinical deterioration following admission. The relation between clinical risk factors, biomarkers, and in-hospital mortality was modelled using Cox proportional hazards regression. Follow-up time was right-censored on April 28, 2020 so that each patient had at least 28 days of observation.
   Findings Between March 2 and April 1, 2020, 1150 adults were admitted to both hospitals with laboratory-confirmed COVID-19, of which 257 (22%) were critically ill. The median age of patients was 62 years (IQR 51-72), 171 (67%) were men. 212 (82%) patients had at least one chronic illness, the most common of which were hypertension (162 [63%]) and diabetes (92 [36%]). 119 (46%) patients had obesity. As of April 28, 2020, 101 (39%) patients had died and 94 (37%) remained hospitalised. 203 (79%) patients received invasive mechanical ventilation for a median of 18 days (IQR 9-28), 170 (66%) of 257 patients received vasopressors and 79 (31%) received renal replacement therapy. The median time to in-hospital deterioration was 3 days (IQR 1-6). In the multivariable Cox model, older age (adjusted hazard ratio [aHR] 1.31 [1.09-1.57] per 10-year increase), chronic cardiac disease (aHR 1.76 [1.08-2.86]), chronic pulmonary disease (aHR 2.94 [1.48-5.84]), higher concentrations of interleukin-6 (aHR 1.11 [95%CI 1.02-1.20] per decile increase), and higher concentrations of D-dimer (aHR 1.10 [1.01-1.19] per decile increase) were independently associated with in-hospital mortality.
   Interpretation Critical illness among patients hospitalised with COVID-19 in New York City is common and associated with a high frequency of invasive mechanical ventilation, extrapulmonary organ dysfunction, and substantial in-hospital mortality. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Cummings, Matthew J.; Baldwin, Matthew R.; Abrams, Darryl; Salazar-Schicchi, John; Yip, Natalie H.; Brodie, Daniel; O'Donnell, Max R.] Columbia Univ, Div Pulm Allergy & Crit Care Med, Irving Med Ctr, New York, NY USA.
   [Aaron, Justin G.] Columbia Univ, Div Infect Dis, Irving Med Ctr, New York, NY USA.
   [Rabbani, LeRoy E.] Columbia Univ, Div Cardiol, Irving Med Ctr, New York, NY USA.
   [Claassen, Jan] Columbia Univ, Dept Med, Irving Med Ctr, New York, NY USA.
   [Claassen, Jan] Columbia Univ, Dept Neurol, Irving Med Ctr, Div Crit Care & Hospitalist Neurol, New York, NY USA.
   [Hastie, Jonathan; Hochman, Beth R.] Columbia Univ, Div Crit Care Med, Irving Med Ctr, Dept Anesthesiol, New York, NY USA.
   [Hochman, Beth R.] Columbia Univ, Div Gen Surg, Irving Med Ctr, Dept Surg, New York, NY USA.
   [Jacobson, Samuel D.; Meyer, Benjamin J.; Balough, Elizabeth M.] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA.
   [O'Donnell, Max R.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
RP O'Donnell, MR (corresponding author), NewYork Presbyterian Hosp, New York, NY 10032 USA.; O'Donnell, MR (corresponding author), Columbia Univ, Dept Med, Div Pulm Allergy & Crit Care Med, Irving Med Ctr, New York, NY 10032 USA.
EM mo2130@columbia.edu
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [F32AI147528-01]; National Center for Advancing Translational
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR001873]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; Columbia University Irving Institute
   for Clinical and Translational Research
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (F32AI147528-01) and the National Center for
   Advancing Translational Sciences (UL1TR001873), National Institutes of
   Health, and the Columbia University Irving Institute for Clinical and
   Translational Research. The authors would like to thank their patients
   and fellow health-care workers for providing outstanding patient care at
   considerable personal risk.
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bhala N, 2020, LANCET, V395, P1673, DOI 10.1016/S0140-6736(20)31102-8
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   CDC (US Centers for Disease Control), 2020, CHARACTERISTICES HLT, V69, P477, DOI DOI 10.15585/MMWR.MM6915E6
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Helms J, 2020, INTENS CARE MED 0504, DOI [DOI 10.1007/S00134-020-06062-X, 10.1007/s00134-020-06062-x]
   Intensive Care National Audit & Research Centre, ICNARC REP COVID 19
   Kelly CA, 2004, ANN EMERG MED, V44, P108, DOI 10.1016/j.annemergmed.2004.03.028
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   New York State Department of Health, NEW YORK STAT COMM H
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   US Food and Drug Administration, 2020, REMD EM US AUTH
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2020, R D BLUEPR COVID 19
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
NR 28
TC 192
Z9 198
U1 12
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUN 6
PY 2020
VL 395
IS 10239
BP 1763
EP 1770
DI 10.1016/S0140-6736(20)31189-2
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA LZ1MK
UT WOS:000540993600022
PM 32442528
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhang, P
   Zhu, LH
   Cai, JJ
   Lei, F
   Qin, JJ
   Xie, J
   Liu, YM
   Zhao, YC
   Huang, XW
   Lin, LJ
   Xia, M
   Chen, MM
   Cheng, X
   Zhang, X
   Guo, DL
   Peng, YY
   Ji, YX
   Chen, J
   She, ZG
   Wang, YB
   Xu, QB
   Tan, RF
   Wang, HT
   Lin, J
   Luo, PC
   Fu, SZ
   Cai, HB
   Ye, P
   Xiao, B
   Mao, WM
   Liu, LM
   Yan, YQ
   Liu, MY
   Chen, MH
   Zhang, XJ
   Wang, XH
   Touyz, RA
   Xia, JH
   Zhang, BH
   Huang, XD
   Yuan, YF
   Rohit, L
   Liu, PP
   Li, HL
AF Zhang, Peng
   Zhu, Lihua
   Cai, Jingjing
   Lei, Fang
   Qin, Juan-Juan
   Xie, Jing
   Liu, Ye-Mao
   Zhao, Yan-Ci
   Huang, Xuewei
   Lin, Lijin
   Xia, Meng
   Chen, Ming-Ming
   Cheng, Xu
   Zhang, Xiao
   Guo, Deliang
   Peng, Yuanyuan
   Ji, Yan-Xiao
   Chen, Jing
   She, Zhi-Gang
   Wang, Yibin
   Xu, Qingbo
   Tan, Renfu
   Wang, Haitao
   Lin, Jun
   Luo, Pengcheng
   Fu, Shouzhi
   Cai, Hongbin
   Ye, Ping
   Xiao, Bing
   Mao, Weiming
   Liu, Liming
   Yan, Youqin
   Liu, Mingyu
   Chen, Manhua
   Zhang, Xiao-Jing
   Wang, Xinghuan
   Touyz, Rhian M.
   Xia, Jiahong
   Zhang, Bing-Hong
   Huang, Xiaodong
   Yuan, Yufeng
   Rohit, Loomba
   Liu, Peter P.
   Li, Hongliang
TI Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors
   and Angiotensin II Receptor Blockers With Mortality Among Patients With
   Hypertension Hospitalized With COVID-19
SO CIRCULATION RESEARCH
LA English
DT Article
DE angiotensin-converting enzyme inhibitor; angiotensin II receptor
   blocker; coronavirus; COVID-19; hypertension; inpatients
ID HEART-FAILURE; SYSTEM
AB Rationale: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with hypertension. Objective: To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in patients with hypertension and hospitalized due to COVID-19. Methods and Results: This retrospective, multi-center study included 1128 adult patients with hypertension diagnosed with COVID-19, including 188 taking ACEI/ARB (ACEI/ARB group; median age 64 [interquartile range, 55-68] years; 53.2% men) and 940 without using ACEI/ARB (non-ACEI/ARB group; median age 64 [interquartile range 57-69]; 53.5% men), who were admitted to 9 hospitals in Hubei Province, China from December 31, 2019 to February 20, 2020. In mixed-effect Cox model treating site as a random effect, after adjusting for age, gender, comorbidities, and in-hospital medications, the detected risk for all-cause mortality was lower in the ACEI/ARB group versus the non-ACEI/ARB group (adjusted hazard ratio, 0.42 [95% CI, 0.19-0.92];P=0.03). In a propensity score-matched analysis followed by adjusting imbalanced variables in mixed-effect Cox model, the results consistently demonstrated lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did not receive ACEI/ARB (adjusted hazard ratio, 0.37 [95% CI, 0.15-0.89];P=0.03). Further subgroup propensity score-matched analysis indicated that, compared with use of other antihypertensive drugs, ACEI/ARB was also associated with decreased mortality (adjusted hazard ratio, 0.30 [95% CI, 0.12-0.70];P=0.01) in patients with COVID-19 and coexisting hypertension. Conclusions: Among hospitalized patients with COVID-19 and coexisting hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB nonusers. While study interpretation needs to consider the potential for residual confounders, it is unlikely that in-hospital use of ACEI/ARB was associated with an increased mortality risk.
C1 [Zhang, Peng; Zhu, Lihua; Qin, Juan-Juan; Xie, Jing; Liu, Ye-Mao; Zhao, Yan-Ci; Huang, Xuewei; Chen, Ming-Ming; Cheng, Xu; She, Zhi-Gang; Zhang, Xiao-Jing; Li, Hongliang] Wuhan Univ, Renmin Hosp, Cardiol, 99 Zhangzhidong Rd, Wuhan 430060, Peoples R China.
   [Zhang, Xiao] Wuhan Univ, Renmin Hosp, Eye Ctr, Wuhan, Peoples R China.
   [Zhang, Bing-Hong] Wuhan Univ, Renmin Hosp, Neonatol, Wuhan, Peoples R China.
   [Zhang, Peng; Ji, Yan-Xiao; Li, Hongliang] Wuhan Univ, Zhongnan Hosp, Med Sci Res Ctr, Wuhan, Peoples R China.
   [Guo, Deliang; Wang, Haitao; Yuan, Yufeng] Wuhan Univ, Zhongnan Hosp, Hepatobiliary & Pancreat Surg, Wuhan, Peoples R China.
   [Peng, Yuanyuan] Wuhan Univ, Zhongnan Hosp, Cardiol, Wuhan, Peoples R China.
   [Lin, Jun] Wuhan Univ, Zhongnan Hosp, Gastroenterol, Wuhan, Peoples R China.
   [Wang, Xinghuan] Wuhan Univ, Zhongnan Hosp, Ctr Evidence Based & Translat Med, Wuhan, Peoples R China.
   [Wang, Xinghuan] Wuhan Univ, Zhongnan Hosp, Urol, Wuhan, Peoples R China.
   [Zhang, Peng; Zhu, Lihua; Lei, Fang; Qin, Juan-Juan; Liu, Ye-Mao; Zhao, Yan-Ci; Huang, Xuewei; Lin, Lijin; Xia, Meng; Chen, Ming-Ming; Cheng, Xu; Ji, Yan-Xiao; Chen, Jing; She, Zhi-Gang; Zhang, Xiao-Jing; Li, Hongliang] Wuhan Univ, Inst Model Anim, Wuhan, Peoples R China.
   [Zhang, Peng; Lin, Lijin; Li, Hongliang] Wuhan Univ, Basic Med Sch, Wuhan, Peoples R China.
   [Cai, Jingjing] Cent South Univ, Xiangya Hosp 3, Cardiol, Changsha, Peoples R China.
   [Wang, Yibin] Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, Anesthesiol, Los Angeles, CA 90095 USA.
   [Xu, Qingbo] Queen Mary Univ London, William Harvey Res Inst, Ctr Clin Pharmacol, London, England.
   [Tan, Renfu] Wuhan Kanghuashuhai Technol Co, Wuhan, Peoples R China.
   [Luo, Pengcheng] Wuhan Univ, Wuhan Hosp 3, Urol, Wuhan, Peoples R China.
   [Fu, Shouzhi] Wuhan Univ, Wuhan Hosp 3, Intens Care Unit, Wuhan, Peoples R China.
   [Huang, Xiaodong] Wuhan Univ, Wuhan Hosp 3, Gastroenterol, Wuhan, Peoples R China.
   [Huang, Xiaodong] Wuhan Univ, Tongren Hosp, Wuhan, Peoples R China.
   [Cai, Hongbin; Liu, Mingyu] Wuhan Ninth Hosp, Wuhan, Peoples R China.
   [Ye, Ping; Chen, Manhua] Cent Hosp Wuhan, Cardiol, Wuhan, Peoples R China.
   [Xia, Jiahong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Cardiovasc Surg, Wuhan, Peoples R China.
   [Xiao, Bing] Xiantao First Peoples Hosp, Stomatol, Xiantao, Peoples R China.
   [Mao, Weiming] Huanggang Cent Hosp, Gen Surg, Wuhan, Peoples R China.
   [Liu, Liming] Ezhou Cent Hosp, Gen Surg, Ezhou, Peoples R China.
   [Yan, Youqin] Wuhan Seventh Hosp, Infect Dept, Wuhan, Peoples R China.
   [Touyz, Rhian M.] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
   [Rohit, Loomba] Univ Calif San Diego, Div Gastroenterol & Epidemiol, NAFLD Res Ctr, San Diego, CA 92103 USA.
   [Liu, Peter P.] Univ Ottawa, Heart Inst, Dept Med, Div Cardiol, Ottawa, ON, Canada.
RP Rohit, L (corresponding author), Univ Calif San Diego, Div Gastroenterol & Epidemiol, San Diego, CA 92103 USA.; Li, HL (corresponding author), Wuhan Univ, Renmin Hosp, Cardiol, 99 Zhangzhidong Rd, Wuhan 430060, Peoples R China.; Yuan, YF (corresponding author), Wuhan Univ, Zhongnan Hosp, Hepatobiliary & Pancreat Surg, Wuhan, Peoples R China.; Liu, PP (corresponding author), Univ Ottawa, Heart Inst, Dept Med, Div Cardiol, Ottawa, ON, Canada.
EM yuanyf1971@whu.edu.cn; roloomba@health.ucsd.edu; pliu@ottawaheart.ca;
   lihl@whu.edu.cn
OI Lei, Fang/0000-0003-0103-9348
FU National Key R&D Program of China [2016YFF0101504, 2020YFC0845500];
   National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81630011, 81970364, 81970070, 81970011, 81870171,
   81700356]; Major Research Plan of the National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [91639304]; Hubei Science and Technology Support Project [2019BFC582,
   2018BEC473, 2017BEC001]; Medical flight plan of Wuhan University
FX This work was supported by grants from National Key R&D Program of China
   (2016YFF0101504, 2020YFC0845500), the National Science Foundation of
   China (81630011, 81970364, 81970070, 81970011, 81870171, and 81700356),
   the Major Research Plan of the National Natural Science Foundation of
   China (91639304), the Hubei Science and Technology Support Project
   (2019BFC582, 2018BEC473, and 2017BEC001), and Medical flight plan of
   Wuhan University.
CR American Heart Association (AHA) Heart Failure Society of America (HFSA) and American College of Cardiology (ACC), 2020, PAT TAK ACE I ARBS W
   Chen M, 2005, DIABETOLOGIA, V48, P486, DOI 10.1007/s00125-005-1673-y
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Dhaun N, 2019, NAT REV CARDIOL, V16, P491, DOI 10.1038/s41569-019-0176-3
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Flack JM, 2020, TRENDS CARDIOVAS MED, V30, P160, DOI 10.1016/j.tcm.2019.05.003
   Gando S, 2013, J THROMB HAEMOST, V11, P826, DOI 10.1111/jth.12190
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haneuse S, 2019, JAMA-J AM MED ASSOC, V321, P602, DOI 10.1001/jama.2018.21554
   Henry Christopher, 2018, Proc (Bayl Univ Med Cent), V31, P419, DOI 10.1080/08998280.2018.1499293
   Igase M, 2008, HYPERTENS RES, V31, P553, DOI 10.1291/hypres.31.553
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   International Society of Hypertension, 2020, STAT INT SOC HYP COV
   Kovell LC, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002315
   Kozhuharov N, 2019, JAMA-J AM MED ASSOC, V322, P2292, DOI 10.1001/jama.2019.18598
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuba K, 2006, CURR OPIN PHARMACOL, V6, P271, DOI 10.1016/j.coph.2006.03.001
   Lai CC, 2018, INT J CHRONIC OBSTR, V13, P867, DOI 10.2147/COPD.S158634
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Mathur MB, 2018, EPIDEMIOLOGY, V29, pE45, DOI 10.1097/EDE.0000000000000864
   Matsuyama R, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3881-4
   Morra ME, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1977
   National Health Commission of China, 2020, NEW COR PNEUM PREV C
   Paulus WJ, 2013, J AM COLL CARDIOL, V62, P263, DOI 10.1016/j.jacc.2013.02.092
   Rodriguez-Iturbe B, 2017, PHYSIOL REV, V97, P1127, DOI 10.1152/physrev.00031.2016
   te Riet L, 2015, CIRC RES, V116, P960, DOI 10.1161/CIRCRESAHA.116.303587
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
   Waljee AK, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002847
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang TZ, 2019, NAT REV NEPHROL, V15, P463, DOI 10.1038/s41581-019-0150-7
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang YX, 2020, NAT REV CARDIOL, V17, P170, DOI 10.1038/s41569-019-0260-8
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 36
TC 277
Z9 283
U1 23
U2 29
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD JUN 5
PY 2020
VL 126
IS 12
BP 1671
EP 1681
DI 10.1161/CIRCRESAHA.120.317134
PG 11
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA MG4AU
UT WOS:000545975700006
PM 32302265
OA Other Gold, Green Accepted, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Samavati, L
   Uhal, BD
AF Samavati, Lobelia
   Uhal, Bruce D.
TI ACE2, Much More Than Just a Receptor for SARS-COV-2
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Article
DE COVID-19; lung; alveolar; angiotensin; coagulopathy
ID ANGIOTENSIN-CONVERTING ENZYME-2; II INDUCES INTERLEUKIN-6;
   SARS-CORONAVIRUS; FUNCTIONAL RECEPTOR; ALTERNATIVE PATHWAYS;
   EPITHELIAL-CELLS; UP-REGULATION; PROTEIN; ACTIVATION; EXPRESSION
AB The rapidly evolving pandemic of severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection worldwide cost many lives. The angiotensin converting enzyme-2 (ACE-2) has been identified as the receptor for the SARS-CoV-2 viral entry. As such, it is now receiving renewed attention as a potential target for anti-viral therapeutics. We review the physiological functions of ACE2 in the cardiovascular system and the lungs, and how the activation of ACE2/MAS/G protein coupled receptor contributes in reducing acute injury and inhibiting fibrogenesis of the lungs and protecting the cardiovascular system. In this perspective, we predominantly focus on the impact of SARS-CoV-2 infection on ACE2 and dysregulation of the protective effect of ACE2/MAS/G protein pathway vs. the deleterious effect of Renin/Angiotensin/Aldosterone. We discuss the potential effect of invasion of SARS-CoV-2 on the function of ACE2 and the loss of the protective effect of the ACE2/MAS pathway in alveolar epithelial cells and how this may amplify systemic deleterious effect of renin-angiotensin aldosterone system (RAS) in the host. Furthermore, we speculate the potential of exploiting the modulation of ACE2/MAS pathway as a natural protection of lung injury by modulation of ACE2/MAS axis or by developing targeted drugs to inhibit proteases required for viral entry.
C1 [Samavati, Lobelia] Wayne State Univ, Sch Med, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Detroit, MI 48201 USA.
   [Samavati, Lobelia] Wayne State Univ, Detroit Med Ctr, Detroit, MI 48201 USA.
   [Samavati, Lobelia] Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48202 USA.
   [Uhal, Bruce D.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.
RP Samavati, L (corresponding author), Wayne State Univ, Sch Med, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Detroit, MI 48201 USA.; Samavati, L (corresponding author), Wayne State Univ, Detroit Med Ctr, Detroit, MI 48201 USA.; Samavati, L (corresponding author), Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48202 USA.; Uhal, BD (corresponding author), Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.
EM ay6003@wayne.edu; bduhal@gmail.com
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01HL150474]; Department of Internal Medicine,
   Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State
   University, Detroiut MI; Department of Physiology, Michigan State
   University, East Lansing, MI
FX This work was supported by a grant by NHLBI (R01HL150474) to LS. This
   work was funded by the Department of Internal Medicine, Division of
   Pulmonary, Critical Care and Sleep Medicine, Wayne State University,
   Detroiut MI and by the Department of Physiology, Michigan State
   University, East Lansing, MI.
CR Abu Nabah YN, 2004, CIRCULATION, V110, P3581, DOI 10.1161/01.CIR.0000148824.93600.F3
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Baud D, 2020, LANCET INFECT DIS, p, DOI [10.1016/S1473-3099(20)30195-X., DOI 10.1016/S1473-3099(20)30195-X., 10.1016/S1473 -3099(20)30195 -X.]
   Becari C, 2011, BRAZ J MED BIOL RES, V44, P914, DOI 10.1590/S0100-879X2011000900013
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cerda-Costa N, 2014, PROTEIN SCI, V23, P123, DOI 10.1002/pro.2400
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Chu CM, 2004, CAN MED ASSOC J, V171, P1349, DOI 10.1503/cmaj.1040398
   Cinatl J, 2005, INT J MOL MED, V15, P323
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   de Kloet AD, 2010, PHYSIOL BEHAV, V100, P525, DOI 10.1016/j.physbeh.2010.03.018
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Fraga-Silva RA, 2010, MOL MED, V16, P210, DOI 10.2119/molmed.2009.00160
   Funakoshi Y, 1999, HYPERTENSION, V34, P118, DOI 10.1161/01.HYP.34.1.118
   Garrido AM, 2009, MOL CELL ENDOCRINOL, V302, P148, DOI 10.1016/j.mce.2008.11.003
   Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030
   Gopallawa Indiwari, 2014, Curr Top Pharmacol, V18, P71
   Gopallawa I, 2016, AM J PHYSIOL-LUNG C, V310, pL240, DOI 10.1152/ajplung.00187.2015
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Gustafsson F, 1999, CARDIOVASC RES, V44, P176, DOI 10.1016/S0008-6363(99)00174-1
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Han YQ, 1999, CIRC RES, V84, P695, DOI 10.1161/01.RES.84.6.695
   Nguyen H, 2016, AM J PHYSIOL-LUNG C, V311, pL846, DOI 10.1152/ajplung.00449.2015
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Jagroop IA, 2000, J HUM HYPERTENS, V14, P581, DOI 10.1038/sj.jhh.1001102
   Jang Y, 2012, J NEGAT RESULTS BIOM, V11, DOI 10.1186/1477-5751-11-6
   Jiang T, 2013, CURR NEUROPHARMACOL, V11, P209, DOI 10.2174/1570159X11311020007
   Kato H, 1996, HYPERTENSION, V28, P153, DOI 10.1161/01.HYP.28.2.153
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Kramkowski K, 2006, J PHYSIOL PHARMACOL, V57, P529
   KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55
   Lambert DW, 2005, J BIOL CHEM, V280, P30113, DOI 10.1074/jbc.M505111200
   leTran Y, 1997, J CARDIOVASC PHARM, V30, P676, DOI 10.1097/00005344-199711000-00019
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li XP, 2008, AM J PHYSIOL-LUNG C, V295, pL178, DOI 10.1152/ajplung.00009.2008
   Liu X, 2020, THERAPEUTIC EFFECTS, DOI [10.1101/2020.02.27.20027557, DOI 10.1101/2020.02.27.20027557]
   Lorenz J. N., 2010, CHYMASE OTHER ACE
   Lu H., 2020, DESCRIPTIVE STUDY IM, DOI [10.1101/2020.02.19.20025031, DOI 10.1101/2020.02.19.20025031]
   Luther JM, 2006, HYPERTENSION, V48, P1050, DOI 10.1161/01.HYP.0000248135.97380.76
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Malhotra A, 2001, DIABETES, V50, P1918, DOI 10.2337/diabetes.50.8.1918
   Marian AJ, 2013, CIRC RES, V112, P1307, DOI 10.1161/CIRCRESAHA.113.301271
   Martin RE, 2009, SCIENCE, V325, P1680, DOI 10.1126/science.1175667
   Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134
   MENTO PF, 1987, HYPERTENSION, V9, P42, DOI 10.1161/01.HYP.9.6_Pt_2.III42
   Moore JX, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.160287
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Oarhe CI, 2015, PEDIATR RES, V77, P656, DOI 10.1038/pr.2015.27
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Pinheiro SVB, 2004, HYPERTENSION, V44, P490, DOI 10.1161/01.HYP.0000141438.64887.42
   Porcheddu R, 2020, J INFECT DEV COUNTR, V14, P125, DOI 10.3855/jidc.12600
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ramachandran V, 2008, J RENIN-ANGIO-ALDO S, V9, P208, DOI 10.1177/1470320308097499
   Rey-Parra GJ, 2012, J MOL MED, V90, P637, DOI 10.1007/s00109-012-0859-2
   Roca-Ho H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030563
   Ruiz-Ortega M, 2002, KIDNEY INT, V62, pS12, DOI 10.1046/j.1523-1755.62.s82.4.x
   Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100
   Schindler C, 2007, VASC HEALTH RISK MAN, V3, P125
   Senchenkova EY, 2010, HYPERTENSION, V56, P1089, DOI 10.1161/HYPERTENSIONAHA.110.158220
   Silva ACSE, 2013, BRIT J PHARMACOL, V169, P477, DOI 10.1111/bph.12159
   Singh KD, 2016, J CELL SIGNAL, V1, P111, DOI [10.4172/jcs.1000111., DOI 10.4172/JCS.1000111]
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Talreja J, 2019, ELIFE, V8, DOI 10.7554/eLife.44519
   Tay K.-H., 2008, WHAT DRIVES LINK REN
   Tikellis Chris, 2012, Int J Pept, V2012, P256294, DOI 10.1155/2012/256294
   Turner AJ, 2002, CAN J PHYSIOL PHARM, V80, P346, DOI 10.1139/Y02-021
   Uehara Y, 2013, CURR PHARM DESIGN, V19, P3054
   Uhal BD, 2011, AM J PHYSIOL-LUNG C, V301, pL269, DOI 10.1152/ajplung.00222.2010
   Ullian ME, 1996, CARDIOVASC RES, V32, P266, DOI 10.1016/0008-6363(96)00053-3
   Wakahara S, 2007, ENDOCRINOLOGY, V148, P2453, DOI 10.1210/en.2006-1287
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang RQ, 1999, AM J PHYSIOL-LUNG C, V276, pL885
   Watanabe T, 2005, HYPERTENSION, V45, P163, DOI 10.1161/01.HYP.0000153321.13792.b9
   World Health Organization, 2013, REV INT CAS DEF REP
   Xue BJ, 2011, AM J PHYSIOL-HEART C, V300, pH555, DOI 10.1152/ajpheart.00847.2010
   Yamamoto K, 2006, HYPERTENSION, V47, P718, DOI 10.1161/01.HYP.0000205833.89478.5b
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu L., 2020, CELL METAB, DOI [10.1016/j.cmet.2020.04.021., DOI 10.1016/J.CMET.2020.04.021.]
NR 89
TC 10
Z9 10
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD JUN 5
PY 2020
VL 10
AR 317
DI 10.3389/fcimb.2020.00317
PG 9
WC Immunology; Microbiology
SC Immunology; Microbiology
GA MD2YW
UT WOS:000543839900001
PM 32582574
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, B
   Lai, JK
   Yan, XY
   Jin, FF
   Yao, C
AF Wang, Bin
   Lai, Junkai
   Yan, Xiaoyan
   Jin, Feifei
   Yao, Chen
TI Implications of the lack of a unified research project framework: an
   investigation into the registration of clinical trials of COVID-19
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE Coronavirus disease 2019; COVID-19; clinical trials; investigation;
   recommendations
ID LESSONS
AB Objective:The aim of this study was to provide recommendations for improving the design of subsequent studies through analysis of the registered coronavirus disease 2019 (COVID-19) clinical trials. Methods:A retrospective analysis of 189 trial retrievals achieved on 20 February 2020. Results:A total of 189 trials are included in the study. There were 69.3% interventional studies, 21.7% observational studies, 5.3% diagnostic tests and 3.7% other studies. The following statistics are provided only for the interventional studies. Severity of disease: 5.3% light and common type, 17.6% severe and critically ill and 59.6% with no restricted classification. Medication use: 51.1% Western medicine, 32.1% Chinese medicine, 10.7% blood related product and 6.1% non-drug therapy. The median and inner quantile range of the sample sizes included in these studies: 104 (IQR: 60, 200). Primary outcome type most used: 45.8% with clinical characteristics and 21.4% with virological. Study design characteristics: 71% of all studies were randomized, 5% of all studies were blinded, 18% of all studies were multicenter and 76% of all studies were single center. Conclusion:Although many COVID-19 studies include randomization in their design, the lack of additional double-blind and placebo-controlled elements in their designs result in a less robust evaluation of intervention safety and efficacy. Furthermore, similar or repeated research and small sample studies that have less promise in gains of new information have possibly led to a shortage of recruitable patients and become a barrier to the completion of large multicenter clinical trial studies.
C1 [Wang, Bin; Lai, Junkai; Jin, Feifei; Yao, Chen] Peking Univ, Hosp 1, 8 Xishiku St, Beijing 100034, Peoples R China.
   [Yan, Xiaoyan; Yao, Chen] Peking Univ, Clin Res Inst, Beijing, Peoples R China.
RP Yao, C (corresponding author), Peking Univ, Hosp 1, 8 Xishiku St, Beijing 100034, Peoples R China.
EM yaochen@hsc.pku.edu.cn
OI Wang, Bin/0000-0003-0012-9835
CR Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Jin Xinyao, 2020, Engineering (Beijing), V6, P1147, DOI 10.1016/j.eng.2020.03.002
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   London AJ, 2020, SCIENCE, V368, P476, DOI 10.1126/science.abc1731
   Muller MP, 2004, EMERG INFECT DIS, V10, P389
   Smith RD, 2006, SOC SCI MED, V63, P3113, DOI 10.1016/j.socscimed.2006.08.004
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
NR 8
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300-7995
EI 1473-4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD JUL 2
PY 2020
VL 36
IS 7
BP 1131
EP 1135
DI 10.1080/03007995.2020.1771294
EA JUN 2020
PG 5
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA MI1EX
UT WOS:000543554500001
PM 32427000
OA Bronze
DA 2021-01-01
ER

PT J
AU Zhang, C
   Qin, L
   Li, K
   Wang, Q
   Zhao, Y
   Xu, B
   Liang, LC
   Dai, YC
   Feng, YM
   Sun, JP
   Li, XM
   Hu, ZJ
   Xiang, HP
   Dong, T
   Jin, RH
   Zhang, YH
AF Zhang, Chi
   Qin, Ling
   Li, Kang
   Wang, Qi
   Zhao, Yan
   Xu, Bin
   Liang, Lianchun
   Dai, Yanchao
   Feng, Yingmei
   Sun, Jianping
   Li, Xuemei
   Hu, Zhongjie
   Xiang, Haiping
   Dong, Tao
   Jin, Ronghua
   Zhang, Yonghong
TI A Novel Scoring System for Prediction of Disease Severity in COVID-19
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Article
DE logistic regression; severity pneumonia; COVID-19; retrospective cohort;
   prediction scoring system
ID CORONAVIRUSES; REPLICATION
AB Background:A novel enveloped RNA beta coronavirus, Corona Virus Disease 2019 (COVID-19) caused severe and even fetal pneumonia in China and other countries from December 2019. Early detection of severe patients with COVID-19 is of great significance to shorten the disease course and reduce mortality. Methods:We assembled a retrospective cohort of 80 patients (including 56 mild and 24 severe) with COVID-19 infection treated at Beijing You'an Hospital. We used univariable and multivariable logistic regression analyses to select the risk factors of severe and even fetal pneumonia and build scoring system for prediction, which was validated later on in a group of 22 COVID-19 patients. Results:Age, white blood cell count, neutrophil, glomerular filtration rate, and myoglobin were selected by multivariate analysis as candidates of scoring system for prediction of disease severity in COVID-19. The scoring system was applied to calculate the predictive value and found that the percentage of ICU admission (20%, 6/30) and ventilation (16.7%, 5/30) in patients with high risk was much higher than those (2%, 1/50; 2%, 1/50) in patients with low risk (p= 0.009;p= 0.026). The AUC of scoring system was 0.906, sensitivity of prediction is 70.8%, and the specificity is 89.3%. According to scoring system, the probability of patients in high risk group developing severe disease was 20.24 times than that in low risk group. Conclusions:The possibility of severity in COVID-19 infection predicted by scoring system could help patients to receiving different therapy strategies at a very early stage. Topic:COVID-19, severe and fetal pneumonia, logistic regression, scoring system, prediction.
C1 [Zhang, Chi; Qin, Ling; Li, Kang; Wang, Qi; Zhao, Yan; Xu, Bin; Liang, Lianchun; Dai, Yanchao; Feng, Yingmei; Sun, Jianping; Li, Xuemei; Hu, Zhongjie; Xiang, Haiping; Jin, Ronghua; Zhang, Yonghong] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China.
   [Dong, Tao; Zhang, Yonghong] Univ Oxford, Oxford Inst COI, Chinese Acad Med Sci, Oxford, England.
   [Dong, Tao] Univ Oxford, MRC Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford, England.
RP Jin, RH; Zhang, YH (corresponding author), Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China.; Zhang, YH (corresponding author), Univ Oxford, Oxford Inst COI, Chinese Acad Med Sci, Oxford, England.
EM jin_eagle@yahoo.com; 13810108505@163.com
FU Beijing Natural Science FoundationBeijing Natural Science Foundation
   [7191004, 7202069]; Beijing Municipal Science & Technology
   CommissionBeijing Municipal Science & Technology Commission
   [Z171100001017078]; Capital health development research project
   [2020-1-2182]; Beijing municipal administration of hospitals
   [DFL20181701, ZYLX201711]; Beijing Key Laboratory [BZ0373]; China
   primary healthcare foundation You'An foundation of liver disease and
   aids scientific research project of You'an Hospital, CCMU
   [YNKTTS20180117]; Chinese Academy of Medical Sciences (CAMS) Innovation
   Fund for Medical Sciences (CIFMS), China [2018-I2M-2-002]; Medical
   Research Council (MRC), UKMedical Research Council UK (MRC)
   [MR/L018942/1]; Medical Research Council (MRC), UK (MRC Human Immunology
   Unit Core)Medical Research Council UK (MRC); Nuffield Department of
   Medicine, Oxford University
FX This work was supported by the Beijing Natural Science Foundation
   (7191004 and 7202069), Beijing Municipal Science & Technology Commission
   (Z171100001017078), Capital health development research project
   (2020-1-2182), Beijing municipal administration of hospitals
   (DFL20181701 and ZYLX201711), Beijing Key Laboratory (BZ0373), China
   primary healthcare foundation You'An foundation of liver disease and
   aids scientific research project of You'an Hospital, CCMU
   (YNKTTS20180117), and Chinese Academy of Medical Sciences (CAMS)
   Innovation Fund for Medical Sciences (CIFMS), China (grant number:
   2018-I2M-2-002); TD is supported by Medical Research Council (MRC), UK
   (MR/L018942/1 and MRC Human Immunology Unit Core) and Nuffield
   Department of Medicine, Oxford University.
CR Abd El-Kader SM, 2018, AFR HEALTH SCI, V18, P417, DOI 10.4314/ahs.v18i2.27
   Arabi YM, 2017, NEW ENGL J MED, V376, P584, DOI 10.1056/NEJMsr1408795
   Chan JWM, 2003, THORAX, V58, P686, DOI 10.1136/thorax.58.8.686
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   China National Health Commission, 2020, NEW COR PNEUM DIAGN
   Dymond T, 2018, VIRAL IMMUNOL, V31, P278, DOI 10.1089/vim.2017.0194
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   da Silva-Malta MCF, 2017, J MED MICROBIOL, V66, P1207, DOI 10.1099/jmm.0.000539
   Gong J, 2020, CLIN INFECT DIS, V71, P833, DOI 10.1093/cid/ciaa443
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Havrilesky LJ, 2008, GYNECOL ONCOL, V110, P374, DOI 10.1016/j.ygyno.2008.04.041
   Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0
   Liu T, 2020, TIME VARYING TRANSMI, DOI [10.1101/2020.01.25.919787, DOI 10.1101/2020.01.25.919787]
   Liu ZM, 2020, J INFECTION, V81, P331, DOI 10.1016/j.jinf.2020.03.054
   Matthews DC, 2018, NEUROIMAGE-CLIN, V20, P572, DOI 10.1016/j.nicl.2018.08.006
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Qin L, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016997
   Tan L, 2020, SIGNAL TRANSDUCTION, V5, P1, DOI [10.1038/s41392-019-0089-y, DOI 10.1038/S41392-019-0089-Y]
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Yang AP, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106504
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 26
TC 8
Z9 8
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD JUN 5
PY 2020
VL 10
AR 318
DI 10.3389/fcimb.2020.00318
PG 7
WC Immunology; Microbiology
SC Immunology; Microbiology
GA MC0HQ
UT WOS:000542979100001
PM 32582575
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abid, MA
   Nunley, L
   Abid, MB
AF Abid, Muhammad Abbas
   Nunley, Loren
   Abid, Muhammad Bilal
TI Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to
   Re-infections? A Spotlight on the Therapeutic Pipeline
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; adaptive immunity; convalescent plasma; vaccine development;
   antibody-dependent enhancement (ADE)
ID ACUTE RESPIRATORY SYNDROME; ANTIBODIES; CELLS
C1 [Abid, Muhammad Abbas] Johns Hopkins Univ, Sch Med, Dept OtolaryngologyHead & Neck Surg, Baltimore, MD USA.
   [Nunley, Loren; Abid, Muhammad Bilal] Med Coll Wisconsin, Dept Med, Div Infect Dis, Milwaukee, WI 53226 USA.
   [Abid, Muhammad Bilal] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA.
RP Abid, MB (corresponding author), Med Coll Wisconsin, Dept Med, Div Infect Dis, Milwaukee, WI 53226 USA.; Abid, MB (corresponding author), Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA.
EM mabid@mcw.edu
RI Abid, Muhammad Abbas/AAA-1987-2019; Abid, Muhammad Bilal/ABF-7163-2020
OI Abid, Muhammad Abbas/0000-0003-2440-4117; Abid, Muhammad
   Bilal/0000-0002-1128-0445
CR Abid MB, 2020, JAMA ONCOL, V6, P1529, DOI 10.1001/jamaoncol.2020.2367
   Bao L, 2020, REINFECTION COULD NO, DOI [10.1101/2020.03.13.990226, DOI 10.1101/2020.03.13.990226, 10.1101/2020.03.13.990226.]
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chinese Clinical Trial Registry, 2020, MULT RAND CONTR TRIA
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang MX, 2020, J MOL CELL BIOL, V12, P322, DOI 10.1093/jmcb/mjaa014
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Koutsakos M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan8405
   Li G, 2003, NEW ENGL J MED, V349, P508, DOI 10.1056/NEJM200307313490520
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   McElroy AK, 2015, P NATL ACAD SCI USA, V112, P4719, DOI 10.1073/pnas.1502619112
   Paul LM, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.72
   Porcheddu R, 2020, J INFECT DEV COUNTR, V14, P125, DOI 10.3855/jidc.12600
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
   Zhao Juanjuan, 2020, Clin Infect Dis, V71, P2027, DOI 10.1093/cid/ciaa344
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 27
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 5
PY 2020
VL 11
AR 1294
DI 10.3389/fimmu.2020.01294
PG 3
WC Immunology
SC Immunology
GA MC3DZ
UT WOS:000543173300001
PM 32582221
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhao, J
   Gao, HY
   Feng, ZY
   Wu, QJ
AF Zhao, Jing
   Gao, Hao-Yu
   Feng, Zi-Yi
   Wu, Qi-Jun
TI A Retrospective Analysis of the Clinical and Epidemiological
   Characteristics of COVID-19 Patients in Henan Provincial People's
   Hospital, Zhengzhou, China
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE coronavirus disease 2019; SARS-CoV-2; epidemiology; clinical
   characteristics; traditional Chinese medicine
ID CORONAVIRUS; PNEUMONIA; SARS
AB Objective:This study evaluated the clinical and epidemiological characteristics of patients with confirmed coronavirus disease 2019 (COVID-19). Methods:This retrospective study evaluated 29 patients with confirmed COVID-19 infection admitted to Henan Provincial People's Hospital between January 27 and February 27, 2020, with follow-up until April 01, 2020. Results:The median age of the patients was 56 years. Nineteen (19/29; 65.5%) had underlying conditions including cardiovascular disease, digestive disease, or type 2 diabetes mellitus. Twenty-two (22/29; 76%) had close contact with acquaintances or family members who were confirmed or probable COVID-19 cases. Many patients had white blood cell counts with abnormal neutrophil and lymphocyte numbers, abnormal hemoglobin concentration, coagulation profiles, and blood biochemistry, and increased infection markers. Mottling and multiple ground-glass opacities were seen in X-ray images of 19 patients (19/29; 65.5%). Most patients (23/29; 79.8%) received supplemental oxygen therapy and antibiotics (23/29; 79.8%) in addition to traditional Chinese medicines (26/29; 89.7%). The most frequent presenting symptoms were fever, cough, and sputum production. One patient, an 86-years-old woman with more than one underlying disease, died during follow-up. Patients with severe disease were significantly older and more likely to have been transferred from other healthcare facilities than those with mild disease. Anemia, decreased activated partial thromboplastin time, calcium, and albumin, and increased D-dimer and interleukin-6 were more frequent in severe disease. Need of oxygen therapy, mechanical ventilation, intravascular immunoglobulin, and duration of antibiotic therapy were increased in those with severe disease. Conclusions:Significant differences in demographical and clinical characteristics were observed in patients with moderate and severe COVID-19.
C1 [Zhao, Jing] Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Lab, Peolples Hosp, Zhengzhou, Peoples R China.
   [Gao, Hao-Yu; Feng, Zi-Yi] China Med Univ, Dept Student, Shenyang, Peoples R China.
   [Wu, Qi-Jun] China Med Univ, Clin Res Ctr, Dept Clin Epidemiol, Shengjing Hosp, Shenyang, Peoples R China.
RP Wu, QJ (corresponding author), China Med Univ, Clin Res Ctr, Dept Clin Epidemiol, Shengjing Hosp, Shenyang, Peoples R China.
EM wuqj@sj-hospital.org
FU National Key R&D Program of China [2017YFC0907401]; 345 Talent Project
   of Shengjing Hospital of China Medical University [M0268]
FX This study was supported by the National Key R&D Program of China (No.
   2017YFC0907401) and the 345 Talent Project of Shengjing Hospital of
   China Medical University (M0268 to Q-JW).
CR [Anonymous], 2004, SUMM PROB SARS CAS O
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Commission CNH, 2020, NEW COR PNEUM DIAGN
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ni L, 2020, FRONT MED-PRC, V14, P210, DOI 10.1007/s11684-020-0757-x
   Province GoH, OVERVIEW HENAN PROVI
   Province HCoH, 2020, NOT REL LIST DES HOS
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CORON DIS 2019 COVID
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, CORONAVIRUS DIS 2019
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang MM, 2004, WORLD J GASTROENTERO, V10, P3500
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 28
TC 4
Z9 4
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUN 5
PY 2020
VL 7
AR 286
DI 10.3389/fmed.2020.00286
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA MC1TF
UT WOS:000543077700001
PM 32582740
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sidiq, KR
   Sabir, DK
   Ali, SM
   Kodzius, R
AF Sidiq, Karzan R.
   Sabir, Dana Khdr
   Ali, Shakhawan M.
   Kodzius, Rimantas
TI Does Early Childhood Vaccination Protect Against COVID-19?
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE children; virus; COVID-19; measles; rubella; immunity; vaccination
ID VIRUS FUSION PROTEIN; IMMUNITY
AB The coronavirus disease 2019 (COVID-19) is an on-going pandemic caused by the SARS-coronavirus-2 (SARS-CoV-2) which targets the respiratory system of humans. The published data show that children, unlike adults, are less susceptible to contracting the disease. This article aims at understanding why children constitute a minor group among hospitalized COVID-19 patients. Here, we hypothesize that the measles, mumps, and rubella (MMR) vaccine could provide a broad neutralizing antibody against numbers of diseases, including COVID-19. Our hypothesis is based on the 30 amino acid sequence homology between the SARS-CoV-2 Spike (S) glycoprotein (PDB: 6VSB) of both the measles virus fusion (F1) glycoprotein (PDB: 5YXW_B) and the rubella virus envelope (E1) glycoprotein (PDB: 4ADG_A). Computational analysis of the homologous region detected the sequence as antigenic epitopes in both measles and rubella. Therefore, we believe that humoral immunity, created through the MMR vaccination, provides children with advantageous protection against COVID-19 as well, however, an experimental analysis is required.
C1 [Sidiq, Karzan R.] Charmo Univ, Charmo Ctr Res Training & Consultancy, Chamchamal, Iraq.
   [Sidiq, Karzan R.; Sabir, Dana Khdr] Charmo Univ, Dept Med Lab Sci, Chamchamal, Iraq.
   [Ali, Shakhawan M.] Univ Sulaimani, Dept Oral & Maxillofacial Surg, Sulaimani, Iraq.
   [Kodzius, Rimantas] Kaunas Technol Univ KTU, Panevezys Fac Technol & Business, Panevezys, Lithuania.
   [Kodzius, Rimantas] Ludwig Maximilian Univ Munich LMU, Fac Med, Munich, Germany.
RP Kodzius, R (corresponding author), Kaunas Technol Univ KTU, Panevezys Fac Technol & Business, Panevezys, Lithuania.; Kodzius, R (corresponding author), Ludwig Maximilian Univ Munich LMU, Fac Med, Munich, Germany.
EM kodzius@enviola.com
OI Sidiq, Karzan/0000-0002-6992-1954; Sabir, Dana/0000-0001-6197-7737; Ali,
   Shaxawan M./0000-0001-8391-5078
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Anaya J.M, 2013, AUTOIMMUNITY BENCH B
   Atabani SF, 1997, J VIROL, V71, P7240, DOI 10.1128/JVI.71.10.7240-7245.1997
   Bechini A, 2013, HUM VACC IMMUNOTHER, V9, P649, DOI 10.4161/hv.23261
   BIN D, 1991, B WORLD HEALTH ORGAN, V69, P415
   Brodin P, 2020, ACTA PAEDIATR, V109, P1082, DOI 10.1111/apa.15271
   Carrozzi G., 2020, EPIDEMIA COVID 19 EP
   Cascella M, 2020, FEATURES EVALUATION
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chinese Center for Disease Control and Prevention, 2020, NOVEL CORONAVIRUS PN, DOI [10.46234/ccdcw2020.032, DOI 10.46234/CCDCW2020.032]
   Choe Young June, 2012, Korean J Pediatr, V55, P455, DOI 10.3345/kjp.2012.55.12.455
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   DuBois RM, 2013, NATURE, V493, P552, DOI 10.1038/nature11741
   Frank S. A., 2002, IMMUNOLOGY EVOLUTION
   Hashiguchi T, 2018, P NATL ACAD SCI USA, V115, P2496, DOI 10.1073/pnas.1718957115
   Hoffmann M, 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Jacob E, 2007, BIOINFORMATICS, V23, pE225, DOI 10.1093/bioinformatics/btl318
   Kontio M, 2012, J INFECT DIS, V206, P1542, DOI 10.1093/infdis/jis568
   Korean Centers for Disease Control Prevention (KCDC), 2020, UPD COVID 19 REP KOR
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MALVOISIN E, 1990, J VIROL, V64, P5160, DOI 10.1128/JVI.64.10.5160-5162.1990
   Montecillo-Aguado MR, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/7239347
   Ponomarenko JV, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-64
   Ralph R, 2020, J INFECT DEV COUNTR, V14, P3, DOI 10.3855/jidc.12425
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Sabir D. K., 2020, INT J SCH HLTH, V7, P37, DOI [10.30476/intjsh.2020.85997.106, DOI 10.30476/INTJSH.2020.85997.106]
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Thapa P, 2019, THORAC SURG CLIN, V29, P123, DOI 10.1016/j.thorsurg.2018.12.001
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   World Health Organization, 2020, 121 WHO
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zheng YM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3422-0
NR 37
TC 5
Z9 5
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD JUN 5
PY 2020
VL 7
AR 120
DI 10.3389/fmolb.2020.00120
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MC3MN
UT WOS:000543195500001
PM 32582766
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Spalek, MJ
   Rutkowski, P
AF Spalek, Mateusz Jacek
   Rutkowski, Piotr
TI Coronavirus Disease (COVID-19) Outbreak: Hypofractionated Radiotherapy
   in Soft Tissue Sarcomas as a Valuable Option in the Environment of
   Limited Medical Resources and Demands for Increased Protection of
   Patients
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE sarcoma; hypofractionation; perioperative radiotherapy; COVID-19;
   multidisciplinary treatment; rare cancers
ID PHASE-I TRIAL; POSTOPERATIVE RADIATION-THERAPY; NEOADJUVANT
   RADIOTHERAPY; HIGH-RISK; PREOPERATIVE RADIOTHERAPY; HISTOLOGIC RESPONSE;
   PLUS SORAFENIB; CHEMOTHERAPY; SUNITINIB; SURGERY
C1 [Spalek, Mateusz Jacek; Rutkowski, Piotr] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland.
RP Spalek, MJ (corresponding author), Maria Sklodowska Curie Natl Res Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland.
EM mateusz.spalek@pib-nio.pl
RI Spalek, Mateusz/AAO-6621-2020
OI Spalek, Mateusz/0000-0002-3960-7673
FU Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw,
   Poland
FX The processing charges cost was covered by the Maria Sklodowska-Curie
   National Research Institute of Oncology, Warsaw, Poland.
CR Achard V, 2020, INT J RADIAT ONCOL, V107, P600, DOI 10.1016/j.ijrobp.2020.03.008
   Canter RJ, 2014, ANN SURG ONCOL, V21, P1616, DOI 10.1245/s10434-014-3543-7
   Canter RJ, 2010, ANN SURG ONCOL, V17, P2578, DOI 10.1245/s10434-010-1156-3
   Davis AM, 2005, RADIOTHER ONCOL, V75, P48, DOI 10.1016/j.radonc.2004.12.020
   Dickie CI, 2009, INT J RADIAT ONCOL, V75, P1119, DOI 10.1016/j.ijrobp.2008.12.006
   Haas RLM, 2016, RADIOTHER ONCOL, V119, P14, DOI 10.1016/j.radonc.2015.12.002
   Haas RLM, 2015, ACTA ONCOL, V54, P1195, DOI 10.3109/0284186X.2015.1037404
   Hui AC, 2006, EJSO-EUR J SURG ONC, V32, P1159, DOI 10.1016/j.ejso.2006.04.003
   Jakob J, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0654-2
   Kalbasi A, 2020, CLIN CANCER RES, V26, P1829, DOI 10.1158/1078-0432.CCR-19-3524
   Kosela-Paterczyk H, 2014, EJSO-EUR J SURG ONC, V40, P1641, DOI 10.1016/j.ejso.2014.05.016
   Kraybill WG, 2006, J CLIN ONCOL, V24, P619, DOI 10.1200/JCO.2005.02.5577
   Lewin J, 2014, BRIT J CANCER, V111, P2254, DOI 10.1038/bjc.2014.537
   MacDermed DM, 2010, INT J RADIAT ONCOL, V76, P1147, DOI 10.1016/j.ijrobp.2009.03.015
   Meyer JM, 2013, CLIN CANCER RES, V19, P6902, DOI 10.1158/1078-0432.CCR-13-1594
   O'Sullivan B, 2002, LANCET, V359, P2235, DOI 10.1016/S0140-6736(02)09292-9
   O'Sullivan B, 2004, J CLIN ONCOL, V22, p819S
   O'Sullivan B, 2013, CANCER-AM CANCER SOC, V119, P1878, DOI 10.1002/cncr.27951
   Parsai S, 2020, EARLY OUTCOMES PREOP, DOI [10.1101/2020.03.20.20038885, DOI 10.1101/2020.03.20.20038885]
   Pennington JD, 2018, AM J CLIN ONCOL-CANC, V41, P1154, DOI 10.1097/COC.0000000000000443
   Pollack A, 1998, INT J RADIAT ONCOL, V42, P563, DOI 10.1016/S0360-3016(98)00277-6
   Qu XLM, 2017, INT J RADIAT ONCOL, V97, P339, DOI 10.1016/j.ijrobp.2016.10.009
   Ryan CW, 2008, CANCER-AM CANCER SOC, V112, P2432, DOI 10.1002/cncr.23478
   Shah D, 2012, ANTICANCER RES, V32, P3911
   Slump J, 2019, J PLAST RECONSTR AES, V72, P1449, DOI 10.1016/j.bjps.2019.05.041
   Spalek M, 2019, INT J RADIAT ONCOL, V105, pS63
   Spalek M, 2019, RADIOTHER ONCOL, V133, pS31, DOI 10.1016/S0167-8140(19)30489-X
   Temple WJ, 1997, ANN SURG ONCOL, V4, P586, DOI 10.1007/BF02305541
   THAMES HD, 1986, INT J RADIAT ONCOL, V12, P687, DOI 10.1016/0360-3016(86)90081-7
   van Leeuwen CM, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-1040-z
   Wang D, 2015, J CLIN ONCOL, V33, P2231, DOI 10.1200/JCO.2014.58.5828
   Yoon SS, 2011, INT J RADIAT ONCOL, V81, P1081, DOI 10.1016/j.ijrobp.2010.07.024
   Zagars GK, 2003, INT J RADIAT ONCOL, V56, P482, DOI 10.1016/S0360-3016(02)04510-8
NR 33
TC 2
Z9 2
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUN 5
PY 2020
VL 10
AR 993
DI 10.3389/fonc.2020.00993
PG 7
WC Oncology
SC Oncology
GA MC1QI
UT WOS:000543070200001
PM 32582558
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Narasaraju, T
   Tang, BM
   Herrmann, M
   Muller, S
   Chow, VTK
   Radic, M
AF Narasaraju, Teluguakula
   Tang, Benjamin M.
   Herrmann, Martin
   Muller, Sylviane
   Chow, Vincent T. K.
   Radic, Marko
TI Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung
   Impairment in Patients With COVID-19
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; acute respiratory distress syndrome; neutrophils;
   neutrophilia; neutrophil extracellular traps; pathogenesis; therapeutics
ID RESPIRATORY-DISTRESS-SYNDROME; CXCR2 ANTAGONIST AZD5069; ELASTASE
   INHIBITOR; EXTRACELLULAR HISTONES; INFLUENZA; PNEUMONIA; INJURY; SAFETY;
   MEDIATORS; AUTOPHAGY
AB There is an urgent need for new therapeutic strategies to contain the spread of the novel coronavirus disease 2019 (COVID-19) and to curtail its most severe complications. Severely ill patients experience pathologic manifestations of acute respiratory distress syndrome (ARDS), and clinical reports demonstrate striking neutrophilia, elevated levels of multiple cytokines, and an exaggerated inflammatory response in fatal COVID-19. Mechanical respirator devices are the most widely applied therapy for ARDS in COVID-19, yet mechanical ventilation achieves strikingly poor survival. Many patients, who recover, experience impaired cognition or physical disability. In this review, we argue the need to develop therapies aimed at inhibiting neutrophil recruitment, activation, degranulation, and neutrophil extracellular trap (NET) release. Moreover, we suggest that currently available pharmacologic approaches should be tested as treatments for ARDS in COVID-19. In our view, targeting host-mediated immunopathology holds promise to alleviate progressive pathologic complications of ARDS and reduce morbidities and mortalities in severely ill patients with COVID-19.
C1 [Narasaraju, Teluguakula] Oklahoma State Univ, Coll Vet Med, Stillwater, OK 74078 USA.
   [Tang, Benjamin M.] Nepean Hosp, Dept Intens Care Med, Sydney, NSW, Australia.
   [Herrmann, Martin] Friedrich Alexander Univ Erlangen Nurnberg, Univ Klinikum Erlangen, Dept Internal Med 3, Erlangen, Germany.
   [Muller, Sylviane] Univ Strasbourg, Biotechnol & Cell Signaling, CNRS, Illkirch Graffenstaden, France.
   [Muller, Sylviane] Inst Sci & Ingn Supramol, Lab Excellence Medalis, Strasbourg, France.
   [Muller, Sylviane] Univ Strasbourg, Inst Adv Study USIAS, Strasbourg, France.
   [Chow, Vincent T. K.] Natl Univ Singapore, Natl Univ Hlth Syst, Sch Med, Infect Dis Program,Dept Microbiol & Immunol, Singapore, Singapore.
   [Radic, Marko] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA.
RP Radic, M (corresponding author), Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA.
EM mradic@uthsc.edu
RI herrmann, martin/AAT-9836-2020
OI Radic, Marko/0000-0002-8004-282X
FU National Institute of General Medical Sciences of the National
   Institutes of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [P20GM103648]; Oklahoma Center for
   the Advancement of Science & Technology (OCAST); Center for Veterinary
   Health Sciences, Oklahoma State University; German Research Foundation
   (DFG)German Research Foundation (DFG) [CRC1181, FOR 2886]; National
   University of SingaporeNational University of Singapore; Lupus Research
   Alliance of NY; UTHSC
FX This work was supported by the National Institute of General Medical
   Sciences of the National Institutes of Health (NIH) under Award Number
   P20GM103648, a grant from the Oklahoma Center for the Advancement of
   Science & Technology (OCAST) and a grant from the Center for Veterinary
   Health Sciences, Oklahoma State University to TN. We thank the German
   Research Foundation (DFG), CRC1181 project C03 and FOR 2886 project B04
   for support to MH. We thank the National University of Singapore for
   support to VC. We thank the Lupus Research Alliance of NY and UTHSC for
   support to MR. The authors thank Dr. Gary Bowlin, Dr. Vera McGhee and
   Mr. Hunter King for help with editing. We thank Ms. Teluguakula
   Mahalakshmi for her assistance in the preparation of the figure.
CR Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC
   Ashar HK, 2018, AM J PATHOL, V188, P135, DOI 10.1016/j.ajpath.2017.09.014
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Bendorius M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02158
   Boeltz S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00874
   Borregaard N, 2007, TRENDS IMMUNOL, V28, P340, DOI 10.1016/j.it.2007.06.002
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Ciceri F., 2020, CRIT CARE RESUSC
   Cortjens B, 2018, THORAX, V73, P578, DOI 10.1136/thoraxjnl-2017-210289
   COVID-19 Treatment Guidelines Panel, 2020, COR DIS 2019 COVID 1
   Dehkordi AH, 2020, J MED VIROL, V92, P868, DOI 10.1002/jmv.25885
   Dunning J, 2018, NAT IMMUNOL, V19, P625, DOI 10.1038/s41590-018-0111-5
   Garcia-Prieto J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14780
   Gong J., 2020, CORRELATION ANAL DIS, DOI [10.1101/2020.02.25.20025643, DOI 10.1101/2020.02.25.20025643]
   Gunawardena KA, 2013, INT J CLIN PHARM TH, V51, P288, DOI 10.5414/CP201674
   Hayakawa M, 2010, SHOCK, V33, P14, DOI 10.1097/SHK.0b013e3181aa95c4
   Holz O, 2010, EUR RESPIR J, V35, P564, DOI 10.1183/09031936.00048509
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang LN, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-017-2903-x
   Ishigaki H, 2011, PEDIATR INT, V53, P669, DOI 10.1111/j.1442-200X.2011.03324.x
   Jimenez-Alcazar M, 2017, SCIENCE, V358, P1202, DOI 10.1126/science.aam8897
   Jurcevic S, 2015, BRIT J CLIN PHARMACO, V80, P1324, DOI 10.1111/bcp.12724
   Kim ES, 2016, J KOREAN MED SCI, V31, P1717, DOI 10.3346/jkms.2016.31.11.1717
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kuckleburg CJ, 2012, J IMMUNOL, V188, P2419, DOI 10.4049/jimmunol.1102540
   Lange S, 2014, J NEUROCHEM, V130, P555, DOI 10.1111/jnc.12744
   LeCount ER, 1919, J AMER MED ASSOC, V72, P1519, DOI 10.1001/jama.1919.02610210015003
   Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374
   Li H., 2017, OXID MED CELL LONGEV, V2017, P4, DOI DOI 10.1155/2017/8272504
   Liang YJ, 2018, EUR J PHARMACOL, V833, P432, DOI 10.1016/j.ejphar.2018.07.005
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Macri C, 2015, AUTOPHAGY, V11, P472, DOI 10.1080/15548627.2015.1017179
   Madan A, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz163
   Maugeri N, 2014, J THROMB HAEMOST, V12, P2074, DOI 10.1111/jth.12710
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mikacenic C, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2290-8
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   Morjaria JB, 2010, DRUG DISCOV TODAY, V15, P396, DOI 10.1016/j.drudis.2010.03.001
   Muller S, 2016, NAT MED, V22, P126, DOI 10.1038/nm.4044
   Munoz LE, 2019, IMMUNITY, V51, P443, DOI 10.1016/j.immuni.2019.07.002
   Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x
   Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013
   Neeli I, 2008, J IMMUNOL, V180, P1895, DOI 10.4049/jimmunol.180.3.1895
   Ng WF, 2006, HUM PATHOL, V37, P381, DOI 10.1016/j.humpath.2006.01.015
   O'Byrne PM, 2016, LANCET RESP MED, V4, P797, DOI 10.1016/S2213-2600(16)30227-2
   Pan C, 2020, AM J RESP CRIT CARE, V201, P1294, DOI 10.1164/rccm.202003-0527LE
   Pedersen F, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00970-2017
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Podolska MJ, 2019, J LEUKOCYTE BIOL, V106, P1359, DOI 10.1002/JLB.3AB0918-370R
   Roberts G, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz072
   Rudd Jennifer M, 2016, J Infect Pulm Dis, V2, DOI 10.16966/2470-3176.114
   Schauer C, 2014, NAT MED, V20, P515, DOI 10.1038/nm.3547
   Silvestre-Roig C, 2016, BLOOD, V127, P2173, DOI 10.1182/blood-2016-01-688887
   Sivanandham R, 2018, J CLIN INVEST, V128, P5178, DOI 10.1172/JCI99420
   Tang BM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11249-y
   Tatsiy O, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02036
   Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001
   Uddin M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00047
   Uddin M, 2017, HAEMATOLOGICA, V102, pE65, DOI 10.3324/haematol.2016.152371
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   von Nussbaum F, 2015, CHEMMEDCHEM, V10, P1163, DOI 10.1002/cmdc.201500131
   W.H.O. Rolling Updates on COVID-19. Coronavirus disease (COVID-19) pandemic, ROLL UPD COVID 19 CO
   Walters KA, 2016, J PATHOL, V238, P85, DOI 10.1002/path.4638
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Wolach O, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan8292
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yago T, 2018, BLOOD ADV, V2, P731, DOI 10.1182/bloodadvances.2017015602
   Yang WJ, 2020, J INFECTION, V80, P388, DOI 10.1016/j.jinf.2020.02.016
   Yildiz C, 2015, ANESTHESIOLOGY, V122, P864, DOI 10.1097/ALN.0000000000000605
   Yokoyama T, 2010, INTERNAL MED, V49, P427, DOI 10.2169/internalmedicine.49.3022
   Yoshikawa S, 2010, EUR J PHARMACOL, V641, P220, DOI 10.1016/j.ejphar.2010.05.039
   Zhang B, 2020, IMMUNE PHENOTYPING B, V7, P157, DOI [10.1101/2020.03.12.20035048, DOI 10.1101/2020.03.12.20035048]
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
   Zhang J, 2020, BIOSCI TRENDS, V14, P206, DOI 10.5582/bst.2020.03069
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu LL, 2018, J INFECT DIS, V217, P428, DOI 10.1093/infdis/jix475
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zimmer R, 2013, ANN RHEUM DIS, V72, P1830, DOI 10.1136/annrheumdis-2012-202460
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 87
TC 7
Z9 8
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 5
PY 2020
VL 11
AR 870
DI 10.3389/fphar.2020.00870
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MC2BF
UT WOS:000543098500001
PM 32581816
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Briguglio, M
   Bona, A
   Porta, M
   Dell'Osso, B
   Pregliasco, FE
   Banfi, G
AF Briguglio, Matteo
   Bona, Alberto
   Porta, Mauro
   Dell'Osso, Bernardo
   Pregliasco, Fabrizio Ernesto
   Banfi, Giuseppe
TI Disentangling the Hypothesis of Host Dysosmia and SARS-CoV-2: The Bait
   Symptom That Hides Neglected Neurophysiological Routes
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE smell; olfactory bulb; coronavirus; SARS-CoV-2; COVID-19; infections;
   virulence; host pathogen interactions
ID ACUTE RESPIRATORY SYNDROME; INTRANASAL DRUG-DELIVERY;
   CENTRAL-NERVOUS-SYSTEM; HERPES-SIMPLEX-VIRUS; CORONAVIRUS SARS-COV;
   PULMONARY-FUNCTION; NEURAL PATHWAYS; OLFACTORY NERVE; SEVERE SEPSIS;
   BRAIN-STEM
AB The respiratory condition COVID-19 arises in a human host upon the infection with SARS-CoV-2, a coronavirus that was first acknowledged in Wuhan, China, at the end of December 2019 after its outbreak of viral pneumonia. The full-blown COVID-19 can lead, in susceptible individuals, to premature death because of the massive viral proliferation, hypoxia, misdirected host immunoresponse, microthrombosis, and drug toxicities. Alike other coronaviruses, SARS-CoV-2 has a neuroinvasive potential, which may be associated with early neurological symptoms. In the past, the nervous tissue of patients infected with other coronaviruses was shown to be heavily infiltrated. Patients with SARS-CoV-2 commonly report dysosmia, which has been related to the viral access in the olfactory bulb. However, this early symptom may reflect the nasal proliferation that should not be confused with the viral access in the central nervous system of the host, which can instead be allowed by means of other routes for spreading in most of the neuroanatomical districts. Axonal, trans-synaptic, perineural, blood, lymphatic, or Trojan routes can gain the virus multiples accesses from peripheral neuronal networks, thus ultimately invading the brain and brainstem. The death upon respiratory failure may be also associated with the local inflammation- and thrombi-derived damages to the respiratory reflexes in both the lung neuronal network and brainstem center. Beyond the infection-associated neurological symptoms, long-term neuropsychiatric consequences that could occur months after the host recovery are not to be excluded. While our article does not attempt to fully comprehend all accesses for host neuroinvasion, we aim at stimulating researchers and clinicians to fully consider the neuroinvasive potential of SARS-CoV-2, which is likely to affect the peripheral nervous system targets first, such as the enteric and pulmonary nervous networks. This acknowledgment may shed some light on the disease understanding further guiding public health preventive efforts and medical therapies to fight the pandemic that directly or indirectly affects healthy isolated individuals, quarantined subjects, sick hospitalized, and healthcare workers.
C1 [Briguglio, Matteo; Banfi, Giuseppe] IRCCS Orthoped Inst Galeazzi, Sci Direct, Milan, Italy.
   [Bona, Alberto] ICCS Ist Clin Citta Studi, Dept Neurosurg, Milan, Italy.
   [Porta, Mauro] IRCCS Orthoped Inst Galeazzi, Movement Disorder Ctr, Milan, Italy.
   [Dell'Osso, Bernardo] Univ Milan, Osped Sacco Polo Univ, Dept Clin & Biomed Sci Luigi Sacco, ASST Fatebenefratelli Sacco, Milan, Italy.
   [Dell'Osso, Bernardo] Univ Milan, Aldo Ravelli Ctr Neurotechnol & Brain Therapeut, Milan, Italy.
   [Dell'Osso, Bernardo] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
   [Pregliasco, Fabrizio Ernesto] IRCCS Orthoped Inst Galeazzi, Hlth Management, Milan, Italy.
   [Pregliasco, Fabrizio Ernesto] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy.
   [Banfi, Giuseppe] Univ Vita Salute San Raffaele, Fac Med & Surg, Milan, Italy.
RP Briguglio, M (corresponding author), IRCCS Orthoped Inst Galeazzi, Sci Direct, Milan, Italy.
EM matteo.briguglio@grupposandonato.it
RI Briguglio, Matteo/J-4957-2018
OI Briguglio, Matteo/0000-0003-0801-2359
CR Adriaensen D, 2003, ANAT REC PART A, V270A, P25, DOI 10.1002/ar.a.10007
   AKERLUND A, 1995, ACTA OTO-LARYNGOL, V115, P88, DOI 10.3109/00016489509133353
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bangash MN, 2020, LANCET GASTROENTEROL, V5, P529, DOI 10.1016/S2468-1253(20)30084-4
   BARNETT EM, 1993, NEUROSCIENCE, V57, P1007, DOI 10.1016/0306-4522(93)90045-H
   Bearer EL, 2000, P NATL ACAD SCI USA, V97, P8146, DOI 10.1073/pnas.97.14.8146
   Benghanem S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-019-2718-9
   Benito N, 2018, J NEUROSCI, V38, P9870, DOI 10.1523/JNEUROSCI.1216-18.2018
   Bodewes R, 2011, AM J PATHOL, V179, P30, DOI 10.1016/j.ajpath.2011.03.026
   Brann D, 2020, NONNEURAL EXPRESSION, DOI [10.1101/2020.03.25.009084, DOI 10.1101/2020.03.25.009084, 10.1101/2020.03.25.009084.]
   Briguglio M, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00146
   Briguglio M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020386
   Briguglio M, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050591
   Brussow H, 2020, MICROB BIOTECHNOL, V13, P607, DOI 10.1111/1751-7915.13557
   Chen BS, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00261
   Chen L, 2020, BRIT J OPHTHALMOL, V104, P748, DOI 10.1136/bjophthalmol-2020-316304
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Conger K, 2020, COVID 19 PATIENTS OF
   Corman VM, 2016, CLIN INFECT DIS, V62, P477, DOI 10.1093/cid/civ951
   Costes LMM, 2013, ORGANOGENESIS, V9, P216, DOI 10.4161/org.25646
   COVID-19_SymptomTracker, 2020, LOSS TAST SMELL
   Crowe TP, 2018, LIFE SCI, V195, P44, DOI 10.1016/j.lfs.2017.12.025
   Davison DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11226
   De Chiara G, 2012, MOL NEUROBIOL, V46, P614, DOI 10.1007/s12035-012-8320-7
   de Jong MD, 2005, NEW ENGL J MED, V352, P686, DOI 10.1056/NEJMoa044307
   Carvalho PMD, 2020, PSYCHIAT RES, V286, DOI 10.1016/j.psychres.2020.112902
   Desforges M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010014
   Doty RL, 2008, ANN NEUROL, V63, P7, DOI 10.1002/ana.21327
   Doty RL, 2001, LARYNGOSCOPE, V111, P409, DOI 10.1097/00005537-200103000-00008
   Dube M, 2018, J VIROL, V92, DOI 10.1128/JVI.00404-18
   DUNCAN HJ, 1995, ARCH OTOLARYNGOL, V121, P1183
   Durrant DM, 2016, ACS CHEM NEUROSCI, V7, P464, DOI 10.1021/acschemneuro.6b00043
   El-Chemaly S, 2008, ANN NY ACAD SCI, V1131, P195, DOI 10.1196/annals.1413.017
   Faber HK, 1933, J EXP MED, V57, P933, DOI 10.1084/jem.57.6.933
   Ganger S, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030116
   Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hopkins C, 2020, LOSS SENSE SMELL MAR
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2005, THORAX, V60, P401, DOI 10.1136/thx.2004.030205
   Hummel T, 1998, EUR J CLIN PHARMACOL, V54, P521, DOI 10.1007/s002280050507
   Hwang Chi-Shin, 2006, Acta Neurol Taiwan, V15, P26
   Kabbani N, 2020, MOL PHARMACOL, V97, P351, DOI 10.1124/molpharm.120.000014
   Keyhan SO, 2020, MAX PLAST RECONSTR S, V42, DOI 10.1186/s40902-020-00254-7
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lam MHB, 2009, ARCH INTERN MED, V169, P2142, DOI 10.1001/archinternmed.2009.384
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020
   Li G, 2013, LUNG, V191, P327, DOI 10.1007/s00408-013-9470-8
   Li K, 2016, J INFECT DIS, V213, P712, DOI 10.1093/infdis/jiv499
   Li LY, 2020, J DIGEST DIS, V21, P199, DOI 10.1111/1751-2980.12862
   Li Y, 2005, GLIA, V52, P245, DOI 10.1002/glia.20241
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Li YC, 2013, J COMP NEUROL, V521, P203, DOI 10.1002/cne.23171
   Li YC, 2012, VIRUS RES, V163, P628, DOI 10.1016/j.virusres.2011.12.021
   Lillicrap D, 2020, J THROMB HAEMOST, V18, P786, DOI 10.1111/jth.14781
   Lochhead JJ, 2015, J CEREBR BLOOD F MET, V35, P371, DOI 10.1038/jcbfm.2014.215
   Lochhead JJ, 2012, ADV DRUG DELIVER REV, V64, P614, DOI 10.1016/j.addr.2011.11.002
   Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432
   Mabbott NA, 2013, MUCOSAL IMMUNOL, V6, P666, DOI 10.1038/mi.2013.30
   MacGibeny MA, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007188
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   McGann JP, 2017, SCIENCE, V356, DOI 10.1126/science.aam7263
   MCLEAN JH, 1993, EXP NEUROL, V122, P209, DOI 10.1006/exnr.1993.1121
   Miller MJ, 2010, ANN NY ACAD SCI, V1207, pE21, DOI 10.1111/j.1749-6632.2010.05708.x
   MOHAMMED AK, 1990, NEUROSCIENCE, V35, P355, DOI 10.1016/0306-4522(90)90089-M
   Morfopoulou S, 2016, NEW ENGL J MED, V375, P497, DOI 10.1056/NEJMc1509458
   Mori I, 2005, J NEUROVIROL, V11, P129, DOI 10.1080/13550280590922793
   Mori I, 2002, J GEN VIROL, V83, P2109, DOI 10.1099/0022-1317-83-9-2109
   Nedergaard M, 2013, SCIENCE, V340, P1529, DOI 10.1126/science.1240514
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Ngai JC, 2010, RESPIROLOGY, V15, P543, DOI 10.1111/j.1440-1843.2010.01720.x
   Oberdorster G, 2004, INHAL TOXICOL, V16, P437, DOI 10.1080/08958370490439597
   Oliveira-Pinto AV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111733
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   PERLMAN S, 1990, J EXP MED, V172, P1127, DOI 10.1084/jem.172.4.1127
   Prescott HC, 2015, JAMA-J AM MED ASSOC, V313, P1055, DOI 10.1001/jama.2015.1410
   Previtali G., PATHOGENESIS THROMBO, DOI [10.1101/2020.04.30.20086397, DOI 10.1101/2020.04.30.20086397]
   Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265
   Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105
   Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985
   Rothaug M, 2016, BBA-MOL CELL RES, V1863, P1218, DOI 10.1016/j.bbamcr.2016.03.018
   Seiden AM, 2004, OTOLARYNG CLIN N AM, V37, P1159, DOI 10.1016/j.otc.2004.06.007
   Setti L., 2020, EVALUATION POTENTIAL
   Severance EG, 2011, SCHIZOPHRENIA BULL, V37, P101, DOI 10.1093/schbul/sbp052
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Shi XY, 2005, AM J GASTROENTEROL, V100, P169, DOI 10.1111/j.1572-0241.2005.40377.x
   Silverman MN, 2005, VIRAL IMMUNOL, V18, P41, DOI 10.1089/vim.2005.18.41
   Simon M, 2013, EMERG INFECT DIS, V19, P1005, DOI 10.3201/eid1906.130062
   Soler ZM, 2020, INT FORUM ALLERGY RH, V10, P814, DOI 10.1002/alr.22578
   Sonne J., 2020, NEUROANATOMY CRANIAL
   St John JA, 2016, INFECT IMMUN, V84, P2681, DOI 10.1128/IAI.00361-16
   Stainsby Brynne, 2011, J Can Chiropr Assoc, V55, P32
   Stamatovic SM, 2005, J CEREBR BLOOD F MET, V25, P593, DOI 10.1038/sj.jcbfm.9600055
   Steardo L, 2020, ACTA PHYSIOL, V229, DOI 10.1111/apha.13473
   Steinke A, 2008, HISTOCHEM CELL BIOL, V130, P339, DOI 10.1007/s00418-008-0441-8
   Sun T, 2020, EUR J NEUROL, V27, pE52, DOI 10.1111/ene.14227
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tan SH, 2014, J NEUROPATH EXP NEUR, V73, P999, DOI 10.1097/NEN.0000000000000122
   Taroc EZM, 2017, BIOL OPEN, V6, P1552, DOI 10.1242/bio.029074
   To K, 2004, J PATHOL, V202, P157, DOI 10.1002/path.1510
   To KF, 2004, J PATHOL, V203, P740, DOI 10.1002/path.1597
   Tsai LK, 2004, ARCH NEUROL-CHICAGO, V61, P1669, DOI 10.1001/archneur.61.11.1669
   Turgay C, 2015, J PEDIATR NEUROSCI, V10, P280, DOI 10.4103/1817-1745.165716
   Undem BJ, 2005, P AM THORAC SOC, V2, P355, DOI DOI 10.1513/PATS.200504-033SR
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   van Riel D, 2015, J PATHOL, V235, P277, DOI 10.1002/path.4461
   Vergnolle N, 2018, PHYSIOLOGY, V33, P269, DOI 10.1152/physiol.00009.2018
   Veronesi MC, 2020, AM J NUCL MED MOLEC, V10, P1
   Wang J, 2020, ACE2 EXPRESSION COLO, DOI [10.1101/2020.02.05.20020545, DOI 10.1101/2020.02.05.20020545]
   Wang YL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02325
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P55, DOI 10.1016/j.bbi.2020.04.043
   Xia HJ, 2008, J NEUROCHEM, V107, P1482, DOI 10.1111/j.1471-4159.2008.05723.x
   Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224
   Xu J, 2020, J DENT RES, V99, P989, DOI 10.1177/0022034520918518
   Xu J, 2005, CLIN INFECT DIS, V41, P1089, DOI 10.1086/444461
   Yamagishi Masuo, 1994, Rhinology (Utrecht), V32, P113
   Ye MX, 2020, BRAIN BEHAV IMMUN, V88, P945, DOI 10.1016/j.bbi.2020.04.017
   Yeo C, 2020, LANCET GASTROENTEROL, V5, P335, DOI 10.1016/S2468-1253(20)30048-0
   Yin J, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/5150678
   Yoo BB, 2017, IMMUNITY, V46, P910, DOI 10.1016/j.immuni.2017.05.011
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang JY, 2015, FASEB J, V29, P1739, DOI 10.1096/fj.14-258822
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004
   Zhao K, 2020, ACUTE MYELITIS SARS, DOI [10.1101/2020.03.16.20035105, DOI 10.1101/2020.03.16.20035105]
   Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zielske J, 2014, EUR ARCH OTO-RHINO-L, V271, P3085, DOI 10.1007/s00405-014-3148-6
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 135
TC 7
Z9 7
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD JUN 5
PY 2020
VL 11
AR 671
DI 10.3389/fphys.2020.00671
PG 13
WC Physiology
SC Physiology
GA MC2FU
UT WOS:000543110400001
PM 32581854
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Giudice, V
   Pagliano, P
   Vatrella, A
   Masullo, A
   Poto, S
   Polverino, BM
   Gammaldi, R
   Maglio, A
   Sellitto, C
   Vitale, C
   Serio, B
   Cuffa, B
   Borrelli, A
   Vecchione, C
   Filippelli, A
   Selleri, C
AF Giudice, Valentina
   Pagliano, Pasquale
   Vatrella, Alessandro
   Masullo, Alfonso
   Poto, Sergio
   Polverino, Benedetto Maria
   Gammaldi, Renato
   Maglio, Angelantonio
   Sellitto, Carmine
   Vitale, Carolina
   Serio, Bianca
   Cuffa, Bianca
   Borrelli, Anna
   Vecchione, Carmine
   Filippelli, Amelia
   Selleri, Carmine
TI Combination of Ruxolitinib and Eculizumab for Treatment of Severe
   SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled
   Study
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE JAK inhibitor; eculizumab; ARDS (acute respiratory distress syndrome);
   COVID-19; SARS-CoV-2
ID SAFETY; SURVIVAL; EFFICACY
AB To date, there are no specific therapeutic strategies for treatment of COVID-19. Based on the hypothesis that complement and coagulation cascades are activated by viral infection, and might trigger an acute respiratory distress syndrome (ARDS), we report clinical outcomes of 17 consecutive cases of SARS-CoV-2-related ARDS treated (N = 7) with the novel combination of ruxolitinib, a JAK1/2 inhibitor, 10 mg/twice daily for 14 days and eculizumab, an anti-C5a complement monoclonal antibody, 900 mg IV/weekly for a maximum of three weeks, or with the best available therapy (N = 10). Patients treated with the combination showed significant improvements in respiratory symptoms and radiographic pulmonary lesions and decrease in circulating D-dimer levels compared to the best available therapy group. Our results support the use of combined ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related ARDS by simultaneously turning off abnormal innate and adaptive immune responses.
C1 [Giudice, Valentina; Pagliano, Pasquale; Vatrella, Alessandro; Poto, Sergio; Sellitto, Carmine; Vecchione, Carmine; Filippelli, Amelia; Selleri, Carmine] Univ Salerno, Dept Med Surg & Dent, Scuola Med Salernitana, Baronissi, Italy.
   [Giudice, Valentina; Sellitto, Carmine; Filippelli, Amelia] Univ Hosp San Giovanni di Dio & Ruggi dAragona, Clin Pharmacol Unit, Salerno, Italy.
   [Pagliano, Pasquale; Masullo, Alfonso] Univ Hosp San Giovanni di Dio & Ruggi dAragona, Infect Dis Unit, Salerno, Italy.
   [Vatrella, Alessandro; Poto, Sergio; Maglio, Angelantonio; Vitale, Carolina] Univ Hosp San Giovanni di Dio & Ruggi dAragona, Intens Care Unit, Salerno, Italy.
   [Polverino, Benedetto Maria] Univ Hosp San Giovanni di Dio & Ruggi dAragona, Resp Dis Unit, Salerno, Italy.
   [Gammaldi, Renato] Univ Hosp San Giovanni di Dio & Ruggi dAragona, Hosp Giovanni Da Procida, Resp Endoscopy Unit, Salerno, Italy.
   [Serio, Bianca; Cuffa, Bianca; Selleri, Carmine] Univ Hosp San Giovanni di Dio & Ruggi dAragona, Hematol & Transplant Unit, Salerno, Italy.
   [Borrelli, Anna] Univ Hosp San Giovanni di Dio & Ruggi dAragona, Execut Board, Salerno, Italy.
RP Giudice, V; Selleri, C (corresponding author), Univ Salerno, Dept Med Surg & Dent, Scuola Med Salernitana, Baronissi, Italy.; Giudice, V (corresponding author), Univ Hosp San Giovanni di Dio & Ruggi dAragona, Clin Pharmacol Unit, Salerno, Italy.; Selleri, C (corresponding author), Univ Hosp San Giovanni di Dio & Ruggi dAragona, Hematol & Transplant Unit, Salerno, Italy.
EM vgiudice@unisa.it; cselleri@unisa.it
RI Giudice, Valentina/H-9329-2019; Vatrella, Alessandro/K-8001-2016
OI Giudice, Valentina/0000-0002-7492-6848; Vatrella,
   Alessandro/0000-0001-8265-3037; Sellitto, Carmine/0000-0002-5595-7841
FU Intramural Program of the Department of Medicine, Surgery and Dentistry,
   University of Salerno, Italy
FX The authors would like to thank Francesca D'Alto (Hematology and
   Transplant Unit, University Hospital "San Giovanni di Dio e Ruggi
   d'Aragona"), and Dr. Maddalena Langella and Dr. Emilia Vaccaro (HLA
   typing and Molecular Biology Section, Transfusion Medicine Unit,
   University Hospital "San Giovanni di Dio e Ruggi d'Aragona") for
   technical assistance. The authors would also like to thank Novartis and
   Alexion for technical support. This research was supported by the
   Intramural Program of the Department of Medicine, Surgery and Dentistry,
   University of Salerno, Italy.
CR Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419
   Cervantes F, 2013, BLOOD, V122, P4047, DOI 10.1182/blood-2013-02-485888
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Diurno F, 2020, EUR REV MED PHARMACO, V24, P4040, DOI 10.26355/eurrev_202004_20875
   Elli EM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01186
   Galimberti S, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104866
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Kluetz Paul G, 2016, Am Soc Clin Oncol Educ Book, V35, P67, DOI 10.14694/EDBK_159514
   Matricardi PM, 2020, PEDIAT ALLERG IMM-UK, V31, P454, DOI 10.1111/pai.13271
   Moore CG, 2011, CTS-CLIN TRANSL SCI, V4, P332, DOI 10.1111/j.1752-8062.2011.00347.x
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Risitano AM, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0320-7
   Rondeau E, 2019, KIDNEY INT REP, V4, P1568, DOI 10.1016/j.ekir.2019.07.016
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Seif F, 2020, INT ARCH ALLERGY IMM, V181, P467, DOI 10.1159/000508247
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Verstovsek S, 2013, HAEMATOLOGICA, V98, P1865, DOI 10.3324/haematol.2013.092155
   Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557
   Woehrl B, 2011, J CLIN INVEST, V121, P3943, DOI 10.1172/JCI57522
NR 20
TC 10
Z9 10
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 5
PY 2020
VL 11
AR 857
DI 10.3389/fphar.2020.00857
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MC2AZ
UT WOS:000543097900001
PM 32581810
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sestili, P
   Stocchi, V
AF Sestili, Piero
   Stocchi, Vilberto
TI Repositioning Chromones for Early Anti-inflammatory Treatment of
   COVID-19
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID-19; inflammation; lung injury; chromones; mast cells
ID SODIUM CROMOGLYCATE; MAST-CELL; OUTBREAK
AB The COVID-19 pandemic is posing an unprecedented sanitary threat. In the absence of specific vaccines and anti-SARS-CoV-2 drugs, medicines that may assist in tackling the emergency and limiting the high number of fatalities are urgently needed. The repositioning of available drugs to treat COVID-19 is the only and rapid option in the face of the lack of direct antiviral agents and vaccines available. In this light it is important to focus on available drugs, which, based on their pharmacodynamics, could plausibly attenuate viral growth as well as COVID-19's worst complications. This is the case of chloroquine and tocilizumab which seem to limit virus replication and the severity of interstitial pneumonia, respectively. However, these treatments, particularly those aimed at containing inflammation, are still reserved for the most severe cases. This commentary elaborates on the pharmacological rationale of repositioning the mast cell stabilizer chromones as an adjunctive treatment for SARS-CoV-2 infection, and proposes their practical clinical testing as an early, safe, and cost-effective anti-inflammatory intervention in COVID-19 to limit the eventual secondary progression toward life-threatening respiratory complications.
C1 [Sestili, Piero; Stocchi, Vilberto] Univ Urbino Carlo Bo, Dept Biomol Sci DISB, Urbino, Italy.
RP Sestili, P (corresponding author), Univ Urbino Carlo Bo, Dept Biomol Sci DISB, Urbino, Italy.
EM piero.sestili@uniurb.it
FU Universita degli Studi di Urbino Carlo Bo
FX The present article has been funded by a grant (recipient PS) from
   Universita degli Studi di Urbino Carlo Bo, Fondi Valorizzazione DISB.
CR Bassler D, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007802.pub2
   Beigel JH, 2019, ANTIVIR RES, V167, P45, DOI 10.1016/j.antiviral.2019.04.006
   D'Acquisto F, 2008, BRIT J PHARMACOL, V155, P152, DOI 10.1038/bjp.2008.252
   de Girolamo L, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018-020-01682-x
   Debbasch C, 2001, J FR OPHTALMOL, V24, P121
   Elmedany SH, 2019, CLIN RHEUMATOL, V38, P2109, DOI 10.1007/s10067-019-04508-2
   Franchini M, 2020, VOX SANG, DOI 10.1111/vox.12940
   Gallo L, 2017, AAPS PHARMSCITECH, V18, P1634, DOI 10.1208/s12249-016-0633-9
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gonzalez-de-Olano D, 2018, J INVEST ALLERG CLIN, V28, P365, DOI 10.18176/jiaci.0327
   Han DP, 2016, INFLUENZA OTHER RESP, V10, P57, DOI 10.1111/irv.12334
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Kolawole EM, 2016, J IMMUNOL, V196, P1461, DOI 10.4049/jimmunol.1501932
   Kowalewski M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02925-3
   Kritas SK, 2020, J BIOL REG HOMEOS AG, V34, P9, DOI 10.23812/20-Editorial-Kritas
   Larsson K, 2001, CLIN EXP ALLERGY, V31, P1356, DOI 10.1046/j.1365-2222.2001.01193.x
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liebler JM, 1998, THORAX, V53, P823, DOI 10.1136/thx.53.10.823
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Lupia T, 2020, J GLOB ANTIMICROB RE, V21, P22, DOI 10.1016/j.jgar.2020.02.021
   Meng D, 2017, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02130
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Oka T, 2012, LAB INVEST, V92, P1472, DOI 10.1038/labinvest.2012.116
   Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1
   PEARCE FL, 1989, DRUGS, V37, P37, DOI 10.2165/00003495-198900371-00009
   Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470
   Phadke M, 2020, DRUG DEVELOP RES, V81, P541, DOI 10.1002/ddr.21666
   Porfidia A, 2020, J THROMB THROMBOLYS, V50, P68, DOI 10.1007/s11239-020-02125-4
   Sadeghi-Hashjin G, 2002, EUR RESPIR J, V20, P867, DOI 10.1183/09031936.02.00382002
   Sestili P, 1998, FREE RADICAL BIO MED, V25, P196, DOI 10.1016/S0891-5849(98)00040-9
   Sheppard M, 2017, HUM VACC IMMUNOTHER, V13, P1972, DOI 10.1080/21645515.2017.1316909
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Sinniah A, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00827
   Theoharides TC, 2020, BIOFACTORS, V46, P306, DOI 10.1002/biof.1633
   Varricchi G, 2019, INT ARCH ALLERGY IMM, V179, P247, DOI 10.1159/000500088
   Veronese N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00170
   Virk H, 2016, TRANSL RES, V174, P60, DOI 10.1016/j.trsl.2016.01.005
   Weng Z, 2015, J ALLERGY CLIN IMMUN, V135, P1044, DOI 10.1016/j.jaci.2014.10.032
   Weng ZY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033805
   Zhang AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075262
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
   Zhang T, 2016, EUR J PHARMACOL, V778, P158, DOI 10.1016/j.ejphar.2015.05.071
NR 43
TC 2
Z9 2
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 5
PY 2020
VL 11
AR 854
DI 10.3389/fphar.2020.00854
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MC2AO
UT WOS:000543096800001
PM 32581809
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bosteels, C
   Maes, B
   Van Damme, K
   De Leeuw, E
   Declercq, J
   Delporte, A
   Demeyere, B
   Vermeersch, S
   Vuylsteke, M
   Willaert, J
   Bolle, L
   Vanbiervliet, Y
   Decuypere, J
   Libeer, F
   Vandecasteele, S
   Peene, I
   Lambrecht, B
AF Bosteels, Cedric
   Maes, Bastiaan
   Van Damme, Karel
   De Leeuw, Elisabeth
   Declercq, Jozefien
   Delporte, Anja
   Demeyere, Benedicte
   Vermeersch, Stefanie
   Vuylsteke, Marnik
   Willaert, Joren
   Bolle, Laura
   Vanbiervliet, Yuri
   Decuypere, Jana
   Libeer, Frederick
   Vandecasteele, Stefaan
   Peene, Isabelle
   Lambrecht, Bart
TI Sargramostim to treat patients with acute hypoxic respiratory failure
   due to COVID-19 (SARPAC): A structured summary of a study protocol for a
   randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; sargramostim; GM-CSF;
   leukine (R); oxygenation; hypoxic failure; PF ratio; A-a gradient;
   inflammatory monocyte; alveolar macrophage
AB ObjectivesThe hypothesis of the proposed intervention is that Granulocyte-macrophage colony-stimulating factor (GM-CSF) has profound effects on antiviral immunity, and can provide the stimulus to restore immune homeostasis in the lung with acute lung injury post COVID-19, and can promote lung repair mechanisms, that lead to a 25% improvement in lung oxygenation parameters. Sargramostim is a man-made form of the naturally-occurring protein GM-CSF.Trial designA phase 4 academic, prospective, 2 arm (1:1 ratio), randomized, open-label, controlled trial.ParticipantsPatients aged 18-80 years admitted to specialized COVID-19 wards in 5 Belgian hospitals with recent (< 2 weeks prior to randomization) confirmed COVID-19 infection and acute respiratory failure defined as a PaO2/FiO(2) below 350 mmHg or SpO(2) below 93% on minimal 2 L/min supplemental oxygen. Patients were excluded from the trial in case of (1) known serious allergic reactions to yeast-derived products, (2) lithium carbonate therapy, (3) mechanical ventilation prior to randomization, (4) peripheral white blood cell count above 25.000/mu L and/or active myeloid malignancy, (5) high dose systemic steroid therapy (> 20 mg methylprednisolone or equivalent), (6) enrolment in another investigational study, (7) pregnant or breastfeeding or (8) ferritin levels > 2000 mu g/mL.Intervention and comparatorInhaled sargramostim 125 mu g twice daily for 5 days in addition to standard care. Upon progression of disease requiring mechanical ventilation or to acute respiratory distress syndrome (ARDS) and initiation of mechanical ventilator support within the 5 day period, inhaled sargramostim will be replaced by intravenous sargramostim 125 mu g/m(2) body surface area once daily until the 5 day period is reached. From day 6 onwards, progressive patients in the active group will have the option to receive an additional 5 days of IV sargramostim, based on the treating physician's assessment. Intervention will be compared to standard of care. Subjects progressing to ARDS and requiring invasive mechanical ventilatory support, from day 6 onwards in the standard of care group will have the option (clinician's decision) to initiate IV sargramostim 125m mu g/m(2) body surface area once daily for 5 days.Main outcomesThe primary endpoint of this intervention is measuring oxygenation after 5 days of inhaled (and intravenous) treatment through assessment of a change in pretreatment and post-treatment ratio of PaO2/FiO(2) and through measurement of the P(A-a)O-2 gradient (PAO(2)= Partial alveolar pressure of oxygen, PaO2=Partial arterial pressure of oxygen; FiO(2)= Fraction of inspired oxygen).RandomisationPatients will be randomized in a 1:1 ratio. Randomization will be done using REDCap (electronic IWRS system).Blinding (masking)In this open-label trial neither participants, caregivers, nor those assessing the outcomes will be blinded to group assignment.Numbers to be randomised (sample size)A total of 80 patients with confirmed COVID-19 and acute hypoxic respiratory failure will be enrolled, 40 in the active and 40 in the control group.Trial StatusSARPAC protocol Version 2.0 (April 15 2020). Participant recruitment is ongoing in 5 Belgian Hospitals (i.e. University Hospital Ghent, AZ Sint-Jan Bruges, AZ Delta Roeselare, University Hospital Brussels and ZNA Middelheim Antwerp). Participant recruitment started on March 26(th) 2020.
   Given the current decline of the COVID-19 pandemic in Belgium, it is difficult to anticipate the rate of participant recruitment.Trial registrationThe trial was registered on Clinical Trials.gov on March 30(th), 2020 (ClinicalTrials.gov Identifier: NCT04326920) - retrospectively registered; https://clinicaltrials.gov/ct2/show/NCT04326920?term=sarpac&recrs=ab&draw=2&rank=1 and on EudraCT on March 24th, 2020 (Identifier: 2020-001254-22).Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Bosteels, Cedric; Maes, Bastiaan; Van Damme, Karel; De Leeuw, Elisabeth; Declercq, Jozefien; Delporte, Anja; Demeyere, Benedicte; Vermeersch, Stefanie; Vuylsteke, Marnik; Willaert, Joren; Bolle, Laura; Vanbiervliet, Yuri; Decuypere, Jana; Libeer, Frederick; Vandecasteele, Stefaan; Peene, Isabelle; Lambrecht, Bart] VIB UGent Inflammatie Res Ctr, Ghent, Belgium.
RP Maes, B (corresponding author), VIB UGent Inflammatie Res Ctr, Ghent, Belgium.
EM bastiaan.maes@irc.vib-ugent.be
RI Lambrecht, Bart N/K-2484-2014; Peene, isabelle/ABA-5213-2020
OI Lambrecht, Bart N/0000-0003-4376-6834; De Leeuw,
   Elisabeth/0000-0002-7826-8141; Van Damme, Karel/0000-0002-4379-1047
FU Flemish Institute for Biotechnology (Vlaams Instituut voor
   Biotechnologie, VIB)
FX The Flemish Institute for Biotechnology (Vlaams Instituut voor
   Biotechnologie, VIB) funds the SARPAC trail and is involved in the
   collection, analysis and interpretation of data.
NR 0
TC 2
Z9 2
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 5
PY 2020
VL 21
IS 1
AR 491
DI 10.1186/s13063-020-04451-7
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1ZO
UT WOS:000540320200012
PM 32503663
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dalili, N
   Kashefizadeh, A
   Nafar, M
   Poorrezagholi, F
   Firouzan, A
   Samadian, F
   Samavat, S
   Ziaie, S
   Fatemizadeh, S
AF Dalili, Nooshin
   Kashefizadeh, Alireza
   Nafar, Mohsen
   Poorrezagholi, Fatemeh
   Firouzan, Ahmad
   Samadian, Fariba
   Samavat, Shiva
   Ziaie, Shadi
   Fatemizadeh, Somayeh
TI Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir
   (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A
   Structured Summary of a Study Protocol for a Randomized Controlled Trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; Colchicine; Oxidative
   Stress; Inflammation
AB ObjectivesColchicine is a well-known drug, which has been used for years to treat a wide range of rheumatic and inflammatory disorders. It helps break the cycle of inflammation through diverse mechanisms including reducing Intereukin-6, Interleukin-8, Tumour Necrosis Factor-alpha besides controlling oxidative stress pathways which all are important and pathologic components in the clinical course and outcome of patients infected with COVID-19. This study aims to assess the anti-inflammatory effects of colchicine in non-severe hospitalized COVID-19 patients.Trial designProspective, randomized (1:1 ratio), double blind study with parallel group design.ParticipantsHospitalized patients with positive nasopharyngeal swab for COVID-19 infection (RT -PCR) and lung Computed tomography scan involvement compatible with COVID-19 pneumonia. The patients are not severely hypoxic, do not need intubation or invasive oxygenation.Exclusion criteria: known hypersensitivity to colchicine; known hepatic failure; estimated glomerular filtration rate (eGFR)<30 ml/min/1.73m(2) (by the CKD-EPI Creatinine Equation for Glomerular Filtration Rate (GFR) which estimates GFR based on serum creatinine. ; kidney transplant recipients, using Digoxin, QTc >450 msec.Participants will be recruited from inpatients at Labbafinejad Meidcal Center , Tehran, Iran.Intervention and comparatorEligible enrolled patients will be randomized into two groups. Group A will receive the antiretroviral Lopinavir/Ritonavir (Kaletra) while group B will receive Lopinavir/Ritonavir (Kaletra) + Colchicine 1.5 mg loading then 0.5 mg twice daily orally. All patients in both groups will receive the same amounts of essential minerals, vitamins as antioxidants, and antibiotics.Patients of both groups will be treated under optimal treatment based on the CDC and WHO guidelines and national consensus proposed in Iran including the same dosages of Lopinavir/Ritonavir, antibiotics, trace elements and antioxidants while only in group-B patients Colchicine will be added on top of this protocol.Main outcomesPrimary: Time for clinical improvement and lung CT score changes 14 days after treatment.Secondary: 14 days after treatment- C-Reactive Protein test x Neutrophil to Lymphocyte Ratio , Interleukin-6, malondialdehyde (MDA) levels reduction- Percentage of patients who require supplemental Oxygen- Mean hospital stay lengthRandomisationPatients will be allocated to each group (ratio 1:1) by using an online randomization tool: http://www.graphpad.com/quickcalcs/index.cfmBlinding (masking)This will be a double-blind study in which participants and those assessing the final outcomes will be blinded to group assignment.Numbers to be randomised (sample size)Regarding the pandemic crisis and our center capacity to hospitalize confirmed COVID-19 patients, a total of 80 patients was found to be logical to be randomized into two groups of 40- patients.Trial StatusRecruitment is ongoing. Recruitment began on 20/03/2020 and the date by which the recruitment is anticipated to be completed is 30/05/2020.Trial registrationClinicalTrials.gov Identifier: NCT04360980, registered 24/04/2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Dalili, Nooshin; Nafar, Mohsen; Poorrezagholi, Fatemeh; Firouzan, Ahmad; Samadian, Fariba; Samavat, Shiva] Shahid Beheshti Univ Med Sci, Dept Nephrol, Shahid Labbafinejad Med Ctr, Boostan 9th St,Pasdaran Av, Tehran, Iran.
   [Dalili, Nooshin; Nafar, Mohsen; Poorrezagholi, Fatemeh; Firouzan, Ahmad; Samadian, Fariba; Samavat, Shiva] Shahid Beheshti Univ Med Sci, Chron Kidney Dis Res Ctr, Tehran, Iran.
   [Kashefizadeh, Alireza] Shahid Beheshti Univ Med Sci, Dept Pulmonol, Shahid Labbafinejad Med Ctr, Tehran, Iran.
   [Ziaie, Shadi] Shahid Beheshti Univ Med Sci, Fac Pharm, Clin Pharm Dept, Tehran, Iran.
   [Fatemizadeh, Somayeh] Shahid Beheshti Univ Med Sci, Dept Internal Med, Shahid Labbafinejad Med Ctr, Tehran, Iran.
RP Dalili, N (corresponding author), Shahid Beheshti Univ Med Sci, Dept Nephrol, Shahid Labbafinejad Med Ctr, Boostan 9th St,Pasdaran Av, Tehran, Iran.; Dalili, N (corresponding author), Shahid Beheshti Univ Med Sci, Chron Kidney Dis Res Ctr, Tehran, Iran.
EM drn.dalili@sbmu.ac.ir
FU Chronic Kidney Disease Research Centre (CKDRC)
FX This study received funding from Chronic Kidney Disease Research Centre
   (CKDRC), affiliated to Shahid Beheshti University of Medical Sciences.
   We declare that the funding body has no role in the design of the study
   and collection, analysis, and interpretation of data and in writing the
   manuscript.
NR 0
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 5
PY 2020
VL 21
IS 1
AR 489
DI 10.1186/s13063-020-04455-3
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1ZO
UT WOS:000540320200010
PM 32503620
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, JW
   Zhang, C
   Wu, Z
   Wang, GQ
   Zhao, H
AF Li, Jiawen
   Zhang, Chi
   Wu, Zhao
   Wang, Guiqiang
   Zhao, Hong
TI The Mechanism and Clinical Outcome of patients with Corona Virus Disease
   2019 Whose Nucleic Acid Test has changed from negative to positive, and
   the therapeutic efficacy of Favipiravir: A structured summary of a study
   protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; Favipiravir
AB ObjectivesA variety of possible mechanisms can make the nucleic acid test of patients who meet the discharge conditions positive again, including reinfection, reactivation of the original virus, lack of strict discharge criteria, new infection, and so on. Different reasons will correspond to different prevention and control measures. We will enroll patients who are discharged after treatment, whose nucleic acid test has changed from negative to positive during the screening visit, regardless of the severity of the symptoms, to investigate the mechanism, clinical outcome and therapeutic efficacy with Favipiravir patients with Corona virus Disease 2019. Favipiravir is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase, it has been used for treatment of some life-threatening infections such as Ebola virus, Lassa virus and rabies. Its therapeutic efficacy has been proven in these diseases.Trial designThis is a multi-center, two arm, open label, parallel group, randomized controlled trial.ParticipantsEligibility criteria:Inclusion criteria:Adults 18 to 80 years, male or female.After the first diagnosis and treatment of COVID-19, the nucleic acid test of respiratory specimens such as sputum or nasopharyngeal swabs, has been negative for two consecutive times (sampling time interval of at least 24 hours), in accordance with the COVID-19's diagnosis and treatment Plan (7th Edition), discharged.During screening visit (follow-up after discharge), The nucleic acid test of COVID-19 is positive in any one of the following samples: sputum, throat swabs, blood, feces or other specimens. Regardless of whether or not they had symptoms and the severity of symptoms.Volunteer to participate in the research and sign the Informed Consent Form.Exclusion Criteria: Allergic to Favipiravjr;Pregnant or lactating womenUncontrolled diseases of the blood and cardiovascular system, liver or kidney.History of mental disorders, drug abuse or dependence;Researchers consider it inappropriate for adults to participate;Participating in other clinical studies.Loss to Follow up:Cases that do not complete the clinical trial program will be regarded as lost to follow up. Including the withdrawal of patients by themselves (such as poor compliance, etc.), or the withdrawal of patients ordered by the researcher (those who need other drugs which affect the judgment of the curative effect, and those who need to stop taking drugs for severe adverse events)Study setting:The participating hospitals are some of the designated hospitals that have been or may be admitting patients who meet the eligibility criteria, mainly in Hubei, Shenzhen, Anhui and Beijing. Participants will be recruited from these 15 hospitals: Wuhan Pulmonary Hospital, Hubei; Jinyintan Hospital of Wuhan, Hubei; Ezhou Central Hospital, Hubei; The Second People's Hospital of Fuyang, Anhui; The First Affiliated Hospital of USTC, Anhui; Beijing Youan Hospital, Beijing; Capital Medical University Beijing Institute of Hepatology, Beijing; Ezhou Hospital of Traditional Chinese Medicine, Hubei; Zhongnan Hospital of Wuhan University, Hubei; The Fifth Hospital of ShiJiazhuang, Hebei; Jinan Infectious Diseases Hospital, Shandong; Public Health Clinical Center of Chengdu, Sichuan; Wuxi No.5 People's Hospital, Jiangsu; The Third People's Hospital of Shenzhen, Guangdong; The First Affiliated Hospital of Bengfu Medical College, AnHui.
   Intervention and comparatorFavipiravir group (experimental): Favipiravir 1600mg each dose, twice a day on the 1st day; 600mg each dose, twice a day from the 2nd to the 7th day, Oral administration, the maximum number of days taken will be no more than 14 days plus routine treatment for COVID-19.Regular treatment group (control): Treatments other than Antiviral drugs can be given. Routine treatment for patients with the corona virus will be administered, this includes oxygen therapy, drugs that reduced phlegm and relieve cough, including thymosin, proprietary Chinese medicine, etc.Main outcomesPrimary Outcome Measures: Viral nucleic acid test negative [Time Frame: 5 months]: Subjects who tested negative for nucleic acid from sputum or nasopharyngeal swabs for two consecutive times (sampling time interval of at least 24 hours).Secondary Outcome Measures: Clinical cure [Time Frame: 5 months]: Body temperature returned to normal for more than 3 days;Lung image improved.Clinical manifestation improved;The viral nucleic acid test of respiratory specimens was negative for two consecutive times (sampling time interval of at least 24 hours).RandomizationThe central randomization system (Interactive Web Response Management System), will be used to randomly divide the subjects into the experimental group and the control group according to the ratio of 2:1. In this study, block randomization will be used, in blocks of 6.Blinding (masking)This is an open label trial. Trial participants, investigators, care givers, outcome assessors, and date analysts are not blinded to group assignment.Numbers to be randomised210 patients are expected to be enrolled and allocated according to the ratio of 2 (Favipiravir group, n=140): 1(regular treatment group, n=70).Trial StatusProtocol version number 3.0, 10 April 2020First Patient, first visit 17 March 2020; recruitment end date anticipated June 1, 2020.Trial registrationClinicalTrials.gov, NCT04333589, April 3, 2020. Registered April 3, 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Li, Jiawen; Zhang, Chi; Wu, Zhao; Wang, Guiqiang; Zhao, Hong] Peking Univ, Hosp 1, Ctr Liver Dis, Dept Infect Dis, 8 Xishiku St, Beijing, Peoples R China.
RP Wang, GQ; Zhao, H (corresponding author), Peking Univ, Hosp 1, Ctr Liver Dis, Dept Infect Dis, 8 Xishiku St, Beijing, Peoples R China.
EM john131212@126.com; haohong_pufh@bjmu.edu.cn
FU  [2020YFC0846800]
FX Under the deployment of the scientific research team in response to
   COVID-19 's epidemic of the State Council, China National Center for
   Biotechnology Development undertakes the drug research and organizes
   Peking University First Hospital to lead the research. The project
   number of this COVID-19 emergency project: 2020YFC0846800. The study
   funders had no role in study design; collection, analysis, and
   interpretation of data and in writing the manuscript.
NR 0
TC 2
Z9 2
U1 7
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 5
PY 2020
VL 21
IS 1
AR 488
DI 10.1186/s13063-020-04430-y
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1ZO
UT WOS:000540320200009
PM 32503657
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lyngbakken, MN
   Berdal, JE
   Eskesen, A
   Kvale, D
   Olsen, IC
   Rangberg, A
   Jonassen, CM
   Omland, T
   Rosjo, H
   Dalgard, O
AF Lyngbakken, Magnus Nakrem
   Berdal, Jan-Erik
   Eskesen, Arne
   Kvale, Dag
   Olsen, Inge Christoffer
   Rangberg, Anbjorg
   Jonassen, Christine Monceyron
   Omland, Torbjorn
   Rosjo, Helge
   Dalgard, Olav
TI Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label
   Study to assess early use of hydroxychloroquine sulphate in moderately
   severe hospitalised patients with coronavirus disease 2019: A structured
   summary of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomized controlled trial; Protocol; Chloroquine; Pragmatic
   trial; Polymerase chain reaction; Viral load; Oropharyngeal sampling
AB ObjectivesThe hypothesis of the study is that treatment with hydroxychloroquine sulphate in hospitalised patients with coronavirus disease 2019 (Covid-19) is safe and will accelerate the virological clearance rate for patients with moderately severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) when compared to standard care. Furthermore, we hypothesize that early treatment with hydroxychloroquine sulphate is associated with more rapid resolve of clinical symptoms as assessed by the National Early Warning Score 2 (NEWS2), decreased admission rate to intensive care units and mortality, and improvement in protein biomarker profiles (C-reactive protein, markers of renal and hepatic injury, and established cardiac biomarkers like cardiac troponin and B-type natriuretic peptide).Trial designThe study is a two-arm, open label, pragmatic randomised controlled group sequential adaptive trial designed to assess the effect on viral loads and clinical outcome of hydroxychloroquine sulphate therapy in addition to standard care compared to standard care alone in patients with established Covid-19. By utilizing resources already paid for by the hospitals (physicians and nurses in daily clinical practice), this pragmatic trial can include a larger number of patients over a short period of time and at a lower cost than studies utilizing traditional randomized controlled trial designs with an external study organization. The pragmatic approach will enable swift initiation of randomisation and allocation to treatment.ParticipantsPatients will be recruited from all inpatients at Akershus University Hospital, LOrenskog, Norway. Electronic real-time surveillance of laboratory reports from the Department of Microbiology will be examined regularly for SARS-CoV-2 positive subjects. All of the following conditions must apply to the prospective patient at screening prior to inclusion: (1) Hospitalisation; (2) Adults 18 years or older; (3) Moderately severe Covid-19 disease (NEWS2 of 6 or less); (4) SARS-CoV-2 positive nasopharyngeal swab; (5) Expected time of hospitalisation > 48 hours; and (6) Signed informed consent must be obtained and documented according to Good Clinical Practice guidelines of the International Conference on Harmonization, and national/local regulations. Patients will be excluded from participation in the study if they meet any of the following criteria: (1) Requiring intensive care unit admission at screening; (2) History of psoriasis; (3) Known adverse reaction to hydroxychloroquine sulphate; (4) Pregnancy; or (5) Prolonged corrected QT interval (>450 ms). Clinical data, including standard hospital biochemistry, medical therapy, vital signs, NEWS2, and microbiology results (including blood culture results and reverse transcriptase polymerase chain reaction [RT-PCR] for other upper airway viruses), will be automatically extracted from the hospital electronic records and merged with the study specific database.Intervention and comparatorIncluded patients will be randomised in a 1:1 ratio to (1) standard care with the addition of 400 mg hydroxychloroquine sulphate (Plaquenil(TM)) twice daily for seven days or (2) standard care alone.Main outcomesThe primary endpoint of the study is the rate of decline in SARS-CoV-2 viral load in oropharyngeal samples as assessed by RT-PCR in samples collected at baseline, 48 and 96 hours after randomization and administration of drug for the intervention arm.
   Secondary endpoints include change in NEWS2 at 96 hours after randomisation, admission to intensive care unit, mortality (in-hospital, and at 30 and 90 days), duration of hospital admission, clinical status on a 7-point ordinal scale 14 days after randomization ([1] Death [2] Hospitalised, on invasive mechanical ventilation or extracorporeal membrane oxygenation [3] Hospitalised, on non-invasive ventilation or high flow oxygen devices [4] Hospitalized, requiring supplemental oxygen [5] Hospitalised, not requiring supplemental oxygen [6] Not hospitalized, but unable to resume normal activities [7] Not hospitalised, with resumption of normal activities), and improvement in protein biomarker profiles (C-reactive protein, markers of renal and hepatic injury, and established cardiac biomarkers like cardiac troponin and B-type natriuretic peptide) at 96 hours after randomization.RandomisationEligible patients will be allocated in a 1:1 ratio, using a computer randomisation procedure. The allocation sequence has been prepared by an independent statistician.Blinding (masking)Open label randomised controlled pragmatic trial without blinding, no active or placebo control. The virologist assessing viral load in the oropharyngeal samples and the statistician responsible for analysis of the data will be blinded to the treatment allocation for the statistical analyses.Numbers to be randomized (sample size)This is a group sequential adaptive trial where analyses are planned after 51, 101, 151 and 202 completed patients, with a maximum sample size of 202 patients (101 patients allocated to intervention and standard care and 101 patients allocated to standard care alone).Trial StatusProtocol version 1.3 (March 26, 2020). Recruitment of first patient on March 26, 2020, and 51 patients were included as per April 28, 2020. Study recruitment is anticipated to be completed by July 2020.Trial registrationClinicalTrials.gov number, NCT04316377. Trial registered March 20, 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Lyngbakken, Magnus Nakrem; Omland, Torbjorn] Akershus Univ Hosp, Div Med, Lorenskog, Norway.
   [Lyngbakken, Magnus Nakrem; Berdal, Jan-Erik; Kvale, Dag; Omland, Torbjorn; Rosjo, Helge; Dalgard, Olav] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway.
   [Berdal, Jan-Erik; Eskesen, Arne; Dalgard, Olav] Akershus Univ Hosp, Div Med, Dept Infect Dis, Lorenskog, Norway.
   [Kvale, Dag] Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway.
   [Olsen, Inge Christoffer] Oslo Univ Hosp, Dept Res Support Clin Trials, Oslo, Norway.
   [Rangberg, Anbjorg; Jonassen, Christine Monceyron] Ostfold Hosp Trust, Ctr Lab Med, Gralum, Norway.
   [Rosjo, Helge] Akershus Univ Hosp, Div Res & Innovat, Lorenskog, Norway.
RP Rosjo, H (corresponding author), Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway.; Rosjo, H (corresponding author), Akershus Univ Hosp, Div Res & Innovat, Lorenskog, Norway.
EM helge.rosjo@medisin.uio.no
FU University of Oslo; Ostfold Hospital Trust; Akershus University
   Hospital; Oslo University Hospital
FX There is no trial-specific funding apart from the regular salaries
   provided to the investigators by the University of Oslo, Akershus
   University Hospital, Oslo University Hospital, and Ostfold Hospital
   Trust. The funding bodies had no role in the design of the study,
   collection, analysis, and interpretation of data or in writing the final
   trial manuscript.
NR 0
TC 2
Z9 2
U1 3
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 5
PY 2020
VL 21
IS 1
AR 485
DI 10.1186/s13063-020-04420-0
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1ZO
UT WOS:000540320200006
PM 32503662
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU ten Doesschate, T
   Moorlag, SJCFM
   van der Vaart, TW
   Taks, E
   Debisarun, P
   ten Oever, J
   Bleeker-Rovers, CP
   Verhagen, PB
   Lalmohamed, A
   ter Heine, R
   van Crevel, R
   van de Wijgert, J
   Janssen, AB
   Bonten, MJ
   van Werkhoven, CH
   Netea, MG
AF ten Doesschate, Thijs
   Moorlag, Simone J. C. F. M.
   van der Vaart, Thomas W.
   Taks, Esther
   Debisarun, Priya
   ten Oever, Jaap
   Bleeker-Rovers, Chantal P.
   Verhagen, Patricia Bruijning
   Lalmohamed, Arief
   ter Heine, Rob
   van Crevel, Reinout
   van de Wijgert, Janneke
   Janssen, Axel B.
   Bonten, Marc J.
   van Werkhoven, Cornelis H.
   Netea, Mihai G.
CA BCG-CORONA Study Team
TI Two Randomized Controlled Trials of Bacillus Calmette-Guerin Vaccination
   to reduce absenteeism among health care workers and hospital admission
   by elderly persons during the COVID-19 pandemic: A structured summary of
   the study protocols for two randomised controlled trials
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; BCG-vaccine;
   Health-Care Workers; Elderly
AB ObjectivesThe objectives of these two separate trials are: (1) to reduce health care workers (HCWs) absenteeism; and (2) to reduce hospital admission among the elderly during the COVID-19 pandemic through BCG vaccination.Trial designTwo separate multi-centre placebo-controlled parallel group randomized trialsParticipants(1) Health care personnel working in the hospital or ambulance service where they will take care of patients with the COVID-19 infection and (2) elderly >= 60 years. The HCW trial is being undertaken in 9 hospitals. The elderly trial is being undertaken in locations in the community in Nijmegen, Utrecht, and Veghel, in the Netherlands, using senior citizen organisations to facilitate recruitment.Intervention and comparatorFor both trials the intervention group will be randomized to vaccination with 0.1 ml of the licensed BCG vaccine (Danish strain 1331, SSI, Denmark, equivalent to 0.075 mg attenuated M. bovis). The placebo group consists of 0.1 ml 0.9% NaCl, which is the same amount, and has the same colour and appearance as the suspended BCG vaccine.Main outcomes(1) Number of days of unplanned work absenteeism in HCWs for any reason which can be continuously measured on a bi-weekly basis, and (2) the cumulative incidence of hospital admission due to documented COVID-19.RandomisationParticipants will be randomized to BCG vaccine or placebo (1;1) centrally using a computer- based system, stratified by study centre.Blinding (masking)Subjects, investigators, physicians and outcome assessors are blinded for the intervention. Only the pharmacist assistant that prepares- and research personnel that administers- study medicines are unblinded.Numbers to be randomised (sample size)(1) The sample size for the first trial is N=1500 HCWs randomised 1:1 to either BCG vaccine (n=750) and placebo (n=750) and (2) The sample size for the second trial is N=1600 elderly persons randomised to BCG vaccine (n=800) and the placebo group (n=800).Trial StatusHCW: version 4.0, 24-04-2020. Recruitment began 25-03-2020 and was completed on the 23-04-2020. Elderly: version 3.0, 04-04-2020. Recruitment began 16-04- 2020 and is ongoing.Trial registrationThe HCWs trial was registered 31-03-2020 at clinicaltrials.gov (identifier: NCT04328441) and registered 20-03-2020 at the Dutch Trial Registry (trialregister.nl, identifier Trial NL8477). The elderly trial was registered 22-04-2020 at the Dutch trial registry with number NL8547.Full protocolThe full protocols will be attached as additional files, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [ten Doesschate, Thijs; van der Vaart, Thomas W.; Verhagen, Patricia Bruijning; Lalmohamed, Arief; van de Wijgert, Janneke; Janssen, Axel B.; Bonten, Marc J.; van Werkhoven, Cornelis H.] Univ Med Ctr, Utrecht, Netherlands.
   [Moorlag, Simone J. C. F. M.; Taks, Esther; Debisarun, Priya; ten Oever, Jaap; Bleeker-Rovers, Chantal P.; ter Heine, Rob; van Crevel, Reinout; Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands.
RP ten Doesschate, T (corresponding author), Univ Med Ctr, Utrecht, Netherlands.
EM t.tendoesschate@umcutrecht.nl
RI Debisarun, Priya/AAC-8859-2019; Moorlag, Simone JCFM/F-4519-2018; Heine,
   Rob ter/A-1757-2016
OI Debisarun, Priya/0000-0003-3171-3903; Moorlag, Simone
   JCFM/0000-0001-8884-8417; 
FU UMCU; Radboudumc
FX The funding for these investigator-initiated studies for the BCG
   injections and the design of the eCRF and the mobile application came
   from the UMCU and Radboudumc. The participating centers contributed
   without financial compensation. The authors received no external funding
   to prepare this trial protocol and summary.
NR 0
TC 5
Z9 5
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 5
PY 2020
VL 21
IS 1
AR 481
DI 10.1186/s13063-020-04389-w
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1ZO
UT WOS:000540320200002
PM 32503602
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Masiero, S
   Maccarone, MC
   Agostini, F
AF Masiero, Stefano
   Maccarone, Maria Chiara
   Agostini, Francesco
TI Health resort medicine can be a suitable setting to recover disabilities
   in patients tested negative for COVID-19 discharged from hospital? A
   challenge for the future
SO INTERNATIONAL JOURNAL OF BIOMETEOROLOGY
LA English
DT Letter
ID BALNEOTHERAPY; REHABILITATION; THERAPY
C1 [Masiero, Stefano] Univ Padua, Dept Neurosci, Rehabil Unit, Via Giustiniani 3, I-35128 Padua, Italy.
   [Masiero, Stefano; Maccarone, Maria Chiara] Univ Padua, Phys Med & Rehabil Sch, Padua, Italy.
   [Agostini, Francesco] Sapienza Univ Rome, Dept Anat & Histol Sci, Legal Med & Orthoped, Rome, Italy.
RP Masiero, S (corresponding author), Univ Padua, Dept Neurosci, Rehabil Unit, Via Giustiniani 3, I-35128 Padua, Italy.; Masiero, S (corresponding author), Univ Padua, Phys Med & Rehabil Sch, Padua, Italy.
EM stef.masiero@unipd.it
RI Masiero, Stefano/K-6473-2016
OI Masiero, Stefano/0000-0002-0361-4898
CR Antonelli M, 2018, INT J BIOMETEOROL, V62, P913, DOI 10.1007/s00484-018-1504-8
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Becker BE, 2009, PM&R, V1, P859, DOI 10.1016/j.pmrj.2009.05.017
   Boldrini P, 2020, EUR J PHYS REHAB MED, V56, P316, DOI 10.23736/S1973-9087.20.06256-5
   Centers for Disease Control and Prevention, 2020, WAT COVID 19 FAQS IN
   Centers for Disease Control and Prevention, 2020, DISC TRANSM BAS PREC
   Finer N, 2020, CLIN OBES, V10, DOI 10.1111/cob.12365
   Fioravanti A, 2011, RHEUMATOL INT, V31, P1, DOI 10.1007/s00296-010-1628-6
   Grabowski DC, 2020, JAMA-J AM MED ASSOC, V323, P2007, DOI 10.1001/jama.2020.4686
   Gutenbrunner C, 2010, INT J BIOMETEOROL, V54, P495, DOI 10.1007/s00484-010-0321-5
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Kubincova A, 2018, MED SCI MONITOR, V24, P6375, DOI 10.12659/MSM.909777
   Masiero S, 2020, INT J BIOMETEOROL, V64, P951, DOI 10.1007/s00484-019-01765-3
   Masiero S, 2019, INT J BIOMETEOROL, V63, P13, DOI 10.1007/s00484-018-1632-1
   Masiero S, 2018, INT J BIOMETEOROL, V62, P243, DOI 10.1007/s00484-017-1445-7
   Nasermoaddeli Ali, 2005, Environmental Health and Preventive Medicine, V10, P171, DOI 10.1007/BF02897707
   Sedaghat Z, 2020, J CLIN NEUROSCI, V76, P233, DOI 10.1016/j.jocn.2020.04.062
   Spagnolo P, 2020, LANCET RESP MED, V8, P750, DOI 10.1016/S2213-2600(20)30222-8
   Talan J, 2020, COVID 19 NEUROLOGIST
   Vitlic A, 2014, AGE, V36, P1169, DOI 10.1007/s11357-014-9631-6
   Wang J, 2020, Zhonghua Shao Shang Za Zhi, V36, P691, DOI 10.3760/cma.j.cn501120-20200307-00132
NR 21
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0020-7128
EI 1432-1254
J9 INT J BIOMETEOROL
JI Int. J. Biometeorol.
PD OCT
PY 2020
VL 64
IS 10
BP 1807
EP 1809
DI 10.1007/s00484-020-01947-4
EA JUN 2020
PG 3
WC Biophysics; Environmental Sciences; Meteorology & Atmospheric Sciences;
   Physiology
SC Biophysics; Environmental Sciences & Ecology; Meteorology & Atmospheric
   Sciences; Physiology
GA NL6HA
UT WOS:000538230700002
PM 32504142
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Eroshenko, N
   Gill, T
   Keaveney, MK
   Church, GM
   Trevejo, JM
   Rajaniemi, H
AF Eroshenko, Nikolai
   Gill, Taylor
   Keaveney, Marianna K.
   Church, George M.
   Trevejo, Jose M.
   Rajaniemi, Hannu
TI Implications of antibody-dependent enhancement of infection for
   SARS-CoV-2 countermeasures
SO NATURE BIOTECHNOLOGY
LA English
DT Letter
ID ACUTE RESPIRATORY SYNDROME; EPITOPE PREDICTION; DENGUE VIRUS; HUMAN-IGG;
   VACCINE; SPIKE; CELLS; IMMUNIZATION; CHALLENGE; MOUSE
C1 [Eroshenko, Nikolai; Gill, Taylor; Keaveney, Marianna K.; Rajaniemi, Hannu] Helix Nanotechnol, Cambridge, MA 02139 USA.
   [Church, George M.] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA.
   [Church, George M.] Wyss Inst Biol Inspired Engn, Boston, MA USA.
   [Trevejo, Jose M.] SmartPharm Therapeut, Cambridge, MA USA.
RP Rajaniemi, H (corresponding author), Helix Nanotechnol, Cambridge, MA 02139 USA.
EM hannu@helixnano.com
OI Gill, Taylor/0000-0002-7400-2354; Rajaniemi, Hannu/0000-0003-4455-9861
FU Schmidt Futures
FX We thank N. Dhar, J. Quinn, E. Webster, Z. Shriver, A. Rovner and C. T.
   Wu for critically reviewing the manuscript. N.E. and H.R. were supported
   by Schmidt Futures.
CR Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   Alford RF, 2017, J CHEM THEORY COMPUT, V13, P3031, DOI 10.1021/acs.jctc.7b00125
   Baerga-Ortiz A, 2002, PROTEIN SCI, V11, P1300, DOI 10.1110/ps.4670102
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Bhardwaj G, 2016, NATURE, V538, P329, DOI 10.1038/nature19791
   Bosio CM, 2003, J INFECT DIS, V188, P1630, DOI 10.1086/379199
   Braun J, 2020, PREPRINT MEDRXIV, DOI [10.1101/2020.04.17.20061440, DOI 10.1101/2020.04.17.20061440]
   Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y
   CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036
   Chen BB, 2019, NAT BIOTECHNOL, V37, P1332, DOI 10.1038/s41587-019-0280-2
   Chen YC, 2002, J VIROL, V76, P9877, DOI 10.1128/JVI.76.19.9877-9887.2002
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Correia BE, 2014, NATURE, V507, P201, DOI 10.1038/nature12966
   Crowley AR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00697
   Dash P, 2017, NATURE, V547, P89, DOI 10.1038/nature22383
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guo N, 2015, EBIOMEDICINE, V2, P859, DOI 10.1016/j.ebiom.2015.06.021
   Hashem AM, 2019, J INFECT DIS, V220, P1558, DOI 10.1093/infdis/jiz137
   Hewitt SL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat9143
   Hezareh M, 2001, J VIROL, V75, P12161, DOI 10.1128/JVI.75.24.12161-12168.2001
   Hu H, 2007, CLIN VACCINE IMMUNOL, V14, P894, DOI 10.1128/CVI.00019-07
   Jaume M, 2012, Hong Kong Med J, V18 Suppl 2, P31
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   Kang TH, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0345-9
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Kula T, 2019, CELL, V178, P1016, DOI 10.1016/j.cell.2019.07.009
   Kuzmina NA, 2018, CELL REP, V24, P1802, DOI 10.1016/j.celrep.2018.07.035
   Larman HB, 2011, NAT BIOTECHNOL, V29, P535, DOI 10.1038/nbt.1856
   Lee J, 2016, NAT MED, V22, P1456, DOI 10.1038/nm.4224
   Li LJ, 2003, J CLIN VIROL, V28, P239, DOI 10.1016/S1386-6532(03)00195-1
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lo M, 2017, J BIOL CHEM, V292, P3900, DOI 10.1074/jbc.M116.767749
   Maamary J, 2017, P NATL ACAD SCI USA, V114, P10172, DOI 10.1073/pnas.1707950114
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   PEDERSEN NC, 1980, AM J VET RES, V41, P868
   Price JV, 2012, NAT MED, V18, P1434, DOI 10.1038/nm.2913
   Puchades C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41179-0
   Racle J, 2019, NAT BIOTECHNOL, V37, P1283, DOI 10.1038/s41587-019-0289-6
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003
   Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9
   Shaw DE, 2014, INT CONF HIGH PERFOR, P41, DOI 10.1109/SC.2014.9
   Smith P, 2012, P NATL ACAD SCI USA, V109, P6181, DOI 10.1073/pnas.1203954109
   Spiekermann GM, 2002, J EXP MED, V196, P303, DOI 10.1084/jem.20020400
   TAO MH, 1989, J IMMUNOL, V143, P2595
   Taylor A, 2015, IMMUNOL REV, V268, P340, DOI 10.1111/imr.12367
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Thul PJ, 2017, SCIENCE, V356, DOI 10.1126/science.aal3321
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   Wan Y, 2020, J VIROL, V94
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Weitzner BD, 2017, NAT PROTOC, V12, P401, DOI 10.1038/nprot.2016.180
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102
   Yip M S, 2016, Hong Kong Med J, V22, P25
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Yip MS, 2011, BMC P S1, V5, P80
   Zhang SQ, 2018, NAT BIOTECHNOL, V36, P1156, DOI 10.1038/nbt.4282
NR 66
TC 16
Z9 16
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
EI 1546-1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD JUL
PY 2020
VL 38
IS 7
BP 789
EP 791
DI 10.1038/s41587-020-0577-1
EA JUN 2020
PG 3
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA MO2MY
UT WOS:000538502900001
PM 32504046
OA Bronze
DA 2021-01-01
ER

PT J
AU Demirci, MDS
   Adan, A
AF Demirci, Muserref Duygu Sacar
   Adan, Aysun
TI Computational analysis of microRNA-mediated interactions in SARS-CoV-2
   infection
SO PEERJ
LA English
DT Article
DE SARS-CoV-2; MicroRNA; COVID19; Host-virus interaction
ID INFLUENZA-A VIRUS; VIRAL REPLICATION; UP-REGULATION; HEPATITIS-C;
   CORONAVIRUS; PROTEIN; IDENTIFICATION; INHIBITION; EXPRESSION; ROLES
AB MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression found in more than 200 diverse organisms. Although it is still not fully established if RNA viruses could generate miRNAs, there are examples of miRNA like sequences from RNA viruses with regulatory functions. In the case of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), there are several mechanisms that would make miRNAs impact the virus, like interfering with viral replication, translation and even modulating the host expression. In this study, we performed a machine learning based miRNA prediction analysis for the SARS-CoV-2 genome to identify miRNA-like hairpins and searched for potential miRNA-based interactions between the viral miRNAs and human genes and human miRNAs and viral genes. Overall, 950 hairpin structured sequences were extracted from the virus genome and based on the prediction results, 29 of them could be precursor miRNAs. Targeting analysis showed that 30 viral mature miRNA-like sequences could target 1,367 different human genes. PANTHER gene function analysis results indicated that viral derived miRNA candidates could target various human genes involved in crucial cellular processes including transcription, metabolism, defense system and several signaling pathways such as Wnt and EGFR signalings. Protein class-based grouping of targeted human genes showed that host transcription might be one of the main targets of the virus since 96 genes involved in transcriptional processes were potential targets of predicted viral miRNAs. For instance, basal transcription machinery elements including several components of human mediator complex (MED1, MED9, MED 12L, MED 19), basal transcription factors such as TAF4, TAF5, TAF7L and site-specific transcription factors such as STATI were found to be targeted. In addition, many known human miRNAs appeared to be able to target viral genes involved in viral life cycle such as S, M, N, E proteins and ORF lab, ORF3a, ORF8, ORF7a and ORF10. Considering the fact that miRNA-based therapies have been paid attention, based on the findings of this study, comprehending mode of actions of miRNAs and their possible roles during SARS-CoV-2 infections could create new opportunities for the development and improvement of new therapeutics.
C1 [Demirci, Muserref Duygu Sacar] Abdullah Gul Univ, Bioinformat, Kayseri, Turkey.
   [Adan, Aysun] Abdullah Gul Univ, Mol Biol & Genet, Kayseri, Turkey.
RP Demirci, MDS (corresponding author), Abdullah Gul Univ, Bioinformat, Kayseri, Turkey.
EM duygu.sacar@agu.edu.tr
RI demirci, muserref duygu sacar/N-7458-2017
OI demirci, muserref duygu sacar/0000-0003-2012-0598
CR Abernathy E, 2015, VIROLOGY, V479, P600, DOI 10.1016/j.virol.2015.02.007
   Ahmad I, 2020, CURR PHARM DESIGN, V26, P446, DOI 10.2174/1381612826666200109181238
   Bandiera S, 2016, J VIROL, V90, P6387, DOI 10.1128/JVI.00619-16
   Berthold MR, 2008, STUD CLASS DATA ANAL, P319, DOI 10.1145/1656274.1656280
   Bruscella P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00824
   Castano-Rodriguez C, 2018, MBIO, V9, DOI 10.1128/mBio.02325-17
   Cen JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066503
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Dai XB, 2011, NUCLEIC ACIDS RES, V39, pW155, DOI 10.1093/nar/gkr319
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   Demirci MDS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00403-z
   Demirci MDS, 2017, PEERJ, V5, DOI 10.7717/peerj.3131
   Demirci MDS, 2016, J INTEGR BIOINFORMAT, V13, DOI 10.2390/biecoll-jib-2016-303
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Engelmann I, 2018, CRIT REV MICROBIOL, V44, P701, DOI 10.1080/1040841X.2018.1499608
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Ghosh Z, 2009, NUCLEIC ACIDS RES, V37, P1035, DOI 10.1093/nar/gkn1004
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Graham RL, 2008, VIRUS RES, V133, P88, DOI 10.1016/j.virusres.2007.02.017
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Harwig A, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100309
   Herbert KM, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060154
   Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599
   Huang SH, 2017, J MICROBIOL IMMUNOL, V50, P277, DOI 10.1016/j.jmii.2015.07.002
   Khatun M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101249
   Klase Z, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-18
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Lau SKP, 2015, J VIROL, V89, P10532, DOI 10.1128/JVI.01048-15
   Li X, 2019, EXRNA, V1, P37, DOI [10.1186/s41544-019-0037-6., DOI 10.1186/S41544-019-0037-6]
   Li XH, 2018, CELL RES, V28, P157, DOI 10.1038/cr.2018.3
   Liang HW, 2014, SCI CHINA LIFE SCI, V57, P973, DOI 10.1007/s11427-014-4759-2
   Lyles DS, 2000, MICROBIOL MOL BIOL R, V64, P709, DOI 10.1128/MMBR.64.4.709-724.2000
   Ma YJ, 2012, J CELL MOL MED, V16, P2539, DOI 10.1111/j.1582-4934.2012.01572.x
   Mallick B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007837
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   McCaskill JL, 2017, MOL THER-NUCL ACIDS, V7, P256, DOI 10.1016/j.omtn.2017.03.008
   Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118
   Mishra R, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03079
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781
   Piedade D, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060156
   Ramalingam D, 2017, SCI REP-UK, V7, DOI 10.1038/srep40813
   Schaecher SR, 2007, J VIROL, V81, P11054, DOI 10.1128/JVI.01266-07
   Simonson B, 2015, MINI-REV MED CHEM, V15, P467, DOI 10.2174/1389557515666150324123208
   Tan YX, 2007, J VIROL, V81, P6346, DOI 10.1128/JVI.00090-07
   Trobaugh DW, 2017, TRENDS MOL MED, V23, P80, DOI 10.1016/j.molmed.2016.11.003
   van der Ree MH, 2017, LANCET, V389, P709, DOI 10.1016/S0140-6736(16)31715-9
   Wilson L, 2004, VIROLOGY, V330, P322, DOI 10.1016/j.virol.2004.09.033
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Ye R, 2004, J VIROL, V78, P9904, DOI 10.1128/JVI.78.18.9904-9917.2004
   Zhang S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25073-9
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 55
TC 8
Z9 8
U1 5
U2 7
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD JUN 5
PY 2020
VL 8
AR e9369
DI 10.7717/peerj.9369
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LV3JD
UT WOS:000538335100008
PM 32547891
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mikuls, TR
   Johnson, SR
   Fraenkel, L
   Arasaratnam, RJ
   Baden, LR
   Bermas, BL
   Chatham, W
   Cohen, S
   Costenbader, K
   Gravallese, EM
   Kalil, AC
   Weinblatt, ME
   Winthrop, K
   Mudano, AS
   Turner, A
   Saag, KG
AF Mikuls, Ted R.
   Johnson, Sindhu R.
   Fraenkel, Liana
   Arasaratnam, Reuben J.
   Baden, Lindsey R.
   Bermas, Bonnie L.
   Chatham, Winn
   Cohen, Stanley
   Costenbader, Karen
   Gravallese, Ellen M.
   Kalil, Andre C.
   Weinblatt, Michael E.
   Winthrop, Kevin
   Mudano, Amy S.
   Turner, Amy
   Saag, Kenneth G.
TI American College of Rheumatology Guidance for the Management of
   Rheumatic Disease in Adult Patients During the COVID-19 Pandemic:
   Version 1
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; HERPES-ZOSTER; SERIOUS INFECTIONS;
   INCREASED RISK; ARTHRITIS; HYDROXYCHLOROQUINE; METHOTREXATE; CRITERIA;
   THERAPY; DISCONTINUATION
AB Objective To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID-19) pandemic.
   Methods A task force, including 10 rheumatologists and 4 infectious disease specialists from North America, was convened. Clinical questions were collated, and an evidence report was rapidly generated and disseminated. Questions and drafted statements were reviewed and assessed using a modified Delphi process. This included 2 rounds of asynchronous anonymous voting by e-mail and 3 webinars with the entire panel. Task force members voted on agreement with draft statements using a 1-9-point numerical scoring system, and consensus was determined to be low, moderate, or high based on the dispersion of votes. For approval, median votes were required to meet predefined levels of agreement (median values of 7-9, 4-6, and 1-3 defined as agreement, uncertainty, or disagreement, respectively) with either moderate or high levels of consensus.
   Results The task force approved 77 initial guidance statements: 36 with moderate and 41 with high consensus. These were combined, resulting in 25 final guidance statements.
   Conclusion These guidance statements are provided to promote optimal care during the current pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document," and future updates are anticipated.
C1 [Mikuls, Ted R.; Kalil, Andre C.] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Mikuls, Ted R.] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA.
   [Johnson, Sindhu R.] Toronto Western Hosp, Mt Sinai Hosp, Toronto, ON, Canada.
   [Johnson, Sindhu R.] Univ Toronto, Toronto, ON, Canada.
   [Fraenkel, Liana] Berkshire Hlth Syst, Pittsfield, MA USA.
   [Fraenkel, Liana] Yale Univ, New Haven, CT USA.
   [Arasaratnam, Reuben J.; Bermas, Bonnie L.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.
   [Baden, Lindsey R.; Costenbader, Karen; Gravallese, Ellen M.; Weinblatt, Michael E.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Chatham, Winn; Mudano, Amy S.; Saag, Kenneth G.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Cohen, Stanley] Metroplex Clin Res Ctr, Dallas, TX USA.
   [Winthrop, Kevin] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Turner, Amy] Amer Coll Rheumatol, 60 Execut Pk S,Suite 150, Atlanta, GA 30329 USA.
RP Mikuls, TR (corresponding author), Univ Nebraska Med Ctr, Div Rheumatol, 986270 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM tmikuls@unmc.edu
OI Mikuls, Ted/0000-0002-0897-2272; Johnson, Sindhu R./0000-0003-0591-2976
FU American College of Rheumatology
FX Supported by the American College of Rheumatology.
CR Al Ghamdi M, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1492-4
   American College of Rheumatology, 2020, COVID 19 PRACT ADV R
   American Heart Association, 2020, PAT TAK ACE I ARBS W
   Andrews J, 2013, J CLIN EPIDEMIOL, V66, P719, DOI 10.1016/j.jclinepi.2012.03.013
   Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003
   Au K, 2011, ANN RHEUM DIS, V70, P785, DOI 10.1136/ard.2010.128637
   Bernatsky S, 2007, RHEUMATOLOGY, V46, P1157, DOI 10.1093/rheumatology/kem076
   Bichile T, 2014, PRESSE MED, V43, pE187, DOI 10.1016/j.lpm.2014.03.009
   Bonow RO, 2020, JAMA CARDIOL
   Brook R, 1994, CLIN PRACTICE GUIDEL, P59
   Burner TW, 2009, CURR OPIN RHEUMATOL, V21, P50, DOI 10.1097/BOR.0b013e32831bc0c4
   Centers for Disease Control and Prevention, 2020, WHAT YOU AR SICK
   Centers for Disease Control and Prevention, 2020, PROT YOURS OTH
   Chen DY, 2017, EXP THER MED, V14, P6222, DOI 10.3892/etm.2017.5297
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Choi Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1574806
   Danser AHJ, 2020, HYPERTENSION
   DAntiga L., 2020, LIVER TRANSPL, P2020
   de Vries-Bouwstra JK, 2020, J RHEUMATOL, V47, P249, DOI 10.3899/jrheum.181173
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   ESDAILE J, 1991, NEW ENGL J MED, V324, P150
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   FitzGerald GA, 2020, SCIENCE, V367, P1434, DOI 10.1126/science.abb8034
   Galloway JB, 2011, RHEUMATOLOGY, V50, P124, DOI 10.1093/rheumatology/keq242
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geraldino-Pardilla L, 2019, LUPUS, V28, P862, DOI 10.1177/0961203319851558
   Giwa A L, 2020, Pediatr Emerg Med Pract, V17, P1
   Grijalva CG, 2011, JAMA-J AM MED ASSOC, V306, P2331, DOI 10.1001/jama.2011.1692
   Hemingway H, 2008, ANN INTERN MED, V149, P221, DOI 10.7326/0003-4819-149-4-200808190-00003
   Ibrahim A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010015
   KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632
   LAROCHELLE GE, 1993, AM J MED, V95, P258, DOI 10.1016/0002-9343(93)90277-V
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Listing J, 2013, RHEUMATOLOGY, V52, P53, DOI 10.1093/rheumatology/kes305
   Liu Z, 2020, J INFECT
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mikuls TR, 2003, BEST PRACT RES CL RH, V17, P729, DOI 10.1016/S1521-6942(03)00041-X
   Mok CC, 2016, ARTHRIT CARE RES, V68, P1295, DOI 10.1002/acr.22837
   National Institute for Health and Care Excellence, 2020, COVID 19 RAP GUID MA
   National Institutes of Health, 2020, THER OPT COVID 19 CU
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Nurmohamed MT, 2015, NAT REV RHEUMATOL, V11, P693, DOI 10.1038/nrrheum.2015.112
   Pappas DA, 2015, ARTHRIT CARE RES, V67, P1671, DOI 10.1002/acr.22628
   Peart E, 2014, CURR OPIN RHEUMATOL, V26, P118, DOI 10.1097/BOR.0000000000000030
   Pimentel-Quiroz VR, 2019, LUPUS, V28, P1101, DOI 10.1177/0961203319860579
   Qin X, 2020, LANCET
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Richardson S., 2020, JAMA
   Richter A, 2016, ANN RHEUM DIS, V75, P1667, DOI 10.1136/annrheumdis-2015-207838
   Robinson PC, 2020, NAT REV RHEUMATOL, V16, P293, DOI 10.1038/s41584-020-0418-0
   Rose-John S, 2017, NAT REV RHEUMATOL, V13, P399, DOI 10.1038/nrrheum.2017.83
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Sears SP, 2016, DRUGS REAL WORLD OUT, V3, P99, DOI [DOI 10.1007/s40801-016-0062-9, 10.1007/s40801-016-0062-9]
   Shekelle PG, 1998, INT J TECHNOL ASSESS, V14, P707, DOI 10.1017/S0266462300012022
   Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607
   Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003
   Shi S, 2020, JAMA CARDIOL
   Singh JA, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-016-0609-5
   Singh JA, 2015, LANCET, V386, P258, DOI 10.1016/S0140-6736(14)61704-9
   Smolen JS, 2014, LANCET, V383, P321, DOI 10.1016/S0140-6736(13)61751-1
   Smolen JS, 2013, LANCET, V381, P918, DOI 10.1016/S0140-6736(12)61811-X
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Strangfeld A, 2011, ANN RHEUM DIS, V70, P1914, DOI 10.1136/ard.2011.151043
   Strangfeld A, 2009, JAMA-J AM MED ASSOC, V301, P737, DOI 10.1001/jama.2009.146
   Takeuchi T, 2019, ANN RHEUM DIS, V78, P171, DOI 10.1136/annrheumdis-2018-213271
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Tsakonas E, 1998, LUPUS, V7, P80
   Tselios K, 2014, SEMIN ARTHRITIS RHEU, V43, P521, DOI 10.1016/j.semarthrit.2013.07.007
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Tudesq JJ, 2018, AUTOIMMUN REV, V17, P115, DOI 10.1016/j.autrev.2017.11.015
   US Food and Drug Administration, 2020, COR COVID 19 UPD DAI
   US Food and Drug Administration, 2020, FDA ADV PAT US NONST
   US Food and Drug Administration, 2020, FDA DRUG SHORT
   van Vollenhoven RF, 2016, ANN RHEUM DIS, V75, P52, DOI 10.1136/annrheumdis-2014-205726
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Winthrop KL, 2017, ARTHRITIS RHEUMATOL, V69, P1960, DOI 10.1002/art.40189
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Xu X, 2020, EFFECTIVE TREATMENT
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yao X, 2020, CLIN INFECT DIS
   Younes A, 2011, ONCOLOGIST, V16, P730, DOI 10.1634/theoncologist.2010-0318
   Youssef J, 2016, RHEUM DIS CLIN N AM, V42, P157, DOI 10.1016/j.rdc.2015.08.004
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang L, 2020, AQUAC RES, V51, P2766, DOI 10.1111/are.14616
   Zhang N, 2012, CLIN EXP RHEUMATOL, V30, P962
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 91
TC 31
Z9 30
U1 2
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD AUG
PY 2020
VL 72
IS 8
BP 1241
EP 1251
DI 10.1002/art.41301
EA JUN 2020
PG 11
WC Rheumatology
SC Rheumatology
GA MQ3BG
UT WOS:000537903100001
PM 32349183
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Andrews, JA
   Berry, JD
   Baloh, RH
   Carberry, N
   Cudkowicz, ME
   Dedi, B
   Glass, J
   Maragakis, NJ
   Miller, TM
   Paganoni, S
   Rothstein, JD
   Shefner, JM
   Simmons, Z
   Weiss, MD
   Bedlack, RS
AF Andrews, Jinsy A.
   Berry, James D.
   Baloh, Robert H.
   Carberry, Nathan
   Cudkowicz, Merit E.
   Dedi, Brixhilda
   Glass, Jonathan
   Maragakis, Nicholas J.
   Miller, Timothy M.
   Paganoni, Sabrina
   Rothstein, Jeffrey D.
   Shefner, Jeremy M.
   Simmons, Zachary
   Weiss, Michael D.
   Bedlack, Richard S.
TI Amyotrophic lateral sclerosis care and research in the United States
   during the COVID-19 pandemic: Challenges and opportunities
SO MUSCLE & NERVE
LA English
DT Article
DE amyotrophic lateral sclerosis; clinical care; clinical trials; COVID-19;
   pandemic
ID MULTIDISCIPLINARY ALS; TELEMEDICINE; DIAGNOSIS; SURVIVAL; CRITERIA
AB Coronavirus disease 2019 has created unprecedented challenges for amyotrophic lateral sclerosis (ALS) clinical care and research in the United States. Traditional evaluations for making an ALS diagnosis, measuring progression, and planning interventions rely on in-person visits that may now be unsafe or impossible. Evidence- and experience-based treatment options, such as multidisciplinary team care, feeding tubes, wheelchairs, home health, and hospice, have become more difficult to obtain and in some places are unavailable. In addition, the pandemic has impacted ALS clinical trials by impairing the ability to obtain measurements for trial eligibility, to monitor safety and efficacy outcomes, and to dispense study drug, as these also often rely on in-person visits. We review opportunities for overcoming some of these challenges through telemedicine and novel measurements. These can reoptimize ALS care and research in the current setting and during future events that may limit travel and face-to-face interactions.
C1 [Andrews, Jinsy A.; Carberry, Nathan; Dedi, Brixhilda] Columbia Univ, Neurol Inst, New York, NY USA.
   [Berry, James D.; Cudkowicz, Merit E.; Paganoni, Sabrina] Massachusetts Gen Hosp, Dept Neurol, Healey Ctr ALS, Boston, MA 02114 USA.
   [Baloh, Robert H.] Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USA.
   [Glass, Jonathan] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
   [Maragakis, Nicholas J.; Rothstein, Jeffrey D.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Miller, Timothy M.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.
   [Shefner, Jeremy M.] Barrow Neurol Inst, Phoenix, AZ 85013 USA.
   [Simmons, Zachary] Penn State Hlth Milton S Hershey Med Ctr, Neurol, Hershey, PA USA.
   [Weiss, Michael D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
   [Bedlack, Richard S.] Duke Univ, Dept Neurol, Durham, NC USA.
RP Bedlack, RS (corresponding author), Duke ALS Clin, 932 Morreene Rd,Box 3333, Durham, NC 27705 USA.
EM richard.bedlack@duke.edu
RI Shefner, Jeremy/ABF-2901-2020
CR Ali SS, 2011, AM J EMERG MED, V29, P33, DOI 10.1016/j.ajem.2009.07.006
   American Academy of Neurology, TEL COVID 19
   American Thoracic Society, PULM FUNCT LAB ADV R
   Andrews JA, 2018, JAMA NEUROL, V75, P58, DOI 10.1001/jamaneurol.2017.3339
   Bloom B, 2020, JAMA NEUROL, DOI [10.1001/jamaneurol.2020.1452, DOI 10.1001/JAMANEUROL.2020.1452]
   Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536
   Cote DJ, 2019, WORLD NEUROSURG, V126, pE241, DOI 10.1016/j.wneu.2019.01.297
   Cui F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192243
   de Carvalho M, 2008, CLIN NEUROPHYSIOL, V119, P497, DOI 10.1016/j.clinph.2007.09.143
   Garcia-Gancedo L, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/13433
   Geronimo A, 2019, AMYOTROPH LAT SCL FR, V20, P348, DOI 10.1080/21678421.2019.1587633
   Geronimo A, 2017, AMYOTROPH LAT SCL FR, V18, P555, DOI 10.1080/21678421.2017.1338298
   Haulman A, 2020, MUSCLE NERVE, V61, P682, DOI 10.1002/mus.26838
   Jacob S, 2020, J NEUROL SCI, V412, DOI 10.1016/j.jns.2020.116803
   Kassardjian CD, 2020, MUSCLE NERVE, V62, P30, DOI 10.1002/mus.26891
   Kaufmann P, 2007, AMYOTROPH LATERAL SC, V8, P42, DOI 10.1080/17482960600888156
   Kwong Mei Wa, 2014, Virtual Mentor, V16, P1010, DOI 10.1001/virtualmentor.2014.16.12.pfor2-1412
   Miller RG, 2009, NEUROLOGY, V73, P1218, DOI 10.1212/WNL.0b013e3181bc0141
   Northeastern ALS Consortium, 2020, NEALS MEMB SIT
   Palese F, 2019, AMYOTROPH LAT SCL FR, V20, P176, DOI 10.1080/21678421.2018.1550517
   Panda N, 2020, JAMA SURG, V155, P123, DOI 10.1001/jamasurg.2019.4702
   Pulley MT, 2019, MUSCLE NERVE, V59, P34, DOI 10.1002/mus.26170
   Pupillo E, 2017, AMYOTROPH LAT SCL FR, V18, P221, DOI 10.1080/21678421.2016.1249886
   Rajabally YA, 2020, MUSCLE NERVE, V62, P34, DOI 10.1002/mus.26896
   Rooney J, 2015, J NEUROL NEUROSUR PS, V86, P496, DOI 10.1136/jnnp-2014-309601
   Ryan C., 2018, AM COMMUNITY SURVEY
   Selkirk SM, 2017, AMYOTROPH LAT SCL FR, V18, P324, DOI 10.1080/21678421.2017.1313867
   Traynor BJ, 2003, J NEUROL NEUROSUR PS, V74, P1258, DOI 10.1136/jnnp.74.9.1258
   US Food and Drug Administration, 2016, US EL INF CONS QUEST
   Van De Rijn M, 2018, AMYOTROPH LAT SCL FR, V19, P143, DOI 10.1080/21678421.2017.1392577
   Van den Berg JP, 2005, NEUROLOGY, V65, P1264, DOI 10.1212/01.wnl.0000180717.29273.12
   Veerapandiyan A, 2020, MUSCLE NERVE, V62, P41, DOI 10.1002/mus.26902
   Veerapandiyan A, 2020, MUSCLE NERVE, V62, P46, DOI 10.1002/mus.26903
NR 33
TC 5
Z9 5
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD AUG
PY 2020
VL 62
IS 2
BP 182
EP 186
DI 10.1002/mus.26989
EA JUN 2020
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MJ7NY
UT WOS:000537897300001
PM 32445195
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Allam, SR
   Dao, A
   Madhrira, MM
   Antiporta, PB
   Nair, RR
   Guiteau, JJ
   Reyad, AI
AF Allam, Sridhar R.
   Dao, Ann
   Madhrira, Machaiah M.
   Antiporta, Philip B.
   Nair, Ranjit R.
   Guiteau, Jacfranz J.
   Reyad, Ashraf I.
TI Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven
   inflammatory syndrome in a kidney transplant recipient
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Letter
DE COVID-19; kidney transplant; SARS-CoV-2; tocilizumab
C1 [Allam, Sridhar R.; Madhrira, Machaiah M.] Tarrant Nephrol Associates, Premier Phys Grp Hlth, Ft Worth, TX 76104 USA.
   [Allam, Sridhar R.; Dao, Ann; Madhrira, Machaiah M.; Guiteau, Jacfranz J.; Reyad, Ashraf I.] Med City Ft Worth Transplant Inst, Ft Worth, TX USA.
   [Antiporta, Philip B.] Infect Dis Doctors PA, Ft Worth, TX USA.
   [Nair, Ranjit R.] Lung & Sleep Ctr North Texas, Ft Worth, TX USA.
RP Allam, SR (corresponding author), Tarrant Nephrol Associates, Premier Phys Grp Hlth, Ft Worth, TX 76104 USA.
EM sallam@tarrantnephrology.com
RI Allam, Sridhar/AAQ-8582-2020
OI Allam, Sridhar/0000-0001-6051-9443; Dao, Ann/0000-0003-3457-1568
NR 0
TC 4
Z9 4
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD AUG
PY 2020
VL 22
IS 4
AR e13326
DI 10.1111/tid.13326
EA JUN 2020
PG 2
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA ND2PU
UT WOS:000537881800001
PM 32406985
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Beura, S
   Chetti, P
AF Beura, Satyajit
   Chetti, Prabhakar
TI In-silico strategies for probing chloroquine based inhibitors against
   SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; pharmacophore model; molecular docking; molecular
   dynamics simulations
ID CORONAVIRUS; PNEUMONIA; COVID-19; BINDING; SARS
AB The global health emergency of novel COVID-19 is due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Currently there are no approved drugs for the treatment of coronaviral disease (COVID-19), although some of the drugs have been tried. Chloroquine is being widely used in treatment of SARS-CoV-2 infection. Hydroxychloroquine, the derivative of Chloroquine shows better inhibition than Chloroquine and has in vitro activity against SARS-CoV-2 also used to treat COVID-19. To study the interactions of Chloroquine and derivatives of Chloroquine with SARS-CoV-2, series of computational approaches like pharmacophore model, molecular docking, MM_GBSA study and ADME property analysis are explored. The pharmacophore model and molecular docking study are used to explore the structural properties of the compounds and the ligand-receptor (PDB_ID: 6LU7) interactions respectively. MM_GBSA study gives the binding free energy of the protein-ligand complex and ADME property analysis explains the pharmacological property of the compounds. The resultant best molecule (CQD15)further subjected to molecular dynamics (MD) simulation study which explains the protein stability (RMSD), ligand properties as well as protein-ligand contacts. Outcomes of the present study conclude with the moleculeCQD15which shows better interactions for the inhibition of SARS-CoV-2 in comparison to Chloroquine and Hydroxychloroquine. Communicated by Ramaswamy H. Sarma
C1 [Beura, Satyajit; Chetti, Prabhakar] Natl Inst Technol, Dept Chem, Kurukshetra, Haryana, India.
RP Chetti, P (corresponding author), Natl Inst Technol, Dept Chem, Kurukshetra, Haryana, India.
EM chetty_prabhakar@yahoo.com
RI Prabhakar, Chetti/N-8463-2013
OI Prabhakar, Chetti/0000-0003-1773-9429
FU MHRD
FX Mr. Satyajit Beura is grateful to MHRD for fellowship. Authors also
   thank to Mr. Vinod Deveraji (Application Scientist from Schrodinger,
   Bangalore) for their technical assistance.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abdelli I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763199
   Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   Amsden GW, 2005, J ANTIMICROB CHEMOTH, V55, P10, DOI 10.1093/jac/dkh519
   [Anonymous], 2020, SCHROD REL 2020 1
   Assistance Publique - Hopitaux de Paris, 2020, COH MULT RAND CONTR
   Beigelman A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-90
   Beijing Chao Yang Hospital, 2020, CLIN TRIAL FAV TABL
   Beura S, 2020, J MOL STRUCT, V1216, DOI 10.1016/j.molstruc.2020.128271
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Dariya B, 2020, CYTOKINE GROWTH F R, V53, P43, DOI 10.1016/j.cytogfr.2020.05.001
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761881
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Ganjoo A, 2020, J BIOMOL STRUCT DYN, V38, P4928, DOI 10.1080/07391102.2019.1688193
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Gyebi GA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764868
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   KIRCHDOERFER RN, 2018, SCI REP UK, V8, DOI DOI https://doi.org/10.1038/s41598-018-34171-7
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779131
   Lobo-Galo N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764393
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Owusu M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099782
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Peking University First Hospital, 2020, PAV COMB TOC TREATM
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Rawel HA, 2005, J AGR FOOD CHEM, V53, P4228, DOI 10.1021/jf0480290
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu X., 2020, CHINAXIV20200300026V
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zavodszky MI, 2005, PROTEIN SCI, V14, P1104, DOI 10.1110/ps.041153605
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 61
TC 7
Z9 7
U1 4
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1772111
EA JUN 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MC7HK
UT WOS:000543453000001
PM 32448039
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Connors, JM
   Levy, JH
AF Connors, Jean M.
   Levy, Jerrold H.
TI COVID-19 and its implications for thrombosis and anticoagulation
SO BLOOD
LA English
DT Article
ID DISSEMINATED INTRAVASCULAR COAGULATION; TISSUE FACTOR ACTIVITY; SPIKE
   PROTEIN; CORONAVIRUS; COAGULOPATHY; PNEUMONIA; DIAGNOSIS; THERAPY;
   SOCIETY; SEPSIS
AB Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be associated with a coagulopathy, findings consistent with infection-induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty regarding management of the complications that arise in the course of this viral illness. The lungs are the target organ for COVID-19; patients develop acute lung injury that can progress to respiratory failure, although multiorgan failure can also occur. The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen-degradation products, whereas abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations. Coagulation test screening, including the measurement of D-dimer and fibrinogen levels, is suggested. COVID19-associated coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and standard supportive care measures for those with sepsis-induced coagulopathy or DIC. Although D-dimer, sepsis physiology, and consumptive coagulopathy are indicators of mortality, current data do not suggest the use of full-intensity anticoagulation doses unless otherwise clinically indicated. Even though there is an associated coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have not been reported. If bleeding does occur, standard guidelines for the management of DIC and bleeding should be followed.
C1 [Connors, Jean M.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Hematol Div, Boston, MA 02115 USA.
   [Levy, Jerrold H.] Duke Univ, Sch Med, Dept Anesthesiol, Durham, NC USA.
   [Levy, Jerrold H.] Duke Univ, Sch Med, Div Crit Care Med, Durham, NC USA.
   [Levy, Jerrold H.] Duke Univ, Dept Surg, Div Cardiothorac Surg, Sch Med, Durham, NC USA.
RP Connors, JM (corresponding author), Brigham & Womens Hosp, Mid Campus 3,75 Francis St, Boston, MA 02115 USA.
EM jconnors@bwh.harvard.edu
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bikdeli B, J AM COLL CARDIOL
   Chen G, 2020, J CLIN INVEST, DOI [10.1172/JCI137244, DOI 10.1172/JCI137244]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Delabranche X, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0339-5
   Du LY, 2007, BIOCHEM BIOPH RES CO, V359, P174, DOI 10.1016/j.bbrc.2007.05.092
   Engelmann B, 2013, NAT REV IMMUNOL, V13, P34, DOI 10.1038/nri3345
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Gould TJ, 2016, SHOCK, V46, P655, DOI 10.1097/SHK.0000000000000680
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Helms J, INTENSIVE CARE MED
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hulswit RJG, 2016, ADV VIRUS RES, V96, P29, DOI 10.1016/bs.aivir.2016.08.004
   Iba T, 2019, J THROMB HAEMOST, V17, P415, DOI 10.1111/jth.14354
   Iba T, 2019, J THROMB HAEMOST, V17, P283, DOI 10.1111/jth.14371
   Iba T, 2018, J THROMB HAEMOST, V16, P231, DOI 10.1111/jth.13911
   Iba T, 2019, J THROMB HAEMOST, V17, P1989, DOI 10.1111/jth.14578
   Iba T, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050728
   Iba T, 2019, J THROMB HAEMOST, V17, P1265, DOI 10.1111/jth.14482
   Iba T, 2019, THROMB RES, V179, P11, DOI 10.1016/j.thromres.2019.04.030
   Iba T, 2018, CLIN APPL THROMB-HEM, V24, p145S, DOI 10.1177/1076029618797474
   Jackson SP, 2019, BLOOD, V133, P906, DOI 10.1182/blood-2018-11-882993
   Kam YW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007870
   Kienast J, 2006, J THROMB HAEMOST, V4, P90, DOI 10.1111/j.1538-7836.2005.01697.x
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Layton DS, 2017, VACCINE, V35, P5967, DOI 10.1016/j.vaccine.2017.07.110
   Levi M, 2018, BLOOD, V131, P845, DOI 10.1182/blood-2017-10-804096
   Levy JH, 2018, ANESTHESIOLOGY, V128, P657, DOI 10.1097/ALN.0000000000001997
   Levy JH, 2015, BLOOD, V125, P1387, DOI 10.1182/blood-2014-08-552000
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Lippi G, 2014, EUR J INTERN MED, V25, P45, DOI 10.1016/j.ejim.2013.07.012
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Noubouossie DF, 2019, BLOOD, V133, P2186, DOI 10.1182/blood-2018-10-862243
   Pannucci CJ, 2018, ANN THORAC SURG, V106, P404, DOI 10.1016/j.athoracsur.2018.02.085
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402
   Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366
   Schnittler HJ, 2003, THROMB HAEMOSTASIS, V89, P967
   Semeraro F, 2018, CRIT CARE MED, V46, pe221, DOI 10.1097/CCM.0000000000002919
   Smith SA, 2006, P NATL ACAD SCI USA, V103, P903, DOI 10.1073/pnas.0507195103
   Smyth SS, 2009, J THROMB HAEMOST, V7, P1759, DOI 10.1111/j.1538-7836.2009.03586.x
   Stein PD, 2004, AM J MED, V116, P435, DOI 10.1016/j.amjmed.2003.11.020
   Subramaniam S, 2017, BLOOD, V129, P2291, DOI 10.1182/blood-2016-11-749879
   Suzuki K, 2018, J THROMB HAEMOST, V16, P1442, DOI 10.1111/jth.14134
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vicenzi E, 2004, EMERG INFECT DIS, V10, P413, DOI 10.3201/eid1003.030683
   Wada H, 2013, J THROMB HAEMOST, V11, P2078, DOI 10.1111/jth.12366
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang TF, 2014, THROMB HAEMOSTASIS, V111, P88, DOI 10.1160/TH13-01-0042
   Woei-A-Jin FJSH, 2014, THROMB RES, V133, P799, DOI 10.1016/j.thromres.2014.03.007
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xie Y, 2020, RADIOL CARDIOTHORAC, V2, pe200067, DOI [10.1148/ryct.2020200067, DOI 10.1148/RYCT.2020200067]
   Yamakawa K, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2587-2
   Zakai NA, 2011, J THROMB HAEMOST, V9, P1877, DOI 10.1111/j.1538-7836.2011.04443.x
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 62
TC 339
Z9 343
U1 45
U2 48
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD JUN 4
PY 2020
VL 135
IS 23
BP 2033
EP 2040
DI 10.1182/blood.2020006000
PG 8
WC Hematology
SC Hematology
GA LW4ZC
UT WOS:000539154800008
PM 32339221
OA Bronze, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Huynh, T
   Wang, HR
   Luan, BQ
AF Tien Huynh
   Wang, Haoran
   Luan, Binquan
TI In Silico Exploration of the Molecular Mechanism of Clinically Oriented
   Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease
SO JOURNAL OF PHYSICAL CHEMISTRY LETTERS
LA English
DT Article
ID CORONAVIRUS; BIOAVAILABILITY; VALIDATION; ALGORITHM; DYNAMICS; DOCKING;
   DESIGN
AB Currently, the new coronavirus disease 2019 (COVID-19) is a global pandemic without any well-calibrated treatment. To inactivate the SARS-CoV-2 virus that causes COVID-19, the main protease (Mpro) that performs key biological functions in the virus has been the focus of extensive studies. With the fast-response experimental efforts, the crystal structures of Mpro of the SARS-CoV-2 virus have just become available recently. Herein, we theoretically investigated the mechanism of binding between the Mpro's pocket and various marketed drug molecules being tested in clinics to fight COVID-19 that show promising outcomes. By combining the existing experimental results with our computational ones, we revealed an important ligand binding mechanism of the Mpro, demonstrating that the binding stability of a ligand inside the Mpro pocket can be significantly improved if part of the ligand occupies its so-called "anchor" site. Along with the highly potent drugs and/or molecules (such as nelfinavir) revealed in this study, the newly discovered binding mechanism paves the way for further optimizations and designs of Mpro's inhibitors with a high binding affinity.
C1 [Tien Huynh; Luan, Binquan] IBM Thomas J Watson Res, Computat Biol Ctr, Yorktown Hts, NY 10598 USA.
   [Wang, Haoran] Neoland Biosci, Medford, MA 02155 USA.
RP Luan, BQ (corresponding author), IBM Thomas J Watson Res, Computat Biol Ctr, Yorktown Hts, NY 10598 USA.
EM bluan@us.ibm.com
FU IBM Bluegene Science Program
FX B.L. gratefully acknowledges the computing resource and the financial
   support from the IBM Bluegene Science Program.
CR Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Azad GK, 2014, MOL BIOL REP, V41, P2717, DOI 10.1007/s11033-014-3181-y
   BEGLOV D, 1994, J CHEM PHYS, V100, P9050, DOI 10.1063/1.466711
   Cao B, 2020, NEW ENGL J MED, V382
   Corbeil CR, 2012, J COMPUT AID MOL DES, V26, P775, DOI 10.1007/s10822-012-9570-1
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Hewlings SJ, 2017, FOODS, V6, DOI 10.3390/foods6100092
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646
   Kasikci MB, 2016, CURR RES NUTR FOOD S, V4, P146, DOI 10.12944/CRNFSJ.4.Special-Issue-October.20
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Li M., 2020, CHINESE J CLIN PHARM
   Liu X, 2020, THERAPEUTIC EFFECTS, DOI [10.1101/2020.02.27.20027557, DOI 10.1101/2020.02.27.20027557]
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Luan BQ, 2019, J AM CHEM SOC, V141, P6545, DOI 10.1021/jacs.8b13144
   MARTINETZ T, 1994, NEURAL NETWORKS, V7, P507, DOI 10.1016/0893-6080(94)90109-0
   MCCHESNEY EW, 1967, TOXICOL APPL PHARM, V10, P501, DOI 10.1016/0041-008X(67)90089-0
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Neil JA, 2018, J IMMUNOL, V201, P1615, DOI 10.4049/jimmunol.1800631
   Neria E, 1996, J CHEM PHYS, V105, P1902, DOI 10.1063/1.472061
   Ohashi H., 2020, BIORXIV, DOI [10.1101/2020.04.14.039925., DOI 10.1101/2020.04.14.039925, 10.1101/ 2020.04.14.039925.]
   Oleg T., 2010, J COMPUT CHEM, DOI [10.1002/jcc.21334., DOI 10.1002/JCC.21334, 10.1002/jcc.21334]
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Prasad S, 2014, CANCER RES TREAT, V46, P2, DOI 10.4143/crt.2014.46.1.2
   Ruiz-Carmona S, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003571
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang Z, 2016, PHYS CHEM CHEM PHYS, V18, P12964, DOI 10.1039/c6cp01555g
   Wohlleber D, 2012, INFECT IMMUNE HOMEOS, P93
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yang QG, 2008, CHEM PHARM BULL, V56, P1400, DOI 10.1248/cpb.56.1400
   Yang Y., 2020, CHINESE PHARM J
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang J., 2020, POTENTIAL ARBIDOL PO
   Zhang L., 2020, SCIENCE
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 47
TC 18
Z9 19
U1 1
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7185
J9 J PHYS CHEM LETT
JI J. Phys. Chem. Lett.
PD JUN 4
PY 2020
VL 11
IS 11
BP 4413
EP 4420
DI 10.1021/acs.jpclett.0c00994
PG 8
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Atomic, Molecular & Chemical
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA LV9IT
UT WOS:000538759600026
PM 32406687
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhang, WF
   Stephen, P
   Theriault, JF
   Wang, RX
   Lin, SX
AF Zhang, Wen-Fa
   Stephen, Preyesh
   Theriault, Jean-Francois
   Wang, Ruixuan
   Lin, Sheng-Xiang
TI Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures:
   Potential to Target New Outbreaks
SO JOURNAL OF PHYSICAL CHEMISTRY LETTERS
LA English
DT Article
ID RNA-POLYMERASE; SARS-COV; COMPLEX; PROTEIN
AB The pandemic outbreak of a new coronavirus (CoV), SARS-CoV-2, has captured the world's attention, demonstrating that CoVs represent a continuous global threat. As this is a highly contagious virus, it is imperative to understand RNA-dependent-RNApolymerase (RdRp), the key component in virus replication. Although the SARS-CoV-2 genome shares 80% sequence identity with severe acute respiratory syndrome SARS-CoV, their RdRps and nucleotidyl-transferases (NiRAN) share 98.1% and 93.2% identity, respectively. Sequence alignment of six coronaviruses demonstrated higher identity among their RdRps (60.9%-98.1%) and lower identity among their Spike proteins (27%-77%). Thus, a 3D structural model of RdRp, NiRAN, non-structural protein 7 (nsp7), and nsp8 of SARS-CoV-2 was generated by modeling starting from the SARS counterpart structures. Furthermore, we demonstrate the binding poses of three viral RdRp inhibitors (Galidesivir, Favipiravir, and Penciclovir), which were recently reported to have clinical significance for SARS-CoV-2. The network of interactions established by these drug molecules affirms their efficacy to inhibit viral RNA replication and provides an insight into their structure-based rational optimization for SARS-CoV-2 inhibition.
C1 [Zhang, Wen-Fa; Stephen, Preyesh; Theriault, Jean-Francois; Wang, Ruixuan; Lin, Sheng-Xiang] CHU Res Ctr, Axe Mol Endocrinol & Nephrol, Quebec City, PQ G1V 4G2, Canada.
   [Zhang, Wen-Fa; Stephen, Preyesh; Theriault, Jean-Francois; Wang, Ruixuan; Lin, Sheng-Xiang] Laval Univ, Quebec City, PQ G1V 4G2, Canada.
   [Stephen, Preyesh] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON K7L 3N6, Canada.
RP Lin, SX (corresponding author), CHU Res Ctr, Axe Mol Endocrinol & Nephrol, Quebec City, PQ G1V 4G2, Canada.; Lin, SX (corresponding author), Laval Univ, Quebec City, PQ G1V 4G2, Canada.
EM sxlin@crchul.ulaval.ca
OI Zhang, Wenfa/0000-0002-8506-1675
FU project 'Design des inhibiteurs des enzymes et proteines pour les
   applications me'dicales et industrielles' by Fondation de CHU de Quebec
   [3681]
FX The work has been supported by the project 'Design des inhibiteurs des
   enzymes et proteines pour les applications me ' dicales et
   industrielles' by Fondation de CHU de Que ' bec (3681). We thank Dr.
   Muriel Kelly for her excellent language editing.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Azzi A, 2004, PROTEINS, V57, P12, DOI 10.1002/prot.20194
   BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x
   Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002
   Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cheng A, 2005, VIROLOGY, V335, P165, DOI 10.1016/j.virol.2005.02.017
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669
   KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Lehmann KC, 2015, NUCLEIC ACIDS RES, V43, P8416, DOI 10.1093/nar/gkv838
   Li YC, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100984
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Tao YZ, 2002, CELL, V111, P733, DOI 10.1016/S0092-8674(02)01110-8
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Velthuis AJWT, 2012, NUCLEIC ACIDS RES, V40, P1737, DOI 10.1093/nar/gkr893
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   Xu X, 2003, NUCLEIC ACIDS RES, V31, P7117, DOI 10.1093/nar/gkg916
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
NR 23
TC 7
Z9 7
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7185
J9 J PHYS CHEM LETT
JI J. Phys. Chem. Lett.
PD JUN 4
PY 2020
VL 11
IS 11
BP 4430
EP 4435
DI 10.1021/acs.jpclett.0c00571
PG 6
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Atomic, Molecular & Chemical
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA LV9IT
UT WOS:000538759600030
PM 32392072
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Malhotra, A
   Ernest, D
   Rogers, BA
   Haylock, D
   Watt, A
   Moeneclaey, G
   Jenkin, G
AF Malhotra, Atul
   Ernest, David
   Rogers, Benjamin A.
   Haylock, David
   Watt, Ashalyn
   Moeneclaey, Guy
   Jenkin, Graham
TI Umbilical cord blood therapy to prevent progression of COVID-19 related
   pneumonia: a structured summary of a study protocol for a pilot
   randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Protocol; Cord blood; Stem cells;
   Pneumonia; ARDS
AB Objectives Objective: To undertake a pilot, feasibility RCT of umbilical cord blood derived cell therapy for treatment of adult patients infected with SARS-CoV-2 virus related moderate-to-severe pneumonia to prevent progression to severe ARDS. Hypothesis: Expanded cord blood derived cell therapy will be feasible, well tolerated and show potential efficacy in the treatment of acute COVID-19 related moderate to severe pneumonia in adult patients because of their powerful anti-inflammatory and immunomodulatory properties. Trial design Pilot, parallel design randomised controlled trial. Participants The trial will recruit 24 hospitalised patients with confirmed SARS-CoV-2 infection and pneumonia from July to December 2020 at Monash Medical Centre in Melbourne, Australia. Intervention and comparator Intervention: Intravenous injection of expanded umbilical cord blood cells at a dose of 5 million cells/kg (maximum dose - 500 million cells). Cell infusion will occur over 30-60 minutes through a peripheral intravenous cannula. Standard supportive care will continue as needed. Comparator: Standard supportive care. Main outcomes Safety and tolerability of cell administration within first 24 hours of administration; clinical improvement on a seven-category clinical improvement ordinal scale. Randomisation Randomisation will be done using computer generated allocation to intervention/ control groups in a 1:1 ratio (in blocks of 6) using sealed opaque envelopes. Blinding (masking) This will be an unblinded study, given that it is the first study using expanded cord blood cells in COVID-19 patients. There will be no placebo infusion. Numbers to be randomised (sample size) Twelve participants in each group. Total n=24. Trial Status CBC-19 protocol v2, dated 23(rd) April 2020. Recruitment has not started yet. Estimated recruitment timeline is between 1st July - 31st December 2020. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Malhotra, Atul] Monash Childrens Hosp, Melbourne, Vic, Australia.
   [Ernest, David; Rogers, Benjamin A.; Jenkin, Graham] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia.
   [Haylock, David] Kabeth Consulting, Melbourne, Vic, Australia.
   [Watt, Ashalyn; Moeneclaey, Guy] Hudson Inst Med Res, Melbourne, Vic, Australia.
RP Malhotra, A (corresponding author), Monash Childrens Hosp, Melbourne, Vic, Australia.
EM atul.malhotra@monash.edu
FU Victorian Government's Operational Infrastructure Program
FX The study is supported by the Victorian Government's Operational
   Infrastructure Program, and specific funding has been applied. No
   funding body was involved in the design of the study, protocol and in
   writing the manuscript.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 4
PY 2020
VL 21
IS 1
AR 474
DI 10.1186/s13063-020-04387-y
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LX3UX
UT WOS:000539761000001
PM 32493459
OA DOAJ Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Hu, ZL
   Chen, W
   Liang, WY
   Xu, CJ
   Sun, WK
   Yi, YX
AF Hu, Zhiliang
   Chen, Wei
   Liang, Wenyan
   Xu, Chuanjun
   Sun, Wenkui
   Yi, Yongxiang
TI Severe exacerbation of immune thrombocytopenia and COVID-19: the
   favorable response to corticosteroid-based therapy-a case report
SO ANNALS OF HEMATOLOGY
LA English
DT Letter; Early Access
C1 [Hu, Zhiliang; Yi, Yongxiang] Nanjing Univ Chinese Med, Hosp Nanjing 2, Nanjing Infect Dis Ctr, Nanjing 210003, Jiangsu, Peoples R China.
   [Hu, Zhiliang] Nanjing Med Univ, Sch Publ Hlth, Ctr Global Hlth, Nanjing 211166, Jiangsu, Peoples R China.
   [Chen, Wei] Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Clin Res Ctr, Nanjing 210003, Jiangsu, Peoples R China.
   [Liang, Wenyan; Sun, Wenkui] Nanjing Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Xu, Chuanjun] Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Radiol, Nanjing 210003, Jiangsu, Peoples R China.
RP Yi, YX (corresponding author), Nanjing Univ Chinese Med, Hosp Nanjing 2, Nanjing Infect Dis Ctr, Nanjing 210003, Jiangsu, Peoples R China.; Sun, WK (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM sunwenkui@njmu.edu.cn; ian0126@126.com
RI Hu, Zhiliang/AAS-3469-2020
OI Hu, Zhiliang/0000-0001-8543-821X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [NSFC 81770009]; project of Jiangsu province
   medical youth talent [QNRC2016059]; Nanjing Medical Science and
   Technique Development Foundation [ZKX17040]
FX This study was funded in part by the National Natural Science Foundation
   of China (NSFC 81770009), project of Jiangsu province medical youth
   talent (QNRC2016059), and Nanjing Medical Science and Technique
   Development Foundation (ZKX17040). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Cooper N, 2019, NEW ENGL J MED, V381, P945, DOI 10.1056/NEJMcp1810479
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Karimi O, 2016, LANCET, V387, P939, DOI [10.1016/S0140-6736(16)00502-X, 10.1016/s0140-6736(16)00502-X]
   Sharp TM, 2016, CLIN INFECT DIS, V63, P1198, DOI 10.1093/cid/ciw476
   Van Dyne EA, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofy325
   WHO, 2020, COR DIS COVID 19 PAN
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 7
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0939-5555
EI 1432-0584
J9 ANN HEMATOL
JI Ann. Hematol.
DI 10.1007/s00277-020-04070-x
EA JUN 2020
PG 3
WC Hematology
SC Hematology
GA LU8GF
UT WOS:000537986300002
PM 32500224
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hooper, PL
AF Hooper, Philip L.
TI COVID-19 and heme oxygenase: novel insight into the disease and
   potential therapies
SO CELL STRESS & CHAPERONES
LA English
DT Article
DE Heme oxygenase; COVID-19; Therapy; Heat shock proteins; Ventilator;
   Inflammation; Cytokine storm; Smoking; Estrogen; Anesthesia; Elderly
ID STRESS-RESPONSE; PATHOGENESIS; EXPRESSION; SEVOFLURANE; INDUCTION;
   ESTROGEN
AB The COVID-19 pandemic needs therapies that are presently available and safe. We propose that subjects with metabolic syndrome, old age, and male gender have the greatest morbidity and mortality and have low stress proteins, in particular, low intracellular heme oxygenase (HO-1), making them particularly vulnerable to the disease. Additionally, COVID-19's heme reduction may contribute to even lower HO-1. Low-grade inflammation associated with these risk factors contributes to triggering a cytokine storm that spreads to multi-organ failure and near death. The high mortality of those treated with ventilator assistance may partially be explained by ventilator-induced inflammation. The cytoprotective and anti-inflammatory properties of HO-1 can limit the infection's damage. A paradox of COVID-19 hospital admissions data suggests that fewer cigarette-smokers are admitted compared with non-smokers in the general population. This unexpected observation may result from smoke induction of HO-1. Therapies with anti-viral properties that raise HO-1 include certain anesthetics (sevoflurane or isoflurane), hemin, estrogen, statins, curcumin, resveratrol, and melatonin. Controlled trials of these HO-1 inducers should be done in order to prevent or treat COVID-19 disease.
C1 [Hooper, Philip L.] Univ Colorado, Dept Med, Div Endocrinol & Metab, Anschutz Med Campus, Aurora, CO 80045 USA.
RP Hooper, PL (corresponding author), Univ Colorado, Dept Med, Div Endocrinol & Metab, Anschutz Med Campus, Aurora, CO 80045 USA.
EM phoopermd@gmail.com
CR Abouhashem AS, 2020, ANTIOXID REDOX SIGN, V33, P59, DOI 10.1089/ars.2020.8111
   Aggarwal BB, 2013, BRIT J PHARMACOL, V169, P1672, DOI 10.1111/bph.12131
   Anderson G, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2109
   Baglole CJ, 2008, AM J PHYSIOL-LUNG C, V295, pL624, DOI 10.1152/ajplung.90215.2008
   Belperio JA, 2006, SEMIN RESP CRIT CARE, V27, P350, DOI 10.1055/s-2006-948289
   Bloomer SA, 2009, J GERONTOL A-BIOL, V64, P419, DOI 10.1093/gerona/gln056
   Brioni JD, 2017, J ANESTH, V31, P764, DOI 10.1007/s00540-017-2375-6
   Chen XZ, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/9413876
   De Maio A, 2020, CELL STRESS CHAPERON, V25, P717, DOI 10.1007/s12192-020-01121-0
   El Kalamouni C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010002
   El-hawary SS, 2019, J ETHNOPHARMACOL, V231, P262, DOI 10.1016/j.jep.2018.11.026
   Espinoza JA, 2017, J IMMUNOL, V199, P212, DOI 10.4049/jimmunol.1601414
   Fedson DS, 2015, MBIO, V6, DOI 10.1128/mBio.00716-15
   Fujioka K, 2017, SHOCK, V47, P242, DOI 10.1097/SHK.0000000000000689
   Geier MR, 2020, JANUARY 2020 ELSEVIE
   Godman CA, 2010, CELL STRESS CHAPERON, V15, P431, DOI 10.1007/s12192-009-0159-0
   Hooper Philip L, 2005, Diabetes Technol Ther, V7, P204, DOI 10.1089/dia.2005.7.204
   Hooper PL, 2014, CELL STRESS CHAPERON, V19, P447, DOI 10.1007/s12192-014-0493-8
   Hooper PL, 2012, CELL STRESS CHAPERON, V17, P647, DOI 10.1007/s12192-012-0352-4
   HOOPER PL, 1989, ANN INTERN MED, V111, P263, DOI 10.7326/0003-4819-111-3-263_2
   Hornuss C, 2010, CASE REP MED, DOI 10.1155/2010/746263
   Hsieh YH, 2010, B MATH BIOL, V72, P122, DOI 10.1007/s11538-009-9440-8
   Hsu JT, 2013, J SURG RES, V182, P319, DOI 10.1016/j.jss.2012.10.926
   Huang HX, 2017, VIROLOGY, V503, P1, DOI 10.1016/j.virol.2016.12.019
   Kapetanovic IM, 2011, CANCER CHEMOTH PHARM, V68, P593, DOI 10.1007/s00280-010-1525-4
   Knowlton AA, 2014, MOL CELL ENDOCRINOL, V389, P31, DOI 10.1016/j.mce.2014.01.002
   Laffont S, 2020, WOMEN, DOI [10.4049/jimmunol.1303400, DOI 10.4049/JIMMUNOL.1303400]
   Lee TS, 2004, CIRCULATION, V110, P1296, DOI 10.1161/01.CIR.0000140694.67251.9C
   Lindenfield J, 2003, J AM COLL CARDIOL, V42, P1238, DOI 10.1016/S0735-1097(03)00938-0
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moghadamtousi SZ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/186864
   Nacoti M, 2018, CLIN CASE REP, V6, P920, DOI 10.1002/ccr3.1490
   Patriarca S, 2007, BIOGERONTOLOGY, V8, P365, DOI 10.1007/s10522-006-9079-x
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Schmidt R, 2004, COBALT PROTOPORPHYRI, P79106, DOI [10.1096/fj.07-0904ltr, DOI 10.1096/FJ.07-0904LTR]
   Suba Z, 2020, PREVENTION THERAPY C, P75
   Takeda T, 2017, BBA-GEN SUBJECTS, V1861, P1813, DOI 10.1016/j.bbagen.2017.03.018
   Wenzhong L., 2020, COVID 19 ATTACKS 1 B, DOI [10.26434/chemrxiv.11938173.v8, DOI 10.26434/CHEMRXIV.11938173.V8]
   Yang GH, 2015, MOL MED REP, V12, P2481, DOI 10.3892/mmr.2015.3722
   Zhang ZH, 2019, NEAT'19: PROCEEDINGS OF THE 2019 ACM SIGCOMM WORKSHOP ON NETWORKING FOR EMERGING APPLICATIONS AND TECHNOLOGIES, P8, DOI 10.1145/3341558.3342199
NR 40
TC 5
Z9 5
U1 3
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1355-8145
EI 1466-1268
J9 CELL STRESS CHAPERON
JI Cell Stress Chaperones
PD SEP
PY 2020
VL 25
IS 5
SI SI
BP 707
EP 710
DI 10.1007/s12192-020-01126-9
EA JUN 2020
PG 4
WC Cell Biology
SC Cell Biology
GA NL5ZG
UT WOS:000538001900001
PM 32500379
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Arslan, G
   Yildirim, M
   Tanhan, A
   Bulus, M
   Allen, KA
AF Arslan, Gokmen
   Yildirim, Murat
   Tanhan, Ahmet
   Bulus, Metin
   Allen, Kelly-Ann
TI Coronavirus Stress, Optimism-Pessimism, Psychological Inflexibility, and
   Psychological Health: Psychometric Properties of the Coronavirus Stress
   Measure
SO INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION
LA English
DT Article; Early Access
DE Coronavirus; COVID-19; Pessimism; Optimism; Psychological inflexibility;
   Mental health; Acceptance commitment therapy
ID ACTION QUESTIONNAIRE-II; MEDIATING ROLE; DISPOSITIONAL OPTIMISM;
   COMMITMENT THERAPY; SELF-EFFICACY; ACCEPTANCE; DISTRESS; FLEXIBILITY;
   MODEL; MINDFULNESS
AB The coronavirus (COVID-19) pandemic is currently a global health threat attributed to negatively affecting the mental health and well-being of people globally. The purpose of the present study is to examine the mediating role of optimism-pessimism and psychological inflexibility in the relationship of coronavirus stress with psychological problems among Turkish adults. The sample of the study included 451 adults (55% women). Participants mainly consisted of young adults with a mean age of 23.30 years, ranging from 18 to 65 years (SD = 6.97). A mediation model indicated that coronavirus stress had a significant predictive effect on optimism-pessimism, psychological inflexibility, and psychological problems. Further, optimism-pessimism and psychological inflexibility mediated the effect of coronavirus stress on psychological problems in adults. Lastly, optimism-pessimism predicted the psychological problems of adults through psychological inflexibility. These results elucidate our understanding of the role of mediators in coronavirus stress and psychological health problems. The findings are useful in terms of providing evidence for tailoring interventions and implementing preventative approaches to mitigate the psychopathological consequences of COVID-19. Based on the present findings, the potential utility of acceptance and commitment therapy is discussed within the context of COVID-19.
C1 [Arslan, Gokmen] Mehmet Akif Ersoy Univ, Burdur, Turkey.
   [Yildirim, Murat] Ibrahim Cecen Univ Agri, Agri, Turkey.
   [Yildirim, Murat] Univ Leicester, Leicester, Leics, England.
   [Tanhan, Ahmet; Bulus, Metin] Adiyaman Univ, Adiyaman, Turkey.
   [Allen, Kelly-Ann] Monash Univ, Clayton, Vic, Australia.
RP Arslan, G (corresponding author), Mehmet Akif Ersoy Univ, Burdur, Turkey.
EM gkmnarslan@gmail.com
RI Allen, Kelly-Ann/L-4989-2018; Yildirim, Murat/AAW-2186-2020; Arslan,
   Gokmen/E-9543-2018
OI Allen, Kelly-Ann/0000-0002-6813-0034; Yildirim,
   Murat/0000-0003-1089-1380; Arslan, Gokmen/0000-0001-9427-1554
CR Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8
   Al Jarrah FN, 2019, INT J PSYCHOL STUDIE, V11, P9
   Andersson G, 1996, PERS INDIV DIFFER, V21, P719, DOI 10.1016/0191-8869(96)00118-3
   Anniko MK, 2019, ANXIETY STRESS COPIN, V32, P155, DOI 10.1080/10615806.2018.1549657
   Arslan G., 2020, CORONAVIRUS STRESS M
   Arslan G., 2020, EXPLORING ASS CORONA
   Badrfam R, 2020, ASIAN J PSYCHIATR, V50, DOI 10.1016/j.ajp.2020.101935
   Bao YP, 2020, LANCET, V395, pE37, DOI 10.1016/S0140-6736(20)30309-3
   Bargai N, 2007, J FAM VIOLENCE, V22, P267, DOI 10.1007/s10896-007-9078-y
   Bhuiyan AKMI, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00307-y
   Bhuiyan MAH, 2020, ASIAN J PSYCHIATR, V50, DOI 10.1016/j.ajp.2020.101944
   Bond FW, 2011, BEHAV THER, V42, P676, DOI 10.1016/j.beth.2011.03.007
   Britton M, 2019, PERS INDIV DIFFER, V151, DOI 10.1016/j.paid.2019.109513
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Carver CS, 2010, CLIN PSYCHOL REV, V30, P879, DOI 10.1016/j.cpr.2010.01.006
   Chalmers RP, 2012, J STAT SOFTW, V48, P1
   Chang EC, 2001, PSYCHOL AGING, V16, P524, DOI 10.1037/0882-7974.16.3.524
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Cicek I., 2020, PSYCHOL INFLEXIBILIT
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Cortese S, 2020, LANCET CHILD ADOLESC, V4, P412, DOI 10.1016/S2352-4642(20)30110-3
   Crosby JM, 2011, CURR PSYCHOL, V30, P117, DOI 10.1007/s12144-011-9104-3
   DAGOSTINO RB, 1990, AM STAT, V44, P316, DOI 10.2307/2684359
   Derogatis LR, 2004, USE PSYCHOL TESTING, P1
   Dick AM, 2014, J CLIN PSYCHOL, V70, P1170, DOI 10.1002/jclp.22104
   Duy B, 2017, CURR PSYCHOL, V36, P410
   Field A., 2009, DISCOVERING STAT USI
   Gallagher MW, 2009, J POSIT PSYCHOL, V4, P548, DOI 10.1080/17439760903157166
   Gaudiano BA, 2017, J CONTEXT BEHAV SCI, V6, P159, DOI 10.1016/j.jcbs.2017.04.010
   Gunnell D, 2020, LANCET PSYCHIAT, V7, P468, DOI 10.1016/S2215-0366(20)30171-1
   Harper CA, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00281-5
   Harris R, 2009, ACT MADE SIMPLE EASY
   Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9
   Hayes SC, 2006, BEHAV RES THER, V44, P1, DOI 10.1016/j.brat.2005.06.006
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Ingram RE, 2005, DEV PSYCHOPATHOL, P32, DOI DOI 10.4135/9781452231655.N2
   Karademas EC, 2006, PERS INDIV DIFFER, V40, P1281, DOI 10.1016/j.paid.2005.10.019
   Kline R.B., 2015, PRINCIPLES PRACTICE
   Kurz AS, 2014, RES DEV DISABIL, V35, P2359, DOI 10.1016/j.ridd.2014.06.003
   Kwok SYCL, 2017, CHILD INDIC RES, V10, P171, DOI 10.1007/s12187-016-9366-2
   Larson RW, 2011, J RES ADOLESCENCE, V21, P317, DOI 10.1111/j.1532-7795.2010.00707.x
   Lee SA, 2020, DEATH STUD, DOI [10.1080/07481187.2020.1853885, 10.1080/07481187.2020.1748481]
   Levens SM, 2012, COGNITION EMOTION, V26, P341, DOI 10.1080/02699931.2011.574110
   Levin ME, 2014, J CONTEXT BEHAV SCI, V3, P155, DOI 10.1016/j.jcbs.2014.06.003
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Masuda A, 2012, J EVID-BASED INTEGR, V17, P66, DOI 10.1177/2156587211423400
   Masuda A, 2011, PERS INDIV DIFFER, V51, P435, DOI 10.1016/j.paid.2011.04.008
   Mendoza H, 2018, CURR PSYCHOL, V37, P172, DOI 10.1007/s12144-016-9500-9
   Nes L. S., 2016, STRESS CONCEPTS COGN, P405, DOI [10.1016/b978-0-12-800951-2.00052-2, DOI 10.1016/B978-0-12-800951-2.00052-2]
   Nes LS, 2006, PERS SOC PSYCHOL REV, V10, P235, DOI 10.1207/s15327957pspr1003_3
   Peterson C, 2003, FLOURISHING: POSITIVE PSYCHOLOGY AND THE LIFE WELL-LIVED, P55, DOI 10.1037/10594-003
   Praharso NF, 2017, PSYCHIAT RES, V247, P265, DOI 10.1016/j.psychres.2016.11.039
   Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879
   Reed DJ, 2016, PSYCHOL RES BEHAV MA, V9, P71, DOI 10.2147/PRBM.S97595
   Sapmaz F, 2012, MERSIN U J FACULTY E, V8, P63
   Satici B, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00305-0
   SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219
   SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063
   SCHEIER MF, 1992, COGNITIVE THER RES, V16, P201, DOI 10.1007/BF01173489
   Scheier MF, 2001, OPTIMISM PESSIMISM I, P189, DOI DOI 10.1037/10385-009
   Tanhan A., 2019, J POSITIVE PSYCHOL W, V3, P197
   Tanhan A., 2020, ELECT J GEN MED
   Tavakoli N, 2019, J CONTEXT BEHAV SCI, V11, P1, DOI 10.1016/j.jcbs.2018.11.001
   Taylor SE, 1996, J PERS, V64, P873, DOI 10.1111/j.1467-6494.1996.tb00947.x
   Taylor S, 2020, J ANXIETY DISORD, V72, DOI 10.1016/j.janxdis.2020.102232
   Towsyfyan N, 2017, INT J HUMANITIES SOC, V7, P239
   Turkish Ministry of Health, 2020, TURK GUNC DUR
   Uur E., 2020, PSYCHOL INFLEXIBILIT
   Vickers KS, 2000, PERS INDIV DIFFER, V28, P259, DOI 10.1016/S0191-8869(99)00095-1
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Woldgabreal Y, 2016, CRIM JUSTICE BEHAV, V43, P697, DOI 10.1177/0093854815620816
   Woodruff SC, 2014, MINDFULNESS, V5, P410, DOI 10.1007/s12671-013-0195-9
   World Health Organization, 2020, NAM COR DIS COVID 19
   Yadavaia JE, 2014, J CONTEXTUAL BEHAV S, V3, P248, DOI 10.1016/j.jcbs.2014.09.002
   Yao H, 2020, ASIAN J PSYCHIATR, V50, DOI 10.1016/j.ajp.2020.102015
   Yavuz F, 2016, KLIN PSIKOFARMAKOL B, V26, P397, DOI 10.5455/bcp.20160223124107
   Yildirim M., 2020, EXPLORING ASS RESILI, DOI [10.31234/osf.io/vpu5q, DOI 10.31234/OSF.IO/VPU5Q]
   Yildirim M., 2018, INT J PSYCHOL STUDIE, V10, P21, DOI DOI 10.5539/ijps.v10n3p21
   Yldrm M., 2020, DEV INITIAL VALIDATI
NR 79
TC 5
Z9 5
U1 13
U2 15
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1557-1874
EI 1557-1882
J9 INT J MENT HEALTH AD
JI Int. J. Mental Health Addict.
DI 10.1007/s11469-020-00337-6
EA JUN 2020
PG 17
WC Psychology, Clinical; Substance Abuse; Psychiatry
SC Psychology; Substance Abuse; Psychiatry
GA LU8II
UT WOS:000537991800001
PM 32837425
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Berardi, G
   Colasanti, M
   Sandri, GBL
   Del Basso, C
   Ferretti, S
   Laurenzi, A
   Guglielmo, N
   Meniconi, RL
   Antonini, M
   D'Offizi, G
   Ettorre, GM
AF Berardi, Giammauro
   Colasanti, Marco
   Sandri, Giovanni Battista Levi
   Del Basso, Celeste
   Ferretti, Stefano
   Laurenzi, Andrea
   Guglielmo, Nicola
   Meniconi, Roberto Luca
   Antonini, Mario
   D'Offizi, Gianpiero
   Ettorre, Giuseppe Maria
TI Continuing our work: transplant surgery and surgical oncology in a
   tertiary referral COVID-19 center
SO UPDATES IN SURGERY
LA English
DT Article
DE COVID-19; General surgery; Surgical oncology
AB COVID-19 is rapidly spreading worldwide. Healthcare systems are struggling to properly allocate resources while ensuring cure for diseases outside of the infection. The aim of this study was to demonstrate how surgical activity was affected by the virus outbreak and show the changes in practice in a tertiary referral COVID-19 center. The official bulletins of the Italian National Institute for the Infectious Diseases "L. Spallanzani" were reviewed to retrieve the number of daily COVID-19 patients. Records of consecutive oncological and transplant procedures performed during the outbreak were reviewed. Patients with a high probability of postoperative intensive care unit (ICU) admission were considered as high risk and defined by an ASA score >= III and/or a Charlson Comorbidity Index (CCI) >= 6 and/or a Revised Cardiac Risk Index for Preoperative Risk (RCRI) >= 3. 72 patients were operated, including 12 (16.6%) liver and kidney transplantations. Patients had few comorbidities (26.3%), low ASA score (1.9 +/- 0.5), CCI (3.7 +/- 1.3), and RCRI (1.2 +/- 0.6) and had overall a low risk of postoperative ICU admission. Few patients had liver cirrhosis (12.5%) or received preoperative systemic therapy (16.6%). 36 (50%) high-risk surgical procedures were performed, including major hepatectomies, pancreaticoduodenectomies, total gastrectomies, multivisceral resections, and transplantations. Despite this, only 15 patients (20.8%) were admitted to the ICU. Only oncologic cases and transplantations were performed during the COVID-19 outbreak. Careful selection of patients allowed to perform major cancer surgeries and transplantations without further stressing hospital resources, meanwhile minimizing collateral damage to patients.
C1 [Berardi, Giammauro; Colasanti, Marco; Sandri, Giovanni Battista Levi; Del Basso, Celeste; Ferretti, Stefano; Laurenzi, Andrea; Guglielmo, Nicola; Meniconi, Roberto Luca; Ettorre, Giuseppe Maria] Italian Natl Inst Infect Dis L Spallanzani, Dept Gen Surg & Liver Transplantat Serv, Via Giacomo Folchi 6A, Rome, Italy.
   [Antonini, Mario] Italian Natl Inst Infect Dis L Spallanzani, Dept Intens Care & Anesthesiol, Rome, Italy.
   [D'Offizi, Gianpiero] Italian Natl Inst Infect Dis L Spallanzani, Dept Infect Dis, Rome, Italy.
RP Berardi, G (corresponding author), Italian Natl Inst Infect Dis L Spallanzani, Dept Gen Surg & Liver Transplantat Serv, Via Giacomo Folchi 6A, Rome, Italy.
EM gberardi1@gmail.com
OI Berardi, Giammauro/0000-0001-8827-9189
CR Agnes S, 2020, LIVER TRANSPLANT, DOI [10.1002/lt.25790, DOI 10.1002/LT.25790]
   Aminian A, 2020, ANN SURG, V272, pE27, DOI 10.1097/SLA.0000000000003925
   Angelico R, 2020, AM J TRANSPLANT, V20, P1780, DOI 10.1111/ajt.15904
   Bartlett DL, 2020, ANN SURG ONCOL, V27, P1717, DOI 10.1245/s10434-020-08461-2
   Berardi G, 2020, BRIT J SURG, V107, pE251, DOI 10.1002/bjs.11698
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Danese S, 2020, NAT REV GASTRO HEPAT, V17, P253, DOI 10.1038/s41575-020-0294-8
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Di Marzo F, 2020, BRIT J SURG, V107, P1104, DOI 10.1002/bjs.11652
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Elaborazione e gestione dati a cura del Dipartimento della Protezione Civile, 2020, EL GEST DAT CUR DIP
   Fiorino G, 2020, J CROHNS COLITIS
   GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601
   Guerci C, 2020, SURGERY, V167, P909, DOI 10.1016/j.surg.2020.03.012
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   IACOBUCCI G, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1106
   Kiran T, 2020, ANN SURG
   Kurihara H, 2020, SURG COMMUNITY J TRA, V88, P719, DOI [10.1097/TA.0000000000002695, DOI 10.1097/TA.0000000000002695]
   Lambertini M, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000759
   Lauterio A, 2020, TRANSPL INT, V33, P969, DOI 10.1111/tri.13633
   Li CC, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1737232, 10.1080/10962247.2020.1717675]
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lisi G, 2020, COLORECTAL DIS, V22, P641, DOI 10.1111/codi.15054
   Mayhew D, 2019, ANAESTHESIA, V74, P373, DOI 10.1111/anae.14569
   Mazzaferro V, 2020, ANN SURG, V272, pE84, DOI 10.1097/SLA.0000000000004005
   McBride KE, 2020, ANZ J SURG, V90, P663, DOI 10.1111/ans.15900
   Mercantini P, 2020, EJSO-EUR J SURG ONC, V46, P1189, DOI 10.1016/j.ejso.2020.04.050
   Nicastri Emanuele, 2003, Recenti Progressi in Medicina, V94, P295
   Nicastri E, 2020, INFECT DIS REP, V12, P3, DOI 10.4081/idr.2020.8543
   Nicastri E, 2017, ADV EXP MED BIOL, V972, P103, DOI 10.1007/5584_2016_134
   Patriti A, 2020, UPDATES SURG, V72, P309, DOI 10.1007/s13304-020-00779-6
   Pellino G, 2020, DIS COLON RECTUM, V63, P720, DOI 10.1097/DCR.0000000000001685
   Peloso A, 2020, SWISS MED WEEKLY, V150, pw20241
   Ramirez PT, 2020, INT J GYNECOL CANCER, V30, P561, DOI 10.1136/ijgc-2020-001419
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rohan P, 2020, Ir Med J, V113, P66
   Spinelli A, 2020, BRIT J SURG, V107, P785, DOI 10.1002/bjs.11627
   Strasberg SM, 2005, J HEPATO-BILIARY-PAN, V12, P351, DOI 10.1007/s00534-005-0999-7
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Zheng MH, 2020, ANN SURG, V272, pE5, DOI 10.1097/SLA.0000000000003924
   Zoia C, 2020, ACTA NEUROCHIR, V162, P1221, DOI 10.1007/s00701-020-04305-w
NR 43
TC 2
Z9 2
U1 2
U2 2
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 2038-131X
EI 2038-3312
J9 UPDATES SURG
JI Updates Surg.
PD JUN
PY 2020
VL 72
IS 2
BP 281
EP 289
DI 10.1007/s13304-020-00825-3
EA JUN 2020
PG 9
WC Surgery
SC Surgery
GA MF1YM
UT WOS:000537977700001
PM 32500431
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Barnabas, RV
   Brown, E
   Bershteyn, A
   Miller, RS
   Wener, M
   Celum, C
   Wald, A
   Chu, H
   Wesche, D
   Baeten, JM
AF Barnabas, Ruanne V.
   Brown, Elizabeth
   Bershteyn, Anna
   Miller, R. Scott
   Wener, Mark
   Celum, Connie
   Wald, Anna
   Chu, Helen
   Wesche, David
   Baeten, Jared M.
CA Hydroxychloroquine COVID-19 PEP
TI Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent
   severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
   among adults exposed to coronavirus disease (COVID-19): a structured
   summary of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; hydroxychloroquine;
   post-exposure prophylaxis; household contact; health care worker
AB ObjectivesPrimary Objective center dot To test the efficacy of Hydroxychloroquine (HCQ) (400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days, to complete 14 days) to prevent incident SARS-CoV-2 infection, compared to ascorbic acid among contacts of persons with SARS-CoV-2 infectionSecondary objectives center dot To determine the safety and tolerability of HCQ as SARS-CoV-2 Post-exposure Prophylaxis (PEP) in adults center dot To test the efficacy of HCQ (400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days, to complete 14 days) to prevent incident SARS-CoV-2 infection 2 weeks after completing therapy, compared to ascorbic acid among contacts of persons with SARS-CoV-2 infection center dot To test the efficacy of HCQ to shorten the duration of SARS-CoV-2 shedding among those with SARS-CoV-2 infection in the HCQ PEP group center dot To test the efficacy of HCQ to prevent incident COVID-19Trial designThis is a randomized, multi-center, placebo-equivalent (ascorbic acid) controlled, blinded study of HCQ PEP for the prevention of SARS-CoV-2 infection in adults exposed to the virus.ParticipantsThis study will enroll up to 2000 asymptomatic adults 18 to 80 years of age (inclusive) at baseline who are close contacts of persons with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 or clinically suspected COVID-19 and a pending SARS-CoV-2 PCR test. This multisite trial will be conducted at seven sites in Seattle (UW), Los Angeles (UCLA), New Orleans (Tulane), Baltimore (UMB), New York City (NYU), Syracuse (SUNY-Upstate), and Boston (BMC).Inclusion criteriaParticipants are eligible to be included in the study only if all of the following criteria apply: Men or women 18 to 80 years of age inclusive, at the time of signing the informed consentWilling and able to provide informed consentHad a close contact of a person (index) with known PCR-confirmed SARS-CoV-2 infection or index who is currently being assessed for COVID-19Close contact is defined as: Household contact (i.e., residing with the index case in the 14 days prior to index diagnosis or prolonged exposure within a residence/vehicle/enclosed space without maintaining social distance)Medical staff, first responders, or other care persons who cared for the index case without personal protection (mask and gloves)Less than 4 days since last exposure (close contact with a person with SARS-CoV-2 infection) to the index caseAccess to device and internet for Telehealth visitsNot planning to take HCQ in addition to the study medicationExclusion criteriaParticipants are excluded from the study if any of the following criteria apply: Known hypersensitivity to HCQ or other 4-aminoquinoline compoundsCurrently hospitalizedSymptomatic with subjective fever, cough, or shortness of breathCurrent medications exclude concomitant use of HCQConcomitant use of other anti-malarial treatment or chemoprophylaxis, including chloroquine, mefloquine, artemether, or lumefantrine.
   History of retinopathy of any etiologyPsoriasisPorphyriaKnown bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes <1500) or thrombocytopenia (<100 K)Concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifenKnown moderate or severe liver diseaseKnown long QT syndromeSevere renal impairmentUse of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of the study drugs or planned use during the study periodIntervention and comparatorHouseholds will be randomized 1:1 (at the level of household), with close contact participants receiving one of the following therapies:center dot HCQ 400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days center dot Placebo-like control (ascorbic acid) 500 mg orally daily for 3 days then 250 mg orally daily for 11 daysMain outcomesThe primary outcome of the study is the incidence of SARS-CoV-2 infection through day 14 among participants who are SARS-CoV-2 negative at baseline by randomization group.RandomisationParticipants will be randomized in a 1:1 ratio to HCQ or ascorbic acid at the level of the household (all eligible participants in 1 household will receive the same intervention). The randomization code and resulting allocation list will be generated and maintained by the Study Statistician. The list will be blocked and stratified by site and contact type (household versus healthcare worker).Blinding (masking)This is a blinded study.HCQ and ascorbic acid will appear similar, and taste will be partially masked as HCQ can be bitter and ascorbic acid will be sour.The participants will be blinded to their randomization group once assigned. Study team members, apart from the Study Pharmacist and the unblinded statistical staff, will be blinded. Laboratory staff are blinded to the group allocation.Numbers to be randomised (sample size)The sample size for the study is N=2 000 participants randomized 1:1 to either HCZ (n=1 000) and ascorbic acid (n=1 000).Trial statusProtocol version: 1.205 April 2020Recruitment is ongoing, started March 31 and anticipated end date is September 30, 2020.Trial registrationClinicalTrials.gov, Protocol Registry Number: NCT04328961Date of registration: April 1, 2020, retrospectively registeredFull protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Barnabas, Ruanne V.; Celum, Connie; Chu, Helen; Baeten, Jared M.] Univ Washington, Int Clin Res Ctr ICRC, Dept Global Hlth, UW Box 359927,325 Ninth Ave, Seattle, WA 98104 USA.
   [Barnabas, Ruanne V.; Celum, Connie; Wald, Anna; Chu, Helen; Baeten, Jared M.] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA.
   [Barnabas, Ruanne V.; Celum, Connie; Wald, Anna; Chu, Helen; Baeten, Jared M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Barnabas, Ruanne V.; Brown, Elizabeth; Wald, Anna] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Brown, Elizabeth] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Wald, Anna] NYU, Sch Med, New York, NY USA.
   [Miller, R. Scott] Bill & Melinda Gates Fdn, Seattle, WA USA.
   [Wener, Mark; Wald, Anna] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
   [Wesche, David] Certara, Princeton, NJ USA.
RP Barnabas, RV (corresponding author), Univ Washington, Int Clin Res Ctr ICRC, Dept Global Hlth, UW Box 359927,325 Ninth Ave, Seattle, WA 98104 USA.; Barnabas, RV (corresponding author), Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA.
EM rbarnaba@uw.edu
OI Barnabas, Ruanne/0000-0002-1793-6003
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [INV-016204]
FX The study is funded by the Bill and Melinda Gates Foundation
   (INV-016204). A funding agency staff member (RSM) is a co-author of the
   manuscript. Sandoz donated the study drug. The funders had no separate
   role, beyond that of other authors, in study design; writing of the
   letter; or in the decision to submit for publication. The corresponding
   author had full access to the study protocol and had final
   responsibility for the decision to submit for publication.
NR 0
TC 3
Z9 3
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 3
PY 2020
VL 21
IS 1
AR 475
DI 10.1186/s13063-020-04446-4
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1YZ
UT WOS:000540318600001
PM 32493478
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cuadrado-Lavin, A
   Olmos, JM
   Cifrian, JM
   Gimenez, T
   Gandarillas, MA
   Garcia-Saiz, M
   Rebollo, MH
   Martinez-Taboada, V
   Lopez-Hoyos, M
   Farinas, MC
   Crespo, J
AF Cuadrado-Lavin, Antonio
   Manuel Olmos, Jose
   Manuel Cifrian, Jose
   Gimenez, Teresa
   Antonio Gandarillas, Marco
   Garcia-Saiz, Mar
   Henar Rebollo, Maria
   Martinez-Taboada, Victor
   Lopez-Hoyos, Marcos
   Carmen Farinas, Maria
   Crespo, Javier
TI Controlled, double-blind, randomized trial to assess the efficacy and
   safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in
   healthcare personnel in the hospital setting: A structured summary of a
   study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Protocol; Healthcare
   professionals; Chemoprophylaxis; Hydroxychloroquine
AB BackgroundSARS-CoV-2 infection presents a high transmission in the group of health professionals in Spain (12-15% infected). Currently there is no accepted chemoprophylaxis but hydroxychloroquine (HDQ) is known to inhibit the coronavirus in vitro. Our hypothesis is that oral administration of hydroxychloroquine to healthcare professionals can reduce the incidence and prevalence of infection as well as its severity in this group.MethodsDesign: Prospective, single center, double blind, randomised, controlled trial (RCT). Participants: Adult health-care professionals (18-65 years) working in areas of high exposure and high risk of transmission of SARS-COV-2 (COVID areas, Intensive Care Unit -ICUs-, Emergency, Anesthesia and all those performing aerosol-generating procedures) will be included. Exclusion criteria include previous infection with SARS CoV2 (positive SARS-CoV-2 PCR or IgG serology), pregnancy or lactation, any contraindication to hydroxychloroquine or evidence of unstable or clinically significant systemic disease.InterventionsPatients will be randomized (1:1) to receive once-daily oral Hydroxychloroquine 200mg for two months (HC group) or placebo (P group) in addition to the protective measures appropriate to the level of exposure established by the hospital. A serological evaluation will be carried out every 15 days with PCR in case of seroconversion, symptoms or risk exposure. Primary outcome is the percentage of subjects presenting infection (seroconversion and/or PCR +ve) by the SARS-Cov-2 virus during the observation period. Additionally, both the percentage of subjects in each group presenting Pneumonia with severity criteria (Curb 65 >= 2) and that of subjects requiring admission to ICU will be determined.DiscussionWhile awaiting a vaccine, hygiene measures, social distancing and personal protective equipment are the only primary prophylaxis measures against SARS-CoV-2, but they have not been sufficient to protect our healthcare professionals. Some evidence of the in vitro efficacy of hydroxychloroquine against this virus is known, along with some clinical data that would support the study of this drug in the chemoprophylaxis of infection. However, there are still no data from controlled clinical trials in this regard. If our hypothesis is confirmed, hydroxychloroquine can help professionals fight this infection with more guarantees.ParticipantsThis is a single-center study that will be carried out at the Marques de Valdecilla University Hospital.450 health professionals working at the Hospital Universitario Marques de Valdecilla in areas of high exposure and high risk of transmission of SARS COV2 (COVID hospital areas, Intensive Care Unit, Emergency, Anesthesia and all those performing aerosol-generating procedures) will be included.Inclusion criteria: 1) Health professionals aged between 18 and 65 years (inclusive) at the time of the first screening visit; 2) They must provide signed written informed consent and agree to comply with the study protocol; 3) Active work in high exposure areas during the last two weeks and during the following weeks.
   Exclusion criteria: 1) Previous infection with SARS CoV2 (positive coronavirus PCR or positive serology with SARS Cov2 negative PCR and absence of symptoms); 2) Current treatment with hydroxychloroquine or chloroquine; 3) Hypersensitivity, allergy or any contraindication for taking hydroxychloroquine, in the technical sheet; 4) Previous or current treatment with tamoxifen or raloxifene; 5) Previous eye disease, especially maculopathy; 6) Known heart failure (Grade III to IV of the New York Heart Association classification) or prolonged QTc; 7) Any type of cancer (except basal cell) in the last 5 years; 6) Refusal to give informed consent; 8) Evidence of any other unstable or clinically significant untreated immune, endocrine, hematological, gastrointestinal, neurological, neoplastic or psychiatric illness; 9) Antibodies positive for the human immunodeficiency virus; 10) Significant kidney or liver disease; 11) Pregnancy or lactation.Intervention and comparatorTwo groups will be analyzed with a 1: 1 randomization rate. Intervention: (n = 225): One 200 mg hydroxychloroquine sulfate coated tablet once daily for two months.Comparator (control group) (n = 225): One hydroxychloroquine placebo tablet (identical to that of the drug) once daily for two monthsMain outcomesThe primary outcome of this study will be to evaluate: number and percentage of healthcare personnel presenting symptomatic and asymptomatic infection (see "Diagnosis of SARS CoV2 infection" below) by the SARS-Cov2 virus during the study observation period (8 weeks) in both treatment arms;number and percentage of healthcare personnel in each group presenting with Pneumonia with severity criteria (Curb 65 >= 2) and number and percentage of healthcare personnel requiring admission to the Intensive Care Unit (ICU) in both treatment arms.Diagnosis of SARS CoV2 infectionDetermination of IgA, IgM and IgG type antibodies against SARS-CoV-2 using the Anti-SARS-CoV-2 ELISA kit (EUROIMMUN Medizinische Labordiagnostika AG, Germany) every two weeks. In cases of seroconversion, a SARS-CoV-2 PCR will be performed to rule out / confirm an active infection (RT-PCR in One Step: RT performed with mastermix (Takara) and IDT probes, following protocol published and validated by the CDC Evaluation of COVID-19 in case of SARS-CoV-2 infectionRandomisationParticipants will be allocated to intervention and comparator groups according to a balanced randomization scheme (1: 1). The assignment will be made through a computer-generated numeric sequence for all participantsBlinding (masking)Both participants and investigators responsible for recruiting and monitoring participants will be blind to the assigned arm.Numbers to be randomised (sample size)Taking into account the current high prevalence of infection in healthcare personnel in Spain (up to 15%), to detect a difference equal to or greater than 8% in the percentage estimates through a two-tailed 95% CI, with a statistical power of 80% and a dropout rate of 5%, a total of 450 participants will need to be included (250 in each arm).Trial StatusThe protocol approved by the health authorities in Spain (Spanish Agency for Medicines and Health Products "AEMPS") and the Ethics and Research Committee of Cantabria (CEIm Cantabria) corresponds to version 1.1 of April 2, 2020.Currently, recruitment has not yet started, with the start scheduled for the second week of May 2020.
   Trial registrationEudra CT number: 2020-001704-42 (Registered on 29 March 2020)Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
C1 [Cuadrado-Lavin, Antonio; Crespo, Javier] Univ Cantabria, Marques Valdecilla Univ Hosp, Sch Med, Dept Gastroenterol & Hepatol, Av Valdecilla 25, Santander 39008, Cantabria, Spain.
   [Cuadrado-Lavin, Antonio; Manuel Olmos, Jose; Manuel Cifrian, Jose; Gimenez, Teresa; Antonio Gandarillas, Marco; Garcia-Saiz, Mar; Henar Rebollo, Maria; Martinez-Taboada, Victor; Lopez-Hoyos, Marcos; Carmen Farinas, Maria; Crespo, Javier] Marques Valdecilla Res Inst IDIVAL, S-N Calle Cardenal Herrera Oria, Santander 39011, Cantabria, Spain.
   [Manuel Olmos, Jose] Univ Cantabria, Marques Valdecilla Univ Hosp, Sch Med, Internal Med Dept, Av Valdecilla 25, Santander 39008, Spain.
   [Manuel Cifrian, Jose] Univ Cantabria, Marques Valdecilla Univ Hosp, Sch Med, Serv Pneumol, Av Valdecilla 25, Santander 39008, Spain.
   [Gimenez, Teresa] Univ Cantabria, Marques Valdecilla Univ Hosp, Sch Med, Pharm Dept, Av Valdecilla 25, Santander 39008, Cantabria, Spain.
   [Antonio Gandarillas, Marco] Univ Cantabria, Marques Valdecilla Univ Hosp, Sch Med, Dept Prevent & Risks,Work Med, Av Valdecilla 25, Santander 39008, Cantabria, Spain.
   [Garcia-Saiz, Mar] Univ Cantabria, Marques Valdecilla Univ Hosp, Sch Med, Dept Clin Pharmacol, Av Valdecilla 25, Santander 39008, Cantabria, Spain.
   [Henar Rebollo, Maria] Univ Cantabria, Marques Valdecilla Univ Hosp, Sch Med, Dept Prevent Med, Av Valdecilla 25, Santander 39008, Cantabria, Spain.
   [Martinez-Taboada, Victor] Univ Cantabria, Marques Valdecilla Univ Hosp, Sch Med, Dept Rheumatol, Av Valdecilla 25, Santander 39008, Cantabria, Spain.
   [Lopez-Hoyos, Marcos] Univ Cantabria, Marques Valdecilla Univ Hosp, Sch Med, Dept Immunol, Av Valdecilla 25, Santander 39008, Cantabria, Spain.
   [Carmen Farinas, Maria] Univ Cantabria, Marques Valdecilla Univ Hosp, Sch Med, Infect Dis Serv, Av Valdecilla 25, Santander 39008, Cantabria, Spain.
RP Crespo, J (corresponding author), Univ Cantabria, Marques Valdecilla Univ Hosp, Sch Med, Dept Gastroenterol & Hepatol, Av Valdecilla 25, Santander 39008, Cantabria, Spain.; Crespo, J (corresponding author), Marques Valdecilla Res Inst IDIVAL, S-N Calle Cardenal Herrera Oria, Santander 39011, Cantabria, Spain.
EM javiercrespo1991@gmail.com
NR 0
TC 1
Z9 2
U1 3
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 3
PY 2020
VL 21
IS 1
AR 472
DI 10.1186/s13063-020-04400-4
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1YM
UT WOS:000540317300018
PM 32493494
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Garcia, IG
   Rodriguez-Rubio, M
   Mariblanca, AR
   de Soto, LM
   Garcia, LD
   Villatoro, JM
   Parada, JQ
   Meseguer, ES
   Rosales, MJ
   Gonzalez, J
   Arribas, JR
   Carcas, AJ
   de la Oliva, P
   Borobia, AM
AF Garcia Garcia, Irene
   Rodriguez-Rubio, Miguel
   Rodriguez Mariblanca, Amelia
   Martinez de Soto, Lucia
   Diaz Garcia, Lucia
   Monserrat Villatoro, Jaime
   Queiruga Parada, Javier
   Seco Meseguer, Enrique
   Rosales, Maria J.
   Gonzalez, Juan
   Arribas, Jose R.
   Carcas, Antonio J.
   de la Oliva, Pedro
   Borobia, Alberto M.
TI A randomized multicenter clinical trial to evaluate the efficacy of
   melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk
   contacts (MeCOVID Trial): A structured summary of a study protocol for a
   randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; melatonin; prophylaxis;
   healthcare workers
AB ObjectivesPrimary objective: to evaluate the efficacy of melatonin as a prophylactic treatment on prevention of symptomatic SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 exposure.Secondary objectives: To evaluate the efficacy of melatonin as a prophylactic treatment on prevention of asymptomatic SARS-CoV-2 infection.To evaluate the efficacy of melatonin to prevent the development of severe COVID-19 in the participants enrolled in this study who develop SARS-CoV-2 infection along the trial.To evaluate the duration of COVID-19 symptoms in participants receiving melatonin before the infection.To evaluate seroconversion timing post-symptom onset.Exploratory objectives:To compare severity of COVID-19 between men and women.To evaluate the influence of sleep and diet on prevention from SARS-CoV-2 infection.To evaluate the effect of melatonin on the incidence and characteristics of lymphopenia and increase of inflammatory cytokines related to COVID-19.Trial designThis is a two-arm parallel randomised double-blind controlled trial to evaluate the efficacy of melatonin versus placebo in the prophylaxis of coronavirus disease 2019 among healthcare workers.ParticipantsInclusion Criteria: Male or female participants >= 18 and <= 80 years of age.Healthcare workers from the public and private Spanish hospital network at risk of SARS-CoV 2 infection.Not having a previous COVID19 diagnosis.Understanding the purpose of the trial and not having taken any pre-exposure prophylaxis (PrEP) including HIV PrEP from March 1st 2020 until study enrolment.Having a negative SARS-CoV 2 reverse-transcription PCR (RT-PCR) result or a negative serologic rapid test (IgM/IgG) result before randomization.Premenopausal women must have a negative urinary pregnancy test in the 7 days before starting the trial treatment.Premenopausal women and males with premenopausal couples must commit to using a high efficiency anticonceptive method.Exclusion Criteria: HIV infection.Active hepatitis B infection.Renal failure (CrCl < 60 mL/min/1.73 m2) or need for hemodialysis.Osteoporosis.Myasthenia gravis.Pre-existent maculopathy.Retinitis pigmentosa.Bradycardia (less than 50 bpm).Weight less than 40 Kg.Participant with any immunosuppressive condition or hematological disease.Treatment with drugs that may prolong QT in the last month before randomization for more than 7 days including: azithromycin, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine, mefloquine, methadone, pentamidine, procainamide, quinidine, quinine, sotalol, sparfloxacin, thioridazine, amiodarone.Hereditary intolerance to galactose, Lapp lactase deficiency or glucose or galactose malabsorption.Treatment with fluvoxamine.Treatment with benzodiazepines or benzodiazepine analogues such as zolpidem, zopiclone or zaleplon.Pregnancy.Breastfeeding.History of potentially immune derived diseases such as: lupus, Crohn's disease, ulcerative colitis, vasculitis or rheumatoid arthritis.Insulin-dependent diabetes mellitus.Known history of hypersensitivity to the study drug or any of its components.Patients that should not be included in the study at the judgment of the research team.Participants will be recruited from the following eight hospitals in Madrid, Spain: Hospital Universitario La Paz, Hospital Ramon y Cajal, Hospital Infanta Sofia, Hospital 12 de Octubre, Hospital Clinico San Carlos, Hospital Central de la defensa Gomez Ulla,Hospital de La Princesa and Hospital Infanta Leonor.
   Intervention and comparatorExperimental: Melatonin (Circadin (R), Exeltis Healthcare, Spain): 2 mg of melatonin orally before bedtime for 12 weeks.Comparator: Identical looking placebo (Laboratorios Liconsa, Spain) orally before bedtime for 12 weeks.Main outcomesNumber of SARS-CoV-2 (COVID-19) symptomatic infections confirmed by polymerase chain reaction (PCR) test or serologic test or according to each centre diagnosis protocol. Primary outcome will be measured until the end of treatment for each participant (until the date of the last dose taken by each patient).RandomisationPatients who meet all inclusion and no exclusion criteria will be randomised, stratified by centres, sex and age (<50 and >= 50 years old). The randomisation sequence was created using SAS version 9.4 statistical software (procedure 'PROC PLAN') with a 1:1 allocation. No randomisation seed was specified. The randomisation seed was generated taking the hour of the computer where the program was executed. Randomization will be done centrally through the electronic system RedCAP (R) in order to conceal the sequence until interventions are assignedBlinding (masking)Participants, caregivers, and those assessing the outcomes are blinded to group assignment.Numbers to be randomised (sample size)A total of 450 participants are planned to be enrolled in this clinical trial, 225 in the experimental arm and 225 in the placebo arm.Trial StatusProtocol version 3.0, 17th of April 2020. Recruitment ongoing.First participant was recruited on the 21st of April 2020. The final participant is anticipated to be recruited on the 31st of May 2020.As of May 18th, 2020, a total of 312 participants have been enrolled (154 at Hospital La Paz, 85 at Hospital Infanta Sofia and 73 at Hospital 12 de Octubre).Trial registrationEU Clinical Trials Register: 2020-001530-35; Date of trial registration: 13th of April 2020; https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001530-35/ESFull protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Garcia Garcia, Irene; Rodriguez Mariblanca, Amelia; Martinez de Soto, Lucia; Diaz Garcia, Lucia; Monserrat Villatoro, Jaime; Queiruga Parada, Javier; Seco Meseguer, Enrique; Carcas, Antonio J.; Borobia, Alberto M.] La Paz Univ Hosp IdiPAZ, Clin Trial Unit, Clin Pharmacol Dept, Paseo Castellana 261, Madrid 28046, Spain.
   [Garcia Garcia, Irene; Rodriguez-Rubio, Miguel; Rodriguez Mariblanca, Amelia; Martinez de Soto, Lucia; Diaz Garcia, Lucia; Monserrat Villatoro, Jaime; Queiruga Parada, Javier; Seco Meseguer, Enrique; Rosales, Maria J.; Gonzalez, Juan; Arribas, Jose R.; Carcas, Antonio J.; de la Oliva, Pedro; Borobia, Alberto M.] Univ Autonoma Madrid, Sch Med, Madrid, Spain.
   [Rodriguez-Rubio, Miguel; de la Oliva, Pedro] La Paz Univ Hosp IdiPAZ, Pediat Intens Care Dept, Paseo Castellana 261, Madrid 28046, Spain.
   [Rosales, Maria J.] La Paz Univ Hosp IdiPAZ, Clin Trial Unit, Madrid, Spain.
   [Gonzalez, Juan; Arribas, Jose R.] La Paz Univ Hosp IdiPAZ, Infect Dis Unit, Internal Med Dept, Madrid, Spain.
RP Borobia, AM (corresponding author), La Paz Univ Hosp IdiPAZ, Clin Trial Unit, Clin Pharmacol Dept, Paseo Castellana 261, Madrid 28046, Spain.; de la Oliva, P; Borobia, AM (corresponding author), Univ Autonoma Madrid, Sch Med, Madrid, Spain.
EM pedro.oliva@salud.madrid.org
RI Rodriguez-Rubio, Miguel/AAQ-6829-2020
OI Rodriguez-Rubio, Miguel/0000-0001-9145-4718; de la Oliva,
   Pedro/0000-0003-2444-0556
NR 0
TC 1
Z9 1
U1 7
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 3
PY 2020
VL 21
IS 1
AR 466
DI 10.1186/s13063-020-04436-6
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1YM
UT WOS:000540317300012
PM 32493475
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gorman, E
   Shankar-Hari, M
   Hopkins, P
   Tunnicliffe, WS
   Perkins, GD
   Silversides, J
   McGuigan, P
   Jackson, C
   Boyle, R
   McFerran, J
   McDowell, C
   Campbell, C
   McFarland, M
   Smythe, J
   Thompson, J
   Williams, B
   Curley, G
   Laffey, JG
   Clarke, M
   O'Kane, C
   McAuley, DF
AF Gorman, Ellen
   Shankar-Hari, Manu
   Hopkins, Phil
   Tunnicliffe, William S.
   Perkins, Gavin D.
   Silversides, Jonathan
   McGuigan, Peter
   Jackson, Colette
   Boyle, Roisin
   McFerran, Jamie
   McDowell, Cliona
   Campbell, Christina
   McFarland, Margaret
   Smythe, Jon
   Thompson, Jacqui
   Williams, Barry
   Curley, Gerard
   Laffey, John G.
   Clarke, Mike
   O'Kane, Cecilia
   McAuley, Daniel F.
TI Repair of Acute Respiratory Distress Syndrome by Stromal Cell
   Administration in COVID-19 (REALIST-COVID-19): A structured summary of a
   study protocol for a randomised, controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; Mesenchymal Stromal
   Cells; Mesenchymal Stem Cells; MSCs; Acute Respiratory Distress
   Syndrome; ARDS
AB ObjectivesThe primary objective of the study is to assess the safety of a single intravenous infusion of Mesenchymal Stromal Cells (MSCs) in patients with Acute Respiratory Distress Syndrome (ARDS) due to COVID-19. Secondary objectives are to determine the effects of MSCs on important clinical outcomes, as described below.Trial designREALIST COVID 19 is a randomised, placebo-controlled, triple blinded trial.ParticipantsThe study will be conducted in Intensive Care Units in hospitals across the United Kingdom. Patients with moderate to severe ARDS as defined by the Berlin definition, receiving invasive mechanical ventilation and with a diagnosis of COVID-19 based on clinical diagnosis or PCR test will be eligible.Patients will be excluded for the following reasons: more than 72 hours from the onset of ARDS; age < 16 years; patient known to be pregnant; major trauma in previous 5 days; presence of any active malignancy (other than non-melanoma skin cancer); WHO Class III or IV pulmonary hypertension; venous thromboembolism currently receiving anti-coagulation or within the past 3 months; patient receiving extracorporeal life support; severe chronic liver disease (Child-Pugh > 12); Do Not Attempt Resuscitation order in place; treatment withdrawal imminent within 24 hours; prisoners; declined consent; non-English speaking patients or those who do not adequately understand verbal or written information unless an interpreter is available; previously enrolled in the REALIST trial.Intervention and comparatorIntervention: Allogeneic donor CD362 enriched human umbilical cord derived mesenchymal stromal cells (REALIST ORBCEL-C) supplied as sterile, single-use cryopreserved cell suspension of a fixed dose of 400 x10(6) cells in 40ml volume, to be diluted in Plasma-Lyte 148 to a total volume of 200mls for administration.Comparator (placebo): Plasma-Lyte 148 Solution for Infusion (200mls).The cellular product (REALIST ORBCEL-C) was developed and patented by Orbsen Therapeutics.Main outcomesThe primary safety outcome is the incidence of serious adverse events. The primary efficacy outcome is Oxygenation Index (OI) at day 7. Secondary outcomes include: OI at days 4 and 14; respiratory compliance, driving pressure and PaO2/FiO(2) ratio (PF ratio) at days 4, 7 and 14; Sequential Organ Failure Assessment (SOFA) score at days 4, 7 and 14; extubation and reintubation; ventilation free days at day 28; duration of mechanical ventilation; length of ICU and hospital stay; 28-day and 90-day mortality.RandomisationAfter obtaining informed consent, patients will be randomised via a centralised automated 24-hour telephone or web-based randomisation system (CHaRT, Centre for Healthcare Randomised Trials, University of Aberdeen). Randomisation will be stratified by recruitment centre and by vasopressor use and patients will be allocated to REALIST ORBCEL-C or placebo control in a 1:1 ratio.Blinding (masking)The investigator, treating physician, other members of the site research team and participants will be blinded. The cell therapy facility and clinical trials pharmacist will be unblinded to facilitate intervention and placebo preparation. The unblinded individuals will keep the treatment information confidential. The infusion bag will be masked at the time of preparation and will be administered via a masked infusion set.Numbers to be randomised (sample size)A sample size of 60 patients with 30 patients randomised to the intervention and 30 to the control group.
   If possible, recruitment will continue beyond 60 patients to provide more accurate and definitive trial results. The total number of patients recruited will depend on the pandemic and be guided by the data monitoring and ethics committee (DMEC).Trial statusREALIST Phase 1 completed in January 2020 prior to the COVID-19 pandemic. This was an open label dose escalation study of REALIST ORBCEL-C in patients with ARDS. The COVID-19 pandemic emerged as REALIST Phase 2 was planned to commence and the investigator team decided to repurpose the Phase 2 trial as a COVID-19 specific trial. This decision was discussed and approved by the Trial Steering Committee (TSC) and DMEC. Submissions were made to the Research Ethics Committee (REC) and MHRA to amend the protocol to a COVID-19 specific patient population and the protocol amendment was accepted by the REC on 27(th) March 2020 and MHRA on 30(th) March 2020 respectively. Other protocol changes in this amendment included an increase in the time of onset of ARDS from 48 to 72 hours, inclusion of clinical outcomes as secondary outcomes, the provision of an option for telephone consent, an indicative sample size and provision to continue recruitment beyond this indicative sample size. The current protocol in use is version 4.0 23.03.2020 (Additional file 1). Urgent Public Health status was awarded by the NIHR on 2 April 2020 and the trial opened to recruitment and recruited the first participant the same day. At the time of publication the trial was open to recruitment at 5 sites across the UK (Belfast Health and Social Care Trust, King's College London, Guys and St Thomas' Hospital London, Birmingham Heartlands Hospital and the Queen Elizabeth Hospital Birmingham) and 12 patients have been recruited across these sites. Additional sites are planned to open and appropriate approvals for these are being obtained. It is estimated recruitment will continue for 6 months.Trial registrationClinicalTrials.gov NCT 03042143 (Registered 3 Feb 2017).EudraCT 2017-000585-33 (Registered 28 Nov 2017).Full protocolThe full protocol (version 4.0 23.03.2020) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
C1 [Gorman, Ellen; O'Kane, Cecilia; McAuley, Daniel F.] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland.
   [Shankar-Hari, Manu] Kings Coll London, Guys & St Thomas NHS Fdn Trust London, London, England.
   [Shankar-Hari, Manu] Kings Coll London, Sch Immunol & Microbial Sci, London, England.
   [Hopkins, Phil] Kings Coll London, Kings Trauma Ctr, Crit Care, London, England.
   [Tunnicliffe, William S.] Queen Elizabeth Hosp, Birmingham, W Midlands, England.
   [Perkins, Gavin D.] Univ Warwick, Coventry, W Midlands, England.
   [Silversides, Jonathan; McFarland, Margaret] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [McGuigan, Peter] Royal Victoria Hosp, Belfast, Antrim, North Ireland.
   [Jackson, Colette; Boyle, Roisin; McFerran, Jamie; McDowell, Cliona; Campbell, Christina] Northern Ireland Clin Trials Unit, Belfast, Antrim, North Ireland.
   [Smythe, Jon; Thompson, Jacqui] NHS Blood & Transplant Serv, London, England.
   [Williams, Barry] Patient & Publ Representat, Belfast, Antrim, North Ireland.
   [Curley, Gerard] Royal Coll Surgeons Ireland, Dublin, Ireland.
   [Laffey, John G.] Natl Univ Ireland, Galway, Ireland.
   [Clarke, Mike] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
RP McAuley, DF (corresponding author), Queens Univ Belfast, Sch Med Dent & Biomed Sci, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland.
EM d.f.mcauley@qub.ac.uk
RI Perkins, Gavin D/E-7613-2010
OI Reis, AlessanRSS/0000-0001-8486-7469; Silversides,
   Jon/0000-0002-9562-5462; Curley, Gerard/0000-0003-0271-195X
FU Wellcome Trust Health Innovation Challenge Fund [106939/Z/15/Z]
FX The Wellcome Trust Health Innovation Challenge Fund [Reference
   106939/Z/15/Z] and the Research and Development Division of the Public
   Health Agency (Northern Ireland) will provide research costs for the
   REALIST study. The funders have no role in the study design, data
   acquisition, data analysis or manuscript preparation.
NR 0
TC 4
Z9 4
U1 5
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 3
PY 2020
VL 21
IS 1
AR 462
DI 10.1186/s13063-020-04416-w
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1YM
UT WOS:000540317300008
PM 32493473
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Irvani, SSN
   Golmohammadi, M
   Pourhoseingholi, MA
   Shokouhi, S
   Darazam, IA
AF Irvani, Seyed Sina Naghibi
   Golmohammadi, Maryam
   Pourhoseingholi, Mohamad Amin
   Shokouhi, Shervin
   Darazam, Ilad Alavi
TI Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and
   the usual therapeutic regimen to treat adults with moderate to severe
   COVID-19: structured summary of a study protocol for a randomized
   controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; SARS-COV-2; Randomized controlled trial; Hydroxychloroquine
   plus Lopinavir; Ritonavir; Interferon-beta 1a; Interferon-beta 1b
AB ObjectivesWe will investigate the effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen in COVID-19 in patients that have tested positive and are moderately to severely ill.Trial designThis is a single center, open label, randomized, controlled, parallel group, clinical trial that will be conducted at Loghman Hakim Medical Education Center in conjunction with Shahid Beheshti University of Medical Sciences.ParticipantsSixty COVID-19 confirmed cases (using the RT-PCR test) will be enrolled in the trial between April 9(th) to April 14(th) 2020. Patients will be randomly assigned to the intervention groups or the control group with the following eligibility criteria: >= 18 years of age AND (oxygen saturation (SPO2) <= 93% OR respiratory rate >= 24) AND at least one of the following: Contactless infrared forehead thermometer temperature of >= 37.8, cough, sputum production, nasal discharge, myalgia, headache or fatigue on admission, and time of onset of the symptoms should be acute (Days <= 14). Although Hydroxychloroquine will be administered in a single dose, patients with heart problems (prolonged QT or PR intervals, second- or third-degree heart block, and arrhythmias including torsade de pointes) will be excluded. Other exclusion criteria include using drugs with potential interaction with Hydroxychloroquine + Lopinavir/Ritonavir, Interferon-beta 1a, Interferon-beta 1b, pregnant or lactating women, history of alcohol or drug addiction in the past 5 years, blood ALT/AST levels > 5 times the upper limit of normal on laboratory results and refusal to participate.This study will be undertaken at the Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services.Intervention and comparatorCOVID-19 confirmed patients will be randomly assigned to one of three groups, with 20 patients in each. The first group (Arm 1) will receive Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon-beta 1a (Recigen), the second group (Arm 2) will be administered Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon-beta 1b (Ziferon), and the control group (Arm 3) will be treated by Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra).Main outcomesTime to clinical improvement is our primary outcome measure. This is an improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&D. Geneva: World Health Organization) or discharge from the hospital, whichever comes first.Secondary outcomes include mortality from the date of randomization until the last day of the study which will be the day all of the patients have had at least one of the following outcomes: 1) Improvement of two points on a seven-category ordinal scale. 2) Discharge from the hospital 3) Death. If any patient dies, we have reached an important secondary outcome. SpO2 Improvement between the last and first day of hospitalization, using pulse-oximetry. Duration of hospitalization from date of randomization until the date of hospital discharge or date of death from any cause, whichever comes first. Incidence of new mechanical ventilation uses from date of randomization until the last day of the study. Please note that we are trying to add further secondary outcomes and this section of the protocol is still evolving.Statistical analysis will be performed by R version 3.6.1 software. We will use Kaplan-Meier to analyze the time to clinical improvement (compared with a log-rank test).
   Hazard ratios with 95% confidence intervals will be calculated using the Cox proportional-hazards model in crude and adjusted analysis.RandomizationEligible patients will be randomly assigned in a 1:1:1 ratio to receive either Interferon Beta 1a, Interferon Beta 1b or standard care only. Patients will be randomly allocated to three therapeutic arms using permuted, block-randomization to balance the number of patients allocated to each group. The permuted block (three or six patients per block) randomization sequence will be generated, using Package 'randomizeR' in R software version 3.6.1. and placed in individual sealed and opaque envelopes by the statistician. The investigator will enroll the patients and only then open envelopes to assign patients to the different treatment groups. This method of allocation concealment will result in minimum selection and confounding biases.Blinding (Masking)The present research is open-label (no masking) of patients and health care professionals who are undertaking outcome assessment of the primary outcome - time to clinical improvement.Numbers to be Randomized (Sample Size)Of the 60 patients who underwent randomization, 20 patients were assigned to receive Interferon beta-1a, 20 patients were assigned to receive Interferon beta 1b plus standard care and the rest of patients were assigned to receive the standard care alone.Trial StatusProtocol version 1.2.1. Recruitment is finished, the start date of recruitment was on 9(th) April 2020 and the end date was on 14(th) April 2020. Last point of data collection will be the last day on which all of the 60 participants have had an outcome of clinical improvement or death, completing the study's follow-up time window.Trial registrationThis study was registered with National Institutes of Health Clinical trials (www.clinicaltrials.gov; identification number NCT04343768, registered April 8, 2020 and first available online April 13, 2020).Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Irvani, Seyed Sina Naghibi; Golmohammadi, Maryam; Pourhoseingholi, Mohamad Amin; Shokouhi, Shervin; Darazam, Ilad Alavi] Shahid Beheshti Univ Med Sci, Loghman Hakim Hosp, Dept Infect Dis, Tehran, Iran.
RP Darazam, IA (corresponding author), Shahid Beheshti Univ Med Sci, Loghman Hakim Hosp, Dept Infect Dis, Tehran, Iran.
EM ilad.alavi@sbmu.ac.ir
FU Clinical Research Development Unit (CRDU) of Loghman Hakim Hospital,
   Shahid Beheshti University of Medical Sciences, Tehran, Iran
FX The authors would like to thank the Clinical Research Development Unit
   (CRDU) of Loghman Hakim Hospital, Shahid Beheshti University of Medical
   Sciences, Tehran, Iran for their support.
NR 0
TC 3
Z9 3
U1 3
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 3
PY 2020
VL 21
IS 1
AR 473
DI 10.1186/s13063-020-04382-3
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1YM
UT WOS:000540317300019
PM 32493468
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Maes, B
   Bosteels, C
   De Leeuw, E
   Declercq, J
   Van Damme, K
   Delporte, A
   Demeyere, B
   Vermeersch, S
   Vuylsteke, M
   Willaert, J
   Bolle, L
   Vanbiervliet, Y
   Decuypere, J
   Libeer, F
   Vandecasteele, S
   Peene, I
   Lambrecht, B
AF Maes, Bastiaan
   Bosteels, Cedric
   De Leeuw, Elisabeth
   Declercq, Jozefien
   Van Damme, Karel
   Delporte, Anja
   Demeyere, Benedicte
   Vermeersch, Stefanie
   Vuylsteke, Marnik
   Willaert, Joren
   Bolle, Laura
   Vanbiervliet, Yuri
   Decuypere, Jana
   Libeer, Frederick
   Vandecasteele, Stefaan
   Peene, Isabelle
   Lambrecht, Bart
TI Treatment of severely ill COVID-19 patients with anti-interleukin drugs
   (COV-AID): A structured summary of a study protocol for a randomised
   controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; systemic cytokine
   release syndrome; hypoxic respiratory failure; interleukin 6 blockade;
   interleukin 1 blockade; Anakinra; Siltuximab; Tocilizumab; Acute
   Respiratory Distress Syndrome
AB ObjectivesThe purpose of this study is to test the safety and effectiveness of individually or simultaneously blocking IL-6, IL-6 receptor and IL-1 versus standard of care on blood oxygenation and systemic cytokine release syndrome in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure and systemic cytokine release syndrome.Trial designA phase 3 prospective, multi-center, interventional, open label, 6-arm 2x2 factorial design study.ParticipantsSubjects will be recruited at the specialized COVID-19 wards and/or ICUs at 16 Belgian participating hospitals. Only adult (>= 18y old) patients will be recruited with recent (<= 16 days) COVID-19 infection and acute hypoxia (defined as PaO2/FiO2 below 350mmHg or PaO2/FiO2 below 280 on supplemental oxygen and immediately requiring high flow oxygen device or mechanical ventilation) and signs of systemic cytokine release syndrome characterized by high serum ferritin, or high D-dimers, or high LDH or deep lymphopenia or a combination of those, who have not been on mechanical ventilation for more than 24 hours before randomisation. Patients should have had a chest X-ray and/or CT scan showing bilateral infiltrates within the last 2 days before randomisation. Patients with active bacterial or fungal infection will be excluded.Intervention and comparatorPatients will be randomized to 1 of 5 experimental arms versus usual care. The experimental arms consist of Anakinra alone (anti-IL-1 binding the IL-1 receptor), Siltuximab alone (anti-IL-6 chimeric antibody), a combination of Siltuximab and Anakinra, Tocilizumab alone (humanised anti-IL-6 receptor antibody) or a combination of Anakinra with Tocilizumab in addition to standard care. Patients treated with Anakinra will receive a daily subcutaneous injection of 100mg for a maximum of 28 days or until hospital discharge, whichever comes first. Siltuximab (11mg/kg) or Tocilizumab (8mg/kg, with a maximum dose of 800mg) are administered as a single intravenous injection immediately after randomization.Main outcomesThe primary end point is the time to clinical improvement defined as the time from randomization to either an improvement of two points on a six-category ordinal scale measured daily till day 28 or discharge from the hospital or death. This ordinal scale is composed of (1) Death; (2) Hospitalized, on invasive mechanical ventilation or ECMO; (3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; (4) Hospitalized, requiring supplemental oxygen; (5) Hospitalized, not requiring supplemental oxygen; (6) Not hospitalized.RandomisationPatients will be randomized using an Interactive Web Response System (REDCap). A 2x2 factorial design was selected with a 2:1 randomization regarding the IL-1 blockade (Anakinra) and a 1:2 randomization regarding the IL-6 blockade (Siltuximab and Tocilizumab).Blinding (masking)In this open-label trial neither participants, caregivers, nor those assessing the outcomes are blinded to group assignment.Numbers to be randomised (sample size)A total of 342 participants will be enrolled: 76 patients will receive usual care, 76 patients will receive Siltuximab alone, 76 patients will receive Tocilizumab alone, 38 will receive Anakinra alone, 38 patients will receive Anakinra and Siltuximab and 38 patients will receive Anakinra and Tocilizumab.Trial StatusCOV-AID protocol version 3.0 (15 Apr 2020). Participant recruitment is ongoing and started on April 4(th) 2020.
   Given the current decline of the COVID-19 pandemic in Belgium, it is difficult to anticipate the rate of participant recruitment.Trial registrationThe trial was registered on Clinical Trials.gov on April 1st, 2020 (ClinicalTrials.gov Identifier: NCT04330638) and on EudraCT on April 3rd 2020 (Identifier: 2020-001500-41).Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Maes, Bastiaan; Bosteels, Cedric; De Leeuw, Elisabeth; Declercq, Jozefien; Van Damme, Karel; Delporte, Anja; Demeyere, Benedicte; Vermeersch, Stefanie; Vuylsteke, Marnik; Willaert, Joren; Bolle, Laura; Vanbiervliet, Yuri; Decuypere, Jana; Libeer, Frederick; Vandecasteele, Stefaan; Peene, Isabelle; Lambrecht, Bart] VIB UGent Inflammatie Res Ctr, Ghent, Belgium.
RP Maes, B (corresponding author), VIB UGent Inflammatie Res Ctr, Ghent, Belgium.
EM bastiaan.maes@irc.vib-ugent.be
RI Peene, isabelle/ABA-5213-2020; Lambrecht, Bart N/K-2484-2014
OI Lambrecht, Bart N/0000-0003-4376-6834; De Leeuw,
   Elisabeth/0000-0002-7826-8141; Van Damme, Karel/0000-0002-4379-1047
FU Belgian Health Care Knowledge Centre (KCE, Federaal Kenniscentrum voor
   de Gezondheidszorg)
FX The Belgian Health Care Knowledge Centre (KCE, Federaal Kenniscentrum
   voor de Gezondheidszorg) funds the COV-AID trial and is involved in the
   trial design, data analysis and interpretation and publication.
NR 0
TC 9
Z9 10
U1 3
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 3
PY 2020
VL 21
IS 1
AR 468
DI 10.1186/s13063-020-04453-5
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1YM
UT WOS:000540317300014
PM 32493441
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pirjani, R
   Soori, T
   Dehpour, AR
   Sepidarkish, M
   Moini, A
   Shizarpour, A
   Jafari, RM
AF Pirjani, Reihaneh
   Soori, Tahereh
   Dehpour, Ahmad Reza
   Sepidarkish, Mahdi
   Moini, Ashraf
   Shizarpour, Arshia
   Jafari, Razieh Mohammad
TI Effect of hydroxychloroquine on prevention of COVID-19 virus infection
   among healthcare professionals: a structured summary of a study protocol
   for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; hydroxychloroquine;
   healthcare professionals; prevention
AB ObjectivesComparison of the effect of hydroxychloroquine with placebo to prevent infection from the COVID -19 virus among healthcare professionalsTrial designSingle centre, 2-arm, double-blind randomised (ratio 1:1) placebo-controlled trialParticipantsTreatment staff who are in contact with patients and have at least 3 shifts a week in Arash hospital affiliated with Tehran University of Medical Sciences, in Iran and who consent to participate in the study. Exclusion criteria include: History of COVID -19 virus infection, clinical symptoms such as fever, nausea, dyspnea and myalgia in the past two months, history of underlying diseases hypersensitivity to hydroxychloroquine and G6PD enzyme deficiency.Intervention and comparatorIntervention group: Hydroxychloroquine 200 mg tablet of Amin Pharmaceutical. Control group: placebo which is completely similar in form and taste to 200 mg hydroxychloroquine tablet and is manufactured by the same factory (Amin Pharmacy). The dosage is two tablets daily, once a week for one to three months (based on the duration of the Coronavirus epidemic in Tehran).Main outcomesConfirmed COVID-19 virus infection using Polymerase chain reaction (PCR) test is the primary outcome. The time period for measuring the primary outcome is any infection within the trial period up to one month after taking the last dose.RandomisationThe randomized block allocation method was developed using Stata version 15 software by an independent researcher, using a block size of six. Allocation to the two treatment groups will be conducted by this researcher using paper labels (random 10-digit codes) in a 1:1 ratio t The labels will be attached to the drug packages in order of randomization. Drug packages will be arranged in a box according to the randomization list.Blinding (masking)Participants and caregivers are blinded to group assignment and the data will be analyzed by an independent statistical expert who is unaware of the treatment allocation.Numbers to be randomised (sample size)A total of 282 participants will be randomised with 141 participants the Hydroxychloroquineeach intervention group and 141 participants to the placebo control groupTrial StatusThe protocol version number is 99-1-101-47091 and the approval ID is IR.TUMS.VCR.REC.1399.001 and recruitment began April 7, 2020, and is anticipated to be complete by August 7, 2020.Trial registrationThe name of the trial register is Iranian registry of clinical trial (IRCT), registration number is IRCT20120826010664N6, date of trial registration is April 7, 2020,Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Pirjani, Reihaneh; Moini, Ashraf] Univ Tehran Med Sci, Arash Womens Hosp, Dept Obstet & Gynecol, Tehran, Iran.
   [Soori, Tahereh] Univ Tehran Med Sci, Arash Hosp, Dept Infect Dis, Tehran, Iran.
   [Dehpour, Ahmad Reza] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran.
   [Dehpour, Ahmad Reza] TUMS, Expt Med Res Ctr, Tehan, Iran.
   [Sepidarkish, Mahdi] Babol Univ Med Sci, Sch Publ Hlth, Dept Biostat & Epidemiol, Babol Sar, Iran.
   [Moini, Ashraf] Royan Inst Reprod Biomed, Reprod Epidemiol Res Ctr, Tehran, Iran.
   [Shizarpour, Arshia] Univ Tehran Med Sci, Sch Med, Tehran, Iran.
   [Jafari, Razieh Mohammad] Univ Tehran Med Sci, Expt Med Res Ctr, Tehran, Iran.
RP Pirjani, R (corresponding author), Univ Tehran Med Sci, Arash Womens Hosp, Dept Obstet & Gynecol, Tehran, Iran.
EM pirjani@razi.tums.ac.ir
RI sepidarkish/N-6176-2019
FU Deputy of Research affairs, Tehran University of Medical Sciences,
   Tehran, Iran [99-1-101-47091]
FX This research has been supported by a research grant No: 99-1-101-47091
   from Deputy of Research affairs, Tehran University of Medical Sciences,
   Tehran, Iran.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 3
PY 2020
VL 21
IS 1
AR 467
DI 10.1186/s13063-020-04439-3
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1YM
UT WOS:000540317300013
PM 32493447
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rilinger, J
   Kern, WV
   Duerschmied, D
   Supady, A
   Bode, C
   Staudacher, DL
   Wengenmayer, T
AF Rilinger, Jonathan
   Kern, Winfried V.
   Duerschmied, Daniel
   Supady, Alexander
   Bode, Christoph
   Staudacher, Dawid L.
   Wengenmayer, Tobias
TI A prospective, randomised, double blind placebo-controlled trial to
   evaluate the efficacy and safety of tocilizumab in patients with severe
   COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol
   for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; Tocilizumab;
   IL-6-Rezeptor blockade; Ventilator free days; Inflammation; Pneumonia;
   SARS-CoV2
AB ObjectivesSARS-CoV2 infection leads to a concomitant pulmonary inflammation. This inflammation is supposed to be the main driver in the pathogenesis of lung failure (Acute Respiratory Distress Syndrome) in COVID-19. Objective of this study is to evaluate the efficacy and safety of a single dose treatment with Tocilizumab in patients with severe COVID-19.We hypothesize that Tocilizumab slows down the progression of SARS-CoV-2 induced pneumonia and inflammation. We expect an improvement in pulmonary function compared to placebo-treated patients.Desirable outcomes would be that tocilizumab reduces the number of days that patients are dependent on mechanical ventilation and reduces the invasiveness of breathing assistance. Furthermore, this treatment might result in fewer admissions to intensive care units.Next to these efficacy parameters, safety of a therapy with Tocilizumab in COVID-19 patients has to be monitored closely, since immunosuppression could lead to an increased rate of bacterial infections, which could negatively influence the patient's outcome.Trial designMulticentre, prospective, 2-arm randomised (ratio 1:1), double blind, placebo-controlled trial with parallel group design.
   Participants: Inclusion criteria
   1.Proof of SARS-CoV2 (Symptoms and positive polymerase chain reaction (PCR))Severe respiratory failure: Ambient air SpO(2) <= 92% orNeed of >= 6l O-2/min orNIV (non-invasive ventilation) orIMV (invasive mechanical ventilation)Age >= 18 yearsExclusion criteria 1. Non-invasive or invasive mechanical ventilation >= 48 hours
   2. Pregnancy or breast feeding
   3. Liver injury or failure (AST/ALT >= 5x ULN)
   4.Leukocytes < 2 x 10(3)/mu l
   5.Thrombocytes < 50 x 10(3)/mu l
   6. Severe bacterial infection (PCT > 3ng/ml)
   7. Acute or chronic diverticulitis
   8. Immunosuppressive therapy (e.g. mycophenolate, azathioprine, methotrexate, biologicals, prednisolone >10mg/d; exceptions are: prednisolone <= 10mg/d, sulfasalazine or hydroxychloroquine)
   9. Known active or chronic tuberculosis
   10. Known active or chronic viral hepatitis
   11. Known allergic reactions to tocilizumab or its ingredients
   12. Life expectation of less than 1 year (independent of COVID-19)
   13. Participation in any other interventional clinical trial within the last 30 days before the start of this trial
   14. Simultaneous participation in other interventional trials (except for participation in COVID-19 trials) which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed
   15. Failure to use one of the following safe methods of contraception: female condoms, diaphragm or coil, each used in combination with spermicides; intra-uterine device; hormonal contraception in combination with a mechanical method of contraception.The data collection of the primary follow up (28 days after randomisation) takes place during the hospital stay. Subsequently, a telephone interview on the quality of life is conducted after 6 and 12 months. Participants will be recruited from inpatients at ten medical centres in Germany.Intervention and comparatorIntervention arm: Application of 8mg/kg body weight (BW) Tocilizumab i.v. once immediately after randomisation (12 mg/kg for patients with <30kg BW; total dose should not exceed 800 mg) AND conventional treatment.Control arm: Placebo (NaCl) i.v. once immediately after randomisation AND conventional treatment.Main outcomesPrimary endpoint is the number of ventilator free days (d) (VFD) in the first 28 days after randomisation. Non-invasive ventilation (NIV), Invasive mechanical ventilation (IMV) and extracorporeal membrane oxygenation (ECMO) are defined as ventilator days. VFD's are counted as zero if the patient dies within the first 28 days.RandomisationThe randomisation code will be generated by the CTU (Clinical Trials Unit, ZKS Freiburg) using the following procedure to ensure that treatment assignment is unbiased and concealed from patients and investigator staff. Randomisation will be stratified by centre and will be performed in blocks of variable length in a ratio of 1:1 within each centre. The block lengths will be documented separately and will not be disclosed to the investigators. The randomisation code will be produced by validated programs based on the Statistical Analysis System (SAS).Blinding (masking)Participants, caregivers, and the study team assessing the outcomes are blinded to group assignment.Numbers to be randomised (sample size)100 participants will be randomised to each group (thus 200 participants in total).Trial StatusProtocol Version: V 1.2, 16.04.2020. Recruitment began 27th April 2020 and is anticipated to be completed by December 2020.Trial registrationThe trial was registered before trial start in trial registries (EudraCT: No. 2020-001408-41, registered 21st April 2020, and DRKS: No. DRKS00021238, registered 22nd April 2020).Full protoco lThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Rilinger, Jonathan; Duerschmied, Daniel; Supady, Alexander; Bode, Christoph; Staudacher, Dawid L.; Wengenmayer, Tobias] Univ Freiburg, Fac Med, Med Ctr, Dept Med 3,Interdisciplinary Med Intens Care, Hugstetterstr 55, D-79106 Freiburg, Germany.
   [Rilinger, Jonathan; Duerschmied, Daniel; Supady, Alexander; Bode, Christoph; Staudacher, Dawid L.; Wengenmayer, Tobias] Univ Freiburg, Dept Cardiol & Angiol 1, Heart Ctr Freiburg Univ, Fac Med, Freiburg, Germany.
   [Kern, Winfried V.] Univ Freiburg, Div Infect Dis, Dept Med 2, Med Ctr,Fac Med, Freiburg, Germany.
RP Rilinger, J (corresponding author), Univ Freiburg, Fac Med, Med Ctr, Dept Med 3,Interdisciplinary Med Intens Care, Hugstetterstr 55, D-79106 Freiburg, Germany.; Rilinger, J (corresponding author), Univ Freiburg, Dept Cardiol & Angiol 1, Heart Ctr Freiburg Univ, Fac Med, Freiburg, Germany.
EM jonathan.rilinger@uniklinik-freiburg.de
RI Wengenmayer, Tobias/ABD-7064-2020; Duerschmied, Daniel/K-8182-2015
OI Wengenmayer, Tobias/0000-0002-3659-0407; Duerschmied,
   Daniel/0000-0001-5249-4012
FU German Federal Ministry of Education and Research (BMBF -
   Bundesministerium fur Bildung und Forschung)Federal Ministry of
   Education & Research (BMBF)
FX Funding for this project has been requested at the German Federal
   Ministry of Education and Research (BMBF - Bundesministerium fur Bildung
   und Forschung). The funding does and will not have an influence on the
   design of the study, collection, analysis and interpretation of data and
   in writing the manuscript besides financial support.
NR 0
TC 11
Z9 11
U1 2
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 3
PY 2020
VL 21
IS 1
AR 470
DI 10.1186/s13063-020-04447-3
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY1YM
UT WOS:000540317300016
PM 32493514
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Reifel, KM
   Swan, BK
   Jellison, ER
   Ambrozak, D
   Baijer, J
   Nguyen, R
   Monard, S
   Lyon, G
   Fontes, B
   Perfetto, SP
AF Reifel, Kristen M.
   Swan, Brandon K.
   Jellison, Evan R.
   Ambrozak, David
   Baijer, Jan
   Nguyen, Richard
   Monard, Simon
   Lyon, Geoffrey
   Fontes, Benjamin
   Perfetto, Stephen P.
TI Procedures for Flow Cytometry-Based Sorting of Unfixed Severe Acute
   Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Cells and Other
   Infectious Agents
SO CYTOMETRY PART A
LA English
DT Article
DE biosafety and cell sorting; infectious cell sorting; ISAC Biosafety
   Committee; SARS-CoV-2 cell sorting procedure; COVID-19; coronavirus
ID INTERNATIONAL SOCIETY; HYDROGEN-PEROXIDE; PARTICLE-SIZE; INACTIVATION;
   CONTAINMENT
AB In response to the recent COVID-19 pandemic, many laboratories are involved in research supporting SARS-CoV-2 vaccine development and clinical trials. Flow cytometry laboratories will be responsible for a large part of this effort by sorting unfixed antigen-specific lymphocytes. Therefore, it is critical and timely that we have an understanding of risk assessment and established procedures of infectious cell sorting. Here we present procedures covering the biosafety aspects of sorting unfixed SARS-CoV-2-infected cells and other infectious agents of similar risk level. These procedures follow the ISAC Biosafety Committee guidelines and were recently approved by the National Institutes of Health Institutional Biosafety Committee for sorting SARS-CoV-2-infected cells. (c) 2020 International Society for Advancement of Cytometry
C1 [Reifel, Kristen M.; Swan, Brandon K.] Natl Biodef Anal & Countermeasures Ctr, Frederick, MD USA.
   [Jellison, Evan R.] UConn Hlth, Dept Immunol, Farmington, CT USA.
   [Ambrozak, David; Nguyen, Richard; Perfetto, Stephen P.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Baijer, Jan] CEA DSV IRCM, Fontenay Aux Roses, France.
   [Monard, Simon] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia.
   [Lyon, Geoffrey] Yale Univ, Flow Cytometry Facil, New Haven, CT USA.
   [Fontes, Benjamin] Yale Univ, Environm Hlth & Safety Off, New Haven, CT USA.
RP Perfetto, SP (corresponding author), NIAID, Vaccine Res Ctr, NIH, MDNIH, 40 Convent Dr, Bethesda, MD 20892 USA.
EM sperfetto@nih.gov
RI Swan, Brandon/O-9824-2018; Reifel, Kristen/J-7052-2014
OI Swan, Brandon/0000-0003-0465-1444; Reifel, Kristen/0000-0002-2394-9185
CR ABSA International Emerging Infectious Diseases Consortium, 2020, CONS HANDL POT SARS
   ALFORD RH, 1966, P SOC EXP BIOL MED, V122, P800, DOI 10.3181/00379727-122-31255
   Alvarez-Barrientos A, 2000, CLIN MICROBIOL REV, V13, P167, DOI 10.1128/CMR.13.2.167-195.2000
   CATE TR, 1965, AM J EPIDEMIOL, V81, P95, DOI 10.1093/oxfordjournals.aje.a120501
   CDC-Centers for Disease Control and Prevention, 2020, INT LAB BIOS GUID HA
   Cossarizza A, 2020, CYTOM PART A, V97, P668, DOI 10.1002/cyto.a.24009
   Cossarizza A, 2020, CYTOM PART A, V97, P340, DOI 10.1002/cyto.a.24002
   DAY WC, 1972, INFECT IMMUN, V5, P77, DOI 10.1128/IAI.5.1.77-82.1972
   Holmes KL, 2014, CYTOM PART A, V85, P434, DOI 10.1002/cyto.a.22454
   Holmes KL, 2011, CYTOM PART A, V79A, P1000, DOI 10.1002/cyto.a.21163
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Knight V, 1980, Ann N Y Acad Sci, V353, P147, DOI 10.1111/j.1749-6632.1980.tb18917.x
   Lewis D, 2020, NATURE, V580, P175, DOI 10.1038/d41586-020-00974-w
   Omidbakhsh N, 2006, AM J INFECT CONTROL, V34, P251, DOI 10.1016/j.ajic.2005.06.002
   Perfetto SP, 2003, CYTOM PART A, V52A, P122, DOI 10.1002/cyto.a.10033
   Perfetto SP, 2019, CYTOM PART A, V95A, P173, DOI 10.1002/cyto.a.23680
   Rabenau HF, 2005, MED MICROBIOL IMMUN, V194, P1, DOI 10.1007/s00430-004-0219-0
   Rutala WA, 2012, INFECT CONT HOSP EP, V33, P1159, DOI 10.1086/668014
   Schmid I, 1997, CYTOMETRY, V28, P99, DOI 10.1002/(SICI)1097-0320(19970601)28:2<99::AID-CYTO2>3.0.CO;2-B
   Schmid I, 2007, CYTOM PART A, V71A, P414, DOI 10.1002/cyto.a.20390
   Thomas RJ, 2013, VIRULENCE, V4, P847, DOI 10.4161/viru.27172
   US Department of Health and Human Services Centers for Disease Control and Prevention National Institutes of Health, 2009, HHS PUBL, V(CDC) 21-1112
   Vincent JH, 2005, J ENVIRON MONITOR, V7, P1037, DOI 10.1039/b509617k
   WHO, 2020, COR DIS COVID 19 TEC
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
NR 25
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4922
EI 1552-4930
J9 CYTOM PART A
JI Cytom. Part A
PD JUL
PY 2020
VL 97
IS 7
SI SI
BP 674
EP 680
DI 10.1002/cyto.a.24040
EA JUN 2020
PG 7
WC Biochemical Research Methods; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MN6DX
UT WOS:000539396200001
PM 32488957
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kumar, A
   Pareek, V
   Kant, K
AF Kumar, Ashutosh
   Pareek, Vikas
   Kant, Kamla
TI Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19
   Patients
SO ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
LA English
DT Letter; Early Access
ID VACCINE
C1 [Kumar, Ashutosh; Pareek, Vikas; Kant, Kamla] Etiologically Elus Disorders Res Network EEDRN, New Delhi, India.
   [Kumar, Ashutosh] All India Inst Med Sci AIIMS, Dept Anat, Patna 801505, Bihar, India.
   [Pareek, Vikas] Natl Brain Res Ctr, Manesar, India.
   [Kant, Kamla] All India Inst Med Sci AIIMS, Dept Microbiol, Bathinda, India.
RP Kumar, A (corresponding author), All India Inst Med Sci AIIMS, Dept Anat, Patna 801505, Bihar, India.
EM drashutoshkumar@aiimspatna.org
CR Chaudhry H, 2013, IN VIVO, V27, P669
   Ingraham NE, 2020, LANCET RESP MED, pS2213
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Sharma P, 2000, INT J LEPROSY, V68, P136
   Sharma SK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03514-1
   SINGH IG, 1992, INFECT IMMUN, V60, P257, DOI 10.1128/IAI.60.1.257-263.1992
   Singh S, 2014, INDIAN J DERMATOL VE, V80, P509, DOI 10.4103/0378-6323.144145
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
NR 8
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-658X
EI 1557-8127
J9 ASSAY DRUG DEV TECHN
JI ASSAY DRUG DEV. TECHNOL.
DI 10.1089/adt.2020.994
EA JUN 2020
PG 2
WC Biochemical Research Methods; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA LV1GC
UT WOS:000538189400001
PM 32493028
OA Bronze
DA 2021-01-01
ER

PT J
AU Ibanez, S
   Martinez, O
   Valenzuela, F
   Silva, F
   Valenzuela, O
AF Ibanez, Sebastian
   Martinez, Oriela
   Valenzuela, Francisca
   Silva, Francisco
   Valenzuela, Omar
TI Hydroxychloroquine and chloroquine in COVID-19: should they be used as
   standard therapy?
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Chloroquine; COVID-19; Hydroxychloroquine; SARS-CoV-2
ID TUMOR-NECROSIS-FACTOR; PH-DEPENDENT ENTRY; CHIKUNGUNYA VIRUS;
   INFLUENZA-VIRUS; TNF-ALPHA; CORONAVIRUS; CELL; INHIBITION; GLYCOPROTEIN;
   RESPONSES
AB The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical ventilation and to decrease mortality from coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine are among the proposed drugs and are the most widely used so far, despite the lack of robust evidence on their usefulness. The objective of this article is to review and discuss the possible role of these drugs in the therapy of COVID-19.
C1 [Ibanez, Sebastian; Silva, Francisco; Valenzuela, Omar] Univ Desarrollo, Med Fac Clin Alemana, Av Manquehue Norte 1410,Piso 7, Santiago 7650567, Chile.
   [Ibanez, Sebastian; Martinez, Oriela; Valenzuela, Francisca; Silva, Francisco; Valenzuela, Omar] Padre Hurtado Hosp, Rheumatol Dept, Santiago, Chile.
RP Ibanez, S (corresponding author), Univ Desarrollo, Med Fac Clin Alemana, Av Manquehue Norte 1410,Piso 7, Santiago 7650567, Chile.; Ibanez, S (corresponding author), Padre Hurtado Hosp, Rheumatol Dept, Santiago, Chile.
EM sibanez@alemana.cl
OI Ibanez, Sebastian/0000-0002-9577-3078
CR Accapezzato D, 2005, J EXP MED, V202, P817, DOI 10.1084/jem.20051106
   [Anonymous], LIGHT RAP WID SPREAD, DOI 10.1101/2020.04.08.20054551v1
   [Anonymous], 2020, WHO INT CLIN TRIALS
   [Anonymous], EFF HYDR PAT COVID 1
   Bakkers MJG, 2017, CELL HOST MICROBE, V21, P356, DOI 10.1016/j.chom.2017.02.008
   Borba MG, 2020, CHLOROQUINE DIPHOSPH
   Briant L, 1998, J VIROL, V72, P6207, DOI 10.1128/JVI.72.7.6207-6214.1998
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chorin E, 2020, QT INTERVAL PATIENTS, V2020, DOI [10.1101/2020.04.02.20047050, DOI 10.1101/2020.04.02.20047050]
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Garulli B, 2013, VACCINE, V31, P1717, DOI 10.1016/j.vaccine.2013.01.037
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gay B, 2012, INFECT GENET EVOL, V12, P1275, DOI 10.1016/j.meegid.2012.02.003
   Groupe Veille Coronavirus GVC, 2020, CLIN MICR EFF COMB H
   Hulme OJ, 2020, 2020 BAYESIAN REANAL, DOI [10.1101/2020.03.31.20048777, DOI 10.1101/2020.03.31.20048777]
   Jang CH, 2006, RHEUMATOLOGY, V45, P703, DOI 10.1093/rheumatology/kei282
   Jeong JY, 1997, J IMMUNOL, V158, P4901
   Khan M, 2010, J MED VIROL, V82, P817, DOI 10.1002/jmv.21663
   Kono M, 2008, ANTIVIR RES, V77, P150, DOI 10.1016/j.antiviral.2007.10.011
   Kwiek JJ, 2004, BIOCHEMISTRY-US, V43, P4538, DOI 10.1021/bi035923w
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Olofsson S, 2005, LANCET INFECT DIS, V5, P184, DOI 10.1016/S1473-3099(05)01311-3
   PICOT S, 1993, IMMUNOLOGY, V80, P127
   RANDOLPH VB, 1990, VIROLOGY, V174, P450, DOI 10.1016/0042-6822(90)90099-D
   Rynes RI, 1993, OPHTHALMOLOGIC SAFET, DOI [10.1177/0961203393002001051, DOI 10.1177/0961203393002001051]
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Seitz M, 2003, J CLIN IMMUNOL, V23, P477, DOI 10.1023/B:JOCI.0000010424.41475.17
   Simmons G, 2011, VIROLOGY, V413, P265, DOI 10.1016/j.virol.2011.02.020
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Tricou Vianney, 2010, PLoS Negl Trop Dis, V4, pe785, DOI 10.1371/journal.pntd.0000785
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weber SM, 2000, J IMMUNOL, V165, P1534, DOI 10.4049/jimmunol.165.3.1534
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Zeng QH, 2008, P NATL ACAD SCI USA, V105, P9065, DOI 10.1073/pnas.0800502105
   ZHU X, 1993, IMMUNOLOGY, V80, P122
NR 43
TC 5
Z9 6
U1 1
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD AUG
PY 2020
VL 39
IS 8
BP 2461
EP 2465
DI 10.1007/s10067-020-05202-4
EA JUN 2020
PG 5
WC Rheumatology
SC Rheumatology
GA MF9QW
UT WOS:000537662100001
PM 32495226
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Montastruc, JL
   Toutain, PL
AF Montastruc, Jean-Louis
   Toutain, Pierre-Louis
TI A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A
   Signal Detection Study
SO DRUG SAFETY
LA English
DT Article
AB Introduction Hydroxychloroquine was recently promoted in patients infected with COVID-19 infection. A recent experimental study has suggested an increased toxicity of hydroxychloroquine in association with metformin in mice. Objective The present study was undertaken to investigate the reality of this putative drug-drug interaction between hydroxychloroquine and metformin using pharmacovigilance data. Methods Using VigiBase(R), the WHO pharmacovigilance database, we performed a disproportionality analysis (case/non-case study). Cases were reports of fatal outcomes with the drugs of interest and non-cases were all other reports for these drugs registered between 1 January 2000 and 31 December 2019. Data with hydroxychloroquine (or metformin) alone were compared with the association hydroxychloroquine + metformin. Results are reported as ROR (reporting odds ratio) with their 95% confidence interval. Results Of the 10,771 Individual Case Safety Reports (ICSR) involving hydroxychloroquine, 52 were recorded as 'fatal outcomes'. In comparison with hydroxychloroquine alone, hydroxychloroquine + metformin was associated with an ROR value of 57.7 (23.9-139.3). In comparison with metformin alone, hydroxychloroquine + metformin was associated with an ROR value of 6.0 (2.6-13.8). Conclusion Our study identified a signal for the association hydroxychloroquine + metformin that appears to be more at risk of fatal outcomes (particularly by completed suicides) than one of the two drugs when given alone.
C1 [Montastruc, Jean-Louis] Ctr Hosp Univ, Fac Med, Ctr PharmacoVigilance Pharmacoepidemiol & Informa, Serv Pharmacol Med & Clin, 37 Allees Jules Guesde, F-31000 Toulouse, France.
   [Toutain, Pierre-Louis] Univ Toulouse, INTHERES, INRA, ENVT, Toulouse, France.
   [Toutain, Pierre-Louis] Univ London, Royal Vet Coll, London, England.
RP Montastruc, JL (corresponding author), Ctr Hosp Univ, Fac Med, Ctr PharmacoVigilance Pharmacoepidemiol & Informa, Serv Pharmacol Med & Clin, 37 Allees Jules Guesde, F-31000 Toulouse, France.
EM jean-louis.montastruc@univ-tlse3.fr
CR Bihan Kevin, 2020, Therapie, V75, P591, DOI 10.1016/j.therap.2020.02.022
   Candore G, 2015, DRUG SAFETY, V38, P577, DOI 10.1007/s40264-015-0289-5
   Faillie JL, 2019, THERAPIE, V74, P225, DOI 10.1016/j.therap.2019.01.006
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Lenzer J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1335
   Moore N, 2020, DRUG SAFETY, V43, P393, DOI 10.1007/s40264-020-00933-4
   Moore N, 2019, THERAPIE, V74, P557, DOI 10.1016/j.therap.2019.09.004
   Purkait I, 2019, DIABETES, V68, DOI 10.2337/db19-1189-P
   Rajeshkumar N. V., 2020, BIORXIV, DOI [10.1101/2020.03.31.018556., DOI 10.1101/2020.03.31.018556, 10.1101/2020.03.31.018556]
   Roustit M, 2020, THERAPIE, DOI [10.1016/j.therap.2020.05.010Reference, DOI 10.1016/J.THERAP.2020.05.010REFERENCE]
   Seabroke S, 2016, DRUG SAFETY, V39, P355, DOI 10.1007/s40264-015-0388-3
   Tan MKX, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040323
   van Puijenbroek EP, 2000, EUR J CLIN PHARMACOL, V56, P733, DOI 10.1007/s002280000215
   Vinetz JM, 2018, GOODMAN GILMANS PHAR, P968
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD JUL
PY 2020
VL 43
IS 7
BP 657
EP 660
DI 10.1007/s40264-020-00955-y
EA JUN 2020
PG 4
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA LZ5CB
UT WOS:000537668100001
PM 32495148
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gopinathannair, R
   Merchant, FM
   Lakkireddy, DR
   Etheridge, SP
   Feigofsky, S
   Han, JK
   Kabra, R
   Natale, A
   Poe, S
   Saha, SA
   Russo, AM
AF Gopinathannair, Rakesh
   Merchant, Faisal M.
   Lakkireddy, Dhanunjaya R.
   Etheridge, Susan P.
   Feigofsky, Suzy
   Han, Janet K.
   Kabra, Rajesh
   Natale, Andrea
   Poe, Stacy
   Saha, Sandeep A.
   Russo, Andrea M.
TI COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia
   characteristics and management strategies
SO JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Arrhythmia; Cardiac arrhythmia; QTc
ID PNEUMONIA
AB Background Cardiovascular and arrhythmic events have been reported in hospitalized COVID-19 patients. However, arrhythmia manifestations and treatment strategies used in these patients have not been well-described. We sought to better understand the cardiac arrhythmic manifestations and treatment strategies in hospitalized COVID-19 patients through a worldwide cross-sectional survey. Methods The Heart Rhythm Society (HRS) sent an online survey (via SurveyMonkey) to electrophysiology (EP) professionals (physicians, scientists, and allied professionals) across the globe. The survey was active from March 27 to April 13, 2020. Results A total of 1197 respondents completed the survey with 50% of respondents from outside the USA, representing 76 countries and 6 continents. Of respondents, 905 (76%) reported having COVID-19-positive patients in their hospital. Atrial fibrillation was the most commonly reported tachyarrhythmia whereas severe sinus bradycardia and complete heart block were the most common bradyarrhythmias. Ventricular tachycardia/ventricular fibrillation arrest and pulseless electrical activity were reported by 4.8% and 5.6% of respondents, respectively. There were 140 of 631 (22.2%) respondents who reported using anticoagulation therapy in all COVID-19-positive patients who did not otherwise have an indication. One hundred fifty-five of 498 (31%) reported regular use of hydroxychloroquine/chloroquine (HCQ) + azithromycin (AZM); concomitant use of AZM was more common in the USA. Sixty of 489 respondents (12.3%) reported having to discontinue therapy with HCQ + AZM due to significant QTc prolongation and 20 (4.1%) reported cases of Torsade de Pointes in patients on HCQ/chloroquine and AZM. Amiodarone was the most common antiarrhythmic drug used for ventricular arrhythmia management. Conclusions In this global survey of > 1100 EP professionals regarding hospitalized COVID-19 patients, a variety of arrhythmic manifestations were observed, ranging from benign to potentially life-threatening. Observed adverse events related to use of HCQ + AZM included prolonged QTc requiring drug discontinuation as well as Torsade de Pointes. Large prospective studies to better define arrhythmic manifestations as well as the safety of treatment strategies in COVID-19 patients are warranted.
C1 [Gopinathannair, Rakesh; Lakkireddy, Dhanunjaya R.] Kansas City Heart Rhythm Inst & Res Fdn, 5100 W 110th St,Ste 200, Overland Pk, KS 66211 USA.
   [Gopinathannair, Rakesh; Lakkireddy, Dhanunjaya R.] Univ Missouri, Columbia, MO 65211 USA.
   [Merchant, Faisal M.] Emory Univ, Sch Med, Atlanta, GA USA.
   [Etheridge, Susan P.] Univ Utah, Salt Lake City, UT USA.
   [Feigofsky, Suzy] Iowa Heart Ctr, Des Moines, IA USA.
   [Han, Janet K.] Univ Calif Los Angeles, Cardiac Arrhythmia Ctr, Los Angeles, CA USA.
   [Han, Janet K.] VA Greater Los Healthcare Ctr, Los Angeles, CA USA.
   [Kabra, Rajesh] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA.
   [Natale, Andrea] Texas Cardiac Arrhythmia Inst, Austin, TX USA.
   [Poe, Stacy] Cleveland Clin, Cleveland, OH 44106 USA.
   [Saha, Sandeep A.] Oregon Heart Ctr, Salem, OR USA.
   [Russo, Andrea M.] Cooper Univ Hosp, Camden, NJ USA.
RP Gopinathannair, R (corresponding author), Kansas City Heart Rhythm Inst & Res Fdn, 5100 W 110th St,Ste 200, Overland Pk, KS 66211 USA.; Gopinathannair, R (corresponding author), Univ Missouri, Columbia, MO 65211 USA.
EM drrakeshg@yahoo.com
RI Natale, Andrea/ABE-7273-2020
FU Heart Rhythm Society
FX The authors would like to convey their sincere appreciation to all the
   arrhythmia professionals who shared their experience by completing this
   survey as well to the Heart Rhythm Society for supporting this endeavor.
CR [Anonymous], 2020, COV 19 INT MAP
   Borba MG, 2020, CHLOROQUINE DIPHOSPH
   Centers for Disease Control and Prevention, 2020, INT CLIN GUID MAN PA
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Guo T, 2020, JAMA CARDIOL
   Kochi AN, 2020, J CARDIOVASC ELECTR, V31, P1003, DOI 10.1111/jce.14479
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Onder G, 2020, JAMA
   Shi S, 2020, JAMA CARDIOL
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Worldometer, 2020, COR CAS
   Yao X, 2020, CLIN INFECT DIS
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 15
TC 4
Z9 5
U1 2
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1383-875X
EI 1572-8595
J9 J INTERV CARD ELECTR
JI J. Interv. Card. Electrophysiol.
PD NOV
PY 2020
VL 59
IS 2
BP 329
EP 336
DI 10.1007/s10840-020-00789-9
EA JUN 2020
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OK5YF
UT WOS:000537652900002
PM 32494896
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Al-Omar, K
   Bakkar, S
   Khasawneh, L
   Donatini, G
   Miccoli, P
AF Al-Omar, Khaled
   Bakkar, Sohail
   Khasawneh, Laith
   Donatini, Gianluca
   Miccoli, Paolo
TI Resuming elective surgery in the time of COVID-19: a safe and
   comprehensive strategy
SO UPDATES IN SURGERY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Pandemic; Elective surgery
AB The 2019 novel corona virus and the disease it causes (COVID-19) is a public health crisis that has profoundly modified the way medical and surgical care is delivered. Countries around the globe had a variable initial response to the COVID-19 pandemic from imposing massive lock downs and quarantine to surrendering to herd immunity. However, healthcare bodies worldwide recognized early on that a triumph against COVID-19 could only be achieved by maintaining the infrastructure of healthcare systems and their capacity to accommodate a potentially overwhelming increase in critical patient care needs. Therefore, they reacted by restricting medical care to emergency cases and postponing elective surgical procedures in all disciplines. The priority was made for treatment of COVID-19 patients and emergency cases. Nevertheless, the battle against the COVID-19 pandemic is still ongoing. In the absence of vaccines or effective drug treatments, its timeline remains uncertain and it cannot be forecast how long healthcare systems will need to cope with it in managing inpatient and outpatient services. Accordingly, extreme measures and restriction may become a recipe for a disaster in the context of the potential adverse health implications imposed by delaying timely medical and surgical care. Therefore, restrictive measures should be substituted with a comprehensive surgical and medical care strategy. One that provides a safe balance between the prevention of COVID-19 and the delivery of essential surgical care. This article provides an overview on how to safely deliver essential surgical care in the time of COIVD-19.
C1 [Al-Omar, Khaled; Bakkar, Sohail; Khasawneh, Laith] Hashemite Univ, Fac Med, Dept Surg, Zarqa 13133, Jordan.
   [Donatini, Gianluca] Univ Poitiers, Dept Gen & Endocrine Surg, Poitiers, France.
   [Miccoli, Paolo] Univ Pisa, Dept Surg Med Pathol & Crit Care, I-56124 Pisa, Italy.
RP Bakkar, S (corresponding author), Hashemite Univ, Fac Med, Dept Surg, Zarqa 13133, Jordan.
EM sohail.bakkar@gmail.com
RI Bakkar, Sohail/I-9838-2019
OI Bakkar, Sohail/0000-0001-8479-5901
CR Adhanom Ghebreyesus T, 2020, COMMUNICATION
   American College of Surgeons (ACS), 2020, COVID 19 UPD GUID TR
   American Society of Anesthesiologists (ASA) and the Anesthesia Patient Safety foundation (APSF), 2020, ASA APSF JOINT STAT
   Aminian A, 2020, ANN SURG, V272, pE27, DOI 10.1097/SLA.0000000000003925
   [Anonymous], 2020, COVID 19 COR VIR PAN
   Centers for Disease Control and Prevention, 2020, DISC TRANSM BAS PREC
   Centers for Disease Control and Prevention, 2016, OV INFL SURV US
   Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases (NCIRD), 2020, TRANSM BAS PREC
   Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases (NCIRD), 2020, CLEAN DIS YOUR FAC
   Commins J, 2020, HLTH LEADERS
   Frost W, 1920, PUBLIC HLTH REP, V35, P584, DOI [DOI 10.2307/4575511, 10.2307/4575511]
   Jordan Edwin O., 1927, EPIDEMIC INFLUENZA S
   Mareiniss DP, 2009, AM J DISASTER MED, V4, P163, DOI [10.5055/ajdm.2009.0025, DOI 10.5055/AJDM.2009.0025]
   Matrajt L, 2020, EMERG INFECT DIS, V26, P1740, DOI 10.3201/eid2608.201093
   Meltzer MI, 2007, NATL VACCINE PROGRAM
   Meltzer MI, 2007, FLUSURGE SOFTWARE
   Stahel PF, 2020, PATIENT SAF SURG, V14, DOI 10.1186/s13037-020-00235-9
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Younes A, 2020, ENCY NEWS
NR 20
TC 2
Z9 2
U1 2
U2 4
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 2038-131X
EI 2038-3312
J9 UPDATES SURG
JI Updates Surg.
PD JUN
PY 2020
VL 72
IS 2
BP 291
EP 295
DI 10.1007/s13304-020-00822-6
EA JUN 2020
PG 5
WC Surgery
SC Surgery
GA MF1YM
UT WOS:000537656000003
PM 32495280
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hammami, MB
   Garibaldi, B
   Shah, P
   Liu, G
   Jain, T
   Chen, PH
   Kim, AK
   Avdic, E
   Petty, B
   Strout, S
   Fine, DM
   Niranjan-Azadi, A
   Garneau, WM
   Cameron, AM
   Trujillo, JMM
   Gurakar, A
   Avery, R
AF Hammami, Muhammad Baraa
   Garibaldi, Brian
   Shah, Pali
   Liu, Gigi
   Jain, Tania
   Chen, Po-Hung
   Kim, Amy K.
   Avdic, Edina
   Petty, Brent
   Strout, Sara
   Fine, Derek M.
   Niranjan-Azadi, Ashwini
   Garneau, William M.
   Cameron, Andrew M.
   Trujillo, Jose M. Monroy
   Gurakar, Ahmet
   Avery, Robin
TI Clinical course of COVID-19 in a liver transplant recipient on
   hemodialysis and response to tocilizumab therapy: A case report
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical research; practice; immunosuppressant - calcineurin inhibitor;
   tacrolimus; immunosuppression; immune modulation; infection and
   infectious agents - viral; infectious disease; liver transplantation;
   hepatology
AB The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease. There are limited published data on the epidemiology and outcomes of COVID-19 infection among organ transplant recipients. After initial flulike symptoms, progression to an inflammatory phase may occur, characterized by cytokine release rapidly leading to respiratory and multiorgan failure. We report the clinical course and management of a liver transplant recipient on hemodialysis, who presented with COVID-19 pneumonia, and despite completing a 5-day course of hydroxychloroquine, later developed marked inflammatory manifestations with rapid improvement after administration of off-label, single-dose tocilizumab. We also highlight the role of lung ultrasonography in early diagnosis of the inflammatory phase of COVID-19. Future investigation of the effects of immunomodulators among transplant recipients with COVID-19 infection will be important.
C1 [Hammami, Muhammad Baraa; Chen, Po-Hung; Kim, Amy K.; Gurakar, Ahmet] Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Baltimore, MD 21205 USA.
   [Garibaldi, Brian; Shah, Pali] Johns Hopkins Univ, Sch Med, Dept Med, Div Pulmonol & Crit Care, Baltimore, MD 21205 USA.
   [Liu, Gigi; Niranjan-Azadi, Ashwini; Garneau, William M.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Jain, Tania] Johns Hopkins Univ, Sch Med, Bone Marrow Transplantat Program, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.
   [Avdic, Edina; Strout, Sara] Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD 21287 USA.
   [Petty, Brent] Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Pharmacol, Baltimore, MD 21205 USA.
   [Fine, Derek M.; Trujillo, Jose M. Monroy] Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA.
   [Cameron, Andrew M.] Johns Hopkins Univ, Sch Med, Dept Surg, Div Transplant Surg, Baltimore, MD 21205 USA.
   [Avery, Robin] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.
RP Avery, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.
EM ravery4@jhmi.edu
RI Chen, Po-Hung/ABD-1749-2020; Jain, Tania/F-2784-2019
OI Chen, Po-Hung/0000-0002-9865-1009; Garibaldi, Brian/0000-0001-8632-5567;
   Jain, Tania/0000-0001-6854-773X; Liu, Gigi/0000-0002-6407-1874
FU NIAAA NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse
   & Alcoholism (NIAAA) [K23 AA028297] Funding Source: Medline
CR Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Fishman JA, 2020, AM J TRANSPLANT, V20, P1765, DOI 10.1111/ajt.15890
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Gardner RA, 2019, BLOOD, V134, P2149, DOI 10.1182/blood.2019001463
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hinton D, 2020, FDA EMERGENCY USE AU
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846
   Peng QY, 2020, INTENS CARE MED, V46, P849, DOI 10.1007/s00134-020-05996-6
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 19
TC 19
Z9 19
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD AUG
PY 2020
VL 20
IS 8
BP 2254
EP 2259
DI 10.1111/ajt.15985
EA JUN 2020
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MS1DI
UT WOS:000537250300001
PM 32359210
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Becerra-Flores, M
   Cardozo, T
AF Becerra-Flores, Manuel
   Cardozo, Timothy
TI SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article
AB Aim The COVID-19 pandemic is caused by infection with the SARS-CoV-2 virus. The major mutation detected to date in the SARS-CoV-2 viral envelope spike protein, which is responsible for virus attachment to the host and is also the main target for host antibodies, is a mutation of an aspartate (D) at position 614 found frequently in Chinese strains to a glycine (G). We sought to infer health impact of this mutation.
   Result Increased case fatality rate correlated strongly with the proportion of viruses bearing G614 on a country by country basis. The amino acid at position 614 occurs at an internal protein interface of the viral spike, and the presence of G at this position was calculated to destabilise a specific conformation of the viral spike, within which the key host receptor binding site is more accessible.
   Conclusion These results imply that G614 is a more pathogenic strain of SARS-CoV-2, which may influence vaccine design. The prevalence of this form of the virus should also be included in epidemiologic models predicting the COVID-19 health burden and fatality over time in specific regions. Physicians should be aware of this characteristic of the virus to anticipate the clinical course of infection.
C1 [Becerra-Flores, Manuel; Cardozo, Timothy] NYU Langone Hlth, Dept Biochem & Mol Pharmacol, New York, NY USA.
RP Cardozo, T (corresponding author), NYU Langone Hlth, 550 First Ave, New York, NY 10016 USA.
EM cardot01@nyumc.org
CR ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052
   Acosta PL, 2016, CLIN VACCINE IMMUNOL, V23, P189, DOI 10.1128/CVI.00609-15
   Cardozo T, 2016, BIOL TREAT SUBSTANCE, P75
   Roser M, 2020, CORONAVIRUS DIS COVI
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xue M, 2019, P NATL ACAD SCI USA, V116, P21031, DOI 10.1073/pnas.1911181116
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
NR 9
TC 34
Z9 34
U1 7
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
PD AUG
PY 2020
VL 74
IS 8
AR e13525
DI 10.1111/ijcp.13525
EA JUN 2020
PG 4
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA MT3YU
UT WOS:000537353100001
PM 32374903
OA Other Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU EL-Arabey, AA
   Abdalla, M
AF EL-Arabey, Amr Ahmed
   Abdalla, Mohnad
TI Metformin and COVID-19: A novel deal of an old drug
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter
C1 [EL-Arabey, Amr Ahmed] Al Azhar Univ, Fac Pharm, Dept Pharmacol & Toxicol, Cairo, Egypt.
   [Abdalla, Mohnad] Chinese Acad Sci, Qingdao Inst Bioenergy & Bioproc Technol, Dept Biol, Qingdao 266101, Shandong, Peoples R China.
   [Abdalla, Mohnad] Shandong Prov Key Lab Synthet Biol, Qingdao 266101, Shandong, Peoples R China.
RP EL-Arabey, AA (corresponding author), Al Azhar Univ, Fac Pharm, Dept Pharmacol & Toxicol, Cairo, Egypt.; Abdalla, M (corresponding author), Chinese Acad Sci, Qingdao Inst Bioenergy & Bioproc Technol, Dept Biol, Qingdao 266101, Shandong, Peoples R China.; Abdalla, M (corresponding author), Shandong Prov Key Lab Synthet Biol, Qingdao 266101, Shandong, Peoples R China.
EM ph.amrcapa@gmail.com; mohnadabdalla200@gmail.com
RI Abdalla, Mohnad/AAH-6532-2020; El-Arabey, Amr Ahmed/I-1884-2019
OI Abdalla, Mohnad/0000-0002-1682-5547; El-Arabey, Amr
   Ahmed/0000-0003-0420-7191
CR Bailey CJ, 2017, DIABETOLOGIA, V60, P1566, DOI 10.1007/s00125-017-4318-z
   Chen Y, 2018, CHINESE MED J-PEKING, V131, P376, DOI 10.4103/0366-6999.223856
   Dietz W, 2020, OBESITY, V28, P1005, DOI 10.1002/oby.22818
   El-Arabey AA, 2019, ADV PHARM BULL, V9, P1, DOI 10.15171/apb.2019.001
   El-Arabey AA, 2018, PRIM CARE DIABETES, V12, P284, DOI 10.1016/j.pcd.2018.02.004
   Eric M, 2018, EUR RESP J S62, V52
   Lai ChihCheng, 2020, International Journal of Antimicrobial Agents, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Wu TD, 2019, ANN AM THORAC SOC, V16, P1527, DOI 10.1513/AnnalsATS.201812-897OC
NR 9
TC 7
Z9 7
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2293
EP 2294
DI 10.1002/jmv.25958
EA JUN 2020
PG 2
WC Virology
SC Virology
GA NU0EN
UT WOS:000537231200001
PM 32347974
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Maghzi, AH
   Houtchens, MK
   Preziosa, P
   Ionete, C
   Beretich, BD
   Stankiewicz, JM
   Tauhid, S
   Cabot, A
   Berriosmorales, I
   Schwartz, THW
   Sloane, JA
   Freedman, MS
   Filippi, M
   Weiner, HL
   Bakshi, R
AF Maghzi, Amir Hadi
   Houtchens, Maria K.
   Preziosa, Paolo
   Ionete, Carolina
   Beretich, Biljana D.
   Stankiewicz, James M.
   Tauhid, Shahamat
   Cabot, Ann
   Berriosmorales, Idanis
   Schwartz, Tamara H. W.
   Sloane, Jacob A.
   Freedman, Mark S.
   Filippi, Massimo
   Weiner, Howard L.
   Bakshi, Rohit
TI COVID-19 in teriflunomide-treated patients with multiple sclerosis
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE Multiple sclerosis; COVID-19; Coronavirus; Teriflunomide; Antiviral
AB The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.
C1 [Maghzi, Amir Hadi; Houtchens, Maria K.; Stankiewicz, James M.; Tauhid, Shahamat; Weiner, Howard L.; Bakshi, Rohit] Harvard Med Sch, Partners Multiple Sclerosis Ctr, Brigham & Womens Hosp, Dept Neurol,Ann Romney Ctr Neurol Dis, 60 Fenwood Rd,Mailbox 9002L, Boston, MA 02115 USA.
   [Preziosa, Paolo; Filippi, Massimo] IRCCS San Raffaele Sci Inst, Neurol Unit, Milan, Italy.
   [Ionete, Carolina; Berriosmorales, Idanis] Univ Massachusetts, Dept Neurol, Worcester, MA 01605 USA.
   [Beretich, Biljana D.; Schwartz, Tamara H. W.] Maine Med Ctr, Dept Neurol, Portland, ME 04102 USA.
   [Cabot, Ann] Concord Hosp, Dept Neurol, Concord, NH USA.
   [Sloane, Jacob A.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02115 USA.
   [Freedman, Mark S.] Univ Ottawa, Ottawa, ON, Canada.
   [Freedman, Mark S.] Ottawa Hosp Res Inst, Ottawa, ON, Canada.
   [Filippi, Massimo] Univ Vita Salute San Raffaele, Milan, Italy.
RP Bakshi, R (corresponding author), Harvard Med Sch, Partners Multiple Sclerosis Ctr, Brigham & Womens Hosp, Dept Neurol,Ann Romney Ctr Neurol Dis, 60 Fenwood Rd,Mailbox 9002L, Boston, MA 02115 USA.
EM rbakshi@post.harvard.edu
RI Filippi, Massimo/K-1755-2018; Preziosa, Paolo/J-9980-2016
OI Filippi, Massimo/0000-0002-5485-0479; Preziosa,
   Paolo/0000-0002-7826-0019
FU National Multiple Sclerosis SocietyNational Multiple Sclerosis Society;
   American Brain Foundation
FX AH Maghzi is supported by a clinician-scientist development fellowship
   from the National Multiple Sclerosis Society and American Brain
   Foundation.
CR Bar-Or A, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000070
   Bar-Or A, 2014, DRUGS, V74, P659, DOI 10.1007/s40265-014-0212-x
   Bar-Or A, 2013, NEUROLOGY, V81, P552, DOI 10.1212/WNL.0b013e31829e6fbf
   Barry B, 2019, NEUROL THER, V8, P241, DOI 10.1007/s40120-019-00160-9
   Barzegar M, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000753
   Bilger A, 2017, ONCOTARGET, V8, P44266, DOI 10.18632/oncotarget.17863
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   Gilli F, 2017, J NEUROVIROL, V23, P825, DOI 10.1007/s13365-017-0570-8
   Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073
   Gong MJ, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109305
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Karamyan A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155795
   Kim W, 2013, EUR J NEUROL, V20, P975, DOI 10.1111/ene.12132
   Lebrun C, 2015, REV NEUROL-FRANCE, V171, P698, DOI 10.1016/j.neurol.2015.05.001
   Luna G, 2020, JAMA NEUROL, V77, P184, DOI 10.1001/jamaneurol.2019.3365
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1252
   Martini S, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0570-1
   Montgomery S, 2013, EUR J NEUROL, V20, P1153, DOI 10.1111/ene.12130
   Novi G, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102120
   Pinti M, 2016, EUR J IMMUNOL, V46, P2286, DOI 10.1002/eji.201546178
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Steelman AJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00520
   Wallin MT, 2019, NEUROLOGY, V92, pE1029, DOI 10.1212/WNL.0000000000007035
   Warnke C, 2013, CLIN NEUROL NEUROSUR, V115, pS90, DOI 10.1016/j.clineuro.2013.09.030
   Xiong R., 2020, BIORXIV, DOI [10.1101/2020.03.11.983056, DOI 10.1101/2020.03.11.983056]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 29
TC 7
Z9 7
U1 1
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD OCT
PY 2020
VL 267
IS 10
BP 2790
EP 2796
DI 10.1007/s00415-020-09944-8
EA JUN 2020
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA NQ3MO
UT WOS:000537643800005
PM 32494856
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Guidon, AC
   Amato, AA
AF Guidon, Amanda C.
   Amato, Anthony A.
TI COVID-19 and neuromuscular disorders
SO NEUROLOGY
LA English
DT Article
ID GUILLAIN-BARRE-SYNDROME; INFLUENZA-A H1N1; ACUTE-RENAL-FAILURE;
   TELENEUROLOGY CURRICULUM; RESPIRATORY SYNDROME; CHLOROQUINE; RISK;
   RHABDOMYOLYSIS; VACCINATION; VACCINES
AB The coronavirus 2019 (COVID-19) pandemic has potential to disproportionately and severely affect patients with neuromuscular disorders. In a short period of time, it has already caused reorganization of neuromuscular clinical care delivery and education, which will likely have lasting effects on the field. This article reviews (1) potential neuromuscular complications of COVID-19, (2) assessment and mitigation of COVID-19-related risk for patients with preexisting neuromuscular disease, (3) guidance for management of immunosuppressive and immunomodulatory therapies, (4) practical guidance regarding neuromuscular care delivery, telemedicine, and education, and (5) effect on neuromuscular research. We outline key unanswered clinical questions and highlight the need for team-based and interspecialty collaboration. Primary goals of clinical research during this time are to develop evidence-based best practices and to minimize morbidity and mortality related to COVID-19 for patients with neuromuscular disorders.
C1 [Guidon, Amanda C.] Massachusetts Gen Hosp, Dept Neurol, Div Neuromuscular Med, Boston, MA 02114 USA.
   [Amato, Anthony A.] Harvard Med Sch, Div Neuromuscular Med, Dept Neurol, Brigham & Womans Hosp, Boston, MA 02115 USA.
RP Guidon, AC (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Div Neuromuscular Med, Boston, MA 02114 USA.; Amato, AA (corresponding author), Harvard Med Sch, Div Neuromuscular Med, Dept Neurol, Brigham & Womans Hosp, Boston, MA 02115 USA.
EM aguidon@partners.org; aamato@bwh.harvard.edu
CR Afshari M, 2019, NEUROLOGY, V93, P170, DOI 10.1212/WNL.0000000000007848
   Algahtani H, 2016, CASE REP NEUROL MED, DOI 10.1155/2016/3502683
   [Anonymous], 2020, WHO VACCINE BLUEPRIN
   [Anonymous], 2020, ANEM COVID WEBSITE
   [Anonymous], 2020, NUMOTION
   Arabi YM, 2015, INFECTION, V43, P495, DOI 10.1007/s15010-015-0720-y
   Arabi YM, 2019, INT J INFECT DIS, V81, P184, DOI 10.1016/j.ijid.2019.01.041
   Arenas-Pinto A, 2016, J NEUROVIROL, V22, P104, DOI 10.1007/s13365-015-0374-7
   Association of British Neurologists Guidance on COVID-19 for people with neurological conditions their doctors and carers [internet]., 2020, ASS BRIT NEUR GUID C
   Benveniste O, 1999, CLIN INFECT DIS, V28, P1180, DOI 10.1086/517777
   Cao B, N ENGL J MED
   Chen LL, 2005, INT J CLIN PRACT, V59, P1162, DOI 10.1111/j.1368-5031.2005.00540.x
   Cheng CH, 2002, AM J HEALTH-SYST PH, V59, P728, DOI 10.1093/ajhp/59.8.728
   Cohen BH, 2020, CONTINUUM MINNEAP MI, V26, P1
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Crawford NW, 2012, MED J AUSTRALIA, V197, P574, DOI 10.5694/mja12.10534
   de Kanter CTMM, 2011, ANTIVIR THER, V16, P435, DOI 10.3851/IMP1747
   De Wals P, 2012, JAMA-J AM MED ASSOC, V308, P175, DOI 10.1001/jama.2012.7342
   Dodd CN, 2013, VACCINE, V31, P4448, DOI 10.1016/j.vaccine.2013.06.032
   Donelan K, 2019, AM J MANAG CARE, V25, P40
   Doughty Christopher T, 2019, Continuum (Minneap Minn), V25, P1712, DOI 10.1212/CON.0000000000000806
   EADIE MJ, 1966, J NEUROL NEUROSUR PS, V29, P331, DOI 10.1136/jnnp.29.4.331
   Ellis RJ, 2008, ANN NEUROL, V64, P566, DOI 10.1002/ana.21484
   Estes M L, 1987, Am J Med, V82, P447, DOI 10.1016/0002-9343(87)90444-X
   Fan Cheng-Kuo, 2006, Journal of Microbiology Immunology and Infection, V39, P45
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Galeotti F, 2013, EUR J EPIDEMIOL, V28, P433, DOI 10.1007/s10654-013-9797-8
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Govindarajan R, 2017, NEUROLOGY, V89, P951, DOI 10.1212/WNL.0000000000004285
   Grave C, NEUROLOGY
   Greene SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067185
   Greene SK, 2012, AM J EPIDEMIOL, V175, P1100, DOI 10.1093/aje/kws195
   Guastalegname M, CLIN INFECT DIS
   Gummi RR, 2019, MUSCLE NERVE, V60, P693, DOI 10.1002/mus.26689
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jacob S, 2020, J NEUROL SCI, V412, DOI 10.1016/j.jns.2020.116803
   Jallouli M, 2012, J NEUROL, V259, P1290, DOI 10.1007/s00415-011-6335-z
   Joyce E, 2013, EUR HEART J-ACUTE CA, V2, P77, DOI 10.1177/2048872612471215
   Keesara S, N ENGL J MED
   Kim JE, 2017, J CLIN NEUROL, V13, P227, DOI 10.3988/jcn.2017.13.3.227
   Kwong JC, 2013, LANCET INFECT DIS, V13, P769, DOI 10.1016/S1473-3099(13)70104-X
   Leung TW, 2005, ARCH NEUROL-CHICAGO, V62, P1113, DOI 10.1001/archneur.62.7.1113
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lurie N, 2020, N ENGL J MED
   Martinez MA, ANTIMICROB AGENTS CH
   MASTAGLIA FL, 1977, J NEUROL SCI, V34, P315, DOI 10.1016/0022-510X(77)90149-6
   Ming JBM, 2003, AIDS PATIENT CARE ST, V17, P207, DOI 10.1089/108729103321655854
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Paganoni S, 2019, MUSCLE NERVE, V59, P3, DOI 10.1002/mus.26311
   Polakowski LL, 2013, AM J EPIDEMIOL, V178, P962, DOI 10.1093/aje/kwt051
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Salmon DA, 2013, LANCET, V381, P1461, DOI 10.1016/S0140-6736(12)62189-8
   Schwamm LH, 2017, CIRCULATION, V135, pE24, DOI 10.1161/CIR.0000000000000475
   Sharma K, 2019, SAGE OPEN MED CASE R, V7, DOI 10.1177/2050313X19838750
   Torbic H, 2019, J CRIT CARE, V49, P179, DOI 10.1016/j.jcrc.2018.10.019
   Tsai LK, 2004, ARCH NEUROL-CHICAGO, V61, P1669, DOI 10.1001/archneur.61.11.1669
   Turgay C, 2015, J PEDIATR NEUROSCI, V10, P280, DOI 10.4103/1817-1745.165716
   Varan O, 2015, REUMATISMO, V67, P125
   Vermaak JR, 2015, AIDS RES THER, V12, DOI 10.1186/s12981-015-0073-8
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang JT, 2004, EMERG INFECT DIS, V10, P818, DOI 10.3201/eid1005.030640
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wasay M, 1998, NEUROLOGY, V51, P1226, DOI 10.1212/WNL.51.4.1226
   WHO, 2020, CLIN MAN SEV AC RESP, P1
   Zhao H, 2020, LANCET NEUROL
NR 65
TC 34
Z9 34
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JUN 2
PY 2020
VL 94
IS 22
BP 959
EP 969
DI 10.1212/WNL.0000000000009566
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA MM1TP
UT WOS:000549941600005
PM 32284362
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Garzotto, F
   Ceresola, E
   Panagiotakopoulou, S
   Spina, G
   Menotto, F
   Benozzi, M
   Casarotto, M
   Lanera, C
   Bonavina, MG
   Gregori, D
   Meneghesso, G
   Opocher, G
AF Garzotto, Francesco
   Ceresola, Erica
   Panagiotakopoulou, Sofia
   Spina, Giovanni
   Menotto, Francesca
   Benozzi, Marco
   Casarotto, Maurizio
   Lanera, Corrado
   Bonavina, Maria Giuseppina
   Gregori, Dario
   Meneghesso, Gaudenzio
   Opocher, Giuseppe
TI COVID-19: ensuring our medical equipment can meet the challenge
SO EXPERT REVIEW OF MEDICAL DEVICES
LA English
DT Article
DE Covid-19; medical devices; equipments; regulatory; healthcare
ID CRITICALLY-ILL PATIENTS; THERAPY
AB To predict the spread of coronavirus disease globally and consequently prepare the hospital facilities with the required technology is a challenge. The availability of essential medical equipment to support patients affected by Covid-19 is globally limited. Areas covered This perspective gives a technical view of the pandemic focusing on the main actions taken by regulatory agencies to cope with the shortage of devices. The risk/benefit assessment and the main infection control policies in the clinical practices are also looked at. Expert opinion Regulatory agencies have amended their medical devices directives to address the pandemic, but each in a different way. In this exceptional situation scientist and technology experts in collaboration with medical specialists should work together to re-assess the risk analysis on medical equipment management and their use and re-use in this context with the aim to improve global health care Every effort must be made to provide the necessary devices at least with the minimum acceptable performances for Covid-19 patients while maintaining a high standard of safety for users. The aim of the present manuscript is to highlight the technical challenges in order to prevent, through targeted actions, operating standards from falling below the standards of care due to a lack of medical devices.
C1 [Garzotto, Francesco; Bonavina, Maria Giuseppina] Veneto Inst Oncol IRCCS, Healthcare Directorate Unit, Via Gattamelata 64, Padua, Italy.
   [Garzotto, Francesco; Lanera, Corrado; Gregori, Dario] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Unit Biostat Epidemiol & Publ Hlth, Padua, Italy.
   [Ceresola, Erica] San Bortolo Hosp, AULSS Ber 8, Bioengn Dept, Vicenza, Italy.
   [Panagiotakopoulou, Sofia] Veneto Inst Oncol IRCCS, Bioengn Dept, Padua, Italy.
   [Spina, Giovanni] Padua Univ Hosp, Tech Dept, Padua, Italy.
   [Menotto, Francesca] Padua Univ Hosp, Tech Dept, Tenders & Contracts Unit, Padua, Italy.
   [Benozzi, Marco] Padua Univ Hosp, Tech Dept, Bioengn Unit, Padua, Italy.
   [Casarotto, Maurizio] AULSS 7 San Bassiano Hosp, Bioengn Dept, Bassano Del Grappa, Italy.
   [Meneghesso, Gaudenzio] Univ Padua, Dept Informat Engn, Padua, Italy.
   [Opocher, Giuseppe] Veneto Inst Oncol IRCCS, Sci Directorate, Padua, Italy.
RP Garzotto, F (corresponding author), Veneto Inst Oncol IRCCS, Healthcare Directorate Unit, Via Gattamelata 64, Padua, Italy.
EM francesco.garzotto@iov.veneto.it
RI garzotto, francesco/K-3552-2018; Opocher, Giuseppe/F-3950-2014
OI garzotto, francesco/0000-0002-0233-3752; Opocher,
   Giuseppe/0000-0002-9845-9623
CR Administration FaD, 2020, COR DIS 2019 COVID 1
   Ankawi G, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2181-z
   [Anonymous], 2020, APSF ASA GUID PURP A
   [Anonymous], 2020, EX DEV REG COR COVID
   [Anonymous], 2020, SPEC VENT BE US UK H
   [Anonymous], 2020, DIS COMM PACK NOV CO
   [Anonymous], 2020, DGE COVID19ITA
   Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x
   European Centre for Disease Prevention and Control, 2020, RISK ASS COVID 19
   Garzotto F, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1355-9
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu C, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1299-0
   Lodi CA, 2010, CLIN J AM SOC NEPHRO, V5, P2004, DOI 10.2215/CJN.01740210
   Mirco Nacoti AC, 2020, NEJM CAT INNOVATIONS, V1, P2
   Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   U.S. Food and Drug Administration, 2020, ENF POL VENT ACC OTH
   US Food and Drug Administration, 2020, COR COVID 19 UPD FDA
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 22
TC 3
Z9 3
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1743-4440
EI 1745-2422
J9 EXPERT REV MED DEVIC
JI Expert Rev. Med. Devices
PD JUN 2
PY 2020
VL 17
IS 6
BP 483
EP 489
DI 10.1080/17434440.2020.1772757
PG 7
WC Engineering, Biomedical
SC Engineering
GA ME1SZ
UT WOS:000544442700004
PM 32434400
OA Bronze
DA 2021-01-01
ER

PT J
AU Kumar, A
   Choudhir, G
   Shukla, SK
   Sharma, M
   Tyagi, P
   Bhushan, A
   Rathore, M
AF Kumar, Anuj
   Choudhir, Gourav
   Shukla, Sanjeev Kumar
   Sharma, Mansi
   Tyagi, Pankaj
   Bhushan, Arvind
   Rathore, Madhu
TI Identification of phytochemical inhibitors against main protease of
   COVID-19 using molecular modeling approaches
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; protease; ursolic acid; carvacrol; oleanolic acid
ID DRUG DESIGN; CORONAVIRUS; CHLOROQUINE; PROTEINASE; SARS
AB Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel corona virus that causes corona virus disease 2019 (COVID-19). The COVID-19 rapidly spread across the nations with high mortality rate even as very little is known to contain the virus at present. In the current study, we report novel natural metabolites namely, ursolic acid, carvacrol and oleanolic acid as the potential inhibitors against main protease (M-pro) of COVID-19 by using integrated molecular modeling approaches. From a combination of molecular docking and molecular dynamic (MD) simulations, we found three ligands bound to protease during 50 ns of MD simulations. Furthermore, the molecular mechanic/generalized/Born/Poisson-Boltzmann surface area (MM/G/P/BSA) free energy calculations showed that these chemical molecules have stable and favourable energies causing strong binding with binding site of M(pro)protein. All these three molecules, namely, ursolic acid, carvacrol and oleanolic acid, have passed the ADME (Absorption, Distribution, Metabolism, and Excretion) property as well as Lipinski's rule of five. The study provides a basic foundation and suggests that the three phytochemicals,viz.ursolic acid, carvacrol and oleanolic acid could serve as potential inhibitors in regulating the M(pro)protein's function and controlling viral replication. Communicated by Ramaswamy H. Sarma
C1 [Kumar, Anuj] Uttarakhand Council Biotechnol UCB, Bioinformat Lab, Pantnagar, Uttar Pradesh, India.
   [Kumar, Anuj] Uttarakhand Council Biotechnol UCB, Adv Ctr Computat & Appl Biotechnol, Dehra Dun, Uttarakhand, India.
   [Choudhir, Gourav] CCS Univ, Dept Bot, Meerut, Uttar Pradesh, India.
   [Shukla, Sanjeev Kumar] Govt Med Coll, Multidisciplinary Res Unit MRU, Haldwani, India.
   [Sharma, Mansi; Rathore, Madhu] Acad Biol Sci & Res Fdn ABSRF, Udaipur, Rajasthan, India.
   [Tyagi, Pankaj] Noida Inst Engn & Technol, Dept Biotechnol, Greater Noida, India.
   [Bhushan, Arvind] IIHMR Univ, Jaipur, Rajasthan, India.
RP Kumar, A (corresponding author), Uttarakhand Council Biotechnol UCB, Adv Ctr Computat & Appl Biotechnol, Dehra Dun, Uttarakhand, India.
EM anujbioinfo91@gmail.com
RI Tyagi, Pankaj Kumar/M-5999-2013
OI Tyagi, Pankaj Kumar/0000-0002-7003-0489; Kumar,
   Anuj/0000-0002-5023-7618; Kumar, Anand/0000-0001-6788-5331; Singh,
   Gurmeet/0000-0001-9734-1896
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abdelli I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763199
   Adem S., 2020, IDENTIFICATION POTEN, V46, P1, DOI [10.20944/preprints202003.0333.v1., 10.20944/preprints202003.0333.v1, DOI 10.20944/PREPRINTS202003.0333.V1]
   Aldeghi M, 2017, J CHEM INF MODEL, V57, P2203, DOI 10.1021/acs.jcim.7b00347
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2005, BIRK ADV INFECT DIS, P173
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Benson NC, 2012, J PHYS CHEM B, V116, P8722, DOI 10.1021/jp302103t
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chandel V., 2020, SILICO IDENTIFICATIO
   Chang CK, 2016, DRUG DISCOV TODAY, V21, P562, DOI 10.1016/j.drudis.2015.11.015
   Chang YC, 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2., 10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Contini A., 2020, VIRTUAL SCREENING FD, DOI [10.26434/Chemrxiv.11847381.V1., DOI 10.26434/CHEMRXIV.11847381.V1, 10.26434/chemrxiv.11847381.v1]
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Gajula M. N. P., 2008, THESIS
   Gajula MNVP, 2016, BIO-PROTOCOL, V6, P1, DOI DOI 10.21769/BIOPROTOC.2051
   Gentile D., 2020, INHIBITORS SARS COV
   Gilling DH, 2014, J APPL MICROBIOL, V116, P1149, DOI 10.1111/jam.12453
   Gonzalez-Paz L. A., 2020, RES SQUARE, DOI [10.21203/rs.3.rs-21206/v1, DOI 10.21203/RS.3.RS-21206/V1]
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Gupta M. K., 2020, J BIOMOLECULAR STRUC, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hemida MG, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100127
   Hyldgaard M, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00012
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jee B, 2018, J BIOMOL STRUCT DYN, V36, P3434, DOI 10.1080/07391102.2017.1389305
   Jesus JA, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/620472
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kaisari E., 2020, KLINISCHEMONATSBLATT
   Kamalabadi M., 2018, INT J MOL LAB, V5, P113
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI 10.20944/preprints202003.0226.v1
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Khwaza V, 2018, MOLECULES, V23, DOI 10.3390/molecules23092300
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kumar Anuj, 2018, Proceedings of the Indian National Science Academy Part B Biological Sciences, V88, P1539, DOI 10.1007/s40011-017-0898-0
   Kumar A, 2018, DATA, V3, DOI 10.3390/data3010007
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Lu IL, 2006, J MED CHEM, V49, P5154, DOI 10.1021/jm060207o
   Mackenzie JS, 2020, MICROBIOL AUST, V41, P45, DOI 10.1071/MA20013
   Marinelli L, 2019, EUR J MED CHEM, V178, P515, DOI 10.1016/j.ejmech.2019.05.093
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Panchangam SS, 2016, AVICENNA J PHYTOMEDI, V6, P604
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pollier J, 2012, PHYTOCHEMISTRY, V77, P10, DOI 10.1016/j.phytochem.2011.12.022
   Sakkiah S, 2012, J BIOMOL STRUCT DYN, V30, P235, DOI 10.1080/07391102.2012.680026
   Salata C, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftaa006
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Seah I, 2020, OCUL IMMUNOL INFLAMM, V28, P391, DOI 10.1080/09273948.2020.1738501
   Sharma AD, 2020, EUCALYPTOL 1 8 CINEO
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Sun N, 2020, PREDICTION POTENTIAL
   Tohme MJ, 2019, INT J ANTIMICROB AG, V54, P601, DOI 10.1016/j.ijantimicag.2019.07.015
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wade R C, 1989, Prog Clin Biol Res, V289, P433
   Wadood A, 2013, OA DRUG DES DELIV, V1, P1, DOI DOI 10.13172/2054-4057-1-1-1119
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wang B, 2020, NEPHRON, V144, P96, DOI 10.1159/000503882
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   World Health Organization, 2020, NAM COR DIS COVID 19
   Wozniak L, 2015, MOLECULES, V20, P20614, DOI 10.3390/molecules201119721
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang HT, 2006, CURR PHARM DESIGN, V12, P4573, DOI 10.2174/138161206779010369
   Yu WB, 2017, METHODS MOL BIOL, V1520, P85, DOI 10.1007/978-1-4939-6634-9_5
   Yuan ML, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230548
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 90
TC 19
Z9 19
U1 5
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1772112
EA JUN 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MC1BB
UT WOS:000543030500001
PM 32448034
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Lv, HB
   Wu, NC
   Tsang, OTY
   Yuan, M
   Perera, RAPM
   Leung, WS
   So, RTY
   Chan, JMC
   Yip, GK
   Chik, TSH
   Wang, Y
   Choi, CYC
   Lin, Y
   Ng, WW
   Zhao, JC
   Poon, LLM
   Peiris, JSM
   Wilson, IA
   Mok, CKP
AF Lv, Huibin
   Wu, Nicholas C.
   Tsang, Owen Tak-Yin
   Yuan, Meng
   Perera, Ranawaka A. P. M.
   Leung, Wai Shing
   So, Ray T. Y.
   Chan, Jacky Man Chun
   Yip, Garrick K.
   Chik, Thomas Shiu Hong
   Wang, Yiquan
   Choi, Chris Yau Chung
   Lin, Yihan
   Ng, Wilson W.
   Zhao, Jincun
   Poon, Leo L. M.
   Peiris, J. S. Malik
   Wilson, Ian A.
   Mok, Chris K. P.
TI Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV
   Infections
SO CELL REPORTS
LA English
DT Article
ID SPIKE GLYCOPROTEIN; CORONAVIRUS; RECEPTOR; PROTECT; VACCINE; EPITOPE
AB The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, a pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV and from infected or immunized mice. Our results show that, although cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of a non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV but also has implications for immunogen design and vaccine development.
C1 [Lv, Huibin; So, Ray T. Y.; Yip, Garrick K.; Wang, Yiquan; Lin, Yihan; Ng, Wilson W.; Poon, Leo L. M.; Peiris, J. S. Malik; Mok, Chris K. P.] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, HKU Pasteur Res Pole, Hong Kong, Peoples R China.
   [Wu, Nicholas C.; Yuan, Meng; Wilson, Ian A.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
   [Tsang, Owen Tak-Yin; Leung, Wai Shing; Chan, Jacky Man Chun; Chik, Thomas Shiu Hong; Choi, Chris Yau Chung] Hosp Author Hong Kong, Princess Margaret Hosp, Infect Dis Ctr, Hong Kong, Peoples R China.
   [Perera, Ranawaka A. P. M.; Peiris, J. S. Malik] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China.
   [Zhao, Jincun] Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
RP Peiris, JSM; Mok, CKP (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, HKU Pasteur Res Pole, Hong Kong, Peoples R China.; Wilson, IA (corresponding author), Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.; Peiris, JSM (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China.; Wilson, IA (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
EM malik@hku.hk; wilson@scripps.edu; ch02mkp@hku.hk
RI Poon, Leo/AAP-6887-2020; Dr, Ranawaka A.P.M Perera -/N-8263-2015
OI Dr, Ranawaka A.P.M Perera -/0000-0003-3936-1535
FU Pasteur International Network Association; Bill and Melinda Gates
   FoundationBill & Melinda Gates Foundation [OPP1170236]; Guangzhou
   Medical University High-level University Innovation Team Training
   Program (Guangzhou Medical University) [159]; US National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [HHSN272201400006C]; National Natural
   Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint
   Research Scheme [N_HKU737/18]; Research Grants Council of the Hong Kong
   Special Administrative Region, ChinaHong Kong Research Grants Council
   [T11-712/19-N]; International Cooperation and Exchange of the National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [8181101118]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [K99 AI139445]
FX This work was supported by Calmette and Yersin scholarship from the
   Pasteur International Network Association (H.L.), NIH K99 AI139445
   (N.C.W.), Bill and Melinda Gates Foundation OPP1170236 (I.A.W.),
   Guangzhou Medical University High-level University Innovation Team
   Training Program (Guangzhou Medical University released [2017] No. 159)
   (C.K.P.M. and J.S.M.P.), the US National Institutes of Health (contract
   no. HHSN272201400006C) (J.S.M.P.), National Natural Science Foundation
   of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme
   (N_HKU737/18) (C.K.P.M. and J.S.M.P.), the Research Grants Council of
   the Hong Kong Special Administrative Region, China (Project no.
   T11-712/19-N) (J.S.M.P.), and the International Cooperation and Exchange
   of the National Natural Science Foundation of China (grant 8181101118)
   (J.Z.). We acknowledge the support of the clinicians who facilitated
   this study, including Drs. John Yu Hong Chan, Daphne Pui-Lin Lau, and
   Ying Man Ho, and the dedicated clinical team at the Infectious Diseases
   Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong, and
   the patients who kindly consented to participate in this investigation.
CR Bajic G, 2019, CELL HOST MICROBE, V25, P827, DOI 10.1016/j.chom.2019.04.003
   Bangaru S, 2019, CELL, V177, P1136, DOI 10.1016/j.cell.2019.04.011
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Bootz A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006601
   Burke CW, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040147
   Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005
   Dreyfus C, 2012, SCIENCE, V337, P1343, DOI 10.1126/science.1222908
   Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839
   Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   HENCHAL EA, 1988, J GEN VIROL, V69, P2101, DOI 10.1099/0022-1317-69-8-2101
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Lee J, 2016, NAT MED, V22, P1456, DOI 10.1038/nm.4224
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Moritz CP, 2019, J IMMUNOL METHODS, V466, P52, DOI 10.1016/j.jim.2019.01.004
   Petro C, 2015, ELIFE, V4, DOI 10.7554/eLife.06054
   Pinto Dora, 2020, bioRxiv, DOI 10.1101/2020.04.07.023903
   Poon LLM, 2020, NAT MED, V26, P317, DOI 10.1038/s41591-020-0796-5
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Walls A, 2017, PROTEIN SCI, V26, P113, DOI 10.1002/pro.3048
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Watanabe A, 2019, CELL, V177, P1124, DOI 10.1016/j.cell.2019.03.048
   WEISS RC, 1981, COMP IMMUNOL MICROB, V4, P175, DOI 10.1016/0147-9571(81)90003-5
   Wong Matthew C, 2020, bioRxiv, DOI 10.1101/2020.02.07.939207
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu NC, 2019, CELL HOST MICROBE, V25, P836, DOI 10.1016/j.chom.2019.04.013
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zost SJ, 2019, J INFECT DIS, V219, pS38, DOI 10.1093/infdis/jiy696
NR 45
TC 45
Z9 44
U1 5
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JUN 2
PY 2020
VL 31
IS 9
AR 107725
DI 10.1016/j.celrep.2020.107725
PG 9
WC Cell Biology
SC Cell Biology
GA LV0XZ
UT WOS:000538168300021
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Munch, U
   Muller, H
   Deffner, T
   von Schmude, A
   Kern, M
   Kiepke-Ziemes, S
   Radbruch, L
AF Muench, Urs
   Mueller, Heidi
   Deffner, Teresa
   von Schmude, Andrea
   Kern, Martina
   Kiepke-Ziemes, Susanne
   Radbruch, Lukas
TI Recommendations for the support of suffering, severely ill, dying or
   grieving persons in the corona pandemic from a palliative care
   perspective Recommendations of the German Society for Palliative
   Medicine (DGP), the German Interdisciplinary Association for Intensive
   and Emergency Medicine (DIVI), the Federal Association for Grief
   Counseling (BVT), the Working Group for Psycho-oncology in the German
   Cancer Society, the German Association for Social Work in the Healthcare
   System (DVSG) and the German Association for Systemic Therapy,
   Counseling and Family Therapy (DGSF)
SO SCHMERZ
LA German
DT Article
DE Corona pandemic; Psychological burden; Social isolation; Palliative
   care; Virtual contact options
AB The corona pandemic has led to a number of restrictions and prohibitions, which in turn place large psychosocial or spiritual burdens on patients with COVID-19, their families and relatives and the treating personnel in the healthcare system. Patients with COVID-19 are not allowed to receive visitors and many hospitals and nursing homes have completely banned visitors. Many support services have been reduced or stopped completely. Necessary treatment interventions for other patients with critical and life-limiting diseases have been delayed or suspended in order to free resources for the expected COVID-19 patients; however, these people need to feel social connectedness with their relatives. Palliative care patients should be exempted from any ban on visitors. Families should be able to visit dying patients even on intensive care units or isolation wards, using adequate protective equipment. Alternative options, such as video telephone calls or via social media should be explored for patients in isolation. Families should also be enabled to say goodbye to the deceased with adequate protective equipment or should be offered alternative real or virtual options for remembrance and commemoration. Health care professionals coping with the exceptional stress should be continuously supported. This requires clear communication and leadership structures, communication training, psychosocial support, but most of all optimal framework conditions for the clinical work.
C1 [Muench, Urs] DRK Kliniken Berlin Westend, Klin Allgemein & Viszeralchirurg, Berlin, Germany.
   [Mueller, Heidi] Trauerzentrum Frankfurt Main, Frankfurt, Germany.
   [Deffner, Teresa] Univ Klinikum Jena, Kinderklin Sekt Neonatol & Padiat Intens Med, Klin Anasthesiol & Intens Med, Jena, Germany.
   [von Schmude, Andrea] Netzwerk Hosp & Palliat Versorgung Bonn Rhein Sie, Bonn, Germany.
   [Kern, Martina] Ansprechstellen Land NRW Palliat Versorgung Hosp, Bonn, Germany.
   [Kiepke-Ziemes, Susanne] Caritasverband Reg Kempen Viersen eV, Viersen, Germany.
   [Radbruch, Lukas] Univ Klinikum Bonn, Klin Palliat Med, Venusberg Campus 1, D-53127 Bonn, Germany.
RP Radbruch, L (corresponding author), Univ Klinikum Bonn, Klin Palliat Med, Venusberg Campus 1, D-53127 Bonn, Germany.
EM lukas.radbruch@ukbonn.de
FU Projekt DEAL
FX Open Access funding provided by Projekt DEAL.
CR [Anonymous], 2019, ERW S3 LEITL PALL PA
   [Anonymous], 2017, DGU GRUNDS 306 001 T
   [Anonymous], 2020, ARB QUAL STEP UP PER
   [Anonymous], 2020, KLIN PSYCH NOTF HAND
   Beerlage I, 2009, ARBEITSBEDINGUNGEN O
   Beerlage I, 2006, ENTWICKLUNG STANDARD
   Eisma MC, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.113031
   Gramm J, 2020, COVID 19 PANDEMIE IM
   Greenberg N, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1211
   Kiepke-Ziemes S, OHNE CORONA VERS ALT
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Mehnert A, 2015, OXFORD TXB PALLIATIV, P221, DOI DOI 10.1093/MED/9780199656097.003.0413
   Munch U, 2020, ANHALTENDE TRAUER WE
   Nehls W, 2020, PNEUMOLOGIE, V74, P652, DOI 10.1055/a-1156-2759
   Oechsle K, 2019, BMC PALLIAT CARE, V18, DOI 10.1186/s12904-019-0469-7
   Sektion Psychologie der Deutschen Gesellschaft fur Palliativmedizin, 2016, PALL BER PSYCH PALL
   Sektion Seelsorge der Deutschen Gesellschaft fur Palliativmedizin, 2007, KONZ SPIR BEGL PALL
   Sektion Soziale Arbeit der Deutschen Gesellschaft fur Palliativmedizin, 2012, PROF SOZ ARB PALL CA
   Shear MK, 2012, CURR PSYCHIAT REP, V14, P169, DOI 10.1007/s11920-012-0270-2
   2007, PSYCHIATRY, V70, P283, DOI DOI 10.1521/PSYC.2007.70.4.283
NR 20
TC 4
Z9 4
U1 9
U2 12
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-433X
EI 1432-2129
J9 SCHMERZ
JI Schmerz
PD AUG
PY 2020
VL 34
IS 4
BP 303
EP 313
DI 10.1007/s00482-020-00483-9
EA JUN 2020
PG 11
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA MT2DK
UT WOS:000537762200001
PM 32488422
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Shi, XD
   Lu, Y
   Li, R
   Tang, YL
   Shi, NN
   Song, FX
   Shan, F
   Chen, GC
   Song, PR
   Shi, YX
AF Shi, Xiudong
   Lu, Yang
   Li, Rong
   Tang, Yanlin
   Shi, Nannan
   Song, Fengxiang
   Shan, Fei
   Chen, Guochao
   Song, Pengrui
   Shi, Yuxin
TI Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia
   in Shanghai, China
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE antiviral drug; COVID-19 pneumonia; CT imaging; therapeutic effect
ID SARS; REMDESIVIR
AB The aim of our study was to evaluate the therapeutic effect of antiviral drugs on coronavirus disease 2019 (COVID-19) pneumonia. Patients confirmed with COVID-19 pneumonia were enrolled and divided into seven groups according to the treatment option. Information including age, sex, and duration from illness onset to admission, clinical manifestations, and laboratory data at admission, and length of hospital stay were evaluated. The chest computed tomography (CT) imaging obtained at admission and after a 5-day treatment cycle were assessed. The clinical symptoms and laboratory tests at discharge were also assessed. At admission, no significant differences were found among the groups, including the duration from illness onset to admission, clinical symptoms, and main laboratory results. No significant differences were found among the groups in terms of the proportion of patients with pneumonia resolution (P = .151) after treatment or the length of hospital stay (P = .116). At discharge, 7 of 184 (4%) patients had a mild cough while their other symptoms had disappeared, and the proportion of patients with abnormal liver function and with increased leukocytes, neutrophils or erythrocyte sedimentation rate among the 184 patients were close to those at admission. According to the results, the inclusion of antiviral drugs in therapeutic regimens based on symptomatic treatment had no significant additional impact on the improvement in COVID-19 patients. In addition, the results of chest CT imaging, clinical manifestations, and laboratory tests at discharge were not completely consistent.
C1 [Shi, Xiudong; Lu, Yang; Shi, Nannan; Song, Fengxiang; Shan, Fei; Chen, Guochao; Song, Pengrui; Shi, Yuxin] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Radiol, Shanghai, Peoples R China.
   [Li, Rong; Tang, Yanlin] Jiangsu Univ, Sch Med, Dept Lab Med, Zhenjiang, Jiangsu, Peoples R China.
   [Shi, Yuxin] Shanghai Key Lab Mol Imaging, Ctr Translat Med, Shanghai, Peoples R China.
RP Shi, YX (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, 921 Tongxin Rd, Shanghai 201508, Peoples R China.
EM shiyx828288@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [61671281]; Shanghai Shenkang Hospital
   Development Center Funding [SHDC12019128]
FX National Natural Science Foundation of China, Grant/Award Number:
   61671281; Shanghai Shenkang Hospital Development Center Funding,
   Grant/Award Number: SHDC12019128
CR Beck B, 2020, PREDICTING COMMERCIA
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chai X, 2020, SPECIFIC ACE2 EXPRES
   Chang Y.-C., 2020, POTENTIAL THERAPEUTI
   Chen X, 2020, RESTORATION LEUKOMON
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Columbus Cristie, 2020, Proc (Bayl Univ Med Cent), V33, P209, DOI 10.1080/08998280.2020.1731272
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Lai ChihCheng, 2020, International Journal of Antimicrobial Agents, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li Y, 2020, EFFICACY SAFETY LOPI
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Luo G, 2020, J MED VIROL, V92, P399, DOI 10.1002/jmv.25683
   Momattin H, 2019, TRAVEL MED INFECT DI, V30, P9, DOI 10.1016/j.tmaid.2019.06.012
   Momattin H, 2013, INT J INFECT DIS, V17, pE792, DOI 10.1016/j.ijid.2013.07.002
   National Health Commission of the People's Republic of China, 2020, DIAGN TREATM PROT PN
   Pan F, RADIOLOGY, DOI [10.1148/radiol.20202003, DOI 10.1148/RADIOL.20202003]
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Song FX, 2020, RADIOLOGY, V295, P210, DOI 10.1148/radiol.2020200274
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, J INFECT DIS, V221, P1688, DOI 10.1093/infdis/jiz656
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang NR, 2020, J MED VIROL, V92, P408, DOI 10.1002/jmv.25674
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu Ying, 2020, J Infect, DOI 10.1016/j.jinf.2020.02.022
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 30
TC 16
Z9 16
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2020
VL 92
IS 10
BP 1922
EP 1931
DI 10.1002/jmv.25893
EA JUN 2020
PG 10
WC Virology
SC Virology
GA NK4OX
UT WOS:000537005000001
PM 32297985
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lauterio, A
   Valsecchi, M
   Santambrogio, S
   De Carlis, R
   Merli, M
   Calini, A
   Centonze, L
   Buscemi, V
   Bottiroli, M
   Puoti, M
   Fumagalli, R
   De Carlis, L
AF Lauterio, Andrea
   Valsecchi, Mila
   Santambrogio, Sara
   De Carlis, Riccardo
   Merli, Marco
   Calini, Angelo
   Centonze, Leonardo
   Buscemi, Vincenzo
   Bottiroli, Maurizio
   Puoti, Massimo
   Fumagalli, Roberto
   De Carlis, Luciano
TI Successful recovery from severe COVID-19 pneumonia after kidney
   transplantation: The interplay between immunosuppression and novel
   therapy including tocilizumab
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE coronavirus; COVID-19; immunosuppression; kidney transplantation;
   pandemic; tocilizumab
AB Although immunosuppressed patients may be more prone to SARS-CoV-2 infection with atypical presentation, long-term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID-19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID-19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID-19 of a kidney-transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid, and tocilizumab.
C1 [Lauterio, Andrea; De Carlis, Riccardo; Centonze, Leonardo; Buscemi, Vincenzo; De Carlis, Luciano] ASST Grande Osped Metropolitano Niguarda, Div Gen Surg & Transplantat, Dept Transplantat, Piazza Osped Maggiore 3, I-20162 Milan, Italy.
   [Valsecchi, Mila; Santambrogio, Sara; Calini, Angelo; Bottiroli, Maurizio; Fumagalli, Roberto] ASST Grande Osped Metropolitano Niguarda, Dept Anesthesiol, Milan, Italy.
   [Merli, Marco; Puoti, Massimo] ASST Grande Osped Metropolitano Niguarda, Div Infect Dis, Milan, Italy.
   [Fumagalli, Roberto; De Carlis, Luciano] Univ Milano Bicocca, Dept Med & Surg, Milan, Italy.
   [De Carlis, Luciano] Univ Milano Bicocca, Int Ctr Digest Hlth, Milan, Italy.
RP Lauterio, A (corresponding author), ASST Grande Osped Metropolitano Niguarda, Div Gen Surg & Transplantat, Dept Transplantat, Piazza Osped Maggiore 3, I-20162 Milan, Italy.
EM andrea.lauterio@ospedaleniguarda.it
RI LAUTERIO, ANDREA/ABE-7865-2020; Bottiroli, Maurizio/L-4801-2019
OI LAUTERIO, ANDREA/0000-0001-6110-8582; Bottiroli,
   Maurizio/0000-0002-1579-7767; Centonze, Leonardo/0000-0001-9371-7411; De
   Carlis, Riccardo/0000-0003-3697-1653; Merli, Marco/0000-0001-5081-8669;
   Puoti, Massimo/0000-0003-3278-7138
CR Abadja F, 2011, TRANSPLANTATION, V92, P396, DOI 10.1097/TP.0b013e3182247b5f
   Ahmadpoor P, 2020, TRANSPL INT, V33, P824, DOI 10.1111/tri.13611
   Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Arpali E, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13296
   Aslam S, 2020, J HEART LUNG TRANSPL, V39, P408, DOI 10.1016/j.healun.2020.03.007
   Bartiromo M, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13286
   Boyarsky BJ, 2020, AM J TRANSPLANT, V20, P1809, DOI 10.1111/ajt.15915
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Fontana F, 2020, AM J TRANSPLANT, V20, P1902, DOI 10.1111/ajt.15935
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Kumar D, 2010, LANCET INFECT DIS, V10, P521, DOI 10.1016/S1473-3099(10)70133-X
   Lansbury L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub3
   Lombardy Section Italian Society Infectious And Tropical Diseases -, 2020, Infez Med, V28, P143
   Marx D, 2020, AM J TRANSPLANT, V20, P1944, DOI 10.1111/ajt.15919
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Seminari E, 2020, AM J TRANSPLANT, V20, P1882, DOI 10.1111/ajt.15902
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zaza G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02978
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 24
TC 7
Z9 7
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD OCT
PY 2020
VL 22
IS 5
AR e13334
DI 10.1111/tid.13334
EA JUN 2020
PG 5
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA OR6XJ
UT WOS:000536997600001
PM 32449235
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ruggiero, G
   Arcangeli, F
   Lotti, T
AF Ruggiero, Giuseppe
   Arcangeli, Fabio
   Lotti, Torello
TI Therapy for probable COVID-19 associated erythema pernio-like lesions in
   pediatric age. Case report
SO DERMATOLOGIC THERAPY
LA English
DT Letter
C1 [Ruggiero, Giuseppe; Arcangeli, Fabio; Lotti, Torello] Univ Rome Guglielmo Marconi, Via Plinio 44, I-00193 Rome, Italy.
RP Arcangeli, F (corresponding author), Univ Rome Guglielmo Marconi, Via Plinio 44, I-00193 Rome, Italy.
EM fabio.arcangeli4@gmail.com
OI ARCANGELI, FABIO/0000-0003-2764-1281
CR Diurno F, 2020, EUR REV MED PHARMACO, V24, P4040, DOI 10.26355/eurrev_202004_20875
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Joob B, 2020, J AM ACAD DERMATOL, V82, pE177, DOI 10.1016/j.jaad.2020.03.036
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan YC, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13310
NR 7
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13616
DI 10.1111/dth.13616
EA JUN 2020
PG 3
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000536999500001
PM 32424851
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Shi, M
   Chen, LH
   Yang, YD
   Zhang, JP
   Xu, J
   Xu, G
   Li, B
   Yin, YP
AF Shi, Ming
   Chen, Lianhua
   Yang, Yadong
   Zhang, Jingpeng
   Xu, Ji
   Xu, Gang
   Li, Bin
   Yin, Yiping
TI Analysis of clinical features and outcomes of 161 patients with severe
   and critical COVID-19: A multicenter descriptive study
SO JOURNAL OF CLINICAL LABORATORY ANALYSIS
LA English
DT Article
DE clinical features; clinical outcomes; COVID-19; laboratory indexes;
   post-admission complications
ID MERS-COV; OUTBREAK; PNEUMONIA; DISEASE
AB Background This study aimed to investigate clinical characteristics, laboratory indexes, treatment regimens, and short-term outcomes of severe and critical coronavirus disease 2019 (COVID-19) patients.
   Methods One hundred and sixty one consecutive severe and critical COVID-19 patients admitted in intensive care unit (ICU) were retrospectively reviewed in this multicenter study. Demographic features, medical histories, clinical symptoms, lung computerized tomography (CT) findings, and laboratory indexes on admission were collected. Post-admission complications, treatment regimens, and clinical outcomes were also documented.
   Results The mean age was 59.38 +/- 16.54 years, with 104 (64.60%) males and 57 (35.40%) females. Hypertension (44 [27.33%]) and diabetes were the most common medical histories. Fever (127 [78.88%]) and dry cough (111 [68.94%]) were the most common symptoms. Blood routine indexes, hepatic and renal function indexes, and inflammation indexes were commonly abnormal. Acute respiratory distress syndrome (ARDS) was the most common post-admission complication (69 [42.86%]), followed by electrolyte disorders (48 [29.81%]), multiple organ dysfunction (MODS) (37 [22.98%]), and hypoproteinemia (36 [22.36%]). The most commonly used antiviral drug was lopinavir/ritonavir tablet. 50 (31.06%) patients died, while 78 (48.45%) patients healed and discharged, and the last 33 (20.50%) patients remained in hospital. Besides, the mean hospital stay of deaths was 21.66 +/- 11.18 days, while the mean hospital stay of discharged patients was 18.42 +/- 12.77 days. Furthermore, ARDS (P < .001) and MODS (P = .008) correlated with increased mortality rate.
   Conclusion Severe and critical COVID-19 presents with high mortality rate, and occurrence of ARDS or MODS greatly increases its mortality risk.
C1 [Shi, Ming] Hubei Univ Med, Affiliated Dongfeng Hosp, Dept Resp Med, Shiyan, Peoples R China.
   [Chen, Lianhua] Hubei Univ Med, Renmin Hosp, Dept Endocrinol, Shiyan, Peoples R China.
   [Yang, Yadong; Zhang, Jingpeng] Huanggang Cent Hosp, Dept Crit Care Med, Huanggang, Peoples R China.
   [Xu, Ji] Qichun Peoples Hosp, Dept Crit Care Med, Qichun, Peoples R China.
   [Xu, Gang] Wuxue Peoples Hosp, Dept Crit Care Med, Wuxue, Peoples R China.
   [Li, Bin] Huanggang Cent Hosp, Dept Med Lab, Huanggang, Peoples R China.
   [Yin, Yiping] Hubei Univ Med, Renmin Hosp, Dept Resp Med, 39 Chaoyang Middle Rd, Shiyan 442000, Peoples R China.
RP Yin, YP (corresponding author), Hubei Univ Med, Renmin Hosp, Dept Resp Med, 39 Chaoyang Middle Rd, Shiyan 442000, Peoples R China.
EM puyou70682834@163.com
CR Ahmadzadeh J, 2020, DIAGN MICR INFEC DIS, V96, DOI 10.1016/j.diagmicrobio.2019.114876
   Alfaraj SH, 2019, TRAVEL MED INFECT DI, V29, P48, DOI 10.1016/j.tmaid.2019.03.004
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cho SY, 2016, LANCET, V388, P994, DOI 10.1016/S0140-6736(16)30623-7
   Cyranoski D, 2017, NATURE, V552, P15, DOI 10.1038/d41586-017-07766-9
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Halim AA, 2016, EGYPT J CHEST DIS TU, V65, P81, DOI 10.1016/j.ejcdt.2015.11.011
   Hayward A, 2014, LANCET RESP MED, V2, P970, DOI 10.1016/S2213-2600(14)70250-4
   Hu Y, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104371
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Mahajan M, 2018, BBA-BIOMEMBRANES, V1860, P407, DOI 10.1016/j.bbamem.2017.10.002
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Siordia JA, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104357
   Yang SG, 2017, LANCET INFECT DIS, V17, P716, DOI 10.1016/S1473-3099(17)30227-X
NR 16
TC 4
Z9 4
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-8013
EI 1098-2825
J9 J CLIN LAB ANAL
JI J. Clin. Lab. Anal.
PD SEP
PY 2020
VL 34
IS 9
AR e23415
DI 10.1002/jcla.23415
EA JUN 2020
PG 7
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA NY8FZ
UT WOS:000537083500001
PM 32488958
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cimolai, N
AF Cimolai, Nevio
TI Defining protective epitopes for COVID-19 vaccination models
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter
DE coronavirus; COVID-19; infection; pathology; pneumonia; vaccine
ID ANIMAL-MODEL; ANTIBODY; MICE
C1 [Cimolai, Nevio] Univ British Columbia, Childrens & Womens Hlth Ctr British Columbia, Pathol & Lab Med, Vancouver, BC, Canada.
RP Cimolai, N (corresponding author), Univ British Columbia, Fac Med, Childrens & Womens Hlth Ctr British Columbia, 4480 Oak St, Vancouver, BC V6H 3V4, Canada.
EM ncimolai@mail.ubc.ca
CR Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   CIMOLAI N, 1992, MICROBIOL IMMUNOL, V36, P465, DOI 10.1111/j.1348-0421.1992.tb02045.x
   Cimolai N, 1996, VACCINE, V14, P1479, DOI 10.1016/S0264-410X(96)00068-0
   CIMOLAI N, 1995, VACCINE, V13, P305, DOI 10.1016/0264-410X(95)93318-4
   Dong SJ, 2020, J MED VIROL, V92, P1542, DOI 10.1002/jmv.25768
   Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Macadam S, 2002, DIAGN MICR INFEC DIS, V43, P247, DOI 10.1016/S0732-8893(02)00396-6
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   SMITH CB, 1967, J AMER MED ASSOC, V199, P353, DOI 10.1001/jama.199.6.353
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Yip M S, 2016, Hong Kong Med J, V22, P25
NR 16
TC 1
Z9 1
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2020
VL 92
IS 10
BP 1772
EP 1773
DI 10.1002/jmv.25876
EA JUN 2020
PG 2
WC Virology
SC Virology
GA NK4OX
UT WOS:000537004900001
PM 32285942
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zylberman, V
   Sanguineti, S
   Pontoriero, AV
   Higa, SV
   Cerutti, ML
   Seijo, SMM
   Pardo, R
   Munoz, L
   Intrieri, MEA
   Alzogaray, VA
   Avaro, MM
   Benedetti, E
   Berguer, PM
   Bocanera, L
   Bukata, L
   Bustelo, MS
   Campos, AM
   Colonna, M
   Correa, E
   Cragnaz, L
   Dattero, ME
   Dellafiore, M
   Foscaldi, S
   Gonzalez, JV
   Guerra, LL
   Klinke, S
   Labanda, MS
   Lauche, C
   Lopez, JC
   Martinez, AM
   Otero, LH
   Peyric, EH
   Ponziani, PF
   Ramondino, R
   Rinaldi, J
   Rodriguez, S
   Russo, JE
   Russo, ML
   Saavedra, SL
   Seigelchifer, M
   Sosa, S
   Vilarino, C
   Biscayart, PL
   Corley, E
   Spatz, L
   Baumeister, EG
   Goldbaum, FA
AF Zylberman, Vanesa
   Sanguineti, Santiago
   Pontoriero, Andrea V.
   Higa, Sandra V.
   Cerutti, Maria L.
   Morrone Seijo, Susana M.
   Pardo, Romina
   Munoz, Luciana
   Acuna Intrieri, Maria E.
   Alzogaray, Vanina A.
   Avaro, Martin M.
   Benedetti, Estefania
   Berguer, Paula M.
   Bocanera, Laura
   Bukata, Lucas
   Bustelo, Marina S.
   Campos, Ana M.
   Colonna, Mariana
   Correa, Elisa
   Cragnaz, Lucia
   Dattero, Maria E.
   Dellafiore, Maria
   Foscaldi, Sabrina
   Gonzalez, Joaquin V.
   Guerra, Luciano L.
   Klinke, Sebastian
   Labanda, Maria S.
   Lauche, Constanza
   Lopez, Juan C.
   Martinez, Anabela M.
   Otero, Lisandro H.
   Peyric, Elias H.
   Ponziani, Pablo F.
   Ramondino, Romina
   Rinaldi, Jimena
   Rodriguez, Santiago
   Russo, Javier E.
   Russo, Mara L.
   Saavedra, Soledad L.
   Seigelchifer, Mauricio
   Sosa, Santiago
   Vilarino, Claudio
   Lopez Biscayart, Patricia
   Corley, Esteban
   Spatz, Linus
   Baumeister, Elsa G.
   Goldbaum, Fernando A.
TI DEVELOPMENT OF A HYPERIMMUNE EQUINE SERUM THERAPY FOR COVID-19 IN
   ARGENTINA
SO MEDICINA-BUENOS AIRES
LA English
DT Article
DE COVID-19; Argentina; hyperimmune horse sera; F(ab ')(2) fragments
AB The disease named COVID-19, caused by the SARS-CoV-2 coronavirus, is currently generating a global pandemic. Vaccine development is no doubt the best long-term immunological approach, but in the current epidemiologic and health emergency there is a need for rapid and effective solutions. Convalescent plasma is the only antibody-based therapy available for COVID-19 patients to date. Equine polyclonal antibodies (EpAbs) put forward a sound alternative. The new generation of processed and purified EpAbs containing highly purified F(ab')(2 )fragments demonstrated to be safe and well tolerated. EpAbs are easy to manufacture allowing a fast development and scaling up for a treatment. Based on these ideas, we present a new therapeutic product obtained after immunization of horses with the receptor-binding domain of the viral Spike glycoprotein. Our product shows around 50 times more potency in in vitro seroneutralization assays than the average of convalescent plasma. This result may allow us to test the safety and efficacy of this product in a phase 2/3 clinical trial to be conducted in July 2020 in the metropolitan area of Buenos Aires, Argentina.
C1 [Zylberman, Vanesa; Sanguineti, Santiago; Morrone Seijo, Susana M.; Pardo, Romina; Munoz, Luciana; Bukata, Lucas; Bustelo, Marina S.; Colonna, Mariana; Gonzalez, Joaquin V.; Lauche, Constanza; Ramondino, Romina; Spatz, Linus; Goldbaum, Fernando A.] Inmunova SA, 25 Mayo 1021, RA-1650 San Martin, Buenos Aires, Argentina.
   [Zylberman, Vanesa; Cerutti, Maria L.; Acuna Intrieri, Maria E.] Consejo Nacl Invest Cient & Tecn CONICET, Buenos Aires, DF, Argentina.
   [Pontoriero, Andrea V.; Avaro, Martin M.; Benedetti, Estefania; Campos, Ana M.; Dattero, Maria E.; Russo, Mara L.; Baumeister, Elsa G.] Ctr Nacl Influenza OMS, Lab Nacl Referencia Enfermedades Resp Virales, Serv Virosis Resp INEI ANLIS Malbran, Buenos Aires, DF, Argentina.
   [Higa, Sandra V.; Lopez, Juan C.; Martinez, Anabela M.; Peyric, Elias H.; Ponziani, Pablo F.; Russo, Javier E.; Saavedra, Soledad L.; Lopez Biscayart, Patricia] Inst Biol Argentino SAIC, Buenos Aires, DF, Argentina.
   [Cerutti, Maria L.; Acuna Intrieri, Maria E.; Vilarino, Claudio; Goldbaum, Fernando A.] CRIP Ctr Rediseno & Ingn Proteinas UNSAM, Campus Miguelete, San Martin, Buenos Aires, Argentina.
   [Alzogaray, Vanina A.; Berguer, Paula M.; Foscaldi, Sabrina; Klinke, Sebastian; Labanda, Maria S.; Otero, Lisandro H.; Rinaldi, Jimena; Sosa, Santiago; Goldbaum, Fernando A.] Consejo Nacl Invest Cient & Tecn, IIBBA, Fdn Inst Leloir, Lab Inmunol & Microbiol Mol, Buenos Aires, DF, Argentina.
   [Bocanera, Laura; Correa, Elisa; Cragnaz, Lucia; Dellafiore, Maria; Guerra, Luciano L.; Rodriguez, Santiago; Seigelchifer, Mauricio; Corley, Esteban] MAbxience, Munro, Buenos Aires, Argentina.
RP Goldbaum, FA (corresponding author), Inmunova SA, 25 Mayo 1021, RA-1650 San Martin, Buenos Aires, Argentina.; Baumeister, EG (corresponding author), Ctr Nacl Influenza OMS, Lab Nacl Referencia Enfermedades Resp Virales, Serv Virosis Resp INEI ANLIS Malbran, Buenos Aires, DF, Argentina.
EM ebaumeister@anlis.gob.ar; fgoldbaum@inmunova.com
OI Otero, Lisandro/0000-0002-5448-5483; Labanda, Maria
   Soledad/0000-0002-4414-9750
FU Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET)Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET); Ministerio de Ciencia, Tecnologia e Innovacion (MINCyT);
   Agencia Nacional de Promocion de la Investigacion, el Desarrollo
   Tecnologico y la Innovacion, under the Coronavirus Unit Initiative
   [609-746]
FX We want to especially acknowledge the continuous support of Grupo Insud
   to the work of Inmunova. This work was partially supported by the
   Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET),
   the Ministerio de Ciencia, Tecnologia e Innovacion (MINCyT), and the
   Agencia Nacional de Promocion de la Investigacion, el Desarrollo
   Tecnologico y la Innovacion, under the Coronavirus Unit Initiative
   (Grant No. IP-COVID-19 #609-746). We are grateful to Andrea Gamarnik and
   coworkers at the Fundacion Instituto Leloir working under the
   Coronavirus Unit Initiative of MINCyT for their assistance in the
   production of RBD. We are also indebted to Claudia Perandones (Technical
   Scientific Director, ANLIS Malbran, Ministerio de Salud de Argentina)
   and Viviana Molina (Director of the Instituto Nacional de Enfermedades
   Infecciosas -ANLIS Malbran) for their help in coordinating activities.
   We acknowledge the support of the authorities of the Ministerio de Salud
   de Argentina, Universidad Nacional de General San Martin and Fundacion
   Argentina de Nanotecnologia. We especially thank all the administrative
   and technical staff of Inmunova (C.D., C.L., F.C., L.M., L.Z.) for their
   great work under very difficult circumstances.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Boyer L, 2013, TOXICON, V76, P386, DOI 10.1016/j.toxicon.2013.07.017
   Chen WH, 2017, J PHARM SCI-US, V106, P1961, DOI 10.1016/j.xphs.2017.04.037
   Hiriart Y, 2018, MEDICINA-BUENOS AIRE, V78, P107
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   McAllister F, MEDICINA B AIRES
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Pan X, 2020, BIORXIV, DOI [10.1101/2020.04.07.029884, DOI 10.1101/2020.04.07.029884]
   Quinlan B. D., 2020, BIORXIV, DOI [10.1101/2020.04.10.036418, DOI 10.1101/2020.04.10.036418]
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang J, 2020, J CLIN TRANSL SCI, P1, DOI [DOI 10.1017/CTS.2020.39, 10.1017/cts.2020.39]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Zhang B, 2020, J CHEM RES, V44, P571, DOI 10.1177/1747519820912675
NR 16
TC 0
Z9 0
U1 0
U2 0
PU MEDICINA (BUENOS AIRES)
PI BUENOS AIRES
PA DONATO ALVAREZ 3150, 1427 BUENOS AIRES, ARGENTINA
SN 0025-7680
EI 1669-9106
J9 MEDICINA-BUENOS AIRE
JI Med.-Buenos Aires
PD JUN
PY 2020
VL 80
SU 3
BP 1
EP 6
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA OK3HE
UT WOS:000584543400001
PM 32658841
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Green, BN
   Pence, TV
   Kwan, L
   Rokicki-Parashar, J
AF Green, Bart N.
   Pence, Ti, V
   Kwan, Lawrence
   Rokicki-Parashar, Jesse
TI Rapid Deployment of Chiropractic Telehealth at 2 Worksite Health Centers
   in Response to the COVID-19 Pandemic: Observations from the Field
SO JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS
LA English
DT Article
DE Chiropractic; Telemedicine; Telecommunications; COVID-19 [Supplementary
   Concept]; Pandemics
ID MUSCULOSKELETAL CONDITIONS; TELEREHABILITATION; TELEMEDICINE; THERAPY;
   CARE; REHABILITATION; SERVICES; SITE; PAIN
AB Objective: The purpose of this paper is to describe the rapid deployment of telehealth, particularly real time video conference, for chiropractic services as a response to COVID-19.
   Methods: Two health centers at 2 campuses of a large California corporation have chiropractic care integrated into physical medicine services. Care was suspended beginning on March 17, 2020 to prevent spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among patients and staff. On March 19, the Governor of California issued a stay at home order. With musculoskeletal problems being common in the employee patient population, telehealth services were quickly developed to continue chiropractic care for patients. Using existing infrastructure, several members of the health center team developed chiropractic telehealth operations within 2 days.
   Results: Musculoskeletal telehealth services included examinations, risk assessment, advice, and rehabilitative exercises. These telehealth visits facilitated care that would have otherwise been unavailable to employees. Patients reported that the appointments were helpful, addressed their concerns, and provided a safe method to see their doctor. Regular interprofessional teamwork and relations between the clinic operator and client company were key contributors to operationalizing this service in our integrated healthcare environment.
   Conclusion: We were able to quickly implement real time video conferencing and other forms of telehealth for chiropractic services at 2 worksite health centers. This paper includes information and insights to providers about setting up similar telehealth systems so they may also provide this benefit for patients in their communities during pandemics or disasters.
C1 [Green, Bart N.; Pence, Ti, V] Stanford Hlth Care, Employer Based Integrated Primary Care Hlth Ctr, San Diego, CA USA.
   [Green, Bart N.] Natl Univ Hlth Sci, San Diego, CA USA.
   [Kwan, Lawrence; Rokicki-Parashar, Jesse] Stanford Hlth Care, Employer Based Integrated Primary Care Hlth Ctr, Palo Alto, CA USA.
   [Kwan, Lawrence; Rokicki-Parashar, Jesse] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
RP Green, BN (corresponding author), 10155 Pacific Hts Blvd,Bldg AZ,2nd Floor, San Diego, CA 92121 USA.
EM bgreen@stanfordhealthcare.org
OI Rokicki-Parashar, Jesse/0000-0002-8843-7498; Green, DC, MSEd, PhD, Bart
   N./0000-0002-9906-6397
CR Adamse C, 2018, J TELEMED TELECARE, V24, P511, DOI 10.1177/1357633X17716576
   American Occupational Therapy Association, 2018, AM J OCCUP THER, V72
   Amorim AB, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-019-2454-y
   [Anonymous], 2018, WORKS MED CLIN 2018
   Ansary AM, 2019, J TELEMED TELECARE, DOI 10.1177/1357633X19878330
   Backman CL, 2008, ARTHRIT RHEUM-ARTHR, V59, P1495, DOI 10.1002/art.24116
   Baker N, 2013, HLTH INFORMATICS, P163
   Brennan David M, 2011, Telemed J E Health, V17, P662, DOI 10.1089/tmj.2011.0036
   Brugh V, 2014, BENEFITS Q, P19
   California Department of Public Health, 2020, STAT OFF ANN LAT COV
   California Telehealth Resource Center, WHAT IS TEL CAL TEL
   Calton B, 2020, J PAIN SYMPTOM MANAG
   Cottrell MA, 2018, INT J TELEREHABILITA, V10, P81, DOI 10.5195/ijt.2018.6249
   Cottrell MA, 2018, MUSCULOSKEL SCI PRAC, V38, P99, DOI 10.1016/j.msksp.2018.09.014
   Cottrell MA, 2017, CLIN REHABIL, V31, P625, DOI 10.1177/0269215516645148
   Davis LE, 2014, TELEMED E-HEALTH, V20, P473, DOI 10.1089/tmj.2013.0217
   Fuld & Company, 2009, GROWTH ON SIT HLTH C
   Galea MD, 2019, PHYS MED REH CLIN N, V30, P473, DOI 10.1016/j.pmr.2018.12.002
   Ganapathy K, 2018, NEUROL INDIA, V66, P642, DOI 10.4103/0028-3886.232346
   Gialanella B, 2017, AM J PHYS MED REHAB, V96, P327, DOI 10.1097/PHM.0000000000000610
   Gwilliam E., BILLING TELEMEDICINE
   Hanna J, 2020, CNN
   Herbert MS, 2017, J PAIN, V18, P200, DOI 10.1016/j.jpain.2016.10.014
   Hollander JE, 2020, NEJM CATALYST, P8, DOI [10.1056/CAT.20.0093, DOI 10.1056/CAT.20.0093]
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Howard IM, 2018, MUSCLE NERVE, V58, P475, DOI 10.1002/mus.26115
   Johnston B, 2006, GLOSSARY TELEMEDICIN
   Kairy D, 2013, INT J ENV RES PUB HE, V10, P3998, DOI 10.3390/ijerph10093998
   Kairy D, 2009, DISABIL REHABIL, V31, P427, DOI 10.1080/09638280802062553
   KAMEROW D, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1784
   Kindermann SL, 2014, J OCCUP ENVIRON MED, V56, P990, DOI 10.1097/JOM.0000000000000215
   Lord DJ, 2019, J OCCUP ENVIRON MED, V61, P382, DOI 10.1097/JOM.0000000000001536
   Magoon Vinita, 2020, Fam Pract Manag, V27, P5
   March L, 2014, BEST PRACT RES CL RH, V28, P353, DOI 10.1016/j.berh.2014.08.002
   Mbada CE, 2019, INT J TELEREHABILITA, V11, P41, DOI 10.5195/ijt.2019.6260
   Newsom G, 2020, N3320 OFF GOV
   Primary Care Collaborative, QUICK COVID 19 PRI 7, V7
   Primary Care Collaborative, QUICK COVID 19 PRI 5
   Rawstorn JC, 2016, HEART, V102, P1183, DOI 10.1136/heartjnl-2015-308966
   Ray KN, 2015, JAMA INTERN MED, V175, P1983, DOI 10.1001/jamainternmed.2015.4468
   Richmond T, 2017, INT J TELEREHABILITA, V9, P63, DOI 10.5195/ijt.2017.6232
   Sarsak HI, 2020, INT PHYS MED REHABIL, V5, P93
   Schmidt JM, 2020, NEJM CATALYST
   Tenforde AS, 2017, PM&R, V9, pS51, DOI 10.1016/j.pmrj.2017.02.013
   Truter P, 2014, TELEMED E-HEALTH, V20, P161, DOI 10.1089/tmj.2013.0088
   Turolla A, 2020, PHYS THER
   US Department of Health and Human Sciences, 2020, NOT ENF DISCR TEL RE
   Varkey P, 2008, J TELEMED TELECARE, V14, P322, DOI 10.1258/jtt.2008.080512
   Wheeler I., ORANGE COUNTY CORONA
   Zhou LM, 2019, INT J TELEREHABILITA, V11, P3, DOI 10.5195/ijt.2019.6276
NR 50
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-4754
J9 J MANIP PHYSIOL THER
JI J. Manip. Physiol. Ther.
PD JUN
PY 2020
VL 43
IS 5
DI 10.1016/j.jmpt.2020.05.008
PG 10
WC Health Care Sciences & Services; Integrative & Complementary Medicine;
   Rehabilitation
SC Health Care Sciences & Services; Integrative & Complementary Medicine;
   Rehabilitation
GA OM2ED
UT WOS:000585839600002
PM 32534739
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Weinstein, E
   Ragazzoni, L
   Burkle, F
   Allen, M
   Hogan, D
   Della Corte, F
AF Weinstein, Eric
   Ragazzoni, Luca
   Burkle, Frederick
   Allen, Mea
   Hogan, David
   Della Corte, Francesco
TI Delayed Primary and Specialty Care: The Coronavirus Disease-2019
   Pandemic Second Wave
SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
LA English
DT Letter
DE COVID-19; disaster recovery; incident command system; primary care;
   surge capacity
AB Time is of the essence to continue the pandemic disaster cycle with a comprehensive post-COVID-19 health care delivery system RECOVERY analysis, plan and operation at the local, regional and state level.The second wave of COVID-19 pandemic response are not the ripples of acute COVID-19 patient clusters that will persist until a vaccine strategy is designed and implemented to effect herd immunity. The COVID-19 second wave are the patients that have had their primary and specialty care delayed. This exponential wave of patients requires prompt health care delivery system planning and response.
C1 [Weinstein, Eric; Ragazzoni, Luca; Della Corte, Francesco] Univ Piemonte Orientale, Res Ctr Emergency & Disaster Med CRIMEDIM, Novara, Italy.
   [Burkle, Frederick] Harvard Univ, Harvard Humanitarian Initiat, Boston, MA 02115 USA.
   [Burkle, Frederick] Woodrow Wilson Int Ctr Scholars, Washington, DC USA.
   [Allen, Mea] Boston Publ Hlth Commiss, Off Publ Hlth Preparedness, Inst Emergency Preparedness, Boston, MA USA.
   [Hogan, David] TeamHlth Acad Consortium, Educ Dev, Moore, OK USA.
RP Weinstein, E (corresponding author), Via Lanino 1, I-28100 Novara, NO, Italy.
EM eswein402@gmail.com
RI Corte, Francesco Della/ABI-7646-2020
OI Corte, Francesco Della/0000-0003-1736-2318; Weinstein,
   Eric/0000-0002-1147-5656
CR Becker's Hospital, 2020, BECKERS HOSP REV
   Healthcare Dive, 2020, WHAT US FRONTL PRIM
   Runkle Jennifer Davis, 2012, Am J Public Health, V102, pe24, DOI 10.2105/AJPH.2012.301027
   The Post and Courier, 2020, THE POST AND COURIER
   US Department of Homeland Security, 2016, NAT DIS REC FRAM
NR 5
TC 2
Z9 2
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1935-7893
EI 1938-744X
J9 DISASTER MED PUBLIC
JI Dis. Med. Public Health Prep.
PD JUN
PY 2020
VL 14
IS 3
BP E19
EP E21
DI 10.1017/dmp.2020.148
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OP8NT
UT WOS:000588347800010
PM 32438940
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Naidoo, J
   Reuss, JE
   Suresh, K
   Feller-Kopman, D
   Forde, PM
   Steinke, SM
   Rock, C
   Johnson, DB
   Nishino, M
   Brahmer, JR
AF Naidoo, Jarushka
   Reuss, Joshua E.
   Suresh, Karthik
   Feller-Kopman, David
   Forde, Patrick M.
   Mehta Steinke, Seema
   Rock, Clare
   Johnson, Douglas B.
   Nishino, Mizuki
   Brahmer, Julie R.
TI Immune-related (IR)-pneumonitis during the COVID-19 pandemic:
   multidisciplinary recommendations for diagnosis and management
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE guidelines as topic; immunotherapy; autoimmunity
ID INHIBITOR-RELATED PNEUMONITIS; THERAPY; WUHAN; CHINA
AB Immune-related (IR)-pneumonitis is a rare and potentially fatal toxicity of anti-PD(L)1 immunotherapy. Expert guidelines for the diagnosis and management of IR-pneumonitis include multidisciplinary input from medical oncology, pulmonary medicine, infectious disease, and radiology specialists. Severe acute respiratory syndrome coronavirus 2 is a recently recognized respiratory virus that is responsible for causing the COVID-19 global pandemic. Symptoms and imaging findings from IR-pneumonitis and COVID-19 pneumonia can be similar, and early COVID-19 viral testing may yield false negative results, complicating the diagnosis and management of both entities. Herein, we present a set of multidisciplinary consensus recommendations for the diagnosis and management of IR-pneumonitis in the setting of COVID-19 including: (1) isolation procedures, (2) recommended imaging and interpretation, (3) adaptations to invasive testing, (4) adaptations to the management of IR-pneumonitis, (5) immunosuppression for steroid-refractory IR-pneumonitis, and (6) management of suspected concurrent IR-pneumonitis and COVID-19 infection. There is an emerging need for the adaptation of expert guidelines for IR-pneumonitis in the setting of the global COVID-19 pandemic. We propose a multidisciplinary consensus on this topic, in this position paper.
C1 [Naidoo, Jarushka; Reuss, Joshua E.; Forde, Patrick M.; Brahmer, Julie R.] Johns Hopkins Med Sidney Kimmel Comprehens Canc C, Oncol, Baltimore, MD 21231 USA.
   [Naidoo, Jarushka; Reuss, Joshua E.; Forde, Patrick M.; Brahmer, Julie R.] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD 21218 USA.
   [Suresh, Karthik; Feller-Kopman, David] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA.
   [Mehta Steinke, Seema] Johns Hopkins Univ, Div Infect Dis, Baltimore, MD USA.
   [Rock, Clare] Johns Hopkins Univ, Div Hosp Epidemiol & Infect Control, Baltimore, MD USA.
   [Johnson, Douglas B.] Vanderbilt Univ, Med Ctr, Oncol, Nashville, TN USA.
   [Nishino, Mizuki] Dana Farber Canc Inst, Radiol, Boston, MA 02115 USA.
RP Naidoo, J (corresponding author), Johns Hopkins Med Sidney Kimmel Comprehens Canc C, Oncol, Baltimore, MD 21231 USA.; Naidoo, J (corresponding author), Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD 21218 USA.
EM jnaidoo1@jhmi.edu
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA203636] Funding Source: Medline
CR Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Andruska Neal, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2018-225937
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Betz ME, 2020, J MED INTERNET RES, V22, DOI 10.2196/16253
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Brahmer JR, 2018, J CLIN ONCOL, V36, P1714, DOI 10.1200/JCO.2017.77.6385
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Delaney JW, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1230-8
   Deng Y, 2020, CHINESE MED J-PEKING, V133, P1261, DOI 10.1097/CM9.0000000000000824
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haanen JBAG, 2018, ANN ONCOL, V29, P264, DOI 10.1093/annonc/mdy162
   Haslam A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2535
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Lei JQ, 2020, RADIOLOGY, V295, P18, DOI 10.1148/radiol.2020200236
   Lewis SR, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004477.pub3
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Naidoo J, 2019, J NATL COMPR CANC NE, V17, P712, DOI 10.6004/jnccn.2018.7268
   Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005
   Nishino M, 2017, RADIOGRAPHICS, V37, P1371, DOI 10.1148/rg.2017170015
   Nishino M, 2016, CLIN CANCER RES, V22, P6051, DOI 10.1158/1078-0432.CCR-16-1320
   Nishino M, 2015, NEW ENGL J MED, V373, P288, DOI 10.1056/NEJMc1505197
   Paolo Ascierto A A, 2020, SITC STATEMENT ANTII
   Petri CR, 2019, RESPIR MED CASE REP, V27, DOI 10.1016/j.rmcr.2019.100834
   Puzanov I, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0300-z
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sanchez GO, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0400-4
   Sears CR, 2019, AM J RESP CRIT CARE, V200, pE31, DOI 10.1164/rccm.201906-1202ST
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shi HS, 2020, RADIOLOGY, V295, P20, DOI 10.1148/radiol.2020200269
   Stroud CRG, 2019, J ONCOL PHARM PRACT, V25, P551, DOI 10.1177/1078155217745144
   Suresh K, 2018, J THORAC ONCOL, V13, P1930, DOI 10.1016/j.jtho.2018.08.2035
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   Thompson JA, 2020, J NATL COMPR CANC NE, V18, P230, DOI 10.6004/jnccn.2020.0012
   Thompson JA, 2018, J NATL COMPR CANC NE, V16, P594, DOI 10.6004/jnccn.2018.0047
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   University JH, 2020, COVID 19 AD CLIN MAN
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang K, 2020, CLIN RADIOL, V75, P341, DOI 10.1016/j.crad.2020.03.004
   Wang YJW, 2020, EARLY LOW DOSE SHORT
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health O, 2020, WHO2019NCOVHCFOPERAT
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhao J P, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P183, DOI 10.3760/cma.j.issn.1001-0939.2020.03.008
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   ZY Z, 2020, RADIOLOGY, V200490
NR 61
TC 2
Z9 2
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PD JUN
PY 2020
VL 8
IS 1
AR e000984
DI 10.1136/jitc-2020-000984
PG 8
WC Oncology; Immunology
SC Oncology; Immunology
GA OP2HY
UT WOS:000587901700001
PM 32554619
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Poljak, M
   Korva, M
   Gasper, NK
   Komlos, KF
   Sagadin, M
   Ursic, T
   Zupanc, TA
   Petrovec, M
AF Poljak, Mario
   Korva, Misa
   Gasper, Natasa Knap
   Komlos, Kristina Fujs
   Sagadin, Martin
   Ursic, Tina
   Zupanc, Tatjana Avsic
   Petrovec, Miroslav
TI Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic
   Platform Switch during 48 Hours in the Midst o the COVID-19 Pandemic
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; cobas; cobas 6800
ID CORONAVIRUS
AB Laboratories are currently witnessing extraordinary demand globally for sampling devices, reagents, consumables, and diagnostic instruments needed for timely diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To meet diagnostic needs as the pandemic grows, the U.S. Food and Drug Administration (FDA) recently granted several commercial SARS-CoV-2 tests Emergency Use Authorization (EUA), but manufacturer-independent evaluation data are scarce. We performed the first manufacturer-independent evaluation of the fully automated sample-to-result two-target test cobas 6800 SARS-CoV-2 (cobas) (Roche Molecular Systems, Branchburg, NJ), which received U.S. FDA EUA on 12 March 2020. The comparator was a standardized 3-h SARS-CoV-2 protocol, consisting of RNA extraction using an automated portable instrument, followed by a two-target reverse transcription real-time PCR (RT-PCR), which our laboratory has routinely used since January 2020 (V. M. Corman, O. Landt, M. Kaiser, R. Molenkamp, et al., Euro Surveill 25(3):pii =2000045, 2020, https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045) . cobas and the comparator showed overall agreement of 98.1% and a kappa value of 0.95 on an in-house validation panel consisting of 217 well-characterized retrospective samples. Immediate prospective head-to-head comparative evaluation followed on 502 samples, and the diagnostic approaches showed overall agreement of 99.6% and a kappa value of 0.98. A good correlation (r(2) = 0.96) between cycle threshold values for SARS-CoV-2-specific targets obtained by cobas and the comparator was observed. Our results showed that cobas is a reliable assay for qualitative detection of SARS-CoV-2 in nasopharyngeal swab samples collected in the Universal Transport Medium System (UTM-RT) (Copan, Brescia, Italy). Under the extraordinary circumstances that laboratories are facing worldwide, a safe diagnostic platform switch is feasible in only 48 h and in the midst of the COVID-19 pandemic if carefully planned and executed.
C1 [Poljak, Mario; Korva, Misa; Gasper, Natasa Knap; Komlos, Kristina Fujs; Sagadin, Martin; Ursic, Tina; Zupanc, Tatjana Avsic; Petrovec, Miroslav] Univ Ljubljana, Fac Med, Inst Microbiol & Immunol, Ljubljana, Slovenia.
RP Petrovec, M (corresponding author), Univ Ljubljana, Fac Med, Inst Microbiol & Immunol, Ljubljana, Slovenia.
EM mirc.petrovec@mf.uni-lj.si
OI Poljak, Mario/0000-0002-3216-7564
FU Slovenian Research AgencySlovenian Research Agency - Slovenia [P3-0083];
   EVAGLOBAL project [GA. 871029]; Institute of Microbiology and
   Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana,
   Slovenia
FX This work was funded by the Slovenian Research Agency (grant P3-0083),
   EVAGLOBAL project (GA. 871029) and by the Institute of Microbiology and
   Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana,
   Slovenia.
CR Anderson TP, 2013, J VIROL METHODS, V191, P118, DOI 10.1016/j.jviromet.2013.04.005
   Berger A, 2004, J CLIN VIROL, V29, P13, DOI 10.1016/j.jcv.2003.09.011
   Chan JFW, 2012, J CLIN MICROBIOL, V50, P2525, DOI 10.1128/JCM.00212-12
   Cordes AK, 2020, J CLIN VIROL, V125, DOI 10.1016/j.jcv.2020.104305
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Haveri A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.11.2000266
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kien DTH, 2011, J VIROL METHODS, V177, P168, DOI 10.1016/j.jviromet.2011.08.002
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Memish ZA, 2020, LANCET, V395, P1063, DOI 10.1016/S0140-6736(19)33221-0
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Pfefferle S, 2020, EUROSURVEILLANCE, V25, P18, DOI 10.2807/1560-7917.ES.2020.25.9.2000152
   Szewczuk E, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-113
   WHO, 2020, LAB TEST STRAT REC C
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 14
Z9 14
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2020
VL 58
IS 6
AR e00599-20
DI 10.1128/JCM.00599-20
PG 7
WC Microbiology
SC Microbiology
GA OH1YZ
UT WOS:000582368300026
PM 32277022
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Krishan, K
   Kanchan, T
AF Krishan, Kewal
   Kanchan, Tanuj
TI Lockdown is an effective 'vaccine' against COVID-19: A message from
   India
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE Novel Coronavirus SARS-CoV-2; COVID-19; lockdown; India
AB This communication stresses the importance of the complete lockdown of a developing nation as a powerful tool against COVID-19 acting as a 'vaccine'. India has been under complete lockdown since 24th March 2020 in addition to other measures emphasized by the Indian Government such as promoting hand washing, social distancing, and use of face masks. A strict lockdown is suggested as an effective measure for containing the novel Corona virus infection transmission worldwide.
C1 [Krishan, Kewal] Panjab Univ, Dept Anthropol, Chandigarh, India.
   [Kanchan, Tanuj] All India Inst Med Sci Jodhpur, Dept Forens Med & Toxicol, Jodhpur, Rajasthan, India.
RP Krishan, K (corresponding author), Panjab Univ, Dept Anthropol, UGC Ctr Adv Study, Sect 14, Chandigarh 160014, India.
EM kewalkrishan@pu.ac.in
RI Krishan, Kewal/I-3285-2014; KANCHAN, TANUJ/L-8547-2015
OI Krishan, Kewal/0000-0001-5321-0958; KANCHAN, TANUJ/0000-0003-0346-1075
FU DST PURSE grant; UGC Center of Advanced Study, CAS II
FX Kewal Krishan is supported by a DST PURSE grant and UGC Center of
   Advanced Study, CAS II awarded to the Department of Anthropology, Panjab
   University, Chandigarh, India.
CR Government of India, 2020, INDIA FIGHTS CORONA
   University of Oxford, 2020, CORONA VIRUS GOVT RE
   World Health Organization, 2020, CORONAVIRUS COVID 19
   World Population Review, 2020, LITERACY RATE COUNTR
NR 4
TC 1
Z9 1
U1 3
U2 3
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD JUN
PY 2020
VL 14
IS 6
BP 545
EP 546
DI 10.3855/jidc.12931
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA OH3KX
UT WOS:000582468600001
PM 32683342
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Jia, ZL
   Song, XY
   Shi, JL
   Wang, WD
   He, KL
AF Jia, Zhilong
   Song, Xinyu
   Shi, Jinlong
   Wang, Weidong
   He, Kunlun
TI Transcriptome-based drug repositioning for coronavirus disease 2019
   (COVID-19)
SO PATHOGENS AND DISEASE
LA English
DT Article
DE SARS-CoV-2; COVID-19; drug repositioning; neutrophil degranulation;
   saquinavir; ribavirin
ID SIGNATURES
AB The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) around the world has led to a pandemic with high morbidity and mortality. However, there are no effective drugs to prevent and treat the disease. Transcriptome-based drug repositioning, identifying new indications for old drugs, is a powerful tool for drug development. Using bronchoalveolar lavage fluid transcriptome data of COVID-19 patients, we found that the endocytosis and lysosome pathways are highly involved in the disease and that the regulation of genes involved in neutrophil degranulation was disrupted, suggesting an intense battle between SARS-CoV-2 and humans. Furthermore, we implemented a coexpression drug repositioning analysis, cogena, and identified two antiviral drugs (saquinavir and ribavirin) and several other candidate drugs (such as dinoprost, dipivefrine, dexamethasone and (-)-isoprenaline). Notably, the two antiviral drugs have also previously been identified using molecular docking methods, and ribavirin is a recommended drug in the diagnosis and treatment protocol for COVID pneumonia (trial version 5-7) published by the National Health Commission of the P.R. of China. Our study demonstrates the value of the cogena-based drug repositioning method for emerging infectious diseases, improves our understanding of SARS-CoV-2-induced disease, and provides potential drugs for the prevention and treatment of COVID-19 pneumonia.
C1 [Jia, Zhilong; Song, Xinyu; Shi, Jinlong; Wang, Weidong; He, Kunlun] Chinese Peoples Liberat Army Gen Hosp, Key Lab Biomed Engn & Translat Med, Minist Ind & Informat Technol, Med Innovat Res Div, Beijing 100853, Peoples R China.
   [Jia, Zhilong; Song, Xinyu; Shi, Jinlong; Wang, Weidong; He, Kunlun] Chinese Peoples Liberat Army Gen Hosp, Beijing Key Lab Precis Med Chron Heart Failure, Med Innovat Res Div, Beijing 100853, Peoples R China.
RP Jia, ZL; Wang, WD; He, KL (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Key Lab Biomed Engn & Translat Med, Minist Ind & Informat Technol, Med Innovat Res Div, Beijing 100853, Peoples R China.
EM jiazhilong@plagh.org; wangwd301@126.com; kunlunhe@plagh.org
OI Jia, Zhilong/0000-0003-2370-5073
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31701155]; National Key Research and
   Development Program of China [2017YFC0908403]
FX This work was supported by the National Natural Science Foundation of
   China [grant number 31701155]; National Key Research and Development
   Program of China [grant number 2017YFC0908403].
CR Arakelyan A, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11120677
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Ayman F, 2020, IDENTIFICATION FDA A, DOI [10.26434/chemrxiv.12049647.ChemRxiv, 10.26434/chemrxiv.12003930.v2, DOI 10.26434/CHEMRXIV.12003930.V2]
   Chong YP, 2015, INFECT CHEMOTHER, V47, P212, DOI 10.3947/ic.2015.47.3.212
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Ge Y, 2020, BIORXIV, DOI [10.1101/2020.03.11.986836, DOI 10.1101/2020.03.11.986836]
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Jahchan NS, 2013, CANCER DISCOV, V3, P1364, DOI 10.1158/2159-8290.CD-13-0183
   Jia ZL, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2737-8
   Kang WY, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00204
   Lam TT-Y, 2020, IDENTIFICATION 2019, DOI [10.1101/2020.02.13.945485, 10.1101/2020.02.13.945485., DOI 10.1101/2020.02.13.945485]
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Matsuyama S., 2020, INHALED CORTICOSTERO, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]
   National Health Commission and State Administration of Traditional Chinese Medicine, 2020, CHIN MED J, V133
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Ruan Z., 2020, PREPRINTS, DOI [10.20944/preprints202003.0024.v1, DOI 10.20944/PREPRINTS202003.0024.V1]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang J, 2020, ACE2 EXPRESSION COLO, DOI [10.1101/2020.02.05.20020545, DOI 10.1101/2020.02.05.20020545]
   Wang L, 2014, CPT-PHARMACOMET SYST, V3, DOI 10.1038/psp.2014.44
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YC, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007540
   Wang YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078518
   Wu ZK, 2013, MOL BIOSYST, V9, P1268, DOI 10.1039/c3mb25382a
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang J, 2020, BIORXIV, DOI [10.1101/2020.02.05.935387., 10.1101/2020.02.05.9353872020.02.05.935387, DOI 10.1101/2020.02.05.935387]
   Zhang Z, 2019, NUCLEIC ACIDS RES, V47, pD8, DOI 10.1093/nar/gky993
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
NR 40
TC 1
Z9 1
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2049-632X
J9 PATHOG DIS
JI Pathog. Dis.
PD JUN
PY 2020
VL 78
IS 4
AR ftaa036
DI 10.1093/femspd/ftaa036
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OH1EW
UT WOS:000582315900007
PM 32667665
OA Green Published
DA 2021-01-01
ER

PT J
AU Montravers, P
   de Tymowski, C
   Assadi, M
   Yung, S
   Kantor, E
AF Montravers, Philippe
   de Tymowski, Christian
   Assadi, Maksud
   Yung, Sonia
   Kantor, Elie
TI Just a little bit more patience ...
SO ANAESTHESIA CRITICAL CARE & PAIN MEDICINE
LA English
DT Letter
DE COVID-19; Antiviral therapy; Clinical trials
C1 [Montravers, Philippe; de Tymowski, Christian; Assadi, Maksud; Yung, Sonia; Kantor, Elie] CHU Bichat Claude Bernard, AP HP, DMU PARABOL, HUPNVS,Dept Anesthesie Reanimat, Paris, France.
   [Montravers, Philippe; de Tymowski, Christian; Assadi, Maksud; Yung, Sonia] Univ Paris, Paris, France.
   [Montravers, Philippe] Univ Paris, INSERM, UMR 1152, Paris, France.
   [de Tymowski, Christian] Univ Paris, INSERM, UMR 1149, Paris, France.
RP Montravers, P (corresponding author), CHU Bichat Claude Bernard, Dept Anesthesie Reanimat, 46 Rue Henri Huchard, F-75018 Paris, France.
EM philippe.montravers@aphp.fr
CR Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478
   Pallmann P, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1017-7
   Sanders JM, 2020, JAMA
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
NR 4
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 2352-5568
J9 ANAESTH CRIT CARE PA
JI Anaesth. Crit. Care Pain Med.
PD JUN
PY 2020
VL 39
IS 3
BP 383
EP 384
DI 10.1016/j.accpm.2020.05.004
PG 2
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA OE6PD
UT WOS:000580649600018
PM 32405519
OA Green Published
DA 2021-01-01
ER

PT J
AU Novy, E
   Scala-Bertola, J
   Roger, C
   Guerci, P
AF Novy, Emmanuel
   Scala-Bertola, Julien
   Roger, Claire
   Guerci, Philippe
TI Preliminary therapeutic drug monitoring data of beta-lactams in
   critically ill patients with SARS-CoV-2 infection
SO ANAESTHESIA CRITICAL CARE & PAIN MEDICINE
LA English
DT Letter
DE beta lactam; Therapeutic drug monitoring; COVID-19
C1 [Novy, Emmanuel; Guerci, Philippe] Univ Hosp Nancy, Dept Anaesthesiol & Intens Care Med, F-54511 Vandoeuvre Les Nancy, France.
   [Novy, Emmanuel; Scala-Bertola, Julien; Guerci, Philippe] Univ Lorraine, F-54000 Nancy, France.
   [Scala-Bertola, Julien] Dept Clin Pharmacol & Toxicol, F-54000 Nancy, France.
   [Roger, Claire] Nimes Caremeau Univ Hosp, Dept Anaesthesiol & Intens Care Pain & Emergency, F-30029 Nimes 9, France.
   [Roger, Claire] Univ Montpellier Nimes, EA Dysfonct Interfaces Vasc 2992, F-30908 Nimes 2, France.
RP Novy, E (corresponding author), Univ Hosp Nancy, Dept Anaesthesiol & Intens Care Med, F-54511 Vandoeuvre Les Nancy, France.
EM e.novy@chru-nancy.fr
OI Guerci, Philippe/0000-0002-4664-1861
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Bellouard R, 2020, J PHARMACEUT BIOMED, V178, DOI 10.1016/j.jpba.2019.112904
   Boschung-Pasquier L, 2020, CLIN MICROBIOL INFEC, V26, P333, DOI 10.1016/j.cmi.2019.06.028
   Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x
   Guilhaumou R, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2378-9
   Leone M, 2019, ANAESTH CRIT CARE PA, V38, P647, DOI 10.1016/j.accpm.2019.09.009
   Quinton MC, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00654-17, 10.1128/aac.00654-17]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 2352-5568
J9 ANAESTH CRIT CARE PA
JI Anaesth. Crit. Care Pain Med.
PD JUN
PY 2020
VL 39
IS 3
BP 387
EP 388
DI 10.1016/j.accpm.2020.04.005
PG 2
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA OE6PD
UT WOS:000580649600020
PM 32315803
OA Green Published
DA 2021-01-01
ER

PT J
AU Velly, L
   Gayat, E
   Quintard, H
   Weiss, E
   De Jong, A
   Cuvillon, P
   Audibert, G
   Amour, J
   Beaussier, M
   Biais, M
   Bloc, S
   Bonnet, MP
   Bouzat, P
   Brezac, G
   Dahyot-Fizelier, C
   Dahmani, S
   de Queiroz, M
   Di Maria, S
   Ecoffey, C
   Futier, E
   Geeraerts, T
   Jaber, H
   Heyer, L
   Hoteit, R
   Joannes-Boyau, O
   Kern, D
   Langeron, O
   Lasocki, S
   Launey, Y
   le Sache, F
   Lukaszewicz, AC
   Maurice-Szamburski, A
   Mayeur, N
   Michel, F
   Minville, V
   Mirek, S
   Montravers, P
   Morau, E
   Muller, L
   Muret, J
   Nouette-Gaulain, K
   Orban, JC
   Orliaguet, G
   Perrigault, PF
   Plantet, F
   Pottecher, J
   Quesnel, C
   Reubrecht, V
   Rozec, B
   Tavernier, B
   Veber, B
   Veyckmans, F
   Charbonneau, H
   Constant, I
   Frasca, D
   Fischer, MO
   Huraux, C
   Blet, A
   Garnier, M
AF Velly, Lionel
   Gayat, Etienne
   Quintard, Herve
   Weiss, Emmanuel
   De Jong, Audrey
   Cuvillon, Philippe
   Audibert, Gerard
   Amour, Julien
   Beaussier, Marc
   Biais, Matthieu
   Bloc, Sebastien
   Bonnet, Marie Pierre
   Bouzat, Pierre
   Brezac, Gilles
   Dahyot-Fizelier, Claire
   Dahmani, Souhayl
   de Queiroz, Mathilde
   Di Maria, Sophie
   Ecoffey, Claude
   Futier, Emmanuel
   Geeraerts, Thomas
   Jaber, Haithem
   Heyer, Laurent
   Hoteit, Rim
   Joannes-Boyau, Olivier
   Kern, Delphine
   Langeron, Olivier
   Lasocki, Sigismond
   Launey, Yoan
   le Sache, Frederic
   Lukaszewicz, Anne Claire
   Maurice-Szamburski, Axel
   Mayeur, Nicolas
   Michel, Fabrice
   Minville, Vincent
   Mirek, Sebastien
   Montravers, Philippe
   Morau, Estelle
   Muller, Laurent
   Muret, Jane
   Nouette-Gaulain, Karine
   Orban, Jean Christophe
   Orliaguet, Gilles
   Perrigault, Pierre Francois
   Plantet, Florence
   Pottecher, Julien
   Quesnel, Christophe
   Reubrecht, Vanessa
   Rozec, Bertrand
   Tavernier, Benoit
   Veber, Benoit
   Veyckmans, Francis
   Charbonneau, Helene
   Constant, Isabelle
   Frasca, Denis
   Fischer, Marc-Olivier
   Huraux, Catherine
   Blet, Alice
   Garnier, Marc
TI Guidelines: Anaesthesia in the context of COVID-19 pandemic
SO ANAESTHESIA CRITICAL CARE & PAIN MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Airway management; Infection prevention and
   control; Personal protective equipment; Viruses
ID RANDOMIZED CLINICAL-TRIAL; N95 RESPIRATORS; MEDICAL MASKS; PREVENTING
   INFLUENZA; INFECTIONS; CHILDREN; OPTIONS
AB Objectives: The world is currently facing an unprecedented healthcare crisis caused by the COVID-19 pandemic. The objective of these guidelines is to produce a framework to facilitate the partial and gradual resumption of intervention activity in the context of the COVID-19 pandemic.
   Methods: The group has endeavoured to produce a minimum number of recommendations to highlight the strengths to be retained in the 7 predefined areas: (1) protection of staff and patients; (2) benefit/risk and patient information; (3) preoperative assessment and decision on intervention; (4) modalities of the preanaesthesia consultation; (5) specificity of anaesthesia and analgesia; (6) dedicated circuits and (7) containment exit type of interventions.
   Results: The SFAR Guideline panel provides 51 statements on anaesthesia management in the context of COVID-19 pandemic. After one round of discussion and various amendments, a strong agreement was reached for 100% of the recommendations and algorithms.
   Conclusion: We present suggestions for how the risk of transmission by and to anaesthetists can be minimised and how personal protective equipment policies relate to COVID-19 pandemic context. (C) 2020 The Author(s). Published by Elsevier Masson SAS on behalf of Societe francaise d'anesthesie et de reanimation (Sfar).
C1 [Velly, Lionel] Aix Marseille Univ, Univ Hosp Timone, AP HM, Dept Anaesthesiol & Crit Care Med, F-13005 Marseille, France.
   [Velly, Lionel] Aix Marseille Univ, Inst Neurosci Timone, UMR7289, CNRS, Marseille, France.
   [Gayat, Etienne] Univ Paris, Lariboisiere Hosp, AP HP Nord, DMU Parabol,Dept Anaesthesiol & Crit Care, Paris, France.
   [Gayat, Etienne; Blet, Alice] Univ Paris, Cardiovasc Markers Stress Condit MASCOT, Inserm UMR S 942, Paris, France.
   [Quintard, Herve] Reg Univ Hosp Montpellier, Dept Anaesthesia & Intens Care Unit, St Eloi Hosp, Montpellier, France.
   [Weiss, Emmanuel] Univ Montpellier, CNRS UMR 9214, Inserm U1046, PhyMedExp, Montpellier, France.
   [Weiss, Emmanuel] Ctr Hosp Univ Nice, Intens Care Unit, Pasteur Hosp 2, Nice, France.
   [De Jong, Audrey; Hoteit, Rim] Beaujon Hosp, AP HP Nord, DMU Parabol, Dept Anaesthesiol & Crit Care, Paris, France.
   [De Jong, Audrey] Univ Paris, INSERM, Inserm UMR S1149, Paris, France.
   [Cuvillon, Philippe] CHU Caremeau, Dept Anaesthesiol, Beaujon Hosp, Nimes, France.
   [Audibert, Gerard] Lorraine Univ, Nancy Univ Hosp, Dept Anaesthesia & Intens Care, F-54000 Nancy, France.
   [Amour, Julien] Hop Prive Jacques Cartier, Cardiovasc & Thorac Surg Dept, F-91300 Massy, France.
   [Beaussier, Marc] Inst Mutualiste Montsouris, Dept Anesthesie, F-75014 Paris, France.
   [Biais, Matthieu] CHU Bordeaux, Dept Anaesthesiol & Crit Care, Pellegrin Hosp, Bordeaux, France.
   [Biais, Matthieu] Bordeaux Univ, Biol Cardiovasc Dis, Inserm UMR S 1034, Bordeaux, France.
   [Bloc, Sebastien] CMC Ambroise Pare, Dept Anesthesie, F-92200 Neuilly Sur Seine, France.
   [Bonnet, Marie Pierre] Armand Trousseau Univ Hosp, Assistance Publ Hop Paris, Dept Anaesthesiol & Crit Care, Paris, France.
   [Bonnet, Marie Pierre] Univ Paris, Inserm INRA, Ctr Epidemiol & Stat Sorbonne Paris Cite CRESS, Obstetr Perinatal & Paediat Epidemiol Res Team EP, Paris, France.
   [Bonnet, Marie Pierre] Hop Cochin, Assistance Publ Hop Paris, Dept Anaesthesiol & Crit Care, Paris, France.
   [Bouzat, Pierre] Grenoble Univ Hosp, Dept Anaesthesiol & Intens Care Med, F-38000 Grenoble, France.
   [Brezac, Gilles] Lenval Childrens Hosp, Anaesthesiol, F-06200 Nice, France.
   [Dahyot-Fizelier, Claire] Univ Hosp Poitiers, Anaesthesia & Intens Care, Poitiers, France.
   [Dahyot-Fizelier, Claire] Univ Poitiers, Pharmacol Antiinfect Agents, Inserm UMR1070, Poitiers, France.
   [Dahmani, Souhayl] Robert Debre Univ Hosp, AP HP, Inserm U1141, DHU PROTECT,Dept Anaesthesia & Intens Care, Paris, France.
   [de Queiroz, Mathilde] Femme Mere Enfant Hosp, Dept Paediat Anaesthesia & Intens Care, Lyon, France.
   [Di Maria, Sophie; Reubrecht, Vanessa] Hop La Pitie Salpetriere, AP HP, Dept Anaesthesiol & Crit Care, Paris, France.
   [Ecoffey, Claude] Rennes 1 Univ, CHU Rennes, Dept Anaesthesia & Intens Care, Inserm UMR 991,CIC 1414, Rennes, France.
   [Futier, Emmanuel] CHU Clermont Ferrand, Dept Anaesthesiol & Crit Care, Estaing Hosp, Clermont Ferrand, France.
   [Futier, Emmanuel] Univ Clermont Auvergne, CNRS, Inserm U 1103, Clermont Ferrand, France.
   [Geeraerts, Thomas] Univ Toulouse 3 Paul Sabatier, CHU Toulouse, Toulouse Neuroimaging Ctr ToNIC, Pole Anesthesie Reanimat,Inserm,UMR 1214, F-31059 Toulouse, France.
   [Jaber, Haithem] Caen Univ Hosp, Dept Anaesthesia, Caen, France.
   [Jaber, Haithem] Caen Univ Hosp, Dept Intens Care, Caen, France.
   [Heyer, Laurent] Croix Rousse Hosp, Dept Anaesthesiol & Intens Care Med, Intens Care Unit, Lyon, France.
   [Joannes-Boyau, Olivier] Ctr Hosp Univ CHU Bordeaux, Ctr Med Chirurg Magellan, Serv Anesthesie Reanimat Sud, F-33000 Bordeaux, France.
   [Kern, Delphine] Univ Hosp Toulouse, Children Hosp, Dept Anaesthesia, Toulouse, France.
   [Kern, Delphine] Univ Hosp Toulouse, Children Hosp, Dept Intens Care, Toulouse, France.
   [Langeron, Olivier] Univ Paris Est Creteil UPEC, Henri Mondor Univ Hosp, Assistance Publ Hop Paris, Dept Anaesthesiol & Crit Care Med, Paris, France.
   [Lasocki, Sigismond] UBL Univ Angers, Dept Anaesthesiol & Crit Care Med, CHU Angers, Angers, France.
   [Launey, Yoan] Ctr Hosp Univ Rennes, Dept Anaesthesiol & Crit Care Med, Rennes, France.
   [le Sache, Frederic] 6 Sorbonne Univ, Dept Anaesthesiol & Intens Care, DMU Dream, AP HP, Paris, France.
   [le Sache, Frederic] Clin Remusat, F-75016 Paris, France.
   [le Sache, Frederic] Clin Jouvenet, F-75016 Paris, France.
   [Lukaszewicz, Anne Claire] Univ Lyon, EA 7426 Pathophysiol Injury Induced Immunosuppres, Lyon, France.
   [Lukaszewicz, Anne Claire] Hosp Civils Lyon, Neurol Hosp, Dept Anaesthesiol & Crit Care, Lyon, France.
   [Maurice-Szamburski, Axel] Clin Monticelli Velodrome, GDS, Dept Anaesthesia, F-13008 Marseille, France.
   [Mayeur, Nicolas; Charbonneau, Helene] Clin Pasteur, Anaesthesiol & Intens Care Med, F-31076 Toulouse, France.
   [Michel, Fabrice] La Timone Hosp, Dept Paediat Intens Care Unit, Assistance Publ Hop Marseille, Marseille, France.
   [Minville, Vincent] Toulouse Univ Hosp, Dept Anaesthesiol & Intens Care, F-31432 Toulouse, France.
   [Minville, Vincent] Univ Paul Sabatier, I2MC, U1048, INSERM,Inst Metab & Cardiovasc Dis, F-31432 Toulouse, France.
   [Mirek, Sebastien] Dijon Univ Hosp, Dept Anaesthesiol & Intens Care, F-21079 Dijon, France.
   [Mirek, Sebastien] Univ Hosp Dijon, U SEEM, Healthcare Simulat Ctr, F-21079 Dijon, France.
   [Montravers, Philippe] Univ Paris, Dept Anaesthesiol & Crit Care, CHU Bichat Claude Bernard, AP HP Nord,DMU Parabol, Paris, France.
   [Montravers, Philippe; Quesnel, Christophe; Garnier, Marc] Univ Paris, Epidemiol & Physiopathol Resp Dis, Inserm UMR S 1152, Paris, France.
   [Morau, Estelle] Hop Univ Arnaud de Villeneuve, Dept Anaesthesiol & Crit Care Med, Montpellier, France.
   [Muller, Laurent] Univ Montpellier, Nimes Caremeau Univ Hosp, Pain & Emergency Med, Dept Anaesthesiol & Intens Care, Pl Prof Robert Debre, F-30029 Nimes 9, France.
   [Muller, Laurent] Montpellier Nimes Univ, Fac Med, Physiol Dept, Univ Montpellier,EA 2992, Nimes, France.
   [Muret, Jane] PSL Res Univ, Inst Curie, F-75005 Paris, France.
   [Nouette-Gaulain, Karine] Inst Curie, Dept Anaesthesiol Intens Care & Pain, F-75005 Paris, France.
   [Orban, Jean Christophe] Nice Univ Hosp, Dept Anaesthesiol & Intens Care Med, Nice, France.
   [Orliaguet, Gilles] Univ Hosp Necker Enfants Malad, Surg Paediat Intens Care Unit, Paris, France.
   [Orliaguet, Gilles] Paris Descartes Univ Paris V, EA08 Pharmacol & Valuat Therapeut Chez Enfant & F, Paris, France.
   [Perrigault, Pierre Francois] Montpellier Univ, Gui de Chauliac Hosp, Dept Anaesthesia & Crit Care Med, Montpellier, France.
   [Plantet, Florence] Clin Gen, Serv Anesthesie Reanimat, 4 Chemin Tour La Reine, Annecy, France.
   [Pottecher, Julien] Hop Univ Strasbourg HUS, Dept Anaesthesiol & Crit Care, Strasbourg, France.
   [Pottecher, Julien] Federat Med Translat Strasbourg FMTS, Strasbourg, France.
   [Quesnel, Christophe] Sorbonne Univ, Sch Med, Tenon Hosp, AP HP,DMU DREAM,Dept Anaesthesiol & Crit Care, Paris, France.
   [Rozec, Bertrand] CHU Nantes, Hop Laennec, Anesthesie Reanimat, 1 Blvd Jacques Monod, F-44093 Nantes, France.
   [Tavernier, Benoit] CHU Lille, Dept Anaesthesiol & Crit Care, Pole Anesthesie Reanimation, F-59000 Lille, France.
   [Veber, Benoit] Univ Rouen Normandie, Dept Anaesthesiol & Crit Care, Rouen, France.
   [Veyckmans, Francis] Univ Hosp Lille, Jeanne de Flandre Hosp, Dept Paediat Anaesthesia, Lille, France.
   [Constant, Isabelle] Sorbonne Univ, Anaesthesiol Dept, DMU DREAM, Hop Armand Trousseau,Assistance Publ Hop Paris, Paris, France.
   [Frasca, Denis] Poitiers Univ, Dept Anaesthesiol & Crit Care, CHU Poitiers, Poitiers, France.
   [Fischer, Marc-Olivier] Normandie Univ, CHU Caen Normandie, UNICAEN, Dept Anaesthesiol & Crit Care, F-14000 Caen, France.
   [Huraux, Catherine] Clin Cedres, Dept Anaesthesiol, F-38130 Echirolles, France.
   [Blet, Alice] Univ Paris, Lariboisiere St Louis Hosp, AP HP Nord, Dept Anaesthesiol,Crit Care & Burn Ctr,DMU Parabo, Paris, France.
   [Blet, Alice] Univ Ottawa, Univ Ottawa Heart Inst, Ottawa, ON, Canada.
   [Garnier, Marc] 6 Sorbonne Univ, DMU Dream, St Antoine Hosp, AP HP,Dept Anaesthesiol & Crit Care, Paris, France.
   [Garnier, Marc] Sorbonne Univ, Sch Med, Paris, France.
RP Velly, L (corresponding author), Ctr Hosp Univ Timone, Serv Anesthesie Reanimat, 264 Rue St Pierre, F-13005 Marseille 5, France.
EM lionel.velly@ap-hm.fr
RI Alice, Blet/V-7940-2017; Minville, Vincent/ABE-4286-2020
OI Alice, Blet/0000-0003-3885-9569; Minville, Vincent/0000-0003-0516-4939;
   Rozec, Bertrand/0000-0002-2226-3982; Frasca, Denis/0000-0003-1230-715X
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Ambulatory Surgery Center Association (ASCA), STAT AMB SURG CTR AS
   [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   [Anonymous], UT AINS CHEZ PAT ATT
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bartoszko JJ, 2020, INFLUENZA OTHER RESP, V14, P365, DOI 10.1111/irv.12745
   Belser JA, 2013, MICROBIOL MOL BIOL R, V77, P144, DOI 10.1128/MMBR.00058-12
   Besnier E, 2020, WORLD J SURG, V44, P1695, DOI 10.1007/s00268-020-05501-6
   Bourouiba L, 2020, JAMA-J AM MED ASSOC, V323, P1837, DOI 10.1001/jama.2020.4756
   Bourouiba L, 2016, NEW ENGL J MED, V375, pE15, DOI 10.1056/NEJMicm1501197
   Breslin Noelle, 2020, Am J Obstet Gynecol MFM, V2, P100118, DOI 10.1016/j.ajogmf.2020.100118
   Brindle M, APPROACHING SURG TRI
   Carenzo L, 2020, ANAESTHESIA, V75, P928, DOI 10.1111/anae.15072
   Caruso D, 2020, RADIOLOGY, V296, pE79, DOI 10.1148/radiol.2020201237
   Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467
   Centers for Disease Control, TRAV COUNTR WID SUST
   Centers for Disease Control and Prevention (CDC), WORKPL SAF HLTH TOP
   Chang D, 2020, LANCET RESP MED, V8, pE13, DOI 10.1016/S2213-2600(20)30066-7
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen XD, 2020, ANESTHESIOLOGY, V132, P1307, DOI 10.1097/ALN.0000000000003301
   Cheng MP, 2020, ANN INTERN MED, V172, P726, DOI 10.7326/M20-1301
   Coccolini F, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00307-2
   Dai X., PEKING U HOSP W GF D
   DePhillipo NN, 2020, J BONE JOINT SURG AM, V102, P933, DOI 10.2106/JBJS.20.00489
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Feng GZ, 2020, CASE STUD THERM ENG, V21, DOI 10.1016/j.csite.2020.100685
   FitzGerald GA, 2020, SCIENCE, V367, P1434, DOI 10.1126/science.abb8034
   French National Authority for Health, 2020, PLAC SER TEST MAN ST
   Greenland JR, 2020, ANESTHESIOLOGY, V132, P1346, DOI 10.1097/ALN.0000000000003303
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Health C for D and R, 2020, N95 RESP SURG MASKS
   KeitaMeyer H, GESTION RISQUE THROM
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Lai YY, 2020, ANESTH ANALG, V131, pE31, DOI 10.1213/ANE.0000000000004869
   Le Bourgeois M, 2016, J PEDIATR-US, V175, P47, DOI 10.1016/j.jpeds.2016.05.025
   Lee-Archer P, 2020, PEDIATR ANESTH, V30, P636, DOI 10.1111/pan.13889
   Li YK, 2020, CURR MED SCI, V40, P295, DOI 10.1007/s11596-020-2176-2
   Lie SA, 2020, CAN J ANESTH, V67, P885, DOI 10.1007/s12630-020-01637-0
   Lindsley WG, 2014, J OCCUP ENVIRON HYG, V11, P509, DOI 10.1080/15459624.2013.877591
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Little P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1185
   Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Loeb M, 2009, JAMA-J AM MED ASSOC, V302, P1865, DOI 10.1001/jama.2009.1466
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   MacIntyre CR, 2013, AM J RESP CRIT CARE, V187, P960, DOI 10.1164/rccm.201207-1164OC
   MacIntyre CR, 2011, INFLUENZA OTHER RESP, V5, P170, DOI 10.1111/j.1750-2659.2011.00198.x
   Matava CT, 2020, ANESTH ANALG, V131, P61, DOI 10.1213/ANE.0000000000004872
   Matava CT, 2020, CAN J ANESTH, V67, P902, DOI 10.1007/s12630-020-01649-w
   Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205
   Montravers P, PROPOSITIONS PRISE C
   Mullen-Fortino M, 2019, TELEMED E-HEALTH, V25, P137, DOI 10.1089/tmj.2017.0133
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Patel R, 2020, MBIO, V11, DOI 10.1128/mBio.00722-20
   Plaud B, 2020, ANAESTH CRIT CARE PA, V39, P125, DOI 10.1016/j.accpm.2020.01.005
   Prachand VN, 2020, J AM COLL SURGEONS, DOI [10.1016/j.jamcoll-surg.2020.04.011, DOI 10.1016/J.JAMCOLL-SURG.2020.04.011]
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Raboud J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010717
   Radonovich LJ, 2019, JAMA-J AM MED ASSOC, V322, P824, DOI 10.1001/jama.2019.11645
   Rajan N, 2020, ANESTH ANALG, V131, P31, DOI 10.1213/ANE.0000000000004847
   Reddy JI, 2015, ANESTHESIOLOGY, V122, P39, DOI 10.1097/ALN.0000000000000512
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Rosero EB, 2017, J SURG RES, V219, P108, DOI 10.1016/j.jss.2017.05.071
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Scharfman BE, 2016, EXP FLUIDS, V57, DOI 10.1007/s00348-015-2078-4
   Seah I, 2020, OCUL IMMUNOL INFLAMM, V28, P391, DOI 10.1080/09273948.2020.1738501
   SFAR -SRLF, REC EXP PORT PRIS CH
   Shoham S, COMP PROTECTION OCUL
   Singh M, 2003, TROP MED INT HEALTH, V8, P408, DOI 10.1046/j.1365-3156.2003.01049.x
   Soldati G, 2020, J ULTRAS MED, V39, P1413, DOI 10.1002/jum.15285
   Stahel PF, 2020, PATIENT SAF SURG, V14, DOI 10.1186/s13037-020-00235-9
   Susen S, TRAITEMENT ANTICOAGU
   Tam A, 2017, INTERN MED J, V47, P933, DOI 10.1111/imj.13484
   Tan TK, 2004, ANAESTH INTENS CARE, V32, P394, DOI 10.1177/0310057X0403200316
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tung A, 2020, BRIT J ANAESTH, V124, P480, DOI 10.1016/j.bja.2019.12.041
   University of Liverpool, COVID 19 DRUG INT
   White PF, 2006, BEST PRACT RES-CLIN, V20, P181, DOI 10.1016/j.bpa.2005.08.001
   Wong J, 2020, CAN J ANESTH, V67, P732, DOI 10.1007/s12630-020-01620-9
   World Health Organization, Q A COR COVID 19
   World Health Organization, PROT YOURS TRAV COR
   World Health Organization, COR DIS COVID 19 TEC
   Xiao SY, 2020, J MED VIROL, V92, P464, DOI 10.1002/jmv.25702
   Yu N, 2020, LANCET INFECT DIS, V20, P559, DOI 10.1016/S1473-3099(20)30176-6
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang S., WHAT IT REALLY MEANS
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhong Q, 2020, BRIT J ANAESTH, V124, P670, DOI 10.1016/j.bja.2020.03.007
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
NR 92
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 2352-5568
J9 ANAESTH CRIT CARE PA
JI Anaesth. Crit. Care Pain Med.
PD JUN
PY 2020
VL 39
IS 3
BP 395
EP 415
DI 10.1016/j.accpm.2020.05.012
PG 21
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA OE6PD
UT WOS:000580649600024
PM 32512197
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Afemikhe, JA
   Esewe, RE
   Enuku, CA
   Ehwarieme, TA
AF Afemikhe, Juliana A.
   Esewe, Roselyd E.
   Enuku, Christie A.
   Ehwarieme, Timothy A.
TI Transmission Based Precaution Practices among Nurses in Edo State,
   Nigeria during COVID-19 Pandemic
SO AFRICAN JOURNAL OF REPRODUCTIVE HEALTH
LA English
DT Article
DE Covid-19; Health facilities; Nurses; Practice; Transmission based
   precautions; Edo State; Nigeria
ID HEALTH-CARE WORKERS; KNOWLEDGE; OUTBREAK
AB The novel covid-19 pandemic is a highly infectious disease without known specific treatment and vaccine. Transmission based precautions are important in the fight against the virus. This study investigated the level of transmission-based precautions practiced, the predictors of correct practices, and the challenges experienced by nurses in public health facilities in Edo State during the outbreak of the Covid-19 pandemic. The study employed a descriptive cross-sectional survey to elicit responses from 367 front line nurses using a Google online questionnaire. Data analysis involved descriptive statistics and logistic regression analysis. The majority 314(85.6%) of the respondents maintained a good level of transmission-based precautions practice. Hand hygiene was performed by 327(89.1%) of the respondents. Academic qualification was a significant predictor of good practice in favour of respondents with a degree in nursing. Challenges identified were lack of financial motivation, fear of infecting family members and fear of contracting the virus (93.5%). It was concluded that nurses in Edo State Nigeria have good transmission-based practices in relation to covid-19 however efforts should be made to ensure 100% compliance and sustain practices.
C1 [Afemikhe, Juliana A.; Esewe, Roselyd E.; Enuku, Christie A.; Ehwarieme, Timothy A.] Univ Benin, Coll Med Sci, Sch Basic Med Sci, Dept Nursing Sci, Benin, Nigeria.
RP Afemikhe, JA (corresponding author), Univ Benin, Coll Med Sci, Sch Basic Med Sci, Dept Nursing Sci, Benin, Nigeria.
EM ayafegbeh@gmail.com
CR Angaw DA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030784
   Arinze-Onyia SU, 2018, NIGER J CLIN PRACT, V21, P149, DOI 10.4103/njcp.njcp_69_17
   Asahafi A, 2016, INT J ENV RES PUB HE, V13, P1
   Denton A, 2020, NURS TIMES, V116, P26
   Department of Health and Social Care, 2020, COVID 19 GUID INF PR, V1, P1
   Efstathiou G, 2011, BMC NURS, V10, DOI 10.1186/1472-6955-10-1
   Fagbo SF, 2015, EMERG INFECT DIS, V21, P1981, DOI 10.3201/eid2111.150944
   Fayaz SH, 2014, J INFECT DEV COUNTR, V8, P535, DOI 10.3855/jidc.4143
   Felix AMS, 2013, J INFECT CONTROL, V2, P106
   Feng S, 2020, LANCET RESP MED, pS2213
   Gebresilassie A, 2014, J COMMUNITY MED HLTH, V4, P286, DOI DOI 10.4172/2161-0711.1000286
   Haile TG, 2017, J ENVIRON PUBLIC HEA, V2017, DOI 10.1155/2017/2050635
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   MEDSCAPE, 2020, MEM HEALTHC WORK WHO
   Ng NaWi, 2012, Global Health Action, V5, P10367
   Nofal Maysa, 2017, J Infect Prev, V18, P182, DOI 10.1177/1757177417693676
   Ogonia D, 2015, J INFECT PREVENTION, V16, P16
   Olum R, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00181
   Park HY, 2015, EUROSURVEILLANCE, V20, P2, DOI 10.2807/1560-7917.ES2015.20.25.21169
   Politi D., 2020, WHO INVESTIGATING RE
   Punia Sangini, 2014, Int Sch Res Notices, V2014, P685072, DOI 10.1155/2014/685072
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   Saqlain M, 2020, J HOSP INFECT, DOI [10.1016/j.jhin/2020.05.007, DOI 10.1016/J.JHIN/2020.05.007]
   Siegel JD, 2007, AM J INFECT CONTROL, V35, pS65, DOI 10.1016/j.ajic.2007.10.007
   Thu TA, 2012, INTERNAL MED, V2, P4
   Tobin EA, 2013, DIRECT RES J HLTH PH, V1, P20
   Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wilson J., 2019, INFECT CONTROL CLIN
   World Health Organization, PROT ASS POT RISK FA
   World Health Organization, MOD TRANSM VIR CAUS
   Zhang M, 2020, J HOSP INFECT, V105, P183, DOI 10.1016/j.jhin.2020.04.012
NR 32
TC 0
Z9 0
U1 0
U2 0
PU WOMENS HEALTH & ACTION RESEARCH CENTRE
PI BENIN CITY
PA IGUE-IHEYA VILLAGE, BENIN-LAGOS EXPRESS RD, PO BOX 10231, UGBOWO, BENIN
   CITY, EDO STATE 00000, NIGERIA
SN 1118-4841
EI 2141-3606
J9 AFR J REPROD HEALTH
JI Afr. J. Reprod. Health
PD JUN
PY 2020
VL 24
IS 2
SI SI
BP 98
EP 107
DI 10.29063/ajrh2020/v24i2s.14
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OC3MV
UT WOS:000579063100014
DA 2021-01-01
ER

PT J
AU Li, QH
   Peng, W
   Ou, Y
AF Li, Qihao
   Peng, Wen
   Ou, Yu
TI Prediction and analysis of key protein structures of 2019-nCoV
SO FUTURE VIROLOGY
LA English
DT Article
DE 2019-nCoV; back mutation; drug screening; homology alignment; structural
   analysis
ID SWISS-MODEL; SPIKE
AB Aim: The purpose of this study was to predict and analyze the structure and function of 2019-novel Coronavirus (nCoV) key proteins. Materials & methods: We obtained the structure and sequence of proteins from related databases and studied them through multiple sequence alignment, homology modeling, sequence analysis, virtual screening, reverse mutation, protein structure overlap and surface property analysis. Results & conclusion: We found no significant changes in envelope protein, membrane protein, nucleocapsid protein and key proteases in open reading frame 1ab, and predicted results of proteins and performed molecular dynamics simulations. Based on the surface properties of spike protein and docking results with angiotensin-converting enzyme 2, we believe that the binding ability of spike protein to angiotensin-converting enzyme 2 may be similar to SARS. These studies will help us in fighting 2019-nCoV.
C1 [Li, Qihao; Peng, Wen; Ou, Yu] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing, Peoples R China.
RP Ou, Y (corresponding author), China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing, Peoples R China.
EM ouyu2008@126.com
CR Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Berry M, 2015, VIRUSES-BASEL, V7, P6642, DOI 10.3390/v7122963
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Chatterjee A, 2009, J VIROL, V83, P1823, DOI 10.1128/JVI.01781-08
   Eurosurveillance Editorial T, 2020, EUROSURVEILL, V25, P2001231
   Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753
   Graham RL, 2008, VIRUS RES, V133, P88, DOI 10.1016/j.virusres.2007.02.017
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Jiang HY, 2006, J MOL MODEL, V12, P221, DOI 10.1007/s00894-005-0030-x
   Kaplan W, 2001, Brief Bioinform, V2, P195, DOI 10.1093/bib/2.2.195
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Kopp J, 2006, NUCLEIC ACIDS RES, V34, pD315, DOI 10.1093/nar/gkj056
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li XG, 2020, J MED VIROL, V92, P448, DOI 10.1002/jmv.25693
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Rha B, 2013, AM J TRANSPLANT, V13, P1606, DOI 10.1111/ajt.12320
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Sievers F, 2018, PROTEIN SCI, V27, P135, DOI 10.1002/pro.3290
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Wang L, 2018, TRENDS MICROBIOL, V26, P466, DOI 10.1016/j.tim.2018.03.001
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yoo JH, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e56
   Zhang LM, 2019, ANN NY ACAD SCI, V1455, P5, DOI 10.1111/nyas.14260
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 29
TC 1
Z9 1
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PD JUN
PY 2020
VL 15
IS 6
BP 349
EP 357
DI 10.2217/fvl-2020-0020
PG 9
WC Virology
SC Virology
GA OC2JF
UT WOS:000578985700006
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, R
   He, H
   Liao, C
   Hu, HT
   Hu, C
   Zhang, J
   Gao, P
   Wu, XY
   Cheng, ZS
   Liao, MY
   Shui, H
AF Wang, Rui
   He, Hong
   Liao, Cong
   Hu, Hongtao
   Hu, Chun
   Zhang, Juan
   Gao, Ping
   Wu, Xiaoyan
   Cheng, Zhenshun
   Liao, Meiyan
   Shui, Hua
TI Clinical outcomes of hemodialysis patients infected with severe acute
   respiratory syndrome coronavirus 2 and impact of proactive chest
   computed tomography scans
SO CLINICAL KIDNEY JOURNAL
LA English
DT Article
DE COVID-19; chronic renal failure; clinical outcome; hemodialysis;
   SARS-CoV-2
ID WUHAN; CHINA
AB Background. Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that first manifested in humans in Wuhan, Hubei Province, China, in December 2019, and has subsequently spread worldwide.
   Methods. We conducted a retrospective, single-center case series of the seven maintenance hemodialysis (HD) patients infected with COVID-19 at Zhongnan Hospital of Wuhan University from 13 January to 7 April 2020 and a proactive search of potential cases by chest computed tomography (CT) scans.
   Results. Of 202 HD patients, 7 (3.5%) were diagnosed with COVID-19. Five were diagnosed by reverse transcription polymerase chain reaction (RT-PCR) because of compatible symptoms, while two were diagnosed by RT-PCR as a result of screening 197 HD patients without respiratory symptoms by chest CT. Thirteen of 197 patients had positive chest CT features and, of these, 2 (15%) were confirmed to have COVID-19. In COVID-19 patients, the most common features at admission were fatigue, fever and diarrhea [5/7 (71%) had all these]. Common laboratory features included lymphocytopenia [6/7 (86%)], elevated lactate dehydrogenase [3/4 (75%)], D-dimer [5/6 (83%)], high-sensitivity C-reactive protein [4/4 (100%)] and procalcitonin [5/5 (100%)]. Chest CT showed bilateral patchy shadows or ground-glass opacity in the lungs of all patients. Four of seven (57%) received oxygen therapy, one (14%) received noninvasive and invasive mechanical ventilation, five (71%) received antiviral and antibacterial drugs, three (43%) recieved glucocorticoid therapy and one (14%) received continuous renal replacement therapy. As the last follow-up, four of the seven patients (57%) had been discharged and three patients were dead.
   Conclusions. Chest CT may identify COVID-19 patients without clear symptoms, but the specificity is low. The mortality of COVID-19 patients on HD was high.
C1 [Wang, Rui; He, Hong; Hu, Chun; Zhang, Juan; Gao, Ping; Wu, Xiaoyan; Shui, Hua] Wuhan Univ, Dept Nephrol, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
   [Liao, Cong] Wuhan Univ, Dept Lab Med, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
   [Hu, Hongtao] Wuhan Univ, Dept Crit Care Med, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
   [Cheng, Zhenshun] Wuhan Univ, Dept Pulm Med, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
   [Liao, Meiyan] Wuhan Univ, Dept Radiol, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
RP Shui, H (corresponding author), Wuhan Univ, Dept Nephrol, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.; Liao, MY (corresponding author), Wuhan Univ, Dept Radiol, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
EM liaomy@whu.edu.cn; shuihua@whu.edu.cn
CR Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Ghani RA, 2006, NEPHROLOGY, V11, P386, DOI 10.1111/j.1440-1797.2006.00600.x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kwan BCH, 2004, J AM SOC NEPHROL, V15, P1883, DOI 10.1097/01.ASN.0000131522.16404.1F
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   National Health Commission of China, 2020, NEW COR PNEUM PREV C
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang R, 2020, AM J KIDNEY DIS, V76, P141, DOI 10.1053/j.ajkd.2020.03.009
   WHO, 2020, CLIN MAN SEV AC RESP
   Wong HYF, 2020, RADIOLOGY, V296, pE72, DOI 10.1148/radiol.2020201160
   Wuhan Municipal Health Commission, 2019, REP CLUST PNEUM UNK
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 2
Z9 2
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2048-8505
EI 2048-8513
J9 CLIN KIDNEY J
JI Clin. Kidney J.
PD JUN
PY 2020
VL 13
IS 3
BP 328
EP 333
DI 10.1093/ckj/sfaa086
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA NZ6UI
UT WOS:000577240400010
PM 32695322
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rubin, S
   Orieux, A
   Prevel, R
   Garric, A
   Bats, ML
   Dabernat, S
   Camou, F
   Guisset, O
   Issa, N
   Mourissoux, G
   Dewitte, A
   Joannes-Boyau, O
   Fleureau, C
   Roze, H
   Carrie, C
   Petit, L
   Clouzeau, B
   Sazio, C
   Bui, HN
   Pillet, O
   Rigothier, C
   Vargas, F
   Combe, C
   Gruson, D
   Boyer, A
AF Rubin, Sebastien
   Orieux, Arthur
   Prevel, Renaud
   Garric, Antoine
   Bats, Marie-Lise
   Dabernat, Sandrine
   Camou, Fabrice
   Guisset, Olivier
   Issa, Nahema
   Mourissoux, Gaelle
   Dewitte, Antoine
   Joannes-Boyau, Olivier
   Fleureau, Catherine
   Roze, Hadrien
   Carrie, Cedric
   Petit, Laurent
   Clouzeau, Benjamin
   Sazio, Charline
   Hoang-Nam Bui
   Pillet, Odile
   Rigothier, Claire
   Vargas, Frederic
   Combe, Christian
   Gruson, Didier
   Boyer, Alexandre
TI Characterization of acute kidney injury in critically ill patients with
   severe coronavirus disease 2019
SO CLINICAL KIDNEY JOURNAL
LA English
DT Article
DE acute interstitial nephritis; acute kidney injury; acute tubular injury;
   COVID-19; critically ill patients; renal replacement therapy
ID RECOVERY
AB Background. Coronavirus disease 2019 (COVID-19)-associated acute kidney injury (AKI) frequency, severity and characterization in critically ill patients has not been reported.
   Methods. Single-centre cohort performed from 3 March 2020 to 14 April 2020 in four intensive care units in Bordeaux University Hospital, France. All patients with COVID-19 and pulmonary severity criteria were included. AKI was defined using Kidney Disease: Improving Global Outcomes (KDIGO) criteria. A systematic urinary analysis was performed. The incidence, severity, clinical presentation, biological characterization (transient versus persistent AKI; proteinuria, haematuria and glycosuria) and short-term outcomes were evaluated.
   Results. Seventy-one patients were included, with basal serum creatinine (SCr) of 69621 mmol/L. At admission, AKI was present in 8/71 (11%) patients. Median [interquartile range (IQR)] follow-up was 17 (12-23) days. AKI developed in a total of 57/71 (80%) patients, with 35% Stage 1, 35% Stage 2 and 30% Stage 3 AKI; 10/57 (18%) required renal replacement therapy (RRT). Transient AKI was present in only 4/55 (7%) patients and persistent AKI was observed in 51/55 (93%). Patients with persistent AKI developed a median (IQR) urine protein/creatinine of 82 (54-140) (mg/mmol) with an albuminuria/proteinuria ratio of 0.23620, indicating predominant tubulointerstitial injury. Only two (4%) patients had glycosuria. At Day 7 after onset of AKI, six (11%) patients remained dependent on RRT, nine (16%) had SCr >200 mmol/L and four (7%) had died. Day 7 and Day 14 renal recovery occurred in 28% and 52%, respectively.
   Conclusion. Severe COVID-19-associated AKI is frequent, persistent, severe and characterized by an almost exclusive tubulointerstitial injury without glycosuria.
C1 [Rubin, Sebastien; Garric, Antoine; Rigothier, Claire; Combe, Christian] CHU Bordeaux, Serv Nephrol Transplantat Dialyse & Aphereses, Hop Pellegrin, Bordeaux, France.
   [Orieux, Arthur; Prevel, Renaud; Camou, Fabrice; Guisset, Olivier; Issa, Nahema; Mourissoux, Gaelle; Clouzeau, Benjamin; Sazio, Charline; Hoang-Nam Bui; Pillet, Odile; Vargas, Frederic; Gruson, Didier; Boyer, Alexandre] CHU Bordeaux, Hop Pellegrin, Serv Med Intens Reanimat, Bordeaux, France.
   [Orieux, Arthur; Prevel, Renaud; Camou, Fabrice; Guisset, Olivier; Issa, Nahema; Mourissoux, Gaelle; Clouzeau, Benjamin; Sazio, Charline; Hoang-Nam Bui; Pillet, Odile; Vargas, Frederic; Gruson, Didier; Boyer, Alexandre] CHU Bordeaux, Hop St Andre, Bordeaux, France.
   [Bats, Marie-Lise; Dabernat, Sandrine] CHU Bordeaux, Hop Pellegrin, Serv Biochim, Bordeaux, France.
   [Dewitte, Antoine; Joannes-Boyau, Olivier; Fleureau, Catherine; Roze, Hadrien] Ctr Hosp Univ CHU Bordeaux, Serv Anesthesie Reanimat Sud, Ctr Med Chirurg Magellan, Bordeaux, France.
   [Carrie, Cedric; Petit, Laurent] Pellegrin CHU Bordeaux, Serv Anesthesie Reanimat, Bordeaux, France.
   [Rubin, Sebastien; Bats, Marie-Lise] Univ Bordeaux, INSERM, U1034, Bordeaux, France.
RP Rubin, S (corresponding author), CHU Bordeaux, Serv Nephrol Transplantat Dialyse & Aphereses, Hop Pellegrin, Bordeaux, France.; Rubin, S (corresponding author), Univ Bordeaux, INSERM, U1034, Bordeaux, France.
EM sebastien.rubin@chu-bordeaux.fr
OI Rubin, Sebastien/0000-0002-1246-0712; ORIEUX,
   Arthur/0000-0001-5680-8701; gruson, didier/0000-0002-1199-5125; BOYER,
   Alexandre/0000-0003-4384-8872
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bhatraju PK, 2020, NEW ENGL J MED, P500
   Billings FT, 2014, NEPHRON CLIN PRACT, V127, P89, DOI 10.1159/000363725
   Chawla LS, 2017, NAT REV NEPHROL, V13, P241, DOI 10.1038/nrneph.2017.2
   Darmon M, 2017, INTENS CARE MED, V43, P829, DOI 10.1007/s00134-017-4799-8
   Darmon M, 2011, CRIT CARE, V15, DOI 10.1186/cc10327
   Dewitte A, 2012, J CRIT CARE, V27, P505, DOI 10.1016/j.jcrc.2012.02.018
   Diao B, 2020, HUMAN KIDNEY IS TARG, DOI [10.1101/2020.03.04.20031120, DOI 10.1101/2020.03.04.20031120]
   Gaudry S, 2016, NEW ENGL J MED, V375, P122, DOI 10.1056/NEJMoa1603017
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pannu N, 2013, CLIN J AM SOC NEPHRO, V8, P194, DOI 10.2215/CJN.06480612
   Rubin S, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122215
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 22
TC 5
Z9 5
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2048-8505
EI 2048-8513
J9 CLIN KIDNEY J
JI Clin. Kidney J.
PD JUN
PY 2020
VL 13
IS 3
BP 354
EP 361
DI 10.1093/ckj/sfaa099
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA NZ6UI
UT WOS:000577240400014
PM 32695326
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, JL
   Shi, SR
   Ma, XL
   Wang, J
   Huang, SJ
AF Wang, Jin-Long
   Shi, Sheng-Rong
   Ma, Xiao-Li
   Wang, Juan
   Huang, Sheng-Jie
TI Clinical Management of Sepsis Resulting from Infections Including
   COVID-19
SO DISCOVERY MEDICINE
LA English
DT Article
ID INTERNATIONAL CONSENSUS DEFINITIONS; COMBINATION ANTIBIOTIC-THERAPY;
   GOAL-DIRECTED THERAPY; SEPTIC SHOCK; ANTIMICROBIAL THERAPY; CYTOKINE
   STORM; GUIDELINES; SURVIVAL; INITIATION; REDUCTION
AB Sepsis is an important disorder in intensive care medicine, and the emphasis is not on infections but the imbalance in body reactions and life-threatening organ dysfunction. The infection, the imbalance in the body's reaction, and the deadly organ dysfunction are three aspects of sepsis. Currently, there is still a debate on suitable criteria for the diagnosis of patients with sepsis with continuing changes in the guidelines on sepsis management. Here we summarize recent advances on the definitions, diagnosis, and treatment in the clinical practice of sepsis management in the emergency department. We also highlight future research directions on sepsis. In particular, given the global outbreak of coronavirus disease 2019 (COVID-19), we briefly describe the relationship between COVID-19 and sepsis. How to manage sepsis caused by emerging pathogens such as COVID-19 is a new challenge for care professionals in the emergency department.
C1 [Wang, Jin-Long; Shi, Sheng-Rong; Ma, Xiao-Li; Wang, Juan; Huang, Sheng-Jie] Fuling Cent Hosp, Emergency Dept, Chongqing 404000, Peoples R China.
RP Wang, JL (corresponding author), Fuling Cent Hosp, Emergency Dept, Chongqing 404000, Peoples R China.
EM drwang1979@dingtalk.com
FU Chongqing Health Committee, China [2019MSXM050]; Fuling Science and
   Technology Committee, China [FLKJ-2018BBB3022]
FX This study was funded by Chongqing Health Committee (No. 2019MSXM050),
   China and Fuling Science and Technology Committee (No.
   FLKJ-2018BBB3022), China.
CR BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Cecconi M, 2014, INTENS CARE MED, V40, P1795, DOI 10.1007/s00134-014-3525-z
   Charles LS, 2015, NEW ENGL J MED, V373, P880
   Cheng MP, 2019, ANN INTERN MED
   Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   Clark IA, 2017, SEMIN IMMUNOPATHOL, V39, P505, DOI 10.1007/s00281-017-0628-y
   Cohen J, 2015, LANCET INFECT DIS, V15, P581, DOI 10.1016/S1473-3099(15)70112-X
   de Jong E, 2016, LANCET INFECT DIS, V16, P819, DOI 10.1016/S1473-3099(16)00053-0
   FERRARA JLM, 1993, TRANSPLANT P, V25, P1216
   Ferrer R, 2014, CRIT CARE MED, V42, P1749, DOI 10.1097/CCM.0000000000000330
   Guan WJ, N ENGL J MED
   Haas SA, 2016, INTENS CARE MED, V42, P202, DOI 10.1007/s00134-015-4127-0
   Iankova I, 2018, CRIT CARE MED, V46, P691, DOI [10.1097/ccm.0000000000002928, 10.1097/CCM.0000000000002928]
   Inoue S, 2013, CRIT CARE MED, V41, P810, DOI 10.1097/CCM.0b013e318274645f
   Inoue S, 2013, SHOCK, V39, P311, DOI 10.1097/SHK.0b013e3182845445
   Jansen TC, 2010, AM J RESP CRIT CARE, V182, P752, DOI 10.1164/rccm.200912-1918OC
   Kalil AC, 2018, CLIN INFECT DIS, V66, P1631, DOI 10.1093/cid/cix997
   Kamali Aghdam M, INFECT DIS LOND, P1
   Klouwenberg PMCK, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1035-1
   Kopterides P, 2010, CRIT CARE MED, V38, P2229, DOI 10.1097/CCM.0b013e3181f17bf9
   Kraut JA, 2014, NEW ENGL J MED, V371, P2309, DOI 10.1056/NEJMra1309483
   Kumar A, 2010, CRIT CARE MED, V38, P1773, DOI 10.1097/CCM.0b013e3181eb3ccd
   Kumar A, 2009, CHEST, V136, P1237, DOI 10.1378/chest.09-0087
   Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9
   Levy MM, 2018, CRIT CARE MED, V46, P997, DOI 10.1097/CCM.0000000000003119
   Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
   Micek ST, 2010, ANTIMICROB AGENTS CH, V54, P1742, DOI 10.1128/AAC.01365-09
   Nichol A, 2011, CRIT CARE, V15, DOI 10.1186/cc10497
   Okazaki Y, 2009, RECENT PATENTS INFLA, V3, P26, DOI 10.2174/187221309787158416
   Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307
   Rowan KM, 2017, NEW ENGL J MED, V376, P2223, DOI 10.1056/NEJMoa1701380
   Sandra LP, 2015, NEW ENGL J MED, V372, P190
   Schuetz P, 2018, LANCET INFECT DIS, V18, P95, DOI [10.1016/S1473-3099(17)30592-3, 10.1016/s1473-3099(17)30592-3]
   Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288
   Shankar-Hari M, 2016, JAMA-J AM MED ASSOC, V315, P775, DOI 10.1001/jama.2016.0289
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI [10.1001/jama.2016.0288, DOI 10.1001/JAMA.2016.0288]
   Stevenson EK, 2014, CRIT CARE MED, V42, P625, DOI 10.1097/CCM.0000000000000026
   Valles J, 2003, CHEST, V123, P1615, DOI 10.1378/chest.123.5.1615
   Wang HF, 2018, BIOCELL, V42, P47, DOI 10.32604/biocell.2018.07006
   Weiss SL, 2020, INTENS CARE MED, V46, P1, DOI 10.1007/s00134-019-05877-7
   World Health Organization, 2017, IMPR PREV DIAGN CLIN
   Yokota Shumpei, 2003, Nihon Rinsho, V61, P1953
   Zahar JR, 2011, CRIT CARE MED, V39, P1886, DOI 10.1097/CCM.0b013e31821b827c
NR 45
TC 0
Z9 0
U1 0
U2 0
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD JUN
PY 2020
VL 29
IS 158
BP 201
EP 208
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NW5EW
UT WOS:000575035700006
PM 33007195
DA 2021-01-01
ER

PT J
AU Hadi, A
   Werge, M
   Kristiansen, KT
   Pedersen, UG
   Karstensen, JG
   Novovic, S
   Gluud, LL
AF Hadi, Amer
   Werge, Mikkel
   Kristiansen, Klaus Tjelle
   Pedersen, Ulf Gottrup
   Karstensen, John Gasdal
   Novovic, Srdan
   Gluud, Lise Lotte
TI Coronavirus Disease-19 (COVID-19) associated with severe acute
   pancreatitis: Case report on three family members
SO PANCREATOLOGY
LA English
DT Article
DE Acute pancreatitis; COVID-19; SARS-CoV-2; Severe acute pancreatitis;
   Viral pancreatitis
AB Background/Objectives: Abdominal pain is one of the known symptoms associated with coronavirus disease 2019. Little is known about the development of acute pancreatitis as a complication of severe acute respiratory syndrome coronavirus 2 infection. This case report describes the presentation of acute pancreatitis in two of three family members with severe COVID-19 infection.
   Methods: Data were collected from three family members admitted with COVID-19 to the intensive care unit in March 2020. This study was reviewed and approved by the local data and ethics committee (31-1521-253).
   Results: Two of the three family members were diagnosed with acute pancreatitis associated with SARS-CoV-2. Other causes of acute pancreatitis were excluded for both patients (including alcohol, biliary obstruction/gall stones, drugs, trauma, hypertriglyceridemia, hypercalcemia, and hypotension).
   Conclusions: These cases highlight acute pancreatitis as a complication associated with COVID-19 and underlines the importance of measuring pancreas-specific plasma amylase in patients with COVID-19 and abdominal pain. (C) 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.
C1 [Hadi, Amer; Werge, Mikkel; Karstensen, John Gasdal; Novovic, Srdan; Gluud, Lise Lotte] Copenhagen Univ Hosp Hvidovre, Pancreatitis Ctr East, Gastrounit, DK-2650 Hvidovre, Denmark.
   [Kristiansen, Klaus Tjelle; Pedersen, Ulf Gottrup] Copenhagen Univ Hosp Hvidovre, Intens Care Unit, Hvidovre, Denmark.
   [Karstensen, John Gasdal; Novovic, Srdan; Gluud, Lise Lotte] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.
RP Hadi, A; Gluud, LL (corresponding author), Copenhagen Univ Hosp Hvidovre, Pancreatitis Ctr East, Gastrounit, DK-2650 Hvidovre, Denmark.
EM amer.hadi@regionh.dk; lise.lotte.gluud.01@regionh.dk
CR Amico FD, 2020, CLIN GASTROENTEROL H, DOI [10.1016/j.cgh.2020.04.001., DOI 10.1016/J.CGH.2020.04.001]
   Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   John Hopkins University and Medicine, 2020, COVID 19 DASHB CTR S, P1
   Lankisch PG, 2015, LANCET, V6736, P1
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Nobel YR, 2020, GASTROENTEROLOGY, V159, P373, DOI 10.1053/j.gastro.2020.04.017
   Peery AF, 2012, GASTROENTEROLOGY, V143, P1179, DOI 10.1053/j.gastro.2012.08.002
   Testoni PA, 2014, WORLD J GASTROENTERO, V20, P16891, DOI 10.3748/wjg.v20.i45.16891
   Tian Y, 2020, ALIMENT PHARM THER, V51, P843, DOI 10.1111/apt.15731
   Wang F, 2020, GASTROENTEROLOGY, V159, P367, DOI 10.1053/j.gastro.2020.03.055
   Wong SH, 2020, J GASTROEN HEPATOL, V35, P744, DOI 10.1111/jgh.15047
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
   Zhu JY, 2020, J MED VIROL, V92, P1902, DOI 10.1002/jmv.25884
NR 15
TC 33
Z9 33
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1424-3903
EI 1424-3911
J9 PANCREATOLOGY
JI Pancreatology
PD JUN
PY 2020
VL 20
IS 4
BP 665
EP 667
DI 10.1016/j.pan.2020.04.021
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NS4UE
UT WOS:000572257600014
PM 32387082
OA Green Published
DA 2021-01-01
ER

PT J
AU Prasithsirikul, W
   Pongpirul, K
   Sakornsakolpat, P
   Burana, C
   Phutrakool, P
   Pongpirul, WA
AF Prasithsirikul, Wisit
   Pongpirul, Krit
   Sakornsakolpat, Phuwanat
   Burana, Chuti
   Phutrakool, Phanupong
   Pongpirul, Wannarat A.
TI Adjunctive favipiravir for severe COVID-19: a retrospective
   observational study of the first 41 patients in Thailand
SO ASIAN BIOMEDICINE
LA English
DT Article
DE COVID-19; favipiravir; SARS-Cov-2
AB Background: Favipiravir is a promising drug for COVID-19, but evidence from a robust clinical trial is limited.
   Objective: To describe the demographics, clinical characteristics, and various antiviral treatment regimens (with and without favipiravir) of patients with severe and nonsevere COVID-19.
   Method: We conducted a retrospective observational study in all COVID-19 patients admitted at Bamrasnaradura Infectious Diseases Institute (BIDI) from January 8 to March 30, 2020. We compared the demographics, clinical characteristics, and various antiviral treatment regimens of 12 severe and 29 nonsevere COVID-19 patients in Thailand.
   Results: Adjunctive favipiravir was given to only severe cases. The median length of hospitalization of patients either receiving favipiravir or not receiving favipiravir was not significantly different (P = 0.8549), but those who received adjunctive favipiravir became reverse transcriptase-polymerase chain reaction negative 2 days sooner than the other group (median: 6 days vs. 8 days; P = 0.1125).
   Conclusion: The findings suggested that adjunctive favipiravir might not be effective for patients with severe COVID-19, but further studies with larger sample sizes are needed.
C1 [Pongpirul, Krit; Phutrakool, Phanupong] Chulalongkorn Univ, Fac Med, Dept Prevent & Social Med, Bangkok 10330, Thailand.
   [Prasithsirikul, Wisit; Sakornsakolpat, Phuwanat; Burana, Chuti; Pongpirul, Wannarat A.] Minist Publ Hlth, Dept Dis Control, Bamrasnaradura Infect Dis Inst, Nonthaburi 11000, Thailand.
   [Pongpirul, Krit] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.
RP Pongpirul, K (corresponding author), Chulalongkorn Univ, Fac Med, Dept Prevent & Social Med, Bangkok 10330, Thailand.
EM krit.po@chula.ac.th
RI Pongpirul, Krit/H-4064-2019
OI Pongpirul, Krit/0000-0003-3818-9761
CR Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Pongpirul WA, 2020, EMERG INFECT DIS, V26, P1580, DOI 10.3201/eid2607.200598
   Pongpirul WA, 2020, NEW ENGL J MED, V382, P1067, DOI 10.1056/NEJMc2001621
   von Elm E, 2007, PLOS MED, V4, P1623, DOI 10.1371/journal.pmed.0040296
NR 8
TC 0
Z9 0
U1 1
U2 1
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1905-7415
EI 1875-855X
J9 ASIAN BIOMED
JI Asian Biomed.
PD JUN
PY 2020
VL 14
IS 3
BP 107
EP 110
DI 10.1515/abm-2020-0016
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NQ0WV
UT WOS:000570589900004
OA Other Gold
DA 2021-01-01
ER

PT J
AU Bansal, P
   Bingemann, TA
   Greenhawt, M
   Mosnaim, G
   Nanda, A
   Oppenheimer, J
   Sharma, H
   Stukus, D
   Shaker, M
AF Bansal, Priya
   Bingemann, Theresa A.
   Greenhawt, Matthew
   Mosnaim, Giselle
   Nanda, Anil
   Oppenheimer, John
   Sharma, Hemant
   Stukus, David
   Shaker, Marcus
TI Clinician Wellness During the COVID-19 Pandemic: Extraordinary Times and
   Unusual Challenges for the Allergist/Immunologist
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
DE Wellness; Physician wellness; SARS-CoV-2; COVID-19; Pandemic; Social
   distancing; Burnout; Depression; Grief; Mindfulness
ID DEPRESSIVE SYMPTOMS; SUICIDAL IDEATION; COLLAPSE THERAPY; HEALTH-CARE;
   BURNOUT; ALLERGY; TUBERCULOSIS; TELEMEDICINE; PREVALENCE; PREVENTION
AB The global spread of coronavirus disease 2019 (COVID-19) has caused sudden and dramatic societal changes. The allergy/ immunology community has quickly responded by mobilizing practice adjustments and embracing new paradigms of care to protect patients and staff from severe acute respiratory syndrome coronavirus 2 exposure. Social distancing is key to slowing contagion but adds to complexity of care and increases isolation and anxiety. Uncertainty exists across a new COVID19 reality, and clinician well-being may be an underappreciated priority. Wellness incorporates mental, physical, and spiritual health to protect against burnout, which impairs both coping and caregiving abilities. Understanding the stressors that COVID-19 is placing on clinicians can assist in recognizing what is needed to return to a point of wellness. Clinicians can leverage easily accessible tools, including the Strength-Focused and Meaning-Oriented Approach to Resilience and Transformation approach, wellness apps, mindfulness, and gratitude. Realizing early warning signs of anxiety, depression, substance abuse, and posttraumatic stress disorder is important to access safe and confidential resources. Implementing wellness strategies can improve flexibility, resilience, and outlook. Historical parallels demonstrate that perseverance is as inevitable as pandemics and that we need not navigate this unprecedented time alone. (c) 2020 American Academy of Allergy, Asthma & Immunology
C1 [Bansal, Priya] Asthma & Allergy Wellness Ctr, St Charles, IL USA.
   [Bingemann, Theresa A.] Univ Rochester, Div Allergy Immunol & Rheumatol, Rochester, NY USA.
   [Greenhawt, Matthew] Univ Colorado, Sch Med, Childrens Hosp Colorado, Sect Allergy Immunol,Dept Pediat, Aurora, CO USA.
   [Mosnaim, Giselle] NorthShore Univ HealthSyst, Dept Med, Div Pulm Allergy & Crit Care, Evanston, IL USA.
   [Nanda, Anil] Asthma & Allergy Ctr, Lewisville, TX USA.
   [Nanda, Anil] Asthma & Allergy Ctr, Flower Mound, TX USA.
   [Nanda, Anil] Univ Texas Southwestern Med Ctr Dallas, Div Allergy & Immunol, Dallas, TX 75390 USA.
   [Oppenheimer, John] UMDMJ Rutgers Univ, Sch Med, Newark, NJ USA.
   [Sharma, Hemant] George Washington Univ, Sch Med & Hlth Sci, Childrens Natl Hosp, Washington, DC 20052 USA.
   [Stukus, David] Ohio State Univ, Nationwide Childrens Hosp, Sch Med, Div Allergy & Immunol, Columbus, OH 43210 USA.
   [Shaker, Marcus] Geisel Sch Med, Lebanon, NH USA.
   [Shaker, Marcus] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
RP Shaker, M (corresponding author), Dartmouth Geisel Sch Med, Sect Allergy & Immunol, Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.
EM marcus.shaker@dartmouth.edu
RI , Polly/AAX-2742-2020
FU Agency for Healthcare Research and QualityUnited States Department of
   Health & Human ServicesAgency for Healthcare Research & Quality
   [5K08HS024599-02]
FX M.G. is supported by the Agency for Healthcare Research and Quality
   (grant no. 5K08HS024599-02).
CR Adams JG, 2020, JAMA-J AM MED ASSOC, V323, P1439, DOI 10.1001/jama.2020.3972
   American Academy of Allergy Asthma and Immunology, COVID 19 PAND SMALL
   American Academy of Allergy Asthma and Immunology, PHYS WELLN TOOLK
   American Academy of Allergy Asthma and Immunology, AAAAI TEL TOOLK
   American Academy of Allergy Asthma and Immunology, SMALL BUS RES
   American Academy of Allergy Asthma and Immunology, US TEL COVID 19 PAND
   American College of Allergy Asthma & Immunology, COR COVID 19 RES
   American College of Allergy Asthma & Immunology, TEL TOOLK
   American Medical Association, AMA COD MED ETH GUID
   American Medical Association, AMA STEPS FORW
   American Psychiatric Association, APP EV MOD
   [Anonymous], ONL WELLN PROGR
   [Anonymous], 2020, NATL LAW REV
   Arias Elizabeth, 2018, Natl Vital Stat Rep, V67, P1
   Bahney A., 2020, CNN BUSINESS    0317
   Bingemann T, 2020, J ALLER CL IMM-PRACT, V8, P1224, DOI 10.1016/j.jaip.2020.01.023
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Chan CLW, 2006, SOC WORK HEALTH CARE, V43, P9, DOI 10.1300/J010v43n02_03
   Chan WSY, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8382
   Corbetta L, 2016, RESPIRATION, V92, P316, DOI 10.1159/000450757
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072
   Doolittle BR, 2015, J EDUC EVAL HEALTH P, V12, DOI 10.3352/jeehp.2015.12.41
   E13. Centers for Disease Control and Prevention, RED STIGM
   E20. American Academy of Allergy Asthma & Immunology, RES A I CLIN COVID 1
   Emmons RA, 2003, J PERS SOC PSYCHOL, V84, P377, DOI 10.1037/0022-3514.84.2.377
   Federation of State Physician Health Programs, STAT PROGR
   Foster BL, 2020, PARENTS
   Gabbe SG, 2002, AM J OBSTET GYNECOL, V186, P601, DOI 10.1067/mob.2002.122391
   Geldsetzer P, 2020, ANN INTERN MED, V173, P157, DOI 10.7326/M20-0912
   Gogo A, 2019, CURR PROB PEDIATR AD, V49, DOI 10.1016/j.cppeds.2019.100663
   Goulia P, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-322
   Greenhawt M, 2020, ANN ALLERG ASTHMA IM, V125, P90, DOI 10.1016/j.anai.2020.01.030
   Greenhawt M, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.18041
   Guille C, 2015, JAMA PSYCHIAT, V72, P1192, DOI 10.1001/jamapsychiatry.2015.1880
   Hampton T, 2005, JAMA-J AM MED ASSOC, V294, P1189, DOI 10.1001/jama.294.10.1189
   Hare K., 2020, WORK HOME KIDS
   Hawes JB, 1932, J AMER MED ASSOC, V98, P2048, DOI 10.1001/jama.1932.02730500014005
   Headspace, WER HER YOU
   Ho CSH, 2020, ANN ACAD MED SINGAP, V49, P155
   Institute for Healthcare Improvement, COVID 19 GUID RES
   Kane L., MEDSCAPE PHYS COMPEN
   Kane L, MEDSCAPE NATL PHYS B
   Kind T, 2011, PEDIATR ANN, V40, P430, DOI 10.3928/00904481-20110815-05
   Kubler-Ross E., 1969, DEATH DYING
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Lazer DMJ, 2018, SCIENCE, V359, P1094, DOI 10.1126/science.aao2998
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Lumry W, TEXAS ALLERGY ASTHMA
   Maciejewski PK, 2007, JAMA-J AM MED ASSOC, V297, P716, DOI 10.1001/jama.297.7.716
   Mata DA, 2015, JAMA-J AM MED ASSOC, V314, P2373, DOI 10.1001/jama.2015.15845
   Mathieu E, 2010, MED DECIS MAKING, V30, p14S, DOI 10.1177/0272989X10381228
   McLuhan A., 2020, AM MIND
   Nanda A, CORONAVIRUS DIS 2019
   Nanda A, 2020, CORONAVIRUS DIS 2019
   Nanda A, 2017, J ALLER CL IMM-PRACT, V5, P1543, DOI 10.1016/j.jaip.2017.05.025
   Nedrow Annie, 2013, Fam Pract Manag, V20, P25
   NHS Improvement, LENS PROF KNOWL
   Portnoy J, 2020, J ALLER CL IMM-PRACT, V8, P1489, DOI 10.1016/j.jaip.2020.03.008
   Portnoy JM, 2020, J ALLERGY CLIN IMMUN, V145, P445, DOI 10.1016/j.jaci.2019.12.903
   Portnoy JM, 2016, ANN ALLERG ASTHMA IM, V117, P241, DOI 10.1016/j.anai.2016.07.012
   Pospos S, 2018, ACAD PSYCHIATR, V42, P109, DOI 10.1007/s40596-017-0868-0
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rippstein-Leuenberger Karin, 2017, BMJ Open, V7, pe015826, DOI 10.1136/bmjopen-2017-015826
   Rolls K, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5312
   Rotenstein LS, 2016, JAMA-J AM MED ASSOC, V316, P2214, DOI 10.1001/jama.2016.17324
   Schatz A, 1944, P SOC EXP BIOL MED, V55, P66, DOI 10.3181/00379727-55-14461
   Schernhammer E, 2005, NEW ENGL J MED, V352, P2473, DOI 10.1056/NEJMp058014
   Shaker M, 2018, ALLERGY, V73, P1707, DOI 10.1111/all.13446
   Shaker M, 2020, ANN ALLERG ASTHMA IM, V125, P252, DOI 10.1016/j.anai.2020.01.029
   Shaker M, 2020, J ALLER CL IMM-PRACT, V8, P565, DOI 10.1016/j.jaip.2019.09.037
   Shaker M, 2019, ANN ALLERG ASTHMA IM, V123, P120, DOI 10.1016/j.anai.2019.05.012
   Shaker M, 2019, ANN ALLERG ASTHMA IM, V122, P79, DOI 10.1016/j.anai.2018.06.035
   Shaker MS, 2020, J ALLER CL IMM-PRACT, V8, P1477, DOI 10.1016/j.jaip.2020.03.012
   Shampo Marc A, 2010, Mayo Clin Proc, V85, pe48, DOI 10.4065/mcp.2010.0379
   Shanafelt TD, 2017, JAMA-J AM MED ASSOC, V317, P901, DOI 10.1001/jama.2017.0076
   Shanafelt TD, 2012, ARCH INTERN MED, V172, P1377, DOI 10.1001/archinternmed.2012.3199
   Shute DA, 7 TIPS RUNNING YOUR
   Slisco A., 2020, NEWSWEEK
   Stukus DR, 2019, IMMUNOL ALLERGY CLIN, V39, P583, DOI 10.1016/j.iac.2019.07.011
   The Schwartz Center, 2020, RES HEALTHC PROF COP
   University of Rochester, 2020, MAK EV EFF CONN DIG
   Weinstein A, 2010, AM J DRUG ALCOHOL AB, V36, P277, DOI [10.3109/00952990.2010.491880, 10.3109/00952990.2010.491879]
   World Health Organization, 2020, COP STRESS 2019 NCOV
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 84
TC 15
Z9 15
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JUN
PY 2020
VL 8
IS 6
BP 1781
EP +
DI 10.1016/j.jaip.2020.04.001
PG 13
WC Allergy; Immunology
SC Allergy; Immunology
GA NI9DM
UT WOS:000565646000001
PM 32259628
OA Green Published
DA 2021-01-01
ER

PT J
AU Pulvirenti, F
   Cinetto, F
   Milito, C
   Bonanni, L
   Pesce, AM
   Leodori, G
   Garzi, G
   Miglionico, M
   Tabolli, S
   Quinti, I
AF Pulvirenti, Federica
   Cinetto, Francesco
   Milito, Cinzia
   Bonanni, Livia
   Pesce, Anna Maria
   Leodori, Giorgia
   Garzi, Giulia
   Miglionico, Marzia
   Tabolli, Stefano
   Quinti, Isabella
TI Health-Related Quality of Life in Common Variable Immunodeficiency
   Italian Patients Switched to Remote Assistance the COVID-19 Pandemic
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
DE Common variable immunodeficiencies; Health-related quality of life;
   General Health Questionnaire; Coronavirus; COVID-19 epidemic; COVID-19;
   Anxiety; Depression; Remote assistance
ID CONVALESCENT PLASMA; THERAPY; CARE
AB BACKGROUND: A rapidly expanding pandemic of the new coronavirus has become the focus of global scientific attention. Data are lacking on the impact of the pandemic caused by the severe acute respiratory syndrome coronavirus 2 on health related quality of life among patients affected by primary antibody deficiencies (PADs).
   OBJECTIVE: To identify factors impacting the health-related quality of life (HRQOL) among Italian patients affected by PADs switched to remote assistance at the time of the corona virus disease 2019 pandemic.
   METHODS: The quality of life was surveyed in 158 patients with PADs by the Common Variable Immune Deficiency Quality of Life questionnaire, a disease-specific tool, and by the 12-item General Health Questionnaire, a generic tool to assess the risk of anxiety/depression. Since the beginning of the coronavirus disease 2019 epidemic, we shifted all patients with PADs to home therapy, and activated remote visits. Questionnaires were sent by email 4 weeks later. Common Variable ImmuneDeficiency Quality of Life questionnaire and 12-item General Health Questionnaire data scores were compared with the same set of data from a survey done in 2017.
   RESULTS: Of 210 patients, 158 (75%) agreed to participate. The quality of life was worse in the group of patients who were at risk of anxiety/depression at the study time. HRQOL was similar in patients forced to shift from hospital-based to home based immunoglobulin treatment and in patients who continued their usual home-based replacement. The risk of anxiety/depression is associated with pandemia caused by the severe acute respiratory syndrome coronavirus 2 and with patients' fragility, and not with related clinical conditions associated with common variable immune deficiencies. Anxiety about running out of medications is a major new issue.
   CONCLUSIONS: The coronavirus disease 2019 epidemic impacted HRQOL and the risk of anxiety/depression of patients with PADs. The remote assistance program was a useful possibility to limit personal contacts without influencing the HRQOL. (c) 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
C1 [Pulvirenti, Federica; Bonanni, Livia; Pesce, Anna Maria; Leodori, Giorgia; Garzi, Giulia] Azienda Univ Policlin Umberto I, Reg Reference Ctr Primary Immune Deficiencies, Rome, Italy.
   [Cinetto, Francesco] Padova Univ, Dept Med DIMED, Clin Immunol & Hematol Unit, Padua, Italy.
   [Milito, Cinzia; Miglionico, Marzia; Tabolli, Stefano; Quinti, Isabella] Sapienza Univ Rome, Dept Mol Med, Viale Univ 37, I-00186 Rome, Italy.
RP Quinti, I (corresponding author), Sapienza Univ Rome, Dept Mol Med, Viale Univ 37, I-00186 Rome, Italy.
EM isabella.quinti@uniroma1.it
RI Cinetto, Francesco/AAE-5328-2019
OI Cinetto, Francesco/0000-0001-8486-5850
FU Jeffery Modell Foundation
FX We thank all patients for their participation in the study as well as
   the study team and nurses of the local health units whose enthusiastic
   collaboration made possible this study. We thank the Jeffery Modell
   Foundation for supporting our center.
CR Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025
   Carsetti R, 2005, J ALLERGY CLIN IMMUN, V115, P412, DOI 10.1016/j.jaci.2004.10.048
   Carsetti R, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02937
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Duffy S, 2018, NEW ENGL J MED, V378, P104, DOI 10.1056/NEJMp1710735
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Hajjar J, 2018, CLIN EXP IMMUNOL, V194, P327, DOI 10.1111/cei.13210
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Lazzerini M, 2020, LANCET GLOB HEALTH, V8, pE641, DOI 10.1016/S2214-109X(20)30110-8
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Picardi A, 2001, J EUR ACAD DERMATOL, V15, P410, DOI 10.1046/j.1468-3083.2001.00336.x
   Pulvirenti F, 2019, J CLIN IMMUNOL, V39, P159, DOI 10.1007/s10875-019-0592-5
   Quinti I, 2017, J CLIN IMMUNOL, V37, P615, DOI 10.1007/s10875-017-0428-0
   Quinti I, 2016, J ALLER CL IMM-PRACT, V4, P1169, DOI 10.1016/j.jaip.2016.07.012
   Rider NL, 2017, J CLIN IMMUNOL, V37, P461, DOI 10.1007/s10875-017-0404-8
   Seidel MG, 2019, J ALLER CL IMM-PRACT, V7, P1763, DOI 10.1016/j.jaip.2019.02.004
   Tabolli S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00605
   Troilo A, 2020, BLOOD, V135, P1452, DOI 10.1182/blood.2019003855
   Tuite AR, 2020, LANCET INFECT DIS, V20, P537, DOI 10.1016/S1473-3099(20)30227-9
   WHO, COR DIS COVID 19 PAN
NR 21
TC 8
Z9 8
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JUN
PY 2020
VL 8
IS 6
BP 1894
EP +
DI 10.1016/j.jaip.2020.04.003
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA NI9DM
UT WOS:000565646000015
PM 32278865
OA Green Published
DA 2021-01-01
ER

PT J
AU Dhawan, G
   Kapoor, R
   Dhawan, R
   Singh, R
   Monga, B
   Giordano, J
   Calabrese, EJ
AF Dhawan, Gaurav
   Kapoor, Rachna
   Dhawan, Rajiv
   Singh, Ravinder
   Monga, Bharat
   Giordano, James
   Calabrese, Edward J.
TI Low dose radiation therapy as a potential life saving treatment for
   COVID-19-induced acute respiratory distress syndrome (ARDS)
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Article
DE Low dose radiotherapy; COVID-19; Acute Respiratory Distress Syndrome
   (ARDS); Anti-inflammatory phenotype; Cytokine storm; Hormesis
ID X-RAYS; APOPTOTIC CELLS; HISTORICAL USE; RADIOTHERAPY; IRRADIATION;
   INFLAMMATION; ARTHRITIS
AB The new coronavirus COVID-19 disease caused by SARS-CoV-2 was declared a global public health emergency by WHO on Jan 30, 2020. Despite massive efforts from various governmental, health and medical organizations, the disease continues to spread globally with increasing fatality rates. Several experimental drugs have been approved by FDA with unknown efficacy and potential adverse effects. The exponentially spreading pandemic of COVID-19 deserves prime public health attention to evaluate yet unexplored arenas of management. We opine that one of these treatment options is low dose radiation therapy for severe and most critical cases. There is evidence in literature that low dose radiation induces an anti-inflammatory phenotype that can potentially afford therapeutic benefit against COVID-19-related complications that are associated with significant morbidity and mortality. Herein, we review the effects and putative mechanisms of low dose radiation that may be viable, useful and of value in counter-acting the acute inflammatory state induced by critical stage COVID-19. (c) 2020 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 147 (2020) 212-216
C1 [Dhawan, Gaurav] Univ Massachusetts, Human Res Protect Off, Amherst, MA 01003 USA.
   [Kapoor, Rachna] St Francis Hosp & Med Ctr, Hartford, CT USA.
   [Dhawan, Rajiv] Govt Med Coll, Radiotherapy Dept, Amritsar, Punjab, India.
   [Singh, Ravinder] MedSurg Urgent Care, Gilbertsville, PA USA.
   [Monga, Bharat] Mt Sinai Morningside Hosp, Div Hosp Med, New York, NY USA.
   [Giordano, James] Georgetown Univ, Pellegrino Ctr Clin Bioeth, Dept Neurol & Biochem & Chief, Neuroeth Studies Program,Med Ctr, Washington, DC 20007 USA.
   [Giordano, James] US Naval War Coll, Program Biosecur Technol & Eth, Newport, RI USA.
   [Calabrese, Edward J.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Environm Hlth Sci, Amherst, MA 01003 USA.
RP Dhawan, G (corresponding author), Univ Massachusetts, Human Res Protect Off, Res Compliance, 100 Venture Way,Suite 116, Hadley, MA 01035 USA.
EM drgdhawan@icloud.com
RI Kapoor, Rachna/AAP-1186-2020; Dhawan, Gaurav/I-7098-2019
OI Dhawan, Gaurav/0000-0003-0511-7323
FU Henry Jackson Foundation; National Center for Advancing Translational
   Sciences (NCATS), National Institutes of Health, through the Clinical
   and Translational Science Awards Program (CTSA), a trademark of the
   Department of Health and Human Services, part of the Roadmap Initiative,
   " [UL1TR001409]; US Air ForceUnited States Department of Defense [AFOSR
   FA955013-1-0047]; ExxonMobil Foundation [S18200000000256]
FX JG's work is supported by the Henry Jackson Foundation, Leadership
   Initiatives, and federal funds UL1TR001409 from the National Center for
   Advancing Translational Sciences (NCATS), National Institutes of Health,
   through the Clinical and Translational Science Awards Program (CTSA), a
   trademark of the Department of Health and Human Services, part of the
   Roadmap Initiative, "Re-Engineering the Clinical Research Enterprise"
   E.J.C. acknowledges longtime support from the US Air Force (AFOSR
   FA955013-1-0047) and ExxonMobil Foundation (S18200000000256). This
   research received no specific grant from any funding agency in the
   public, commercial, or not-for-profit sectors.
CR Abd El-Fatah HA, 2020, ARAB J NUCL SCI APPL, V53, P172, DOI 10.21608/ajnsa.2019.12214.1209
   American Thoracic Society, AC RESP DISTR SYNDR
   Arenas M, 2008, RADIOTHER ONCOL, V86, P399, DOI 10.1016/j.radonc.2007.10.032
   Arenas M, 2006, INT J RADIAT ONCOL, V66, P560, DOI 10.1016/j.ijrobp.2006.06.004
   Calabrese EJ, 2019, HUM EXP TOXICOL, V38, P888, DOI 10.1177/0960327119846925
   Calabrese EJ, 2014, HUM EXP TOXICOL, V33, P542, DOI 10.1177/0960327113493303
   Calabrese EJ, 2018, PHARMACOL RES, V137, P236, DOI 10.1016/j.phrs.2018.10.010
   Calabrese EJ, 2017, DOSE-RESPONSE, V15, DOI 10.1177/1559325817704760
   Calabrese EJ, 2015, RADIAT RES, V184, P180, DOI 10.1667/RR14080.1
   Calabrese EJ, 2014, ARCH TOXICOL, V88, P1503, DOI 10.1007/s00204-014-1295-6
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   Calabrese EJ, 2013, DOSE-RESPONSE, V11, P469, DOI 10.2203/dose-response.13-004.Calabrese
   Calabrese EJ, 2013, HUM EXP TOXICOL, V32, P817, DOI 10.1177/0960327112467046
   Calabrese EJ, 2013, INT J RADIAT BIOL, V89, P278, DOI 10.3109/09553002.2013.752594
   Calabrese EJ, 2012, DOSE-RESPONSE, V10, P626, DOI 10.2203/dose-response.12-016.Calabrese
   Cascella M, 2020, STATPEARLS
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Dhawan G, 2019, DOSE-RESPONSE, V17, DOI 10.1177/1559325819871757
   DosReis GA, 2009, MEM I OSWALDO CRUZ, V104, P259, DOI 10.1590/S0074-02762009000900033
   Esmann L, 2010, J IMMUNOL, V184, P391, DOI 10.4049/jimmunol.0900564
   Ferri LA, 2009, ATHEROSCLEROSIS, V205, P391, DOI 10.1016/j.atherosclerosis.2008.12.042
   Frey B, 2009, AUTOIMMUNITY, V42, P346, DOI 10.1080/08916930902831738
   Genard G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00828
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hildebrandt G, 1998, INT J RADIAT BIOL, V74, P367, DOI 10.1080/095530098141500
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638
   Kern P, 1999, INT J RADIAT BIOL, V75, P995
   Klug F, 2013, CANCER CELL, V24, P589, DOI 10.1016/j.ccr.2013.09.014
   Madsbad S., 2020, TOUCH ENDOCRINOL
   Nakatsukasa H, 2008, J RADIAT RES, V49, P381, DOI 10.1269/jrr.08002
   Nakatsukasa H, 2010, RADIAT RES, V174, P313, DOI 10.1667/RR2121.1
   Perruche S, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2750
   Pinto AT, 2016, SCI REP-UK, V6, DOI 10.1038/srep18765
   Ren Y, 2008, J IMMUNOL, V180, P4978, DOI 10.4049/jimmunol.180.7.4978
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Schaue D, 2005, INT J RADIAT BIOL, V81, P657, DOI 10.1080/09553000500385556
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Weng L, 2010, ANN RHEUM DIS, V69, P1519, DOI 10.1136/ard.2009.121111
   Yang PH, 2020, CELL MOL IMMUNOL, V17, P555, DOI 10.1038/s41423-020-0407-x
   Zhou LY, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101642
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
NR 45
TC 20
Z9 20
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-8140
EI 1879-0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD JUN
PY 2020
VL 147
BP 212
EP 216
DI 10.1016/j.radonc.2020.05.002
PG 5
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA NI7QW
UT WOS:000565544600037
PM 32437820
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Kirsch, DG
   Diehn, M
   Cucinotta, FA
   Weichselbaum, R
AF Kirsch, David G.
   Diehn, Maximilian
   Cucinotta, Francis A.
   Weichselbaum, Ralph
TI Lack of supporting data make the risks of a clinical trial of radiation
   therapy as a treatment for COVID-19 pneumonia unacceptable
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Letter
ID DISEASE
C1 [Kirsch, David G.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27708 USA.
   [Kirsch, David G.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA.
   [Diehn, Maximilian] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA.
   [Diehn, Maximilian] Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.
   [Diehn, Maximilian] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA.
   [Cucinotta, Francis A.] Univ Nevada, Dept Hlth Phys & Diagnost Sci, Las Vegas, NV 89154 USA.
   [Weichselbaum, Ralph] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA.
RP Kirsch, DG (corresponding author), Duke Univ, Med Ctr, DUMC Box 91006, Durham, NC 27708 USA.
EM david.kirsch@duke.edu
RI Cucinotta, Francis/AAZ-5941-2020
OI Diehn, Maximilian/0000-0003-2032-0581
CR BAYLIN GJ, 1946, AM J ROENTGENOL, V55, P473
   Bhatraju PK, 2020, N ENGL J MED
   Correll HL, 1943, US NAV M B, V1943, P980
   Cucinotta F.A., 2013, 2013217375 NASA TP
   Cucinotta FA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096099
   Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825
   Day M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1375
   DUBIN IN, 1946, AM J ROENTGENOL, V55, P478
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Kirkby C, 2020, RADIOTHER ONCOL, V147, P221, DOI 10.1016/j.radonc.2020.04.004
   Little MP, 2012, ENVIRON HEALTH PERSP, V120, P1503, DOI 10.1289/ehp.1204982
   Miyashita H, 2020, ANN ONCOL
   Mizumoto K., 2020, EUROSURVEILLANCE, P25, DOI DOI 10.2807/1560-7917.ES.2020.25.10.200018032183930
   Myers LC, 2020, JAMA, DOI 10.1001/jama.2020.7202
   National Academy of Sciences Committee on the Biological Effects of Radiation, 2006, HLTH RISKS EXP LOW L
   Oppenheimer A, 1943, AM J ROENTGENOL RADI, V49, P635
   Richardson S., 2020, JAMA
   Sutton D, 2020, N ENGL J MED
   United Nations Scientific Committee on the Effects of Atomic Radiation, 2008, SOURC EFF ION RAD U
NR 20
TC 13
Z9 13
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-8140
EI 1879-0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD JUN
PY 2020
VL 147
BP 217
EP 220
DI 10.1016/j.radonc.2020.04.060
PG 4
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA NI7QW
UT WOS:000565544600038
PM 32413531
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kirkby, C
   Mackenzie, M
AF Kirkby, Charles
   Mackenzie, Marc
TI Is low dose radiation therapy a potential treatment for COVID-19
   pneumonia?
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Letter
ID RADIOTHERAPY; MECHANISMS
C1 [Kirkby, Charles] Jack Ady Canc Ctr, Dept Med Phys, Lethbridge, AB, Canada.
   [Kirkby, Charles] Univ Calgary, Dept Oncol, Calgary, AB, Canada.
   [Kirkby, Charles] Univ Calgary, Dept Phys & Astron, Calgary, AB, Canada.
   [Mackenzie, Marc] Univ Alberta, Dept Oncol, Edmonton, AB, Canada.
RP Kirkby, C (corresponding author), Jack Ady Canc Ctr, Dept Med Phys, Lethbridge, AB, Canada.; Kirkby, C (corresponding author), Univ Calgary, Dept Oncol, Calgary, AB, Canada.; Kirkby, C (corresponding author), Univ Calgary, Dept Phys & Astron, Calgary, AB, Canada.
EM charles.kirkby@ahs.ca
OI MacKenzie, Marc/0000-0001-7260-5795
CR Arenas M, 2008, RADIOTHER ONCOL, V86, P399, DOI 10.1016/j.radonc.2007.10.032
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   DUBIN IN, 1946, AM J ROENTGENOL, V55, P478
   Moldoveanu B, 2009, J INFLAMM RES, V2, P1
   Oppenheimer A, 1943, J PEDIAT, V41, P404
   Powell EV, 1936, TEX STATE J MED, V32, P237
   Rodel F, 2007, INT J RADIAT BIOL, V83, P357, DOI 10.1080/09553000701317358
   Schaue D, 2005, INT J RADIAT BIOL, V81, P657, DOI 10.1080/09553000500385556
   Royo LT, 2020, REP PRACT ONCOL RADI, V25, P250, DOI 10.1016/j.rpor.2020.02.004
   Zhou F., 2020, LANCET
NR 10
TC 29
Z9 29
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-8140
EI 1879-0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD JUN
PY 2020
VL 147
BP 221
EP 221
DI 10.1016/j.radonc.2020.04.004
PG 1
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA NI7QW
UT WOS:000565544600039
PM 32342871
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kefayat, A
   Ghahremani, F
AF Kefayat, Amirhosein
   Ghahremani, Fatemeh
TI Low dose radiation therapy for COVID-19 pneumonia: A double-edged sword
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Letter
ID RADIOTHERAPY
C1 [Kefayat, Amirhosein] Isfahan Univ Med Sci, Dept Oncol, Canc Prevent Res Ctr, Esfahan 8174673461, Iran.
   [Ghahremani, Fatemeh] Arak Univ Med Sci, Arak Sch Paramed, Dept Med Phys & Radiotherapy, Arak 3848176941, Iran.
RP Ghahremani, F (corresponding author), Arak Univ Med Sci, Arak Sch Paramed, Dept Med Phys & Radiotherapy, Arak 3848176941, Iran.
EM F.ghahremani@arakmu.ac.ir
CR Arenas M, 2012, STRAHLENTHER ONKOL, V188, P975, DOI 10.1007/s00066-012-0170-8
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   Ceccaldi PE, 1996, INT J RADIAT BIOL, V70, P69, DOI 10.1080/095530096145346
   Iordanskiy S, 2015, VIROLOGY, V485, P1, DOI 10.1016/j.virol.2015.06.021
   Keller S, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-29
   Kirkby C, 2020, RADIOTHER ONCOL, V147, P221, DOI 10.1016/j.radonc.2020.04.004
   McIntire F., 1937, TEX STATE J MED, V33, P422, DOI 10.1148/33.3.331.
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mezhir JJ, 2005, CANCER RES, V65, P9479, DOI 10.1158/0008-5472.CAN-05-1927
   Ramirez-Fort MK, 2018, J CLIN VIROL, V98, P18, DOI 10.1016/j.jcv.2017.11.004
   Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201
   Scott WRJR, 1939, RADIOLOGY, V33, P331, DOI [DOI 10.1148/33.3.331, 10.1148/33.3.331]
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 14
TC 12
Z9 12
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-8140
EI 1879-0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD JUN
PY 2020
VL 147
BP 224
EP 225
DI 10.1016/j.radonc.2020.04.026
PG 2
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA NI7QW
UT WOS:000565544600041
PM 32342874
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kirkby, C
   Mackenzie, M
AF Kirkby, Charles
   Mackenzie, Marc
TI Response to: Low dose radiation therapy for COVID-19 pneumonia a
   double-edged sword
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Letter
C1 [Kirkby, Charles] Jack Ady Canc Ctr, Dept Med Phys, Lethbridge, AB, Canada.
   [Kirkby, Charles] Univ Calgary, Dept Oncol, Calgary, AB, Canada.
   [Kirkby, Charles] Univ Calgary, Dept Phys & Astron, Calgary, AB, Canada.
   [Mackenzie, Marc] Univ Alberta, Dept Oncol, Edmonton, AB, Canada.
RP Kirkby, C (corresponding author), Jack Ady Canc Ctr, Dept Med Phys, Lethbridge, AB, Canada.; Kirkby, C (corresponding author), Univ Calgary, Dept Oncol, Calgary, AB, Canada.; Kirkby, C (corresponding author), Univ Calgary, Dept Phys & Astron, Calgary, AB, Canada.
CR Marks LB, 2010, INT J RADIAT ONCOL, V76, pS70, DOI 10.1016/j.ijrobp.2009.06.091
   Thureau S, 2020, J BONE ONCOL, V22, DOI 10.1016/j.jbo.2020.100291
NR 2
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-8140
EI 1879-0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD JUN
PY 2020
VL 147
BP 226
EP 226
DI 10.1016/j.radonc.2020.04.042
PG 1
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA NI7QW
UT WOS:000565544600002
PM 32387544
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Basu, BV
   Brown, OR
AF Basu, Babu, V
   Brown, Olen R.
TI Comparative analysis of Coronaviridae nucleocapsid and surface
   glycoprotein sequences
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE Coronavirus; Nucleocapsid Protein; SARSOCoV-2; Sequence Homology;
   Surface Glycoprotein
AB We analyzed the nucleocapsid and surface proteins from several Coronaviridae viruses using an alignment-free computer program. Three isolates of novel, human coronavirus (SARS0CoV-2) (2019) that are responsible for the current pandemic and older SARS strains of human and animal coronaviruses were examined. The nucleocapsid and glycoprotein sequences are identical for the three novel 2019 human isolates and they are closely related to these sequences in six bat and human SARS coronaviruses. This strongly supports the bat origin of the pandemic, novel coronavirus. One surface glycoprotein fragment of 111 amino acids is the largest, conserved, common permutation in the examined bat SARS-like and human SARS viruses, including the Covid-19 virus. BLAST analysis confirmed that this fragment is conserved only in the human and bat SARS strains. This fragment likely is involved in infectivity and is of interest for vaccine development. Surface glycoprotein and nucleocapsid protein sequence homologies of 58.9% and 82.5%, respectively, between the novel SARS0CoV-2 strains and the human SARS (2018) virus suggest that existing anti-SARS vaccines may provide some protection against the novel coronavirus.
C1 [Basu, Babu, V] Southern Univ & A&M Coll, Baton Rouge, LA 70813 USA.
   [Brown, Olen R.] Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65211 USA.
RP Basu, BV (corresponding author), Southern Univ & A&M Coll, Dept Environm Toxicol, 108 Fisher Hall,POB 9264, Baton Rouge, LA 70813 USA.
EM bb-assa9824@gmail.com
CR Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   Deng SQ, 2020, J CLIN MED E, V575, P992
   Snijder EJ., 2004, BIOCHEM BIOPH RES CO, V316, P476
   Tao Y, 2019, MICROBIOL RESOUR ANN, V8, DOI [10.1128/mra.00548-19, 10.1128/MRA.00548-19]
   Vinga S, 2003, BIOINFORMATICS, V19, P513, DOI 10.1093/bioinformatics/btg005
   Wu F., 2020, NOVEL CORONAVIRUS AS
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 7
TC 0
Z9 0
U1 2
U2 3
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093-9946
EI 1093-4715
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD JUN 1
PY 2020
VL 25
BP 1894
EP 1900
AR PMID 32472763
DI 10.2741/4883
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NG1UK
UT WOS:000563772000005
PM 32472763
DA 2021-01-01
ER

PT J
AU Moore, HB
   Barrett, CD
   Moore, EE
   McIntyre, RC
   Moore, PK
   Talmor, DS
   Moore, FA
   Yaffe, MB
AF Moore, Hunter B.
   Barrett, Christopher D.
   Moore, Ernest E.
   McIntyre, Robert C.
   Moore, Peter K.
   Talmor, Daniel S.
   Moore, Frederick A.
   Yaffe, Michael B.
TI Is there a role for tissue plasminogen activator as a novel treatment
   for refractory COVID-19 associated acute respiratory distress syndrome?
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
ID ACUTE LUNG INJURY; COAGULATION; PNEUMONIA; THERAPY
C1 [Moore, Hunter B.; Moore, Ernest E.; McIntyre, Robert C.] Univ Colorado, Dept Surg, Denver, CO 80202 USA.
   [Barrett, Christopher D.; Yaffe, Michael B.] MIT, Koch Inst Integrat Canc Res, Ctr Precis Canc Med, Dept Biol Engn, Cambridge, MA 02139 USA.
   [Barrett, Christopher D.; Yaffe, Michael B.] MIT, Koch Inst Integrat Canc Res, Ctr Precis Canc Med, Dept Biol, Cambridge, MA 02139 USA.
   [Barrett, Christopher D.; Yaffe, Michael B.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Acute Care Surg Trauma & Surg Crit Care, Dept Surg, Boston, MA 02115 USA.
   [Moore, Peter K.] Univ Colorado, Ernest E Moore Shock Trauma Ctr Denver Hlth, Denver, CO 80202 USA.
   [Moore, Peter K.] Univ Colorado, Dept Med, Denver, CO USA.
   [Talmor, Daniel S.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA.
   [Moore, Frederick A.] Univ Florida, Dept Surg, Gainesville, FL USA.
RP Yaffe, MB (corresponding author), MIT, Koch Inst Integrat Canc Res, Ctr Precis Canc Med, Dept Biol Engn, Cambridge, MA 02139 USA.; Yaffe, MB (corresponding author), MIT, Koch Inst Integrat Canc Res, Ctr Precis Canc Med, Dept Biol, Cambridge, MA 02139 USA.
EM myaffe@mit.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [UM1-HL120877, F32-HL134244,
   L30-GM120751]; DoD Peer Reviewed Medical Research Program
   [W81XWH-16-1-0464]
FX This work was supported by NIH Grants UM1-HL120877 (EEM, MBY),
   F32-HL134244 (CDB), and L30-GM120751 (CDB); and DoD Peer Reviewed
   Medical Research Program, Contract Number W81XWH-16-1-0464 (MBY).
CR Bastarache JA, 2006, SEMIN RESP CRIT CARE, V27, P365, DOI 10.1055/s-2006-948290
   BONE RC, 1976, AM J MED, V61, P585, DOI 10.1016/0002-9343(76)90135-2
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Gunther A, 2000, AM J RESP CRIT CARE, V161, P454
   Hardaway RM, 2001, AM SURGEON, V67, P377
   HARDAWAY RM, 1990, CRIT CARE MED, V18, P1413, DOI 10.1097/00003246-199012000-00021
   Kaufman C, 2018, J CLIN MED, V7, DOI 10.3390/jcm7050111
   Laterre PF, 2003, CRIT CARE MED, V31, pS329, DOI 10.1097/01.CCM.0000057912.71499.A5
   Liu C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01898
   MacLaren R, 2007, PHARMACOTHERAPY, V27, P860, DOI 10.1592/phco.27.6.860
   Schultz MJ, 2006, CRIT CARE MED, V34, P871, DOI [10.1097/01.CCM.0000201882.23917.B8, 10.1097/01.CCM.0000202136.91651.34]
   Stringer KA, 1998, FREE RADICAL BIO MED, V25, P184, DOI 10.1016/S0891-5849(98)00047-1
   Tian S, 2020, J THORAC ONCOL
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wardlaw JM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub3
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware Lorraine B., 2005, Keio Journal of Medicine, V54, P142, DOI 10.2302/kjm.54.142
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Ware LB, 2006, AM J PHYSIOL-LUNG C, V291, pL307, DOI 10.1152/ajplung.00157.2006
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Y, 2016, CELL MOL IMMUNOL, V13, P432, DOI 10.1038/cmi.2016.1
NR 21
TC 24
Z9 25
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD JUN
PY 2020
VL 88
IS 6
BP 713
EP 714
DI 10.1097/TA.0000000000002694
PG 2
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA NE5VY
UT WOS:000562670100013
PM 32281766
OA Other Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Cure, E
   Cure, MC
AF Cure, Erkan
   Cure, Medine Cumhur
TI Comment on 'Can angiotensin receptor-blocking drugs perhaps be harmful
   in the COVID-19 pandemic?'
SO JOURNAL OF HYPERTENSION
LA English
DT Letter
ID EXPRESSION
C1 [Cure, Erkan] Ota & Jinemed Hosp, Dept Internal Med, Deryadil Sokagi 1, TR-34357 Istanbul, Turkey.
   [Cure, Erkan; Cure, Medine Cumhur] Dept Biochem, Istanbul, Turkey.
RP Cure, E (corresponding author), Ota & Jinemed Hosp, Dept Internal Med, Deryadil Sokagi 1, TR-34357 Istanbul, Turkey.
EM erkancure@yahoo.com
RI cumhur cure, medine/A-1089-2018; CURE, Erkan/W-4922-2017
OI cumhur cure, medine/0000-0001-9253-6459; CURE, Erkan/0000-0001-7807-135X
CR Brosnihan KB, 2005, HYPERTENSION, V46, P1097, DOI 10.1161/01.HYP.0000185149.56516.0a
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Li YH, 2013, J GERIATR CARDIOL, V10, P151, DOI 10.3969/j.issn.1671-5411.2013.02.009
   Rocha ND, 2018, DIABETES VASC DIS RE, V15, P375, DOI 10.1177/1479164118783756
   Romani-Perez M, 2015, ENDOCRINOLOGY, V156, P3559, DOI 10.1210/en.2014-1685
   Thomas MC, 2012, PPAR RES, V2012, DOI 10.1155/2012/456529
NR 7
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0263-6352
EI 1473-5598
J9 J HYPERTENS
JI J. Hypertens.
PD JUN
PY 2020
VL 38
IS 6
BP 1189
EP 1189
DI 10.1097/HJH.0000000000002481
PG 1
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA NE3DF
UT WOS:000562476900025
PM 32371810
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Fernandez-Fernandez, FJ
AF Jose Fernandez-Fernandez, Francisco
TI COVID-19, hypertension and angiotensin receptor-blocking drugs
SO JOURNAL OF HYPERTENSION
LA English
DT Letter
C1 [Jose Fernandez-Fernandez, Francisco] Complejo Hosp Univ Ferrol, Dept Internal Med, Ferrol 15405, Spain.
RP Fernandez-Fernandez, FJ (corresponding author), Complejo Hosp Univ Ferrol, Dept Internal Med, Ferrol 15405, Spain.
EM fjf.fernandez2@gmail.com
CR Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Imai Y, 2007, CELL MOL LIFE SCI, V64, P2006, DOI 10.1007/s00018-007-6228-6
   Kuba K, 2010, PHARMACOL THERAPEUT, V128, P119, DOI 10.1016/j.pharmthera.2010.06.003
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 6
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0263-6352
EI 1473-5598
J9 J HYPERTENS
JI J. Hypertens.
PD JUN
PY 2020
VL 38
IS 6
BP 1191
EP 1191
DI 10.1097/HJH.0000000000002468
PG 1
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA NE3DF
UT WOS:000562476900027
PM 32371812
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bourgeois, LF
   Harell, A
   Stephenson, LB
AF Bourgeois, Laura French
   Harell, Allison
   Stephenson, Laura B.
TI To Follow or Not to Follow: Social Norms and Civic Duty during a
   Pandemic
SO CANADIAN JOURNAL OF POLITICAL SCIENCE-REVUE CANADIENNE DE SCIENCE
   POLITIQUE
LA English
DT Article
AB The outbreak of COVID-19 has put substantial pressure on individuals to adapt and change their behaviours. As the hope of a vaccine remains at least a year away, everyone is urged to take action to slow the spread of the virus. Thus, "flattening the curve" has become vital in preventing medical systems from being overrun, and it relies on massive collective action by citizens to follow specific public health measures such as physical distancing, hand washing, and physical isolation for vulnerable individuals. Despite the recommendations, the public has often been confronted with the reality that some individuals are not respecting them, including elected officials (Aguilar, 2020).
C1 [Bourgeois, Laura French; Harell, Allison] Univ Quebec Montreal, 405 Rue St Catherine Est, Montreal, PQ H2L 2C4, Canada.
   [Stephenson, Laura B.] Univ Western Ontario, 1151 Richmond St, Richmond, ON N6A 3K7, Canada.
RP Bourgeois, LF (corresponding author), Univ Quebec Montreal, 405 Rue St Catherine Est, Montreal, PQ H2L 2C4, Canada.
EM french_bourgeois.laura@ens.uqam.ca
OI French Bourgeois, Laura/0000-0002-4785-9889
CR Bicchieri C., 2005, GRAMMAR SOC NATURE D
   Blais A, 2019, POLIT STUD REV, V17, P328, DOI 10.1177/1478929919865467
   Blais A, 2019, POLIT BEHAV, V41, P473, DOI 10.1007/s11109-018-9459-3
   Blais Andre, 2020, MOTIVATION VOTE EXPL
   Blais Andre, 2000, VOTE NOT VOTE
   Daoust Jean-Francois, 2020, OSF, DOI [10.31235/osf.io/gursd, DOI 10.31235/OSF.IO/GURSD]
   Government of Canada, 2020, PREV COR
   Harell Allison, 2020, DEMOCRACY CHECKUP DA
   Hayes A. F., 2017, INTRO MEDIATION MODE
   Jetten J., 2020, TOGETHER APART PSYCH
   Merkley Eric, 2020, OSF PREPRINTS, DOI [10.31219/osf.io/yht9v, DOI 10.31219/OSF.IO/YHT9V]
   Morin-Chasse A, 2017, POLIT SCI RES METH, V5, P575, DOI 10.1017/psrm.2016.31
   Nadler Eric, 2020, Sarcoma, V2020, P1765319, DOI 10.1155/2020/1765319
   Prentice Deborah, 2012, UNDERSTANDING SOCIAL
   Sherif M., 1936, PSYCHOL SOCIAL NORMS
   Steffens Niklas, 2020, TOGETHER APART PSYCH
   Thibaut J. W., 1959, SOCIAL PSYCHOL GROUP
   2016, CIRE ANTILLES GUYANE, V4, P1
NR 18
TC 2
Z9 2
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0008-4239
EI 1744-9324
J9 CAN J POLIT SCI
JI Can. J. Polit. Sci.-Rev. Can. Sci. Polit.
PD JUN
PY 2020
VL 53
IS 2
SI SI
BP 273
EP 278
AR PII S0008423920000554
DI 10.1017/S0008423920000554
PG 6
WC Political Science
SC Government & Law
GA ND3VV
UT WOS:000561832200008
OA Other Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Miller, JM
AF Miller, Joanne M.
TI Do COVID-19 Conspiracy Theory Beliefs Form a Monological Belief System?
SO CANADIAN JOURNAL OF POLITICAL SCIENCE-REVUE CANADIENNE DE SCIENCE
   POLITIQUE
LA English
DT Article
AB Along with criticisms of the U.S. government's response to the COVID-19 pandemic, the disruptions to home, work, and school life resulting from social distancing orders recommended by public health experts, as well as the uncertainty about how long the disruptions will be necessary and when (if ever) we will have a vaccine, have come COVID-19 conspiracy theories (CTs).
C1 [Miller, Joanne M.] Univ Delaware, Polit Sci & Int Relat, 347 Smith Hall,18 Amstel Ave, Newark, DE 19716 USA.
RP Miller, JM (corresponding author), Univ Delaware, Polit Sci & Int Relat, 347 Smith Hall,18 Amstel Ave, Newark, DE 19716 USA.
EM jomiller@udel.edu
OI Miller, Joanne/0000-0002-9823-5005
CR GOERTZEL T, 1994, POLIT PSYCHOL, V15, P731, DOI 10.2307/3791630
   Lynas M., 2020, COVID TOP 10 CURRENT
   Miller JM, 2016, AM J POLIT SCI, V60, P824, DOI 10.1111/ajps.12234
   Motta M, 2020, CAN J POLIT SCI, V53, P335, DOI 10.1017/S0008423920000396
   Pennycook Gordon, 2020, PREDICTORS ATTITUDES, DOI [10.31234/osf.io/zhjkp, DOI 10.31234/0SF.I0/ZHJKP]
   Schaffner BF, 2018, PUBLIC OPIN QUART, V82, P135, DOI 10.1093/poq/nfx042
   Uscinski J. E., 2014, AM CONSPIRACY THEORI
   Uscinski JE, 2016, POLIT RES QUART, V69, P57, DOI 10.1177/1065912915621621
   Uscinski Joseph E., 2020, HARVARD KENNEDY SCH, DOI 10.37016/mr-2020-015
   Van Prooijen JW, 2015, APPL COGNITIVE PSYCH, V29, P753, DOI 10.1002/acp.3161
   van Prooijen Jan-Willem, 2018, CONSPIRACY THEORIES
   Wood MJ, 2012, SOC PSYCHOL PERS SCI, V3, P767, DOI 10.1177/1948550611434786
NR 12
TC 6
Z9 6
U1 2
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0008-4239
EI 1744-9324
J9 CAN J POLIT SCI
JI Can. J. Polit. Sci.-Rev. Can. Sci. Polit.
PD JUN
PY 2020
VL 53
IS 2
SI SI
BP 319
EP 326
AR PII S0008423920000517
DI 10.1017/S0008423920000517
PG 8
WC Political Science
SC Government & Law
GA ND3VV
UT WOS:000561832200015
OA Green Accepted, Other Gold
DA 2021-01-01
ER

PT J
AU Silva-Arrieta, S
   Goulder, PJR
   Brander, C
AF Silva-Arrieta, Sandra
   Goulder, Philip J. R.
   Brander, Christian
TI In silico veritas? Potential limitations for SARS-CoV-2 vaccine
   development based on T-cell epitope prediction
SO PLOS PATHOGENS
LA English
DT Article
ID EPSTEIN-BARR-VIRUS; HLA
C1 [Silva-Arrieta, Sandra; Brander, Christian] Hosp Badalona Germans Trias & Pujol, IrsiCaixa AIDS Res Inst, Inst Hlth Sci Res Germans Trias & Pujol IGTP, Badalona, Spain.
   [Goulder, Philip J. R.] Univ Oxford, Dept Paediat, Oxford, England.
   [Goulder, Philip J. R.] Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, Durban, South Africa.
   [Goulder, Philip J. R.] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA.
   [Brander, Christian] Univ Vic Cent Univ Catalonia, Catalonia, Vic, Spain.
   [Brander, Christian] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain.
RP Brander, C (corresponding author), Hosp Badalona Germans Trias & Pujol, IrsiCaixa AIDS Res Inst, Inst Hlth Sci Res Germans Trias & Pujol IGTP, Badalona, Spain.; Brander, C (corresponding author), Univ Vic Cent Univ Catalonia, Catalonia, Vic, Spain.; Brander, C (corresponding author), Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain.
EM cbrander@irsicaixa.es
OI Brander, Christian/0000-0002-0548-5778
FU Wellcome TrustWellcome Trust [WT104748MA]; NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [P01-AI131568, RO1 AI133673]; European Union's Horizon 2020 research and
   innovation program [681137-EAVI2020]
FX The present work was in parts support by grants from the Wellcome Trust
   WT104748MA and NIH RO1 AI133673 to PJRG and by the European Union's
   Horizon 2020 research and innovation program under grant agreement
   681137-EAVI2020 and NIH grant P01-AI131568 to CB. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Brander C, 1995, HIV MOL IMMUNOLOGY D, P1
   Burrows SR, 2006, TRENDS IMMUNOL, V27, P11, DOI 10.1016/j.it.2005.11.001
   Chen G, 2020, J CLIN INVEST, DOI [10.1172/JCI137244, DOI 10.1172/JCI137244]
   DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013
   FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0
   Frahm N, 2007, EUR J IMMUNOL, V37, P2419, DOI 10.1002/eji.200737365
   Friberg H, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006975
   GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0
   Goulder PJR, 2000, J VIROL, V74, P5291, DOI 10.1128/JVI.74.11.5291-5299.2000
   Gutierrez MI, 1998, BLOOD, V92, P600, DOI 10.1182/blood.V92.2.600.414k33_600_606
   Llano A, 2019, HIV MOL IMMUNOLOGY 2, P3
   NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0
   Ruiz-Riol M, 2015, J INFECT DIS, V211, P936, DOI 10.1093/infdis/jiu534
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   Walters LC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05459-z
   Yaciuk JC, 2014, J VIROL, V88, P12992, DOI 10.1128/JVI.01914-14
NR 16
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUN
PY 2020
VL 16
IS 6
AR e1008607
DI 10.1371/journal.ppat.1008607
PG 5
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA NA3PS
UT WOS:000559725500009
PM 32497149
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Diez, JM
   Romero, C
   Gajardo, R
AF Diez, Jose-Maria
   Romero, Carolina
   Gajardo, Rodrigo
TI Currently available intravenous immunoglobulin contains antibodies
   reacting against severe acute respiratory syndrome coronavirus 2
   antigens
SO IMMUNOTHERAPY
LA English
DT Article
DE antibody content; COVID-19; intravenous immunoglobulin; SARS-CoV-2
ID CONVALESCENT PLASMA; SARS PATIENTS; EXPERIENCE; INFECTION; COVID-19;
   HKU1
AB Aim: There is a critical need for effective therapies that are immediately available to control the spread of COVID-19 disease. Material & methods: Gamunex((R))-C and Flebogamma((R)) DIF (Grifols) intravenous immunoglobulin (IVIG) products were tested using ELISA techniques for antibodies against several antigens of human common betacoronaviruses that may crossreact with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Results: Both IVIGs showed consistent reactivity to components of the tested viruses. Positive crossreactivity was seen in SARS-CoV, middle east respiratory syndrome-CoV and SARS-CoV-2. For SARS-CoV-2, positive reactivity was observed at IVIG concentrations ranging from 100 mu g/ml with Gamunex-C to 1 mg/ml with Flebogamma 5% DIF. Conclusion: Gamunex-C and Flebogamma DIF contain antibodies reacting against SARS-CoV-2 antigens. Studies to confirm the utility of IVIG preparations for COVID-19 management may be warranted.
C1 [Diez, Jose-Maria; Romero, Carolina; Gajardo, Rodrigo] Biosci Ind Grp, Res & Dev, Barcelona, Spain.
RP Diez, JM (corresponding author), Biosci Ind Grp, Res & Dev, Barcelona, Spain.
EM josemaria.diez@grifols.com
FU Grifols S.A.
FX Editorial assistance has been provided by Content Ed Net Spain with
   funding by Grifols S.A.
CR Anthony SJ, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex012
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Ballow M, 2011, CLIN IMMUNOL, V139, P208, DOI 10.1016/j.clim.2011.02.006
   Bozzo J, 2017, EXPERT REV ANTI-INFE, V15, P585, DOI 10.1080/14787210.2017.1328278
   Cao W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa102
   Chan KH, 2013, J INFECTION, V67, P130, DOI 10.1016/j.jinf.2013.03.015
   Che XY, 2005, J INFECT DIS, V191, P2033, DOI 10.1086/430355
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Esper F, 2006, EMERG INFECT DIS, V12, P775, DOI 10.3201/eid1205.051316
   European Centre for Disease Prevention and Control, 2020, COVID 19 SIT UPD WOR
   Farbu E, 2007, EUR J NEUROL, V14, P60, DOI 10.1111/j.1468-1331.2006.01552.x
   Fernandez-Cruz E, 2009, CLIN EXP IMMUNOL, V157, P1, DOI 10.1111/j.1365-2249.2009.03955.x
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Issekutz AC, 2011, CLIN IMMUNOL, V141, P187, DOI 10.1016/j.clim.2011.08.003
   Jordan SC, 2009, TRANSPLANTATION, V88, P1, DOI 10.1097/TP.0b013e3181a9e89a
   Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360
   Matsuda A, 2012, EUR J IMMUNOL, V42, P2121, DOI 10.1002/eji.201242398
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Patrick David M, 2006, Can J Infect Dis Med Microbiol, V17, P330
   Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Wu KH, 2006, PEDIAT ALLERG IMM-UK, V17, P60, DOI 10.1111/j.1399-3038.2005.00344.x
   Xie Y, 2020, J INFECTION, V81, P340, DOI 10.1016/j.jinf.2020.03.044
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
NR 29
TC 14
Z9 14
U1 2
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-743X
EI 1750-7448
J9 IMMUNOTHERAPY-UK
JI Immunotherapy
PD JUN
PY 2020
VL 12
IS 8
BP 571
EP 576
DI 10.2217/imt-2020-0095
PG 6
WC Immunology
SC Immunology
GA MY3JE
UT WOS:000558314900006
PM 32397847
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Moneriz, C
   Castro-Salguedo, C
AF Moneriz, Carlos
   Castro-Salguedo, Cristian
TI Promising and potential drugs for the treatment of COVID-19
SO REVISTA CHILENA DE INFECTOLOGIA
LA Spanish
DT Article
DE coronavirus; SARS-CoV-2; COVID-19; drug; treatment
ID ACUTE RESPIRATORY SYNDROME; MERS-COV; SARS; LOPINAVIR/RITONAVIR;
   CHLOROQUINE; PNEUMONIA; REMDESIVIR; RIBAVIRIN; EFFICACY; OUTBREAK
AB Coronavirus disease 2019 (COVID-19) is characterized by respiratory alterations with varied symptoms ranging from mild manifestations to more severe conditions that can cause death. The objective of this narrative review of the literature is to synthesize in a concrete way the information available on potential drugs for the treatment of patients with COVID-19 and to serve as a support guide for health professionals. Taking into account previous experiences for the management of SARS-CoV and MERS-CoV in the past, some of these drugs have been used as a starting point to seek the elimination of SARS-CoV-2. This review presents the current state of research on promising drugs as potential treatments for COVID-19 worldwide and is developed in the text on four types of anti-SARS-Cov-2 agents: regulators of the immune response, intracellular medium modifiers, viral RNA polymerase inhibitors and protease inhibitors. To date all the drugs described in this review need clinical studies to validate their use. However, until the results of these trials are available, the best available evidence should be used for the prevention and treatment of COVID-19.
C1 [Moneriz, Carlos] Univ Cartagena Cartagena, Fac Med, Grp Invest Bioquim & Enfermedad, Cartagena, Colombia.
   [Castro-Salguedo, Cristian] Univ San Buenaventura, Grp Invest Biomed GIB, Cartagena, Colombia.
RP Moneriz, C (corresponding author), Univ Cartagena Cartagena, Fac Med, Grp Invest Bioquim & Enfermedad, Cartagena, Colombia.
EM cmonerizp@unicartagena.edu.co
CR Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   [Anonymous], 2020, INFEZ MED, V28, P143
   Arabi Y, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1490-9
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Barnard DL, 2011, FUTURE VIROL, V6, P615, DOI 10.2217/fvl.11.33
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   BECK BR, 2020, BIORXIV, DOI DOI 10.1101/2020.01.31.929547
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Bhatnagar T, 2020, INDIAN J MED RES, DOI [10.4103/ijmr.IJMR_502_20, DOI 10.4103/IJMR.IJMR_502_20]
   Borba MGS, 2020, CHLOROQUINE DIPHOSPH, DOI [10.1101/2020.04.07.20, DOI 10.1101/2020.04.07.20]
   Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cellina M, 2020, DIAGN INTERV IMAG, V101, P323, DOI 10.1016/j.diii.2020.03.010
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cheng C-Y, 2020, J MICROBIOL IMMUNOL, DOI [10.1016/j., DOI 10.1016/J]
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Contini A., 2020, VIRTUAL SCREENING FD, DOI [10.26434/Chemrxiv.11847381.V1., DOI 10.26434/CHEMRXIV.11847381.V1, 10.26434/chemrxiv.11847381.v1]
   Cortegiani A, 2020, J CRIT CARE, DOI [10.1016/j.issn.1008-9292.2020.03.03., DOI 10.1016/J.ISSN.1008-9292.2020.03.03]
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004
   DAVEY K, 2020, AM J EMERG MED, V13, DOI DOI 10.1016/J.AJEM.2020.04.035
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Deng L, 2020, J INFECTION, DOI [10.1016/j., DOI 10.1016/J]
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Elfiky A., 2020, ANTI SARS ANTI HCV D, DOI [10.21203/rs.2.23280/v1, DOI 10.21203/RS.2.23280/V1]
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Fontana F, 2020, AM J TRANSPLANT, V20, P1902, DOI 10.1111/ajt.15935
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gbinigie Kome, 2020, BJGP Open, V4, DOI 10.3399/bjgpopen20X101069
   Graci JD, 2006, REV MED VIROL, V16, P37, DOI 10.1002/rmv.483
   Grein J, 2020, NEW ENGL J MED, V382
   Habib AMG, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4555-5
   Hillaker E, 2020, PHARMACOTHERAPY, V40, P592, DOI 10.1002/phar.2403
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jean S-S, 2020, J MICROBIOL IMMUNOL, DOI [10.1016/j., DOI 10.1016/J]
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Khalili JS, 2020, J MED VIROL, V92, P740, DOI 10.1002/jmv.25798
   Kim Y, 2020, AM J TRANSPLANT, V20, P2269, DOI 10.1111/ajt.15947
   Knowles SR, 2003, CLIN INFECT DIS, V37, P1139, DOI 10.1086/378304
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lin FC, 2014, CYTOKINE GROWTH F R, V25, P369, DOI 10.1016/j.cytogfr.2014.07.015
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu L, 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.02.20.20025536, DOI 10.1101/2020.02.20.20025536]
   Liu X., 2020, POTENTIAL INHIBITORS, DOI [10.1101/2020.01.29.924100, DOI 10.1101/2020.01.29.924100]
   Lokugamage Kumari G, 2020, bioRxiv, DOI 10.1101/2020.03.07.982264
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Meziyerh S, 2020, AM J TRANSPLANT, V20, P1896, DOI 10.1111/ajt.15943
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Mosaddeghi P., 2020, THERAPEUTIC APPROACH, DOI [10.20944/preprints202003.0206.v1., DOI 10.20944/PREPRINTS202003.0206.V1]
   NAKAMURA Y, 2020, J INFECT CHEMOTHER, DOI DOI 10.1016/J
   Ortiz-Martinez Y, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101678
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Qin X, 2020, SSRN LANCET RES 0220, DOI [10.2139/ssrn.3541147., DOI 10.2139/SSRN.3541147.]
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Sekhar T., 2020, PREPRINTS, DOI [10.20944/ preprints202002.0418.v2, DOI 10.20944/PREPRINTS202002.0418.V2, 10.20944/preprints202002.0418.v2]
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Q., 2020, VIRTUAL SCREENING AP
   World Health Organization, CLIN MAN SEV AC RESP
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Zhang J, 2020, BIORXIV, DOI [10.1101/2020.02.05.935387., 10.1101/2020.02.05.9353872020.02.05.935387, DOI 10.1101/2020.02.05.935387]
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhavoronkov A, 2020, POTENTIAL COVID2019, DOI [10.26434/chemrxiv.11829102.v2., DOI 10.26434/CHEMRXIV.11829102.V2.]
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
NR 88
TC 0
Z9 0
U1 1
U2 1
PU SOC CHILENA INFECTOLOGIA
PI PROVIDENCIA
PA BERNARDA MORIN 488, 2 PISO, PROVIDENCIA, SANTIAGO 00000, CHILE
SN 0716-1018
EI 0717-6341
J9 REV CHIL INFECTOL
JI Rev. Chil. Infectol.
PD JUN
PY 2020
VL 37
IS 3
BP 205
EP 215
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA MZ1ZI
UT WOS:000558919900002
PM 32853310
OA Other Gold, Bronze
DA 2021-01-01
ER

PT J
AU Rozas, BA
   Urra, JV
   Garzon, JG
AF Abarca Rozas, Bastian
   Vargas Urra, Jocelyn
   Garcia Garzon, Javier
TI Pathogenic, clinical and diagnostic characteristics of the SARS-CoV-2
   pandemic
SO REVISTA CHILENA DE INFECTOLOGIA
LA Spanish
DT Article
DE SARS-CoV-2; CoVID-19; coronavirus disease; infectious disease
ID CORONAVIRUS; SARS
AB SARS-CoV-2 is the pathogen responsible for COVID-19, an infectious disease that can evolve from a mild viral illness to multiple organ failure and death. This disease is characterized by a high transmissibility rate, which has lead to its spread throughout the world. There are no clear prognostic markers to guide the severity of the condition; however, some clinical elements could be considered possible predictors of severity. Knowing its viral structure and pathogenesis has allowed to recognize specific molecular pathways candidates as therapeutic targets for various drugs, which are still under investigation and will set the guidelines for future protocols.
C1 [Abarca Rozas, Bastian] Univ San Sebastian, Fac Med, Santiago, Chile.
   [Vargas Urra, Jocelyn; Garcia Garzon, Javier] Univ Chile, Hosp Clin, Santiago, Chile.
RP Rozas, BA (corresponding author), Univ San Sebastian, Fac Med, Santiago, Chile.
EM fds.baar@gmail.com
OI Abarca Rozas, Bastian/0000-0002-7643-9496
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Aylward B., 2020, REPORT WHO CHINA JOI, P16
   Bao L., 2020, REINFECTION COULD NO
   Bunyavanich S, 2020, JAMA-J AM MED ASSOC, V323, P2427, DOI 10.1001/jama.2020.8707
   Cantuti-Castelvetri L, 2020, NEUROPILIN 1 FACILIT, DOI 10.1101/2020.06.07.137802v1
   Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chandrashekar A., 2020, SCIENCE, V4776, DOI [10.1126/science.abc4776, DOI 10.1126/SCIENCE.ABC4776.]
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Culp WC, 2020, A A PRACT, V14, DOI 10.1213/XAA.0000000000001218
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Casas CG, 2020, BRIT J DERMATOL, V183, P71, DOI 10.1111/bjd.19163
   Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jones VG, 2020, HOSP PEDIAT, P2020
   Kampf G., 2020, INFECT PREV PRACT, V2, DOI [10.1016/j.infpip.2020.100044, DOI 10.1016/J.INFPIP.2020.100044]
   Keyhan SO, 2020, MAX PLAST RECONSTR S, V42, DOI 10.1186/s40902-020-00254-7
   Kirkcaldy RD, 2020, JAMA-J AM MED ASSOC, V323, P2245, DOI 10.1001/jama.2020.7869
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Korber B, 2020, SPIKE MUTATION PIPEL, V2020, DOI 10.1101/2020.04.29.069054v2
   Lala A, 2020, PREVALENCE IMPACT MY
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   McGonagle D, 2020, LANCET RHEUMATOL, V2019, P1, DOI DOI 10.1016/S2665-9913(20)30121-1
   Mehta N, 2020, JAMA CARDIOL
   Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730
   Qifang B, 2020, EPIDEMIOLOGY TRANSMI, P1, DOI [10.1101/2020.03.03.20028423v3, DOI 10.1101/2020.03.03.20028423V3]
   Qiu H, 2019, LANCET INFECT DIS, V2020, P1
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Sethuraman N, 2020, JAMA
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Spinato G., 2020, JAMA
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Wilson NM, 2020, ANAESTHESIA, V75, P1086, DOI 10.1111/anae.15093
   Wu P, 2020, JAMA OPHTHALMOL, V138, P575, DOI 10.1001/jamaophthalmol.2020.1291
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Xia W, 2020, PEDIATR PULM, V55, P1169, DOI 10.1002/ppul.24718
   Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071
   Xing CY, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02876-9
   Xing YY, 2020, EUROSURVEILLANCE, V25, P12, DOI 10.2807/1560-7917.ES.2020.25.10.2000191
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou L, 2020, NEW ENGL J MED, V382, P12
   Zubair AS, 2020, JAMA NEUROL, V77, P1018, DOI 10.1001/jamaneurol.2020.2065
NR 57
TC 0
Z9 0
U1 2
U2 2
PU SOC CHILENA INFECTOLOGIA
PI PROVIDENCIA
PA BERNARDA MORIN 488, 2 PISO, PROVIDENCIA, SANTIAGO 00000, CHILE
SN 0716-1018
EI 0717-6341
J9 REV CHIL INFECTOL
JI Rev. Chil. Infectol.
PD JUN
PY 2020
VL 37
IS 3
BP 265
EP 275
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA MZ1ZI
UT WOS:000558919900011
PM 32853319
OA Bronze, Other Gold
DA 2021-01-01
ER

PT J
AU Barbu, MG
   Thompson, DC
   Popescu, MN
   Beiu, C
   Mihai, MM
   Enachescu, CI
AF Barbu, Madalina-Gabriela
   Thompson, Dana-Claudia
   Popescu, Marius Nicolae
   Beiu, Cristina
   Mihai, Mara-Madalina
   Enachescu, Catalin-Ionel
TI A ROMANIAN SURVEY ON THE IMPACT OF SARS-COV-2 PANDEMIC ON DYSTONIA
   PATIENTS
SO ROMANIAN JOURNAL OF LEGAL MEDICINE
LA English
DT Article
DE dystonia; botulinum toxin; BoNT; medical rehabilitation; SARS-CoV-2;
   COVID-19
ID CERVICAL DYSTONIA
AB Background. The SARS-CoV-2 pandemic largely restricted the access of chronic patients to basic healthcare. One of the categories heavily affected by the lockdown were patients with dystonia.
   Objective. To assess the impact of botulinum toxin (BoNT) injection therapy discontinuation on the physical status and quality of life (QoL) of patients suffering from dystonia.
   Methods. A questionnaire was applied between April 1st and April 15th, 2020 to a group of 50 dystonia patients that met the inclusion criteria for this study.
   Results. The majority of the respondents (92%) indicated that their greatest issue during SARS-CoV-2 lockdown was the lack of access to regular BoNT injections. Over 50% of respondents stated that they experienced atypical physical pain, followed by the inability to perform usual activities, with further impact on the QoL. Alteration of the physical status due to the inability to follow an in-clinic rehabilitation program was also reported by up to 25% of patients. In 10% of patients, dystonia became more severe, and led to further afflictions, with a great impact on their QoL. Younger dystonia participants registered lower QoL scores than older participants. Furthermore, isolation and income reduction were found to cause a moderate impact on QoL in most patients and may be associated with mild to moderate forms of depression.
   Conclusion. The healthcare field must work to ensure that all these patients have access to their regular treatment plan in a safe environment. Meanwhile, recommendations should be made for these individuals to follow an adequate physical therapy program at home.
C1 [Barbu, Madalina-Gabriela; Thompson, Dana-Claudia; Popescu, Marius Nicolae; Beiu, Cristina; Mihai, Mara-Madalina; Enachescu, Catalin-Ionel] Elias Univ, Emergency Hosp, Bucharest, Romania.
   [Barbu, Madalina-Gabriela; Thompson, Dana-Claudia] Alessandrescu Rusescu Natl Inst Mother & Child Hl, Fetal Med Excellence Res Ctr, Bucharest, Romania.
   [Popescu, Marius Nicolae; Beiu, Cristina; Mihai, Mara-Madalina; Enachescu, Catalin-Ionel] Carol Davila Univ Med & Pharm, 37 Dionisie Lupu St,Dist 2, Bucharest 020021, Romania.
RP Popescu, MN (corresponding author), Carol Davila Univ Med & Pharm, 37 Dionisie Lupu St,Dist 2, Bucharest 020021, Romania.
EM popescunm@gmail.com
RI Thompson, Dana/AAK-9276-2020; Barbu, Madalina-Gabriela/AAX-3352-2020;
   Mihai, Mara/AAZ-1168-2020
OI Barbu, Madalina-Gabriela/0000-0002-3469-2020; 
CR AE Castagna Anna, 2020, MANAGING DYSTONIA BO
   Albanese A, 2013, MOVEMENT DISORD, V28, P863, DOI 10.1002/mds.25475
   Chan C., 2019, MANAGING DYSTONIA EX
   Defazio Giovanni, 2013, Tremor Other Hyperkinet Mov (N Y), V3, DOI 10.7916/D80C4TGJ
   Eggink H, 2019, PARKINSONISM RELAT D, V58, P50, DOI 10.1016/j.parkreldis.2018.08.008
   Hu W, 2019, PARKINSONISM RELAT D, V63, P195, DOI 10.1016/j.parkreldis.2019.02.035
   Mittal SO, 2019, EXPERT OPIN ORPHAN D, V7, P199, DOI 10.1080/21678707.2019.1613978
   Popescu MN, 2019, REV CHIM-BUCHAREST, V70, P3490
   Popescu MN, 2018, PALESTRICA 3 MILLENN, V19, P86
   Relja M, 2020, NEUROLOGY, V94
   Queiroz MAR, 2012, FUNCT NEUROL, V27, P187
   Soland VL, 1996, J NEUROL NEUROSUR PS, V60, P204, DOI 10.1136/jnnp.60.2.204
   Truong D, 2010, PARKINSONISM RELAT D, V16, P316, DOI 10.1016/j.parkreldis.2010.03.002
   WHO, 2019, COR DIS COVID 19 OUT
   Worldometers, 2020, COR WORLDW GRAPH 202
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ROMANIAN LEGAL MED SOC
PI BUCHAREST
PA SOS VITAN-BIRZESTI 9, BUCHAREST, 75669, ROMANIA
SN 1221-8618
J9 ROM J LEG MED
JI Rom. J. Leg. Med.
PD JUN
PY 2020
VL 28
IS 2
BP 208
EP 211
DI 10.4323/rjlm.2020.208
PG 4
WC Medicine, Legal
SC Legal Medicine
GA MX6BR
UT WOS:000557806700017
DA 2021-01-01
ER

PT J
AU Wagener, FADTG
   Pickkers, P
   Peterson, SJ
   Immenschuh, S
   Abraham, NG
AF Wagener, Frank A. D. T. G.
   Pickkers, Peter
   Peterson, Stephen J.
   Immenschuh, Stephan
   Abraham, Nader G.
TI Targeting the Heme-Heme Oxygenase System to Prevent Severe Complications
   Following COVID-19 Infections
SO ANTIOXIDANTS
LA English
DT Article
DE heme; heme oxygenase; SARS-CoV-2; inflammation; COVID-19
ID CARBON-MONOXIDE; ENDOTHELIAL-CELLS; DISEASE-ACTIVITY; PROTECTIVE ROLE;
   HEMOGLOBIN; EXPRESSION; ALVEOLAR; PATHOGENESIS; ADHESION; PROTEIN
AB SARS-CoV-2 is causing a pandemic resulting in high morbidity and mortality. COVID-19 patients suffering from acute respiratory distress syndrome (ARDS) are often critically ill and show lung injury and hemolysis. Heme is a prosthetic moiety crucial for the function of a wide variety of heme-proteins, including hemoglobin and cytochromes. However, injury-derived free heme promotes adhesion molecule expression, leukocyte recruitment, vascular permeabilization, platelet activation, complement activation, thrombosis, and fibrosis. Heme can be degraded by the anti-inflammatory enzyme heme oxygenase (HO) generating biliverdin/bilirubin, iron/ferritin, and carbon monoxide. We therefore postulate that free heme contributes to many of the inflammatory phenomena witnessed in critically ill COVID-19 patients, whilst induction of HO-1 or harnessing heme may provide protection. HO-activity not only degrades injurious heme, but its effector molecules possess also potent salutary anti-oxidative and anti-inflammatory properties. Until a vaccine against SARS-CoV-2 becomes available, we need to explore novel strategies to attenuate the pro-inflammatory, pro-thrombotic, and pro-fibrotic consequences of SARS-CoV-2 leading to morbidity and mortality. The heme-HO system represents an interesting target for novel "proof of concept" studies in the context of COVID-19.
C1 [Wagener, Frank A. D. T. G.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Dent Orthodont & Craniofacial Biol, Philips van Leydenlaan 25, NL-6525 EX Nijmegen, Netherlands.
   [Pickkers, Peter] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Intens Care Med, NL-6500 HB Nijmegen, Netherlands.
   [Peterson, Stephen J.] Weill Cornell Med, Dept Med, New York, NY 10065 USA.
   [Immenschuh, Stephan] Hannover Med Sch, Inst Transfus Med, D-30625 Hannover, Germany.
   [Abraham, Nader G.] New York Med Coll, Dept Med, Valhalla, NY 10595 USA.
   [Abraham, Nader G.] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.
RP Wagener, FADTG (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Dent Orthodont & Craniofacial Biol, Philips van Leydenlaan 25, NL-6525 EX Nijmegen, Netherlands.
EM frank.wagener@radboudumc.nl; peter.pickkers@radboudumc.nl;
   stp9039@nyp.org; Immenschuh.Stephan@mh-hannover.de;
   NADER_ABRAHAM@NYMC.EDU
RI Wagener, Frank/O-6225-2014; Pickkers, Peter/H-8080-2014
OI Wagener, Frank/0000-0003-4837-1559; Pickkers, Peter/0000-0002-1104-4303
FU Osteology Foundation [19-054]
FX FW is supported by a grant from the Osteology Foundation 19-054.
CR Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104
   Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Aggarwal S., 2020, PHYSIOLOGY, DOI [10.1101/2020.01.22.909879, DOI 10.1101/2020.01.22.909879]
   Aggarwal S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120694
   Aggarwal S, 2016, ANTIOXID REDOX SIGN, V24, P99, DOI 10.1089/ars.2015.6347
   Albini A, 2020, INTERN EMERG MED, V15, P759, DOI 10.1007/s11739-020-02364-6
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Balla J, 2003, NEPHROL DIAL TRANSPL, V18, P8, DOI 10.1093/ndt/gfg1034
   BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285
   Bastarache JA, 2012, THORAX, V67, P1032, DOI 10.1136/thoraxjnl-2012-201781
   Belcher JD, 2014, BLOOD, V123, P377, DOI 10.1182/blood-2013-04-495887
   Benhamou D, 2020, ANAESTH CRIT CARE PA, V39, P351, DOI 10.1016/j.accpm.2020.05.003
   Bloomer SA, 2009, J GERONTOL A-BIOL, V64, P419, DOI 10.1093/gerona/gln056
   Bourne Joshua H, 2020, Haematologica, DOI 10.3324/haematol.2020.246488
   BUNN HF, 1968, J BIOL CHEM, V243, P465
   Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419
   Casey K, 2020, AM J EMERG MED, V38, DOI 10.1016/j.ajem.2020.04.011
   Chan KH, 2020, AM J EMERG MED, V38, DOI 10.1016/j.ajem.2020.05.015
   de Lusignan S, 2020, LANCET INFECT DIS, V20, P1034, DOI 10.1016/S1473-3099(20)30371-6
   Deem S, 2004, FREE RADICAL BIO MED, V36, P698, DOI 10.1016/j.freeradbiomed.2003.11.025
   Dekker D, 2018, BRIT J CLIN PHARMACO, V84, P268, DOI 10.1111/bcp.13458
   Dekker D, 2011, ARTERIOSCL THROM VAS, V31, P458, DOI 10.1161/ATVBAHA.110.211789
   Deng X, 2019, TOHOKU J EXP MED, V247, P215, DOI 10.1620/tjem.247.215
   Dorresteijn MJ, 2015, FREE RADICAL BIO MED, V78, P224, DOI 10.1016/j.freeradbiomed.2014.10.579
   Drummond GS, 2019, ARCH BIOCHEM BIOPHYS, V673, DOI 10.1016/j.abb.2019.108073
   Dutra FF, 2014, P NATL ACAD SCI USA, V111, pE4110, DOI 10.1073/pnas.1405023111
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Erdei J, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4310816
   Espinoza JA, 2017, AM J PATHOL, V187, P487, DOI 10.1016/j.ajpath.2016.11.011
   Exner M, 2004, FREE RADICAL BIO MED, V37, P1097, DOI 10.1016/j.freeradbiomed.2004.07.008
   Fagone P, 2012, CLIN EXP IMMUNOL, V167, P179, DOI 10.1111/j.1365-2249.2011.04491.x
   Fagone P, 2013, J NEUROIMMUNOL, V261, P82, DOI 10.1016/j.jneuroim.2013.04.013
   Farsalinos K, 2020, INTERN EMERG MED, V15, P845, DOI 10.1007/s11739-020-02355-7
   Ferreira A, 2008, J MOL MED, V86, P1097, DOI 10.1007/s00109-008-0368-5
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Frimat M, 2019, TOXINS, V11, DOI 10.3390/toxins11110660
   Gaggar A, 2016, AM J PHYSIOL-LUNG C, V311, pL714, DOI 10.1152/ajplung.00312.2016
   Gargaglioni LH, 2020, J APPL PHYSIOL, V128, P1533, DOI 10.1152/japplphysiol.00335.2020
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3
   Gold R, 2020, THER ADV NEUROL DISO, V13, DOI 10.1177/1756286420915005
   Goldenstein H, 2012, PHARMACOL RES, V66, P1, DOI 10.1016/j.phrs.2012.02.011
   Gozzelino R, 2011, ADV EXP MED BIOL, V691, P211, DOI 10.1007/978-1-4419-6612-4_22
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gutierrez-Grobe Y, 2011, ANN HEPATOL, V10, P105
   Higdon AN, 2012, AM J PHYSIOL-HEART C, V302, pH1394, DOI 10.1152/ajpheart.00584.2011
   Immenschuh S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00146
   Ito Y, 2009, BIOGERONTOLOGY, V10, P173, DOI 10.1007/s10522-008-9164-4
   Janz DR, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0086-3
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kah J, 2017, LIVER INT, V37, P1128, DOI 10.1111/liv.13347
   Kartikasari AER, 2009, J CELL MOL MED, V13, P3091, DOI 10.1111/j.1582-4934.2008.00494.x
   Korakas E, 2020, AM J PHYSIOL-ENDOC M, V319, pE105, DOI 10.1152/ajpendo.00198.2020
   Korenblat KM, 2005, CLIN GASTROENTEROL H, V3, P303, DOI 10.1016/S1542-3565(05)00083-2
   Krishnamoorthy S, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96409
   Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118
   Leismann D.E., 2020, INTENS CARE MED, V28, P1
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Li QW, 2014, CELL BIOCHEM BIOPHYS, V69, P495, DOI 10.1007/s12013-014-9823-9
   Loh D., COVID 19 ARDS CELL F
   Lundvig DMS, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00081
   Ma ZQ, 2017, J GEN VIROL, V98, P2982, DOI 10.1099/jgv.0.000955
   Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002
   Meegan JE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228727
   Mendonca R, 2016, INFLAMM RES, V65, P665, DOI 10.1007/s00011-016-0955-9
   Merle NS, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96910
   Miyara M, 2020, QEIOS, DOI [10.32388/WPP19W.3., DOI 10.32388/WPP19W.3, 10.32388/WPP19W.3]
   MULLEREBERHARD U, 1970, NEW ENGL J MED, V283, P1090, DOI 10.1056/NEJM197011122832007
   Nader E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00454
   NATH KA, 1995, KIDNEY INT, V47, P592, DOI 10.1038/ki.1995.75
   Nath KA, 2020, AM J PHYSIOL-HEART C, V318, pH671, DOI 10.1152/ajpheart.00280.2019
   NEELY SM, 1984, AM J PATHOL, V115, P390
   Nikolic I, 2014, DIABETOLOGIA, V57, P980, DOI 10.1007/s00125-014-3170-7
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Presser L., MED WORKER DESCRIBES
   Quaye IK, 2008, T ROY SOC TROP MED H, V102, P735, DOI 10.1016/j.trstmh.2008.04.010
   Rafikova O, 2018, AM J RESP CELL MOL, V59, P334, DOI 10.1165/rcmb.2017-0308OC
   Raval CM, 2010, CURR DRUG TARGETS, V11, P1532
   Rentsch Christopher T, 2020, medRxiv, DOI 10.1101/2020.04.09.20059964
   Ryter SW, 2018, AM J PHYSIOL-CELL PH, V314, pC211, DOI 10.1152/ajpcell.00022.2017
   Sabaawy HE, 2001, HYPERTENSION, V38, P210, DOI 10.1161/01.HYP.38.2.210
   SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354
   Santangelo R, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00036
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shaver CM, 2016, AM J PHYSIOL-LUNG C, V310, pL532, DOI 10.1152/ajplung.00155.2015
   Slebos DJ, 2004, EUR RESPIR J, V23, P652, DOI 10.1183/09031936.04.00127904
   Soares MP, 2016, CURR OPIN IMMUNOL, V38, P94, DOI 10.1016/j.coi.2015.11.006
   Soares MP, 2001, IMMUNOL REV, V184, P275, DOI 10.1034/j.1600-065x.2001.1840124.x
   Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063
   Suliman HB, 2002, FREE RADICAL BIO MED, V32, P246, DOI 10.1016/S0891-5849(01)00797-3
   Tindle HA, 2020, NICOTINE TOB RES, V22, P1669, DOI 10.1093/ntr/ntaa077
   Toth B, 2003, ARCH SURG-CHICAGO, V138, P1375, DOI 10.1001/archsurg.138.12.1375
   Tseng CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep32176
   Vallelian F, 2010, BLOOD, V116, P5347, DOI 10.1182/blood-2010-04-277319
   van Bon L, 2016, RHEUMATOLOGY, V55, P2066, DOI 10.1093/rheumatology/kew251
   van Loon RLE, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00071
   Vijayan V, 2018, BIOCHEM PHARMACOL, V153, P159, DOI 10.1016/j.bcp.2018.02.010
   Vitek L, 2020, MED RES REV, V40, P1335, DOI 10.1002/med.21660
   Wagener FADTG, 1999, J PHARMACOL EXP THER, V291, P416
   Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456
   Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5
   Wagener FADTG, 2003, BLOOD, V102, P521, DOI 10.1182/blood-2002-07-2248
   Wagener FADTG, 2001, TRENDS PHARMACOL SCI, V22, P52, DOI 10.1016/S0165-6147(00)01609-6
   Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802
   Wagener FADTG, 2008, ARTHRITIS RHEUM, V58, P3388, DOI 10.1002/art.23970
   Wagener FADTG, 2013, CURR PHARM DESIGN, V19, P2698
   Wagener FADTG, 2010, CURR DRUG TARGETS, V11, P1571
   Wegiel B, 2015, FREE RADICAL BIO MED, V89, P651, DOI 10.1016/j.freeradbiomed.2015.08.020
   Weir LR, 2005, MUTAT RES-FUND MOL M, V574, P67, DOI 10.1016/j.mrfmmm.2005.01.023
   Xiao L, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050491
   Zhang AK, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00412
   Zhu JY, 2020, FAM MED COMMUNITY HE, V8, DOI 10.1136/fmch-2020-000406
NR 112
TC 4
Z9 4
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD JUN
PY 2020
VL 9
IS 6
AR 540
DI 10.3390/antiox9060540
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA MS9PS
UT WOS:000554604400001
PM 32575554
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bosch-Barrera, J
   Martin-Castillo, B
   Buxo, M
   Brunet, J
   Encinar, JA
   Menendez, JA
AF Bosch-Barrera, Joaquim
   Martin-Castillo, Begona
   Buxo, Maria
   Brunet, Joan
   Encinar, Jose Antonio
   Menendez, Javier A.
TI Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and
   Virus Replication Machinery for Clinical Management of COVID-19 Patients
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE coronavirus; stat3; cytokine storm; IL-6; JAK; remdesivir; senescence
ID RESPIRATORY SYNDROME CORONAVIRUS; CHRONIC HEPATITIS-C; MILK THISTLE;
   SARS-COV; KAPPA-B; INTRAVENOUS SILIBININ; SIGNAL TRANSDUCERS; KINASE
   INHIBITORS; IMMUNE-RESPONSES; RESCUE TREATMENT
AB COVID-19, the illness caused by infection with the novel coronavirus SARS-CoV-2, is a rapidly spreading global pandemic in urgent need of effective treatments. Here we present a comprehensive examination of the host- and virus-targeted functions of the flavonolignan silibinin, a potential drug candidate against COVID-19/SARS-CoV-2. As a direct inhibitor of STAT3-a master checkpoint regulator of inflammatory cytokine signaling and immune response-silibinin might be expected to phenotypically integrate the mechanisms of action of IL-6-targeted monoclonal antibodies and pan-JAK1/2 inhibitors to limit the cytokine storm and T-cell lymphopenia in the clinical setting of severe COVID-19. As a computationally predicted, remdesivir-like inhibitor of RNA-dependent RNA polymerase (RdRp)-the central component of the replication/transcription machinery of SARS-CoV-2-silibinin is expected to reduce viral load and impede delayed interferon responses. The dual ability of silibinin to target both the host cytokine storm and the virus replication machinery provides a strong rationale for the clinical testing of silibinin against the COVID-19 global public health emergency. A randomized, open-label, phase II multicentric clinical trial (SIL-COVID19) will evaluate the therapeutic efficacy of silibinin in the prevention of acute respiratory distress syndrome in moderate-to-severe COVID-19-positive onco-hematological patients at the Catalan Institute of Oncology in Catalonia, Spain.
C1 [Bosch-Barrera, Joaquim; Brunet, Joan] Dr Josep Trueta Hosp Girona, Catalan Inst Oncol ICO, Med Oncol, Girona 17007, Spain.
   [Bosch-Barrera, Joaquim] Univ Girona, Med Sch, Dept Med Sci, Girona 17003, Spain.
   [Martin-Castillo, Begona] Catalan Inst Oncol, Unit Clin Res, Girona 17007, Spain.
   [Buxo, Maria; Menendez, Javier A.] Girona Biomed Res Inst, Salt 17190, Girona, Spain.
   [Brunet, Joan] IDIBELL, Catalan Inst Oncol, Barcelona 08908, Spain.
   [Encinar, Jose Antonio] Miguel Hernandez Univ UMH, Inst Res Dev & Innovat Biotechnol Elche IDiBE, Elche 03202, Spain.
   [Encinar, Jose Antonio] Miguel Hernandez Univ UMH, Mol & Cell Biol Inst IBMC, Elche 03202, Spain.
   [Menendez, Javier A.] Catalan Inst Oncol, Program Canc Therapeut Resistance ProCURE, Metab & Canc Grp, Girona 17007, Spain.
RP Bosch-Barrera, J (corresponding author), Dr Josep Trueta Hosp Girona, Catalan Inst Oncol ICO, Med Oncol, Girona 17007, Spain.; Bosch-Barrera, J (corresponding author), Univ Girona, Med Sch, Dept Med Sci, Girona 17003, Spain.; Menendez, JA (corresponding author), Girona Biomed Res Inst, Salt 17190, Girona, Spain.; Encinar, JA (corresponding author), Miguel Hernandez Univ UMH, Inst Res Dev & Innovat Biotechnol Elche IDiBE, Elche 03202, Spain.; Encinar, JA (corresponding author), Miguel Hernandez Univ UMH, Mol & Cell Biol Inst IBMC, Elche 03202, Spain.; Menendez, JA (corresponding author), Catalan Inst Oncol, Program Canc Therapeut Resistance ProCURE, Metab & Canc Grp, Girona 17007, Spain.
EM jbosch@iconcologia.net; bmartin@iconcologia.net; mbuxo@idibgi.org;
   jbrunet@iconcologia.net; jant.encinar@umh.es; jmenendez@idibgi.org
RI MENENDEZ, JAVIER A/C-6148-2016; Encinar, Jose Antonio/AAE-9141-2020;
   Brunet, Joan/C-5292-2018
OI MENENDEZ, JAVIER A/0000-0001-8733-4561; Encinar, Jose
   Antonio/0000-0002-7219-3863; Buxo, Maria/0000-0001-7165-7737; Bosch
   Barrera, Joaquim/0000-0002-0893-7821; Brunet, Joan/0000-0003-1945-3512
FU Spanish Ministry of Science and InnovationSpanish Government
   [SAF2016-80639-P]; Fundacio Oncolliga Girona (Lliga catalana d'ajuda al
   malalt de cancer, Girona); Spanish Ministry of Economy and
   Competitiveness (MINECO) [RTI2018-096724-B-C21]; Generalitat
   ValencianaGeneralitat Valenciana [PROMETEO/2016/006]; La Marato de TV3
   foundation [201906]; Health Research and Innovation Strategic Plan
   [SLT006/17/114]
FX Work in the Menendez laboratory is supported by the Spanish Ministry of
   Science and Innovation (Grant SAF2016-80639-P, Plan Nacional de I+D+I,
   founded by the European Regional Development Fund, Spain) and by an
   unrestricted research grant from the Fundacio Oncolliga Girona (Lliga
   catalana d'ajuda al malalt de cancer, Girona). The Spanish Ministry of
   Economy and Competitiveness (MINECO, RTI2018-096724-B-C21) and the
   Generalitat Valenciana (PROMETEO/2016/006) supports work in the Encinar
   laboratory. Joaquim Bosch-Barrera is the recipient of Research Grants
   from La Marato de TV3 foundation (201906) and the Health Research and
   Innovation Strategic Plan (SLT006/17/114; PERIS 2016-2020; Pla strategic
   de recerca i innovacio en salut; Departament de Salut, Generalitat de
   Catalunya).
CR Abenavoli L, 2018, PHYTOTHER RES, V32, P2202, DOI 10.1002/ptr.6171
   Adnot S, 2019, AM J RESP CELL MOL, V61, P5, DOI 10.1165/rcmb.2019-0013ED
   Agarwal C, 2007, CARCINOGENESIS, V28, P1463, DOI 10.1093/carcin/bgm042
   Ahn DG, 2012, ARCH VIROL, V157, P2095, DOI 10.1007/s00705-012-1404-x
   Baas T, 2008, J VIROL, V82, P9465, DOI 10.1128/JVI.00489-08
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bechman K, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104392
   Belli V, 2017, ONCOTARGET, V8, P68305, DOI 10.18632/oncotarget.20054
   Biermer M, 2012, J VIRAL HEPATITIS, V19, P547, DOI 10.1111/j.1365-2893.2011.01572.x
   Bijak M, 2017, MOLECULES, V22, DOI 10.3390/molecules22111942
   Blaising J, 2013, CELL MICROBIOL, V15, P1866, DOI 10.1111/cmi.12155
   Bosch-Barrera J, 2017, CANCER TREAT REV, V58, P61, DOI 10.1016/j.ctrv.2017.06.003
   Bosch-Barrera J, 2016, ONCOTARGET, V7, P32006, DOI 10.18632/oncotarget.7900
   Bosch-Barrera J, 2015, CANCER TREAT REV, V41, P540, DOI 10.1016/j.ctrv.2015.04.008
   Braun DL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133028
   Carnesecchi S, 2014, INT J CLIN EXP PATHO, V7, P537
   Ceribelli A, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102442
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chang JH, 2013, ANTIVIR RES, V99, P251, DOI 10.1016/j.antiviral.2013.06.011
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Choy EHS, 2019, CLIN EXP RHEUMATOL, V37, P694
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   Cufi S, 2013, FOOD CHEM TOXICOL, V60, P360, DOI 10.1016/j.fct.2013.07.063
   Cuyas E, 2016, CELL CYCLE, V15, P3413, DOI 10.1080/15384101.2016.1245249
   Favalli EG, 2020, LANCET INFECT DIS, V20, P1012, DOI 10.1016/S1473-3099(20)30262-0
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Ferenci P, 2008, GASTROENTEROLOGY, V135, P1561, DOI 10.1053/j.gastro.2008.07.072
   Fleming SB, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030023
   Gadina M, 2019, RHEUMATOLOGY, V58, P4, DOI 10.1093/rheumatology/key432
   Gao HW, 2007, EXPERT OPIN THER TAR, V11, P869, DOI 10.1517/14728222.11.7.869
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Gazak R, 2007, CURR MED CHEM, V14, P315, DOI 10.2174/092986707779941159
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hackett ES, 2013, J VET INTERN MED, V27, P10, DOI 10.1111/jvim.12002
   Hickson LJ, 2019, EBIOMEDICINE, V47, P446, DOI 10.1016/j.ebiom.2019.08.069
   Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Honda S, 2020, EXPERT OPIN DRUG SAF, V19, P545, DOI 10.1080/14740338.2020.1743263
   Inoue Y, 2007, J VIROL, V81, P8722, DOI 10.1128/JVI.00253-07
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jin HY, 2018, AM J PHYSIOL-LUNG C, V314, pL882, DOI 10.1152/ajplung.00418.2017
   Ju J., 2020, BIORXIV, DOI [10.1101/2020.01.30.927574, DOI 10.1101/2020.01.30.927574, 10.1101/2020.01.30.927574.]
   Jung SH, 2008, STAT MED, V27, P568, DOI 10.1002/sim.2961
   Kim NC, 2003, ORG BIOMOL CHEM, V1, P1684, DOI 10.1039/b300099k
   Kindler E, 2016, CELL HOST MICROBE, V19, P139, DOI 10.1016/j.chom.2016.01.012
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Knapstein Johanna, 2014, J Med Case Rep, V8, P257, DOI 10.1186/1752-1947-8-257
   Kojima Hirotada, 2013, JAKSTAT, V2, pe25763, DOI 10.4161/jkst.25763
   Kojima H, 2012, CELL CYCLE, V11, P730, DOI 10.4161/cc.11.4.19172
   Kuchipudi SV, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/272359
   Kwok HH, 2016, SCI REP-UK, V6, DOI 10.1038/srep18941
   Li Q, 2016, MOL MED REP, V14, P343, DOI 10.3892/mmr.2016.5222
   Li SW, 2016, SCI REP-UK, V6, DOI 10.1038/srep25754
   Liang YF, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658-018-0117-x
   Liao M., 2020, LANDSCAPE LUNG BRONC, P23, DOI [10.1101/2020.02.23.20026690, DOI 10.1101/2020.02.23.20026690]
   Liu CH, 2019, MOLECULES, V24, DOI 10.3390/molecules24081552
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Malaguarnera M, 2015, AM J TRANSL RES, V7, P2510
   Malavolta M, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/4159013
   McDonald SM, 2013, WIRES RNA, V4, P351, DOI 10.1002/wrna.1164
   Michot J.M., 2020, ANN ONCOL, V7534, P36387
   Mizushina Y, 2015, J BIOL CHEM, V290, P5065, DOI 10.1074/jbc.M114.603217
   Molto J, 2012, ANTIMICROB AGENTS CH, V56, P2837, DOI 10.1128/AAC.00025-12
   Parikh P, 2019, AM J PHYSIOL-LUNG C, V316, pL826, DOI 10.1152/ajplung.00424.2018
   Payer BA, 2010, J CLIN VIROL, V49, P131, DOI 10.1016/j.jcv.2010.07.006
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Perez-Sanchez A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071606
   Praveen D, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105967
   Priego N, 2018, NAT MED, V24, P1024, DOI 10.1038/s41591-018-0044-4
   Rendina M, 2014, TRANSPL INT, V27, P696, DOI 10.1111/tri.12324
   Rho JK, 2010, MOL CANCER THER, V9, P3233, DOI 10.1158/1535-7163.MCT-10-0625
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Richardson PJ, 2020, LANCET INFECT DIS, V20, P1013, DOI 10.1016/S1473-3099(20)30270-X
   Rutter K, 2011, ANTIVIR THER, V16, P1327, DOI 10.3851/IMP1942
   Sargiacomo C, 2020, AGING-US, V12, P6511, DOI 10.18632/aging.103001
   Segler MHS, 2018, NATURE, V555, P604, DOI 10.1038/nature25978
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shi ZZ, 2019, LIFE SCI, V217, P70, DOI 10.1016/j.lfs.2018.11.037
   Singh RR, 2009, CLIN CANCER RES, V15, P613, DOI 10.1158/1078-0432.CCR-08-1846
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Somerville VS, 2016, ADV NUTR, V7, P488, DOI 10.3945/an.115.010538
   Son Y, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0055-6
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Suarez AAR, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006839
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Tian L, 2017, MICROB PATHOGENESIS, V108, P104, DOI 10.1016/j.micpath.2017.05.011
   Totura AL, 2019, EXPERT OPIN DRUG DIS, V14, P397, DOI 10.1080/17460441.2019.1581171
   Tsai MH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01448
   Tyagi A, 2012, MOL CARCINOGEN, V51, P832, DOI 10.1002/mc.20851
   Tyagi A, 2009, CANCER PREV RES, V2, P74, DOI 10.1158/1940-6207.CAPR-08-0095
   Verdura S, 2020, AGING-US, V12, P8, DOI 10.18632/aging.102646
   Verdura S, 2018, FOOD CHEM TOXICOL, V116, P161, DOI 10.1016/j.fct.2018.04.028
   Wang ZN, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00059
   Waters DW, 2019, AM J RESP CELL MOL, V61, P61, DOI 10.1165/rcmb.2018-0328OC
   World Health Organization, COR DIS COVID 19 OUT
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zhang B, 2017, INT J MOL MED, V39, P1111, DOI 10.3892/ijmm.2017.2935
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang D., 2020, COVID 19 INFECT INDU, DOI [10.1101/2020.03.24, DOI 10.1101/2020.03.24.20042655, 10.1101/2020.03.24.20042655]
   Zhang JF, 2019, THER ADV RESPIR DIS, V13, DOI 10.1177/1753466619879840
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao JP, 2016, AM J PHYSIOL-LUNG C, V311, pL868, DOI 10.1152/ajplung.00281.2016
   Zhao XS, 2015, ANTIMICROB AGENTS CH, V59, P206, DOI 10.1128/AAC.03999-14
   Zhavoronkov A, 2020, AGING-US, V12, P6492, DOI 10.18632/aging.102988
   Zheng RJ, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1562010
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 118
TC 2
Z9 2
U1 4
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2020
VL 9
IS 6
AR 1770
DI 10.3390/jcm9061770
PG 22
WC Medicine, General & Internal
SC General & Internal Medicine
GA MS9FE
UT WOS:000554576900001
PM 32517353
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lim, JH
   Park, SH
   Jeon, Y
   Cho, JH
   Jung, HY
   Choi, JY
   Kim, CD
   Lee, YH
   Seo, H
   Lee, JH
   Kwon, KT
   Kim, SW
   Chang, HH
   Kim, YL
AF Lim, Jeong-Hoon
   Park, Sun-Hee
   Jeon, Yena
   Cho, Jang-Hee
   Jung, Hee-Yeon
   Choi, Ji-Young
   Kim, Chan-Duck
   Lee, Yong-Hoon
   Seo, Hyewon
   Lee, Jaehee
   Kwon, Ki Tae
   Kim, Shin-Woo
   Chang, Hyun-Ha
   Kim, Yong-Lim
TI Fatal Outcomes of COVID-19 in Patients with Severe Acute Kidney Injury
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE acute kidney injury; AKI severity; COVID-19; mortality; renal
   replacement therapy
ID SARS
AB The outcome of coronavirus disease 2019 (COVID-19) is associated with organ damage; however, the information about the relationship between acute kidney injury (AKI) and COVID-19 is still rare. We evaluated the clinical features and prognosis of COVID-19 patients with AKI according to the AKI severity. Medical data of hospitalized COVID-19 patients in two university-based hospitals during an outbreak in Daegu, South Korea, were retrospectively analyzed. AKI and its severity were defined according to the Acute Kidney Injury Network. Of the 164 hospitalized patients with COVID-19, 30 patients (18.3%) had AKI; 14, 4, and 12 patients had stage 1, 2, and 3, respectively. The median age was significantly higher in AKI patients than in non-AKI patients (75.5 vs. 67.0 years,p= 0.005). There were 17 deaths (56.7%) among AKI patients; 4 (28.6%), 1 (25.0%), and 12 (100.0%), respectively. In-hospital mortality was higher in AKI patients than in non-AKI patients (56.7% vs. 20.8%,p< 0.001). After adjusting for potential confounding factors, stage 3 AKI was associated with higher mortality than either non-AKI or stage 1 AKI (hazard ratio (HR) = 3.62 (95% confidence interval (CI) = 1.75-7.48),p= 0.001; HR = 15.65 (95% CI = 2.43-100.64),p= 0.004). Among the AKI patients, acute respiratory distress syndrome and low serum albumin on admission were considered independent risk factors for stage 3 AKI (bothp <0.05). Five patients with stage 3 AKI underwent dialysis and eventually died. In conclusion, COVID-19 patients with severe AKI had fatal outcomes.
C1 [Lim, Jeong-Hoon; Park, Sun-Hee; Cho, Jang-Hee; Jung, Hee-Yeon; Choi, Ji-Young; Kim, Chan-Duck; Kim, Yong-Lim] Kyungpook Natl Univ, Sch Med, Div Nephrol, Dept Internal Med, Daegu 41944, South Korea.
   [Jeon, Yena] Kyungpook Natl Univ, Dept Stat, Daegu 41566, South Korea.
   [Lee, Yong-Hoon; Seo, Hyewon; Lee, Jaehee] Kyungpook Natl Univ, Div Pulmonol & Crit Care Med, Dept Internal Med, Sch Med, Daegu 41566, South Korea.
   [Kwon, Ki Tae; Kim, Shin-Woo; Chang, Hyun-Ha] Kyungpook Natl Univ, Div Infect Dis, Dept Internal Med, Sch Med, Daegu 41944, South Korea.
RP Kim, YL (corresponding author), Kyungpook Natl Univ, Sch Med, Div Nephrol, Dept Internal Med, Daegu 41944, South Korea.; Chang, HH (corresponding author), Kyungpook Natl Univ, Div Infect Dis, Dept Internal Med, Sch Med, Daegu 41944, South Korea.
EM jh-lim@knu.ac.kr; sh-park@knu.ac.kr; yeahnah@naver.com;
   jh-cho@knu.ac.kr; hy-jung@knu.ac.kr; jyss1002@hanmail.net;
   drcdkim@knu.ac.kr; id0121@naver.com; dallyu17@hanmail.net;
   jaelee@knu.ac.kr; idktkwon@gmail.com; ksw2kms@knu.ac.kr;
   changhha@knu.ac.kr; ylkim@knu.ac.kr
RI Cho, Jang-hee/ABD-3534-2020; Lim, Jeong-Hoon/ABE-6003-2020
OI Cho, Jang-hee/0000-0002-7031-5214; Lim, Jeong-Hoon/0000-0001-5517-9886;
   Jung, Hee-Yeon/0000-0003-0232-7202
FU Daegu Medical Association COVID-19 scientific committee; Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea
   [HI15C0001]
FX We would like to thank all medical staff for their effort in COVID-19
   patient care. This study was supported by research grants from the Daegu
   Medical Association COVID-19 scientific committee and the Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic
   of Korea (grant number: HI15C0001).
CR Alkindi F., 2020, KIDNEY INT REP, V5, pS13, DOI [10.1016/j.ekir.2020.02.033, DOI 10.1016/J.EKIR.2020.02.033]
   [Anonymous], 2020, 51 WHO
   Bagshaw SM, 2007, CLIN J AM SOC NEPHRO, V2, P431, DOI 10.2215/CJN.03681106
   Bagshaw SM, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-123
   Basu RK, 2014, KIDNEY INT, V85, P659, DOI 10.1038/ki.2013.349
   Boldog P, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020571
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Farkash EA, 2020, J AM SOC NEPHROL, V31, P1683, DOI 10.1681/ASN.2020040432
   Finlay S, 2013, CLIN MED, V13, P233, DOI 10.7861/clinmedicine.13-3-233
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han SJ, 2019, KIDNEY RES CLIN PRAC, V38, P427, DOI 10.23876/j.krcp.19.062
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim SW, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e152
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Li Z, 2020, CAUTION KIDNEY DYSFU, DOI [10.1101/2020.02.08.20021212, DOI 10.1101/2020.02.08.20021212]
   Malhotra R, 2017, NEPHROL DIAL TRANSPL, V32, P814, DOI 10.1093/ndt/gfx026
   Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Peerapornratana S, 2019, KIDNEY INT, V96, P1083, DOI 10.1016/j.kint.2019.05.026
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Silver SA, 2018, J AM SOC NEPHROL, V29, P1001, DOI 10.1681/ASN.2017080882
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Wang HE, 2012, AM J NEPHROL, V35, P349, DOI 10.1159/000337487
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 34
TC 6
Z9 6
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2020
VL 9
IS 6
AR 1718
DI 10.3390/jcm9061718
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA MT1ED
UT WOS:000554710700001
PM 32503180
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Eleftheriou, P
   Amanatidou, D
   Petrou, A
   Geronikaki, A
AF Eleftheriou, Phaedra
   Amanatidou, Dionysia
   Petrou, Anthi
   Geronikaki, Athina
TI In Silico Evaluation of the Effectivity of Approved Protease Inhibitors
   against the Main Protease of the Novel SARS-CoV-2 Virus
SO MOLECULES
LA English
DT Article
DE coronavirus; SARS-CoV-2; protease inhibitors; HCV protease inhibitors;
   DPP-4 inhibitors; a-thrombin inhibitors; docking
ID SUBSTRATE-SPECIFICITY; DOCKING ANALYSIS; PHARMACOKINETICS; CORONAVIRUS;
   PREDICTION; PNEUMONIA; DISCOVERY; ENZYME; SAFETY; PTP1B
AB The coronavirus disease, COVID-19, caused by the novel coronavirus SARS-CoV-2, which first emerged in Wuhan, China and was made known to the World in December 2019 turned into a pandemic causing more than 126,124 deaths worldwide up to April 16th, 2020. It has 79.5% sequence identity with SARS-CoV-1 and the same strategy for host cell invasion through the ACE-2 surface protein. Since the development of novel drugs is a long-lasting process, researchers look for effective substances among drugs already approved or developed for other purposes. The 3D structure of the SARS-CoV-2 main protease was compared with the 3D structures of seven proteases, which are drug targets, and docking analysis to the SARS-CoV-2 protease structure of thirty four approved and on-trial protease inhibitors was performed. Increased 3D structural similarity between the SARS-CoV-2 main protease, the HCV protease and alpha-thrombin was found. According to docking analysis the most promising results were found for HCV protease, DPP-4, alpha-thrombin and coagulation Factor Xa known inhibitors, with several of them exhibiting estimated free binding energy lower than -8.00 kcal/mol and better prediction results than reference compounds. Since some of the compounds are well-tolerated drugs, the promising in silico results may warrant further evaluation for viral anticipation. DPP-4 inhibitors with anti-viral action may be more useful for infected patients with diabetes, while anti-coagulant treatment is proposed in severe SARS-CoV-2 induced pneumonia.
C1 [Eleftheriou, Phaedra; Amanatidou, Dionysia] Int Hellen Univ, Sch Hlth, Dept Biomed Sci, Thessaloniki 57400, Greece.
   [Petrou, Anthi; Geronikaki, Athina] Aristotle Univ Thessaloniki, Sch Pharm, Dept Pharmaceut Chem, Thessaloniki 54124, Greece.
RP Eleftheriou, P (corresponding author), Int Hellen Univ, Sch Hlth, Dept Biomed Sci, Thessaloniki 57400, Greece.; Geronikaki, A (corresponding author), Aristotle Univ Thessaloniki, Sch Pharm, Dept Pharmaceut Chem, Thessaloniki 54124, Greece.
EM elfther@ihu.gr; dionusiaam@gmail.com;
   anthi.petrou.thessalonikil@gmail.com; geronik@pharm.auth.gr
OI Petrou, Anthi/0000-0001-8587-2710; Geronikaki,
   Athina/0000-0001-9894-7777
CR Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], 2015, DPP 4 INH TYPN 2 DIA
   Bikadi Z, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-15
   Calligari P, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040445
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Di Nisio M, 2005, NEW ENGL J MED, V353, P1028, DOI 10.1056/NEJMra044440
   Drag M, 2010, NAT REV DRUG DISCOV, V9, P690, DOI 10.1038/nrd3053
   Eleftheriou P, 2015, SAR QSAR ENVIRON RES, V26, P557, DOI 10.1080/1062936X.2015.1074939
   Gallwitz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031756
   Ganou CA, 2018, SAR QSAR ENVIRON RES, V29, P133, DOI 10.1080/1062936X.2017.1414874
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Gu N, 2014, DRUG DES DEV THER, V8, P1709, DOI 10.2147/DDDT.S65678
   Gyebi GA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764868
   Hsu HJ, 2008, J BIOL CHEM, V283, P12343, DOI 10.1074/jbc.M708843200
   Huang FL, 2015, ANTIMICROB AGENTS CH, V59, P251, DOI 10.1128/AAC.03359-14
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi T, 2020, EUR REV MED PHARMACO, V24, P4529, DOI 10.26355/eurrev_202004_21036
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kumada H, 2014, HEPATOLOGY, V59, P2083, DOI 10.1002/hep.27113
   Lankas GR, 2005, DIABETES, V54, P2988, DOI 10.2337/diabetes.54.10.2988
   Lawitz E, 2013, ANTIVIR RES, V99, P214, DOI 10.1016/j.antiviral.2013.05.015
   Lechtenberg BC, 2012, BIOL CHEM, V393, P889, DOI 10.1515/hsz-2012-0178
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Madej T, 2014, NUCLEIC ACIDS RES, V42, pD297, DOI 10.1093/nar/gkt1208
   Masuyer G, 2012, SCI REP-UK, V2, DOI 10.1038/srep00717
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Nakagawa T, 2007, BIOL CHEM, V388, P237, DOI 10.1515/BC.2007.026
   Nguyen Douglas L, 2012, Clin Liver Dis (Hoboken), V1, P54
   Salvo F, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2231
   Shiryaev SA, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0035759, 10.1371/journal.pone.0040029]
   SOLIS FJ, 1981, MATH OPER RES, V6, P19, DOI 10.1287/moor.6.1.19
   The Use of Stems in the Selection of International Nonproprietary Names (INN), 2016, US STEMS SEL INT NON
   Tozser J, 2010, VIRUSES-BASEL, V2, P147, DOI 10.3390/v2010147
   Tsuji M, 2020, FEBS OPEN BIO, V10, P995, DOI 10.1002/2211-5463.12875
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 43
TC 9
Z9 9
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD JUN
PY 2020
VL 25
IS 11
AR 2529
DI 10.3390/molecules25112529
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA MR8RU
UT WOS:000553858800066
PM 32485894
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ngwa, W
   Kumar, R
   Thompson, D
   Lyerly, W
   Moore, R
   Reid, TE
   Lowe, H
   Toyang, N
AF Ngwa, Wilfred
   Kumar, Rajiv
   Thompson, Daryl
   Lyerly, William
   Moore, Roscoe
   Reid, Terry-Elinor
   Lowe, Henry
   Toyang, Ngeh
TI Potential of Flavonoid-Inspired Phytomedicines against COVID-19
SO MOLECULES
LA English
DT Article
DE flavonoids and their derivatives; phytomedicine; COVID-19; SARS-COV-2;
   smart nanoparticles
ID CORONAVIRUS; RESPONSES
AB Flavonoids are widely used as phytomedicines. Here, we report on flavonoid phytomedicines with potential for development into prophylactics or therapeutics against coronavirus disease 2019 (COVID-19). These flavonoid-based phytomedicines include: caflanone, Equivir, hesperetin, myricetin, and Linebacker. Our in silico studies show that these flavonoid-based molecules can bind with high affinity to the spike protein, helicase, and protease sites on the ACE2 receptor used by the severe acute respiratory syndrome coronavirus 2 to infect cells and cause COVID-19. Meanwhile, in vitro studies show potential of caflanone to inhibit virus entry factors including, ABL-2, cathepsin L, cytokines (IL-1 beta, IL-6, IL-8, Mip-1 alpha, TNF-alpha), and PI4Kiii beta as well as AXL-2, which facilitates mother-to-fetus transmission of coronavirus. The potential for the use of smart drug delivery technologies like nanoparticle drones loaded with these phytomedicines to overcome bioavailability limitations and improve therapeutic efficacy are discussed.
C1 [Ngwa, Wilfred] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Ngwa, Wilfred] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Kumar, Rajiv] Northeastern Univ, Boston, MA 02115 USA.
   [Kumar, Rajiv] Millipore Sigma, R&D Biomed Mat, Milwaukee, WI 53209 USA.
   [Thompson, Daryl; Lyerly, William; Moore, Roscoe] Global Res & Discovery Grp Sci, Winter Haven, FL 33884 USA.
   [Reid, Terry-Elinor] Concordia Univ Wisconsin, Sch Pharm, Mequon, WI 53097 USA.
   [Lowe, Henry; Toyang, Ngeh] Vilotos Pharmaceut Inc, Baltimore, MD 21202 USA.
   [Lowe, Henry; Toyang, Ngeh] Flavocure Biotech Inc, Baltimore, MD 21202 USA.
RP Ngwa, W (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA.; Ngwa, W (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.
EM wngwa@bwh.harvard.edu; rajivtondak@gmail.com; d.thompson@globalrdg.com;
   william.lyerly@gmail.com; rmoore@phrockwood.com;
   Terry-Elinor.Reid@cuw.edu; lowebiotech@gmail.com;
   ngeh.toyang@flavocure.com
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA239042] Funding Source: Medline
CR Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017
   Chan D.M., 2013, WHO TRADITIONAL MED
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Cui H.-T., 2020, MED RES, V16, P1708
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Guerrero L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049493
   Herter-Sprie GS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6870
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Kostarelos K, 2020, NAT NANOTECHNOL, V15, P343, DOI 10.1038/s41565-020-0687-4
   Kumar R, 2013, TRANSL CANCER RES, V2, P228, DOI 10.3978/j.issn.2218-676X.2013.07.02
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Ledford H, 2020, NATURE, V580, P311, DOI 10.1038/d41586-020-01056-7
   Li M., 2020, BIORXIV, V15
   Maxmen A, 2020, NATURE, V578, P347, DOI 10.1038/d41586-020-00444-3
   Mayr NA, 2014, INT J RADIAT ONCOL, V89, P481, DOI 10.1016/j.ijrobp.2013.12.052
   Minuesa G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10523-3
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   MOREAU M, 2019, FRONT ONCOL, V9, DOI DOI 10.3389/FONC.2019.00660
   Mueller R., NANOPARTICLE DRONES
   Ngwa W, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00208
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Springer TI, 2019, J BIOL CHEM, V294, P19012, DOI 10.1074/jbc.RA119.010278
   Thilakarathna SH, 2013, NUTRIENTS, V5, P3367, DOI 10.3390/nu5093367
   Tih F., WHO STUDY MADAGASCAR
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wholey WY, 2020, BIOCONJUGATE CHEM, V31, P685, DOI 10.1021/acs.bioconjchem.9b00825
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang N, 2012, J BIOL CHEM, V287, P8457, DOI 10.1074/jbc.M111.312561
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zakaryan H, 2017, ARCH VIROL, V162, P2539, DOI 10.1007/s00705-017-3417-y
   Zhang HB, 2019, P NATL ACAD SCI USA, V116, P7744, DOI 10.1073/pnas.1817251116
NR 33
TC 7
Z9 7
U1 5
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD JUN
PY 2020
VL 25
IS 11
AR 2707
DI 10.3390/molecules25112707
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA MR8RU
UT WOS:000553858800244
PM 32545268
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kim, SJ
   Nguyen, V
   Park, YH
   Park, BK
   Chung, HC
AF Kim, Sung-Jae
   Nguyen, Van-Giap
   Park, Yong-Ho
   Park, Bong-Kyun
   Chung, Hee-Chun
TI A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect
   Their Antigenicity and Immunogenicity?
SO VACCINES
LA English
DT Article
DE COVID-19; SARS-CoV-2; spike protein; antigenicity
ID CORONAVIRUS SPIKE PROTEIN; PREDICTION; EVOLUTION; ALGORITHM; SEQUENCE;
   FUSION
AB The S glycoprotein of coronaviruses is important for viral entry and pathogenesis with most variable sequences. Therefore, we analyzed the S gene sequences of SARS-CoV-2 to better understand the antigenicity and immunogenicity of this virus in this study. In phylogenetic analysis, two subtypes (SARS-CoV-2a and -b) were confirmed within SARS-CoV-2 strains. These two subtypes were divided by a novel synonymous mutation of D614G. This may play a crucial role in the evolution of SARS-CoV-2 to evade the host immune system. The region containing this mutation point was confirmed as a B-cell epitope located in the S1 domain, and SARS-CoV-2b strains exhibited severe reduced antigenic indexes compared to SARS-CoV-2a in this area. This may allow these two subtypes to have different antigenicity. If the two subtypes have different serological characteristics, a vaccine for both subtypes will be more effective to prevent COVID-19. Thus, further study is urgently required to confirm the antigenicity of these two subtypes.
C1 [Kim, Sung-Jae; Park, Bong-Kyun; Chung, Hee-Chun] Seoul Natl Univ, Dept Vet Med Virol Lab, Coll Vet Med, Seoul 08826, South Korea.
   [Kim, Sung-Jae; Park, Bong-Kyun; Chung, Hee-Chun] Seoul Natl Univ, Res Inst Vet Sci, Seoul 08826, South Korea.
   [Nguyen, Van-Giap] Vietnam Natl Univ Agr, Dept Vet Microbiol & Infect Dis, Fac Vet Med, Hanoi 100000, Vietnam.
   [Park, Yong-Ho] Seoul Natl Univ, Dept Vet Microbiol, Coll Vet Med, Seoul 151742, South Korea.
   [Park, Yong-Ho] Seoul Natl Univ, Res Inst Vet Sci, Seoul 151742, South Korea.
RP Chung, HC (corresponding author), Seoul Natl Univ, Dept Vet Med Virol Lab, Coll Vet Med, Seoul 08826, South Korea.; Chung, HC (corresponding author), Seoul Natl Univ, Res Inst Vet Sci, Seoul 08826, South Korea.; Park, YH (corresponding author), Seoul Natl Univ, Dept Vet Microbiol, Coll Vet Med, Seoul 151742, South Korea.; Park, YH (corresponding author), Seoul Natl Univ, Res Inst Vet Sci, Seoul 151742, South Korea.
EM kvirus7734@gmail.com; nguyengiap83@gmail.com; yhp@snu.ac.kr;
   parkx026@snu.ac.kr; heeskyi@snu.ac.kr
OI Nguyen, Van Giap/0000-0001-5250-1825; Chung,
   Hee-Chun/0000-0003-4666-5393; Kim, Sung-Jae/0000-0002-8813-012X
FU BioGreen 21 Program, Rural Development AdministrationRural Development
   Administration (RDA) [PJ009015]
FX This study was supported by the BioGreen 21 Program, Rural Development
   Administration (grant no. PJ009015). The funder had no role in this
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ABRAHAM S, 1990, VIROLOGY, V176, P296, DOI 10.1016/0042-6822(90)90257-R
   Ballesteros ML, 1997, VIROLOGY, V227, P378, DOI 10.1006/viro.1996.8344
   CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002
   Chung HC, 2019, CAN J VET RES, V83, P97
   Hoang DT, 2018, MOL BIOL EVOL, V35, P518, DOI 10.1093/molbev/msx281
   Du LY, 2009, BIOCHEM BIOPH RES CO, V384, P486, DOI 10.1016/j.bbrc.2009.05.003
   JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li J, 2020, LANCET INFECT DIS, V20, P275, DOI 10.1016/S1473-3099(20)30063-3
   Lin YM, 2013, SCI WORLD J, DOI 10.1155/2013/571875
   Luo ZL, 1998, VIROLOGY, V244, P483, DOI 10.1006/viro.1998.9121
   Martinez N, 2012, INFECT GENET EVOL, V12, P1870, DOI 10.1016/j.meegid.2012.05.007
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Nagata S, 2009, ADV DRUG DELIVER REV, V61, P977, DOI 10.1016/j.addr.2009.07.014
   Ntafis V, 2013, INFECT GENET EVOL, V16, P129, DOI 10.1016/j.meegid.2013.01.014
   PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013
   Pereira CAD, 2007, INFECT GENET EVOL, V7, P399, DOI 10.1016/j.meegid.2006.03.007
   SANCHEZ CM, 1992, VIROLOGY, V190, P92, DOI 10.1016/0042-6822(92)91195-Z
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang XB, 2016, ARCH VIROL, V161, P537, DOI 10.1007/s00705-015-2694-6
   Wilson S, 2014, VACCINE, V32, P5420, DOI 10.1016/j.vaccine.2014.07.102
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zehender G, 2020, J MED VIROL, V92, P1637, DOI 10.1002/jmv.25794
NR 31
TC 8
Z9 8
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD JUN
PY 2020
VL 8
IS 2
AR 220
DI 10.3390/vaccines8020220
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA MT0EL
UT WOS:000554643900001
PM 32422894
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ianevski, A
   Yao, R
   Fenstad, MH
   Biza, S
   Zusinaite, E
   Reisberg, T
   Lysvand, H
   Loseth, K
   Landsem, VM
   Malmring, JF
   Oksenych, V
   Erlandsen, SE
   Aas, PA
   Hagen, L
   Pettersen, CH
   Tenson, T
   Afset, JE
   Nordbo, SA
   Bjoras, M
   Kainov, DE
AF Ianevski, Aleksandr
   Yao, Rouan
   Fenstad, Mona Hoysaeter
   Biza, Svetlana
   Zusinaite, Eva
   Reisberg, Tuuli
   Lysvand, Hilde
   Loseth, Kirsti
   Landsem, Veslemoy Malm
   Malmring, Janne Fossum
   Oksenych, Valentyn
   Erlandsen, Sten Even
   Aas, Per Arne
   Hagen, Lars
   Pettersen, Caroline H.
   Tenson, Tanel
   Afset, Jan Egil
   Nordbo, Svein Arne
   Bjoras, Magnar
   Kainov, Denis E.
TI Potential Antiviral Options against SARS-CoV-2 Infection
SO VIRUSES-BASEL
LA English
DT Article
DE antivirals; broad-spectrum antivirals; antiviral drug combinations
ID PROTEASE INHIBITOR NELFINAVIR; ZIKA VIRUS-INFECTION; IN-VITRO;
   REPLICATION; SALIPHENYLHALAMIDE; IDENTIFICATION; OBATOCLAX; FUTURE;
   DRUGS; CELLS
AB As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.
C1 [Ianevski, Aleksandr; Yao, Rouan; Biza, Svetlana; Lysvand, Hilde; Loseth, Kirsti; Landsem, Veslemoy Malm; Oksenych, Valentyn; Erlandsen, Sten Even; Aas, Per Arne; Hagen, Lars; Pettersen, Caroline H.; Afset, Jan Egil; Nordbo, Svein Arne; Bjoras, Magnar; Kainov, Denis E.] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, N-7028 Trondheim, Norway.
   [Fenstad, Mona Hoysaeter; Malmring, Janne Fossum; Afset, Jan Egil; Nordbo, Svein Arne] St Olavs Hosp, Dept Med Microbiol, N-7006 Trondheim, Norway.
   [Fenstad, Mona Hoysaeter] St Olavs Hosp, Dept Immunol & Transfus Med, N-7006 Trondheim, Norway.
   [Zusinaite, Eva; Tenson, Tanel; Kainov, Denis E.] Univ Tartu, Inst Technol, EE-50090 Tartu, Estonia.
   [Reisberg, Tuuli] Univ Tartu, Inst Genom Core Facil, EE-51010 Tartu, Estonia.
RP Kainov, DE (corresponding author), Norwegian Univ Sci & Technol, Dept Clin & Mol Med, N-7028 Trondheim, Norway.; Kainov, DE (corresponding author), Univ Tartu, Inst Technol, EE-50090 Tartu, Estonia.
EM aleksandr.ianevski@ntnu.no; rouany@stud.ntnu.no;
   Mona.Hoyseter.Fenstad@stolav.no; svetlana.biza@yandex.ru;
   Eva.Zusinaite@ut.ee; tuuli.reisberg@ut.ee; Hilde.Lysvand@ntnu.no;
   kirsti.loseth@ntnu.no; veslemoy.m.landsem@ntnu.no;
   Janne.Fossum.Malmring@stolav.no; valentyn.oksenych@ntnu.no;
   sten.e.erlandsen@ntnu.no; per.a.aas@ntnu.no; lars.hagen@ntnu.no;
   caroline.h.pettersen@ntnu.no; tanel.tenson@ut.ee; jan.afset@ntnu.no;
   svein.a.nordbo@ntnu.no; magnar.bjoras@ntnu.no; denis.kainov@ntnu.no
OI Nordbo, Svein Arne/0000-0002-7620-4355; Oksenych,
   Valentyn/0000-0002-5088-3791
FU European Regional Development FundEuropean Union (EU); Mobilitas Pluss
   Project [MOBTT39]
FX This research was funded the European Regional Development Fund, the
   Mobilitas Pluss Project MOBTT39 (to D.K.).
CR Andersen PI, 2020, INT J INFECT DIS, V93, P268, DOI 10.1016/j.ijid.2020.02.018
   Andersen PI, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100964
   Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   Bekerman E, 2015, SCIENCE, V348, P282, DOI 10.1126/science.aaa3778
   Boonyasuppayakorn S, 2014, ANTIVIR RES, V106, P125, DOI 10.1016/j.antiviral.2014.03.014
   Bosl K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02186
   Bulanova D, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100271
   Cadnum Jennifer L, 2020, Pathog Immun, V5, P52, DOI 10.20411/pai.v5i1.372
   Cairns M, 2010, ANTIMICROB AGENTS CH, V54, P1265, DOI 10.1128/AAC.01161-09
   Cao JZ, 2015, ANTIVIR RES, V114, P1, DOI 10.1016/j.antiviral.2014.11.010
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Valadao ALC, 2015, MOLECULES, V20, P11474, DOI 10.3390/molecules200611474
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   Debing Y, 2015, CURR OPIN INFECT DIS, V28, P596, DOI 10.1097/QCO.0000000000000212
   Demongeot J, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9050094
   Denisova OV, 2012, J BIOL CHEM, V287, P35324, DOI 10.1074/jbc.M112.392142
   DESMYTER J, 1968, J VIROL, V2, P955, DOI 10.1128/JVI.2.10.955-961.1968
   Dong HJ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110601
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Fu Y, 2016, ANTIVIR RES, V133, P23, DOI 10.1016/j.antiviral.2016.07.008
   Gunn BM, 2018, CELL HOST MICROBE, V24, P221, DOI 10.1016/j.chom.2018.07.009
   HASHIMOTO G, 1983, J INFECT DIS, V148, P785, DOI 10.1093/infdis/148.5.785
   Hayden EC, 2018, NATURE, V557, P475, DOI 10.1038/d41586-018-05205-x
   Howard CR, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.47
   Hulseberg CE, 2019, J VIROL, V93, DOI [10.1128/jvi.02185-18, 10.1128/JVI.02185-18]
   Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216
   Ianevski A, 2019, DRUG DISCOV TODAY, V24, P1224, DOI 10.1016/j.drudis.2019.04.006
   Ianevski A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030207
   Ianevski A, 2018, ANTIVIR RES, V154, P174, DOI 10.1016/j.antiviral.2018.04.016
   Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162
   Jaishankar D, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan5861
   Jang Y, 2018, J VIROL, V92, DOI 10.1128/JVI.01441-18
   Jenks JA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02110
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Kalu NN, 2014, J VIROL, V88, P5455, DOI 10.1128/JVI.03790-13
   Kapoor A, 2013, ANTIMICROB AGENTS CH, V57, P2761, DOI 10.1128/AAC.00029-13
   Khandelwal N, 2017, ANTIVIR RES, V144, P196, DOI 10.1016/j.antiviral.2017.06.006
   Kim JE, 2019, J MICROBIOL, V57, P74, DOI 10.1007/s12275-019-8514-z
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kim YJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104558
   Kuivanen S, 2017, ANTIVIR RES, V139, P117, DOI 10.1016/j.antiviral.2016.12.022
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   MacGibeny MA, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007188
   MASTRANGELO MJ, 1973, CANCER-AM CANCER SOC, V31, P1170, DOI 10.1002/1097-0142(197305)31:5<1170::AID-CNCR2820310520>3.0.CO;2-4
   Mazzon M, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020176
   Mothay Dipti, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00585-z
   Mukhopadhyay R, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005717
   Musarrat F, 2020, J MED VIROL, V92, P2087, DOI 10.1002/jmv.25985
   Nishimura Y, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01068
   Norris MJ, 2018, AM J RESP CELL MOL, V59, P733, DOI 10.1165/rcmb.2017-0345OC
   Oberacker P, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000107
   Pizzorno A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00531
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Romero MR, 2007, PLANTA MED, V73, P552, DOI 10.1055/s-2007-967184
   Sakurai Y, 2018, ANTIVIR RES, V160, P175, DOI 10.1016/j.antiviral.2018.10.025
   Sareen D, 2014, J COMP NEUROL, V522, P2707, DOI 10.1002/cne.23578
   Schimmer AD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108694
   Schor S, 2018, DNA CELL BIOL, V37, P63, DOI 10.1089/dna.2017.4033
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Sobral MFF, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.138997
   Toma S, 2009, J VIRAL HEPATITIS, V16, P506, DOI 10.1111/j.1365-2893.2009.01102.x
   Ursu O, 2019, NUCLEIC ACIDS RES, V47, pD963, DOI 10.1093/nar/gky963
   van Erp EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00548
   Varghese FS, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.02227-16, 10.1128/aac.02227-16]
   WHO, WHO PUBL LIST TOP EM
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yang S, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0034-1
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yu F, 2013, VIRUSES-BASEL, V5, P127, DOI 10.3390/v5010127
   Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x
   Zhang KYE, 2001, ANTIMICROB AGENTS CH, V45, P1086, DOI 10.1128/AAC.45.4.1086-1093.2001
   Zhang Ya-Nan, 2020, Emerg Microbes Infect, V9, P1170, DOI 10.1080/22221751.2020.1772676
   Zheng W, 2018, BRIT J PHARMACOL, V175, P181, DOI 10.1111/bph.13895
   Zhou T, 2017, CELL STEM CELL, V21, P274, DOI 10.1016/j.stem.2017.06.017
NR 80
TC 5
Z9 5
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD JUN
PY 2020
VL 12
IS 6
AR 642
DI 10.3390/v12060642
PG 19
WC Virology
SC Virology
GA MS9VN
UT WOS:000554620300001
PM 32545799
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Almeida, A
   Faustino, MAF
   Neves, MGPMS
AF Almeida, Adelaide
   Faustino, M. Amparo F.
   Neves, Maria G. P. M. S.
TI Antimicrobial Photodynamic Therapy in the Control of COVID-19
SO ANTIBIOTICS-BASEL
LA English
DT Article
DE antimicrobial photodynamic therapy; coronaviruses; SARS-CoV-2; COVID-19;
   control; disinfection
ID RESISTANT STAPHYLOCOCCUS-AUREUS; WASTE-WATER; ESCHERICHIA-COLI; MEMBRANE
   PHOSPHOLIPIDS; INACTIVATION; BACTERIA; PORPHYRINS; VIRUS;
   PHOTOINACTIVATION; PHOTOSENSITIZER
AB Antimicrobial photodynamic therapy (aPDT), using well known, safe and cost-effective photosensitizers, such as phenothiazines, e.g., methylene blue (MB), or porphyrins, e.g., protoporphyrin-IX (PP-IX), might help to mitigate the COVID-19 either to prevent infections or to develop photoactive fabrics (e.g., masks, suits, gloves) to disinfect surfaces, air and wastewater, under artificial light and/or natural sunlight.
C1 [Almeida, Adelaide] Univ Aveiro, Dept Biol CESAM, P-3810193 Aveiro, Portugal.
   [Faustino, M. Amparo F.; Neves, Maria G. P. M. S.] Univ Aveiro, Dept Chem, P-3810193 Aveiro, Portugal.
   [Faustino, M. Amparo F.; Neves, Maria G. P. M. S.] Univ Aveiro, LAQV REQUIMTE, P-3810193 Aveiro, Portugal.
RP Almeida, A (corresponding author), Univ Aveiro, Dept Biol CESAM, P-3810193 Aveiro, Portugal.
EM aalmeida@ua.pt; faustino@ua.pt; gneves@ua.pt
RI Almeida, Adelaide/D-9899-2011
OI Almeida, Adelaide/0000-0002-8422-8664
FU University of Aveiro; FCT/MCTES through national funds (PIDDAC)
   [UID/AMB/50017 - POCI-01-0145-FEDER-007638, UIDB/50006/2020,
   FCT-PTDC/ASPPES/29576/2017]; FEDER, within the PT2020 Partnership
   Agreement; Compete 2020
FX Thanks are due for the financial support to the University of Aveiro and
   the FCT/MCTES for the financial support to CESAM (UID/AMB/50017 -
   POCI-01-0145-FEDER-007638), LAQV-REQUIMTE (UIDB/50006/2020) and the FCT
   project PREVINE (FCT-PTDC/ASPPES/29576/2017), through national funds
   (PIDDAC), and the co-funding by the FEDER, within the PT2020 Partnership
   Agreement and Compete 2020.
CR Almeida A, 2011, COMPR SER PHOTOCH, V11, P83
   Almeida A, 2015, FUTURE MED CHEM, V7, P1221, DOI [10.4155/FMC.15.59, 10.4155/fmc.15.59]
   Almeida A, 2009, MAR DRUGS, V7, P268, DOI 10.3390/md7030268
   Almeida J, 2014, PHOTOCH PHOTOBIO SCI, V13, P626, DOI 10.1039/c3pp50195g
   Alves E, 2008, J IND MICROBIOL BIOT, V35, P1447, DOI 10.1007/s10295-008-0446-2
   Alves E, 2015, J PHOTOCH PHOTOBIO C, V22, P34, DOI 10.1016/j.jphotochemrev.2014.09.003
   Alves E, 2014, DYES PIGMENTS, V110, P80, DOI 10.1016/j.dyepig.2014.05.016
   Alves E, 2014, FUTURE MED CHEM, V6, P141, DOI 10.4155/fmc.13.211
   Alves E, 2013, RAPID COMMUN MASS SP, V27, P2717, DOI 10.1002/rcm.6739
   Alves E, 2013, RAPID COMMUN MASS SP, V27, P1607, DOI 10.1002/rcm.6614
   Alves E, 2013, BIOORGAN MED CHEM, V21, P4311, DOI 10.1016/j.bmc.2013.04.065
   Bartolomeu M, 2017, WATER-SUI, V9, DOI 10.3390/w9090630
   Bartolomeu M, 2016, J PORPHYR PHTHALOCYA, V20, P331, DOI 10.1142/S1088424616500127
   Bartolomeu M, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00267
   Bertoloni G, 2000, BBA-GEN SUBJECTS, V1475, P169, DOI 10.1016/S0304-4165(00)00071-4
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Brown S.B., 2002, Patent, Patent No. [WO2002GB02278, 2002GB02278]
   Carvalho CMB, 2007, J PHOTOCH PHOTOBIO B, V88, P112, DOI 10.1016/j.jphotobiol.2007.04.015
   Carvalho CMB, 2010, ACS NANO, V4, P7133, DOI 10.1021/nn1026092
   Castro KADF, 2019, APPL MATER TODAY, V16, P332, DOI 10.1016/j.apmt.2019.06.010
   Castro KADF, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102522
   Castro KADF, 2017, DYES PIGMENTS, V137, P265, DOI 10.1016/j.dyepig.2016.10.020
   CDC, SEV AC RESP SYNDR CO
   Cieplik F, 2018, CRIT REV MICROBIOL, V44, P571, DOI 10.1080/1040841X.2018.1467876
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Costa L, 2014, J VIROL METHODS, V209, P103, DOI 10.1016/j.jviromet.2014.09.013
   Costa L, 2012, PHOTOCH PHOTOBIO SCI, V11, P1520, DOI 10.1039/c2pp25156f
   Costa L, 2012, VIRUSES-BASEL, V4, P1034, DOI 10.3390/v4071034
   Costa L, 2011, ANTIVIR RES, V91, P278, DOI 10.1016/j.antiviral.2011.06.007
   Diogo P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00498
   Diogo P, 2019, J FUNCT BIOMATER, V10, DOI 10.3390/jfb10040044
   Diogo P, 2018, PHOTODIAGN PHOTODYN, V22, P205, DOI 10.1016/j.pdpdt.2018.04.009
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Eickmann M, 2018, TRANSFUSION, V58, P2202, DOI 10.1111/trf.14652
   El-Adly A.A., 2008, J APPL SCI RES, V4, P1817
   Falas P, 2012, WATER SCI TECHNOL, V66, P783, DOI 10.2166/wst.2012.243
   FDA, COR COVID 19 UPD FDA
   Fekrazad R, 2020, PHOTOBIOMOD PHOTOMED, V38, P255, DOI 10.1089/photob.2020.4868
   Friedman L.I., 2000, Patent, Patent No. [WO/2001/049328, 2001049328]
   Frigon D, 2013, APPL ENVIRON MICROB, V79, P835, DOI 10.1128/AEM.02789-12
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Grinholc M, 2007, ACTA BIOCHIM POL, V54, P665, DOI 10.18388/abp.2007_3240
   Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885
   Hamblin MR, 2004, PHOTOCH PHOTOBIO SCI, V3, P436, DOI 10.1039/b311900a
   Heinemann F, 2017, ACCOUNTS CHEM RES, V50, P2727, DOI 10.1021/acs.accounts.7b00180
   Henry M, 2020, SUBSTANTIA S1, V4, P888, DOI [10.13128/Substantia-888, DOI 10.13128/SUBSTANTIA-888]
   Hu XQ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01299
   Jaffe S, 2020, LANCET, V395, P1179, DOI 10.1016/S0140-6736(20)30817-5
   Jori Giulio, 2007, Anti-Infective Agents in Medicinal Chemistry, V6, P119, DOI 10.2174/187152107780361652
   Kim MJ, 2017, APPL ENVIRON MICROB, V83, DOI [10.1128/AEM.02582-16, 10.1128/aem.02582-16]
   Komerik N, 2000, PHOTOCHEM PHOTOBIOL, V72, P676, DOI 10.1562/0031-8655(2000)072<0676:TEOPAO>2.0.CO;2
   Lane J.C., 2020, SAFETY HYDROXYCHLORO, DOI [10.1101/2020.04.08.20054551, DOI 10.1101/2020.04.08.20054551]
   Le Gall T, 2018, CHEMMEDCHEM, V13, P2229, DOI 10.1002/cmdc.201800392
   Lentini G, 2020, MOLECULES, V25, DOI 10.3390/molecules25081834
   Lodder W, 2020, LANCET GASTROENTEROL, V5, P533, DOI 10.1016/S2468-1253(20)30087-X
   Lourenco LMO, 2019, CHEMPHOTOCHEM, V3, P251, DOI 10.1002/cptc.201900020
   Macauley JJ, 2006, WATER RES, V40, P2017, DOI 10.1016/j.watres.2006.03.021
   Mansor NA, 2020, SCI TOTAL ENVIRON, V714, DOI 10.1016/j.scitotenv.2020.136745
   Marciel L, 2018, FUTURE MED CHEM, V10, P1821, DOI 10.4155/fmc-2018-0010
   Medema G., 2020, ENVIRON SCI TECH LET, V7, P511, DOI DOI 10.1021/ACS.ESTLETT.0C00357
   Mesquita MQ, 2018, MOLECULES, V23, DOI 10.3390/molecules23102424
   Mesquita MQ, 2014, DYES PIGMENTS, V110, P123, DOI 10.1016/j.dyepig.2014.04.025
   Mokwena MG, 2018, PHOTODIAGN PHOTODYN, V22, P147, DOI 10.1016/j.pdpdt.2018.03.006
   Moreira JA, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/44/446002
   Nitzan Y, 2004, PHOTOCH PHOTOBIO SCI, V3, P430, DOI 10.1039/b315633h
   NORTH J, 1994, J ACQ IMMUN DEF SYND, V7, P891
   Nunez-Delgado A, 2020, SCI TOTAL ENVIRON, V727, DOI 10.1016/j.scitotenv.2020.138647
   Oliveira A, 2009, J APPL MICROBIOL, V106, P1986, DOI 10.1111/j.1365-2672.2009.04168.x
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Prata C, 2012, J ENVIRON MONITOR, V14, P64, DOI 10.1039/c1em10603a
   Pruss A., 2017, SAFE MANAGEMENT WAST
   Publications & Data, PUBL DAT
   Rana D.R., 2020, NO THERAPEUTIC APPL, DOI [10.1101/2020.03.22.20040964, DOI 10.1101/2020.03.22.20040964]
   RIVM, NOV COR FOUND WAST
   Schafer M, 1998, INT J RADIAT BIOL, V74, P249, DOI 10.1080/095530098141636
   Shafirstein G, 2016, ANN AM THORAC SOC, V13, P265, DOI 10.1513/AnnalsATS.201509-650FR
   Silva EMP, 2005, BIOORG MED CHEM LETT, V15, P3333, DOI 10.1016/j.bmcl.2005.05.044
   Song W, 2018, ACS NANO, V12, P1978, DOI 10.1021/acsnano.7b09112
   Tan Y, 2018, PHOTODIAGN PHOTODYN, V24, P88, DOI 10.1016/j.pdpdt.2018.07.005
   Tavares A, 2010, MAR DRUGS, V8, P91, DOI 10.3390/md8010091
   Tomb RM, 2018, PHOTOCHEM PHOTOBIOL, V94, P445, DOI 10.1111/php.12883
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Tubby S, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-211
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Vaz-Moreira I, 2014, FEMS MICROBIOL REV, V38, P761, DOI 10.1111/1574-6976.12062
   Vieira C, 2019, J PORPHYR PHTHALOCYA, V23, P534, DOI 10.1142/S1088424619500408
   Vieira C, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02665
   Wainwright M, 2004, INT BIODETER BIODEGR, V53, P119, DOI 10.1016/j.ibiod.2003.11.006
   Wainwright M, 1998, J ANTIMICROB CHEMOTH, V42, P13, DOI 10.1093/jac/42.1.13
   Wainwright M, 2017, LANCET INFECT DIS, V17, pE49, DOI 10.1016/S1473-3099(16)30268-7
   Wainwright M, 2017, DYES PIGMENTS, V136, P590, DOI 10.1016/j.dyepig.2016.09.015
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wiehe A, 2019, PHOTOCH PHOTOBIO SCI, V18, P2565, DOI 10.1039/c9pp00211a
   WILSON M, 1995, J MED MICROBIOL, V42, P62, DOI 10.1099/00222615-42-1-62
   Wozniak A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00930
   Yao TT, 2019, J MATER CHEM B, V7, P5089, DOI 10.1039/c9tb01069f
NR 97
TC 2
Z9 2
U1 7
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2079-6382
J9 ANTIBIOTICS-BASEL
JI Antibiotics-Basel
PD JUN
PY 2020
VL 9
IS 6
AR 320
DI 10.3390/antibiotics9060320
PG 10
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA MR8QW
UT WOS:000553856400001
PM 32545171
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Maarefvand, M
   Hosseinzadeh, S
   Farmani, O
   Farahani, AS
   Khubchandani, J
AF Maarefvand, Masoomeh
   Hosseinzadeh, Samaneh
   Farmani, Ozra
   Farahani, Atefeh Safarabadi
   Khubchandani, Jagdish
TI Coronavirus Outbreak and Stress in Iranians
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE coronavirus; pandemic; stress; Iran; outbreak
ID MENTAL-HEALTH; CHINA
AB Iran has faced one of the worst COVID-19 outbreaks in the world, and no studies to date have examined COVID-19-related stress in the general Iranian population. In this first population-based study, a web-based survey was conducted during the peak of the outbreak to assess stress and its correlates in the Iranian population. A 54-item, valid, and reliable questionnaire, including items on demographic characteristics and past medical history, stress levels, awareness about signs and symptoms of COVID-19, knowledge about at-risk groups and prevention methods, knowledge about transmission methods, trust in sources of information, and availability of facemasks and sanitizers, was deployed via social and mass media networks. A total of 3787 Iranians participated in the study where the majority of the participants were females (67.4%), employed (56.1%), from developed provinces (81.6%), without chronic diseases (66.6%), and with >= 13 years of formal education (87.9%). The mean age of study participants was 34.9 years (range = 12-73), and the average stress score was 3.33 (SD = +/- 1.02). Stress score was significantly higher for females, those who were 30-39 years old, housewives, those with chronic diseases, individuals who were aware that there is no vaccine to prevent COVID-19, those who could not get facemasks or sanitizers, and individuals with higher knowledge about at-risk groups (p< 0.05). There was a significant correlation of stress scores with knowledge about prevention methods for COVID-19 (r = 0.21,p= 0.01) and trust in sources of information about COVID-19 (r = -0.18,p= 0.01). All of the predictors, except knowledge of two important at-risk groups and education, had a significant effect on stress scores based on a multivariate regression model. The COVID-19 outbreak could increase stress among all population groups, with certain groups at higher risk. In the high-risk groups and based on experience with previous pandemics, interventions are needed to prevent long-term psychological effects. Professional support and family-centered programs should be a part of pandemic mitigation-related policymaking and public health practices.
C1 [Maarefvand, Masoomeh] Univ Social Welf & Rehabil Sci, Dept Social Work, Tehran 1985713834, Iran.
   [Maarefvand, Masoomeh; Farmani, Ozra; Farahani, Atefeh Safarabadi] Iranian Sci Assoc Social Work, Tehran 1985713834, Iran.
   [Hosseinzadeh, Samaneh] Univ Social Welf & Rehabil Sci, Dept Biostat, Tehran 1985713834, Iran.
   [Khubchandani, Jagdish] Ball State Univ, Coll Hlth, Dept Nutr & Hlth Sci, Muncie, IN 47306 USA.
RP Maarefvand, M (corresponding author), Univ Social Welf & Rehabil Sci, Dept Social Work, Tehran 1985713834, Iran.; Maarefvand, M (corresponding author), Iranian Sci Assoc Social Work, Tehran 1985713834, Iran.
EM arammaref@gmail.com; hosseinzadeh.sam@gmail.com; n1713388@gmail.com;
   atefeh.s.farahani@gmail.com; jkhubchandan@bsu.edu
RI Khubchandani, Jagdish/D-1831-2014
OI Khubchandani, Jagdish/0000-0002-9058-4278
FU Iranian Scientific Association of Social Work [98/D/418]
FX This work was supported by the Iranian Scientific Association of Social
   Work (Grant #98/D/418).
CR Betancourt TS, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002073
   Cowling BJ, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.6.2000110
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Gentilini U, SOCIAL PROTECTION JO
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hua JL, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072309
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Huremovi D., 2019, PSYCHIAT PANDEMICS M
   International Labor Organization, NEW GUID HELP EMPL S
   Jalloh MF, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000471
   Jernigan SR, 2020, BIOMED ENG ONLINE, V19, DOI 10.1186/s12938-020-00794-z
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Mukhtar S, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102069
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Nemati M, 2020, ARCH CLIN INFECT DIS, V15, DOI 10.5812/archcid.102848
   Park JS, 2018, ARCH PSYCHIAT NURS, V32, P2, DOI 10.1016/j.apnu.2017.09.006
   Peyravi M, 2020, DISASTER MED PUBLIC, V14, pE5, DOI [10.1017/dmp.2020.441, 10.1017/dmp.2020.94]
   Rubin G.J, 2014, HLTH SERV DELIV RES, DOI 10.3310/hsdr02410
   Sahlqvist S, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-62
   Shokri A, 2020, MED J ISLAMIC REPUB, V34, P400
   Shultz JM, 2015, JAMA-J AM MED ASSOC, V313, P567, DOI 10.1001/jama.2014.17934
   The New York Times Coronavirus Map, NY TIMES
   Tuite AR, 2020, ANN INTERN MED, V172, P699, DOI 10.7326/M20-0696
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang CY, 2020, J RISK FINANC MANAG, V13, DOI 10.3390/jrfm13020036
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   Xie B, 2020, J ASSOC INF SCI TECH, V71, P1419, DOI 10.1002/asi.24357
   Zarghami M, 2020, IRAN J PSYCHIATRY BE, V14, DOI 10.5812/ijpbs.102957
   Zhang J, 2020, PRECISION CLIN MED, V3, P3, DOI [10.1093/pcmedi/pbaa006, DOI 10.1093/pcmedi/pbaa006]
NR 34
TC 2
Z9 2
U1 5
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUN
PY 2020
VL 17
IS 12
AR 4441
DI 10.3390/ijerph17124441
PG 11
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA MR9PO
UT WOS:000553921500001
PM 32575763
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jung, HY
   Lim, JH
   Kang, SH
   Kim, SG
   Lee, YH
   Lee, J
   Chang, HH
   Kim, SW
   Choi, JY
   Cho, JH
   Kim, CD
   Kim, YL
   Park, SH
AF Jung, Hee-Yeon
   Lim, Jeong-Hoon
   Kang, Seok Hui
   Kim, Seong Gyu
   Lee, Yong-Hoon
   Lee, Jaehee
   Chang, Hyun-Ha
   Kim, Shin-Woo
   Choi, Ji-Young
   Cho, Jang-Hee
   Kim, Chan-Duck
   Kim, Yong-Lim
   Park, Sun-Hee
TI Outcomes of COVID-19 among Patients on In-Center Hemodialysis: An
   Experience from the Epicenter in South Korea
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; hemodialysis; South Korea
ID CORONAVIRUS; PROCALCITONIN; EPIDEMIC; WUHAN
AB Patients with advanced chronic kidney disease (CKD) or who are on hemodialysis (HD) could have increased susceptibility to the 2019 coronavirus disease (COVID-19) given their pre-existing comorbidities, older age, compromised immune system, and regular visits to populated outpatient dialysis centers. This study included 14 consecutive patients on HD or with advanced CKD who initiated HD after being diagnosed with laboratory-confirmed COVID-19 from February to April 2020 in hospitals throughout Daegu, South Korea. The included patients, 42.9% of whom were men, had a mean age of 63.5 years. Four patients had a history of contact with a patient suffering from COVID-19. The most common symptom was cough (50.0%), followed by dyspnea (35.7%). The mean time from symptom onset to diagnosis and admission was 2.6 and 3.5 days, respectively. Patients exhibited lymphopenia and elevated inflammatory markers, including C-reactive protein and ferritin. Chest radiography findings showed pulmonary infiltration in 10 patients. All patients underwent regular HD in a negative pressure room and received antiviral agents. Four patients received mechanical ventilation and continuous renal replacement therapy at a median duration of 14.0 and 8.5 days, respectively. One patient underwent extracorporeal membrane oxygenation for three days. Among the 14 patients included, two died due to acute respiratory distress syndrome, nine were discharged from the hospital, and three remained hospitalized. Despite the high-risk conditions associated with worse outcomes, patients on HD did not exhibit extremely poor overall COVID-19 outcomes perhaps due to early diagnosis, prompt hospitalization, and antiviral therapy.
C1 [Jung, Hee-Yeon; Lim, Jeong-Hoon; Choi, Ji-Young; Cho, Jang-Hee; Kim, Chan-Duck; Kim, Yong-Lim; Park, Sun-Hee] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Div Nephrol,Dept Internal Med, Daegu 41944, South Korea.
   [Kang, Seok Hui] Yeungnam Univ, Dept Internal Med, Div Nephrol, Med Ctr, Daegu 42415, South Korea.
   [Kim, Seong Gyu] Daegu Catholic Univ, Dept Internal Med, Div Nephrol, Med Ctr, Daegu 42472, South Korea.
   [Lee, Yong-Hoon; Lee, Jaehee] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Div Pulm & Crit Care Med,Dept Internal Med, Daegu 41944, South Korea.
   [Chang, Hyun-Ha; Kim, Shin-Woo] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Div Infect Dis,Dept Internal Med, Daegu 41944, South Korea.
RP Kim, YL; Park, SH (corresponding author), Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Div Nephrol,Dept Internal Med, Daegu 41944, South Korea.
EM hy-jung@knu.ac.kr; jh-lim@knu.ac.kr; kangkang@ynu.ac.kr;
   shaorangun@gmail.com; id0121@naver.com; jaelee@knu.ac.kr;
   changhha@knu.ac.kr; ksw2kms@knu.ac.kr; jyss1002@hanmail.net;
   jh-cho@knu.ac.kr; drcdkim@knu.ac.kr; ylkim@knu.ac.kr; sh-park@knu.ac.kr
RI Lim, Jeong-Hoon/ABE-6003-2020; Cho, Jang-hee/ABD-3534-2020
OI Lim, Jeong-Hoon/0000-0001-5517-9886; Cho, Jang-hee/0000-0002-7031-5214;
   Kim, Seong Gyu/0000-0001-7900-7560; Jung, Hee-Yeon/0000-0003-0232-7202
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI15C0001]
FX This research was supported by a grant of the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
   (grant number: HI15C0001).
CR Ahmed SB, 2016, NEPHROL DIAL TRANSPL, V31, P1787, DOI 10.1093/ndt/gfw084
   Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Delevaux I, 2003, ANN RHEUM DIS, V62, P337, DOI 10.1136/ard.62.4.337
   Dudreuilh C, 2020, KIDNEY INT, V98, P236, DOI 10.1016/j.kint.2020.04.021
   Ferrey AJ, 2020, AM J NEPHROL, V51, P337, DOI 10.1159/000507417
   Goicoechea M, 2020, KIDNEY INT, V98, P27, DOI 10.1016/j.kint.2020.04.031
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Henry BM, 2020, INT UROL NEPHROL, V52, P1193, DOI 10.1007/s11255-020-02451-9
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ikizler TA, 2020, AM J KIDNEY DIS, V76, P1, DOI [10.1053/j.ajkd.2020.03.008, 10.1053/j.ajkd.2020.05.006]
   Jaillon S, 2019, CLIN REV ALLERG IMMU, V56, P308, DOI 10.1007/s12016-017-8648-x
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   Laird E, 2020, Ir Med J, V113, P81
   Lippi G, 2020, CLIN CHIM ACTA, V505, P190, DOI 10.1016/j.cca.2020.03.004
   Ma Y., 2019, NOVEL CORONAVIRUS DI
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620
   Park HC, 2020, KIDNEY RES CLIN PRAC, V39, P145, DOI 10.23876/j.krcp.20.046
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang R, 2020, AM J KIDNEY DIS, V76, P141, DOI 10.1053/j.ajkd.2020.03.009
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 25
TC 4
Z9 4
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2020
VL 9
IS 6
AR 1688
DI 10.3390/jcm9061688
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA MR9JF
UT WOS:000553904500001
PM 32498262
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mohan, S
AF Mohan, Sumit
CA Columbia Univ Kidney Transplant
TI Early Description of Coronavirus 2019 Disease in Kidney Transplant
   Recipients in New York
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
DE transplant outcomes; kidney transplantation; Epidemiology and outcomes;
   COVID-19
AB Significance Statement Currently, the clinical presentation, optimal management strategy, and outcomes for patients with kidney transplants who develop COVID-19 infection remain unknown. The description of our cohort represents the first cohort of patients with kidney transplants and COVID-19 infection and includes clinical features, markers of inflammation, and a strategy for management that includes both immunosuppression reduction and the use of adjuvant therapy, including hydroxychloroquine, azithromycin, and tocilizumab. This approach appears to have resulted in favorable outcomes in our cohort of hospitalized kidney transplant patients and provides an effective treatment strategy for the management of these patients
   Background The novel SARS-CoV-2 virus has caused a global pandemic of coronavirus disease 2019 (COVID-19). Although immunosuppressed individuals are thought to be at an increased risk of severe disease, little is known about their clinical presentation, disease course, or outcomes.
   Methods We report 15 kidney transplant recipients from the Columbia University kidney transplant program who required hospitalization for confirmed COVID-19, and describe their management, clinical course, and outcomes.
   Results Patients presented most often with a fever (87%) and/or cough (67%). Initial chest x-ray most commonly showed bilateral infiltrates, but 33% had no acute radiographic findings. Patients were managed with immunosuppression reduction and the addition of hydroxychloroquine and azithromycin. Although 27% of our patients needed mechanical ventilation, over half were discharged home by the end of follow-up.
   Conclusions Kidney transplant recipients with COVID-19 have presentations that are similar to that of the general population. Our current treatment protocol appears to be associated with favorable outcomes, but longer follow-up of a larger cohort of patients is needed.
C1 [Columbia Univ Kidney Transplant] Columbia Univ Vagelos Coll Phys & Surg, Dept Med, Div Nephrol, New York, NY USA.
RP Mohan, S (corresponding author), Columbia Univ Irving Med Ctr, Dept Med, Div Nephrol, 622 West 168th St,PH4-124, New York, NY 10032 USA.
EM sm2206@cumc.columbia.edu
RI Mohan, Sumit/I-5625-2019
OI Mohan, Sumit/0000-0002-5305-9685
FU National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2-TR001874]; National Institute of Diabetes and Digestive and Kidney
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01-DK114893, U01-DK116066];
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD) [R01-MD14161]; National Heart, Lung, and Blood
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [T32-HL007854-21]
FX Dr. Husainis supported by National Center for Advancing Translational
   Sciences grant KL2-TR001874. Dr. Mohan is supported by National
   Institute of Diabetes and Digestive and Kidney Diseases grants
   R01-DK114893 and U01-DK116066, and National Institute on Minority Health
   and Health Disparities grant R01-MD14161. Dr. Hardy is supported by
   National Heart, Lung, and Blood Institute grant T32-HL007854-21.
CR Centers for Disease Control and Prevention, 2020, INT CLIN GUID MAN PA
   Chang D, 2020, AM J RESP CRIT CARE, V201, P1150, DOI 10.1164/rccm.202003-0524LE
   Chu CM, 2004, CAN MED ASSOC J, V171, P1349, DOI 10.1503/cmaj.1040398
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 10
TC 62
Z9 63
U1 3
U2 5
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD JUN
PY 2020
VL 31
IS 6
BP 1150
EP 1156
DI 10.1681/ASN.2020030375
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA MU2RW
UT WOS:000555522300005
PM 32317402
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Park, HC
   Kim, DH
   Yoo, KD
   Kim, YG
   Lee, SH
   Yoon, HE
   Kim, DK
   Kim, SN
   Kim, MS
   Jung, YC
   Kim, YS
   Lee, YK
AF Park, Hayne Cho
   Kim, Do Hyoung
   Yoo, Kyung Don
   Kim, Yang-Gyun
   Lee, Sang-Ho
   Yoon, Hye Eun
   Kim, Dong Ki
   Kim, Seong Nam
   Kim, Myeong Sung
   Jung, Yoon Chul
   Kim, Yon Su
   Lee, Young-Ki
CA Korean Soc Nephrology COVID-19 Tas
TI Korean clinical practice guidelines for preventing transmission of
   coronavirus disease 2019 (COVID-19) in hemodialysis facilities
SO KIDNEY RESEARCH AND CLINICAL PRACTICE
LA English
DT Article
DE COVID-19; Hemodialysis units; Infection control; Practice guideline
AB Coronavirus disease 2019 (COVID-19) is a highly contagious viral disease that is caused by the novel virus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). COVID-19 has become pandemic since December 2019, when the first case developed in Wuhan, China. Patients receiving hemodialysis are more vulnerable to viral transmission because their immune functions are impaired and they receive treatment within a narrow space. Calling on previous experience with Middle East Respiratory Syndrome during the 2015 outbreak, the joint committee of the Korean Society of Nephrology and the Korean Society of Dialysis Therapy quickly formed a COVID-19 task force team to develop a manual before the first index case was diagnosed in the hemodialysis unit. This special article introduces clinical practice guidelines to prevent secondary transmission of COVID-19 within hemodialysis facilities, which were developed to protect patients, healthcare workers, and caregivers from this highly transmissible virus. The areas of infection control covered by these guidelines include standard precautions, performing dialysis therapy for confirmed or suspected cases, performing cohort isolation for contact patients, and disease monitoring and contact surveillance. We hope these guidelines help healthcare workers and hemodialysis patients around the world cope with the COVID-19 pandemic.
C1 [Park, Hayne Cho; Kim, Do Hyoung; Lee, Young-Ki] Hallym Univ, Dept Internal Med, Coll Med, Seoul, South Korea.
   [Yoo, Kyung Don] Univ Ulsan, Ulsan Univ Hosp, Dept Internal Med, Div Nephrol,Coll Med, Ulsan, South Korea.
   [Kim, Yang-Gyun; Lee, Sang-Ho] Kyung Hee Univ, Dept Internal Med, Coll Med, Seoul, South Korea.
   [Yoon, Hye Eun] Catholic Univ Korea, Dept Internal Med, Coll Med, Seoul, South Korea.
   [Kim, Dong Ki; Kim, Yon Su] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea.
   [Kim, Seong Nam] Kim Seong Nam Internal Med Clin, Seoul, South Korea.
   [Kim, Myeong Sung] Gojan Myeong Internal Med Clin, Ansan, South Korea.
   [Jung, Yoon Chul] Bundang Jesaeng Gen Hosp, Dept Internal Med, Seongnam, South Korea.
RP Lee, YK (corresponding author), Hallym Univ, Coll Med, Dept Internal Med, Kangnam Sacred Heart Hosp, 1 Singil Ro, Seoul 07441, South Korea.
EM km2071@naver.com
RI ; Kim, Dong Ki/J-5389-2012
OI Yoo, Kyung Don/0000-0001-6545-6517; Kim, Dong Ki/0000-0002-5195-7852;
   Kim, Do Hyoung/0000-0002-8664-8830; Park, Hayne Cho/0000-0002-1128-3750
CR Basile C, 2020, NEPHROL DIAL TRANSPL, V35, P737, DOI 10.1093/ndt/gfaa069
   [中华医学会肾脏病学分会专家组 Expert Team of Chinese Medical Association Nephrology Branch], 2020, [中华肾脏病杂志, Chinese Journal of Nephrology], V36, P82
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MAHASE E, 2020, BMJ-BRIT MED J, V368, P48071, DOI DOI 10.1136/BMJ.M641
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Park HC, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018782
   Park HC, 2018, KIDNEY RES CLIN PRAC, V37, P8, DOI 10.23876/j.krcp.2018.37.1.8
   Park HC, 2017, KIDNEY RES CLIN PRAC, V36, P111, DOI 10.23876/j.krcp.2017.36.2.111
   World Health Organization, 2020, COR DIS COVID 2019 S
NR 13
TC 4
Z9 4
U1 1
U2 1
PU KOREAN SOC NEPHROLOGY
PI SEOCHO-GU
PA 1401 HYUNDAI KIRIM BLDG, 1330-18 SEOCHO 2-DONG, SEOCHO-GU, SEOUL
   137-858, SOUTH KOREA
SN 2211-9132
EI 2211-9140
J9 KIDNEY RES CLIN PRAC
JI Kidney Res. Clin. Pract.
PD JUN
PY 2020
VL 39
IS 2
BP 145
EP 150
DI 10.23876/j.krcp.20.046
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA MS1GL
UT WOS:000554033000005
PM 32408730
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tarasova, O
   Ivanov, S
   Filimonov, DA
   Poroikov, V
AF Tarasova, Olga
   Ivanov, Sergey
   Filimonov, Dmitry A.
   Poroikov, Vladimir
TI Data and Text Mining Help Identify Key Proteins Involved in the
   Molecular Mechanisms Shared by SARS-CoV-2 and HIV-1
SO MOLECULES
LA English
DT Article
DE data mining; text mining; virus-host interactions; SARS; SARS-CoV-2;
   HIV-1
ID COMPLEMENT ACTIVATION; VIRUS; INTERLEUKIN-6; RESISTANCE; CANCER
AB Viruses can be spread from one person to another; therefore, they may cause disorders in many people, sometimes leading to epidemics and even pandemics. New, previously unstudied viruses and some specific mutant or recombinant variants of known viruses constantly appear. An example is a variant of coronaviruses (CoV) causing severe acute respiratory syndrome (SARS), named SARS-CoV-2. Some antiviral drugs, such as remdesivir as well as antiretroviral drugs including darunavir, lopinavir, and ritonavir are suggested to be effective in treating disorders caused by SARS-CoV-2. There are data on the utilization of antiretroviral drugs against SARS-CoV-2. Since there are many studies aimed at the identification of the molecular mechanisms of human immunodeficiency virus type 1 (HIV-1) infection and the development of novel therapeutic approaches against HIV-1, we used HIV-1 for our case study to identify possible molecular pathways shared by SARS-CoV-2 and HIV-1. We applied a text and data mining workflow and identified a list of 46 targets, which can be essential for the development of infections caused by SARS-CoV-2 and HIV-1. We show that SARS-CoV-2 and HIV-1 share some molecular pathways involved in inflammation, immune response, cell cycle regulation.
C1 [Tarasova, Olga; Ivanov, Sergey; Filimonov, Dmitry A.; Poroikov, Vladimir] Inst Biomed Chem, Dept Bioinformat, Moscow 107076, Russia.
   [Ivanov, Sergey] Pirogov Russian Natl Res Med Univ, Dept Bioinformat, Moscow 107076, Russia.
RP Tarasova, O (corresponding author), Inst Biomed Chem, Dept Bioinformat, Moscow 107076, Russia.
EM olga.a.tarasova@gmail.com; smivanov7@gmail.com;
   dmitry.filimonov@ibmc.msk.ru; vladimir.poroikov@ibmc.msk.ru
RI Ivanov, Sergey M/F-4457-2017; Tarasova, Olga A./F-1248-2017; Poroikov,
   Vladimir/O-2769-2013; Filimonov, Dmitry/F-4463-2017
OI Ivanov, Sergey M/0000-0002-3177-6237; Tarasova, Olga
   A./0000-0002-3723-7832; Poroikov, Vladimir/0000-0001-7937-2621;
   Filimonov, Dmitry/0000-0002-0339-8478
FU Russian Science FoundationRussian Science Foundation (RSF) [19-75-10097]
FX This research was funded by the Russian Science Foundation, grant number
   19-75-10097.
CR Allen AG, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02940
   Alsuliman T, 2020, CURR RES TRANSL MED, V68, P93, DOI 10.1016/j.retram.2020.05.004
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Bateman A, 2017, NUCLEIC ACIDS RES, V45, pD158, DOI 10.1093/nar/gkw1099
   Cantres-Rosario Y, 2013, AIDS, V27, P347, DOI 10.1097/QAD.0b013e32835b3e47
   Cantres-Rosario YM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44463-1
   Capuzzi SJ, 2018, J CHEM INF MODEL, V58, P212, DOI 10.1021/acs.jcim.7b00589
   Carmona-Gutierrez D., 2020, CELL, V7, P119, DOI [10.15698/mic2020.05.715, DOI 10.15698/mic2020.05.715, DOI 10.15698/MIC2020.05.715]
   Chakraborty C, 2020, MOL THER-NUCL ACIDS, V20, P606, DOI 10.1016/j.omtn.2020.04.002
   Chandrasekaran P, 2012, J BIOL CHEM, V287, P41481, DOI 10.1074/jbc.M112.361782
   Chen KC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034240
   Chen XJ, 2014, PROTEIN CELL, V5, P912, DOI 10.1007/s13238-014-0104-6
   Cheng L, 2018, J CLIN INVEST, V128, P4387, DOI 10.1172/JCI99005
   Ciliberto G, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01590-2
   Clay CC, 2014, IMMUN AGEING, V11, DOI 10.1186/1742-4933-11-4
   Dash PK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10366-y
   Diamond MS, 2020, CELL HOST MICROBE, V27, P699, DOI 10.1016/j.chom.2020.04.021
   Divani AA, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104941
   Ford N, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25489
   Gassen NC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13659-4
   Gaudet P, 2011, BRIEF BIOINFORM, V12, P449, DOI 10.1093/bib/bbr042
   Giat E, 2017, AUTOIMMUN REV, V16, P1049, DOI 10.1016/j.autrev.2017.07.022
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holt N, 2010, NAT BIOTECHNOL, V28, P839, DOI 10.1038/nbt.1663
   Hopkins J, 2018, J VIROL, V92, DOI 10.1128/JVI.01179-18
   Hu Y, 2017, J VIROL, V91, DOI 10.1128/JVI.02143-16
   Huik K, 2013, INFECT GENET EVOL, V20, P78, DOI 10.1016/j.meegid.2013.08.008
   Huson MAM, 2015, J INFECT DIS, V212, P474, DOI 10.1093/infdis/jiv074
   JIANG BC, 2020, PHARMACOL THERAPEUT, V212
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Kim JD, 2003, BIOINFORMATICS, V19, pi180, DOI 10.1093/bioinformatics/btg1023
   Kim Ji-Won, 2020, Korean J Intern Med, DOI 10.3904/kjim.2020.224
   Lapierre J, 2018, J NEUROIMMUNE PHARM, V13, P355, DOI 10.1007/s11481-018-9788-3
   Lim SY, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4521
   Lima WG, 2020, ARCH VIROL, V165, P1729, DOI 10.1007/s00705-020-04693-5
   Liu AY, 2020, INFECT DIS CLIN N AM, V34, P211, DOI 10.1016/j.idc.2020.02.003
   Mandal PK, 2014, CELL STEM CELL, V15, P643, DOI 10.1016/j.stem.2014.10.004
   Mastaglio S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108450
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Monaco DC, 2017, CURR TOP MICROBIOL, V407, P31, DOI 10.1007/82_2017_33
   Muema DM, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01529-6
   Nissinen L, 2014, BBA-GEN SUBJECTS, V1840, P2571, DOI 10.1016/j.bbagen.2014.03.007
   Nitkiewicz J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0794-9
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Panagopoulos P, 2020, J CHEMOTHERAPY, DOI 10.1080/1120009X.2020.1775424
   Parang K, 2020, MOLECULES, V25, DOI 10.3390/molecules25102343
   Pawar AY, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105984
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Perricone C, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102468
   Pinero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Pooladanda V, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117765
   Rivera LE, 2014, CURR HIV RES, V12, P111, DOI 10.2174/1570162X12666140526120249
   Sallenave JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01229
   Sayad B, 2020, ARCH MED RES, V51, P577, DOI 10.1016/j.arcmed.2020.04.018
   Sharp PM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006841
   Shi CS, 2014, J IMMUNOL, V193, P3080, DOI 10.4049/jimmunol.1303196
   Sironi M, 2012, J IMMUNOL, V188, P818, DOI 10.4049/jimmunol.1102179
   Soy M, 2020, CLIN RHEUMATOL, V39, P2085, DOI 10.1007/s10067-020-05190-5
   Tabish SA, 2020, J PUBLIC HEALTH RES, V9, P19, DOI 10.4081/jphr.2020.1786
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tarasova OA, 2019, J CHEM INF MODEL, V59, P3635, DOI 10.1021/acs.jcim.9b00164
   Titanji BK, 2017, J GEN VIROL, V98, P821, DOI 10.1099/jgv.0.000728
   Wang XL, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-020-0424-9
   Weydert C, 2016, CURR TOP MED CHEM, V16, P1167, DOI 10.2174/1568026615666150901115106
   Xiao C, 2020, EMERG MICROBES INFEC, V9, P378, DOI 10.1080/22221751.2020.1727299
   Xu Y, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.01.84
   Yin Qing, 2020, Semin Cancer Biol, V67, P117, DOI 10.1016/j.semcancer.2020.03.003
   Yoshii H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019352
   Yu QG, 2010, CELL MOL IMMUNOL, V7, P334, DOI 10.1038/cmi.2010.8
   Zeng WH, 2020, BIOCHEM BIOPH RES CO, V527, P618, DOI 10.1016/j.bbrc.2020.04.136
   Zheng XJ, 2017, J VIROL, V91, DOI [10.1128/JVI.00088-17, 10.1128/jvi.00088-17]
   Zhou GB, 2020, FRONT MED-PRC, V14, P117, DOI 10.1007/s11684-020-0773-x
NR 76
TC 1
Z9 1
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD JUN
PY 2020
VL 25
IS 12
AR 2944
DI 10.3390/molecules25122944
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA MR8WU
UT WOS:000553871800001
PM 32604797
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Garofalo, M
   Staniszewska, M
   Salmaso, S
   Caliceti, P
   Pancer, KW
   Wieczorek, M
   Kuryk, L
AF Garofalo, Mariangela
   Staniszewska, Monika
   Salmaso, Stefano
   Caliceti, Paolo
   Pancer, Katarzyna Wanda
   Wieczorek, Magdalena
   Kuryk, Lukasz
TI Prospects of Replication-Deficient Adenovirus Based Vaccine Development
   against SARS-CoV-2
SO VACCINES
LA English
DT Article
DE SARS-CoV-2; vaccine; adjuvant; adenovirus; COVID-19
ID GENE-THERAPY; IMMUNE-RESPONSES; INNATE IMMUNITY; CORONAVIRUS; VECTORS;
   IMMUNOGENICITY; IMMUNIZATION; ADJUVANTS; EFFICACY; RECEPTOR
AB The current appearance of the new SARS coronavirus 2 (SARS-CoV-2) and it quickly spreading across the world poses a global health emergency. The serious outbreak position is affecting people worldwide and requires rapid measures to be taken by healthcare systems and governments. Vaccinations represent the most effective strategy to prevent the epidemic of the virus and to further reduce morbidity and mortality with long-lasting effects. Nevertheless, currently there are no licensed vaccines for the novel coronaviruses. Researchers and clinicians from all over the world are advancing the development of a vaccine against novel human SARS-CoV-2 using various approaches. Herein, we aim to present and discuss the progress and prospects in the field of vaccine research towards SARS-CoV-2 using adenovirus (AdV) replication deficient-based strategies, with a comprehension that may support research and combat this recent world health emergency.
C1 [Garofalo, Mariangela; Salmaso, Stefano; Caliceti, Paolo] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Via F Marzolo 5, I-35131 Padua, Italy.
   [Staniszewska, Monika] Warsaw Univ Technol, Fac Chem, Chair Drug & Cosmet Biotechnol, Noakowskiego 3, PL-00664 Warsaw, Poland.
   [Pancer, Katarzyna Wanda; Wieczorek, Magdalena; Kuryk, Lukasz] Natl Inst Hyg, Dept Virol, Natl Inst Publ Hlth, Chocimska 24, PL-00791 Warsaw, Poland.
   [Kuryk, Lukasz] Targovax Oy, Clin Sci, Saukonpaadenranta 2, Helsinki 00180, Finland.
RP Garofalo, M (corresponding author), Univ Padua, Dept Pharmaceut & Pharmacol Sci, Via F Marzolo 5, I-35131 Padua, Italy.; Kuryk, L (corresponding author), Natl Inst Hyg, Dept Virol, Natl Inst Publ Hlth, Chocimska 24, PL-00791 Warsaw, Poland.; Kuryk, L (corresponding author), Targovax Oy, Clin Sci, Saukonpaadenranta 2, Helsinki 00180, Finland.
EM mariangela.garofalo@unipd.it; mstaniszewska@ch.pw.edu.pl;
   stefano.salmaso@unipd.it; paolo.caliceti@unipd.it; kpancer@pzh.gov.pl;
   mrechnio@pzh.gov.pl; lkuryk@pzh.gov.pl
RI Kuryk, Lukasz/D-9596-2018
OI Kuryk, Lukasz/0000-0003-1887-6361; Staniszewska,
   Monika/0000-0002-6271-3482; Wieczorek, Magdalena/0000-0001-8770-5131
FU Warsaw University of Technology; EU COST actionEuropean Union
   (EU)European Cooperation in Science and Technology (COST) [CA17140];
   National Science Centre, PolandNational Science Centre, Poland
   [2019/32/C/NZ7/00156, 2018/02/X/NZ7/00727]; University of Padua
   [GARO_SID19_02]
FX M.S. was supported by Warsaw University of Technology; EU COST action
   CA17140 (M.G. & L.K.); SONATINA (2019/32/C/NZ7/00156), National Science
   Centre, Poland (L.K.); MINIATURA (2018/02/X/NZ7/00727), National Science
   Centre, Poland (L.K.); by PRID-J (Grant Number: GARO_SID19_02) funded by
   University of Padua (M.G.).
CR Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   Andre FE, 2003, VACCINE, V21, P593, DOI 10.1016/S0264-410X(02)00702-8
   Badur S, 2020, HUM VACC IMMUNOTHER, V16, P1007, DOI 10.1080/21645515.2020.1740559
   Barouch DH, 2004, J IMMUNOL, V172, P6290, DOI 10.4049/jimmunol.172.10.6290
   Bezstarosti K., 2020, TARGETED PROTEOMICS, DOI [10.1101/2020.04.23.057810, DOI 10.1101/2020.04.23.057810]
   Capasso C, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1319028
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen H, 2010, J VIROL, V84, P10522, DOI 10.1128/JVI.00450-10
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   CLERICI M, 1991, EUR J IMMUNOL, V21, P1345, DOI 10.1002/eji.1830210603
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Crenshaw BJ, 2019, BIOMEDICINES, V7, DOI 10.3390/biomedicines7030061
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Enjuanes L, 2016, ADV VIRUS RES, V96, P245, DOI 10.1016/bs.aivir.2016.08.003
   Francesco N, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20249
   Garofalo M, 2019, J CONTROL RELEASE, V294, P165, DOI 10.1016/j.jconrel.2018.12.022
   Garofalo M, 2019, THERANOSTICS, V9, P5681, DOI 10.7150/thno.34824
   Garofalo M, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100558
   Hartman ZC, 2008, VIRUS RES, V132, P1, DOI 10.1016/j.virusres.2007.10.005
   Hendrickx R, 2014, HUM GENE THER, V25, P265, DOI 10.1089/hum.2014.001
   Hirvinen M, 2015, MOL THER, V23, pS31, DOI 10.1016/S1525-0016(16)33676-0
   Holterman L, 2004, J VIROL, V78, P13207, DOI 10.1128/JVI.78.23.13207-13215.2004
   Institute T.M, COVID 19 TREATM VACC
   Jia WX, 2019, EMERG MICROBES INFEC, V8, P760, DOI 10.1080/22221751.2019.1620083
   Jin H., 2020, STROKE VASC NEUROL, DOI [10.1136/svn-2020-00038232385132, DOI 10.1136/SVN-2020-00038232385132]
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Klugman KP, 2018, P NATL ACAD SCI USA, V115, P12896, DOI 10.1073/pnas.1721095115
   Kuryk L, 2020, J MED VIROL, V92, P1309, DOI 10.1002/jmv.25677
   Kuryk L, 2019, J MED VIROL, V91, P1702, DOI 10.1002/jmv.25501
   Kuryk L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030621
   Kuryk L, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1532763
   Kuryk L, 2019, CANCER GENE THER, V26, P26, DOI 10.1038/s41417-018-0038-x
   Kuryk L, 2018, J MED VIROL, V90, P1669, DOI 10.1002/jmv.25229
   Kuryk L, 2016, INT J CANCER, V139, P1883, DOI 10.1002/ijc.30228
   Lauer KB, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00298-16
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lipiec A., 2018, PZWL, V1, P31
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Lowenstein PR, 2003, GENE THER, V10, P946, DOI 10.1038/sj.gt.3302048
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lucchese G, 2020, CELL MOL IMMUNOL, V17, P539, DOI 10.1038/s41423-020-0377-z
   Modjarrad K, 2019, LANCET INFECT DIS, V19, P1013, DOI 10.1016/S1473-3099(19)30266-X
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Palmu AA, 2014, LANCET INFECT DIS, V14, P205, DOI [10.1016/S1473-3099(13)70338-4, 10.1016]
   Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.0818-9641.2004.01272.x
   Ranki T, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0121-5
   Ranki T, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.958937
   Remy V, 2014, VALUE HEALTH, V17, pA450, DOI 10.1016/j.jval.2014.08.1211
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sharma A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056996
   Sharma PK, 2018, CANCER GENE THER, V25, DOI 10.1038/s41417-017-0002-1
   Singh S, 2019, ADENOVIRUSES, P53, DOI [10.5772/intechopen.79697, DOI 10.5772/INTECHOPEN.79697]
   Small JC, 2011, CURR OPIN VIROL, V1, P241, DOI 10.1016/j.coviro.2011.07.009
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Spiering MJ, 2015, ALCOHOL RES-CURR REV, V37, P171
   Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Vassilev L, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1017702
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wold WSM, 2013, CURR GENE THER, V13, P421
   Zhang B-z, 2020, BIORXIV, DOI [10.1101/2020.04.23.056853, DOI 10.1101/2020.04.23.056853]
   Zhang C, 2016, HUM VACC IMMUNOTHER, V12, P2064, DOI 10.1080/21645515.2016.1165908
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Weigong, 2003, MMWR Surveill Summ, V52, P1
NR 68
TC 2
Z9 2
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD JUN
PY 2020
VL 8
IS 2
AR 293
DI 10.3390/vaccines8020293
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA MR9EY
UT WOS:000553893000001
PM 32531955
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Subramanian, S
   Iles, T
   Ikramuddin, S
   Steer, CJ
AF Subramanian, Subbaya
   Iles, Tinen
   Ikramuddin, Sayeed
   Steer, Clifford J.
TI Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients
SO VACCINES
LA English
DT Article
DE Coronavirus; COVID-19; cytokine storm; ursodeoxycholic acid; clinical
   trial
ID DRUGS
AB Corona Virus Disease 2019 (COVID-19) has affected over 8 million people worldwide. We underscore the potential benefits of conducting a randomized open-label unblinded clinical trial to evaluate the role of ursodeoxycholic acid (UDCA) in the treatment of COVID-19. Some COVID-19 patients are characterized with cytokine storm syndrome that can cause severe and irreversible damage to organs leading to multi-organ failure and death. Therefore, it is critical to control both programmed cell death (apoptosis) and the hyper-immune inflammatory response in COVID-19 patients to reduce the rising morbidity and mortality. UDCA is an existing drug with proven safety profiles that can reduce inflammation and prevent cell death.National Geographicreported that, "China Promotes Bear Bile as Coronavirus Treatment". Bear bile is rich in UDCA, comprising up to 40-50% of the total bile acid. UDCA is a logical and attainable replacement for bear bile that is available in pill form and merits clinical trial consideration.
C1 [Subramanian, Subbaya; Iles, Tinen; Ikramuddin, Sayeed] Univ Minnesota, Dept Surg, Box 242 UMHC, Minneapolis, MN 55455 USA.
   [Steer, Clifford J.] Univ Minnesota, Dept Med & Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
RP Steer, CJ (corresponding author), Univ Minnesota, Dept Med & Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
EM subree@umn.edu; thealy@umn.edu; ikram001@umn.edu; steer001@umn.edu
OI Subramanian, Subbaya/0000-0002-2544-480X
CR Chen YS, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030253
   Cohen J, 2020, SCIENCE, V368, P221, DOI 10.1126/science.368.6488.221
   Daruich A, 2019, MOL VIS, V25, P610
   England James T, 2020, Blood Rev, P100707, DOI 10.1016/j.blre.2020.100707
   Fobar R., CHINA PROMOTES BEAR
   Guo CS, 2016, IMMUNITY, V45, P802, DOI 10.1016/j.immuni.2016.09.008
   Hang SY, 2019, NATURE, V576, P143, DOI 10.1038/s41586-019-1785-z
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Isik S, 2017, ALLERGOL IMMUNOPATH, V45, P339, DOI 10.1016/j.aller.2016.12.003
   Keely SJ, 2019, AM J PHYSIOL-GASTR L, V317, pG872, DOI 10.1152/ajpgi.00163.2019
   Ko WK, 2019, MOL NEUROBIOL, V56, P267, DOI 10.1007/s12035-018-0994-z
   Ko WK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180673
   Lutz C, 2020, HUM GENOMICS, V14, DOI 10.1186/s40246-020-00272-6
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Min JH, 2012, J KOREAN MED SCI, V27, P200, DOI 10.3346/jkms.2012.27.2.200
   Niu FF, 2019, J CELL PHYSIOL, V234, P20057, DOI 10.1002/jcp.28602
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Singanayagam A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04574-1
   Song XY, 2020, NATURE, V577, P410, DOI 10.1038/s41586-019-1865-0
   Soy M, 2020, CLIN RHEUMATOL, V39, P2085, DOI 10.1007/s10067-020-05190-5
   Talebian R, 2020, J PERIODONTOL, V91, P1098, DOI 10.1002/JPER.19-0013
   Vang Sheila, 2014, Glob Adv Health Med, V3, P58, DOI 10.7453/gahmj.2014.017
   Williamson BN, 2020, NATURE, DOI 10.1038/s41586-020-2423-5
   Yang Y, 2020, J ALLERGY CLIN IMMUN, V146, P119, DOI 10.1016/j.jaci.2020.04.027
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 25
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD JUN
PY 2020
VL 8
IS 2
AR 320
DI 10.3390/vaccines8020320
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA MR8QE
UT WOS:000553854600001
PM 32575350
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Narzisi, A
AF Narzisi, Antonio
TI Phase 2 and Later of COVID-19 Lockdown: Is it Possible to Perform Remote
   Diagnosis and Intervention for Autism Spectrum Disorder? An
   Online-Mediated Approach
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE autism; COVID-19; children; diagnosis; intervention; parents; remote
ID OBSERVATION SCHEDULE; CHILDREN; TELEHEALTH; INDIVIDUALS; BEHAVIOR;
   THERAPY
AB COVID-19 is still in phase 2. The lockdown has been significantly reduced compared to phase 1. The centers and institutions that deal with the diagnosis and intervention of children with autism spectrum disorder (ASD) require rapid functional adaptation to respond to patients' needs. The possibility of using technology to activate and manage diagnostic (preliminary diagnosis) and intervention processes should be explored. Two developed telemedicine working models for diagnosis and intervention, including synchronous and asynchronous transmissions, are presented. They are proposals not yet supported by the data. The diagnosis step is composed by two different and consecutives phases: (A) pre-specialistic consultation (PSC) and (B) specialistic assessment. The intervention step implemented well-recognized evidence-based models for preschoolers, school-aged, and older children in an online format. Parents' support is also included. The described working models have the purpose of carrying out preliminary specialistic answers to the families without aiming to replace preferable in-person assessment. Based on previous research findings, the telemedicine approach is accepted by parents, increases their sense of competence, increases the parent intervention adhesion, and improves the social communication competencies for children with ASD. In conclusion, the presented working models must be considered partial responses to the current emergency status and at the same time as possible integrations into traditional approaches.
C1 [Narzisi, Antonio] IRCCS Stella Maris Fdn, I-56018 Pisa, Italy.
RP Narzisi, A (corresponding author), IRCCS Stella Maris Fdn, I-56018 Pisa, Italy.
EM antonio.narzisi@fsm.unipi.it
RI narzisi, antonio/K-3962-2016
OI narzisi, antonio/0000-0003-3996-3827
CR Abidin RR, 2012, PARENTING STRESS IND
   Achenbach T. M., 2000, MANUAL ASEBA PRESCHO
   American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT
   Ausderau KK, 2019, AM J OCCUP THER, V73, DOI 10.5014/ajot.2019.024612
   Balboni G., 2016, VINELAND 2 VINELAND
   Balboni G, 2016, J AUTISM DEV DISORD, V46, P42, DOI 10.1007/s10803-015-2533-3
   Bearss K, 2018, J AUTISM DEV DISORD, V48, P1020, DOI 10.1007/s10803-017-3363-2
   Carter AS, 2011, J CHILD PSYCHOL PSYC, V52, P741, DOI 10.1111/j.1469-7610.2011.02395.x
   CASP, COUNC AUT ORG GUID S
   Colombi C, 2018, AUTISM, V22, P126, DOI 10.1177/1362361316665792
   Constantino J. N., 2005, SOCIAL RESPONSIVENES
   Dawson G, 2010, PEDIATRICS, V125, pE17, DOI 10.1542/peds.2009-0958
   Dunn W., 1999, SENSORY PROFILE HARC
   Fenson L, 2000, APPL PSYCHOLINGUIST, V21, P95, DOI 10.1017/S0142716400001053
   Fusaro VA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093533
   Gioia G.A., 2015, BEHAV RATING INVENTO
   Gotham K, 2007, J AUTISM DEV DISORD, V37, P613, DOI 10.1007/s10803-006-0280-1
   Green J, 2010, LANCET, V375, P2152, DOI 10.1016/S0140-6736(10)60587-9
   Greene J.A, 2019, CISC VIS NETW IND GL
   Greenspan S.I., 1998, CHILD SPECIAL NEEDS
   Grzadzinski R, 2016, J AUTISM DEV DISORD, V46, P2464, DOI 10.1007/s10803-016-2782-9
   Hepburn SL, 2016, AUTISM, V20, P207, DOI 10.1177/1362361315575164
   Ingersoll B, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4913
   James K, 2011, COMPR PSYCHIAT, V52, P715, DOI 10.1016/j.comppsych.2010.11.010
   Johnsson Genevieve, 2019, Rural Remote Health, V19, P5358, DOI 10.22605/RRH5358
   Juarez AP, 2018, J AUTISM DEV DISORD, V48, P2601, DOI 10.1007/s10803-018-3524-y
   Lai MC, 2019, LANCET PSYCHIAT, V6, P819, DOI 10.1016/S2215-0366(19)30289-5
   Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z
   LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145
   Lord C, 2012, ADOS 2 MANUAL 2
   Maenner MJ, 2020, MMWR SURVEILL SUMM, V69, P1, DOI 10.15585/mmwr.ss6904a1
   Narzisi A, 2020, EPIDEMIOL PSYCH SCI, V29, DOI 10.1017/S2045796018000483
   Narzisi A, 2020, BRAIN SCI, P1
   Nazneen N, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.4393
   Parsons D, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.6651
   Peckett H, 2016, AUTISM, V20, P879, DOI 10.1177/1362361315621054
   Rogers S. J., 2012, EARLY START YOUR CHI
   Roid GH, 1997, LEITER INT PERFORMAN
   Rutter M., 2000, SOCIAL COMMUNICATION
   Schopler E, 2010, CHILDHOOD AUTISM RAT
   Schreibman L, 2015, J AUTISM DEV DISORD, V45, P2411, DOI 10.1007/s10803-015-2407-8
   Schutte JL, 2015, TELEMED E-HEALTH, V21, P176, DOI 10.1089/tmj.2014.0011
   Smith CJ, 2017, PSYCHOL ASSESSMENT, V29, P245, DOI 10.1037/pas0000317
   Sparrow SS, 2005, VINELAND 2 VINELAND
   Stainbrook JA, 2019, AUTISM, V23, P1051, DOI 10.1177/1362361318787797
   Sutantio JD, 2020, TELEMED E-HEALTH, DOI 10.1089/tmj.2020.0035
   Sutherland R, 2019, INT J LANG COMM DIS, V54, P281, DOI 10.1111/1460-6984.12440
   Towey MP, 2012, INT J TELEREHABILITA, V4, P73, DOI [10.5195/IJT.2012.6112, 10.5195/ijt.2012.6112]
   Townsend E, 2020, LANCET PSYCHIAT, V7, P381, DOI 10.1016/S2215-0366(20)30150-4
   Vismara LA, 2018, FOCUS AUTISM DEV DIS, V33, P67, DOI 10.1177/1088357616651064
NR 50
TC 2
Z9 2
U1 2
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2020
VL 9
IS 6
AR 1850
DI 10.3390/jcm9061850
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA MR3VM
UT WOS:000553518100001
PM 32545809
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mukherjee, S
   Tworowski, D
   Detroja, R
   Mukherjee, SB
   Frenkel-Morgenstern, M
AF Mukherjee, Sumit
   Tworowski, Dmitry
   Detroja, Rajesh
   Mukherjee, Sunanda Biswas
   Frenkel-Morgenstern, Milana
TI Immunoinformatics and Structural Analysis for Identification of
   Immunodominant Epitopes in SARS-CoV-2 as Potential Vaccine Targets
SO VACCINES
LA English
DT Article
DE SARS-CoV-2; COVID-19; immunodominant epitope; HLA; vaccine target
ID IMMUNE-RESPONSES; PREDICTION; CORONAVIRUS; PNEUMONIA; COVID-19;
   HOMOLOGY; HLA
AB A new coronavirus infection, COVID-19, has recently emerged, and has caused a global pandemic along with an international public health emergency. Currently, no licensed vaccines are available for COVID-19. The identification of immunodominant epitopes for both B- and T-cells that induce protective responses in the host is crucial for effective vaccine design. Computational prediction of potential epitopes might significantly reduce the time required to screen peptide libraries as part of emergent vaccine design. In our present study, we used an extensive immunoinformatics-based approach to predict conserved immunodominant epitopes from the proteome of SARS-CoV-2. Regions from SARS-CoV-2 protein sequences were defined as immunodominant, based on the following three criteria regarding B- and T-cell epitopes: (i) they were both mapped, (ii) they predicted protective antigens, and (iii) they were completely identical to experimentally validated epitopes of SARS-CoV. Further, structural and molecular docking analyses were performed in order to understand the binding interactions of the identified immunodominant epitopes with human major histocompatibility complexes (MHC). Our study provides a set of potential immunodominant epitopes that could enable the generation of both antibody- and cell-mediated immunity. This could contribute to developing peptide vaccine-based adaptive immunotherapy against SARS-CoV-2 infections and prevent future pandemic outbreaks.
C1 [Mukherjee, Sumit; Tworowski, Dmitry; Detroja, Rajesh; Mukherjee, Sunanda Biswas; Frenkel-Morgenstern, Milana] Bar Ilan Univ, Azrieli Fac Med, Canc Genom & BioComp Complex Dis Lab, IL-1311502 Safed, Israel.
RP Frenkel-Morgenstern, M (corresponding author), Bar Ilan Univ, Azrieli Fac Med, Canc Genom & BioComp Complex Dis Lab, IL-1311502 Safed, Israel.
EM sumit.mukherjee@biu.ac.il; dmitwor@gmail.com; rajesh.detroja@biu.ac.il;
   mukhers1@biu.ac.il; milana.morgenstern@biu.ac.il
OI Mukherjee, Sumit/0000-0001-9807-7994
FU PBC (Planning and Budgeting Committee) fellowship from Council of Higher
   Education in Israel; Israel Innovation Authority [66824]; COVID-19 Data
   Science Institute grant, Bar-Ilan University [247017]
FX S.M. was supported by a PBC (Planning and Budgeting Committee)
   fellowship for outstanding post-doctoral researchers from the Council of
   Higher Education in Israel (at the M.F-M. lab). M.F.-M. was supported by
   the Israel Innovation Authority (Kamin grant #66824, 2019-2020) and a
   COVID-19 Data Science Institute grant (#247017), Bar-Ilan University.
   M.F.-M. is a member of the Dangoor Center for Personalized Medicine, and
   a board member of the Data Science Institute (DSI), Bar-Ilan University.
CR Ahmad B, 2019, MICROB PATHOGENESIS, V132, P243, DOI 10.1016/j.micpath.2019.05.010
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Altschul S.F, 2005, BLAST ALGORITHM ENCY
   Anwar S, 2020, CURR PHARM BIOTECHNO, V21, P325, DOI 10.2174/1389201020666191112161743
   Asai A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082839
   Backert L, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0245-0
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bhasin M, 2004, VACCINE, V22, P3195, DOI 10.1016/j.vaccine.2004.02.005
   Blackwell JM, 2009, CLIN MICROBIOL REV, V22, P370, DOI 10.1128/CMR.00048-08
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0
   De Gregorio E, 2012, MICROB BIOTECHNOL, V5, P149, DOI 10.1111/j.1751-7915.2011.00276.x
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Ehreth J, 2003, VACCINE, V21, P596, DOI 10.1016/S0264-410X(02)00623-0
   Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278
   Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Ikram A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34254-5
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Khan A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196484
   Lai ChihCheng, 2020, International Journal of Antimicrobial Agents, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lata Sneh, 2007, V409, P201, DOI 10.1007/978-1-60327-118-9_14
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   London N, 2010, STRUCTURE, V18, P188, DOI 10.1016/j.str.2009.11.012
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lucas M, 2001, INT J EXP PATHOL, V82, P269, DOI 10.1046/j.1365-2613.2001.00204.x
   Mahajan S, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3109-6
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   OBOYLE NM, 2008, CHEM CENT J, V2, DOI DOI 10.1186/1752-153X-2-5
   Patronov A, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120139
   Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12
   Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Powell AM, 2001, CLIN EXP DERMATOL, V26, P427, DOI 10.1046/j.1365-2230.2001.00852.x
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Scarselli M, 2005, TRENDS BIOTECHNOL, V23, P84, DOI 10.1016/j.tibtech.2004.12.008
   Shahid F, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104199
   Singh H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062216
   Soria-Guerra RE, 2015, J BIOMED INFORM, V53, P405, DOI 10.1016/j.jbi.2014.11.003
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   ul Qamar MT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1672-7
   Van Regenmortel MHV, 2009, METHODS MOL BIOL, V524, P3, DOI 10.1007/978-1-59745-450-6_1
   Vanderlugt CJ, 1996, CURR OPIN IMMUNOL, V8, P831, DOI 10.1016/S0952-7915(96)80012-4
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048
   Wang Q, 2008, NAT PROTOC, V3, P1832, DOI 10.1038/nprot.2008.184
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 60
TC 6
Z9 6
U1 2
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD JUN
PY 2020
VL 8
IS 2
AR 290
DI 10.3390/vaccines8020290
PG 17
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA MR3UD
UT WOS:000553514600001
PM 32526960
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fan, ZY
   Chen, LP
   Li, J
   Cheng, X
   Yang, JM
   Tian, C
   Zhang, YJ
   Huang, SP
   Liu, ZJ
   Cheng, JL
AF Fan, Zhenyu
   Chen, Liping
   Li, Jun
   Cheng, Xin
   Yang, Jingmao
   Tian, Cheng
   Zhang, Yajun
   Huang, Shaoping
   Liu, Zhanju
   Cheng, Jilin
TI Clinical Features of COVID-19-Related Liver Functional Abnormality
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Prognosis; Liver Injury; ALP; Antiviral Drug
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS; MECHANISMS; PNEUMONIA;
   OUTBREAK; INJURY
AB BACKGROUND & AIMS: Some patients with SARS-CoV-2 infection have abnormal liver function. We aimed to clarify the features of COVID-19-related liver damage to provide references for clinical treatment.
   METHODS: We performed a retrospective, single-center study of 148 consecutive patients with confirmed COVID-19 (73 female, 75 male; mean age, 50 years) at the Shanghai Public Health Clinical Center from January 20 through January 31, 2020. Patient outcomes were followed until February 19, 2020. Patients were analyzed for clinical features, laboratory parameters (including liver function tests), medications, and length of hospital stay. Abnormal liver function was defined as increased levels of alanine and aspartate aminotransferase, gamma glutamyltransferase, alkaline phosphatase, and total bilirubin.
   RESULTS: Fifty-five patients (37.2%) had abnormal liver function at hospital admission; 14.5% of these patients had high fever (14.5%), compared with 4.3% of patients with normal liver function (P =.027). Patients with abnormal liver function were more likely to be male, and had higher levels of procalcitonin and C-reactive protein. There was no statistical difference between groups in medications taken before hospitalization; a significantly higher proportion of patients with abnormal liver function (57.8%) had received lopinavir/ritonavir after admission compared to patients with normal liver function (31.3%). Patients with abnormal liver function had longer mean hospital stays (15.09 +/- 4.79 days) than patients with normal liver function (12.76 +/- 4.14 days) (P =.021).
   CONCLUSIONS: More than one third of patients admitted to the hospital with SARS-CoV-2 infection have abnormal liver function, and this is associated with longer hospital stay. A significantly higher proportion of patients with abnormal liver function had received lopinavir/ritonavir after admission; these drugs should be given with caution.
C1 [Fan, Zhenyu; Chen, Liping; Li, Jun; Cheng, Xin; Yang, Jingmao; Tian, Cheng; Zhang, Yajun; Huang, Shaoping; Cheng, Jilin] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Gastroenterol & Hepatol, Shanghai 201508, Peoples R China.
   [Liu, Zhanju] Tongji Univ, Shanghai Peoples Hosp 10, Dept Gastroenterol, Shanghai 200072, Peoples R China.
RP Cheng, JL (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Gastroenterol & Hepatol, Shanghai 201508, Peoples R China.; Liu, ZJ (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Gastroenterol, Shanghai 200072, Peoples R China.
EM liuzhanju88@126.com; chengjilin@shphc.org.cn
FU Shanghai Science and Technology CommissionShanghai Science & Technology
   CommitteeScience & Technology Commission of Shanghai Municipality
   (STCSM) [17411969500]; National Science and Technology Major Project
   [2017ZX10203202-003-007]
FX This work was supported in part by Shanghai Science and Technology
   Commission Fund Project 17411969500 and National Science and Technology
   Major Project 2017ZX10203202-003-007. The funder of the study had no
   role in study design, data collection, data analysis, data
   interpretation, or writing of the report.
CR Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   [陈军 Chen Jun], 2020, [中华传染病杂志, Chinese Journal of Infections Diseases], V38, P86
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   China National Health Commission, 2020, DIAGN TREAM SCHEM NE
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Farcas GA, 2005, J INFECT DIS, V191, P193, DOI 10.1086/426870
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guo Y, 2008, VIRUS RES, V133, P4, DOI 10.1016/j.virusres.2007.01.022
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jaeschke H, 2012, DRUG METAB REV, V44, P88, DOI 10.3109/03602532.2011.602688
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Sherman KE, 2005, CLIN INFECT DIS, V41, P1186, DOI 10.1086/444501
   Shi XY, 2005, AM J GASTROENTEROL, V100, P169, DOI 10.1111/j.1572-0241.2005.40377.x
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yancheva N, 2019, INT J STD AIDS, V30, P620, DOI 10.1177/0956462419826723
   Yang Qingbin Lu, 2020, EPIDEMIOLOGICAL CLIN, DOI [10.1101/2020.02.06., DOI 10.1101/2020.02.06]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 23
TC 122
Z9 125
U1 3
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD JUN
PY 2020
VL 18
IS 7
BP 1561
EP 1566
DI 10.1016/j.cgh.2020.04.002
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA MP8JS
UT WOS:000552446400008
PM 32283325
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Sorensen, MS
AF Sorensen, Michala Skovlund
TI Adapting palliative radiation therapy for bone metastases during the
   Covid-19 pandemic: GEMO position paper Response
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Letter
EM michala.skovlund@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212-1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD JUN
PY 2020
VL 22
AR 100286
DI 10.1016/j.jbo.2020.100286
PG 1
WC Oncology
SC Oncology
GA MQ1KG
UT WOS:000552655400008
PM 32274325
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Thureau, S
   Faivre, JC
   Assaker, R
   Biver, E
   Confavreux, CB
   Debiais, F
   Duterque-Coquillaud, M
   Giammarile, F
   Heymann, D
   Lecouvet, FE
   Morardet, L
   Paycha, F
   Body, JJ
   Vieillard, MH
AF Thureau, Sebastien
   Faivre, Jean Christophe
   Assaker, Richard
   Biver, Emmanuel
   Confavreux, Cyrille B.
   Debiais, Francoise
   Duterque-Coquillaud, Martine
   Giammarile, Francesco
   Heymann, Dominique
   Lecouvet, Frederic E.
   Morardet, Laetitia
   Paycha, Frederic
   Body, Jean-Jacques
   Vieillard, Marie-Helene
TI Adapting palliative radiation therapy for bone metastases during the
   Covid-19 pandemic: GEMO position paper
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
ID STEREOTACTIC BODY RADIOTHERAPY; SPINAL-CORD COMPRESSION;
   SINGLE-FRACTION; CANCER
AB The current health crisis caused by COVID-19 is a challenge for oncology treatment, especially when it comes to radiotherapy. Cancer patients are already known to be very fragile and COVID-19 brings about the risk of severe respiratory complications. In order to treat patients safely while protecting medical teams, the entire health care system must optimize the way it approaches prevention and treatment at a time when social distancing is key to stemming this pandemic. All indications and treatment modalities must be re-discussed. This is particularly the case for radiotherapy of bone metastases for which it is possible to reduce the number of sessions, the frequency of transport and the complexity of treatments. These changes will have to be discussed according to the organization of each radiotherapy department and the health situation, while medical teams must remain vigilant about the risks of complications of bone metastases, particularly spinal metastases. In this short piece, the members of the GEMO (the European Study Group of Bone Metastases) offer a number of recommendations to achieve the above objectives, both in general and in relation to five of the most common situations on radiation therapy for bone metastases.
C1 [Thureau, Sebastien] Univ Rouen, Ctr Henri Becquerel, Radiat Dept, Quantif Litis EA 4108, Rouen, France.
   [Faivre, Jean Christophe] Inst Cancerol Lorraine Alexis Vautrin, Radiat Dept, Vanduvre Les Nancy, France.
   [Assaker, Richard] Lille Univ Hosp, Univ Dept Neurosurg, Lille, France.
   [Biver, Emmanuel] Univ Geneva, Geneva Univ Hosp, Div Bone Dis, Geneva, Switzerland.
   [Biver, Emmanuel] Univ Geneva, Fac Med, Geneva, Switzerland.
   [Confavreux, Cyrille B.] Univ Lyon, Ctr Hosp Lyon Sud, UMR 1033,Bone Metastasis Expert Ctr CEMOS, Canc Inst,Hosp Civils Lyon,Rheumatol Dept,INSERM, F-69310 Pierre Benite, France.
   [Debiais, Francoise] CHU Poitiers, Rheumatol Dept, Poitiers, France.
   [Duterque-Coquillaud, Martine] Univ Lille, Inst Pasteur Lille, CHU Lille, CNRS,INSERM,UMR1277, Lille, France.
   [Giammarile, Francesco] Ctr Leon Berard, Nucl Med LUMEN, Lyon, France.
   [Heymann, Dominique] Univ Nantes, Inst Cancerol Ouest, CRCINA, St Herblain, France.
   [Lecouvet, Frederic E.] Univ Catholique Louvain UCLouvain, Clin Univ St Luc, Inst Rech Expt & Clin IREC, Inst Canc Roi Albert 2,Serv Radiol & Imagerie Med, Brussels, Belgium.
   [Morardet, Laetitia] Hop La Pitie Salpetriere, Oncol Dept, Paris, France.
   [Paycha, Frederic] Lariboisiere Univ Hosp, AP HP, Nucl Med Dept, Paris, France.
   [Body, Jean-Jacques] Univ Libre Bruxelles ULB, Dept Med, CHU Brugmann, Brussels, Belgium.
   [Vieillard, Marie-Helene] Lille Univ Hosp, Univ Dept Rheumatol, Lille, France.
   [Vieillard, Marie-Helene] Oscar Lambret Ctr, Lille, France.
   [Vieillard, Marie-Helene] Univ Lille, Inst Pasteur, CNRS, UMR9020,INSERM,UMR1277, Lille, France.
RP Thureau, S (corresponding author), Ctr Henri Becquerel Canc Ctr Unicanc, Acad Dept Radiat Therapy & Med Phys, Rue Amiens, F-76038 Rouen, France.
EM sebastien.thureau@chb.unicancer.fr
OI Heymann, Dominique/0000-0001-7777-0669
CR Bollen L, 2018, EUR J CANCER, V104, P81, DOI 10.1016/j.ejca.2018.08.028
   Filippi AR, 2020, INT J RAD ONCOL BIOL
   Hashmi A, 2016, J NEUROSURG-SPINE, V25, P646, DOI 10.3171/2016.4.SPINE151523
   Hoskin PJ, 2019, JAMA-J AM MED ASSOC, V322, P2084, DOI 10.1001/jama.2019.17913
   Husain ZA, 2017, J NEUROSURG-SPINE, V27, P295, DOI 10.3171/2017.1.SPINE16684
   Kumar A, 2017, CLIN SPINE SURG, V30, P156, DOI 10.1097/BSD.0000000000000528
   Lutz S, 2017, PRACT RADIAT ONCOL, V7, P4, DOI 10.1016/j.prro.2016.08.001
   Lutz S, 2011, INT J RADIAT ONCOL, V79, P965, DOI 10.1016/j.ijrobp.2010.11.026
   Rades D, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-0968-3
   Skeoch GD, 2017, GLOB SPINE J, V7, P272, DOI 10.1177/2192568217699189
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   van der Linden YM, 2004, INT J RADIAT ONCOL, V59, P528, DOI 10.1016/j.ijrobp.2003.10.006
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Willeumier JJ, 2016, RADIOTHER ONCOL, V121, P138, DOI 10.1016/j.radonc.2016.07.009
NR 14
TC 6
Z9 6
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212-1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD JUN
PY 2020
VL 22
AR 100291
DI 10.1016/j.jbo.2020.100291
PG 3
WC Oncology
SC Oncology
GA MQ1KG
UT WOS:000552655400007
PM 32292693
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Phumthum, M
   Balslev, H
AF Phumthum, Methee
   Balslev, Henrik
TI Anti-Infectious Plants of the Thai Karen: A Meta-Analysis
SO ANTIBIOTICS-BASEL
LA English
DT Article
DE ethnobotany; ethnomedicinal plants; infectious diseases; antimicrobial;
   bacterial; fungal; viral; Tinospora crispa; Cleidion javanicum; Litsea
   cubeba
ID TRADITIONAL MEDICINE; CHEMICAL-COMPOSITION
AB Pharmacology has developed many drugs to treat infections, but many people, especially in developing countries, cannot afford to purchase them, and still depend on traditional knowledge and local medicinal plants to fight off infections. In addition, numerous microbes have developed resistance to the pharmaceutical drugs developed to fight them, and for many, such as Covid-19, effective drugs remain to be found. Ethnomedicinal knowledge is useful, not only for local people as a source of medicine for primary health care, but also for new pharmacological discoveries. This study aimed to identify the plants that the Karen, the largest hill-tribe ethnic minority in northern and western Thailand, use for treatments of infectious diseases. We present a meta-analysis of data from 16 ethnobotanical studies of 25 Karen villages with the aim of understanding traditional knowledge and treatments and point to potential plants for further pharmacological development. The Karen used 127 plant species from 59 plant families to treat infections and infectious diseases. The Cultural Important Index (CI) showed that the Leguminosae, Euphorbiaceae, Asteraceae, Lauraceae, Apocynaceae, Menispermaceae, and Lamiaceae were the most commonly used families. As for species,Cleidion javanicum,Tinospora crispa,Litsea cubeba,Aesculus assamica,Tadehagi triquetrum,Senna alata,Tithonia diversifolia,Embelia sessiliflora, andCombretum indicumwere the most commonly used in treatments of infectious diseases. We suggest that these plant species should be the first to be pharmacologically tested for possible development of medicines, and the remaining species registered should subsequently undergo testing.
C1 [Phumthum, Methee] Mahidol Univ, Fac Pharm, Dept Pharmaceut Bot, Bangkok 10400, Thailand.
   [Phumthum, Methee] Mahidol Univ, Sireeruckhacharti Nat Learning Pk, Salaya 73170, Nakhon Pathom, Thailand.
   [Balslev, Henrik] Aarhus Univ, Fac Nat Sci, Dept Biol, DK-8000 Aarhus, Denmark.
RP Phumthum, M (corresponding author), Mahidol Univ, Fac Pharm, Dept Pharmaceut Bot, Bangkok 10400, Thailand.; Phumthum, M (corresponding author), Mahidol Univ, Sireeruckhacharti Nat Learning Pk, Salaya 73170, Nakhon Pathom, Thailand.
EM methee.phu@mahidol.edu; henrik.balslev@bios.au.dk
RI ; Balslev, Henrik/J-9191-2013
OI Phumthum, Methee/0000-0002-1450-3448; Balslev,
   Henrik/0000-0002-7101-7120
FU Mahidol University; Carlsberg FoundationCarlsberg Foundation
FX This research was funded by Mahidol University and the Carlsberg
   Foundation.
CR Achan J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-144
   Acuna-Soto R, 2002, EMERG INFECT DIS, V8, P360, DOI 10.3201/eid0804.010175
   Ahmad W, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00059
   Alves NSF, 2019, J ETHNOPHARMACOL, V232, P90, DOI 10.1016/j.jep.2018.12.021
   Anderson E., 1993, PLANTS PEOPLE GOLDEN
   Bennett BC, 2008, J ETHNOPHARMACOL, V116, P422, DOI 10.1016/j.jep.2007.12.006
   Bloom DE, 2017, P NATL ACAD SCI USA, V114, P4055, DOI 10.1073/pnas.1701410114
   Chiavari-Frederico MO, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227023
   Cook F.E.M., 1995, EC BOT DATA COLLECTI
   Edelman A., 2014, STATE TROPICS 2014 R
   Fabricant DS, 2001, ENVIRON HEALTH PERSP, V109, P69, DOI 10.2307/3434847
   Fred-Jaiyesimi A. A., 2010, Pharmacognosy Journal, V2, P1
   Kaewsangsai K., 2017, ETHNOBOTANY KAREN KH
   Kamwong K., 2010, THESIS
   Kot B, 2019, NAT PROD RES, V33, P3587, DOI 10.1080/14786419.2018.1486314
   Kuspradini H., 2018, F1000RESEARCH, V7, P1839, DOI [10.12688/f1000research.16620.1, DOI 10.12688/F1000RESEARCH.16620.1]
   Lee JH, 2019, PHYTOMEDICINE, V63, DOI 10.1016/j.phymed.2019.153033
   Moerman DE, 1996, J ETHNOPHARMACOL, V52, P1, DOI 10.1016/0378-8741(96)01393-1
   Mohammed A.I.C., 2012, INT J RES AYURVEDA P, V3, P41
   Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501
   Norn Svend, 2005, Dan Medicinhist Arbog, V33, P171
   PHILLIPS O, 1993, ECON BOT, V47, P15, DOI 10.1007/BF02862203
   Phumthum M, 2020, ETHNOBIOL CONSERV, V9, DOI 10.15451/ec2020-05-9.21-1-12
   Phumthum M, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9050220
   Phumthum M, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01125
   Phumthum M, 2019, ECON BOT, V73, P64, DOI 10.1007/s12231-018-9428-0
   Phumthum M, 2018, J ETHNOPHARMACOL, V214, P90, DOI 10.1016/j.jep.2017.12.003
   Pina-Perez MC, 2018, TRENDS FOOD SCI TECH, V72, P114, DOI 10.1016/j.tifs.2017.12.007
   Pooma R., 2014, T SMITINANDS THAI PL
   Potter CW, 2001, J APPL MICROBIOL, V91, P572, DOI 10.1046/j.1365-2672.2001.01492.x
   Premsrirat S., 2004, ETHNOLINGUISTIC MAPS
   Sanseera D, 2012, J ESSENT OIL BEAR PL, V15, P186, DOI 10.1080/0972060X.2012.10644035
   Saslis-Lagoudakis CH, 2012, P NATL ACAD SCI USA, V109, P15835, DOI 10.1073/pnas.1202242109
   Sorasak Sanoprai K.M., KAREN
   Sowmiya K., 2019, INT J SCI TECH RES, V8, P1003
   Srisawat B., 2002, HILL TRIBES THAILAND, V2
   Srithi K, 2019, ECON BOT, V73, P86, DOI 10.1007/s12231-018-9435-1
   Sulaiman F.A., 2016, J TEKNOL, V78, P78, DOI [10.11113/jt.v78.9941, DOI 10.11113/JT.V78.9941]
   Sultana S., 2015, ASIAN PAC J TROP DIS, V5, pS202, DOI DOI 10.1016/S2222-1808(14)60663-0
   Tardio J, 2008, ECON BOT, V62, P24, DOI 10.1007/s12231-007-9004-5
   Thielmann J, 2019, J ESSENT OIL RES, V31, P361, DOI 10.1080/10412905.2019.1611671
   Tipraqsa P, 2009, AGR ECON-BLACKWELL, V40, P43, DOI 10.1111/j.1574-0862.2008.00343.x
   Tu YY, 2011, NAT MED, V17, P1217, DOI 10.1038/nm.2471
   Weckerle CS, 2011, J ETHNOPHARMACOL, V137, P837, DOI 10.1016/j.jep.2011.07.002
   Wolff HG, 1940, J CLIN INVEST, V19, P659, DOI 10.1172/JCI101169
   World Health Organization, 2010, WHO MOD LIST ESS MED
   World Health Organization, 2015, GUID TREATM MAL
   Zhang L, 2014, FITOTERAPIA, V97, P142, DOI 10.1016/j.fitote.2014.05.018
NR 48
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2079-6382
J9 ANTIBIOTICS-BASEL
JI Antibiotics-Basel
PD JUN
PY 2020
VL 9
IS 6
AR 298
DI 10.3390/antibiotics9060298
PG 11
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA MO7BS
UT WOS:000551677100001
PM 32498413
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Singh, AP
   Tousif, S
   Umbarkar, P
   Lal, H
AF Singh, Anand Prakash
   Tousif, Sultan
   Umbarkar, Prachi
   Lal, Hind
TI A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile:
   Potential Implication in COVID-19 Mitigation
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE Hydroxychloroquine; QT prolongation; torsades de pointes; cardiac
   dysfunction; pharmacovigilance analysis; arrhythmias; COVID-19;
   cardiovascular adverse events
AB In light of the favorable outcomes of few small, non-randomized clinical studies, the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to Hydroxychloroquine (HCQ) for hospitalized coronavirus disease 2019 (COVID-19) patients. In fact, subsequent clinical studies with COVID-19 and HCQ have reported limited efficacy and poor clinical benefits. Unfortunately, a robust clinical trial for its effectiveness is not feasible at this emergency. Additionally, HCQ was suspected of causing cardiovascular adverse reactions (CV-AEs), but it has never been directly investigated. The objective of this pharmacovigilance analysis was to determine and characterize HCQ-associated cardiovascular adverse events (CV-AEs). We performed a disproportionality analysis of HCQ-associated CV-AEs using the FDA adverse event reporting system (FAERS) database. The FAERS database, comprising more than 11,901,836 datasets and 10,668,655 patient records with drug-adverse reactions, was analyzed. The disproportionality analysis was used to calculate the reporting odds ratios (ROR) with 95% confidence intervals (CI) to predict HCQ-associated CV-AEs. HCQ was associated with higher reporting of right ventricular hypertrophy (ROR: 6.68; 95% CI: 4.02 to 11.17), left ventricular hypertrophy (ROR: 3.81; 95% CI: 2.57 to 5.66), diastolic dysfunction (ROR: 3.54; 95% CI: 2.19 to 5.71), pericarditis (ROR: 3.09; 95% CI: 2.27 to 4.23), torsades de pointes (TdP) (ROR: 3.05; 95% CI: 2.30 to 4.10), congestive cardiomyopathy (ROR: 2.98; 95% CI: 2.01 to 4.42), ejection fraction decreased (ROR: 2.41; 95% CI: 1.80 to 3.22), right ventricular failure (ROR: 2.40; 95% CI: 1.64 to 3.50), atrioventricular block complete (ROR: 2.30; 95% CI: 1.55 to 3.41) and QT prolongation (ROR: 2.09; 95% CI: 1.74 to 2.52). QT prolongation and TdP are most relevant to the COVID-19 treatment regimen of high doses for a comparatively short period and represent the most common HCQ-associated AEs. The patients receiving HCQ are at higher risk of various cardiac AEs, including QT prolongation and TdP. These findings highlight the urgent need for prospective, randomized, controlled studies to assess the risk/benefit ratio of HCQ in the COVID-19 setting before its widespread adoption as therapy.
C1 [Singh, Anand Prakash; Tousif, Sultan; Umbarkar, Prachi; Lal, Hind] Univ Alabama Birmingham UAB, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
RP Singh, AP; Lal, H (corresponding author), Univ Alabama Birmingham UAB, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
EM apsingh@uabmc.edu; sana80@uab.edu; pumbarkar@uabmc.edu;
   hindlal@uabmc.edu
RI Singh, Anand Prakash/AAK-4979-2020; Umbarkar, Prachi/AAF-1754-2019
OI Singh, Anand Prakash/0000-0002-9409-1366; Umbarkar,
   Prachi/0000-0002-7989-577X; Lal, Hind/0000-0001-8980-9874; Tousif,
   Sultan/0000-0001-6174-6541
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01HL133290, R01HL143074]; American Heart Fellowship
   (AHA) [19POST34460025]
FX This work was supported by research grants to H.L. from the NHLBI
   (R01HL133290, R01HL143074). P.U. is supported by American Heart
   Fellowship (AHA) postdoctoral Fellowship (19POST34460025).
CR Abena PM, 2020, AM J TROP MED HYG, V102, P1184, DOI 10.4269/ajtmh.20-0290
   Anand K., 2019, J COLL CARDIOL CARDI, V1, P172, DOI DOI 10.1016/J.JACCAO.2019.10.006
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Bate A, 2009, PHARMACOEPIDEM DR S, V18, P427, DOI 10.1002/pds.1742
   Bohm R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157753
   Bohm R, 2012, NAT BIOTECHNOL, V30, P137, DOI 10.1038/nbt.2113
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chorin E., 2020, HEART RHYTHM, DOI [10.1016/j.hrthm.2020.05.01432407884, DOI 10.1016/J.HRTHM.2020.05.01432407884]
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Drugs.com, 2020, HYDR SULF MON PROF
   Evans SJW, 2001, PHARMACOEPIDEM DR S, V10, P483, DOI 10.1002/pds.677
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guo T., 2020, JAMA CARDIOL, V2020, DOI 10.1001/jamacardio.2020.101732219356
   Hua A, 2020, EUR HEART J, V41, P2130, DOI 10.1093/eurheartj/ehaa253
   Huang J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61571-5
   Inciardi R.M., 2020, JAMA CARDIOL, DOI [10.1001/jamacardio.2020.109632219357, DOI 10.1001/JAMACARDIO.2020.109632219357]
   Kapoor Aditya, 2020, Indian Pacing Electrophysiol J, V20, P117, DOI 10.1016/j.ipej.2020.04.003
   Kitzman Dalane W., 2000, Cardiology Clinics, V18, P597, DOI 10.1016/S0733-8651(05)70164-8
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Magagnoli J, 2020, MED, DOI [10.1016/j.medj.2020.06.001, DOI 10.1016/J.MEDJ.2020.06.001]
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Mayo Clinic, 2020, GUID PAT RISK DRUG I
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   Meng L, 2019, INT J CLIN PRACT, V73, DOI 10.1111/ijcp.13331
   Meyerowitz EA, 2020, FASEB J, V34, P6027, DOI 10.1096/fj.202000919
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   OHDSI-Observational Health Data Sciences and Informatics, 2020, HYDR SAF POT EFF ANT
   Page RL, 2016, CIRCULATION, V134, pE32, DOI 10.1161/CIR.0000000000000426
   Sacre K, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3895
   Sarayani Amir, 2021, Res Social Adm Pharm, V17, P483, DOI 10.1016/j.sapharm.2020.04.016
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   U.S. Food and Drug Administration, 2020, EUA HYDR SULF HLTH C
   U.S. Food & Drug Administration, 1998, HYDR SULF DRUGS FDA
   US Food & Drug Administration, 2020, FDA CAUT US HYDR CHL
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, COR DIS COVID 2019 S
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 41
TC 3
Z9 3
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2020
VL 9
IS 6
AR 1867
DI 10.3390/jcm9061867
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA MP8WC
UT WOS:000552478600001
PM 32549293
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nikaeen, G
   Abbaszadeh, S
   Yousefinejad, S
AF Nikaeen, Ghazal
   Abbaszadeh, Sepideh
   Yousefinejad, Saeed
TI Application of nanomaterials in treatment, anti-infection and detection
   of coronaviruses
SO NANOMEDICINE
LA English
DT Article
DE antiviral; bio-labeling; coronaviruses; COVID-19; gold nanoparticles;
   protein nanoparticles; severe acute respiratory syndrome coronavirus;
   silver nanoparticles; transmissible gastroenteritis virus; vaccine
   nanotechnology
ID GOLD NANOPARTICLES; ANTIVIRAL ACTIVITY; RAPID DETECTION; VIRUS; NANO;
   NANOTECHNOLOGY; IMMUNOSENSOR; SILVER; NANOMEDICINE; DIAGNOSTICS
AB Nanotechnology and nanomedicine have excellent potential in dealing with a range of different health problems, including viruses, which are considered to be a serious challenge in the medical field. Application of nanobiotechnology could represent a new avenue for the treatment or disinfection of viruses. There is increasing concern regarding the control of coronaviruses, among these, Middle East respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus-2 are well known and dangerous examples. This article aims to provide an overview of recent studies on the effectiveness of nanoparticles as diagnostic or antiviral tools against coronaviruses. The possibilities of effectively using nanomaterials as vaccines and nanosensors in this field are also presented.
C1 [Nikaeen, Ghazal; Abbaszadeh, Sepideh; Yousefinejad, Saeed] Shiraz Univ Med Sci, Inst Hlth, Sch Hlth, Res Ctr Hlth Sci, Shiraz, Iran.
RP Yousefinejad, S (corresponding author), Shiraz Univ Med Sci, Inst Hlth, Sch Hlth, Res Ctr Hlth Sci, Shiraz, Iran.
EM yousefisa@sums.ac.ir
RI Yousefinejad, Saeed/L-1898-2016
OI Yousefinejad, Saeed/0000-0001-5940-1229
FU Shiraz University of Medical Sciences [98-01-106-22094]
FX The support of Shiraz University of Medical Sciences (98-01-106-22094)
   is acknowledged. Special thanks to Reviewers and Editorial office of
   Nanomedicine for their useful comments which improved the quality of
   this article.
CR Afrough B, 2019, CLIN EXP IMMUNOL, V196, P157, DOI 10.1111/cei.13295
   Ahmed SR, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00766
   Ahmed SR, 2017, RSC ADV, V7, P40849, DOI 10.1039/c7ra07175b
   Balasuriya UBR, 2016, FENNERS VET VIROLOGY
   Calderon L, 2013, EUR J PHARM SCI, V48, P216, DOI 10.1016/j.ejps.2012.11.002
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chen YN, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13040430
   Cho IH, 2014, Patent No. [US8673331, 8673331]
   Ciejka J, 2017, MAT SCI ENG C-MATER, V76, P735, DOI 10.1016/j.msec.2017.03.047
   Curtis A, 2001, TRENDS BIOTECHNOL, V19, P97, DOI 10.1016/S0167-7799(00)01536-5
   Du T, 2018, ACS APPL MATER INTER, V10, P4369, DOI 10.1021/acsami.7b13811
   Emerich DF, 2003, EXPERT OPIN BIOL TH, V3, P655, DOI 10.1517/14712598.3.4.655
   Gaikwad A, 2019, ACS APPL BIOMATER, V2, P5829
   Hu CMJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13316-0
   Huang XY, 2019, ACS APPL MATER INTER, V11, P19799, DOI 10.1021/acsami.9b04240
   Ishikawa FN, 2009, ACS NANO, V3, P1219, DOI 10.1021/nn900086c
   Jung SY, 2018, VACCINE, V36, P3468, DOI 10.1016/j.vaccine.2018.04.082
   Kato T, 2019, J BIOTECHNOL, V306, P177, DOI 10.1016/j.jbiotec.2019.10.007
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kim JE, 2016, BIOSENS BIOELECTRON, V80, P543, DOI 10.1016/j.bios.2016.02.015
   Kim YS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01093
   Koh D, 2010, ASIA-PAC J PUBLIC HE, V22, p132S, DOI 10.1177/1010539510373010
   Kumar A, 2013, BIOTECHNOL ADV, V31, P593, DOI 10.1016/j.biotechadv.2012.10.002
   Labhasetwar V, 2007, BIOMEDICAL APPL NANO
   Layqah LA, 2019, MICROCHIM ACTA, V186, DOI 10.1007/s00604-019-3345-5
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Lin LCW, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201807616
   Liu IL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092216
   Loczechin A, 2019, ACS APPL MATER INTER, V11, P42964, DOI 10.1021/acsami.9b15032
   Lv XN, 2014, BIOMATERIALS, V35, P4195, DOI 10.1016/j.biomaterials.2014.01.054
   Mansur HS, 2013, J MATER CHEM B, V1, P1696, DOI 10.1039/c3tb00498h
   Misra R, 2010, DRUG DISCOV TODAY, V15, P842, DOI 10.1016/j.drudis.2010.08.006
   Miyako E, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/7/075106
   Mungrue K., 2014, ADV LAB MED INT, V4, P1
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0392-8
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Poon WL, 2017, NANOTOXICOLOGY, V11, P936, DOI 10.1080/17435390.2017.1382600
   Prasad R, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01014
   Pyrc K, 2007, EXPERT REV ANTI-INFE, V5, P245, DOI 10.1586/14787210.5.2.245
   Riley MK, 2017, NANOMATERIALS-BASEL, V7, DOI 10.3390/nano7050094
   Sekimukai H, 2020, MICROBIOL IMMUNOL, V64, P33, DOI 10.1111/1348-0421.12754
   Staroverov SA, 2011, B EXP BIOL MED+, V151, P436, DOI 10.1007/s10517-011-1350-8
   Streicher RM, 2007, NANOMEDICINE-UK, V2, P861, DOI 10.2217/17435889.2.6.861
   Teengam P, 2017, ANAL CHEM, V89, P5428, DOI 10.1021/acs.analchem.7b00255
   Vaseashta A, 2005, SCI TECHNOL ADV MAT, V6, P312, DOI 10.1016/j.stam.2005.02.018
   Wang HR, 2018, NANO RES, V11, P3244, DOI 10.1007/s12274-017-1858-y
   Wang K, 2017, PAK VET J, V37, P225
   Wei F, 2010, PEDIATR RES, V67, P458, DOI 10.1203/PDR.0b013e3181d361c3
   Weng X, 2018, IEEE SENS J, V18, P4358, DOI 10.1109/JSEN.2018.2829084
   WHO, 2019, MIDDL E RESP SYNDR C
   WHO, 2020, COR DIS COVID 19 PAN
   WHO, 2005, INT HLTH REG
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yang S, 2004, LANCET INFECT DIS, V4, P337, DOI 10.1016/S1473-3099(04)01044-8
   Zaman M, 2013, METHODS, V60, P226, DOI 10.1016/j.ymeth.2013.04.014
NR 55
TC 8
Z9 8
U1 11
U2 19
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PD JUN
PY 2020
VL 15
IS 15
BP 1501
EP 1512
DI 10.2217/nnm-2020-0117
PG 12
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA MO4KH
UT WOS:000551496300005
PM 32378459
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Jin, LR
   Xu, Y
   Yuan, H
AF Jin, Lairun
   Xu, Yan
   Yuan, Hui
TI Effects of four types of integrated Chinese and Western medicines for
   the treatment of COVID-19 in China: a network meta-analysis
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA English
DT Article
DE Coronavirus Infections; Coronavirus; Medicine; Chinese Traditional;
   Drugs; Chinese Herbal; Meta-Analysis
ID EFFICACY
AB OBJECTIVE: Various integrated Chinese and Western medicines might be beneficial for the treatment of Coronavirus disease 2019 (COVID-19). This study aims to evaluate the efficacy of lung computed tomography (CT) of four integrated Chinese and Western medicines in the treatment of COVID-19 using network meta-analysis (NMA).
   METHODS: Multiple databases were consulted to find randomized controlled trials of four different types of integrated Chinese and Western medicines for the treatment of COVID-19. NMA was conducted on the data using Stata (13.0) software. The odds ratio (OR) was calculated. The studies included in this paper were divided into a control group (Western medicine) and an observation group (one of four integrated Chinese and Western medicines).
   RESULTS: 5 eligible publications were identified. A total of 598 cases were included in the study, and the results showed that the four types of integrated Chinese and Western medicines (symptomatic and supportive care with Qingfei Touxie Fuzheng, Lianhua Qingke, and Xuebijing) were significantly superior (P < 0.05) to symptomatic and supportive care alone, except for symptomatic and supportive care with Lianhua Qingwen. The combination of symptomatic and supportive care with Lianhua Qingke had the highest probability of being the most clinically efficacious intervention, with a surface under the cumulative ranking (SUCRA) curve of 85.7.
   CONCLUSIONS: A combination of symptomatic and supportive care with Lianhua Qingke is the best option among the four integrated Chinese and Western medicines considered for the treatment of COVID-19.
C1 [Jin, Lairun; Xu, Yan] Wannan Med Coll, Affiliated Hosp 1, Off Educ Adm, Yijishan Hosp, Wuhu 241001, Anhui, Peoples R China.
   [Yuan, Hui] Wannan Med Coll, Sch Publ Hlth, Wuhu 241001, Anhui, Peoples R China.
RP Xu, Y (corresponding author), Wannan Med Coll, Sch Publ Hlth, 22 Rd Wenchangxi, Wuhu 241002, Anhui, Peoples R China.
EM yuanhui0553@126.com
CR [Anonymous], 2020, Glob Health J, V4, P1, DOI 10.1016/j.glohj.2020.03.001
   Bahji A, 2020, J AFFECT DISORDERS, V269, P154, DOI 10.1016/j.jad.2020.03.030
   Cheng D, 2020, TIANJIN CHIN MED
   Ding X, 2020, MED HERALD
   Jain Amita, 2020, Indian J Pathol Microbiol, V63, P171, DOI 10.4103/IJPM.IJPM_280_20
   Leung PC, 2007, AM J CHINESE MED, V35, P575, DOI 10.1142/S0192415X07005077
   Li X, 2020, INT J INFECT DIS, V94, P128, DOI 10.1016/j.ijid.2020.03.053
   Macdonell M, 2020, HOSP PHARM, DOI 10.1177/0018578720931456
   Sun H, 2020, CHIN J EXPT PRESCRIP
   Vaira LA, 2020, HEAD NECK-J SCI SPEC, V42, P1570, DOI 10.1002/hed.26228
   Yu P, 2020, CHIN J PHARM
   Zhang LY, 2020, AM J CHINESE MED, V48, P763, DOI [10.1142/S0192415X2050038X, 10.1159/000509628]
NR 12
TC 0
Z9 0
U1 1
U2 1
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
EI 1806-9282
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PD JUN
PY 2020
VL 66
IS 6
BP 771
EP 777
DI 10.1590/1806-9282.66.6.771
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA MP0GU
UT WOS:000551893100014
PM 32696884
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Seong, JT
AF Seong, Jin-Taek
TI Group Testing-Based Robust Algorithm for Diagnosis of COVID-19
SO DIAGNOSTICS
LA English
DT Article
DE COVID-19; diagnosis; group testing; posterior probability; robust
   algorithm
ID BOUNDS; CODES
AB At the time of writing, the COVID-19 infection is spreading rapidly. Currently, there is no vaccine or treatment, and researchers around the world are attempting to fight the infection. In this paper, we consider a diagnosis method for COVID-19, which is characterized by a very rapid rate of infection and is widespread. A possible method for avoiding severe infections is to stop the spread of the infection in advance by the prompt and accurate diagnosis of COVID-19. To this end, we exploit a group testing (GT) scheme, which is used to find a small set of confirmed cases out of a large population. For the accurate detection of false positives and negatives, we propose a robust algorithm (RA) based on the maximum a posteriori probability (MAP). The key idea of the proposed RA is to exploit iterative detection to propagate beliefs to neighbor nodes by exchanging marginal probabilities between input and output nodes. As a result, we show that our proposed RA provides the benefit of being robust against noise in the GT schemes. In addition, we demonstrate the performance of our proposal with a number of tests and successfully find a set of infected samples in both noiseless and noisy GT schemes with different COVID-19 incidence rates.
C1 [Seong, Jin-Taek] Mokpo Natl Univ, Dept Convergence Software, Muan 58554, South Korea.
RP Seong, JT (corresponding author), Mokpo Natl Univ, Dept Convergence Software, Muan 58554, South Korea.
EM jtseong@mokpo.ac.kr
FU National Research Foundation of Korea (NRF) - Korean government
   [NRF-2017R1C1B5075823]
FX This paper was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korean government (NRF-2017R1C1B5075823).
CR Aldridge M, 2014, IEEE T INFORM THEORY, V60, P3671, DOI 10.1109/TIT.2014.2314472
   Atia GK, 2012, IEEE T INFORM THEORY, V58, P1880, DOI 10.1109/TIT.2011.2178156
   Baldassini L., 2013, P 2013 IEEE INT S IN
   BARDAVID I, 1993, IEEE T INFORM THEORY, V39, P1671, DOI 10.1109/18.259654
   BARLEV SK, 1990, NAV RES LOG, V37, P647, DOI 10.1002/1520-6750(199010)37:5<647::AID-NAV3220370505>3.0.CO;2-6
   Candes EJ, 2006, IEEE T INFORM THEORY, V52, P489, DOI 10.1109/TIT.2005.862083
   Chan C.L., 2011, P 49 ANN ALL C COMM
   Cover T.M., 2009, ELEMENTS INFORM THEO
   Desmedt Y, 2009, ADV MATH COMMUN, V3, P273, DOI 10.3934/amc.2009.3.273
   Dorfman R, 1943, ANN MATH STAT, V14, P436, DOI 10.1214/aoms/1177731363
   Du DZ, 2006, SER APPL M, V18, P1, DOI 10.1142/9789812773463
   FAN PZ, 1995, IEEE T INFORM THEORY, V41, P1178, DOI 10.1109/18.391266
   Gollier C., 2020, COVID EC
   Key J. D., 1992, DESIGNS THEIR CODES
   Knill E, 1996, J COMPUT BIOL, V3, P395, DOI 10.1089/cmb.1996.3.395
   Laarhoven T., 2013, P 51 ANN ALL C COMM
   MacKay DJC, 1999, IEEE T INFORM THEORY, V45, P399, DOI 10.1109/18.748992
   Mentus C., 2020, ANAL APPL NONADAPTIV, DOI [10.1101/2020.04.05.20050245, DOI 10.1101/2020.04.05.20050245]
   Richardson T., 2008, MODERN CODING THEORY
   Scarlett J, 2019, IEEE T INFORM THEORY, V65, P3646, DOI 10.1109/TIT.2018.2883604
   Sejdinovic D., 2010, P 48 ANN ALL C MONT
   Seong JT, 2019, IEICE T INF SYST, VE102D, P1081, DOI 10.1587/transinf.2018EDL8200
   Sinnott-Armstrong N, 2020, EVALUATION GROUP TES, DOI [10.1101/2020.03.27.20043968, DOI 10.1101/2020.03.27.20043968]
   Varshney L.R., 2007, P 2007 IEEE INF THEO
NR 24
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD JUN
PY 2020
VL 10
IS 6
AR 396
DI 10.3390/diagnostics10060396
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA MO0XP
UT WOS:000551260400001
PM 32545224
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kiekens, C
   Boldrini, P
   Andreoli, A
   Avesani, R
   Gamna, F
   Grandi, M
   Lombardi, F
   Lusuardi, M
   Molteni, F
   Perboni, A
   Negrini, S
AF Kiekens, Carlotte
   Boldrini, Paolo
   Andreoli, Arnaldo
   Avesani, Renato
   Gamna, Federica
   Grandi, Maurizio
   Lombardi, Francesco
   Lusuardi, Mirco
   Molteni, Franco
   Perboni, Alberto
   Negrini, Stefano
TI Rehabilitation and respiratory management in the acute and early
   post-acute phase "Instant paper from the field" on rehabilitation
   answers to the COVID-19 emergency
SO EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE
LA English
DT Article
DE COVID-19; Rehabilitation; Severe acute respiratory syndrome; Respiratory
   therapy
AB COVID-19 is a respiratory infectious disease that can cause respiratory, physical and psychological long-term dysfunctions in patients. First recommendations on respiratory management were published, but they were not based on the specific needs due to COVID-19. In this paper we share the early experiences from the clinical field in Northern Italy, where the epidemic started in February. This paper summarizes the second webinar on COVID-19 (230 live attendees, 11,600 viewers of the recorded version) organized by the Italian Society of Physical and Rehabilitation Medicine about rehabilitation and in particular respiratory management in the acute (Intensive Care Unit [ICU]) and immediate post-acute phases. There is the need to prepare for the post-acute phase. ICU length of stay is relatively long, with immobilization in prone position. Some specific problems are described. including severe muscle weakness and fatigue, joint stiffness, dysphagia, (neuro)psychological problems, impaired functioning concerning mobility, activities of daily life and work. A lot is yet unknown and patients can experience long-term consequences as we know from the literature on the postintensive care syndrome, but COVID-19 has unique features to be investigated and understood. As a colleague stated during the Covinar: this is a marathon, not a sprint....
C1 [Kiekens, Carlotte] Montecatone Rehabil Inst, Spinal Unit, Bologna, Italy.
   [Boldrini, Paolo] Italian Soc Phys & Rehabil Med SIMPER, Rome, Italy.
   [Boldrini, Paolo] European Soc Phys & Rehabil Med ESPRM, Rotterdam, Netherlands.
   [Andreoli, Arnaldo] ASST FBF Sacco, Unita Operat Complessa Riabilitaz Specialist, Milan, Italy.
   [Avesani, Renato] IRCCS Sacro Cuore Don Calabria, Verona, Italy.
   [Gamna, Federica] San Luigi Gonzaga Univ Hosp, Dept Phys Med & Neurorehabil, Turin, Italy.
   [Grandi, Maurizio; Molteni, Franco] Valduce Villa Beretta Hosp, Costa Masnaga, Lecco, Italy.
   [Lombardi, Francesco] IRCCS S Sebastiano Hosp, Neurorehabil Unit, Reggio Emilia, Italy.
   [Lusuardi, Mirco] IRCCS S Sebastiano Hosp, Dept Resp Rehabil & Neuromuscular Rehabil, Reggio Emilia, Italy.
   [Perboni, Alberto] San Luigi Gonzaga Univ Hosp, Unit Pneumol, Turin, Italy.
   [Negrini, Stefano] Univ La Statale, Dept Biomed Surg & Dent Sci, Milan, Italy.
   [Negrini, Stefano] IRCCS, Ist Ortoped Galeazzi, Milan, Italy.
RP Kiekens, C (corresponding author), Montecatone Rehabil Inst, Spinal Unit, Phys & Rehabil Med, Via Montecatone 37, I-40026 Imola, BO, Italy.
EM carlotte.kiekens@montecatone.com
RI Negrini, Stefano/B-6667-2013
OI Negrini, Stefano/0000-0002-1878-2747
CR Boldrini P, 2020, EUR J PHYS REHABIL M
   Chinese Association of Rehabilitation Medicine, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE029, DOI 10.3760/cma.j.cn112147-20200228-00206
   HEYDARI M, 2020, FRONT MED, P1
   Koh GC, 2020, ARCH PHYS MED REHAB
   Lazzeri M, 2020, MONALDI ARCH CHEST D, V90, DOI 10.4081/monaldi.2020.1285
   Mehrholz J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010942.pub2
   Needham DM, 2012, CRIT CARE MED, V40, P502, DOI 10.1097/CCM.0b013e318232da75
   Negrini S, 2020, EUR J PHYS REHABIL M
   Thomas P, 2020, J PHYSIOTHER
NR 9
TC 15
Z9 16
U1 3
U2 6
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 1973-9087
EI 1973-9095
J9 EUR J PHYS REHAB MED
JI Eur. J. Phys. Rehabil. Med.
PD JUN
PY 2020
VL 56
IS 3
BP 323
EP 326
DI 10.23736/S1973-9087.20.06305-4
PG 4
WC Rehabilitation
SC Rehabilitation
GA MO4FU
UT WOS:000551484600011
PM 32293817
DA 2021-01-01
ER

PT J
AU Li, ZL
   Zheng, CJ
   Duan, C
   Zhang, YP
   Li, QL
   Dou, ZL
   Li, JN
   Xia, WG
AF Li, Zhengliang
   Zheng, Chanjuan
   Duan, Can
   Zhang, Yangpu
   Li, Qinglin
   Dou, Zulin
   Li, Jianan
   Xia, Wenguang
TI Rehabilitation needs of the first cohort of post-acute COVID-19 patients
   in Hubei, China
SO EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE
LA English
DT Article
DE COVID-19; Dysfunction; Rehabilitation
ID ANXIETY
AB BACKGROUND: Corona Virus Disease-2019 (COVID-19) is an acute respiratory infectious disease. Despite being clinically cured, some patients still find it difficult to return to their normal life and work due to the varying degree of dysfunctions that they have, as part of the disease's aftereffect. Through this study, we aim to learn more about the dysfunctions and rehabilitation needs of COVID-19 patients.
   METHODS: In this survey, the basic information, dysfunctions, and rehabilitation needs of the hospitalized COVID-19 patients, who were selected by convenience sampling in Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine, were obtained using a self-designed questionnaire. The research was conducted from February 29, 2020 to March 2.2020.
   RESULTS: A total of 280 patients were finally included, who were mainly over 51 years of age (64.2%). The main physical dysfunctions that the patients had were sleep disorders (63.6%), decreased activity endurance (61.4%), and respiratory dysfunction (57.9%), while the main logical dysfunctions included anxiety (62.1%) and fear (50.0%). Rehabilitation that mainly requested by the patients included exercise guidance, dietary instruction, traditional Chinese medicine therapy, physical therapy, and Chinese traditional health exercises.
   CONCLUSIONS: The demand for rehabilitation is high among COVID-19 patients, which requires the quick establishment of a comprehensive and individualized rehabilitation program, to be fulfilled.
C1 [Li, Zhengliang; Zheng, Chanjuan; Duan, Can; Zhang, Yangpu; Li, Qinglin; Xia, Wenguang] Hubei Prov Hosp Integrated Tradit Chinese & Weste, 11 Lingjiaohu Rd, Wuhan 430000, Hubei, Peoples R China.
   [Li, Zhengliang; Zheng, Chanjuan; Duan, Can; Zhang, Yangpu; Li, Qinglin; Xia, Wenguang] Hubei Prov Clin Res Ctr Rehabil Integrated Tradit, Wuhan, Peoples R China.
   [Dou, Zulin] Sun Yat Sen Univ, Dept Rehabil Med, Affiliated Hosp 3, Guangzhou, Peoples R China.
   [Li, Jianan] Nanjing Med Univ, Dept Rehabil Med, Affiliated Hosp 1, Nanjing, Peoples R China.
RP Xia, WG (corresponding author), Hubei Prov Hosp Integrated Tradit Chinese & Weste, 11 Lingjiaohu Rd, Wuhan 430000, Hubei, Peoples R China.
EM docxwg@163.com
FU Ministry of Science and Technology of the People's Republic of
   ChinaMinistry of Science and Technology, China [2020YFC0841600]; Science
   and Technology Department of Hubei Province [2020FCA027]
FX This work was supported by the Ministry of Science and Technology of the
   People's Republic of China [2020YFC0841600] and Science and Technology
   Department of Hubei Province [2020FCA027].
CR Baig AM, 2020, CNS NEUROSCI THER, V26, P499, DOI 10.1111/cns.13372
   China-world health organization COVID-19 joint investigation group, 2020, CHIN WHO NOV COR PNE
   Chinese Association of Rehabilitation Medicine, 2020, CHIN J PHYS MED REHA, V42, P7
   Chinese Association of Rehabilitation Medicine, 2020, CHINESE J TUBERCULOS, V43
   de Voogd JN, 2011, ANXIETY STRESS COPIN, V24, P439, DOI 10.1080/10615806.2010.520081
   Gordon CS, 2019, CHEST, V156, P80, DOI 10.1016/j.chest.2019.04.009
   Hong X, 2009, GEN HOSP PSYCHIAT, V31, P546, DOI 10.1016/j.genhosppsych.2009.06.008
   Lacasse Y, 1996, LANCET, V348, P1115, DOI 10.1016/S0140-6736(96)04201-8
   Lau HMC, 2005, AUST J PHYSIOTHER, V51, P213, DOI 10.1016/S0004-9514(05)70002-7
   Lee SM, 2018, COMPR PSYCHIAT, V87, P123, DOI 10.1016/j.comppsych.2018.10.003
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Likert R, 1932, ARCH PSYCHOL, V140, P55
   Liu Q, 2020, WORLD J MICROB BIOT, V36, DOI 10.1007/s11274-019-2794-7
   Liu XD, 2020, SHANGHAI J TRADIT CH, V54, P9, DOI DOI 10.16305/J.1007-1334.2020.03.003
   National Health Commission of the People's Republic of China, 2020, NAT HLTH COMM CHIN I
   National Health Commission of the People's Republic of China, 2020, DIAGN TREATM NEW COR
   Newton K, 2014, CLIN CHEST MED, V35, P451, DOI 10.1016/j.ccm.2014.06.001
   Siu JYM, 2016, HEALTH EXPECT, V19, P762, DOI 10.1111/hex.12270
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 19
TC 1
Z9 1
U1 3
U2 3
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 1973-9087
EI 1973-9095
J9 EUR J PHYS REHAB MED
JI Eur. J. Phys. Rehabil. Med.
PD JUN
PY 2020
VL 56
IS 3
BP 339
EP 344
DI 10.23736/S1973-9087.20.06298-X
PG 6
WC Rehabilitation
SC Rehabilitation
GA MO4FU
UT WOS:000551484600015
PM 32672029
DA 2021-01-01
ER

PT J
AU Abadias, L
   Estrada-Rodriguez, G
   Estrada, E
AF Abadias, Luciano
   Estrada-Rodriguez, Gissell
   Estrada, Ernesto
TI FRACTIONAL-ORDER SUSCEPTIBLE-INFECTED MODEL: DEFINITION AND APPLICATIONS
   TO THE STUDY OF COVID-19 MAIN PROTEASE
SO FRACTIONAL CALCULUS AND APPLIED ANALYSIS
LA English
DT Article
DE Caputo derivative; Mittag-Leffler matrix functions; susceptible-infected
   model; COVID-19; SARS CoV-2 protease
ID DYNAMICS
AB We propose a model for the transmission of perturbations across the amino acids of a protein represented as an interaction network. The dynamics consists of a Susceptible-Infected (SI) model based on the Caputo fractional-order derivative. We find an upper bound to the analytical solution of this model which represents the worse-case scenario on the propagation of perturbations across a protein residue network. This upper bound is expressed in terms of Mittag-Leffler functions of the adjacency matrix of the network of inter-amino acids interactions. We then apply this model to the analysis of the propagation of perturbations produced by inhibitors of the main protease of SARS CoV-2. We find that the perturbations produced by strong inhibitors of the protease are propagated far away from the binding site, confirming the long-range nature of intra-protein communication. On the contrary, the weakest inhibitors only transmit their perturbations across a close environment around the binding site. These findings may help to the design of drug candidates against this new coronavirus.
C1 [Abadias, Luciano] Univ Zaragoza, Fac Ciencias, Dept Matemat, Zaragoza 50009, Spain.
   [Abadias, Luciano; Estrada, Ernesto] Univ Zaragoza, Inst Univ Matemat & Aplicac, Zaragoza 50009, Spain.
   [Estrada-Rodriguez, Gissell] Univ Pierre & Marie Curie UPMC, Lab Jacques Louis Lions, 4 Pl Jussieu, F-75005 Paris, France.
   [Estrada, Ernesto] Govt Aragon, ARAID Fdn, Zaragoza 50018, Spain.
RP Estrada, E (corresponding author), Univ Zaragoza, Inst Univ Matemat & Aplicac, Zaragoza 50009, Spain.; Estrada, E (corresponding author), Govt Aragon, ARAID Fdn, Zaragoza 50018, Spain.
EM labadias@unizar.es; estradarodriguez@ljll.math.upmc.fr;
   estrada66@unizar.es
RI Estrada, Ernesto/S-7303-2019
OI Estrada, Ernesto/0000-0002-3066-7418
FU DGI-FEDER, of the MCYTS [MTM2016-77710-P, E26-17R]; Fundacion Ibercaja;
   Universidad de Zaragoza, Spain
FX The first author has been partly supported by Project MTM2016-77710-P,
   DGI-FEDER, of the MCYTS, Project E26-17R, D.G. Aragon, and Project for
   Young Researchers, Fundacion Ibercaja and Universidad de Zaragoza,
   Spain.
CR Abadias L, 2018, TOPOL METHOD NONL AN, V52, P707, DOI 10.12775/TMNA.2018.038
   Abadias L, 2016, BANACH J MATH ANAL, V10, P169, DOI 10.1215/17358787-3345137
   Angstmann CN, 2017, SIAM J APPL MATH, V77, P430, DOI 10.1137/16M1069249
   Bazhlekova E., 1998, FRACT CALC APPL ANAL, V1, P255
   Berry H., 2003, PHYS REV E, V67, P1
   COOPER A, 1984, EUR BIOPHYS J BIOPHY, V11, P103, DOI 10.1007/BF00276625
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   DIETHELM K., 2010, ANAL FRACTIONAL DIFF
   Dubay KH, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002168
   Estrada E, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.056103
   Estrada E, 2012, STRUCTURE COMPLEX NE
   Estrada E, 2020, CHAOS, V30, DOI 10.1063/5.0013029
   Estrada E, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.026102
   Fulger D, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.021122
   Garrappa R, 2018, J SCI COMPUT, V77, P129, DOI 10.1007/s10915-018-0699-5
   Garrappa R, 2015, SIAM J NUMER ANAL, V53, P1350, DOI 10.1137/140971191
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Goren~o R., 2001, TRENDS MATH, P171180
   Gorenflo R., 2014, MITTAG LEFFER FUNCTI
   Hu G, 2013, CURR PROTEIN PEPT SC, V14, P121, DOI 10.2174/1389203711314020004
   Latora V., 2017, COMPLEX NETWORKS PRI
   Lu SY, 2018, DRUG DISCOV TODAY, V23, P359, DOI 10.1016/j.drudis.2017.10.001
   Mainardi F, 2000, J COMPUT APPL MATH, V118, P283, DOI 10.1016/S0377-0427(00)00294-6
   Mainardi F., 2010, FRACTIONAL CALCULUS
   Matychyn I., 2017, ARXIV170601538
   Mei WJ, 2017, ANNU REV CONTROL, V44, P116, DOI 10.1016/j.arcontrol.2017.09.002
   Miotto M, 2020, J CHEM INF MODEL, V60, P1884, DOI 10.1021/acs.jcim.9b01027
   Mishra SK, 2019, ANALOG INTEGR CIRC S, V100, P377, DOI 10.1007/s10470-018-1328-9
   Mugnolo D, 2018, DISCRETE CONT DYN-B, V23, P1945, DOI 10.3934/dcdsb.2018190
   Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751
   Paris RB, 2002, P ROY SOC A-MATH PHY, V458, P3041, DOI 10.1098/rspa.2002.0977
   Podlubny I., 1999, FRACTIONAL DIFFERENT
   Protein Data Bank, 2019, NUCLEIC ACIDS RES, V47, P520
   Sadeghi A, 2018, APPL MATH COMPUT, V338, P733, DOI 10.1016/j.amc.2018.06.037
   Sharma N, 2019, 2019 7TH INTERNATIONAL CONFERENCE ON ROBOT INTELLIGENCE TECHNOLOGY AND APPLICATIONS (RITA), P199, DOI 10.1109/RITAPP.2019.8932889
   Whitley MJ, 2009, CURR PROTEIN PEPT SC, V10, P116, DOI 10.2174/138920309787847563
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu FY, 2015, INT J ADV ROBOT SYST, V12, DOI 10.5772/60865
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 40
TC 1
Z9 1
U1 5
U2 5
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1311-0454
EI 1314-2224
J9 FRACT CALC APPL ANAL
JI Fract. Calc. Appl. Anal.
PD JUN
PY 2020
VL 23
IS 3
BP 635
EP 655
DI 10.1515/fca-2020-0033
PG 21
WC Mathematics, Applied; Mathematics, Interdisciplinary Applications;
   Mathematics
SC Mathematics
GA MN6WQ
UT WOS:000550984400003
DA 2021-01-01
ER

PT J
AU Meijer, EFJ
   Dofferhoff, ASM
   Hoiting, O
   Buil, JB
   Meis, JF
AF Meijer, Eelco F. J.
   Dofferhoff, Anton S. M.
   Hoiting, Oscar
   Buil, Jochem B.
   Meis, Jacques F.
TI Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an
   Immunocompetent Host: A Case Report
SO JOURNAL OF FUNGI
LA English
DT Article
DE SARS-CoV-2; co-infection; pulmonary aspergillosis; ICU;
   azole-resistantAspergillus; Aspergillus fumigatus; CAPA; TR(34)L98H
ID BRONCHOALVEOLAR LAVAGE FLUID; CRITICALLY-ILL PATIENTS; LATERAL-FLOW
   DEVICE; BETA-D-GLUCAN; FUNGAL DISEASES; GALACTOMANNAN; DIAGNOSIS;
   FUMIGATUS
AB COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients with severe pulmonary abnormalities treated in intensive care units. Delays in diagnosis contribute to a delayed start of antifungal therapy. In addition, the emergence of resistance to triazole antifungal agents puts emphasis on early surveillance for azole-resistantAspergillusspecies. We present a patient with putative CAPA due toAspergillus fumigatuswith identification of a triazole-resistant isolate during therapy. We underline the challenges faced in the management of these cases, the importance of early diagnosis and need for surveillance given the emergence of triazole resistance.
C1 [Meijer, Eelco F. J.; Buil, Jochem B.; Meis, Jacques F.] Radboud Univ Nijmegen, Dept Med Microbiol, Med Ctr, NL-6500 HB Nijmegen, Netherlands.
   [Meijer, Eelco F. J.; Buil, Jochem B.; Meis, Jacques F.] Ctr Expertise Mycol Radboudumc CWZ, NL-6532 SZ Nijmegen, Netherlands.
   [Meijer, Eelco F. J.; Dofferhoff, Anton S. M.; Meis, Jacques F.] Canisius Wilhelmina Hosp CWZ, Dept Med Microbiol & Infect Dis, NL-6532 SZ Nijmegen, Netherlands.
   [Dofferhoff, Anton S. M.] Canisius Wilhelmina Hosp CWZ, Dept Internal Med, NL-6532 SZ Nijmegen, Netherlands.
   [Hoiting, Oscar] Canisius Wilhelmina Hosp CWZ, Dept Intens Care Med, NL-6532 SZ Nijmegen, Netherlands.
   [Meis, Jacques F.] Univ Fed Parana, Bioproc Engn & Biotechnol Grad Program, BR-81531970 Curitiba, Parana, Brazil.
RP Meis, JF (corresponding author), Radboud Univ Nijmegen, Dept Med Microbiol, Med Ctr, NL-6500 HB Nijmegen, Netherlands.; Meis, JF (corresponding author), Ctr Expertise Mycol Radboudumc CWZ, NL-6532 SZ Nijmegen, Netherlands.; Meis, JF (corresponding author), Canisius Wilhelmina Hosp CWZ, Dept Med Microbiol & Infect Dis, NL-6532 SZ Nijmegen, Netherlands.; Meis, JF (corresponding author), Univ Fed Parana, Bioproc Engn & Biotechnol Grad Program, BR-81531970 Curitiba, Parana, Brazil.
EM Eelco.Meijer@radboudumc.nl; A.Dofferhoff@cwz.nl; O.Hoiting@cwz.nl;
   Jochem.Buil@radboudumc.nl; jacques.meis@gmail.com
RI JF, Meis/A-9241-2010
OI JF, Meis/0000-0003-3253-6080; Meijer, Eelco/0000-0002-0226-024X
CR Acosta J, 2012, EUR J CLIN MICROBIOL, V31, P721, DOI 10.1007/s10096-011-1365-0
   Acosta J, 2011, CLIN MICROBIOL INFEC, V17, P1053, DOI 10.1111/j.1469-0691.2010.03357.x
   Ahmad S, 2015, J ANTIMICROB CHEMOTH, V70, P412, DOI 10.1093/jac/dku410
   Alanio A, 2020, LANCET RESP MED, V8, pE48, DOI 10.1016/S2213-2600(20)30237-X
   Blaize M, 2020, EMERG INFECT DIS, V26, P1636, DOI 10.3201/eid2607.201603
   Blot S, 2019, CURR OPIN CRIT CARE, V25, P430, DOI 10.1097/MCC.0000000000000637
   Blot SI, 2012, AM J RESP CRIT CARE, V186, P56, DOI 10.1164/rccm.201111-1978OC
   Boch T, 2018, J CRIT CARE, V47, P198, DOI 10.1016/j.jcrc.2018.07.001
   Buil JB, 2020, MYCOSES, V63, P625, DOI 10.1111/myc.13089
   Chowdhary A, 2017, J INFECT DIS, V216, pS436, DOI 10.1093/infdis/jix210
   Chowdhary A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003633
   Clancy Cornelius J, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa524
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   De Vlieger G, 2011, J CLIN MICROBIOL, V49, P3783, DOI 10.1128/JCM.00879-11
   Donnelly JP, 2020, CLIN INFECT DIS, V71, P1367, DOI 10.1093/cid/ciz1008
   Eigl S, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0905-x
   Hoenigl M, 2014, J CLIN MICROBIOL, V52, P2039, DOI 10.1128/JCM.00467-14
   Jenks JD, 2019, MYCOSES, V62, P230, DOI 10.1111/myc.12881
   Johnson GL, 2015, J CLIN MICROBIOL, V53, P2103, DOI 10.1128/JCM.00110-15
   Koehler P, 2020, MYCOSES, V63, P528, DOI 10.1111/myc.13096
   Lahmer T, 2016, J CRIT CARE, V36, P259, DOI 10.1016/j.jcrc.2016.06.026
   Lestrade PPA, 2019, CLIN MICROBIOL INFEC, V25, P799, DOI 10.1016/j.cmi.2018.11.027
   Lestrade PPA, 2020, EMERG INFECT DIS, V26, P1447, DOI 10.3201/eid2607.200088
   Meersseman W, 2008, AM J RESP CRIT CARE, V177, P27, DOI 10.1164/rccm.200704-606OC
   Meis JF, 2016, PHILOS T R SOC B, V371, DOI 10.1098/rstb.2015.0460
   Oostdijk E.A., 2018, SWAB RICHTLIJN SELEC
   Prattes Juergen, 2020, Med Mycol Case Rep, DOI 10.1016/j.mmcr.2020.05.001
   Prokop M, 2020, RADIOLOGY, V296, pE97, DOI 10.1148/radiol.2020201473
   Schauwvlieghe AFAD, 2018, LANCET RESP MED, V6, P782, DOI 10.1016/S2213-2600(18)30274-1
   Singh A, 2020, J FUNGI, V6, DOI 10.3390/jof6020067
   Talento AF, 2018, MYCOSES, V61, P570, DOI 10.1111/myc.12770
   Talento AF, 2017, J CRIT CARE, V40, P119, DOI 10.1016/j.jcrc.2017.03.025
   Ullmann AJ, 2018, CLIN MICROBIOL INFEC, V24, pE1, DOI 10.1016/j.cmi.2018.01.002
   van Arkel ALE, 2020, AM J RESP CRIT CARE, V202, P132, DOI 10.1164/rccm.202004-1038LE
   Vanderbeke L, 2020, CURR FUNGAL INFECT R, V14, P166, DOI 10.1007/s12281-020-00383-6
   Vergidis P, 2020, CLIN MICROBIOL INFEC, V26, P935, DOI 10.1016/j.cmi.2019.11.019
   Verweij Paul E, 2020, Lancet Microbe, V1, pe53, DOI 10.1016/S2666-5247(20)30027-6
   Verweij PE, 2000, J CLIN MICROBIOL, V38, P3900, DOI 10.1128/JCM.38.10.3900-3901.2000
   Wahidi MM, 2020, J BRONCHOL INTERN PU, V27, pE52, DOI 10.1097/LBR.0000000000000681
NR 39
TC 10
Z9 10
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2309-608X
J9 J FUNGI
JI J. Fungi
PD JUN
PY 2020
VL 6
IS 2
AR 79
DI 10.3390/jof6020079
PG 8
WC Microbiology; Mycology
SC Microbiology; Mycology
GA MO0WP
UT WOS:000551257800012
PM 32517166
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lee, J
   Shin, HW
   Lee, JY
   Kim, JS
   Yang, JW
   Lee, KH
   Kronbichler, A
   Shin, JI
AF Lee, Jinhee
   Shin, Han Wul
   Lee, Jun Young
   Kim, Jae Seok
   Yang, Jae Won
   Lee, Keum Hwa
   Kronbichler, Andreas
   Shin, Jae Il
TI A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era
SO MEDICINA-LITHUANIA
LA English
DT Article
DE COVID-19; clinical trials
ID CORTICOSTEROID-THERAPY; REMDESIVIR; EQUIPOISE
AB Background and objective:Despite medical advances, we are facing the unprecedented disaster of the coronavirus disease 2019 (COVID-19) pandemic without available treatments and effective vaccines. As the COVID-19 pandemic has approached its culmination, desperate efforts have been made to seek proper treatments and response strategies, and the number of clinical trials has been rapidly increasing. In this time of the pandemic, it is believed that learning lessons from it would be meaningful in preparing for future pandemics. Thus, this study aims at providing a comprehensive landscape of COVID-19 related clinical trials based on the ClinicalTrials.gov database.Materials and methods:Up to 30 March 2020, we identified a total of 147 eligible clinical trials and reviewed the overview of the studies.Results:Until then, the most clinical trials were set up in China. Treatment approaches are the most frequent purpose of the registered studies. Chloroquine, interferon, and antiviral agents such as remdesivir, lopinavir, and ritonavir are agents under investigation in these trials.Conclusions:In this study, we introduced the promising therapeutic options that many researchers and clinicians are interested in, and to address the hidden issues behind clinical trials in this COVID-19 pandemic.
C1 [Lee, Jinhee] Yonsei Univ, Wonju Coll Med, Dept Psychiat, Wonju Kangwon 26426, South Korea.
   [Shin, Han Wul; Lee, Jun Young; Kim, Jae Seok; Yang, Jae Won] Yonsei Univ, Wonju Coll Med, Dept Nephrol, Wonju Kangwon 26426, South Korea.
   [Lee, Keum Hwa; Shin, Jae Il] Yonsei Univ, Dept Pediat, Coll Med, Yonsei Ro 50,CPO Box 8044, Seoul 03722, South Korea.
   [Kronbichler, Andreas] Med Univ Innsbruck, Dept Internal Med 4, Nephrol & Hypertens, A-6020 Innsbruck, Austria.
RP Shin, JI (corresponding author), Yonsei Univ, Dept Pediat, Coll Med, Yonsei Ro 50,CPO Box 8044, Seoul 03722, South Korea.
EM jinh.lee95@yonsei.ac.kr; dragonshw@yonsei.ac.kr;
   junyoung07@yonsei.ac.kr; ripplesong@yonsei.ac.kr; kidney74@yonsei.ac.kr;
   AZSAGM@yuhs.ac; andreas.kronbichler@i-med.ac.at; shinji@yuhs.ac
RI SHIN, JAE IL/J-6922-2017
OI SHIN, JAE IL/0000-0003-2326-1820; Kronbichler,
   Andreas/0000-0002-2945-2946; yang, jae won/0000-0003-3689-5865; Lee,
   Jinhee/0000-0003-4255-1831; Lee, Keum Hwa/0000-0002-1511-9587; Kim, Jae
   Seok/0000-0002-1350-3526; Lee, Jun Young/0000-0001-8047-4190
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Channappanavar R, 2015, J INFECT DIS, V212, P1894, DOI 10.1093/infdis/jiv325
   De Angelis C, 2004, NEW ENGL J MED, V351, P1250, DOI 10.1056/NEJMe048225
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Deftereos S, 2020, EUR HEART J-CARD PHA, V6, P255, DOI 10.1093/ehjcvp/pvaa033
   Deftereos SG, 2020, HELL J CARDIOL, V61, P42, DOI 10.1016/j.hjc.2020.03.002
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gentile P, 2020, EXPERT OPIN BIOL TH, V20, P711, DOI 10.1080/14712598.2020.1761322
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Greisen G, 2016, ACTA PAEDIATR, V105, P1259, DOI 10.1111/apa.13549
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Mehta N., 2020, AM J EMERG MED, DOI [10.1016/j.ajem.2020.04.035, DOI 10.1016/J.AJEM.2020.04.035]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Misawa T, 2013, NAT IMMUNOL, V14, P454, DOI 10.1038/ni.2550
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Morra ME, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1977
   Rabinstein AA, 2016, CIRC RES, V119, P798, DOI 10.1161/CIRCRESAHA.116.309594
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Taccone FS, 2020, LANCET RESP MED, V8, P539, DOI 10.1016/S2213-2600(20)30172-7
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weijer C, 2000, BMJ-BRIT MED J, V321, P756, DOI 10.1136/bmj.321.7263.756
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang SY, 2020, CLIN DRUG INVEST, V40, P511, DOI 10.1007/s40261-020-00917-3
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 38
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD JUN
PY 2020
VL 56
IS 6
AR 315
DI 10.3390/medicina56060315
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA MN9TU
UT WOS:000551182800051
PM 32604775
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lo, JJ
   Wang, SC
   Lee, HY
   Lee, SS
   Lee, HC
   Hung, CT
   Huang, SH
AF Lo, Jing-Jou
   Wang, Su-Chen
   Lee, Hsiu-Ying
   Lee, Su-Shin
   Lee, Hsiao-Chen
   Hung, Ching-Tzu
   Huang, Shu-Hung
TI Proactive COVID-19 Infection Prevention Measures in a Hyperbaric Oxygen
   Therapy Center
SO MEDICINA-LITHUANIA
LA English
DT Letter
DE coronavirus disease 2019; SARS-CoV-2; infection control; cross
   infection; HBOT
AB Since the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China in December 2019 and its subsequent global spread, Taiwan has been combatting this pandemic. COVID-19 is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As SARS-CoV-2 can be transmitted through droplets and aerosols, we cannot ignore the risk of transmission during hyperbaric oxygen therapy (HBOT). Our hyperbaric oxygen therapy center prioritizes preventing the spread of COVID-19 and maintaining operation for the patients during the pandemic. The aim of this article is to share the protocol that we have adopted in our hyperbaric oxygen therapy center to help prevent the spread of COVID-19.
C1 [Lo, Jing-Jou] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Gen Med, Kaohsiung 807, Taiwan.
   [Wang, Su-Chen; Lee, Hsiu-Ying; Lee, Su-Shin; Lee, Hsiao-Chen; Huang, Shu-Hung] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hyperbar Oxygen Therapy Ctr, Kaohsiung 807, Taiwan.
   [Wang, Su-Chen; Lee, Hsiu-Ying; Lee, Su-Shin; Lee, Hsiao-Chen; Huang, Shu-Hung] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Plast Surg, Kaohsiung 807, Taiwan.
   [Hung, Ching-Tzu] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Infect Control Ctr, Kaohsiung 807, Taiwan.
   [Huang, Shu-Hung] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Surg, Kaohsiung 807, Taiwan.
RP Huang, SH (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hyperbar Oxygen Therapy Ctr, Kaohsiung 807, Taiwan.; Huang, SH (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Plast Surg, Kaohsiung 807, Taiwan.; Huang, SH (corresponding author), Kaohsiung Med Univ, Coll Med, Sch Med, Dept Surg, Kaohsiung 807, Taiwan.
EM ljingjou@gmail.com; h870812@yahoo.com.tw; 910033@kmuh.org.tw;
   sushin@kmu.edu.tw; s640125@yahoo.com.tw; 830293@kmuh.org.tw;
   huangsh63@gmail.com
OI Lo, Jing-Jou/0000-0003-2314-005X; Huang, Shu-Hung/0000-0002-2903-1703
FU Kaohsiung Medical University Hospital [KMUH108-8R30]
FX We acknowledge the grant support for this study provided by the
   Kaohsiung Medical University Hospital (KMUH108-8R30).
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Ferioli M, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0068-2020
   Gautier JF, 2020, OBESITY, V28, P848, DOI 10.1002/oby.22809
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Taiwan Centers for Disease Control, 20200514 TAIW CDC
   Taiwan Centers for Disease Control, GUID INF CONTR MED I
   Undersea & Hyperbaric Medical Society, HYPERBARIC OXYGEN TH
   World Health Organization, 115 WHO
   World Health Organization, RAT US PERS PROT EQ
   Yu XX, 2020, INFLUENZA OTHER RESP, V14, P474, DOI 10.1111/irv.12743
NR 12
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD JUN
PY 2020
VL 56
IS 6
AR 261
DI 10.3390/medicina56060261
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MN9TU
UT WOS:000551182800031
PM 32471203
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Stachowska, E
   Folwarski, M
   Jamiol-Milc, D
   Maciejewska, D
   Skonieczna-Zydecka, K
AF Stachowska, Ewa
   Folwarski, Marcin
   Jamiol-Milc, Dominika
   Maciejewska, Dominika
   Skonieczna-Zydecka, Karolina
TI Nutritional Support in Coronavirus 2019 Disease
SO MEDICINA-LITHUANIA
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus; nutrition support; nutrition
ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL; VITAMIN-D; ZINC; PREVALENCE;
   PNEUMONIA; INFECTION; DYSPHAGIA; SEVERITY; THERAPY
AB The epidemic that broke out in Chinese Wuhan at the beginning of 2020 presented how important the rapid diagnosis of malnutrition (elevating during intensive care unit stay) and the immediate implementation of caloric and protein-balanced nutrition care are. According to specialists from the Chinese Medical Association for Parenteral and Enteral Nutrition (CSPEN), these activities are crucial for both the therapy success and reduction of mortality rates. The Chinese have published their recommendations including principles for the diagnosis of nutritional status along with the optimal method for nutrition supply including guidelines when to introduce education approach, oral nutritional supplement, tube feeding, and parenteral nutrition. They also calculated energy demand and gave their opinion on proper monitoring and supplementation of immuno-nutrients, fluids and macronutrients intake. The present review summarizes Chinese observations and compares these with the latest European Society for Clinical Nutrition and Metabolism guidelines. Nutritional approach should be an inseparable element of therapy in patients with COVID-19.
C1 [Stachowska, Ewa; Jamiol-Milc, Dominika; Maciejewska, Dominika; Skonieczna-Zydecka, Karolina] Pomeranian Med Univ, Dept Human Nutr & Metabol, PL-71460 Szczecin, Poland.
   [Folwarski, Marcin] Med Univ Gdansk, Dept Clin Nutr & Dietet, PL-80210 Gdansk, Poland.
   [Folwarski, Marcin] Nicolaus Copernicus Hosp, Home Enteral & Parenteral Nutr Unit, PL-80803 Gdansk, Poland.
RP Stachowska, E (corresponding author), Pomeranian Med Univ, Dept Human Nutr & Metabol, PL-71460 Szczecin, Poland.
EM ewast@pum.edu.pl; marcinfol@gmail.com; dominika.jamiol@pum.edu.pl;
   dmaciejewska.pum@gmail.com; karzyd@pum.edu.pl
RI Maciejewska, Dominika/T-9081-2018; Skonieczna-Zydecka,
   Karolina/K-7252-2014
OI Maciejewska, Dominika/0000-0002-2293-6489; Folwarski,
   Marcin/0000-0002-7301-1689; Skonieczna-Zydecka,
   Karolina/0000-0002-3430-9079
CR Belafsky PC, 2008, ANN OTO RHINOL LARYN, V117, P919, DOI 10.1177/000348940811701210
   Besecker BY, 2011, AM J CLIN NUTR, V93, P1356, DOI 10.3945/ajcn.110.008417
   Burk M, 2016, EUR RESPIR REV, V25, P178, DOI 10.1183/16000617.0076-2015
   Cabre M, 2010, AGE AGEING, V39, P39, DOI 10.1093/ageing/afp100
   Calder PC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041181
   Campbell Christina Gayer, 2005, Nutr Clin Pract, V20, P276, DOI 10.1177/0115426505020002276
   Cander B, 2011, J CRIT CARE, V26, P42, DOI 10.1016/j.jcrc.2010.06.002
   Cascella M, FEATURES EVALUATION
   Cereda E, 2016, CLIN NUTR, V35, P1282, DOI 10.1016/j.clnu.2016.03.008
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Christopher KB, 2016, CURR OPIN CRIT CARE, V22, P332, DOI 10.1097/MCC.0000000000000328
   Davison JM, 2019, NUTRITION, V59, P29, DOI 10.1016/j.nut.2018.07.017
   Ferrie S, 2016, JPEN-PARENTER ENTER, V40, P795, DOI 10.1177/0148607115618449
   Frankenfield DC, 2009, JPEN-PARENTER ENTER, V33, P27, DOI 10.1177/0148607108322399
   Han JE, 2016, J CLIN TRANSL ENDOCR, V4, P59, DOI 10.1016/j.jcte.2016.04.004
   He F, 2020, J MED VIROL, V92, P719, DOI [10.1002/jmv.25766, 10.3171/2020.3.JNS193202]
   Holter JC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148741
   Jiang H, 2011, CLIN NUTR, V30, P730, DOI 10.1016/j.clnu.2011.05.006
   Langlois PL, 2018, CLIN NUTR, V37, P1238, DOI 10.1016/j.clnu.2017.05.006
   Lee YH, 2019, BIOL TRACE ELEM RES, V188, P316, DOI 10.1007/s12011-018-1429-4
   Li X Y, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE026, DOI 10.3760/cma.j.cn112147-20200224-00159
   Linko R, 2011, ACTA ANAESTH SCAND, V55, P615, DOI 10.1111/j.1399-6576.2011.02425.x
   Liu J., 2020, J CLIN MED, V27, P1
   Manzanares W, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1434-y
   McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI 10.1177/0148607115621863
   Park MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075368
   Perren A, 2019, DYSPHAGIA, V34, P475, DOI 10.1007/s00455-019-09977-w
   Port AM, 2010, CURR OPIN CLIN NUTR, V13, P184, DOI 10.1097/MCO.0b013e328335f1e6
   Rech M, 2014, NUTR CLIN PRACT, V29, P78, DOI 10.1177/0884533613515724
   Reignier J, 2015, INTENS CARE MED, V41, P875, DOI 10.1007/s00134-015-3730-4
   ROBINSON JD, 1983, AM J HOSP PHARM, V40, P1016, DOI 10.1093/ajhp/40.6.1016
   Schefold JC, 2017, CRIT CARE MED, V45, P2061, DOI 10.1097/CCM.0000000000002765
   Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037
   Skalny AV, 2020, INT J MOL MED, V46, P17, DOI 10.3892/ijmm.2020.4575
   Sorensen J, 2008, CLIN NUTR, V27, P340, DOI 10.1016/j.clnu.2008.03.012
   Stefanowicz F, 2014, J CRIT CARE, V29, P214, DOI 10.1016/j.jcrc.2013.10.012
   Tian F, 2018, CRIT CARE MED, V46, P1049, DOI 10.1097/CCM.0000000000003152
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang DP, 2020, IMMUNOLOGY, V159, P156, DOI 10.1111/imm.13139
   Yeo HJ, 2019, KOREAN J INTERN MED, V34, P841, DOI 10.3904/kjim.2018.037
   Youn HN, 2012, ANTIVIR RES, V93, P138, DOI 10.1016/j.antiviral.2011.11.004
   Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zuercher P, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2400-2
NR 44
TC 4
Z9 5
U1 4
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD JUN
PY 2020
VL 56
IS 6
AR 289
DI 10.3390/medicina56060289
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA MN9TU
UT WOS:000551182800008
PM 32545556
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Palmeira, A
   Sousa, E
   Koseler, A
   Sabirli, R
   Goren, T
   Turkcuer, I
   Kurt, O
   Pinto, MM
   Vasconcelos, MH
AF Palmeira, Andreia
   Sousa, Emilia
   Koseler, Aylin
   Sabirli, Ramazan
   Goren, Tarik
   Turkcuer, Ibrahim
   Kurt, Ozgur
   Pinto, Madalena M.
   Helena Vasconcelos, M.
TI Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which
   May Interfere with SARS-CoV-2 Infection
SO PHARMACEUTICALS
LA English
DT Article
DE Covid-19; SARS-CoV-2; GRP78; gene expression; virtual screening;
   antiviral; repurposed drugs
ID TYROSINE KINASE INHIBITOR; BINDING-SITE; CHAPERONE; CORONAVIRUS; CELLS;
   RESISTANCE; TARGETS; DRUGS; HSP70
AB SARS-CoV-2 Spike protein was predicted by molecular docking to bind the host cell surface GRP78, which was suggested as a putative good molecular target to inhibit Covid-19. We aimed to confirm that GRP78 gene expression was increased in blood of SARS-CoV-2 (+) versus SARS-CoV-2 (-) pneumonia patients. In addition, we aimed to identify drugs that could be repurposed to inhibit GRP78, thus with potential anti-SARS-CoV-2 activity. Gene expression studies were performed in 10 SARS-CoV-2 (-) and 24 SARS-CoV-2 (+) pneumonia patients. A structure-based virtual screen was performed with 10,761 small molecules retrieved from DrugBank, using the GRP78 nucleotide binding domain and substrate binding domain as molecular targets. Results indicated that GRP78 mRNA levels were approximately four times higher in the blood of SARS-CoV-2 (+) versus SARS-CoV-2 (-) pneumonia patients, further suggesting that GRP78 might be a good molecular target to treat Covid-19. In addition, a total of 409 compounds were identified with potential as GRP78 inhibitors. In conclusion, we found preliminary evidence that further proposes GRP78 as a possible molecular target to treat Covid-19 and that many clinically approved drugs bind GRP78 as an off-target effect. We suggest that further work should be urgently carried out to confirm if GRP78 is indeed a good molecular target and if some of those drugs have potential to be repurposed for SARS-CoV-2 antiviral activity.
C1 [Palmeira, Andreia; Sousa, Emilia; Pinto, Madalena M.] Univ Porto, Fac Pharm, Dept Chem Sci, Lab Organ & Pharmaceut Chem LQOF, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.
   [Palmeira, Andreia; Sousa, Emilia; Pinto, Madalena M.] Interdisciplinary Ctr Marine & Environm Res CIIMA, P-4450208 Matosinhos, Portugal.
   [Koseler, Aylin] Pamukkale Univ, Dept Biophys, Fac Med, TR-20190 Denizli, Turkey.
   [Sabirli, Ramazan] Kafkas Univ, Dept Emergency Med, Fac Med, TR-36000 Kars, Turkey.
   [Goren, Tarik; Turkcuer, Ibrahim] Pamukkale Univ, Dept Emergency Med, Fac Med, TR-20190 Denizli, Turkey.
   [Kurt, Ozgur] Acibadem Mehmet Ali Aydinlar Univ, Dept Microbiol, Sch Med, TR-34752 Istanbul, Turkey.
   [Helena Vasconcelos, M.] Univ Porto, Inst Invest & Inovacao Saude i3S, P-4200135 Porto, Portugal.
   [Helena Vasconcelos, M.] Univ Porto IPATIMUP, Canc Drug Resistance Grp, Inst Mol Pathol & Immunol, P-4200135 Porto, Portugal.
   [Helena Vasconcelos, M.] Univ Porto, Fac Pharm, Dept Biol Sci, Lab Microbiol, P-4050313 Porto, Portugal.
RP Koseler, A (corresponding author), Pamukkale Univ, Dept Biophys, Fac Med, TR-20190 Denizli, Turkey.; Vasconcelos, MH (corresponding author), Univ Porto, Inst Invest & Inovacao Saude i3S, P-4200135 Porto, Portugal.; Vasconcelos, MH (corresponding author), Univ Porto IPATIMUP, Canc Drug Resistance Grp, Inst Mol Pathol & Immunol, P-4200135 Porto, Portugal.; Vasconcelos, MH (corresponding author), Univ Porto, Fac Pharm, Dept Biol Sci, Lab Microbiol, P-4050313 Porto, Portugal.
EM andreiapalmeira@gmail.com; esousa@ff.up.pt; akoseler@pau.edu.tr;
   ramazan_sabirli@hotmail.com; tarikgoren92@hotmail.com;
   iturkcuer@pau.edu.trs; ozgur.kurt@acibadem.edu.tr;
   madalenakijjoa@gmail.com; hvasconcelos@ipatimup.pt
RI GOREN, TARIK/ABI-3119-2020; Pinto, Madalena/L-1835-2014; Sousa, Maria
   Emilia/L-1126-2014; Kurt, Ozgur/D-2306-2015
OI GOREN, TARIK/0000-0002-8292-6717; Palmeira, Andreia/0000-0002-1391-2143;
   TURKCUER, IBRAHIM/0000-0001-8342-4615; Pinto,
   Madalena/0000-0002-4676-1409; Sousa, Maria Emilia/0000-0002-5397-4672;
   Koseler, Aylin/0000-0003-4832-0436; Kurt, Ozgur/0000-0001-5575-588X
FU FCT (Foundation for Science and Technology)Portuguese Foundation for
   Science and Technology [UIDB/04423/2020, UIDP/04423/2020]; COMPETE 2020,
   Portugal 2020 [PTDC/SAU-PUB/28736/2017, POCI-01-0145-FEDER-028736];
   European Union through the ERDFEuropean Union (EU); FCTPortuguese
   Foundation for Science and Technology; project "Evaluation of Reticulum
   Stress Markers in Viral Pneumonia Cases"
FX This research was supported by national funds through FCT (Foundation
   for Science and Technology) within the scope of UIDB/04423/2020,
   UIDP/04423/2020, and under the project PTDC/SAU-PUB/28736/2017
   (reference POCI-01-0145-FEDER-028736), co-financed by COMPETE 2020,
   Portugal 2020, the European Union through the ERDF, and by FCT through
   national funds. This research was also financed by project "Evaluation
   of Reticulum Stress Markers in Viral Pneumonia Cases".
CR Aguiar J.A., 2020, GENE EXPRESSION SITU, DOI DOI 10.1101/2020.04.07.030742V2
   Asling J, 2016, CELL STRESS CHAPERON, V21, P1065, DOI 10.1007/s12192-016-0730-4
   Barabutis N, 2019, LUNG, V197, P827, DOI 10.1007/s00408-019-00279-4
   Birukova AA, 2014, MOL BIOL CELL, V25, P2006, DOI 10.1091/mbc.E13-12-0743
   Bromberg Z, 2005, J ANESTH, V19, P236, DOI 10.1007/s00540-005-0308-2
   Chen HH, 2017, ANTIVIR RES, V142, P158, DOI 10.1016/j.antiviral.2017.02.015
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   De Luca A, 2010, IDRUGS, V13, P636
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761881
   Engstrom LD, 2017, CLIN CANCER RES, V23, P6661, DOI 10.1158/1078-0432.CCR-17-1192
   Ermakova SP, 2006, CANCER RES, V66, P9260, DOI 10.1158/0008-5472.CAN-06-1586
   Girona J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111793
   Gurusinghe KRDSNS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22905-6
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Haider T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46034-w
   Hati S, 2020, BIORXIV, DOI [10.1101/2020.05.07.083147, DOI 10.1101/2020.05.07.083147]
   Huang LT, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01453
   Huang MX, 2020, J MOL CELL BIOL, V12, P322, DOI 10.1093/jmcb/mjaa014
   Hughes SJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154862
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Ibrahim IM, 2019, LIFE SCI, V226, P156, DOI 10.1016/j.lfs.2019.04.022
   Kosakowska-Cholody T, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.203
   Koseler A, 2020, IN VIVO, V34, P1645, DOI 10.21873/invivo.11956
   Langdon SP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55096-9
   Langer R, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-70
   Lee A.S., 2019, PATENT APPL PUBLICAT
   Macias AT, 2011, J MED CHEM, V54, P4034, DOI 10.1021/jm101625x
   Martin S, 2013, BRIT J CANCER, V109, P433, DOI 10.1038/bjc.2013.325
   Mehra MR, 2020, LANCET, V395, P18209, DOI [10.1016/S0140-6736(20)31324-6, DOI 10.1016/S0140-6736(20)31324-6]
   Meulenbeld HJ, 2012, EXPERT OPIN INV DRUG, V21, P383, DOI 10.1517/13543784.2012.652303
   Nadeem MS, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9040307
   Nagano T, 2019, DRUG TODAY, V55, P231, DOI 10.1358/dot.2019.55.4.2965337
   Nain M, 2017, J VIROL, V91, DOI [10.1128/JVI.02274-16, 10.1128/jvi.02274-16]
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Paranjpe R, 2019, ANN PHARMACOTHER, V53, P612, DOI 10.1177/1060028018824088
   Quinones QJ, 2008, HISTOL HISTOPATHOL, V23, P1409, DOI 10.14670/HH-23.1409
   Reid SP, 2014, ANTIVIR RES, V109, P171, DOI 10.1016/j.antiviral.2014.07.004
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Serafin MB, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105969
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Spinello A, 2020, J PHYS CHEM LETT, V11, P4785, DOI 10.1021/acs.jpclett.0c01148
   Tan FH, 2019, ONCOTARGETS THER, V12, P635, DOI 10.2147/OTT.S189391
   Triantafilou K, 2002, J VIROL, V76, P633, DOI 10.1128/JVI.76.2.633-643.2002
   Verhagen CVM, 2015, RADIOTHER ONCOL, V116, P358, DOI 10.1016/j.radonc.2015.03.028
   Versteeg GA, 2007, J VIROL, V81, P10981, DOI 10.1128/JVI.01033-07
   Vilar S, 2008, CURR TOP MED CHEM, V8, P1555, DOI 10.2174/156802608786786624
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang N, 2014, CARCINOGENESIS, V35, P2544, DOI 10.1093/carcin/bgu187
   Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu YP, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-128
   Yang J, 2015, STRUCTURE, V23, P2191, DOI 10.1016/j.str.2015.10.012
   Zhang Y, 2010, J BIOL CHEM, V285, P15065, DOI 10.1074/jbc.M109.087445
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 59
TC 3
Z9 3
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD JUN
PY 2020
VL 13
IS 6
AR 132
DI 10.3390/ph13060132
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MO0TH
UT WOS:000551249100029
PM 32630514
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sungurtekin, H
   Arslan, U
   Ozgen, C
   Akbudak, IH
   Kahramanoglu, M
   Erbay, H
   Atalay, H
   Caliskan, A
   Karaduman, S
AF Sungurtekin, Hulya
   Arslan, Ulku
   Ozgen, Cansu
   Akbudak, Ismail Hakki
   Kahramanoglu, Mithat
   Erbay, Hakan
   Atalay, Habip
   Caliskan, Ahmet
   Karaduman, Simay
TI Prognosis of COVID-19 Patients Requiring Intensive Care Unit Care
SO SIGNA VITAE
LA English
DT Article
DE COVID-19; Intensive care; Viral infection
AB Background: There is gobal concern regarding the prognosis of COVID-19 patients requiring care in the Intensive Care Unit (ICU). The aim of this study is to report the demographics, clinical features, comorbidities, imaging findings, and prognosis among critically ill patients with COVID-19 in the ICU. Methods: This retrospective study included patients with laboratory-confirmed COVID-19 infection or clinical and radiological confirmed COVID-19 infection who were admitted to adult ICUs between March 18 and April 22, 2020. Demographic data. the recent exposure history, clinical symptoms. laboratory findings and comorbidities were recorded. Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores were calculated. as well as mechanical ventilation parameters and blood gas results. Results: Twenty-four adult patients were admitted to the ICU with laboratory-confirmed COVID-19 (n = 15) or clinical and radiological confirmed COVID-19 (n = 9). One or more comorbidities were detected in 22/24 of the patients. All patients had abnormal radiography imaging on admission. Twenty patients had bilateral ground-glass pacification on computerized tomography (CT) scan. Almost all patients (23/24) underwent invasive mechanical ventilation therapy. Three patients underwent noninvasive mechanical ventilation. Ten patients died. The mean length of ICU stay in patients who died was 9.6 +/- 9 days (2-18 days). The mean length of ICU stay of the four patients who were discharged from the ICU to the floor was 17 +/- 12.9 days. The mean length of ICU stay of patients still in the ICU was (n =10) was 13.36 +/- 10.92 days. Conclusion: The vast majority of patients admitted to the ICU with the diagnosis of COVID-I 9 have multiple co-morbidities. require ventilator support, and experience a high mortality rate.
C1 [Sungurtekin, Hulya; Arslan, Ulku; Ozgen, Cansu; Kahramanoglu, Mithat; Erbay, Hakan; Atalay, Habip; Karaduman, Simay] Pamukkale Univ, Dept Anesthesiol & Reanimat, Crit Care Unit, Denizli, Turkey.
   [Akbudak, Ismail Hakki] Pamukkale Univ, Dept Internal Med, Denizli, Turkey.
   [Caliskan, Ahmet] Pamukkale Univ, Dept Med Microbiol, Denizli, Turkey.
RP Sungurtekin, H (corresponding author), Pamukkale Univ, Dept Anesthesiol & Reanimat, Crit Care Unit, Denizli, Turkey.
EM hsungurtekin@yahoo.com
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Arentz M, 2020, JAMA
   Bai HX, 2020, RADIOLOGY
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Phua J, 2020, LANCET RESP MED
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Richardson S., 2020, JAMA
   Sanders JM, 2020, JAMA
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   T. C. Ministry of Health general directorate of public health, 2020, COVID 19 SARS COV 2
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, COR DIS COVID 19 TEC
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhao S, 2020, INFECT DIS-NOR, V52, P284, DOI 10.1080/23744235.2020.1717598
NR 17
TC 0
Z9 0
U1 0
U2 0
PU MRE PRESS
PI SINGAPORE
PA 14 ROBINSON RD #08-01A FAR EAST FINANCE, SINGAPORE, SINGAPORE
SN 1334-5605
J9 SIGNA VITAE
JI Signa Vitae
PD JUN
PY 2020
VL 16
IS 1
BP 147
EP 151
DI 10.22514/sv.2020.16.0019
PG 5
WC Emergency Medicine
SC Emergency Medicine
GA MO4SY
UT WOS:000551519100019
OA Bronze
DA 2021-01-01
ER

PT J
AU Fan, OY
   Fu, Q
   Guo, SH
   Yang, HB
   Li, XY
   Tang, M
   Yang, L
AF Ouyang Fan
   Fu Qiang
   Guo Shuhong
   Yang Haibing
   Li Xiangyan
   Tang Ming
   Yang Li
TI Recovery from Critical COVID-19 Despite Delays in Diagnosis and
   Respiratory Treatment: a Cautionary Tale
SO SIGNA VITAE
LA English
DT Article
DE COVID-19; Respiratory; Glucocorticoids therapy; ARDS
ID PLASMA; THERAPY
AB Although an acute, usually self-resolving disease, COVID-19 can also be deadly. Thus far, no approved specific treatments for this novel highly contagious disease are available, which posed great challenges on clinicians worldwide. Here we present the case of a relatively young COVID-19 patient who recovered well, despite delayed diagnosis and initiation of aggressive treatment. From the case. we speculated that: (a) Delayed diagnosis may miss the optimal antiviral treatment period for severe cases. (b) Monitoring of inflammatory markers and blood gas analysis in early stage may assist in identifying high-risk patients. (c) Glucocorticoids therapy in early stage may be harmful to the patient. (d) Once progressed to ARDS, mechanical ventilatory support should be considered as soon as possible in case of refractory hypoxemia, (e) ECMO, a scarce medical resource, should not be abused to treat COVID-19 patients with very low expected survival rates, especially during the period when medical resources are run out. (f) convalescent plasma therapy should be initiated in earlier stage of disease.
C1 [Ouyang Fan; Fu Qiang; Guo Shuhong; Yang Haibing; Li Xiangyan; Tang Ming; Yang Li] Zhuzhou Cent Hosp, Dept Cardiovasc Med, Zhuzhou, Hunan, Peoples R China.
RP Yang, L (corresponding author), Zhuzhou Cent Hosp, Dept Cardiovasc Med, Zhuzhou, Hunan, Peoples R China.
EM 251957922@qq.com
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Liu BC, 2020, RESP MED, V161, DOI 10.1016/j.rmed.2019.09.009
   Liu Qian, 2020, J FORENSIC MED, V36, P19, DOI DOI 10.12116/J.ISSN.1004-5619.2020.01.00
   MacLennan S, 2006, BEST PRACT RES CL HA, V19, P169, DOI 10.1016/j.beha.2005.01.033
   MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Schmidt M, 2014, AM J RESP CRIT CARE, V189, P1374, DOI 10.1164/rccm.201311-2023OC
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z, 2020, LANCET RESP MED
NR 13
TC 0
Z9 0
U1 1
U2 1
PU MRE PRESS
PI SINGAPORE
PA 14 ROBINSON RD #08-01A FAR EAST FINANCE, SINGAPORE, SINGAPORE
SN 1334-5605
J9 SIGNA VITAE
JI Signa Vitae
PD JUN
PY 2020
VL 16
IS 1
BP 193
EP 198
DI 10.22514/sv.2020.16.0027
PG 6
WC Emergency Medicine
SC Emergency Medicine
GA MO4SY
UT WOS:000551519100027
OA Bronze
DA 2021-01-01
ER

PT J
AU Addi, RA
   Benksim, A
   Cherkaoui, M
AF Addi, Rachid Ait
   Benksim, Abdelhafid
   Cherkaoui, Mohamed
TI Vulnerability of People with Cancer and the Potential Risks of COVID-9
   Pandemic: A perspective in Morocco
SO SIGNA VITAE
LA English
DT Article
DE COVID-19; Cancer; Pandemic; Morocco
AB Cancer affects almost 18 million around the world in 2018, of these 9.5 million cases were in men and 8.5 million in women. COVID-19 is an acute respiratory disease caused by novel coronavirus SARS-CoV-2 or 2019-nCoV and was first reported in Wuhan, China in December 2019. Recently, on March 11, 2020, COVID-19 was declared by the World Health Organization (WHO) as a virus pandemic disease. Furthermore, it has been known that the malignancy and anticancer treatments, such as chemotherapy or surgery cause systemic inununosuppressive state inpatients with cancer which exposes them to infection more than others especially for COVID-19 and with a high probability of complications. Additionally, the major concern for patients with cancer is the incapacity to get fundamental medical services due to the pandemic spread. In Morocco, thanks to measures such as contamination prevention, prioritization of care, and price control of therapies, cancer patients were able to continue their treatment during the covid-19 pandemic.
C1 [Addi, Rachid Ait; Benksim, Abdelhafid] Cadi Ayyad Univ, Sch Sci Semlalia, Dept Biol, Lab Human Ecol, Marrakech, Morocco.
   [Benksim, Abdelhafid; Cherkaoui, Mohamed] High Inst Nursing & Tech Hlth, Marrakech, Morocco.
RP Addi, RA (corresponding author), Cadi Ayyad Univ, Sch Sci Semlalia, Dept Biol, Lab Human Ecol, Marrakech, Morocco.
EM dr.rachid.aitaddi@gmail.com
RI ADDI, RACHID AIT/AAT-4061-2020
OI ADDI, RACHID AIT/0000-0001-8825-4133
CR Addi RA, 2020, ELECTRON J GEN MED, V17, DOI 10.29333/ejgm/7857
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Centers for disease control and prevention, COR DIS 2019 COVID 1
   Cortiula F, 2020, ANN ONCOL, V31, P553, DOI 10.1016/j.annonc.2020.03.286
   Gao YM, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1737634
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Lambertini M, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000759
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lu H, 2020, EUR J SURG ONCOL
   National Cancer Institute, RISK FACT CANC
   National Cancer Institute, CANC TREATMENT
   Rivera A, 2020, ADV RADIAT ONCOL, V5, P538, DOI 10.1016/j.adro.2020.03.006
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Worldwide cancer data Global, CANC STAT MOST COMM
   Yuen E, 2020, ORAL ONCOL, V105, DOI 10.1016/j.oraloncology.2020.104738
NR 17
TC 0
Z9 0
U1 2
U2 2
PU MRE PRESS
PI SINGAPORE
PA 14 ROBINSON RD #08-01A FAR EAST FINANCE, SINGAPORE, SINGAPORE
SN 1334-5605
J9 SIGNA VITAE
JI Signa Vitae
PD JUN
PY 2020
VL 16
IS 1
BP 207
EP 208
DI 10.22514/sv.2020.16.0030
PG 2
WC Emergency Medicine
SC Emergency Medicine
GA MO4SY
UT WOS:000551519100030
OA Bronze
DA 2021-01-01
ER

PT J
AU Ortega, JT
   Serrano, ML
   Jastrzebska, B
AF Ortega, Joseph T.
   Serrano, Maria Luisa
   Jastrzebska, Beata
TI Class A G Protein-Coupled Receptor Antagonist Famotidine as a
   Therapeutic Alternative against SARS-CoV2: An In Silico Analysis
SO BIOMOLECULES
LA English
DT Article
DE antiviral therapy; G protein-coupled receptor; inhibitors; proteases;
   SARS-CoV2
ID HIV-1 PROTEASE; VIRUS; INHIBITORS; COVID-19; HYDROXYCHLOROQUINE;
   DISCOVERY; EFFICACY; BINDING; FUTURE; SARS
AB The pandemic associated with Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV2) and its disease named COVID-19 challenged the scientific community to discover effective therapeutic solutions in a short period. Repurposing existing drugs is one viable approach that emphasizes speed during these urgent times. Famotidine, a class A G protein-coupled receptor antagonist used for the treatment of gastroesophageal reflux was recently identified in an in silico screening. Additionally, a recent retrospective clinical report showed that the treatment with famotidine provided a good outcome in patients infected with SARS-CoV2. A clinical trial testing effectiveness of famotidine in combination with hydroxychloroquine is currently ongoing in the United States (US). In the 1990s, famotidine was described as an antiviral agent against human immunodeficiency virus (HIV). Interestingly, some HIV protease inhibitors are presently being used against SARS-CoV2. However, it is not clear if famotidine could be effective against SARS-CoV2. Thus, by using a computational analysis, we aimed to examine if the antiviral effect of famotidine could be related to the inhibition of proteases involved in the virus replication. Our results showed that famotidine could interact within the catalytic site of the three proteases associated with SARS-CoV2 replication. However, weak binding affinity of famotidine to these proteases suggests that a successful famotidine therapy could likely be achieved only in combination with other antiviral drugs. Finally, analysis of famotidine's pharmacokinetic parameters indicated that its effect against SARS-CoV2 infection could be reached only upon intravenous administration. This work will contribute to the pharmacological knowledge of famotidine as an antiviral agent against SARS-CoV2.
C1 [Ortega, Joseph T.; Jastrzebska, Beata] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland Ctr Membrane & Struct Biol, Cleveland, OH 44106 USA.
   [Serrano, Maria Luisa] Cent Univ Venezuela, Fac Farm, Unidad Quim Med, Caracas 1041A, Venezuela.
RP Ortega, JT; Jastrzebska, B (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland Ctr Membrane & Struct Biol, Cleveland, OH 44106 USA.
EM jto22@case.edu; maria.serrano@ucv.ve; bxj27@case.edu
OI Serrano, Maria Luisa/0000-0002-2936-5092; Jastrzebska,
   Beata/0000-0001-5209-8685
FU NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [EY025214] Funding Source: Medline
CR Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Ali J, 2012, J CHEM INF MODEL, V52, P420, DOI 10.1021/ci200387c
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770
   Arts EJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007161
   Arya R, 2020, POTENTIAL INHIBITORS, DOI [10.26434/chemrxiv.11860011.v2, DOI 10.26434/CHEMRXIV.11860011.V2, 10.26434/chemrxiv.11860011.v2.]
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bohnert T, 2013, J PHARM SCI-US, V102, P2953, DOI 10.1002/jps.23614
   Bourinbaiar AS, 1997, AIDS RES HUM RETROV, V13, P281, DOI 10.1089/aid.1997.13.281
   Bourinbaiar AS, 1996, LIFE SCI, V59, pPL365, DOI 10.1016/S0024-3205(96)00553-X
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Delaney JS, 2004, J CHEM INF COMP SCI, V44, P1000, DOI 10.1021/ci034243x
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Engelman A, 2012, NAT REV MICROBIOL, V10, P279, DOI 10.1038/nrmicro2747
   Freedberg D. E., 2020, FAMOTIDINE USE IS AS, DOI [10.1101/2020.05.01.20086694, DOI 10.1101/2020.05.01.20086694]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Gildenhuys S, 2020, BIOCHEM J, V477, P1479, DOI 10.1042/BCJ20200223
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Graham RL, 2020, IMMUNITY, V52, P734, DOI 10.1016/j.immuni.2020.04.016
   He JH, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040428
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Howard ML, 2010, COMB CHEM HIGH T SCR, V13, P170, DOI 10.2174/138620710790596745
   Hsu A, 2003, ANTIMICROB AGENTS CH, V47, P350, DOI 10.1128/AAC.47.1.350-359.2003
   Jan Hasnain, 2020, Discoveries (Craiova), V8, pe108, DOI 10.15190/d.2020.5
   Jaspe RC, 2016, INVEST CLIN, V57, P93
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Lai ST, 2005, EUR J CLIN MICROBIOL, V24, P583, DOI 10.1007/s10096-005-0004-z
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li C, 2020, EUR REV MED PHARMACO, V24, P4576, DOI 10.26355/eurrev_202004_21044
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Manns MP, 2006, GUT, V55, P1350, DOI 10.1136/gut.2005.076646
   Maradey-Romero C, 2014, J NEUROGASTROENTEROL, V20, P6, DOI 10.5056/jnm.2014.20.1.6
   McCreary EK, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz538
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Mengist HM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0178-y
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008
   Ortega JT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246218
   Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Pedretti A, 2004, J COMPUT AID MOL DES, V18, P167, DOI 10.1023/B:JCAM.0000035186.90683.f2
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Rut W.Z., 2020, ACTIVITY PROFILING S, DOI [10.1101/2020.04.29.068890, DOI 10.1101/2020.04.29.068890]
   Sanchez-Linares I, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S14-S13
   Savarino A, 2005, J CLIN VIROL, V34, P170, DOI 10.1016/j.jcv.2005.03.005
   Sayer JM, 2009, PROTEINS, V75, P556, DOI 10.1002/prot.22271
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Te Helen S, 2007, Gastroenterol Hepatol (N Y), V3, P218
   Ortega JT, 2019, EXCLI J, V18, P1037, DOI 10.17179/excli2019-1837
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yan YX, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072323
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhao N, 2020, EUR REV MED PHARMACO, V24, P4597, DOI 10.26355/eurrev_202004_21046
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 69
TC 4
Z9 4
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD JUN
PY 2020
VL 10
IS 6
AR 954
DI 10.3390/biom10060954
PG 21
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MN5NW
UT WOS:000550889000001
PM 32599963
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU El-Hage, W
   Hingray, C
   Lemogne, C
   Yrondi, A
   Brunault, P
   Bienvenu, T
   Etain, B
   Paquet, C
   Gohier, B
   Bennabi, D
   Birmes, P
   Sauvaget, A
   Fakra, E
   Prieto, N
   Bulteau, S
   Vidailhet, P
   Camus, V
   Leboyer, M
   Krebs, MO
   Aouizerate, B
AF El-Hage, W.
   Hingray, C.
   Lemogne, C.
   Yrondi, A.
   Brunault, P.
   Bienvenu, T.
   Etain, B.
   Paquet, C.
   Gohier, B.
   Bennabi, D.
   Birmes, P.
   Sauvaget, A.
   Fakra, E.
   Prieto, N.
   Bulteau, S.
   Vidailhet, P.
   Camus, V
   Leboyer, M.
   Krebs, M-O
   Aouizerate, B.
TI Health professionals facing the coronavirus disease 2019 (COVID-19)
   pandemic: What are the mental health risks?
SO ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
LA French
DT Article
DE COVID-19; Health personnel; Mental health; Anxiety; Depression;
   Post-traumatic stress disorder
ID ACUTE-RESPIRATORY-SYNDROME; PSYCHOLOGICAL IMPACT; CARE WORKERS; HOSPITAL
   WORKERS; SYNDROME SARS; OUTBREAK; TORONTO; NURSES; STRESS
AB Objectives. - The coronavirus disease 2019 (COVID-19) pandemic has caused major sanitary crisis worldwide. Half of the world has been placed in quarantine. In France, this large-scale health crisis urgently triggered the restructuring and reorganization of health service delivery to support emergency services, medical intensive care units and continuing care units. Health professionals mobilized all their resources to provide emergency aid in a general climate of uncertainty. Concerns about the mental health, psychological adjustment, and recovery of health care workers treating and caring for patients with COVID-19 are now arising. The goal of the present article is to provide up-to-date information on potential mental health risks associated with exposure of health professionals to the COVID-19 pandemic.
   Methods. - Authors performed a narrative review identifying relevant results in the scientific and medical literature considering previous epidemics of 2003 (SARS-CoV-1) and 2009 (H1N1) with the more recent data about the COVID-19 pandemic. We highlighted most relevant data concerning the disease characteristics, the organizational factors and personal factors that may contribute to developing psychological distress and other mental health symptoms.
   Results. - The disease characteristics of the current COVID-19 pandemic provoked a generalized climate of wariness and uncertainty, particularly among health professionals, due to a range of causes such as the rapid spread of COVID-19, the severity of symptoms it can cause in a segment of infected individuals, the lack of knowledge of the disease, and deaths among health professionals. Stress may also be caused by organizational factors, such as depletion of personal protection equipment, concerns about not being able to provide competent care if deployed to new area, concerns about rapidly changing information, lack of access to up-to-date information and communication, lack of specific drugs, the shortage of ventilators and intensive care unit beds necessary to care for the surge of critically ill patients, and significant change in their daily social and family life. Further risk factors have been identified, including feelings of being inadequately supported, concerns about health of self, fear of taking home infection to family members or others, and not having rapid access to testing through occupational health if needed, being isolated, feelings of uncertainty and social stigmatization, overwhelming workload, or insecure attachment. Additionally, we discussed positive social and organizational factors that contribute to enhance resilience in the face of the pandemic. There is a consensus in all the relevant literature that health care professionals are at an increased risk of high levels of stress, anxiety, depression, burnout, addiction and post-traumatic stress disorder, which could have long-term psychological implications.
   Conclusions. - In the long run, this tragic health crisis should significantly enhance our understanding of the mental health risk factors among the health care professionals facing the COVID-19 pandemic. Reporting information such as this is essential to plan future prevention strategies. Protecting health care professionals is indeed an important component of public health measures to address large-scale health crisis. Thus, interventions to promote mental well-being in health care professionals exposed to COVID-19 need to be immediately implemented, and to strengthen prevention and response strategies by training health care professionals on mental help and crisis management. (C) 2020 L'Encephale, Paris.
C1 [El-Hage, W.; Brunault, P.; Camus, V] CHRU Tours, Pole Psychiat & Daddictiol, Tours, France.
   [El-Hage, W.; Camus, V] Univ Tours, iBrain, Inserm, UMR 1253, Tours, France.
   [Hingray, C.] Ctr Psychotherap Nancy, Pole Hosp Univ Psychiat Adultes Grand Nancy, Laxou, France.
   [Lemogne, C.] Univ Paris, Inst Psychiat & Neurosci Paris, UMR S1266, Inserm, Paris, France.
   [Lemogne, C.] Ctr Univ Paris, Hop Europeen Georges Pompidou, AP HP, Serv Psychiat & Addictol Adulte & Sujet Age, Paris, France.
   [Yrondi, A.] Univ Toulouse, Ctr Expert Depress Resistante FondaMental, ToNIC Toulouse NeuroImaging Ctr,Inserm,UPS, Serv Psychiat & Psychol Med Adulte,Hop Purpan,CHU, Toulouse, France.
   [Brunault, P.] Univ Tours, Dept Psychol, Qualite Vie & Sante Psychol, QualiPsy EE 1901, Tours, France.
   [Bienvenu, T.; Aouizerate, B.] Univ Bordeaux, Pole Psychiat Gen & Univ, Ctr Reference Reg Pathol Anxieuses & Depress, CH Charles Perrens, Bordeaux, France.
   [Bienvenu, T.] Neuroctr Magendie, Inserm U1215, Bordeaux, France.
   [Etain, B.; Paquet, C.] Univ Paris, Inserm, UMRS 1144, Paris, France.
   [Etain, B.] Hop Fernand Widal, AP HP Nord, Ctr Expert Troubles Bipolaires FondaMental, DMU Neurosci, Paris, France.
   [Paquet, C.] Hop Lariboisiere, AP HP Nord, Ctr Neurol Cognit, DMU Neurosci, Paris, France.
   [Gohier, B.] Univ Angers, Dept Psychiat & Addictol, CHU Angers, UPRES,EA 4638, Angers, France.
   [Bennabi, D.] Univ Bourgogne Franche Comte, Ctr Expert Depress Resistante FondaMental, Serv Psychiat Adulte, CHU Besancon, Besancon, France.
   [Birmes, P.] Univ Toulouse, Toulouse NeuroImaging Ctr, UPS, Inserm, Toulouse, France.
   [Sauvaget, A.] Univ Nantes, CHU Nantes, Movement Interact Performance MIP, EA 4334, Nantes, France.
   [Fakra, E.] Univ St Etienne Lyon 1, Ctr Rech Neurosci Lyon, CHU St Etienne, Equipe PsyR2,Pole Univ Psychiat,CNRS,UMR 5292,Ins, St Etienne, France.
   [Prieto, N.] Hosp Civils Lyon, Grp Hosp Edouard Herriot, Ctr Reg Psychotraumatol Auvergne Rhone Alpes, Serv Med Legale, Lyon, France.
   [Bulteau, S.] Univ Nantes, SPHERE, U1246, Inserm, Nantes, France.
   [Bulteau, S.] Univ Tours, Nantes, France.
   [Vidailhet, P.] Univ Strasbourg, Ctr Reg Psychotraumatol Grand Est, U1114, Inserm, Strasbourg, France.
   [Leboyer, M.] Hop H Mondor, AP HP, Dept Med Univ Psychait & Addictol, DMU IMPACT, Creteil, France.
   [Leboyer, M.] Fdn Fondamental, Creteil, France.
   [Leboyer, M.] Univ Paris Est Creteil, U955, INSERM, Equipe Neuropsychiat Translat 15,UPEC, Creteil, France.
   [Krebs, M-O] Univ Paris 05, GDR 3557 Inst Psychiat, CNRS, IPNP,UMR 1266,Inserm, Paris, France.
   [Krebs, M-O] GHU Paris St Anne, Serv Hosp Univ, Paris, France.
RP El-Hage, W (corresponding author), CHRU Tours, Pole Psychiat & Daddictiol, Tours, France.
EM wissam.el-hage@univ-tours.fr
CR Adams JG, JAMA
   Bansal P, 2020, J ALLERGY CLIN IMMUN
   Bransi A, 2020, NERVENARZT, V91, P77, DOI 10.1007/s00115-019-00854-3
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Chahraoui K, 2011, ANN FR ANESTH REANIM, V30, P342
   Chan AOM, 2004, OCCUP MED-OXFORD, V54, P190, DOI 10.1093/occmed/kqh027
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Chong MY, 2004, BRIT J PSYCHIAT, V185, P127, DOI 10.1192/bjp.185.2.127
   Dutheil F, 2019, PLOS ONE, V14
   Garre C., 2020, PSY ECOUTE SOIGNANTS
   Goulia P, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-322
   Greenberg N, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1211
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang JT, 2020, DEV POLICY REV, V38, DOI 10.1111/dpr.12420
   Kang L, 2020, BRAIN BEHAV IMMUN
   Kang LJ, 2020, LANCET PSYCHIAT, V7, pE14, DOI 10.1016/S2215-0366(20)30047-X
   Koh D, 2005, MED CARE, V43, P676, DOI 10.1097/01.mlr.0000167181.36730.cc
   Koob GF, 2019, NEUROSCI BIOBEHAV R, V106, P245, DOI 10.1016/j.neubiorev.2018.09.008
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Lancee WJ, 2008, PSYCHIAT SERV, V59, P91, DOI 10.1176/ps.2008.59.1.91
   Lee SH, 2005, GEN HOSP PSYCHIAT, V27, P352, DOI 10.1016/j.genhosppsych.2005.04.007
   Li Z, BRAIN BEHAV IMMUN
   Lu W, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112936
   Mata DA, 2015, JAMA-J AM MED ASSOC, V314, P2373, DOI 10.1001/jama.2015.15845
   Matsuishi K, 2012, PSYCHIAT CLIN NEUROS, V66, P353, DOI 10.1111/j.1440-1819.2012.02336.x
   Maunder R, 2004, PHILOS T R SOC B, V359, P1117, DOI 10.1098/rstb.2004.1483
   Maunder RG, 2004, PSYCHOSOM MED, V66, P938, DOI 10.1097/01.psy.0000145673.84698.18
   Maunder RG, 2006, EMERG INFECT DIS, V12, P1924
   McAlonan GM, 2007, CAN J PSYCHIAT, V52, P241, DOI 10.1177/070674370705200406
   OCDE, 2018, LITS HOP
   Organisation mondiale de la sante, 2020, CONS LIEES SANT MENT, P6
   Reger MA, JAMA PSYCHIAT
   Schreiber M, 2019, MIL MED, V184, P114, DOI 10.1093/milmed/usy400
   Shanafelt T, JAMA
   Smereka J, 2020, AM J EMERG MED
   Su TP, 2020, J PSYCHIAT RES, V368
   Tam CWC, 2004, PSYCHOL MED, V34, P1197, DOI 10.1017/S0033291704002247
   Vayr F, 2019, DRUG ALCOHOL DEPEN, V199, P116, DOI 10.1016/j.drugalcdep.2019.04.004
   Wu P, 2008, ALCOHOL ALCOHOLISM, V43, P706, DOI 10.1093/alcalc/agn073
   Zhu Z, 2020, COVID 19 WUHAN IMMED, V2020
NR 40
TC 21
Z9 21
U1 28
U2 28
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0013-7006
J9 ENCEPHALE
JI Enceph.-Rev. Psychiatr. Clin. Biol. Ther.
PD JUN
PY 2020
VL 46
IS 3
SU S
BP S73
EP S80
DI 10.1016/j.encep.2020.014.008
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA MF8UE
UT WOS:000545613500010
PM 32370984
DA 2021-01-01
ER

PT J
AU Dutta, NK
   Mazumdar, K
   Gordy, JT
AF Dutta, Noton K.
   Mazumdar, Kaushiki
   Gordy, James T.
TI The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development
SO JOURNAL OF VIROLOGY
LA English
DT Letter
DE coronavirus disease 2019 (COVID-19); severe acute respiratory syndrome
   coronavirus 2 (SARS-CoV-2); nucleocapsid protein; vaccine
ID SARS-CORONAVIRUS; GENOME SEQUENCE; NEUTRALIZATION; ANTIBODIES; VIRUS
C1 [Dutta, Noton K.] Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21205 USA.
   [Mazumdar, Kaushiki] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
   [Gordy, James T.] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD USA.
RP Dutta, NK (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21205 USA.
EM ndutta1@jhmi.edu
RI Dutta, Noton K./K-5202-2012; Mazumdar, Kaushiki/AAW-6879-2020; Gordy,
   James/AAV-4024-2020
OI Dutta, Noton K./0000-0002-5066-3342; Mazumdar,
   Kaushiki/0000-0002-1036-1980; Gordy, James/0000-0003-2588-0756
CR Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Chen S., 2020, BIORXIV, DOI [10.1101/2020.03.06.977876., DOI 10.1101/2020.03.06.977876]
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Dutta NK, 2008, IMMUNOL LETT, V118, P65, DOI 10.1016/j.imlet.2008.03.003
   Gao WT, 2003, LANCET, V362, P1895, DOI 10.1016/S0140-6736(03)14962-8
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Holmes KV, 2003, SCIENCE, V300, P1377, DOI 10.1126/science.1086418
   Jaimes JA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010083
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Lee HK, 2008, J MICROBIOL BIOTECHN, V18, P1717
   Lee HK, 2010, J VET SCI, V11, P165, DOI 10.4142/jvs.2010.11.2.165
   Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Okada M, 2005, VACCINE, V23, P2269, DOI 10.1016/j.vaccine.2005.01.036
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Sheikh A, 2020, J VIROL METHODS, V277, DOI 10.1016/j.jviromet.2019.113806
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu Y, 2005, VIRUS GENES, V30, P93, DOI 10.1007/s11262-004-4586-9
NR 25
TC 6
Z9 7
U1 1
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUN
PY 2020
VL 94
IS 13
AR e00647-20
DI 10.1128/JVI.00647-20
PG 2
WC Virology
SC Virology
GA MM4ZV
UT WOS:000550167600010
PM 32546606
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Yamamoto, M
   Kiso, M
   Sakai-Tagawa, Y
   Iwatsuki-Horimoto, K
   Imai, M
   Takeda, M
   Kinoshita, N
   Ohmagari, N
   Gohda, J
   Semba, K
   Matsuda, Z
   Kawaguchi, Y
   Kawaoka, Y
   Inoue, J
AF Yamamoto, Mizuki
   Kiso, Maki
   Sakai-Tagawa, Yuko
   Iwatsuki-Horimoto, Kiyoko
   Imai, Masaki
   Takeda, Makoto
   Kinoshita, Noriko
   Ohmagari, Norio
   Gohda, Jin
   Semba, Kentaro
   Matsuda, Zene
   Kawaguchi, Yasushi
   Kawaoka, Yoshihiro
   Inoue, Jun-ichiro
TI The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S
   Protein-Mediated Fusion in a Cell Fusion Assay System and Viral
   Infection In Vitro in a Cell-Type-Dependent Manner
SO VIRUSES-BASEL
LA English
DT Article
DE SARS-CoV-2; TMPRSS2; fusion inhibitor
ID CORONAVIRUS; SERINE
AB Although infection by SARS-CoV-2, the causative agent of coronavirus pneumonia disease (COVID-19), is spreading rapidly worldwide, no drug has been shown to be sufficiently effective for treating COVID-19. We previously found that nafamostat mesylate, an existing drug used for disseminated intravascular coagulation (DIC), effectively blocked Middle East respiratory syndrome coronavirus (MERS-CoV) S protein-mediated cell fusion by targeting transmembrane serine protease 2 (TMPRSS2), and inhibited MERS-CoV infection of human lung epithelium-derived Calu-3 cells. Here we established a quantitative fusion assay dependent on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein, angiotensin I converting enzyme 2 (ACE2) and TMPRSS2, and found that nafamostat mesylate potently inhibited the fusion while camostat mesylate was about 10-fold less active. Furthermore, nafamostat mesylate blocked SARS-CoV-2 infection of Calu-3 cells with an effective concentration (EC)(50)around 10 nM, which is below its average blood concentration after intravenous administration through continuous infusion. On the other hand, a significantly higher dose (EC(50)around 30 mu M) was required for VeroE6/TMPRSS2 cells, where the TMPRSS2-independent but cathepsin-dependent endosomal infection pathway likely predominates. Together, our study shows that nafamostat mesylate potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and also inhibits SARS-CoV-2 infection in vitro in a cell-type-dependent manner. These findings, together with accumulated clinical data regarding nafamostat's safety, make it a likely candidate drug to treat COVID-19.
C1 [Yamamoto, Mizuki; Gohda, Jin; Matsuda, Zene; Kawaguchi, Yasushi; Inoue, Jun-ichiro] Univ Tokyo, Res Ctr Asian Infect Dis, Inst Med Sci, Tokyo 1088639, Japan.
   [Kiso, Maki; Sakai-Tagawa, Yuko; Iwatsuki-Horimoto, Kiyoko; Imai, Masaki; Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol, Tokyo 1088639, Japan.
   [Takeda, Makoto] Natl Inst Infect Dis, Dept Virol 3, Musashimurayama, Tokyo 2080011, Japan.
   [Kinoshita, Noriko; Ohmagari, Norio] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo 1628655, Japan.
   [Semba, Kentaro] Waseda Univ, Dept Life Sci & Med Biosci, Shinjuku Ku, Tokyo 1628480, Japan.
   [Kawaguchi, Yasushi] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Mol Virol, Tokyo 1088639, Japan.
   [Kawaoka, Yoshihiro] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Influenza Res Inst, Madison, WI 53711 USA.
   [Kawaoka, Yoshihiro] Univ Tokyo, Int Res Ctr Infect Dis, Inst Med Sci, Dept Special Pathogens, Tokyo 1088639, Japan.
   [Inoue, Jun-ichiro] Univ Tokyo, Senior Prof Off, Tokyo 1130033, Japan.
RP Inoue, J (corresponding author), Univ Tokyo, Res Ctr Asian Infect Dis, Inst Med Sci, Tokyo 1088639, Japan.; Inoue, J (corresponding author), Univ Tokyo, Senior Prof Off, Tokyo 1130033, Japan.
EM mizuyama@ims.u-tokyo.ac.jp; kisomaki@ims.u-tokyo.ac.jp;
   ytsakai@ims.u-tokyo.ac.jp; kenken@ims.u-tokyo.ac.jp;
   mimai@ims.u-tokyo.ac.jp; mtakeda@nih.go.jp; nkinoshita@hosp.ncgm.go.jp;
   nohmagari@hosp.ncgm.go.jp; jgohda@ims.u-tokyo.ac.jp; ksemba@waseda.jp;
   zmatsuda@ims.u-tokyo.ac.jp; ykawagu@ims.u-tokyo.ac.jp;
   yoshihiro.kawaoka@wisc.edu; jun-i@ims.u-tokyo.ac.jp
RI Takeda, Makoto/J-2550-2018; Yamamoto, Mizuki/AAW-1688-2020
OI Takeda, Makoto/0000-0002-8194-7727; Kawaguchi,
   Yasushi/0000-0001-8232-6925; Inoue, Jun-ichiro/0000-0001-6389-7036;
   Yamamoto, Mizuki/0000-0003-3731-1702
FU Japanese Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [16H06575, 18K15235]; Program of Japan
   Initiative for Global Research Network on Infectious Diseases (JGRID)
   from AMED [JP18fm0108006]; NIAIDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [HHSN272201400008C];
   Research Program on Emerging and Re-emerging Infectious Diseases from
   AMED [19fk0108113]
FX This work was supported in part by grants-in-aid from the Japanese
   Society for the Promotion of Science (16H06575 to JI, 18K15235 to MY), a
   Program of Japan Initiative for Global Research Network on Infectious
   Diseases (JGRID) from AMED (JP18fm0108006 to YaK), NIAID-funded Center
   for Research on Influenza Pathogenesis (CRIP; HHSN272201400008C to YoK)
   and a Research Program on Emerging and Re-emerging Infectious Diseases
   from AMED (19fk0108113 to YoK).
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Asakura H, 2020, J THROMB HAEMOST, V18, P1521, DOI 10.1111/jth.14858
   Chen CL, 2006, J ALLERGY CLIN IMMUN, V118, P105, DOI 10.1016/j.jaci.2006.02.047
   Esumi Y., 1984, CLIN REP, V15, P4050
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Kim J. Z. J., 2020, ADV BIOINFORMATICS R, DOI [10.26434/chemrxiv.12037416.v1, DOI 10.26434/CHEMRXIV.12037416.V1]
   Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005
   Matsuyama S., 2020, INHALED CORTICOSTERO, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Ramakrishnan Muthannan Andavar, 2016, World J Virol, V5, P85, DOI 10.5501/wjv.v5.i2.85
   Rensi Stefano, 2020, ChemRxiv, DOI 10.26434/chemrxiv.12009582.v1
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Wang HB, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0113880, 10.1371/journal.pone.0089155, 10.1371/journal.pone.0091730]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yamamoto M, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0547-7
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Zhou L., 2020, SYSTEMIC ANAL TISSUE, DOI [10.1101/2020.04.06.028522v1, DOI 10.1101/2020.04.06.028522V1]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 24
TC 17
Z9 17
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD JUN
PY 2020
VL 12
IS 6
AR 629
DI 10.3390/v12060629
PG 9
WC Virology
SC Virology
GA MO0UB
UT WOS:000551251100001
PM 32532094
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Savarino, EV
   Iovino, P
   Santonicola, A
   Ghisa, M
   Laserra, G
   Barberio, B
   Maniero, D
   Lorenzon, G
   Ciacci, C
   Savarino, V
   Zingone, F
AF Savarino, Edoardo Vincenzo
   Iovino, Paola
   Santonicola, Antonella
   Ghisa, Matteo
   Laserra, Giorgio
   Barberio, Brigida
   Maniero, Daria
   Lorenzon, Greta
   Ciacci, Carolina
   Savarino, Vincenzo
   Zingone, Fabiana
TI Clinical and Psychological Impact of COVID-19 Infection in Adult
   Patients with Eosinophilic Gastrointestinal Disorders during the
   SARS-CoV-2 Outbreak
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE EGID (Eosinophilic gastrointestinal disease); SARS-CoV-2; COVID-19;
   eosinophilic esophagitis; eosinophils; steroid; immunosuppression;
   coronavirus
ID PROTON PUMP INHIBITORS; COMMUNITY-ACQUIRED PNEUMONIA; QUALITY-OF-LIFE;
   CLOSTRIDIUM-DIFFICILE INFECTION; ESOPHAGITIS; RISK; THERAPY; DIAGNOSIS;
   RECOMMENDATIONS; DEPRESSION
AB Eosinophilic gastrointestinal diseases (EGIDs) are chronic gastrointestinal conditions requiring corticosteroid and immunosuppressive therapy for disease control. Patients with EGIDs usually report impaired quality of life. We aimed to report the clinical and psychological impact of COVID-19 infection in EGID patients. In this prospective web-based study we invited all consecutive EGID patients attending the University Hospital of Salerno (Campania) and Padua (Veneto) to fill an ad hoc COVID-19 survey. Moreover, a telemedicine service for direct consultation was organized. Data regarding the occurrence and perception of COVID-19 infection as well as clinical information were recorded. The study population included 102 EGID patients (mean age 36.6 years, 34 females), of whom 89 had eosinophilic esophagitis, nine had gastroenteritis, and four had colitis. No patient was diagnosed with COVID-19 or had recurrence of his/her primary disease. All of them were adherent to therapy and preventive measures adoption. Most patients were worried because of COVID-19 and social preventing measures but did not consider themselves at major risk or susceptible to COVID-19 or other infections due to their chronic condition or therapy. Female gender and low education level were associated to a higher psychological perception of COVID-19 compared to lockdown status or other demographic and clinical factors (p< 0.05). Overall, COVID-19 had a limited clinical impact on patients with EGIDs. The degree of education and sex, but not the fact of living in a lockdown area, influenced the perception of SARS-CoV-2 infection.
C1 [Savarino, Edoardo Vincenzo; Ghisa, Matteo; Laserra, Giorgio; Barberio, Brigida; Maniero, Daria; Lorenzon, Greta; Zingone, Fabiana] Univ Padua, Dept Surg Oncol & Gastroenterol, Gastroenterol Unit, I-35128 Padua, Italy.
   [Iovino, Paola; Santonicola, Antonella; Ciacci, Carolina] Univ Salerno, Univ Hosp San Giovanni Dio & Ruggi dAragona, Dept Med Surg Dent, Scuola Med Salernitana, I-84131 Salerno, Italy.
   [Savarino, Vincenzo] Univ Genoa, Dept Internal Med, Gastroenterol Unit, I-16126 Genoa, Italy.
RP Savarino, EV (corresponding author), Univ Padua, Dept Surg Oncol & Gastroenterol, Gastroenterol Unit, I-35128 Padua, Italy.
EM edoardo.savarino@unipd.it; piovino@unisa.it;
   antonellasantonicola83@gmail.com; matteoghisa@yahoo.it;
   giorgiolaserra91@gmail.com; brigida.barberio@gmail.com;
   dariamaniero@gmail.com; gretalorenzon90@gmail.com; cciacci@unisa.it;
   vsavarin@unige.it; fabiana.zingone@unipd.it
RI ; Santonicola, Antonella/F-2389-2016; Zingone, Fabiana/O-5361-2018;
   IOVINO, PAOLA/G-6195-2011; ciacci, carolina/A-2594-2012
OI ghisa, Matteo/0000-0002-6026-5639; Santonicola,
   Antonella/0000-0001-9094-765X; Zingone, Fabiana/0000-0003-1133-1502;
   IOVINO, PAOLA/0000-0002-9568-0680; ciacci, carolina/0000-0002-7426-1145;
   Savarino, Edoardo/0000-0002-3187-2894
CR Bedell A, 2018, DIGEST DIS SCI, V63, P1148, DOI 10.1007/s10620-018-4978-7
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Bjelland I, 2008, SOC SCI MED, V66, P1334, DOI 10.1016/j.socscimed.2007.12.019
   de Bortoli N, 2017, DIGEST LIVER DIS, V49, P254, DOI 10.1016/j.dld.2016.11.012
   Dellon ES, 2018, GASTROENTEROLOGY, V155, P1022, DOI 10.1053/j.gastro.2018.07.009
   Dellon ES, 2018, GASTROENTEROLOGY, V154, P319, DOI 10.1053/j.gastro.2017.06.067
   Dellon ES, 2017, NAT REV GASTRO HEPAT, V14, P479, DOI 10.1038/nrgastro.2017.56
   Dellon ES, 2012, GASTROENTEROLOGY, V143, P321, DOI 10.1053/j.gastro.2012.04.049
   Deshpande A, 2012, CLIN GASTROENTEROL H, V10, P225, DOI 10.1016/j.cgh.2011.09.030
   Eom CS, 2011, CAN MED ASSOC J, V183, P310, DOI 10.1503/cmaj.092129
   Fardet L, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002024
   Filion KB, 2014, GUT, V63, P552, DOI 10.1136/gutjnl-2013-304738
   Ford AC, 2013, AM J GASTROENTEROL, V108, P1268, DOI 10.1038/ajg.2013.138
   Frazzoni M, 2019, AM J GASTROENTEROL, V114, P1606, DOI 10.14309/ajg.0000000000000379
   Geldsetzer P, 2020, ANN INTERN MED, V173, P157, DOI 10.7326/M20-0912
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Gulmez SE, 2007, ARCH INTERN MED, V167, P950, DOI 10.1001/archinte.167.9.950
   Hanzel J, 2020, CLIN GASTROENTEROL H, V18, P2143, DOI 10.1016/j.cgh.2020.04.033
   Imhann F, 2016, GUT, V65, P740, DOI 10.1136/gutjnl-2015-310376
   Janarthanan S, 2012, AM J GASTROENTEROL, V107, P1001, DOI 10.1038/ajg.2012.179
   Jnr B.A., 2020, J MED SYST, V44, P13
   Kaleta Dorota, 2009, Central European Journal of Public Health, V17, P122
   KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8
   Kinoshita Y, 2019, ALLERGOL INT, V68, P420, DOI 10.1016/j.alit.2019.03.003
   Kwok CS, 2012, AM J GASTROENTEROL, V107, P1011, DOI 10.1038/ajg.2012.108
   Laheij RJF, 2004, JAMA-J AM MED ASSOC, V292, P1955, DOI 10.1001/jama.292.16.1955
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Laserna-Mendieta EJ, 2020, CLIN GASTROENTEROL H, V18, P2903, DOI 10.1016/j.cgh.2020.01.024
   Liacouras CA, 1998, J PEDIATR GASTR NUTR, V26, P380, DOI 10.1097/00005176-199804000-00004
   Lo WK, 2013, CLIN GASTROENTEROL H, V11, P483, DOI 10.1016/j.cgh.2012.12.011
   Lucendo AJ, 2017, UNITED EUR GASTROENT, V5, P335, DOI 10.1177/2050640616689525
   Lukin DJ, 2020, GASTROENTEROLOGY, V159, P1541, DOI 10.1053/j.gastro.2020.05.066
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Miehlke S, 2016, GUT, V65, P390, DOI 10.1136/gutjnl-2014-308815
   Molina-Infante J, 2018, J ALLERGY CLIN IMMUN, V141, P1365, DOI 10.1016/j.jaci.2017.08.038
   Molina-Infante J, 2018, AM J GASTROENTEROL, V113, P972, DOI 10.1038/s41395-018-0035-6
   Mukkada V, 2018, CLIN GASTROENTEROL H, V16, P495, DOI 10.1016/j.cgh.2017.06.036
   Nussbaumer-Streit B, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013574
   O'Shea KM, 2018, GASTROENTEROLOGY, V154, P333, DOI 10.1053/j.gastro.2017.06.065
   Remes O, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.497
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Roman S, 2013, DIGEST LIVER DIS, V45, P871, DOI 10.1016/j.dld.2013.02.015
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Safroneeva E, 2015, ALIMENT PHARM THER, V42, P1000, DOI 10.1111/apt.13370
   Savarino V, 2020, DIGEST LIVER DIS, V52, P842, DOI 10.1016/j.dld.2020.04.020
   Savarino V, 2018, EXPERT REV CLIN PHAR, V11, P1123, DOI 10.1080/17512433.2018.1531703
   Savarino V, 2016, DIGEST LIVER DIS, V48, P851, DOI 10.1016/j.dld.2016.05.018
   Schaefer ET, 2008, CLIN GASTROENTEROL H, V6, P165, DOI 10.1016/j.cgh.2007.11.008
   Schoepfer A, 2018, ANN NY ACAD SCI, V1434, P84, DOI 10.1111/nyas.13731
   Singh S, 2020, CLIN GASTROENTEROL H, V18, P69, DOI 10.1016/j.cgh.2019.02.044
   Siniscalchi M, 2020, DIGEST LIVER DIS, V52, P1071, DOI 10.1016/j.dld.2020.05.014
   Stern E, 2018, DIS ESOPHAGUS, V31, DOI 10.1093/dote/dox128
   Straumann A, 2018, GASTROENTEROLOGY, V154, P346, DOI 10.1053/j.gastro.2017.05.066
   Taft TH, 2019, J ASTHMA ALLERGY, V12, P389, DOI 10.2147/JAA.S193045
   Tinsley A, 2019, INFLAMM BOWEL DIS, V25, P369, DOI 10.1093/ibd/izy243
   Vaezi MF, 2017, GASTROENTEROLOGY, V153, P35, DOI 10.1053/j.gastro.2017.04.047
   Wang CH, 2019, EXPERT OPIN DRUG SAF, V18, P163, DOI 10.1080/14740338.2019.1577820
   Wechsler JB, 2018, J ALLERGY CLIN IMMUN, V142, P24, DOI 10.1016/j.jaci.2018.05.018
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 61
TC 1
Z9 1
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2020
VL 9
IS 6
AR 2011
DI 10.3390/jcm9062011
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA ML5AK
UT WOS:000549478300001
PM 32604895
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, J
   Dong, YQ
   Yin, J
   He, GJ
   Wu, XX
   Li, JP
   Qiu, YQ
   He, XL
AF Liu, Jian
   Dong, Yong-Quan
   Yin, Jie
   He, Guojun
   Wu, Xiaoxin
   Li, Jianping
   Qiu, Yunqing
   He, Xuelin
TI Critically ill patients with COVID-19 with ECMO and artificial liver
   plasma exchange A retrospective study
SO MEDICINE
LA English
DT Article
DE artificial liver plasma exchange; COVID-19; critically; ECMO; ill
ID CYTOKINE; PNEUMONIA; IL-6
AB COVID-19 is an emerging infectious disease capable of causing severe pneumonia. We aimed to characterize a group of critically ill patients in a single-center study. This was a retrospective case series of 23 patients with confirmed COVID-19-related critical illness in the intensive care unit (ICU) of a hospital in Hangzhou Zhejiang Province between January 22 and March 20, 2020. Of the 23 critically ill patients, the median age was 66 years (interquartile range [IQR] 59-80 years). The median time from disease onset to ICU admission was 10 days (IQR 6-11 days), to mechanical ventilation (MV) was 11 days (IQR 7.75-13 days), to artificial liver plasma exchange was 12 days (IQR 9.75-14.75 days), and to extracorporeal membrane oxygenation (ECMO) was 22 days (IQR 17.5-30 days). Nine patients required high flow oxygen. Fourteen patients received MV. Six required ECMO. Nine received artificial liver plasma exchange. Mortality was 0 at day 28. Mortality was 0 at day 28 in our single-center study. Extracorporeal membrane oxygenation reduced the requirements for ventilator support. Artificial liver plasma exchange significantly reduced inflammatory cytokine levels. These supportive therapies helped to extend the patients' survival times and increase the chance of follow-up treatments.
C1 [Li, Jianping] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Tradit Chinese Med, Hangzhou, Peoples R China.
   [Liu, Jian; He, Guojun] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Intens Care Unit, Hangzhou, Peoples R China.
   [Dong, Yong-Quan] Yinzhou 2 Hosp, Dept Resp Dis, Ningbo, Peoples R China.
   [Wu, Xiaoxin; Qiu, Yunqing] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Infect Dis, Hangzhou, Zhejiang, Peoples R China.
   [Yin, Jie] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China.
   [He, Xuelin] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Kidney Dis Ctr, Hangzhou, Zhejiang, Peoples R China.
RP Li, JP; Qiu, YQ (corresponding author), 79 Qing Chun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM qiuyq@zju.edu.cn; 1197029@zju.edu.cn
OI Wu, Xiaoxin/0000-0001-9785-8916
FU Zhejiang Province Public Welfare Technology Application Research Project
   (CN), China [2019 LGF19H010009]
FX This work was supported by Zhejiang Province Public Welfare Technology
   Application Research Project (CN), China (2019 LGF19H010009).
CR Bermejo-Martin JF, 2017, EBIOMEDICINE, V24, P231, DOI 10.1016/j.ebiom.2017.09.023
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Fowler RA, 2003, JAMA-J AM MED ASSOC, V290, P367, DOI 10.1001/jama.290.3.367
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hardin CC, 2018, NEW ENGL J MED, V378, P2032, DOI 10.1056/NEJMe1802676
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Marshall JC, 2008, CLIN CHEST MED, V29, P605, DOI 10.1016/j.ccm.2008.08.001
   Pathan N, 2004, LANCET, V363, P203, DOI 10.1016/S0140-6736(03)15326-3
   Richman D.D., 2016, CLIN VIROLOGY
   Shorr AF, 2002, CHEST, V121, P1262, DOI 10.1378/chest.121.4.1262
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0158-2
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, NOV COR 2019 NCOV SI
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Wu JY, 2020, INFECT DIS THER, V9, P17, DOI 10.1007/s40121-020-00286-6
   Xu K, 2020, ZHEJIANG DA XUE XUE, V49
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 28
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUN
PY 2020
VL 99
IS 26
AR e21012
DI 10.1097/MD.0000000000021012
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA MM1AE
UT WOS:000549890000094
PM 32590819
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Al-Shomrani, BM
   Manee, MM
   Alharbi, SN
   Altammami, MA
   Alshehri, MA
   Nassar, MS
   Bakhrebah, MA
   Al-Fageeh, MB
AF Al-Shomrani, Badr M.
   Manee, Manee M.
   Alharbi, Sultan N.
   Altammami, Mussad A.
   Alshehri, Manal A.
   Nassar, Majed S.
   Bakhrebah, Muhammed A.
   Al-Fageeh, Mohamed B.
TI Genomic Sequencing and Analysis of Eight Camel-Derived Middle East
   Respiratory Syndrome Coronavirus (MERS-CoV) Isolates in Saudi Arabia
SO VIRUSES-BASEL
LA English
DT Article
DE dromedary camel; MERS-CoV; 2019-nCov; phylogenetic analysis; vaccine
   design
ID DROMEDARY CAMELS; TRANSMISSION; PREVALENCE; INFECTION
AB Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory illness in humans; the second-largest and most deadly outbreak to date occurred in Saudi Arabia. The dromedary camel is considered a possible host of the virus and also to act as a reservoir, transmitting the virus to humans. Here, we studied evolutionary relationships for 31 complete genomes of betacoronaviruses, including eight newly sequenced MERS-CoV genomes isolated from dromedary camels in Saudi Arabia. Through bioinformatics tools, we also used available sequences and 3D structure of MERS-CoV spike glycoprotein to predict MERS-CoV epitopes and assess antibody binding affinity. Phylogenetic analysis showed the eight new sequences have close relationships with existing strains detected in camels and humans in Arabian Gulf countries. The 2019-nCov strain appears to have higher homology to both bat coronavirus and SARS-CoV than to MERS-CoV strains. The spike protein tree exhibited clustering of MERS-CoV sequences similar to the complete genome tree, except for one sequence from Qatar (KF961222). B cell epitope analysis determined that the MERS-CoV spike protein has 24 total discontinuous regions from which just six epitopes were selected with score values of >80%. Our results suggest that the virus circulates by way of camels crossing the borders of Arabian Gulf countries. This study contributes to finding more effective vaccines in order to provide long-term protection against MERS-CoV and identifying neutralizing antibodies.
C1 [Al-Shomrani, Badr M.; Manee, Manee M.; Alharbi, Sultan N.; Altammami, Mussad A.; Alshehri, Manal A.; Nassar, Majed S.; Bakhrebah, Muhammed A.; Al-Fageeh, Mohamed B.] King Abdulaziz City Sci & Technol, Natl Ctr Biotechnol, Riyadh 11442, Saudi Arabia.
   [Manee, Manee M.] Univ Georgia, Inst Bioinformat, Athens, GA 30602 USA.
RP Al-Shomrani, BM; Manee, MM (corresponding author), King Abdulaziz City Sci & Technol, Natl Ctr Biotechnol, Riyadh 11442, Saudi Arabia.; Manee, MM (corresponding author), Univ Georgia, Inst Bioinformat, Athens, GA 30602 USA.
EM shomrani@kacst.edu.sa; malmanee@kacst.edu.sa; snharbi@kacst.edu.sa;
   mtammami@kacst.edu.sa; Manalalshehri@kacst.edu.sa; mnassar@kacst.edu.sa;
   mbakhrbh@kacst.edu.sa; mfageeh@kacst.edu.sa
OI Manee, Manee/0000-0001-9493-619X; ALHARBI, SULTAN/0000-0002-5232-3165;
   Nassar, Majed/0000-0003-4939-922X; Al-Shomrani, Badr
   M/0000-0002-7015-6110
FU Life Science and Environment Research Institute [20-0098]; King
   Abdulaziz City for Science and Technology, Saudi Arabia
FX This work was funded by the Life Science and Environment Research
   Institute (grant 20-0098), King Abdulaziz City for Science and
   Technology, Saudi Arabia.
CR Al-Tawfiq JA, 2014, TRENDS MICROBIOL, V22, P573, DOI 10.1016/j.tim.2014.08.001
   Alagaili AN, 2014, MBIO, V5, DOI DOI 10.1128/MBIO.00884-14
   Andersen PH, 2006, PROTEIN SCI, V15, P2558, DOI 10.1110/ps.062405906
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Cauchemez S, 2016, P NATL ACAD SCI USA, V113, P9081, DOI 10.1073/pnas.1519235113
   Conzade R, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080425
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   El-Manzalawy Y, 2008, J MOL RECOGNIT, V21, P243, DOI 10.1002/jmr.893
   Fowler M., 2011, MED SURG CAMELIDS
   Goo J, 2020, VIRUS RES, V278, DOI 10.1016/j.virusres.2020.197863
   Hemida MG, 2015, EMERG INFECT DIS, V21, P699, DOI 10.3201/eid2104.141949
   Hemida MG, 2014, EMERG INFECT DIS, V20, P1231, DOI 10.3201/eid2007.140571
   Hemida MG, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100127
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Killerby ME, 2020, EMERG INFECT DIS, V26, P191, DOI 10.3201/eid2602.190697
   Kim JI, 2016, SCI REP-UK, V6, DOI 10.1038/srep18825
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Memish ZA, 2014, EMERG INFECT DIS, V20, P1012, DOI 10.3201/eid2006.140402
   Milek J, 2018, J VET RES, V62, P249, DOI 10.2478/jvetres-2018-0035
   Millet JK, 2016, ANTIVIR RES, V133, P1, DOI 10.1016/j.antiviral.2016.07.011
   Muller MA, 2014, EMERG INFECT DIS, V20, P2093, DOI 10.3201/eid2012.141026
   Nowotny N, 2014, EUROSURVEILLANCE, V19, P11, DOI 10.2807/1560-7917.ES2014.19.16.20781
   Paden CR, 2018, ZOONOSES PUBLIC HLTH, V65, P322, DOI 10.1111/zph.12435
   Park BK, 2019, INT J PEPT RES THER, V25, P819, DOI 10.1007/s10989-018-9731-8
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Peters B, 2005, PLOS BIOL, V3, P379, DOI 10.1371/journal.pbio.0030091
   Rambaut A., TRACER V1 6
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   van Doremalen N, 2015, ANTIVIR RES, V122, P28, DOI 10.1016/j.antiviral.2015.07.005
   Wang RC, 2020, J INFECTION, V80, P354, DOI 10.1016/j.jinf.2020.01.017
   Wernery U, 2017, VET J, V220, P75, DOI 10.1016/j.tvjl.2016.12.020
   World Health Organization, 2018, MIDDL E RESP SYNDR C
   Wu HJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5515
   Yao B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062249
   Yusof MF, 2015, VIRUS GENES, V50, P509, DOI 10.1007/s11262-015-1174-0
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
NR 41
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD JUN
PY 2020
VL 12
IS 6
AR 611
DI 10.3390/v12060611
PG 13
WC Virology
SC Virology
GA MO0TV
UT WOS:000551250500001
PM 32503352
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lackland, DT
   Sims-Robinson, C
   Buie, JNJ
   Voeks, JH
AF Lackland, Daniel T.
   Sims-Robinson, Catrina
   Buie, Joy N. Jones
   Voeks, Jenifer H.
TI IMPACT OF COVID-19 ON CLINICAL RESEARCH AND INCLUSION OF DIVERSE
   POPULATIONS
SO ETHNICITY & DISEASE
LA English
DT Article
DE Clinical Research; Undeserved Minorities; External Validity; Clinical
   Trials
ID BARRIERS
AB The randomized clinical trial (RCT) has long been recognized as the 'gold standard' for developing evidence for clinical treatments and vaccines; however, the successful implementation and translation of these findings is predicated upon external validity. The generalization of RCT findings are jeopardized by the lack of participation of at-risk groups such as African Americans, with long-recognized disproportional representation. Distinct factors that deter participation in RCTs include distrust, access, recruitment strategies, perceptions of research, and socioeconomic factors. While strategies have been implemented to improve external validity with greater participation among all segments of the population in RC:Ts, the coronavirus disease 2019 (COVID-19) pandemic may exacerbate disparities in RCT participation with the potential impact of delaying treatment development and vaccine interventions that are applicable and generalizable. Thus, it is essential to include diverse populations in such strategies and RCTs. This Perspective aims to direct attention to the additional harm from the pandemic as well as a refocus on the unresolved lack of inclusion of diverse populations in conducting RCTs.
C1 [Lackland, Daniel T.; Sims-Robinson, Catrina; Buie, Joy N. Jones; Voeks, Jenifer H.] Med Univ South Carolina, Dept Neurol, Div Translat Neurosci & Populat Studies, 96 Jonathan Lucas St,Suite 301, Charleston, SC 29425 USA.
RP Lackland, DT (corresponding author), Med Univ South Carolina, Dept Neurol, Div Translat Neurosci & Populat Studies, 96 Jonathan Lucas St,Suite 301, Charleston, SC 29425 USA.
EM lackland@musc.edu
CR Crawley LM, 2001, J NATL MED ASSOC, V93, p14S
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   George S, 2014, AM J PUBLIC HEALTH, V104, pE16, DOI 10.2105/AJPH.2013.301706
   Hamel LM, 2016, CANCER CONTROL, V23, P327, DOI 10.1177/107327481602300404
   Lackland Daniel T, 2006, J Clin Hypertens (Greenwich), V8, P427, DOI 10.1111/j.1524-6175.2006.04721.x
   Newman LA, 2008, ANN SURG ONCOL, V15, P1818, DOI 10.1245/s10434-008-9869-2
   U.S. Department of Health and Human Services, 2020, FDA GUID COND CLIN T
NR 7
TC 1
Z9 1
U1 3
U2 3
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
EI 1945-0826
J9 ETHNIC DIS
JI Ethn. Dis.
PD SUM
PY 2020
VL 30
IS 3
BP 429
EP 432
DI 10.18865/ed.30.3.429
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MK4FB
UT WOS:000548740000009
OA Bronze
DA 2021-01-01
ER

PT J
AU Choi, MH
   Ahn, H
   Ryu, HS
   Kim, BJ
   Jang, J
   Jung, M
   Kim, J
   Jeong, SH
AF Choi, Min Hyuk
   Ahn, Hyunmin
   Ryu, Han Seok
   Kim, Byung-Jun
   Jang, Joonyong
   Jung, Moonki
   Kim, Jinuoung
   Jeong, Seok Hoon
TI Clinical Characteristics and Disease Progression in Early-Stage COVID-19
   Patients in South Korea
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE coronavirus disease-19 (COVID-19); severe acute respiratory syndrome
   coronavirus 2 (SARS-CoV-2); angiotensin II receptor blockers (ARB);
   ibuprofen; Korea centers for disease control and prevention (KCDC)
   classification
ID RECEPTOR BLOCKERS; PREDICTION; PNEUMONIA; WUHAN
AB A rapid increase in the number of patients with coronavirus disease 19 (COVID-19) may overwhelm the available medical resources. We aimed to evaluate risk factors for disease severity in the early stages of COVID-19. The cohort comprised 293 patients with COVID-19 from 5 March 2020, to 18 March 2020. The Korea Centers for Disease Control and Prevention (KCDC) classification system was used to triage patients. The clinical course was summarized, including the impact of drugs (angiotensin II receptor blockers [ARB], ibuprofen, and dipeptidyl peptidase-4 inhibitors [DPP4i]) and the therapeutic effect of lopinavir/ritonavir. After adjusting for confounding variables, prior history of drug use, including ARB, ibuprofen, and DPP4i was not a risk factor associated with disease progression. Patients treated with lopinavir/ritonavir had significantly shorter progression-free survival than those not receiving lopinavir/ritonavir. KCDC classification I clearly distinguished the improvement/stabilization group from the progression group of COVID-19 patients (AUC 0.817; 95% CI, 0.740-0.895).
C1 [Choi, Min Hyuk; Jeong, Seok Hoon] Yonsei Univ, Dept Lab Med, Coll Med, Seoul 06273, South Korea.
   [Choi, Min Hyuk; Jeong, Seok Hoon] Yonsei Univ, Res Inst Bacterial Resistance, Coll Med, Seoul 06273, South Korea.
   [Choi, Min Hyuk] Armed Forces Daegu Hosp, Dept Lab Med, Daegu 712906, South Korea.
   [Ahn, Hyunmin] Armed Forces Daegu Hosp, Dept Ophthalmol, Daegu 712906, South Korea.
   [Ryu, Han Seok; Kim, Byung-Jun; Jang, Joonyong; Jung, Moonki; Kim, Jinuoung] Armed Forces Daegu Hosp, Dept Internal Med, Daegu 712906, South Korea.
RP Jeong, SH (corresponding author), Yonsei Univ, Dept Lab Med, Coll Med, Seoul 06273, South Korea.; Jeong, SH (corresponding author), Yonsei Univ, Res Inst Bacterial Resistance, Coll Med, Seoul 06273, South Korea.
EM tcmhwd@yuhs.ac; overhyun@gmail.com; cpcforever@nate.com;
   rla20404@naver.com; zun54@naver.com; yessu188@naver.com;
   jinote0504@gmail.com; kscpjsh@yuhs.ac
OI Choi, Min Hyuk/0000-0001-9801-9874; Seok Hoon,
   Jeong/0000-0001-9290-897X; Ryu, HanSeok/0000-0003-2110-4936
CR [Anonymous], 2020, FREQ ASK QUEST KCDC
   [Anonymous], 2020, UPD COV 19 KOR 23 FE
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hill J, 2008, STAT MED, V27, P2055, DOI 10.1002/sim.3245
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Peng Y D, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P450, DOI 10.3760/cma.j.cn112148-20200220-00105
   Qiao WL, 2015, CARDIOLOGY, V131, P97, DOI 10.1159/000375362
   Richman D.D., 2016, CLIN VIROLOGY
   Shi Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2833-7
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Verdecchia P, 2010, CURR VASC PHARMACOL, V8, P742, DOI 10.2174/157016110793563924
   Vuille-Dit-Bille RN, 2015, AMINO ACIDS, V47, P693, DOI 10.1007/s00726-014-1889-6
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, COR DIS COVID 2019 S
   Wyss R, 2013, PHARMACOEPIDEM DR S, V22, P77, DOI 10.1002/pds.3356
   Xiong Y, 2020, INVEST RADIOL, V55, P332, DOI 10.1097/RLI.0000000000000674
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zubrod C.G, 1960, J CHRON DIS, V11, P7, DOI DOI 10.1016/0021-9681(60)90137-5
NR 39
TC 4
Z9 4
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2020
VL 9
IS 6
AR 1959
DI 10.3390/jcm9061959
PG 19
WC Medicine, General & Internal
SC General & Internal Medicine
GA ML4NG
UT WOS:000549444100001
PM 32585855
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kaden, R
AF Kaden, Rene
TI Early Phylogenetic Diversification of SARS-CoV-2: Determination of
   Variants and the Effect on Epidemiology, Immunology, and Diagnostics
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE molecular epidemiology; SARS-CoV-2; COVID-19; virus variant detection
AB The phylogenetic clustering of 95 SARS-CoV-2 sequences from the first 3 months of the pandemic reveals insights into the early evolution of the virus and gives first indications of how the variants are globally distributed. Variants might become a challenge in terms of diagnostics, immunology, and effectiveness of drugs. All available whole genome sequence data from the NCBI database (March 16, 2020) were phylogenetically analyzed, and gene prediction as well as analysis of selected variants were performed. Antigenic regions and the secondary protein structure were predicted for selected variants. While some clusters are presenting the same variant with 100% identical bases, other SARS-CoV-2 lineages show a beginning diversification and phylogenetic clustering due to base substitutions and deletions in the genomes. First molecular epidemiological investigations are possible with the results by adding metadata as travelling history to the presented data. The advantage of variants in source tracing can be a challenge in terms of virulence, immune response, and immunological memory. Variants of viruses often show differences in virulence or antigenicity. This must also be considered in decisions like herd immunity. Diagnostic methods might not work if the variations or deletions are in target regions for the detection of the pathogen. One base substitution was detected in a primer binding site.
C1 [Kaden, Rene] Uppsala Univ, Dept Med Sci, S-75236 Uppsala, Sweden.
RP Kaden, R (corresponding author), Uppsala Univ, Dept Med Sci, S-75236 Uppsala, Sweden.
EM rene.kaden@medsci.uu.se
RI Kaden, Rene/T-8840-2017
OI Kaden, Rene/0000-0002-2111-9751
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Cohen BJ, 2006, J CLIN VIROL, V36, P152, DOI 10.1016/j.jcv.2006.01.011
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   DOMINGO E, 1993, J GEN VIROL, V74, P2039, DOI 10.1099/0022-1317-74-10-2039
   Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910
   Jiang DK, 2013, NAT GENET, V45, P72, DOI 10.1038/ng.2483
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Pung R, 2020, LANCET, V395, P1039, DOI 10.1016/S0140-6736(20)30528-6
   Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2
   Salipante SJ, 2015, J CLIN MICROBIOL, V53, P1072, DOI 10.1128/JCM.03385-14
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   World Health Organization (WHO), 84 WHO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
NR 14
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2020
VL 9
IS 6
AR 1615
DI 10.3390/jcm9061615
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA ML0XO
UT WOS:000549200100001
PM 32466577
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Guan, WJ
   Wei, CH
   Chen, AL
   Sun, XC
   Guo, GY
   Zou, X
   Shi, JD
   Lai, PZ
   Zheng, ZG
   Zhong, NS
AF Guan, Wei-Jie
   Wei, Chun-Hua
   Chen, Ai-Lan
   Sun, Xiao-Cong
   Guo, Guang-Yun
   Zou, Xu
   Shi, Jin-Dong
   Lai, Pei-Zhen
   Zheng, Ze-Guang
   Zhong, Nan-Shan
TI Hydrogen/oxygen mixed gas inhalation improves disease severity and
   dyspnea in patients with Coronavirus disease 2019 in a recent
   multicenter, open-label clinical trial
SO JOURNAL OF THORACIC DISEASE
LA English
DT Article
C1 [Guan, Wei-Jie; Zheng, Ze-Guang; Zhong, Nan-Shan] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou Inst Resp Hlth,Natl Clin Res Ctr Resp D, 151 Yanjiang Rd, Guangzhou, Peoples R China.
   [Wei, Chun-Hua] Weifang Weien Hosp, Dept Resp Med, Weifang, Peoples R China.
   [Wei, Chun-Hua] Wuhan Hanyang Hosp, Dept Resp Med, Wuhan, Peoples R China.
   [Chen, Ai-Lan] Guangzhou Med Univ, Affiliated Hosp 1, Dept Cardiol, Guangzhou, Peoples R China.
   [Chen, Ai-Lan] Wuhan Hankou Hosp, Dept Resp & Crit Care Med, Wuhan, Peoples R China.
   [Sun, Xiao-Cong] Guangdong Med Univ, Intens Care Unit, Affiliated Hosp, Zhanjiang, Peoples R China.
   [Sun, Xiao-Cong] Shishou Hosp Tradit Chinese Med, Intens Care Unit, Shishou, Peoples R China.
   [Guo, Guang-Yun] Wuhan Pulm Hosp, Dept Resp & Crit Care Med, Wuhan, Peoples R China.
   [Zou, Xu] Guangdong Hosp Tradit Chinese Med, Dept Resp & Crit Care Med, Guangzhou, Peoples R China.
   [Zou, Xu; Shi, Jin-Dong] Leishenshan Hosp, Dept Infect Dis, Wuhan, Peoples R China.
   [Shi, Jin-Dong] Shanghai Fifth Peoples Hosp, Dept Resp & Crit Care Med, Shanghai, Peoples R China.
   [Lai, Pei-Zhen] Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei, Taiwan.
RP Zhong, NS (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou Inst Resp Hlth,Natl Clin Res Ctr Resp D, 151 Yanjiang Rd, Guangzhou, Peoples R China.
EM nanshan@vip.163.com
CR Kneyber MCJ, 2006, INTENS CARE MED, V32, P1676, DOI 10.1007/s00134-006-0348-6
   Morgan SE, 2014, RESP CARE, V59, pE166, DOI 10.4187/respcare.02728
   National Health Commission, DIAGN TREATM PROT CO
   World Health Organization, COR DIS 2019 COVID 1
   Wu C, 2020, JAMA INT MED, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou ZQ, 2019, RESPIRATION, V97, P42, DOI 10.1159/000492031
NR 7
TC 5
Z9 5
U1 4
U2 4
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2072-1439
EI 2077-6624
J9 J THORAC DIS
JI J. Thorac. Dis.
PD JUN
PY 2020
VL 12
IS 6
BP 3448
EP 3452
DI 10.21037/jtd-2020-057
PG 5
WC Respiratory System
SC Respiratory System
GA MJ7IP
UT WOS:000548261200063
PM 32642277
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Buselli, R
   Baldanzi, S
   Corsi, M
   Chiumiento, M
   Del Lupo, E
   Carmassi, C
   Dell'Osso, L
   Cristaudo, A
AF Buselli, Rodolfo
   Baldanzi, Sigrid
   Corsi, Martina
   Chiumiento, Martina
   Del Lupo, Elena
   Carmassi, Claudia
   Dell'Osso, Liliana
   Cristaudo, Alfonso
TI Psychological Care of Health Workers during the COVID-19 Outbreak in
   Italy: Preliminary Report of an Occupational Health Department (AOUP)
   Responsible for Monitoring Hospital Staff Condition
SO SUSTAINABILITY
LA English
DT Article
DE COVID-19; pandemic; health care workers; occupational teams;
   multidisciplinary; psychological; psychiatric; combination therapy
ID MENTAL-HEALTH; DISORDERS; STRESS; INTERVENTIONS; FLEXIBILITY;
   PREVALENCE; SERVICES; CHINA
AB The recent worldwide COVID-19 outbreak provided a timely demonstration of the mental health needs of health care workers on the front lines of the response to the pandemic. In addition to international guidelines, local institutions demand rapid and practical approaches easily replicable in different populations and contests. The principal aim of this paper is to highlight and share the experience of an Occupational Health Department responsible for monitoring hospital staff conditions during the SARS-COV-2 pandemic phase 1. The multidisciplinary team of the Occupational Health Department of a major university hospital in central Italy (AOUP) developed a specific protocol calledPsicoCovid19in order to provide targeted help, based on new psychosocial risk factors, to workers involved in the COVID-19 emergency to preserve hospital staff health. As of the date of this report, 106 workers (79 female, 27 male, mean age respectively, 51 +/- 9.8, 45.7 +/- 10.1) requested this service, reporting mild to moderate subjective distress. Approximately 81% of all the participants were already monitored before the outbreak of the pandemic. Among the total sample, 60% received a remodeling of a previous therapeutic program. Meanwhile, 7% passed from a psychiatric therapy to a combination therapy with the addition of a psychological treatment. The results demonstrate that those who asked for help were primarily female nurses who already presented with mental health vulnerabilities. A more gender-specific, clinical approach is needed.
C1 [Buselli, Rodolfo; Baldanzi, Sigrid; Corsi, Martina; Chiumiento, Martina; Del Lupo, Elena; Cristaudo, Alfonso] Azienda Osped Univ Pisana, Dept Occupat Hlth, I-56100 Pisa, Italy.
   [Carmassi, Claudia; Dell'Osso, Liliana] Univ Pisa, Dept Clin & Expt Med, Psychiat Clin, I-56100 Pisa, Italy.
RP Corsi, M (corresponding author), Azienda Osped Univ Pisana, Dept Occupat Hlth, I-56100 Pisa, Italy.
EM r.buselli@gmail.com; sigridbaldanzi@gmail.com;
   dott.martinacorsi@gmail.com; martina.chiumiento@gmail.com;
   psico.ele@gmail.com; ccarmassi@gmail.com; liliana.dellosso@med.unipi.it;
   alfonso.cristaudo@med.unipi.it
RI ; Corsi, Martina/J-7227-2018
OI Buselli, Rodolfo/0000-0002-8641-812X; Chiumiento,
   Martina/0000-0002-0575-427X; Carmassi, Claudia/0000-0002-3662-8073;
   Corsi, Martina/0000-0002-1957-6160
CR Adalja AA, 2020, JAMA-J AM MED ASSOC, V323, P1343, DOI 10.1001/jama.2020.3413
   Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13
   Bond FW, 2006, J ORGAN BEHAV MANAGE, V26, P25, DOI 10.1300/J075v26n01_02
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Buselli R, 2016, MED LAV, V107, P92
   Buselli R, 2009, G Ital Med Lav Ergon, V31, P149
   Buselli R., 2020, MED LAV, V111
   Buselli R., 2020, CNS SPECTRUM
   Buselli R, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1298
   Carmassi C, 2018, ANN GEN PSYCHIATR, V17, DOI 10.1186/s12991-018-0184-4
   Carrieri D, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021273
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Cirrincione L, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12093603
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Howard F, 2008, AUST PSYCHOL, V43, P105, DOI 10.1080/00050060801978647
   Kang LJ, 2020, BRAIN BEHAV IMMUN, V87, P11, DOI 10.1016/j.bbi.2020.03.028
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593
   Kvaal K, 2005, INT J GERIATR PSYCH, V20, P629, DOI 10.1002/gps.1330
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Li W, 2020, INT J BIOL SCI, V16, P1732, DOI 10.7150/ijbs.45120
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Lloyd J, 2013, WORK STRESS, V27, P181, DOI 10.1080/02678373.2013.782157
   Olff M, 2017, EUR J PSYCHOTRAUMATO, V8, DOI 10.1080/20008198.2017.1351204
   Park JS, 2018, ARCH PSYCHIAT NURS, V32, P2, DOI 10.1016/j.apnu.2017.09.006
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Ramaci T, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12093834
   Remes O, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.497
   Ruotsalainen J, 2008, SCAND J WORK ENV HEA, V34, P169, DOI 10.5271/sjweh.1240
   RUOTSALAINEN JH, 2014, COCHRANE DB SYST REV, V13
   Tang WJ, 2020, J AFFECT DISORDERS, V274, P1, DOI 10.1016/j.jad.2020.05.009
   Walton M, 2020, EUR HEART J-ACUTE CA, V9, P241, DOI 10.1177/2048872620922795
   Williams P.G., 2017, OXFORD HDB ONLINE, P1
   World Health Organization, 2018, HLTH WORK OCC HLTH
   Xiang Y T, 2014, East Asian Arch Psychiatry, V24, P37
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   Zgueb Y, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113042
   Zhang J, 2020, PRECISION CLIN MED, V3, P3, DOI [10.1093/pcmedi/pbaa006, DOI 10.1093/pcmedi/pbaa006]
   2007, PSYCHIATRY, V70, P283, DOI DOI 10.1521/PSYC.2007.70.4.283
NR 39
TC 4
Z9 4
U1 8
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2071-1050
J9 SUSTAINABILITY-BASEL
JI Sustainability
PD JUN
PY 2020
VL 12
IS 12
AR 5039
DI 10.3390/su12125039
PG 16
WC Green & Sustainable Science & Technology; Environmental Sciences;
   Environmental Studies
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA ML1CC
UT WOS:000549212000001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Liu, S
   Zheng, Q
   Wang, ZY
AF Liu, Sen
   Zheng, Qiang
   Wang, Zhiying
TI Potential covalent drugs targeting the main protease of the SARS-CoV-2
   coronavirus
SO BIOINFORMATICS
LA English
DT Article
ID DISCOVERY; INHIBITORS; OPTIMIZATION; PROTEINASE; DOCKING
AB Motivation: Since December 2019, the newly identified coronavirus SARS-CoV-2 has caused a massive health crisis worldwide and resulted in over 70 000 COVID-19 infections so far. Clinical drugs targeting SARS-CoV-2 are urgently needed to decrease the high fatality rate of confirmed COVID-19 patients. Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19.
   Results: Compared with traditional non-covalent drugs, covalent drugs have attracted escalating attention recent years due to their advantages in potential specificity upon careful design, efficiency and patient burden. We recently developed a computational protocol named as SCAR (steric-clashes alleviating receptors) for discovering covalent drugs. In this work, we used the SCAR protocol to identify possible covalent drugs (approved or clinically tested) targeting the main protease (3CLpro) of SARS-CoV-2. We identified 11 potential hits, among which at least six hits were exclusively enriched by the SCAR protocol. Since the preclinical or clinical information of these identified drugs is already available, they might be ready for being clinically tested in the treatment of COVID-19.
C1 [Liu, Sen; Zheng, Qiang; Wang, Zhiying] Hubei Univ Technol, Minist Educ, Key Lab Ind Fermentat, Natl Ctr Cellular Regulat & Mol Pharmaceut 111, Wuhan 430068, Peoples R China.
   [Liu, Sen; Zheng, Qiang; Wang, Zhiying] Hubei Univ Technol, Sch Food & Biol Engn, Hubei Key Lab Ind Microbiol, Inst Biomed & Pharmaceut Sci, Wuhan 430068, Peoples R China.
RP Liu, S (corresponding author), Hubei Univ Technol, Minist Educ, Key Lab Ind Fermentat, Natl Ctr Cellular Regulat & Mol Pharmaceut 111, Wuhan 430068, Peoples R China.; Liu, S (corresponding author), Hubei Univ Technol, Sch Food & Biol Engn, Hubei Key Lab Ind Microbiol, Inst Biomed & Pharmaceut Sci, Wuhan 430068, Peoples R China.
EM senliu.ctgu@gmail.com
OI Liu, Sen/0000-0001-5182-7241
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31670768, 31971150]; Hubei Provincial
   Science and Technology Department [2019CFA069]; Wuhan Science and
   Technology Bureau of China [2018060401011319]
FX This work has been supported by the grants from National Natural Science
   Foundation of China [31670768 and 31971150], Hubei Provincial Science
   and Technology Department [2019CFA069] and Wuhan Science and Technology
   Bureau of China [2018060401011319].
CR Ai YB, 2016, J CHEM INF MODEL, V56, P1563, DOI 10.1021/acs.jcim.6b00334
   Barrett DG, 2004, BIOORG MED CHEM LETT, V14, P4897, DOI 10.1016/j.bmcl.2004.07.031
   Cha Y, 2018, BRIT J PHARMACOL, V175, P168, DOI 10.1111/bph.13798
   Cuesta A, 2020, J AM CHEM SOC, V142, P3392, DOI 10.1021/jacs.9b09684
   Furber M, 2014, J MED CHEM, V57, P2357, DOI 10.1021/jm401705g
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   Iberoamerica C, 2020, LANCET, V395, P497
   Kaitin KI, 2010, CLIN PHARMACOL THER, V87, P356, DOI 10.1038/clpt.2009.293
   Leaver-Fay A, 2011, METHOD ENZYMOL, P545, DOI [10.1016/S0076-6879(11)87019-9, 10.1016/B978-0-12-381270-4.00019-6]
   Liao CZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10754
   Mah R, 2014, BIOORG MED CHEM LETT, V24, P33, DOI 10.1016/j.bmcl.2013.10.003
   Maxmen A, 2020, NATURE, V578, P347, DOI 10.1038/d41586-020-00444-3
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Shannon DA, 2014, J AM CHEM SOC, V136, P3330, DOI 10.1021/ja4116204
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Zhang LJ, 2016, J MOL RECOGNIT, V29, P520, DOI 10.1002/jmr.2551
   Zhang Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00248
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 20
TC 6
Z9 6
U1 9
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
EI 1460-2059
J9 BIOINFORMATICS
JI Bioinformatics
PD JUN
PY 2020
VL 36
IS 11
BP 3295
EP 3298
DI 10.1093/bioinformatics/btaa224
PG 4
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA MM4GO
UT WOS:000550117300001
PM 32239142
OA Green Published
DA 2021-01-01
ER

PT J
AU Cleemput, S
   Dumon, W
   Fonseca, V
   Karim, WA
   Giovanetti, M
   Alcantara, LC
   Deforche, K
   de Oliveira, T
AF Cleemput, Sara
   Dumon, Wim
   Fonseca, Vagner
   Karim, Wasim Abdool
   Giovanetti, Marta
   Alcantara, Luiz Carlos
   Deforche, Koen
   de Oliveira, Tulio
TI Genome Detective Coronavirus Typing Tool for rapid identification and
   characterization of novel coronavirus genomes
SO BIOINFORMATICS
LA English
DT Article
ID MULTIPLE SEQUENCE ALIGNMENT; ALGORITHM
AB Genome detective is a web-based, user-friendly software application to quickly and accurately assemble all known virus genomes from next-generation sequencing datasets. This application allows the identification of phylogenetic clusters and genotypes from assembled genomes in FASTA format. Since its release in 2019, we have produced a number of typing tools for emergent viruses that have caused large outbreaks, such as Zika and Yellow Fever Virus in Brazil. Here, we present the Genome Detective Coronavirus Typing Tool that can accurately identify the novel severe acute respiratory syndrome (SARS)-related coronavirus (SARS-CoV-2) sequences isolated in China and around the world. The tool can accept up to 2000 sequences per submission and the analysis of a new whole-genome sequence will take approximately 1 min. The tool has been tested and validated with hundreds of whole genomes from 10 coronavirus species, and correctly classified all of the SARS-related coronavirus (SARSr-CoV) and all of the available public data for SARS-CoV-2. The tool also allows tracking of new viral mutations as the outbreak expands globally, which may help to accelerate the development of novel diagnostics, drugs and vaccines to stop the COVID-19 disease.
C1 [Cleemput, Sara; Dumon, Wim; Deforche, Koen] Emweb Bv, Herent, Belgium.
   [Fonseca, Vagner; Karim, Wasim Abdool; de Oliveira, Tulio] Univ KwaZulu Natal, KwaZulu Natal Res Innovat & Sequencing Platform K, Sch Lab Med & Med Sci, Coll Hlth Sci, Durban, South Africa.
   [Fonseca, Vagner; Alcantara, Luiz Carlos] Univ Fed Minas Gerais, Inst Ciencias Biol, Lab Genet Celular & Mol, Belo Horizonte, MG, Brazil.
   [Fonseca, Vagner] Minist Saude, Coordenacao Geral Lab Saude Publ, Secretaria Vigilancia Saude, CGLAB,SVS,MS, Brasilia, DF, Brazil.
   [Giovanetti, Marta; Alcantara, Luiz Carlos] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Flavivirus, Rio De Janeiro, RJ, Brazil.
   [de Oliveira, Tulio] Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa.
   [de Oliveira, Tulio] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
RP Deforche, K (corresponding author), Emweb Bv, Herent, Belgium.; de Oliveira, T (corresponding author), Univ KwaZulu Natal, KwaZulu Natal Res Innovat & Sequencing Platform K, Sch Lab Med & Med Sci, Coll Hlth Sci, Durban, South Africa.; de Oliveira, T (corresponding author), Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa.; de Oliveira, T (corresponding author), Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
EM koen@emweb.be; deoliveira@ukzn.ac.za
OI Fonseca, Vagner/0000-0001-5521-6448; Alcantara, Luiz/0000-0002-6769-9931
FU South African Medical Research Council [MRC-RFA-UFSP01-2013/UKZN
   HIVEPI]; VIROGENESIS project - European Union [634650]; National Human
   Genome Research Institute of the National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)
   [U24HG006941]
FX Research reported in this publication was supported by a research
   Flagship grant from the South African Medical Research Council
   (MRC-RFA-UFSP01-2013/UKZN HIVEPI), the VIROGENESIS project, which
   received funding from the European Union's Horizon 2020 Research and
   Innovation Programme (under Grant Agreement no. 634650) and the National
   Human Genome Research Institute of the National Institutes of Health
   under Award Number U24HG006941. H3ABioNet is an initiative of the Human
   Health and Heredity in Africa Consortium (H3Africa). The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.
CR Deforche K., 2017, BIORXIV, DOI [10.1101/200394, DOI 10.1101/200394]
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Fonseca V, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007231
   GOTOH O, 1982, J MOL BIOL, V162, P705, DOI 10.1016/0022-2836(82)90398-9
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Iberoamerica C, 2020, LANCET, V395, P497
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Lemoine F, 2018, NATURE, V556, P452, DOI 10.1038/s41586-018-0043-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Rambaut A., 2018, FIGTREE V1 4 4 I EVO
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5
   SWOFFORD D, 2003, PAUP 4 0 PHYLOGENETI
   Vilsker M, 2019, BIOINFORMATICS, V35, P871, DOI 10.1093/bioinformatics/bty695
   WHO, 2020, NOV COR COVID 19 SIT
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 16
TC 12
Z9 12
U1 9
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
EI 1460-2059
J9 BIOINFORMATICS
JI Bioinformatics
PD JUN
PY 2020
VL 36
IS 11
BP 3552
EP 3555
DI 10.1093/bioinformatics/btaa145
PG 4
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA MM4GO
UT WOS:000550117300035
PM 32108862
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Unni, JC
AF Unni, Jeeson C.
TI Coronavirus Disease (COVID-19) With Relevance to Pediatrics
SO INDIAN PEDIATRICS
LA English
DT Letter
ID VACCINES
C1 [Unni, Jeeson C.] Aster Medcity, Kochi, Kerala, India.
RP Unni, JC (corresponding author), Aster Medcity, Kochi, Kerala, India.
EM jeeson1955@gmail.com
CR Akmatov MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048508
   Balasubramanian H, 2020, INDIAN J PEDIATR, V87, P817, DOI 10.1007/s12098-020-03223-0
   Daniel H, 2015, ANN INTERN MED, V163, P787, DOI 10.7326/M15-0498
   Rodriguez-Gonzalez CG, 2019, J EVAL CLIN PRACT, V25, P28, DOI 10.1111/jep.13014
   Kirkpatrick BD, 2015, AM J TROP MED HYG, V92, P744, DOI 10.4269/ajtmh.14-0518
   Lurie N, 2018, JAMA INTERN MED, V178, P745, DOI 10.1001/jamainternmed.2018.1314
   Martinez KA, 2018, J GEN INTERN MED, V33, P1768, DOI 10.1007/s11606-018-4621-5
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   WHO, BAC CALM GUER BCG VA
NR 9
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0019-6061
EI 0974-7559
J9 INDIAN PEDIATR
JI Indian Pediatrics
PD JUN
PY 2020
VL 57
IS 6
BP 582
EP 583
AR PII S097475591600164
PG 2
WC Pediatrics
SC Pediatrics
GA MI5QN
UT WOS:000547462300028
PM 32336685
DA 2021-01-01
ER

PT J
AU Kumar, J
   Meena, J
AF Kumar, Jogender
   Meena, Jitendra
TI Demystifying BCG Vaccine and COVID-19 Relationship
SO INDIAN PEDIATRICS
LA English
DT Letter
C1 [Kumar, Jogender] Postgrad Inst Med Educ & Res, Dept Pediat, Chandigarh, India.
   [Meena, Jitendra] All India Inst Med Sci, New Delhi, India.
RP Kumar, J (corresponding author), Postgrad Inst Med Educ & Res, Dept Pediat, Chandigarh, India.
EM Jogendrayadv@gmail.com
CR Abbott S, 2019, VACCINE, V37, P5067, DOI 10.1016/j.vaccine.2019.06.056
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Ella KM, 2020, INDIAN PEDIAT
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   SAGE Working Group on BCG Vaccines and WHO Secretariat, 2017, REP BCG VACC US PROT
   Usher NT, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.12014
   WHO, BAC CALM GUER BCG VA
NR 7
TC 8
Z9 8
U1 1
U2 2
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0019-6061
EI 0974-7559
J9 INDIAN PEDIATR
JI Indian Pediatrics
PD JUN
PY 2020
VL 57
IS 6
BP 588
EP 589
AR PII S097475591600168
PG 2
WC Pediatrics
SC Pediatrics
GA MI5QN
UT WOS:000547462300033
PM 32358227
DA 2021-01-01
ER

PT J
AU Ding, ZQ
   Xie, LL
   Guan, AC
   Huang, DD
   Mao, ZF
   Liang, XH
AF Ding, Zhuqing
   Xie, Lingling
   Guan, Anchen
   Huang, Dandan
   Mao, Zongfu
   Liang, Xiaohui
TI Global COVID-19: Warnings and suggestions based on experience of China
SO JOURNAL OF GLOBAL HEALTH
LA English
DT Article
AB Background Corona Virus Disease 2019 (COVID-19) is spreading around the world currently, seriously threatening people's health and global security as an international public health emergency. The objective of this study is to summarize China's countermeasures and experience in response to the COVID-19 emergence in order to serve as a warning for the global COVID-19 prevention and control, and further provide some suggestions for global fighting to COVID-19.
   Methods Content analysis, expert consultation, and high frequency word analysis were applied in this study. Relevant data and information were collected from official websites, the experience accumulated in China during the fighting to the novel coronavirus, and suggestions from some experts.
   Results As of March 29, 2020, China had accumulated 82 419 confirmed diagnoses, and the mortality rate was 4.01%; in the mean time, the global had accumulated 596 042 confirmed diagnoses, and the mortality rate was 4.76%. Although the mortality of COVID-19 was not so high, its harmfulness couldn't be ignored. Ten facts during COVID-19 epidemic in China were summarized in the study, including: the COVID-19 is highly contagious and can be spread through many channels; although elderly people and people with underlying diseases are susceptible, young people can also be victims; isolation is the most effective way to reduce the risk of COVID-19, and secondary disasters induced by COVID-19 should be emphasized in advance. High frequent words of experts' suggestions mainly includes: material, prevention and control, pathogeny, propaganda, education, hygiene, technology, medical care, overall planning, policy, panic, etc. The main concerns of experts are from four aspects: publicity and education, various subjects, medical materials and law construction.
   Conclusions COVI D-19 is a new infectious disease worldwide, and its infectious source, transmission route, susceptible population, and therapy are not clear. In the face of the COVID-19 epidemic, no country can stand alone to maintain its own safety. People from all over the world should put aside their difference in ideology, religious belief, politics, economy, and culture, and only by global cooperation and globally unified actions, can we successfully overcome COVID-19 in the end.
C1 [Ding, Zhuqing; Xie, Lingling; Guan, Anchen; Huang, Dandan; Mao, Zongfu; Liang, Xiaohui] Wuhan Univ, Sch Hlth Sci, Global Hlth Inst, Wuhan, Peoples R China.
RP Liang, XH (corresponding author), Wuhan Univ, Sch Hlth Sci, Global Hlth Inst, Wuhan, Peoples R China.
EM xhliang@whu.edu.cn
FU National key research and development plan of China [2017YFC1200500];
   National natural science foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [71573192]
FX National key research and development plan of China (Project number:
   2017YFC1200500) and National natural science foundation of China
   (Project number: 71573192).
CR [Anonymous], 2020, NETEASE NEWS
   [Anonymous], 2020, CHINATIMES
   [Anonymous], 2020, HLTH 2 DIMENSIONAL C
   [Anonymous], 2020, SOHU
   [Anonymous], 2020, IFENG
   [Anonymous], 2020, 11 CABIN HOSP WERE B
   [Anonymous], 2020, TENCENT
   [Anonymous], 2020, WUH CLOS CIT
   [Anonymous], 2020, CHINANEWS       0304
   [Anonymous], 2020, 11048000000000 YUAN
   [Anonymous], 2020, CHINA DAILY
   [Anonymous], 2020, GUANGMING
   [Anonymous], 2020, CHINA CAIXIN
   [Anonymous], 2020, PEOPLES DAILY
   [Anonymous], 2020, CHINANEWS
   Beijing Youth Daily, 2020, BEIJING YOUTH DAILY
   CCTV, 2020, CCTV
   Central commission for discipline inspection and state supervision, 2020, CLIN TRIAL REMDESIVI
   Chang D, 2020, LANCET RESP MED, V8, pE13, DOI 10.1016/S2213-2600(20)30066-7
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li H, 2020, GLOBAL HLTH RES POLI, P5
   National health commission of PRC, 2020, COVID 19 EP PREV CON
   Zhu H, 2020, GLOBAL HLTH RES POLI, P5
NR 24
TC 0
Z9 1
U1 21
U2 25
PU UNIV EDINBURGH, GLOBAL HEALTH SOC
PI EDINBURGH
PA CENTRE POPULATION HEALTH SCIENCES, OLD MEDICAL SCH, TEVIOT PL,
   EDINBURGH, EH8 9AG, SCOTLAND
SN 2047-2978
EI 2047-2986
J9 J GLOB HEALTH
JI J. Glob. Health
PD JUN
PY 2020
VL 10
IS 1
AR 011005
DI 10.7189/jogh.10.011005
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MM1DB
UT WOS:000549898000145
PM 32509294
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zipprich, HM
   Teschner, U
   Witte, OW
   Schonenberg, A
   Prell, T
AF Zipprich, Hannah M.
   Teschner, Ulrike
   Witte, Otto W.
   Schoenenberg, Aline
   Prell, Tino
TI Knowledge, Attitudes, Practices, and Burden During the COVID-19 Pandemic
   in People with Parkinson's Disease in Germany
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE knowledge; attitudes; practices; COVID-19; pandemic
ID NONMOTOR SYMPTOMS QUESTIONNAIRE
AB Background:Adherence to measures that have been adopted during the COVID-19 pandemic is crucial to control the spread of the coronavirus.Methods:Semi-structured telephone interviews were performed with 99 patients with Parkinson's disease (PD) and 21 controls to explore knowledge, attitudes, practices, and burden in order to elucidate nonadherence to preventive measures.Results:The majority of patients understood the preventive measures and felt sufficiently informed. Analysis of qualitative answers, however, showed that about 30% of patients had an insufficient level of knowledge, which was not associated with educational level, cognitive disorders, or depression. Changes in behaviour were reported by 73 patients (99% performed at least one specific preventive behavior, and 86.9% have reduced social contacts and stayed home). A closer analysis of qualitative answers showed that 27.3% of patients continued to meet relatives face-to-face almost daily. Anxiety and worries about the current situation were reported by 58.6% of patients; 31.3% complained about a decrease in their mobility since the beginning of the restrictions, mainly because of worsening of PD and because regular therapies (e.g., physiotherapy) were canceled.Conclusions:About 30% of PD patients are nonadherent to preventive measures. Use of simple dichotomous questions overestimates adherence to preventive measures in patients with PD.
C1 [Zipprich, Hannah M.; Teschner, Ulrike; Witte, Otto W.; Schoenenberg, Aline; Prell, Tino] Jena Univ Hosp, Dept Neurol, D-07743 Jena, Germany.
   [Zipprich, Hannah M.; Witte, Otto W.; Prell, Tino] Jena Univ Hosp, Ctr Hlth Ageing, D-07743 Jena, Germany.
RP Prell, T (corresponding author), Jena Univ Hosp, Dept Neurol, D-07743 Jena, Germany.; Prell, T (corresponding author), Jena Univ Hosp, Ctr Hlth Ageing, D-07743 Jena, Germany.
EM hannah.zipprich@med.uni-jena.de; ulrike.teschner@med.uni-jena.de;
   otto.witte@med.uni-jena.de; aschoenenberg@online.de;
   tino.prell@med.uni-jena.de
FU Bundesministerium fur Bildung und Forschung (BMBF)Federal Ministry of
   Education & Research (BMBF) [01GY1804]
FX This work was supported by a Bundesministerium fur Bildung und Forschung
   (BMBF) grant to TP (01GY1804).
CR do Nascimento IB, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040941
   Chaudhuri KR, 2006, MOVEMENT DISORD, V21, P916, DOI 10.1002/mds.20844
   Goetz CG, 2007, MOVEMENT DISORD, V22, P41, DOI 10.1002/mds.21198
   Helmich RC, 2020, J PARKINSON DIS, V10, P351, DOI 10.3233/JPD-202038
   Koo JR, 2020, LANCET INFECT DIS, V20, P678, DOI 10.1016/S1473-3099(20)30162-6
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   Person B, 2004, EMERG INFECT DIS, V10, P358, DOI 10.3201/eid1002.030750
   Prasad S, 2020, MOVEMENT DISORD, V35, P912, DOI 10.1002/mds.28088
   Prell T, 2019, DATA BRIEF, V23, DOI 10.1016/j.dib.2019.103855
   Prell T, 2019, RES SOC ADMIN PHARM, V15, P1419, DOI 10.1016/j.sapharm.2019.01.001
   Prell T, 2019, PATIENT PREFER ADHER, V13, P151, DOI 10.2147/PPA.S186732
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Romenets SR, 2012, PARKINSONISM RELAT D, V18, P54, DOI 10.1016/j.parkreldis.2011.08.013
   Shahid Z, 2020, J AM GERIATR SOC, V68, P926, DOI 10.1111/jgs.16472
   Tachfouti N, 2012, PAN AFR MED J, V12
   Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221
NR 16
TC 7
Z9 7
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2020
VL 9
IS 6
AR 1643
DI 10.3390/jcm9061643
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA ML1DE
UT WOS:000549214800001
PM 32486074
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jozaghi, E
   Maynard, R
   Hamm, D
   Marsh, S
AF Jozaghi, Ehsan
   Maynard, Russ
   Hamm, Dave
   Marsh, Samona
TI COVID-19 and people who use drugs: a call for action
SO CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE
LA English
DT Letter
C1 [Jozaghi, Ehsan] British Columbia Ctr Dis Control, 655 W 12th Ave, Vancouver, BC V5Z 4R4, Canada.
   [Jozaghi, Ehsan] Univ British Columbia, Sch Populat & Publ Hlth, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.
   [Maynard, Russ] PHS Community Serv Soc, 9 E Hastings St, Vancouver, BC V6A 1M9, Canada.
   [Hamm, Dave] Vancouver Area Network Drug Users, 380 E Hastings St, Vancouver, BC V6A 1P4, Canada.
   [Marsh, Samona] Western Aboriginal Harm Reduct Soc, 380 E Hastings St, Vancouver, BC V6A 1P4, Canada.
   [Marsh, Samona] BC Yukon Assoc Drug War Survivors, 380 E Hastings St, Vancouver, BC V6A 1P4, Canada.
   [Marsh, Samona] Sex Workers United Violence, 334 Alexander St, Vancouver, BC V6A 1C3, Canada.
   [Marsh, Samona] Canadian Assoc People Who Use Drugs, Vancouver, BC, Canada.
RP Jozaghi, E (corresponding author), British Columbia Ctr Dis Control, 655 W 12th Ave, Vancouver, BC V5Z 4R4, Canada.; Jozaghi, E (corresponding author), Univ British Columbia, Sch Populat & Publ Hlth, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.
EM ejozaghi@yahoo.com
OI /0000-0002-3555-085X
CR [Anonymous], 2019, NOVEL CORONAVIRUS 20
   Ling J, 2020, VICE NEWS
   The Canadian Press, 2020, VANCOUVER SUN
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Woo A, 2020, THE GLOBE MAIL
NR 5
TC 5
Z9 3
U1 1
U2 1
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0008-4263
EI 1920-7476
J9 CAN J PUBLIC HEALTH
JI Can. J. Public Health-Rev. Can. Sante Publ.
PD JUN
PY 2020
VL 111
IS 3
SI SI
BP 401
EP 402
DI 10.17269/s41997-020-00326-1
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MH7ZB
UT WOS:000546941100013
PM 32406015
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Priyadarshini, I
   Mohanty, P
   Kumar, R
   Son, LH
   Chau, HTM
   Nhu, VH
   Ngo, PTT
   Bui, DT
AF Priyadarshini, Ishaani
   Mohanty, Pinaki
   Kumar, Raghvendra
   Son, Le Hoang
   Chau, Hoang Thi Minh
   Nhu, Viet-Ha
   Thi Ngo, Phuong Thao
   Tien Bui, Dieu
TI Analysis of Outbreak and Global Impacts of the COVID-19
SO HEALTHCARE
LA English
DT Article
DE corona virus; global impacts; global pandemic; COVID-19; severe acute
   respiratory syndrome (SARS)
ID CORONAVIRUS COVID-19; PNEUMONIA; WUHAN; CHINA; SARS
AB Corona viruses are a large family of viruses that are not only restricted to causing illness in humans but also affect animals such as camels, cattle, cats, and bats, thus affecting a large group of living species. The outbreak of Corona virus in late December 2019 (also known as COVID-19) raised major concerns when the outbreak started getting tremendous. While the first case was discovered in Wuhan, China, it did not take long for the disease to travel across the globe and infect every continent (except Antarctica), killing thousands of people. Since it has become a global concern, different countries have been working toward the treatment and generation of vaccine, leading to different speculations. While some argue that the vaccine may only be a few weeks away, others believe that it may take some time to create the vaccine. Given the increasing number of deaths, the COVID-19 has caused havoc worldwide and is a matter of serious concern. Thus, there is a need to study how the disease has been propagating across continents by numbers as well as by regions. This study incorporates a detailed description of how the COVID-19 outbreak started in China and managed to spread across the globe rapidly. We take into account the COVID-19 outbreak cases (confirmed, recovered, death) in order to make some observations regarding the pandemic. Given the detailed description of the outbreak, this study would be beneficial to certain industries that may be affected by the outbreak in order to take timely precautionary measures in the future. Further, the study lists some industries that have witnessed the impact of the COVID-19 outbreak on a global scale.
C1 [Priyadarshini, Ishaani] Univ Delaware, Dept Elect & Comp Sci, Newark, DE 19716 USA.
   [Mohanty, Pinaki] Purdue Univ, Dept Comp Sci, 610 Purdue Mall, W Lafayette, IN 47907 USA.
   [Kumar, Raghvendra] GIET Univ, Comp Sci & Engn Dept, Gunupur 765022, Odisha, India.
   [Son, Le Hoang] Vietnam Natl Univ, VNU Informat Technol Inst, Hanoi 010000, Vietnam.
   [Chau, Hoang Thi Minh] Univ Econ & Tech Ind, Fac Informat Technol, Hanoi 010000, Vietnam.
   [Nhu, Viet-Ha] Ton Duc Thang Univ, Geog Informat Sci Res Grp, Ho Chi Minh City 700000, Vietnam.
   [Nhu, Viet-Ha] Ton Duc Thang Univ, Fac Environm & Labour Safety, Ho Chi Minh City 700000, Vietnam.
   [Thi Ngo, Phuong Thao] Duy Tan Univ, Inst Res & Dev, Da Nang 550000, Vietnam.
   [Tien Bui, Dieu] Univ South Eastern Norway, Dept Business & IT, Gullbringvegen 36, N-3800 Boitelemark, Norway.
RP Nhu, VH (corresponding author), Ton Duc Thang Univ, Geog Informat Sci Res Grp, Ho Chi Minh City 700000, Vietnam.; Nhu, VH (corresponding author), Ton Duc Thang Univ, Fac Environm & Labour Safety, Ho Chi Minh City 700000, Vietnam.
EM ishaani@udel.edu; mohantypinakiranjan@gmail.com;
   raghvendraagrawal7@gmail.com; sonlh@vnu.edu.vn; hgchau85@gmail.com;
   nhuvietha@tdtu.edu.vn; ngotphuongthao5@duytan.edu.vn; Dieu.T.Bui@usn.no
RI priyadarshini, ishaani/AAW-3437-2020; Tien Bui, Dieu/K-2125-2012
OI priyadarshini, ishaani/0000-0002-8826-8065; Tien Bui,
   Dieu/0000-0001-5161-6479; Thi Phuong Thao, Ngo/0000-0002-6574-5762
FU University of South-Eastern Norway; BOiTelemark, Norway
FX The open access fee was supported by the University of South-Eastern
   Norway, BOiTelemark, Norway.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa011
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Chowell G, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0450-0
   Dorigatti I., 2020, IMP COLL LOND, V4, P1
   Du Z., 2020, EMERG INFECT DIS, V26, P234
   Feng YJ, 2007, COMP IMMUNOL MICROB, V30, P309, DOI 10.1016/j.cimid.2007.05.009
   Gaythorpe K., SYMPTOM PROGRESSION
   Gough C., 2020, NHL REVENUE LOSS DUE
   Gough C., 2020, FORMULA ONE REVENUE
   Gough C., 2020, TOKYO 2020 COST DUE
   Guarner J., 2020, AM J CLIN PATHOL, V5, P54
   Hassan SA, 2020, CUREUS, V12, DOI 10.7759/cureus.7355
   Huang W.H., 2020, J MICROBIOL IMMUNOL, V20, P1182
   Imai N., 2020, IMP COLL LOND, V2, P1
   Ivorra B., 2020, VALIDATION FORECASTS
   Ji Y., 2020, LANCET GLOB HEALTH, V8, P21
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Lock S., 2020, COVID19 DAILYYEARONY
   Lock S., 2020, COVID19 TRAVEL TOURI
   MacIntyre C.R., 2020, GLOB BIOSECURITY, V1, P74, DOI [10.31646/gbio.13, DOI 10.31646/GBIO.13]
   MacIntyre CR, 2020, PUBLIC HEALTH RES PR, V30, DOI 10.17061/phrp3012000
   Millán-Oñate José, 2020, Infect., V24, P187, DOI 10.22354/in.v24i3.848
   Millet JK, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.125
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Qian L, 2020, RADIOL CARDIOTHORAC, V2, pe200033, DOI DOI 10.1148/RYCT.2020200033
   Raj VS, 2014, CURR OPIN VIROL, V5, P58, DOI 10.1016/j.coviro.2014.01.010
   Sahin A., 2020, EURASIAN J MED ONCOL, V4, P1, DOI DOI 10.14744/ejmo.2020.12220
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Smith N, 2020, AM J PUBLIC HEALTH, V110, P648, DOI 10.2105/AJPH.2020.305618
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Statista Research Department, 2020, COVID19 IMP FLIGHT F
   Stoecklin SB, 2020, EUROSURVEILLANCE, V25, P20, DOI 10.2807/1560-7917.ES.2020.25.6.2000094
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Walker P., 2020, GLOBAL IMPACT COVID, DOI [DOI 10.25561/77735, 10.25561/77735]
   Watson A., 2020, REVENUE IMPACT CORON
   WHO, 2020, COR VIR DIS 2019 COV
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang S, 2020, INT J INFECT DIS, V93, P201, DOI 10.1016/j.ijid.2020.02.033
   Zhou P, 2018, NATURE, V556, P255, DOI 10.1038/s41586-018-0010-9
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zu Z.Y., 2020, RADIOLOGY, V295, P200490
NR 45
TC 1
Z9 1
U1 5
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9032
J9 HEALTHCARE-BASEL
JI Healthcare
PD JUN
PY 2020
VL 8
IS 2
AR 148
DI 10.3390/healthcare8020148
PG 17
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA MJ4KA
UT WOS:000548056900011
PM 32485875
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, LM
AF Li, Luming
TI Challenges and Priorities in Responding to COVID-19 in Inpatient
   Psychiatry
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID THERAPY
AB This Open Forum focuses on specific challenges, contingency planning considerations, and downstream impacts of COVID-19 on inpatient psychiatric care. COVID-19 is a novel coronavirus that has been declared a pandemic. Challenges for inpatient psychiatry include risky close contact among staff and patients, space constraints, and structural barriers in care delivery. Nuanced considerations of five contingency planning strategies in response to COVID-19 are described, including COVID-19-specific precautions, visitor restrictions, physician workforce considerations, operational adjustments, and group therapy changes. Organized leadership and clear communication are identified as early priorities in pandemic response to minimize misinformation and address immediate challenges.
C1 [Li, Luming] Yale Sch Med, Dept Psychiat, New Haven, CT 06510 USA.
   [Li, Luming] Yale New Haven Psychiat Hosp, New Haven, CT 06519 USA.
RP Li, LM (corresponding author), Yale Sch Med, Dept Psychiat, New Haven, CT 06510 USA.; Li, LM (corresponding author), Yale New Haven Psychiat Hosp, New Haven, CT 06519 USA.
EM luming.li@yale.edu
CR Al-Tawfiq J.A., 2020, TRAVEL MED INFECT DI
   [Anonymous], 2020, IMPL MIT STRAT COMM
   Clarke JR, 2007, AM J MED QUAL, V22, P311, DOI 10.1177/1062860607304743
   Esseling Petra, 2018, Manag Care, V27, P37
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Linden M, 2006, PSYCHOTHER PSYCH MED, V56, P390, DOI 10.1055/s-2006-940012
   Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1036
   PRUNIER P, 1989, GEN HOSP PSYCHIAT, V11, P278, DOI 10.1016/0163-8343(89)90076-5
   Salmoiraghi A, 2015, J PSYCHIATR PRACT, V21, P389, DOI 10.1097/PRA.0000000000000103
   Springer T, 1996, HARVARD REV PSYCHIAT, V3, P268, DOI 10.3109/10673229609017194
   Stuart S, 1997, GEN HOSP PSYCHIAT, V19, P42, DOI 10.1016/S0163-8343(96)00122-3
   van Doremalen N, 2020, N ENGL J MED
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 14
TC 16
Z9 16
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI WASHINGTON
PA 800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUN
PY 2020
VL 71
IS 6
BP 624
EP 626
DI 10.1176/appi.ps.202000166
PG 3
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychiatry
GA MG8YX
UT WOS:000546320700017
PM 32321388
OA Bronze
DA 2021-01-01
ER

PT J
AU Younes, AB
   Hasan, Z
AF Younes, Ahmad Bani
   Hasan, Zeaid
TI COVID-19: Modeling, Prediction, and Control
SO APPLIED SCIENCES-BASEL
LA English
DT Article
DE coronavirus; Lotka-Volterra; Kalman Filter; modeling; epidemic
AB The newly emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, has been recognized as a pandemic by the World Health Organization (WHO) on 11th March 2020. There are many unknowns about this virus to date and no vaccine or conclusive treatment due to the lack of understanding of its pathogenesis and proliferation pathways which are unknown and cannot be traced. The prime objective is to stop its spread worldwide. This article aims to provide predictions of its spread using a stochastic Lotka-Volterra model coupled with an extended Kalman Filter (EKF) algorithm to model the COVID-19 dynamics. Our results show the feasibility of utilizing this model for predicting the spread of the virus and the ability of different control measures (e.g., social distancing) on reducing the number of affected people.
C1 [Younes, Ahmad Bani] San Diego State Univ, Aerosp Engn, 5500 Campanile Dr, San Diego, CA 92182 USA.
   [Hasan, Zeaid] Natl Univ, San Diego, CA 92123 USA.
RP Younes, AB (corresponding author), San Diego State Univ, Aerosp Engn, 5500 Campanile Dr, San Diego, CA 92182 USA.
EM abaniyounes@sdsu.edu; zeadnws@gmail.com
OI Bani Younes, Ahmad/0000-0002-3329-5824
CR Alshawaqfeh M, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3605-x
   [Anonymous], 2020, 13 PHOTOS NEW YORK C
   [Anonymous], 2020, CORONAVIRUS DIS COVI
   [Anonymous], 2020, FLIGHT TRACKING STAT
   Bani-Younes A., 2013, THESIS
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa008
   Crassidis J. L., 2011, CHAPMAN HALL CRC APP
   GOEL NS, 1971, REV MOD PHYS, V43, P231, DOI 10.1103/RevModPhys.43.231
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   Lotka AJ, 1910, J PHYS CHEM-US, V14, P271, DOI 10.1021/j150111a004
   Rismanbaf A, 2020, ARCH ACAD EMERG MED, V8
   Stein RR, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003388
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
NR 13
TC 5
Z9 5
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3417
J9 APPL SCI-BASEL
JI Appl. Sci.-Basel
PD JUN
PY 2020
VL 10
IS 11
AR 3666
DI 10.3390/app10113666
PG 14
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Engineering; Materials Science; Physics
GA MC6HQ
UT WOS:000543385900003
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Roschewski, M
   Lionakis, MS
   Sharman, JP
   Roswarski, J
   Goy, A
   Monticelli, MA
   Roshon, M
   Wrzesinski, SH
   Desai, JV
   Zarakas, MA
   Collen, J
   Rose, KM
   Hamdy, A
   Izumi, R
   Wright, GW
   Chung, KK
   Baselga, J
   Staudt, LM
   Wilson, WH
AF Roschewski, Mark
   Lionakis, Michail S.
   Sharman, Jeff P.
   Roswarski, Joseph
   Goy, Andre
   Monticelli, M. Andrew
   Roshon, Michael
   Wrzesinski, Stephen H.
   Desai, Jigar V.
   Zarakas, Marissa A.
   Collen, Jacob
   Rose, Keith M.
   Hamdy, Ahmed
   Izumi, Raquel
   Wright, George W.
   Chung, Kevin K.
   Baselga, Jose
   Staudt, Louis M.
   Wilson, Wyndham H.
TI Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
SO SCIENCE IMMUNOLOGY
LA English
DT Article
ID ACALABRUTINIB ACP-196; PNEUMONIA; INFLAMMASOMES; PATHOGENESIS;
   MACROPHAGES; INTERFERON; CYTOKINES; DISEASE; CHINA; CELLS
AB Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off label to 19 patients hospitalized with severe COVID-19 (11 on supplemental oxygen and 8 on mechanical ventilation), 18 of whom had increasing oxygen requirements at baseline. Over a 10- to 14-day treatment course, initiation of acalabrutinib treatment was associated with improved oxygenation in a majority of patients, often within 1 to 3 days, and had no discernable toxicity. Measures of inflammation-C-reactive protein and interleukin-6 (IL-6)-normalized quickly in most patients, as did lymphopenia, in correlation with improved oxygenation. At the end of acalabrutinib treatment, 8 of 11 (72.7%) patients in the supplemental oxygen cohort had been discharged on room air, and 4 of 8 (50%) patients in the mechanical ventilation cohort had been successfully extubated, with 2 of 8 (25%) discharged on room air. Ex vivo analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production in blood monocytes from patients with severe COVID-19 compared with blood monocytes from healthy volunteers. These results suggest that targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19 and has led to a confirmatory international prospective randomized controlled clinical trial.
C1 [Roschewski, Mark; Staudt, Louis M.; Wilson, Wyndham H.] NCI, Lymphoid Malignancies Branch, Bethesda, MD 20892 USA.
   [Lionakis, Michail S.; Desai, Jigar V.; Zarakas, Marissa A.] NIAID, Fungal Pathogenesis Sect, Lab Clin Immunol & Microbiol, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Sharman, Jeff P.] US Oncol, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA.
   [Roswarski, Joseph] Walter Reed Natl Mil Med Ctr, Dept Hematol Oncol, Bethesda, MD USA.
   [Goy, Andre; Rose, Keith M.] Hackensack Meridian & Sch Med, John Theurer Canc Ctr, Seton Hall, NJ USA.
   [Monticelli, M. Andrew] US Oncol, Rocky Mt Canc Ctr, Colorado Springs, CO USA.
   [Roshon, Michael] Penrose St Francis Hlth Serv, Dept Emergency Med, Colorado Springs, CO USA.
   [Roshon, Michael] US Acute Care Solut, Canton, OH USA.
   [Wrzesinski, Stephen H.; Chung, Kevin K.] St Peters Hosp, Dept Med, Albany, NY USA.
   [Wrzesinski, Stephen H.; Chung, Kevin K.] US Oncol, Albany, NY USA.
   [Collen, Jacob] Uniformed Serv Univ Hlth Sci, Dept Med, Room A3060, Bethesda, MD 20814 USA.
   [Hamdy, Ahmed; Izumi, Raquel] Acerta Pharma, San Francisco, CA USA.
   [Wright, George W.] NCI, Biometr Res Branch, Div Canc Diag & Treatment, Bethesda, MD 20892 USA.
   [Baselga, Jose] AstraZeneca, One MedImmune Way, Gaithersburg, MD USA.
RP Wilson, WH (corresponding author), NCI, Lymphoid Malignancies Branch, Bethesda, MD 20892 USA.
EM wilsonw@nih.gov
OI Roshon, Michael/0000-0002-8929-5583; Roschewski,
   Mark/0000-0003-0278-2635
FU Intramural Research Program of the NIH: National Cancer Institute,
   Center for Cancer ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); National Institute of Allergy and Infectious
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID)
FX This work is supported by the Intramural Research Program of the NIH:
   National Cancer Institute, Center for Cancer Research, and National
   Institute of Allergy and Infectious Diseases. Individual hospitals
   provided commercial supply of the study drug for off-label use.
CR Ahn IE, 2016, BLOOD, V128, P1940, DOI 10.1182/blood-2016-06-722991
   Atianand MK, 2013, CELL, V153, P272, DOI 10.1016/j.cell.2013.03.009
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Barf T, 2017, J PHARMACOL EXP THER, V363, P240, DOI 10.1124/jpet.117.242909
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Bittner Z. A., 2020, BIORXIV
   Bracaglia C, 2017, PEDIATR RHEUMATOL, V15, DOI 10.1186/s12969-016-0130-4
   Buja LM, 2020, CARDIOVASC PATHOL, V48, DOI 10.1016/j.carpath.2020.107233
   Byrd JC, 2016, NEW ENGL J MED, V374, P323, DOI 10.1056/NEJMoa1509981
   Byrne JC, 2013, J IMMUNOL, V190, P5207, DOI 10.4049/jimmunol.1300057
   Chang BY, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3400
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Crayne CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00119
   Feng MY, 2015, P NATL ACAD SCI USA, V112, P2145, DOI 10.1073/pnas.1424907112
   Florence JM, 2018, AM J PHYSIOL-LUNG C, V315, pL52, DOI 10.1152/ajplung.00047.2018
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   Herold S, 2015, EUR RESPIR J, V45, P1463, DOI 10.1183/09031936.00186214
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Ito M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8360
   Joyce E, 2013, EUR HEART J-ACUTE CA, V2, P77, DOI 10.1177/2048872612471215
   Kamphuis E, 2006, BLOOD, V108, P3253, DOI 10.1182/blood-2006-06-027599
   Lionakis MS, 2018, ANNU REV IMMUNOL, V36, P157, DOI 10.1146/annurev-immunol-042617-053318
   Lionakis MS, 2017, CANCER CELL, V31, P833, DOI 10.1016/j.ccell.2017.04.012
   Lionakis MS, 2003, LANCET, V362, P1828, DOI 10.1016/S0140-6736(03)14904-5
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
   Nicolson Phillip L R, 2020, Haematologica, DOI 10.3324/haematol.2019.218545
   Owen C, 2019, CURR ONCOL, V26, pE233, DOI 10.3747/co.26.4345
   Page TH, 2018, BIOCHEM BIOPH RES CO, V499, P260, DOI 10.1016/j.bbrc.2018.03.140
   Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Spada C, 2011, J CRIT CARE, V26, P510, DOI 10.1016/j.jcrc.2010.08.015
   Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759
   Sun LJ, 2010, CELL, V140, P436, DOI 10.1016/j.cell.2010.01.041
   Sun QZ, 2017, J ALLERGY CLIN IMMUN, V140, P510, DOI 10.1016/j.jaci.2016.11.013
   Tatematsu M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2857
   Treon SP, 2020, BLOOD, V135, P1912, DOI 10.1182/blood.2020006288
   Volmering S, 2016, IMMUNITY, V44, P73, DOI 10.1016/j.immuni.2015.11.011
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang M, 2018, LANCET, V391, P659, DOI 10.1016/S0140-6736(17)33108-2
   Weber ANR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01454
   WHO, 2016, GUID MAN ETH ISS INF
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Yoshikawa T, 2009, J VIROL, V83, P3039, DOI 10.1128/JVI.01792-08
NR 54
TC 44
Z9 45
U1 3
U2 3
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2470-9468
J9 SCI IMMUNOL
JI Sci. Immunol.
PD JUN
PY 2020
VL 5
IS 48
AR eabd0110
DI 10.1126/sciimmunol.abd0110
PG 13
WC Immunology
SC Immunology
GA MH8TC
UT WOS:000546993600010
PM 32503877
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Weiskopf, D
   Schmitz, KS
   Raadsen, MP
   Grifoni, A
   Okba, NMA
   Endeman, H
   van den Akker, JPC
   Molenkamp, R
   Koopmans, MPG
   van Gorp, ECM
   Haagmans, BL
   de Swart, RL
   Sette, A
   de Vries, RD
AF Weiskopf, Daniela
   Schmitz, Katharina S.
   Raadsen, Matthijs P.
   Grifoni, Alba
   Okba, Nisreen M. A.
   Endeman, Henrik
   van den Akker, Johannes P. C.
   Molenkamp, Richard
   Koopmans, Marion P. G.
   van Gorp, Eric C. M.
   Haagmans, Bart L.
   de Swart, Rik L.
   Sette, Alessandro
   de Vries, Rory D.
TI Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19
   patients with acute respiratory distress syndrome
SO SCIENCE IMMUNOLOGY
LA English
DT Article
ID MEMORY; RESPONSES; SUBSETS
AB SARS-CoV-2 has been identified as the causative agent of a global outbreak of respiratory tract disease (COVID-19). In some patients the infection results in moderate to severe acute respiratory distress syndrome (ARDS), requiring invasive mechanical ventilation. High serum levels of IL-6, IL-10 and an immune hyperresponsiveness referred to as a 'cytokine storm' have been associated with poor clinical outcome. Despite the large numbers of COVID-19 cases and deaths, information on the phenotype and kinetics of SARS-CoV-2-specific T cells is limited. Here, we studied 10 COVID-19 patients who required admission to an intensive care unit and detected SARS-CoV-2-specific CD4(+) and CD8(+) T cells in 10 out of 10 and 8 out of 10 patients, respectively. We also detected low levels of SARS-CoV-2-reactive T cells in 2 out of 10 healthy controls not previously exposed to SARS-CoV-2, which is indicative of cross-reactivity due to past infection with 'common cold' coronaviruses. The strongest T-cell responses were directed to the spike (S) surface glycoprotein, and SARS-CoV-2-specific T cells predominantly produced effector and Th1 cytokines, although Th2 and Th17 cytokines were also detected. Furthermore, we studied T-cell kinetics and showed that SARS-CoV-2-specific T cells are present relatively early and increase over time. Collectively, these data shed light on the potential variations in T-cell responses as a function of disease severity, an issue that is key to understanding the potential role of immunopathology in the disease, and also inform vaccine design and evaluation.
C1 [Weiskopf, Daniela; Grifoni, Alba; Sette, Alessandro] La Jolla Inst Immunol, Ctr Infect Dis, La Jolla, CA 92037 USA.
   [Schmitz, Katharina S.; Raadsen, Matthijs P.; Okba, Nisreen M. A.; Molenkamp, Richard; Koopmans, Marion P. G.; van Gorp, Eric C. M.; Haagmans, Bart L.; de Swart, Rik L.; de Vries, Rory D.] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
   [Endeman, Henrik; van den Akker, Johannes P. C.] Erasmus MC, Dept Intens Care, Rotterdam, Netherlands.
   [Sette, Alessandro] Univ Calif San Diego, Dept Pathol, San Diego, CA 92037 USA.
   [Sette, Alessandro] Univ Calif San Diego, Dept Med, San Diego, CA 92037 USA.
RP de Vries, RD (corresponding author), Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
EM r.d.devries@erasmusmc.nl
RI Okba, Nisreen MA/K-9984-2017; de Swart, Rik L./E-6508-2011; de Vries,
   Rory/L-2264-2015
OI Okba, Nisreen MA/0000-0002-2394-1079; de Swart, Rik
   L./0000-0003-3599-8969; de Vries, Rory/0000-0003-2817-0127; Haagmans,
   Bart/0000-0001-6221-2015; Schmitz, Katharina S./0000-0002-8537-0646
FU European UnionEuropean Union (EU) [874735]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [75N9301900065]
FX This work has received funding from the European Union's Horizon 2020
   research and innovation program under grant agreements No. 874735 (VEO)
   (MPGK, EvG and MPR). This work was also funded by the National
   Institutes of Health contract Nr. 75N9301900065 (AS and DW).
CR Bert NL, 2020, DIFFERENT PATTERN PR, DOI [10.1101/2020.05.26.115832, DOI 10.1101/2020.05.26.115832]
   Braun J., 2020, PRESENCE SARS COV 2, DOI [10.1101/2020.04.17.20061440, 10.1101/2020.04.17.20061440., DOI 10.1101/2020.04.17.20061440]
   Pro SC, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/763461
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dhanda SK, 2019, NUCLEIC ACIDS RES, V47, pW502, DOI 10.1093/nar/gkz452
   Gimenez E., 2020, SARS COV 2 REACT INT, DOI [10.1101/2020.05.18.20106245, DOI 10.1101/2020.05.18.20106245]
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Mahnke YD, 2013, EUR J IMMUNOL, V43, P2797, DOI 10.1002/eji.201343751
   Meckiff Benjamin J, 2020, bioRxiv, DOI 10.1101/2020.06.12.148916
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12
   Paul S, 2015, J IMMUNOL METHODS, V422, P28, DOI 10.1016/j.jim.2015.03.022
   Peng Yanchun, 2020, bioRxiv, DOI 10.1101/2020.06.05.134551
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Thieme C. J., 2020, SARS COV 2 T CELL IM, DOI [10.1101/2020.05.13.20100636, DOI 10.1101/2020.05.13.20100636]
   Wang ZF, 2014, P NATL ACAD SCI USA, V111, P769, DOI 10.1073/pnas.1321748111
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhao JX, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5393
NR 29
TC 69
Z9 69
U1 5
U2 5
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2470-9468
J9 SCI IMMUNOL
JI Sci. Immunol.
PD JUN
PY 2020
VL 5
IS 48
AR eabd2071
DI 10.1126/sciimmunol.abd2071
PG 14
WC Immunology
SC Immunology
GA MH8TC
UT WOS:000546993600011
PM 32591408
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Derendorf, H
AF Derendorf, Hartmut
TI Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
ID TISSUE DISTRIBUTION; RAT FIBROBLASTS; FLUID-PHASE; CHLOROQUINE;
   CORONAVIRUS; ACCUMULATION; COMBINATION; INHIBITION; PROTEIN; DRUGS
AB A recent report identified significant reductions or disappearance of viral load in COVID-19 patients given a combination of hydroxychloroquine and azithromycin. The present communication discusses some common pharmacokinetic properties of these two drugs that may be linked to a potential underlying mechanism of action for these antiviral effects. The physicochemical properties of both hydroxychloroquine and azithromycin are consistent with particularly high affinity for the intracellular lysosomal space, which has been implicated as a target site for antiviral activity. The properties of both drugs predict dramatic accumulation in lysosomes, with calculated lysosomal drug concentrations that exceed cytosolic and extracellular concentrations by more than 50 000-fold. These predictions are consistent with previously reported experimentally measured cellular and extracellular concentrations of azithromycin. This is also reflected in the very large volumes of distribution of these drugs, which are among the highest of all drugs currently in use. The combination of hydroxychloroquine and azithromycin produces very high local concentrations in lysosomes. The clinical significance of this observation is unclear; however, the magnitude of this mechanism of drug accumulation via ion-trapping in lysosomes could be an important factor for the pharmacodynamic effects of this drug combination. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Derendorf, Hartmut] Univ Florida, Gainesville, FL 32611 USA.
RP Derendorf, H (corresponding author), Univ Florida, Gainesville, FL 32611 USA.
EM hartmut@ufl.edu
CR AUBERTTULKENS G, 1979, LAB INVEST, V40, P481
   Barbour A, 2010, INT J ANTIMICROB AG, V35, P431, DOI 10.1016/j.ijantimicag.2010.01.023
   CARLIER MB, 1994, INT J TISSUE REACT, V16, P211
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Concordia PLAQUENIL, 2015, CONCORDIA PLAQUENIL
   Cook JA, 2006, AM J TROP MED HYG, V74, P407, DOI 10.4269/ajtmh.2006.74.407
   Cutler DF, 2002, SEMIN CELL DEV BIOL, V13, P261, DOI 10.1016/S108495210200054X
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Fossa AA, 2007, AM J TROP MED HYG, V77, P929, DOI 10.4269/ajtmh.2007.77.929
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Kakeya H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091293
   Kazmi F, 2013, DRUG METAB DISPOS, V41, P897, DOI 10.1124/dmd.112.050054
   Lemaire S, 2010, ANTIMICROB AGENTS CH, V54, P2540, DOI 10.1128/AAC.01723-09
   MACINTYRE AC, 1988, BIOPHARM DRUG DISPOS, V9, P513, DOI 10.1002/bod.2510090602
   MACINTYRE AC, 1988, J PHARM SCI, V77, P196, DOI 10.1002/jps.2600770303
   Min JY, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/649570
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Ohrt C, 2002, ANTIMICROB AGENTS CH, V46, P2518, DOI 10.1128/AAC.46.8.2518-2524.2002
   Pfizer, 2019, ZITHR PROD INF
   POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Schroeder RL, 2014, TOXICOL REP, V1, P963, DOI 10.1016/j.toxrep.2014.10.019
   Simmons G, 2011, VIROLOGY, V413, P265, DOI 10.1016/j.virol.2011.02.020
   STEINMAN RM, 1976, J CELL BIOL, V68, P665, DOI 10.1083/jcb.68.3.665
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   Thummel KE, 2006, GOODMAN GILMANS PHAR
   Tyteca D, 2002, EXP CELL RES, V281, P86, DOI 10.1006/excr.2002.5613
   Tyteca D, 2001, EUR J CELL BIOL, V80, P466, DOI 10.1078/0171-9335-00180
   VanBambeke F, 1996, EUR J PHARMACOL, V314, P203, DOI 10.1016/S0014-2999(96)00552-3
   WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zheng SM, 2014, ANTIMICROB AGENTS CH, V58, P6675, DOI 10.1128/AAC.02904-14
NR 36
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD JUN
PY 2020
VL 55
IS 6
AR 106007
DI 10.1016/j.ijantimicag.2020.106007
PG 5
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MF4JL
UT WOS:000545310600029
PM 32389720
OA Green Published
DA 2021-01-01
ER

PT J
AU Kara, E
   Inkaya, AC
   Demirkan, K
AF Kara, Emre
   Inkaya, Ahmet Cagkan
   Demirkan, Kutay
TI May drug-related cardiovascular toxicities persist after hospital
   discharge in COVID-19 patients?
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Letter
C1 [Kara, Emre; Demirkan, Kutay] Hacettepe Univ, Fac Pharm, Dept Clin Pharm, Ankara, Turkey.
   [Inkaya, Ahmet Cagkan] Hacettepe Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Ankara, Turkey.
RP Kara, E (corresponding author), Hacettepe Univ, Fac Pharm, Dept Clin Pharm, Ankara, Turkey.
EM emrekara@hacettepe.edu
CR Giudicessi JR, 2020, MAYO CLIN P
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Stokkermans TJ, 2020, CHLOROQUINE HYDROXYC
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 5
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD JUN
PY 2020
VL 55
IS 6
AR 106003
DI 10.1016/j.ijantimicag.2020.106003
PG 1
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MF4JL
UT WOS:000545310600026
PM 32360773
OA Green Published
DA 2021-01-01
ER

PT J
AU Lee, SH
   Son, H
   Peck, KR
AF Lee, Sun Hee
   Son, Hyunjin
   Peck, Kyong Ran
TI Can post-exposure prophylaxis for COVID-19 be considered as an outbreak
   response strategy in long-term care hospitals?
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE Post-exposure prophylaxis; Hydroxychloroquine; SARS-CoV-2; COVID-19;
   Long-term care hospital
AB In the context of the ongoing global outbreak of coronavirus disease 2019 (COVID-19), management of exposure events is a concern. Long-term care hospitals (LTCHs) are particularly vulnerable to cluster outbreaks because facilities for patient isolation and healthcare personnel to care for these patients in isolation are difficult to arrange in a large outbreak situation. Although several drugs have been proposed as treatment options, there are no data on the effectiveness and safety of post-exposure prophylaxis (PEP) for COVID-19. After a large COVID-19 exposure event in an LTCH in Korea, PEP using hydroxychloroquine (HCQ) was administered to 211 individuals, including 189 patients and 22 careworkers, whose baseline polymerase chain reaction (PCR) tests for COVID-19 were negative. PEP was completed in 184 (97.4%) patients and 21 (95.5%) careworkers without serious adverse events. At the end of 14 days of quarantine, all follow-up PCR tests were negative. Based on our experience, further clinical studies are recommended for COVID-19 PEP. (c) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Lee, Sun Hee] Pusan Natl Univ, Sch Med, Dept Internal Med, Div Infect Dis, 179 Gudeok Ro, Busan 49241, South Korea.
   [Lee, Sun Hee] Pusan Natl Univ Hosp, Med Res Inst, 179 Gudeok Ro, Busan 49241, South Korea.
   [Son, Hyunjin] Pusan Natl Univ Hosp, Busan Ctr Infect Dis Control & Prevent, 1001 Jungang Daero, Busan 47545, South Korea.
   [Son, Hyunjin] Epidem Invest Team Busan Metropolitan City, 1001 Jungang Daero, Busan 47545, South Korea.
   [Peck, Kyong Ran] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Infect Dis, 81 Irwon Ro, Seoul 06351, South Korea.
RP Peck, KR (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Infect Dis, 81 Irwon Ro, Seoul 135710, South Korea.
EM krpeck@skku.edu
CR Colson P, 2020, INT J ANTIMICROB AG
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   Multicenter collaboration group of Department of S Technology of Guangdong P Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p, 2020, ZHONGHUA JIE HE HE H, V43, pE019, DOI DOI 10.3760/CMA.J.ISSN.1001-0939.2020.0019
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 10
TC 17
Z9 17
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD JUN
PY 2020
VL 55
IS 6
AR 105988
DI 10.1016/j.ijantimicag.2020.105988
PG 3
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MF4JL
UT WOS:000545310600015
PM 32305587
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Luo, P
   Liu, D
   Li, J
AF Luo, Pan
   Liu, Dong
   Li, Juan
TI Pharmacological perspective: glycyrrhizin may be an efficacious
   therapeutic agent for COVID-19
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE COVID-19; SARS-COV-2; Glycyrrhizin
ID CORONAVIRUS; SARS; PNEUMONIA; ACID
AB Coronavirus disease 2019 (COVID-19) caused by the previously unknown pathogen, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) is now a global pandemic. There are no vaccines or specific treatments against this new virus; therefore, there is an urgent need to advance novel therapeutic interventions for COVID-19. Glycyrrhizin is a triterpene saponin with various biological functions and pharmacological effects. This brief article discusses the therapeutic potential of glycyrrhizin for the treatment of COVID-19 from the perspective of its pharmacological action, including binding angiotensinconverting enzyme II (ACE2), downregulating proinflammatory cytokines, inhibiting the accumulation of intracellular reactive oxygen species (ROS), inhibiting thrombin, inhibiting the hyperproduction of airway exudates, and inducing endogenous interferon. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Luo, Pan; Liu, Dong; Li, Juan] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Peoples R China.
RP Liu, D; Li, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Peoples R China.
EM l_d2069@163.com; lijuan@tjh.tjmu.edu.cn
CR ABE N, 1982, MICROBIOL IMMUNOL, V26, P535, DOI 10.1111/j.1348-0421.1982.tb00207.x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Fujii Takeshi, 2004, Journal of Infection and Chemotherapy, V10, P1, DOI 10.1007/s10156-003-0296-9
   Hoever G, 2005, J MED CHEM, V48, P1256, DOI 10.1021/jm0493008
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5
   Letko M, 2020, BIORXIV PREPRINT
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Mauricio I, 1997, BIOCHEM BIOPH RES CO, V235, P259, DOI 10.1006/bbrc.1997.6735
   Mendes-Silva W, 2003, THROMB RES, V112, P93, DOI 10.1016/j.thromres.2003.10.014
   Michaelis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019705
   Nishimoto Y, 2010, J PHARMACOL SCI, V113, P76, DOI 10.1254/jphs.09344FP
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Tong T, 2020, SMALL, V16, DOI 10.1002/smll.201906206
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang B, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.101300
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang XM, 2020, POTENTIAL ANAL, DOI 10.1007/s11118-019-09821-8
   Xu XG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02321
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 23
TC 6
Z9 6
U1 7
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD JUN
PY 2020
VL 55
IS 6
AR 105995
DI 10.1016/j.ijantimicag.2020.105995
PG 3
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MF4JL
UT WOS:000545310600024
PM 32335281
OA Green Published
DA 2021-01-01
ER

PT J
AU Serafin, MB
   Bottega, A
   Foletto, VS
   da Rosa, TF
   Horner, A
   Horner, R
AF Serafin, Marissa B.
   Bottega, Angelita
   Foletto, Vitoria S.
   da Rosa, Tacieli F.
   Horner, Andreas
   Horner, Rosmari
TI Drug repositioning is an alternative for the treatment of coronavirus
   COVID-19
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE Repositioning; COVID-19; SARS-CoV-2
ID RESPIRATORY SYNDROME CORONAVIRUS; CHLOROQUINE; REPLICATION; INHIBIT
AB Given the extreme importance of the current pandemic caused by COVID-19, and as scientists agree there is no identified pharmacological treatment, where possible, therapeutic alternatives are raised through drug repositioning. This paper presents a selection of studies involving drugs from different pharmaceu- tical classes with activity against SARS-CoV-2 and SARS-CoV, with the potential for use in the treatment of COVID-19 disease. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Serafin, Marissa B.; Bottega, Angelita; Foletto, Vitoria S.; da Rosa, Tacieli F.; Horner, Rosmari] Univ Fed Santa Maria, Programa Posgrad Ciencias Farmaceut, Santa Maria, RS, Brazil.
   [Horner, Rosmari] Univ Fed Santa Maria, Dept Anal Clin & Toxicol, Ave Roraima 1000 Cidade Univ, BR-97105900 Santa Maria, RS, Brazil.
   [Horner, Andreas] Univ Fed Santa Maria, Posgrad Mestrado Profiss Ciencias Saude, Santa Maria, RS, Brazil.
RP Horner, R (corresponding author), Univ Fed Santa Maria, Programa Posgrad Ciencias Farmaceut, Santa Maria, RS, Brazil.; Horner, R (corresponding author), Univ Fed Santa Maria, Dept Anal Clin & Toxicol, Ave Roraima 1000 Cidade Univ, BR-97105900 Santa Maria, RS, Brazil.
EM rosmari.ufsm@gmail.com
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001.
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Foletto VS, 2020, MED CHEM RES, V29, P556, DOI 10.1007/s00044-020-02507-6
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Serafin MB, 2018, BRAZ J INFECT DIS, V22, P252, DOI 10.1016/j.bjid.2018.05.007
   Sun M L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P219, DOI [10.3760/cma.j.issn.1001-0939.2020.0014, 10.3760/cma.j.issn.1001-0939.2020.03.016]
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao X, 2020, CLIN INFECT DIS
   Zhang J, 2020, BIORXIV, DOI [10.1101/2020.02.05.935387., 10.1101/2020.02.05.9353872020.02.05.935387, DOI 10.1101/2020.02.05.935387]
   Zheng W, 2018, BRIT J PHARMACOL, V175, P181, DOI 10.1111/bph.13895
NR 21
TC 14
Z9 14
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD JUN
PY 2020
VL 55
IS 6
AR 105969
DI 10.1016/j.ijantimicag.2020.105969
PG 4
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MF4JL
UT WOS:000545310600031
PM 32278811
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Smieszek, SP
   Przychodzen, BP
   Polymeropoulos, MH
AF Smieszek, Sandra P.
   Przychodzen, Bart P.
   Polymeropoulos, Mihael H.
TI Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19
   treatment
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; IDENTIFICATION; RESISTANCE; SPIKE
AB SARS-coronavirus 2 is the causal agent of the COVID-19 outbreak. SARS-Cov-2 entry into a cell is dependent upon binding of the viral spike (S) protein to cellular receptor and on cleavage of the spike protein by the host cell proteases such as Cathepsin L and Cathepsin B. CTSL/B are crucial elements of lysosomal pathway and both enzymes are almost exclusively located in the lysosomes. CTSL disruption offers potential for CoVID-19 therapies. The mechanisms of disruption include: decreasing expression of CTSL, direct inhibition of CTSL activity and affecting the conditions of CTSL environment (increase pH in the lysosomes).
   We have conducted a high throughput drug screen gene expression analysis to identify compounds that would downregulate the expression of CTSL/CTSB. One of the top significant results shown to downregulate the expression of the CTSL gene is amantadine (10uM). Amantadine was approved by the US Food and Drug Administration in 1968 as a prophylactic agent for influenza and later for Parkinson's disease. It is available as a generic drug.
   Amantadine in addition to downregulating CTSL appears to further disrupt lysosomal pathway, hence, interfering with the capacity of the virus to replicate. It acts as a lysosomotropic agent altering the CTSL functional environment. We hypothesize that amantadine could decrease the viral load in SARS-CoV-2 positive patients and as such it may serve as a potent therapeutic decreasing the replication and infectivity of the virus likely leading to better clinical outcomes. Clinical studies will be needed to examine the therapeutic utility of amantadine in COVID-19 infection. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Smieszek, Sandra P.; Przychodzen, Bart P.; Polymeropoulos, Mihael H.] Vanda Pharmaceut, 2200 Penn NW,Suite 300 E, Washington, DC 20037 USA.
RP Smieszek, SP (corresponding author), Vanda Pharmaceut, 2200 Penn NW,Suite 300 E, Washington, DC 20037 USA.
EM sandra.smieszek@vandapharma.com
OI Polymeropoulos, Mihael/0000-0001-5065-5353
FU Vanda Pharmaceuticals
FX Vanda Pharmaceuticals
CR deVries T, 2019, NEUROL THER, V8, P449, DOI 10.1007/s40120-019-0144-1
   DUFF KC, 1993, BIOCHIM BIOPHYS ACTA, V1145, P149, DOI 10.1016/0005-2736(93)90392-D
   Elshabrawy HA, 2014, J VIROL, V88, P4353, DOI 10.1128/JVI.03050-13
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Haines KM, 2012, VIROLOGY, V432, P20, DOI 10.1016/j.virol.2012.05.018
   Herst C., 2020, BIORXIV, DOI [10.1101/2020.02.25.963546, DOI 10.1101/2020.02.25.963546]
   Hindson J, 2020, NAT REV GASTRO HEPAT, V17, P259, DOI 10.1038/s41575-020-0295-7
   Hoffmann M, 2020, CELL
   Karczewski K.J., 2019, GENOMICS, DOI [10.1101/531210, DOI 10.1101/531210]
   Kirschke H, 2013, HANDBOOK OF PROTEOLYTIC ENZYMES, VOLS 1 AND 2, 3RD EDITION, P1808, DOI 10.1016/B978-0-12-382219-2.00410-5
   Kolocouris A, 2014, J MED CHEM, V57, P4629, DOI 10.1021/jm500598u
   Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Ma CL, 2009, P NATL ACAD SCI USA, V106, P12283, DOI 10.1073/pnas.0905726106
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Mbewe-Campbell N, 2012, J HYPERTENS, V30, P1961, DOI 10.1097/HJH.0b013e328356b86a
   Pisonero-Vaquero S, 2017, CURR DRUG METAB, V18, P1147, DOI 10.2174/1389200218666170925125940
   Polymeropoulos MH, 2009, SCHIZOPHR RES, V108, P134, DOI 10.1016/j.schres.2008.11.025
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Smedley D, 2015, NUCLEIC ACIDS RES, V43, pW589, DOI 10.1093/nar/gkv350
   Takadate Y, 2020, CELL REP, V30, P308, DOI 10.1016/j.celrep.2019.12.042
   Takahashi Y, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3012
   Withrock IC, 2015, GENES DIS, V2, P247, DOI 10.1016/j.gendis.2015.02.008
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 26
TC 9
Z9 9
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD JUN
PY 2020
VL 55
IS 6
AR 106004
DI 10.1016/j.ijantimicag.2020.106004
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MF4JL
UT WOS:000545310600028
PM 32361028
OA Green Published
DA 2021-01-01
ER

PT J
AU Zhao, M
AF Zhao, Ming
TI Cytokine storm and immunomodulatory therapy in COVID-19: Role of
   chloroquine and anti-IL-6 monoclonal antibodies
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE COVID-19; Cytokine storm; Chloroquine; Hydroxychloroquine; Tocilizumab
C1 [Zhao, Ming] Beijing Hosp, Natl Ctr Gerontol, Dept Pharm, Beijing, Peoples R China.
   [Zhao, Ming] Chinese Acad Med Sci, Inst Geriatr Med, Beijing, Peoples R China.
RP Zhao, M (corresponding author), 1 Dahua Rd, Beijing 100730, Peoples R China.
EM zhaoming4287@bjhmoh.cn
CR [Anonymous], 2020, CHINESE MED J-PEKING, V133, P1087, DOI 10.1097/CM9.0000000000000819
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   He G, 2020, HERZ, V45, P335, DOI 10.1007/s00059-018-4732-0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kawada J, 2013, MOD RHEUMATOL, V23, P972, DOI [10.1007/s10165-012-0780-0, 10.3109/s10165-012-0780-0]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Rutherford AI, 2018, ANN RHEUM DIS, V77, P905, DOI 10.1136/annrheumdis-2017-212825
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shanghai Expert Group on Clinical Treatment of Novel Coronavirus Disease, 2020, CHIN J INFECT, V38, DOI [10.3760/cma.j.issn.1000-6680.2020.0016, DOI 10.3760/CMA.J.ISSN.1000-6680.2020.0016]
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Xiaoling, EFFECTIVE TREATMENT
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577
NR 19
TC 58
Z9 60
U1 24
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD JUN
PY 2020
VL 55
IS 6
AR 105982
DI 10.1016/j.ijantimicag.2020.105982
PG 3
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MF4JL
UT WOS:000545310600030
PM 32305588
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Giudicessi, JR
   Noseworthy, PA
   Friedman, PA
   Ackerman, MJ
AF Giudicessi, John R.
   Noseworthy, Peter A.
   Friedman, Paul A.
   Ackerman, Michael J.
TI Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and
   Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus
   Disease 19 (COVID-19)
SO MAYO CLINIC PROCEEDINGS
LA English
DT Article
ID SUDDEN CARDIAC DEATH; RISK; INTERVAL; ARREST; PROLONGATION; AZITHROMYCIN
AB As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the ?off -label ? repurposing of drugs such as hydroxy- chloroquine and lopinavir/ritonavir, which have the potential for unwanted QT -interval prolongation and a risk of drug -induced sudden cardiac death. With the possibility that a considerable proportion of the world ?s population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug -induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.
C1 [Giudicessi, John R.] Mayo Clin, Clinician Investigator Training Program, Dept Cardiovasc Med, Rochester, MN USA.
   [Giudicessi, John R.; Noseworthy, Peter A.; Friedman, Paul A.; Ackerman, Michael J.] Mayo Clin, Div Heart Rhythm Serv, Dept Cardiovasc Med, Rochester, MN USA.
   [Ackerman, Michael J.] Mayo Clin, Dept Pediatnc & Adolescent Med, Div Pediat Cardiol, Rochester, MN USA.
   [Ackerman, Michael J.] Mayo Clin, Windland Smith Rice Sudden Death Genom Lab, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA.
RP Ackerman, MJ (corresponding author), Mayo Clin, Windland Smith Rice Genet Heart Rhythm Clin, 200 First St SW, Rochester, MN 55905 USA.
EM ackerman.michael@mayo.edu
FU Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death
   Program
FX This work was supported by the Mayo Clinic Windland Smith Rice
   Comprehensive Sudden Cardiac Death Program.
CR Arellano-Rodrigo E, 2001, MED CLIN-BARCELONA, V117, P118, DOI 10.1016/S0025-7753(01)72036-2
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Garabelli P, 2016, J CARDIOVASC ELECTR, V27, P827, DOI 10.1111/jce.12976
   Gautret P, 2020, HYDROXYCHLOROQUINE A, DOI [10.1101/2020.03.16.20037135, DOI 10.1101/2020.03.16.20037135]
   Giudicessi JR, 2018, NEUROGASTROENT MOTIL, V30, DOI 10.1111/nmo.13302
   Giudicessi JR, 2019, CIRCULATION, V139, P2711, DOI 10.1161/CIRCULATIONAHA.119.039598
   Giudicessi JR, 2013, CLEV CLIN J MED, V80, P539, DOI 10.3949/ccjm.80a.13077
   Goldenberg I, 2008, CIRCULATION, V117, P2184, DOI 10.1161/CIRCULATIONAHA.107.701243
   Haugaa KH, 2013, MAYO CLIN PROC, V88, P315, DOI 10.1016/j.mayocp.2013.01.013
   Hobbs JB, 2006, JAMA-J AM MED ASSOC, V296, P1249, DOI 10.1001/jama.296.10.1249
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Roden DM, 2006, J INTERN MED, V259, P59, DOI 10.1111/j.1365-2796.2005.01589.x
   Sauer AJ, 2007, J AM COLL CARDIOL, V49, P329, DOI 10.1016/j.jacc.2006.08.057
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Shah A, 2020, MAYO CLIN PROC, V95, P646, DOI 10.1016/j.mayocp.2020.02.003
   Sharma S, 2018, EUR HEART J, V39, P1466, DOI 10.1093/eurheartj/ehw631
   Soliman EZ, 2011, AIDS, V25, P367, DOI 10.1097/QAD.0b013e328341dcc0
   Stas P, 2008, INT J CARDIOL, V127, pE80, DOI 10.1016/j.ijcard.2007.04.055
   Traebert M, 2004, EUR J PHARMACOL, V484, P41, DOI 10.1016/j.ejphar.2003.11.003
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Vink AS, 2018, CIRCULATION, V138, P2345, DOI 10.1161/CIRCULATIONAHA.118.033943
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 26
TC 101
Z9 103
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD JUN
PY 2020
VL 95
IS 6
BP 1213
EP 1221
DI 10.1016/j.mayocp.2020.03.024
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA MG0NU
UT WOS:000545732800024
PM 32359771
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Saleh, M
   Gabriels, J
   Chang, D
   Kim, BS
   Mansoor, A
   Mahmood, E
   Makker, P
   Ismail, H
   Goldner, B
   Willner, J
   Beldner, S
   Mitra, R
   John, R
   Chinitz, J
   Skipitaris, N
   Mountantonakis, S
   Epstein, LM
AF Saleh, Moussa
   Gabriels, James
   Chang, David
   Kim, Beom Soo
   Mansoor, Amtul
   Mahmood, Eitezaz
   Makker, Parth
   Ismail, Haisam
   Goldner, Bruce
   Willner, Jonathan
   Beldner, Stuart
   Mitra, Raman
   John, Roy
   Chinitz, Jason
   Skipitaris, Nicholas
   Mountantonakis, Stavros
   Epstein, Laurence M.
TI Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the
   Corrected QT Interval in Patients With SARS-CoV-2 Infection
SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
LA English
DT Article
DE azithromycin; chloroquine; COVID-19; hydroxychloroquine; pandemic; QT
   prolongation
ID TORSADE-DE-POINTES; LONG QT; PROLONGATION; RISK
AB BACKGROUND: The novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is responsible for the global coronavirus disease 2019 pandemic. Small studies have shown a potential benefit of chloroquine/hydroxychloroquine +/- azithromycin for the treatment of coronavirus disease 2019. Use of these medications alone, or in combination, can lead to a prolongation of the QT interval, possibly increasing the risk of Torsade de pointes and sudden cardiac death.
   METHODS: Hospitalized patients treated with chloroquine/hydroxychloroquine +/- azithromycin from March 1 to the 23 at 3 hospitals within the Northwell Health system were included in this prospective, observational study. Serial assessments of the QT interval were performed. The primary outcome was QT prolongation resulting in Torsade de pointes. Secondary outcomes included QT prolongation, the need to prematurely discontinue any of the medications due to QT prolongation, and arrhythmogenic death.
   RESULTS: Two hundred one patients were treated for coronavirus disease 2019 with chloroquine/hydroxychloroquine. Ten patients (5.0%) received chloroquine, 191 (95.0%) received hydroxychloroquine, and 119 (59.2%) also received azithromycin. The primary outcome of torsade de pointes was not observed in the entire population. Baseline corrected QT interval intervals did not differ between patients treated with chloroquine/hydroxychloroquine (monotherapy group) versus those treated with combination group (chloroquine/hydroxychloroquine and azithromycin; 440.6 +/- 24.9 versus 439.9 +/- 24.7 ms, P=0.834). The maximum corrected QT interval during treatment was significantly longer in the combination group versus the monotherapy group (470.4 +/- 45.0 ms versus 453.3 +/- 37.0 ms, P=0.004). Seven patients (3.5%) required discontinuation of these medications due to corrected QT interval prolongation. No arrhythmogenic deaths were reported.
   CONCLUSIONS: In the largest reported cohort of coronavirus disease 2019 patients to date treated with chloroquine/hydroxyc hloroquine +/- azithromycin, no instances of Torsade de pointes, or arrhythmogenic death were reported. Although use of these medications resulted in QT prolongation, clinicians seldomly needed to discontinue therapy. Further study of the need for QT interval monitoring is needed before final recommendations can be made.
C1 [Saleh, Moussa; Gabriels, James; Chang, David; Kim, Beom Soo; Mansoor, Amtul; Mahmood, Eitezaz; Makker, Parth; Willner, Jonathan; Beldner, Stuart; Mitra, Raman; John, Roy; Epstein, Laurence M.] Northwell Hlth, North Shore Univ Hosp, Div Electrophysiol, Dept Cardiol, Manhasset, NY 11030 USA.
   [Ismail, Haisam; Goldner, Bruce] Northwell Hlth, Long Isl Jewish Med Ctr, Dept Cardiol, Div Electrophysiol, New Hyde Pk, NY USA.
   [Chinitz, Jason] Northwell Hlth, Southside Hosp, Dept Cardiol, Div Electrophysiol, Bay Shore, NY USA.
   [Saleh, Moussa; Makker, Parth; Skipitaris, Nicholas; Mountantonakis, Stavros] Northwell Hlth, Div Electrophysiol, Dept Cardiol, Lenox Hill Hosp, New York, NY USA.
RP Saleh, M (corresponding author), Northwell Hlth, N Shore Univ Hosp, Div Electrophysiol, Dept Cardiol, 300 Community Dr, Manhasset, NY 11030 USA.
EM moussa.a.saleh@gmail.com
RI Epstein, Laurence/ABB-1592-2020; Saleh, Moussa/AAM-9208-2020
OI Epstein, Laurence/0000-0001-5410-0291; Saleh,
   Moussa/0000-0001-7647-397X; Makker, Parth/0000-0002-1468-6504; Goldner,
   Bruce/0000-0002-5957-4143
CR Arellano-Rodrigo E, 2001, MED CLIN-BARCELONA, V117, P118, DOI 10.1016/S0025-7753(01)72036-2
   Bouchaud O, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-289
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   CHEN Y, 2020, PHYS REV ACCEL BEAMS, V23
   Chico RM, 2011, EXPERT OPIN DRUG MET, V7, P1153, DOI 10.1517/17425255.2011.598506
   Drici MD, 2001, DRUG SAFETY, V24, P575, DOI 10.2165/00002018-200124080-00002
   Huang BH, 2007, PACE, V30, P1579, DOI 10.1111/j.1540-8159.2007.00912.x
   Kezerashvili A, 2007, J INTERV CARD ELECTR, V18, P243, DOI 10.1007/s10840-007-9124-y
   Khan Q, 2018, POSTGRAD MED, V130, P660, DOI 10.1080/00325481.2018.1516106
   Kim MH, 2005, PACE, V28, P1221, DOI 10.1111/j.1540-8159.2005.50146.x
   Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Matsunaga Naohisa, 2003, N Z Med J, V116, pU666
   Mitra Raman L, 2020, HeartRhythm Case Rep, V6, P244, DOI 10.1016/j.hrcr.2020.03.016
   MONLUN E, 1993, LANCET, V341, P1541
   Morgan ND, 2013, JCR-J CLIN RHEUMATOL, V19, P286, DOI 10.1097/RHU.0b013e31829d5e50
   Negoescu A, 2013, ARTHRITIS RHEUM-US, V65, pS872
   Organization WH, 2015, WORLD MAL REP 2015
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Roden DM, 2016, J PHYSIOL-LONDON, V594, P2459, DOI 10.1113/JP270526
   Roden DM, 1998, PACE, V21, P1029, DOI 10.1111/j.1540-8159.1998.tb00148.x
   Roden DM, 2005, SUDDEN CARDIAC DEATH
   Russo Vincenzo, 2006, Acta Biomed, V77, P30
   Samarendra P, 2001, PACE, V24, P1572, DOI 10.1046/j.1460-9592.2001.01572.x
   Sarganas G, 2014, EUROPACE, V16, P101, DOI 10.1093/europace/eut214
   SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Van Laecke S, 2019, ACTA CLIN BELG, V74, P41, DOI 10.1080/17843286.2018.1516173
   Vandenberk B, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003264
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wan Y, 2020, J VIROL, V94, pe00127, DOI DOI 10.1128/JVI.00127-20
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   Wilders R, 2018, FRONT CARDIOVASC MED, V5, DOI [10.3389/fcvm.2018.00106, 10.3389/fcvm.2018.00137]
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yang ZJ, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.115.003560
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 38
TC 66
Z9 66
U1 6
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3149
EI 1941-3084
J9 CIRC-ARRHYTHMIA ELEC
JI Circ.-Arrhythmia Electrophysiol.
PD JUN
PY 2020
VL 13
IS 6
AR e008662
DI 10.1161/CIRCEP.120.008662
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA ME5TF
UT WOS:000544717400007
PM 32347743
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Cianetti, S
   Pagano, S
   Nardone, M
   Lombardo, G
AF Cianetti, Stefano
   Pagano, Stefano
   Nardone, Michele
   Lombardo, Guido
TI Model for Taking Care of Patients with Early Childhood Caries during the
   SARS-Cov-2 Pandemic
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE SARS-CoV-2; early childhood caries; minimally invasive; infection
   control
ID COVID-19; REMOVAL; PREVENTION; MANAGEMENT; DENTISTRY; OUTBREAK;
   DISEASES; HEALTH
AB Pending the availability of vaccines to contain the SARS-CoV-2 pandemic, the current solution is "social distancing" with a reduction of dental treatments to those assessed as urgent and emergency cases. These treatments also involve Early Childhood Caries (ECC) due to the fact that this disease affects preschool children (a vulnerable population) and, in addition, shows a propensity to evolve into more serious complications (dental pain, infections). A narrative review was carried out to support a protocol for treating ECC with efficacious and safe (in terms of SARS-CoV-2 transmission) procedures. Protocol involves criteria for patients' selection remotely (telemedicine), and well-detailed criteria/equipment and hygiene procedures to combat against SARS-CoV-2 transmission. Moreover, the protocol proposes innovative caries treatments, named Minimally Invasive Treatments (MITs), well known in pedodontics for their high level of children's acceptance during dental care. MITs allow for caries removal (particularly in primary teeth) without any high-speed rotating instrument cooled with nebulized air-water spray (with high risk of virus environmental diffusion), usually adopted during traditional treatments. For evaluating MITs effectiveness in caries management, only Systematic Review and Randomized Controlled Trials (RCTs) were included in our study, without any risk of bias assessment. The indications proposed in this protocol could support clinicians for the temporary management of ECC until the SARS-CoV-2 pandemic ends.
C1 [Cianetti, Stefano; Pagano, Stefano; Lombardo, Guido] Univ Perugia, Unit Paediat Dent, Biomed Sci, I-06100 Perugia, Italy.
   [Nardone, Michele] Azienda Sociosanit Terr Melegnano & Martesana, I-20070 Milan, Regione Lombard, Italy.
RP Pagano, S (corresponding author), Univ Perugia, Unit Paediat Dent, Biomed Sci, I-06100 Perugia, Italy.
EM stefano.cianetti@unipg.it; stefano.pagano@unipg.it; logu68@libero.it;
   guido.lombardo@unipg.it
OI nardone, michele/0000-0001-6268-432X
CR Abramovitz I, 2020, QUINTESSENCE INT, V51, P418, DOI 10.3290/j.qi.a44392
   Ahovuo-Saloranta A, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001830.pub5
   Alharbi A, 2020, SAUDI DENT J, V32, P181, DOI 10.1016/j.sdentj.2020.04.001
   Anthonappa RP, 2017, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD012676, 10.1002/14651858.CD012676]
   BAGGA BSR, 1984, J AM DENT ASSOC, V109, P712, DOI 10.14219/jada.archive.1984.0168
   Caprioglio A, 2020, PROG ORTHOD, V21, DOI 10.1186/s40510-020-00310-y
   Carrouel F, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041126
   Carrouel F, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10010140
   Casamassimo PS, 2020, PEDIATR DENT, V42, P87
   Chieruzzi M, 2018, J MATER RES, V33, P638, DOI 10.1557/jmr.2018.36
   Cianetti S, 2017, EUR J PAEDIATR DENT, V18, P15, DOI 10.23804/ejpd.2017.18.01.03
   Correa-Faria P, 2020, BMC ORAL HEALTH, V20, DOI 10.1186/s12903-020-01067-w
   de Silva A.M., 2016, COCHRANE DB SYST REV, V12, pCD009837
   Dondi A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020379
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dorri M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008072.pub2
   Duangthip D, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14101204
   Molina GF, 2015, BRAZ ORAL RES, V29, DOI 10.1590/1807-3107BOR-2015.vol29.0097
   Frencken JE, 2017, BRIT DENT J, V223, P183, DOI 10.1038/sj.bdj.2017.664
   Fung ICH, 2007, INT J ENVIRON HEAL R, V17, P161, DOI 10.1080/09603120701254276
   Gao SS, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010080
   Gao SS, 2016, BMC ORAL HEALTH, V16, DOI 10.1186/s12903-016-0171-6
   Guo JC, 2020, CLIN ORAL INVEST, V24, P2137, DOI 10.1007/s00784-020-03291-8
   Huang YH, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101606
   Innes NPT, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005512.pub3
   Kagihara LE, 2009, J AM ACAD NURSE PRAC, V21, P1, DOI 10.1111/j.1745-7599.2008.00367.x
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Koo JR, 2020, LANCET INFECT DIS, V20, P678, DOI 10.1016/S1473-3099(20)30162-6
   Lai G, 2015, ACTA ODONTOL SCAND, V73, P569, DOI 10.3109/00016357.2015.1023353
   Lai THT, 2020, GRAEF ARCH CLIN EXP, V258, P1135, DOI 10.1007/s00417-020-04653-4
   Law Clarice S, 2013, J Calif Dent Assoc, V41, P612
   Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
   Li YQ, 2020, MOL ORAL MICROBIOL, V35, P141, DOI 10.1111/omi.12289
   Lim SN, 2017, INT J PAEDIATR DENT, V27, P551, DOI 10.1111/ipd.12296
   Lindenmuller IH, 2011, CURR PROBL DERMATOL, V40, P107, DOI 10.1159/000321060
   Lombardo G, 2019, EUR J PAEDIATR DENT, V20, P295, DOI 10.23804/ejpd.2019.20.04.07
   Ma XL, 2019, BMC ORAL HEALTH, V19, DOI 10.1186/s12903-019-0977-0
   Machado RA, 2020, ORAL ONCOL, V105, DOI 10.1016/j.oraloncology.2020.104685
   Mallineni SK, 2020, INT J PAEDIATR DENT, V30, P245, DOI 10.1111/ipd.12653
   Mansoori Shahnaz, 2019, J Oral Biol Craniofac Res, V9, P222, DOI 10.1016/j.jobcr.2019.05.005
   Maragakis GM, 2001, INT DENT J, V51, P291, DOI 10.1002/j.1875-595X.2001.tb00841.x
   Maret D, 2020, INT ENDOD J, V53, P880, DOI 10.1111/iej.13312
   Marinho VCC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002279.pub2
   Mathus-Vliegen EMH, 2007, INT DENT J, V57, P249
   Mickenautsch S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146512
   Montedori A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010229.pub2
   Neville P, 2020, COMMUNITY DENT HLTH, V37, P51, DOI 10.1922/CDH_4664Neville08
   Nielsen F, 2017, SOC SCI RES, V62, P29, DOI 10.1016/j.ssresearch.2016.12.009
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Peres MA, 2019, LANCET, V394, P249, DOI 10.1016/S0140-6736(19)31146-8
   Phonghanyudh A, 2012, COMMUNITY DENT HLTH, V29, P173, DOI 10.1922/CDH_2762Phonghanyudh06
   Prati C, 2020, INT ENDOD J, V53, P723, DOI 10.1111/iej.13291
   Pung R, 2020, LANCET, V395, P1039, DOI 10.1016/S0140-6736(20)30528-6
   Riggs E, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012155.pub2
   Riley P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004346.pub4
   SAMARANAYAKE LP, 1989, J DENT CHILD, V56, P442
   Schmoeckel J, 2020, CARIES RES, V54, P102, DOI 10.1159/000504335
   Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6
   SFSCMFCO, 2020, J STOMATOL ORAL MAXI, V121, pE3, DOI 10.1016/j.jormas.2020.03.012
   Sheikhtaheri A, 2018, STUD HEALTH TECHNOL, V248, P148, DOI 10.3233/978-1-61499-858-7-148
   Shulman Jay D., 1997, Pediatric Dentistry, V19, P404
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Spagnuolo G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062094
   Steiner-Oliveira C, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.10.108003
   Tao SY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196660
   Verbeek JH, 2020, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011621.pub4, 10.1002/14651858.CD011621.pub5]
   Verbeek JH, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011621.pub3
   Volgenant C M C, 2018, Curr Oral Health Rep, V5, P221, DOI 10.1007/s40496-018-0201-3
   Volgenant CMC, 2020, ORAL DIS, DOI 10.1111/odi.13408
   Yhim HB, 2020, BMC ANESTHESIOL, V20, DOI 10.1186/s12871-020-00995-y
   Zhao IS, 2018, INT DENT J, V68, P67, DOI 10.1111/idj.12320
NR 72
TC 4
Z9 4
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUN
PY 2020
VL 17
IS 11
AR 3751
DI 10.3390/ijerph17113751
PG 17
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA MB5FY
UT WOS:000542629600004
PM 32466392
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cvetkovic, VM
   Nikolic, N
   Nenadic, UR
   Ocal, A
   Noji, EK
   Zecevic, M
AF Cvetkovic, Vladimir M.
   Nikolic, Neda
   Nenadic, Una Radovanovic
   Ocal, Adem
   Noji, Eric K.
   Zecevic, Miodrag
TI Preparedness and Preventive Behaviors for a Pandemic Disaster Caused by
   COVID-19 in Serbia
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE disaster; epidemic risk; pandemic; citizen preparedness; coronavirus;
   COVID-19; Serbia
ID KNOWLEDGE; ATTITUDES; STUDENTS
AB Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. The disease was first detected in Wuhan, the capital of China's Hubei province, in December 2019 and has since spread globally, especially to Europe and North America, resulting in the ongoing global coronavirus pandemic disaster of 2019-2020. Although most cases have mild symptoms, there is some progression to viral pneumonia and multi-organ failure and death. More than 4.6 million cases have been registered across 216 countries and territories as of 19 April 2020, resulting in more than 311,000 deaths. Risk to communities with continued widespread disease transmission depends on characteristics of the virus, including how well it spreads between people; the severity of resulting illness; and the medical or other measures available to control the impact of the virus (for example, vaccines or medications that can treat the illness) and the relative success of these. In the absence of vaccines or medications, non-pharmaceutical interventions were the most important response strategy based on community interventions such as person-to-person distancing, mask-wearing, isolation and good personal hygiene (hand-washing)-all of which have been demonstrated can reduce the impact of this seemingly unstoppable globally spreading natural disaster. This paper presents the results of quantitative research regarding the level of citizen preparedness for disasters caused by coronavirus disease (COVID-19) in Serbia. The survey was conducted using a questionnaire that was requested and then collected online among 975 respondents during disaster in April 2020. The questionnaire examined citizens' basic socio-economic and demographic characteristics, their knowledge, preparedness, risk perception and preventive measures taken individually and as a community to prevent the death and widespread transmission of novel coronavirus disease 2019 in the Republic of Serbia. Based on the findings that there are major differences in the public's perception of risks posed by communicable disease threats such as presented by COVID-19, emergency management agencies should use these differences to develop targeted strategies to enhance community and national preparedness by promoting behavioral change and improving risk management decision-making.
C1 [Cvetkovic, Vladimir M.] Univ Belgrade, Fac Secur Studies, Gospodara Vucica 50, Belgrade 11040, Serbia.
   [Nikolic, Neda] Univ Kragujevac, Fac Tehn Sci Cacak, Cacak 32000, Serbia.
   [Nenadic, Una Radovanovic] Sci Profess Soc Disaster Risk Management, Dimitrija Tucovica 121, Belgrade 11040, Serbia.
   [Ocal, Adem] Independent Researcher, TR-06500 Ankara, Turkey.
   [Noji, Eric K.] King Saud Univ Hosp & Coll Med, Riyadh 11564, Saudi Arabia.
   [Zecevic, Miodrag] European Univ, Fac Int Engn Management Belgrade, Belgrade 11000, Serbia.
RP Cvetkovic, VM (corresponding author), Univ Belgrade, Fac Secur Studies, Gospodara Vucica 50, Belgrade 11040, Serbia.
EM vmc@fb.bg.ac.rs; neda.nikolic@ftn.kg.ac.rs; una.radovanovic@gmail.com;
   ocadem@gmail.com; nojie@alumni.stanford.edu; misko.zecevic@gmail.com
RI Ocal, Adem/X-7314-2018; Cvetkovic, Vladimir M./J-3501-2015
OI Ocal, Adem/0000-0003-4067-968X; Cvetkovic, Vladimir
   M./0000-0002-3450-0658
FU Scientific-Professional Society for Disaster Risk Management, Belgrade,
   Serbia
FX This research was funded by Scientific-Professional Society for Disaster
   Risk Management, Belgrade, Serbia (http://upravljanje-rizicima.com/).
CR Abebe G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013339
   [Anonymous], 2010, AN EP PAND GRUP AH1N
   Anti-Corruption Council Government of Republic of Serbia [Savet za borbu protiv korupcije Vlada Republike Srbije], 2011, IZV PRIT KONTR MED
   Balicer RD, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-99
   Barr M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-117
   Brewer PR, 2004, POLIT BEHAV, V26, P317, DOI 10.1007/s11109-004-0899-6
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chor JSY, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3391
   Cvetkovi V., 2018, BEZBEDNOST, V60, P5, DOI [10.5937/bezbednost1803005C, DOI 10.5937/BEZBEDNOST1803005C]
   Cvetkovic V.M., 2019, INT J DISASTER RISK, V1, P81, DOI [10.18485/ijdrm.2019.1.1.5, DOI 10.18485/IJDRM.2019.1.1.5]
   Cvetkovic VM, 2019, ACTA GEOGR SLOV, V59, P27, DOI 10.3986/AGS.5445
   Cvetkovic VM, 2019, INT J DISAST RISK RE, V35, DOI 10.1016/j.ijdrr.2019.101095
   Cvetkovic VM, 2018, REV KRIMINALISTIKO K, V69, P279
   Cvetkovic VM, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15122761
   Cvetkovic VM, 2018, IRAN J PUBLIC HEALTH, V47, P1213
   Cvetkovic VM, 2015, J GEOGR INST JOVAN C, V65, P323, DOI 10.2298/IJGI1503323C
   Dan A., 2016, STAVOVI GRADANA POLI
   Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6
   Glanz K., 2008, HLTH BEHAV HLTH ED T
   Goodwin R, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-166
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hunter W., 1919, P SECT EP STAT MED 2, DOI 10.1177/003591572001301502
   Ibuka Y, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-296
   Keki D., 2016, UPRAVLJANJE BEZBEDNO
   Krivokapi D., 2017, SHARE WORK 2016 MONI
   Kwok K.O., 2020, COMMUNITY RESPONSES, V26, P200500
   Lau JTF, 2010, AM J INFECT CONTROL, V38, P374, DOI 10.1016/j.ajic.2010.03.002
   Leung GM, 2003, J EPIDEMIOL COMMUN H, V57, P857, DOI 10.1136/jech.57.11.857
   Libertarijanski klub [Libertharian Club] Libek, 2015, LIB ISTR POV GRAD ME
   Miki D., 2010, ZARAZNE BOLESTI SRPS
   Montgomery D. C., 2012, INTRO LINEAR REGRESS, V821
   Oliveira ER, 2002, AIDS CARE, V14, P569, DOI 10.1080/09540120220133099
   Park JH, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-222
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Nenadic UR, 2020, HEALTH SECUR, V18, P29, DOI 10.1089/hs.2019.0046
   Ramzan Musarat, 2015, J Ayub Med Coll Abbottabad, V27, P402
   Ristanovi E., 2015, GAZZETTA SERBIAN MIN, V57, P5, DOI [10.5937/bezbednost1502005R, DOI 10.5937/BEZBED-NOST1502005R]
   Rubin GJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2651
   Seale H, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-99
   Seneviratne K, 2010, INT J STRATEG PROP M, V14, P376, DOI 10.3846/ijspm.2010.28
   Setbon M, 2010, EUR J PUBLIC HEALTH, V20, P490, DOI 10.1093/eurpub/ckq054
   Shaw R., 2020, PROGR DISASTER SCI, V6, P100090, DOI [10.1016/j.pdisas.2020.100090, DOI 10.1016/J.PDISAS.2020.100090]
   Statistical Office of Serbia, STANOVNITVO
   uki G.J., 2018, ACTA MED MEDIAN, V57, P145
   Wang YB, 2020, J HEALTH PSYCHOL, V25, P733, DOI 10.1177/1359105320919177
   WHO, COR DIS COVID 19 PAN
   World Health Organisation, 2020, CRIT PREP READ RESP
   World Health Organization, 2020, NAM COR DIS COVID 19
   World Health Organization, 2003, SUMM TABL SARS CAS C
   Wray R, 2004, BIOSECUR BIOTERROR, V2, P208, DOI 10.1089/15387130460759272
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 51
TC 6
Z9 6
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUN
PY 2020
VL 17
IS 11
AR 4124
DI 10.3390/ijerph17114124
PG 23
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA MB5FY
UT WOS:000542629600377
PM 32527056
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhai, F
   Zhai, YX
   Cong, C
   Song, TY
   Xiang, RW
   Feng, TY
   Liang, ZX
   Zeng, Y
   Yang, J
   Yang, J
   Liang, JK
AF Zhai, Fei
   Zhai, Yuxuan
   Cong, Chuang
   Song, Tingyan
   Xiang, Rongwu
   Feng, Tianyi
   Liang, Zhengxuan
   Zeng, Ya
   Yang, Jing
   Yang, Jie
   Liang, Jiankun
TI Research Progress of Coronavirus Based on Bibliometric Analysis
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE bibliometrics; coronavirus; SARS-CoV-2; COVID-19
ID VIRUS; VACCINES
AB Background: COVID-19 has become one of the most serious global epidemics in the 21st Century. This study aims to explore the distribution of research capabilities of countries, institutions, and researchers, and the hotspots and frontiers of coronavirus research in the past two decades. In it, references for funding support of urgent projects and international cooperation among research institutions are provided. Method: the Web of Science core collection database was used to retrieve the documents related to coronavirus published from 2003 to 2020. Citespace.5.6.R2, VOSviewer1.6.12, and Excel 2016 were used for bibliometric analysis. Results: 11,036 documents were retrieved, of which China and the United States have contributed the most coronavirus studies, Hong Kong University being the top contributor. Regarding journals, the Journal of Virology has contributed the most, while in terms of researchers, Yuen Kwok Yung has made the most contributions. The proportion of documents published by international cooperation has been rising for decades. Vaccines for SARS-CoV-2 are under development, and clinical trials of several drugs are ongoing. Conclusions: international cooperation is an important way to accelerate research progress and achieve success. Developing corresponding vaccines and drugs are the current hotspots and research directions.
C1 [Zhai, Fei; Zhai, Yuxuan; Song, Tingyan; Xiang, Rongwu; Liang, Jiankun] Shenyang Pharmaceut Univ, Sch Med Equipment, Shenyang 110016, Peoples R China.
   [Zhai, Fei; Zhai, Yuxuan; Xiang, Rongwu; Liang, Jiankun] Liaoning Med Big Data & Artificial Intelligence E, Shenyang 110016, Peoples R China.
   [Cong, Chuang] Shenyang Hlth Serv & Adm Law Enforcement Ctr, Shenyang 110031, Peoples R China.
   [Feng, Tianyi] Tsinghua Univ, Sch Mat Sci & Engn, Beijing 100084, Peoples R China.
   [Liang, Zhengxuan] Univ Minnesota, Coll Pharm, Pharmaceut Mat Sci & Engn Lab, Minneapolis, MN 55455 USA.
   [Zeng, Ya; Yang, Jing; Yang, Jie] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China.
RP Liang, JK (corresponding author), Shenyang Pharmaceut Univ, Sch Med Equipment, Shenyang 110016, Peoples R China.; Liang, JK (corresponding author), Liaoning Med Big Data & Artificial Intelligence E, Shenyang 110016, Peoples R China.
EM zhaifei1978@gmail.com; zyxllgg@163.com; congchuang76@163.com;
   songty214@yeah.net; xrwlove@163.com; fty17@mails.tsinghua.edu.cn;
   liangzx0312@gmail.com; zengtracy_stu@163.com; emljaneyang@163.com;
   Youngyuj@163.com; teacherljk@163.com
OI Liang, Jiankun/0000-0003-1689-7396
FU Natural Science Foundation of Liaoning ProvinceNatural Science
   Foundation of Liaoning Province [20180550345]; Shenyang Science and
   technology plan project [YJ2020-9-005]; Young and middle-aged teachers
   development support program of Shenyang Pharmaceutical University
   [ZQN2018012]; Chinese college students' innovation and Entrepreneurship
   Project [201910163237]
FX This research was funded by Natural Science Foundation of Liaoning
   Province, grant number 20180550345; Shenyang Science and technology plan
   project, grant number YJ2020-9-005; Young and middle-aged teachers
   development support program of Shenyang Pharmaceutical University, grant
   number ZQN2018012; Chinese college students' innovation and
   Entrepreneurship Project, grant number 201910163237.
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Alburikan KA, 2020, SAUDI PHARM J, V28, P161, DOI 10.1016/j.jsps.2019.11.016
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Arabi YM, 2017, NEW ENGL J MED, V376, P584, DOI 10.1056/NEJMsr1408795
   Arens MQ, 2010, J CLIN MICROBIOL, V48, P2387, DOI 10.1128/JCM.00220-10
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Berry M, 2015, VIRUSES-BASEL, V7, P996, DOI 10.3390/v7030996
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Chen CM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223994
   Chen CM, 2014, J ASSOC INF SCI TECH, V65, P334, DOI 10.1002/asi.22968
   Chen yue, 2015, STUDY SCIENFIOLOGY, V33, P242, DOI DOI 10.3969/j.issn.1003-2053.2015.02.009
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Esposito S, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01260-2020
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoever G, 2005, J MED CHEM, V48, P1256, DOI 10.1021/jm0493008
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Huan CC, 2020, TRANSBOUND EMERG DIS, V67, P65, DOI 10.1111/tbed.13321
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Kim YJ, 2020, ANN LAB MED, V40, P349, DOI 10.3343/alm.2020.40.5.349
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Lu S, 2020, EMERG MICROBES INFEC, V9, P542, DOI 10.1080/22221751.2020.1737580
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Shi Y, 2020, Zhonghua Yu Fang Yi Xue Za Zhi, V54, P614, DOI 10.3760/cma.j.cn112150-20200317-00366
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Sweileh WM, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-017-0233-9
   Tseng YT, 2010, J BIOL CHEM, V285, P12862, DOI 10.1074/jbc.M109.030270
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang ZT, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13060583
   Wong Matthew C, 2020, bioRxiv, DOI 10.1101/2020.02.07.939207
   World Health Organization, NOV COR 2019 NCOV SI
   Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153
   Zyoud SH, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1600-5
NR 42
TC 8
Z9 9
U1 16
U2 17
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUN
PY 2020
VL 17
IS 11
AR 3766
DI 10.3390/ijerph17113766
PG 15
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA MB5FY
UT WOS:000542629600019
PM 32466477
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gimeno, A
   Mestres-Truyol, J
   Ojeda-Montes, MJ
   Macip, G
   Saldivar-Espinoza, B
   Cereto-Massague, A
   Pujadas, G
   Garcia-Vallve, S
AF Gimeno, Aleix
   Mestres-Truyol, Julia
   Jose Ojeda-Montes, Maria
   Macip, Guillem
   Saldivar-Espinoza, Bryan
   Cereto-Massague, Adria
   Pujadas, Gerard
   Garcia-Vallve, Santiago
TI Prediction of Novel Inhibitors of the Main Protease (M-pro) of
   SARS-CoV-2 through Consensus Docking and Drug Reposition
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE SARS coronavirus; COVID-19; SARS-CoV-2; 3CL-pro; M-pro;
   chymotrypsin-like protease; 2019-nCov
AB Since the outbreak of the COVID-19 pandemic in December 2019 and its rapid spread worldwide, the scientific community has been under pressure to react and make progress in the development of an effective treatment against the virus responsible for the disease. Here, we implement an original virtual screening (VS) protocol for repositioning approved drugs in order to predict which of them could inhibit the main protease of the virus (M-pro), a key target for antiviral drugs given its essential role in the virus' replication. Two different libraries of approved drugs were docked against the structure of M-pro using Glide, FRED and AutoDock Vina, and only the equivalent high affinity binding modes predicted simultaneously by the three docking programs were considered to correspond to bioactive poses. In this way, we took advantage of the three sampling algorithms to generate hypothetic binding modes without relying on a single scoring function to rank the results. Seven possible SARS-CoV-2 M-pro inhibitors were predicted using this approach: Perampanel, Carprofen, Celecoxib, Alprazolam, Trovafloxacin, Sarafloxacin and ethyl biscoumacetate. Carprofen and Celecoxib have been selected by the COVID Moonshot initiative for in vitro testing; they show 3.97 and 11.90% M-pro inhibition at 50 mu M, respectively.
C1 [Gimeno, Aleix; Mestres-Truyol, Julia; Macip, Guillem; Saldivar-Espinoza, Bryan; Cereto-Massague, Adria; Pujadas, Gerard; Garcia-Vallve, Santiago] Univ Rovira & Virgili, Dept Bioquim & Biotecnol, Res Grp Cheminformat & Nutr, Campus Sescelades, Tarragona 43007, Catalonia, Spain.
   [Jose Ojeda-Montes, Maria] Escoles Univ Gimbernat & Tomas Cerda, Barcelona 08174, Catalonia, Spain.
   [Pujadas, Gerard; Garcia-Vallve, Santiago] CEICS, TECNIO, EURECAT, Reus 43204, Catalonia, Spain.
RP Pujadas, G; Garcia-Vallve, S (corresponding author), Univ Rovira & Virgili, Dept Bioquim & Biotecnol, Res Grp Cheminformat & Nutr, Campus Sescelades, Tarragona 43007, Catalonia, Spain.; Pujadas, G; Garcia-Vallve, S (corresponding author), CEICS, TECNIO, EURECAT, Reus 43204, Catalonia, Spain.
EM aleix.givi2@gmail.com; julia.mestres@estudiants.urv.cat;
   mjoseom88@gmail.com; guillem.macip@gmail.com; bsaldivar.emc2@gmail.com;
   ssorgatem@gmail.com; gerard.pujadas@gmail.com;
   santi.garcia-vallve@urv.cat
RI MJose, Ojeda/ABB-5745-2020; Garcia-Vallve, Santi/A-4226-2008; Cereto i
   Massague, Adria/I-1643-2015; Pujadas, Gerard/B-1457-2010
OI Garcia-Vallve, Santi/0000-0002-0348-7497; Cereto i Massague,
   Adria/0000-0002-9319-6377; Gimeno, Aleix/0000-0002-7654-6689; Saldivar
   Espinoza, Bryan Percy/0000-0002-9667-2818; Macip,
   Guillem/0000-0003-4016-5558; Pujadas, Gerard/0000-0003-2598-8089
FU European Union's Horizon 2020 research and innovation programme under
   the Marie Sklodowska-Curie grantEuropean Union (EU) [713679];
   Universitat Rovira i Virgili (URV)
FX This project has received funding from the European Union's Horizon 2020
   research and innovation programme under the Marie Sklodowska-Curie grant
   agreement No. 713679 and from the Universitat Rovira i Virgili (URV).
CR Adem S., 2020, IDENTIFICATION POTEN, V46, P1, DOI [10.20944/preprints202003.0333.v1., 10.20944/preprints202003.0333.v1, DOI 10.20944/PREPRINTS202003.0333.V1]
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], 2019, OEDOCKING 3 4 0 2 OP
   [Anonymous], 2019, QUACPAC 2 0 2 2 OPEN
   [Anonymous], 2019, SCHROD REL 2019 3 EP
   [Anonymous], 2019, SCHRODINGER RELEASE
   [Anonymous], 2020, SCHRSCHRDINGER REL 2
   [Anonymous], 2019, SCHROD REL 2019 3 GL
   [Anonymous], 2019, SCHROD REL 2019 3 PR
   [Anonymous], 2019, SCHROD REL 2019 3
   [Anonymous], 2019, OMEGA 3 1 1 2 OPENEY
   [Anonymous], 2019, SCHROD REL 2019 3 IM
   Basille D, 2017, LUNG, V195, P201, DOI 10.1007/s00408-016-9973-1
   Bouchentouf S., 2020, IDENTIFICATION COMPO, DOI [10.26434/chemrxiv.12055716.v1, DOI 10.26434/CHEMRXIV.12055716.V1]
   Bzowka M., 2020, MOL DYNAMICS SIMULAT, DOI [10.1101/2020.02.27.968008, DOI 10.1101/2020.02.27.968008]
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chaput L, 2017, J CHEMINFORMATICS, V9, DOI 10.1186/s13321-017-0227-x
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Dang M., 2020, PREPRINTS, DOI [10.31219/osf.io/skznv, DOI 10.31219/OSF.IO/SKZNV]
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Douguet D, 2018, ACS MED CHEM LETT, V9, P204, DOI 10.1021/acsmedchemlett.7b00462
   Elsevier, 2020, REAXYS DAT
   Gimeno A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061375
   Hada M., 2020, PREPRINT, DOI [10.13140/RG.2.2.26979.91689, DOI 10.13140/RG.2.2.26979.91689]
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Herraez A, 2006, BIOCHEM MOL BIOL EDU, V34, P255, DOI 10.1002/bmb.2006.494034042644
   Hevener KE, 2009, J CHEM INF MODEL, V49, P444, DOI 10.1021/ci800293n
   Hosseini FS, 2020, SIMEPREVIR POTENTIAL, DOI 10.20944/preprints202002.0438.v1
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Kong R., 2020, 200300163V1 ARXIV
   Li J, 2019, INTERDISCIP SCI, V11, P320, DOI 10.1007/s12539-019-00327-w
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Liu ZC, 2013, DRUG DISCOV TODAY, V18, P110, DOI 10.1016/j.drudis.2012.08.005
   Macchiagodena M., 2020, ARXIV200209937
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   Mirza M. U., 2020, STRUCTURAL ELUCIDATI, DOI [10.20944/preprints202003.0085.v1, DOI 10.20944/PREPRINTS202003.0085.V1]
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Novi M., 2016, METHODS ALGORITHMS M, P99
   Olsson MHM, 2011, J CHEM THEORY COMPUT, V7, P525, DOI 10.1021/ct100578z
   Singh BK, 2014, EXPERT OPIN DRUG MET, V10, P143, DOI 10.1517/17425255.2014.856881
   Statista, COR COVID 19 DEATH R
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Tang B., 2020, AIDED DESIGN NOVEL T, DOI [10.1101/2020.03.03.972133, DOI 10.1101/2020.03.03.972133]
   Torres PHM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184574
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Ul-Haq Z., 2017, FRONTIERS COMPUTATIO, V3
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yoshino R., 2020, IDENTIFICATION KEY I, DOI [10.26434/chemrxiv.12009636.v1, DOI 10.26434/CHEMRXIV.12009636.V1]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 53
TC 9
Z9 9
U1 7
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2020
VL 21
IS 11
AR 3793
DI 10.3390/ijms21113793
PG 29
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA MC6ND
UT WOS:000543400300055
PM 32471205
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hagar, M
   Ahmed, HA
   Aljohani, G
   Alhaddad, OA
AF Hagar, Mohamed
   Ahmed, Hoda A.
   Aljohani, Ghadah
   Alhaddad, Omaima A.
TI Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug:
   Molecular Docking and DFT Calculations
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE COVID 19; N-heterocycles; molecular docking; DFT calculations;
   hydroxychloroquine
ID STRUCTURAL FEATURES; CORONAVIRUS; VIRUS
AB The novel coronavirus, COVID-19, caused by SARS-CoV-2, is a global health pandemic that started in December 2019. The effective drug target among coronaviruses is the main protease M-pro, because of its essential role in processing the polyproteins that are translated from the viral RNA. In this study, the bioactivity of some selected heterocyclic drugs named Favipiravir (1), Amodiaquine (2), 2 '-Fluoro-2 '-deoxycytidine (3), and Ribavirin (4) was evaluated as inhibitors and nucleotide analogues for COVID-19 using computational modeling strategies. The density functional theory (DFT) calculations were performed to estimate the thermal parameters, dipole moment, polarizability, and molecular electrostatic potential of the present drugs; additionally, Mulliken atomic charges of the drugs as well as the chemical reactivity descriptors were investigated. The nominated drugs were docked on SARS-CoV-2 main protease (PDB: 6LU7) to evaluate the binding affinity of these drugs. Besides, the computations data of DFT the docking simulation studies was predicted that the Amodiaquine (2) has the least binding energy (-7.77 Kcal/mol) and might serve as a good inhibitor to SARS-CoV-2 comparable with the approved medicines, hydroxychloroquine, and remdesivir which have binding affinity -6.06 and -4.96 Kcal/mol, respectively. The high binding affinity of 2 was attributed to the presence of three hydrogen bonds along with different hydrophobic interactions between the drug and the critical amino acids residues of the receptor. Finally, the estimated molecular electrostatic potential results by DFT were used to illustrate the molecular docking findings. The DFT calculations showed that drug 2 has the highest of lying HOMO, electrophilicity index, basicity, and dipole moment. All these parameters could share with different extent to significantly affect the binding affinity of these drugs with the active protein sites.
C1 [Hagar, Mohamed] Taibah Univ, Coll Sci, Chem Dept, Yanbu 30799, Saudi Arabia.
   [Hagar, Mohamed] Alexandria Univ, Fac Sci, Chem Dept, Alexandria 21321, Egypt.
   [Ahmed, Hoda A.] Cairo Univ, Fac Sci, Dept Chem, Cairo 12613, Egypt.
   [Aljohani, Ghadah; Alhaddad, Omaima A.] Taibah Univ, Coll Sci, Chem Dept, Al Madina 30002, Saudi Arabia.
RP Hagar, M (corresponding author), Taibah Univ, Coll Sci, Chem Dept, Yanbu 30799, Saudi Arabia.; Hagar, M (corresponding author), Alexandria Univ, Fac Sci, Chem Dept, Alexandria 21321, Egypt.; Ahmed, HA (corresponding author), Cairo Univ, Fac Sci, Dept Chem, Cairo 12613, Egypt.
EM mhagar@taibahu.edu.sa; ahoda@sci.cu.edu.eg; gjohani@taibahu.edu.sa;
   OHADDAD@taibahu.edu.sa
OI Hagar, Mohamed Esam/0000-0003-0169-7738; Ahmed, Hoda/0000-0003-3966-7024
CR Almutairi MS, 2019, J MOL STRUCT, V1180, P110, DOI 10.1016/j.molstruc.2018.11.088
   Alnoman RB, 2020, J PHOTOCH PHOTOBIO A, V395, DOI 10.1016/j.jphotochem.2020.112508
   Alnoman RB, 2020, J BIOMOL STRUCT DYN, V38, P5429, DOI 10.1080/07391102.2019.1701555
   [Anonymous], 2009, GAUSSIAN 09 REVISION
   Avorn J, 2015, NEW ENGL J MED, V372, P1877, DOI 10.1056/NEJMp1500848
   Chand K, 2020, ARAB J CHEM, V13, P8248, DOI [10.1142/S0192415X20500378, 10.1016/j.arabjc.2020.01.009]
   Cheng Feixiong, 2019, Methods Mol Biol, V1878, P243, DOI 10.1007/978-1-4939-8868-6_15
   Cheng FX, 2016, TRENDS MOL MED, V22, P919, DOI 10.1016/j.molmed.2016.09.006
   Cheng FX, 2017, BRIEF BIOINFORM, V18, P682, DOI 10.1093/bib/bbw051
   Dennington R., 2009, GAUSS VIEW VERSION 5
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Glue P, 1999, SEMIN LIVER DIS, V19, P17
   Gong HH, 2016, CURR TOP MED CHEM, V16, P3303, DOI 10.2174/1568026616666160506145943
   Grimstein M, 2019, J PHARM SCI-US, V108, P21, DOI 10.1016/j.xphs.2018.10.033
   Hagar M, 2020, J MOL STRUCT, V1199, DOI 10.1016/j.molstruc.2019.126926
   Kouza M, 2018, MOLECULES, V23, DOI 10.3390/molecules23081995
   Liu C., 2020, RES DEV THERAPEUTIC
   Liu C, 2020, PHYS REP, V846, P1, DOI 10.1016/j.physrep.2019.12.004
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Majumdar D, 2020, J MOL STRUCT, V1209, DOI 10.1016/j.molstruc.2020.127936
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nasief NN, 2017, EUR J MED CHEM, V125, P975, DOI 10.1016/j.ejmech.2016.09.038
   Nishiura H, 2020, INT J INFECT DIS, V93, P284, DOI 10.1016/j.ijid.2020.02.060
   Oehninger L, 2013, DALTON T, V42, P3269, DOI 10.1039/c2dt32617e
   Olliaro P, 1996, LANCET, V348, P1196, DOI 10.1016/S0140-6736(96)06217-4
   Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189
   Sato R, 2020, J MOL GRAPH MODEL, V98, DOI 10.1016/j.jmgm.2020.107611
   Shawon J, 2018, INTERDISCIP SCI, V10, P525, DOI 10.1007/s12539-016-0186-3
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shetty Rohit, 2020, Indian J Ophthalmol, V68, P693, DOI 10.4103/ijo.IJO_639_20
   Theerawatanasirikul S, 2020, ANTIVIR RES, V174, DOI 10.1016/j.antiviral.2019.104697
   Uzzaman M., 2018, INT J SCI RES MANAG, V6, pC, DOI [10.18535/ijsrm/v6i9.c01, DOI 10.18535/IJSRM/V6I9.C01]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   WOHLRAB F, 1985, BIOCHIM BIOPHYS ACTA, V824, P233, DOI 10.1016/0167-4781(85)90053-3
   Xavier S, 2015, SPECTROCHIM ACTA A, V137, P306, DOI 10.1016/j.saa.2014.08.039
   Yang PH, 2020, CELL MOL IMMUNOL, V17, P555, DOI 10.1038/s41423-020-0407-x
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhou D, 2020, EMERGING UNDERSTANDI, DOI [10.20944/preprints202002.0283.v1, DOI 10.20944/PREPRINTS202002.0283.V1]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 44
TC 9
Z9 9
U1 3
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2020
VL 21
IS 11
AR 3922
DI 10.3390/ijms21113922
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA MC6ND
UT WOS:000543400300184
PM 32486229
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Snijder, EJ
   Limpens, RWAL
   de Wilde, AH
   de Jong, AWM
   Zevenhoven-Dobbe, JC
   Maier, HJ
   Faas, FFGA
   Koster, AJ
   Barcena, M
AF Snijder, Eric J.
   Limpens, Ronald W. A. L.
   de Wilde, Adriaan H.
   de Jong, Anja W. M.
   Zevenhoven-Dobbe, Jessika C.
   Maier, Helena J.
   Faas, Frank F. G. A.
   Koster, Abraham J.
   Barcena, Montserrat
TI A unifying structural and functional model of the coronavirus
   replication organelle: Tracking down RNA synthesis
SO PLOS BIOLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; DOUBLE-STRANDED-RNA; ELECTRON-MICROSCOPY;
   SARS-CORONAVIRUS; ULTRASTRUCTURAL CHARACTERIZATION; NONSTRUCTURAL
   PROTEINS; MONOCLONAL-ANTIBODIES; AVIAN CORONAVIRUS; COMPLEX;
   GLYCOPROTEIN
AB Zoonotic coronavirus (CoV) infections, such as those responsible for the current severe acute respiratory syndrome-CoV 2 (SARS-CoV-2) pandemic, cause grave international public health concern. In infected cells, the CoV RNA-synthesizing machinery associates with modified endoplasmic reticulum membranes that are transformed into the viral replication organelle (RO). Although double-membrane vesicles (DMVs) appear to be a pan-CoV RO element, studies to date describe an assortment of additional CoV-induced membrane structures. Despite much speculation, it remains unclear which RO element(s) accommodate viral RNA synthesis. Here we provide detailed 2D and 3D analyses of CoV ROs and show that diverse CoVs essentially induce the same membrane modifications, including the small open double-membrane spherules (DMSs) previously thought to be restricted to gamma- and delta-CoV infections and proposed as sites of replication. Metabolic labeling of newly synthesized viral RNA followed by quantitative electron microscopy (EM) autoradiography revealed abundant viral RNA synthesis associated with DMVs in cells infected with the beta-CoVs Middle East respiratory syndrome-CoV (MERS-CoV) and SARS-CoV and the gamma-CoV infectious bronchitis virus. RNA synthesis could not be linked to DMSs or any other cellular or virus-induced structure. Our results provide a unifying model of the CoV RO and clearly establish DMVs as the central hub for viral RNA synthesis and a potential drug target in CoV infection.
C1 [Snijder, Eric J.; de Wilde, Adriaan H.; Zevenhoven-Dobbe, Jessika C.] Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, Leiden, Netherlands.
   [Limpens, Ronald W. A. L.; de Jong, Anja W. M.; Faas, Frank F. G. A.; Koster, Abraham J.; Barcena, Montserrat] Leiden Univ, Med Ctr, Dept Cell & Chem Biol, Sect Elect Microscopy, Leiden, Netherlands.
   [Maier, Helena J.] Pirbright Inst, Surrey, England.
   [de Wilde, Adriaan H.] Pharmaceut Co Johnson & Johnson, Janssen Vaccines & Prevent, Leiden, Netherlands.
RP Snijder, EJ (corresponding author), Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, Leiden, Netherlands.; Barcena, M (corresponding author), Leiden Univ, Med Ctr, Dept Cell & Chem Biol, Sect Elect Microscopy, Leiden, Netherlands.
EM e.j.snijder@lumc.nl; m.barcena@lumc.nl
RI Barcena, Montserrat/B-5823-2012; Koster, Abraham/I-7665-2017
OI Barcena, Montserrat/0000-0002-7719-4443; Limpens,
   Ronald/0000-0002-6243-6729; de Jong, Anja/0000-0001-8110-8520; Faas,
   Frank/0000-0002-1774-700X; Koster, Abraham/0000-0003-1717-2549
FU Netherlands Organization for Scientific Research (NWO)Netherlands
   Organization for Scientific Research (NWO) [NWO-MEERVOUD-863.10.003]
FX This research was partially funded by the Netherlands Organization for
   Scientific Research (NWO, https://www.nwo.nl/en) through a grant to M.B.
   (NWO-MEERVOUD-863.10.003). The funder had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Al-Mulla HMN, 2014, MBIO, V5, DOI 10.1128/mBio.01107-13
   Almsherqi ZA, 2006, J CELL BIOL, V173, P839, DOI 10.1083/jcb.200603055
   Angelini MM, 2013, MBIO, V4, DOI 10.1128/mBio.00524-13
   Beachboard DC, 2015, J VIROL, V89, P2080, DOI 10.1128/JVI.02776-14
   Becker W B, 1967, J Virol, V1, P1019
   Belov GA, 2012, J VIROL, V86, P302, DOI 10.1128/JVI.05937-11
   BIENZ KA, 1977, MICROSC ACTA, V79, P1
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bozzola JJ, 1999, AUTORADIOGRAPHY RADI, P293
   Casais R, 2001, J VIROL, V75, P12359, DOI 10.1128/JVI.75.24.12359-12369.2001
   de Castro IF, 2017, J CELL SCI, V130, P260, DOI 10.1242/jcs.181586
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   Deng Y, 2010, TRENDS CELL BIOL, V20, P371, DOI 10.1016/j.tcb.2010.04.001
   Denison MR, 1999, J VIROL, V73, P6862, DOI 10.1128/JVI.73.8.6862-6871.1999
   Doerflinger SY, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006705
   Doyle N, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111030
   Faas FGA, 2012, J CELL BIOL, V198, P457, DOI 10.1083/jcb.201201140
   GINSEL LA, 1979, HISTOCHEMISTRY, V61, P343, DOI 10.1007/BF00508456
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Hagemeijer MC, 2014, VIROLOGY, V458, P125, DOI 10.1016/j.virol.2014.04.027
   Hagemeijer MC, 2012, J VIROL, V86, P5808, DOI 10.1128/JVI.07207-11
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Harak C, 2015, VIROLOGY, V479, P418, DOI 10.1016/j.virol.2015.02.029
   Kallio K, 2013, J VIROL, V87, P9125, DOI 10.1128/JVI.00660-13
   Karreman MA, 2013, J HISTOCHEM CYTOCHEM, V61, P236, DOI 10.1369/0022155412473756
   Kindler E, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006195
   KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994
   Knoops K, 2012, J VIROL, V86, P2474, DOI 10.1128/JVI.06677-11
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Kopek BG, 2007, PLOS BIOL, V5, P2022, DOI 10.1371/journal.pbio.0050220
   Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013
   Kukulski W, 2011, J CELL BIOL, V192, P111, DOI 10.1083/jcb.201009037
   Limpens RWAL, 2011, MBIO, V2, DOI 10.1128/mBio.00166-11
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lucocq JM, 2004, J HISTOCHEM CYTOCHEM, V52, P991, DOI 10.1369/jhc.3a6178.2004
   Lundin A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004166
   MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944
   Maier HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep27126
   Maier HJ, 2013, MBIO, V4, DOI 10.1128/mBio.00801-13
   Mayhew TM, 2002, J MICROSC-OXFORD, V205, P153, DOI 10.1046/j.0022-2720.2001.00977.x
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Melia CE, 2018, MBIO, V9, DOI 10.1128/mBio.00420-18
   Melia CE, 2017, CELL REP, V21, P587, DOI 10.1016/j.celrep.2017.09.068
   Muller C, 2018, J VIROL, V92, DOI 10.1128/JVI.01463-17
   Nagy PD, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005912
   Neuman BW, 2013, MBIO, V4, DOI 10.1128/mBio.00987-13
   Ng ML, 2003, J GEN VIROL, V84, P3291, DOI 10.1099/vir.0.19505-0
   Ogando NS, J GEN VIROL
   OPSTELTEN DJE, 1995, J CELL BIOL, V131, P339, DOI 10.1083/jcb.131.2.339
   Oudshoorn D, 2017, MBIO, V8, DOI 10.1128/mBio.01658-17
   Paul D, 2013, J VIROL, V87, P10612, DOI 10.1128/JVI.01370-13
   Romero-Brey I, 2014, VIRUSES-BASEL, V6, P2826, DOI 10.3390/v6072826
   Romero-Brey I, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003056
   SCHONBORN J, 1991, NUCLEIC ACIDS RES, V19, P2993, DOI 10.1093/nar/19.11.2993
   Schwartz M, 2002, MOL CELL, V9, P505, DOI 10.1016/S1097-2765(02)00474-4
   Scutigliani EM, 2017, CYTOKINE GROWTH F R, V37, P17, DOI 10.1016/j.cytogfr.2017.05.007
   Sims AC, 2000, J VIROL, V74, P5647, DOI 10.1128/JVI.74.12.5647-5654.2000
   Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   Ulasli M, 2010, CELL MICROBIOL, V12, P844, DOI 10.1111/j.1462-5822.2010.01437.x
   V'kovski P, 2019, ELIFE, V8, DOI 10.7554/eLife.42037
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   van den Worm SHE, 2011, J VIROL, V85, P5669, DOI 10.1128/JVI.00403-11
   van der Meer Y, 1999, J VIROL, V73, P7641, DOI 10.1128/JVI.73.9.7641-7657.1999
   van Hemert MJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000054
   Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006
   Welsch S, 2009, CELL HOST MICROBE, V5, P365, DOI 10.1016/j.chom.2009.03.007
   Widjaja I, 2019, EMERG MICROBES INFEC, V8, P516, DOI 10.1080/22221751.2019.1597644
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200919
   Zhou XD, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9090251
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 76
TC 18
Z9 18
U1 4
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1544-9173
EI 1545-7885
J9 PLOS BIOL
JI PLoS. Biol.
PD JUN
PY 2020
VL 18
IS 6
AR e3000715
DI 10.1371/journal.pbio.3000715
PG 25
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA MD5RF
UT WOS:000544028700005
PM 32511245
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bornstein, SR
   Gallwitz, B
   Kellerer, M
   Ludwig, B
   Muller-Wieland, D
   Neu, A
   Reuter, HM
   Roden, M
   Seufert, J
AF Bornstein, Stefan R.
   Gallwitz, Baptist
   Kellerer, Monika
   Ludwig, Barbara
   Mueller-Wieland, Dirk
   Neu, Andreas
   Reuter, Hans-Martin
   Roden, Michael
   Seufert, Jochen
TI Practical Recommendations for diabetes management in patients with
   COVID-19 disease
SO DIABETOLOGIE UND STOFFWECHSEL
LA German
DT Article
DE diabetes therapy; COVID 19 disease; SARS CoV 2 infection; type 1
   diabetes; type 2 diabetes
ID ACE2
AB In subjects with an infection with the novel corona virus SARS-CoV-2 and COVID-19 disease, diabetes mellitus and cardiovascular diseases are highly prevalent comorbidities. Diabetes patients with comorbidities and/or diabetes complications seem to have a higher risk for a severe course of the COVID-19 disease including the development of ARDS or multiorgan failure. The exact interrelations between diabetes and the individual clinical course of COVID-19 are not completely understood at this time. The German Diabetes Association (DDG) summarizes basic principle practice recommendations for the treatment of patients with diabetes and concomitant COVID-19 disease.
C1 [Bornstein, Stefan R.; Ludwig, Barbara] Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 3, Dresden, Germany.
   [Gallwitz, Baptist] Univ Klinikum Tubingen, Dept Innere Med, Abt 4, Tubingen, Germany.
   [Kellerer, Monika] Marienhospital, Zentrum Innere Med 1, Stuttgart, Germany.
   [Mueller-Wieland, Dirk] Rhein Westfal TH Aachen, Med Klin 1, Univ Klinikum, Aachen, Germany.
   [Neu, Andreas] Univ Klinikum Tubingen, Klin Kinder & Jugendmed, Tubingen, Germany.
   [Roden, Michael] Univ Klinikum Dusseldorf, Med Klin, Klin Endokrinol & Diabetol, Dusseldorf, Germany.
   [Seufert, Jochen] Univ Klinikum Freiburg, Klin Innere Med 2, Freiburg, Germany.
RP Kellerer, M (corresponding author), Marienhosp Stuttgart, Zentrum Innere Med 1, Boheimstr 37, D-70199 Stuttgart, Germany.
EM monika.kellerer@vinzenz.de
CR Bindom SM, 2009, MOL CELL ENDOCRINOL, V302, P193, DOI 10.1016/j.mce.2008.09.020
   Bornstein SR, 2020, NAT REV ENDOCRINOL, V16, P297, DOI 10.1038/s41574-020-0353-9
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Deutsche Sepsis-Gesellschaft e.V. (DSG) und Deutsche Interdisziplinare Vereinigung fur Intensiv- und Notfallmedizin (DIVI), 2010, PRAV DIAGN THER NACH
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kavanagh BP, 2010, NEW ENGL J MED, V363, P2540, DOI 10.1056/NEJMcp1001115
   Roca-Ho H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030563
   Shetty S, 2012, ENDOCR PRACT, V18, P363, DOI 10.4158/EP11260.OR
   Silva ACSE, 2013, BRIT J PHARMACOL, V169, P477, DOI 10.1111/bph.12159
   Wendt R, 2020, DTSCH ARZTEBL, V117, pA
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 13
TC 0
Z9 0
U1 5
U2 5
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 1861-9002
EI 1861-9010
J9 DIABETOL STOFFWECHS
JI Diabetol. Stoffwechs.
PD JUN
PY 2020
VL 15
IS 3
BP 241
EP 246
DI 10.1055/a-1159-1486
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MD1LI
UT WOS:000543736400011
DA 2021-01-01
ER

PT J
AU Yao, YS
   Luo, Z
   Zhang, XW
AF Yao, Yushan
   Luo, Zhen
   Zhang, Xuewu
TI In silicoevaluation of marine fish proteins as nutritional supplements
   for COVID-19 patients
SO FOOD & FUNCTION
LA English
DT Article
ID INHIBITORY PEPTIDES; TRANSPORT; DESIGN; SPECIFICITY
AB To date, no specific drug has been discovered for the treatment of COVID-19 and hence, people are in a state of anxiety. Thus, there is an urgent need to search for various possible strategies including nutritional supplementation. In this study, we have tried to provide a reference for protein supplementation. Specifically, 20 marine fish proteins were subjected toin silicohydrolysis by gastrointestinal enzymes, and a large number of active peptides were generated. Then, the binding abilities of these peptides to SARS-CoV-2 main protease and monoamine oxidase A were assessed. The results showed that NADH dehydrogenase could be a good protein source in generating potent binders to the two enzymes, followed by cytochrome b. In addition, some high-affinity oligopeptides (VIQY, ICIY, PISQF, VISAW, AIPAW, and PVSQF) were identified as dual binders to the two enzymes. In summary, the supplementation of some fish proteins can be helpful for COVID-19 patients; the identified oligopeptides can be used as the lead compounds to design potential inhibitors against COVID-19 and anxiety.
C1 [Yao, Yushan; Luo, Zhen; Zhang, Xuewu] South China Univ Technol, Coll Food Sci & Engn, Guangzhou, Peoples R China.
RP Zhang, XW (corresponding author), South China Univ Technol, Coll Food Sci & Engn, Guangzhou, Peoples R China.
EM snow_dance@sina.com
CR Aito-Inoue M, 2007, J PEPT SCI, V13, P468, DOI 10.1002/psc.870
   Akaji K, 2011, J MED CHEM, V54, P7962, DOI 10.1021/jm200870n
   Choe J, 2019, INT J FOOD PROP, V22, P1112, DOI 10.1080/10942912.2019.1629690
   Chothe P, 2011, AM J PHYSIOL-CELL PH, V300, pC1260, DOI 10.1152/ajpcell.00299.2010
   Dhiman P, 2018, CURR TOP MED CHEM, V18, P1857, DOI 10.2174/1568026618666181115095204
   Hirata H, 2007, PEPTIDES, V28, P1998, DOI 10.1016/j.peptides.2007.07.024
   Hong SM, 2016, J AGR FOOD CHEM, V64, P2072, DOI 10.1021/acs.jafc.6b00279
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Li XL, 2013, CHEMOSPHERE, V92, P795, DOI 10.1016/j.chemosphere.2013.04.022
   Minkiewicz P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235978
   Nongonierma AB, 2019, J FOOD BIOCHEM, V43, DOI 10.1111/jfbc.12451
   Oda A, 2012, J NEUROCHEM, V122, P356, DOI 10.1111/j.1471-4159.2012.07777.x
   Ohinata K, 2007, BIOSCI BIOTECH BIOCH, V71, P2618, DOI 10.1271/bbb.70516
   Pan SK, 2016, FOOD CHEM, V211, P423, DOI 10.1016/j.foodchem.2016.05.087
   Shulman KI, 2013, CNS DRUGS, V27, P789, DOI 10.1007/s40263-013-0097-3
   Steuber H, 2010, CURR TOP MED CHEM, V10, P323, DOI 10.2174/156802610790725470
   Thanigaimalai P, 2013, EUR J MED CHEM, V65, P436, DOI 10.1016/j.ejmech.2013.05.005
   Theoduloz C, 2019, CHEM BIOL DRUG DES, V93, P290, DOI 10.1111/cbdd.13415
   Tripathi SK, 2013, J THEOR BIOL, V334, P87, DOI 10.1016/j.jtbi.2013.05.014
   Vij R, 2016, FOOD CHEM, V190, P681, DOI 10.1016/j.foodchem.2015.05.121
   Xia B, 2011, PROTEIN CELL, V2, P282, DOI 10.1007/s13238-011-1034-1
   Yu ZP, 2016, FOOD FUNCT, V7, P491, DOI 10.1039/c5fo00697j
   Zhou P, 2018, NUCLEIC ACIDS RES, V46, pW443, DOI 10.1093/nar/gky357
   Zhu LL, 2011, ANTIVIR RES, V92, P204, DOI 10.1016/j.antiviral.2011.08.001
NR 24
TC 0
Z9 0
U1 5
U2 5
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042-6496
EI 2042-650X
J9 FOOD FUNCT
JI Food Funct.
PD JUN 1
PY 2020
VL 11
IS 6
BP 5565
EP 5572
DI 10.1039/d0fo00530d
PG 8
WC Biochemistry & Molecular Biology; Food Science & Technology
SC Biochemistry & Molecular Biology; Food Science & Technology
GA MB8JY
UT WOS:000542844600057
PM 32520031
DA 2021-01-01
ER

PT J
AU Koh, GCH
   Hoenig, H
AF Koh, Gerald Choon-Huat
   Hoenig, Helen
TI How Should the Rehabilitation Community Prepare for 2019-nCoV?
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE 2019-nCoV; COVID-19; Distancing; Epidemiology; Infection control;
   Rehabilitation
AB With the novel coronavirus 2019 (2019-nCoV) pandemic spreading quickly in the United States and the world, it is urgent that the rehabilitation community quickly understands the epidemiology of the virus and what we can and must do to face this microbial adversary at the early stages of this likely long global pandemic. The 2019-nCoV is a novel virus so most of the world's population does not have prior immunity to it. It is more infectious and fatal than seasonal influenza, and definitive treatment and a vaccine are months away. Our arsenal against it is currently mainly social distancing and infection control measures. (C) 2020 by the American Congress of Rehabilitation Medicine
C1 [Koh, Gerald Choon-Huat] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 12 Sci Dr 2,10-01, Singapore, Singapore.
   [Hoenig, Helen] Durham VA Med Ctr, Phys Med & Rehabil Serv, Durham, NC USA.
RP Koh, GCH (corresponding author), Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 12 Sci Dr 2,10-01, Singapore, Singapore.
EM gerald_koh@nuhs.edu.sg
FU Singapore Ministry of Health's National Medical Research Council under
   the Centre Grant Programme - Singapore Population Health Improvement
   CentreMinistry of Health-SingaporeNational Medical Research Council,
   Singapore [NMRC/CG/C026/2017_NUHS]
FX Gerald Choon-Huat Koh is supported by the Singapore Ministry of Health's
   National Medical Research Council under the Centre Grant Programme -
   Singapore Population Health Improvement Centre (NMRC/CG/C026/2017_NUHS).
CR Aljadi Sameera H, 2017, J Phys Ther Sci, V29, P1014, DOI 10.1589/jpts.29.1014
   CDC, DIS BURD INFL
   CDC, CDC CONF PERS TO PER
   CDC, COR DIS 2019 COVID 1
   Centers for Disease Control and Prevention, WASH YOUR HANDS
   Centre for Health Security. John Hopkins Bloomberg School of Public Health, SER TEST COVID 19
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Lambert I, 2000, J HOSP INFECT, V44, P59, DOI 10.1053/jhin.1999.0647
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li Y, 2020, EUR RADIOL, V30, P6186, DOI 10.1007/s00330-020-06969-5
   Mobin M, 2011, PHYSIOTHERAPY, V97, P273, DOI 10.1016/j.physio.2010.11.010
   Oesterle ME, 2019, AM J INFECT CONTROL, V47, P456, DOI 10.1016/j.ajic.2018.09.031
   Peeri NC, 2020, INT J EPIDEMIOL
   Sarfo FS, 2018, J STROKE CEREBROVASC, V27, P2306, DOI 10.1016/j.jstrokecerebrovasdis.2018.05.013
   Spratt HG, 2019, PHYSIOTHER THEOR PR, V35, P163, DOI 10.1080/09593985.2018.1441935
   Stebbing J, 2020, LANCET INFECT DIS
   WHO, REP WHO CHIN JOINT M
   World Health Organization, COR DIS 2019 COVID 1
   Zhang S, 2020, INT J INFECT DIS, V93, P201, DOI 10.1016/j.ijid.2020.02.033
NR 19
TC 18
Z9 19
U1 6
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
EI 1532-821X
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD JUN
PY 2020
VL 101
IS 6
BP 1068
EP 1071
DI 10.1016/j.apmr.2020.03.003
PG 4
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA MC1BC
UT WOS:000543030600015
PM 32194034
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hornuss, D
   Laubner, K
   Monasterio, C
   Thimme, R
   Wagner, D
AF Hornuss, Daniel
   Laubner, Katharina
   Monasterio, Carmen
   Thimme, Robert
   Wagner, Dirk
TI COVID-19 associated pneumonia despite repeatedly negative PCR-analysis
   from oropharyngeal swabs
SO DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
LA German
DT Article
DE COVID-19; SARS; CoV-2; COVID-19 associated pneumonia
AB Patient history and clinical findings A 46-year old construction worker presented at the emergency department with two orthostatic syncopes. The patient complained of prolonged fever and coughs for 7 days which had not improved after oral treatment with sultamicillin for 5 days, prescribed by the patient's general practitioner. Physical examination showed high blood pressure due to previously known hypertension. Other vital signs without pathological findings. Pulmonary auscultation showed basal soft crackling noises of the left lung
   Findings and Diagnosis Laboratory examination showed increased values for LDH, pro-BNP and CRP and normal values for leucocytes and procalcitonin. Conventional X-Ray of the chest showed bipulmonal lateral atypical infiltrates. After the first PCR turned in negative another PCR-analysis for SARS-CoV-2 of a deep oral swab-sample was performed since the clinical, laboratory and radiological findings were typical for COVID-19. Again, SARS-CoV-2-RNA was not detected. A CT-scan of the chest showed bipulmonal lateral ground-glass attenuation, again typical for COVID-19 associated pneumonia. After a third attempt for a PCR-analysis of a deep oral swab-sample was negative, analysis of a sputum was performed which finally confirmed the diagnosis of COVID-19 associated pneumonia.
   Therapy and Course of events The patient was admitted for evaluation of syncopes and suspect of COVID-19 associated pneumonia. The patient was prophylactically isolated while the result of SARS-CoV-2-PCR from a deep oral swab was pending. Suspecting a possible secondary bacterial infection at the beginning, intravenous antibiotic treatment with ampicillin/sulbactam was initiated. While further examinations showed no indication for bacterial infection, antibiotics were discontinued after 3 days. Due to clinical recovery antiviral therapy was not performed after confirming the diagnosis. The patient was discharged 17 days after onset of first symptoms without any requirements for further isolation.
   Conclusion This casuistic describes a case of COVID-19 associated pneumonia presenting with typical clinical features, laboratory and radiological findings. Detection of viral RNA was not successful from deep oral swab-samples despite repeated attempts. Finally, PCR-analysis of sputum confirmed the diagnosis. Analysis of deeper airway samples (sputum, bronchoalveolar lavage, tracheal secretions) or stool for SARS-CoV-2 should be performed in cases of evident clinical suspicion of COVID-19 and negative PCR results from deep oral swabs.
C1 [Hornuss, Daniel; Laubner, Katharina; Monasterio, Carmen; Thimme, Robert; Wagner, Dirk] Univ Klinikum Freiburg, Klin Innere Med Gastroenterol Hepatol Endokrinol, Hugstetter Str 55, D-79106 Freiburg, Germany.
RP Hornuss, D (corresponding author), Univ Klinikum Freiburg, Klin Innere Med Gastroenterol Hepatol Endokrinol, Hugstetter Str 55, D-79106 Freiburg, Germany.
EM daniel.hornuss@uniklinik-freiburg.de
CR ACR, 2020, ACR REC US CHEST RAD
   Ai T, 2020, RADIOLOGY, DOI [10.1148/radiol.2020200642:200642, DOI 10.1148/RADIOL.2020200642:200642]
   Deutsche Rontgengesellschaft, 2020, PRESS INF COVID 19 U
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Konrad R, 2020, EUROSURVEILLANCE, V25, P13, DOI 10.2807/1560-7917.ES.2020.25.9.2000173
   Long CQ, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108961
   RKI, 2020, HINW TEST PAT INF NE
   Robert Koch-Institut (RKI), 2020, COVID 19 DASHB
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang Yang M, 2020, EVALUATING ACCURACY, DOI [10.1101/2020.02.11.20021493, DOI 10.1101/2020.02.11.20021493]
NR 11
TC 1
Z9 1
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0012-0472
EI 1439-4413
J9 DEUT MED WOCHENSCHR
JI Dtsch. Med. Wochenschr.
PD JUN
PY 2020
VL 145
IS 12
BP 844
EP 849
DI 10.1055/a-1170-6061
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA MB9VK
UT WOS:000542945400018
PM 32403153
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU de Oliveira, OV
   Rocha, GB
   Paluch, AS
   Costa, LT
AF de Oliveira, Osmair Vital
   Rocha, Gerd B.
   Paluch, Andrew S.
   Costa, Luciano T.
TI Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from
   molecular modeling and virtual screening
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2 virus; Spike protein; drug design; molecular
   modeling
ID LINEAR CONSTRAINT SOLVER; HYDROXYCHLOROQUINE; ELECTROSTATICS;
   AZITHROMYCIN; EFFICIENT; DYNAMICS; GROMACS; LINCS
AB Herein, molecular modeling techniques were used with the main goal to obtain candidates from a drug database as potential targets to be used against SARS-CoV-2. This novel coronavirus, responsible by the COVID-19 outbreak since the end of 2019, became a challenge since there is not vaccine for this disease. The first step in this investigation was to solvate the isolated S-protein in water for molecular dynamics (MD) simulation, being observed a transition from "up" to "down" conformation of receptor-binding domain (RBD) of the S-protein with angle of 54.3 and 43.0 degrees, respectively. The RBD region was more exposed to the solvent and to the possible drugs due to its enhanced surface area. From the equilibrated MD structure, virtual screening by docking calculations were performed using a library contained 9091 FDA approved drugs. Among them, 24 best-scored ligands (14 traditional herbal isolate and 10 approved drugs) with the binding energy below -8.1 kcal/mol were selected as potential candidates to inhibit the SARS-CoV-2 S-protein, preventing the human cell infection and their replication. For instance, the ivermectin drug (present in our list of promise candidates) was recently used successful to control viral replicationin vitro.MD simulations were performed for the three best ligands@S-protein complexes and the binding energies were calculated using the MM/PBSA approach. Overall, it is highlighted an important strategy, some key residues, and chemical groups which may be considered on clinical trials for COVID-19 outbreak.
C1 [de Oliveira, Osmair Vital] Inst Fed Educ Ciencia & Tecnol Sao Paulo, Campus Catanduva, BR-15808305 Catanduva, SP, Brazil.
   [Rocha, Gerd B.] Univ Fed Paraiba, Dept Quim, Joao Pessoa, Paraiba, Brazil.
   [Paluch, Andrew S.] Miami Univ, Dept Chem Paper & Biomed Engn, Oxford, OH 45056 USA.
   [Costa, Luciano T.] Univ Fed Fluminense Outeiro Sao Joao Batista, Inst Quim, MolMod CS, Niteroi, RJ, Brazil.
RP de Oliveira, OV (corresponding author), Inst Fed Educ Ciencia & Tecnol Sao Paulo, Campus Catanduva, BR-15808305 Catanduva, SP, Brazil.
EM osmairvital@gmail.com
OI Paluch, Andrew/0000-0002-2748-0783; Rocha, Gerd
   Bruno/0000-0001-9805-9497
FU FAPESP (Sao Paulo Research Foundation)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2018/19844-8]; FAPERJCarlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES) through the research project Bioinformatica Estrutural de
   Proteinas: Modelos, Algoritmos e Aplicacoes BiotecnologicasCAPES
   [AUXPE1375/2014]; Brazilian National Council for Scientific and
   Technological Development (CNPq)National Council for Scientific and
   Technological Development (CNPq) [309761/2017-4]; CNPqNational Council
   for Scientific and Technological Development (CNPq)
FX This work was financial supported by FAPESP (Sao Paulo Research
   Foundation) under process number of 2018/19844-8. LTC is thankful for
   CNPq award fellowship and FAPERJ for the financial support. Also, this
   study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brasil (CAPES) through the research project
   Bioinformatica Estrutural de Proteinas: Modelos, Algoritmos e Aplicacoes
   Biotecnologicas (Edital Biologia Computacional 51/2013, No.
   AUXPE1375/2014 da CAPES). G.B.R. acknowledges support from the Brazilian
   National Council for Scientific and Technological Development (CNPq
   grant no. 309761/2017-4).
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Berendsen H. J. C., 2007, SIMULATING PHYS WORL
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Berendsen HJC, 1981, INTERMOLECULAR FORCE, V1981, P331, DOI [10.1007/978-94-015-7658-1_21, DOI 10.1007/978-94-015-7658-1_21]
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chen SA, 2006, CURR PHARM DESIGN, V12, P4539, DOI 10.2174/138161206779010459
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   DeLano W.L., 2009, PYMOL MOL GRAPHICS S
   Deserno M, 1998, J CHEM PHYS, V109, P7678, DOI 10.1063/1.477414
   Discovery Studio Visualizer Software, 2020, DISCOVERY STUDIO VIS
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P116, DOI 10.1021/ct700200b
   HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Li Q.-H., 2020, ASIAN TOXICOLOGY RES, V1, P1, DOI DOI 10.1007/s00362-017-0958-9
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morse P. M., 1953, METHODS THEORETICAL, VPart I, P434
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Novick PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079568
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Peng C., 2020, EXPLORING BINDING ME, DOI [10.26434/chemrxiv.11877492.v1, DOI 10.26434/CHEMRXIV.11877492.V1]
   Sandeep S., 2020, ENERGETICS BASED MOD, DOI [10.26434/chemrxiv.12015792.v1, DOI 10.26434/CHEMRXIV.12015792.V1]
   Schmid N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/s00249-011-0700-9
   Shah M., 2020, RES SQ, DOI [10.21203/rs.3.rs-16932/v1., DOI 10.21203/RS.3.RS-16932/V1]
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+
   Stroet M, 2018, J CHEM THEORY COMPUT, V14, P5834, DOI 10.1021/acs.jctc.8b00768
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Utomo R. Y., 2020, REVEALING POTENCY CI, DOI [10.20944/preprints202003.0214.v1, DOI 10.20944/PREPRINTS202003.0214.V1, 10.20944/preprints202003.0214.v1.]
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
NR 49
TC 11
Z9 11
U1 10
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1772885
EA JUN 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MC4CZ
UT WOS:000543238400001
PM 32448085
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Poh, CM
   Carissimo, G
   Wang, B
   Amrun, SN
   Lee, CYP
   Chee, RSL
   Fong, SW
   Yeo, NKW
   Lee, WH
   Torres-Ruesta, A
   Leo, YS
   Chen, MIC
   Tan, SY
   Chai, LYA
   Kalimuddin, S
   Kheng, SSG
   Thien, SY
   Young, BE
   Lye, DC
   Hanson, BJ
   Wang, CI
   Renia, L
   Ng, LFP
AF Poh, Chek Meng
   Carissimo, Guillaume
   Wang, Bei
   Amrun, Siti Naqiah
   Lee, Cheryl Yi-Pin
   Chee, Rhonda Sin-Ling
   Fong, Siew-Wai
   Yeo, Nicholas Kim-Wah
   Lee, Wen-Hsin
   Torres-Ruesta, Anthony
   Leo, Yee-Sin
   Chen, Mark I-Cheng
   Tan, Seow-Yen
   Chai, Louis Yi Ann
   Kalimuddin, Shirin
   Kheng, Shirley Seah Gek
   Thien, Siew-Yee
   Young, Barnaby Edward
   Lye, David C.
   Hanson, Brendon John
   Wang, Cheng-, I
   Renia, Laurent
   Ng, Lisa F. P.
TI Two linear epitopes on the SARS-CoV-2 spike protein that elicit
   neutralising antibodies in COVID-19 patients
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; VIRUS; TARGETS; DOMAIN
AB Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus.
C1 [Poh, Chek Meng; Carissimo, Guillaume; Wang, Bei; Amrun, Siti Naqiah; Lee, Cheryl Yi-Pin; Chee, Rhonda Sin-Ling; Fong, Siew-Wai; Yeo, Nicholas Kim-Wah; Lee, Wen-Hsin; Torres-Ruesta, Anthony; Wang, Cheng-, I; Renia, Laurent; Ng, Lisa F. P.] Agcy Sci Technol & Res, Immunos, Biopolis, Singapore Immunol Network, Singapore 138648, Singapore.
   [Fong, Siew-Wai] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore.
   [Torres-Ruesta, Anthony; Ng, Lisa F. P.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, 8 Med Dr, Singapore 117596, Singapore.
   [Leo, Yee-Sin; Chen, Mark I-Cheng; Young, Barnaby Edward; Lye, David C.] Natl Ctr Infect Dis, 16 Jalan Tan Tock Seng, Singapore 308442, Singapore.
   [Leo, Yee-Sin; Chai, Louis Yi Ann; Young, Barnaby Edward; Lye, David C.] Tan Tock Seng Hosp, Dept Infect Dis, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
   [Leo, Yee-Sin; Young, Barnaby Edward; Lye, David C.] Nanyang Technol Univ, Lee Kong Chian Sch Med, 11 Mandalay Rd, Singapore 308232, Singapore.
   [Leo, Yee-Sin; Lye, David C.] Natl Univ Singapore, Yong Loo Lin Sch Med, 10 Med Dr, Singapore 117597, Singapore.
   [Leo, Yee-Sin; Lye, David C.] Natl Univ Hlth Syst, 10 Med Dr, Singapore 117597, Singapore.
   [Chen, Mark I-Cheng] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 12 Sci Dr 2,10-01, Singapore 117549, Singapore.
   [Chen, Mark I-Cheng] Natl Univ Hlth Syst, 12 Sci Dr 2,10-01, Singapore 117549, Singapore.
   [Tan, Seow-Yen] Changi Gen Hosp, Dept Infect Dis, 2 Simei St 3, Singapore 529889, Singapore.
   [Chai, Louis Yi Ann] Natl Univ Singapore Hosp, Dept Med, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.
   [Kalimuddin, Shirin; Thien, Siew-Yee] Singapore Gen Hosp, Dept Infect Dis, 31 Third Hosp Ave,03-03 Bowyer Block C, Singapore 168753, Singapore.
   [Kalimuddin, Shirin] Duke NUS Med Sch, Emerging Infect Dis Program, 8 Coll Rd, Singapore 169857, Singapore.
   [Kheng, Shirley Seah Gek; Hanson, Brendon John] DSO Natl Labs, Biol Def Program, 27 Med Dr, Singapore 117510, Singapore.
   [Ng, Lisa F. P.] Univ Liverpool, Inst Infect Vet & Ecol Sci, 8 West Derby St, Liverpool L7 3EA, Merseyside, England.
RP Ng, LFP (corresponding author), Agcy Sci Technol & Res, Immunos, Biopolis, Singapore Immunol Network, Singapore 138648, Singapore.; Ng, LFP (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, 8 Med Dr, Singapore 117596, Singapore.; Ng, LFP (corresponding author), Univ Liverpool, Inst Infect Vet & Ecol Sci, 8 West Derby St, Liverpool L7 3EA, Merseyside, England.
EM lisa_ng@immunol.a-star.edu.sg
OI Carissimo, Guillaume/0000-0002-9703-9096; Lye,
   David/0000-0003-0324-0205; Torres-Ruesta, Anthony/0000-0003-0447-3131
FU Biomedical Research Council (BMRC)Agency for Science Technology &
   Research (ASTAR); A*ccelerate GAP from the Agency of Science, Technology
   and Research (A*STAR) [ACCL/19-GAP064-R20H-H]; National Medical Research
   Council (NMRC) COVID-19 Research fund [COVID19RF-001]
FX We thank Professor Yee-Joo Tan (Department of Microbiology, NUS;
   Institute of Molecular and Cell Biology-IMCB, A*STAR) who kindly
   provided CHO-ACE2 cells and pXJ3'-S plasmid. We acknowledge the
   excellent technical work in the BSL3 facility of Wong Pui San (Wong
   P.S.) and Chye De Ho (Chye D.H.). We also like to thank the study
   participants who donated their blood samples to this project, and the
   healthcare workers caring for COVID-19 patients. This work was supported
   by core research grants provided to Singapore Immunology Network by the
   Biomedical Research Council (BMRC), and by the A*ccelerate GAP-funded
   project (ACCL/19-GAP064-R20H-H) from the Agency of Science, Technology
   and Research (A*STAR). Subject recruitment and sample collection were
   funded by the National Medical Research Council (NMRC) COVID-19 Research
   fund (COVID19RF-001).
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Alsaadi EAJ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090825
   Amrun SN, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1066
   Cohen J, 2020, SCIENCE, V367, P234, DOI 10.1126/science.367.6475.234
   Darnell MER, 2006, TRANSFUSION, V46, P1770, DOI 10.1111/j.1537-2995.2006.00976.x
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kam YW, 2012, EMBO MOL MED, V4, P330, DOI 10.1002/emmm.201200213
   Lee CYP, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1126
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Lip KM, 2006, J VIROL, V80, P941, DOI 10.1128/JVI.80.2.941-950.2006
   Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725
   Madu IG, 2009, J VIROL, V83, P7411, DOI 10.1128/JVI.00079-09
   Ng OW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102415
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang H, 2020, PREPRINT, DOI [10.1101/2020.03.26.994756, DOI 10.1101/2020.03.26.994756]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F., 2020, NEUTRALIZING ANTIBOD, DOI [10.2139/ssrn.3566211, DOI 10.2139/SSRN.3566211]
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhao Wenming, 2020, Yichuan, V42, P212, DOI 10.16288/j.yczz.20-030
   Zheng M, 2020, CELL MOL IMMUNOL, V17, P536, DOI 10.1038/s41423-020-0385-z
NR 23
TC 25
Z9 25
U1 5
U2 7
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN 1
PY 2020
VL 11
IS 1
AR 2806
DI 10.1038/s41467-020-16638-2
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MC0JL
UT WOS:000542983900001
PM 32483236
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liebl, ME
   Gutenbrunner, C
   Glaesener, JJ
   Schwarzkopf, S
   Best, N
   Lichti, G
   Kraft, E
   Krischak, G
   Reisshauer, A
AF Liebl, Max Emanuel
   Gutenbrunner, Chrlstoph
   Glaesener, Jean Jacques
   Schwarzkopf, Susanne
   Best, Norman
   Lichti, Gabriele
   Kraft, Eduard
   Krischak, Gert
   Reisshauer, Anett
TI Early Rehabilitation in COVID-19-Best Practice Recommendations for the
   Early Rehabilitation of COVID-19 Patients
SO PHYSIKALISCHE MEDIZIN REHABILITATIONSMEDIZIN KURORTMEDIZIN
LA German
DT Article
DE rehabilitation; Physical and rehabilitation medicine; COVID-19;
   SARS-CoV2; physiotherapy
ID PHYSIOTHERAPY
AB The COVID-19 pandemic poses new challenges to physical medicine, physiotherapy, and acute care rehabilitation in rehabilitation clinics as well as in hospitals. We have to assume that COVID-19 patients may need early mobilization and acute care rehabilitation, despite of a possible scarcity of suitable facilities or services. It is the aim of this article to provide conceptual suggestions for the early rehabilitation of COVID-19, combining the existing experience in the acute care rehabilitation of patients with respiratory infections with the currently available sources and experience. These recommendations comprise a checklist of logistical and organisational preparations, aspects of infectivity and personal protective equipment, adjustment of the patients' surroundings, interprofessional team work and co-therapy, respiratory therapy, mobilisation, activating care, ADL training, training intensity, and psychosocial management.
C1 [Liebl, Max Emanuel; Reisshauer, Anett] Charite Univ Med Berlin, Arbeitsbereich Phys Med & Rehabil, Berlin, Germany.
   [Liebl, Max Emanuel; Reisshauer, Anett] Free Univ Berlin, Berlin, Germany.
   [Liebl, Max Emanuel; Reisshauer, Anett] Humboldt Univ, Berlin, Germany.
   [Liebl, Max Emanuel; Reisshauer, Anett] Berlin Inst Hlth, Berlin, Germany.
   [Gutenbrunner, Chrlstoph] Med Hsch, Klin Rehabil med, Hannover, Germany.
   [Glaesener, Jean Jacques] Ifi Inst Interdisziplinare Med, Rehabil Med, Hamburg, Germany.
   [Schwarzkopf, Susanne] ZAR Erding, Zentrum Ambulante Rehabil, Nurnberg, Germany.
   [Schwarzkopf, Susanne] Paracelsus Med Privatuniv, Klinikum Nurnberg, Nurnberg, Germany.
   [Best, Norman] Univ Klinikum Jena, Inst Physiotherapie, Jena, Germany.
   [Best, Norman] Univ Klinikum Jena, Posture & Mot Grp, Jena, Germany.
   [Lichti, Gabriele] Klinikum Bad Salzungen, Zentrum Phys & Rehabil Med, Bad Salzungen, Germany.
   [Kraft, Eduard] Ludwig Maximilians Univ Munchen, Klin Orthopadie Phys Med & Rehabil, Munich, Germany.
   [Krischak, Gert] Univ Ulm, Inst Rehabil Med Forsch, Ulm, Germany.
   [Krischak, Gert] Federseeklin Bad Buchau, Abt Orthopadie & Unfallchirurg, Bad Buchau, Germany.
RP Liebl, ME (corresponding author), Charite Univ Med Berlin, Phys Med & Rehabil, Charitepl 1, D-10117 Berlin, Germany.
EM max.liebl@charite.de
CR Alhazzani, 2020, CRITICAL CARE MED
   Beyer J, 2015, PHYS MED REHAB KUROR, V25, P260, DOI 10.1055/s-0035-1564089
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Boldrini P, 2020, EUROPEAN J PHYS REHA
   Deffner T, KLIN PSYCHOSOZIALE N
   Drahnak DM, 2015, CRIT CARE NURSE, V35, P29, DOI 10.4037/ccn2015753
   Gosselink R, 2011, NETH J CRIT CARE, V15, P66
   Grabowski DC, 2020, JAMA
   Jaber S, 2011, AM J RESP CRIT CARE, V183, P364, DOI 10.1164/rccm.201004-0670OC
   Kim WY, 2011, CRIT CARE MED, V39, P2627, DOI 10.1097/CCM.0b013e3182266408
   Koczulla AR, 2018, DTSCH ARZTEBL INT, V115, P871, DOI 10.3238/arztebl.2018.0871
   Liang T., 2020, HDB COVID 19 PREVENT
   Liebl ME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0169010
   Liebl ME, 2018, REHABILITATION, V57, P372, DOI 10.1055/s-0043-117547
   Liebl ME, 2018, PHYS MED REHAB KUROR, V28, P114, DOI 10.1055/s-0043-124373
   Liebl ME, 2019, PHYSIOPRAXIS, V17, P34
   Magnussen H, 2008, Pneumologie, V62, P748, DOI 10.1055/s-2008-1038290
   McNeary L, 2020, PM&R, V12, P512, DOI 10.1002/pmrj.12369
   Negrini S, 2020, EUROPEAN J PHYS REHA
   Reisshauer A, 2020, PHYS MED REHAB KUROR, V30, P64, DOI 10.1055/a-1147-7402
   Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9
   Thomas P, 2020, PHYSIOTHERAPY MANAGE
   WHO, 2020, CLIN MAN SEV AC RESP
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Zonghua J, 2020, RECOMMENDATIONS RESP, DOI 10.3760/cma.j.cn112147-20200228-00206
NR 25
TC 2
Z9 2
U1 14
U2 14
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0940-6689
EI 1439-085X
J9 PHYS MED REHAB KUROR
JI Physik. Med. Rehabilitationsmed. Kurort.
PD JUN
PY 2020
VL 30
IS 3
BP 129
EP 134
DI 10.1055/a-1162-4919
PG 6
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA MC0CR
UT WOS:000542965500005
OA Bronze
DA 2021-01-01
ER

PT J
AU Kuebler, WM
   Jordt, SE
   Liedtke, WB
AF Kuebler, Wolfgang M.
   Jordt, Sven-Eric
   Liedtke, Wolfgang B.
TI Urgent reconsideration of lung edema as a preventable outcome in
   COVID-19: inhibition of TRPV4 represents a promising and feasible
   approach
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE COVID-19; pulmonary edema; SARS-CoV-2; TRPV4; TRPV4 inhibitor
ID ACUTE RESPIRATORY SYNDROME; POTENTIAL VANILLOID 4; PULMONARY PATHOLOGY;
   SYNDROME SARS; ACTIVATION; INFLAMMATION; CORONAVIRUS; REMDESIVIR; INJURY
AB Lethality of coronavirus disease (COVID-19) during the 2020 pandemic, currently still in the exponentially accelerating phase in most countries, is critically driven by disruption of the alveolo-capillary barrier of the lung, leading to lung edema as a direct consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We argue for inhibition of the transient receptor potential vanilloid 4 (TRPV4) calcium-permeable ion channel as a strategy to address this issue, based on the rationale that TRPV4 inhibition is protective in various preclinical models of lung edema and that TRPV4 hyperactivation potently damages the alveolo-capillary barrier, with lethal outcome. We believe that TRPV4 inhibition has a powerful prospect at protecting this vital barrier in COVID-19 patients, even to rescue a damaged barrier. A clinical trial using a selective TRPV4 inhibitor demonstrated a benign safety profile in healthy volunteers and in patients suffering from cardiogenic lung edema. We argue for expeditious clinical testing of this inhibitor in COVID-19 patients with respiratory malfunction and at risk for lung edema. Perplexingly, among the currently pursued therapeutic strategies against COVID-19, none is designed to directly protect the alveolo-capillary barrier. Successful protection of the alveolo-capillary barrier will not only reduce COVID-19 lethality but will also preempt a distressing healthcare scenario with insufficient capacity to provide ventilator-assisted respiration.
C1 [Kuebler, Wolfgang M.] Charite Med Univ Berlin, Inst Physiol, Berlin, Germany.
   [Jordt, Sven-Eric; Liedtke, Wolfgang B.] Duke Univ, Dept Anesthesiol, Durham, NC 27708 USA.
   [Liedtke, Wolfgang B.] Duke Univ, Dept Neurol, Durham, NC 27708 USA.
   [Liedtke, Wolfgang B.] Duke Univ, Dept Neurobiol, Durham, NC 27708 USA.
RP Kuebler, WM (corresponding author), Charite Med Univ Berlin, Inst Physiol, Berlin, Germany.; Jordt, SE; Liedtke, WB (corresponding author), Duke Univ, Dept Anesthesiol, Durham, NC 27708 USA.; Liedtke, WB (corresponding author), Duke Univ, Dept Neurol, Durham, NC 27708 USA.; Liedtke, WB (corresponding author), Duke Univ, Dept Neurobiol, Durham, NC 27708 USA.
EM wolfgang.kuebler@charite.de; sven.jordt@duke.edu; liedt001@duke.edu
RI Jordt, Sven-Eric/ABE-6517-2020
OI Jordt, Sven-Eric/0000-0001-6171-5622
FU National Institute of Environmental Health SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Environmental Health Sciences (NIEHS)
   [U01ES015674]; Michael Ross Haffner Fund (Charlotte, NC)
FX This work was supported in part by National Institute of Environmental
   Health Sciences Grant U01ES015674 to S.-E. Jordt. W. B. Liedtke
   acknowledges support from the Michael Ross Haffner Fund (Charlotte, NC).
CR Alvarez DF, 2006, CIRC RES, V99, P988, DOI 10.1161/01.RES.0000247065.11756.19
   Balakrishna S, 2014, AM J PHYSIOL-LUNG C, V307, pL158, DOI 10.1152/ajplung.00065.2014
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Brooks CA, 2019, ACS MED CHEM LETT, V10, P1228, DOI 10.1021/acsmedchemlett.9b00274
   Chand K, 2020, ARAB J CHEM, V13, P8248, DOI [10.1142/S0192415X20500378, 10.1016/j.arabjc.2020.01.009]
   Chow KC, 2004, AM J CLIN PATHOL, V121, P574, DOI 10.1309/C0EDU0RAQBTXBHCE
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dutta B, 2020, LAB INVEST, V100, P178, DOI 10.1038/s41374-019-0334-6
   Echtermeyer F, 2019, FASEB J, V33, P10257, DOI 10.1096/fj.201802233R
   Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20
   Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8
   Goldenberg NM, 2015, ANESTHESIOLOGY, V122, P1338, DOI 10.1097/ALN.0000000000000647
   Goldenberg NM, 2015, N-S ARCH PHARMACOL, V388, P421, DOI 10.1007/s00210-014-1058-1
   Goyal N, 2019, AM J CARDIOVASC DRUG, V19, P335, DOI 10.1007/s40256-018-00320-6
   Grove LM, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau1533
   Hamanaka K, 2007, AM J PHYSIOL-LUNG C, V293, pL923, DOI 10.1152/ajplung.00221.2007
   Hamanaka K, 2010, AM J PHYSIOL-LUNG C, V299, pL353, DOI 10.1152/ajplung.00315.2009
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsiao CH, 2005, J FORMOS MED ASSOC, V104, P75
   Huh D, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004249
   Hwang DM, 2005, MODERN PATHOL, V18, P1, DOI 10.1038/modpathol.3800247
   Ketai L, 2006, J THORAC IMAG, V21, P276, DOI 10.1097/01.rti.0000213581.14225.f1
   Li J, 2019, APL BIOENG, V3, DOI 10.1063/1.5122967
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Michalick L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00413
   Michalick L, 2017, ANESTHESIOLOGY, V126, P300, DOI 10.1097/ALN.0000000000001443
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Morty RE, 2014, AM J PHYSIOL-LUNG C, V307, pL817, DOI 10.1152/ajplung.00254.2014
   Pairet N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196055
   Radovanovic D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041191
   Rahaman SO, 2014, J CLIN INVEST, V124, P5225, DOI 10.1172/JCI75331
   Rayees S, 2019, CELL REP, V27, P793, DOI 10.1016/j.celrep.2019.03.053
   Scheraga RG, 2020, J IMMUNOL, V204, P1310, DOI 10.4049/jimmunol.1901033
   Scheraga RG, 2016, J IMMUNOL, V196, P428, DOI 10.4049/jimmunol.1501688
   Seth RK, 2017, FREE RADICAL BIO MED, V102, P260, DOI 10.1016/j.freeradbiomed.2016.11.047
   Stewart GM, 2020, EUR J HEART FAIL, V22, P1641, DOI 10.1002/ejhf.1809
   Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Willette RN, 2008, J PHARMACOL EXP THER, V326, P443, DOI 10.1124/jpet.107.134551
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yin J, 2008, CIRC RES, V102, P966, DOI 10.1161/CIRCRESAHA.107.168724
   Yin J, 2016, AM J RESP CELL MOL, V54, P370, DOI 10.1165/rcmb.2014-0225OC
   Yu Q, 2020, AM J PHYSIOL-LUNG C, V318, pL723, DOI 10.1152/ajplung.00255.2019
   Zhao PS, 2015, J BIOL CHEM, V290, P13875, DOI 10.1074/jbc.M115.642736
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 48
TC 3
Z9 3
U1 2
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUN
PY 2020
VL 318
IS 6
BP L1239
EP L1243
DI 10.1152/ajplung.00161.2020
PG 5
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA MA8DH
UT WOS:000542140500017
PM 32401673
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kumar, K
   Hinks, TSC
   Singanayagam, A
AF Kumar, Kartik
   Hinks, Timothy S. C.
   Singanayagam, Aran
TI Treatment of COVID-19-exacerbated asthma: should systemic
   corticosteroids be used?
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE asthma; corticosteroid; COVID-19; exacerbation
ID RHINOVIRUS; INFECTION; INFLAMMATION; RESPONSES; CYTOKINE; CELLS
AB Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a new rapidly spreading infectious disease. Current guidance from the World Health Organization (WHO) highlights asthmatics as a high-risk group for severe illness from COVID-19. Viruses are common triggers of asthma exacerbations and the current SARS-CoV-2 pandemic raises several questions regarding the optimum management strategies. Here, we discuss the contentious issue of whether the mainstay therapy systemic corticosteroids should be used in the routine management of COVID-19-associated asthma exacerbations. Recent guidance from the WHO has advised against the use of corticosteroids if COVID-19 is suspected due to concerns that these agents may impair protective innate antiviral immune responses. This may not be appropriate in the unique case of asthma exacerbation, a syndrome associated with augmented type 2 inflammation, a disease feature that is known to directly inhibit antiviral immunity. Corticosteroids, through their suppressive effects on type 2 inflammation, are thus likely to restore impaired antiviral immunity in asthma and, in contrast to non-asthmatic subjects, have beneficial clinical effects in the context of SARS-CoV-2 infection.
C1 [Kumar, Kartik; Singanayagam, Aran] Imperial Coll London, Natl Heart & Lung Inst, London, England.
   [Hinks, Timothy S. C.] Univ Oxford, Nuffield Dept Med Expt Med, Oxford Biomed Res Ctr, Resp Med Unit, Oxford, England.
   [Hinks, Timothy S. C.] Univ Oxford, Nuffield Dept Med Expt Med, Oxford Biomed Res Ctr, Natl Inst Hlth Res, Oxford, England.
RP Singanayagam, A (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, London, England.
EM a.singanayagam@imperial.ac.uk
OI Singanayagam, Aran/0000-0001-9849-0033
FU National Institute for Health Research (NIHR) Biomedical Research
   CentreNational Institute for Health Research (NIHR); Wellcome
   TrustWellcome Trust [104553/z/14/z, 211050/Z/18/z, 215275/Z/19/Z]; NIHR
   Oxford Biomedical Research Centre (BRC); Association of Physicians of
   Great Britain Ireland
FX K.K. is supported by funding from the National Institute for Health
   Research (NIHR) Biomedical Research Centre. T.S.C.H. is supported by
   grants from the Wellcome Trust (104553/z/14/z, 211050/Z/18/z) and the
   NIHR Oxford Biomedical Research Centre (BRC). A.S. is supported by
   funding from the Wellcome Trust (215275/Z/19/Z) and the Association of
   Physicians of Great Britain & Ireland.
CR Contoli M, 2015, ALLERGY, V70, P910, DOI 10.1111/all.12627
   Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462
   Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308
   Global Initiative for Asthma (GINA), 2019, MAN PREV GUID
   Grunberg K, 2001, AM J RESP CRIT CARE, V164, P1816
   Gustafson LM, 1996, J ALLERGY CLIN IMMUN, V97, P1009, DOI 10.1016/S0091-6749(96)80077-7
   Hewson CA, 2010, EUR RESPIR J, V36, P1425, DOI 10.1183/09031936.00026910
   Huber JP, 2010, J IMMUNOL, V185, P813, DOI 10.4049/jimmunol.1000469
   Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC
   Message SD, 2001, EUR RESPIR J, V18, P1013, DOI 10.1183/09031936.01.00228701
   Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105
   Normansell R, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011801.pub2
   Pritchard AL, 2012, J IMMUNOL, V188, P5898, DOI 10.4049/jimmunol.1103507
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Satia I, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228544
   Singanayagam A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04574-1
   Thomas BJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep07176
   Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901
   World Health Organization, CLIN MAN SEV AC RESP
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zheng XY, 2018, ARCH VIROL, V163, P845, DOI 10.1007/s00705-017-3700-y
NR 23
TC 2
Z9 2
U1 2
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUN
PY 2020
VL 318
IS 6
BP L1244
EP L1247
DI 10.1152/ajplung.00144.2020
PG 4
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA MA8DH
UT WOS:000542140500018
PM 32401670
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Jiang, HJ
   Nan, J
   Lv, ZY
   Yang, J
AF Jiang, Hong-juan
   Nan, Jiang
   Lv, Zhi-yue
   Yang, Juan
TI Psychological impacts of the COVID-19 epidemic on Chinese people:
   Exposure, post-traumatic stress symptom, and emotion regulation
SO ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE
LA English
DT Article
DE COVID; 19 exposures; Post-traumatic stress symptoms; Expressive
   suppression; Cognitive reappraisal
ID SARS; DEPRESSION; PERCEPTION; SURVIVORS; DISORDER
AB Objective: To examine the effects of coronavirus disease-2019 (COVID-19) exposure, expressive suppression/cognitive reappraisal, and demographic variables on post-traumatic stress symptoms (PTS) among Chinese. Methods: Participants were recruited by social media through WeChat and 6 049 Chinese (aged from 17 to 63 years; median=24) from 31 provinces were included in the study. PTS symptoms, expressive suppression, and cognitive reappraisal were assessed after the outbreak of COVID-19. A regression mixture analysis was conducted in Mplus 7. Results: A regression mixture model identified three latent classes that were primarily distinguished by differential effects of COVID- 19 exposures on PTS symptoms: (1) Class 1 (mildly PTS symptoms, 80.9%), (2) Class 2 (moderate PTS symptoms, 13.0%), and (3) Class 3 (high PTS symptoms, 6.1%). The results demonstrated that the young, women and people with responsibilities and concerns for others were more vulnerable to PTS symptoms; and they had more expression inhibition and less cognitive reappraisal in three latent classes. Conclusions: The findings suggest that more attention needs to be paid to vulnerable groups such as the young, women and people with responsibilities and concerns for others. Therapies to encourage emotional expression and increase cognitive reappraisal may also be helpful for trauma survivors.
C1 [Jiang, Hong-juan] Hainan Med Univ, Affliated Hosp 1, Dept Psychol, Haikou 571199, Hainan, Peoples R China.
   [Nan, Jiang] Hainan Med Univ, Student Affairs Off, Haikou 571199, Hainan, Peoples R China.
   [Lv, Zhi-yue] Hainan Med Univ, Key Lab Trop Translat Med, Minist Educ, Haikou 571199, Peoples R China.
   [Yang, Juan] Hainan Med Univ, Key Lab Emegency & Trauma, Key Lab Brain Sci Res & Transformat Trop Environm, Dept Psychol,Affliated Hosp 1,Minist Educ, Haikou 571199, Hainan, Peoples R China.
RP Lv, ZY (corresponding author), Hainan Med Univ, Key Lab Trop Translat Med, Minist Educ, Haikou 571199, Peoples R China.; Yang, J (corresponding author), Hainan Med Univ, Key Lab Emegency & Trauma, Key Lab Brain Sci Res & Transformat Trop Environm, Dept Psychol,Affliated Hosp 1,Minist Educ, Haikou 571199, Hainan, Peoples R China.
EM lvzhiyue@mail.sysu.edu.cn; juanyang0609@qq.com
FU Hainan Medical University [XGZX2020003]; Working Committee for Talents
   of Hainan Province [20192166]; Project of Basic Platform of National
   Science and Technology Resources of the Ministry of Sciences and
   Technology of China [TDRC-2019-194-30]; Science and Technology Planning
   Project of Guangdong Province [2019B030316025]; 111 ProjectMinistry of
   Education, China - 111 Project [B12003]
FX The study was supported by the research grant from Hainan Medical
   University (No. XGZX2020003), the fund from Working Committee for
   Talents of Hainan Province (No. 20192166), the Project of Basic Platform
   of National Science and Technology Resources of the Ministry of Sciences
   and Technology of China (No. TDRC-2019-194-30), Science and Technology
   Planning Project of Guangdong Province (No. 2019B030316025), and the 111
   Project (No. B12003). This council had no further role in study design;
   in the collection, analysis and interpretation of data; in the writing
   of the report; and in the decision to submit the paper for publication.
CR Asparouhov T., 2012, USING MPLUS TECH11 T
   Boden MT, 2013, J SOC CLIN PSYCHOL, V32, P296, DOI 10.1521/jscp.2013.32.3.296
   Cao X, 2015, J AFFECT DISORDERS, V186, P58, DOI 10.1016/j.jad.2015.06.058
   Carragher N, 2009, J AFFECT DISORDERS, V113, P88, DOI 10.1016/j.jad.2008.05.015
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Gao Y., 2008, J RADIOIMMUNOL, V21, P59
   Gross J. J., 1998, REV GEN PSYCHOL, V2, P271, DOI DOI 10.1037/1089-2680.2.3.271
   Gross JJ, 1998, J PERS SOC PSYCHOL, V74, P224, DOI 10.1037/0022-3514.74.1.224
   Hawryluck L, 2004, EMERG INFECT DIS, V10, P1206, DOI 10.3201/eid1007.030703
   Hipp JR, 2006, PSYCHOL METHODS, V11, P36, DOI 10.1037/1082-989X.11.1.36
   Hong X, 2009, GEN HOSP PSYCHIAT, V31, P546, DOI 10.1016/j.genhosppsych.2009.06.008
   Lau JTF, 2005, EMERG INFECT DIS, V11, P417
   Lee AM, 2007, CAN J PSYCHIAT, V52, P233, DOI 10.1177/070674370705200405
   Ma N, 2020, CHIN J PSYCHIAT, V53, pE001, DOI [10.3760/cma.j.issn.1006-7884.2020.0001, DOI 10.3760/CMA.J.ISSN.1006-7884.2020.0001]
   Moore SA, 2008, BEHAV RES THER, V46, P993, DOI 10.1016/j.brat.2008.05.001
   Muthen L., 2012, MPLUS USERS GUIDE
   Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396
   Park BJ, 2010, ACCIDENT ANAL PREV, V42, P741, DOI 10.1016/j.aap.2009.11.002
   Roemer L, 2001, J TRAUMA STRESS, V14, P149, DOI 10.1023/A:1007895817502
   Ryu S, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020006
   Sala MN, 2009, INT J DEV ED PSYCHOL, V21, P393
   Shi K, 2003, CHINESE SCI BULL, V48, P1297, DOI 10.1007/BF03184166
   Van Horn ML, 2009, DEV PSYCHOL, V45, P1298, DOI 10.1037/a0016427
   Vujanovic AA, 2011, J PSYCHOPATHOL BEHAV, V33, P129, DOI 10.1007/s10862-010-9209-2
   Wang L., 2007, CHINA J HLTH PSYCHOL, V15, P503, DOI DOI 10.13342/J.CNKI.CJHP.2007.06.012
   Weathers F. W., 2013, PTSD CHECKLIST DSM 5
   WEDEL M, 1995, J CLASSIF, V12, P21, DOI 10.1007/BF01202266
   World Health Organization, 2020, 62 WHO
   Wu P, 2009, CAN J PSYCHIAT, V54, P302, DOI 10.1177/070674370905400504
NR 29
TC 4
Z9 4
U1 13
U2 13
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1995-7645
EI 2352-4146
J9 ASIAN PAC J TROP MED
JI Asian Pac. J. Trop. Med.
PD JUN
PY 2020
VL 13
IS 6
BP 252
EP 259
DI 10.4103/1995-7645.281614
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA MA7WY
UT WOS:000542123900004
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Robson, B
AF Robson, B.
TI COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a
   peptidomimetic antagonist, and therapeutic drugs, and analysis of a
   proposed achilles' heel conserved region to minimize probability of
   escape mutations and drug resistance
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Coronavirus; 2019-nCoV; SARS-CoV-2; COVID-19; Wuhan seafood market
   coronavirus; Bionformatics; Synthetic vaccine; Peptidomimetic;
   Retroinverso; Q-UEL language
ID NOVO MOLECULAR DESIGN; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; SARS
   CORONAVIRUS; PRO-LIGAND; UNIVERSAL EXCHANGE; INFERENCE LANGUAGE; EXPERT
   SYSTEM; ENTRY; INHIBITORS; NETWORKS
AB This paper continues a recent study of the spike protein sequence of the COVID-19 virus (SARS-CoV-2). It is also in part an introductory review to relevant computational techniques for tackling viral threats, using COVID-19 as an example. Q-UEL tools for facilitating access to knowledge and bioinformatics tools were again used for efficiency, but the focus in this paper is even more on the virus. Subsequence KRSFIEDLLFNKV of the S2' spike glycoprotein proteolytic cleavage site continues to appear important. Here it is shown to be recognizable in the common cold coronaviruses, avian coronaviruses and possibly as traces in the nidoviruses of reptiles and fish. Its function or functions thus seem important to the coronaviruses. It might represent SARS-CoV-2 Achilles' heel, less likely to acquire resistance by mutation, as has happened in some early SARS vaccine studies discussed in the previous paper. Preliminary conformational analysis of the receptor (ACE2) binding site of the spike protein is carried out suggesting that while it is somewhat conserved, it appears to be more variable than KRSFIEDLLFNKV. However compounds like emodin that inhibit SARS entry, apparently by binding ACE2, might also have functions at several different human protein binding sites. The enzyme 11 beta-hydroxysteroid dehydrogenase type 1 is again argued to be a convenient model pharmacophore perhaps representing an ensemble of targets, and it is noted that it occurs both in lung and alimentary tract. Perhaps it benefits the virus to block an inflammatory response by inhibiting the dehydrogenase, but a fairly complex web involves several possible targets.
C1 [Robson, B.] Ingine Inc, Cleveland, OH 44106 USA.
   [Robson, B.] Dirac Fdn, Witney, Oxon, England.
RP Robson, B (corresponding author), Ingine Inc, Cleveland, OH 44106 USA.; Robson, B (corresponding author), Dirac Fdn, Witney, Oxon, England.
EM barryrobson@ingine.com
CR Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   Ball J., 1990, CHEM STRUCTURE INFOR, P107
   Barre O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105984
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bosch BJ, 2008, J VIROL, V82, P2580, DOI 10.1128/JVI.02287-07
   Bruley C, 2006, ENDOCRINOLOGY, V147, P2879, DOI 10.1210/en.2005-1621
   Chu Y., 2019, BRIEF BIOINFORM, V152, DOI [10.1093/bib/bbz152.Oxford Academic., DOI 10.1093/BIB/BBZ152.OXFORDACADEMIC]
   CLARK DE, 1995, J COMPUT AID MOL DES, V9, P13, DOI 10.1007/BF00117275
   de Lima DP, 1999, QUIM NOVA, V22, P375
   Feng Y, 2010, BRIT J PHARMACOL, V161, P113, DOI 10.1111/j.1476-5381.2010.00826.x
   Figliozzi G.M., 1996, PROTEIN SCI S1, V5, P72
   Fishleigh R.V., 1990, patent Patent, Patent No. [EP00371046A1, 00371046]
   Fishleigh R.V., 1998, patent, Patent No. [US05773572, 05773572]
   Fishleigh R.V., 1995, patent, Patent No. [EU0636145, 0636145]
   FISHLEIGH RV, 1987, FEBS LETT, V214, P219, DOI 10.1016/0014-5793(87)80060-1
   Forni D, 2015, SCI REP-UK, V5, DOI 10.1038/srep14480
   FRENKEL D, 1995, J COMPUT AID MOL DES, V9, P213, DOI 10.1007/BF00124453
   Fulford T, 2000, STUD ROMANTICISM, V39, P139, DOI 10.2307/25601434
   Garnier J., FRT85T0606 INRAUC
   Garnier J., 1989, PREDICTION PROTEIN S, P417, DOI DOI 10.1007/978-1-4613-1571-1_10
   Grifoni A., CANDIDATE TARGETS IM, DOI 10.1101/2020.02.12.946087v1. full.pdf
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Gurwitz D., 2020, ANGIOTENSIN RECEPTOR, DOI 10.1002/ddr.21656
   HAGLER AT, 1980, SCIENCE, V208, P599, DOI 10.1126/science.7367882
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Ho TY, 2007, ANTIVIR RES, V74, P92, DOI 10.1016/j.antiviral.2006.04.014
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kaliamurthi S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010063
   Kam YW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007870
   Kao DJ, 2009, CHEM BIOL DRUG DES, V74, P33, DOI 10.1111/j.1747-0285.2009.00825.x
   Katz BA, 2004, J MOL BIOL, V344, P527, DOI 10.1016/j.jmb.2004.09.032
   KAUSHIK AC, 2019, INTERDISCIP SCI COMP
   Kaushik AC, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2019.1708796
   Khan Mohammad Yaseen, 2019, J Tradit Complement Med, V9, P73, DOI 10.1016/j.jtcme.2018.02.001
   Kumar SP, 2018, J MOL MODEL, V24, DOI 10.1007/s00894-018-3820-7
   Lennart M.R., 2017, PLOS ONE, V12
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Liu IJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082081
   Loeffler J.R., 2020, J CHEM INF MODEL, DOI [10.1021/acs.jcim.9b01165, DOI 10.1021/ACS.JCIM.9B01165.AM.CHEM.SOC]
   Lu R., 2020, GENOMIC CHARACTERIZA
   Ma-Lauer Y, 2016, P NATL ACAD SCI USA, V113, pE5192, DOI 10.1073/pnas.1603435113
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Mehmood A, 2019, CHEM BIOL DRUG DES, V94, P1868, DOI 10.1111/cbdd.13602
   Morris GE, 2006, FASEB J, V20, P2153, DOI 10.1096/fj.06-5910fje
   Niespodziana K, 2012, FASEB J, V26, P1001, DOI 10.1096/fj.11-193557
   Palatnik-de-Sousa CB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00826
   Rai J, 2019, CHEM BIOL DRUG DES, V93, P724, DOI 10.1111/cbdd.13472
   ROBSON B, 1987, NATURE, V325, P395, DOI 10.1038/325395a0
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   Robson B, 2018, COMPUT BIOL MED, V95, P147, DOI 10.1016/j.compbiomed.2018.02.013
   Robson B, 1996, NAT BIOTECHNOL, V14, P892, DOI 10.1038/nbt0796-892
   ROBSON B, 1987, J MOL GRAPHICS, V5, P8, DOI 10.1016/0263-7855(87)80038-3
   Robson B., 1982, BIOPHYSICS WATER, P66
   Robson B., 1998, PSEUDOPROTEINS NONPR
   Robson B., 1986, APPL BIOTECHNOLOGY, V1, pB9
   Robson B., 1992, THEORETICAL BIOCH MO, V2, P207
   Robson B., ZIKA FLU BACK AGAIN
   Robson B., 1998, INTRO PROTEINS PROTE
   Robson B., 2020, PRELIMINARY BIOINFOR, DOI [10.13140/RG.2.2.18275.09761, DOI 10.13140/RG.2.2.18275.09761]
   Robson B., 1986, CHEM DES AUTOM NEWS, V1, P9
   Robson B, 2020, COMPUT BIOL MED, V117, DOI 10.1016/j.compbiomed.2020.103621
   Robson B, 2016, COMPUT BIOL MED, V79, P299, DOI 10.1016/j.compbiomed.2016.10.009
   Robson B, 2015, COMPUT BIOL MED, V66, P82, DOI 10.1016/j.compbiomed.2015.07.015
   Robson B, 2013, COMPUT BIOL MED, V43, P2297, DOI 10.1016/j.compbiomed.2013.09.010
   Robson B, 2011, J COMPUT AID MOL DES, V25, P427, DOI 10.1007/s10822-011-9429-x
   Sachdeva S, 2017, INT J PEPT RES THER, V23, P49, DOI 10.1007/s10989-016-9534-8
   Schwarz S, 2011, ANTIVIR RES, V90, P64, DOI 10.1016/j.antiviral.2011.02.008
   Soria-Guerr R.E., 2015, J BIOMED INFORM, V53, P405
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   WASZKOWYCZ B, 1994, J MED CHEM, V37, P3994, DOI 10.1021/jm00049a019
   WESTHEAD DR, 1995, J COMPUT AID MOL DES, V9, P139, DOI 10.1007/BF00124404
   Westphal U., 1986, MONOGRAPHS ENDOCRINO, V27
   Yang X, 2018, DRUG METAB DISPOS, V46, P1023, DOI 10.1124/dmd.118.081083
NR 74
TC 14
Z9 14
U1 12
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD JUN
PY 2020
VL 121
AR 103749
DI 10.1016/j.compbiomed.2020.103749
PG 28
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA MA8UY
UT WOS:000542187300002
PM 32568687
OA Green Published
DA 2021-01-01
ER

PT J
AU Maillart, E
   Leemans, S
   Van Noten, H
   Vandergraesen, T
   Mahadeb, B
   Salaouatchi, MT
   De Bels, D
   Clevenbergh, P
AF Maillart, E.
   Leemans, S.
   Van Noten, H.
   Vandergraesen, T.
   Mahadeb, B.
   Salaouatchi, M. T.
   De Bels, D.
   Clevenbergh, P.
TI A case report of serious haemolysis in a glucose-6-phosphate
   dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine
SO INFECTIOUS DISEASES
LA English
DT Article
DE Covid-19; hydroxychloroquine; adverse event; haemolysis;
   glucose-6-phosphate dehydrogenase (G6PD) deficiency evidence-based
   medicine
AB While the COVID-19 epidemic occurred since December 2019, as of end April 2020, no treatment has been validated or invalidated by accurate clinical trials. Use of hydroxychloroquine has been popularised on mass media and put forward as a valid treatment option without strong evidence of efficacy. Hydroxychloroquine (HCQ) has its own side effects, some of which are very serious like acute haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient patients. Side effects may be worse than the disease itself. Belgian national treatment guidelines recommend the use of HCQ in mild to severe COVID-19 disease. As opinions, politics, media and beliefs are governing COVID-19 therapy, performance of randomised controlled blinded clinical trials became difficult. Results of sound clinical trials are eagerly awaited. We report a case of acute haemolysis leading to admission in intensive care unit and renal failure in a patient with uncovered G6PD deficiency.
C1 [Maillart, E.; Leemans, S.; Van Noten, H.; Clevenbergh, P.] Univ Hosp Brugmann, Infect Dis Clin, Brussels, Belgium.
   [Vandergraesen, T.; Salaouatchi, M. T.] Univ Hosp Brugmann, Internal Med Dept, Brussels, Belgium.
   [Mahadeb, B.] Brussels Acad Hosp Lab, Brussels, Belgium.
   [De Bels, D.] Univ Hosp Brugmann, Intens Care Unit, Brussels, Belgium.
RP Clevenbergh, P (corresponding author), Univ Hosp Brugmann, Infect Dis Clin, Brussels, Belgium.
EM pclevenbergh@gmail.com
CR Alexander PE, 2020, J CLIN EPIDEMIOL
   Beauverd Y, 2020, EUR J HAEMATOL, V105, P357, DOI 10.1111/ejh.13432
   Caplan AL, 2020, J CLIN INVEST, V130, P2752, DOI 10.1172/JCI139562
   Chew CY, 2020, AUSTRALAS J DERMATOL, V61, pE150, DOI 10.1111/ajd.13168
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Esposito Silvano, 2020, Infez Med, V28, P198
   FDA-Approved Drugs, APPR DAT HIST LETT L
   Lee Jangwoo, 2019, MSMR, V26, P14
   Mohammad S, 2018, ARTHRIT CARE RES, V70, P481, DOI 10.1002/acr.23296
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Richardson SR, 2020, GLUCOSE 6 PHOSPHATE
   Sciensano Epidemiology of Infectious Disease, 2020, INTERIM CLIN GUIDANC
NR 12
TC 4
Z9 4
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2374-4235
EI 2374-4243
J9 INFECT DIS-NOR
JI Infect. Dis.
PD SEP 1
PY 2020
VL 52
IS 9
BP 659
EP 661
DI 10.1080/23744235.2020.1774644
EA JUN 2020
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA MI1GO
UT WOS:000542793300001
PM 32496938
OA Green Published, Bronze
DA 2021-01-01
ER

EF